15882284
D001241_D007674 NONE aspirin_6\NN\2707683|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|the_17|of_8 (r_acl) risk_1\NN\14541044|was_37|to_49|,_90|and_92|was_99 (r_nsubjpass) related_8\VBN\628491|NONE_0 (l_conj) was_20\VBD\0|risk_99|was_62|to_50|,_9|and_7 (l_acomp) high_22\JJ\5093890|it_20|]_99|._100 (l_prep) among_23\IN\0|particularly_18 (l_pobj) subset_25\NN\7999699|NONE_0 (l_prep) of_26\IN\0|the_11 (l_pobj) patients_27\NNS\9898892|NONE_0 (l_prep) with_28\IN\0|as_26 (l_pobj) nephropathy_30\NN\14573196|NONE_0
D001241_D007676 CID aspirin_11\NN\2707683|NONE_0 (l_conj) drugs_20\NNS\14778436|and_55 (l_appos) nsaids_22\NNPS\2721538|other_58|analgesic_52|inflammatory_20|(_1 (l_conj) disease_29\NN\14061805|)_22|and_20
D001241_D007676 CID aspirin_11\NN\2707683|NONE_0 (l_conj) drugs_20\NNS\14778436|and_55 (l_appos) nsaids_22\NNPS\2721538|other_58|analgesic_52|inflammatory_20|(_1 (l_conj) disease_29\NN\14061805|)_22|and_20 (l_appos) esrd_31\NNP\0|stage_21|renal_15|(_1|)_4
D001241_D007676 CID aspirin_6\NN\2707683|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|the_17|of_8 (r_acl) risk_1\NN\14541044|was_37|to_49|,_90|and_92|was_99 (l_prep) of_2\IN\0|the_9|associated_8 (l_pobj) esrd_3\NNS\0|NONE_0
D001241_D007676 CID aspirin_6\NN\2707683|NONE_0 (r_pobj) of_5\IN\0|the_16|chronic_12 (r_prep) use_4\NN\407535|however_21|,_14|may_15|risk_32|._44 (r_nsubj) increase_8\VB\13576355|NONE_0 (l_dobj) risk_10\NN\14541044|however_53|,_46|use_32|may_17|._12 (l_prep) of_11\IN\0|the_9 (l_pobj) esrd_12\NNP\0|NONE_0
17159032
D006886_D014786 CID hydroxychloroquine_8\NN\2721538|NONE_0 (r_dobj) taking_7\VBG\37396|NONE_0 (r_acl) patients_6\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|paracentral_30|visual_18|field_11|._37 (r_prep) loss_4\NN\13252973|NONE_0
D006886_D014786 CID hydroxychloroquine_17\JJ\2721538|in_29 (r_compound) treatment_18\NN\654885|NONE_0 (r_pobj) to_16\IN\0|which_22|were_16 (r_prep) attributed_15\VBN\670261|field_32|,_13 (r_relcl) abnormalities_11\NNS\14034177|patients_34|._89
7018927
D006220_D006966 CID haloperidol_9\NN\3713736|-_11 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) hyperprolactinemia_12\NN\0|NONE_0
D006220_D006966 CID haloperidol_4\NN\3713736|NONE_0 (r_amod) infusions_5\NNS\14589223|NONE_0 (r_pobj) of_3\IN\0|the_11 (r_prep) course_2\NN\883297|NONE_0 (r_pobj) during_0\IN\0|,_42|hyperprolactinemia_56|was_75|,_84|with_95|,_140|compared_145|._188 (r_prep) found_10\VBN\13279262|NONE_0 (l_nsubjpass) hyperprolactinemia_8\NN\0|during_56|,_14|was_19|,_28|with_39|,_84|compared_89|._132
6305660
2553470
D010862_D013226 CID pilocarpine_8\NN\14712692|the_12|of_18 (r_compound) model_9\NN\5888929|mk-801_34 (r_pobj) on_4\IN\0|actions_18|in_55|._62 (r_prep) epilepticus_12\NN\0|NONE_0
D010862_D013226 CID pilocarpine_14\NN\14712692|and_4 (r_conj) lithium_12\NN\14625458|NONE_0 (r_pobj) by_11\IN\0|by_27|prior_64 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9 (r_dobj) block_8\VB\21939|although_34|it_25|easy_8 (r_xcomp) is_4\VBZ\0|third_19|,_14|,_129|it_131|difficult_142|ongoing_165|._231 (r_advcl) is_24\VBZ\0|NONE_0 (l_xcomp) ongoing_29\JJ\0|third_184|,_179|is_165|,_36|it_34|difficult_23|._66 (l_advmod) epilepticus_31\NN\0|NONE_0
D010862_D013226 CID pilocarpine_21\NN\14712692|NONE_0 (r_pobj) to_20\IN\0|NONE_0 (r_prep) prior_19\RB\10675876|by_64|by_37 (r_advmod) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9 (r_dobj) block_8\VB\21939|although_34|it_25|easy_8 (r_xcomp) is_4\VBZ\0|third_19|,_14|,_129|it_131|difficult_142|ongoing_165|._231 (r_advcl) is_24\VBZ\0|NONE_0 (l_xcomp) ongoing_29\JJ\0|third_184|,_179|is_165|,_36|it_34|difficult_23|._66 (l_advmod) epilepticus_31\NN\0|NONE_0
D010862_D013226 CID pilocarpine_8\NN\14712692|NONE_0 (r_pobj) after_7\IN\0|30_13 (r_prep) min_6\NN\15154774|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|,_55|i.e._57|,_61|during_63|,_88|gradually_90|activity_142|and_151|enhanced_163|._189 (r_nsubj) reduced_17\VBD\441445|NONE_0 (l_prep) during_12\IN\0|administration_63|,_8|i.e._6|,_2|,_25|gradually_27|activity_79|and_88|enhanced_100|._126 (l_pobj) epilepticus_14\NN\0|status_7
D010862_D013226 CID pilocarpine_22\NN\14712692|the_12 (r_compound) model_23\NN\5888929|NONE_0 (r_pobj) in_18\IN\13603305|status_36|epilepticus_29 (r_prep) damage_17\NN\7296428|NONE_0 (l_amod) epilepticus_14\NN\0|status_7|in_29
D010862_D013226 CID pilocarpine_13\NN\14712692|and_4 (r_conj) nmda_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|that_25|nonconvulsive_20 (r_prep) doses_9\NNS\3740161|NONE_0 (r_dobj) showing_6\VBG\6887726|NONE_0 (r_acl) results_5\NNS\34213|NONE_0 (r_pobj) by_4\IN\0|this_27|was_22|further_18|were_68|._142 (r_agent) supported_3\VBN\0|NONE_0 (l_conj) were_14\VBD\0|this_95|was_90|further_86|by_68|._74 (l_advcl) resulting_17\VBG\2633881|synergistic_13|,_2 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) mortality_23\NN\5054863|NONE_0 (l_amod) epilepticus_20\NN\0|status_7
D016291_D013226 NONE mk-801_3\NNP\0|model_34 (r_punct) on_4\IN\0|actions_18|in_55|._62 (r_prep) epilepticus_12\NN\0|NONE_0
D016291_D013226 NONE mk-801_2\NNP\0|or_10|60_13 (r_punct) 30_3\CD\13745420|after_13 (r_nummod) min_6\NN\15154774|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|,_55|i.e._57|,_61|during_63|,_88|gradually_90|activity_142|and_151|enhanced_163|._189 (r_nsubj) reduced_17\VBD\441445|NONE_0 (l_prep) during_12\IN\0|administration_63|,_8|i.e._6|,_2|,_25|gradually_27|activity_79|and_88|enhanced_100|._126 (l_pobj) epilepticus_14\NN\0|status_7
D016202_D013226 NONE nmda_6\NNP\0|NONE_0 (r_compound) receptors_7\NNS\5225602|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) activation_4\NN\13561719|that_5|role_48 (r_nsubj) plays_8\VBZ\7007684|results_50|._95 (l_dobj) role_11\NN\719494|that_53|activation_48 (l_prep) in_12\IN\13603305|an_18|important_15 (l_pobj) damage_17\NN\7296428|NONE_0 (l_amod) epilepticus_14\NN\0|status_7|in_29
D016202_D013226 NONE nmda_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|that_25|nonconvulsive_20 (r_prep) doses_9\NNS\3740161|NONE_0 (r_dobj) showing_6\VBG\6887726|NONE_0 (r_acl) results_5\NNS\34213|NONE_0 (r_pobj) by_4\IN\0|this_27|was_22|further_18|were_68|._142 (r_agent) supported_3\VBN\0|NONE_0 (l_conj) were_14\VBD\0|this_95|was_90|further_86|by_68|._74 (l_advcl) resulting_17\VBG\2633881|synergistic_13|,_2 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) mortality_23\NN\5054863|NONE_0 (l_amod) epilepticus_20\NN\0|status_7
D010862_D001930 NONE pilocarpine_22\NN\14712692|the_12 (r_compound) model_23\NN\5888929|NONE_0 (r_pobj) in_18\IN\13603305|status_36|epilepticus_29 (r_prep) damage_17\NN\7296428|NONE_0
D016202_D001930 NONE nmda_6\NNP\0|NONE_0 (r_compound) receptors_7\NNS\5225602|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) activation_4\NN\13561719|that_5|role_48 (r_nsubj) plays_8\VBZ\7007684|results_50|._95 (l_dobj) role_11\NN\719494|that_53|activation_48 (l_prep) in_12\IN\13603305|an_18|important_15 (l_pobj) damage_17\NN\7296428|NONE_0
D010862_D012640 NONE pilocarpine_33\NN\14712692|and_4 (r_conj) lithium_31\NN\14625458|NONE_0 (r_pobj) of_30\IN\0|and_27|administration_31 (r_prep) coadministration_29\NN\0|two_20|seizure_16|,_2|of_63 (r_conj) models_27\NNS\5888929|NONE_0 (l_compound) seizure_26\NN\14081375|two_4|,_14|coadministration_16|of_79
D010862_D012640 NONE pilocarpine_41\NN\14712692|NONE_0 (r_pobj) of_40\IN\0|a_12|high_10|alone_15 (r_prep) dose_39\NN\3740161|NONE_0 (r_pobj) of_36\IN\0|two_83|seizure_79|,_65|coadministration_63 (r_prep) models_27\NNS\5888929|NONE_0 (l_compound) seizure_26\NN\14081375|two_4|,_14|coadministration_16|of_79
D010862_D012640 NONE pilocarpine_18\NN\14712692|the_12 (r_compound) model_19\NN\5888929|NONE_0 (r_pobj) with_14\IN\0|an_54|effective_51|anticonvulsant_22 (r_prep) action_13\NN\30358|first_88|,_83|pretreatment_81|mk-801_63|but_42|with_50|,_90|suggesting_92|._177 (r_dobj) produced_5\VBD\1617192|NONE_0 (l_advcl) suggesting_29\VBG\1010118|first_180|,_175|pretreatment_173|mk-801_155|action_92|but_50|with_42|,_2|._85 (l_dobj) seizures_35\NNS\14081375|NONE_0
D010862_D012640 NONE pilocarpine_26\NN\14712692|NONE_0 (r_pobj) with_25\IN\0|alone_17 (r_prep) treated_24\VBN\2376958|NONE_0 (r_acl) rats_23\NNS\2329401|not_9 (r_pobj) with_22\IN\0|first_138|,_133|pretreatment_131|mk-801_113|action_50|but_8|,_40|suggesting_42|._127 (r_conj) produced_5\VBD\1617192|NONE_0 (l_advcl) suggesting_29\VBG\1010118|first_180|,_175|pretreatment_173|mk-801_155|action_92|but_50|with_42|,_2|._85 (l_dobj) seizures_35\NNS\14081375|NONE_0
D010862_D012640 NONE pilocarpine_11\NN\14712692|the_12 (r_compound) model_12\NN\5888929|mk-801_34 (r_pobj) in_7\IN\13603305|second_44|,_38|effect_17|only_33|after_47|._88 (r_prep) occurred_14\VBD\0|NONE_0 (l_prep) after_15\IN\0|second_91|,_85|effect_64|in_47|only_14|._41 (l_pobj) periods_17\NNS\13575869|NONE_0 (l_prep) of_18\IN\0|initial_16 (l_pobj) activity_20\NN\30358|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D010862_D012640 NONE pilocarpine_14\NN\14712692|and_4 (r_conj) lithium_12\NN\14625458|NONE_0 (r_pobj) by_11\IN\0|by_27|prior_64 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9
D010862_D012640 NONE pilocarpine_14\NN\14712692|and_4 (r_conj) lithium_12\NN\14625458|NONE_0 (r_pobj) by_11\IN\0|by_27|prior_64 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9 (r_dobj) block_8\VB\21939|although_34|it_25|easy_8 (r_xcomp) is_4\VBZ\0|third_19|,_14|,_129|it_131|difficult_142|ongoing_165|._231 (r_advcl) is_24\VBZ\0|NONE_0 (l_xcomp) ongoing_29\JJ\0|third_184|,_179|is_165|,_36|it_34|difficult_23|._66 (l_advmod) epilepticus_31\NN\0|NONE_0 (l_conj) block_33\VB\21939|status_23|and_4 (l_dobj) lethality_35\NN\4790449|NONE_0 (l_prep) of_36\IN\0|the_14 (l_pobj) seizures_38\NNS\14081375|NONE_0
D010862_D012640 NONE pilocarpine_21\NN\14712692|NONE_0 (r_pobj) to_20\IN\0|NONE_0 (r_prep) prior_19\RB\10675876|by_64|by_37 (r_advmod) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9
D010862_D012640 NONE pilocarpine_21\NN\14712692|NONE_0 (r_pobj) to_20\IN\0|NONE_0 (r_prep) prior_19\RB\10675876|by_64|by_37 (r_advmod) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9 (r_dobj) block_8\VB\21939|although_34|it_25|easy_8 (r_xcomp) is_4\VBZ\0|third_19|,_14|,_129|it_131|difficult_142|ongoing_165|._231 (r_advcl) is_24\VBZ\0|NONE_0 (l_xcomp) ongoing_29\JJ\0|third_184|,_179|is_165|,_36|it_34|difficult_23|._66 (l_advmod) epilepticus_31\NN\0|NONE_0 (l_conj) block_33\VB\21939|status_23|and_4 (l_dobj) lethality_35\NN\4790449|NONE_0 (l_prep) of_36\IN\0|the_14 (l_pobj) seizures_38\NNS\14081375|NONE_0
D010862_D012640 NONE pilocarpine_8\NN\14712692|NONE_0 (r_pobj) after_7\IN\0|30_13 (r_prep) min_6\NN\15154774|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|,_55|i.e._57|,_61|during_63|,_88|gradually_90|activity_142|and_151|enhanced_163|._189 (r_nsubj) reduced_17\VBD\441445|NONE_0 (l_dobj) activity_22\NN\30358|administration_142|,_87|i.e._85|,_81|during_79|,_54|gradually_52|and_9|enhanced_21|._47 (l_compound) seizure_21\NN\14081375|NONE_0
D008094_D012640 NONE lithium_31\NN\14625458|NONE_0 (r_pobj) of_30\IN\0|and_27|administration_31 (r_prep) coadministration_29\NN\0|two_20|seizure_16|,_2|of_63 (r_conj) models_27\NNS\5888929|NONE_0 (l_compound) seizure_26\NN\14081375|two_4|,_14|coadministration_16|of_79
D008094_D012640 NONE lithium_16\NN\14625458|-_7 (r_compound) pilocarpine_18\NN\14712692|the_12 (r_compound) model_19\NN\5888929|NONE_0 (r_pobj) with_14\IN\0|an_54|effective_51|anticonvulsant_22 (r_prep) action_13\NN\30358|first_88|,_83|pretreatment_81|mk-801_63|but_42|with_50|,_90|suggesting_92|._177 (r_dobj) produced_5\VBD\1617192|NONE_0 (l_advcl) suggesting_29\VBG\1010118|first_180|,_175|pretreatment_173|mk-801_155|action_92|but_50|with_42|,_2|._85 (l_dobj) seizures_35\NNS\14081375|NONE_0
D008094_D012640 NONE lithium_9\NN\14625458|-_7 (r_compound) pilocarpine_11\NN\14712692|the_12 (r_compound) model_12\NN\5888929|mk-801_34 (r_pobj) in_7\IN\13603305|second_44|,_38|effect_17|only_33|after_47|._88 (r_prep) occurred_14\VBD\0|NONE_0 (l_prep) after_15\IN\0|second_91|,_85|effect_64|in_47|only_14|._41 (l_pobj) periods_17\NNS\13575869|NONE_0 (l_prep) of_18\IN\0|initial_16 (l_pobj) activity_20\NN\30358|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D008094_D012640 NONE lithium_12\NN\14625458|NONE_0 (r_pobj) by_11\IN\0|by_27|prior_64 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9
D008094_D012640 NONE lithium_12\NN\14625458|NONE_0 (r_pobj) by_11\IN\0|by_27|prior_64 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9 (r_dobj) block_8\VB\21939|although_34|it_25|easy_8 (r_xcomp) is_4\VBZ\0|third_19|,_14|,_129|it_131|difficult_142|ongoing_165|._231 (r_advcl) is_24\VBZ\0|NONE_0 (l_xcomp) ongoing_29\JJ\0|third_184|,_179|is_165|,_36|it_34|difficult_23|._66 (l_advmod) epilepticus_31\NN\0|NONE_0 (l_conj) block_33\VB\21939|status_23|and_4 (l_dobj) lethality_35\NN\4790449|NONE_0 (l_prep) of_36\IN\0|the_14 (l_pobj) seizures_38\NNS\14081375|NONE_0
D008094_D013226 CID lithium_6\NN\14625458|-_7 (r_compound) pilocarpine_8\NN\14712692|the_12|of_18 (r_compound) model_9\NN\5888929|mk-801_34 (r_pobj) on_4\IN\0|actions_18|in_55|._62 (r_prep) epilepticus_12\NN\0|NONE_0
D008094_D013226 CID lithium_12\NN\14625458|NONE_0 (r_pobj) by_11\IN\0|by_27|prior_64 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) seizures_9\NNS\14081375|to_9 (r_dobj) block_8\VB\21939|although_34|it_25|easy_8 (r_xcomp) is_4\VBZ\0|third_19|,_14|,_129|it_131|difficult_142|ongoing_165|._231 (r_advcl) is_24\VBZ\0|NONE_0 (l_xcomp) ongoing_29\JJ\0|third_184|,_179|is_165|,_36|it_34|difficult_23|._66 (l_advmod) epilepticus_31\NN\0|NONE_0
D008094_D013226 CID lithium_20\NN\14625458|-_7 (r_compound) pilocarpine_22\NN\14712692|the_12 (r_compound) model_23\NN\5888929|NONE_0 (r_pobj) in_18\IN\13603305|status_36|epilepticus_29 (r_prep) damage_17\NN\7296428|NONE_0 (l_amod) epilepticus_14\NN\0|status_7|in_29
D016291_D012640 NONE mk-801_0\NNP\0|,_6|antagonist_62|was_74|for_85|._244 (r_punct) tested_18\VBN\670261|NONE_0 (l_prep) for_19\IN\0|mk-801_85|,_79|antagonist_23|was_11|._159 (l_pobj) effects_21\NNS\13245626|NONE_0 (l_acl) using_24\VBG\418025|anticonvulsant_31|in_8 (l_dobj) models_27\NNS\5888929|NONE_0 (l_compound) seizure_26\NN\14081375|two_4|,_14|coadministration_16|of_79
D016291_D012640 NONE mk-801_4\NNP\0|first_25|,_20|pretreatment_18|action_63|but_105|with_113|,_153|suggesting_155|._240 (r_punct) produced_5\VBD\1617192|NONE_0 (l_advcl) suggesting_29\VBG\1010118|first_180|,_175|pretreatment_173|mk-801_155|action_92|but_50|with_42|,_2|._85 (l_dobj) seizures_35\NNS\14081375|NONE_0
D016291_D012640 NONE mk-801_6\NNP\0|model_34 (r_punct) in_7\IN\13603305|second_44|,_38|effect_17|only_33|after_47|._88 (r_prep) occurred_14\VBD\0|NONE_0 (l_prep) after_15\IN\0|second_91|,_85|effect_64|in_47|only_14|._41 (l_pobj) periods_17\NNS\13575869|NONE_0 (l_prep) of_18\IN\0|initial_16 (l_pobj) activity_20\NN\30358|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D016291_D012640 NONE mk-801_2\NNP\0|or_10|60_13 (r_punct) 30_3\CD\13745420|after_13 (r_nummod) min_6\NN\15154774|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|,_55|i.e._57|,_61|during_63|,_88|gradually_90|activity_142|and_151|enhanced_163|._189 (r_nsubj) reduced_17\VBD\441445|NONE_0 (l_dobj) activity_22\NN\30358|administration_142|,_87|i.e._85|,_81|during_79|,_54|gradually_52|and_9|enhanced_21|._47 (l_compound) seizure_21\NN\14081375|NONE_0
D008094_D001930 NONE lithium_20\NN\14625458|-_7 (r_compound) pilocarpine_22\NN\14712692|the_12 (r_compound) model_23\NN\5888929|NONE_0 (r_pobj) in_18\IN\13603305|status_36|epilepticus_29 (r_prep) damage_17\NN\7296428|NONE_0
D016202_D012640 NONE aspartate_10\NNP\0|a_28|noncompetitive_26|(_10|nmda_11|)_15|receptor_17|,_36 (r_nmod) antagonist_15\NN\7846|mk-801_62|,_56|was_12|for_23|._182 (r_nsubjpass) tested_18\VBN\670261|NONE_0 (l_prep) for_19\IN\0|mk-801_85|,_79|antagonist_23|was_11|._159 (l_pobj) effects_21\NNS\13245626|NONE_0 (l_acl) using_24\VBG\418025|anticonvulsant_31|in_8 (l_dobj) models_27\NNS\5888929|NONE_0 (l_compound) seizure_26\NN\14081375|two_4|,_14|coadministration_16|of_79
D016202_D012640 NONE nmda_12\NNP\0|a_39|noncompetitive_37|aspartate_11|(_1|)_4|receptor_6|,_25 (r_nmod) antagonist_15\NN\7846|mk-801_62|,_56|was_12|for_23|._182 (r_nsubjpass) tested_18\VBN\670261|NONE_0 (l_prep) for_19\IN\0|mk-801_85|,_79|antagonist_23|was_11|._159 (l_pobj) effects_21\NNS\13245626|NONE_0 (l_acl) using_24\VBG\418025|anticonvulsant_31|in_8 (l_dobj) models_27\NNS\5888929|NONE_0 (l_compound) seizure_26\NN\14081375|two_4|,_14|coadministration_16|of_79
9132810
D008727_D054198 NONE methotrexate_34\NN\2722166|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) treated_29\VBN\2376958|acute_29|lymphoblastic_23 (r_acl) leukemia_28\NN\14239918|NONE_0
D008727_D056784 CID methotrexate_34\NN\2722166|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) treated_29\VBN\2376958|acute_29|lymphoblastic_23 (r_acl) leukemia_28\NN\14239918|NONE_0 (r_pobj) from_25\IN\0|which_16 (r_prep) developed_24\VBD\1753788|disseminated_52|necrotizing_39|,_8 (r_relcl) leukoencephalopathy_21\JJ\0|NONE_0
10219427
12828076
D000082_D062787 NONE paracetamol_12\JJ\0|NONE_0 (r_compound) overdose_13\NN\84738|to_15
D000082_D062787 NONE paracetamol_12\JJ\0|(_21|median_22|,_28|ml_37|;_39|range_41 (r_compound) overdose_13\NN\84738|to_15|than_60
D000082_D017114 CID paracetamol_12\JJ\0|NONE_0 (r_compound) overdose_13\NN\84738|to_15 (r_pobj) due_10\IN\5174653|increased_65|fas_41|in_37|._27 (r_prep) serum_1\NN\5397468|NONE_0 (l_prep) in_4\IN\13603305|increased_28|fas_4|due_37|._64 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|NONE_0 (l_pobj) failure_9\NN\66216|NONE_0
D000082_D017114 CID paracetamol_12\JJ\0|(_21|median_22|,_28|ml_37|;_39|range_41 (r_compound) overdose_13\NN\84738|to_15|than_60 (r_pobj) due_10\IN\5174653|with_25 (r_prep) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|due_25 (l_pobj) failure_9\NN\66216|NONE_0
D000082_D056486 NONE paracetamol_12\JJ\0|(_21|median_22|,_28|ml_37|;_39|range_41 (r_compound) overdose_13\NN\84738|to_15|than_60 (r_pobj) due_10\IN\5174653|with_25 (r_prep) patients_5\NNS\9898892|NONE_0 (r_pobj) in_4\IN\13603305|significantly_22 (r_prep) greater_3\JJR\0|levels_26|ml_179|._221 (r_acomp) were_1\VBD\0|NONE_0 (l_npadvmod) ml_51\NN\13616054|levels_205|greater_179|._42 (l_punct) ,_47\,\0|u_7|/_8|;_11|range_13|p_42|)_50 (l_punct) to_42\IN\0|a_2 (l_pobj) hepatitis_44\NN\14127211|NONE_0
11229942
C066444_D002303 CID ce_1\NNP\14625458|NONE_0 (r_compound) levels_2\NNS\4916342|were_7|with_23|decrease_68|._254 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_conj) decrease_25\NN\7296428|levels_68|were_61|with_45|._186 (l_prep) in_26\IN\13603305|ci_26|(_18|0.05_23|)_27|,_28|%_34|)_91|(_93|p_94|)_164|(_166|0.025_171|)_176 (l_pobj) output_28\NN\4007894|NONE_0
C066444_D000437 NONE cocaethylene_5\NN\0|,_6|and_4 (l_prep) in_7\IN\13603305|cardiotoxity_13 (l_pobj) model_10\NN\5888929|NONE_0 (l_prep) of_11\IN\0|an_16|animal_13 (l_pobj) cocaine_12\NN\3492717|NONE_0 (l_conj) abuse_15\NN\418025|and_12
D003042_D019970 NONE cocaine_0\NN\3492717|NONE_0 (l_appos) ethanol_2\NN\14708720|,_2|._86 (l_conj) cocaethylene_5\NN\0|,_6|and_4 (l_prep) in_7\IN\13603305|cardiotoxity_13 (l_pobj) model_10\NN\5888929|NONE_0 (l_prep) of_11\IN\0|an_16|animal_13 (l_pobj) cocaine_12\NN\3492717|NONE_0 (l_conj) abuse_15\NN\418025|and_12
C066444_D066126 NONE cocaethylene_5\NN\0|,_6|and_4 (l_dobj) cardiotoxity_6\NN\0|in_13
C066444_D066126 NONE cocaethylene_22\NN\0|to_3 (r_pobj) due_20\JJ\5174653|be_70|;_28|however_26|,_19|they_17|may_12|also_8|._85 (r_acomp) be_19\VB\14625458|NONE_0 (l_ccomp) be_5\VB\14625458|;_42|however_44|,_51|they_53|may_58|also_62|due_70|._155 (l_nsubj) toxicity_3\NN\13576101|may_9|due_16
C066444_D066126 NONE ce_24\NNP\14625458|,_3|metabolite_15 (r_appos) cocaethylene_22\NN\0|to_3 (r_pobj) due_20\JJ\5174653|be_70|;_28|however_26|,_19|they_17|may_12|also_8|._85 (r_acomp) be_19\VB\14625458|NONE_0 (l_ccomp) be_5\VB\14625458|;_42|however_44|,_51|they_53|may_58|also_62|due_70|._155 (l_nsubj) toxicity_3\NN\13576101|may_9|due_16
C066444_D066126 NONE ce_11\NNP\14625458|NONE_0 (r_pobj) of_10\IN\0|the_9|in_6 (r_prep) role_9\NN\719494|to_17 (l_prep) in_12\IN\13603305|the_15|of_6 (l_pobj) cardiotoxicity_15\NN\0|NONE_0
C066444_D019970 NONE cocaethylene_5\NN\0|,_6|and_4 (l_prep) in_7\IN\13603305|cardiotoxity_13 (l_pobj) model_10\NN\5888929|NONE_0 (l_prep) of_11\IN\0|an_16|animal_13 (l_pobj) cocaine_12\NN\3492717|NONE_0 (l_conj) abuse_15\NN\418025|and_12
D003042_D000437 NONE cocaine_0\NN\3492717|NONE_0 (l_appos) ethanol_2\NN\14708720|,_2|._86 (l_conj) cocaethylene_5\NN\0|,_6|and_4 (l_prep) in_7\IN\13603305|cardiotoxity_13 (l_pobj) model_10\NN\5888929|NONE_0 (l_prep) of_11\IN\0|an_16|animal_13 (l_pobj) cocaine_12\NN\3492717|NONE_0 (l_conj) abuse_15\NN\418025|and_12
D000431_D000437 NONE ethanol_2\NN\14708720|,_2|._86 (l_conj) cocaethylene_5\NN\0|,_6|and_4 (l_prep) in_7\IN\13603305|cardiotoxity_13 (l_pobj) model_10\NN\5888929|NONE_0 (l_prep) of_11\IN\0|an_16|animal_13 (l_pobj) cocaine_12\NN\3492717|NONE_0 (l_conj) abuse_15\NN\418025|and_12
C066444_D009202 NONE cocaethylene_2\NN\0|peak_11|serum_6 (r_compound) concentrations_3\NNS\4916342|were_15|with_31|._67 (r_nsubjpass) associated_5\VBN\628491|NONE_0 (l_prep) with_6\IN\0|concentrations_31|were_16|._36 (l_pobj) depression_9\NN\14373582|NONE_0
D000431_D019970 NONE ethanol_2\NN\14708720|,_2|._86 (l_conj) cocaethylene_5\NN\0|,_6|and_4 (l_prep) in_7\IN\13603305|cardiotoxity_13 (l_pobj) model_10\NN\5888929|NONE_0 (l_prep) of_11\IN\0|an_16|animal_13 (l_pobj) cocaine_12\NN\3492717|NONE_0 (l_conj) abuse_15\NN\418025|and_12
D003042_D066126 NONE cocaine_0\NN\3492717|NONE_0 (l_appos) ethanol_2\NN\14708720|,_2|._86 (l_conj) cocaethylene_5\NN\0|,_6|and_4 (l_dobj) cardiotoxity_6\NN\0|in_13
D003042_D066126 NONE cocaine_28\NN\3492717|a_2|formed_19 (r_compound) metabolite_29\NN\20090|ce_15|,_12 (r_appos) cocaethylene_22\NN\0|to_3 (r_pobj) due_20\JJ\5174653|be_70|;_28|however_26|,_19|they_17|may_12|also_8|._85 (r_acomp) be_19\VB\14625458|NONE_0 (l_ccomp) be_5\VB\14625458|;_42|however_44|,_51|they_53|may_58|also_62|due_70|._155 (l_nsubj) toxicity_3\NN\13576101|may_9|due_16
D003042_D066126 NONE cocaine_17\NN\3492717|NONE_0 (r_pobj) of_16\IN\0|the_28|combined_24|in_23 (r_prep) cardiotoxicity_15\NN\0|NONE_0
D000431_D066126 NONE ethanol_2\NN\14708720|,_2|._86 (l_conj) cocaethylene_5\NN\0|,_6|and_4 (l_dobj) cardiotoxity_6\NN\0|in_13
D000431_D066126 NONE ethanol_36\NN\14708720|NONE_0 (r_pobj) of_35\IN\0|the_13 (r_prep) presence_34\NN\13954253|only_12 (r_pobj) in_32\IN\13603305|NONE_0 (r_prep) formed_30\VBN\1617192|a_21|cocaine_19 (r_acl) metabolite_29\NN\20090|ce_15|,_12 (r_appos) cocaethylene_22\NN\0|to_3 (r_pobj) due_20\JJ\5174653|be_70|;_28|however_26|,_19|they_17|may_12|also_8|._85 (r_acomp) be_19\VB\14625458|NONE_0 (l_ccomp) be_5\VB\14625458|;_42|however_44|,_51|they_53|may_58|also_62|due_70|._155 (l_nsubj) toxicity_3\NN\13576101|may_9|due_16
D000431_D066126 NONE ethanol_19\NN\14708720|and_4 (r_conj) cocaine_17\NN\3492717|NONE_0 (r_pobj) of_16\IN\0|the_28|combined_24|in_23 (r_prep) cardiotoxicity_15\NN\0|NONE_0
12487093
C009591_D006973 NONE triphenyltetrazolium_15\NN\0|NONE_0 (r_dobj) using_14\VBG\418025|which_20|was_14 (r_advcl) evaluated_13\VBN\670261|the_19|,_12 (r_relcl) bbb_9\NN\0|to_15 (r_dobj) destroy_7\VB\1619231|hypertension_25|was_12 (r_xcomp) used_5\VBN\0|NONE_0 (l_nsubjpass) hypertension_3\NN\14057371|was_13|destroy_25
C009591_D006973 NONE ttc_17\NNP\0|)_3|staining_5 (r_appos) triphenyltetrazolium_15\NN\0|NONE_0 (r_dobj) using_14\VBG\418025|which_20|was_14 (r_advcl) evaluated_13\VBN\670261|the_19|,_12 (r_relcl) bbb_9\NN\0|to_15 (r_dobj) destroy_7\VB\1619231|hypertension_25|was_12 (r_xcomp) used_5\VBN\0|NONE_0 (l_nsubjpass) hypertension_3\NN\14057371|was_13|destroy_25
D004837_D006973 CID adrenaline_0\NN\14807929|-_10 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hypertension_3\NN\14057371|was_13|destroy_25
D004837_D006973 CID adrenaline_27\NN\14807929|for_11 (r_dobj) giving_26\VBG\1085793|just_11 (r_pcomp) after_25\IN\0|of_25 (r_prep) staining_19\NN\275424|ttc_5|)_2 (r_appos) triphenyltetrazolium_15\NN\0|NONE_0 (r_dobj) using_14\VBG\418025|which_20|was_14 (r_advcl) evaluated_13\VBN\670261|the_19|,_12 (r_relcl) bbb_9\NN\0|to_15 (r_dobj) destroy_7\VB\1619231|hypertension_25|was_12 (r_xcomp) used_5\VBN\0|NONE_0 (l_nsubjpass) hypertension_3\NN\14057371|was_13|destroy_25
256433
D002228_D007239 NONE carbenicillin_5\NN\0|NONE_0 (l_prep) for_6\IN\0|NONE_0 (l_pobj) infections_7\NNS\14052046|NONE_0
D014031_D007239 NONE tobramycin_2\NN\2716866|NONE_0 (l_acl) combined_3\VBN\2630189|continuous_31|infusion_20|._61 (l_prep) with_4\IN\0|NONE_0 (l_pobj) carbenicillin_5\NN\0|NONE_0 (l_prep) for_6\IN\0|NONE_0 (l_pobj) infections_7\NNS\14052046|NONE_0
D002228_D009503 NONE carbenicillin_18\NN\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) combined_15\VBN\2630189|overcome_93|,_50|tobramycin_48|was_37|by_27|and_4|._40 (r_conj) given_10\VBN\5892096|NONE_0 (l_advcl) overcome_1\VB\0|,_43|tobramycin_45|was_56|by_66|and_89|combined_93|._133 (l_dobj) effects_4\NNS\13245626|to_24 (l_prep) of_5\IN\0|the_20|adverse_16 (l_pobj) neutropenia_6\NN\14196405|NONE_0
D003404_D053099 NONE creatinine_4\NN\0|major_22|(_7|)_62 (r_appos) azotemia_1\NN\14204950|in_89|._99
D014031_D053099 CID tobramycin_10\JJ\2716866|therapy_17 (r_amod) concentration_11\NN\4916342|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) duration_5\NN\15113229|NONE_0 (r_pobj) to_4\IN\0|azotemia_25|was_16|not_12|._56 (r_prep) related_3\VBN\628491|NONE_0 (l_nsubjpass) azotemia_0\NNP\14204950|was_9|not_13|to_25|._81
D002228_D009369 NONE carbenicillin_5\NN\0|NONE_0 (l_prep) for_6\IN\0|NONE_0 (l_pobj) infections_7\NNS\14052046|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_compound) cancer_9\NN\14239425|NONE_0
D014031_D009503 NONE tobramycin_8\JJ\2716866|overcome_45|,_2|was_11|by_21|and_44|combined_48|._88 (r_nsubjpass) given_10\VBN\5892096|NONE_0 (l_advcl) overcome_1\VB\0|,_43|tobramycin_45|was_56|by_66|and_89|combined_93|._133 (l_dobj) effects_4\NNS\13245626|to_24 (l_prep) of_5\IN\0|the_20|adverse_16 (l_pobj) neutropenia_6\NN\14196405|NONE_0
D014031_D009369 NONE tobramycin_2\NN\2716866|NONE_0 (l_acl) combined_3\VBN\2630189|continuous_31|infusion_20|._61 (l_prep) with_4\IN\0|NONE_0 (l_pobj) carbenicillin_5\NN\0|NONE_0 (l_prep) for_6\IN\0|NONE_0 (l_pobj) infections_7\NNS\14052046|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_compound) cancer_9\NN\14239425|NONE_0
612112
D005045_D009207 CID etomidate_5\NN\0|that_5|will_10|be_24 (r_nsubj) prove_7\VB\2604760|it_46|is_43|unlikely_29|._165 (l_xcomp) be_9\VB\14625458|that_29|etomidate_24|will_14 (l_prep) because_22\IN\0|to_86|hypnotic_76 (l_pobj) incidence_26\NN\13821570|of_12 (l_prep) of_27\IN\0|the_19|high_15|after_13 (l_pobj) myoclonia_28\NN\0|NONE_0
12752472
D010862_D006985 NONE pilocarpine_11\NN\14712692|-_11|and_20|control_24 (r_npadvmod) treated_13\VBN\2376958|NONE_0 (r_amod) rats_16\NNS\2329401|NONE_0 (r_pobj) in_10\IN\13603305|spontaneous_24 (r_prep) ventilation_9\NN\248977|NONE_0 (r_pobj) in_7\IN\13603305|a_11 (r_prep) decrease_6\NN\7296428|:_41|maneuver_18|._75 (r_dobj) caused_4\VBD\1617192|NONE_0 (l_nsubj) maneuver_3\NN\955060|:_23|decrease_18|._93 (l_compound) hyperventilation_2\NN\831191|the_4
D010862_D004827 CID pilocarpine_15\NN\14712692|-_11 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) epilepsy_18\NN\14085708|NONE_0
15096374
D016559_D003872 NONE tacrolimus_11\NN\0|NONE_0 (r_compound) ointment_12\NN\4074482|NONE_0 (r_pobj) with_10\IN\0|facial_31|inflammatory_24 (r_prep) dermatoses_9\NNS\14219661|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) during_4\IN\0|of_26|._75 (r_prep) induction_0\NN\7450842|NONE_0 (l_prep) of_1\IN\0|during_26|._101 (l_pobj) dermatitis_3\NN\14226056|NONE_0
D016559_D003872 NONE tacrolimus_11\NN\0|NONE_0 (r_compound) ointment_12\NN\4074482|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treatment_9\NN\654885|NONE_0 (r_pobj) of_8\IN\0|a_15 (r_prep) complication_7\NN\1073995|NONE_0 (r_pobj) as_5\IN\14622893|we_36|on_26|._55 (r_prep) report_1\VBP\6470073|NONE_0 (l_prep) on_2\IN\0|we_10|as_26|._81 (l_pobj) dermatitis_4\NN\14226056|NONE_0
D016559_D003872 NONE tacrolimus_15\NN\0|NONE_0 (r_compound) ointment_16\NN\4074482|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treatment_13\NN\654885|NONE_0 (r_pobj) of_12\IN\0|a_15 (r_prep) complication_11\NN\1073995|NONE_0 (r_pobj) as_9\IN\14622893|the_39|of_26 (r_prep) spectrum_5\NN\7939382|that_9|heterogeneous_94 (l_prep) of_6\IN\0|the_13|as_26 (l_pobj) dermatitis_8\NN\14226056|NONE_0
D016559_D005148 NONE tacrolimus_11\NN\0|NONE_0 (r_compound) ointment_12\NN\4074482|NONE_0 (r_pobj) with_10\IN\0|facial_31|inflammatory_24 (r_prep) dermatoses_9\NNS\14219661|NONE_0
D016559_D005148 NONE tacrolimus_10\NN\0|NONE_0 (r_compound) ointment_11\NN\4074482|NONE_0 (r_pobj) with_9\IN\0|patients_58|were_13|because_25|._78 (r_prep) treated_8\VBN\2376958|NONE_0 (l_nsubjpass) patients_2\NNS\9898892|were_45|with_58|because_83|._136 (l_prep) with_3\IN\0|six_19|adult_15 (l_pobj) dermatoses_6\NNS\14219661|NONE_0
D016559_D019557 NONE tacrolimus_0\NNP\0|NONE_0 (r_compound) ointment_1\NN\4074482|is_9|increasingly_12|for_30|,_97|and_99|indicate_123 (r_nsubjpass) used_4\VBN\0|NONE_0 (l_conj) indicate_21\VBP\952524|ointment_123|is_114|increasingly_111|for_93|,_26|and_24 (l_ccomp) is_25\VBZ\0|observations_41|._66 (l_acomp) effective_26\JJ\0|that_22|treatment_13 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) rosacea_31\NN\14222112|NONE_0 (l_conj) dermatitis_34\NN\14226056|aggravated_32|and_13
D013256_D012393 NONE steroid_28\NN\14727670|-_7 (r_npadvmod) aggravated_30\VBN\126264|and_19|dermatitis_32 (r_amod) rosacea_31\NN\14222112|NONE_0
D013256_D019557 NONE steroid_28\NN\14727670|-_7 (r_npadvmod) aggravated_30\VBN\126264|and_19|dermatitis_32 (r_amod) rosacea_31\NN\14222112|NONE_0 (l_conj) dermatitis_34\NN\14226056|aggravated_32|and_13
D016559_D012393 CID tacrolimus_0\NNP\0|NONE_0 (r_compound) ointment_1\NN\4074482|is_9|increasingly_12|for_30|,_97|and_99|indicate_123 (r_nsubjpass) used_4\VBN\0|NONE_0 (l_conj) indicate_21\VBP\952524|ointment_123|is_114|increasingly_111|for_93|,_26|and_24 (l_ccomp) is_25\VBZ\0|observations_41|._66 (l_acomp) effective_26\JJ\0|that_22|treatment_13 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) rosacea_31\NN\14222112|NONE_0
20495512
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|:_24|review_38|._44 (r_amod) thrombocytopenia_3\NN\14189204|NONE_0
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|hit_26 (r_amod) thrombocytopenia_3\NN\14189204|recognized_37|._92
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|hit_26 (r_amod) thrombocytopenia_3\NN\14189204|recognized_37|._92 (l_appos) hit_5\NN\36762|induced_26
D006493_D013921 CID heparin_16\JJ\2718259|NONE_0 (r_compound) exposure_17\NN\5042871|NONE_0 (r_pobj) after_15\IN\0|whenever_27|thrombosis_18 (r_prep) occurs_14\VBZ\0|NONE_0 (r_ccomp) suspected_11\VBN\916909|hit_73|must_69|be_64|for_48|and_4|._59 (r_conj) acknowledged_3\VBN\822367|NONE_0 (l_nsubjpass) hit_0\NNP\36762|must_4|be_9|for_25|and_69|suspected_73|._132
D006493_D013921 CID heparin_10\JJ\2718259|all_4|and_17|institution_25 (r_compound) exposure_11\NN\5042871|NONE_0 (r_pobj) of_8\IN\0|an_23|immediate_20 (r_prep) cessation_7\NN\7365849|treatment_39|,_82|using_98|._131 (r_dobj) mandates_4\NNS\6479665|NONE_0 (l_nsubj) treatment_1\NN\654885|cessation_39|,_121|using_137|._170 (l_prep) of_2\IN\0|the_14 (l_pobj) hit_3\NNP\36762|NONE_0
D006493_D013921 CID heparin_11\NN\2718259|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) history_16\NN\15120823|NONE_0 (l_prep) of_17\IN\0|a_10|,_6|need_12 (l_pobj) hit_18\NN\36762|NONE_0
D006493_D013921 CID heparin_1\NN\2718259|as_3|one_16|today_60|with_66 (r_nsubj) remains_2\VBZ\2684|,_108|vigilance_118|must_147|be_152|initiated_185|._194 (l_prep) with_11\IN\0|as_69|heparin_66|one_50|today_6 (l_pobj) potential_12\NN\14481929|NONE_0 (l_prep) for_13\IN\0|with_8 (l_pobj) hit_14\NN\36762|NONE_0
D006493_D013921 CID heparin_17\JJ\2718259|every_6 (r_compound) exposure_18\NN\5042871|NONE_0 (r_pobj) with_15\IN\0|for_8 (r_prep) potential_12\NN\14481929|NONE_0 (l_prep) for_13\IN\0|with_8 (l_pobj) hit_14\NN\36762|NONE_0
D006493_D013921 CID heparin_30\JJ\2718259|whenever_9|is_8 (r_nsubjpass) initiated_32\VBN\1617192|remains_185|,_77|vigilance_67|must_38|be_33|._9 (r_advcl) practiced_28\VBN\0|NONE_0 (l_advcl) remains_2\VBZ\2684|,_108|vigilance_118|must_147|be_152|initiated_185|._194 (l_prep) with_11\IN\0|as_69|heparin_66|one_50|today_6 (l_pobj) potential_12\NN\14481929|NONE_0 (l_prep) for_13\IN\0|with_8 (l_pobj) hit_14\NN\36762|NONE_0
D006493_D013927 CID heparin_16\JJ\2718259|NONE_0 (r_compound) exposure_17\NN\5042871|NONE_0 (r_pobj) after_15\IN\0|whenever_27|thrombosis_18 (r_prep) occurs_14\VBZ\0|NONE_0 (r_ccomp) suspected_11\VBN\916909|hit_73|must_69|be_64|for_48|and_4|._59 (r_conj) acknowledged_3\VBN\822367|NONE_0 (l_prep) for_4\IN\0|hit_25|must_21|be_16|and_44|suspected_48|._107 (l_pobj) predilection_7\NN\6200178|NONE_0 (l_prep) for_8\IN\0|its_25|intense_21 (l_pobj) thrombosis_9\NN\14100769|NONE_0
D006493_D013927 CID heparin_16\JJ\2718259|NONE_0 (r_compound) exposure_17\NN\5042871|NONE_0 (r_pobj) after_15\IN\0|whenever_27|thrombosis_18 (r_prep) occurs_14\VBZ\0|NONE_0 (l_nsubj) thrombosis_13\NN\14100769|whenever_9|after_18
D000991_D013921 NONE inhibitor_26\NN\20090|commonly_33 (r_dobj) using_22\VBG\418025|treatment_137|cessation_98|,_16|._33 (r_advcl) mandates_4\NNS\6479665|NONE_0 (l_nsubj) treatment_1\NN\654885|cessation_39|,_121|using_137|._170 (l_prep) of_2\IN\0|the_14 (l_pobj) hit_3\NNP\36762|NONE_0
D000991_D013921 NONE inhibitors_2\NNS\20090|alternatives_43|._156 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) alternatives_9\NNS\5788149|inhibitors_43|._113 (l_prep) to_10\IN\0|appropriate_41|,_30|based_19 (l_pobj) heparin_11\NN\2718259|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) history_16\NN\15120823|NONE_0 (l_prep) of_17\IN\0|a_10|,_6|need_12 (l_pobj) hit_18\NN\36762|NONE_0
8825380
D011692_D006130 NONE pan_15\NNP\3101986|chronic_8 (r_compound) nephropathy_16\NN\14573196|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) rats_12\NNS\2329401|NONE_0 (r_pobj) in_11\IN\13603305|growth_15 (r_prep) failure_10\NN\66216|NONE_0
D011692_D007674 CID aminonucleoside_15\JJ\0|in_28 (r_amod) nephropathy_16\NN\14573196|on_37
D011692_D007674 CID aminonucleoside_15\NN\0|(_16|pan_17|,_33|model_51 (r_nmod) nephropathy_19\NN\14573196|puromycin_32
D011692_D007674 CID aminonucleoside_15\NN\0|(_16|pan_17|,_33|model_51 (r_nmod) nephropathy_19\NN\14573196|puromycin_32 (l_appos) model_23\NN\5888929|aminonucleoside_51|(_35|pan_34|,_18 (l_prep) of_24\IN\0|an_22|experimental_19 (l_pobj) disease_26\NN\14061805|NONE_0
D011692_D007674 CID pan_17\NNP\3101986|aminonucleoside_17|(_1|,_16|model_34 (r_nmod) nephropathy_19\NN\14573196|puromycin_32
D011692_D007674 CID pan_17\NNP\3101986|aminonucleoside_17|(_1|,_16|model_34 (r_nmod) nephropathy_19\NN\14573196|puromycin_32 (l_appos) model_23\NN\5888929|aminonucleoside_51|(_35|pan_34|,_18 (l_prep) of_24\IN\0|an_22|experimental_19 (l_pobj) disease_26\NN\14061805|NONE_0
D011692_D007674 CID pan_15\NNP\3101986|chronic_8 (r_compound) nephropathy_16\NN\14573196|NONE_0
D011692_D007674 CID pan_9\NNP\3101986|NONE_0 (r_pobj) of_8\IN\0|seven_24|serial_18 (r_prep) injections_7\NNS\320852|NONE_0 (r_pobj) by_4\IN\0|glomerulopathy_27|was_12|over_34|._44 (r_agent) induced_3\VBN\1627355|NONE_0 (l_nsubjpass) glomerulopathy_1\NN\0|was_15|by_27|over_61|._71
D011692_D007674 CID pan_6\NNP\3101986|chronic_8 (r_compound) nephropathy_7\NN\14573196|NONE_0
D011692_D007674 CID pan_33\NNP\3101986|NONE_0 (r_compound) nephropathy_34\NN\14573196|untreated_14
D011692_D007674 CID pan_3\NNP\3101986|,_15|administration_17 (r_compound) nephropathy_4\NN\14573196|NONE_0
D011692_D007674 CID pan_19\NNP\3101986|chronic_8 (r_compound) nephropathy_20\NN\14573196|NONE_0
D008315_-1 NONE malondialdehyde_22\NN\0|renal_15 (r_compound) content_23\NN\7951464|tubulointerstitial_61|,_36|or_34 (r_conj) injury_17\NN\14052046|increased_59|segmental_49|,_21
D008315_D007674 NONE malondialdehyde_22\NN\0|renal_15 (r_compound) content_23\NN\7951464|tubulointerstitial_61|,_36|or_34 (r_conj) injury_17\NN\14052046|increased_59|segmental_49|,_21 (r_conj) glomerulosclerosis_14\NN\0|enhanced_55|glomerular_46|or_23 (r_conj) hypertrophy_10\NN\14365950|NONE_0
D008315_D007674 NONE malondialdehyde_35\NN\0|renal_15|,_23|or_25|damage_61 (r_compound) content_36\NN\7951464|glomerular_55|planar_44|,_33 (l_conj) damage_42\NN\7296428|renal_76|malondialdehyde_61|,_38|or_36
D008315_D005921 NONE malondialdehyde_22\NN\0|renal_15 (r_compound) content_23\NN\7951464|tubulointerstitial_61|,_36|or_34 (r_conj) injury_17\NN\14052046|increased_59|segmental_49|,_21 (r_conj) glomerulosclerosis_14\NN\0|enhanced_55|glomerular_46|or_23
D008315_D011507 NONE malondialdehyde_35\NN\0|renal_15|,_23|or_25|damage_61 (r_compound) content_36\NN\7951464|glomerular_55|planar_44|,_33 (r_conj) area_31\NN\8630985|,_20 (r_conj) gfr_27\NNP\0|,_2 (r_conj) proteinuria_25\NN\14299637|blood_16|,_2
20192893
D003287_D064420 NONE cm_13\NNP\13649268|NONE_0 (r_compound) toxicity_14\NN\13576101|NONE_0
D003287_D007674 CID medium_1\NN\3575240|contrast_9|after_22|._65 (r_amod) nephrotoxicity_2\NN\0|NONE_0
D003287_D007674 CID medium_6\NN\3575240|iodinated_19|contrast_9|(_7 (r_amod) cm_8\NNP\13649268|)_2 (r_nmod) administration_10\NN\1133281|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|renal_18 (r_acl) dysfunction_1\NN\14204950|can_69|benefit_86|)_172|._173
D003287_D007674 CID cm_8\NNP\13649268|)_2 (r_nmod) administration_10\NN\1133281|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|renal_18 (r_acl) dysfunction_1\NN\14204950|can_69|benefit_86|)_172|._173
D003287_D007674 CID cm_8\NNP\13649268|NONE_0 (r_pobj) of_7\IN\0|nephrotoxic_19|in_6 (r_prep) effect_6\NN\34213|NONE_0 (l_amod) nephrotoxic_5\JJ\0|of_19|in_25
D003287_D007674 CID cm_17\NNP\13649268|than_18 (r_compound) administration_18\NN\1133281|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|renal_13 (r_acl) damage_14\NN\7296428|NONE_0
7739955
D002220_D004802 CID carbamazepine_10\NN\0|-_13 (r_npadvmod) induced_12\VBN\1627355|a_16|acute_8|eosinophilic_14 (r_amod) myocarditis_15\NN\14338942|had_80|,_53|one_51|,_11|and_13|had_21
D002220_D009205 CID carbamazepine_10\NN\0|-_13 (r_npadvmod) induced_12\VBN\1627355|a_16|acute_8|eosinophilic_14 (r_amod) myocarditis_15\NN\14338942|had_80|,_53|one_51|,_11|and_13|had_21 (r_dobj) had_8\VBD\0|NONE_0 (l_ccomp) had_2\VBD\0|,_27|one_29|myocarditis_80|,_91|and_93|had_101 (l_dobj) myocarditis_5\NN\14338942|patients_25
D002220_D009205 CID carbamazepine_10\NN\0|-_13 (r_npadvmod) induced_12\VBN\1627355|a_16|acute_8|eosinophilic_14 (r_amod) myocarditis_15\NN\14338942|had_80|,_53|one_51|,_11|and_13|had_21
D002220_D012770 NONE carbamazepine_10\NN\0|-_13 (r_npadvmod) induced_12\VBN\1627355|a_16|acute_8|eosinophilic_14 (r_amod) myocarditis_15\NN\14338942|had_80|,_53|one_51|,_11|and_13|had_21 (r_dobj) had_8\VBD\0|NONE_0 (l_conj) had_19\VBD\0|had_101|,_74|one_72|myocarditis_21|,_10|and_8 (l_dobj) hemosiderosis_21\NN\14299637|one_16|._50 (l_acl) resulting_22\VBG\2633881|cardiac_22 (l_prep) in_23\IN\13603305|NONE_0 (l_pobj) shock_26\NN\7510495|NONE_0
24653743
C042288_D016757 CID pilsicainide_8\NNP\0|-_12 (r_npadvmod) induced_10\VBN\1627355|torsades_8|de_17 (r_amod) pointes_13\NNP\831651|to_36 (r_pobj) due_6\IN\5174653|a_31|of_24|._47 (r_amod) case_1\NN\7283608|NONE_0 (l_prep) of_2\IN\0|a_7|due_24|._71 (l_pobj) death_5\NNP\7296428|NONE_0
C042288_D016757 CID pilsicainide_7\NN\0|male_19|convert_76 (r_dobj) received_5\VBD\2210855|;_150|patient_156|death_189|later_204|._209 (r_ccomp) developed_32\VBD\1753788|NONE_0 (l_dobj) death_35\NN\7296428|received_189|;_39|patient_33|later_15|._20
C042288_D016171 CID pilsicainide_8\NNP\0|-_12 (r_npadvmod) induced_10\VBN\1627355|torsades_8|de_17 (r_amod) pointes_13\NNP\831651|to_36
C042288_D016171 CID pilsicainide_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|the_9 (r_prep) dose_12\NN\3740161|low_25 (r_nsubj) was_15\VBD\0|although_91|function_62|not_49|impaired_38|and_29 (r_conj) was_6\VBD\0|,_60|concentration_73|may_103|have_107|high_117|,_121|produce_133|._180 (r_advcl) been_25\VBN\0|NONE_0 (l_advcl) produce_30\VB\7555863|was_133|,_73|concentration_60|may_30|have_26|high_16|,_12|._47 (l_dobj) pointes_33\FW\831651|which_30|can_24
C042288_D016171 CID pilsicainide_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|the_25|plasma_21 (r_prep) concentration_20\NN\4916342|was_73|,_13|may_30|have_34|high_44|,_48|produce_60|._107 (r_nsubj) been_25\VBN\0|NONE_0 (l_advcl) produce_30\VB\7555863|was_133|,_73|concentration_60|may_30|have_26|high_16|,_12|._47 (l_dobj) pointes_33\FW\831651|which_30|can_24
C042288_D001281 NONE pilsicainide_7\NN\0|male_19|convert_76 (r_dobj) received_5\VBD\2210855|;_150|patient_156|death_189|later_204|._209 (l_advcl) convert_20\VB\7846|male_95|pilsicainide_76 (l_dobj) fibrillation_24\NN\14361664|to_33|to_13
C042288_D001281 NONE pilsicainide_10\NN\0|NONE_0 (r_pobj) including_9\VBG\0|the_43|oral_39|of_19|,_2 (r_prep) administration_3\NN\1133281|although_18|,_56|effective_61 (r_nsubj) is_12\VBZ\0|,_45|consideration_55|must_69|be_74|before_83|._125 (l_acomp) effective_13\JJ\0|although_79|administration_61|,_5 (l_xcomp) terminate_15\VB\126264|NONE_0 (l_dobj) fibrillation_17\NN\14361664|to_20
D012964_D001281 NONE sodium_11\NN\14625458|pure_5 (r_compound) channel_12\NN\6251781|a_14|with_16 (r_compound) blocker_13\NN\10101634|oral_41|,_24|,_35 (r_appos) pilsicainide_7\NN\0|male_19|convert_76 (r_dobj) received_5\VBD\2210855|;_150|patient_156|death_189|later_204|._209 (l_advcl) convert_20\VB\7846|male_95|pilsicainide_76 (l_dobj) fibrillation_24\NN\14361664|to_33|to_13
D012964_D016757 NONE sodium_11\NN\14625458|pure_5 (r_compound) channel_12\NN\6251781|a_14|with_16 (r_compound) blocker_13\NN\10101634|oral_41|,_24|,_35 (r_appos) pilsicainide_7\NN\0|male_19|convert_76 (r_dobj) received_5\VBD\2210855|;_150|patient_156|death_189|later_204|._209 (r_ccomp) developed_32\VBD\1753788|NONE_0 (l_dobj) death_35\NN\7296428|received_189|;_39|patient_33|later_15|._20
9071336
D017239_D064420 NONE paclitaxel_0\NNP\0|5-fluorouracil_15|cytotoxicity_44|._76 (r_nsubj) have_3\VBP\7846|NONE_0 (l_dobj) cytotoxicity_5\NN\13583478|paclitaxel_44|5-fluorouracil_29|._32
D005472_D064420 NONE 5-fluorouracil_2\CD\0|paclitaxel_15|cytotoxicity_29|._61 (r_punct) have_3\VBP\7846|NONE_0 (l_dobj) cytotoxicity_5\NN\13583478|paclitaxel_44|5-fluorouracil_29|._32
D017239_D001943 NONE paclitaxel_0\NNP\0|trial_93|._98 (l_conj) acid_6\NN\14818238|,_30|,_14|and_12 (l_prep) in_7\IN\13603305|folinic_13|:_27 (l_pobj) cancer_10\NN\14239425|NONE_0
D017239_D001943 NONE paclitaxel_3\NN\0|folinic_17|and_4 (r_conj) acid_1\NN\14818238|taxol_21|therapies_95|._142 (r_nsubj) are_17\VBP\13600404|NONE_0 (l_attr) therapies_20\NNS\657604|acid_95|taxol_74|._47 (l_prep) for_21\IN\0|effective_28|salvage_18 (l_pobj) patients_25\NNS\9898892|NONE_0 (l_compound) cancer_24\NN\14239425|metastatic_18
D017239_D001943 NONE taxol_5\NNP\0|acid_21|therapies_74|._121 (r_nsubj) are_17\VBP\13600404|NONE_0 (l_attr) therapies_20\NNS\657604|acid_95|taxol_74|._47 (l_prep) for_21\IN\0|effective_28|salvage_18 (l_pobj) patients_25\NNS\9898892|NONE_0 (l_compound) cancer_24\NN\14239425|metastatic_18
D017239_D001943 NONE paclitaxel_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|ii_9 (r_prep) trial_5\NN\786195|we_24|phase_9|m2_27|._201 (r_dobj) performed_1\VBD\0|NONE_0 (l_dobj) phase_3\NN\15113229|we_15|trial_9|m2_36|._210 (l_relcl) followed_18\VBD\1835496|a_63 (l_agent) by_19\IN\0|i_11 (l_pobj) acid_21\NN\14818238|NONE_0 (l_prep) in_44\IN\13603305|folinic_99|before_67|on_35|days_11 (l_pobj) women_45\NNS\9605289|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) cancer_49\NN\14239425|NONE_0
D016179_D009503 NONE factor_54\NN\7326557|reported_265|;_76|cycles_63|due_7 (r_dobj) required_49\VBN\0|;_65|patient_70|transfusions_96|._108 (l_ccomp) reported_2\VBN\831651|;_189|cycles_202|factor_265|due_272 (l_ccomp) associated_32\VBN\628491|analysis_138|is_129|on_117 (l_prep) with_33\IN\0|cycles_28|were_16 (l_pobj) hospitalization_38\NN\15113229|NONE_0 (l_det) neutropenia_36\NN\14196405|3/4_4|requiring_12
D016179_D009503 NONE factor_54\NN\7326557|reported_265|;_76|cycles_63|due_7 (r_dobj) required_49\VBN\0|;_65|patient_70|transfusions_96|._108 (l_prep) due_55\JJ\5174653|reported_272|;_83|cycles_70|factor_7 (l_pobj) neutropenia_57\NN\14196405|to_3
D002955_D001943 NONE acid_6\NN\14818238|,_30|,_14|and_12 (l_prep) in_7\IN\13603305|folinic_13|:_27 (l_pobj) cancer_10\NN\14239425|NONE_0
D002955_D001943 NONE acid_1\NN\14818238|taxol_21|therapies_95|._142 (r_nsubj) are_17\VBP\13600404|NONE_0 (l_attr) therapies_20\NNS\657604|acid_95|taxol_74|._47 (l_prep) for_21\IN\0|effective_28|salvage_18 (l_pobj) patients_25\NNS\9898892|NONE_0 (l_compound) cancer_24\NN\14239425|metastatic_18
D002955_D001943 NONE acid_21\NN\14818238|NONE_0 (l_prep) in_44\IN\13603305|folinic_99|before_67|on_35|days_11 (l_pobj) women_45\NNS\9605289|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) cancer_49\NN\14239425|NONE_0
D005472_D001943 NONE 5-fluorouracil_2\CD\0|NONE_0 (r_punct) ,_3\,\0|,_16|and_2|acid_14 (r_punct) paclitaxel_0\NNP\0|trial_93|._98 (l_conj) acid_6\NN\14818238|,_30|,_14|and_12 (l_prep) in_7\IN\13603305|folinic_13|:_27 (l_pobj) cancer_10\NN\14239425|NONE_0
D005472_D001943 NONE 5-fluorouracil_28\CD\0|350_15|mg_19|/_21 (r_punct) m2_32\NN\13357178|hour_34 (r_pobj) before_27\IN\0|folinic_32|on_32|days_56|in_67 (r_prep) acid_21\NN\14818238|NONE_0 (l_prep) in_44\IN\13603305|folinic_99|before_67|on_35|days_11 (l_pobj) women_45\NNS\9605289|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) cancer_49\NN\14239425|NONE_0
19967075
D005839_D007674 CID gentamicin_17\NNP\2716866|-_10 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) nephropathy_20\NNP\14573196|NONE_0
D005839_D007674 CID gentamicin_17\NN\2716866|-_10 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) nephropathy_20\NN\14573196|NONE_0
D005839_D007674 CID gentamicin_0\NNP\2716866|-_10 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) nephropathy_3\NN\14573196|may_12|in_25|be_33|causally_36|with_53|._127
D011188_D007674 NONE k_5\NNP\13608598|na_3|/_1|-_1|,_8|nhe3_10|in_35 (r_compound) atpase_7\NNP\0|NONE_0 (l_prep) in_16\IN\13603305|na_38|/_36|k_35|-_34|,_27|nhe3_25 (l_pobj) nephropathy_20\NNP\14573196|NONE_0
D011188_D007674 NONE na(+)/k(+)-atpase_17\NNP\0|NONE_0 (r_pobj) of_16\IN\0|a_23|decreased_21 (r_prep) expression_15\NN\4679549|NONE_0 (r_pobj) with_12\IN\0|nephropathy_53|may_41|in_28|be_20|causally_17|._74 (r_prep) related_11\VBN\628491|NONE_0 (l_nsubjpass) nephropathy_3\NN\14573196|may_12|in_25|be_33|causally_36|with_53|._127
D012964_D007674 NONE na_3\NNP\14625458|/_2|k_3|-_4|,_11|nhe3_13|in_38 (r_nmod) atpase_7\NNP\0|NONE_0 (l_prep) in_16\IN\13603305|na_38|/_36|k_35|-_34|,_27|nhe3_25 (l_pobj) nephropathy_20\NNP\14573196|NONE_0
D012964_D007674 NONE na(+)/k(+)-atpase_17\NNP\0|NONE_0 (r_pobj) of_16\IN\0|a_23|decreased_21 (r_prep) expression_15\NN\4679549|NONE_0 (r_pobj) with_12\IN\0|nephropathy_53|may_41|in_28|be_20|causally_17|._74 (r_prep) related_11\VBN\628491|NONE_0 (l_nsubjpass) nephropathy_3\NN\14573196|may_12|in_25|be_33|causally_36|with_53|._127
17879100
D001241_D005334 NONE aspirin_4\JJ\2707683|NONE_0 (r_pobj) on_3\IN\0|he_11|was_8|following_11|and_29|took_33|._97 (r_prep) put_2\VBN\13241600|NONE_0 (l_conj) took_8\VBD\2367363|he_44|was_41|on_33|following_22|and_4|._64 (l_prep) for_10\IN\0|ibuprofen_10|for_10 (l_pobj) fever_11\NN\14299637|NONE_0
D007052_D005334 NONE ibuprofen_9\NN\3828465|for_10|for_20 (r_dobj) took_8\VBD\2367363|he_44|was_41|on_33|following_22|and_4|._64 (l_prep) for_10\IN\0|ibuprofen_10|for_10 (l_pobj) fever_11\NN\14299637|NONE_0
24999722
D005446_D007249 NONE acetonide_5\NN\0|(_18|mg_24|)_26 (r_compound) implant_6\NN\4013729|that_28 (r_dobj) fluocinolone_4\NN\0|data_18|helps_41|._142 (r_ccomp) suggest_2\VBP\1010118|NONE_0 (l_ccomp) helps_11\VBZ\407535|data_59|fluocinolone_41|._101 (l_xcomp) control_13\VB\5190804|NONE_0 (l_dobj) inflammation_14\NN\14299637|to_11
D005446_C537630 NONE acetonide_5\NN\0|safety_36|intravitreal_10|(_31|mg_37|)_39|in_41|._72 (r_compound) implant_7\NN\4013729|NONE_0 (l_prep) in_12\IN\13603305|safety_77|acetonide_41|intravitreal_31|(_10|mg_4|)_2|._31 (l_pobj) retinochoroidopathy_14\JJ\0|NONE_0
D005446_C537630 NONE acetonide_8\NN\0|intravitreal_10|(_31|mg_37|)_39|in_41 (r_amod) implant_10\NN\4013729|to_76|outcomes_52|._146 (l_prep) in_15\IN\13603305|acetonide_41|intravitreal_31|(_10|mg_4|)_2 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) retinochoroidopathy_19\JJ\0|NONE_0
D005446_C537630 NONE acetonide_5\NN\0|(_18|mg_24|)_26 (r_compound) implant_6\NN\4013729|that_28 (r_dobj) fluocinolone_4\NN\0|data_18|helps_41|._142 (r_ccomp) suggest_2\VBP\1010118|NONE_0 (l_ccomp) helps_11\VBZ\407535|data_59|fluocinolone_41|._101 (l_xcomp) control_13\VB\5190804|NONE_0 (l_dobj) inflammation_14\NN\14299637|to_11 (l_prep) in_15\IN\13603305|NONE_0 (l_pobj) cases_20\NNS\7283608|NONE_0 (l_prep) of_21\IN\0|otherwise_37|refractory_17 (l_pobj) retinochoroidopathy_23\JJ\0|NONE_0
9323412
D015742_D009325 NONE propofol_3\JJ\0|a_2|and_18|avoidance_22|of_32 (r_amod) infusion_4\NN\14589223|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) anaesthesia_0\NNP\14034177|course_113|without_120|._167 (r_nsubj) provided_10\VBD\2199590|NONE_0 (l_dobj) course_16\NN\883297|anaesthesia_113|without_7|._54 (l_amod) free_14\JJ\7942152|a_9|postoperative_5 (l_npadvmod) nausea_12\NN\14299637|-_6
D015742_D003866 NONE propofol_3\JJ\0|a_2|and_18|avoidance_22|of_32 (r_amod) infusion_4\NN\14589223|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) anaesthesia_0\NNP\14034177|course_113|without_120|._167 (r_nsubj) provided_10\VBD\2199590|NONE_0 (l_prep) without_17\IN\0|anaesthesia_120|course_7|._47 (l_pobj) exacerbation_18\NN\374224|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) disorder_22\NN\14034177|NONE_0
D017294_D003866 NONE ondansetron_7\NN\0|NONE_0 (r_pobj) following_3\VBG\8180190|acute_24|severe_18|._36 (r_prep) depression_2\NN\14373582|NONE_0
D012701_D003865 NONE serotonin_20\NN\14807737|a_2 (r_compound) antagonist_21\NN\7846|NONE_0 (r_pobj) of_18\IN\0|the_8 (r_prep) use_17\NN\407535|NONE_0 (r_pobj) to_15\IN\0|possibly_17 (r_prep) related_14\VBN\628491|she_99|had_95|disorder_49|thereafter_21|,_11|._44 (r_advcl) developed_2\VBN\1753788|NONE_0 (l_dobj) disorder_8\NN\14034177|she_50|had_46|thereafter_28|,_38|related_49|._93
D012701_D003866 NONE serotonin_8\NN\14807737|NONE_0 (r_compound) antagonists_9\NNS\7846|NONE_0 (r_pobj) of_7\IN\0|a_34|propofol_32|and_14|avoidance_10 (r_prep) infusion_4\NN\14589223|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) anaesthesia_0\NNP\14034177|course_113|without_120|._167 (r_nsubj) provided_10\VBD\2199590|NONE_0 (l_prep) without_17\IN\0|anaesthesia_120|course_7|._47 (l_pobj) exacerbation_18\NN\374224|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) disorder_22\NN\14034177|NONE_0
D017294_D020250 NONE ondansetron_25\NN\0|NONE_0 (r_compound) prophylaxis_26\NN\1077350|where_18|had_12|been_16 (r_nsubjpass) used_29\VBN\0|a_62|previous_60 (r_relcl) anaesthetic_23\NN\3247620|months_24 (r_pobj) after_20\IN\0|woman_111|for_36|._72 (r_prep) presented_14\VBN\2137132|NONE_0 (l_nsubj) woman_4\NN\9605289|for_75|after_111|._183 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) history_8\NN\15120823|NONE_0 (l_prep) of_9\IN\0|a_17|strong_15 (l_pobj) nausea_11\NN\14299637|NONE_0 (l_conj) vomiting_13\NN\116687|postoperative_25|and_4
D012701_D009325 NONE serotonin_8\NN\14807737|NONE_0 (r_compound) antagonists_9\NNS\7846|NONE_0 (r_pobj) of_7\IN\0|a_34|propofol_32|and_14|avoidance_10 (r_prep) infusion_4\NN\14589223|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) anaesthesia_0\NNP\14034177|course_113|without_120|._167 (r_nsubj) provided_10\VBD\2199590|NONE_0 (l_dobj) course_16\NN\883297|anaesthesia_113|without_7|._54 (l_amod) free_14\JJ\7942152|a_9|postoperative_5 (l_npadvmod) nausea_12\NN\14299637|-_6
2131034
D008727_D020258 CID methotrexate_8\NNP\2722166|NONE_0 (r_pobj) with_5\IN\0|toxicities_31|have_20|been_15|._57 (r_prep) described_4\VBN\1001294|NONE_0 (l_nsubjpass) toxicities_1\NNS\13576101|have_11|been_16|with_31|._88
D008727_D020258 CID mtx_16\NNP\0|NONE_0 (r_pobj) with_15\IN\0|its_16 (r_prep) combination_14\NN\7951464|in_57|,_6|could_45|neurotoxicity_64|._77 (r_nsubj) cause_24\VB\7323922|NONE_0 (l_dobj) neurotoxicity_26\NN\0|in_121|,_70|combination_64|could_19|._13
D013852_D020258 CID thiotepa_19\NNS\2722458|NONE_0 (r_pobj) including_18\VBG\0|intrathecal_42|it_29|combination_25 (r_prep) chemotherapy_17\NN\661091|NONE_0 (r_pobj) of_11\IN\0|the_19 (r_prep) administration_10\NN\1133281|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) related_7\VBN\628491|severe_35|delayed_28|neurologic_20 (r_acl) toxicity_6\NN\13576101|NONE_0
D013852_D020258 CID tspa_21\NNS\0|NONE_0 (r_appos) thiotepa_19\NNS\2722458|NONE_0 (r_pobj) including_18\VBG\0|intrathecal_42|it_29|combination_25 (r_prep) chemotherapy_17\NN\661091|NONE_0 (r_pobj) of_11\IN\0|the_19 (r_prep) administration_10\NN\1133281|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) related_7\VBN\628491|severe_35|delayed_28|neurologic_20 (r_acl) toxicity_6\NN\13576101|NONE_0
D013852_D020258 CID tspa_17\NNP\0|,_33|cytosine_28|and_7 (r_conj) arabinoside_13\NN\0|it_29|-_27 (r_conj) methotrexate_8\NNP\2722166|NONE_0 (r_pobj) with_5\IN\0|toxicities_31|have_20|been_15|._57 (r_prep) described_4\VBN\1001294|NONE_0 (l_nsubjpass) toxicities_1\NNS\13576101|have_11|been_16|with_31|._88
D013852_D020258 CID tspa_6\NNP\0|that_5|agent_20 (r_nsubj) is_7\VBZ\0|the_19 (r_acl) fact_4\NN\5816287|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) spite_1\NN\7550369|NONE_0 (r_pobj) in_0\IN\13603305|,_51|combination_57|could_102|neurotoxicity_121|._134 (r_prep) cause_24\VB\7323922|NONE_0 (l_dobj) neurotoxicity_26\NN\0|in_121|,_70|combination_64|could_19|._13
D013852_D011115 CID thiotepa_7\NNS\2722458|NONE_0 (r_compound) combination_8\NN\7951464|:_24|description_26 (r_compound) chemotherapy_9\NN\661091|NONE_0 (r_pobj) after_5\IN\0|severe_37|and_15|loss_5|._77 (r_prep) polyneuropathy_1\NN\0|NONE_0
D003561_D020258 CID arabinoside_13\NN\0|it_29|-_27 (r_conj) methotrexate_8\NNP\2722166|NONE_0 (r_pobj) with_5\IN\0|toxicities_31|have_20|been_15|._57 (r_prep) described_4\VBN\1001294|NONE_0 (l_nsubjpass) toxicities_1\NNS\13576101|have_11|been_16|with_31|._88
D003561_D020258 CID c_20\NN\13714184|,_6 (r_conj) mtx_16\NNP\0|NONE_0 (r_pobj) with_15\IN\0|its_16 (r_prep) combination_14\NN\7951464|in_57|,_6|could_45|neurotoxicity_64|._77 (r_nsubj) cause_24\VB\7323922|NONE_0 (l_dobj) neurotoxicity_26\NN\0|in_121|,_70|combination_64|could_19|._13
10672628
D009569_D002375 NONE oxide_7\NN\14818238|NONE_0 (r_compound) synthesis_8\NN\13446390|NONE_0 (r_pobj) of_4\IN\0|chronic_19 (r_prep) inhibition_3\NN\1068773|catalepsy_66|._126 (r_nsubj) modifies_9\VBZ\109660|NONE_0 (l_dobj) catalepsy_13\NN\14023236|inhibition_66|._60
D009569_D002375 NONE oxide_18\NN\14818238|(_15|nos_16|)_19 (r_compound) synthase_19\NN\0|NONE_0 (r_pobj) of_15\IN\0|an_13 (r_prep) inhibitor_14\NN\20090|nitro_31|-_26|l_25|-_24|noarg_11|,_5|,_40 (r_appos) arginine_6\NN\14605787|catalepsy_73|in_83|._90 (r_nsubj) induces_24\VBZ\1627355|NONE_0 (l_dobj) catalepsy_25\NN\14023236|arginine_73|in_10|._17
D004298_D002375 NONE dopamine_8\NN\14807737|NONE_0 (r_compound) receptors_9\NNS\5225602|which_21 (r_dobj) block_7\VBP\21939|,_8|,_24 (r_relcl) haloperidol_4\NN\3713736|such_8 (r_pobj) as_3\IN\14622893|neuroleptic_23 (r_prep) drugs_1\NNS\14778436|also_59|catalepsy_70|in_80|._90 (r_nsubj) cause_12\VBP\7323922|NONE_0 (l_dobj) catalepsy_13\NN\14023236|drugs_70|also_11|in_10|._20
D009249_D002375 NONE nadph_18\NNP\0|-_5 (r_compound) diaphorase_20\NN\0|NONE_0 (r_compound) neurons_21\NNS\5430628|NONE_0 (r_pobj) of_17\IN\0|the_11|in_28 (r_prep) number_16\NN\5107765|induced_26|and_8 (r_conj) catalepsy_13\NN\14023236|inhibition_66|._60
D006220_D002375 CID haloperidol_10\NN\3713736|-_11 (r_npadvmod) induced_12\VBN\1627355|and_18|number_26 (r_amod) catalepsy_13\NN\14023236|inhibition_66|._60
D006220_D002375 CID haloperidol_4\NN\3713736|such_8 (r_pobj) as_3\IN\14622893|neuroleptic_23 (r_prep) drugs_1\NNS\14778436|also_59|catalepsy_70|in_80|._90 (r_nsubj) cause_12\VBP\7323922|NONE_0 (l_dobj) catalepsy_13\NN\14023236|drugs_70|also_11|in_10|._20
D006220_D002375 CID haloperidol_11\NN\3713736|-_11 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_amod) catalepsy_14\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_16\NN\3713736|-_11 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) catalepsy_19\NN\14023236|NONE_0
D019335_D002375 NONE arginine_6\NN\14605787|catalepsy_73|in_83|._90 (r_nsubj) induces_24\VBZ\1627355|NONE_0 (l_dobj) catalepsy_25\NN\14023236|arginine_73|in_10|._17
D019335_D002375 NONE noarg_10\NNP\0|nitro_20|-_15|l_14|-_13|,_6|inhibitor_11|,_51 (r_appos) arginine_6\NN\14605787|catalepsy_73|in_83|._90 (r_nsubj) induces_24\VBZ\1627355|NONE_0 (l_dobj) catalepsy_25\NN\14023236|arginine_73|in_10|._17
D019335_D002375 NONE noarg_8\NNP\0|subchronic_13|in_16|and_49|number_57 (r_compound) treatment_9\NN\654885|NONE_0 (l_prep) in_10\IN\13603305|subchronic_29|noarg_16|and_33|number_41 (l_pobj) catalepsy_14\NN\14023236|NONE_0
D019335_D002375 NONE noarg_3\NNP\0|chronic_10 (r_nmod) administration_7\NN\1133281|:_22|tolerance_24|._81 (r_nsubj) produced_8\VBD\1617192|NONE_0 (l_dobj) tolerance_9\NN\5032565|:_46|administration_24|._57 (l_prep) of_10\IN\0|NONE_0 (l_conj) of_15\IN\0|noarg_10|and_4 (l_pobj) catalepsy_19\NN\14023236|NONE_0
D019335_D002375 NONE noarg_13\NNP\0|and_6|of_10 (r_pobj) of_10\IN\0|NONE_0 (l_conj) of_15\IN\0|noarg_10|and_4 (l_pobj) catalepsy_19\NN\14023236|NONE_0
3711722
D003035_D009202 CID cobalt_4\NN\14625458|NONE_0 (r_compound) cardiomyopathy_5\NN\14103288|in_21|,_9|was_15|in_27
D004317_D006333 CID doxorubicin_4\RB\2716866|-_11 (r_npadvmod) induced_6\VBN\1627355|heart_8 (r_amod) failure_8\NN\66216|NONE_0
19020118
11988250
D007052_D004374 NONE ibuprofen_8\NNP\3828465|NONE_0 (r_compound) administration_9\NN\1133281|NONE_0 (r_pobj) after_7\IN\0|we_43|cases_27|during_31|._197 (r_prep) report_1\VBP\6470073|NONE_0 (l_prep) during_10\IN\0|we_74|cases_58|after_31|._166 (l_pobj) trial_14\NN\786195|NONE_0 (l_prep) of_15\IN\0|a_30|randomised_28|controlled_17|in_69 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|prophylactic_23|with_28 (l_pobj) arteriosus_21\NN\0|NONE_0
D007052_D004374 NONE ibuprofen_23\NN\3828465|NONE_0 (r_pobj) with_22\IN\0|prophylactic_51|of_28 (r_prep) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|prophylactic_23|with_28 (l_pobj) arteriosus_21\NN\0|NONE_0
D007052_D006976 CID ibuprofen_3\NNP\3828465|in_22 (r_compound) prophylaxis_4\NN\1077350|NONE_0 (r_pobj) after_2\IN\0|pulmonary_23|._51 (r_prep) hypertension_1\NN\14057371|NONE_0
D009569_D000860 NONE oxide_6\NN\14818238|inhaled_15|nitric_7 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) on_3\IN\0|hypoxaemia_28|quickly_8|._31 (r_prep) resolved_1\VBD\352826|NONE_0 (l_nsubj) hypoxaemia_0\NNP\0|quickly_20|on_28|._59
D007052_D000860 CID ibuprofen_8\NNP\3828465|NONE_0 (r_compound) administration_9\NN\1133281|NONE_0 (r_pobj) after_7\IN\0|we_43|cases_27|during_31|._197 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) cases_3\NNS\7283608|we_16|after_27|during_58|._224 (l_prep) of_4\IN\0|three_12 (l_pobj) hypoxaemia_6\JJ\0|NONE_0
D007052_D000860 CID ibuprofen_23\NN\3828465|NONE_0 (r_pobj) with_22\IN\0|prophylactic_51|of_28 (r_prep) treatment_17\NN\654885|NONE_0 (r_pobj) of_15\IN\0|a_30|randomised_28|controlled_17|in_69 (r_prep) trial_14\NN\786195|NONE_0 (r_pobj) during_10\IN\0|we_74|cases_58|after_31|._166 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) cases_3\NNS\7283608|we_16|after_27|during_58|._224 (l_prep) of_4\IN\0|three_12 (l_pobj) hypoxaemia_6\JJ\0|NONE_0
D007052_D000860 CID ibuprofen_21\NNP\3828465|NONE_0 (r_pobj) of_20\IN\0|prophylactic_28 (r_prep) administration_19\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|if_21|hypoxaemia_18 (r_prep) occurs_16\VBZ\0|that_102|investigators_97|attention_46|to_36 (l_nsubj) hypoxaemia_15\JJ\0|if_3|after_18
17351238
D001285_D007022 NONE sulphate_23\NN\15010703|NONE_0 (r_pobj) by_21\IN\0|experienced_79|,_21|this_19|was_14|._42 (r_agent) rectified_20\VBN\918872|NONE_0 (l_advcl) experienced_7\VBD\2108377|,_58|this_60|was_65|by_79|._121 (l_dobj) drop_10\NN\13899200|minutes_55|after_47|gtn_37 (l_prep) in_11\IN\13603305|a_14|sudden_12 (l_pobj) pressure_13\NN\11419404|NONE_0
D005996_D007022 CID gtn_8\NNP\0|prehospital_12 (r_compound) administration_9\NN\1133281|NONE_0 (r_pobj) following_6\VBG\8180190|a_34|dramatic_32|in_18|._40 (r_prep) drop_2\NN\13899200|NONE_0 (l_prep) in_3\IN\13603305|a_16|dramatic_14|following_18|._58 (l_pobj) pressure_5\NN\11419404|NONE_0
D005996_D007022 CID gtn_4\NNP\0|minutes_18|after_10|drop_37 (r_nsubj) experienced_7\VBD\2108377|,_58|this_60|was_65|by_79|._121 (l_dobj) drop_10\NN\13899200|minutes_55|after_47|gtn_37 (l_prep) in_11\IN\13603305|a_14|sudden_12 (l_pobj) pressure_13\NN\11419404|NONE_0
17223814
D015251_D054537 CID epirubicin_11\NNS\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) chemotherapy_9\NN\661091|NONE_0 (r_pobj) of_8\IN\0|a_9 (r_prep) result_7\NN\34213|NONE_0 (r_pobj) as_5\IN\14622893|operative_33|atrioventricular_23|._58 (r_prep) block_4\NN\21939|NONE_0
D017239_D054537 CID paclitaxel_13\NN\0|and_4 (r_conj) epirubicin_11\NNS\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) chemotherapy_9\NN\661091|NONE_0 (r_pobj) of_8\IN\0|a_9 (r_prep) result_7\NN\34213|NONE_0 (r_pobj) as_5\IN\14622893|operative_33|atrioventricular_23|._58 (r_prep) block_4\NN\21939|NONE_0
7457821
25031906
D017311_D012678 NONE amlodipine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|drug_15 (r_prep) treatment_12\NN\654885|NONE_0 (r_pobj) on_10\IN\0|essential_23 (r_prep) hypertension_9\NN\14057371|NONE_0 (r_pobj) with_7\IN\0|a_9 (r_prep) female_6\NN\15388|NONE_0 (r_pobj) about_4\IN\0|a_7 (r_prep) case_3\NN\7283608|we_12|loss_92|._115 (r_dobj) report_1\VBP\6470073|NONE_0 (l_dobj) loss_16\NN\13252973|we_104|case_92|._23 (l_prep) of_17\IN\0|developed_15 (l_pobj) sensation_19\NN\5708432|NONE_0
D017311_D006973 NONE amlodipine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|drug_15 (r_prep) treatment_12\NN\654885|NONE_0 (r_pobj) on_10\IN\0|essential_23 (r_prep) hypertension_9\NN\14057371|NONE_0
D017311_D004408 CID amlodipine_14\NNP\0|NONE_0 (r_pobj) of_13\IN\0|rare_29|-_8 (r_prep) effect_12\NN\34213|to_30 (r_attr) be_4\VB\14625458|is_22|dysguesia_19|?_47 (r_xcomp) going_2\VBG\30358|NONE_0 (l_compound) dysguesia_1\NNP\0|is_3|be_19|?_66
D017311_D004408 CID amlodipine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|a_24|rare_17|side_12|-_8 (r_prep) effect_5\NN\34213|dysguesia_24|._33 (r_nsubj) is_8\VBZ\0|NONE_0 (l_acomp) dysguesia_9\JJ\0|effect_24|._9
D017311_D004408 CID amlodipine_3\NN\0|that_5|can_11|dysguesia_21 (r_nsubj) cause_5\VB\7323922|we_32|._15 (l_dobj) dysguesia_6\NN\0|that_26|amlodipine_21|can_10
D017311_D004408 CID amlodipine_13\NN\0|NONE_0 (l_conj) dysguesia_15\NN\0|and_4
4082192
D000082_D007683 CID acetaminophen_0\NNP\2707683|necrosis_47|in_56|._82 (r_nsubj) produces_4\VBZ\7555863|NONE_0 (l_dobj) necrosis_7\NN\11444117|acetaminophen_47|in_9|._35
D000082_D007683 CID apap_2\NNP\0|(_1|)_4 (r_appos) acetaminophen_0\NNP\2707683|necrosis_47|in_56|._82 (r_nsubj) produces_4\VBZ\7555863|NONE_0 (l_dobj) necrosis_7\NN\11444117|acetaminophen_47|in_9|._35
D000082_D007683 CID apap_18\NNP\0|-_4 (r_npadvmod) induced_20\VBN\1627355|renal_8|tubular_14 (r_amod) necrosis_23\NN\11444117|NONE_0
C026729_D007683 CID pap_4\NNP\6612266|NONE_0 (r_compound) formation_5\NN\7938773|that_9|,_9|in_11|,_18|,_28|in_39|,_46|for_48 (r_nsubj) accounts_10\NNS\6647206|it_45|is_42|._67 (l_prep) for_17\IN\0|that_57|formation_48|,_39|in_37|,_30|,_20|in_9|,_2 (l_pobj) necrosis_23\NN\11444117|NONE_0
D000082_D007674 NONE acetaminophen_7\RB\2707683|-_13 (r_advmod) induced_9\VBN\1627355|NONE_0 (r_amod) nephrotoxicity_10\NN\0|NONE_0
D000082_D007674 NONE acetaminophen_7\RB\2707683|-_13 (r_advmod) induced_9\VBN\1627355|NONE_0 (r_amod) nephrotoxicity_10\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|the_26|of_17|:_39|effect_41|._164 (r_prep) role_1\NN\719494|NONE_0 (l_appos) effect_12\NN\34213|the_67|of_58|in_41|:_2|._123 (l_prep) of_13\IN\0|NONE_0 (l_pobj) phosphate_18\NN\15010703|NONE_0 (l_conj) nephrotoxicity_25\NN\0|nitrophenyl_58|)_47|on_35|and_18
D000082_D007674 NONE acetaminophen_20\NN\2707683|NONE_0 (r_pobj) on_19\IN\0|nitrophenyl_23|)_12|and_17|nephrotoxicity_35 (r_prep) phosphate_18\NN\15010703|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) effect_12\NN\34213|the_67|of_58|in_41|:_2|._123 (r_appos) role_1\NN\719494|NONE_0 (l_prep) in_6\IN\13603305|the_26|of_17|:_39|effect_41|._164 (l_pobj) nephrotoxicity_10\NN\0|NONE_0
D000082_D007674 NONE acetaminophen_20\NN\2707683|NONE_0 (r_pobj) on_19\IN\0|nitrophenyl_23|)_12|and_17|nephrotoxicity_35 (r_prep) phosphate_18\NN\15010703|NONE_0 (l_conj) nephrotoxicity_25\NN\0|nitrophenyl_58|)_47|on_35|and_18
D000082_D007674 NONE apap_16\NNP\0|-_4 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) nephrotoxicity_19\NN\0|NONE_0
D000082_D007674 NONE apap_19\NNP\0|NONE_0 (l_conj) nephrotoxicity_22\NN\0|and_8
D000082_D007674 NONE apap_7\NNP\0|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) prior_5\RB\10675876|of_21 (r_advmod) pretreatment_0\NN\0|in_79|._160 (r_nsubj) resulted_11\VBD\2633881|NONE_0 (l_prep) in_12\IN\13603305|pretreatment_79|._81 (l_pobj) reduction_14\NN\351485|NONE_0 (l_appos) nephrotoxicity_25\NN\0|marked_64|of_47 (l_nmod) nephrotoxicity_21\NN\0|not_19|pap_23
D000082_D007674 NONE apap_7\NNP\0|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) prior_5\RB\10675876|of_21 (r_advmod) pretreatment_0\NN\0|in_79|._160 (r_nsubj) resulted_11\VBD\2633881|NONE_0 (l_prep) in_12\IN\13603305|pretreatment_79|._81 (l_pobj) reduction_14\NN\351485|NONE_0 (l_appos) nephrotoxicity_25\NN\0|marked_64|of_47
D000082_D007674 NONE apap_16\NNP\0|NONE_0 (r_pobj) of_15\IN\0|marked_17|nephrotoxicity_47 (r_prep) reduction_14\NN\351485|NONE_0 (l_appos) nephrotoxicity_25\NN\0|marked_64|of_47 (l_nmod) nephrotoxicity_21\NN\0|not_19|pap_23
D000082_D007674 NONE apap_16\NNP\0|NONE_0 (r_pobj) of_15\IN\0|marked_17|nephrotoxicity_47 (r_prep) reduction_14\NN\351485|NONE_0 (l_appos) nephrotoxicity_25\NN\0|marked_64|of_47
D000082_D007674 NONE apap_8\NNP\0|-_4 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) nephrotoxicity_11\NN\0|NONE_0
D000082_D007674 NONE apap_19\NNP\0|NONE_0 (r_compound) deacetylation_20\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) inhibition_17\NN\1068773|to_3 (r_pobj) due_15\JJ\5174653|to_6 (r_acomp) be_14\VB\14625458|therefore_80|,_71|reduction_52|._42 (r_xcomp) appears_12\VBZ\2604760|NONE_0 (l_nsubj) reduction_6\NN\351485|therefore_28|,_19|be_52|._94 (l_prep) in_7\IN\13603305|the_27|induced_18 (l_pobj) nephrotoxicity_11\NN\0|NONE_0
C026729_D007674 NONE aminophenol_5\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_9|in_17|:_56|effect_58|._181 (r_prep) role_1\NN\719494|NONE_0 (l_prep) in_6\IN\13603305|the_26|of_17|:_39|effect_41|._164 (l_pobj) nephrotoxicity_10\NN\0|NONE_0
C026729_D007674 NONE aminophenol_5\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_9|in_17|:_56|effect_58|._181 (r_prep) role_1\NN\719494|NONE_0 (l_appos) effect_12\NN\34213|the_67|of_58|in_41|:_2|._123 (l_prep) of_13\IN\0|NONE_0 (l_pobj) phosphate_18\NN\15010703|NONE_0 (l_conj) nephrotoxicity_25\NN\0|nitrophenyl_58|)_47|on_35|and_18
C026729_D007674 NONE aminophenol_24\NN\0|and_27|metabolism_31|in_42 (r_amod) nephrotoxicity_25\NN\0|nitrophenyl_58|)_47|on_35|and_18 (r_conj) phosphate_18\NN\15010703|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) effect_12\NN\34213|the_67|of_58|in_41|:_2|._123 (r_appos) role_1\NN\719494|NONE_0 (l_prep) in_6\IN\13603305|the_26|of_17|:_39|effect_41|._164 (l_pobj) nephrotoxicity_10\NN\0|NONE_0
C026729_D007674 NONE aminophenol_24\NN\0|and_27|metabolism_31|in_42 (r_amod) nephrotoxicity_25\NN\0|nitrophenyl_58|)_47|on_35|and_18
C026729_D007674 NONE pap_9\NNP\6612266|NONE_0 (r_compound) formation_10\NN\7938773|if_7|step_25 (r_nsubj) is_11\VBZ\0|to_30 (l_attr) step_14\NN\168237|if_32|formation_25 (l_prep) in_15\IN\13603305|a_17|requisite_15 (l_pobj) nephrotoxicity_19\NN\0|NONE_0
C026729_D007674 NONE pap_21\NNP\6612266|and_19|metabolism_23 (r_compound) nephrotoxicity_22\NN\0|and_8
C026729_D007674 NONE pap_9\NNP\6612266|NONE_0 (r_compound) administration_10\NN\1133281|or_7 (r_conj) apap_7\NNP\0|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) prior_5\RB\10675876|of_21 (r_advmod) pretreatment_0\NN\0|in_79|._160 (r_nsubj) resulted_11\VBD\2633881|NONE_0 (l_prep) in_12\IN\13603305|pretreatment_79|._81 (l_pobj) reduction_14\NN\351485|NONE_0 (l_appos) nephrotoxicity_25\NN\0|marked_64|of_47 (l_nmod) nephrotoxicity_21\NN\0|not_19|pap_23
C026729_D007674 NONE pap_9\NNP\6612266|NONE_0 (r_compound) administration_10\NN\1133281|or_7 (r_conj) apap_7\NNP\0|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) prior_5\RB\10675876|of_21 (r_advmod) pretreatment_0\NN\0|in_79|._160 (r_nsubj) resulted_11\VBD\2633881|NONE_0 (l_prep) in_12\IN\13603305|pretreatment_79|._81 (l_pobj) reduction_14\NN\351485|NONE_0 (l_appos) nephrotoxicity_25\NN\0|marked_64|of_47
C026729_D007674 NONE pap_24\NNP\6612266|nephrotoxicity_23|not_4 (r_compound) nephrotoxicity_25\NN\0|marked_64|of_47 (l_nmod) nephrotoxicity_21\NN\0|not_19|pap_23
C026729_D007674 NONE pap_24\NNP\6612266|nephrotoxicity_23|not_4 (r_compound) nephrotoxicity_25\NN\0|marked_64|of_47
C002887_D007674 NONE phosphate_18\NN\15010703|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) effect_12\NN\34213|the_67|of_58|in_41|:_2|._123 (r_appos) role_1\NN\719494|NONE_0 (l_prep) in_6\IN\13603305|the_26|of_17|:_39|effect_41|._164 (l_pobj) nephrotoxicity_10\NN\0|NONE_0
C002887_D007674 NONE phosphate_18\NN\15010703|NONE_0 (l_conj) nephrotoxicity_25\NN\0|nitrophenyl_58|)_47|on_35|and_18
C002887_D007674 NONE phosphate_9\NN\15010703|NONE_0 (r_pobj) of_4\IN\0|the_11|on_66 (r_prep) effect_3\NN\34213|therefore_15|,_6|was_119|._133 (l_prep) on_18\IN\0|the_77|of_66 (l_pobj) apap_19\NNP\0|NONE_0 (l_conj) nephrotoxicity_22\NN\0|and_8
C002887_D007674 NONE bnpp_11\NNP\0|nitrophenyl_24|,_5|inhibitor_22|,_31 (r_appos) phosphate_9\NN\15010703|NONE_0 (r_pobj) of_4\IN\0|the_11|on_66 (r_prep) effect_3\NN\34213|therefore_15|,_6|was_119|._133 (l_prep) on_18\IN\0|the_77|of_66 (l_pobj) apap_19\NNP\0|NONE_0 (l_conj) nephrotoxicity_22\NN\0|and_8
C002887_D007674 NONE bnpp_4\NNP\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) animals_2\NNS\4475|NONE_0 (r_pobj) of_1\IN\0|prior_21 (r_prep) pretreatment_0\NN\0|in_79|._160 (r_nsubj) resulted_11\VBD\2633881|NONE_0 (l_prep) in_12\IN\13603305|pretreatment_79|._81 (l_pobj) reduction_14\NN\351485|NONE_0 (l_appos) nephrotoxicity_25\NN\0|marked_64|of_47 (l_nmod) nephrotoxicity_21\NN\0|not_19|pap_23
C002887_D007674 NONE bnpp_4\NNP\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) animals_2\NNS\4475|NONE_0 (r_pobj) of_1\IN\0|prior_21 (r_prep) pretreatment_0\NN\0|in_79|._160 (r_nsubj) resulted_11\VBD\2633881|NONE_0 (l_prep) in_12\IN\13603305|pretreatment_79|._81 (l_pobj) reduction_14\NN\351485|NONE_0 (l_appos) nephrotoxicity_25\NN\0|marked_64|of_47
C002887_D007674 NONE bnpp_3\NNP\0|-_4 (r_npadvmod) induced_5\VBN\1627355|the_9|in_18 (r_amod) reduction_6\NN\351485|therefore_28|,_19|be_52|._94 (l_prep) in_7\IN\13603305|the_27|induced_18 (l_pobj) nephrotoxicity_11\NN\0|NONE_0
6299641
D007545_D013610 CID isoproterenol_28\NN\3740161|-_13 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) tachycardia_31\NN\14110674|both_41|and_26|in_12
D007545_D013610 CID isoproterenol_3\NN\3740161|NONE_0 (r_compound) tachycardia_4\NNS\14110674|NONE_0
D007545_D013610 CID isoproterenol_29\NN\3740161|whereas_8|1-_34|remains_103|blocked_142 (r_nsubj) activates_30\VBZ\1641914|data_208|consistent_199|,_24|._160 (r_advcl) are_2\VBP\13600404|NONE_0 (l_acomp) consistent_3\JJ\0|data_9|,_175|activates_199|._359 (l_prep) with_4\IN\0|NONE_0 (l_pobj) hypothesis_6\NN\7162194|NONE_0 (l_relcl) results_12\NNS\34213|the_49 (l_nsubj) tachycardia_11\NN\14110674|that_22|largely_20|from_28
D001262_D013610 NONE atenolol_10\NN\2832168|NONE_0 (r_pobj) of_7\IN\0|single_13 (r_prep) doses_6\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|the_12 (r_prep) effects_3\NNS\13245626|we_16 (r_dobj) compared_1\VBD\644583|,_72|mg_77|(_92|nonselective_93|)_105|,_106|and_108|placebo_112|._225 (r_ccomp) propranolol_17\NN\0|NONE_0 (l_conj) placebo_23\NN\3740161|compared_112|,_40|mg_35|(_20|nonselective_19|)_7|,_6|and_4|._113 (l_prep) on_24\IN\0|NONE_0 (l_pobj) exercise-_26\JJ\0|NONE_0 (l_conj) tachycardia_31\NN\14110674|both_41|and_26|in_12
D011433_D013610 NONE propranolol_17\NN\0|NONE_0 (l_conj) placebo_23\NN\3740161|compared_112|,_40|mg_35|(_20|nonselective_19|)_7|,_6|and_4|._113 (l_prep) on_24\IN\0|NONE_0 (l_pobj) exercise-_26\JJ\0|NONE_0 (l_conj) tachycardia_31\NN\14110674|both_41|and_26|in_12
D001285_D013610 NONE atropine_10\NN\14712692|NONE_0 (r_pobj) after_9\IN\0|mg/kg_21 (r_prep) iv_14\NNP\13741022|and_31 (r_conj) before_7\RB\0|effects_53|were_16|)_40|._41 (r_prep) determined_6\VBN\0|NONE_0 (l_nsubjpass) effects_1\NNS\13245626|were_37|before_53|)_93|._94 (l_prep) on_2\IN\0|the_12 (l_pobj) tachycardia_4\NNS\14110674|NONE_0
24132704
D003976_D006949 CID diazinon_7\NN\0|-_8 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) hyperlipemia_10\NN\14299637|erk_36|and_21
D003976_D006949 CID diazinon_10\NN\0|-_8 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) hyperlipemia_13\NN\14299637|NONE_0
C029036_D006949 NONE crocin_0\NNS\0|inhibition_15|and_78|levels_92|._117 (r_nsubj) reduced_1\VBD\441445|NONE_0 (l_dobj) inhibition_2\NN\1068773|crocin_15|and_63|levels_77|._102 (l_prep) of_3\IN\0|NONE_0 (l_pobj) activation_5\NN\13561719|NONE_0 (l_conj) hyperlipemia_10\NN\14299637|erk_36|and_21
C029036_D006949 NONE crocin_0\NNS\0|may_7|be_11|as_25|through_86|._151 (r_nsubjpass) considered_3\VBN\689344|NONE_0 (l_prep) as_4\IN\14622893|crocin_25|may_18|be_14|through_61|._126 (l_pobj) agent_8\NN\7347|NONE_0 (l_prep) in_9\IN\13603305|a_25|novel_23|protective_17 (l_pobj) hyperlipemia_13\NN\14299637|NONE_0
6321816
D003900_D006973 CID doca_9\NNP\0|-_4 (r_compound) salt_11\NN\14818238|NONE_0 (r_compound) hypertension_12\NN\14057371|NONE_0
D003900_D006973 CID doca_33\NNP\0|-_4 (r_compound) salt_35\NN\14818238|NONE_0 (r_compound) treatment_36\NN\654885|NONE_0 (r_pobj) after_32\IN\0|since_110|elevation_100|not_68|substantial_64 (r_prep) was_20\VBD\0|vasopressin_116|role_90|in_85|,_40|._97 (r_advcl) plays_1\VBZ\7007684|NONE_0 (l_prep) in_5\IN\13603305|vasopressin_31|role_5|,_45|was_85|._182 (l_pobj) pathogenesis_7\NN\13533470|NONE_0 (l_prep) of_8\IN\0|the_17 (l_pobj) hypertension_12\NN\14057371|NONE_0
D008094_D003919 CID lithium_27\NN\14625458|-_7 (r_npadvmod) treated_29\VBN\2376958|NONE_0 (r_amod) diabetes_30\NN\14075199|NONE_0 (r_compound) insipidus_31\NN\0|NONE_0
D008094_D006973 NONE lithium_27\NN\14625458|-_7 (r_npadvmod) treated_29\VBN\2376958|NONE_0 (r_amod) diabetes_30\NN\14075199|NONE_0 (r_compound) insipidus_31\NN\0|NONE_0 (r_pobj) with_26\IN\0|the_9 (r_prep) rats_25\NNS\2329401|NONE_0 (r_pobj) in_23\IN\13603305|NONE_0 (r_prep) substantial_22\JJ\0|since_46|elevation_36|not_4|after_64 (r_acomp) was_20\VBD\0|vasopressin_116|role_90|in_85|,_40|._97 (r_advcl) plays_1\VBZ\7007684|NONE_0 (l_prep) in_5\IN\13603305|vasopressin_31|role_5|,_45|was_85|._182 (l_pobj) pathogenesis_7\NN\13533470|NONE_0 (l_prep) of_8\IN\0|the_17 (l_pobj) hypertension_12\NN\14057371|NONE_0
D014667_D003919 NONE vasopressin_0\NNP\5407119|role_26|in_31|,_76|was_116|._213 (r_nsubj) plays_1\VBZ\7007684|NONE_0 (l_advcl) was_20\VBD\0|vasopressin_116|role_90|in_85|,_40|._97 (l_acomp) substantial_22\JJ\0|since_46|elevation_36|not_4|after_64 (l_prep) in_23\IN\13603305|NONE_0 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_prep) with_26\IN\0|the_9 (l_pobj) insipidus_31\NN\0|NONE_0
D014667_D006973 NONE vasopressin_0\NNP\5407119|NONE_0 (l_prep) as_1\IN\14622893|._41 (l_pobj) contributor_4\NN\10025730|NONE_0 (l_prep) to_5\IN\0|a_23|possible_21 (l_pobj) hypertension_6\NN\14057371|NONE_0
D014667_D006973 NONE vasopressin_3\NN\5407119|NONE_0 (r_pobj) of_2\IN\0|the_9|as_15 (r_prep) role_1\NN\719494|was_67|._79 (l_prep) as_4\IN\14622893|the_24|of_15 (l_pobj) agent_7\NN\7347|NONE_0 (l_prep) to_8\IN\0|a_16|pressor_14 (l_pobj) process_11\NN\407535|NONE_0 (l_amod) hypertensive_10\JJ\10405694|the_4
D014667_D006973 NONE vasopressin_0\NNP\5407119|role_26|in_31|,_76|was_116|._213 (r_nsubj) plays_1\VBZ\7007684|NONE_0 (l_prep) in_5\IN\13603305|vasopressin_31|role_5|,_45|was_85|._182 (l_pobj) pathogenesis_7\NN\13533470|NONE_0 (l_prep) of_8\IN\0|the_17 (l_pobj) hypertension_12\NN\14057371|NONE_0
D014667_D006973 NONE vasopressin_6\NN\5407119|NONE_0 (r_pobj) of_5\IN\0|the_19|pressor_15 (r_prep) action_4\NN\30358|furthermore_25|,_14|be_33|,_94|observed_157|._202 (r_nsubj) appears_7\VBZ\2604760|NONE_0 (l_xcomp) be_9\VB\14625458|furthermore_58|,_47|action_33|,_61|observed_124|._169 (l_prep) in_11\IN\13603305|to_16|important_10 (l_pobj) development_13\NN\248977|NONE_0 (l_prep) of_14\IN\0|the_16 (l_pobj) model_16\NN\5888929|NONE_0 (l_prep) of_17\IN\0|this_11 (l_pobj) hypertension_18\NN\14057371|NONE_0
D014667_D006973 NONE vasopressin_6\NN\5407119|NONE_0 (r_pobj) of_5\IN\0|the_19|pressor_15 (r_prep) action_4\NN\30358|furthermore_25|,_14|be_33|,_94|observed_157|._202 (r_nsubj) appears_7\VBZ\2604760|NONE_0 (l_advcl) observed_29\VBN\2163746|furthermore_182|,_171|action_157|be_124|,_63|._45 (l_prep) in_30\IN\13603305|since_70|responsiveness_43|was_13 (l_pobj) stage_33\NN\15113229|NONE_0 (l_prep) of_34\IN\0|the_18|initial_14 (l_pobj) hypertension_35\NN\14057371|NONE_0
D014667_D006973 NONE vasopressin_3\NN\5407119|NONE_0 (r_pobj) of_2\IN\0|increased_20|from_15 (r_prep) secretion_1\NN\13526110|also_46|function_64|._128 (r_nsubj) promotes_7\VBZ\2556126|NONE_0 (l_dobj) function_9\NN\13783581|secretion_64|also_18|._64 (l_prep) as_13\IN\14622893|the_28|of_15 (l_pobj) factor_16\NN\7326557|NONE_0 (l_prep) in_17\IN\13603305|a_22|pathogenetic_20 (l_pobj) hypertension_18\NN\14057371|NONE_0
D014667_D006973 NONE vasopressin_5\NN\5407119|NONE_0 (r_pobj) of_4\IN\0|the_9 (r_prep) role_3\NN\719494|however_13|,_6|determined_34|._76 (r_nsubj) remains_6\VBZ\2684|NONE_0 (l_xcomp) determined_9\VBN\0|however_47|,_40|role_34|._42 (l_prep) in_10\IN\13603305|to_17|be_14 (l_pobj) hypertension_13\NN\14057371|NONE_0
D003900_D003919 NONE doca_9\NNP\0|-_4 (r_compound) salt_11\NN\14818238|NONE_0 (r_compound) hypertension_12\NN\14057371|NONE_0 (r_pobj) of_8\IN\0|the_17 (r_prep) pathogenesis_7\NN\13533470|NONE_0 (r_pobj) in_5\IN\13603305|vasopressin_31|role_5|,_45|was_85|._182 (r_prep) plays_1\VBZ\7007684|NONE_0 (l_advcl) was_20\VBD\0|vasopressin_116|role_90|in_85|,_40|._97 (l_acomp) substantial_22\JJ\0|since_46|elevation_36|not_4|after_64 (l_prep) in_23\IN\13603305|NONE_0 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_prep) with_26\IN\0|the_9 (l_pobj) insipidus_31\NN\0|NONE_0
D003900_D003919 NONE doca_33\NNP\0|-_4 (r_compound) salt_35\NN\14818238|NONE_0 (r_compound) treatment_36\NN\654885|NONE_0 (r_pobj) after_32\IN\0|since_110|elevation_100|not_68|substantial_64 (r_prep) was_20\VBD\0|vasopressin_116|role_90|in_85|,_40|._97 (l_acomp) substantial_22\JJ\0|since_46|elevation_36|not_4|after_64 (l_prep) in_23\IN\13603305|NONE_0 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_prep) with_26\IN\0|the_9 (l_pobj) insipidus_31\NN\0|NONE_0
6884395
D003276_D000784 CID contraceptives_19\NNS\3183080|,_11|and_9 (r_conj) smoke_15\NN\11422597|,_2 (r_conj) hypertension_13\NN\14057371|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) association_11\NN\8008335|NONE_0 (r_pobj) in_10\IN\13603305|the_19|basilar_15 (r_prep) artery_9\NN\5417975|NONE_0 (r_pobj) of_6\IN\0|dissecting_20 (r_prep) aneurysm_5\NN\14057371|NONE_0
D003276_D011782 NONE contraceptives_19\NNS\3183080|,_11|and_9 (r_conj) smoke_15\NN\11422597|,_2 (r_conj) hypertension_13\NN\14057371|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) association_11\NN\8008335|NONE_0 (r_pobj) in_10\IN\13603305|the_19|basilar_15 (r_prep) artery_9\NN\5417975|NONE_0 (r_pobj) of_6\IN\0|dissecting_20 (r_prep) aneurysm_5\NN\14057371|NONE_0 (r_pobj) of_2\IN\0|a_7 (r_prep) case_1\NN\7283608|is_128|in_140|._191 (r_nsubjpass) reported_21\VBN\831651|NONE_0 (l_prep) in_22\IN\13603305|case_140|is_12|._51 (l_pobj) patient_26\NN\9898892|NONE_0 (l_prep) with_27\IN\0|a_23|young_21|female_15 (l_pobj) syndrome_32\NN\5870365|NONE_0
D003276_D006973 NONE contraceptives_19\NNS\3183080|,_11|and_9 (r_conj) smoke_15\NN\11422597|,_2 (r_conj) hypertension_13\NN\14057371|NONE_0
24739405
D006220_D006948 NONE haloperidol_23\NN\3713736|used_56 (r_nsubj) induced_29\VBD\1627355|climbing_41|,_33|and_31 (r_conj) induced_19\VBN\1627355|amphetamine_95|locomotion_56|sc_5|)_2|._116 (r_conj) induced_6\VBD\1627355|NONE_0 (l_dobj) locomotion_8\NN\4773351|amphetamine_39|sc_51|)_54|induced_56|._172 (l_amod) hyper_7\JJ\0|,_16|apomorphine_18
D001058_D002375 NONE apomorphine_10\NN\3786417|hyper_18|,_2 (r_conj) locomotion_8\NN\4773351|amphetamine_39|sc_51|)_54|induced_56|._172 (r_dobj) induced_6\VBD\1627355|NONE_0 (l_conj) induced_19\VBN\1627355|amphetamine_95|locomotion_56|sc_5|)_2|._116 (l_conj) induced_29\VBD\1627355|climbing_41|,_33|and_31 (l_ccomp) used_33\VBN\0|haloperidol_56 (l_nsubjpass) tests_31\NNS\5798043|were_6|as_16 (l_compound) catalepsy_30\NN\14023236|NONE_0
D001058_D012559 CID apomorphine_10\NN\3786417|hyper_18|,_2 (r_conj) locomotion_8\NN\4773351|amphetamine_39|sc_51|)_54|induced_56|._172 (r_dobj) induced_6\VBD\1627355|NONE_0 (l_conj) induced_19\VBN\1627355|amphetamine_95|locomotion_56|sc_5|)_2|._116 (l_conj) induced_29\VBD\1627355|climbing_41|,_33|and_31 (l_ccomp) used_33\VBN\0|haloperidol_56 (l_prep) as_34\IN\14622893|tests_16|were_10 (l_pobj) models_36\NNS\5888929|NONE_0 (l_prep) of_37\IN\0|animal_14 (l_pobj) schizophrenia_38\NN\14398067|NONE_0
D000661_D002375 NONE amphetamine_0\NN\3248958|locomotion_39|sc_90|)_93|induced_95|._211 (r_nsubj) induced_6\VBD\1627355|NONE_0 (l_conj) induced_19\VBN\1627355|amphetamine_95|locomotion_56|sc_5|)_2|._116 (l_conj) induced_29\VBD\1627355|climbing_41|,_33|and_31 (l_ccomp) used_33\VBN\0|haloperidol_56 (l_nsubjpass) tests_31\NNS\5798043|were_6|as_16 (l_compound) catalepsy_30\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_23\NN\3713736|used_56 (r_nsubj) induced_29\VBD\1627355|climbing_41|,_33|and_31 (l_ccomp) used_33\VBN\0|haloperidol_56 (l_nsubjpass) tests_31\NNS\5798043|were_6|as_16 (l_compound) catalepsy_30\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_9\NN\3713736|-_11 (r_npadvmod) induced_11\VBN\1627355|the_16|catalepsy_8|(_23|p<0.05_24|)_30 (r_amod) test_13\NN\5798043|NONE_0 (l_compound) catalepsy_12\NN\14023236|the_24|induced_8|(_15|p<0.05_16|)_22
D000661_D006948 NONE amphetamine_0\NN\3248958|locomotion_39|sc_90|)_93|induced_95|._211 (r_nsubj) induced_6\VBD\1627355|NONE_0 (l_dobj) locomotion_8\NN\4773351|amphetamine_39|sc_51|)_54|induced_56|._172 (l_amod) hyper_7\JJ\0|,_16|apomorphine_18
D001058_D006948 NONE apomorphine_10\NN\3786417|hyper_18|,_2 (r_conj) locomotion_8\NN\4773351|amphetamine_39|sc_51|)_54|induced_56|._172 (l_amod) hyper_7\JJ\0|,_16|apomorphine_18
D000661_D012559 CID amphetamine_4\NN\3248958|-_11 (r_npadvmod) induced_6\VBN\1627355|schizophrenia_8|in_29 (r_amod) models_8\NNS\5888929|NONE_0 (l_compound) schizophrenia_7\NN\14398067|induced_8|in_21
D000661_D012559 CID amphetamine_0\NN\3248958|locomotion_39|sc_90|)_93|induced_95|._211 (r_nsubj) induced_6\VBD\1627355|NONE_0 (l_conj) induced_19\VBN\1627355|amphetamine_95|locomotion_56|sc_5|)_2|._116 (l_conj) induced_29\VBD\1627355|climbing_41|,_33|and_31 (l_ccomp) used_33\VBN\0|haloperidol_56 (l_prep) as_34\IN\14622893|tests_16|were_10 (l_pobj) models_36\NNS\5888929|NONE_0 (l_prep) of_37\IN\0|animal_14 (l_pobj) schizophrenia_38\NN\14398067|NONE_0
D006220_D012559 CID haloperidol_23\NN\3713736|used_56 (r_nsubj) induced_29\VBD\1627355|climbing_41|,_33|and_31 (l_ccomp) used_33\VBN\0|haloperidol_56 (l_prep) as_34\IN\14622893|tests_16|were_10 (l_pobj) models_36\NNS\5888929|NONE_0 (l_prep) of_37\IN\0|animal_14 (l_pobj) schizophrenia_38\NN\14398067|NONE_0
D003687_D002375 NONE dhea_3\NNP\0|reduced_5|locomotor_13|and_32|catalepsy_46 (r_nsubj) activity_6\NN\30358|we_40|that_28|,_46|had_57|._91 (l_conj) catalepsy_9\NN\14023236|dhea_46|reduced_41|locomotor_33|and_14
D003687_D012559 NONE dehydroepiandrosterone_2\NN\0|NONE_0 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) models_8\NNS\5888929|NONE_0 (l_compound) schizophrenia_7\NN\14398067|induced_8|in_21
D003687_D012559 NONE dehydroepiandrosterone_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_12|on_33 (r_prep) effects_3\NNS\13245626|to_15|._74 (l_prep) on_9\IN\0|the_45|of_33 (l_pobj) models_11\NNS\5888929|NONE_0 (l_prep) of_12\IN\0|animal_14 (l_pobj) schizophrenia_13\NN\14398067|NONE_0
D003687_D012559 NONE dhea_7\NNP\0|NONE_0 (r_appos) dehydroepiandrosterone_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_12|on_33 (r_prep) effects_3\NNS\13245626|to_15|._74 (l_prep) on_9\IN\0|the_45|of_33 (l_pobj) models_11\NNS\5888929|NONE_0 (l_prep) of_12\IN\0|animal_14 (l_pobj) schizophrenia_13\NN\14398067|NONE_0
D003687_D012559 NONE dhea_3\NNP\0|that_5|effects_39|,_46|and_48|used_59 (r_nsubj) displays_4\VBZ\6879180|we_21|._92 (l_conj) used_14\VBN\0|that_64|dhea_59|effects_20|,_13|and_11 (l_prep) in_15\IN\13603305|may_12|be_8 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) schizophrenia_19\NN\14398067|NONE_0
23871786
C006780_D001008 CID a_4\DT\13649268|NONE_0 (r_pobj) to_2\IN\0|pubertal_18 (r_prep) exposure_1\NN\5042871|behavior_47|and_56|decreases_60|._133 (r_nsubj) increases_5\VBZ\13576355|NONE_0 (l_dobj) behavior_9\NN\407535|exposure_47|and_9|decreases_13|._86 (l_amod) like_8\JJ\5839024|NONE_0 (l_npadvmod) anxiety_6\NN\14373582|-_7
C006780_D001008 CID bpa_17\NNP\0|NONE_0 (r_pobj) to_16\IN\0|NONE_0 (r_prep) exposed_15\VBN\2110927|NONE_0 (r_acl) mice_14\NNS\2329401|NONE_0 (r_pobj) in_13\IN\13603305|that_41|behavior_23|was_14 (r_prep) increased_12\VBN\169651|results_81|._32 (l_nsubjpass) behavior_10\NN\407535|that_18|was_9|in_23 (l_amod) like_9\JJ\5839024|NONE_0 (l_npadvmod) anxiety_7\NN\14373582|-_7
C006780_D001008 CID bpa_5\NNP\0|pubertal_9 (r_compound) exposure_6\NN\5042871|that_18|behavior_32 (r_nsubj) increased_7\VBN\169651|findings_43|._123 (l_dobj) behavior_11\NN\407535|that_50|exposure_32 (l_amod) like_10\JJ\5839024|,_13|associated_28 (l_npadvmod) anxiety_8\NN\14373582|NONE_0
12699527
D002712_-1 NONE chloride_14\NN\14818238|NONE_0 (r_compound) channel_15\NN\6251781|the_29|muscle_16|,_16 (r_compound) function_16\NN\13783581|NONE_0 (r_pobj) in_10\IN\13603305|a_9|cause_60 (r_prep) defect_9\NN\14462666|NONE_0 (l_relcl) cause_20\VB\7323922|a_69|in_60 (l_dobj) depolarisation_23\NN\11412727|which_35|may_29
D002712_D009224 NONE chloride_14\NN\14818238|NONE_0 (r_compound) channel_15\NN\6251781|the_29|muscle_16|,_16 (r_compound) function_16\NN\13783581|NONE_0 (r_pobj) in_10\IN\13603305|a_9|cause_60 (r_prep) defect_9\NN\14462666|NONE_0 (r_pobj) by_7\IN\0|congenita_25|is_10|._111 (r_agent) caused_6\VBN\1617192|NONE_0 (l_nsubjpass) congenita_1\NN\0|is_15|by_25|._136
D002712_D009224 NONE chloride_14\NN\14818238|NONE_0 (r_compound) channel_15\NN\6251781|the_29|muscle_16|,_16 (r_compound) function_16\NN\13783581|NONE_0 (r_pobj) in_10\IN\13603305|a_9|cause_60 (r_prep) defect_9\NN\14462666|NONE_0 (r_pobj) by_7\IN\0|congenita_25|is_10|._111 (r_agent) caused_6\VBN\1617192|NONE_0 (l_nsubjpass) congenita_1\NN\0|is_15|by_25|._136 (l_appos) mc_3\NNP\15286249|myotonia_20|(_1|)_2
D013390_D013035 CID suxamethonium_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|a_25|preoperative_23 (r_prep) injection_24\NN\320852|NONE_0 (r_pobj) following_21\VBG\8180190|who_85|spasm_45 (r_prep) developed_10\VBD\1753788|a_43|healthy_30|old_14 (l_dobj) spasm_16\NN\14299637|who_40|following_45
7315949
D009638_D013035 CID norepinephrine_9\NN\14807929|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|medial_33|in_18|._27 (r_acl) changes_1\NNS\7283608|NONE_0 (l_prep) in_2\IN\13603305|medial_15|induced_18|._45 (l_pobj) spasm_4\NN\14299637|NONE_0
D009638_D006547 NONE norepinephrine_17\NN\14807929|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|NONE_0 (r_acl) vasoconstriction_12\NN\1149911|in_60|,_2|hernias_72|within_80|._97 (r_nsubj) produced_18\VBD\1617192|NONE_0 (l_dobj) hernias_25\NNS\14295248|in_132|,_74|vasoconstriction_72|within_8|._25
3439580
D007099_D009447 NONE imipramine_5\NN\4482543|NONE_0 (r_pobj) by_4\IN\0|hypertension_38|._13 (r_prep) induced_3\VBN\1627355|NONE_0 (l_nsubj) hypertension_0\NN\14057371|by_38|._51 (l_prep) in_1\IN\13603305|NONE_0 (l_pobj) neuroblastoma_2\NN\14239425|NONE_0
D007099_D009447 NONE imipramine_23\NNP\4482543|who_14|was_10|control_14 (r_dobj) given_22\VBN\5892096|NONE_0 (r_relcl) neuroblastoma_19\NN\14239425|NONE_0
D007099_D002653 NONE imipramine_23\NNP\4482543|who_14|was_10|control_14 (r_dobj) given_22\VBN\5892096|NONE_0 (l_advcl) control_25\VB\5190804|who_28|was_24|imipramine_14 (l_dobj) disorder_28\NN\14034177|to_22
D007099_D006973 CID imipramine_5\NN\4482543|NONE_0 (r_pobj) by_4\IN\0|hypertension_38|._13 (r_prep) induced_3\VBN\1627355|NONE_0 (l_nsubj) hypertension_0\NN\14057371|by_38|._51
D007099_D006973 CID imipramine_23\NNP\4482543|who_14|was_10|control_14 (r_dobj) given_22\VBN\5892096|NONE_0 (r_relcl) neuroblastoma_19\NN\14239425|NONE_0 (r_pobj) with_18\IN\0|a_18|old_9 (r_prep) girl_17\NN\10787470|NONE_0 (r_pobj) in_12\IN\13603305|(_25|blood_24|190/160_9|)_2 (r_prep) pressure_9\NN\11419404|severe_27 (r_appos) hypertension_6\NN\14057371|NONE_0
D007099_D006973 CID imipramine_16\NNP\4482543|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) discontinuation_13\NN\209943|NONE_0 (r_dobj) following_12\VBG\8180190|(_44|was_54|)_75 (r_acl) none_11\NN\15228378|no_53|pressure_44|at_25|and_4 (r_conj) elevation_6\NN\7445480|since_32|she_26 (r_dobj) had_2\VBD\0|,_138|we_140|caused_207|._230 (r_advcl) believe_27\VBP\686447|NONE_0 (l_ccomp) caused_37\VBD\1617192|had_207|,_69|we_67|._23 (l_dobj) hypertension_39\NN\14057371|that_67|drug_57
17151160
D018967_D011618 NONE risperidone_58\NN\0|to_48|with_35|(_19|day_8|)_5|or_3 (r_conj) treatment_46\NN\654885|,_94|disorder_75|were_26|randomly_21 (r_xcomp) assigned_44\VBN\2475922|subjects_172|years_138|)_122|with_120|._81 (l_nsubjpass) disorder_29\NN\14034177|,_19|were_49|randomly_54|treatment_75
D018967_D011618 NONE risperidone_58\NN\0|to_48|with_35|(_19|day_8|)_5|or_3 (r_conj) treatment_46\NN\654885|,_94|disorder_75|were_26|randomly_21 (r_xcomp) assigned_44\VBN\2475922|subjects_172|years_138|)_122|with_120|._81 (l_nsubjpass) disorder_29\NN\14034177|,_19|were_49|randomly_54|treatment_75 (l_conj) disorder_37\NN\14034177|schizophreniform_52|(_26|%_23|)_22|,_21|or_19
D018967_D015430 CID risperidone_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) than_7\IN\0|gain_30|with_16|:_21|was_86 (r_prep) occurred_4\VBD\0|NONE_0 (l_nsubj) gain_3\NN\13576355|with_14|than_30|:_51|was_116
D018967_D015430 CID risperidone_43\NN\0|NONE_0 (r_pobj) with_42\IN\0|11.3_26|(_20|%_3|)_2 (r_prep) %_35\NN\0|and_8 (r_conj) olanzapine_32\NN\0|NONE_0 (r_pobj) with_31\IN\0|17.3_27|(_21|%_18 (r_prep) %_24\NN\0|increase_67|._85 (r_attr) was_22\VBD\0|gain_116|with_102|than_86|:_65 (r_conj) occurred_4\VBD\0|NONE_0 (l_nsubj) gain_3\NN\13576355|with_14|than_30|:_51|was_116
D018967_D001480 CID risperidone_28\NN\0|NONE_0 (r_pobj) with_27\IN\0|differ_93|1.6_5|)_2|._57 (r_prep) were_18\VBD\0|NONE_0 (l_ccomp) differ_11\VB\0|1.6_88|)_91|with_93|._150 (l_prep) between_12\IN\0|outcomes_67|did_15|not_11 (l_pobj) scores_17\NNS\13757724|NONE_0 (l_compound) symptom_15\NN\5823932|extrapyramidal_15|severity_8
C076029_D012559 NONE olanzapine_3\NN\0|NONE_0 (l_prep) versus_4\IN\0|NONE_0 (l_pobj) risperidone_5\NN\0|NONE_0 (l_prep) for_6\IN\0|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) schizophrenia_13\NN\14398067|NONE_0
C076029_D012559 NONE olanzapine_9\NN\0|NONE_0 (l_prep) versus_10\IN\0|NONE_0 (l_pobj) risperidone_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) disorders_20\NNS\14034177|NONE_0 (l_compound) schizophrenia_18\NN\14398067|episode_8|spectrum_14
C076029_D012559 NONE olanzapine_48\NN\0|NONE_0 (r_pobj) with_47\IN\0|to_13|(_16|day_27|)_30|or_32|risperidone_35 (r_prep) treatment_46\NN\654885|,_94|disorder_75|were_26|randomly_21 (r_xcomp) assigned_44\VBN\2475922|subjects_172|years_138|)_122|with_120|._81 (r_conj) mean_9\JJ\6021761|NONE_0 (l_prep) with_18\IN\0|subjects_52|years_18|)_2|assigned_120|._201 (l_pobj) schizophrenia_22\NN\14398067|NONE_0
C076029_D001480 CID olanzapine_39\NN\0|NONE_0 (r_pobj) with_38\IN\0|and_25|%_14|ci=1.0_12|)_2 (r_prep) risperidone_28\NN\0|NONE_0 (r_pobj) with_27\IN\0|differ_93|1.6_5|)_2|._57 (r_prep) were_18\VBD\0|NONE_0 (l_ccomp) differ_11\VB\0|1.6_88|)_91|with_93|._150 (l_prep) between_12\IN\0|outcomes_67|did_15|not_11 (l_pobj) scores_17\NNS\13757724|NONE_0 (l_compound) symptom_15\NN\5823932|extrapyramidal_15|severity_8
D018967_D012559 NONE risperidone_5\NN\0|NONE_0 (l_prep) for_6\IN\0|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) schizophrenia_13\NN\14398067|NONE_0
D018967_D012559 NONE risperidone_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) disorders_20\NNS\14034177|NONE_0 (l_compound) schizophrenia_18\NN\14398067|episode_8|spectrum_14
D018967_D012559 NONE risperidone_58\NN\0|to_48|with_35|(_19|day_8|)_5|or_3 (r_conj) treatment_46\NN\654885|,_94|disorder_75|were_26|randomly_21 (r_xcomp) assigned_44\VBN\2475922|subjects_172|years_138|)_122|with_120|._81 (r_conj) mean_9\JJ\6021761|NONE_0 (l_prep) with_18\IN\0|subjects_52|years_18|)_2|assigned_120|._201 (l_pobj) schizophrenia_22\NN\14398067|NONE_0
C076029_D015430 CID olanzapine_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|gain_14|than_16|:_37|was_102 (r_prep) occurred_4\VBD\0|NONE_0 (l_nsubj) gain_3\NN\13576355|with_14|than_30|:_51|was_116
C076029_D015430 CID olanzapine_32\NN\0|NONE_0 (r_pobj) with_31\IN\0|17.3_27|(_21|%_18 (r_prep) %_24\NN\0|increase_67|._85 (r_attr) was_22\VBD\0|gain_116|with_102|than_86|:_65 (r_conj) occurred_4\VBD\0|NONE_0 (l_nsubj) gain_3\NN\13576355|with_14|than_30|:_51|was_116
C076029_D015430 CID olanzapine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) greater_12\JJR\0|gain_9|._23 (r_acomp) was_11\VBD\0|medications_66|gain_22|,_18|but_16 (r_conj) caused_2\VBD\1617192|NONE_0 (l_dobj) gain_6\NN\13576355|medications_44|,_4|but_6|was_22
C076029_D015430 CID olanzapine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) greater_12\JJR\0|gain_9|._23 (r_acomp) was_11\VBD\0|medications_66|gain_22|,_18|but_16 (l_nsubj) gain_10\NN\13576355|greater_9|._32
C076029_D011618 NONE olanzapine_48\NN\0|NONE_0 (r_pobj) with_47\IN\0|to_13|(_16|day_27|)_30|or_32|risperidone_35 (r_prep) treatment_46\NN\654885|,_94|disorder_75|were_26|randomly_21 (r_xcomp) assigned_44\VBN\2475922|subjects_172|years_138|)_122|with_120|._81 (l_nsubjpass) disorder_29\NN\14034177|,_19|were_49|randomly_54|treatment_75
C076029_D011618 NONE olanzapine_48\NN\0|NONE_0 (r_pobj) with_47\IN\0|to_13|(_16|day_27|)_30|or_32|risperidone_35 (r_prep) treatment_46\NN\654885|,_94|disorder_75|were_26|randomly_21 (r_xcomp) assigned_44\VBN\2475922|subjects_172|years_138|)_122|with_120|._81 (l_nsubjpass) disorder_29\NN\14034177|,_19|were_49|randomly_54|treatment_75 (l_conj) disorder_37\NN\14034177|schizophreniform_52|(_26|%_23|)_22|,_21|or_19
C076029_D017109 NONE olanzapine_39\NN\0|NONE_0 (r_pobj) with_38\IN\0|and_25|%_14|ci=1.0_12|)_2 (r_prep) risperidone_28\NN\0|NONE_0 (r_pobj) with_27\IN\0|differ_93|1.6_5|)_2|._57 (r_prep) were_18\VBD\0|NONE_0 (l_ccomp) differ_11\VB\0|1.6_88|)_91|with_93|._150 (l_nsubj) outcomes_2\NNS\7291312|did_52|not_56|between_67 (l_conj) akathisia_8\NN\0|negative_59|symptom_50|and_33|measures_29|and_4
C076029_D010302 NONE olanzapine_39\NN\0|NONE_0 (r_pobj) with_38\IN\0|and_25|%_14|ci=1.0_12|)_2 (r_prep) risperidone_28\NN\0|NONE_0 (r_pobj) with_27\IN\0|differ_93|1.6_5|)_2|._57 (r_prep) were_18\VBD\0|NONE_0 (l_ccomp) differ_11\VB\0|1.6_88|)_91|with_93|._150 (l_nsubj) outcomes_2\NNS\7291312|did_52|not_56|between_67 (l_conj) measures_4\NNS\168237|negative_30|symptom_21|and_4|and_25|akathisia_29 (l_prep) of_5\IN\0|NONE_0 (l_pobj) parkinsonism_6\NN\14085708|NONE_0
D018967_D017109 NONE risperidone_28\NN\0|NONE_0 (r_pobj) with_27\IN\0|differ_93|1.6_5|)_2|._57 (r_prep) were_18\VBD\0|NONE_0 (l_ccomp) differ_11\VB\0|1.6_88|)_91|with_93|._150 (l_nsubj) outcomes_2\NNS\7291312|did_52|not_56|between_67 (l_conj) akathisia_8\NN\0|negative_59|symptom_50|and_33|measures_29|and_4
D018967_D010302 NONE risperidone_28\NN\0|NONE_0 (r_pobj) with_27\IN\0|differ_93|1.6_5|)_2|._57 (r_prep) were_18\VBD\0|NONE_0 (l_ccomp) differ_11\VB\0|1.6_88|)_91|with_93|._150 (l_nsubj) outcomes_2\NNS\7291312|did_52|not_56|between_67 (l_conj) measures_4\NNS\168237|negative_30|symptom_21|and_4|and_25|akathisia_29 (l_prep) of_5\IN\0|NONE_0 (l_pobj) parkinsonism_6\NN\14085708|NONE_0
439781
D012964_D007022 NONE sodium_4\NN\14625458|NONE_0 (r_npadvmod) depleted_7\VBN\2267060|NONE_0 (r_amod) rats_8\NNS\2329401|indomethacin_63|hypotension_42|._4 (r_dobj) induced_1\VBD\1627355|NONE_0 (l_dobj) hypotension_2\NN\14057371|indomethacin_21|rats_42|._46
D007213_D007022 CID indomethacin_0\NNP\3828465|hypotension_21|rats_63|._67 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) hypotension_2\NN\14057371|indomethacin_21|rats_42|._46
19419794
C005177_D004409 NONE dopa+benserazide_4\NNP\0|NONE_0 (r_pobj) with_1\IN\0|)_33 (r_prep) treatment_0\NN\654885|in_54|._106 (r_nsubj) resulted_9\VBD\2633881|NONE_0 (l_prep) in_10\IN\13603305|treatment_54|._52 (l_pobj) dyskinesias_13\NNS\14084880|NONE_0
D016627_D004409 NONE 6-hydroxydopamine_3\CD\0|and_25|development_37 (r_compound) lesion_4\NN\14204950|NONE_0 (l_conj) development_7\NN\248977|6-hydroxydopamine_37|and_12 (l_prep) of_8\IN\0|reduced_20|in_15 (l_pobj) dyskinesias_9\NNS\14084880|NONE_0
D007980_D004409 CID dopa_24\NNP\14601829|l_2|-_1|-_4 (r_compound) induced_26\VBN\1627355|NONE_0 (r_amod) dyskinesias_27\NNS\14084880|NONE_0
D007980_D004409 CID dopa_19\NNP\14601829|l_2|-_1|-_4 (r_compound) induced_21\VBN\1627355|NONE_0 (r_amod) dyskinesias_22\NNS\14084880|NONE_0
D004298_D004409 NONE da_17\NNP\10484858|NONE_0 (r_compound) lesion_18\NN\14204950|motor_24|and_7 (r_conj) impairment_15\NN\7296428|NONE_0 (r_pobj) of_13\IN\0|the_13 (r_prep) severity_12\NN\5036394|that_57|lack_48|,_42|and_44|reduced_48 (r_dobj) increased_10\VBD\169651|results_60|._96 (l_conj) reduced_21\VBN\441445|that_105|lack_96|severity_48|,_6|and_4 (l_dobj) dyskinesias_27\NNS\14084880|NONE_0
23864035
C400082_D009101 NONE bortezomib_0\NNP\0|NONE_0 (l_conj) dexamethasone_2\NN\2721538|and_4|._127 (l_prep) in_6\IN\13603305|as_19 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) myeloma_13\NN\14239425|NONE_0
C400082_D009101 NONE bortezomib_0\NNP\0|therapy_54|._113 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) therapy_9\NN\657604|bortezomib_54|._59 (l_prep) for_10\IN\0|an_21|effective_18 (l_pobj) r_17\NNP\13635336|NONE_0 (l_appos) myeloma_20\NN\14239425|relapsed_35|/_27|refractory_26|(_15|r_14|/_13|)_11
C400082_D009101 NONE bortezomib_0\NNP\0|therapy_54|._113 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) therapy_9\NN\657604|bortezomib_54|._59 (l_prep) for_10\IN\0|an_21|effective_18 (l_pobj) r_17\NNP\13635336|NONE_0 (l_appos) myeloma_20\NN\14239425|relapsed_35|/_27|refractory_26|(_15|r_14|/_13|)_11 (l_appos) mm_22\NNP\13649268|multiple_18|)_2
C400082_D009101 NONE bort)-dexamethasone_2\NNP\0|(_1|(_20|)_24 (r_nmod) dex_4\NN\0|NONE_0 (r_appos) bortezomib_0\NNP\0|therapy_54|._113 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) therapy_9\NN\657604|bortezomib_54|._59 (l_prep) for_10\IN\0|an_21|effective_18 (l_pobj) r_17\NNP\13635336|NONE_0 (l_appos) myeloma_20\NN\14239425|relapsed_35|/_27|refractory_26|(_15|r_14|/_13|)_11
C400082_D009101 NONE bort)-dexamethasone_2\NNP\0|(_1|(_20|)_24 (r_nmod) dex_4\NN\0|NONE_0 (r_appos) bortezomib_0\NNP\0|therapy_54|._113 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) therapy_9\NN\657604|bortezomib_54|._59 (l_prep) for_10\IN\0|an_21|effective_18 (l_pobj) r_17\NNP\13635336|NONE_0 (l_appos) myeloma_20\NN\14239425|relapsed_35|/_27|refractory_26|(_15|r_14|/_13|)_11 (l_appos) mm_22\NNP\13649268|multiple_18|)_2
C400082_D009101 NONE bort_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_16|(_8|m(2_16|)_19|on_21 (r_prep) combination_5\NN\7951464|study_23|)_70|and_72|dex_76|after_173|._250 (r_dobj) investigated_3\VBD\644583|NONE_0 (l_conj) dex_29\NN\0|study_99|combination_76|)_6|and_4|after_97|._174 (l_prep) as_43\IN\14622893|(_45|mg_41|and_24|day_16|)_2 (l_pobj) treatment_45\NN\654885|NONE_0 (l_prep) in_46\IN\13603305|salvage_18 (l_pobj) patients_48\NNS\9898892|NONE_0 (l_prep) with_49\IN\0|85_12 (l_pobj) mm_53\NNP\13649268|NONE_0
C400082_D009101 NONE bort_41\NN\0|NONE_0 (r_pobj) after_40\IN\0|the_8 (r_prep) day_39\NN\15154774|(_29|mg_25|and_8|)_14|as_16 (r_conj) dex_29\NN\0|study_99|combination_76|)_6|and_4|after_97|._174 (l_prep) as_43\IN\14622893|(_45|mg_41|and_24|day_16|)_2 (l_pobj) treatment_45\NN\654885|NONE_0 (l_prep) in_46\IN\13603305|salvage_18 (l_pobj) patients_48\NNS\9898892|NONE_0 (l_prep) with_49\IN\0|85_12 (l_pobj) mm_53\NNP\13649268|NONE_0
C400082_D009101 NONE bort_0\NNP\0|-_4 (r_compound) dex_2\NN\0|treatment_29|._95 (r_nsubj) was_3\VBD\0|NONE_0 (l_attr) treatment_7\NN\654885|dex_29|._66 (l_prep) for_8\IN\0|an_31|effective_28|salvage_18|,_15|for_30 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_compound) mm_9\NNP\13649268|NONE_0
D003907_D009101 NONE dexamethasone_2\NN\2721538|and_4|._127 (l_prep) in_6\IN\13603305|as_19 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) myeloma_13\NN\14239425|NONE_0
D003907_D009101 NONE bort)-dexamethasone_2\NNP\0|(_1|(_20|)_24 (r_nmod) dex_4\NN\0|NONE_0 (r_appos) bortezomib_0\NNP\0|therapy_54|._113 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) therapy_9\NN\657604|bortezomib_54|._59 (l_prep) for_10\IN\0|an_21|effective_18 (l_pobj) r_17\NNP\13635336|NONE_0 (l_appos) myeloma_20\NN\14239425|relapsed_35|/_27|refractory_26|(_15|r_14|/_13|)_11
D003907_D009101 NONE bort)-dexamethasone_2\NNP\0|(_1|(_20|)_24 (r_nmod) dex_4\NN\0|NONE_0 (r_appos) bortezomib_0\NNP\0|therapy_54|._113 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) therapy_9\NN\657604|bortezomib_54|._59 (l_prep) for_10\IN\0|an_21|effective_18 (l_pobj) r_17\NNP\13635336|NONE_0 (l_appos) myeloma_20\NN\14239425|relapsed_35|/_27|refractory_26|(_15|r_14|/_13|)_11 (l_appos) mm_22\NNP\13649268|multiple_18|)_2
D003907_D009101 NONE dex_4\NN\0|NONE_0 (r_appos) bortezomib_0\NNP\0|therapy_54|._113 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) therapy_9\NN\657604|bortezomib_54|._59 (l_prep) for_10\IN\0|an_21|effective_18 (l_pobj) r_17\NNP\13635336|NONE_0 (l_appos) myeloma_20\NN\14239425|relapsed_35|/_27|refractory_26|(_15|r_14|/_13|)_11
D003907_D009101 NONE dex_4\NN\0|NONE_0 (r_appos) bortezomib_0\NNP\0|therapy_54|._113 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) therapy_9\NN\657604|bortezomib_54|._59 (l_prep) for_10\IN\0|an_21|effective_18 (l_pobj) r_17\NNP\13635336|NONE_0 (l_appos) myeloma_20\NN\14239425|relapsed_35|/_27|refractory_26|(_15|r_14|/_13|)_11 (l_appos) mm_22\NNP\13649268|multiple_18|)_2
D003907_D009101 NONE dex_29\NN\0|study_99|combination_76|)_6|and_4|after_97|._174 (l_prep) as_43\IN\14622893|(_45|mg_41|and_24|day_16|)_2 (l_pobj) treatment_45\NN\654885|NONE_0 (l_prep) in_46\IN\13603305|salvage_18 (l_pobj) patients_48\NNS\9898892|NONE_0 (l_prep) with_49\IN\0|85_12 (l_pobj) mm_53\NNP\13649268|NONE_0
D003907_D009101 NONE dex_2\NN\0|treatment_29|._95 (r_nsubj) was_3\VBD\0|NONE_0 (l_attr) treatment_7\NN\654885|dex_29|._66 (l_prep) for_8\IN\0|an_31|effective_28|salvage_18|,_15|for_30 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_compound) mm_9\NNP\13649268|NONE_0
7931490
D017829_D009325 NONE granisetron_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|and_11|safety_7|,_14|antagonist_59|,_69|in_71|._142 (r_prep) efficacy_0\NN\5199286|NONE_0 (l_prep) in_12\IN\13603305|and_82|safety_78|of_71|,_57|antagonist_12|,_2|._71 (l_pobj) prevention_14\NN\1073995|NONE_0 (l_prep) of_15\IN\0|the_15|and_10|vomiting_14|induced_23 (l_pobj) nausea_16\NN\14299637|NONE_0
D017829_D009325 NONE granisetron_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|four_21|different_16|(_15|kytril_16|;_22|pharmaceuticals_43|)_76 (r_prep) doses_11\NNS\3740161|NONE_0 (r_pobj) of_8\IN\0|safety_15 (r_prep) profile_7\NN\6999802|the_34|antiemetic_30|and_11 (r_conj) effects_4\NNS\13245626|to_25|administered_134|._237 (r_dobj) assess_1\VB\5220461|NONE_0 (l_advcl) administered_26\VBN\2436349|to_159|effects_134|._103 (l_dobj) dose_34\NN\3740161|when_47|as_29 (l_prep) for_35\IN\0|NONE_0 (l_pobj) prophylaxis_36\NN\1077350|NONE_0 (l_prep) of_37\IN\0|NONE_0 (l_pobj) nausea_41\NN\14299637|NONE_0
D017829_D009325 NONE kytril_15\NNP\0|four_37|different_32|of_16|(_1|;_6|pharmaceuticals_27|)_60 (r_appos) doses_11\NNS\3740161|NONE_0 (r_pobj) of_8\IN\0|safety_15 (r_prep) profile_7\NN\6999802|the_34|antiemetic_30|and_11 (r_conj) effects_4\NNS\13245626|to_25|administered_134|._237 (r_dobj) assess_1\VB\5220461|NONE_0 (l_advcl) administered_26\VBN\2436349|to_159|effects_134|._103 (l_dobj) dose_34\NN\3740161|when_47|as_29 (l_prep) for_35\IN\0|NONE_0 (l_pobj) prophylaxis_36\NN\1077350|NONE_0 (l_prep) of_37\IN\0|NONE_0 (l_pobj) nausea_41\NN\14299637|NONE_0
D002945_D009325 CID cisplatin_24\NN\0|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|the_38|of_23|and_13|vomiting_9 (r_acl) prevention_14\NN\1073995|NONE_0 (l_prep) of_15\IN\0|the_15|and_10|vomiting_14|induced_23 (l_pobj) nausea_16\NN\14299637|NONE_0
D002945_D009325 CID cisplatin_38\NN\0|-_9 (r_advmod) induced_40\VBN\1627355|and_15|vomiting_19 (r_amod) nausea_41\NN\14299637|NONE_0
D012701_D014839 NONE 5-hydroxytryptamine-3_8\CD\0|a_12|selective_10|receptor_22 (r_nummod) antagonist_10\NN\7846|and_70|safety_66|of_59|,_45|,_10|in_12|._83 (r_appos) efficacy_0\NN\5199286|NONE_0 (l_prep) in_12\IN\13603305|and_82|safety_78|of_71|,_57|antagonist_12|,_2|._71 (l_pobj) prevention_14\NN\1073995|NONE_0 (l_conj) vomiting_18\VBG\116687|the_29|of_14|and_4|induced_9
D017829_D014839 NONE granisetron_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|and_11|safety_7|,_14|antagonist_59|,_69|in_71|._142 (r_prep) efficacy_0\NN\5199286|NONE_0 (l_prep) in_12\IN\13603305|and_82|safety_78|of_71|,_57|antagonist_12|,_2|._71 (l_pobj) prevention_14\NN\1073995|NONE_0 (l_conj) vomiting_18\VBG\116687|the_29|of_14|and_4|induced_9
D017829_D014839 NONE granisetron_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|four_21|different_16|(_15|kytril_16|;_22|pharmaceuticals_43|)_76 (r_prep) doses_11\NNS\3740161|NONE_0 (r_pobj) of_8\IN\0|safety_15 (r_prep) profile_7\NN\6999802|the_34|antiemetic_30|and_11 (r_conj) effects_4\NNS\13245626|to_25|administered_134|._237 (r_dobj) assess_1\VB\5220461|NONE_0 (l_advcl) administered_26\VBN\2436349|to_159|effects_134|._103 (l_dobj) dose_34\NN\3740161|when_47|as_29 (l_prep) for_35\IN\0|NONE_0 (l_pobj) prophylaxis_36\NN\1077350|NONE_0 (l_prep) of_37\IN\0|NONE_0 (l_pobj) nausea_41\NN\14299637|NONE_0 (l_conj) vomiting_43\NN\116687|induced_19|and_4
D017829_D014839 NONE kytril_15\NNP\0|four_37|different_32|of_16|(_1|;_6|pharmaceuticals_27|)_60 (r_appos) doses_11\NNS\3740161|NONE_0 (r_pobj) of_8\IN\0|safety_15 (r_prep) profile_7\NN\6999802|the_34|antiemetic_30|and_11 (r_conj) effects_4\NNS\13245626|to_25|administered_134|._237 (r_dobj) assess_1\VB\5220461|NONE_0 (l_advcl) administered_26\VBN\2436349|to_159|effects_134|._103 (l_dobj) dose_34\NN\3740161|when_47|as_29 (l_prep) for_35\IN\0|NONE_0 (l_pobj) prophylaxis_36\NN\1077350|NONE_0 (l_prep) of_37\IN\0|NONE_0 (l_pobj) nausea_41\NN\14299637|NONE_0 (l_conj) vomiting_43\NN\116687|induced_19|and_4
D017829_D014839 NONE granisetron_1\NN\0|of_18|,_22|10_24 (r_compound) doses_2\NNS\3740161|NONE_0 (l_appos) 10_6\CD\13745420|granisetron_24|of_6|,_2 (l_conj) micrograms_12\NNS\13717155|20_11|,_9|and_7 (l_appos) response_18\NN\11410625|40_26|/_13|kg_12|,_10 (l_acl) vomiting_24\NN\116687|a_29|major_27|(_12|,_29|and_31|rescue_49
D017829_D014839 NONE granisetron_1\NN\0|of_18|,_22|10_24 (r_compound) doses_2\NNS\3740161|NONE_0 (r_pobj) after_0\IN\0|was_146|in_159|and_212|response_227|._339 (r_prep) recorded_35\VBN\2225492|NONE_0 (l_conj) response_57\NN\11410625|after_227|was_81|in_68|and_15|._112 (l_appos) vomiting_60\NN\116687|a_24|complete_22|(_4|)_46|in_48
D017829_D014839 NONE granisetron_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|kg_8 (r_prep) dose_8\NN\3740161|,_22|or_20 (r_conj) 20-_2\CD\0|,_2 (r_conj) 10-_0\LS\0|effective_54|._224 (r_nsubj) was_11\VBD\0|NONE_0 (l_acomp) effective_12\JJ\0|10-_54|._170 (l_prep) in_13\IN\13603305|NONE_0 (l_pcomp) controlling_14\VBG\0|NONE_0 (l_dobj) vomiting_15\NN\116687|NONE_0
D017829_D014839 NONE granisetron_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|kg_8 (r_prep) dose_8\NN\3740161|,_22|or_20 (r_conj) 20-_2\CD\0|,_2 (r_conj) 10-_0\LS\0|effective_54|._224 (r_nsubj) was_11\VBD\0|NONE_0 (l_acomp) effective_12\JJ\0|10-_54|._170 (l_prep) in_13\IN\13603305|NONE_0 (l_pcomp) controlling_14\VBG\0|NONE_0 (l_dobj) vomiting_15\NN\116687|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) %_21\NN\0|NONE_0 (l_prep) of_22\IN\0|60_4 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_relcl) received_25\VBD\2210855|NONE_0 (l_conj) prevented_37\VBN\0|who_66|cisplatin_53|at_43|and_12 (l_dobj) vomiting_38\VBG\116687|totally_18|to_16
D002945_D014839 CID cisplatin_24\NN\0|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|the_38|of_23|and_13|vomiting_9 (r_acl) prevention_14\NN\1073995|NONE_0 (l_conj) vomiting_18\VBG\116687|the_29|of_14|and_4|induced_9
D002945_D014839 CID cisplatin_38\NN\0|-_9 (r_advmod) induced_40\VBN\1627355|and_15|vomiting_19 (r_amod) nausea_41\NN\14299637|NONE_0 (l_conj) vomiting_43\NN\116687|induced_19|and_4
D002945_D014839 CID cisplatin_26\NN\0|who_13|at_10|and_41|prevented_53 (r_dobj) received_25\VBD\2210855|NONE_0 (r_relcl) patients_23\NNS\9898892|NONE_0 (r_pobj) of_22\IN\0|60_4 (r_prep) %_21\NN\0|NONE_0 (r_pobj) in_16\IN\13603305|NONE_0 (r_prep) vomiting_15\NN\116687|NONE_0
D002945_D014839 CID cisplatin_26\NN\0|who_13|at_10|and_41|prevented_53 (r_dobj) received_25\VBD\2210855|NONE_0 (l_conj) prevented_37\VBN\0|who_66|cisplatin_53|at_43|and_12 (l_dobj) vomiting_38\VBG\116687|totally_18|to_16
D012701_D009325 NONE 5-hydroxytryptamine-3_8\CD\0|a_12|selective_10|receptor_22 (r_nummod) antagonist_10\NN\7846|and_70|safety_66|of_59|,_45|,_10|in_12|._83 (r_appos) efficacy_0\NN\5199286|NONE_0 (l_prep) in_12\IN\13603305|and_82|safety_78|of_71|,_57|antagonist_12|,_2|._71 (l_pobj) prevention_14\NN\1073995|NONE_0 (l_prep) of_15\IN\0|the_15|and_10|vomiting_14|induced_23 (l_pobj) nausea_16\NN\14299637|NONE_0
931801
D000617_D003681 NONE aminoglycoside_11\NN\0|NONE_0 (r_compound) antibiotics_12\NNS\2716205|NONE_0 (r_pobj) of_10\IN\0|single_17|combined_30 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) following_7\VBG\8180190|acute_20|renal_14 (r_acl) failure_6\NN\66216|rats_35|regularly_30|._109 (r_dobj) develop_3\VBP\1753788|NONE_0 (l_nsubj) rats_1\NNS\2329401|regularly_5|failure_35|._144 (l_amod) dehydrated_0\JJ\212414|NONE_0
D009005_D007674 NONE monosaccharides_12\NNS\14792703|NONE_0 (r_pobj) by_11\IN\0|when_41|they_36|were_31|from_19 (r_agent) spared_7\VBN\2725714|rats_42|urine_21|._44 (l_prep) from_8\IN\0|when_22|they_17|were_12|by_19 (l_pobj) lesions_10\NNS\14204950|NONE_0
D007612_D051437 NONE kanamycin_21\NN\2716866|-_9 (r_compound) dextran_23\NN\0|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|renal_14 (r_acl) failure_18\NN\66216|NONE_0
D000617_D007674 NONE aminoglycoside_16\NN\0|peptide_39|as_11 (r_conj) antibiotics_11\NNS\2716205|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_agent) induced_8\VBN\1627355|renal_13 (r_acl) damage_7\NN\7296428|NONE_0
C038936_D051437 NONE 6,3-dilactone_13\CD\0|-_22|acetyl_21|-_15|-_13 (r_appos) d_9\NNP\15089472|o_9|protected_28|against_43 (r_nmod) rats_15\NNS\2329401|NONE_0 (l_prep) against_16\IN\0|o_52|d_43|protected_15 (l_pobj) failure_18\NN\66216|NONE_0
D005937_D007674 NONE glucarates_4\NNP\0|NONE_0 (r_pobj) of_1\IN\0|on_16|._64 (r_prep) effect_0\NN\34213|NONE_0 (l_prep) on_5\IN\0|of_16|._48 (l_pobj) damage_11\NN\7296428|NONE_0
D005937_D007674 NONE glucarates_2\NNP\0|effective_16|antibitocis_112|._123 (r_nsubj) were_3\VBD\0|NONE_0 (l_acomp) effective_4\JJ\0|glucarates_16|antibitocis_96|._107 (l_prep) against_5\IN\0|NONE_0 (l_pobj) damage_7\NN\7296428|NONE_0
D005937_D007674 NONE glucarate_4\NN\0|NONE_0 (r_pobj) with_0\IN\0|,_42|degree_67|was_88|against_101|._236 (r_prep) obtained_19\VBN\2210855|NONE_0 (l_prep) against_20\IN\0|with_101|,_59|degree_34|was_13|._135 (l_pobj) damages_22\NNS\13282550|NONE_0
D005937_D007674 NONE glucarates_2\NNP\0|ability_19|but_51|cure_62|._69 (r_nsubj) had_3\VBD\0|NONE_0 (l_dobj) ability_5\NN\4723816|glucarates_19|but_32|cure_43|._50 (l_acl) prevent_7\VB\0|the_15 (l_dobj) damage_9\NN\7296428|to_17
D005937_D007674 NONE glucarates_6\NNS\0|NONE_0 (l_prep) against_7\IN\0|d_13|-_12 (l_pobj) nephrotoxicity_8\NN\0|NONE_0
D000617_D058186 CID aminoglycoside_11\NN\0|NONE_0 (r_compound) antibiotics_12\NNS\2716205|NONE_0 (r_pobj) of_10\IN\0|single_17|combined_30 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) following_7\VBG\8180190|acute_20|renal_14 (r_acl) failure_6\NN\66216|rats_35|regularly_30|._109
7967231
D002118_D020195 NONE calcium_11\NN\14625458|type_5 (r_compound) channel_12\NN\6251781|NONE_0 (r_compound) antagonists_13\NNS\7846|not_36|,_25|,_11 (r_conj) s-312-l_6\NNP\0|s-312_24|,_10|but_8 (r_conj) s-312-d_2\NNP\0|effects_84|;_141|and_143|were_165 (r_nsubj) showed_15\VBD\2137132|NONE_0 (l_dobj) effects_17\NNS\13245626|s-312-d_84|;_57|and_59|were_81 (l_prep) on_18\IN\0|anticonvulsant_23 (l_pobj) convulsions_22\NNS\14081375|NONE_0
D010852_D012640 CID picrotoxin_49\NN\0|methyl_20|d_13|-_12|,_2 (r_conj) aspartate_47\NNP\0|NONE_0 (r_pobj) by_40\IN\0|in_53 (r_agent) induced_39\VBN\1627355|NONE_0 (r_acl) convulsions_38\NNS\14081375|NONE_0 (r_pobj) in_37\IN\13603305|observed_143|,_27|effects_22|were_14|:_82|mice_87|._91 (r_prep) observed_36\VBN\2163746|NONE_0 (l_advcl) observed_10\VBN\2163746|,_116|effects_121|were_129|in_143|:_225|mice_230|._234 (l_prep) against_11\IN\0|although_82|effects_49|were_14 (l_pobj) convulsions_14\NNS\14081375|NONE_0
D010852_D012640 CID picrotoxin_49\NN\0|methyl_20|d_13|-_12|,_2 (r_conj) aspartate_47\NNP\0|NONE_0 (r_pobj) by_40\IN\0|in_53 (r_agent) induced_39\VBN\1627355|NONE_0 (r_acl) convulsions_38\NNS\14081375|NONE_0
C059447_D004827 NONE s-312-d_0\NN\0|may_8|useful_15|in_22|._71 (r_nsubj) be_2\VB\14625458|NONE_0 (l_prep) in_4\IN\13603305|s-312-d_22|may_14|useful_7|._49 (l_pobj) therapy_6\NN\657604|NONE_0 (l_prep) of_7\IN\0|the_12 (l_pobj) types_9\NNS\5839024|NONE_0 (l_prep) of_10\IN\0|certain_14 (l_pobj) epilepsy_12\NN\14085708|NONE_0
-1_D020195 NONE s-312-l_6\NNP\0|s-312_24|,_10|but_8 (r_conj) s-312-d_2\NNP\0|effects_84|;_141|and_143|were_165 (r_nsubj) showed_15\VBD\2137132|NONE_0 (l_dobj) effects_17\NNS\13245626|s-312-d_84|;_57|and_59|were_81 (l_prep) on_18\IN\0|anticonvulsant_23 (l_pobj) convulsions_22\NNS\14081375|NONE_0
D001534_D012640 CID bemegride_25\NN\0|(_20|mg/kg_16|)_5|or_3 (r_conj) pentylenetetrazole_17\NN\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|the_23|clonic_19 (r_acl) convulsions_14\NNS\14081375|NONE_0
D001534_D012640 CID bemegride_25\NN\0|(_20|mg/kg_16|)_5|or_3 (r_conj) pentylenetetrazole_17\NN\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|the_23|clonic_19 (r_acl) convulsions_14\NNS\14081375|NONE_0 (r_pobj) against_11\IN\0|although_82|effects_49|were_14 (r_prep) observed_10\VBN\2163746|,_116|effects_121|were_129|in_143|:_225|mice_230|._234 (r_advcl) observed_36\VBN\2163746|NONE_0 (l_prep) in_37\IN\13603305|observed_143|,_27|effects_22|were_14|:_82|mice_87|._91 (l_pobj) convulsions_38\NNS\14081375|NONE_0
C059447_D012640 NONE s-312-d_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|moderate_32|anticonvulsant_23 (r_prep) effects_3\NNS\13245626|although_33|were_35|against_49 (r_nsubjpass) observed_10\VBN\2163746|,_116|effects_121|were_129|in_143|:_225|mice_230|._234 (l_prep) against_11\IN\0|although_82|effects_49|were_14 (l_pobj) convulsions_14\NNS\14081375|NONE_0
C059447_D012640 NONE s-312-d_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|moderate_32|anticonvulsant_23 (r_prep) effects_3\NNS\13245626|although_33|were_35|against_49 (r_nsubjpass) observed_10\VBN\2163746|,_116|effects_121|were_129|in_143|:_225|mice_230|._234 (r_advcl) observed_36\VBN\2163746|NONE_0 (l_prep) in_37\IN\13603305|observed_143|,_27|effects_22|were_14|:_82|mice_87|._91 (l_pobj) convulsions_38\NNS\14081375|NONE_0
D005444_D020195 NONE flunarizine_57\NN\0|NONE_0 (r_pobj) of_56\IN\0|NONE_0 (r_prep) that_55\DT\0|while_6|34.0_24 (r_nsubj) was_58\VBD\0|values_115|18.4_103|mg/kg_86|,_28|p.o._28 (r_advcl) were_31\VBD\0|s-312-d_165|effects_81|;_24|and_22 (r_conj) showed_15\VBD\2137132|NONE_0 (l_dobj) effects_17\NNS\13245626|s-312-d_84|;_57|and_59|were_81 (l_prep) on_18\IN\0|anticonvulsant_23 (l_pobj) convulsions_22\NNS\14081375|NONE_0
C059447_D020195 NONE s-312_0\NNP\0|,_14|but_16|s-312-l_24 (r_punct) s-312-d_2\NNP\0|effects_84|;_141|and_143|were_165 (r_nsubj) showed_15\VBD\2137132|NONE_0 (l_dobj) effects_17\NNS\13245626|s-312-d_84|;_57|and_59|were_81 (l_prep) on_18\IN\0|anticonvulsant_23 (l_pobj) convulsions_22\NNS\14081375|NONE_0
C059447_D020195 NONE s-312-d_2\NNP\0|effects_84|;_141|and_143|were_165 (r_nsubj) showed_15\VBD\2137132|NONE_0 (l_dobj) effects_17\NNS\13245626|s-312-d_84|;_57|and_59|were_81 (l_prep) on_18\IN\0|anticonvulsant_23 (l_pobj) convulsions_22\NNS\14081375|NONE_0
D010433_D012640 CID pentylenetetrazole_17\NN\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|the_23|clonic_19 (r_acl) convulsions_14\NNS\14081375|NONE_0
D010433_D012640 CID pentylenetetrazole_17\NN\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|the_23|clonic_19 (r_acl) convulsions_14\NNS\14081375|NONE_0 (r_pobj) against_11\IN\0|although_82|effects_49|were_14 (r_prep) observed_10\VBN\2163746|,_116|effects_121|were_129|in_143|:_225|mice_230|._234 (r_advcl) observed_36\VBN\2163746|NONE_0 (l_prep) in_37\IN\13603305|observed_143|,_27|effects_22|were_14|:_82|mice_87|._91 (l_pobj) convulsions_38\NNS\14081375|NONE_0
D016202_D012640 NONE aspartate_47\NNP\0|NONE_0 (r_pobj) by_40\IN\0|in_53 (r_agent) induced_39\VBN\1627355|NONE_0 (r_acl) convulsions_38\NNS\14081375|NONE_0 (r_pobj) in_37\IN\13603305|observed_143|,_27|effects_22|were_14|:_82|mice_87|._91 (r_prep) observed_36\VBN\2163746|NONE_0 (l_advcl) observed_10\VBN\2163746|,_116|effects_121|were_129|in_143|:_225|mice_230|._234 (l_prep) against_11\IN\0|although_82|effects_49|were_14 (l_pobj) convulsions_14\NNS\14081375|NONE_0
D016202_D012640 NONE aspartate_47\NNP\0|NONE_0 (r_pobj) by_40\IN\0|in_53 (r_agent) induced_39\VBN\1627355|NONE_0 (r_acl) convulsions_38\NNS\14081375|NONE_0
17828434
D008094_D012640 NONE lithium_15\NN\14625458|NONE_0 (r_pobj) of_14\IN\0|the_12|in_11 (r_prep) effects_13\NNS\13245626|NONE_0 (l_prep) in_16\IN\13603305|the_23|of_11 (l_pobj) model_24\NN\5888929|NONE_0 (l_compound) seizures_23\NNS\14081375|the_43|sensitive_30
D007294_D012640 NONE inositol_18\JJ\15090742|NONE_0 (r_npadvmod) sensitive_19\JJ\10488309|the_13|seizures_30 (r_amod) model_24\NN\5888929|NONE_0 (l_compound) seizures_23\NNS\14081375|the_43|sensitive_30
C002647_D012640 NONE mip_4\NNP\0|synthase_4 (r_compound) inhibition_6\NN\1068773|that_18|does_11|not_16|or_30|augment_33 (r_nsubj) replicate_9\VB\2035919|study_50|._104 (l_conj) augment_11\VB\153263|that_51|inhibition_33|does_22|not_17|or_3 (l_dobj) effects_13\NNS\13245626|NONE_0 (l_prep) in_16\IN\13603305|the_23|of_11 (l_pobj) model_24\NN\5888929|NONE_0 (l_compound) seizures_23\NNS\14081375|the_43|sensitive_30
D010862_D012640 CID pilocarpine_20\NN\14712692|-_11 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) seizures_23\NNS\14081375|the_43|sensitive_30
20859899
D000450_D006947 NONE aldosterone_14\NN\14751863|an_3 (r_compound) antagonist_15\NN\7846|,_17 (r_appos) spiranolactone_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|several_14 (r_prep) doses_9\NNS\3740161|to_14|,_50|in_52 (r_attr) be_7\VB\14625458|cause_40|was_18|._128 (r_xcomp) considered_5\VBN\689344|NONE_0 (l_nsubjpass) cause_1\NN\7323922|was_22|be_40|._168 (l_prep) of_2\IN\0|the_10 (l_pobj) hyperkalemia_3\NN\14299637|NONE_0
D011188_D007674 NONE potassium_21\NN\14625458|sparing_10 (r_compound) agents_23\NNS\7347|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) combination_19\NN\7951464|NONE_0 (r_pobj) in_18\IN\13603305|arb_4 (r_prep) using_14\VBG\418025|elderly_17 (r_acl) patients_13\NNS\9898892|especially_22|and_68|have_76 (r_pobj) in_11\IN\13603305|clinicians_74|should_63|alert_53|,_13|._114 (l_conj) have_26\VBP\7846|especially_98|patients_76|and_8 (l_dobj) disturbance_29\NN\407535|who_20
D000809_D013575 NONE angiotensin_12\NN\4522421|-_11 (r_npadvmod) converting_14\VBG\126264|the_16|enzyme_11|and_28|spironolactone_32 (r_amod) inhibitor_16\NN\20090|NONE_0 (r_pobj) with_10\IN\0|a_19|combined_17 (r_prep) therapy_9\NN\657604|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) use_5\NN\407535|NONE_0 (r_pobj) during_4\IN\0|by_16 (r_prep) caused_1\VBD\1617192|._123 (r_acl) syncope_0\NNP\7478169|NONE_0
D011188_D006947 NONE potassium_21\NN\14625458|sparing_10 (r_compound) agents_23\NNS\7347|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) combination_19\NN\7951464|NONE_0 (r_pobj) in_18\IN\13603305|arb_4 (r_prep) using_14\VBG\418025|elderly_17 (r_acl) patients_13\NNS\9898892|especially_22|and_68|have_76 (r_pobj) in_11\IN\13603305|clinicians_74|should_63|alert_53|,_13|._114 (r_prep) be_2\VB\14625458|NONE_0 (l_acomp) alert_3\JJ\14031108|clinicians_21|should_10|,_40|in_53|._167 (l_prep) to_4\IN\0|NONE_0 (l_pobj) possibility_6\NN\5944958|NONE_0 (l_prep) of_7\IN\0|the_16 (l_pobj) hyperkalemia_8\NN\14299637|NONE_0
D013148_D006947 CID spironolactone_18\NN\2721160|the_48|converting_32|enzyme_21|and_4 (r_conj) inhibitor_16\NN\20090|NONE_0 (r_pobj) with_10\IN\0|a_19|combined_17 (r_prep) therapy_9\NN\657604|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) use_5\NN\407535|NONE_0 (r_pobj) during_4\IN\0|by_16 (r_prep) caused_1\VBD\1617192|._123 (l_agent) by_2\IN\0|during_16 (l_pobj) hyperkalemia_3\NN\14299637|NONE_0
D013148_D006947 CID spiranolactone_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|several_14 (r_prep) doses_9\NNS\3740161|to_14|,_50|in_52 (r_attr) be_7\VB\14625458|cause_40|was_18|._128 (r_xcomp) considered_5\VBN\689344|NONE_0 (l_nsubjpass) cause_1\NN\7323922|was_22|be_40|._168 (l_prep) of_2\IN\0|the_10 (l_pobj) hyperkalemia_3\NN\14299637|NONE_0
D013148_D013575 NONE spironolactone_18\NN\2721160|the_48|converting_32|enzyme_21|and_4 (r_conj) inhibitor_16\NN\20090|NONE_0 (r_pobj) with_10\IN\0|a_19|combined_17 (r_prep) therapy_9\NN\657604|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) use_5\NN\407535|NONE_0 (r_pobj) during_4\IN\0|by_16 (r_prep) caused_1\VBD\1617192|._123 (r_acl) syncope_0\NNP\7478169|NONE_0
D017257_D006947 CID ramipril_26\NN\2673637|NONE_0 (r_pobj) of_25\IN\0|the_21|term_12|,_11|inhibitor_20 (r_prep) intake_24\NN\13440063|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_prep) addition_18\NN\3081021|NONE_0 (r_pobj) in_17\IN\13603305|to_66|doses_52|,_2 (r_prep) be_7\VB\14625458|cause_40|was_18|._128 (r_xcomp) considered_5\VBN\689344|NONE_0 (l_nsubjpass) cause_1\NN\7323922|was_22|be_40|._168 (l_prep) of_2\IN\0|the_10 (l_pobj) hyperkalemia_3\NN\14299637|NONE_0
D000809_D006947 NONE angiotensin_12\NN\4522421|-_11 (r_npadvmod) converting_14\VBG\126264|the_16|enzyme_11|and_28|spironolactone_32 (r_amod) inhibitor_16\NN\20090|NONE_0 (r_pobj) with_10\IN\0|a_19|combined_17 (r_prep) therapy_9\NN\657604|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) use_5\NN\407535|NONE_0 (r_pobj) during_4\IN\0|by_16 (r_prep) caused_1\VBD\1617192|._123 (l_agent) by_2\IN\0|during_16 (l_pobj) hyperkalemia_3\NN\14299637|NONE_0
26115410
D001152_D009369 CID ias_14\NNP\0|to_13|,_56|in_71 (r_compound) exposure_15\NN\5042871|that_27 (l_prep) in_25\IN\13603305|ias_71|to_58|,_15 (l_pobj) relationship_26\NN\31921|particularly_16 (l_prep) to_27\IN\0|NONE_0 (l_pobj) cancer_28\NN\14239425|NONE_0
D001152_D009369 CID ias_25\NNP\0|NONE_0 (r_compound) exposure_26\NN\5042871|NONE_0 (r_pobj) with_21\IN\0|that_19|is_14 (r_prep) associated_20\VBN\628491|the_62|increased_58|of_43|in_21 (r_relcl) risk_12\NN\14541044|that_28 (l_prep) of_13\IN\0|the_19|increased_15|in_22|associated_43 (l_pobj) development_15\NN\248977|NONE_0 (l_compound) cancer_14\NN\14239425|NONE_0
D001152_D009369 CID ias_28\NNP\0|NONE_0 (r_compound) exposure_29\NN\5042871|by_24|effects_37 (r_nsubj) elicits_30\VBZ\1617192|plausible_65|underlying_55 (r_relcl) mechanisms_22\NNS\13446390|reprogramming_150|,_86|development_80|._79 (r_attr) are_19\VBP\13600404|NONE_0 (l_nsubj) development_11\NN\248977|reprogramming_70|,_6|mechanisms_80|._159 (l_prep) of_12\IN\0|the_16|,_20|and_22|immunomodulation_26 (l_pobj) cells_15\NNS\3080309|NONE_0 (l_compound) cancer_13\NN\14239425|stem_7
D001152_D009369 CID ias_8\NNP\0|and_13|development_24 (r_compound) exposure_9\NN\5042871|that_28|later_32 (l_conj) development_12\NN\248977|ias_24|and_11 (l_compound) cancer_11\NN\14239425|NONE_0
1359137
D014150_D000568 CID neuroleptic_12\NN\4470232|-_11 (r_npadvmod) associated_14\VBN\628491|and_30|galactorrhea_45 (r_amod) hyperprolactinemia_15\NN\0|NONE_0 (l_conj) galactorrhea_19\NN\0|associated_45|and_15 (l_nmod) amenorrhea_17\NN\14299637|/_10
D001971_D005687 NONE bromocriptine_3\NN\0|that_5|should_14|be_21|further_24|as_42 (r_nsubjpass) evaluated_7\VBN\670261|this_51|._104 (l_prep) as_8\IN\14622893|that_47|bromocriptine_42|should_28|be_21|further_18 (l_pobj) therapy_10\NN\657604|NONE_0 (l_prep) for_11\IN\0|potential_18 (l_pobj) hyperprolactinemia_15\NN\0|NONE_0 (l_conj) galactorrhea_19\NN\0|associated_45|and_15
D014150_D006966 CID neuroleptic_0\RB\4470232|-_11 (r_npadvmod) associated_2\VBN\628491|._29 (r_amod) hyperprolactinemia_3\NN\0|NONE_0
D014150_D006966 CID neuroleptic_12\NN\4470232|-_11 (r_npadvmod) associated_14\VBN\628491|and_30|galactorrhea_45 (r_amod) hyperprolactinemia_15\NN\0|NONE_0
D001971_D009839 NONE bromocriptine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|were_13 (r_prep) treated_7\VBN\2376958|oligomenorrhea_66|with_40|._26 (r_advcl) associated_1\VBN\628491|NONE_0 (l_nsubj) oligomenorrhea_0\NN\13513747|with_26|treated_66|._92
D014150_D005687 NONE neuroleptic_12\NN\4470232|-_11 (r_npadvmod) associated_14\VBN\628491|and_30|galactorrhea_45 (r_amod) hyperprolactinemia_15\NN\0|NONE_0 (l_conj) galactorrhea_19\NN\0|associated_45|and_15
D014150_D009839 CID medications_5\NNS\3247620|NONE_0 (r_pobj) with_2\IN\0|oligomenorrhea_26|treated_40|._66 (r_prep) associated_1\VBN\628491|NONE_0 (l_nsubj) oligomenorrhea_0\NN\13513747|with_26|treated_66|._92
D001971_D000568 NONE bromocriptine_3\NN\0|that_5|should_14|be_21|further_24|as_42 (r_nsubjpass) evaluated_7\VBN\670261|this_51|._104 (l_prep) as_8\IN\14622893|that_47|bromocriptine_42|should_28|be_21|further_18 (l_pobj) therapy_10\NN\657604|NONE_0 (l_prep) for_11\IN\0|potential_18 (l_pobj) hyperprolactinemia_15\NN\0|NONE_0 (l_conj) galactorrhea_19\NN\0|associated_45|and_15 (l_nmod) amenorrhea_17\NN\14299637|/_10
D001971_D011618 CID bromocriptine_11\NN\0|while_13 (r_dobj) taking_10\VBG\37396|woman_62|,_57|however_55|,_48|symptoms_15|,_20|and_22|discontinued_33 (r_advcl) developed_5\VBN\1753788|NONE_0 (l_dobj) symptoms_8\NNS\5823932|woman_47|,_42|however_40|,_33|taking_15|,_35|and_37|discontinued_48
D001971_D006966 NONE bromocriptine_3\NN\0|that_5|should_14|be_21|further_24|as_42 (r_nsubjpass) evaluated_7\VBN\670261|this_51|._104 (l_prep) as_8\IN\14622893|that_47|bromocriptine_42|should_28|be_21|further_18 (l_pobj) therapy_10\NN\657604|NONE_0 (l_prep) for_11\IN\0|potential_18 (l_pobj) hyperprolactinemia_15\NN\0|NONE_0
24067251
C418563_D007674 NONE fumarate_17\NN\0|NONE_0 (r_pobj) to_14\IN\0|NONE_0 (r_prep) exposed_13\VBN\2110927|positive_17 (r_acl) persons_12\NNS\7347|NONE_0 (r_pobj) in_8\IN\13603305|kidney_14 (r_prep) injury_7\NN\14052046|NONE_0
C418563_D007674 NONE tdf_12\NNP\0|-_3 (r_npadvmod) related_14\VBN\628491|kidney_8|,_22|%_39|)_40 (r_amod) disease_16\NN\14061805|NONE_0
C418563_D007674 NONE tdf_12\NNP\0|-_3 (r_npadvmod) related_14\VBN\628491|kidney_8|,_22|%_39|)_40 (r_amod) disease_16\NN\14061805|NONE_0 (r_pobj) for_11\IN\0|,_25|106_23|satisfied_19 (r_prep) criteria_10\NNS\13577171|NONE_0 (r_dobj) analysed_6\VBN\0|the_28|407_24|card_13 (r_acl) records_5\NNS\6643408|NONE_0 (r_pobj) of_0\IN\0|features_118|found_172|had_234|._254 (r_prep) had_25\VBD\0|NONE_0 (l_dobj) features_26\NNS\5849040|of_118|found_54|had_116|._136 (l_prep) of_27\IN\0|,_29|35_31|(_34|%_37|)_38 (l_pobj) dysfunction_30\NN\14204950|NONE_0
C418563_D007674 NONE tdf_12\NNP\0|-_3 (r_npadvmod) related_14\VBN\628491|kidney_8|,_22|%_39|)_40 (r_amod) disease_16\NN\14061805|NONE_0 (r_pobj) for_11\IN\0|,_25|106_23|satisfied_19 (r_prep) criteria_10\NNS\13577171|NONE_0 (r_dobj) analysed_6\VBN\0|the_28|407_24|card_13 (r_acl) records_5\NNS\6643408|NONE_0 (r_pobj) of_0\IN\0|features_118|found_172|had_234|._254 (r_prep) had_25\VBD\0|NONE_0 (l_conj) found_38\VBN\13279262|of_172|features_54|had_62|._82 (l_advcl) have_40\VB\7846|were_14 (l_dobj) features_41\NNS\5849040|to_8 (l_prep) of_42\IN\0|and_26|%_36 (l_pobj) dysfunction_44\NN\14204950|NONE_0
C418563_D005198 CID tdf_12\NNP\0|-_3 (r_npadvmod) related_14\VBN\628491|kidney_8|,_22|%_39|)_40 (r_amod) disease_16\NN\14061805|NONE_0 (r_pobj) for_11\IN\0|,_25|106_23|satisfied_19 (r_prep) criteria_10\NNS\13577171|NONE_0 (r_dobj) analysed_6\VBN\0|the_28|407_24|card_13 (r_acl) records_5\NNS\6643408|NONE_0 (r_pobj) of_0\IN\0|features_118|found_172|had_234|._254 (r_prep) had_25\VBD\0|NONE_0 (l_conj) had_51\VBD\0|of_234|features_116|found_62|._20 (l_dobj) syndrome_53\NN\5870365|NONE_0
C418563_D005198 CID tdf_5\NNP\0|kidney_4|adverse_11 (r_compound) effects_8\NNS\13245626|NONE_0 (r_pobj) for_4\IN\0|NONE_0 (r_prep) hospitalisation_3\NN\657604|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) incidence_1\NN\13821570|high_64|,_68|amongst_83|._133 (r_nsubj) was_9\VBD\0|NONE_0 (l_prep) amongst_13\IN\0|incidence_83|high_19|,_15|._50 (l_pobj) patients_14\NNS\9898892|particularly_21 (l_prep) with_15\IN\0|NONE_0 (l_pobj) features_16\NNS\5849040|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) syndrome_19\NN\5870365|NONE_0
8659767
D002045_D009203 NONE bupivacaine_4\NN\0|whether_8|dysrhythmogenicity_23|in_86 (r_nsubj) alters_5\VBZ\0|we_42|therefore_39|._152 (l_prep) in_13\IN\13603305|whether_94|bupivacaine_86|dysrhythmogenicity_63 (l_conj) in_19\IN\13603305|dogs_9|and_4 (l_pobj) dogs_21\NNS\2083346|NONE_0 (l_prep) with_22\IN\0|anesthetized_18 (l_pobj) infarction_24\NN\14204950|NONE_0
D002045_D017180 NONE bupivacaine_0\NNP\0|dysrhythmogenicity_36|._157 (r_nsubj) antagonizes_1\VBZ\1787955|NONE_0 (l_dobj) dysrhythmogenicity_3\NN\0|bupivacaine_36|._121 (l_prep) in_4\IN\13603305|epinephrine_31 (l_pobj) dogs_6\NNS\2083346|and_23|in_27 (l_amod) susceptible_7\JJ\0|conscious_15 (l_prep) to_8\IN\0|NONE_0 (l_pobj) vt_9\NNP\0|NONE_0
D002045_D001145 NONE bupivacaine_1\NN\0|NONE_0 (r_pobj) since_0\IN\0|dysrhythmias_55|could_120|effects_153|._175 (r_prep) potentiate_15\VB\229605|NONE_0 (l_nsubj) dysrhythmias_7\NNS\0|since_55|could_65|effects_98|._120
D002045_D001145 NONE bupivacaine_10\NN\0|may_47|both_43|precipitate_38|,_14 (r_appos) dysrhythmias_7\NNS\0|since_55|could_65|effects_98|._120
D002045_D001145 NONE bupivacaine_0\NNP\0|dysrhythmogenicity_36|._157 (r_nsubj) antagonizes_1\VBZ\1787955|NONE_0 (l_dobj) dysrhythmogenicity_3\NN\0|bupivacaine_36|._121 (l_prep) in_4\IN\13603305|epinephrine_31 (l_conj) in_11\IN\13603305|dogs_27|and_4 (l_pobj) dogs_13\NNS\2083346|NONE_0 (l_prep) with_14\IN\0|anesthetized_18 (l_pobj) dysrhythmias_17\NNS\0|NONE_0
D004837_D001145 NONE epinephrine_3\NN\14807929|and_4 (r_conj) bupivacaine_1\NN\0|NONE_0 (r_pobj) since_0\IN\0|dysrhythmias_55|could_120|effects_153|._175 (r_prep) potentiate_15\VB\229605|NONE_0 (l_nsubj) dysrhythmias_7\NNS\0|since_55|could_65|effects_98|._120
D004837_D001145 NONE epinephrine_19\NN\14807929|NONE_0 (r_pobj) of_18\IN\0|dysrhythmogenic_24 (r_prep) effects_17\NNS\13245626|since_153|dysrhythmias_98|could_33|._22 (r_dobj) potentiate_15\VB\229605|NONE_0 (l_nsubj) dysrhythmias_7\NNS\0|since_55|could_65|effects_98|._120
D004837_D001145 NONE epinephrine_2\NN\14807929|in_31 (r_amod) dysrhythmogenicity_3\NN\0|bupivacaine_36|._121 (l_prep) in_4\IN\13603305|epinephrine_31 (l_conj) in_11\IN\13603305|dogs_27|and_4 (l_pobj) dogs_13\NNS\2083346|NONE_0 (l_prep) with_14\IN\0|anesthetized_18 (l_pobj) dysrhythmias_17\NNS\0|NONE_0
D006221_D017180 NONE halothane_9\NN\3570838|-_9 (r_npadvmod) anesthetized_11\VBN\84738|six_25|additional_21 (r_amod) dogs_12\NNS\2083346|after_80|,_40|epinephrine_38|appeared_59|._67 (r_nsubj) received_13\VBD\2210855|NONE_0 (l_advcl) appeared_19\VBD\2604760|after_139|,_99|dogs_59|epinephrine_21|._8 (l_nsubj) vt_18\NNP\0|until_6
D004837_D009203 NONE epinephrine_12\NN\14807929|NONE_0 (r_pobj) of_11\IN\0|subsequent_26 (r_prep) administration_10\NN\1133281|NONE_0 (r_pobj) of_8\IN\0|the_23 (r_prep) dysrhythmogenicity_7\NN\0|whether_31|bupivacaine_23|in_63 (r_dobj) alters_5\VBZ\0|we_42|therefore_39|._152 (l_prep) in_13\IN\13603305|whether_94|bupivacaine_86|dysrhythmogenicity_63 (l_conj) in_19\IN\13603305|dogs_9|and_4 (l_pobj) dogs_21\NNS\2083346|NONE_0 (l_prep) with_22\IN\0|anesthetized_18 (l_pobj) infarction_24\NN\14204950|NONE_0
D004837_D009203 NONE epinephrine_16\NN\14807929|after_118|,_78|dogs_38|appeared_21|._29 (r_dobj) received_13\VBD\2210855|NONE_0 (l_prep) after_2\IN\0|,_40|dogs_80|epinephrine_118|appeared_139|._147 (l_pobj) infarction_5\NN\14204950|day_34
D006221_D009203 NONE halothane_9\NN\3570838|-_9 (r_npadvmod) anesthetized_11\VBN\84738|six_25|additional_21 (r_amod) dogs_12\NNS\2083346|after_80|,_40|epinephrine_38|appeared_59|._67 (r_nsubj) received_13\VBD\2210855|NONE_0 (l_prep) after_2\IN\0|,_40|dogs_80|epinephrine_118|appeared_139|._147 (l_pobj) infarction_5\NN\14204950|day_34
D004837_D017180 CID epinephrine_16\NN\14807929|after_118|,_78|dogs_38|appeared_21|._29 (r_dobj) received_13\VBD\2210855|NONE_0 (l_advcl) appeared_19\VBD\2604760|after_139|,_99|dogs_59|epinephrine_21|._8 (l_nsubj) vt_18\NNP\0|until_6
D004837_D017180 CID epinephrine_2\NN\14807929|in_31 (r_amod) dysrhythmogenicity_3\NN\0|bupivacaine_36|._121 (l_prep) in_4\IN\13603305|epinephrine_31 (l_pobj) dogs_6\NNS\2083346|and_23|in_27 (l_amod) susceptible_7\JJ\0|conscious_15 (l_prep) to_8\IN\0|NONE_0 (l_pobj) vt_9\NNP\0|NONE_0
12678199
D004077_D007008 NONE digoxin_19\JJ\15060131|NONE_0 (r_compound) excess_20\NN\5119367|and_12 (r_conj) hypokalemia_17\NN\14299637|NONE_0
D004077_D016171 NONE digoxin_19\JJ\15060131|NONE_0 (r_compound) excess_20\NN\5119367|and_12 (r_conj) hypokalemia_17\NN\14299637|NONE_0 (r_pobj) including_16\VBG\0|multiple_30|exacerbating_21 (r_prep) factors_15\NNS\7326557|NONE_0 (r_pobj) of_12\IN\0|the_12 (r_prep) context_11\NN\6284777|NONE_0 (r_pobj) in_9\IN\13603305|consistent_56|case_21|._88 (r_prep) occurred_8\VBD\0|NONE_0 (l_nsubj) case_5\NN\7283608|consistent_35|in_21|._109 (l_prep) of_6\IN\0|this_10 (l_pobj) tdp_7\NNP\0|NONE_0
D000638_D016171 CID amiodarone_0\NN\2715941|-_10 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) torsade_3\NN\0|de_8|during_19|:_44|presentation_57|._84 (r_nmod) pointes_5\FW\831651|NONE_0
D000638_D016171 CID amiodarone_23\NN\2715941|oral_5 (r_compound) therapy_24\NN\657604|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) associated_20\VBN\628491|torsade_25|de_17|(_6|tdp_5|)_2 (r_acl) pointes_16\FW\831651|NONE_0
D000638_D016171 CID amiodarone_23\NN\2715941|oral_5 (r_compound) therapy_24\NN\657604|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) associated_20\VBN\628491|torsade_25|de_17|(_6|tdp_5|)_2 (r_acl) pointes_16\FW\831651|NONE_0 (l_appos) tdp_18\NN\0|torsade_20|de_12|(_1|)_3|associated_5
D000638_D016171 CID amiodarone_4\NN\2715941|NONE_0 (r_compound) therapy_5\NN\657604|NONE_0 (r_pobj) of_3\IN\0|the_12 (r_prep) absence_2\NN\14449405|NONE_0 (r_pobj) in_0\IN\13603305|,_36|irrigation_55|did_66|not_70|tdp_81|despite_85|._123 (r_prep) induce_13\VB\1627355|NONE_0 (l_dobj) tdp_14\NN\0|in_81|,_45|irrigation_26|did_15|not_11|despite_4|._42
D000638_C537153 NONE amiodarone_4\NN\2715941|NONE_0 (r_compound) therapy_5\NN\657604|NONE_0 (r_pobj) of_3\IN\0|the_12 (r_prep) absence_2\NN\14449405|NONE_0 (r_pobj) in_0\IN\13603305|,_36|irrigation_55|did_66|not_70|tdp_81|despite_85|._123 (r_prep) induce_13\VB\1627355|NONE_0 (l_prep) despite_15\IN\7501545|in_85|,_49|irrigation_30|did_19|not_15|tdp_4|._38 (l_pobj) hypokalemia_16\NN\14299637|NONE_0 (l_conj) hypomagnesemia_18\NN\0|and_4
D000638_D007008 NONE amiodarone_4\NN\2715941|NONE_0 (r_compound) therapy_5\NN\657604|NONE_0 (r_pobj) of_3\IN\0|the_12 (r_prep) absence_2\NN\14449405|NONE_0 (r_pobj) in_0\IN\13603305|,_36|irrigation_55|did_66|not_70|tdp_81|despite_85|._123 (r_prep) induce_13\VB\1627355|NONE_0 (l_prep) despite_15\IN\7501545|in_85|,_49|irrigation_30|did_19|not_15|tdp_4|._38 (l_pobj) hypokalemia_16\NN\14299637|NONE_0
D000638_-1 NONE amiodarone_20\NN\2715941|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|the_12 (r_prep) context_18\NN\6284777|NONE_0 (r_pobj) in_16\IN\13603305|that_75|tone_50|in_46 (r_prep) resulted_22\VBD\2633881|authors_130|._44 (l_prep) in_23\IN\13603305|that_121|tone_96|in_46 (l_pobj) proarrhythmia_27\NN\0|NONE_0
D000638_-1 NONE amiodarone_24\NN\2715941|-_10 (r_npadvmod) induced_26\VBN\1627355|NONE_0 (r_amod) proarrhythmia_27\NN\0|NONE_0
20828385
C401859_D009369 NONE temsirolimus_19\NN\0|NONE_0 (r_compound) treatment_20\NN\654885|months_26 (r_pobj) after_18\IN\0|who_36|regression_22|,_28 (r_prep) had_13\VBD\0|refractory_19 (l_dobj) regression_15\NN\14501726|who_14|after_22|,_50 (l_compound) tumor_14\NN\14234074|NONE_0
C401859_D009369 NONE temsirolimus_7\NN\0|that_5|proliferation_34|through_48|,_73|but_75|induce_87 (r_nsubj) inhibited_8\JJ\2510337|comparison_56|._130 (l_dobj) proliferation_11\NN\13489037|that_39|temsirolimus_34|through_14|,_39|but_41|induce_53 (l_compound) cell_10\NN\3080309|NONE_0 (l_compound) tumor_9\NN\14234074|NONE_0
C401859_D009369 NONE temsirolimus_7\NN\0|that_5|proliferation_34|through_48|,_73|but_75|induce_87 (r_nsubj) inhibited_8\JJ\2510337|comparison_56|._130 (l_conj) induce_20\VB\1627355|that_92|temsirolimus_87|proliferation_53|through_39|,_14|but_12 (l_dobj) change_22\NN\7283608|did_19|not_15 (l_prep) in_23\IN\13603305|any_11 (l_pobj) number_25\NN\5107765|NONE_0 (l_prep) of_26\IN\0|the_11 (l_pobj) cells_29\NNS\3080309|NONE_0 (l_compound) tumor_28\NN\14234074|apoptotic_10
C401859_D009369 NONE temsirolimus_6\NNS\0|apart_35|,_2|effect_35|._107 (r_nsubj) had_7\VBD\0|NONE_0 (l_dobj) effect_10\NN\34213|apart_70|,_37|temsirolimus_35|._72 (l_prep) with_11\IN\0|an_25|antiangiogenic_22 (l_pobj) decrease_12\NN\7296428|and_38|of_42 (l_prep) of_13\IN\0|NONE_0 (l_pobj) density_16\NN\4941325|NONE_0 (l_compound) tumor_14\NN\14234074|microvessel_6
C401859_D009369 NONE temsirolimus_2\NNS\0|thus_6|,_2|burden_27|through_34|._91 (r_nsubj) reduced_3\VBN\441445|NONE_0 (l_dobj) burden_5\NN\5832264|thus_33|,_29|temsirolimus_27|through_7|._64 (l_compound) tumor_4\NN\14234074|NONE_0
C401859_D009369 NONE temsirolimus_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|this_17|dual_12|on_16 (r_prep) effect_2\NN\34213|could_39|to_56|._148 (l_prep) on_5\IN\0|this_33|dual_28|of_16 (l_pobj) tissue_7\NN\5220461|NONE_0 (l_compound) tumor_6\NN\14234074|NONE_0
C401859_D020522 NONE temsirolimus_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|cytostatic_39|angiogenic_19|in_16|._50 (r_prep) effects_5\NNS\13245626|NONE_0 (l_prep) in_8\IN\13603305|cytostatic_55|angiogenic_35|of_16|._34 (l_pobj) lymphoma_12\NN\14239918|NONE_0
C401859_D020522 NONE temsirolimus_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) treated_14\VBN\2376958|however_75|,_68|rate_50|has_45|been_41|recently_36|in_18|._43 (r_advcl) reported_10\VBN\831651|NONE_0 (l_prep) in_11\IN\13603305|however_57|,_50|rate_32|has_27|been_23|recently_18|treated_18|._61 (l_pobj) mcl_13\NN\0|NONE_0
C401859_D020522 NONE temsirolimus_19\NN\0|NONE_0 (r_compound) treatment_20\NN\654885|months_26 (r_pobj) after_18\IN\0|who_36|regression_22|,_28 (r_prep) had_13\VBD\0|refractory_19 (r_relcl) mcl_11\NNP\0|NONE_0
C401859_D020522 NONE temsirolimus_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|this_17|dual_12|on_16 (r_prep) effect_2\NN\34213|could_39|to_56|._148 (r_nsubj) contribute_9\VB\126264|NONE_0 (l_prep) to_10\IN\0|effect_56|could_17|._92 (l_pobj) efficiency_14\NN\13819207|NONE_0 (l_prep) in_15\IN\13603305|its_33|reported_20|resistant_18 (l_pobj) mcl_17\NN\0|NONE_0
C401859_D009336 CID temsirolimus_23\NN\0|6-month_8 (r_compound) therapy_24\NN\657604|NONE_0 (r_pobj) after_21\IN\0|moreover_112|,_104|areas_63|,_13|were_11|._34 (r_prep) found_20\VBN\13279262|NONE_0 (l_nsubjpass) areas_9\NNS\8630985|moreover_49|,_41|,_50|were_52|after_63|._97 (l_amod) compatible_11\JJ\0|numerous_46|patchy_37|,_31|limited_24|fibrotic_16|,_2 (l_prep) with_12\IN\0|NONE_0 (l_pobj) repair_17\NN\248977|NONE_0 (l_amod) necrotic_15\JJ\0|tissue_9
15696449
D003404_D058186 NONE creatinine_31\NN\0|the_10|serum_6 (r_compound) level_32\NN\4916342|NONE_0 (r_pobj) in_28\IN\13603305|a_48|minimum_46|of_29|is_35 (r_prep) increase_16\NN\13576355|NONE_0 (r_pobj) by_13\IN\0|insufficiency_58|after_38|melphalan_22|was_12|._148 (r_agent) defined_12\VBN\2604760|NONE_0 (l_nsubjpass) insufficiency_2\NN\14462946|after_20|melphalan_36|was_46|by_58|._206
D003404_D058186 NONE creatinine_31\NN\0|the_10|serum_6 (r_compound) level_32\NN\4916342|NONE_0 (r_pobj) in_28\IN\13603305|a_48|minimum_46|of_29|is_35 (r_prep) increase_16\NN\13576355|NONE_0 (r_pobj) by_13\IN\0|insufficiency_58|after_38|melphalan_22|was_12|._148 (r_agent) defined_12\VBN\2604760|NONE_0 (l_nsubjpass) insufficiency_2\NN\14462946|after_20|melphalan_36|was_46|by_58|._206 (l_appos) ari_4\NNP\0|acute_27|renal_21|(_1|)_3
D008558_C531616 NONE melphalan_7\NN\2722458|NONE_0 (l_prep) in_8\IN\13603305|dose_15 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) amyloidosis_13\NN\14061805|NONE_0
D008558_D058186 CID melphalan_7\NN\2722458|NONE_0 (r_pobj) after_3\IN\0|acute_26|renal_20|._104 (r_prep) insufficiency_2\NN\14462946|NONE_0
D008558_D058186 CID melphalan_12\NN\2722458|NONE_0 (r_compound) conditioning_13\NN\5752544|immediately_28 (r_pobj) after_11\IN\0|the_57|of_41 (r_prep) development_5\NN\248977|authors_23|have_15|._81 (l_prep) of_6\IN\0|the_16|after_41 (l_pobj) insufficiency_9\NN\14462946|NONE_0
D008558_D058186 CID melphalan_10\NN\2722458|insufficiency_36|after_16|was_10|by_22|._170 (r_nsubjpass) defined_12\VBN\2604760|NONE_0 (l_nsubjpass) insufficiency_2\NN\14462946|after_20|melphalan_36|was_46|by_58|._206
D008558_D058186 CID melphalan_10\NN\2722458|insufficiency_36|after_16|was_10|by_22|._170 (r_nsubjpass) defined_12\VBN\2604760|NONE_0 (l_nsubjpass) insufficiency_2\NN\14462946|after_20|melphalan_36|was_46|by_58|._206 (l_appos) ari_4\NNP\0|acute_27|renal_21|(_1|)_3
D008558_D058186 CID melphalan_18\NN\2722458|NONE_0 (r_pobj) after_14\IN\0|of_67|,_41|ari_39|in_25|._25 (r_prep) developed_7\VBD\1753788|NONE_0 (l_nsubj) ari_6\NNP\0|of_28|,_2|in_14|after_39|._64
D008558_D058186 CID melphalan_8\NN\2722458|patients_37|dialysis_20|often_34|p_41|,_51|and_53|had_57|._95 (r_nsubj) underwent_9\VBD\109660|NONE_0 (l_nsubj) patients_0\NNS\9898892|melphalan_37|dialysis_57|often_71|p_78|,_88|and_90|had_94|._132 (l_relcl) had_2\VBD\0|NONE_0 (l_dobj) ari_3\NNP\0|who_8|after_4
D008558_D058186 CID melphalan_7\NN\2722458|timing_41|strongly_18|._32 (r_dobj) suggests_6\VBZ\1010118|NONE_0 (l_nsubj) timing_1\NN\5044673|strongly_23|melphalan_41|._73 (l_prep) of_2\IN\0|the_11 (l_pobj) injury_4\NN\14052046|NONE_0
D008558_D058186 CID melphalan_11\NN\2722458|NONE_0 (r_pobj) by_10\IN\0|renal_13 (r_prep) injury_9\NN\14052046|NONE_0
D008558_-1 NONE melphalan_11\NN\2722458|NONE_0 (r_pobj) by_10\IN\0|renal_13 (r_prep) injury_9\NN\14052046|NONE_0 (r_pobj) for_7\IN\0|a_15 (r_prep) prerequisite_6\NN\1129920|injury_16|may_9|evidenced_46|._86 (r_attr) be_4\VB\14625458|NONE_0 (l_nsubj) injury_2\NN\14052046|may_7|prerequisite_16|evidenced_62|._102
19139825
D019772_D005910 NONE topotecan_0\NNP\0|option_27|exhibits_40|._111 (r_nsubj) is_1\VBZ\0|NONE_0 (l_advcl) exhibits_7\VBZ\6733939|topotecan_40|option_13|._71 (l_dobj) inhibition_9\NN\1068773|as_22|it_19 (l_prep) of_10\IN\0|growth_18 (l_pobj) glioma_12\NN\14236743|NONE_0
D019772_D005909 NONE topotecan_0\JJ\0|NONE_0 (l_prep) in_1\IN\13603305|._78 (l_pobj) combination_2\NN\7951464|NONE_0 (l_prep) with_3\IN\0|NONE_0 (l_pobj) radiotherapy_4\NN\661091|NONE_0 (l_prep) in_5\IN\13603305|NONE_0 (l_pobj) glioblastoma_7\NN\14236743|NONE_0
D019772_D005909 NONE topotecan_15\JJ\0|study_80|combination_61|._117 (l_prep) in_34\IN\13603305|m(2)/day_42 (l_pobj) adults_36\NNS\7846|NONE_0 (l_prep) with_37\IN\0|50_10 (l_pobj) gbm_42\NNP\0|NONE_0
3383127
D002945_D015179 NONE cisplatin_18\NN\0|cddp_11 (r_pobj) with_17\IN\0|while_20|being_14 (r_prep) treated_16\VBN\2376958|symptoms_108|in_65|5-fu_50|._55 (r_advcl) developed_6\VBN\1753788|NONE_0 (l_prep) in_7\IN\13603305|symptoms_43|treated_65|5-fu_115|._120 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|three_15 (l_pobj) carcinoma_13\NN\14239918|NONE_0
D002945_D015179 NONE cddp_20\NNP\0|cisplatin_11 (r_pobj) with_17\IN\0|while_20|being_14 (r_prep) treated_16\VBN\2376958|symptoms_108|in_65|5-fu_50|._55 (r_advcl) developed_6\VBN\1753788|NONE_0 (l_prep) in_7\IN\13603305|symptoms_43|treated_65|5-fu_115|._120 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|three_15 (l_pobj) carcinoma_13\NN\14239918|NONE_0
D005472_D007022 CID 5-fluorouracil_12\CD\0|NONE_0 (r_punct) ._13\.\0|as_93 (r_punct) hypotension_0\NN\14057371|NONE_0
D005472_D007022 CID 5-fluorouracil_23\CD\0|(_15|)_20 (r_punct) 5-fu_25\CD\0|symptoms_158|in_115|treated_50|._5 (r_npadvmod) developed_6\VBN\1753788|NONE_0 (l_nsubj) symptoms_1\NNS\5823932|in_43|treated_108|5-fu_158|._163 (l_prep) including_3\VBG\0|cardiac_18|,_2|,_21 (l_pobj) hypotension_4\NN\14057371|NONE_0
D005472_D007022 CID 5-fu_25\CD\0|symptoms_158|in_115|treated_50|._5 (r_npadvmod) developed_6\VBN\1753788|NONE_0 (l_nsubj) symptoms_1\NNS\5823932|in_43|treated_108|5-fu_158|._163 (l_prep) including_3\VBG\0|cardiac_18|,_2|,_21 (l_pobj) hypotension_4\NN\14057371|NONE_0
D005472_D015179 NONE 5-fluorouracil_23\CD\0|(_15|)_20 (r_punct) 5-fu_25\CD\0|symptoms_158|in_115|treated_50|._5 (r_npadvmod) developed_6\VBN\1753788|NONE_0 (l_prep) in_7\IN\13603305|symptoms_43|treated_65|5-fu_115|._120 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|three_15 (l_pobj) carcinoma_13\NN\14239918|NONE_0
D005472_D015179 NONE 5-fu_25\CD\0|symptoms_158|in_115|treated_50|._5 (r_npadvmod) developed_6\VBN\1753788|NONE_0 (l_prep) in_7\IN\13603305|symptoms_43|treated_65|5-fu_115|._120 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|three_15 (l_pobj) carcinoma_13\NN\14239918|NONE_0
D002945_D066126 NONE cisplatin_10\NN\0|NONE_0 (r_dobj) receiving_9\VBG\2210855|three_15 (r_acl) patients_8\NNS\9898892|NONE_0 (r_pobj) in_6\IN\13603305|a_34|of_18 (r_prep) manifestation_3\NN\7321772|NONE_0 (l_prep) of_4\IN\0|a_16|in_18 (l_pobj) cardiotoxicity_5\NN\0|NONE_0
D002945_D066126 NONE cddp_27\NNP\0|NONE_0 (r_pobj) by_26\IN\0|that_23|may_18|be_14 (r_agent) influenced_25\VBN\137313|new_54|of_35 (r_relcl) manifestations_18\NNS\7321772|presentation_118|._68 (l_prep) of_19\IN\0|new_19|influenced_35 (l_pobj) cardiotoxicity_21\NN\0|NONE_0
D005472_D066126 NONE 5-fluorouracil_12\CD\0|NONE_0 (r_punct) ._13\.\0|as_93 (r_punct) hypotension_0\NN\14057371|NONE_0 (l_prep) as_1\IN\14622893|._93 (l_pobj) manifestation_3\NN\7321772|NONE_0 (l_prep) of_4\IN\0|a_16|in_18 (l_pobj) cardiotoxicity_5\NN\0|NONE_0
D005472_D066126 NONE 5-fu_20\CD\0|NONE_0 (r_compound) cardiotoxicity_21\NN\0|NONE_0
D002945_D007022 CID cisplatin_10\NN\0|NONE_0 (r_dobj) receiving_9\VBG\2210855|three_15 (r_acl) patients_8\NNS\9898892|NONE_0 (r_pobj) in_6\IN\13603305|a_34|of_18 (r_prep) manifestation_3\NN\7321772|NONE_0 (r_pobj) as_1\IN\14622893|._93 (r_prep) hypotension_0\NN\14057371|NONE_0
D002945_D007022 CID cisplatin_18\NN\0|cddp_11 (r_pobj) with_17\IN\0|while_20|being_14 (r_prep) treated_16\VBN\2376958|symptoms_108|in_65|5-fu_50|._55 (r_advcl) developed_6\VBN\1753788|NONE_0 (l_nsubj) symptoms_1\NNS\5823932|in_43|treated_108|5-fu_158|._163 (l_prep) including_3\VBG\0|cardiac_18|,_2|,_21 (l_pobj) hypotension_4\NN\14057371|NONE_0
D002945_D007022 CID cddp_20\NNP\0|cisplatin_11 (r_pobj) with_17\IN\0|while_20|being_14 (r_prep) treated_16\VBN\2376958|symptoms_108|in_65|5-fu_50|._55 (r_advcl) developed_6\VBN\1753788|NONE_0 (l_nsubj) symptoms_1\NNS\5823932|in_43|treated_108|5-fu_158|._163 (l_prep) including_3\VBG\0|cardiac_18|,_2|,_21 (l_pobj) hypotension_4\NN\14057371|NONE_0
20431083
D014859_-1 NONE warfarin_57\NN\2718259|(_15|difference=0.01_18|)_33 (r_amod) users_58\NNS\7846|NONE_0 (r_pobj) in_56\IN\13603305|(_18|,_12|3.5_10|)_2 (r_prep) range_50\NN\5123416|9.7_36|)_33|in_31 (r_parataxis) 3.4_40\CD\0|5.7_12|(_8|,_2 (r_appos) range_38\NN\5123416|NONE_0 (r_pobj) to_35\IN\0|(_56|odds_55|;_45|range_43|in_27 (r_prep) ratio_24\NN\13815152|2.8_10 (r_pobj) from_20\IN\0|excess_17|._174 (r_prep) increased_19\VBD\169651|,_81|mb_79|frequent_66|in_57|vs_50|,_17|but_15 (r_conj) were_2\VBD\0|NONE_0 (l_nsubj) mb_1\NNS\13601596|,_2|frequent_13|in_22|vs_29|,_62|but_64|increased_79
D014859_-1 NONE warfarin_8\JJ\2718259|vs_15 (r_amod) users_9\NNS\7846|NONE_0 (r_pobj) in_7\IN\13603305|an_16|of_6 (r_prep) excess_4\NN\5119367|there_18|also_8|but_88|none_92|._180 (l_prep) of_5\IN\0|an_10|in_6 (l_pobj) mb_6\NN\13601596|NONE_0
D014859_-1 NONE warfarin_32\JJ\2718259|with_15 (r_amod) users_33\NNS\7846|NONE_0 (r_pobj) in_31\IN\13603305|NONE_0 (r_prep) none_30\NN\15228378|there_110|also_100|excess_92|but_4|._88 (r_attr) was_1\VBD\0|NONE_0 (l_attr) excess_4\NN\5119367|there_18|also_8|but_88|none_92|._180 (l_prep) of_5\IN\0|an_10|in_6 (l_pobj) mb_6\NN\13601596|NONE_0
D014859_-1 NONE warfarin_5\JJ\2718259|with_15 (r_amod) users_6\NNS\7846|NONE_0 (r_pobj) in_4\IN\13603305|the_17|of_6|compared_27 (r_prep) excess_1\NN\5119367|increase_82|._126 (l_prep) of_2\IN\0|the_11|in_6|compared_33 (l_pobj) mb_3\NN\13601596|NONE_0
D014859_-1 NONE warfarin_5\JJ\2718259|with_15 (r_amod) users_6\NNS\7846|NONE_0 (r_pobj) in_4\IN\13603305|the_17|of_6|compared_27 (r_prep) excess_1\NN\5119367|increase_82|._126 (r_nsubj) suggests_13\VBZ\1010118|NONE_0 (l_ccomp) increase_16\VBP\13576355|excess_82|._44 (l_nsubj) mb_15\NN\13601596|that_5|risk_16
D014859_-1 NONE warfarin_20\NN\2718259|-_8 (r_npadvmod) associated_22\VBN\628491|NONE_0 (r_amod) ich_23\NNP\0|NONE_0 (r_pobj) of_19\IN\0|the_9 (r_prep) risk_18\NN\14541044|that_21|mb_16 (r_dobj) increase_16\VBP\13576355|excess_82|._44 (r_ccomp) suggests_13\VBZ\1010118|NONE_0 (l_nsubj) excess_1\NN\5119367|increase_82|._126 (l_prep) of_2\IN\0|the_11|in_6|compared_33 (l_pobj) mb_3\NN\13601596|NONE_0
D014859_-1 NONE warfarin_20\NN\2718259|-_8 (r_npadvmod) associated_22\VBN\628491|NONE_0 (r_amod) ich_23\NNP\0|NONE_0 (r_pobj) of_19\IN\0|the_9 (r_prep) risk_18\NN\14541044|that_21|mb_16 (r_dobj) increase_16\VBP\13576355|excess_82|._44 (l_nsubj) mb_15\NN\13601596|that_5|risk_16
D014859_D002543 CID warfarin_57\NN\2718259|(_15|difference=0.01_18|)_33 (r_amod) users_58\NNS\7846|NONE_0 (r_pobj) in_56\IN\13603305|(_18|,_12|3.5_10|)_2 (r_prep) range_50\NN\5123416|9.7_36|)_33|in_31 (r_parataxis) 3.4_40\CD\0|5.7_12|(_8|,_2 (r_appos) range_38\NN\5123416|NONE_0 (r_pobj) to_35\IN\0|(_56|odds_55|;_45|range_43|in_27 (r_prep) ratio_24\NN\13815152|2.8_10 (r_pobj) from_20\IN\0|excess_17|._174 (r_prep) increased_19\VBD\169651|,_81|mb_79|frequent_66|in_57|vs_50|,_17|but_15 (r_conj) were_2\VBD\0|NONE_0 (l_prep) in_5\IN\13603305|,_24|mb_22|frequent_9|vs_7|,_40|but_42|increased_57 (l_pobj) ich_6\NNP\0|NONE_0
D014859_D002543 CID warfarin_8\JJ\2718259|vs_15 (r_amod) users_9\NNS\7846|NONE_0 (l_prep) vs_10\IN\13634784|warfarin_15 (l_pobj) nonusers_11\NNS\0|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) ich_13\NNP\0|NONE_0
D014859_D002543 CID warfarin_32\JJ\2718259|with_15 (r_amod) users_33\NNS\7846|NONE_0 (r_pobj) in_31\IN\13603305|NONE_0 (r_prep) none_30\NN\15228378|there_110|also_100|excess_92|but_4|._88 (r_attr) was_1\VBD\0|NONE_0 (l_attr) excess_4\NN\5119367|there_18|also_8|but_88|none_92|._180 (l_prep) in_7\IN\13603305|an_16|of_6 (l_pobj) users_9\NNS\7846|NONE_0 (l_prep) vs_10\IN\13634784|warfarin_15 (l_pobj) nonusers_11\NNS\0|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) ich_13\NNP\0|NONE_0
D014859_D002543 CID warfarin_5\JJ\2718259|with_15 (r_amod) users_6\NNS\7846|NONE_0 (l_prep) with_7\IN\0|warfarin_15 (l_pobj) ich_8\NNP\0|NONE_0
D014859_D002543 CID warfarin_5\JJ\2718259|with_15 (r_amod) users_6\NNS\7846|NONE_0 (r_pobj) in_4\IN\13603305|the_17|of_6|compared_27 (r_prep) excess_1\NN\5119367|increase_82|._126 (r_nsubj) suggests_13\VBZ\1010118|NONE_0 (l_ccomp) increase_16\VBP\13576355|excess_82|._44 (l_dobj) risk_18\NN\14541044|that_21|mb_16 (l_prep) of_19\IN\0|the_9 (l_pobj) ich_23\NNP\0|NONE_0
D014859_D002543 CID warfarin_20\NN\2718259|-_8 (r_npadvmod) associated_22\VBN\628491|NONE_0 (r_amod) ich_23\NNP\0|NONE_0 (r_pobj) of_19\IN\0|the_9 (r_prep) risk_18\NN\14541044|that_21|mb_16 (r_dobj) increase_16\VBP\13576355|excess_82|._44 (r_ccomp) suggests_13\VBZ\1010118|NONE_0 (l_nsubj) excess_1\NN\5119367|increase_82|._126 (l_prep) in_4\IN\13603305|the_17|of_6|compared_27 (l_pobj) users_6\NNS\7846|NONE_0 (l_prep) with_7\IN\0|warfarin_15 (l_pobj) ich_8\NNP\0|NONE_0
D014859_D002543 CID warfarin_20\NN\2718259|-_8 (r_npadvmod) associated_22\VBN\628491|NONE_0 (r_amod) ich_23\NNP\0|NONE_0
D014859_D002544 NONE warfarin_57\NN\2718259|(_15|difference=0.01_18|)_33 (r_amod) users_58\NNS\7846|NONE_0 (r_pobj) in_56\IN\13603305|(_18|,_12|3.5_10|)_2 (r_prep) range_50\NN\5123416|9.7_36|)_33|in_31 (r_parataxis) 3.4_40\CD\0|5.7_12|(_8|,_2 (r_appos) range_38\NN\5123416|NONE_0 (r_pobj) to_35\IN\0|(_56|odds_55|;_45|range_43|in_27 (r_prep) ratio_24\NN\13815152|2.8_10 (r_pobj) from_20\IN\0|excess_17|._174 (r_prep) increased_19\VBD\169651|,_81|mb_79|frequent_66|in_57|vs_50|,_17|but_15 (r_conj) were_2\VBD\0|NONE_0 (l_prep) vs_7\IN\13634784|,_31|mb_29|frequent_16|in_7|,_33|but_35|increased_50 (l_pobj) tia_10\NNP\14166118|NONE_0 (l_nmod) is_8\NNP\0|/_2|in_7
D014859_D002544 NONE warfarin_8\JJ\2718259|vs_15 (r_amod) users_9\NNS\7846|NONE_0 (r_pobj) in_7\IN\13603305|an_16|of_6 (r_prep) excess_4\NN\5119367|there_18|also_8|but_88|none_92|._180 (r_attr) was_1\VBD\0|NONE_0 (l_attr) none_30\NN\15228378|there_110|also_100|excess_92|but_4|._88 (l_prep) in_31\IN\13603305|NONE_0 (l_pobj) users_33\NNS\7846|NONE_0 (l_prep) with_34\IN\0|warfarin_15 (l_pobj) tia_37\NNP\14166118|NONE_0 (l_nmod) is_35\NNP\0|/_2|(_7|or_8|;_15|ci_21|)_59
D014859_D002544 NONE warfarin_32\JJ\2718259|with_15 (r_amod) users_33\NNS\7846|NONE_0 (l_prep) with_34\IN\0|warfarin_15 (l_pobj) tia_37\NNP\14166118|NONE_0 (l_nmod) is_35\NNP\0|/_2|(_7|or_8|;_15|ci_21|)_59
D014859_D002546 NONE warfarin_57\NN\2718259|(_15|difference=0.01_18|)_33 (r_amod) users_58\NNS\7846|NONE_0 (r_pobj) in_56\IN\13603305|(_18|,_12|3.5_10|)_2 (r_prep) range_50\NN\5123416|9.7_36|)_33|in_31 (r_parataxis) 3.4_40\CD\0|5.7_12|(_8|,_2 (r_appos) range_38\NN\5123416|NONE_0 (r_pobj) to_35\IN\0|(_56|odds_55|;_45|range_43|in_27 (r_prep) ratio_24\NN\13815152|2.8_10 (r_pobj) from_20\IN\0|excess_17|._174 (r_prep) increased_19\VBD\169651|,_81|mb_79|frequent_66|in_57|vs_50|,_17|but_15 (r_conj) were_2\VBD\0|NONE_0 (l_prep) vs_7\IN\13634784|,_31|mb_29|frequent_16|in_7|,_33|but_35|increased_50 (l_pobj) tia_10\NNP\14166118|NONE_0
D014859_D002546 NONE warfarin_8\JJ\2718259|vs_15 (r_amod) users_9\NNS\7846|NONE_0 (r_pobj) in_7\IN\13603305|an_16|of_6 (r_prep) excess_4\NN\5119367|there_18|also_8|but_88|none_92|._180 (r_attr) was_1\VBD\0|NONE_0 (l_attr) none_30\NN\15228378|there_110|also_100|excess_92|but_4|._88 (l_prep) in_31\IN\13603305|NONE_0 (l_pobj) users_33\NNS\7846|NONE_0 (l_prep) with_34\IN\0|warfarin_15 (l_pobj) tia_37\NNP\14166118|NONE_0
D014859_D002546 NONE warfarin_32\JJ\2718259|with_15 (r_amod) users_33\NNS\7846|NONE_0 (l_prep) with_34\IN\0|warfarin_15 (l_pobj) tia_37\NNP\14166118|NONE_0
16920333
D010852_D012640 CID picrotoxin_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|in_14 (r_prep) microperfusion_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|NONE_0 (r_acl) seizures_12\NNS\14081375|NONE_0
D010852_D012640 CID picrotoxin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|threshold_16 (r_prep) doses_6\NNS\3740161|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) treated_3\VBN\2376958|the_12 (r_acl) animals_2\NNS\4475|NONE_0 (r_pobj) in_0\IN\13603305|,_57|number_71|2.3+/-1.2_94|,_103|and_105|was_134 (r_prep) was_15\VBD\0|NONE_0 (l_nsubj) number_12\NN\5107765|in_71|,_14|2.3+/-1.2_23|,_32|and_34|was_63 (l_prep) of_13\IN\0|the_19|average_15 (l_pobj) seizures_14\NNS\14081375|NONE_0
D010852_D012640 CID picrotoxin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|threshold_16 (r_prep) doses_6\NNS\3740161|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) treated_3\VBN\2376958|the_12 (r_acl) animals_2\NNS\4475|NONE_0 (r_pobj) in_0\IN\13603305|,_57|number_71|2.3+/-1.2_94|,_103|and_105|was_134 (r_prep) was_15\VBD\0|NONE_0 (l_conj) was_22\VBD\0|in_134|,_77|number_63|2.3+/-1.2_40|,_31|and_29 (l_nsubj) duration_21\NN\15113229|39.5+/-8.4s_13|._24 (l_compound) seizure_20\NN\14081375|average_8
D010852_D012640 CID picrotoxin_11\NN\0|NONE_0 (r_compound) microperfusion_12\NN\0|treatment_55|before_18|seizures_25|in_34|._56 (r_nsubj) prevented_13\VBD\0|NONE_0 (l_dobj) seizures_14\NNS\14081375|treatment_80|before_43|microperfusion_25|in_9|._31
C416835_D012640 NONE acetate_4\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|anticonvulsant_22|on_39|._131 (r_prep) effect_1\NN\34213|NONE_0 (l_prep) on_11\IN\0|anticonvulsant_61|of_39|._92 (l_pobj) seizures_12\NNS\14081375|NONE_0
C416835_D012640 NONE 093_9\CD\0|eslicarbazepine_31 (r_appos) acetate_4\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|anticonvulsant_22|on_39|._131 (r_prep) effect_1\NN\34213|NONE_0 (l_prep) on_11\IN\0|anticonvulsant_61|of_39|._92 (l_pobj) seizures_12\NNS\14081375|NONE_0
C416835_D012640 NONE acetate_10\NN\15010703|NONE_0 (l_prep) on_11\IN\0|eslicarbazepine_24 (l_pobj) model_16\NN\5888929|NONE_0 (l_relcl) elicited_23\VBN\1617192|a_54|animal_46 (l_nsubjpass) seizures_20\NNS\14081375|in_17|can_9|be_13|repeatedly_25|on_36|without_54
C416835_D012640 NONE acetate_10\NN\15010703|NONE_0 (l_prep) on_11\IN\0|eslicarbazepine_24 (l_pobj) model_16\NN\5888929|NONE_0 (l_relcl) elicited_23\VBN\1617192|a_54|animal_46 (l_prep) without_28\IN\0|in_71|seizures_54|can_45|be_41|repeatedly_29|on_18 (l_pobj) changes_29\NNS\7283608|NONE_0 (l_prep) in_30\IN\13603305|NONE_0 (l_pobj) threshold_31\NN\15265518|NONE_0 (l_conj) patterns_34\NNS\5726345|or_11 (l_compound) seizure_33\NN\14081375|NONE_0
15482540
D012254_D000743 CID ribavirin_2\RB\2725367|and_4 (r_conj) interferon_0\NNP\2725367|combination_25|for_45 (r_nmod) therapy_4\NN\657604|anemia_51|._57 (r_nsubj) produces_9\VBZ\7555863|NONE_0 (l_dobj) anemia_11\NN\14189204|therapy_51|._6
D012254_D019698 NONE ribavirin_2\RB\2725367|and_4 (r_conj) interferon_0\NNP\2725367|combination_25|for_45 (r_nmod) therapy_4\NN\657604|anemia_51|._57 (l_prep) for_5\IN\0|interferon_45|combination_20 (l_pobj) c_8\NNP\13714184|NONE_0
D012254_D019698 NONE ribavirin_27\RB\2725367|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) combination_25\NN\7951464|NONE_0 (r_pobj) in_24\IN\13603305|intramuscularly_29|for_13 (r_prep) administered_19\VBN\2436349|a_15|of_8 (r_acl) dose_15\NN\3740161|NONE_0 (r_pobj) at_13\IN\14622893|who_33|alpha-2b_9 (r_prep) received_9\VBD\2210855|chronic_24|hepatitis_16 (r_relcl) c_7\NNP\13714184|NONE_0
D016898_D019698 NONE interferon_0\NNP\2725367|combination_25|for_45 (r_nmod) therapy_4\NN\657604|anemia_51|._57 (l_prep) for_5\IN\0|interferon_45|combination_20 (l_pobj) c_8\NNP\13714184|NONE_0
D016898_D019698 NONE alpha-2b_12\NN\0|who_24|at_9 (r_dobj) received_9\VBD\2210855|chronic_24|hepatitis_16 (r_relcl) c_7\NNP\13714184|NONE_0
D012254_D000740 NONE ribavirin_3\RB\2725367|-_9 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) anemia_6\NN\14189204|NONE_0
D012254_D000740 NONE ribavirin_10\RB\2725367|-_9 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) anemia_13\NN\14189204|NONE_0
D012254_D000740 NONE ribavirin_12\RB\2725367|-_9 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) anemia_15\NN\14189204|NONE_0
D012254_D000740 NONE ribavirin_0\RB\2725367|-_9 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) anemia_3\NN\14189204|in_16|during_39|._55
D016898_D000743 CID interferon_0\NNP\2725367|combination_25|for_45 (r_nmod) therapy_4\NN\657604|anemia_51|._57 (r_nsubj) produces_9\VBZ\7555863|NONE_0 (l_dobj) anemia_11\NN\14189204|therapy_51|._6
19549709
D010984_D002289 NONE platinum_18\NN\14627081|based_9|(_15|1_24|)_25|or_27|chemotherapy_35|inhibitors_101 (r_nmod) stratum_21\NN\8591680|two_62|prior_49|chemotherapy_43|,_22|,_107 (r_appos) regimens_15\NNS\5898568|NONE_0 (r_pobj) with_9\IN\0|:_35|iiib_27|,_2 (r_prep) methods_0\NNS\5616786|rad001_227|day_240|until_244|._286 (l_appos) iiib_3\NNS\0|:_8|,_25|with_27 (l_conj) patients_7\NNS\9898892|stage_23|or_12 (l_compound) nsclc_6\NNP\0|iv_3
C107135_D064420 NONE rad001_41\NNP\0|methods_227|day_13|until_17|._59 (r_dobj) received_40\VBD\2210855|NONE_0 (l_prep) until_46\IN\0|methods_244|rad001_17|day_4|._42 (l_pobj) progression_47\NN\8457976|NONE_0 (l_conj) toxicity_50\NN\13576101|or_16
D014443_D002289 NONE tyrosine_32\NN\14601829|kinase_9|(_27|stratum_28|)_37 (r_compound) inhibitors_34\NNS\20090|platinum_101|based_92|(_86|1_77|)_76|or_74|chemotherapy_66 (r_conj) stratum_21\NN\8591680|two_62|prior_49|chemotherapy_43|,_22|,_107 (r_appos) regimens_15\NNS\5898568|NONE_0 (r_pobj) with_9\IN\0|:_35|iiib_27|,_2 (r_prep) methods_0\NNS\5616786|rad001_227|day_240|until_244|._286 (l_appos) iiib_3\NNS\0|:_8|,_25|with_27 (l_conj) patients_7\NNS\9898892|stage_23|or_12 (l_compound) nsclc_6\NNP\0|iv_3
D020123_D002289 NONE rapamycin_10\NNS\0|(_10|)_15 (r_nmod) mtor_12\NNP\0|NONE_0 (r_pobj) of_9\IN\0|the_21|mammalian_17 (r_prep) target_8\NN\7258332|NONE_0 (r_pobj) of_5\IN\0|an_18|oral_15 (r_prep) inhibitor_4\NN\20090|,_10|,_53 (r_appos) rad001_0\NNP\0|has_71|phase_81|._106 (r_nsubj) shown_16\VBN\2137132|NONE_0 (l_dobj) phase_17\NN\15113229|rad001_81|has_10|._25 (l_prep) in_20\IN\13603305|i_11|efficacy_9 (l_pobj) nsclc_21\NNP\0|NONE_0
D014443_D064420 NONE tyrosine_32\NN\14601829|kinase_9|(_27|stratum_28|)_37 (r_compound) inhibitors_34\NNS\20090|platinum_101|based_92|(_86|1_77|)_76|or_74|chemotherapy_66 (r_conj) stratum_21\NN\8591680|two_62|prior_49|chemotherapy_43|,_22|,_107 (r_appos) regimens_15\NNS\5898568|NONE_0 (r_pobj) with_9\IN\0|:_35|iiib_27|,_2 (r_prep) methods_0\NNS\5616786|rad001_227|day_240|until_244|._286 (r_nsubj) received_40\VBD\2210855|NONE_0 (l_prep) until_46\IN\0|methods_244|rad001_17|day_4|._42 (l_pobj) progression_47\NN\8457976|NONE_0 (l_conj) toxicity_50\NN\13576101|or_16
C107135_D002289 NONE everolimus_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_23|._138 (r_prep) efficacy_0\NN\5199286|NONE_0 (l_prep) in_6\IN\13603305|of_23|._115 (l_pobj) patients_7\NNS\9898892|or_72|with_75 (l_prep) with_8\IN\0|treated_31 (l_pobj) nsclc_10\NNP\0|NONE_0
C107135_D002289 NONE rad001_4\NNP\0|(_1|)_6 (r_appos) everolimus_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_23|._138 (r_prep) efficacy_0\NN\5199286|NONE_0 (l_prep) in_6\IN\13603305|of_23|._115 (l_pobj) patients_7\NNS\9898892|or_72|with_75 (l_prep) with_8\IN\0|treated_31 (l_pobj) nsclc_10\NNP\0|NONE_0
C107135_D002289 NONE rad001_0\NNP\0|has_71|phase_81|._106 (r_nsubj) shown_16\VBN\2137132|NONE_0 (l_dobj) phase_17\NN\15113229|rad001_81|has_10|._25 (l_prep) in_20\IN\13603305|i_11|efficacy_9 (l_pobj) nsclc_21\NNP\0|NONE_0
C107135_D002289 NONE rad001_41\NNP\0|methods_227|day_13|until_17|._59 (r_dobj) received_40\VBD\2210855|NONE_0 (l_nsubj) methods_0\NNS\5616786|rad001_227|day_240|until_244|._286 (l_appos) iiib_3\NNS\0|:_8|,_25|with_27 (l_conj) patients_7\NNS\9898892|stage_23|or_12 (l_compound) nsclc_6\NNP\0|iv_3
C107135_D002289 NONE rad001_2\NNP\0|NONE_0 (r_pobj) of_1\IN\0|plus_10|therapy_24 (r_prep) evaluation_0\NN\874067|nsclc_58|._73 (r_nsubj) continues_9\VBZ\2367363|NONE_0 (l_nsubj) nsclc_8\NNP\0|evaluation_58|._15
D010984_D064420 NONE platinum_18\NN\14627081|based_9|(_15|1_24|)_25|or_27|chemotherapy_35|inhibitors_101 (r_nmod) stratum_21\NN\8591680|two_62|prior_49|chemotherapy_43|,_22|,_107 (r_appos) regimens_15\NNS\5898568|NONE_0 (r_pobj) with_9\IN\0|:_35|iiib_27|,_2 (r_prep) methods_0\NNS\5616786|rad001_227|day_240|until_244|._286 (r_nsubj) received_40\VBD\2210855|NONE_0 (l_prep) until_46\IN\0|methods_244|rad001_17|day_4|._42 (l_pobj) progression_47\NN\8457976|NONE_0 (l_conj) toxicity_50\NN\13576101|or_16
7671401
D000806_D000799 CID inhibitor_19\NN\20090|NONE_0 (r_pobj) with_14\IN\0|term_13 (r_prep) therapy_13\NN\657604|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) related_8\VBN\628491|angio_13|-_8 (r_acl) oedema_7\NN\14315192|NONE_0
D000806_D000799 CID inhibitors_6\NNS\20090|NONE_0 (r_pobj) of_4\IN\0|the_17 (r_prep) introduction_3\NN\235435|NONE_0 (r_pobj) after_1\IN\0|soon_5|,_40|bouts_48|were_70|in_84|._126 (r_prep) reported_15\VBN\831651|NONE_0 (l_nsubjpass) bouts_9\NNS\5867413|soon_53|after_48|,_8|were_22|in_36|._78 (l_prep) of_10\IN\0|acute_12 (l_pobj) oedema_13\NN\14315192|NONE_0
D000806_D000799 CID inhibitors_13\NNS\20090|NONE_0 (r_pobj) to_11\IN\0|adverse_18|after_18 (r_prep) reactions_10\NNS\13446390|NONE_0 (l_prep) after_14\IN\0|adverse_36|to_18 (l_conj) in_20\IN\13603305|use_8|and_4 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|NONE_0 (l_pobj) oedema_28\NN\14315192|NONE_0
D000806_D006973 NONE inhibitors_7\NNS\20090|converting_24 (l_acl) used_9\VBD\0|(_18|ace_17|)_14|,_2|,_55 (l_xcomp) treat_11\VB\7570720|NONE_0 (l_dobj) hypertension_12\NN\14057371|to_9
D000806_D006333 NONE inhibitors_7\NNS\20090|converting_24 (l_acl) used_9\VBD\0|(_18|ace_17|)_14|,_2|,_55 (l_xcomp) treat_11\VB\7570720|NONE_0 (l_dobj) hypertension_12\NN\14057371|to_9 (l_conj) failure_16\NN\66216|and_21
24464946
D015251_D008228 NONE epirubicin_13\NNS\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|five_40|with_26 (r_acl) patients_5\NNS\9898892|:_15 (l_prep) with_6\IN\0|five_14|treated_26 (l_pobj) lymphoma_10\NN\14239918|NONE_0
D015251_D006331 NONE epirubicin_25\NNS\0|NONE_0 (r_compound) exposure_26\NN\5042871|NONE_0 (r_pobj) after_24\IN\0|whether_139|alterations_131|could_53|dysfunction_24 (r_prep) predict_18\VB\916909|to_107|._72 (l_dobj) dysfunction_21\NN\14204950|whether_115|alterations_107|could_29|after_24
D015251_D066126 CID epirubicine_22\NN\0|-_11 (r_npadvmod) based_24\VBN\0|NONE_0 (r_amod) chemotherapy_25\NN\661091|NONE_0 (r_pobj) during_21\IN\0|early_49|and_33|prediction_29 (r_prep) detection_16\NN\5708432|NONE_0 (l_conj) prediction_18\NN\5772356|early_20|and_4|during_29 (l_prep) of_19\IN\0|NONE_0 (l_pobj) cardiotoxicity_20\NN\0|NONE_0
D015251_D009202 NONE epirubicin_25\NNS\0|NONE_0 (r_compound) exposure_26\NN\5042871|NONE_0 (r_pobj) after_24\IN\0|whether_139|alterations_131|could_53|dysfunction_24 (r_prep) predict_18\VB\916909|to_107|._72 (l_nsubj) alterations_3\NNS\7283608|whether_8|could_78|dysfunction_107|after_131 (l_prep) of_4\IN\0|NONE_0 (l_pobj) strain_6\NN\7358060|NONE_0
D018943_D006331 NONE anthracycline_20\NN\0|-_13 (r_advmod) based_22\VBN\0|NONE_0 (r_amod) chemotherapy_23\NN\661091|NONE_0 (r_dobj) receiving_19\VBG\2210855|NONE_0 (r_acl) patients_18\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|cardiac_20 (r_prep) dysfunction_16\NN\14204950|to_19
1756784
D010862_D013226 CID pilocarpine_7\NN\14712692|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) status_10\NN\24720|NONE_0 (r_pobj) during_6\IN\0|of_36 (r_prep) damage_0\NN\7296428|in_89|:_99|study_121|._181 (r_nsubj) epilepticus_11\NN\0|NONE_0
D010862_D013226 CID pilocarpine_12\NN\14712692|NONE_0 (r_pobj) of_11\IN\0|systemic_19|in_15 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) by_8\IN\0|in_46|,_33|epilepticus_24|was_12|._44 (r_agent) induced_7\VBN\1627355|NONE_0 (l_nsubjpass) epilepticus_5\NN\0|in_22|,_9|was_12|by_24|._68
D002118_D009422 NONE calcium_10\NN\14625458|-_7 (r_npadvmod) binding_12\VBG\4688246|the_28|specific_17|,_15|parvalbumin_17 (r_amod) protein_13\NN\14944888|NONE_0 (r_pobj) against_5\IN\0|nissl_30|-_25|and_15|antibodies_11|,_64 (r_prep) staining_2\VBG\275424|detect_100|._129 (r_nsubj) served_17\VBD\2669789|NONE_0 (l_xcomp) detect_19\VB\2163746|staining_100|._29 (l_dobj) damage_21\NN\7296428|to_19
D010862_D001930 CID pilocarpine_7\NN\14712692|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) status_10\NN\24720|NONE_0 (r_pobj) during_6\IN\0|of_36 (r_prep) damage_0\NN\7296428|in_89|:_99|study_121|._181 (l_prep) of_1\IN\0|during_36 (l_pobj) reticulata_5\NNS\0|NONE_0
9570197
D003042_D002637 NONE hydrochloride_78\NN\14817592|control_29|)_13|or_11 (r_conj) subjects_74\NNS\6598915|(_15|,_10 (r_appos) n=10_71\NNP\0|lv_125|and_114|fraction_101|before_92 (r_appos) volumes_50\NNS\33615|referred_176|,_107|we_105|rate_87|,_9|and_7|._186 (r_conj) measured_28\VBD\697589|NONE_0 (l_ccomp) referred_16\VBD\730052|,_69|we_71|rate_89|,_167|and_169|volumes_176|._362 (l_prep) for_17\IN\0|:_67|in_65|patients_59 (l_pobj) catheterization_19\NN\671351|NONE_0 (l_prep) for_20\IN\0|cardiac_24 (l_pobj) evaluation_22\NN\874067|NONE_0 (l_prep) of_23\IN\0|the_15 (l_pobj) pain_25\NN\14299637|NONE_0
D003042_D018487 CID cocaine_8\NN\3492717|NONE_0 (r_pobj) of_6\IN\0|a_15|large_13 (r_prep) amount_5\NN\13329641|in_17|,_10|deterioration_48|._149 (r_nsubj) causes_9\VBZ\7323922|NONE_0 (l_dobj) deterioration_12\NN\14560612|in_65|,_58|amount_48|._101 (l_prep) of_13\IN\0|a_25|profound_23|and_43|increase_50 (l_pobj) function_20\NN\13783581|NONE_0
D003042_D018487 CID cocaine_7\NN\3492717|NONE_0 (r_pobj) of_6\IN\0|the_27|intracoronary_23|sufficient_11 (r_prep) infusion_5\NN\14589223|in_29|,_20|deterioration_111|._165 (r_nsubj) causes_21\VBZ\7323922|NONE_0 (l_dobj) deterioration_23\NN\14560612|in_140|,_131|infusion_111|._54 (l_prep) of_24\IN\0|a_16 (l_pobj) performance_29\NN\6619065|NONE_0
24691439
C075773_D009798 NONE 4-phenylbutyrate_11\RB\0|NONE_0 (r_pobj) with_9\IN\0|of_23 (r_prep) reduction_2\NN\351485|furthermore_13|,_2|hypertension_101|._124 (r_nsubj) prevented_12\VBN\0|NONE_0 (l_dobj) hypertension_17\NN\14057371|furthermore_114|,_103|reduction_101|._23
D003907_D009798 CID dexamethasone_2\NN\2721538|-_13 (r_npadvmod) induced_4\VBN\1627355|ocular_8 (r_amod) hypertension_6\NN\14057371|furthermore_42|,_31|was_13|with_28|._82
D003907_D009798 CID dexamethasone_0\NN\2721538|chop_49|in_87|,_118|and_120|reduced_138 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_conj) reduced_23\VBN\441445|dexamethasone_138|chop_89|in_51|,_20|and_18 (l_conj) prevented_30\VBN\0|deletion_48|stress_28|in_21|and_4|._51 (l_dobj) hypertension_35\NN\14057371|NONE_0
D003907_D009798 CID dexamethasone_31\NN\2721538|-_13 (r_npadvmod) induced_33\VBN\1627355|ocular_8 (r_amod) hypertension_35\NN\14057371|NONE_0
D003907_D009798 CID dexamethasone_13\NN\2721538|-_13 (r_npadvmod) induced_15\VBN\1627355|ocular_8|in_28 (r_amod) hypertension_17\NN\14057371|furthermore_114|,_103|reduction_101|._23
D003907_D009410 CID dexamethasone_9\NN\2721538|NONE_0 (r_pobj) with_4\IN\0|of_11 (r_prep) treatment_0\NN\654885|to_64|,_189|resembling_191|._251 (r_nsubj) led_10\VBN\3202760|NONE_0 (l_prep) to_11\IN\0|treatment_64|,_125|resembling_127|._187 (l_pobj) elevation_12\NN\7445480|NONE_0 (l_prep) of_13\IN\0|NONE_0 (l_pobj) pressure_15\NN\11419404|NONE_0 (l_appos) loss_23\NN\13252973|intraocular_54|(_33|iop_32 (l_conj) degeneration_31\NN\29677|functional_69|of_38|,_13|and_11
D003907_D012173 NONE dexamethasone_9\NN\2721538|NONE_0 (r_pobj) with_4\IN\0|of_11 (r_prep) treatment_0\NN\654885|to_64|,_189|resembling_191|._251 (r_nsubj) led_10\VBN\3202760|NONE_0 (l_prep) to_11\IN\0|treatment_64|,_125|resembling_127|._187 (l_pobj) elevation_12\NN\7445480|NONE_0 (l_prep) of_13\IN\0|NONE_0 (l_pobj) pressure_15\NN\11419404|NONE_0 (l_appos) loss_23\NN\13252973|intraocular_54|(_33|iop_32 (l_prep) of_24\IN\0|functional_31|,_25|and_27|degeneration_38 (l_pobj) cells_27\NNS\3080309|NONE_0 (l_compound) ganglion_26\NN\5462674|retinal_8
D003907_D005901 CID dexamethasone_9\NN\2721538|NONE_0 (r_pobj) with_4\IN\0|of_11 (r_prep) treatment_0\NN\654885|to_64|,_189|resembling_191|._251 (r_nsubj) led_10\VBN\3202760|NONE_0 (l_advcl) resembling_33\VBG\2657219|treatment_191|to_127|,_2|._60 (l_dobj) glaucoma_37\NN\14252864|NONE_0
24971338
D004801_D007674 NONE eosin_7\NN\14987695|and_4|,_5|schiff_21 (r_conj) hematoxylin_5\NN\0|NONE_0 (r_pobj) in_4\IN\13603305|lesions_22|were_14|._77 (r_prep) analyzed_3\VBN\0|NONE_0 (l_nsubjpass) lesions_1\NNS\14204950|were_8|in_22|._99
D006416_D007674 NONE hematoxylin_5\NN\0|NONE_0 (r_pobj) in_4\IN\13603305|lesions_22|were_14|._77 (r_prep) analyzed_3\VBN\0|NONE_0 (l_nsubjpass) lesions_1\NNS\14204950|were_8|in_22|._99
D020123_D011507 CID srl_0\NN\0|-_3 (r_npadvmod) treated_2\VBN\2376958|NONE_0 (r_amod) rats_3\NNS\2329401|proteinuria_15|)_54|as_56|._95 (r_nsubj) presented_4\VBD\2137132|NONE_0 (l_dobj) proteinuria_5\NN\14299637|rats_15|)_39|as_41|._80
D020123_D007674 NONE sirolimus_2\VB\0|NONE_0 (r_relcl) conversion_0\NN\7359599|nephropathy_57|in_69 (r_nsubj) ameliorates_3\VBZ\126264|:_55|on_63|._125 (l_dobj) nephropathy_7\NN\14573196|conversion_57|in_12
D020123_D007674 NONE sirolimus_10\VB\0|NONE_0 (r_pobj) to_9\TO\0|from_25 (r_prep) conversion_2\NN\7359599|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) protocols_0\NNS\6652242|(_62|srl_63|)_66|have_68|been_73|widely_78|in_90|after_107|,_163|but_165|remain_221 (r_nsubjpass) used_17\VBN\0|NONE_0 (l_prep) after_20\IN\0|protocols_107|(_45|srl_44|)_41|have_39|been_34|widely_29|in_17|,_56|but_58|remain_114 (l_pobj) transplantation_21\NN\671351|NONE_0 (l_relcl) prevent_23\VB\0|NONE_0 (l_dobj) nephropathy_27\NN\14573196|to_23
D020123_D007674 NONE srl_12\NN\0|protocols_63|(_1|)_3|have_5|been_10|widely_15|in_27|after_44|,_100|but_102|remain_158 (r_nsubjpass) used_17\VBN\0|NONE_0 (l_prep) after_20\IN\0|protocols_107|(_45|srl_44|)_41|have_39|been_34|widely_29|in_17|,_56|but_58|remain_114 (l_pobj) transplantation_21\NN\671351|NONE_0 (l_relcl) prevent_23\VB\0|NONE_0 (l_dobj) nephropathy_27\NN\14573196|to_23
D020123_D007674 NONE srl_0\NN\0|-_3 (r_npadvmod) treated_2\VBN\2376958|NONE_0 (r_amod) rats_3\NNS\2329401|proteinuria_15|)_54|as_56|._95 (r_nsubj) presented_4\VBD\2137132|NONE_0 (l_prep) as_13\IN\14622893|rats_56|proteinuria_41|)_2|._39 (l_pobj) markers_16\NNS\21939|NONE_0 (l_prep) of_17\IN\0|the_17|best_13 (l_pobj) impairment_19\NN\7296428|NONE_0
D020123_D007674 NONE srl_2\NNP\0|NONE_0 (r_pobj) to_1\IN\0|NONE_0 (r_prep) conversion_0\NN\7359599|evolution_53|,_90|seems_124|._182 (r_nsubj) prevented_3\VBN\0|NONE_0 (l_dobj) evolution_9\NN\29677|conversion_53|,_37|seems_71|._129 (l_compound) damage_8\NN\7296428|induced_14|renal_6|lesions_36
D020123_D007674 NONE srl_35\NNP\0|NONE_0 (r_pobj) to_34\IN\0|csa_16 (r_prep) replacement_33\NN\196485|NONE_0 (r_pobj) of_31\IN\0|a_21|feasible_19 (r_prep) biomarker_30\NN\0|to_17 (r_attr) be_27\VB\14625458|while_41|ngal_35 (r_xcomp) seems_25\VBZ\2604760|conversion_124|evolution_71|,_34|._58 (r_advcl) prevented_3\VBN\0|NONE_0 (l_dobj) evolution_9\NN\29677|conversion_53|,_37|seems_71|._129 (l_compound) damage_8\NN\7296428|induced_14|renal_6|lesions_36
D016572_D007674 CID cyclosporine_4\NN\0|-_12 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) nephropathy_7\NN\14573196|conversion_57|in_12
D016572_D007674 CID a_5\NNP\13649268|NONE_0 (r_pobj) from_3\IN\0|to_25 (r_prep) conversion_2\NN\7359599|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) protocols_0\NNS\6652242|(_62|srl_63|)_66|have_68|been_73|widely_78|in_90|after_107|,_163|but_165|remain_221 (r_nsubjpass) used_17\VBN\0|NONE_0 (l_prep) after_20\IN\0|protocols_107|(_45|srl_44|)_41|have_39|been_34|widely_29|in_17|,_56|but_58|remain_114 (l_pobj) transplantation_21\NN\671351|NONE_0 (l_relcl) prevent_23\VB\0|NONE_0 (l_dobj) nephropathy_27\NN\14573196|to_23
D016572_D007674 CID csa_7\NNP\0|cyclosporin_15 (r_appos) a_5\NNP\13649268|NONE_0 (r_pobj) from_3\IN\0|to_25 (r_prep) conversion_2\NN\7359599|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) protocols_0\NNS\6652242|(_62|srl_63|)_66|have_68|been_73|widely_78|in_90|after_107|,_163|but_165|remain_221 (r_nsubjpass) used_17\VBN\0|NONE_0 (l_prep) after_20\IN\0|protocols_107|(_45|srl_44|)_41|have_39|been_34|widely_29|in_17|,_56|but_58|remain_114 (l_pobj) transplantation_21\NN\671351|NONE_0 (l_relcl) prevent_23\VB\0|NONE_0 (l_dobj) nephropathy_27\NN\14573196|to_23
D016572_D007674 CID csa_24\NNP\0|-_3 (r_npadvmod) induced_26\VBN\1627355|NONE_0 (r_amod) nephropathy_27\NN\14573196|to_23
D016572_D007674 CID csa_1\NNP\0|short_6 (r_compound) treatment_2\NN\654885|lesions_49|kim-1_94|,_99|and_101|ctgf_105|._146 (r_nsubj) presented_3\VBD\2137132|NONE_0 (l_dobj) lesions_9\NNS\14204950|treatment_49|kim-1_45|,_50|and_52|ctgf_56|._97
D016572_D007674 CID csa_1\NNP\0|prolonged_10 (r_compound) exposure_2\NN\5042871|damage_26|,_32|without_34|b_116|._170 (r_nsubj) aggravated_3\VBD\126264|NONE_0 (l_dobj) damage_5\NN\7296428|exposure_26|,_6|without_8|b_90|._144
D016572_D007674 CID csa_4\NNP\0|-_3 (r_npadvmod) induced_6\VBN\1627355|renal_8|damage_14|lesions_50 (r_amod) evolution_9\NN\29677|conversion_53|,_37|seems_71|._129 (l_compound) damage_8\NN\7296428|induced_14|renal_6|lesions_36
D016572_D007674 CID csa_32\NNP\0|to_16 (r_compound) replacement_33\NN\196485|NONE_0 (r_pobj) of_31\IN\0|a_21|feasible_19 (r_prep) biomarker_30\NN\0|to_17 (r_attr) be_27\VB\14625458|while_41|ngal_35 (r_xcomp) seems_25\VBZ\2604760|conversion_124|evolution_71|,_34|._58 (r_advcl) prevented_3\VBN\0|NONE_0 (l_dobj) evolution_9\NN\29677|conversion_53|,_37|seems_71|._129 (l_compound) damage_8\NN\7296428|induced_14|renal_6|lesions_36
24671324
D003907_D001424 NONE dexamethasone_5\NN\2721538|-_13 (r_npadvmod) containing_7\VBG\2632940|dose_19 (r_amod) regimens_8\NNS\5898568|and_39 (r_conj) bortezomib_0\NNP\0|are_59|be_77|._173 (r_nsubjpass) considered_10\VBN\689344|NONE_0 (l_xcomp) be_12\VB\14625458|bortezomib_77|are_18|._96 (l_acomp) tolerable_14\JJ\0|to_16 (l_prep) with_15\IN\0|generally_20 (l_pobj) infections_19\NNS\14052046|NONE_0
D003907_D001424 NONE dexamethasone_16\NN\2721538|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) related_9\VBN\628491|fatal_27|bacterial_21 (r_acl) infections_8\NNS\14052046|NONE_0
C400082_D008258 NONE bortezomib_3\NNS\0|containing_29|in_48 (r_amod) regimen_8\NN\5898568|NONE_0 (l_prep) in_9\IN\13603305|bortezomib_48|containing_19 (l_pobj) patient_12\NN\9898892|NONE_0 (l_prep) of_13\IN\0|an_19|elderly_16 (l_pobj) macroglobulinaemia_15\NN\0|NONE_0
C400082_D008258 NONE bortezomib_24\NNS\0|,_10|dose_17|and_36|rituximab_40 (r_amod) dexamethasone_29\NN\2721538|NONE_0 (r_pobj) with_23\IN\0|the_26|combination_22 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_19\IN\0|who_55|fasciitis_30|without_20 (r_prep) suffered_14\VBD\2110220|a_58|old_48|with_40 (r_relcl) man_9\NN\9605289|NONE_0 (l_prep) with_10\IN\0|a_18|old_8|suffered_40 (l_pobj) macroglobulinaemia_12\NN\0|NONE_0
C400082_D009369 NONE bortezomib_0\NNP\0|are_59|be_77|._173 (r_nsubjpass) considered_10\VBN\689344|NONE_0 (l_xcomp) be_12\VB\14625458|bortezomib_77|are_18|._96 (l_acomp) tolerable_14\JJ\0|to_16 (l_prep) with_15\IN\0|generally_20 (l_pobj) infections_19\NNS\14052046|NONE_0 (l_prep) in_20\IN\13603305|few_32|severe_28|bacterial_21 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|NONE_0 (l_pobj) malignancies_26\NNS\14070360|NONE_0
D003907_D008258 NONE dexamethasone_5\NN\2721538|-_13 (r_npadvmod) containing_7\VBG\2632940|bortezomib_29|in_19 (r_amod) regimen_8\NN\5898568|NONE_0 (l_prep) in_9\IN\13603305|bortezomib_48|containing_19 (l_pobj) patient_12\NN\9898892|NONE_0 (l_prep) of_13\IN\0|an_19|elderly_16 (l_pobj) macroglobulinaemia_15\NN\0|NONE_0
D003907_D008258 NONE dexamethasone_29\NN\2721538|NONE_0 (r_pobj) with_23\IN\0|the_26|combination_22 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_19\IN\0|who_55|fasciitis_30|without_20 (r_prep) suffered_14\VBD\2110220|a_58|old_48|with_40 (r_relcl) man_9\NN\9605289|NONE_0 (l_prep) with_10\IN\0|a_18|old_8|suffered_40 (l_pobj) macroglobulinaemia_12\NN\0|NONE_0
D003907_D009503 NONE dexamethasone_29\NN\2721538|NONE_0 (r_pobj) with_23\IN\0|the_26|combination_22 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_19\IN\0|who_55|fasciitis_30|without_20 (r_prep) suffered_14\VBD\2110220|a_58|old_48|with_40 (l_prep) without_17\IN\0|who_35|fasciitis_10|after_20 (l_pobj) neutropenia_18\NN\14196405|NONE_0
C400082_D019115 CID bortezomib_3\NNS\0|containing_29|in_48 (r_amod) regimen_8\NN\5898568|NONE_0 (r_pobj) after_2\IN\0|necrotising_22|._109 (r_prep) fasciitis_1\NN\0|NONE_0
C400082_D019115 CID bortezomib_24\NNS\0|,_10|dose_17|and_36|rituximab_40 (r_amod) dexamethasone_29\NN\2721538|NONE_0 (r_pobj) with_23\IN\0|the_26|combination_22 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_19\IN\0|who_55|fasciitis_30|without_20 (r_prep) suffered_14\VBD\2110220|a_58|old_48|with_40 (l_dobj) fasciitis_16\NN\0|who_25|without_10|after_30
C400082_D009503 NONE bortezomib_24\NNS\0|,_10|dose_17|and_36|rituximab_40 (r_amod) dexamethasone_29\NN\2721538|NONE_0 (r_pobj) with_23\IN\0|the_26|combination_22 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_19\IN\0|who_55|fasciitis_30|without_20 (r_prep) suffered_14\VBD\2110220|a_58|old_48|with_40 (l_prep) without_17\IN\0|who_35|fasciitis_10|after_20 (l_pobj) neutropenia_18\NN\14196405|NONE_0
D003907_D009369 NONE dexamethasone_5\NN\2721538|-_13 (r_npadvmod) containing_7\VBG\2632940|dose_19 (r_amod) regimens_8\NNS\5898568|and_39 (r_conj) bortezomib_0\NNP\0|are_59|be_77|._173 (r_nsubjpass) considered_10\VBN\689344|NONE_0 (l_xcomp) be_12\VB\14625458|bortezomib_77|are_18|._96 (l_acomp) tolerable_14\JJ\0|to_16 (l_prep) with_15\IN\0|generally_20 (l_pobj) infections_19\NNS\14052046|NONE_0 (l_prep) in_20\IN\13603305|few_32|severe_28|bacterial_21 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|NONE_0 (l_pobj) malignancies_26\NNS\14070360|NONE_0
C400082_D001424 NONE bortezomib_0\NNP\0|are_59|be_77|._173 (r_nsubjpass) considered_10\VBN\689344|NONE_0 (l_xcomp) be_12\VB\14625458|bortezomib_77|are_18|._96 (l_acomp) tolerable_14\JJ\0|to_16 (l_prep) with_15\IN\0|generally_20 (l_pobj) infections_19\NNS\14052046|NONE_0
C400082_D001424 NONE bortezomib_11\NNS\0|dose_21|in_40 (r_amod) dexamethasone_16\NN\2721538|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) related_9\VBN\628491|fatal_27|bacterial_21 (r_acl) infections_8\NNS\14052046|NONE_0
D003907_D019115 CID dexamethasone_5\NN\2721538|-_13 (r_npadvmod) containing_7\VBG\2632940|bortezomib_29|in_19 (r_amod) regimen_8\NN\5898568|NONE_0 (r_pobj) after_2\IN\0|necrotising_22|._109 (r_prep) fasciitis_1\NN\0|NONE_0
D003907_D019115 CID dexamethasone_29\NN\2721538|NONE_0 (r_pobj) with_23\IN\0|the_26|combination_22 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_19\IN\0|who_55|fasciitis_30|without_20 (r_prep) suffered_14\VBD\2110220|a_58|old_48|with_40 (l_dobj) fasciitis_16\NN\0|who_25|without_10|after_30
16801510
D008691_D016171 NONE methadone_8\NN\3808564|the_4 (r_compound) group_9\NN\2137|NONE_0 (r_pobj) in_6\IN\13603305|six_20|(_7|%_3|)_2 (r_prep) patients_1\NNS\9898892|pointes_61|._68 (r_nsubj) presented_10\VBD\2137132|NONE_0 (l_dobj) pointes_13\FW\831651|patients_61|._7
D008691_D007008 NONE methadone_12\NN\3808564|NONE_0 (r_compound) dose_13\NN\3740161|NONE_0 (r_pobj) to_11\IN\0|of_28 (r_prep) attribution_4\NN\5732756|analysis_17|cytochrome_59|._143 (r_dobj) allowed_3\VBD\0|NONE_0 (l_conj) cytochrome_15\NN\14888884|analysis_76|attribution_59|._84 (l_dobj) interactions_21\NNS\37396|,_33 (l_appos) hypokalemia_23\NN\14299637|3a4_28|drug_19|,_2
D011188_D008133 NONE potassium_3\NN\14625458|,_15|and_17|function_27 (r_compound) level_4\NN\4916342|3a4_26|,_12 (r_conj) inhibitors_1\NNS\20090|to_59|._77 (r_nsubj) contribute_9\VBP\126264|NONE_0 (l_prep) to_10\IN\0|inhibitors_59|._18 (l_pobj) prolongation_12\NN\1017987|NONE_0
D008691_D008133 CID methadone_11\NN\3808564|NONE_0 (r_dobj) receiving_10\VBG\2210855|drug_11 (r_acl) users_9\NNS\7846|NONE_0 (r_pobj) in_6\IN\13603305|induced_25|long_17|qt_12|._101 (r_prep) syndrome_5\NN\5870365|NONE_0
D008691_D008133 CID methadone_12\NN\3808564|NONE_0 (r_compound) treatment_13\NN\654885|NONE_0 (r_pobj) with_11\IN\0|qt_25|interval_22 (r_prep) prolongation_10\NN\1017987|NONE_0
D008691_D008133 CID methadone_3\NN\3808564|NONE_0 (r_compound) dose_4\NN\3740161|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) addition_1\NN\3081021|NONE_0 (r_pobj) in_0\IN\13603305|,_29|variables_79|were_89|as_105|._150 (r_prep) considered_15\VBN\689344|NONE_0 (l_prep) as_16\IN\14622893|in_105|,_76|variables_26|were_16|._45 (l_pobj) factors_19\NNS\7326557|NONE_0 (l_prep) for_20\IN\0|potential_23|risk_13 (l_pobj) prolongation_22\NN\1017987|NONE_0
D008691_D008133 CID methadone_4\NN\3808564|maintenance_10|hospitalized_31 (r_compound) patients_6\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|qt_25|interval_22 (r_prep) prolongation_2\NN\1017987|finding_100|._107
D008691_D008133 CID methadone_9\NN\3808564|NONE_0 (r_pobj) of_8\IN\0|low_10 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) with_5\IN\0|syndrome_19|can_10|._27 (r_prep) occur_4\VB\0|NONE_0 (l_nsubj) syndrome_2\NN\5870365|can_9|with_19|._46
24158386
D002945_D064420 NONE cisplatin_2\NN\0|and_4 (r_conj) gemcitabine_0\NNP\0|activity_31|,_105|and_107|delivered_118|._152 (r_nsubj) have_3\VBP\7846|NONE_0 (l_dobj) activity_4\NN\30358|gemcitabine_31|,_74|and_76|delivered_87|._121 (l_prep) in_5\IN\13603305|NONE_0 (l_pobj) toxicity_11\NN\13576101|NONE_0
C056507_D064420 NONE gemcitabine_0\NNP\0|activity_31|,_105|and_107|delivered_118|._152 (r_nsubj) have_3\VBP\7846|NONE_0 (l_dobj) activity_4\NN\30358|gemcitabine_31|,_74|and_76|delivered_87|._121 (l_prep) in_5\IN\13603305|NONE_0 (l_pobj) toxicity_11\NN\13576101|NONE_0
D002945_D006689 NONE cisplatin_2\NN\0|and_4 (r_conj) gemcitabine_0\NNP\0|activity_31|,_105|and_107|delivered_118|._152 (r_nsubj) have_3\VBP\7846|NONE_0 (l_dobj) activity_4\NN\30358|gemcitabine_31|,_74|and_76|delivered_87|._121 (l_prep) in_5\IN\13603305|NONE_0 (l_pobj) toxicity_11\NN\13576101|NONE_0 (l_amod) overlapping_10\VBG\3122748|with_21 (l_npadvmod) hl_6\NNP\13616054|-_7
D002945_D006689 NONE cisplatin_38\NN\0|were_49|._62 (r_nsubjpass) included_55\VBN\0|in_239|,_195|patients_193|with_145|methylprednisolone_92|;_60|and_58 (r_conj) treated_14\VBN\2376958|NONE_0 (l_nsubj) patients_8\NNS\9898892|in_46|,_2|with_48|methylprednisolone_101|;_133|and_135|included_193 (l_prep) with_9\IN\0|NONE_0 (l_pobj) hl_13\NN\13616054|NONE_0
D008775_D006689 NONE methylprednisolone_30\NN\0|in_147|,_103|patients_101|with_53|;_32|and_34|included_92 (r_advcl) treated_14\VBN\2376958|NONE_0 (l_nsubj) patients_8\NNS\9898892|in_46|,_2|with_48|methylprednisolone_101|;_133|and_135|included_193 (l_prep) with_9\IN\0|NONE_0 (l_pobj) hl_13\NN\13616054|NONE_0
C056507_D006689 NONE gem_0\NN\2743547|-_3 (r_compound) p_2\NN\14622893|NONE_0 (r_compound) chemotherapy_3\NN\661091|active_16|._68 (r_nsubj) is_4\VBZ\0|NONE_0 (l_acomp) active_5\JJ\14779550|chemotherapy_16|._52 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) lymphoma_12\NN\14239918|NONE_0
C056507_D006689 NONE gemcitabine_0\NNP\0|activity_31|,_105|and_107|delivered_118|._152 (r_nsubj) have_3\VBP\7846|NONE_0 (l_dobj) activity_4\NN\30358|gemcitabine_31|,_74|and_76|delivered_87|._121 (l_prep) in_5\IN\13603305|NONE_0 (l_pobj) toxicity_11\NN\13576101|NONE_0 (l_amod) overlapping_10\VBG\3122748|with_21 (l_npadvmod) hl_6\NNP\13616054|-_7
C056507_D006689 NONE gemcitabine_16\NN\0|)_24|(_30|d)1_31|;_46 (r_amod) day_22\NN\15154774|NONE_0 (r_pobj) with_15\IN\0|in_94|,_50|patients_48|methylprednisolone_53|;_85|and_87|included_145 (r_prep) treated_14\VBN\2376958|NONE_0 (l_nsubj) patients_8\NNS\9898892|in_46|,_2|with_48|methylprednisolone_101|;_133|and_135|included_193 (l_prep) with_9\IN\0|NONE_0 (l_pobj) hl_13\NN\13616054|NONE_0
C056507_D006689 NONE gem_50\NNP\2743547|-_3 (r_compound) p_52\NNP\14622893|every_19|28_13|(_5|)_1 (r_appos) days_48\NNS\15140892|m(2_19|)_16|,_11 (r_appos) d15_44\NNP\0|NONE_0 (r_dobj) cisplatin_38\NN\0|were_49|._62 (r_nsubjpass) included_55\VBN\0|in_239|,_195|patients_193|with_145|methylprednisolone_92|;_60|and_58 (r_conj) treated_14\VBN\2376958|NONE_0 (l_nsubj) patients_8\NNS\9898892|in_46|,_2|with_48|methylprednisolone_101|;_133|and_135|included_193 (l_prep) with_9\IN\0|NONE_0 (l_pobj) hl_13\NN\13616054|NONE_0
C056507_D006689 NONE gem_0\NN\2743547|-_3 (r_compound) p_2\NNP\14622893|chemotherapy_15|,_63|leading_65|,_126|in_128|._173 (r_nsubj) is_3\VBZ\0|NONE_0 (l_prep) in_21\IN\13603305|p_128|chemotherapy_113|,_65|leading_63|,_2|._45 (l_pobj) treatment_23\NN\654885|NONE_0 (l_prep) of_24\IN\0|the_14 (l_pobj) hl_28\NN\13616054|NONE_0
2931989
D015474_C563492 NONE isotretinoin_0\NNP\0|is_13|in_32|because_45|._195 (r_nsubjpass) contraindicated_2\VBN\872886|NONE_0 (l_prep) because_5\IN\0|isotretinoin_45|is_32|in_13|._150 (l_pobj) abnormalities_11\NNS\14034177|of_32 (l_prep) after_12\IN\0|the_43|many_39|reported_34|congenital_25 (l_pobj) use_14\NN\407535|NONE_0 (l_prep) including_16\VBG\0|maternal_14|(_1|)_75 (l_pobj) microphthalmos_17\NNS\0|NONE_0 (l_conj) hypertelorism_20\NN\0|,_10 (l_conj) hypoplasia_25\NN\14365950|orbital_39|,_18|and_16
D015474_D000013 NONE isotretinoin_0\NNP\0|is_13|in_32|because_45|._195 (r_nsubjpass) contraindicated_2\VBN\872886|NONE_0 (l_prep) because_5\IN\0|isotretinoin_45|is_32|in_13|._150 (l_pobj) abnormalities_11\NNS\14034177|of_32
D015474_D000152 NONE isotretinoin_13\JJ\0|who_13 (r_dobj) received_12\VBD\2210855|237_17|,_21|drug_39 (r_relcl) patients_10\NNS\9898892|NONE_0 (l_appos) drug_18\NN\14778436|237_56|received_39|,_18 (l_prep) in_19\IN\13603305|a_21|used_10 (l_pobj) treatment_21\NN\654885|NONE_0 (l_prep) of_22\IN\0|the_14 (l_pobj) acne_25\NN\14171682|NONE_0
D015474_D006972 NONE isotretinoin_0\NNP\0|is_13|in_32|because_45|._195 (r_nsubjpass) contraindicated_2\VBN\872886|NONE_0 (l_prep) because_5\IN\0|isotretinoin_45|is_32|in_13|._150 (l_pobj) abnormalities_11\NNS\14034177|of_32 (l_prep) after_12\IN\0|the_43|many_39|reported_34|congenital_25 (l_pobj) use_14\NN\407535|NONE_0 (l_prep) including_16\VBG\0|maternal_14|(_1|)_75 (l_pobj) microphthalmos_17\NNS\0|NONE_0 (l_conj) hypertelorism_20\NN\0|,_10
D015474_D008850 NONE isotretinoin_0\NNP\0|is_13|in_32|because_45|._195 (r_nsubjpass) contraindicated_2\VBN\872886|NONE_0 (l_prep) because_5\IN\0|isotretinoin_45|is_32|in_13|._150 (l_pobj) abnormalities_11\NNS\14034177|of_32 (l_prep) after_12\IN\0|the_43|many_39|reported_34|congenital_25 (l_pobj) use_14\NN\407535|NONE_0 (l_prep) including_16\VBG\0|maternal_14|(_1|)_75 (l_pobj) microphthalmos_17\NNS\0|NONE_0
18987260
D004317_D014511 CID adr_9\NNP\0|advanced_9|in_16 (r_compound) nephropathy_10\NN\14573196|NONE_0 (r_pobj) in_7\IN\13603305|urea_15 (r_prep) clearance_6\NN\5089947|NONE_0 (r_dobj) increased_4\VBN\169651|losartan_29|uraemia_12|and_4|._59 (r_conj) reduced_1\VBD\441445|NONE_0 (l_dobj) uraemia_2\RB\14204950|losartan_17|and_8|increased_12|._71
D004317_D006973 NONE adriamycin_3\JJ\0|NONE_0 (r_amod) nephropathy_4\NN\14573196|NONE_0 (r_pobj) of_2\IN\0|reduced_20|in_26|._80 (r_prep) progression_1\NN\8457976|NONE_0 (l_prep) in_5\IN\13603305|reduced_46|of_26|._54 (l_pobj) rats_8\NNS\2329401|NONE_0 (l_amod) hypertensive_7\JJ\10405694|treated_18
D004317_D006973 NONE adriamycin_37\NNS\0|(_11|adr_12|)_15 (r_nmod) nephropathy_41\NN\14573196|NONE_0 (r_pobj) with_36\IN\0|renal_67|disease_61|in_41 (r_prep) progression_28\NN\8457976|down_19 (l_prep) in_29\IN\13603305|renal_26|disease_20|with_41 (l_pobj) rats_32\NNS\2329401|NONE_0 (l_amod) hypertensive_31\JJ\10405694|(_18|shr_19|)_22
D004317_D006973 NONE adr_39\NNP\0|adriamycin_12|(_1|)_3 (r_nmod) nephropathy_41\NN\14573196|NONE_0 (r_pobj) with_36\IN\0|renal_67|disease_61|in_41 (r_prep) progression_28\NN\8457976|down_19 (l_prep) in_29\IN\13603305|renal_26|disease_20|with_41 (l_pobj) rats_32\NNS\2329401|NONE_0 (l_amod) hypertensive_31\JJ\10405694|(_18|shr_19|)_22
D014508_D007674 NONE urea_5\NN\14727670|in_15 (r_compound) clearance_6\NN\5089947|NONE_0 (l_prep) in_7\IN\13603305|urea_15 (l_pobj) nephropathy_10\NN\14573196|NONE_0
D004317_D007674 NONE adriamycin_3\JJ\0|NONE_0 (r_amod) nephropathy_4\NN\14573196|NONE_0
D004317_D007674 NONE adriamycin_37\NNS\0|(_11|adr_12|)_15 (r_nmod) nephropathy_41\NN\14573196|NONE_0 (r_pobj) with_36\IN\0|renal_67|disease_61|in_41 (r_prep) progression_28\NN\8457976|down_19 (l_compound) disease_27\NN\14061805|renal_6|in_20|with_61
D004317_D007674 NONE adriamycin_37\NNS\0|(_11|adr_12|)_15 (r_nmod) nephropathy_41\NN\14573196|NONE_0
D004317_D007674 NONE adr_39\NNP\0|adriamycin_12|(_1|)_3 (r_nmod) nephropathy_41\NN\14573196|NONE_0 (r_pobj) with_36\IN\0|renal_67|disease_61|in_41 (r_prep) progression_28\NN\8457976|down_19 (l_compound) disease_27\NN\14061805|renal_6|in_20|with_61
D004317_D007674 NONE adr_39\NNP\0|adriamycin_12|(_1|)_3 (r_nmod) nephropathy_41\NN\14573196|NONE_0
D004317_D007674 NONE adr_9\NNP\0|advanced_9|in_16 (r_compound) nephropathy_10\NN\14573196|NONE_0
D004317_D007674 NONE adr_15\NNP\0|NONE_0 (r_compound) nephropathy_16\NN\14573196|NONE_0
D000804_D007674 NONE ii_13\CD\13741022|type-1_3|receptor_10|,_26|losartan_28 (r_compound) blocker_16\NN\10101634|NONE_0 (l_conj) losartan_18\NN\0|ii_28|type-1_25|receptor_18|,_2 (l_conj) potential_22\NN\14481929|,_10|and_8 (l_prep) in_23\IN\13603305|its_14 (l_pcomp) slowing_24\VBG\7296428|NONE_0 (l_dobj) progression_28\NN\8457976|down_19 (l_compound) disease_27\NN\14061805|renal_6|in_20|with_61
D000804_D007674 NONE ii_13\CD\13741022|type-1_3|receptor_10|,_26|losartan_28 (r_compound) blocker_16\NN\10101634|NONE_0 (l_conj) losartan_18\NN\0|ii_28|type-1_25|receptor_18|,_2 (l_conj) potential_22\NN\14481929|,_10|and_8 (l_prep) in_23\IN\13603305|its_14 (l_pcomp) slowing_24\VBG\7296428|NONE_0 (l_dobj) progression_28\NN\8457976|down_19 (l_prep) with_36\IN\0|renal_67|disease_61|in_41 (l_pobj) nephropathy_41\NN\14573196|NONE_0
D019808_D011507 NONE losartan_4\NN\0|term_5 (r_amod) treatment_5\NN\654885|:_22|,_9|besides_11|,_42|rate_75|._149 (r_nsubj) improved_11\VBD\126264|NONE_0 (l_dobj) rate_14\NN\13815152|:_97|treatment_75|,_66|besides_64|,_33|._74 (l_acl) resulting_18\VBG\2633881|glomerular_62|filtration_51|and_35|glomerulosclerosis_19 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) proteinuria_21\NN\14299637|NONE_0
D019808_D011507 NONE losartan_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|prolonged_20 (r_prep) treatment_1\NN\654885|reduction_39|,_151|preventing_158|._212 (r_nsubj) showed_4\VBD\2137132|NONE_0 (l_advcl) preventing_21\VBG\0|treatment_158|reduction_119|,_7|._54 (l_dobj) proteinuria_23\NN\14299637|thus_22
D004317_D001284 NONE adr_15\NNP\0|NONE_0 (r_compound) nephropathy_16\NN\14573196|NONE_0 (r_pobj) in_14\IN\13603305|tubular_56|,_41|infiltration_26 (r_prep) atrophy_8\NN\14299637|that_36|losartan_31|could_22
D019808_D001284 NONE losartan_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|prolonged_20 (r_prep) treatment_1\NN\654885|reduction_39|,_151|preventing_158|._212 (r_nsubj) showed_4\VBD\2137132|NONE_0 (l_dobj) reduction_6\NN\351485|treatment_39|,_112|preventing_119|._173 (l_prep) of_7\IN\0|further_18 (l_pobj) glomerulosclerosis_8\NN\0|NONE_0 (l_acl) associated_9\VBN\628491|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) progression_12\NN\8457976|NONE_0 (l_prep) of_13\IN\0|reduced_20 (l_pobj) atrophy_15\NN\14299637|NONE_0
D019808_D001284 NONE losartan_4\NN\0|that_5|could_9|atrophy_31 (r_nsubj) prevent_6\VB\0|examination_39|._82 (l_dobj) atrophy_8\NN\14299637|that_36|losartan_31|could_22
D019808_D007674 NONE losartan_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) treated_9\VBN\2376958|hypertensive_18 (r_acl) rats_8\NNS\2329401|NONE_0 (r_pobj) in_5\IN\13603305|reduced_46|of_26|._54 (r_prep) progression_1\NN\8457976|NONE_0 (l_prep) of_2\IN\0|reduced_20|in_26|._80 (l_pobj) nephropathy_4\NN\14573196|NONE_0
D019808_D007674 NONE losartan_18\NN\0|ii_28|type-1_25|receptor_18|,_2 (l_conj) potential_22\NN\14481929|,_10|and_8 (l_prep) in_23\IN\13603305|its_14 (l_pcomp) slowing_24\VBG\7296428|NONE_0 (l_dobj) progression_28\NN\8457976|down_19 (l_compound) disease_27\NN\14061805|renal_6|in_20|with_61
D019808_D007674 NONE losartan_18\NN\0|ii_28|type-1_25|receptor_18|,_2 (l_conj) potential_22\NN\14481929|,_10|and_8 (l_prep) in_23\IN\13603305|its_14 (l_pcomp) slowing_24\VBG\7296428|NONE_0 (l_dobj) progression_28\NN\8457976|down_19 (l_prep) with_36\IN\0|renal_67|disease_61|in_41 (l_pobj) nephropathy_41\NN\14573196|NONE_0
D019808_D007674 NONE losartan_0\NNP\0|uraemia_17|and_25|increased_29|._88 (r_nsubj) reduced_1\VBD\441445|NONE_0 (l_conj) increased_4\VBN\169651|losartan_29|uraemia_12|and_4|._59 (l_dobj) clearance_6\NN\5089947|NONE_0 (l_prep) in_7\IN\13603305|urea_15 (l_pobj) nephropathy_10\NN\14573196|NONE_0
D019808_D007674 NONE losartan_4\NN\0|that_5|could_9|atrophy_31 (r_nsubj) prevent_6\VB\0|examination_39|._82 (l_dobj) atrophy_8\NN\14299637|that_36|losartan_31|could_22 (l_prep) in_14\IN\13603305|tubular_56|,_41|infiltration_26 (l_pobj) nephropathy_16\NN\14573196|NONE_0
D019808_D005921 NONE losartan_4\NN\0|term_5 (r_amod) treatment_5\NN\654885|:_22|,_9|besides_11|,_42|rate_75|._149 (r_nsubj) improved_11\VBD\126264|NONE_0 (l_dobj) rate_14\NN\13815152|:_97|treatment_75|,_66|besides_64|,_33|._74 (l_conj) glomerulosclerosis_17\NN\0|glomerular_43|filtration_32|and_16|resulting_19
D019808_D005921 NONE losartan_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|prolonged_20 (r_prep) treatment_1\NN\654885|reduction_39|,_151|preventing_158|._212 (r_nsubj) showed_4\VBD\2137132|NONE_0 (l_dobj) reduction_6\NN\351485|treatment_39|,_112|preventing_119|._173 (l_prep) of_7\IN\0|further_18 (l_pobj) glomerulosclerosis_8\NN\0|NONE_0
D019808_D007676 NONE losartan_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|prolonged_20 (r_prep) treatment_1\NN\654885|reduction_39|,_151|preventing_158|._212 (r_nsubj) showed_4\VBD\2137132|NONE_0 (l_advcl) preventing_21\VBG\0|treatment_158|reduction_119|,_7|._54 (l_dobj) proteinuria_23\NN\14299637|thus_22 (l_conj) failure_27\NN\66216|heavy_36|and_18
D019808_D007676 NONE losartan_0\NNP\0|rate_21|to_91|._124 (r_nsubj) reduces_1\VBZ\441445|NONE_0 (l_prep) to_13\IN\0|losartan_91|rate_70|._33 (l_pobj) disease_18\NN\14061805|NONE_0
D019808_D014511 NONE losartan_0\NNP\0|uraemia_17|and_25|increased_29|._88 (r_nsubj) reduced_1\VBD\441445|NONE_0 (l_dobj) uraemia_2\RB\14204950|losartan_17|and_8|increased_12|._71
D004317_D007676 NONE adr_7\NNP\0|-_3 (r_npadvmod) induced_9\VBN\1627355|focal_8|segmental_14 (r_amod) glomerulosclerosis_12\NN\0|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) progression_5\NN\8457976|NONE_0 (r_pobj) of_4\IN\0|the_9 (r_prep) rate_3\NN\13815152|losartan_21|to_70|._103 (r_dobj) reduces_1\VBZ\441445|NONE_0 (l_prep) to_13\IN\0|losartan_91|rate_70|._33 (l_pobj) disease_18\NN\14061805|NONE_0
D019808_D006973 NONE losartan_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) treated_9\VBN\2376958|hypertensive_18 (r_acl) rats_8\NNS\2329401|NONE_0 (l_amod) hypertensive_7\JJ\10405694|treated_18
D019808_D006973 NONE losartan_18\NN\0|ii_28|type-1_25|receptor_18|,_2 (l_conj) potential_22\NN\14481929|,_10|and_8 (l_prep) in_23\IN\13603305|its_14 (l_pcomp) slowing_24\VBG\7296428|NONE_0 (l_dobj) progression_28\NN\8457976|down_19 (l_prep) in_29\IN\13603305|renal_26|disease_20|with_41 (l_pobj) rats_32\NNS\2329401|NONE_0 (l_amod) hypertensive_31\JJ\10405694|(_18|shr_19|)_22
D004317_D005923 CID adr_7\NNP\0|-_3 (r_npadvmod) induced_9\VBN\1627355|focal_8|segmental_14 (r_amod) glomerulosclerosis_12\NN\0|NONE_0
D000804_D006973 NONE ii_13\CD\13741022|type-1_3|receptor_10|,_26|losartan_28 (r_compound) blocker_16\NN\10101634|NONE_0 (l_conj) losartan_18\NN\0|ii_28|type-1_25|receptor_18|,_2 (l_conj) potential_22\NN\14481929|,_10|and_8 (l_prep) in_23\IN\13603305|its_14 (l_pcomp) slowing_24\VBG\7296428|NONE_0 (l_dobj) progression_28\NN\8457976|down_19 (l_prep) in_29\IN\13603305|renal_26|disease_20|with_41 (l_pobj) rats_32\NNS\2329401|NONE_0 (l_amod) hypertensive_31\JJ\10405694|(_18|shr_19|)_22
D019808_D005355 NONE losartan_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|prolonged_20 (r_prep) treatment_1\NN\654885|reduction_39|,_151|preventing_158|._212 (r_nsubj) showed_4\VBD\2137132|NONE_0 (l_dobj) reduction_6\NN\351485|treatment_39|,_112|preventing_119|._173 (l_prep) of_7\IN\0|further_18 (l_pobj) glomerulosclerosis_8\NN\0|NONE_0 (l_acl) associated_9\VBN\628491|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) progression_12\NN\8457976|NONE_0 (l_prep) of_13\IN\0|reduced_20 (l_pobj) atrophy_15\NN\14299637|NONE_0 (l_conj) fibrosis_18\NN\14204950|tubular_33|and_17
D019808_D005355 NONE losartan_4\NN\0|that_5|could_9|atrophy_31 (r_nsubj) prevent_6\VB\0|examination_39|._82 (l_dobj) atrophy_8\NN\14299637|that_36|losartan_31|could_22 (l_conj) infiltration_11\NN\975452|tubular_30|,_15|in_26 (l_conj) fibrosis_13\NN\14204950|interstitial_30|and_4
D019808_D005923 NONE losartan_0\NNP\0|rate_21|to_91|._124 (r_nsubj) reduces_1\VBZ\441445|NONE_0 (l_dobj) rate_3\NN\13815152|losartan_21|to_70|._103 (l_prep) of_4\IN\0|the_9 (l_pobj) progression_5\NN\8457976|NONE_0 (l_prep) of_6\IN\0|NONE_0 (l_pobj) glomerulosclerosis_12\NN\0|NONE_0
D004317_D005355 NONE adr_15\NNP\0|NONE_0 (r_compound) nephropathy_16\NN\14573196|NONE_0 (r_pobj) in_14\IN\13603305|tubular_56|,_41|infiltration_26 (r_prep) atrophy_8\NN\14299637|that_36|losartan_31|could_22 (l_conj) infiltration_11\NN\975452|tubular_30|,_15|in_26 (l_conj) fibrosis_13\NN\14204950|interstitial_30|and_4
D014508_D014511 NONE urea_5\NN\14727670|in_15 (r_compound) clearance_6\NN\5089947|NONE_0 (r_dobj) increased_4\VBN\169651|losartan_29|uraemia_12|and_4|._59 (r_conj) reduced_1\VBD\441445|NONE_0 (l_dobj) uraemia_2\RB\14204950|losartan_17|and_8|increased_12|._71
1522360
D012293_D006461 CID rifampin_8\NN\2716205|intermittent_13 (r_amod) therapy_9\NN\657604|NONE_0 (r_dobj) following_6\VBG\8180190|intravascular_48|and_24|failure_8|._39 (r_prep) hemolysis_1\NN\13509528|NONE_0
D012293_D006461 CID rifampin_8\NN\2716205|hemolysis_51|therapy_9|rare_30|._34 (r_advmod) is_10\VBZ\0|NONE_0 (l_nsubj) hemolysis_1\NN\13509528|rifampin_51|therapy_60|rare_81|._85
D012293_D006461 CID rifampin_12\NN\2716205|NONE_0 (r_pobj) following_11\VBG\8180190|who_48|failure_8 (r_prep) developed_5\VBD\1753788|two_30|with_17 (l_dobj) failure_10\NN\66216|who_40|following_8 (l_nmod) hemolysis_6\NN\13509528|acute_14|renal_20
D012293_D007918 NONE rifampin_12\NN\2716205|NONE_0 (r_pobj) following_11\VBG\8180190|who_48|failure_8 (r_prep) developed_5\VBD\1753788|two_30|with_17 (r_relcl) patients_1\NNS\9898892|are_89|._101 (l_prep) with_2\IN\0|two_13|developed_17 (l_pobj) leprosy_3\NN\14127211|NONE_0
D012293_D058186 CID rifampin_8\NN\2716205|intermittent_13 (r_amod) therapy_9\NN\657604|NONE_0 (r_dobj) following_6\VBG\8180190|intravascular_48|and_24|failure_8|._39 (r_prep) hemolysis_1\NN\13509528|NONE_0 (l_conj) failure_5\NN\66216|intravascular_40|and_16|following_8|._47
D012293_D058186 CID rifampin_8\NN\2716205|hemolysis_51|therapy_9|rare_30|._34 (r_advmod) is_10\VBZ\0|NONE_0 (l_nsubj) hemolysis_1\NN\13509528|rifampin_51|therapy_60|rare_81|._85 (l_acl) leading_2\VBG\4339291|intravascular_24 (l_prep) to_3\IN\0|NONE_0 (l_pobj) failure_6\NN\66216|NONE_0
D012293_D058186 CID rifampin_12\NN\2716205|NONE_0 (r_pobj) following_11\VBG\8180190|who_48|failure_8 (r_prep) developed_5\VBD\1753788|two_30|with_17 (l_dobj) failure_10\NN\66216|who_40|following_8
D012293_D051437 NONE rifampin_11\NN\2716205|NONE_0 (r_pobj) of_10\IN\0|the_8 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|a_20|rare_18 (r_acl) complication_5\NN\1073995|failure_18|._48 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) failure_1\NN\66216|complication_18|._66
24283660
D016559_D012640 CID tacrolimus_0\NNP\0|-_10 (r_npadvmod) related_2\VBN\628491|after_16|--_53|experience_71|._81 (r_amod) seizure_3\NN\14081375|NONE_0
D016559_D012640 CID tac_41\NNP\0|NONE_0 (r_compound) level_42\NN\4916342|NONE_0 (r_pobj) trough_40\NN\9366017|total_35|after_19|,_6|and_4 (r_conj) bilirubin_35\NN\14756039|showed_191|,_47|pugh_39|before_28|,_14|._45 (r_conj) score_29\NN\5736149|NONE_0 (l_ccomp) showed_2\VBD\2137132|,_144|pugh_152|before_163|,_177|bilirubin_191|._236 (l_ccomp) included_13\VBD\0|analysis_82 (l_nsubj) factors_6\NNS\7326557|that_14|after_33|lt_49|gender_61 (l_acl) associated_7\VBN\628491|the_17|risk_13 (l_prep) with_8\IN\0|NONE_0 (l_pobj) seizures_9\NNS\14081375|NONE_0
D016559_D012640 CID tac_5\NNP\0|trough_7 (r_compound) level_6\NN\4916342|that_16|factor_36 (r_nsubj) was_7\VBD\0|analysis_38|._65 (l_attr) factor_12\NN\7326557|that_52|level_36 (l_acl) associated_13\VBN\628491|the_33|only_29|independent_24|risk_12 (l_prep) with_14\IN\0|NONE_0 (l_pobj) seizures_16\NNS\14081375|NONE_0
D016559_D012640 CID tac_2\NNP\0|high_12|trough_7 (r_compound) level_3\NN\4916342|factor_26|._115 (r_nsubj) was_4\VBD\0|NONE_0 (l_attr) factor_7\NN\7326557|level_26|._89 (l_relcl) contributed_9\VBD\126264|the_28|predominant_24 (l_prep) to_10\IN\0|that_17 (l_pobj) seizures_11\NNS\14081375|NONE_0
D016559_D012640 CID tac_22\NNP\0|-_3 (r_npadvmod) related_24\VBN\628491|NONE_0 (r_amod) seizures_25\NNS\14081375|NONE_0
D001663_D012640 NONE bilirubin_35\NN\14756039|showed_191|,_47|pugh_39|before_28|,_14|._45 (r_conj) score_29\NN\5736149|NONE_0 (l_ccomp) showed_2\VBD\2137132|,_144|pugh_152|before_163|,_177|bilirubin_191|._236 (l_ccomp) included_13\VBD\0|analysis_82 (l_nsubj) factors_6\NNS\7326557|that_14|after_33|lt_49|gender_61 (l_acl) associated_7\VBN\628491|the_17|risk_13 (l_prep) with_8\IN\0|NONE_0 (l_pobj) seizures_9\NNS\14081375|NONE_0
D016559_D058625 NONE tac_41\NNP\0|NONE_0 (r_compound) level_42\NN\4916342|NONE_0 (r_pobj) trough_40\NN\9366017|total_35|after_19|,_6|and_4 (r_conj) bilirubin_35\NN\14756039|showed_191|,_47|pugh_39|before_28|,_14|._45 (r_conj) score_29\NN\5736149|NONE_0 (l_ccomp) showed_2\VBD\2137132|,_144|pugh_152|before_163|,_177|bilirubin_191|._236 (l_ccomp) included_13\VBD\0|analysis_82 (l_dobj) gender_14\NN\6309383|that_75|factors_61|after_28|lt_12 (l_conj) score_22\NN\5736149|,_36 (l_compound) disease_21\NN\14061805|before_14
D001663_D058625 NONE bilirubin_35\NN\14756039|showed_191|,_47|pugh_39|before_28|,_14|._45 (r_conj) score_29\NN\5736149|NONE_0 (l_ccomp) showed_2\VBD\2137132|,_144|pugh_152|before_163|,_177|bilirubin_191|._236 (l_ccomp) included_13\VBD\0|analysis_82 (l_dobj) gender_14\NN\6309383|that_75|factors_61|after_28|lt_12 (l_conj) score_22\NN\5736149|,_36 (l_compound) disease_21\NN\14061805|before_14
2453942
D005680_D012640 NONE gaba_21\NNP\14601829|NONE_0 (r_pobj) of_20\IN\0|the_18 (r_prep) concentration_19\NN\4916342|in_52|at_69 (r_dobj) measuring_17\VBG\407535|NONE_0 (l_prep) at_31\IN\14622893|concentration_69|in_17 (l_pobj) onset_33\NN\7325190|NONE_0 (l_prep) of_34\IN\0|the_10 (l_pobj) seizures_35\NNS\14081375|NONE_0
D001556_D012640 CID lindane_5\NN\14919948|NONE_0 (r_pobj) of_4\IN\0|the_11|(_11|mg/kg_16|)_21|on_23 (r_prep) effect_3\NN\34213|we_15|by_72|._182 (r_dobj) studied_1\VBD\0|NONE_0 (l_prep) by_16\IN\0|we_87|effect_72|._110 (l_pcomp) measuring_17\VBG\407535|NONE_0 (l_prep) at_31\IN\14622893|concentration_69|in_17 (l_pobj) onset_33\NN\7325190|NONE_0 (l_prep) of_34\IN\0|the_10 (l_pobj) seizures_35\NNS\14081375|NONE_0
D001556_D012640 CID lindane_11\NN\14919948|NONE_0 (r_compound) administration_12\NN\1133281|NONE_0 (r_pobj) after_10\IN\0|+/-_12|1.4_8 (r_prep) min_9\NN\15154774|NONE_0 (r_pobj) at_5\IN\14622893|animals_35|convulsions_12|._48 (r_prep) suffered_2\VBD\2110220|NONE_0 (l_dobj) convulsions_4\NNS\14081375|animals_23|at_12|._60
D001556_D020258 NONE lindane_0\NN\14919948|insecticide_59|._100 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) insecticide_9\NN\14980215|lindane_59|._41 (l_prep) with_10\IN\0|an_30|organochlorine_27 (l_pobj) effects_13\NNS\13245626|NONE_0 (l_amod) neurotoxic_12\JJ\0|known_6
D001556_D020258 NONE hexachlorocyclohexane_4\NN\0|(_7|)_21 (r_appos) lindane_0\NN\14919948|insecticide_59|._100 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) insecticide_9\NN\14980215|lindane_59|._41 (l_prep) with_10\IN\0|an_30|organochlorine_27 (l_pobj) effects_13\NNS\13245626|NONE_0 (l_amod) neurotoxic_12\JJ\0|known_6
D004298_D012640 NONE dopamine_23\NN\14807737|,_2 (r_conj) gaba_21\NNP\14601829|NONE_0 (r_pobj) of_20\IN\0|the_18 (r_prep) concentration_19\NN\4916342|in_52|at_69 (r_dobj) measuring_17\VBG\407535|NONE_0 (l_prep) at_31\IN\14622893|concentration_69|in_17 (l_pobj) onset_33\NN\7325190|NONE_0 (l_prep) of_34\IN\0|the_10 (l_pobj) seizures_35\NNS\14081375|NONE_0
20009434
D008727_D001656 NONE mtx_11\NNP\0|in_12 (r_compound) therapy_12\NN\657604|NONE_0 (r_pobj) after_8\IN\0|we_40|case_28 (r_prep) report_1\VBP\6470073|,_85|patient_91|boy_116|._206 (r_ccomp) was_21\VBD\0|NONE_0 (l_attr) boy_26\NN\9624168|report_116|,_31|patient_25|._90 (l_relcl) received_29\VBN\2210855|a_25|old_16 (l_dobj) transplantation_35\NN\671351|who_40|had_36 (l_prep) for_36\IN\0|a_39|related_30|liver_22 (l_pobj) atresia_39\NN\14501726|NONE_0
D008727_D002051 NONE methotrexate_3\NN\2722166|treatment_38|,_68|but_70|cause_78|._140 (r_nsubj) is_9\VBZ\0|NONE_0 (l_attr) treatment_12\NN\654885|methotrexate_38|,_30|but_32|cause_40|._102 (l_prep) for_13\IN\0|an_23|important_20 (l_pobj) lymphoma_15\NN\14239918|NONE_0
D008727_D002051 NONE mtx_7\NNP\0|dose_22|)_3 (r_appos) methotrexate_3\NN\2722166|treatment_38|,_68|but_70|cause_78|._140 (r_nsubj) is_9\VBZ\0|NONE_0 (l_attr) treatment_12\NN\654885|methotrexate_38|,_30|but_32|cause_40|._102 (l_prep) for_13\IN\0|an_23|important_20 (l_pobj) lymphoma_15\NN\14239918|NONE_0
D008727_D007674 NONE methotrexate_3\NN\2722166|treatment_38|,_68|but_70|cause_78|._140 (r_nsubj) is_9\VBZ\0|NONE_0 (l_conj) cause_19\VB\7323922|methotrexate_78|treatment_40|,_10|but_8|._62 (l_dobj) toxicity_23\NN\13576101|can_28|delayed_31
D008727_D007674 NONE mtx_7\NNP\0|dose_22|)_3 (r_appos) methotrexate_3\NN\2722166|treatment_38|,_68|but_70|cause_78|._140 (r_nsubj) is_9\VBZ\0|NONE_0 (l_conj) cause_19\VB\7323922|methotrexate_78|treatment_40|,_10|but_8|._62 (l_dobj) toxicity_23\NN\13576101|can_28|delayed_31
D008727_D056486 NONE methotrexate_3\NN\2722166|treatment_38|,_68|but_70|cause_78|._140 (r_nsubj) is_9\VBZ\0|NONE_0 (l_conj) cause_19\VB\7323922|methotrexate_78|treatment_40|,_10|but_8|._62 (l_dobj) toxicity_23\NN\13576101|can_28|delayed_31
D008727_D056486 NONE mtx_7\NNP\0|dose_22|)_3 (r_appos) methotrexate_3\NN\2722166|treatment_38|,_68|but_70|cause_78|._140 (r_nsubj) is_9\VBZ\0|NONE_0 (l_conj) cause_19\VB\7323922|methotrexate_78|treatment_40|,_10|but_8|._62 (l_dobj) toxicity_23\NN\13576101|can_28|delayed_31
D008727_D058186 CID methotrexate_7\NN\2722166|dose_5|in_21 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) after_3\IN\0|acute_20|renal_14|._64 (r_prep) failure_2\NN\66216|NONE_0
D008727_D058186 CID mtx_11\NNP\0|in_12 (r_compound) therapy_12\NN\657604|NONE_0 (r_pobj) after_8\IN\0|we_40|case_28 (r_prep) report_1\VBP\6470073|,_85|patient_91|boy_116|._206 (l_dobj) case_3\NN\7283608|we_12|after_28 (l_prep) of_4\IN\0|a_7 (l_pobj) failure_7\NN\66216|NONE_0
D008727_D058186 CID mtx_3\NNP\0|subsequent_14 (r_compound) therapy_4\NN\657604|failure_27|._72 (r_nsubj) caused_5\VBD\1617192|NONE_0 (l_dobj) failure_8\NN\66216|therapy_27|._45
14616590
D015742_D010146 CID disoprivan_32\NNP\0|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) than_30\IN\0|am149_6 (r_prep) with_28\IN\0|pain_114|frequently_11|._31 (r_prep) occurred_25\VBD\0|NONE_0 (l_nsubj) pain_0\NN\14299637|frequently_103|with_114|._145
D015742_D013924 CID disoprivan_32\NNP\0|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) than_30\IN\0|am149_6 (r_prep) with_28\IN\0|pain_114|frequently_11|._31 (r_prep) occurred_25\VBD\0|NONE_0 (l_nsubj) pain_0\NN\14299637|frequently_103|with_114|._145 (l_conj) thrombophlebitis_14\NN\14352890|on_40|(_27|%_17|,_16|0.01_10|)_6|and_4
23846525
C055162_D056486 CID clopidogrel_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBD\628491|acute_16|:_27|report_36|._71 (r_acl) hepatitis_1\NN\14127211|NONE_0
C055162_D056486 CID clopidogrel_5\RB\0|-_11 (r_npadvmod) related_7\VBN\628491|acute_8 (r_amod) hepatitis_9\NN\14127211|NONE_0
C055162_D056486 CID clopidogrel_7\NN\0|to_3 (r_pobj) due_5\JJ\5174653|about_30 (r_amod) reports_0\NNS\6470073|are_57|in_72|,_93|after_95|._131 (l_prep) about_1\IN\0|due_30 (l_pobj) cases_2\NNS\7283608|NONE_0 (l_prep) of_3\IN\0|NONE_0 (l_pobj) hepatotoxicity_4\NN\0|NONE_0
C055162_D056486 CID clopidogrel_19\JJ\0|when_5|is_12 (r_nsubjpass) prescribed_21\VBN\748282|that_102|physicians_97|should_86|carefully_79|risk_56 (r_advcl) consider_9\VB\689344|in_59|,_46|we_44|._79 (l_dobj) risk_11\NN\14541044|that_46|physicians_41|should_30|carefully_23|prescribed_56 (l_prep) of_12\IN\0|the_9 (l_pobj) injury_17\NN\14052046|NONE_0
1779253
D002211_D051474 NONE capsaicin_3\NN\15032661|NONE_0 (l_prep) in_4\IN\13603305|topical_25|%_12|:_34|efficacy_36|._89 (l_pobj) neuralgia_9\NN\14322699|NONE_0
D002211_D051474 NONE capsaicin_18\NN\15032661|NONE_0 (r_pobj) to_16\IN\0|NONE_0 (r_prep) response_15\NN\11410625|NONE_0 (r_pobj) of_14\IN\0|and_15|predictors_11 (r_prep) action_11\NN\30358|NONE_0 (r_pobj) of_10\IN\0|time_12|-_8 (r_prep) course_9\NN\883297|,_64|39_66|with_78|,_120|duration_129 (r_nmod) patients_21\NNS\9898892|in_109|,_76|,_78|were_80|with_93|for_121|._132 (l_prep) with_22\IN\0|course_78|,_14|39_12|,_42|duration_51 (l_pobj) neuralgia_27\NN\14322699|NONE_0
D002211_D051474 NONE capsaicin_18\NN\15032661|NONE_0 (r_pobj) to_16\IN\0|NONE_0 (r_prep) response_15\NN\11410625|NONE_0 (r_pobj) of_14\IN\0|and_15|predictors_11 (r_prep) action_11\NN\30358|NONE_0 (r_pobj) of_10\IN\0|time_12|-_8 (r_prep) course_9\NN\883297|,_64|39_66|with_78|,_120|duration_129 (r_nmod) patients_21\NNS\9898892|in_109|,_76|,_78|were_80|with_93|for_121|._132 (l_prep) with_22\IN\0|course_78|,_14|39_12|,_42|duration_51 (l_pobj) neuralgia_27\NN\14322699|NONE_0 (l_appos) phn_29\NNP\0|chronic_33|herpetic_20|(_1|)_3
D002211_D051474 NONE capsaicin_42\NN\15032661|%_2 (r_compound) cream_43\NN\8386555|NONE_0 (r_pobj) with_39\IN\0|in_202|,_169|patients_93|,_15|were_13|for_28|._39 (r_prep) treated_38\VBN\2376958|NONE_0 (l_nsubjpass) patients_21\NNS\9898892|in_109|,_76|,_78|were_80|with_93|for_121|._132 (l_prep) with_22\IN\0|course_78|,_14|39_12|,_42|duration_51 (l_pobj) neuralgia_27\NN\14322699|NONE_0
D002211_D051474 NONE capsaicin_42\NN\15032661|%_2 (r_compound) cream_43\NN\8386555|NONE_0 (r_pobj) with_39\IN\0|in_202|,_169|patients_93|,_15|were_13|for_28|._39 (r_prep) treated_38\VBN\2376958|NONE_0 (l_nsubjpass) patients_21\NNS\9898892|in_109|,_76|,_78|were_80|with_93|for_121|._132 (l_prep) with_22\IN\0|course_78|,_14|39_12|,_42|duration_51 (l_pobj) neuralgia_27\NN\14322699|NONE_0 (l_appos) phn_29\NNP\0|chronic_33|herpetic_20|(_1|)_3
D002211_D051474 NONE capsaicin_26\NN\15032661|NONE_0 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) phn_28\NNP\0|NONE_0
D002211_D008413 CID capsaicin_28\NN\15032661|-_9 (r_npadvmod) induced_30\VBN\1627355|intolerable_22|burning_8|(_27|4_28|;_46|15_48 (r_amod) sensations_32\NNS\5708432|such_46 (l_appos) 4_34\CD\13741022|intolerable_50|induced_28|burning_20|(_1|;_18|15_20 (l_conj) mastitis_37\NN\14336539|)_5|or_3
573555
D011433_D006932 NONE propranolol_27\NN\0|chronic_8 (r_amod) therapy_28\NN\657604|NONE_0 (r_pobj) with_25\IN\0|can_35|not_32|be_28|statistically_25 (r_prep) correlated_24\VBN\2657219|that_152|hypoglycemia_127|not_43|invariable_39|and_28 (r_conj) are_16\VBP\13600404|we_117|._90 (l_nsubj) hypoglycemia_5\NN\14299637|that_25|not_84|invariable_88|and_99|correlated_127 (l_conj) hyperbilirubinemia_7\NN\14204950|reported_23|,_2
D011433_D001049 NONE propranolol_27\NN\0|chronic_8 (r_amod) therapy_28\NN\657604|NONE_0 (r_pobj) with_25\IN\0|can_35|not_32|be_28|statistically_25 (r_prep) correlated_24\VBN\2657219|that_152|hypoglycemia_127|not_43|invariable_39|and_28 (r_conj) are_16\VBP\13600404|we_117|._90 (l_nsubj) hypoglycemia_5\NN\14299637|that_25|not_84|invariable_88|and_99|correlated_127 (l_conj) hyperbilirubinemia_7\NN\14204950|reported_23|,_2 (l_conj) polycythemia_9\NN\14189204|,_2 (l_conj) apnea_12\NN\14299637|,_11
D011433_D007003 NONE propranolol_27\NN\0|chronic_8 (r_amod) therapy_28\NN\657604|NONE_0 (r_pobj) with_25\IN\0|can_35|not_32|be_28|statistically_25 (r_prep) correlated_24\VBN\2657219|that_152|hypoglycemia_127|not_43|invariable_39|and_28 (r_conj) are_16\VBP\13600404|we_117|._90 (l_nsubj) hypoglycemia_5\NN\14299637|that_25|not_84|invariable_88|and_99|correlated_127
D011433_D001919 NONE propranolol_27\NN\0|chronic_8 (r_amod) therapy_28\NN\657604|NONE_0 (r_pobj) with_25\IN\0|can_35|not_32|be_28|statistically_25 (r_prep) correlated_24\VBN\2657219|that_152|hypoglycemia_127|not_43|invariable_39|and_28 (r_conj) are_16\VBP\13600404|we_117|._90 (l_nsubj) hypoglycemia_5\NN\14299637|that_25|not_84|invariable_88|and_99|correlated_127 (l_conj) hyperbilirubinemia_7\NN\14204950|reported_23|,_2 (l_conj) polycythemia_9\NN\14189204|,_2 (l_conj) apnea_12\NN\14299637|,_11 (l_conj) bradycardia_15\NN\14110674|neonatal_20|,_6|and_4
D011433_D011086 NONE propranolol_27\NN\0|chronic_8 (r_amod) therapy_28\NN\657604|NONE_0 (r_pobj) with_25\IN\0|can_35|not_32|be_28|statistically_25 (r_prep) correlated_24\VBN\2657219|that_152|hypoglycemia_127|not_43|invariable_39|and_28 (r_conj) are_16\VBP\13600404|we_117|._90 (l_nsubj) hypoglycemia_5\NN\14299637|that_25|not_84|invariable_88|and_99|correlated_127 (l_conj) hyperbilirubinemia_7\NN\14204950|reported_23|,_2 (l_conj) polycythemia_9\NN\14189204|,_2
7173007
D003287_D064420 NONE media_9\NNS\3575240|polyvidone_44|are_33|and_32|preferred_91|._100 (r_oprd) considered_5\VBN\689344|NONE_0 (l_conj) preferred_22\VBN\1777210|polyvidone_135|are_124|media_91|and_59|._9 (l_prep) because_14\IN\0|hexabrix_28|should_37|be_44 (l_pobj) toxicity_18\NN\13576101|perhaps_27|of_11
C025504_D004244 CID x_3\NNP\13745420|the_10 (r_compound) group_4\NN\2137|incidence_19|._52 (r_nsubj) had_5\VBD\0|NONE_0 (l_dobj) incidence_8\NN\13821570|group_19|._33 (l_prep) of_9\IN\0|a_19|higher_17 (l_pobj) nausea_10\NN\14299637|NONE_0 (l_conj) dizziness_12\NN\14299637|and_4
C025504_D009325 CID x_3\NNP\13745420|the_10 (r_compound) group_4\NN\2137|incidence_19|._52 (r_nsubj) had_5\VBD\0|NONE_0 (l_dobj) incidence_8\NN\13821570|group_19|._33 (l_prep) of_9\IN\0|a_19|higher_17 (l_pobj) nausea_10\NN\14299637|NONE_0
D007485_D064420 NONE hexabrix_0\NNP\0|NONE_0 (r_nmod) polyvidone_3\NN\0|are_11|media_44|and_76|preferred_135|._144 (r_nsubjpass) considered_5\VBN\689344|NONE_0 (l_conj) preferred_22\VBN\1777210|polyvidone_135|are_124|media_91|and_59|._9 (l_prep) because_14\IN\0|hexabrix_28|should_37|be_44 (l_pobj) toxicity_18\NN\13576101|perhaps_27|of_11
D007485_D064420 NONE hexabrix_19\NNP\0|because_28|should_9|be_16 (r_nsubjpass) preferred_22\VBN\1777210|polyvidone_135|are_124|media_91|and_59|._9 (l_prep) because_14\IN\0|hexabrix_28|should_37|be_44 (l_pobj) toxicity_18\NN\13576101|perhaps_27|of_11
D000100_D064420 NONE polyvidone_3\NN\0|are_11|media_44|and_76|preferred_135|._144 (r_nsubjpass) considered_5\VBN\689344|NONE_0 (l_conj) preferred_22\VBN\1777210|polyvidone_135|are_124|media_91|and_59|._9 (l_prep) because_14\IN\0|hexabrix_28|should_37|be_44 (l_pobj) toxicity_18\NN\13576101|perhaps_27|of_11
C006753_D015746 CID endografine_1\NNP\0|the_4 (r_compound) group_2\NN\2137|incidence_19|._46 (r_nsubj) had_3\VBD\0|NONE_0 (l_dobj) incidence_6\NN\13821570|group_19|._27 (l_prep) of_7\IN\0|a_19|higher_17 (l_pobj) pain_9\NN\14299637|NONE_0
1449452
D004077_D001281 NONE digoxin_5\NN\15060131|NONE_0 (l_compound) fibrillation_4\NN\14361664|NONE_0
D004077_D009203 NONE digoxin_19\NN\15060131|that_5|may_8|mortality_21|after_31 (r_nsubj) increase_21\VB\13576355|a_31 (l_prep) after_23\IN\0|that_36|digoxin_31|may_23|mortality_10 (l_pobj) infarction_25\NN\14204950|NONE_0
D004077_D009203 NONE digoxin_19\NN\15060131|that_5|may_8|mortality_21|after_31 (r_nsubj) increase_21\VB\13576355|a_31 (l_prep) after_23\IN\0|that_36|digoxin_31|may_23|mortality_10 (l_pobj) infarction_25\NN\14204950|NONE_0 (l_appos) mi_27\NNP\14207561|myocardial_23|(_1|)_2
D004077_D001145 CID digoxin_2\NN\15060131|also_6|,_2|effects_24|._120 (r_nsubj) has_3\VBZ\13888491|NONE_0 (l_dobj) effects_5\NNS\13245626|also_30|,_26|digoxin_24|._96 (l_prep) as_7\IN\14622893|undesirable_25 (l_pcomp) increasing_8\VBG\169651|such_8 (l_conj) causing_16\VBG\30358|resistance_39|,_6|and_4 (l_dobj) arrhythmias_17\NNS\14103288|NONE_0
9197951
D004053_D011681 NONE dep_4\NNP\0|while_9 (l_appos) changes_7\NNS\7283608|,_13 (l_prep) in_8\IN\13603305|especially_19 (l_pobj) power_11\NN\4723816|NONE_0 (l_prep) of_12\IN\0|the_16|total_12 (l_pobj) oscillation_14\NN\13518963|NONE_0
D004053_D001714 CID diethylpropion_23\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_25|anticraving_21 (r_prep) efficacy_18\NN\5199286|NONE_0 (r_dobj) evaluating_15\VBG\670261|a_8 (r_acl) study_14\NN\635850|NONE_0 (r_pobj) in_12\IN\13603305|a_10 (r_prep) subject_11\NN\6598915|who_10 (r_attr) was_9\VBD\0|a_40|old_30|dependent_18 (r_relcl) man_7\NN\9605289|manic_125|during_131|._171 (r_nsubj) became_27\VBD\146138|NONE_0 (l_acomp) manic_28\JJ\0|man_125|during_6|._46
D004053_D001714 CID dep_25\NNP\0|the_41|stimulant_37|medication_27 (r_appos) diethylpropion_23\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_25|anticraving_21 (r_prep) efficacy_18\NN\5199286|NONE_0 (r_dobj) evaluating_15\VBG\670261|a_8 (r_acl) study_14\NN\635850|NONE_0 (r_pobj) in_12\IN\13603305|a_10 (r_prep) subject_11\NN\6598915|who_10 (r_attr) was_9\VBD\0|a_40|old_30|dependent_18 (r_relcl) man_7\NN\9605289|manic_125|during_131|._171 (r_nsubj) became_27\VBD\146138|NONE_0 (l_acomp) manic_28\JJ\0|man_125|during_6|._46
D004053_D001714 CID dep_4\NNP\0|while_9 (r_pobj) on_3\IN\0|pupillometric_28 (r_prep) changes_1\NNS\7283608|,_84|different_104|._192 (r_nsubj) were_16\VBD\0|NONE_0 (l_acomp) different_18\JJ\0|changes_104|,_20|._88 (l_prep) than_19\IN\0|dramatically_23 (l_pobj) those_20\DT\0|NONE_0 (l_acl) observed_21\VBN\2163746|NONE_0 (l_prep) in_22\IN\13603305|NONE_0 (l_pobj) subjects_27\NNS\6598915|NONE_0 (l_relcl) become_31\VB\146138|the_43|eight_39|other_33|study_27 (l_acomp) manic_32\JJ\0|who_19|did_15|not_11
D003042_D001714 NONE cocaine_4\NN\3492717|-_7 (r_npadvmod) dependent_6\JJ\9627906|a_22|old_12|was_18 (r_amod) man_7\NN\9605289|manic_125|during_131|._171 (r_nsubj) became_27\VBD\146138|NONE_0 (l_acomp) manic_28\JJ\0|man_125|during_6|._46
25006961
D008094_D011141 CID lithium_20\NN\14625458|-_7 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) polyuria_23\NN\14113228|NONE_0
D008094_D011141 CID lithium_18\NN\14625458|-_7 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) ndi_21\NNP\0|NONE_0 (r_pobj) in_17\IN\13603305|that_83|ablation_78|expression_28|,_22|and_24|prevents_28 (r_prep) preserves_7\VBZ\7597145|data_32|._168 (l_conj) prevents_24\VBZ\0|that_111|ablation_106|expression_56|in_28|,_6|and_4 (l_dobj) development_26\NN\248977|NONE_0 (l_prep) of_27\IN\0|the_16 (l_pobj) polyuria_30\NN\14113228|NONE_0
D008094_D011141 CID lithium_33\NN\14625458|NONE_0 (r_compound) therapy_34\NN\657604|NONE_0 (r_pobj) with_32\IN\0|NONE_0 (r_prep) associated_31\VBN\628491|the_20|severe_16 (r_acl) polyuria_30\NN\14113228|NONE_0
D008094_D018500 CID lithium_6\NN\14625458|-_7 (r_npadvmod) induced_8\VBN\1627355|diabetes_20 (r_amod) insipidus_11\NN\0|absence_69|._9
D008094_D018500 CID lithium_0\NN\14625458|insipidus_66|in_82|._101 (r_nsubj) induces_6\VBZ\1627355|NONE_0 (l_dobj) insipidus_9\NN\0|lithium_66|in_16|._35
D008094_D018500 CID lithium_0\NN\14625458|insipidus_66|in_82|._101 (r_nsubj) induces_6\VBZ\1627355|NONE_0 (l_dobj) insipidus_9\NN\0|lithium_66|in_16|._35 (l_appos) ndi_11\NNP\0|nephrogenic_32|diabetes_20|(_1|)_3
D008094_D018500 CID lithium_18\NN\14625458|-_7 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) ndi_21\NNP\0|NONE_0
D008094_D018500 CID lithium_33\NN\14625458|NONE_0 (r_compound) therapy_34\NN\657604|NONE_0 (r_pobj) with_32\IN\0|NONE_0 (r_prep) associated_31\VBN\628491|the_20|severe_16 (r_acl) polyuria_30\NN\14113228|NONE_0 (r_pobj) of_27\IN\0|the_16 (r_prep) development_26\NN\248977|NONE_0 (r_dobj) prevents_24\VBZ\0|that_111|ablation_106|expression_56|in_28|,_6|and_4 (r_conj) preserves_7\VBZ\7597145|data_32|._168 (l_prep) in_17\IN\13603305|that_83|ablation_78|expression_28|,_22|and_24|prevents_28 (l_pobj) ndi_21\NNP\0|NONE_0
6316193
D010852_D012640 CID picrotoxin_12\NN\0|-_10 (r_npadvmod) induced_14\VBN\1627355|by_17 (r_amod) seizures_15\NNS\14081375|NONE_0
D010852_D012640 CID picrotoxin_24\NN\0|NONE_0 (r_pobj) by_23\IN\0|in_14 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) seizures_21\NNS\14081375|NONE_0
D010852_D012640 CID picrotoxin_31\NN\0|-_10 (r_npadvmod) induced_33\VBN\1627355|and_17|mortality_21 (r_amod) seizures_34\NNS\14081375|mumol_96|,_49|,_39|totally_37
D002766_D012640 NONE cholecystokinin_17\NN\5408684|NONE_0 (r_pobj) by_16\IN\0|induced_17 (r_prep) seizures_15\NNS\14081375|NONE_0
D002766_D012640 NONE cholecystokinin_23\NN\5408684|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) analogues_21\NNS\4743605|and_4 (r_conj) fragments_19\NNS\9385911|,_2|in_43 (r_conj) cholecystokinin_17\NN\5408684|NONE_0 (r_pobj) by_16\IN\0|induced_17 (r_prep) seizures_15\NNS\14081375|NONE_0
D003975_D012640 NONE diazepam_27\NN\2830852|NONE_0 (r_preconj) ,_26\,\0|mumol_47|,_10|totally_12|seizures_49 (r_punct) prevented_30\VBD\0|peptide_155|activity_115|,_73|._51 (l_dobj) seizures_34\NNS\14081375|mumol_96|,_49|,_39|totally_37
D012844_D012640 NONE octapeptide_4\JJ\0|sulphate_12 (r_compound) ester_6\NN\14727670|NONE_0 (r_appos) cholecystokinin_3\NN\5408684|NONE_0 (r_pobj) of_2\IN\0|intraperitoneal_31|cck-8-se_47|and_57|cholecystokinin_74 (r_prep) administration_1\NN\1133281|latency_141|._190 (r_nsubj) enhanced_17\VBD\227165|NONE_0 (l_dobj) latency_19\NN\15269513|administration_141|._49 (l_prep) of_20\IN\0|the_12 (l_pobj) seizures_21\NNS\14081375|NONE_0
D012844_D012640 NONE cck-8-se_8\NNP\0|intraperitoneal_78|of_47|and_10|cholecystokinin_27 (r_parataxis) administration_1\NN\1133281|latency_141|._190 (r_nsubj) enhanced_17\VBD\227165|NONE_0 (l_dobj) latency_19\NN\15269513|administration_141|._49 (l_prep) of_20\IN\0|the_12 (l_pobj) seizures_21\NNS\14081375|NONE_0
D012844_D012640 NONE octapeptide_13\RB\0|nonsulphated_29|)_21 (r_appos) cholecystokinin_12\NN\5408684|intraperitoneal_105|of_74|cck-8-se_27|and_17 (r_conj) administration_1\NN\1133281|latency_141|._190 (r_nsubj) enhanced_17\VBD\227165|NONE_0 (l_dobj) latency_19\NN\15269513|administration_141|._49 (l_prep) of_20\IN\0|the_12 (l_pobj) seizures_21\NNS\14081375|NONE_0
D012844_D012640 NONE cck-8-ns_15\NNP\0|NONE_0 (r_appos) octapeptide_13\RB\0|nonsulphated_29|)_21 (r_appos) cholecystokinin_12\NN\5408684|intraperitoneal_105|of_74|cck-8-se_27|and_17 (r_conj) administration_1\NN\1133281|latency_141|._190 (r_nsubj) enhanced_17\VBD\227165|NONE_0 (l_dobj) latency_19\NN\15269513|administration_141|._49 (l_prep) of_20\IN\0|the_12 (l_pobj) seizures_21\NNS\14081375|NONE_0
4631913
D014750_D007970 CID sulfate_11\NN\15010703|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) mg_8\NN\13717155|2.0_11|to_7 (r_quantmod) 2.5_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|intratracheal_26 (r_prep) inoculation_3\NN\828990|or_17 (r_conj) intravenous_0\JJ\0|was_81|by_94|._122 (r_nsubjpass) followed_13\VBN\1835496|NONE_0 (l_agent) by_14\IN\0|intravenous_94|was_13|._28 (l_pobj) leukopenia_15\NN\14189204|NONE_0
D014750_D011552 CID sulfate_3\NN\15010703|NONE_0 (l_prep) on_4\IN\0|vincristine_20 (l_pobj) infections_6\NNS\14052046|NONE_0
19681452
D000431_D020520 NONE alcohol_10\NN\7881800|and_4 (r_conj) cocaine_8\NN\3492717|NONE_0 (r_nmod) intoxication_11\NN\14034177|NONE_0 (r_pobj) after_7\IN\0|the_20|globus_16 (r_prep) pallidus_6\NN\0|NONE_0
D003042_D020520 NONE cocaine_8\NN\3492717|NONE_0 (r_nmod) intoxication_11\NN\14034177|NONE_0 (r_pobj) after_7\IN\0|the_20|globus_16 (r_prep) pallidus_6\NN\0|NONE_0
D003042_D020520 NONE cocaine_8\NN\3492717|NONE_0 (r_pobj) of_7\IN\0|the_8 (r_prep) use_6\NN\407535|NONE_0 (r_pobj) after_4\IN\0|bilateral_33|basal_23|ganglia_17|,_24|without_26|,_55 (r_prep) infarcts_3\NNS\14204950|have_66|never_71|been_77|._90
D003042_D001145 NONE cocaine_12\NN\3492717|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) related_10\VBN\628491|transient_56|cardiac_46|or_27|dysfunction_12 (r_acl) arrhythmia_6\NN\14103288|in_34|,_20|causes_97|._129
D000431_D002543 NONE alcohol_10\NN\7881800|and_4 (r_conj) cocaine_8\NN\3492717|NONE_0 (r_nmod) intoxication_11\NN\14034177|NONE_0 (r_pobj) after_7\IN\0|the_20|globus_16 (r_prep) pallidus_6\NN\0|NONE_0
D000431_D002545 NONE alcohol_19\NN\7881800|NONE_0 (r_pobj) after_17\IN\0|the_77|of_68 (r_prep) case_3\NN\7283608|we_15|._123 (l_prep) of_4\IN\0|the_9|after_68 (l_pobj) man_9\NN\9605289|NONE_0 (l_prep) with_10\IN\0|a_18|old_8 (l_pobj) ischemia_12\NN\14195315|NONE_0 (l_prep) of_13\IN\0|bilateral_19 (l_pobj) pallidus_16\NN\0|NONE_0
D003042_D012131 NONE cocaine_12\NN\3492717|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) related_10\VBN\628491|transient_56|cardiac_46|or_27|dysfunction_12 (r_acl) arrhythmia_6\NN\14103288|in_34|,_20|causes_97|._129 (l_conj) dysfunction_9\NN\14204950|transient_44|cardiac_34|or_15|related_12
D000431_D012131 NONE ethanol_14\NN\14708720|NONE_0 (r_compound) use_15\NN\407535|and/or_15 (r_conj) cocaine_12\NN\3492717|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) related_10\VBN\628491|transient_56|cardiac_46|or_27|dysfunction_12 (r_acl) arrhythmia_6\NN\14103288|in_34|,_20|causes_97|._129 (l_conj) dysfunction_9\NN\14204950|transient_44|cardiac_34|or_15|related_12
D003042_D002543 NONE cocaine_8\NN\3492717|NONE_0 (r_nmod) intoxication_11\NN\14034177|NONE_0 (r_pobj) after_7\IN\0|the_20|globus_16 (r_prep) pallidus_6\NN\0|NONE_0
D000431_D001145 NONE ethanol_14\NN\14708720|NONE_0 (r_compound) use_15\NN\407535|and/or_15 (r_conj) cocaine_12\NN\3492717|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) related_10\VBN\628491|transient_56|cardiac_46|or_27|dysfunction_12 (r_acl) arrhythmia_6\NN\14103288|in_34|,_20|causes_97|._129
D003042_D002545 CID cocaine_22\NN\3492717|intranasal_11 (r_compound) use_23\NN\407535|excessive_41|and_23 (r_conj) alcohol_19\NN\7881800|NONE_0 (r_pobj) after_17\IN\0|the_77|of_68 (r_prep) case_3\NN\7283608|we_15|._123 (l_prep) of_4\IN\0|the_9|after_68 (l_pobj) man_9\NN\9605289|NONE_0 (l_prep) with_10\IN\0|a_18|old_8 (l_pobj) ischemia_12\NN\14195315|NONE_0 (l_prep) of_13\IN\0|bilateral_19 (l_pobj) pallidus_16\NN\0|NONE_0
D000431_-1 NONE ethanol_14\NN\14708720|NONE_0 (r_compound) use_15\NN\407535|and/or_15 (r_conj) cocaine_12\NN\3492717|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) related_10\VBN\628491|transient_56|cardiac_46|or_27|dysfunction_12 (r_acl) arrhythmia_6\NN\14103288|in_34|,_20|causes_97|._129 (r_nsubj) were_16\VBD\0|NONE_0 (l_attr) causes_20\NNS\7323922|in_131|,_117|arrhythmia_97|._32 (l_prep) of_21\IN\0|the_23|likely_14 (l_pobj) hypoperfusion_23\NN\0|NONE_0
D003042_D002544 NONE cocaine_0\NN\3492717|factor_18|._66 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) factor_4\NN\7326557|cocaine_18|._48 (l_prep) for_5\IN\0|a_14|risk_12 (l_pobj) stroke_10\NN\556313|NONE_0
D003932_D020520 CID heroin_11\NN\3492717|NONE_0 (r_pobj) with_10\IN\0|infarctions_38|are_26|often_17|._11 (r_prep) associated_9\VBN\628491|NONE_0 (l_nsubjpass) infarctions_5\NNS\14204950|are_12|often_21|with_38|._49
D003932_D020520 CID heroin_12\NN\3492717|concurrent_11 (r_compound) use_13\NN\407535|NONE_0 (r_pobj) without_10\IN\0|bilateral_59|basal_49|ganglia_43|after_26|,_2|,_29 (r_prep) infarcts_3\NNS\14204950|have_66|never_71|been_77|._90
D003042_-1 NONE cocaine_12\NN\3492717|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) related_10\VBN\628491|transient_56|cardiac_46|or_27|dysfunction_12 (r_acl) arrhythmia_6\NN\14103288|in_34|,_20|causes_97|._129 (r_nsubj) were_16\VBD\0|NONE_0 (l_attr) causes_20\NNS\7323922|in_131|,_117|arrhythmia_97|._32 (l_prep) of_21\IN\0|the_23|likely_14 (l_pobj) hypoperfusion_23\NN\0|NONE_0
D003042_D020521 NONE cocaine_0\NN\3492717|factor_18|._66 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) factor_4\NN\7326557|cocaine_18|._48 (l_prep) for_5\IN\0|a_14|risk_12 (l_pobj) stroke_10\NN\556313|NONE_0
2320485
D008750_D000743 CID methyldopa_0\NNP\2721160|-_10|anemia_29|in_36|presenting_53|._79 (r_nsubj) induced_2\VBN\1627355|NONE_0 (l_dobj) anemia_4\NN\14189204|methyldopa_29|-_19|in_7|presenting_24|._50
D008750_D000743 CID methyldopa_5\NN\2721160|-_10 (r_npadvmod) induced_7\VBN\1627355|hemolytic_8|in_25 (r_amod) anemia_9\NN\14189204|NONE_0
D008750_D014947 NONE methyldopa_7\NN\2721160|NONE_0 (r_pobj) with_5\IN\0|boy_21|had_17|been_13|during_28|._87 (r_prep) treated_4\VBN\2376958|NONE_0 (l_prep) during_8\IN\0|boy_49|had_45|been_41|with_28|._59 (l_pobj) admission_11\NN\49003|NONE_0 (l_compound) trauma_10\NN\14052046|a_2|prior_29
D008750_D000744 NONE methyldopa_0\NNP\2721160|anemia_42|._100 (r_nsubj) causes_1\VBZ\7323922|NONE_0 (l_dobj) anemia_5\NN\14189204|methyldopa_42|._58
D008750_D013575 NONE methyldopa_0\NNP\2721160|-_10|anemia_29|in_36|presenting_53|._79 (r_nsubj) induced_2\VBN\1627355|NONE_0 (l_advcl) presenting_10\VBG\2137132|methyldopa_53|-_43|anemia_24|in_17|._26 (l_prep) as_11\IN\14622893|NONE_0 (l_pobj) syncope_14\NN\7478169|NONE_0
D008750_D013575 NONE methyldopa_5\NN\2721160|-_10 (r_npadvmod) induced_7\VBN\1627355|hemolytic_8|in_25 (r_amod) anemia_9\NN\14189204|NONE_0 (l_prep) in_10\IN\13603305|induced_25|hemolytic_17 (l_pobj) boy_15\NN\9624168|NONE_0 (l_relcl) presented_17\VBD\2137132|a_22|old_12 (l_prep) with_22\IN\0|who_42|to_28 (l_pobj) syncope_25\NN\7478169|NONE_0
D008750_D004630 NONE methyldopa_5\NN\2721160|-_10 (r_npadvmod) induced_7\VBN\1627355|hemolytic_8|in_25 (r_amod) anemia_9\NN\14189204|NONE_0 (l_prep) in_10\IN\13603305|induced_25|hemolytic_17 (l_pobj) boy_15\NN\9624168|NONE_0 (l_relcl) presented_17\VBD\2137132|a_22|old_12 (l_prep) to_18\IN\0|who_14|with_28 (l_pobj) department_21\NN\8220714|NONE_0
16092435
D004317_D066126 NONE adriamycin_10\NNS\0|-_10 (r_npadvmod) evoked_12\VBN\1617192|in_22 (r_amod) cardiotoxicity_13\NN\0|NONE_0
D004317_D066126 NONE adriamycin_0\NNP\0|in_11|toxicity_77|._85 (r_cc) evoked_8\VBN\1617192|NONE_0 (l_dobj) toxicity_12\NN\13576101|adriamycin_77|in_66|._8
D004317_D066126 NONE adr_13\NNP\0|NONE_0 (r_compound) cardiotoxicity_14\NN\0|ribose_64|did_22|not_18|._14
D004317_D009202 CID adriamycin_7\NNS\0|-_10 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) myocardiopathy_10\NN\14103288|NONE_0
D012266_D009202 NONE ribose_5\NN\14792703|NONE_0 (l_prep) on_6\IN\0|d_9|-_8|in_37 (l_pobj) myocardiopathy_10\NN\14103288|NONE_0
D012266_D066126 NONE ribose_8\NN\14792703|NONE_0 (l_prep) on_9\IN\0|d_9|-_8 (l_pobj) cardiotoxicity_13\NN\0|NONE_0
D012266_D066126 NONE ribose_2\NN\14792703|did_42|not_46|cardiotoxicity_64|._78 (r_nsubj) influence_12\VB\5190804|NONE_0 (l_dobj) cardiotoxicity_14\NN\0|ribose_64|did_22|not_18|._14
2782734
D000420_D001249 NONE salbutamol_15\NN\0|tachyphylaxis_102|in_11|._24 (r_dobj) inhaled_14\VBN\1198101|NONE_0 (l_prep) in_16\IN\13603305|tachyphylaxis_113|salbutamol_11|._13 (l_pobj) asthmatics_17\NNS\7846|NONE_0
D000420_D001249 NONE salbutamol_4\NN\0|NONE_0 (r_pobj) of_2\IN\0|high_11 (r_prep) doses_1\NNS\3740161|improvements_48|,_103|and_105|associated_113|._180 (r_nsubj) produce_5\VB\7555863|NONE_0 (l_dobj) improvements_7\NNS\7359599|doses_48|,_55|and_57|associated_65|._132 (l_prep) in_8\IN\13603305|substantial_25 (l_pobj) response_10\NN\11410625|NONE_0 (l_prep) in_11\IN\13603305|airway_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) asthma_14\NN\14145095|NONE_0
D000420_D001249 NONE salbutamol_34\NN\0|high_18 (r_appos) dose_32\NN\3740161|NONE_0 (r_pobj) with_30\IN\0|a_19|14-day_17 (r_prep) treatment_29\NN\654885|predicted_103|were_20|daily_68|salbutamol_92|._218 (r_dobj) given_26\VBN\5892096|NONE_0 (l_nsubjpass) predicted_10\VBD\916909|were_83|treatment_103|daily_171|salbutamol_195|._321 (l_nsubj) patients_2\NNS\9898892|%_24|)_35|,_36|requiring_38|,_107 (l_amod) asthmatic_1\JJ\7846|twelve_7|(_19|fev1_20
D000420_D001249 NONE salbutamol_46\NN\0|predicted_195|were_112|treatment_92|daily_24|._126 (r_dobj) given_26\VBN\5892096|NONE_0 (l_nsubjpass) predicted_10\VBD\916909|were_83|treatment_103|daily_171|salbutamol_195|._321 (l_nsubj) patients_2\NNS\9898892|%_24|)_35|,_36|requiring_38|,_107 (l_amod) asthmatic_1\JJ\7846|twelve_7|(_19|fev1_20
24675088
D004317_D066126 NONE doxorubicin_12\RB\2716866|-_11 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_15\NN\0|NONE_0
D004317_D064420 NONE doxorubicin_12\NN\2716866|NONE_0 (r_pobj) of_10\IN\0|a_12|rat_10 (r_prep) model_9\NN\5888929|in_38|,_25|we_23|have_20|,_61|applying_63|._298 (r_dobj) utilized_6\VBN\0|NONE_0 (l_advcl) applying_17\VBG\0|in_101|,_88|we_86|have_83|model_63|,_2|._235 (l_conj) provide_31\VB\2199590|approaches_67|,_5 (l_dobj) characterization_35\NN\6724763|to_34 (l_prep) to_36\IN\0|the_40|comprehensive_31 (l_pobj) date_37\NN\15155220|NONE_0 (l_prep) of_38\IN\0|NONE_0 (l_pobj) timecourse_40\NN\0|NONE_0 (l_prep) of_41\IN\0|the_15 (l_pobj) events_48\NNS\23100|NONE_0 (l_acl) underlying_49\VBG\2604760|serological_49 (l_dobj) toxicity_51\NN\13576101|NONE_0
D004317_D064420 NONE dox)-induced_14\VBN\0|(_1 (r_amod) cardiomyopathy_15\NN\14103288|progressive_38 (r_appos) doxorubicin_12\NN\2716866|NONE_0 (r_pobj) of_10\IN\0|a_12|rat_10 (r_prep) model_9\NN\5888929|in_38|,_25|we_23|have_20|,_61|applying_63|._298 (r_dobj) utilized_6\VBN\0|NONE_0 (l_advcl) applying_17\VBG\0|in_101|,_88|we_86|have_83|model_63|,_2|._235 (l_conj) provide_31\VB\2199590|approaches_67|,_5 (l_dobj) characterization_35\NN\6724763|to_34 (l_prep) to_36\IN\0|the_40|comprehensive_31 (l_pobj) date_37\NN\15155220|NONE_0 (l_prep) of_38\IN\0|NONE_0 (l_pobj) timecourse_40\NN\0|NONE_0 (l_prep) of_41\IN\0|the_15 (l_pobj) events_48\NNS\23100|NONE_0 (l_acl) underlying_49\VBG\2604760|serological_49 (l_dobj) toxicity_51\NN\13576101|NONE_0
D005682_D018754 NONE gadolinium_9\NN\14625458|contrast_11|,_31|grading_51 (r_compound) enhancement_11\NN\248977|NONE_0 (l_conj) grading_14\NN\1009871|gadolinium_51|contrast_40|,_20 (l_conj) dysfunction_18\NN\14204950|histopathological_41|,_16|and_14
D004317_D009202 CID doxorubicin_12\NN\2716866|NONE_0 (l_appos) cardiomyopathy_15\NN\14103288|progressive_38
D004317_D009202 CID dox)-induced_14\VBN\0|(_1 (r_amod) cardiomyopathy_15\NN\14103288|progressive_38
24100055
D006493_D013921 CID heparin_2\NN\2718259|-_7 (r_npadvmod) induced_4\VBN\1627355|thrombocytopenia_8|type_25 (r_amod) ii_7\NNP\13741022|NONE_0
D006493_D013921 CID heparin_6\NN\2718259|-_7 (r_npadvmod) induced_8\VBN\1627355|mediated_17|thrombocytopenia_8|type_25|(_33|ii_43|)_45 (r_amod) ii_11\NNP\13741022|NONE_0
D006493_D013921 CID heparin_6\NN\2718259|-_7 (r_npadvmod) induced_8\VBN\1627355|mediated_17|thrombocytopenia_8|type_25|(_33|ii_43|)_45 (r_amod) ii_11\NNP\13741022|NONE_0 (l_appos) ii_15\NNP\13741022|mediated_60|induced_43|thrombocytopenia_35|type_18|(_10|)_2
D006493_D013921 CID heparin_6\NN\2718259|-_7 (r_npadvmod) induced_8\VBN\1627355|mediated_17|thrombocytopenia_8|type_25|(_33|ii_43|)_45 (r_amod) ii_11\NNP\13741022|NONE_0 (r_pobj) of_2\IN\0|the_11|as_74 (r_prep) impact_1\NN\7339329|is_140|not_143|yet_147|,_161|with_163|._224 (l_prep) as_17\IN\14622893|the_85|of_74 (l_pobj) cause_19\NN\7323922|NONE_0 (l_prep) of_20\IN\0|a_8 (l_pobj) thrombocytopenia_21\NN\14189204|NONE_0
D006493_D013921 CID heparin_12\NN\2718259|NONE_0 (r_pobj) of_10\IN\0|the_8 (r_prep) use_9\NN\407535|for_42|,_6|should_27|be_34|and_45|performed_92 (r_nsubjpass) avoided_15\VBN\0|NONE_0 (l_prep) for_0\IN\0|,_36|use_42|should_69|be_76|and_87|performed_134 (l_pobj) reduction_2\NN\351485|NONE_0 (l_prep) of_3\IN\0|further_18 (l_pobj) ii_6\NNP\13741022|NONE_0
D006493_D013921 CID heparin_29\NN\2718259|NONE_0 (r_pobj) with_23\IN\0|anticoagulation_36|should_20|be_13|after_34|._71 (r_prep) performed_22\VBN\0|for_134|,_98|use_92|should_65|be_58|and_47 (r_conj) avoided_15\VBN\0|NONE_0 (l_prep) for_0\IN\0|,_36|use_42|should_69|be_76|and_87|performed_134 (l_pobj) reduction_2\NN\351485|NONE_0 (l_prep) of_3\IN\0|further_18 (l_pobj) ii_6\NNP\13741022|NONE_0
1837756
D012701_D003866 NONE serotonin_37\NN\14807737|reuptake_10 (r_compound) inhibitors_39\NNS\20090|NONE_0 (r_pobj) with_36\IN\0|NONE_0 (r_prep) associated_35\VBN\628491|paranoid_23 (r_acl) exacerbations_34\NNS\374224|NONE_0 (r_pobj) to_32\IN\0|disorders_193|may_37|vulnerability_14|._71 (r_prep) present_29\VB\28270|NONE_0 (l_nsubj) disorders_2\NNS\14034177|may_156|vulnerability_179|to_193|._264
D005473_D010259 CID fluoxetine_10\NN\4169152|five_75|of_64 (r_advmod) cases_1\NNS\7283608|are_99|here_112|._116 (l_prep) of_2\IN\0|five_11|fluoxetine_64 (l_pobj) exacerbation_4\NN\374224|NONE_0 (l_amod) paranoid_3\JJ\10490141|with_22
D004298_D010259 NONE dopamine_18\NN\14807737|5ht3_23|mediated_9 (r_compound) release_19\NN\3748886|NONE_0 (r_pobj) including_13\VBG\0|cryptic_29|,_22|several_20|,_2 (r_prep) mechanisms_11\NNS\13446390|although_79|pharmacology_66 (r_attr) remain_7\VBP\2604760|,_85|downregulation_115|,_280|might_282|to_294|._312 (l_nsubj) pharmacology_2\NN\6043075|although_13|mechanisms_66 (l_prep) of_5\IN\0|the_34|and_17|neurobiology_13 (l_pobj) paranoia_6\NN\14398067|NONE_0
D012701_D011605 NONE serotonin_37\NN\14807737|reuptake_10 (r_compound) inhibitors_39\NNS\20090|NONE_0 (r_pobj) with_36\IN\0|NONE_0 (r_prep) associated_35\VBN\628491|paranoid_23 (r_acl) exacerbations_34\NNS\374224|NONE_0 (r_pobj) to_32\IN\0|disorders_193|may_37|vulnerability_14|._71 (r_prep) present_29\VB\28270|NONE_0 (l_nsubj) disorders_2\NNS\14034177|may_156|vulnerability_179|to_193|._264 (l_prep) including_4\VBG\0|complicated_34|depressive_22|(_1|)_143 (l_pobj) atypicality_5\NN\14501726|in_97 (l_conj) chronicity_11\NN\0|of_30|,_2 (l_conj) psychosis_13\NN\14380140|,_2
D012701_D011605 NONE serotonin_37\NN\14807737|reuptake_10 (r_compound) inhibitors_39\NNS\20090|NONE_0 (r_pobj) with_36\IN\0|NONE_0 (r_prep) associated_35\VBN\628491|paranoid_23 (r_acl) exacerbations_34\NNS\374224|NONE_0 (r_pobj) to_32\IN\0|disorders_193|may_37|vulnerability_14|._71 (r_prep) present_29\VB\28270|NONE_0 (l_nsubj) disorders_2\NNS\14034177|may_156|vulnerability_179|to_193|._264 (l_prep) including_4\VBG\0|complicated_34|depressive_22|(_1|)_143 (l_prep) in_20\IN\13603305|atypicality_97 (l_pobj) course_22\NN\883297|NONE_0 (l_prep) of_23\IN\0|the_11 (l_pobj) psychosis_26\NN\14380140|NONE_0
D012701_D010259 NONE serotonin_0\NNP\14807737|reuptake_10|,_29|paranoia_31|._70 (r_compound) inhibitors_2\NNS\20090|NONE_0 (l_appos) paranoia_4\NN\14398067|serotonin_31|reuptake_21|,_2|._39
D012701_D010259 NONE serotonin_7\NN\14807737|the_4|reuptake_10 (r_compound) inhibitors_9\NNS\20090|NONE_0 (r_pobj) with_5\IN\0|paranoid_22 (r_prep) exacerbation_4\NN\374224|NONE_0 (l_amod) paranoid_3\JJ\10490141|with_22
D012701_D010259 NONE serotonin_37\NN\14807737|reuptake_10 (r_compound) inhibitors_39\NNS\20090|NONE_0 (r_pobj) with_36\IN\0|NONE_0 (r_prep) associated_35\VBN\628491|paranoid_23 (r_acl) exacerbations_34\NNS\374224|NONE_0 (l_amod) paranoid_33\JJ\10490141|associated_23
D012701_D010259 NONE serotonin_9\NN\14807737|reuptake_10 (r_compound) blockers_11\NNS\10101634|NONE_0 (r_pobj) with_8\IN\0|possible_32|paranoid_23|in_33 (r_prep) exacerbations_7\NNS\374224|NONE_0 (l_amod) paranoid_6\JJ\10490141|possible_9|with_23|in_56
D012701_D010259 NONE serotonin_9\NN\14807737|reuptake_10 (r_compound) blockers_11\NNS\10101634|NONE_0 (r_pobj) with_8\IN\0|possible_32|paranoid_23|in_33 (r_prep) exacerbations_7\NNS\374224|NONE_0 (r_pobj) to_4\IN\0|cases_21|attention_10|and_87|raise_91|._146 (r_prep) call_2\VBP\6272290|NONE_0 (l_conj) raise_16\VB\5108947|cases_112|attention_101|to_91|and_4|._55 (l_dobj) considerations_18\NNS\5770926|NONE_0 (l_acl) regarding_19\VBG\689344|neurobiological_31 (l_pobj) paranoia_20\NN\14398067|NONE_0
D000639_D010259 CID amitriptyline_12\NN\4482543|and_4 (r_conj) fluoxetine_10\NN\4169152|five_75|of_64 (r_advmod) cases_1\NNS\7283608|are_99|here_112|._116 (l_prep) of_2\IN\0|five_11|fluoxetine_64 (l_pobj) exacerbation_4\NN\374224|NONE_0 (l_amod) paranoid_3\JJ\10490141|with_22
3297909
D013827_D007565 NONE thiabendazole_12\NN\2720201|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) exposure_10\NN\5042871|wk_9 (r_pobj) after_9\IN\0|man_28|jaundice_14|._31 (r_prep) developed_5\VBD\1753788|NONE_0 (l_dobj) jaundice_6\NN\14299637|man_14|after_14|._45
D013827_D001649 NONE thiabendazole_5\NN\2720201|NONE_0 (r_compound) administration_6\NN\1133281|NONE_0 (r_pobj) after_4\IN\0|progressive_29|duct_12|._34 (r_prep) injury_3\NN\14052046|NONE_0
6106951
D005479_D012640 CID fzp_2\NNP\0|in_13 (r_compound) toxocity_3\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) signs_0\NNS\6643763|salivation_49|retching_92|._132 (r_nsubj) included_6\VBD\0|NONE_0 (l_advcl) retching_14\NN\72989|signs_92|salivation_43|._40 (l_dobj) tremors_17\NNS\345926|,_9 (l_conj) convulsions_19\NNS\14081375|muscle_19|and_4
D005479_D012640 CID fzp_6\NNP\0|as_23|,_2|first_4|against_20|._49 (r_nsubj) protected_8\VBD\1127795|NONE_0 (l_prep) against_9\IN\0|as_43|,_22|fzp_20|first_16|._29 (l_pobj) convulsions_10\NNS\14081375|NONE_0
D005479_D012640 CID fzp_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|these_12 (r_prep) doses_1\NNS\3740161|lower_18|cause_52|._69 (r_nsubj) were_4\VBD\0|NONE_0 (l_prep) cause_11\VB\7323922|doses_52|lower_34|._17 (l_dobj) convulsions_12\NNS\14081375|NONE_0
D005479_D014202 NONE fzp_2\NNP\0|in_13 (r_compound) toxocity_3\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) signs_0\NNS\6643763|salivation_49|retching_92|._132 (r_nsubj) included_6\VBD\0|NONE_0 (l_advcl) retching_14\NN\72989|signs_92|salivation_43|._40 (l_dobj) tremors_17\NNS\345926|,_9
D005479_D012798 NONE fzp_2\NNP\0|in_13 (r_compound) toxocity_3\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) signs_0\NNS\6643763|salivation_49|retching_92|._132 (r_nsubj) included_6\VBD\0|NONE_0 (l_dobj) salivation_8\NN\13553916|signs_49|retching_43|._83
D005479_D064420 NONE fzp_2\NNP\0|in_13 (r_compound) toxocity_3\NN\0|NONE_0
D005479_D004827 NONE fzp_9\NNP\0|NONE_0 (r_pobj) of_8\IN\0|the_8|in_7 (r_prep) use_7\NN\407535|NONE_0 (l_prep) in_10\IN\13603305|the_15|of_7 (l_pobj) situations_12\NNS\24720|NONE_0 (l_relcl) is_16\VBZ\0|clinical_35 (l_attr) excitability_19\NN\5653575|in_35|there_26 (l_prep) as_22\IN\14622893|increased_36|neural_26|,_7 (l_pobj) epilepsy_23\NN\14085708|such_8
44072
C024986_D001145 CID bacl2_9\NN\0|,_5|with_7|,_33 (r_pobj) with_8\IN\0|types_43|are_10|--_2|with_40|._78 (r_prep) used_6\VBN\0|NONE_0 (l_nsubjpass) types_1\NNS\5839024|are_33|--_41|with_43|with_83|._121 (l_prep) of_2\IN\0|four_11 (l_pobj) arrhythmia_4\NN\14103288|NONE_0
C024986_D001145 CID bacl2_32\NN\0|NONE_0 (r_pobj) with_31\IN\0|90_17|)_6|and_4 (r_conj) in_25\IN\13603305|inhibition_63|(_1 (r_prep) causing_13\VBG\30358|compound_90|activity_56|,_2|._127 (r_advcl) manifests_2\VBZ\6479665|NONE_0 (l_dobj) activity_4\NN\30358|compound_34|,_54|causing_56|._183 (l_prep) in_5\IN\13603305|antiarrhythmic_24|used_41 (l_pobj) models_7\NNS\5888929|NONE_0 (l_prep) of_8\IN\0|all_11 (l_pobj) arrhythmia_10\NN\14103288|NONE_0
C024986_D001145 CID bacl2_32\NN\0|NONE_0 (r_pobj) with_31\IN\0|90_17|)_6|and_4 (r_conj) in_25\IN\13603305|inhibition_63|(_1 (r_prep) causing_13\VBG\30358|compound_90|activity_56|,_2|._127 (l_dobj) inhibition_15\NN\1068773|(_62|in_63 (l_prep) on_16\IN\0|greatest_20 (l_pobj) arrhythmia_18\NN\14103288|NONE_0
D000157_D001145 CID aconitine_21\NN\0|NONE_0 (r_pobj) with_20\IN\0|g_6|and_4 (r_conj) with_16\IN\0|types_83|are_50|--_42|with_40|._38 (r_prep) used_6\VBN\0|NONE_0 (l_nsubjpass) types_1\NNS\5839024|are_33|--_41|with_43|with_83|._121 (l_prep) of_2\IN\0|four_11 (l_pobj) arrhythmia_4\NN\14103288|NONE_0
D002725_D001145 CID chloroform_12\NN\14620895|-_10 (r_compound) adrenaline_14\NN\14807929|NONE_0 (r_pobj) with_11\IN\0|bacl2_7|,_2|,_26 (r_conj) with_8\IN\0|types_43|are_10|--_2|with_40|._78 (r_prep) used_6\VBN\0|NONE_0 (l_nsubjpass) types_1\NNS\5839024|are_33|--_41|with_43|with_83|._121 (l_prep) of_2\IN\0|four_11 (l_pobj) arrhythmia_4\NN\14103288|NONE_0
D002725_D001145 CID chloroform_21\NN\14620895|-_10 (r_compound) adrenaline_23\NN\14807929|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|the_15 (r_acl) arrhythmia_18\NN\14103288|NONE_0 (r_pobj) on_16\IN\0|greatest_20 (r_prep) inhibition_15\NN\1068773|(_62|in_63 (r_dobj) causing_13\VBG\30358|compound_90|activity_56|,_2|._127 (r_advcl) manifests_2\VBZ\6479665|NONE_0 (l_dobj) activity_4\NN\30358|compound_34|,_54|causing_56|._183 (l_prep) in_5\IN\13603305|antiarrhythmic_24|used_41 (l_pobj) models_7\NNS\5888929|NONE_0 (l_prep) of_8\IN\0|all_11 (l_pobj) arrhythmia_10\NN\14103288|NONE_0
D002725_D001145 CID chloroform_21\NN\14620895|-_10 (r_compound) adrenaline_23\NN\14807929|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|the_15 (r_acl) arrhythmia_18\NN\14103288|NONE_0
D010042_D001145 CID g_18\NN\13717155|and_2|with_6 (r_pobj) with_16\IN\0|types_83|are_50|--_42|with_40|._38 (r_prep) used_6\VBN\0|NONE_0 (l_nsubjpass) types_1\NNS\5839024|are_33|--_41|with_43|with_83|._121 (l_prep) of_2\IN\0|four_11 (l_pobj) arrhythmia_4\NN\14103288|NONE_0
D004837_D001145 CID adrenaline_14\NN\14807929|NONE_0 (r_pobj) with_11\IN\0|bacl2_7|,_2|,_26 (r_conj) with_8\IN\0|types_43|are_10|--_2|with_40|._78 (r_prep) used_6\VBN\0|NONE_0 (l_nsubjpass) types_1\NNS\5839024|are_33|--_41|with_43|with_83|._121 (l_prep) of_2\IN\0|four_11 (l_pobj) arrhythmia_4\NN\14103288|NONE_0
D004837_D001145 CID adrenaline_23\NN\14807929|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|the_15 (r_acl) arrhythmia_18\NN\14103288|NONE_0 (r_pobj) on_16\IN\0|greatest_20 (r_prep) inhibition_15\NN\1068773|(_62|in_63 (r_dobj) causing_13\VBG\30358|compound_90|activity_56|,_2|._127 (r_advcl) manifests_2\VBZ\6479665|NONE_0 (l_dobj) activity_4\NN\30358|compound_34|,_54|causing_56|._183 (l_prep) in_5\IN\13603305|antiarrhythmic_24|used_41 (l_pobj) models_7\NNS\5888929|NONE_0 (l_prep) of_8\IN\0|all_11 (l_pobj) arrhythmia_10\NN\14103288|NONE_0
D004837_D001145 CID adrenaline_23\NN\14807929|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|the_15 (r_acl) arrhythmia_18\NN\14103288|NONE_0
10087562
D004280_D006333 NONE dobutamine_9\NN\0|low_22|dose_18|intermittent_13|in_21 (r_compound) treatment_10\NN\654885|NONE_0 (l_prep) in_11\IN\13603305|low_43|dose_39|intermittent_34|dobutamine_21 (l_pobj) patient_13\NN\9898892|NONE_0 (l_prep) with_14\IN\0|a_10 (l_pobj) failure_20\NN\66216|NONE_0
D004280_D006333 NONE dobutamine_52\NN\0|NONE_0 (r_pobj) of_40\IN\0|one_10 (r_prep) cycle_39\NN\15269513|NONE_0 (r_pobj) during_37\IN\0|who_77|prolongation_60 (r_prep) developed_28\VBD\1753788|significant_40|ventricular_28 (r_relcl) arrhythmias_26\NNS\14103288|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) absence_22\NN\14449405|to_30|cardiomyopathy_19|and_4 (r_conj) dilated_19\VBN\303465|authors_97|case_76|._224 (r_xcomp) describe_2\VBP\1001294|NONE_0 (l_dobj) case_4\NN\7283608|authors_21|dilated_76|._300 (l_prep) of_5\IN\0|the_9 (l_pobj) woman_10\NN\9605289|NONE_0 (l_prep) with_11\IN\0|a_20|old_10 (l_pobj) failure_16\NN\66216|NONE_0
D004280_D008133 NONE dobutamine_52\NN\0|NONE_0 (r_pobj) of_40\IN\0|one_10 (r_prep) cycle_39\NN\15269513|NONE_0 (r_pobj) during_37\IN\0|who_77|prolongation_60 (r_prep) developed_28\VBD\1753788|significant_40|ventricular_28 (l_dobj) prolongation_30\NN\1017987|who_17|during_60
D004280_D001145 NONE dobutamine_52\NN\0|NONE_0 (r_pobj) of_40\IN\0|one_10 (r_prep) cycle_39\NN\15269513|NONE_0 (r_pobj) during_37\IN\0|who_77|prolongation_60 (r_prep) developed_28\VBD\1753788|significant_40|ventricular_28 (r_relcl) arrhythmias_26\NNS\14103288|NONE_0
D004280_D001145 NONE dobutamine_10\NN\0|NONE_0 (r_pobj) during_8\IN\0|this_58|of_46 (r_prep) report_1\NN\6470073|hypothesis_97|._241 (r_nsubj) supports_11\VBZ\407535|NONE_0 (l_dobj) hypothesis_13\NN\7162194|report_97|._144 (l_acl) occur_19\VB\0|the_56 (l_nsubj) arrhythmias_17\NNS\14103288|that_25|may_12|with_27
D004280_D016171 CID dobutamine_9\NN\0|low_22|dose_18|intermittent_13|in_21 (r_compound) treatment_10\NN\654885|NONE_0 (r_pobj) during_5\IN\0|torsade_43|de_35|tachycardia_12|._119 (r_prep) pointes_2\VBZ\831651|NONE_0
D004280_D016171 CID dobutamine_52\NN\0|NONE_0 (r_pobj) of_40\IN\0|one_10 (r_prep) cycle_39\NN\15269513|NONE_0 (r_pobj) during_37\IN\0|who_77|prolongation_60 (r_prep) developed_28\VBD\1753788|significant_40|ventricular_28 (l_dobj) prolongation_30\NN\1017987|who_17|during_60 (l_conj) tachycardia_36\NN\14110674|qt_51|and_35 (l_nmod) pointes_34\FW\831651|ventricular_8
D004280_D016171 CID dobutamine_10\NN\0|NONE_0 (r_pobj) during_8\IN\0|this_58|of_46 (r_prep) report_1\NN\6470073|hypothesis_97|._241 (l_prep) of_2\IN\0|this_12|during_46 (l_pobj) tachycardia_7\NN\14110674|NONE_0 (l_nmod) pointes_5\FW\831651|ventricular_8
D004280_D002311 NONE dobutamine_9\NN\0|low_22|dose_18|intermittent_13|in_21 (r_compound) treatment_10\NN\654885|NONE_0 (l_prep) in_11\IN\13603305|low_43|dose_39|intermittent_34|dobutamine_21 (l_pobj) patient_13\NN\9898892|NONE_0 (l_prep) with_14\IN\0|a_10 (l_pobj) failure_20\NN\66216|NONE_0 (l_amod) cardiomyopathy_16\NN\14103288|dilated_8|heart_30
D004280_D002311 NONE dobutamine_52\NN\0|NONE_0 (r_pobj) of_40\IN\0|one_10 (r_prep) cycle_39\NN\15269513|NONE_0 (r_pobj) during_37\IN\0|who_77|prolongation_60 (r_prep) developed_28\VBD\1753788|significant_40|ventricular_28 (r_relcl) arrhythmias_26\NNS\14103288|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) absence_22\NN\14449405|to_30|cardiomyopathy_19|and_4 (r_conj) dilated_19\VBN\303465|authors_97|case_76|._224 (l_advmod) cardiomyopathy_20\NN\14103288|to_11|and_15|absence_19
D004280_D017180 NONE dobutamine_9\NN\0|low_22|dose_18|intermittent_13|in_21 (r_compound) treatment_10\NN\654885|NONE_0 (r_pobj) during_5\IN\0|torsade_43|de_35|tachycardia_12|._119 (r_prep) pointes_2\VBZ\831651|NONE_0 (l_appos) tachycardia_4\NN\14110674|torsade_31|de_23|during_12|._131
D004280_D017180 NONE dobutamine_52\NN\0|NONE_0 (r_pobj) of_40\IN\0|one_10 (r_prep) cycle_39\NN\15269513|NONE_0 (r_pobj) during_37\IN\0|who_77|prolongation_60 (r_prep) developed_28\VBD\1753788|significant_40|ventricular_28 (l_dobj) prolongation_30\NN\1017987|who_17|during_60 (l_conj) tachycardia_36\NN\14110674|qt_51|and_35
D004280_D017180 NONE dobutamine_10\NN\0|NONE_0 (r_pobj) during_8\IN\0|this_58|of_46 (r_prep) report_1\NN\6470073|hypothesis_97|._241 (l_prep) of_2\IN\0|this_12|during_46 (l_pobj) tachycardia_7\NN\14110674|NONE_0
3083835
D010406_D000707 CID penicillin_0\NNP\2716866|._22 (r_compound) anaphylaxis_1\NN\14533203|NONE_0
D010406_D000707 CID penicillin_4\NN\2716866|oral_5 (r_compound) anaphylaxis_5\NN\14533203|NONE_0
D010406_D000707 CID penicillin_4\NN\2716866|oral_5 (r_compound) anaphylaxis_5\NN\14533203|NONE_0 (r_pobj) of_2\IN\0|a_7 (r_prep) case_1\NN\7283608|is_36|,_48|and_50|reviewed_167 (r_nsubjpass) described_7\VBN\1001294|NONE_0 (l_conj) reviewed_27\VBN\644583|case_167|is_131|,_119|and_117 (l_nsubjpass) terminology_11\NN\6286395|are_105|._117 (l_conj) occurrence_13\NN\29378|the_17|,_2 (l_conj) manifestations_16\NNS\7321772|,_11 (l_conj) pathogenesis_18\NN\13533470|clinical_25|,_2 (l_conj) prevention_20\NN\1073995|,_2 (l_conj) treatment_23\NN\654885|,_6|and_4 (l_prep) of_24\IN\0|NONE_0 (l_pobj) anaphylaxis_25\NN\14533203|NONE_0
D010406_D000707 CID penicillin_7\NN\2716866|oral_5 (r_compound) anaphylaxis_8\NN\14533203|NONE_0
2767010
D013327_D001145 CID strophanthidin_9\NN\0|-_14 (r_npadvmod) induced_11\VBN\1627355|in_20 (r_amod) arrhythmias_12\NNS\14103288|NONE_0
C043114_D001145 NONE acc-9653_4\NN\0|phenytoin_12|necessary_29 (r_nmod) sodium_7\NN\14625458|NONE_0 (l_amod) necessary_8\JJ\2452|acc-9653_29|phenytoin_17 (l_xcomp) convert_10\VB\7846|NONE_0 (l_dobj) arrhythmia_12\NN\14103288|to_15|to_11
C043114_D001145 NONE sodium_7\NN\14625458|NONE_0 (l_amod) necessary_8\JJ\2452|acc-9653_29|phenytoin_17 (l_xcomp) convert_10\VB\7846|NONE_0 (l_dobj) arrhythmia_12\NN\14103288|to_15|to_11
C043114_D001145 NONE sodium_2\NN\14625458|in_17|._118 (r_nsubj) displayed_3\VBD\2137132|NONE_0 (l_prep) in_4\IN\13603305|sodium_17|._101 (l_pobj) activity_7\NN\30358|NONE_0 (l_prep) against_8\IN\0|vitro_30|antiarrhythmic_24 (l_pobj) arrhythmias_12\NNS\14103288|NONE_0
D010042_D017180 CID ouabain_7\NN\0|-_7 (r_npadvmod) induced_9\VBN\1627355|ventricular_8 (r_amod) tachycardia_11\NN\14110674|NONE_0
C043114_D064420 NONE acc-9653_4\NNP\0|phenytoin_13 (r_nmod) sodium_7\NN\14625458|NONE_0 (r_pobj) of_3\IN\0|acute_23|toxicity_17 (r_prep) studies_2\NNS\635850|were_41|out_54|in_58|by_91|._139 (l_compound) toxicity_1\NN\13576101|acute_6|of_17
C043114_D064420 NONE sodium_7\NN\14625458|NONE_0 (r_pobj) of_3\IN\0|acute_23|toxicity_17 (r_prep) studies_2\NNS\635850|were_41|out_54|in_58|by_91|._139 (l_compound) toxicity_1\NN\13576101|acute_6|of_17
C043114_D017180 NONE sodium_1\NN\14625458|activity_35|in_92|._112 (r_nsubj) have_2\VBP\7846|NONE_0 (l_dobj) activity_5\NN\30358|sodium_35|in_57|._77 (l_prep) against_6\IN\0|similar_32|antiarrhythmic_24 (l_pobj) tachycardia_11\NN\14110674|NONE_0
C043114_D012640 NONE acc-9653_0\NN\0|NONE_0 (l_conj) have_4\VBP\7846|and_21 (l_dobj) activity_7\NN\30358|sodium_38|._116 (l_prep) against_8\IN\0|equivalent_35|anticonvulsant_24 (l_pobj) seizures_9\NNS\14081375|NONE_0
C043114_D012640 NONE sodium_3\NN\14625458|activity_38|._154 (r_nsubj) have_4\VBP\7846|and_21 (l_dobj) activity_7\NN\30358|sodium_38|._116 (l_prep) against_8\IN\0|equivalent_35|anticonvulsant_24 (l_pobj) seizures_9\NNS\14081375|NONE_0
9272404
D007052_D010146 CID ibuprofen_6\NNP\3828465|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) administration_4\NN\1133281|described_19|,_2|was_28|by_41|,_133|indicating_135|._264 (r_nsubjpass) followed_8\VBN\1835496|NONE_0 (l_agent) by_9\IN\0|described_60|,_43|administration_41|was_13|,_92|indicating_94|._223 (l_pobj) decrease_11\NN\7296428|NONE_0 (l_prep) in_12\IN\13603305|a_11|-_37|increase_41 (l_pobj) pain_14\NN\14299637|NONE_0
D007052_D010146 CID ibuprofen_6\NNP\3828465|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) administration_4\NN\1133281|described_19|,_2|was_28|by_41|,_133|indicating_135|._264 (r_nsubjpass) followed_8\VBN\1835496|NONE_0 (l_agent) by_9\IN\0|described_60|,_43|administration_41|was_13|,_92|indicating_94|._223 (l_pobj) decrease_11\NN\7296428|NONE_0 (l_appos) increase_22\NN\13576355|a_52|in_41|-_4 (l_prep) in_23\IN\13603305|an_12 (l_pobj) correlates_24\NNS\5857459|NONE_0 (l_prep) of_25\IN\0|NONE_0 (l_pobj) pain_27\NN\14299637|NONE_0
D007052_D010146 CID ibuprofen_6\NNP\3828465|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) administration_4\NN\1133281|described_19|,_2|was_28|by_41|,_133|indicating_135|._264 (r_nsubjpass) followed_8\VBN\1835496|NONE_0 (l_advcl) indicating_29\VBG\952524|described_154|,_137|administration_135|was_107|by_94|,_2|._129 (l_dobj) effect_32\NN\34213|NONE_0 (l_prep) on_35\IN\0|a_31|specific_29|of_13 (l_pobj) interaction_37\NN\37396|NONE_0 (l_prep) between_38\IN\0|the_16 (l_pobj) stimuli_41\NNS\5816287|NONE_0 (l_compound) pain_40\NN\14299637|the_4|under_13
D007052_D010146 CID ibuprofen_34\NN\3828465|NONE_0 (r_pobj) of_33\IN\0|a_18|specific_16|on_13 (r_prep) effect_32\NN\34213|NONE_0 (r_dobj) indicating_29\VBG\952524|described_154|,_137|administration_135|was_107|by_94|,_2|._129 (r_advcl) followed_8\VBN\1835496|NONE_0 (l_agent) by_9\IN\0|described_60|,_43|administration_41|was_13|,_92|indicating_94|._223 (l_pobj) decrease_11\NN\7296428|NONE_0 (l_prep) in_12\IN\13603305|a_11|-_37|increase_41 (l_pobj) pain_14\NN\14299637|NONE_0
D007052_D010146 CID ibuprofen_34\NN\3828465|NONE_0 (r_pobj) of_33\IN\0|a_18|specific_16|on_13 (r_prep) effect_32\NN\34213|NONE_0 (r_dobj) indicating_29\VBG\952524|described_154|,_137|administration_135|was_107|by_94|,_2|._129 (r_advcl) followed_8\VBN\1835496|NONE_0 (l_agent) by_9\IN\0|described_60|,_43|administration_41|was_13|,_92|indicating_94|._223 (l_pobj) decrease_11\NN\7296428|NONE_0 (l_appos) increase_22\NN\13576355|a_52|in_41|-_4 (l_prep) in_23\IN\13603305|an_12 (l_pobj) correlates_24\NNS\5857459|NONE_0 (l_prep) of_25\IN\0|NONE_0 (l_pobj) pain_27\NN\14299637|NONE_0
D007052_D010146 CID ibuprofen_34\NN\3828465|NONE_0 (r_pobj) of_33\IN\0|a_18|specific_16|on_13 (r_prep) effect_32\NN\34213|NONE_0 (l_prep) on_35\IN\0|a_31|specific_29|of_13 (l_pobj) interaction_37\NN\37396|NONE_0 (l_prep) between_38\IN\0|the_16 (l_pobj) stimuli_41\NNS\5816287|NONE_0 (l_compound) pain_40\NN\14299637|the_4|under_13
D002245_D010146 NONE co2_10\NN\14836127|NONE_0 (r_pobj) of_9\IN\0|short_13 (r_prep) pulses_8\NNS\7345593|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) means_5\NNS\44150|NONE_0 (r_pobj) by_4\IN\0|pain_17|was_12|to_32|duration_62 (r_agent) applied_3\VBN\0|NONE_0 (l_nsubjpass) pain_1\NN\14299637|was_5|by_17|to_49|duration_79
D002245_D010146 NONE co2_10\NN\14836127|NONE_0 (r_pobj) of_9\IN\0|short_13 (r_prep) pulses_8\NNS\7345593|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) means_5\NNS\44150|NONE_0 (r_pobj) by_4\IN\0|pain_17|was_12|to_32|duration_62 (r_agent) applied_3\VBN\0|NONE_0 (l_parataxis) duration_17\NN\15113229|pain_79|was_74|by_62|to_30 (l_conj) induced_31\VBN\1627355|(_76|stimulus_75|ms_53|,_51|interval_49|,_21|and_19 (l_nsubjpass) pain_29\NN\14299637|was_5|in_17|by_37|%_123|)_154|._155
D002245_D010146 NONE co2_17\NN\14836127|the_4 (r_compound) stimuli_18\NNS\5816287|NONE_0 (r_pobj) to_15\IN\0|NONE_0 (r_prep) response_14\NN\11410625|NONE_0 (r_pobj) in_13\IN\13603305|csseps_74|were_14|._30 (r_prep) obtained_12\VBN\2210855|NONE_0 (l_nsubjpass) csseps_1\NNS\0|were_60|in_74|._104 (l_prep) as_6\IN\14622893|both_32|as_20 (l_pobj) correlates_8\NNS\5857459|NONE_0 (l_prep) of_9\IN\0|peripheral_22 (l_pobj) pain_10\NN\14299637|NONE_0
18340638
D010718_D000740 NONE phosphatidylserine_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|at_27 (r_prep) exposure_17\NN\5042871|NONE_0 (r_pobj) by_16\IN\0|which_23|is_17 (r_agent) characterized_15\VBN\609683|accelerated_62|suicidal_50|erythrocyte_41|or_23|eryptosis_20|,_11 (r_relcl) death_9\NN\7296428|NONE_0 (r_pobj) from_5\IN\0|alternatively_35|,_22|anemia_20|could_13|._168 (r_prep) result_4\VB\34213|NONE_0 (l_nsubj) anemia_2\NN\14189204|alternatively_15|,_2|could_7|from_20|._188
D010718_D000740 NONE ps_21\NNP\6763273|NONE_0 (r_appos) phosphatidylserine_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|at_27 (r_prep) exposure_17\NN\5042871|NONE_0 (r_pobj) by_16\IN\0|which_23|is_17 (r_agent) characterized_15\VBN\609683|accelerated_62|suicidal_50|erythrocyte_41|or_23|eryptosis_20|,_11 (r_relcl) death_9\NN\7296428|NONE_0 (r_pobj) from_5\IN\0|alternatively_35|,_22|anemia_20|could_13|._168 (r_prep) result_4\VB\34213|NONE_0 (l_nsubj) anemia_2\NN\14189204|alternatively_15|,_2|could_7|from_20|._188
D001379_D000740 CID azathioprine_4\NN\3740161|NONE_0 (r_pobj) of_3\IN\0|the_17|side_13 (r_prep) effects_2\NNS\13245626|anemia_32|._92 (r_nsubj) include_5\VBP\0|NONE_0 (l_dobj) anemia_6\NN\14189204|effects_32|._60
D001379_D000740 CID azathioprine_0\NN\3740161|death_43|,_48|effect_53|._114 (r_nsubj) triggers_1\VBZ\3659292|NONE_0 (l_npadvmod) effect_7\NN\34213|azathioprine_53|death_10|,_5|._61 (l_acl) contributing_9\VBG\126264|an_21 (l_prep) to_10\IN\0|presumably_24 (l_pobj) anemia_14\NN\14189204|NONE_0
D001379_D000740 CID azathioprine_11\RB\3740161|-_12 (r_advmod) induced_13\VBN\1627355|NONE_0 (r_amod) anemia_14\NN\14189204|NONE_0
10726030
D006493_D013927 NONE heparin_3\NN\2718259|-_7 (r_npadvmod) induced_5\VBN\1627355|and_25|thrombosis_29 (r_amod) thrombocytopenia_6\NN\14189204|NONE_0 (l_conj) thrombosis_8\NN\14100769|induced_29|and_4
D006493_D013927 NONE heparin_14\JJ\2718259|NONE_0 (r_compound) therapy_15\NN\657604|NONE_0 (r_pobj) of_13\IN\0|other_19|side_13 (r_prep) effects_12\NNS\13245626|and_15 (r_conj) thrombosis_8\NN\14100769|induced_29|and_4
D006493_D013927 NONE heparin_0\NNP\2718259|,_7|first_9|prevent_23 (r_nsubj) used_3\VBD\0|,_46|has_48|been_52|clinically_57|treat_76|._115 (r_ccomp) used_16\VBN\0|NONE_0 (l_xcomp) treat_18\VB\7570720|used_76|,_30|has_28|been_24|clinically_19|._39 (l_dobj) thrombosis_19\NN\14100769|to_9|for_11
D006493_D013927 NONE heparin_9\NN\2718259|are_20|,_2|anticoagulant_20|treat_47|._78 (r_nsubj) remains_10\VBZ\2684|NONE_0 (l_xcomp) treat_16\VB\7570720|are_67|,_49|heparin_47|anticoagulant_27|._31 (l_dobj) episodes_19\NNS\7283608|to_26 (l_amod) thrombotic_18\JJ\0|acute_6
D006493_D013927 NONE heparin_18\NN\2718259|NONE_0 (r_pobj) of_17\IN\0|the_29|widespread_15 (r_prep) use_16\NN\407535|NONE_0 (r_pobj) given_12\VBN\5892096|,_45|some_47|common_62|._104 (r_prep) are_21\VBP\13600404|effects_107|rare_84|in_79|,_58|but_56 (l_acomp) common_23\JJ\8673395|given_62|,_17|some_15|._42 (l_conj) hitt_26\NNP\0|quite_27|,_15
D006493_D006994 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2 (l_conj) hypoaldosteronism_37\NN\0|,_2
D006493_D006994 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2 (l_conj) hypoaldosteronism_37\NN\0|,_2
D006493_D006994 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2 (l_conj) hypoaldosteronism_37\NN\0|,_2
D006493_D000505 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2
D006493_D000505 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2
D006493_D000505 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2
D006493_D006947 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2
D006493_D006947 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2
D006493_D006947 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2
D006493_D010024 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21
D006493_D010024 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21
D006493_D010024 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21
D006493_D010024 CID heparin_18\NN\2718259|NONE_0 (r_pobj) of_17\IN\0|the_29|widespread_15 (r_prep) use_16\NN\407535|NONE_0 (r_pobj) given_12\VBN\5892096|,_45|some_47|common_62|._104 (r_prep) are_21\VBP\13600404|effects_107|rare_84|in_79|,_58|but_56 (l_acomp) common_23\JJ\8673395|given_62|,_17|some_15|._42 (l_conj) hitt_26\NNP\0|quite_27|,_15 (l_conj) osteoporosis_28\NN\14204950|particularly_22|and_4
D006493_D004802 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2
D006493_D004802 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2
D006493_D004802 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2
D006493_D013921 CID heparin_3\NN\2718259|-_7 (r_npadvmod) induced_5\VBN\1627355|and_25|thrombosis_29 (r_amod) thrombocytopenia_6\NN\14189204|NONE_0
D006493_D013921 CID heparin_14\JJ\2718259|NONE_0 (r_compound) therapy_15\NN\657604|NONE_0 (r_pobj) of_13\IN\0|other_19|side_13 (r_prep) effects_12\NNS\13245626|and_15 (r_conj) thrombosis_8\NN\14100769|induced_29|and_4 (r_conj) thrombocytopenia_6\NN\14189204|NONE_0
D006493_D013921 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201
D006493_D013921 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0
D006493_D013921 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201
D006493_D013921 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0
D006493_D013921 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (r_conj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201
D006493_D013921 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0
D006493_D013921 NONE heparin_18\NN\2718259|NONE_0 (r_pobj) of_17\IN\0|the_29|widespread_15 (r_prep) use_16\NN\407535|NONE_0 (r_pobj) given_12\VBN\5892096|,_45|some_47|common_62|._104 (r_prep) are_21\VBP\13600404|effects_107|rare_84|in_79|,_58|but_56 (l_acomp) common_23\JJ\8673395|given_62|,_17|some_15|._42 (l_conj) hitt_26\NNP\0|quite_27|,_15
D006493_D004342 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11
D006493_D004342 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11
D006493_D004342 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11
D006493_D012871 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7
D006493_D012871 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7
D006493_D012871 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7
D006493_D006470 NONE heparin_7\NN\2718259|NONE_0 (r_pobj) of_6\IN\0|the_28|primary_24|untoward_16 (r_prep) effect_5\NN\34213|bleeding_33|._17 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) bleeding_0\VBG\14285662|effect_33|._50
D006493_D006470 NONE heparin_9\JJ\2718259|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_dobj) receiving_8\VBG\2210855|NONE_0 (r_acl) patients_7\NNS\9898892|NONE_0 (r_pobj) in_6\IN\13603305|primary_16 (r_prep) concern_5\NN\5682950|NONE_0 (r_pobj) of_3\IN\0|bleeding_12|._56 (r_prep) is_2\VBZ\0|NONE_0 (l_nsubj) bleeding_1\NN\14285662|of_12|._68
D006493_D011317 CID heparin_7\JJ\2718259|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|additional_38|important_27|untoward_17 (r_prep) effects_5\NNS\13245626|however_39|,_32|thrombocytopenia_51|._252 (r_nsubj) include_9\VBP\0|NONE_0 (l_dobj) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2 (l_conj) hypoaldosteronism_37\NN\0|,_2 (l_conj) priapism_40\NN\14204950|,_6|and_4
D006493_D011317 CID heparin_10\NN\2718259|-_7 (r_npadvmod) induced_12\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_13\NN\14189204|however_90|,_83|effects_51|._201 (l_conj) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2 (l_conj) hypoaldosteronism_37\NN\0|,_2 (l_conj) priapism_40\NN\14204950|,_6|and_4
D006493_D011317 CID heparin_15\NN\2718259|-_7 (r_npadvmod) associated_17\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_18\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_20\NN\14299637|associated_25|,_2 (l_conj) reactions_23\NNS\13446390|,_7 (l_conj) reactions_26\NNS\13446390|skin_25|,_11 (l_amod) other_27\JJ\0|allergic_19 (l_prep) than_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_29\JJ\14189204|NONE_0 (l_conj) alopecia_31\NN\14457041|,_2 (l_conj) transaminasemia_33\NN\0|,_2 (l_conj) hyperkalemia_35\NN\14299637|,_2 (l_conj) hypoaldosteronism_37\NN\0|,_2 (l_conj) priapism_40\NN\14204950|,_6|and_4
10427794
C065757_D056486 CID meloxicam_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|liver_8|._22 (r_amod) toxicity_4\NN\13576101|NONE_0
C065757_D056486 CID meloxicam_18\NN\0|to_3 (r_pobj) due_16\IN\5174653|who_40|hepatitis_10 (r_prep) developed_12\VBD\1753788|rheumatoid_25 (l_dobj) hepatitis_15\NN\14127211|who_30|due_10
C065757_D056486 CID meloxicam_7\NNP\0|NONE_0 (r_compound) administration_8\NN\1133281|NONE_0 (r_pobj) after_6\IN\0|hepatitis_27|rapidly_8|and_31|associated_39|._136 (r_prep) occurred_4\VBD\0|NONE_0 (l_nsubj) hepatitis_3\NN\14127211|rapidly_19|after_27|and_58|associated_66|._163
C065757_D056486 CID meloxicam_4\NNP\0|related_10|liver_18 (r_nmod) toxicity_7\NN\13576101|NONE_0
C065757_D056486 CID meloxicam_4\NNP\0|related_10|liver_18 (r_nmod) toxicity_7\NN\13576101|NONE_0 (r_pobj) of_3\IN\0|this_16|first_11 (r_prep) case_2\NN\7283608|potential_58|induce_84|._105 (r_nsubj) demonstrates_8\VBZ\2137132|NONE_0 (l_xcomp) induce_15\VB\1627355|case_84|potential_26|._21 (l_dobj) damage_17\NN\7296428|to_18
C065757_D004342 CID meloxicam_7\NNP\0|NONE_0 (r_compound) administration_8\NN\1133281|NONE_0 (r_pobj) after_6\IN\0|hepatitis_27|rapidly_8|and_31|associated_39|._136 (r_prep) occurred_4\VBD\0|NONE_0 (l_conj) associated_11\VBN\628491|hepatitis_66|rapidly_47|after_39|and_8|._97 (l_advcl) suggesting_18\VBG\1010118|was_62|with_47 (l_dobj) mechanism_21\NN\13446390|NONE_0 (l_compound) hypersensitivity_20\NN\14531772|a_2
C065757_D001172 NONE meloxicam_18\NN\0|to_3 (r_pobj) due_16\IN\5174653|who_40|hepatitis_10 (r_prep) developed_12\VBD\1753788|rheumatoid_25 (r_relcl) arthritis_10\NN\14171682|NONE_0
19184102
D014635_D009765 CID vpa_20\NNP\0|NONE_0 (r_compound) treatment_21\NN\654885|NONE_0 (r_pobj) during_19\IN\0|who_22|obesity_8 (r_prep) developed_17\VBD\1753788|a_12 (l_dobj) obesity_18\NN\4999401|who_14|during_8
D014635_D009765 CID vpa_18\NNP\0|NONE_0 (r_pobj) with_17\IN\0|term_15 (r_prep) treatment_16\NN\654885|insulin_34|,_16|and_14 (r_conj) resistance_10\NN\37396|,_10 (r_conj) hyperinsulinemia_7\NN\0|,_2 (r_conj) obesity_5\NN\4999401|that_5|may_80|be_84|all_87|with_102
D014635_D009765 CID vpa_35\NNP\0|NONE_0 (r_compound) withdrawal_36\NN\7206096|NONE_0 (r_pobj) after_34\IN\0|suggests_178|;_33|effect_21|reversible_11|._20 (r_prep) is_32\VBZ\0|NONE_0 (l_ccomp) suggests_3\VBZ\1010118|;_145|effect_157|reversible_167|after_178|._198 (l_ccomp) associated_22\VBN\628491|case_110 (l_nsubjpass) obesity_5\NN\4999401|that_5|may_80|be_84|all_87|with_102
D014635_D006946 CID vpa_18\NNP\0|NONE_0 (r_pobj) with_17\IN\0|term_15 (r_prep) treatment_16\NN\654885|insulin_34|,_16|and_14 (r_conj) resistance_10\NN\37396|,_10 (r_conj) hyperinsulinemia_7\NN\0|,_2
D014635_D006946 CID vpa_35\NNP\0|NONE_0 (r_compound) withdrawal_36\NN\7206096|NONE_0 (r_pobj) after_34\IN\0|suggests_178|;_33|effect_21|reversible_11|._20 (r_prep) is_32\VBZ\0|NONE_0 (l_ccomp) suggests_3\VBZ\1010118|;_145|effect_157|reversible_167|after_178|._198 (l_ccomp) associated_22\VBN\628491|case_110 (l_nsubjpass) obesity_5\NN\4999401|that_5|may_80|be_84|all_87|with_102 (l_conj) hyperinsulinemia_7\NN\0|,_2
D014635_D007333 CID vpa_18\NNP\0|NONE_0 (r_pobj) with_17\IN\0|term_15 (r_prep) treatment_16\NN\654885|insulin_34|,_16|and_14 (r_conj) resistance_10\NN\37396|,_10
D014635_D007333 CID vpa_35\NNP\0|NONE_0 (r_compound) withdrawal_36\NN\7206096|NONE_0 (r_pobj) after_34\IN\0|suggests_178|;_33|effect_21|reversible_11|._20 (r_prep) is_32\VBZ\0|NONE_0 (l_ccomp) suggests_3\VBZ\1010118|;_145|effect_157|reversible_167|after_178|._198 (l_ccomp) associated_22\VBN\628491|case_110 (l_nsubjpass) obesity_5\NN\4999401|that_5|may_80|be_84|all_87|with_102 (l_conj) hyperinsulinemia_7\NN\0|,_2 (l_conj) resistance_10\NN\37396|,_10
D014635_D065626 CID valproate_5\NN\0|NONE_0 (r_amod) therapy_6\NN\657604|NONE_0 (r_pobj) during_4\IN\0|nonalcoholic_33|fatty_20|liver_14|._24 (r_prep) disease_3\NN\14061805|NONE_0
D014635_D065626 CID vpa_20\NNP\0|NONE_0 (r_compound) treatment_21\NN\654885|NONE_0 (r_pobj) during_19\IN\0|who_22|obesity_8 (r_prep) developed_17\VBD\1753788|a_12 (r_relcl) child_15\NN\9622049|NONE_0 (r_pobj) in_13\IN\13603305|NONE_0 (r_prep) arising_12\VBG\2623529|nonalcoholic_41|fatty_28|liver_22|(_8|nafld_7|)_2 (r_acl) disease_8\NN\14061805|NONE_0
D014635_D065626 CID vpa_20\NNP\0|NONE_0 (r_compound) treatment_21\NN\654885|NONE_0 (r_pobj) during_19\IN\0|who_22|obesity_8 (r_prep) developed_17\VBD\1753788|a_12 (r_relcl) child_15\NN\9622049|NONE_0 (r_pobj) in_13\IN\13603305|NONE_0 (r_prep) arising_12\VBG\2623529|nonalcoholic_41|fatty_28|liver_22|(_8|nafld_7|)_2 (r_acl) disease_8\NN\14061805|NONE_0 (l_appos) nafld_10\NNP\0|nonalcoholic_34|fatty_21|liver_15|(_1|)_5|arising_7
D014635_D065626 CID vpa_18\NNP\0|NONE_0 (r_pobj) with_17\IN\0|term_15 (r_prep) treatment_16\NN\654885|insulin_34|,_16|and_14 (r_conj) resistance_10\NN\37396|,_10 (r_conj) hyperinsulinemia_7\NN\0|,_2 (r_conj) obesity_5\NN\4999401|that_5|may_80|be_84|all_87|with_102 (r_nsubjpass) associated_22\VBN\628491|case_110 (l_prep) with_23\IN\0|that_107|obesity_102|may_22|be_18|all_15 (l_pobj) development_25\NN\248977|NONE_0 (l_prep) of_26\IN\0|the_16 (l_pobj) nafld_27\NNP\0|NONE_0
D014635_D065626 CID vpa_35\NNP\0|NONE_0 (r_compound) withdrawal_36\NN\7206096|NONE_0 (r_pobj) after_34\IN\0|suggests_178|;_33|effect_21|reversible_11|._20 (r_prep) is_32\VBZ\0|NONE_0 (l_ccomp) suggests_3\VBZ\1010118|;_145|effect_157|reversible_167|after_178|._198 (l_ccomp) associated_22\VBN\628491|case_110 (l_prep) with_23\IN\0|that_107|obesity_102|may_22|be_18|all_15 (l_pobj) development_25\NN\248977|NONE_0 (l_prep) of_26\IN\0|the_16 (l_pobj) nafld_27\NNP\0|NONE_0
D014635_D004827 NONE acid_1\NN\14818238|effective_14|,_67|but_69|associated_88 (r_nsubj) is_5\VBZ\0|NONE_0 (l_acomp) effective_6\JJ\0|acid_14|,_53|but_55|associated_74 (l_prep) for_7\IN\0|NONE_0 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_14 (l_pobj) types_12\NNS\5839024|NONE_0 (l_prep) of_13\IN\0|many_11 (l_pobj) epilepsy_14\NN\14085708|NONE_0
D014635_D004827 NONE vpa_3\NNP\0|valproic_15|(_1|)_3 (r_appos) acid_1\NN\14818238|effective_14|,_67|but_69|associated_88 (r_nsubj) is_5\VBZ\0|NONE_0 (l_acomp) effective_6\JJ\0|acid_14|,_53|but_55|associated_74 (l_prep) for_7\IN\0|NONE_0 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_14 (l_pobj) types_12\NNS\5839024|NONE_0 (l_prep) of_13\IN\0|many_11 (l_pobj) epilepsy_14\NN\14085708|NONE_0
D014635_D015431 NONE vpa_4\NNP\0|NONE_0 (r_compound) therapy_5\NN\657604|NONE_0 (r_pobj) of_3\IN\0|the_15 (r_prep) withdrawal_2\NN\7206096|NONE_0 (r_pobj) after_0\IN\0|,_35|patient_41|loss_77 (r_prep) showed_9\VBD\2137132|;_120|moreover_122|,_130|measurements_143|normalization_174|._187 (l_dobj) loss_13\NN\13252973|after_77|,_42|patient_36
18399341
D004837_D007022 NONE epinephrine_24\NN\14807929|,_19|p=_17|required_9|treat_24|._41 (r_amod) infusion_25\NN\14589223|four_115|in_93|and_67|1_63 (l_relcl) treat_27\VB\7570720|,_43|p=_41|required_33|epinephrine_24|._17 (l_dobj) hypotension_28\NN\14057371|to_9
24742750
D015283_D016171 CID citalopram_8\NNP\0|and_4 (r_conj) terfenadine_6\NNP\0|finally_27|,_20|ikr_14|,_2|,_26|reported_38|._143 (r_appos) blockers_4\NNS\10101634|NONE_0 (l_relcl) reported_12\VBN\831651|finally_65|,_58|ikr_52|,_40|terfenadine_38|,_12|._105 (l_xcomp) cause_14\VB\7323922|which_22|are_16 (l_ccomp) produced_25\VBD\1617192|to_56 (l_nsubj) pointes_17\NNP\831651|ead_72|)_75
D015283_D016171 CID citalopram_8\NNP\0|and_4 (r_conj) terfenadine_6\NNP\0|finally_27|,_20|ikr_14|,_2|,_26|reported_38|._143 (r_appos) blockers_4\NNS\10101634|NONE_0 (l_relcl) reported_12\VBN\831651|finally_65|,_58|ikr_52|,_40|terfenadine_38|,_12|._105 (l_xcomp) cause_14\VB\7323922|which_22|are_16 (l_ccomp) produced_25\VBD\1617192|to_56 (l_nsubj) pointes_17\NNP\831651|ead_72|)_75 (l_appos) tdp_19\NNP\0|torsade_20|de_12|(_1|)_3|in_5|,_25
D016593_D016171 CID terfenadine_6\NNP\0|finally_27|,_20|ikr_14|,_2|,_26|reported_38|._143 (r_appos) blockers_4\NNS\10101634|NONE_0 (l_relcl) reported_12\VBN\831651|finally_65|,_58|ikr_52|,_40|terfenadine_38|,_12|._105 (l_xcomp) cause_14\VB\7323922|which_22|are_16 (l_ccomp) produced_25\VBD\1617192|to_56 (l_nsubj) pointes_17\NNP\831651|ead_72|)_75
D016593_D016171 CID terfenadine_6\NNP\0|finally_27|,_20|ikr_14|,_2|,_26|reported_38|._143 (r_appos) blockers_4\NNS\10101634|NONE_0 (l_relcl) reported_12\VBN\831651|finally_65|,_58|ikr_52|,_40|terfenadine_38|,_12|._105 (l_xcomp) cause_14\VB\7323922|which_22|are_16 (l_ccomp) produced_25\VBD\1617192|to_56 (l_nsubj) pointes_17\NNP\831651|ead_72|)_75 (l_appos) tdp_19\NNP\0|torsade_20|de_12|(_1|)_3|in_5|,_25
2358093
D003613_D054179 NONE danazol_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_21|term_12|in_11|with_20|._46 (r_prep) safety_4\NN\13920835|NONE_0 (l_prep) with_9\IN\0|the_41|term_32|of_20|in_9|._26 (l_pobj) angioedema_11\NN\14316714|NONE_0
D003613_D054179 NONE danazol_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|the_21|term_12 (r_prep) safety_7\NN\13920835|we_40|therefore_37|by_18|._176 (r_dobj) investigated_2\VBD\644583|NONE_0 (l_prep) by_10\IN\0|we_58|therefore_55|safety_18|._158 (l_pcomp) performing_11\VBG\407535|NONE_0 (l_dobj) review_15\NN\5733583|NONE_0 (l_prep) of_16\IN\0|a_29|retrospective_27|chart_13|treated_49 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|60_19|female_16 (l_pobj) angioedema_22\NN\14316714|NONE_0
D003613_D054179 NONE danazol_25\NN\0|NONE_0 (r_pobj) with_24\IN\0|for_13 (r_prep) treated_23\VBN\2376958|a_78|retrospective_76|chart_62|of_49 (r_acl) review_15\NN\5733583|NONE_0 (l_prep) of_16\IN\0|a_29|retrospective_27|chart_13|treated_49 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|60_19|female_16 (l_pobj) angioedema_22\NN\14316714|NONE_0
15859361
C105934_D004342 NONE ce_5\NNP\14625458|NONE_0 (r_pobj) to_4\IN\0|one_30|hypersensitivity_26 (r_prep) reaction_3\NN\13446390|was_15|among_30|._79 (l_compound) hypersensitivity_2\NN\14531772|one_4|to_26
D000082_D004342 NONE p_7\NN\14622893|NONE_0 (r_pobj) to_6\IN\0|with_11 (r_prep) hypersensitivity_5\NN\14531772|NONE_0
D000082_D004342 NONE p_10\NN\14622893|9_2|nsaids_15|intolerant_22 (r_nmod) patients_17\NNS\9898892|NONE_0 (r_pobj) among_8\IN\0|reaction_30|was_15|._49 (r_prep) documented_7\VBN\1000214|NONE_0 (l_nsubjpass) reaction_3\NN\13446390|was_15|among_30|._79 (l_compound) hypersensitivity_2\NN\14531772|one_4|to_26
D000082_D003875 CID acetaminophen_10\RB\2707683|NONE_0 (r_pobj) to_9\IN\0|adverse_23|skin_15|paracetamol_18 (r_prep) reactions_8\NNS\13446390|NONE_0
D000082_D003875 CID paracetamol_12\NNP\0|adverse_41|skin_33|to_18 (r_appos) reactions_8\NNS\13446390|NONE_0
D000082_D003875 CID p_20\NN\14622893|NONE_0 (r_pobj) to_19\IN\0|adverse_28|cutaneous_20|associated_11 (r_prep) reactions_18\NNS\13446390|NONE_0
D000082_D003875 CID p_3\NN\14622893|skin_16 (r_nmod) reactions_9\NNS\13446390|NONE_0
C012655_D004342 NONE n_9\NN\14622893|and_4 (r_conj) p_7\NN\14622893|NONE_0 (r_pobj) to_6\IN\0|with_11 (r_prep) hypersensitivity_5\NN\14531772|NONE_0
C012655_D004342 NONE n_12\NN\14622893|and_4 (r_conj) p_10\NN\14622893|9_2|nsaids_15|intolerant_22 (r_nmod) patients_17\NNS\9898892|NONE_0 (r_pobj) among_8\IN\0|reaction_30|was_15|._49 (r_prep) documented_7\VBN\1000214|NONE_0 (l_nsubjpass) reaction_3\NN\13446390|was_15|among_30|._79 (l_compound) hypersensitivity_2\NN\14531772|one_4|to_26
C105934_D003875 NONE celecoxib_2\NN\3124700|NONE_0 (r_pobj) of_1\IN\0|in_13|._166 (r_prep) safety_0\NN\13920835|NONE_0 (l_prep) in_3\IN\13603305|of_13|._153 (l_pobj) patients_4\NNS\9898892|NONE_0 (l_prep) with_5\IN\0|NONE_0 (l_pobj) reactions_8\NNS\13446390|NONE_0
C105934_D003875 NONE ce_6\NNP\14625458|NONE_0 (r_pobj) of_5\IN\0|the_17 (r_prep) tolerability_4\NN\0|:_19|we_17|in_19|._143 (r_dobj) evaluated_2\VBD\670261|NONE_0 (l_prep) in_7\IN\13603305|:_38|we_36|tolerability_19|._124 (l_pobj) group_9\NN\2137|NONE_0 (l_prep) of_10\IN\0|a_8 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) history_14\NN\15120823|NONE_0 (l_prep) of_15\IN\0|documented_19 (l_pobj) reactions_18\NNS\13446390|NONE_0
C012655_D003875 CID nimesulide_15\NN\0|(_18|)_6|and_4 (r_conj) paracetamol_12\NNP\0|adverse_41|skin_33|to_18 (r_appos) reactions_8\NNS\13446390|NONE_0
C012655_D003875 CID n_22\NNP\14622893|and_4 (r_conj) p_20\NN\14622893|NONE_0 (r_pobj) to_19\IN\0|adverse_28|cutaneous_20|associated_11 (r_prep) reactions_18\NNS\13446390|NONE_0
C012655_D003875 CID n_5\NN\14622893|-_1 (r_npadvmod) induced_7\VBN\1627355|and_6 (r_conj) p_3\NN\14622893|skin_16 (r_nmod) reactions_9\NNS\13446390|NONE_0
3088653
D012601_D000647 CID scopolamine_2\NN\14712692|-_11 (r_npadvmod) induced_4\VBN\1627355|of_16 (r_amod) amnesia_5\NN\5669934|NONE_0
D012601_D000647 CID scopolamine_0\NNP\14712692|amnesia_68|measured_79|._122 (r_nsubj) induced_13\VBD\1627355|NONE_0 (l_dobj) amnesia_15\NN\5669934|scopolamine_68|measured_11|._54
D012601_D000647 CID scopolamine_21\NN\14712692|-_11 (r_npadvmod) induced_23\VBN\1627355|the_16 (r_amod) amnesia_24\NN\5669934|administration_108|also_40|._7
D012601_D008569 NONE scopolamine_14\NN\14712692|-_11 (r_npadvmod) induced_16\VBN\1627355|a_14|retention_8 (r_amod) deficit_18\NN\5113133|NONE_0
D012601_D008569 NONE scopolamine_38\NN\14712692|-_11 (r_npadvmod) induced_40\VBN\1627355|the_16|retention_8 (r_amod) deficit_42\NN\5113133|NONE_0
D019832_D000647 NONE scopolamine_5\NN\14712692|,_17|but_15 (r_conj) scopolamine_0\NNP\14712692|amnesia_68|measured_79|._122 (r_nsubj) induced_13\VBD\1627355|NONE_0 (l_dobj) amnesia_15\NN\5669934|scopolamine_68|measured_11|._54
D009270_D008569 NONE naloxone_11\NN\3808977|NONE_0 (l_prep) on_12\IN\0|in_43 (l_pobj) deficit_18\NN\5113133|NONE_0
D009270_D008569 NONE naloxone_0\NN\3808977|prior_44|attenuated_62|._129 (r_nsubj) injected_12\VBD\81072|NONE_0 (l_advcl) attenuated_16\VBD\224901|naloxone_62|prior_18|._67 (l_dobj) deficit_19\NN\5113133|with_8|at_32
D009270_D008569 NONE naloxone_14\NN\3808977|pain_31 (r_appos) sensitivity_9\NN\5651971|NONE_0 (r_pobj) in_7\IN\13603305|neither_20|an_12|)_42|nor_44|state_68 (r_prep) increase_6\NN\13576355|that_16|be_118 (r_nsubj) appear_27\VBP\2604760|experiments_146|._99 (l_xcomp) be_29\VB\14625458|that_134|increase_118 (l_acomp) responsible_30\JJ\0|to_6 (l_prep) for_31\IN\0|NONE_0 (l_pobj) influence_33\NN\5190804|NONE_0 (l_prep) of_34\IN\0|the_14 (l_pobj) naloxone_35\NN\3808977|NONE_0 (l_prep) on_36\IN\0|NONE_0 (l_pobj) deficit_42\NN\5113133|NONE_0
D009270_D008569 NONE naloxone_25\NN\3808977|an_41|induced_38|aversive_30|)_8 (r_appos) state_20\NN\8491826|neither_88|an_80|in_68|)_26|nor_24 (r_conj) increase_6\NN\13576355|that_16|be_118 (r_nsubj) appear_27\VBP\2604760|experiments_146|._99 (l_xcomp) be_29\VB\14625458|that_134|increase_118 (l_acomp) responsible_30\JJ\0|to_6 (l_prep) for_31\IN\0|NONE_0 (l_pobj) influence_33\NN\5190804|NONE_0 (l_prep) of_34\IN\0|the_14 (l_pobj) naloxone_35\NN\3808977|NONE_0 (l_prep) on_36\IN\0|NONE_0 (l_pobj) deficit_42\NN\5113133|NONE_0
D009270_D008569 NONE naloxone_35\NN\3808977|NONE_0 (l_prep) on_36\IN\0|NONE_0 (l_pobj) deficit_42\NN\5113133|NONE_0
D009270_D000647 NONE naloxone_15\NN\3808977|NONE_0 (r_pobj) by_9\IN\0|passive_18 (r_prep) avoidance_8\NN\203342|NONE_0 (r_pobj) of_6\IN\0|induced_16 (r_prep) amnesia_5\NN\5669934|NONE_0
D009270_D000647 NONE naloxone_5\NN\3808977|NONE_0 (r_pobj) of_4\IN\0|training_24|as_37 (r_prep) administration_3\NN\1133281|also_68|amnesia_108|._115 (r_nsubj) attenuated_19\VBD\224901|NONE_0 (l_dobj) amnesia_24\NN\5669934|administration_108|also_40|._7
D012601_D010146 NONE scopolamine_38\NN\14712692|-_11 (r_npadvmod) induced_40\VBN\1627355|the_16|retention_8 (r_amod) deficit_42\NN\5113133|NONE_0 (r_pobj) on_36\IN\0|NONE_0 (r_prep) naloxone_35\NN\3808977|NONE_0 (r_pobj) of_34\IN\0|the_14 (r_prep) influence_33\NN\5190804|NONE_0 (r_pobj) for_31\IN\0|NONE_0 (r_prep) responsible_30\JJ\0|to_6 (r_acomp) be_29\VB\14625458|that_134|increase_118 (r_xcomp) appear_27\VBP\2604760|experiments_146|._99 (l_nsubj) increase_6\NN\13576355|that_16|be_118 (l_prep) in_7\IN\13603305|neither_20|an_12|)_42|nor_44|state_68 (l_pobj) sensitivity_9\NN\5651971|NONE_0 (l_compound) pain_8\NN\14299637|naloxone_31
D009270_D010146 NONE naloxone_14\NN\3808977|pain_31 (r_appos) sensitivity_9\NN\5651971|NONE_0 (l_compound) pain_8\NN\14299637|naloxone_31
D009270_D010146 NONE naloxone_25\NN\3808977|an_41|induced_38|aversive_30|)_8 (r_appos) state_20\NN\8491826|neither_88|an_80|in_68|)_26|nor_24 (r_conj) increase_6\NN\13576355|that_16|be_118 (l_prep) in_7\IN\13603305|neither_20|an_12|)_42|nor_44|state_68 (l_pobj) sensitivity_9\NN\5651971|NONE_0 (l_compound) pain_8\NN\14299637|naloxone_31
D009270_D010146 NONE naloxone_35\NN\3808977|NONE_0 (r_pobj) of_34\IN\0|the_14 (r_prep) influence_33\NN\5190804|NONE_0 (r_pobj) for_31\IN\0|NONE_0 (r_prep) responsible_30\JJ\0|to_6 (r_acomp) be_29\VB\14625458|that_134|increase_118 (r_xcomp) appear_27\VBP\2604760|experiments_146|._99 (l_nsubj) increase_6\NN\13576355|that_16|be_118 (l_prep) in_7\IN\13603305|neither_20|an_12|)_42|nor_44|state_68 (l_pobj) sensitivity_9\NN\5651971|NONE_0 (l_compound) pain_8\NN\14299637|naloxone_31
8808730
D009569_D001745 NONE oxide_5\NN\14818238|neuronal_16|nitric_7|in_15 (r_compound) synthase_6\NN\0|NONE_0 (r_pobj) of_2\IN\0|increased_21|following_63|._99 (r_prep) expression_1\NN\4679549|NONE_0 (l_prep) following_11\VBG\8180190|increased_84|of_63|._36 (l_pobj) irritation_14\NN\14373582|NONE_0
D000171_D003556 NONE acrolein_13\NN\14584765|NONE_0 (r_pobj) to_12\IN\0|which_21|is_15 (r_prep) metabolized_11\VBN\0|(_15|)_11 (r_relcl) cyp_7\NNP\0|NONE_0 (r_appos) cyclophosphamide_5\NN\0|NONE_0 (r_pobj) by_4\IN\0|cystitis_21|was_12 (r_agent) induced_3\VBN\1627355|,_66|irritant_71|in_91|._103 (l_nsubjpass) cystitis_1\NN\14566129|was_9|by_21
D003520_D003556 CID cyclophosphamide_5\NN\0|NONE_0 (r_pobj) by_4\IN\0|cystitis_21|was_12 (r_agent) induced_3\VBN\1627355|,_66|irritant_71|in_91|._103 (l_nsubjpass) cystitis_1\NN\14566129|was_9|by_21
D003520_D003556 CID cyp_7\NNP\0|NONE_0 (r_appos) cyclophosphamide_5\NN\0|NONE_0 (r_pobj) by_4\IN\0|cystitis_21|was_12 (r_agent) induced_3\VBN\1627355|,_66|irritant_71|in_91|._103 (l_nsubjpass) cystitis_1\NN\14566129|was_9|by_21
D009569_D014570 NONE oxide_13\NN\14818238|neuronal_16|nitric_7|(_15|nos_16|)_19|in_21 (r_compound) synthase_14\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_15 (r_prep) expression_9\NN\4679549|NONE_0 (r_pobj) in_7\IN\13603305|following_78 (r_prep) alterations_6\NNS\7283608|to_11 (l_prep) following_21\VBG\8180190|in_78 (l_pobj) irritation_25\NN\14373582|NONE_0 (l_prep) of_26\IN\0|acute_29 (l_pobj) tract_29\NN\8574314|NONE_0
24753331
C083440_D064420 NONE s-23121_2\NN\0|and_4 (r_conj) s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) retardation_25\NN\7296428|phenylimide_130|and_107|embryolethality_94|,_79|teratogenicity_77|,_13|and_11 (l_prep) in_26\IN\13603305|growth_19 (l_pobj) rats_27\NNS\2329401|NONE_0 (l_prep) in_28\IN\13603305|NONE_0 (l_pobj) studies_33\NNS\635850|NONE_0 (l_compound) toxicity_32\NN\13576101|conventional_32|oral_19
C083440_D006345 CID s-23121_2\NN\0|and_4 (r_conj) s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) teratogenicity_12\NN\0|phenylimide_53|and_30|embryolethality_17|,_2|,_64|and_66|retardation_77 (l_conj) defects_17\NNS\14462666|(_27|)_21
C083440_D006345 CID s-23121_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|dermal_22|at_11 (r_prep) administration_1\NN\1133281|in_48|,_122|but_124|observed_158 (r_nsubj) resulted_7\VBD\2633881|NONE_0 (l_prep) in_8\IN\13603305|administration_48|,_74|but_76|observed_110 (l_pobj) incidence_11\NN\13821570|NONE_0 (l_prep) of_12\IN\0|an_23|increased_20 (l_pobj) death_14\NN\7296428|NONE_0 (l_conj) defect_18\NN\14462666|embryonic_39|and_23
C083440_D006345 CID s-23121_34\NN\0|NONE_0 (r_pobj) to_33\IN\0|oral_14 (r_prep) exposure_32\NN\5042871|as_25|it_22|was_19 (r_dobj) following_30\VBG\8180190|growth_34|was_27|not_23|._34 (r_advcl) observed_26\VBN\2163746|administration_158|in_110|,_36|but_34 (r_conj) resulted_7\VBD\2633881|NONE_0 (l_prep) in_8\IN\13603305|administration_48|,_74|but_76|observed_110 (l_pobj) incidence_11\NN\13821570|NONE_0 (l_prep) of_12\IN\0|an_23|increased_20 (l_pobj) death_14\NN\7296428|NONE_0 (l_conj) defect_18\NN\14462666|embryonic_39|and_23
C106487_D064793 CID s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) teratogenicity_12\NN\0|phenylimide_53|and_30|embryolethality_17|,_2|,_64|and_66|retardation_77
C106487_D064793 CID s-53482_5\NNS\0|based_22|,_2|teratogenic_25|administered_42|._122 (r_nsubj) were_8\VBD\0|NONE_0 (l_acomp) teratogenic_9\JJ\0|based_47|,_27|s-53482_25|administered_17|._97
C083440_D020964 CID s-23121_2\NN\0|and_4 (r_conj) s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) embryolethality_10\NN\0|phenylimide_36|and_13|,_15|teratogenicity_17|,_81|and_83|retardation_94
C083440_D020964 CID s-23121_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|dermal_22|at_11 (r_prep) administration_1\NN\1133281|in_48|,_122|but_124|observed_158 (r_nsubj) resulted_7\VBD\2633881|NONE_0 (l_prep) in_8\IN\13603305|administration_48|,_74|but_76|observed_110 (l_pobj) incidence_11\NN\13821570|NONE_0 (l_prep) of_12\IN\0|an_23|increased_20 (l_pobj) death_14\NN\7296428|NONE_0
C083440_D020964 CID s-23121_34\NN\0|NONE_0 (r_pobj) to_33\IN\0|oral_14 (r_prep) exposure_32\NN\5042871|as_25|it_22|was_19 (r_dobj) following_30\VBG\8180190|growth_34|was_27|not_23|._34 (r_advcl) observed_26\VBN\2163746|administration_158|in_110|,_36|but_34 (r_conj) resulted_7\VBD\2633881|NONE_0 (l_prep) in_8\IN\13603305|administration_48|,_74|but_76|observed_110 (l_pobj) incidence_11\NN\13821570|NONE_0 (l_prep) of_12\IN\0|an_23|increased_20 (l_pobj) death_14\NN\7296428|NONE_0
C106487_D006345 CID s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) teratogenicity_12\NN\0|phenylimide_53|and_30|embryolethality_17|,_2|,_64|and_66|retardation_77 (l_conj) defects_17\NNS\14462666|(_27|)_21
C106487_D005317 CID s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) retardation_25\NN\7296428|phenylimide_130|and_107|embryolethality_94|,_79|teratogenicity_77|,_13|and_11
C106487_D020964 CID s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) embryolethality_10\NN\0|phenylimide_36|and_13|,_15|teratogenicity_17|,_81|and_83|retardation_94
C083440_D005317 CID s-23121_2\NN\0|and_4 (r_conj) s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) retardation_25\NN\7296428|phenylimide_130|and_107|embryolethality_94|,_79|teratogenicity_77|,_13|and_11
C106487_D064420 NONE s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) retardation_25\NN\7296428|phenylimide_130|and_107|embryolethality_94|,_79|teratogenicity_77|,_13|and_11 (l_prep) in_26\IN\13603305|growth_19 (l_pobj) rats_27\NNS\2329401|NONE_0 (l_prep) in_28\IN\13603305|NONE_0 (l_pobj) studies_33\NNS\635850|NONE_0 (l_compound) toxicity_32\NN\13576101|conventional_32|oral_19
C106487_D064420 NONE s-53482_5\NNS\0|NONE_0 (r_pobj) to_4\IN\0|dermal_24|of_8|at_11|._113 (r_prep) exposure_1\NN\5042871|NONE_0 (l_prep) at_6\IN\14622893|dermal_35|of_19|to_11|._102 (l_pobj) patterns_10\NNS\5726345|NONE_0 (l_prep) of_11\IN\0|mg/kg_24|produced_18 (l_pobj) toxicity_13\NN\13576101|NONE_0
C083440_D064793 CID s-23121_2\NN\0|and_4 (r_conj) s-53482_0\NNS\0|herbicides_38|._227 (r_nsubj) are_3\VBP\13600404|NONE_0 (l_attr) herbicides_7\NNS\14806838|s-53482_38|._189 (l_conj) teratogenicity_12\NN\0|phenylimide_53|and_30|embryolethality_17|,_2|,_64|and_66|retardation_77
C083440_D064793 CID s-23121_7\NN\0|and_4 (r_conj) s-53482_5\NNS\0|based_22|,_2|teratogenic_25|administered_42|._122 (r_nsubj) were_8\VBD\0|NONE_0 (l_acomp) teratogenic_9\JJ\0|based_47|,_27|s-53482_25|administered_17|._97
24209900
D007069_D008223 NONE ifosfamide_0\NNP\0|agent_28|._149 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_4\NN\7347|ifosfamide_28|._121 (l_amod) useful_5\JJ\0|an_20|alkylating_17 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) range_12\NN\5123416|NONE_0 (l_prep) of_13\IN\0|a_13|wide_11 (l_pobj) cancers_14\NNS\14239425|NONE_0 (l_prep) including_15\VBG\0|NONE_0 (l_pobj) sarcomas_16\NNS\14239918|NONE_0 (l_conj) cancers_23\NNS\14239425|,_39 (l_nmod) lymphoma_18\NN\14239918|gynecologic_10
D007069_D009369 NONE ifosfamide_0\NNP\0|agent_28|._149 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_4\NN\7347|ifosfamide_28|._121 (l_amod) useful_5\JJ\0|an_20|alkylating_17 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) range_12\NN\5123416|NONE_0 (l_prep) of_13\IN\0|a_13|wide_11 (l_pobj) cancers_14\NNS\14239425|NONE_0
D007069_D009369 NONE ifosfamide_0\NNP\0|agent_28|._149 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_4\NN\7347|ifosfamide_28|._121 (l_amod) useful_5\JJ\0|an_20|alkylating_17 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) range_12\NN\5123416|NONE_0 (l_prep) of_13\IN\0|a_13|wide_11 (l_pobj) cancers_14\NNS\14239425|NONE_0 (l_prep) including_15\VBG\0|NONE_0 (l_pobj) sarcomas_16\NNS\14239918|NONE_0 (l_conj) cancers_23\NNS\14239425|,_39
D007069_D009369 NONE ifosfamide_29\RB\0|NONE_0 (r_advmod) related_30\VBN\628491|acute_8 (r_amod) encephalopathy_32\NN\14084880|who_39 (r_dobj) developed_28\VBD\1753788|review_148|was_98|on_89|,_73|admitted_71|,_6|._49 (r_relcl) done_10\VBN\0|NONE_0 (l_advcl) admitted_15\VBN\822367|review_77|was_27|on_18|,_2|,_65|developed_71|._120 (l_prep) to_16\IN\0|between_29 (l_pobj) center_20\NNP\8497294|NONE_0 (l_compound) cancer_19\NNP\14239425|md_12|anderson_9
D007069_D012509 NONE ifosfamide_0\NNP\0|agent_28|._149 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_4\NN\7347|ifosfamide_28|._121 (l_amod) useful_5\JJ\0|an_20|alkylating_17 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) range_12\NN\5123416|NONE_0 (l_prep) of_13\IN\0|a_13|wide_11 (l_pobj) cancers_14\NNS\14239425|NONE_0 (l_prep) including_15\VBG\0|NONE_0 (l_pobj) sarcomas_16\NNS\14239918|NONE_0
D007069_D001927 NONE ifosfamide_0\IN\0|related_11|:_33|need_39|._71 (r_nmod) encephalopathy_2\NN\14084880|NONE_0
D007069_D001927 NONE ifosfamide_16\NN\0|NONE_0 (r_dobj) receiving_11\VBG\2210855|NONE_0 (r_acl) patients_10\NNS\9898892|NONE_0 (r_pobj) of_9\IN\0|40_4 (r_prep) %_8\NN\0|NONE_0 (r_pobj) in_4\IN\13603305|encephalopathy_33|has_18|been_14|._55 (r_prep) reported_3\VBN\831651|NONE_0 (l_nsubjpass) encephalopathy_0\NNP\14084880|has_15|been_19|in_33|._88
D007069_D001927 NONE ifosfamide_16\JJ\0|NONE_0 (r_advmod) related_17\VBN\628491|NONE_0 (r_amod) encephalopathy_18\NN\14084880|NONE_0
D007069_D001927 NONE ifosfamide_29\RB\0|NONE_0 (r_advmod) related_30\VBN\628491|acute_8 (r_amod) encephalopathy_32\NN\14084880|who_39
D007069_D001927 NONE ifosfamide_17\RB\0|NONE_0 (r_advmod) receiving_16\VBG\2210855|:_91|patients_80|symptoms_59|after_27|(_21|within_20|)_2|._20 (r_advcl) experienced_4\VBD\2108377|NONE_0 (l_dobj) symptoms_5\NNS\5823932|:_32|patients_21|after_32|(_38|within_39|)_57|receiving_59|._79 (l_prep) of_6\IN\0|NONE_0 (l_pobj) encephalopathy_7\JJ\14084880|NONE_0
D007069_D001927 NONE ifosfamide_2\JJ\0|NONE_0 (r_advmod) related_3\JJ\628491|NONE_0 (r_amod) encephalopathy_4\JJ\14084880|NONE_0
D007069_D001927 NONE ifosfamide_9\RB\0|NONE_0 (l_relcl) develop_11\VBP\1753788|NONE_0 (l_dobj) features_12\NNS\5849040|who_12 (l_prep) of_13\IN\0|NONE_0 (l_pobj) encephalopathy_14\NN\14084880|NONE_0
24733133
C031942_D013921 NONE argatroban_2\NN\0|with_46|in_61 (r_amod) thrombolysis_7\NN\13509528|NONE_0 (l_prep) in_10\IN\13603305|argatroban_61|with_15 (l_pobj) patient_13\NN\9898892|NONE_0 (l_prep) with_14\IN\0|an_20|oncology_17 (l_pobj) thrombocytopenia_18\NN\14189204|NONE_0
C031942_D013921 NONE argatroban_21\NN\0|directed_25|(_47|cdt_48|)_51 (r_amod) thrombolysis_26\NN\13509528|NONE_0 (r_pobj) with_20\IN\0|was_12|with_58 (r_prep) treated_19\VBN\2376958|who_78|thrombocytopenia_48|and_8 (r_conj) developed_7\VBD\1753788|an_24|oncology_21 (l_dobj) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48
C031942_D013921 NONE argatroban_21\NN\0|directed_25|(_47|cdt_48|)_51 (r_amod) thrombolysis_26\NN\13509528|NONE_0 (r_pobj) with_20\IN\0|was_12|with_58 (r_prep) treated_19\VBN\2376958|who_78|thrombocytopenia_48|and_8 (r_conj) developed_7\VBD\1753788|an_24|oncology_21 (l_dobj) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48 (l_prep) with_12\IN\0|induced_25 (l_pobj) thrombosis_13\NN\14100769|NONE_0 (l_appos) hitt_15\NNP\0|NONE_0
C031942_D013921 NONE argatroban_18\NN\0|NONE_0 (r_amod) with_17\IN\0|man_87|was_25|successfully_21|with_24|._38 (r_prep) treated_16\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_62|successfully_66|with_87|with_111|._125 (l_prep) to_12\IN\0|a_68|old_58|with_50 (l_pobj) hitt_13\NNP\0|NONE_0
C031942_D004844 NONE argatroban_13\NN\0|NONE_0 (r_amod) on_12\IN\0|patient_22|was_14|._13 (r_prep) restarted_11\VBN\1857717|epistaxis_53|day_25|,_22|and_20 (r_conj) resolved_2\VBD\352826|NONE_0 (l_nsubj) epistaxis_1\NN\14288235|day_28|,_31|and_33|restarted_53
D006493_D013921 CID heparin_15\NN\2718259|-_7 (r_npadvmod) induced_17\VBN\1627355|with_25 (r_amod) thrombocytopenia_18\NN\14189204|NONE_0
D006493_D013921 CID heparin_8\NN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|with_25 (r_amod) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48
D006493_D013921 CID heparin_38\NN\2718259|-_7 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_41\NN\14189204|NONE_0
D006493_D013921 NONE heparin_8\NN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|with_25 (r_amod) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48 (l_prep) with_12\IN\0|induced_25 (l_pobj) thrombosis_13\NN\14100769|NONE_0 (l_appos) hitt_15\NNP\0|NONE_0
D006493_D011655 CID heparin_38\NN\2718259|-_7 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_41\NN\14189204|NONE_0 (r_pobj) to_37\IN\0|NONE_0 (r_prep) secondary_36\JJ\8426461|pulmonary_19 (r_amod) embolism_35\NN\15269513|extensive_79|bilateral_69|extremity_53|venous_38|(_20|dvt_19|)_16|and_14
D006493_D013927 NONE heparin_15\NN\2718259|-_7 (r_npadvmod) induced_17\VBN\1627355|with_25 (r_amod) thrombocytopenia_18\NN\14189204|NONE_0 (l_prep) with_19\IN\0|induced_25 (l_pobj) thrombosis_20\NN\14100769|NONE_0
D006493_D013927 NONE heparin_8\NN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|with_25 (r_amod) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48 (l_prep) with_12\IN\0|induced_25 (l_pobj) thrombosis_13\NN\14100769|NONE_0
D006493_D013927 NONE heparin_8\NN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|with_25 (r_amod) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48 (l_prep) with_12\IN\0|induced_25 (l_pobj) thrombosis_13\NN\14100769|NONE_0 (l_appos) hitt_15\NNP\0|NONE_0
D006493_D000686 NONE heparin_38\NN\2718259|-_7 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_41\NN\14189204|NONE_0 (r_pobj) to_37\IN\0|NONE_0 (r_prep) secondary_36\JJ\8426461|pulmonary_19 (r_amod) embolism_35\NN\15269513|extensive_79|bilateral_69|extremity_53|venous_38|(_20|dvt_19|)_16|and_14 (r_conj) thrombosis_29\NN\14100769|man_173|._85 (r_dobj) developed_21\VBD\1753788|NONE_0 (l_nsubj) man_5\NN\9605289|thrombosis_173|._258 (l_prep) with_6\IN\0|a_28|old_18|caucasian_14 (l_pobj) amyloidosis_8\NN\14061805|NONE_0
D006493_D055499 NONE heparin_15\NN\2718259|-_7 (r_npadvmod) induced_17\VBN\1627355|with_25 (r_amod) thrombocytopenia_18\NN\14189204|NONE_0 (r_pobj) with_14\IN\0|an_20|oncology_17 (r_prep) patient_13\NN\9898892|NONE_0 (r_pobj) in_10\IN\13603305|argatroban_61|with_15 (r_prep) thrombolysis_7\NN\13509528|NONE_0
D006493_D055499 NONE heparin_8\NN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|with_25 (r_amod) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48 (r_dobj) developed_7\VBD\1753788|an_24|oncology_21 (l_conj) treated_19\VBN\2376958|who_78|thrombocytopenia_48|and_8 (l_prep) with_20\IN\0|was_12|with_58 (l_pobj) thrombolysis_26\NN\13509528|NONE_0
C031942_D055499 NONE argatroban_2\NN\0|with_46|in_61 (r_amod) thrombolysis_7\NN\13509528|NONE_0
C031942_D055499 NONE argatroban_21\NN\0|directed_25|(_47|cdt_48|)_51 (r_amod) thrombolysis_26\NN\13509528|NONE_0
D006493_D056824 NONE heparin_38\NN\2718259|-_7 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_41\NN\14189204|NONE_0 (r_pobj) to_37\IN\0|NONE_0 (r_prep) secondary_36\JJ\8426461|pulmonary_19 (r_amod) embolism_35\NN\15269513|extensive_79|bilateral_69|extremity_53|venous_38|(_20|dvt_19|)_16|and_14 (r_conj) thrombosis_29\NN\14100769|man_173|._85
D006493_D020246 CID heparin_38\NN\2718259|-_7 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_41\NN\14189204|NONE_0 (r_pobj) to_37\IN\0|NONE_0 (r_prep) secondary_36\JJ\8426461|pulmonary_19 (r_amod) embolism_35\NN\15269513|extensive_79|bilateral_69|extremity_53|venous_38|(_20|dvt_19|)_16|and_14 (r_conj) thrombosis_29\NN\14100769|man_173|._85 (l_appos) dvt_31\NNP\0|extensive_60|bilateral_50|extremity_34|venous_19|(_1|)_3|and_5|embolism_19
C031942_D013479 NONE argatroban_18\NN\0|NONE_0 (r_amod) with_17\IN\0|man_87|was_25|successfully_21|with_24|._38 (r_prep) treated_16\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_62|successfully_66|with_87|with_111|._125 (l_prep) with_5\IN\0|a_18|old_8|to_50 (l_pobj) amyloidosis_7\NN\14061805|NONE_0 (l_conj) syndrome_10\NN\5870365|renal_26|and_8
C031942_D000686 NONE argatroban_18\NN\0|NONE_0 (r_amod) with_17\IN\0|man_87|was_25|successfully_21|with_24|._38 (r_prep) treated_16\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_62|successfully_66|with_87|with_111|._125 (l_prep) with_5\IN\0|a_18|old_8|to_50 (l_pobj) amyloidosis_7\NN\14061805|NONE_0
C031942_D013927 NONE argatroban_2\NN\0|with_46|in_61 (r_amod) thrombolysis_7\NN\13509528|NONE_0 (l_prep) in_10\IN\13603305|argatroban_61|with_15 (l_pobj) patient_13\NN\9898892|NONE_0 (l_prep) with_14\IN\0|an_20|oncology_17 (l_pobj) thrombocytopenia_18\NN\14189204|NONE_0 (l_prep) with_19\IN\0|induced_25 (l_pobj) thrombosis_20\NN\14100769|NONE_0
C031942_D013927 NONE argatroban_21\NN\0|directed_25|(_47|cdt_48|)_51 (r_amod) thrombolysis_26\NN\13509528|NONE_0 (r_pobj) with_20\IN\0|was_12|with_58 (r_prep) treated_19\VBN\2376958|who_78|thrombocytopenia_48|and_8 (r_conj) developed_7\VBD\1753788|an_24|oncology_21 (l_dobj) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48 (l_prep) with_12\IN\0|induced_25 (l_pobj) thrombosis_13\NN\14100769|NONE_0
C031942_D013927 NONE argatroban_21\NN\0|directed_25|(_47|cdt_48|)_51 (r_amod) thrombolysis_26\NN\13509528|NONE_0 (r_pobj) with_20\IN\0|was_12|with_58 (r_prep) treated_19\VBN\2376958|who_78|thrombocytopenia_48|and_8 (r_conj) developed_7\VBD\1753788|an_24|oncology_21 (l_dobj) thrombocytopenia_11\NN\14189204|who_30|and_40|treated_48 (l_prep) with_12\IN\0|induced_25 (l_pobj) thrombosis_13\NN\14100769|NONE_0 (l_appos) hitt_15\NNP\0|NONE_0
C031942_D013927 NONE argatroban_18\NN\0|NONE_0 (r_amod) with_17\IN\0|man_87|was_25|successfully_21|with_24|._38 (r_prep) treated_16\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_62|successfully_66|with_87|with_111|._125 (l_prep) to_12\IN\0|a_68|old_58|with_50 (l_pobj) hitt_13\NNP\0|NONE_0
24928523
C400082_D009101 NONE bortezomib_2\NNS\0|NONE_0 (r_pobj) of_1\IN\0|thalidomide_15|as_52|._175 (r_prep) combination_0\NN\7951464|NONE_0 (l_prep) as_11\IN\14622893|of_52|thalidomide_37|._123 (l_pobj) therapy_14\NN\657604|NONE_0 (l_prep) after_15\IN\0|a_24|consolidation_22 (l_pobj) transplantation_19\NN\671351|NONE_0 (l_prep) for_20\IN\0|autologous_37|cell_21 (l_pobj) myeloma_23\NN\14239425|NONE_0
C400082_D009101 NONE bortezomib_15\NNS\0|NONE_0 (r_pobj) of_14\IN\0|combination_20 (r_prep) regimen_13\NNS\5898568|NONE_0 (r_pobj) of_11\IN\0|the_24|and_13|efficacy_9 (r_prep) safety_8\NN\13920835|in_47|,_34|we_32|retrospectively_29|as_95|._167 (r_dobj) analyzed_6\VBD\0|NONE_0 (l_prep) as_24\IN\14622893|in_142|,_129|we_127|retrospectively_124|safety_95|._72 (l_pobj) therapy_26\NN\657604|NONE_0 (l_prep) in_27\IN\13603305|consolidation_22 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_prep) with_31\IN\0|24_21|japanese_18 (l_pobj) mm_34\NNP\13649268|NONE_0
D013792_D009101 NONE thalidomide_4\NN\4166841|of_15|as_37|._160 (r_conj) combination_0\NN\7951464|NONE_0 (l_prep) as_11\IN\14622893|of_52|thalidomide_37|._123 (l_pobj) therapy_14\NN\657604|NONE_0 (l_prep) after_15\IN\0|a_24|consolidation_22 (l_pobj) transplantation_19\NN\671351|NONE_0 (l_prep) for_20\IN\0|autologous_37|cell_21 (l_pobj) myeloma_23\NN\14239425|NONE_0
D013792_D009101 NONE thalidomide_17\NN\4166841|,_2 (r_conj) bortezomib_15\NNS\0|NONE_0 (r_pobj) of_14\IN\0|combination_20 (r_prep) regimen_13\NNS\5898568|NONE_0 (r_pobj) of_11\IN\0|the_24|and_13|efficacy_9 (r_prep) safety_8\NN\13920835|in_47|,_34|we_32|retrospectively_29|as_95|._167 (r_dobj) analyzed_6\VBD\0|NONE_0 (l_prep) as_24\IN\14622893|in_142|,_129|we_127|retrospectively_124|safety_95|._72 (l_pobj) therapy_26\NN\657604|NONE_0 (l_prep) in_27\IN\13603305|consolidation_22 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_prep) with_31\IN\0|24_21|japanese_18 (l_pobj) mm_34\NNP\13649268|NONE_0
D003907_D009101 NONE dexamethasone_7\NN\2721538|,_6|and_4 (r_conj) thalidomide_4\NN\4166841|of_15|as_37|._160 (r_conj) combination_0\NN\7951464|NONE_0 (l_prep) as_11\IN\14622893|of_52|thalidomide_37|._123 (l_pobj) therapy_14\NN\657604|NONE_0 (l_prep) after_15\IN\0|a_24|consolidation_22 (l_pobj) transplantation_19\NN\671351|NONE_0 (l_prep) for_20\IN\0|autologous_37|cell_21 (l_pobj) myeloma_23\NN\14239425|NONE_0
D003907_D009101 NONE dexamethasone_20\NN\2721538|,_6|and_4 (r_conj) thalidomide_17\NN\4166841|,_2 (r_conj) bortezomib_15\NNS\0|NONE_0 (r_pobj) of_14\IN\0|combination_20 (r_prep) regimen_13\NNS\5898568|NONE_0 (r_pobj) of_11\IN\0|the_24|and_13|efficacy_9 (r_prep) safety_8\NN\13920835|in_47|,_34|we_32|retrospectively_29|as_95|._167 (r_dobj) analyzed_6\VBD\0|NONE_0 (l_prep) as_24\IN\14622893|in_142|,_129|we_127|retrospectively_124|safety_95|._72 (l_pobj) therapy_26\NN\657604|NONE_0 (l_prep) in_27\IN\13603305|consolidation_22 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_prep) with_31\IN\0|24_21|japanese_18 (l_pobj) mm_34\NNP\13649268|NONE_0
2904523
D004837_D006973 CID adrenaline_2\NN\14807929|-_10 (r_compound) hypertension_4\NN\14057371|NONE_0
D004837_D006973 CID adrenaline_14\NN\14807929|hours_6 (r_compound) infusion_15\NN\14589223|NONE_0 (r_pobj) after_11\IN\0|hour_20|pressor_15 (r_prep) effect_10\NN\34213|for_56|:_18|._40 (r_appos) support_0\NN\407535|NONE_0 (l_prep) for_1\IN\0|:_38|effect_56|._96 (l_pobj) hypothesis_5\NN\7162194|NONE_0 (l_compound) hypertension_4\NN\14057371|NONE_0
D004837_D006973 CID adrenaline_7\NN\14807929|-_10 (r_compound) hypertension_9\NN\14057371|the_15|in_24
24114426
D018817_D020920 CID ecstasy_26\NN\13985818|NONE_0 (r_compound) users_27\NNS\7846|NONE_0 (r_pobj) of_25\IN\0|the_23|current_19 (r_prep) generation_24\NN\7942152|NONE_0 (r_pobj) for_21\IN\0|the_14 (r_prep) prognosis_20\NN\6748969|given_128|,_6|cause_65|._82 (r_nsubj) is_28\VBZ\0|NONE_0 (l_prep) given_0\VBN\5892096|,_122|prognosis_128|cause_193|._210 (l_pobj) record_2\NN\6643408|NONE_0 (l_prep) of_3\IN\0|this_12 (l_pobj) memory_5\NN\5926676|NONE_0 (l_conj) levels_9\NNS\4916342|impaired_43|and_27 (l_prep) of_10\IN\0|significant_19 (l_pobj) depression_11\NN\14373582|NONE_0 (l_conj) impulsiveness_13\NN\4661706|,_2 (l_conj) disturbance_17\NN\407535|,_12|and_10
D018817_D003866 CID 3,4-methylenedioxymethamphetamine_15\NNP\0|ecstasy_41 (r_pobj) of_14\IN\0|polydrug_15|)_51 (r_prep) users_13\NNS\7846|,_64|impulsiveness_62|in_29|and_21|._58 (r_conj) depression_0\NN\14373582|NONE_0
D018817_D003866 CID mdma_17\NNP\3054098|NONE_0 (r_nmod) ecstasy_19\NN\13985818|3,4-methylenedioxymethamphetamine_41 (r_pobj) of_14\IN\0|polydrug_15|)_51 (r_prep) users_13\NNS\7846|,_64|impulsiveness_62|in_29|and_21|._58 (r_conj) depression_0\NN\14373582|NONE_0
D018817_D003866 CID ecstasy_19\NN\13985818|3,4-methylenedioxymethamphetamine_41 (r_pobj) of_14\IN\0|polydrug_15|)_51 (r_prep) users_13\NNS\7846|,_64|impulsiveness_62|in_29|and_21|._58 (r_conj) depression_0\NN\14373582|NONE_0
D018817_D003866 CID ecstasy_26\NN\13985818|NONE_0 (r_compound) users_27\NNS\7846|NONE_0 (r_pobj) of_25\IN\0|the_23|current_19 (r_prep) generation_24\NN\7942152|NONE_0 (r_pobj) for_21\IN\0|the_14 (r_prep) prognosis_20\NN\6748969|given_128|,_6|cause_65|._82 (r_nsubj) is_28\VBZ\0|NONE_0 (l_prep) given_0\VBN\5892096|,_122|prognosis_128|cause_193|._210 (l_pobj) record_2\NN\6643408|NONE_0 (l_prep) of_3\IN\0|this_12 (l_pobj) memory_5\NN\5926676|NONE_0 (l_conj) levels_9\NNS\4916342|impaired_43|and_27 (l_prep) of_10\IN\0|significant_19 (l_pobj) depression_11\NN\14373582|NONE_0
D018817_D010554 CID 3,4-methylenedioxymethamphetamine_15\NNP\0|ecstasy_41 (r_pobj) of_14\IN\0|polydrug_15|)_51 (r_prep) users_13\NNS\7846|,_64|impulsiveness_62|in_29|and_21|._58 (r_conj) depression_0\NN\14373582|NONE_0 (l_conj) impulsiveness_2\NN\4661706|,_2|in_33|and_41|users_62|._120
D018817_D010554 CID mdma_17\NNP\3054098|NONE_0 (r_nmod) ecstasy_19\NN\13985818|3,4-methylenedioxymethamphetamine_41 (r_pobj) of_14\IN\0|polydrug_15|)_51 (r_prep) users_13\NNS\7846|,_64|impulsiveness_62|in_29|and_21|._58 (r_conj) depression_0\NN\14373582|NONE_0 (l_conj) impulsiveness_2\NN\4661706|,_2|in_33|and_41|users_62|._120
D018817_D010554 CID ecstasy_19\NN\13985818|3,4-methylenedioxymethamphetamine_41 (r_pobj) of_14\IN\0|polydrug_15|)_51 (r_prep) users_13\NNS\7846|,_64|impulsiveness_62|in_29|and_21|._58 (r_conj) depression_0\NN\14373582|NONE_0 (l_conj) impulsiveness_2\NN\4661706|,_2|in_33|and_41|users_62|._120
D018817_D010554 CID ecstasy_26\NN\13985818|NONE_0 (r_compound) users_27\NNS\7846|NONE_0 (r_pobj) of_25\IN\0|the_23|current_19 (r_prep) generation_24\NN\7942152|NONE_0 (r_pobj) for_21\IN\0|the_14 (r_prep) prognosis_20\NN\6748969|given_128|,_6|cause_65|._82 (r_nsubj) is_28\VBZ\0|NONE_0 (l_prep) given_0\VBN\5892096|,_122|prognosis_128|cause_193|._210 (l_pobj) record_2\NN\6643408|NONE_0 (l_prep) of_3\IN\0|this_12 (l_pobj) memory_5\NN\5926676|NONE_0 (l_conj) levels_9\NNS\4916342|impaired_43|and_27 (l_prep) of_10\IN\0|significant_19 (l_pobj) depression_11\NN\14373582|NONE_0 (l_conj) impulsiveness_13\NN\4661706|,_2
D018817_D008569 NONE ecstasy_26\NN\13985818|NONE_0 (r_compound) users_27\NNS\7846|NONE_0 (r_pobj) of_25\IN\0|the_23|current_19 (r_prep) generation_24\NN\7942152|NONE_0 (r_pobj) for_21\IN\0|the_14 (r_prep) prognosis_20\NN\6748969|given_128|,_6|cause_65|._82 (r_nsubj) is_28\VBZ\0|NONE_0 (l_prep) given_0\VBN\5892096|,_122|prognosis_128|cause_193|._210 (l_pobj) record_2\NN\6643408|NONE_0 (l_prep) of_3\IN\0|this_12 (l_pobj) memory_5\NN\5926676|NONE_0
978847
D006145_D006973 NONE guanethidine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_33|intravenous_29|(_17|i.v._16|)_12|(_16|mg_19|)_21|,_22|hexamethonium_24 (r_prep) injection_11\NN\320852|NONE_0 (r_pobj) by_5\IN\0|response_35|was_26|significantly_22|,_104|and_106|potentiated_122|._312 (r_agent) reduced_4\VBN\441445|NONE_0 (l_conj) potentiated_34\VBN\229605|response_157|was_148|significantly_144|by_122|,_18|and_16|._190 (l_advcl) propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_prep) of_54\IN\0|the_16|and_18|tachycardia_26 (l_pobj) pressure_56\NN\11419404|NONE_0
D018738_D006973 NONE hexamethonium_19\NN\0|the_57|intravenous_53|(_41|i.v._40|)_36|of_24|(_8|mg_5|)_3|,_2 (r_conj) injection_11\NN\320852|NONE_0 (r_pobj) by_5\IN\0|response_35|was_26|significantly_22|,_104|and_106|potentiated_122|._312 (r_agent) reduced_4\VBN\441445|NONE_0 (l_conj) potentiated_34\VBN\229605|response_157|was_148|significantly_144|by_122|,_18|and_16|._190 (l_advcl) propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_prep) of_54\IN\0|the_16|and_18|tachycardia_26 (l_pobj) pressure_56\NN\11419404|NONE_0
D002217_D006973 CID carbachol_62\NN\0|NONE_0 (r_dobj) following_60\VBG\8180190|the_16 (r_acl) tachycardia_59\NNS\14110674|the_42|of_26|and_8 (r_conj) enlargement_53\NN\363260|selectively_26 (l_prep) of_54\IN\0|the_16|and_18|tachycardia_26 (l_pobj) pressure_56\NN\11419404|NONE_0
D011433_D013610 NONE propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_conj) tachycardia_59\NNS\14110674|the_42|of_26|and_8
D003891_D006973 CID desmethylimipramine_37\NN\0|NONE_0 (r_pobj) by_35\IN\0|conversely_24|,_14|,_36|propranolol_44 (r_agent) potentiated_34\VBN\229605|response_157|was_148|significantly_144|by_122|,_18|and_16|._190 (l_advcl) propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_prep) of_54\IN\0|the_16|and_18|tachycardia_26 (l_pobj) pressure_56\NN\11419404|NONE_0
D010646_D006973 NONE phentolamine_25\NN\4537602|(_11|mg_7|)_5|or_3 (r_conj) hexamethonium_19\NN\0|the_57|intravenous_53|(_41|i.v._40|)_36|of_24|(_8|mg_5|)_3|,_2 (r_conj) injection_11\NN\320852|NONE_0 (r_pobj) by_5\IN\0|response_35|was_26|significantly_22|,_104|and_106|potentiated_122|._312 (r_agent) reduced_4\VBN\441445|NONE_0 (l_conj) potentiated_34\VBN\229605|response_157|was_148|significantly_144|by_122|,_18|and_16|._190 (l_advcl) propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_prep) of_54\IN\0|the_16|and_18|tachycardia_26 (l_pobj) pressure_56\NN\11419404|NONE_0
D011433_D006973 NONE propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_prep) of_54\IN\0|the_16|and_18|tachycardia_26 (l_pobj) pressure_56\NN\11419404|NONE_0
D018738_D013610 NONE hexamethonium_19\NN\0|the_57|intravenous_53|(_41|i.v._40|)_36|of_24|(_8|mg_5|)_3|,_2 (r_conj) injection_11\NN\320852|NONE_0 (r_pobj) by_5\IN\0|response_35|was_26|significantly_22|,_104|and_106|potentiated_122|._312 (r_agent) reduced_4\VBN\441445|NONE_0 (l_conj) potentiated_34\VBN\229605|response_157|was_148|significantly_144|by_122|,_18|and_16|._190 (l_advcl) propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_conj) tachycardia_59\NNS\14110674|the_42|of_26|and_8
D003891_D013610 NONE desmethylimipramine_37\NN\0|NONE_0 (r_pobj) by_35\IN\0|conversely_24|,_14|,_36|propranolol_44 (r_agent) potentiated_34\VBN\229605|response_157|was_148|significantly_144|by_122|,_18|and_16|._190 (l_advcl) propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_conj) tachycardia_59\NNS\14110674|the_42|of_26|and_8
D006145_D013610 NONE guanethidine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_33|intravenous_29|(_17|i.v._16|)_12|(_16|mg_19|)_21|,_22|hexamethonium_24 (r_prep) injection_11\NN\320852|NONE_0 (r_pobj) by_5\IN\0|response_35|was_26|significantly_22|,_104|and_106|potentiated_122|._312 (r_agent) reduced_4\VBN\441445|NONE_0 (l_conj) potentiated_34\VBN\229605|response_157|was_148|significantly_144|by_122|,_18|and_16|._190 (l_advcl) propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_conj) tachycardia_59\NNS\14110674|the_42|of_26|and_8
D010646_D013610 NONE phentolamine_25\NN\4537602|(_11|mg_7|)_5|or_3 (r_conj) hexamethonium_19\NN\0|the_57|intravenous_53|(_41|i.v._40|)_36|of_24|(_8|mg_5|)_3|,_2 (r_conj) injection_11\NN\320852|NONE_0 (r_pobj) by_5\IN\0|response_35|was_26|significantly_22|,_104|and_106|potentiated_122|._312 (r_agent) reduced_4\VBN\441445|NONE_0 (l_conj) potentiated_34\VBN\229605|response_157|was_148|significantly_144|by_122|,_18|and_16|._190 (l_advcl) propranolol_44\NN\0|conversely_68|,_58|by_44|,_8 (l_conj) inhibited_51\VBD\2510337|while_44|mg_21|i.v._17 (l_dobj) enlargement_53\NN\363260|selectively_26 (l_conj) tachycardia_59\NNS\14110674|the_42|of_26|and_8
D002217_D013610 CID carbachol_62\NN\0|NONE_0 (r_dobj) following_60\VBG\8180190|the_16 (r_acl) tachycardia_59\NNS\14110674|the_42|of_26|and_8
8392553
D004837_D007511 NONE epinephrine_3\NN\14807929|2-week_15|chronic_8 (r_compound) infusion_4\NN\14589223|NONE_0 (r_pobj) with_0\IN\0|,_40|rats_51|within_61|,_74|and_76|observed_145 (r_prep) died_10\VBD\146138|NONE_0 (l_conj) observed_26\VBN\2163746|with_145|,_105|rats_94|within_84|,_71|and_69 (l_nsubjpass) lesions_18\NNS\14204950|were_44|._57
D004837_D007511 NONE epinephrine_4\RB\14807929|-_11 (r_npadvmod) induced_6\VBN\1627355|(_14|p_15|)_22 (r_amod) death_7\NN\7296428|treatment_56|,_15|and_17|attenuated_21|._105 (r_dobj) prevented_3\VBD\0|NONE_0 (l_conj) attenuated_15\VBD\224901|treatment_77|death_21|,_6|and_4|._84 (l_dobj) lesions_19\NNS\14204950|,_20|in_22
C056595_D006331 NONE clentiazem_3\NN\0|NONE_0 (l_prep) against_4\IN\0|NONE_0 (l_pobj) injury_9\NN\14052046|NONE_0
C056595_D006331 NONE clentiazem_3\NN\0|in_15|,_2|injury_50|,_56|through_67|._111 (r_npadvmod) attenuated_4\VBD\224901|NONE_0 (l_dobj) injury_9\NN\14052046|in_65|,_52|clentiazem_50|,_6|through_17|._61
D004837_D009202 CID epinephrine_13\NN\14807929|-_11 (r_npadvmod) induced_15\VBN\1627355|in_23 (r_amod) cardiomyopathy_16\NN\14103288|NONE_0
C106746_D009202 NONE 1,5-benzothiazepine_8\CD\0|a_2|calcium_20 (r_amod) antagonist_10\NN\7846|the_57|of_45|,_32|,_10|on_12 (r_appos) effects_3\NNS\13245626|we_20|._110 (l_prep) on_12\IN\0|the_69|of_57|,_44|antagonist_12|,_2 (l_pobj) cardiomyopathy_16\NN\14103288|NONE_0
C056595_D007511 NONE clentiazem_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|death_56|,_71|and_73|attenuated_77|._161 (r_nsubj) prevented_3\VBD\0|NONE_0 (l_conj) attenuated_15\VBD\224901|treatment_77|death_21|,_6|and_4|._84 (l_dobj) lesions_19\NNS\14204950|,_20|in_22
C056595_D005355 NONE clentiazem_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|death_56|,_71|and_73|attenuated_77|._161 (r_nsubj) prevented_3\VBD\0|NONE_0 (l_conj) attenuated_15\VBD\224901|treatment_77|death_21|,_6|and_4|._84 (l_dobj) lesions_19\NNS\14204950|,_20|in_22 (l_conj) fibrosis_21\NN\14204950|the_37|ventricular_33|ischemic_21|and_4
C056595_D009202 NONE clentiazem_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_12|,_13|antagonist_45|,_55|on_57 (r_prep) effects_3\NNS\13245626|we_20|._110 (l_prep) on_12\IN\0|the_69|of_57|,_44|antagonist_12|,_2 (l_pobj) cardiomyopathy_16\NN\14103288|NONE_0
D004837_D005355 NONE epinephrine_3\NN\14807929|2-week_15|chronic_8 (r_compound) infusion_4\NN\14589223|NONE_0 (r_pobj) with_0\IN\0|,_40|rats_51|within_61|,_74|and_76|observed_145 (r_prep) died_10\VBD\146138|NONE_0 (l_conj) observed_26\VBN\2163746|with_145|,_105|rats_94|within_84|,_71|and_69 (l_nsubjpass) lesions_18\NNS\14204950|were_44|._57 (l_conj) fibrosis_20\NN\14204950|severe_28|ischemic_21|and_4|of_9
D004837_D005355 NONE epinephrine_4\RB\14807929|-_11 (r_npadvmod) induced_6\VBN\1627355|(_14|p_15|)_22 (r_amod) death_7\NN\7296428|treatment_56|,_15|and_17|attenuated_21|._105 (r_dobj) prevented_3\VBD\0|NONE_0 (l_conj) attenuated_15\VBD\224901|treatment_77|death_21|,_6|and_4|._84 (l_dobj) lesions_19\NNS\14204950|,_20|in_22 (l_conj) fibrosis_21\NN\14204950|the_37|ventricular_33|ischemic_21|and_4
D004837_D006331 NONE epinephrine_5\NN\14807929|-_11 (r_npadvmod) induced_7\VBN\1627355|cardiac_8|in_23 (r_amod) injury_9\NN\14052046|NONE_0
D004837_D006331 NONE epinephrine_5\NN\14807929|-_11 (r_npadvmod) induced_7\VBN\1627355|cardiac_8 (r_amod) injury_9\NN\14052046|in_65|,_52|clentiazem_50|,_6|through_17|._61
D002118_D009202 NONE calcium_9\NN\14625458|a_22|1,5-benzothiazepine_20 (r_compound) antagonist_10\NN\7846|the_57|of_45|,_32|,_10|on_12 (r_appos) effects_3\NNS\13245626|we_20|._110 (l_prep) on_12\IN\0|the_69|of_57|,_44|antagonist_12|,_2 (l_pobj) cardiomyopathy_16\NN\14103288|NONE_0
7369302
D011803_D015845 CID sulfate_30\NN\15010703|NONE_0 (r_pobj) of_28\IN\0|the_8 (r_prep) use_27\NN\407535|NONE_0 (r_pobj) after_25\IN\0|in_21 (r_prep) developed_18\VBN\1753788|abnormal_34|evoked_18 (r_acl) potentials_17\NNS\14481929|denervation_57|,_29|and_27 (r_conj) supersensitivity_10\NN\0|a_50|transient_48|tonic_38|pupillary_32|,_14 (r_conj) response_7\NN\11410625|NONE_0 (l_amod) pupillary_6\JJ\0|a_18|transient_16|tonic_6|,_18|supersensitivity_32
D011803_D015845 CID quinine_16\NN\2721948|NONE_0 (r_compound) toxicity_17\NN\13576101|NONE_0 (r_pobj) in_15\IN\13603305|abnormal_34|evoked_18 (r_prep) potentials_14\NNS\14481929|denervation_57|,_29|and_27 (r_conj) supersensitivity_7\NN\0|a_50|transient_48|tonic_38|pupillary_32|,_14|,_75|to_77 (r_conj) response_4\NN\11410625|,_115|have_117|not_122|been_126|previously_131|._150 (l_amod) pupillary_3\JJ\0|a_18|transient_16|tonic_6|,_18|supersensitivity_32|,_107|to_109
D011803_D001766 CID sulfate_30\NN\15010703|NONE_0 (r_pobj) of_28\IN\0|the_8 (r_prep) use_27\NN\407535|NONE_0 (r_pobj) after_25\IN\0|in_21 (r_prep) developed_18\VBN\1753788|abnormal_34|evoked_18 (r_acl) potentials_17\NNS\14481929|denervation_57|,_29|and_27 (r_conj) supersensitivity_10\NN\0|a_50|transient_48|tonic_38|pupillary_32|,_14 (r_conj) response_7\NN\11410625|NONE_0 (r_pobj) with_2\IN\0|total_16|._189 (r_prep) blindness_1\NN\14552802|NONE_0
D011803_D000550 CID quinine_10\NN\2721948|NONE_0 (r_compound) amblyopia_11\NN\14552802|NONE_0
D011803_D064420 NONE quinine_16\NN\2721948|NONE_0 (r_compound) toxicity_17\NN\13576101|NONE_0
D011803_D009120 NONE sulfate_30\NN\15010703|NONE_0 (l_prep) for_31\IN\0|quinine_16 (l_pobj) cramps_33\NNS\14299637|NONE_0
3812624
D002220_D015835 CID carbamazepine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) associated_7\VBN\628491|two_48|of_38|._29 (r_acl) cases_1\NNS\7283608|NONE_0 (l_prep) of_2\IN\0|two_10|associated_38|._67 (l_pobj) nystagmus_4\NN\337486|NONE_0 (l_conj) oscillopsia_6\NN\0|downbeat_23|and_4
D002220_D009759 NONE carbamazepine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) associated_7\VBN\628491|two_48|of_38|._29 (r_acl) cases_1\NNS\7283608|NONE_0 (l_prep) of_2\IN\0|two_10|associated_38|._67 (l_pobj) nystagmus_4\NN\337486|NONE_0
D002220_D009759 NONE carbamazepine_14\NN\0|NONE_0 (r_compound) therapy_15\NN\657604|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|reversible_30|downbeat_19 (r_amod) nystagmus_11\NN\337486|NONE_0
D002220_D009759 NONE carbamazepine_11\NN\0|the_10 (r_compound) levels_12\NNS\4916342|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) reduction_7\NN\351485|NONE_0 (r_pobj) after_6\IN\0|nystagmus_36|._49 (r_prep) resolved_5\VBN\352826|NONE_0 (l_nsubj) nystagmus_1\NN\337486|after_36|._85
3798047
D008775_D006331 NONE mp_3\NNP\10249459|may_3|be_7|in_26|._62 (r_nsubjpass) contraindicated_6\VBN\872886|NONE_0 (l_prep) in_7\IN\13603305|mp_26|may_23|be_19|._36 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) disease_12\NN\14061805|NONE_0
D008775_D001172 NONE methylprednisolone_13\NN\0|who_35|daily_37|for_43|)_70 (r_dobj) received_8\VBD\2210855|5_53|consecutive_51|with_30 (r_relcl) patients_3\NNS\9898892|NONE_0 (l_prep) with_4\IN\0|5_23|consecutive_21|received_30 (l_pobj) arthritis_6\NN\14171682|NONE_0
D008775_D001172 NONE mp_15\NNP\10249459|(_1|)_2|(_12 (r_nmod) therapy_17\NN\657604|intravenous_46|dose_29 (r_appos) methylprednisolone_13\NN\0|who_35|daily_37|for_43|)_70 (r_dobj) received_8\VBD\2210855|5_53|consecutive_51|with_30 (r_relcl) patients_3\NNS\9898892|NONE_0 (l_prep) with_4\IN\0|5_23|consecutive_21|received_30 (l_pobj) arthritis_6\NN\14171682|NONE_0
D008775_D001919 CID methylprednisolone_6\NN\0|dose_17|intravenous_12 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) after_1\IN\0|._54 (r_prep) bradycardia_0\NNS\14110674|NONE_0
17721298
D016578_D003320 CID cocaine_6\NN\3492717|crack_6 (r_compound) use_7\NN\407535|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|corneal_15|._45 (r_acl) ulcers_1\NNS\14211294|NONE_0
D016578_D003320 CID cocaine_8\NN\3492717|crack_6 (r_compound) use_9\NN\407535|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|corneal_15 (r_acl) ulcers_4\NNS\14211294|NONE_0
D016578_D003320 CID cocaine_2\NN\3492717|crack_6 (r_compound) use_3\NN\407535|can_4|be_8|with_22|._60 (r_nsubjpass) associated_6\VBN\628491|NONE_0 (l_prep) with_7\IN\0|use_22|can_18|be_14|._38 (l_pobj) development_9\NN\248977|NONE_0 (l_prep) of_10\IN\0|the_16 (l_pobj) ulcers_12\NNS\14211294|NONE_0
1655018
D000728_D006528 CID androgen_8\JJ\14745635|NONE_0 (r_pobj) with_7\IN\0|carcinoma_38|._32 (r_prep) treated_6\VBN\2376958|NONE_0 (l_nsubj) carcinoma_1\NN\14239918|with_38|._70
D000305_D006528 CID corticosteroid_10\NN\14745635|and_4 (r_conj) androgen_8\JJ\14745635|NONE_0 (r_pobj) with_7\IN\0|carcinoma_38|._32 (r_prep) treated_6\VBN\2376958|NONE_0 (l_nsubj) carcinoma_1\NN\14239918|with_38|._70
D000305_D010382 CID corticosteroid_22\NN\14745635|-_14 (r_npadvmod) treated_24\VBN\2376958|and_19 (r_conj) androgen-_20\NN\0|fanconi_37 (r_amod) anemia_27\NN\14189204|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) patients_18\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|that_66|neoplasms_35|can_12 (r_prep) develop_16\VB\1753788|the_84|previous_80 (l_nsubj) neoplasms_12\NNS\14234074|that_31|can_23|in_35 (l_conj) peliosis_14\NN\14189204|metastasizing_36|hepatic_22|and_4
D000728_D010382 CID androgen-_20\NN\0|fanconi_37 (r_amod) anemia_27\NN\14189204|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) patients_18\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|that_66|neoplasms_35|can_12 (r_prep) develop_16\VB\1753788|the_84|previous_80 (l_nsubj) neoplasms_12\NNS\14234074|that_31|can_23|in_35 (l_conj) peliosis_14\NN\14189204|metastasizing_36|hepatic_22|and_4
D000305_D005199 NONE corticosteroid_10\NN\14745635|and_4 (r_conj) androgen_8\JJ\14745635|NONE_0 (r_pobj) with_7\IN\0|carcinoma_38|._32 (r_prep) treated_6\VBN\2376958|NONE_0 (l_nsubj) carcinoma_1\NN\14239918|with_38|._70 (l_prep) in_2\IN\13603305|hepatocellular_25 (l_pobj) anemia_5\NN\14189204|NONE_0
D000305_D005199 NONE corticosteroids_27\NNS\14745635|,_2 (r_conj) androgens_25\NNS\14745635|NONE_0 (r_pobj) with_24\IN\0|was_12 (r_prep) treated_23\VBN\2376958|who_59|was_55|have_42|and_8 (r_conj) known_12\VBN\0|case_47|is_20|._107 (l_xcomp) have_14\VB\7846|who_17|was_13|and_34|treated_42 (l_dobj) anemia_17\NN\14189204|to_18
D000305_D005199 NONE corticosteroid_22\NN\14745635|-_14 (r_npadvmod) treated_24\VBN\2376958|and_19 (r_conj) androgen-_20\NN\0|fanconi_37 (r_amod) anemia_27\NN\14189204|NONE_0
D000728_D008113 NONE androgen-_20\NN\0|fanconi_37 (r_amod) anemia_27\NN\14189204|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) patients_18\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|that_66|neoplasms_35|can_12 (r_prep) develop_16\VB\1753788|the_84|previous_80 (l_nsubj) neoplasms_12\NNS\14234074|that_31|can_23|in_35
D000305_D008113 NONE corticosteroid_22\NN\14745635|-_14 (r_npadvmod) treated_24\VBN\2376958|and_19 (r_conj) androgen-_20\NN\0|fanconi_37 (r_amod) anemia_27\NN\14189204|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) patients_18\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|that_66|neoplasms_35|can_12 (r_prep) develop_16\VB\1753788|the_84|previous_80 (l_nsubj) neoplasms_12\NNS\14234074|that_31|can_23|in_35
D000728_D005199 NONE androgen_8\JJ\14745635|NONE_0 (r_pobj) with_7\IN\0|carcinoma_38|._32 (r_prep) treated_6\VBN\2376958|NONE_0 (l_nsubj) carcinoma_1\NN\14239918|with_38|._70 (l_prep) in_2\IN\13603305|hepatocellular_25 (l_pobj) anemia_5\NN\14189204|NONE_0
D000728_D005199 NONE androgens_25\NNS\14745635|NONE_0 (r_pobj) with_24\IN\0|was_12 (r_prep) treated_23\VBN\2376958|who_59|was_55|have_42|and_8 (r_conj) known_12\VBN\0|case_47|is_20|._107 (l_xcomp) have_14\VB\7846|who_17|was_13|and_34|treated_42 (l_dobj) anemia_17\NN\14189204|to_18
D000728_D005199 NONE androgen-_20\NN\0|fanconi_37 (r_amod) anemia_27\NN\14189204|NONE_0
10975596
D007545_D013610 CID isoproterenol_20\NN\3740161|-_13 (r_npadvmod) induced_22\VBN\1627355|the_18 (r_amod) tachycardia_23\NN\14110674|at_57|,_38|._11 (r_dobj) decreased_18\VBD\169651|dronedarone_108|significantly_81|tachycardia_38|and_26|,_23 (r_conj) reduced_5\VBD\441445|NONE_0 (l_dobj) tachycardia_10\NN\14110674|dronedarone_70|significantly_43|and_12|,_15|decreased_38
D007545_D013610 CID isoproterenol_20\NN\3740161|-_13 (r_npadvmod) induced_22\VBN\1627355|the_18 (r_amod) tachycardia_23\NN\14110674|at_57|,_38|._11
D000638_D009203 NONE amiodarone_7\NN\2715941|and_4 (l_prep) with_10\IN\0|in_11 (l_pobj) infarction_14\NN\14204950|NONE_0
D000638_D009203 NONE amiodarone_14\NN\2715941|NONE_0 (r_pobj) to_13\IN\0|compound_30|structurally_21 (r_prep) related_12\VBN\628491|the_96|hemodynamic_92|of_53|,_39|,_21 (r_amod) effects_4\NNS\13245626|were_84|with_98|._261 (r_nsubjpass) compared_17\VBN\644583|NONE_0 (l_prep) with_18\IN\0|effects_98|were_14|._163 (l_pobj) those_19\DT\0|NONE_0 (l_prep) at_28\IN\14622893|of_56|after_42|,_7 (l_conj) during_31\IN\0|both_17|rest_9|and_4 (l_pobj) stimulation_33\NN\242808|NONE_0 (l_prep) in_34\IN\13603305|sympathetic_24 (l_pobj) dogs_36\NNS\2083346|NONE_0 (l_prep) with_37\IN\0|conscious_15 (l_pobj) infarction_41\NN\14204950|NONE_0
D000638_D009203 NONE amiodarone_21\NN\2715941|NONE_0 (r_pobj) of_20\IN\0|after_14|,_49|at_56 (r_prep) those_19\DT\0|NONE_0 (l_prep) at_28\IN\14622893|of_56|after_42|,_7 (l_conj) during_31\IN\0|both_17|rest_9|and_4 (l_pobj) stimulation_33\NN\242808|NONE_0 (l_prep) in_34\IN\13603305|sympathetic_24 (l_pobj) dogs_36\NNS\2083346|NONE_0 (l_prep) with_37\IN\0|conscious_15 (l_pobj) infarction_41\NN\14204950|NONE_0
D000638_D013610 NONE amiodarone_3\NN\2715941|both_21|and_4 (r_conj) dronedarone_1\NN\0|significantly_27|tachycardia_70|and_82|,_85|decreased_108 (r_nsubj) reduced_5\VBD\441445|NONE_0 (l_dobj) tachycardia_10\NN\14110674|dronedarone_70|significantly_43|and_12|,_15|decreased_38
D000638_D013610 NONE amiodarone_3\NN\2715941|both_21|and_4 (r_conj) dronedarone_1\NN\0|significantly_27|tachycardia_70|and_82|,_85|decreased_108 (r_nsubj) reduced_5\VBD\441445|NONE_0 (l_conj) decreased_18\VBD\169651|dronedarone_108|significantly_81|tachycardia_38|and_26|,_23 (l_dobj) tachycardia_23\NN\14110674|at_57|,_38|._11
C118667_D001145 NONE dronedarone_2\NN\0|consequently_14|,_2|might_12|suitable_34|,_107|without_109|._159 (r_nsubj) be_4\VB\14625458|NONE_0 (l_acomp) suitable_6\JJ\0|consequently_48|,_36|dronedarone_34|might_22|,_73|without_75|._125 (l_prep) for_7\IN\0|particularly_22 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_29|and_15|prevention_11 (l_pobj) arrhythmias_15\NNS\14103288|NONE_0
C118667_D009203 NONE dronedarone_5\NN\0|NONE_0 (l_conj) amiodarone_7\NN\2715941|and_4 (l_prep) with_10\IN\0|in_11 (l_pobj) infarction_14\NN\14204950|NONE_0
C118667_D009203 NONE dronedarone_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_43|hemodynamic_39|,_14|related_53|,_74 (r_prep) effects_4\NNS\13245626|were_84|with_98|._261 (r_nsubjpass) compared_17\VBN\644583|NONE_0 (l_prep) with_18\IN\0|effects_98|were_14|._163 (l_pobj) those_19\DT\0|NONE_0 (l_prep) at_28\IN\14622893|of_56|after_42|,_7 (l_conj) during_31\IN\0|both_17|rest_9|and_4 (l_pobj) stimulation_33\NN\242808|NONE_0 (l_prep) in_34\IN\13603305|sympathetic_24 (l_pobj) dogs_36\NNS\2083346|NONE_0 (l_prep) with_37\IN\0|conscious_15 (l_pobj) infarction_41\NN\14204950|NONE_0
C118667_D013610 NONE dronedarone_1\NN\0|significantly_27|tachycardia_70|and_82|,_85|decreased_108 (r_nsubj) reduced_5\VBD\441445|NONE_0 (l_dobj) tachycardia_10\NN\14110674|dronedarone_70|significantly_43|and_12|,_15|decreased_38
C118667_D013610 NONE dronedarone_1\NN\0|significantly_27|tachycardia_70|and_82|,_85|decreased_108 (r_nsubj) reduced_5\VBD\441445|NONE_0 (l_conj) decreased_18\VBD\169651|dronedarone_108|significantly_81|tachycardia_38|and_26|,_23 (l_dobj) tachycardia_23\NN\14110674|at_57|,_38|._11
24618873
C002752_D012640 CID norpethidine_35\NN\0|its_27|neurotoxic_23|,_2|,_12 (r_appos) metabolite_33\NN\20090|NONE_0 (r_pobj) through_30\IN\0|system_21|(_14|cns_13|)_10|resulting_49 (r_prep) effects_29\NNS\13245626|in_155|,_62|pethidine_60|may_50|._101 (l_acl) resulting_37\VBG\2633881|system_70|(_63|cns_62|)_59|through_49 (l_prep) in_38\IN\13603305|NONE_0 (l_pobj) irritability_39\NN\7552087|NONE_0 (l_conj) attack_42\NN\955060|and_12 (l_compound) seizure_41\NN\14081375|NONE_0
D008614_D012640 NONE pethidine_19\NN\0|in_95|,_2|may_10|effects_60|._161 (r_nsubj) cause_21\VB\7323922|NONE_0 (l_dobj) effects_29\NNS\13245626|in_155|,_62|pethidine_60|may_50|._101 (l_acl) resulting_37\VBG\2633881|system_70|(_63|cns_62|)_59|through_49 (l_prep) in_38\IN\13603305|NONE_0 (l_pobj) irritability_39\NN\7552087|NONE_0 (l_conj) attack_42\NN\955060|and_12 (l_compound) seizure_41\NN\14081375|NONE_0
D008614_D010146 NONE pethidine_0\NNP\0|opioid_16|._118 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) opioid_3\NN\0|pethidine_16|._102 (l_relcl) gains_5\VBZ\13576355|an_15 (l_prep) for_8\IN\0|that_26|popularity_11|through_31 (l_pobj) control_12\NN\5190804|NONE_0 (l_compound) pain_11\NN\14299637|the_14|effective_10
D008614_D010146 NONE pethidine_19\NN\0|in_95|,_2|may_10|effects_60|._161 (r_nsubj) cause_21\VB\7323922|NONE_0 (l_prep) in_0\IN\13603305|,_93|pethidine_95|may_105|effects_155|._256 (l_conj) those_10\DT\0|patients_53|,_6|and_4 (l_relcl) need_12\VBP\13920835|NONE_0 (l_dobj) control_17\NN\5190804|who_24 (l_compound) pain_16\NN\14299637|term_5
C002752_D001523 NONE norpethidine_35\NN\0|its_27|neurotoxic_23|,_2|,_12 (r_appos) metabolite_33\NN\20090|NONE_0 (r_pobj) through_30\IN\0|system_21|(_14|cns_13|)_10|resulting_49 (r_prep) effects_29\NNS\13245626|in_155|,_62|pethidine_60|may_50|._101 (l_acl) resulting_37\VBG\2633881|system_70|(_63|cns_62|)_59|through_49 (l_prep) in_38\IN\13603305|NONE_0 (l_pobj) irritability_39\NN\7552087|NONE_0
D008614_D002526 NONE pethidine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|rapid_15 (r_prep) infusion_7\NN\14589223|NONE_0 (r_pobj) by_5\IN\0|dysfunction_20|._30 (r_agent) induced_4\VBN\1627355|NONE_0 (l_nsubj) dysfunction_3\NN\14204950|by_20|._50
D008614_D020258 NONE pethidine_19\NN\0|in_95|,_2|may_10|effects_60|._161 (r_nsubj) cause_21\VB\7323922|NONE_0 (l_dobj) effects_29\NNS\13245626|in_155|,_62|pethidine_60|may_50|._101 (l_prep) through_30\IN\0|system_21|(_14|cns_13|)_10|resulting_49 (l_pobj) metabolite_33\NN\20090|NONE_0 (l_amod) neurotoxic_32\JJ\0|its_4|,_21|norpethidine_23|,_35
C002752_D017093 NONE norpethidine_35\NN\0|its_27|neurotoxic_23|,_2|,_12 (r_appos) metabolite_33\NN\20090|NONE_0 (r_pobj) through_30\IN\0|system_21|(_14|cns_13|)_10|resulting_49 (r_prep) effects_29\NNS\13245626|in_155|,_62|pethidine_60|may_50|._101 (r_dobj) cause_21\VB\7323922|NONE_0 (l_prep) in_0\IN\13603305|,_93|pethidine_95|may_105|effects_155|._256 (l_pobj) patients_1\NNS\9898892|,_47|and_49|those_53 (l_prep) with_2\IN\0|NONE_0 (l_pobj) function_7\NN\13783581|NONE_0
D008614_D005128 NONE pethidine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|rapid_15 (r_prep) infusion_7\NN\14589223|NONE_0 (r_pobj) by_5\IN\0|dysfunction_20|._30 (r_agent) induced_4\VBN\1627355|NONE_0 (l_nsubj) dysfunction_3\NN\14204950|by_20|._50
D008614_D051437 NONE pethidine_19\NN\0|in_95|,_2|may_10|effects_60|._161 (r_nsubj) cause_21\VB\7323922|NONE_0 (l_prep) in_0\IN\13603305|,_93|pethidine_95|may_105|effects_155|._256 (l_pobj) patients_1\NNS\9898892|,_47|and_49|those_53 (l_prep) with_2\IN\0|NONE_0 (l_pobj) function_7\NN\13783581|NONE_0
D008614_D017093 NONE pethidine_19\NN\0|in_95|,_2|may_10|effects_60|._161 (r_nsubj) cause_21\VB\7323922|NONE_0 (l_prep) in_0\IN\13603305|,_93|pethidine_95|may_105|effects_155|._256 (l_pobj) patients_1\NNS\9898892|,_47|and_49|those_53 (l_prep) with_2\IN\0|NONE_0 (l_pobj) function_7\NN\13783581|NONE_0
C002752_D020258 NONE norpethidine_35\NN\0|its_27|neurotoxic_23|,_2|,_12 (r_appos) metabolite_33\NN\20090|NONE_0 (l_amod) neurotoxic_32\JJ\0|its_4|,_21|norpethidine_23|,_35
C002752_D051437 NONE norpethidine_35\NN\0|its_27|neurotoxic_23|,_2|,_12 (r_appos) metabolite_33\NN\20090|NONE_0 (r_pobj) through_30\IN\0|system_21|(_14|cns_13|)_10|resulting_49 (r_prep) effects_29\NNS\13245626|in_155|,_62|pethidine_60|may_50|._101 (r_dobj) cause_21\VB\7323922|NONE_0 (l_prep) in_0\IN\13603305|,_93|pethidine_95|may_105|effects_155|._256 (l_pobj) patients_1\NNS\9898892|,_47|and_49|those_53 (l_prep) with_2\IN\0|NONE_0 (l_pobj) function_7\NN\13783581|NONE_0
C002752_D010146 NONE norpethidine_35\NN\0|its_27|neurotoxic_23|,_2|,_12 (r_appos) metabolite_33\NN\20090|NONE_0 (r_pobj) through_30\IN\0|system_21|(_14|cns_13|)_10|resulting_49 (r_prep) effects_29\NNS\13245626|in_155|,_62|pethidine_60|may_50|._101 (r_dobj) cause_21\VB\7323922|NONE_0 (l_prep) in_0\IN\13603305|,_93|pethidine_95|may_105|effects_155|._256 (l_conj) those_10\DT\0|patients_53|,_6|and_4 (l_relcl) need_12\VBP\13920835|NONE_0 (l_dobj) control_17\NN\5190804|who_24 (l_compound) pain_16\NN\14299637|term_5
D008614_D001523 NONE pethidine_19\NN\0|in_95|,_2|may_10|effects_60|._161 (r_nsubj) cause_21\VB\7323922|NONE_0 (l_dobj) effects_29\NNS\13245626|in_155|,_62|pethidine_60|may_50|._101 (l_acl) resulting_37\VBG\2633881|system_70|(_63|cns_62|)_59|through_49 (l_prep) in_38\IN\13603305|NONE_0 (l_pobj) irritability_39\NN\7552087|NONE_0
7411769
D007213_D015210 NONE indomethacin_0\NNP\3828465|-_12 (r_npadvmod) induced_2\VBN\1627355|in_21|._59 (r_amod) hyperkalemia_3\NN\14299637|NONE_0 (l_prep) in_4\IN\13603305|induced_21|._38 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|three_15 (l_pobj) arthritis_9\NN\14171682|NONE_0
D007213_D015210 NONE indomethacin_23\NN\3828465|NONE_0 (r_pobj) with_22\IN\0|of_25 (r_prep) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|with_25 (l_pobj) arthritis_21\NN\14171682|NONE_0
D007213_D051437 CID indomethacin_23\NN\3828465|NONE_0 (r_pobj) with_22\IN\0|of_25 (r_prep) treatment_17\NN\654885|NONE_0 (r_pobj) after_16\IN\0|NONE_0 (r_prep) developed_15\VBD\1753788|three_85|hyperkalemia_37 (r_acl) patients_3\NNS\9898892|we_18|._147 (l_appos) hyperkalemia_11\NN\14299637|three_48|developed_37 (l_conj) insufficiency_14\NN\14462946|in_56|severe_48|,_42|threatening_35|and_10
D007213_D006947 CID indomethacin_0\NNP\3828465|-_12 (r_npadvmod) induced_2\VBN\1627355|in_21|._59 (r_amod) hyperkalemia_3\NN\14299637|NONE_0
D007213_D006947 CID indomethacin_23\NN\3828465|NONE_0 (r_pobj) with_22\IN\0|of_25 (r_prep) treatment_17\NN\654885|NONE_0 (r_pobj) after_16\IN\0|NONE_0 (r_prep) developed_15\VBD\1753788|three_85|hyperkalemia_37 (r_acl) patients_3\NNS\9898892|we_18|._147 (l_appos) hyperkalemia_11\NN\14299637|three_48|developed_37
D011188_D007674 NONE potassium_6\NN\14625458|NONE_0 (r_compound) balance_7\NN\13934900|renal_29|and_14|in_8 (r_conj) function_4\NN\13783581|NONE_0 (r_pobj) to_2\IN\0|careful_18 (r_prep) attention_1\NN\5701944|,_131|in_146|,_215|will_217|prevent_227|._272 (r_nsubj) help_33\VB\407535|NONE_0 (l_prep) in_21\IN\13603305|attention_146|,_15|,_69|will_71|prevent_81|._126 (l_pobj) patients_23\NNS\9898892|particularly_22 (l_prep) with_24\IN\0|those_15 (l_pobj) mellitus_26\NN\0|NONE_0 (l_conj) disease_30\NN\14061805|diabetes_39|or_21
D007213_D007674 NONE indomethacin_11\NN\3828465|NONE_0 (r_dobj) receiving_10\VBG\2210855|NONE_0 (r_acl) patients_9\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|renal_37|and_22|balance_8 (r_prep) function_4\NN\13783581|NONE_0 (r_pobj) to_2\IN\0|careful_18 (r_prep) attention_1\NN\5701944|,_131|in_146|,_215|will_217|prevent_227|._272 (r_nsubj) help_33\VB\407535|NONE_0 (l_prep) in_21\IN\13603305|attention_146|,_15|,_69|will_71|prevent_81|._126 (l_pobj) patients_23\NNS\9898892|particularly_22 (l_prep) with_24\IN\0|those_15 (l_pobj) mellitus_26\NN\0|NONE_0 (l_conj) disease_30\NN\14061805|diabetes_39|or_21
D011453_D006994 NONE prostaglandin_8\JJ\5414534|and_24|hypoaidosteronism_53 (r_amod) synthesis_9\NN\13446390|NONE_0 (l_conj) hypoaidosteronism_13\NN\0|prostaglandin_53|and_29
D011188_D003920 NONE potassium_6\NN\14625458|NONE_0 (r_compound) balance_7\NN\13934900|renal_29|and_14|in_8 (r_conj) function_4\NN\13783581|NONE_0 (r_pobj) to_2\IN\0|careful_18 (r_prep) attention_1\NN\5701944|,_131|in_146|,_215|will_217|prevent_227|._272 (r_nsubj) help_33\VB\407535|NONE_0 (l_prep) in_21\IN\13603305|attention_146|,_15|,_69|will_71|prevent_81|._126 (l_pobj) patients_23\NNS\9898892|particularly_22 (l_prep) with_24\IN\0|those_15 (l_pobj) mellitus_26\NN\0|NONE_0
D007213_D003920 NONE indomethacin_11\NN\3828465|NONE_0 (r_dobj) receiving_10\VBG\2210855|NONE_0 (r_acl) patients_9\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|renal_37|and_22|balance_8 (r_prep) function_4\NN\13783581|NONE_0 (r_pobj) to_2\IN\0|careful_18 (r_prep) attention_1\NN\5701944|,_131|in_146|,_215|will_217|prevent_227|._272 (r_nsubj) help_33\VB\407535|NONE_0 (l_prep) in_21\IN\13603305|attention_146|,_15|,_69|will_71|prevent_81|._126 (l_pobj) patients_23\NNS\9898892|particularly_22 (l_prep) with_24\IN\0|those_15 (l_pobj) mellitus_26\NN\0|NONE_0
9061777
D016202_D001930 NONE nmda_31\NNP\0|an_14|excitatory_11|mediated_14 (r_compound) mechanism_35\NN\13446390|NONE_0 (r_pobj) through_28\IN\0|brain_13 (r_prep) damage_27\NN\7296428|indicate_185|,_41|elevation_35|may_16|._61
D012601_D012640 NONE scopolamine_0\NNP\14712692|development_61|but_115|mg/kg_131|)_136 (r_nsubj) prevented_11\VBN\0|not_91|2_96|._97 (l_dobj) development_12\NN\248977|scopolamine_61|but_54|mg/kg_70|)_75 (l_prep) of_13\IN\0|NONE_0 (l_pobj) seizure_18\NN\14081375|NONE_0
D012601_D012640 NONE scopolamine_0\NNP\14712692|seizure_77|,_84|augmented_103|._162 (r_nsubj) blocked_3\VBD\1476483|NONE_0 (l_dobj) seizure_9\NN\14081375|scopolamine_77|,_7|augmented_26|._85
D012601_D012640 NONE scopolamine_0\NNP\14712692|seizure_77|,_84|augmented_103|._162 (r_nsubj) blocked_3\VBD\1476483|NONE_0 (l_conj) augmented_13\VBD\153263|scopolamine_103|seizure_26|,_19|._59 (l_dobj) seizure_16\NN\14081375|treatment_39
D016202_D013226 NONE nmda_31\NNP\0|an_14|excitatory_11|mediated_14 (r_compound) mechanism_35\NN\13446390|NONE_0 (r_pobj) through_28\IN\0|brain_13 (r_prep) damage_27\NN\7296428|indicate_185|,_41|elevation_35|may_16|._61 (r_dobj) cause_25\VB\7323922|NONE_0 (l_ccomp) indicate_2\VBP\952524|,_144|elevation_150|may_169|damage_185|._246 (l_ccomp) initiated_10\VBN\1617192|results_67 (l_nsubjpass) status_4\NN\24720|that_5|is_42|by_55|and_86|propagated_90 (l_acl) induced_6\VBN\1627355|NONE_0 (l_advmod) epilepticus_5\NN\0|by_20
D010862_D001930 NONE pilocarpine_2\NN\14712692|-_11 (r_npadvmod) induced_4\VBN\1627355|electrographic_8 (r_amod) seizure_6\NN\14081375|mk-801_51|but_8|protects_12|._49 (r_dobj) augments_1\VBZ\153263|NONE_0 (l_conj) protects_8\VBZ\1127795|mk-801_63|seizure_12|but_4|._37 (l_prep) against_9\IN\0|NONE_0 (l_pobj) damage_11\NN\7296428|NONE_0
D010862_D001930 NONE pilocarpine_10\NN\14712692|NONE_0 (r_pobj) by_9\IN\0|the_17|brain_13 (r_prep) damage_8\NN\7296428|mk-801_27
D010862_D001930 NONE pilocarpine_8\NN\14712692|NONE_0 (r_pobj) by_7\IN\0|epilepticus_20 (r_agent) induced_6\VBN\1627355|NONE_0 (r_acl) status_4\NN\24720|that_5|is_42|by_55|and_86|propagated_90 (r_nsubjpass) initiated_10\VBN\1617192|results_67 (r_ccomp) indicate_2\VBP\952524|,_144|elevation_150|may_169|damage_185|._246 (r_ccomp) cause_25\VB\7323922|NONE_0 (l_dobj) damage_27\NN\7296428|indicate_185|,_41|elevation_35|may_16|._61
D010424_D001930 NONE pentobarbital_0\JJ\2792049|,_79|though_81|in_88|,_115|cells_131|darker_161|._179 (l_appos) scopolamine_2\NN\14712692|,_2 (l_conj) protected_5\VBD\1127795|and_11 (l_dobj) damage_8\NN\7296428|mk-801_27
D010862_D013226 CID pilocarpine_8\NN\14712692|NONE_0 (r_pobj) by_7\IN\0|epilepticus_20 (r_agent) induced_6\VBN\1627355|NONE_0 (l_advmod) epilepticus_5\NN\0|by_20
D010424_D012640 NONE pentobarbital_6\NN\2792049|mg/kg_11|and_4 (r_conj) scopolamine_0\NNP\14712692|development_61|but_115|mg/kg_131|)_136 (r_nsubj) prevented_11\VBN\0|not_91|2_96|._97 (l_dobj) development_12\NN\248977|scopolamine_61|but_54|mg/kg_70|)_75 (l_prep) of_13\IN\0|NONE_0 (l_pobj) seizure_18\NN\14081375|NONE_0
D010424_D012640 NONE pentobarbital_2\NN\2792049|and_4 (r_conj) scopolamine_0\NNP\14712692|seizure_77|,_84|augmented_103|._162 (r_nsubj) blocked_3\VBD\1476483|NONE_0 (l_dobj) seizure_9\NN\14081375|scopolamine_77|,_7|augmented_26|._85
D010424_D012640 NONE pentobarbital_2\NN\2792049|and_4 (r_conj) scopolamine_0\NNP\14712692|seizure_77|,_84|augmented_103|._162 (r_nsubj) blocked_3\VBD\1476483|NONE_0 (l_conj) augmented_13\VBD\153263|scopolamine_103|seizure_26|,_19|._59 (l_dobj) seizure_16\NN\14081375|treatment_39
D010862_D009410 CID pilocarpine_0\NNP\14712692|death_30|._85 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) death_3\NN\7296428|pilocarpine_30|._55
D012601_D001930 NONE scopolamine_2\NN\14712692|,_2 (l_conj) protected_5\VBD\1127795|and_11 (l_dobj) damage_8\NN\7296428|mk-801_27
D010862_D012640 CID pilocarpine_2\NN\14712692|-_11 (r_npadvmod) induced_4\VBN\1627355|electrographic_8 (r_amod) seizure_6\NN\14081375|mk-801_51|but_8|protects_12|._49
D010862_D012640 CID pilocarpine_10\NN\14712692|-_11 (r_npadvmod) induced_12\VBN\1627355|the_16|seizure_8 (r_amod) model_14\NN\5888929|mk-801_42 (l_compound) seizure_13\NN\14081375|the_24|induced_8
D010862_D012640 CID pilocarpine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|intraperitoneal_26|mg/kg_20 (r_prep) injection_1\NN\320852|seizure_62|._69 (r_nsubj) induced_8\VBN\1627355|NONE_0 (l_dobj) seizure_12\NN\14081375|injection_62|._7
D010862_D012640 CID pilocarpine_14\NN\14712692|-_11 (r_npadvmod) induced_16\VBN\1627355|behavioral_8 (r_amod) seizure_18\NN\14081375|NONE_0
D010862_D012640 CID pilocarpine_10\NN\14712692|-_11 (r_npadvmod) treated_12\VBN\2376958|the_16 (r_amod) group_13\NN\2137|NONE_0 (r_pobj) in_8\IN\13603305|seizure_47|._32 (r_prep) appeared_7\VBD\2604760|NONE_0 (l_nsubj) seizure_2\NN\14081375|in_47|._79
D010862_D012640 CID pilocarpine_5\NN\14712692|-_11 (r_npadvmod) induced_7\VBN\1627355|the_16|electrographic_8 (r_amod) seizure_9\NN\14081375|scopolamine_77|,_7|augmented_26|._85
D010862_D012640 CID pilocarpine_5\NN\14712692|-_11 (r_npadvmod) induced_7\VBN\1627355|the_16|electrographic_8 (r_amod) seizure_9\NN\14081375|scopolamine_77|,_7|augmented_26|._85 (r_dobj) blocked_3\VBD\1476483|NONE_0 (l_conj) augmented_13\VBD\153263|scopolamine_103|seizure_26|,_19|._59 (l_dobj) seizure_16\NN\14081375|treatment_39
D010862_D012640 CID pilocarpine_19\NN\14712692|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|the_27|electrographic_23 (r_acl) seizure_16\NN\14081375|treatment_39 (r_dobj) augmented_13\VBD\153263|scopolamine_103|seizure_26|,_19|._59 (r_conj) blocked_3\VBD\1476483|NONE_0 (l_dobj) seizure_9\NN\14081375|scopolamine_77|,_7|augmented_26|._85
D010862_D012640 CID pilocarpine_19\NN\14712692|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|the_27|electrographic_23 (r_acl) seizure_16\NN\14081375|treatment_39
D016291_D001930 NONE mk-801_0\NNP\0|seizure_51|but_59|protects_63|._100 (r_punct) augments_1\VBZ\153263|NONE_0 (l_conj) protects_8\VBZ\1127795|mk-801_63|seizure_12|but_4|._37 (l_prep) against_9\IN\0|NONE_0 (l_pobj) damage_11\NN\7296428|NONE_0
D016291_D001930 NONE mk-801_4\NNP\0|damage_27 (r_punct) protected_5\VBD\1127795|and_11 (l_dobj) damage_8\NN\7296428|mk-801_27
D016291_D001930 NONE mk-801-treated_15\JJ\0|the_4 (r_amod) group_16\NN\2137|NONE_0 (r_pobj) in_13\IN\13603305|pentobarbital_88|,_9|though_7|,_27|cells_43|darker_73|._91 (r_prep) appeared_23\VBD\2604760|NONE_0 (l_nsubj) pentobarbital_0\JJ\2792049|,_79|though_81|in_88|,_115|cells_131|darker_161|._179 (l_appos) scopolamine_2\NN\14712692|,_2 (l_conj) protected_5\VBD\1127795|and_11 (l_dobj) damage_8\NN\7296428|mk-801_27
D016291_D012640 CID mk-801_0\NNP\0|seizure_51|but_59|protects_63|._100 (r_punct) augments_1\VBZ\153263|NONE_0 (l_dobj) seizure_6\NN\14081375|mk-801_51|but_8|protects_12|._49
D016291_D012640 CID mk-801_7\NNP\0|model_42 (r_punct) on_8\IN\0|the_37|anticonvulsant_33|of_10 (l_pobj) model_14\NN\5888929|mk-801_42 (l_compound) seizure_13\NN\14081375|the_24|induced_8
D016291_D012640 CID mk-801_20\NNP\0|(_7 (r_punct) 0.5_22\CD\0|NONE_0 (r_nummod) mg/kg_23\NN\0|scopolamine_131|development_70|but_16|)_5 (r_conj) prevented_11\VBN\0|not_91|2_96|._97 (l_dobj) development_12\NN\248977|scopolamine_61|but_54|mg/kg_70|)_75 (l_prep) of_13\IN\0|NONE_0 (l_pobj) seizure_18\NN\14081375|NONE_0
D016291_D012640 CID mk-801_11\NNP\0|NONE_0 (r_punct) treatment_12\NN\654885|seizure_39 (r_nsubj) augmented_13\VBD\153263|scopolamine_103|seizure_26|,_19|._59 (r_conj) blocked_3\VBD\1476483|NONE_0 (l_dobj) seizure_9\NN\14081375|scopolamine_77|,_7|augmented_26|._85
D016291_D012640 CID mk-801_11\NNP\0|NONE_0 (r_punct) treatment_12\NN\654885|seizure_39 (r_nsubj) augmented_13\VBD\153263|scopolamine_103|seizure_26|,_19|._59 (l_dobj) seizure_16\NN\14081375|treatment_39
24881749
D063325_D006816 NONE tiapride_10\NN\0|and_4|in_9 (r_conj) tetrabenazine_8\NN\0|NONE_0 (l_prep) in_11\IN\13603305|and_13|tiapride_9 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_19|japanese_17 (l_pobj) disease_18\NN\14061805|NONE_0
D063325_D006816 NONE tiapride_27\NN\0|NONE_0 (r_pobj) with_26\IN\0|the_38|of_23|(_14|day_21|)_24|and_26|tetrabenazine_30|for_58 (r_prep) initiation_22\NN\7450842|days_15 (l_prep) for_42\IN\0|the_96|of_81|with_58|(_44|day_37|)_34|and_32|tetrabenazine_28 (l_pobj) disease_45\NN\14061805|NONE_0
D063325_D001943 NONE tiapride_10\NN\0|and_4|in_9 (r_conj) tetrabenazine_8\NN\0|NONE_0 (l_prep) in_11\IN\13603305|and_13|tiapride_9 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_19|japanese_17 (l_pobj) disease_18\NN\14061805|NONE_0 (l_prep) at_19\IN\14622893|huntington_21 (l_pobj) stage_22\NN\15113229|NONE_0 (l_prep) of_23\IN\0|the_19|terminal_15 (l_pobj) cancer_26\NN\14239425|NONE_0
D013747_D006816 NONE tetrabenazine_8\NN\0|NONE_0 (l_prep) in_11\IN\13603305|and_13|tiapride_9 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_19|japanese_17 (l_pobj) disease_18\NN\14061805|NONE_0
D013747_D006816 NONE tetrabenazine_35\NN\0|the_68|of_53|with_30|(_16|day_9|)_6|and_4|for_28 (r_conj) initiation_22\NN\7450842|days_15 (l_prep) for_42\IN\0|the_96|of_81|with_58|(_44|day_37|)_34|and_32|tetrabenazine_28 (l_pobj) disease_45\NN\14061805|NONE_0
D013747_D009459 CID tetrabenazine_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|syndrome_40|by_23|._128 (r_prep) induced_3\VBN\1627355|NONE_0 (l_nsubj) syndrome_2\NN\5870365|by_17|with_40|._168
D013747_D009459 CID tetrabenazine_35\NN\0|the_68|of_53|with_30|(_16|day_9|)_6|and_4|for_28 (r_conj) initiation_22\NN\7450842|days_15 (r_pobj) after_20\IN\0|that_22 (r_prep) occurred_17\VBD\0|an_71|old_60|japanese_56|with_41 (r_relcl) woman_11\NN\9605289|NONE_0 (l_prep) with_12\IN\0|an_30|old_19|japanese_15|occurred_41 (l_pobj) syndrome_15\NN\5870365|NONE_0
D013747_D009459 CID tetrabenazine_18\NN\0|NONE_0 (r_pobj) with_17\IN\0|combination_20 (r_prep) therapy_16\NN\657604|to_15 (r_pobj) due_13\IN\5174653|the_49|of_34 (r_prep) occurrence_8\NN\29378|to_34|,_6|has_104|not_108|been_112|previously_117|._136 (l_prep) of_9\IN\0|the_15|due_34 (l_pobj) syndrome_12\NN\5870365|NONE_0
D013747_D001943 NONE tetrabenazine_8\NN\0|NONE_0 (l_prep) in_11\IN\13603305|and_13|tiapride_9 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_19|japanese_17 (l_pobj) disease_18\NN\14061805|NONE_0 (l_prep) at_19\IN\14622893|huntington_21 (l_pobj) stage_22\NN\15113229|NONE_0 (l_prep) of_23\IN\0|the_19|terminal_15 (l_pobj) cancer_26\NN\14239425|NONE_0
D063325_D009459 CID tiapride_10\NN\0|and_4|in_9 (r_conj) tetrabenazine_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|syndrome_40|by_23|._128 (r_prep) induced_3\VBN\1627355|NONE_0 (l_nsubj) syndrome_2\NN\5870365|by_17|with_40|._168
D063325_D009459 CID tiapride_27\NN\0|NONE_0 (r_pobj) with_26\IN\0|the_38|of_23|(_14|day_21|)_24|and_26|tetrabenazine_30|for_58 (r_prep) initiation_22\NN\7450842|days_15 (r_pobj) after_20\IN\0|that_22 (r_prep) occurred_17\VBD\0|an_71|old_60|japanese_56|with_41 (r_relcl) woman_11\NN\9605289|NONE_0 (l_prep) with_12\IN\0|an_30|old_19|japanese_15|occurred_41 (l_pobj) syndrome_15\NN\5870365|NONE_0
D063325_D009459 CID tiapride_20\NN\0|and_4 (r_conj) tetrabenazine_18\NN\0|NONE_0 (r_pobj) with_17\IN\0|combination_20 (r_prep) therapy_16\NN\657604|to_15 (r_pobj) due_13\IN\5174653|the_49|of_34 (r_prep) occurrence_8\NN\29378|to_34|,_6|has_104|not_108|been_112|previously_117|._136 (l_prep) of_9\IN\0|the_15|due_34 (l_pobj) syndrome_12\NN\5870365|NONE_0
3155884
D013311_D003920 CID streptozotocin_13\JJ\0|diabetic_15 (r_nmod) rats_15\NNS\2329401|NONE_0 (l_amod) diabetic_14\JJ\10595647|streptozotocin_15
D013311_D003920 CID streptozotocin_13\JJ\0|against_24 (r_compound) diabetes_14\NNS\14075199|NONE_0
D013311_D003920 CID streptozotocin_10\JJ\0|that_5|resistance_40 (r_nsubj) causes_13\VBZ\7323922|the_46 (l_dobj) resistance_16\NN\37396|that_45|streptozotocin_40 (l_conj) points_18\NNS\5868954|the_23|iso_19|and_4 (l_prep) towards_19\IN\0|NONE_0 (l_pobj) effect_23\NN\34213|NONE_0 (l_prep) on_24\IN\0|a_24|direct_22|insulin_15 (l_pobj) sensitivity_27\NN\5651971|NONE_0 (l_prep) in_28\IN\13603305|myocardial_37|catecholamine_26 (l_pobj) rats_30\NNS\2329401|NONE_0 (l_amod) diabetic_29\JJ\10595647|NONE_0
D013311_D066126 NONE streptozotocin_13\JJ\0|diabetic_15 (r_nmod) rats_15\NNS\2329401|NONE_0 (r_pobj) in_12\IN\13603305|the_40|cardiotoxic_36|of_17 (r_prep) effect_9\NN\34213|NONE_0 (l_amod) cardiotoxic_8\JJ\0|the_4|of_19|in_36
D013311_D066126 NONE streptozotocin_13\JJ\0|against_24 (r_compound) diabetes_14\NNS\14075199|NONE_0 (l_prep) against_15\IN\0|streptozotocin_24 (l_pobj) effect_18\NN\34213|NONE_0 (l_amod) cardiotoxic_17\JJ\0|the_4|of_19
D002395_D003920 NONE catecholamines_4\NNS\5407119|NONE_0 (r_pobj) of_3\IN\0|the_23|myocardial_19 (r_prep) content_2\NN\7951464|was_26|in_40|._68 (r_nsubjpass) estimated_6\VBN\637259|NONE_0 (l_prep) in_7\IN\13603305|content_40|was_14|._28 (l_pobj) rats_12\NNS\2329401|NONE_0 (l_amod) diabetic_11\JJ\10595647|these_12|day_4
D002395_D003920 NONE catecholamine_26\NN\5407119|myocardial_11|in_26 (r_compound) sensitivity_27\NN\5651971|NONE_0 (l_prep) in_28\IN\13603305|myocardial_37|catecholamine_26 (l_pobj) rats_30\NNS\2329401|NONE_0 (l_amod) diabetic_29\JJ\10595647|NONE_0
D005947_D005355 NONE glucose_52\NN\14710501|NONE_0 (r_pobj) in_50\IN\13603305|the_9 (r_prep) fall_49\NN\15236475|NONE_0 (r_pobj) of_47\IN\0|the_10 (r_prep) slope_46\NN\9287968|NONE_0 (r_pobj) to_44\IN\0|a_57|significant_48|(_24|0.83_19 (r_prep) correlation_33\NN\13841213|was_65|morphometrically_61|later_28|,_23|appeared_102 (r_conj) analyzed_25\VBN\0|after_142|,_100|iso_98|was_94|subcutaneously_84|and_69|induced_56|._154 (r_conj) given_13\VBN\5892096|NONE_0 (l_conj) induced_18\VBD\1627355|after_86|,_44|iso_42|was_38|subcutaneously_28|and_13|analyzed_56|._210 (l_dobj) fibrosis_19\NN\14204950|when_17|iso_12|in_9
D007545_D005355 CID isoproterenol_4\NN\3740161|NONE_0 (r_pobj) of_3\IN\0|a_21|morphometric_19 (r_prep) study_2\NN\635850|fibrosis_42|._50 (r_nsubj) induced_5\VBN\1627355|NONE_0 (l_dobj) fibrosis_7\NN\14204950|study_42|._8
D007545_D005355 CID iso_11\NN\0|after_44|,_2|was_4|subcutaneously_14|and_29|induced_42|analyzed_98|._252 (r_nsubjpass) given_13\VBN\5892096|NONE_0 (l_conj) induced_18\VBD\1627355|after_86|,_44|iso_42|was_38|subcutaneously_28|and_13|analyzed_56|._210 (l_dobj) fibrosis_19\NN\14204950|when_17|iso_12|in_9
D007545_D005355 CID iso_17\NN\0|when_5|fibrosis_12|in_21 (r_nsubj) induced_18\VBD\1627355|after_86|,_44|iso_42|was_38|subcutaneously_28|and_13|analyzed_56|._210 (l_dobj) fibrosis_19\NN\14204950|when_17|iso_12|in_9
D007545_D003920 NONE isoproterenol_11\NN\3740161|NONE_0 (r_pobj) of_10\IN\0|the_23|cardiotoxic_19|in_17 (r_prep) effect_9\NN\34213|NONE_0 (l_prep) in_12\IN\13603305|the_40|cardiotoxic_36|of_17 (l_pobj) rats_15\NNS\2329401|NONE_0 (l_amod) diabetic_14\JJ\10595647|streptozotocin_15
D007545_D003920 NONE isoproterenol_23\NN\3740161|NONE_0 (r_pobj) of_22\IN\0|high_11|(_17|iso_18|)_21 (r_prep) doses_21\NNS\3740161|NONE_0 (r_pobj) of_19\IN\0|the_23|cardiotoxic_19 (r_prep) effect_18\NN\34213|NONE_0 (r_pobj) against_15\IN\0|streptozotocin_24 (r_prep) diabetes_14\NNS\14075199|NONE_0
D007545_D003920 NONE iso_25\NN\0|high_29|of_18|(_1|)_3 (r_appos) doses_21\NNS\3740161|NONE_0 (r_pobj) of_19\IN\0|the_23|cardiotoxic_19 (r_prep) effect_18\NN\34213|NONE_0 (r_pobj) against_15\IN\0|streptozotocin_24 (r_prep) diabetes_14\NNS\14075199|NONE_0
D007545_D003920 NONE iso_15\NN\0|the_4|and_15|points_19 (r_compound) resistance_16\NN\37396|that_45|streptozotocin_40 (l_conj) points_18\NNS\5868954|the_23|iso_19|and_4 (l_prep) towards_19\IN\0|NONE_0 (l_pobj) effect_23\NN\34213|NONE_0 (l_prep) on_24\IN\0|a_24|direct_22|insulin_15 (l_pobj) sensitivity_27\NN\5651971|NONE_0 (l_prep) in_28\IN\13603305|myocardial_37|catecholamine_26 (l_pobj) rats_30\NNS\2329401|NONE_0 (l_amod) diabetic_29\JJ\10595647|NONE_0
D007545_D066126 NONE isoproterenol_11\NN\3740161|NONE_0 (r_pobj) of_10\IN\0|the_23|cardiotoxic_19|in_17 (r_prep) effect_9\NN\34213|NONE_0 (l_amod) cardiotoxic_8\JJ\0|the_4|of_19|in_36
D007545_D066126 NONE isoproterenol_23\NN\3740161|NONE_0 (r_pobj) of_22\IN\0|high_11|(_17|iso_18|)_21 (r_prep) doses_21\NNS\3740161|NONE_0 (r_pobj) of_19\IN\0|the_23|cardiotoxic_19 (r_prep) effect_18\NN\34213|NONE_0 (l_amod) cardiotoxic_17\JJ\0|the_4|of_19
D007545_D066126 NONE iso_25\NN\0|high_29|of_18|(_1|)_3 (r_appos) doses_21\NNS\3740161|NONE_0 (r_pobj) of_19\IN\0|the_23|cardiotoxic_19 (r_prep) effect_18\NN\34213|NONE_0 (l_amod) cardiotoxic_17\JJ\0|the_4|of_19
25096313
D013256_D009422 NONE steroid_5\NN\14727670|at_18 (r_compound) injection_6\NN\320852|NONE_0 (r_pobj) after_4\IN\0|lateral_42|antebrachial_34|cutaneous_21|._45 (r_prep) neuropathy_3\NN\14204950|NONE_0
D013256_D009422 NONE steroid_19\NN\14727670|a_2|in_18 (r_compound) injection_20\NN\320852|NONE_0 (r_pobj) after_17\IN\0|that_14|treat_55 (r_prep) occurred_16\VBD\0|lateral_55|antebrachial_47|cutaneous_34|(_13|lacnp_12|)_7 (r_relcl) neuropathy_11\NN\14204950|NONE_0
D013256_D010292 CID steroid_23\NN\14727670|a_2|in_18|before_59 (r_compound) injection_24\NN\320852|NONE_0 (r_pobj) after_21\IN\0|presented_112|;_31|paresthesia_25|had_13|._73 (r_prep) occurred_20\VBN\0|NONE_0 (l_ccomp) presented_5\VBN\2137132|;_81|paresthesia_87|had_99|after_112|._185 (l_prep) with_6\IN\0|woman_16 (l_pobj) sensation_8\NN\5708432|NONE_0 (l_conj) paresthesia_10\NN\14299637|decreased_24|and_4|over_12
D013256_D010292 CID steroid_23\NN\14727670|a_2|in_18|before_59 (r_compound) injection_24\NN\320852|NONE_0 (r_pobj) after_21\IN\0|presented_112|;_31|paresthesia_25|had_13|._73 (r_prep) occurred_20\VBN\0|NONE_0 (l_nsubj) paresthesia_18\NN\14299637|presented_87|;_6|had_12|after_25|._98
D013256_D013716 NONE steroid_19\NN\14727670|a_2|in_18 (r_compound) injection_20\NN\320852|NONE_0 (r_pobj) after_17\IN\0|that_14|treat_55 (r_prep) occurred_16\VBD\0|lateral_55|antebrachial_47|cutaneous_34|(_13|lacnp_12|)_7 (l_advcl) treat_26\VB\7570720|that_69|after_55 (l_dobj) epicondylitis_28\NN\14336539|to_17|in_14
D013256_D013716 NONE steroid_14\NN\14727670|a_2|for_18 (r_compound) injection_15\NN\320852|NONE_0 (l_prep) for_16\IN\0|a_20|steroid_18 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) epicondylitis_21\NN\14336539|NONE_0
24664478
C104457_D020258 NONE nelarabine_0\JJ\0|with_25|:_65 (r_compound) neurotoxicity_1\NN\0|NONE_0
C104457_D020258 NONE nelarabine_1\JJ\0|severe_7|in_25 (r_compound) neurotoxicity_2\NN\0|is_81|._92
C104457_D020258 NONE nelarabine_16\NN\0|NONE_0 (r_pobj) by_15\IN\0|NONE_0 (r_agent) caused_14\VBN\1617192|severe_21 (r_acl) neurotoxicity_13\NN\0|NONE_0
24659727
D003520_D009503 CID ctx_22\NNP\0|NONE_0 (r_pobj) of_19\IN\0|the_20|first_16 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) after_15\IN\0|frequency_33 (r_prep) neutropenia_14\NN\14196405|neutropenia_81|effect_45|,_39|and_37|was_50|._91 (r_conj) was_1\VBD\0|NONE_0 (l_nsubj) neutropenia_0\NNP\14196405|effect_36|,_42|and_44|neutropenia_81|was_131|._172
D003520_D009503 CID ctx_22\NNP\0|NONE_0 (r_pobj) of_19\IN\0|the_20|first_16 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) after_15\IN\0|frequency_33 (r_prep) neutropenia_14\NN\14196405|neutropenia_81|effect_45|,_39|and_37|was_50|._91
D008130_D064420 NONE lomustine_10\NN\2722458|NONE_0 (r_pobj) of_9\IN\0|a_11|in_47 (r_prep) protocol_8\NN\6652242|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|NONE_0 (r_acl) toxicity_4\NN\13576101|study_16|._104
D008130_D064420 NONE ccnu_12\NNP\0|(_1|)_4|and_6|cyclophosphamide_10 (r_appos) lomustine_10\NN\2722458|NONE_0 (r_pobj) of_9\IN\0|a_11|in_47 (r_prep) protocol_8\NN\6652242|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|NONE_0 (r_acl) toxicity_4\NN\13576101|study_16|._104
D008130_D009503 CID ccnu_20\NNP\0|/_4 (r_nmod) ctx_22\NNP\0|NONE_0 (r_pobj) of_19\IN\0|the_20|first_16 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) after_15\IN\0|frequency_33 (r_prep) neutropenia_14\NN\14196405|neutropenia_81|effect_45|,_39|and_37|was_50|._91 (r_conj) was_1\VBD\0|NONE_0 (l_nsubj) neutropenia_0\NNP\14196405|effect_36|,_42|and_44|neutropenia_81|was_131|._172
D008130_D009503 CID ccnu_20\NNP\0|/_4 (r_nmod) ctx_22\NNP\0|NONE_0 (r_pobj) of_19\IN\0|the_20|first_16 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) after_15\IN\0|frequency_33 (r_prep) neutropenia_14\NN\14196405|neutropenia_81|effect_45|,_39|and_37|was_50|._91
D008130_D008223 NONE lomustine_2\NN\2722458|NONE_0 (l_prep) in_7\IN\13603305|in_37 (l_pobj) dogs_8\NNS\2083346|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) lymphoma_10\NN\14239918|NONE_0
D008130_D008223 NONE lomustine_10\NN\2722458|NONE_0 (r_pobj) of_9\IN\0|a_11|in_47 (r_prep) protocol_8\NN\6652242|NONE_0 (l_prep) in_19\IN\13603305|a_58|of_47 (l_pobj) dogs_20\NNS\2083346|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) lymphoma_22\NN\14239918|NONE_0
D008130_D008223 NONE ccnu_12\NNP\0|(_1|)_4|and_6|cyclophosphamide_10 (r_appos) lomustine_10\NN\2722458|NONE_0 (r_pobj) of_9\IN\0|a_11|in_47 (r_prep) protocol_8\NN\6652242|NONE_0 (l_prep) in_19\IN\13603305|a_58|of_47 (l_pobj) dogs_20\NNS\2083346|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) lymphoma_22\NN\14239918|NONE_0
D003520_D008223 NONE cyclophosphamide_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) combination_4\NN\7951464|NONE_0 (r_pobj) in_3\IN\13603305|in_37 (r_prep) lomustine_2\NN\2722458|NONE_0 (l_prep) in_7\IN\13603305|in_37 (l_pobj) dogs_8\NNS\2083346|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) lymphoma_10\NN\14239918|NONE_0
D003520_D008223 NONE cyclophosphamide_15\NN\0|(_11|ccnu_10|)_6|and_4 (r_conj) lomustine_10\NN\2722458|NONE_0 (r_pobj) of_9\IN\0|a_11|in_47 (r_prep) protocol_8\NN\6652242|NONE_0 (l_prep) in_19\IN\13603305|a_58|of_47 (l_pobj) dogs_20\NNS\2083346|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) lymphoma_22\NN\14239918|NONE_0
D003520_D008223 NONE ctx_17\NNP\0|(_1|)_3 (r_appos) cyclophosphamide_15\NN\0|(_11|ccnu_10|)_6|and_4 (r_conj) lomustine_10\NN\2722458|NONE_0 (r_pobj) of_9\IN\0|a_11|in_47 (r_prep) protocol_8\NN\6652242|NONE_0 (l_prep) in_19\IN\13603305|a_58|of_47 (l_pobj) dogs_20\NNS\2083346|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) lymphoma_22\NN\14239918|NONE_0
D003520_D064420 NONE cyclophosphamide_15\NN\0|(_11|ccnu_10|)_6|and_4 (r_conj) lomustine_10\NN\2722458|NONE_0 (r_pobj) of_9\IN\0|a_11|in_47 (r_prep) protocol_8\NN\6652242|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|NONE_0 (r_acl) toxicity_4\NN\13576101|study_16|._104
D003520_D064420 NONE ctx_17\NNP\0|(_1|)_3 (r_appos) cyclophosphamide_15\NN\0|(_11|ccnu_10|)_6|and_4 (r_conj) lomustine_10\NN\2722458|NONE_0 (r_pobj) of_9\IN\0|a_11|in_47 (r_prep) protocol_8\NN\6652242|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|NONE_0 (r_acl) toxicity_4\NN\13576101|study_16|._104
15991002
D010433_D001008 CID pentylenetetrazole_18\NN\0|another_25|anxiogenic_17|,_2|,_18|in_20 (r_appos) drug_16\NN\14778436|and_23 (r_conj) caffeine_12\NN\14712692|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) anxiety_9\NN\14373582|NONE_0
D010433_D001008 CID pentylenetetrazole_11\NN\0|not_4|-_18 (r_advmod) induced_13\VBN\1627355|NONE_0 (r_amod) anxiety_14\NN\14373582|nicotine_92|caffeine-_45|but_35|._7
D009538_D001008 NONE nicotine_7\NN\14712692|NONE_0 (r_pobj) of_6\IN\0|the_12|on_12 (r_prep) effects_5\NNS\13245626|study_23|._107 (l_prep) on_8\IN\0|the_24|of_12 (l_pobj) anxiety_9\NN\14373582|NONE_0
D009538_D001008 NONE nicotine_0\NNP\14712692|caffeine-_47|but_57|anxiety_92|._99 (r_nsubj) blocked_6\VBD\1476483|NONE_0 (l_conj) anxiety_14\NN\14373582|nicotine_92|caffeine-_45|but_35|._7
D009538_D001008 NONE nicotine_8\NN\14712692|NONE_0 (r_pobj) of_7\IN\0|the_24|antagonistic_20|on_12 (r_prep) effect_6\NN\34213|that_22|specific_50|,_70|of_80 (l_prep) on_9\IN\0|the_36|antagonistic_32|of_12 (l_pobj) anxiety_13\NN\14373582|NONE_0
D002110_D001008 CID caffeine_12\NN\14712692|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) anxiety_9\NN\14373582|NONE_0
D002110_D001008 CID caffeine-_8\NN\0|nicotine_47|but_10|anxiety_45|._52 (r_dobj) blocked_6\VBD\1476483|NONE_0 (l_conj) anxiety_14\NN\14373582|nicotine_92|caffeine-_45|but_35|._7
D002110_D001008 CID caffeine_10\NN\14712692|-_8 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) anxiety_13\NN\14373582|NONE_0
D002110_D001008 CID caffeine_17\NN\14712692|NONE_0 (r_pobj) to_16\IN\0|NONE_0 (r_prep) specific_15\JJ\5817396|that_72|effect_50|,_20|of_30 (r_acomp) is_14\VBZ\0|results_85|._68 (l_nsubj) effect_6\NN\34213|that_22|specific_50|,_70|of_80 (l_prep) on_9\IN\0|the_36|antagonistic_32|of_12 (l_pobj) anxiety_13\NN\14373582|NONE_0
3987172
D010665_D006973 CID phenylpropanolamine_3\NN\2682038|-_19 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) hypertension_6\NN\14057371|NONE_0
D010665_D006973 CID phenylpropanolamine_0\NNP\2682038|(_20|ppa_21|)_24 (r_nmod) overdose_4\NN\84738|can_9|hypertension_26|._75 (r_nsubj) cause_6\VB\7323922|NONE_0 (l_dobj) hypertension_8\NN\14057371|overdose_26|can_17|._49
D010665_D006973 CID ppa_2\NNP\0|phenylpropanolamine_21|(_1|)_3 (r_nmod) overdose_4\NN\84738|can_9|hypertension_26|._75 (r_nsubj) cause_6\VB\7323922|NONE_0 (l_dobj) hypertension_8\NN\14057371|overdose_26|can_17|._49
D010665_D006973 CID ppa_12\NN\0|-_3 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) hypertension_15\NN\14057371|NONE_0
D010665_D062787 NONE phenylpropanolamine_0\NNP\2682038|(_20|ppa_21|)_24 (r_nmod) overdose_4\NN\84738|can_9|hypertension_26|._75
D010665_D062787 NONE ppa_2\NNP\0|phenylpropanolamine_21|(_1|)_3 (r_nmod) overdose_4\NN\84738|can_9|hypertension_26|._75
D011433_D006973 NONE propranolol_0\NNP\0|of_23|._66 (r_compound) antagonism_1\NN\24720|NONE_0 (l_prep) of_2\IN\0|propranolol_23|._43 (l_pobj) hypertension_6\NN\14057371|NONE_0
D011433_D006973 NONE propranolol_7\NN\0|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) treatment_10\NN\654885|NONE_0 (l_prep) of_11\IN\0|the_14 (l_pobj) hypertension_15\NN\14057371|NONE_0
D010665_D002543 NONE phenylpropanolamine_0\NNP\2682038|(_20|ppa_21|)_24 (r_nmod) overdose_4\NN\84738|can_9|hypertension_26|._75 (r_nsubj) cause_6\VB\7323922|NONE_0 (l_dobj) hypertension_8\NN\14057371|overdose_26|can_17|._49 (l_conj) hemorrhage_11\NN\14285662|severe_35|,_16
D010665_D002543 NONE ppa_2\NNP\0|phenylpropanolamine_21|(_1|)_3 (r_nmod) overdose_4\NN\84738|can_9|hypertension_26|._75 (r_nsubj) cause_6\VB\7323922|NONE_0 (l_dobj) hypertension_8\NN\14057371|overdose_26|can_17|._49 (l_conj) hemorrhage_11\NN\14285662|severe_35|,_16
D010665_D020521 NONE ppa_10\NNP\0|that_5|volume_25|%_34|from_37|ml_73|)_75 (r_nsubj) increased_11\VBD\169651|assessed_46|,_72|fraction_87|._195 (l_dobj) volume_14\NN\33615|that_30|ppa_25|%_9|from_12|ml_48|)_50 (l_compound) stroke_13\NN\556313|the_4
20408947
D000082_D056486 CID acetaminophen_0\NNP\2707683|-_13 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hepatotoxicity_3\NN\0|cause_34|._78
D000082_D008107 NONE acetaminophen_34\RB\2707683|-_13 (r_advmod) induced_36\VBN\1627355|n=36_13 (r_amod) alf_37\NNP\0|NONE_0 (l_appos) n=36_39\NNP\0|induced_13 (l_prep) with_41\IN\0|(_7|)_2 (l_pobj) patients_47\NNS\9898892|NONE_0 (l_acl) undergoing_48\VBG\109660|age-_30|matched_17 (l_dobj) lt_50\NN\0|NONE_0 (l_prep) for_51\IN\0|emergent_12 (l_pobj) alf_57\NNP\0|NONE_0 (l_conj) lt_63\NN\0|induced_32|(_20|n=35_19|)_15|and_13 (l_prep) for_64\IN\0|elective_12 (l_pobj) disease_67\NN\14061805|NONE_0
D000082_D008107 NONE acetaminophen_34\RB\2707683|-_13 (r_advmod) induced_36\VBN\1627355|n=36_13 (r_amod) alf_37\NNP\0|NONE_0 (l_appos) n=36_39\NNP\0|induced_13 (l_prep) with_41\IN\0|(_7|)_2 (l_pobj) patients_47\NNS\9898892|NONE_0 (l_acl) undergoing_48\VBG\109660|age-_30|matched_17 (l_dobj) lt_50\NN\0|NONE_0 (l_prep) for_51\IN\0|emergent_12 (l_pobj) alf_57\NNP\0|NONE_0 (l_conj) lt_63\NN\0|induced_32|(_20|n=35_19|)_15|and_13 (l_prep) for_64\IN\0|elective_12 (l_pobj) disease_67\NN\14061805|NONE_0 (l_appos) cld_69\NNP\0|chronic_23|liver_15|(_1|)_9
D000082_D008107 NONE acetaminophen_54\RB\2707683|non_4|-_1|-_13 (r_advmod) induced_56\VBN\1627355|(_12|n=35_13|)_17|and_19|lt_32 (r_amod) alf_57\NNP\0|NONE_0 (l_conj) lt_63\NN\0|induced_32|(_20|n=35_19|)_15|and_13 (l_prep) for_64\IN\0|elective_12 (l_pobj) disease_67\NN\14061805|NONE_0
D000082_D008107 NONE acetaminophen_54\RB\2707683|non_4|-_1|-_13 (r_advmod) induced_56\VBN\1627355|(_12|n=35_13|)_17|and_19|lt_32 (r_amod) alf_57\NNP\0|NONE_0 (l_conj) lt_63\NN\0|induced_32|(_20|n=35_19|)_15|and_13 (l_prep) for_64\IN\0|elective_12 (l_pobj) disease_67\NN\14061805|NONE_0 (l_appos) cld_69\NNP\0|chronic_23|liver_15|(_1|)_9
D000082_D008107 NONE acetaminophen_5\RB\2707683|-_13 (r_advmod) induced_7\VBN\1627355|twenty_27|(_20|%_17|alf_8 (r_amod) patients_9\NNS\9898892|diagnosis_34|before_44 (r_nsubj) had_10\VBD\0|;_90|p<0.01_92|attempt_146|._153 (l_prep) before_15\IN\0|patients_44|diagnosis_10 (l_pobj) lt_16\NNP\0|NONE_0 (l_appos) alf=0/35_23\NNP\0|NONE_0 (l_appos) cld=2/34_25\NNP\0|non_36|induced_18|,_2
D000082_D008107 NONE acetaminophen_20\RB\2707683|-_13 (r_advmod) induced_22\VBN\1627355|non_18|,_16|cld=2/34_18 (r_amod) alf=0/35_23\NNP\0|NONE_0 (l_appos) cld=2/34_25\NNP\0|non_36|induced_18|,_2
D000082_D008107 NONE acetaminophen_31\RB\2707683|-_13 (r_advmod) induced_33\VBN\1627355|year_14 (r_amod) alf_34\NNP\0|the_34|(_23|;_27|alf_55 (r_appos) groups_29\NNS\2137|NONE_0 (r_pobj) between_27\IN\0|graft_26|or_12|survival_9 (r_prep) failure_24\NN\66216|no_67|significant_64|in_40|,_8|cld_131 (r_conj) differences_14\NNS\4723816|during_61|,_28|there_26|:_195|rank_207|)_211|._212 (l_conj) cld_57\NNP\0|no_198|significant_195|in_171|,_139|failure_131
D000082_D008107 NONE acetaminophen_47\RB\2707683|-_13 (r_advmod) induced_49\VBN\1627355|-_15 (r_acomp) non_45\AFX\0|%_32|;_38 (r_nmod) alf_50\NNP\0|the_89|(_78|alf_55|;_28 (r_appos) groups_29\NNS\2137|NONE_0 (r_pobj) between_27\IN\0|graft_26|or_12|survival_9 (r_prep) failure_24\NN\66216|no_67|significant_64|in_40|,_8|cld_131 (r_conj) differences_14\NNS\4723816|during_61|,_28|there_26|:_195|rank_207|)_211|._212 (l_conj) cld_57\NNP\0|no_198|significant_195|in_171|,_139|failure_131
D000082_D008107 NONE acetaminophen_14\RB\2707683|-_13 (r_advmod) induced_16\VBN\1627355|NONE_0 (r_amod) alf_17\NNP\0|NONE_0 (r_pobj) for_13\IN\0|emergently_11 (r_prep) transplanted_11\VBN\2013571|NONE_0 (r_acl) patients_10\NNS\9898892|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) outcomes_8\NNS\7291312|despite_54|,_2|comparable_81|._170 (r_nsubj) were_18\VBD\0|NONE_0 (l_acomp) comparable_19\JJ\0|despite_135|,_83|outcomes_81|._89 (l_prep) to_20\IN\0|NONE_0 (l_pobj) those_21\DT\0|NONE_0 (l_acl) transplanted_22\VBN\2013571|NONE_0 (l_prep) for_32\IN\0|for_49 (l_pobj) cld_33\NNP\0|electively_15
D000082_D008107 NONE acetaminophen_26\RB\2707683|non_4|-_1|-_13 (r_advmod) induced_28\VBN\1627355|NONE_0 (r_amod) alf_29\NNP\0|and_4 (r_pobj) for_23\IN\0|for_49 (r_prep) transplanted_22\VBN\2013571|NONE_0 (l_prep) for_32\IN\0|for_49 (l_pobj) cld_33\NNP\0|electively_15
D000082_D017114 CID acetaminophen_8\RB\2707683|-_13 (r_advmod) induced_10\VBN\1627355|acute_8|liver_14 (r_amod) failure_13\NN\66216|NONE_0
D000082_D017114 CID acetaminophen_0\NNP\2707683|-_13 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hepatotoxicity_3\NN\0|cause_34|._78 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) cause_8\NN\7323922|hepatotoxicity_34|._44 (l_prep) of_9\IN\0|the_22|common_13 (l_pobj) failure_12\NN\66216|NONE_0
D000082_D017114 CID acetaminophen_0\NNP\2707683|-_13 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hepatotoxicity_3\NN\0|cause_34|._78 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) cause_8\NN\7323922|hepatotoxicity_34|._44 (l_prep) of_9\IN\0|the_22|common_13 (l_pobj) failure_12\NN\66216|NONE_0 (l_appos) alf_14\NNP\0|acute_21|liver_15|(_1|in_5
D000082_D017114 CID acetaminophen_34\RB\2707683|-_13 (r_advmod) induced_36\VBN\1627355|n=36_13 (r_amod) alf_37\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_34\RB\2707683|-_13 (r_advmod) induced_36\VBN\1627355|n=36_13 (r_amod) alf_37\NNP\0|NONE_0 (l_appos) n=36_39\NNP\0|induced_13 (l_prep) with_41\IN\0|(_7|)_2 (l_pobj) patients_47\NNS\9898892|NONE_0 (l_acl) undergoing_48\VBG\109660|age-_30|matched_17 (l_dobj) lt_50\NN\0|NONE_0 (l_prep) for_51\IN\0|emergent_12 (l_pobj) alf_57\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_54\RB\2707683|non_4|-_1|-_13 (r_advmod) induced_56\VBN\1627355|(_12|n=35_13|)_17|and_19|lt_32 (r_amod) alf_57\NNP\0|NONE_0 (r_pobj) for_51\IN\0|emergent_12 (r_prep) lt_50\NN\0|NONE_0 (r_dobj) undergoing_48\VBG\109660|age-_30|matched_17 (r_acl) patients_47\NNS\9898892|NONE_0 (r_pobj) with_41\IN\0|(_7|)_2 (r_prep) n=36_39\NNP\0|induced_13 (r_appos) alf_37\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_54\RB\2707683|non_4|-_1|-_13 (r_advmod) induced_56\VBN\1627355|(_12|n=35_13|)_17|and_19|lt_32 (r_amod) alf_57\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_0\NNP\2707683|-_13 (r_npadvmod) induced_2\VBN\1627355|alf_8|undergoing_21 (r_amod) patients_4\NNS\9898892|severity_37|._209 (l_compound) alf_3\NNP\0|induced_8|undergoing_13
D000082_D017114 CID acetaminophen_5\RB\2707683|-_13 (r_advmod) induced_7\VBN\1627355|twenty_27|(_20|%_17|alf_8 (r_amod) patients_9\NNS\9898892|diagnosis_34|before_44 (l_compound) alf_8\NNP\0|twenty_35|(_28|%_25|induced_8
D000082_D017114 CID acetaminophen_5\RB\2707683|-_13 (r_advmod) induced_7\VBN\1627355|twenty_27|(_20|%_17|alf_8 (r_amod) patients_9\NNS\9898892|diagnosis_34|before_44 (r_nsubj) had_10\VBD\0|;_90|p<0.01_92|attempt_146|._153 (l_prep) before_15\IN\0|patients_44|diagnosis_10 (l_pobj) lt_16\NNP\0|NONE_0 (l_appos) alf=0/35_23\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_20\RB\2707683|-_13 (r_advmod) induced_22\VBN\1627355|non_18|,_16|cld=2/34_18 (r_amod) alf=0/35_23\NNP\0|NONE_0 (r_appos) lt_16\NNP\0|NONE_0 (r_pobj) before_15\IN\0|patients_44|diagnosis_10 (r_prep) had_10\VBD\0|;_90|p<0.01_92|attempt_146|._153 (l_nsubj) patients_9\NNS\9898892|diagnosis_34|before_44 (l_compound) alf_8\NNP\0|twenty_35|(_28|%_25|induced_8
D000082_D017114 CID acetaminophen_20\RB\2707683|-_13 (r_advmod) induced_22\VBN\1627355|non_18|,_16|cld=2/34_18 (r_amod) alf=0/35_23\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_31\RB\2707683|-_13 (r_advmod) induced_33\VBN\1627355|year_14 (r_amod) alf_34\NNP\0|the_34|(_23|;_27|alf_55
D000082_D017114 CID acetaminophen_31\RB\2707683|-_13 (r_advmod) induced_33\VBN\1627355|year_14 (r_amod) alf_34\NNP\0|the_34|(_23|;_27|alf_55 (r_appos) groups_29\NNS\2137|NONE_0 (l_appos) alf_50\NNP\0|the_89|(_78|alf_55|;_28
D000082_D017114 CID acetaminophen_47\RB\2707683|-_13 (r_advmod) induced_49\VBN\1627355|-_15 (r_acomp) non_45\AFX\0|%_32|;_38 (r_nmod) alf_50\NNP\0|the_89|(_78|alf_55|;_28 (r_appos) groups_29\NNS\2137|NONE_0 (l_appos) alf_34\NNP\0|the_34|(_23|;_27|alf_55
D000082_D017114 CID acetaminophen_47\RB\2707683|-_13 (r_advmod) induced_49\VBN\1627355|-_15 (r_acomp) non_45\AFX\0|%_32|;_38 (r_nmod) alf_50\NNP\0|the_89|(_78|alf_55|;_28
D000082_D017114 CID acetaminophen_1\RB\2707683|-_13 (r_advmod) induced_3\VBN\1627355|two_18|alf_8 (r_amod) patients_5\NNS\9898892|lt_34|._63 (l_compound) alf_4\NNP\0|two_26|induced_8
D000082_D017114 CID acetaminophen_14\RB\2707683|-_13 (r_advmod) induced_16\VBN\1627355|NONE_0 (r_amod) alf_17\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_14\RB\2707683|-_13 (r_advmod) induced_16\VBN\1627355|NONE_0 (r_amod) alf_17\NNP\0|NONE_0 (r_pobj) for_13\IN\0|emergently_11 (r_prep) transplanted_11\VBN\2013571|NONE_0 (r_acl) patients_10\NNS\9898892|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) outcomes_8\NNS\7291312|despite_54|,_2|comparable_81|._170 (r_nsubj) were_18\VBD\0|NONE_0 (l_acomp) comparable_19\JJ\0|despite_135|,_83|outcomes_81|._89 (l_prep) to_20\IN\0|NONE_0 (l_pobj) those_21\DT\0|NONE_0 (l_acl) transplanted_22\VBN\2013571|NONE_0 (l_prep) for_23\IN\0|for_49 (l_pobj) alf_29\NNP\0|and_4
D000082_D017114 CID acetaminophen_26\RB\2707683|non_4|-_1|-_13 (r_advmod) induced_28\VBN\1627355|NONE_0 (r_amod) alf_29\NNP\0|and_4 (r_pobj) for_23\IN\0|for_49 (r_prep) transplanted_22\VBN\2013571|NONE_0 (r_acl) those_21\DT\0|NONE_0 (r_pobj) to_20\IN\0|NONE_0 (r_prep) comparable_19\JJ\0|despite_135|,_83|outcomes_81|._89 (r_acomp) were_18\VBD\0|NONE_0 (l_nsubj) outcomes_8\NNS\7291312|despite_54|,_2|comparable_81|._170 (l_prep) for_9\IN\0|NONE_0 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_acl) transplanted_11\VBN\2013571|NONE_0 (l_prep) for_13\IN\0|emergently_11 (l_pobj) alf_17\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_26\RB\2707683|non_4|-_1|-_13 (r_advmod) induced_28\VBN\1627355|NONE_0 (r_amod) alf_29\NNP\0|and_4
1423336
D010649_D007022 NONE phenylalanine_0\NNP\14605787|with_59 (r_nsubj) competing_10\VBG\0|,_68|effects_115|._134 (r_advcl) reduced_22\VBD\441445|NONE_0 (l_dobj) effects_27\NNS\13245626|competing_115|,_47|._19 (l_amod) hypotensive_24\JJ\10405694|the_4|of_41
D000596_D007022 NONE acid_6\NN\14818238|,_24 (r_appos) phenylalanine_0\NNP\14605787|with_59 (r_nsubj) competing_10\VBG\0|,_68|effects_115|._134 (r_advcl) reduced_22\VBD\441445|NONE_0 (l_dobj) effects_27\NNS\13245626|competing_115|,_47|._19 (l_amod) hypotensive_24\JJ\10405694|the_4|of_41
D007980_D007022 CID levodopa_6\NN\14604959|NONE_0 (r_pobj) of_5\IN\0|the_23|hypotensive_19 (r_prep) effect_4\NN\34213|NONE_0 (l_amod) hypotensive_3\JJ\10405694|the_4|of_19
D007980_D007022 CID levodopa_7\NN\14604959|NONE_0 (r_pobj) of_6\IN\0|the_23|hypotensive_19 (r_prep) effect_5\NN\34213|NONE_0 (l_amod) hypotensive_4\JJ\10405694|the_4|of_19
D007980_D007022 CID levodopa_12\NN\14604959|NONE_0 (r_pobj) with_11\IN\0|phenylalanine_59 (r_prep) competing_10\VBG\0|,_68|effects_115|._134 (r_advcl) reduced_22\VBD\441445|NONE_0 (l_dobj) effects_27\NNS\13245626|competing_115|,_47|._19 (l_amod) hypotensive_24\JJ\10405694|the_4|of_41
D007980_D007022 CID levodopa_29\NN\14604959|NONE_0 (r_pobj) of_28\IN\0|the_45|hypotensive_41 (r_prep) effects_27\NNS\13245626|competing_115|,_47|._19 (l_amod) hypotensive_24\JJ\10405694|the_4|of_41
D007980_D007022 CID levodopa_3\NN\14604959|that_5|action_35 (r_nsubj) has_4\VBZ\13888491|we_26|._89 (l_dobj) action_8\NN\30358|that_40|levodopa_35 (l_amod) hypotensive_7\JJ\10405694|a_10|central_8|parallels_24
D007980_D010300 NONE levodopa_6\NN\14604959|NONE_0 (l_prep) in_7\IN\13603305|NONE_0 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_amod) parkinsonian_8\JJ\0|NONE_0
D007980_D010300 NONE levodopa_5\NN\14604959|NONE_0 (r_pobj) of_3\IN\0|pressure_17 (r_prep) effects_2\NNS\13245626|were_25|in_39|levodopa_105|._113 (r_nsubjpass) examined_7\VBN\0|NONE_0 (l_prep) in_8\IN\13603305|effects_39|were_14|levodopa_66|._74 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) parkinsonian_9\JJ\0|with_22
D007980_D010300 NONE levodopa_17\VB\14604959|effects_105|were_80|in_66|._8 (r_advcl) examined_7\VBN\0|NONE_0 (l_prep) in_8\IN\13603305|effects_39|were_14|levodopa_66|._74 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) parkinsonian_9\JJ\0|with_22
16906379
D008911_D011565 NONE minocycline_9\NN\4416530|who_20|had_16|been_12|for_12|with_104 (r_dobj) taking_8\VBG\37396|a_31|old_21|._149 (l_prep) for_10\IN\0|who_32|had_28|been_24|minocycline_12|with_92 (l_pobj) fever_14\NN\14299637|NONE_0 (l_nmod) pustulosis_12\NN\0|developed_11|,_26|myalgias_28|,_73
D008911_D005334 NONE minocycline_9\NN\4416530|who_20|had_16|been_12|for_12|with_104 (r_dobj) taking_8\VBG\37396|a_31|old_21|._149 (l_prep) for_10\IN\0|who_32|had_28|been_24|minocycline_12|with_92 (l_pobj) fever_14\NN\14299637|NONE_0
D008911_D014657 NONE minocycline_0\NNP\4416530|-_11 (r_npadvmod) induced_2\VBN\1627355|fulfilling_19|._66 (r_amod) vasculitis_3\NN\14336539|NONE_0
D008911_D014657 NONE minocycline_10\NN\4416530|-_11 (r_npadvmod) induced_12\VBN\1627355|satisfying_19 (r_amod) vasculitis_13\NN\14336539|NONE_0
D008911_D011115 NONE minocycline_9\NN\4416530|who_20|had_16|been_12|for_12|with_104 (r_dobj) taking_8\VBG\37396|a_31|old_21|._149 (l_prep) for_10\IN\0|who_32|had_28|been_24|minocycline_12|with_92 (l_pobj) fever_14\NN\14299637|NONE_0 (l_conj) myalgias_16\NNS\14322699|pustulosis_28|developed_17|,_2|,_45 (l_conj) polyneuropathy_18\VBP\0|,_2
D008911_D013733 NONE minocycline_9\NN\4416530|who_20|had_16|been_12|for_12|with_104 (r_dobj) taking_8\VBG\37396|a_31|old_21|._149 (l_prep) for_10\IN\0|who_32|had_28|been_24|minocycline_12|with_92 (l_pobj) fever_14\NN\14299637|NONE_0 (l_conj) myalgias_16\NNS\14322699|pustulosis_28|developed_17|,_2|,_45 (l_conj) polyneuropathy_18\VBP\0|,_2 (l_conj) pain_22\NN\14299637|,_17|and_15
D008911_D010488 CID minocycline_0\NNP\4416530|-_11 (r_npadvmod) induced_2\VBN\1627355|fulfilling_19|._66 (r_amod) vasculitis_3\NN\14336539|NONE_0 (l_acl) fulfilling_4\VBG\484166|induced_19|._47 (l_dobj) criteria_6\NNS\13577171|NONE_0 (l_prep) of_7\IN\0|the_13 (l_pobj) nodosa_9\NN\0|NONE_0
D008911_D063806 NONE minocycline_9\NN\4416530|who_20|had_16|been_12|for_12|with_104 (r_dobj) taking_8\VBG\37396|a_31|old_21|._149 (l_prep) for_10\IN\0|who_32|had_28|been_24|minocycline_12|with_92 (l_pobj) fever_14\NN\14299637|NONE_0 (l_conj) myalgias_16\NNS\14322699|pustulosis_28|developed_17|,_2|,_45
12523489
D000661_D006948 NONE amphetamine_12\NN\3248958|-_11 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) hyperactivity_15\NN\14052403|NONE_0 (r_pobj) than_11\IN\0|hyperactivity_64|is_50|more_47|by_31|._38 (r_prep) influenced_6\VBN\137313|NONE_0 (l_nsubjpass) hyperactivity_3\NN\14052403|is_14|more_17|by_33|than_64|._102
D000661_D006948 NONE amphetamine_12\NN\3248958|-_11 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) hyperactivity_15\NN\14052403|NONE_0
D000661_D006948 NONE amphetamine_12\NN\3248958|-_11 (r_npadvmod) induced_14\VBN\1627355|-_17|and_16 (r_conj) cocaine_9\NN\3492717|NONE_0 (r_nmod) hyperactivity_15\NN\14052403|NONE_0
D000661_D006948 NONE amphetamine_7\NN\3248958|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) hyperactivity_10\NN\14052403|similarly_73|,_64|agonists_39|,_13|but_15|at_19|._100
D000661_D006948 NONE amphetamine_7\NN\3248958|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) hyperactivity_10\NN\14052403|similarly_73|,_64|agonists_39|,_13|but_15|at_19|._100 (r_dobj) decreased_6\VBD\169651|NONE_0 (l_conj) at_13\IN\14622893|similarly_92|,_83|agonists_58|hyperactivity_19|,_6|but_4|._81 (l_pobj) doses_16\NNS\3740161|NONE_0 (l_prep) than_17\IN\0|the_17|higher_13 (l_pobj) those_18\DT\0|NONE_0 (l_relcl) were_20\VBD\0|NONE_0 (l_acomp) active_21\JJ\14779550|which_11 (l_prep) in_22\IN\13603305|NONE_0 (l_pobj) hyperactivity_26\NN\14052403|NONE_0
D000661_D006948 NONE amphetamine_17\NN\3248958|-_11 (r_npadvmod) induced_19\VBN\1627355|locomotor_8 (r_amod) activity_21\NN\30358|that_99|agonists_71|cocaine-_43|and_34|and_9|indicate_13 (r_dobj) reduce_14\VBP\441445|results_68|have_60|._223 (l_conj) indicate_23\VBP\952524|that_112|agonists_84|cocaine-_56|and_47|activity_13|and_4 (l_ccomp) influenced_31\VBN\137313|NONE_0 (l_nsubjpass) hyperactivity_28\NN\14052403|that_21|is_14|more_17|by_33|than_92
D000661_D006948 NONE amphetamine_17\NN\3248958|-_11 (r_npadvmod) induced_19\VBN\1627355|locomotor_8 (r_amod) activity_21\NN\30358|that_99|agonists_71|cocaine-_43|and_34|and_9|indicate_13 (r_dobj) reduce_14\VBP\441445|results_68|have_60|._223 (l_conj) indicate_23\VBP\952524|that_112|agonists_84|cocaine-_56|and_47|activity_13|and_4 (l_ccomp) influenced_31\VBN\137313|NONE_0 (l_prep) than_41\IN\0|that_113|hyperactivity_92|is_78|more_75|by_59 (l_pobj) hyperactivity_45\NN\14052403|NONE_0
D000661_D006948 NONE amphetamine_42\NN\3248958|-_11 (r_npadvmod) induced_44\VBN\1627355|NONE_0 (r_amod) hyperactivity_45\NN\14052403|NONE_0 (r_pobj) than_41\IN\0|that_113|hyperactivity_92|is_78|more_75|by_59 (r_prep) influenced_31\VBN\137313|NONE_0 (l_nsubjpass) hyperactivity_28\NN\14052403|that_21|is_14|more_17|by_33|than_92
D000661_D006948 NONE amphetamine_42\NN\3248958|-_11 (r_npadvmod) induced_44\VBN\1627355|NONE_0 (r_amod) hyperactivity_45\NN\14052403|NONE_0
D003042_D006948 NONE cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hyperactivity_3\NN\14052403|is_14|more_17|by_33|than_64|._102
D003042_D006948 NONE cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hyperactivity_3\NN\14052403|is_14|more_17|by_33|than_64|._102 (r_nsubjpass) influenced_6\VBN\137313|NONE_0 (l_prep) than_11\IN\0|hyperactivity_64|is_50|more_47|by_31|._38 (l_pobj) hyperactivity_15\NN\14052403|NONE_0
D003042_D006948 NONE cocaine_9\NN\3492717|NONE_0 (r_nmod) hyperactivity_15\NN\14052403|NONE_0
D003042_D006948 NONE cocaine_23\NN\3492717|-_7 (r_npadvmod) induced_25\VBN\1627355|NONE_0 (r_amod) hyperactivity_26\NN\14052403|NONE_0 (r_pobj) in_22\IN\13603305|NONE_0 (r_prep) active_21\JJ\14779550|which_11 (r_acomp) were_20\VBD\0|NONE_0 (r_relcl) those_18\DT\0|NONE_0 (r_pobj) than_17\IN\0|the_17|higher_13 (r_prep) doses_16\NNS\3740161|NONE_0 (r_pobj) at_13\IN\14622893|similarly_92|,_83|agonists_58|hyperactivity_19|,_6|but_4|._81 (r_conj) decreased_6\VBD\169651|NONE_0 (l_dobj) hyperactivity_10\NN\14052403|similarly_73|,_64|agonists_39|,_13|but_15|at_19|._100
D003042_D006948 NONE cocaine_23\NN\3492717|-_7 (r_npadvmod) induced_25\VBN\1627355|NONE_0 (r_amod) hyperactivity_26\NN\14052403|NONE_0
D003042_D006948 NONE cocaine-_15\JJ\0|that_56|agonists_28|and_9|activity_43|and_52|indicate_56 (r_dobj) reduce_14\VBP\441445|results_68|have_60|._223 (l_conj) indicate_23\VBP\952524|that_112|agonists_84|cocaine-_56|and_47|activity_13|and_4 (l_ccomp) influenced_31\VBN\137313|NONE_0 (l_nsubjpass) hyperactivity_28\NN\14052403|that_21|is_14|more_17|by_33|than_92
D003042_D006948 NONE cocaine-_15\JJ\0|that_56|agonists_28|and_9|activity_43|and_52|indicate_56 (r_dobj) reduce_14\VBP\441445|results_68|have_60|._223 (l_conj) indicate_23\VBP\952524|that_112|agonists_84|cocaine-_56|and_47|activity_13|and_4 (l_ccomp) influenced_31\VBN\137313|NONE_0 (l_prep) than_41\IN\0|that_113|hyperactivity_92|is_78|more_75|by_59 (l_pobj) hyperactivity_45\NN\14052403|NONE_0
D003042_D006948 NONE cocaine_25\NN\3492717|-_7 (r_npadvmod) induced_27\VBN\1627355|NONE_0 (r_amod) hyperactivity_28\NN\14052403|that_21|is_14|more_17|by_33|than_92
D003042_D006948 NONE cocaine_25\NN\3492717|-_7 (r_npadvmod) induced_27\VBN\1627355|NONE_0 (r_amod) hyperactivity_28\NN\14052403|that_21|is_14|more_17|by_33|than_92 (r_nsubjpass) influenced_31\VBN\137313|NONE_0 (l_prep) than_41\IN\0|that_113|hyperactivity_92|is_78|more_75|by_59 (l_pobj) hyperactivity_45\NN\14052403|NONE_0
D000241_D006948 NONE adenosine_8\NN\14964367|receptor_10 (r_amod) agonists_10\NNS\0|NONE_0 (r_pobj) by_7\IN\0|hyperactivity_33|is_19|more_16|than_31|._69 (r_agent) influenced_6\VBN\137313|NONE_0 (l_nsubjpass) hyperactivity_3\NN\14052403|is_14|more_17|by_33|than_64|._102
D000241_D006948 NONE adenosine_8\NN\14964367|receptor_10 (r_amod) agonists_10\NNS\0|NONE_0 (r_pobj) by_7\IN\0|hyperactivity_33|is_19|more_16|than_31|._69 (r_agent) influenced_6\VBN\137313|NONE_0 (l_prep) than_11\IN\0|hyperactivity_64|is_50|more_47|by_31|._38 (l_pobj) hyperactivity_15\NN\14052403|NONE_0
D000241_D006948 NONE adenosine_3\NN\14964367|receptor_10|and_28|antagonists_32 (r_amod) agonists_5\NNS\0|NONE_0 (l_conj) antagonists_7\NNS\7846|adenosine_32|receptor_22|and_4 (l_prep) on_8\IN\0|NONE_0 (l_pobj) hyperactivity_15\NN\14052403|NONE_0
D000241_D006948 NONE adenosine_3\NN\14964367|all_4|receptor_10 (r_amod) agonists_5\NNS\0|similarly_34|,_25|hyperactivity_39|,_52|but_54|at_58|._139 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_dobj) hyperactivity_10\NN\14052403|similarly_73|,_64|agonists_39|,_13|but_15|at_19|._100
D000241_D006948 NONE adenosine_3\NN\14964367|all_4|receptor_10 (r_amod) agonists_5\NNS\0|similarly_34|,_25|hyperactivity_39|,_52|but_54|at_58|._139 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_conj) at_13\IN\14622893|similarly_92|,_83|agonists_58|hyperactivity_19|,_6|but_4|._81 (l_pobj) doses_16\NNS\3740161|NONE_0 (l_prep) than_17\IN\0|the_17|higher_13 (l_pobj) those_18\DT\0|NONE_0 (l_relcl) were_20\VBD\0|NONE_0 (l_acomp) active_21\JJ\14779550|which_11 (l_prep) in_22\IN\13603305|NONE_0 (l_pobj) hyperactivity_26\NN\14052403|NONE_0
D000241_D006948 NONE adenosine_6\NN\14964367|all_4|receptor_10|(_28|a1_29|)_38 (r_amod) agonists_8\NNS\0|that_28|cocaine-_28|and_37|activity_71|and_80|indicate_84 (r_nsubj) reduce_14\VBP\441445|results_68|have_60|._223 (l_conj) indicate_23\VBP\952524|that_112|agonists_84|cocaine-_56|and_47|activity_13|and_4 (l_ccomp) influenced_31\VBN\137313|NONE_0 (l_nsubjpass) hyperactivity_28\NN\14052403|that_21|is_14|more_17|by_33|than_92
D000241_D006948 NONE adenosine_6\NN\14964367|all_4|receptor_10|(_28|a1_29|)_38 (r_amod) agonists_8\NNS\0|that_28|cocaine-_28|and_37|activity_71|and_80|indicate_84 (r_nsubj) reduce_14\VBP\441445|results_68|have_60|._223 (l_conj) indicate_23\VBP\952524|that_112|agonists_84|cocaine-_56|and_47|activity_13|and_4 (l_ccomp) influenced_31\VBN\137313|NONE_0 (l_prep) than_41\IN\0|that_113|hyperactivity_92|is_78|more_75|by_59 (l_pobj) hyperactivity_45\NN\14052403|NONE_0
D000241_D006948 NONE adenosine_33\NN\14964367|receptor_10|(_28|receptors_45|)_54 (r_amod) agonists_35\NNS\0|NONE_0 (r_pobj) by_32\IN\0|that_54|hyperactivity_33|is_19|more_16|than_59 (r_agent) influenced_31\VBN\137313|NONE_0 (l_nsubjpass) hyperactivity_28\NN\14052403|that_21|is_14|more_17|by_33|than_92
D000241_D006948 NONE adenosine_33\NN\14964367|receptor_10|(_28|receptors_45|)_54 (r_amod) agonists_35\NNS\0|NONE_0 (r_pobj) by_32\IN\0|that_54|hyperactivity_33|is_19|more_16|than_59 (r_agent) influenced_31\VBN\137313|NONE_0 (l_prep) than_41\IN\0|that_113|hyperactivity_92|is_78|more_75|by_59 (l_pobj) hyperactivity_45\NN\14052403|NONE_0
D000241_D004409 NONE adenosine_1\NN\14964367|all_4|receptor_10 (r_amod) agonists_3\NNS\0|significantly_9|activity_47|,_63|and_65|were_81 (r_nsubj) decreased_5\VBD\169651|NONE_0 (l_dobj) activity_8\NN\30358|agonists_47|significantly_38|,_16|and_18|were_34
6453500
D004221_D056486 CID disulfiram_4\NN\3740161|NONE_0 (r_pobj) by_3\IN\0|hepatitis_18|in_14|._32 (r_prep) induced_2\VBN\1627355|NONE_0 (l_nsubj) hepatitis_1\NN\14127211|by_18|in_32|._50
D004221_D056486 CID disulfiram_15\NN\3740161|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|a_22|alcoholic_16 (r_acl) woman_12\NN\9605289|NONE_0 (r_pobj) in_7\IN\13603305|damage_20|was_13|._48 (r_prep) observed_6\VBN\2163746|NONE_0 (l_nsubjpass) damage_4\NN\7296428|was_7|in_20|._68
146391
D010672_D003875 CID diphenylhydantoin_13\NN\3550533|NONE_0 (r_dobj) taking_12\VBG\37396|a_10 (r_acl) patient_11\NN\9898892|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) lymphadenopathy_8\NN\14204950|toxic_21|and_4 (r_conj) dermatitis_6\NN\14226056|pure_29|cell_20|,_8|._68
D010672_D012010 CID diphenylhydantoin_13\NN\3550533|NONE_0 (r_dobj) taking_12\VBG\37396|a_10 (r_acl) patient_11\NN\9898892|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) lymphadenopathy_8\NN\14204950|toxic_21|and_4 (r_conj) dermatitis_6\NN\14226056|pure_29|cell_20|,_8|._68 (r_conj) aplasia_3\NN\14365950|NONE_0
D010672_D012010 CID diphenylhydantoin_3\NN\3550533|for_18 (r_dobj) taking_2\VBG\37396|a_10 (r_acl) patient_1\NN\9898892|rash_74|._121 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) rash_11\NN\14321469|patient_74|._47 (l_appos) aplasia_18\NN\14365950|a_59|generalized_57|skin_45|,_36
D010672_D012010 CID diphenylhydantoin_6\NN\3550533|NONE_0 (r_compound) medication_7\NN\3247620|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|pure_22|cell_13 (r_acl) aplasia_3\NN\14365950|has_53|been_57|in_71|._84
D010672_D012010 CID diphenylhydantoin_10\NN\3550533|NONE_0 (r_pobj) of_9\IN\0|the_14|and_21|occurrence_29 (r_prep) ingestion_8\NN\13440063|NONE_0 (l_conj) occurrence_13\NN\29378|the_43|of_29|and_8 (l_prep) of_14\IN\0|the_15 (l_pobj) rash_17\NN\14321469|NONE_0 (l_conj) lymphadenopathy_19\JJ\14204950|the_15|skin_11|,_2 (l_conj) aplasia_24\NN\14365950|and_18
D010672_D005076 NONE diphenylhydantoin_3\NN\3550533|for_18 (r_dobj) taking_2\VBG\37396|a_10 (r_acl) patient_1\NN\9898892|rash_74|._121 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) rash_11\NN\14321469|patient_74|._47
D010672_D005076 NONE diphenylhydantoin_9\NN\3550533|NONE_0 (r_compound) treatment_10\NN\654885|NONE_0 (r_pobj) of_8\IN\0|a_26|known_19 (r_prep) complication_7\NN\1073995|rash_21|is_47|._86 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) rash_1\NN\14321469|complication_21|is_68|._107
D010672_D005076 NONE diphenylhydantoin_10\NN\3550533|NONE_0 (r_pobj) of_9\IN\0|the_14|and_21|occurrence_29 (r_prep) ingestion_8\NN\13440063|NONE_0 (l_conj) occurrence_13\NN\29378|the_43|of_29|and_8 (l_prep) of_14\IN\0|the_15 (l_pobj) rash_17\NN\14321469|NONE_0
D010672_D008206 CID diphenylhydantoin_13\NN\3550533|NONE_0 (r_dobj) taking_12\VBG\37396|a_10 (r_acl) patient_11\NN\9898892|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) lymphadenopathy_8\NN\14204950|toxic_21|and_4
D010672_D008206 CID diphenylhydantoin_3\NN\3550533|for_18 (r_dobj) taking_2\VBG\37396|a_10 (r_acl) patient_1\NN\9898892|rash_74|._121 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) rash_11\NN\14321469|patient_74|._47 (l_appos) aplasia_18\NN\14365950|a_59|generalized_57|skin_45|,_36 (l_amod) lymphadenopathy_13\JJ\14204950|pure_20|cell_29
D010672_D008206 CID diphenylhydantoin_9\NN\3550533|NONE_0 (r_compound) treatment_10\NN\654885|NONE_0 (r_pobj) of_8\IN\0|a_26|known_19 (r_prep) complication_7\NN\1073995|rash_21|is_47|._86 (r_attr) is_2\VBZ\0|NONE_0 (l_advcl) is_12\VBZ\0|rash_68|complication_47|._39 (l_acomp) lymphadenopathy_16\NN\14204950|as_27
D010672_D008206 CID diphenylhydantoin_10\NN\3550533|NONE_0 (r_pobj) of_9\IN\0|the_14|and_21|occurrence_29 (r_prep) ingestion_8\NN\13440063|NONE_0 (l_conj) occurrence_13\NN\29378|the_43|of_29|and_8 (l_prep) of_14\IN\0|the_15 (l_pobj) rash_17\NN\14321469|NONE_0 (l_conj) lymphadenopathy_19\JJ\14204950|the_15|skin_11|,_2
6673474
D009599_D007022 CID nitroprusside_14\NN\0|NONE_0 (r_amod) sodium_13\NN\14625458|NONE_0 (r_pobj) under_12\IN\0|NONE_0 (r_prep) dogs_11\NNS\2083346|NONE_0 (r_pobj) in_10\IN\13603305|flow_47|were_13|and_41|trimetaphan_45|._136 (r_prep) studied_9\VBN\0|NONE_0 (l_conj) trimetaphan_19\NN\0|flow_92|were_58|in_45|and_4|._91 (l_pobj) hypotension_24\NN\14057371|NONE_0
D009599_D007022 CID snp_16\NNP\11493266|NONE_0 (r_appos) nitroprusside_14\NN\0|NONE_0 (r_amod) sodium_13\NN\14625458|NONE_0 (r_pobj) under_12\IN\0|NONE_0 (r_prep) dogs_11\NNS\2083346|NONE_0 (r_pobj) in_10\IN\13603305|flow_47|were_13|and_41|trimetaphan_45|._136 (r_prep) studied_9\VBN\0|NONE_0 (l_conj) trimetaphan_19\NN\0|flow_92|were_58|in_45|and_4|._91 (l_pobj) hypotension_24\NN\14057371|NONE_0
D009599_D007022 CID nitroprusside_30\JJ\0|NONE_0 (r_amod) hypotension_31\NN\14057371|that_19|could_12|be_18|safely_21|to_33|decrease_60 (r_nsubjpass) used_35\VBN\0|regarding_195|we_64|could_61|._114 (r_ccomp) confirm_28\VB\0|NONE_0 (l_prep) regarding_0\VBG\689344|we_131|could_134|used_195|._309 (l_pobj) effects_2\NNS\13245626|NONE_0 (l_prep) of_3\IN\0|the_12 (l_pobj) hypotension_7\NN\14057371|NONE_0
D009599_D007022 CID nitroprusside_30\JJ\0|NONE_0 (r_amod) hypotension_31\NN\14057371|that_19|could_12|be_18|safely_21|to_33|decrease_60
D009599_D007022 CID nitroprusside_30\JJ\0|NONE_0 (r_amod) hypotension_31\NN\14057371|that_19|could_12|be_18|safely_21|to_33|decrease_60 (r_nsubjpass) used_35\VBN\0|regarding_195|we_64|could_61|._114 (l_advcl) decrease_42\NN\7296428|that_79|hypotension_60|could_48|be_42|safely_39|to_27 (l_conj) decrease_54\NN\7296428|mean_94|pressure_83|from_65|,_53 (l_dep) hypotension_47\NN\14057371|trimetaphan_12|mean_19|pressure_30
D009599_D007022 CID snp_6\NNP\11493266|NONE_0 (r_compound) hypotension_7\NN\14057371|NONE_0
D014294_D007022 CID trimetaphan_19\NN\0|flow_92|were_58|in_45|and_4|._91 (l_pobj) hypotension_24\NN\14057371|NONE_0
D014294_D007022 CID tmp_21\NNP\0|(_1|)_3|deliberate_5|(_28|%_31|decrease_55 (r_nmod) hypotension_24\NN\14057371|NONE_0
D014294_D007022 CID trimetaphan_46\NN\0|hypotension_12|mean_31|pressure_42 (r_mark) decrease_54\NN\7296428|mean_94|pressure_83|from_65|,_53 (r_conj) decrease_42\NN\7296428|that_79|hypotension_60|could_48|be_42|safely_39|to_27 (r_advcl) used_35\VBN\0|regarding_195|we_64|could_61|._114 (r_ccomp) confirm_28\VB\0|NONE_0 (l_prep) regarding_0\VBG\689344|we_131|could_134|used_195|._309 (l_pobj) effects_2\NNS\13245626|NONE_0 (l_prep) of_3\IN\0|the_12 (l_pobj) hypotension_7\NN\14057371|NONE_0
D014294_D007022 CID trimetaphan_46\NN\0|hypotension_12|mean_31|pressure_42 (r_mark) decrease_54\NN\7296428|mean_94|pressure_83|from_65|,_53 (r_conj) decrease_42\NN\7296428|that_79|hypotension_60|could_48|be_42|safely_39|to_27 (r_advcl) used_35\VBN\0|regarding_195|we_64|could_61|._114 (l_nsubjpass) hypotension_31\NN\14057371|that_19|could_12|be_18|safely_21|to_33|decrease_60
D014294_D007022 CID trimetaphan_46\NN\0|hypotension_12|mean_31|pressure_42 (r_mark) decrease_54\NN\7296428|mean_94|pressure_83|from_65|,_53 (l_dep) hypotension_47\NN\14057371|trimetaphan_12|mean_19|pressure_30
20046642
D002330_D008569 CID bcnu_1\NNP\0|then_5|after_27|data_52|resulted_91|._314 (r_nsubj) revealed_16\VBD\2137132|NONE_0 (l_ccomp) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D002330_D008569 CID bcnu_18\NNP\0|NONE_0 (r_compound) administration_19\NN\1133281|that_10|in_24|,_80|measured_85 (r_nsubj) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D008315_D064420 NONE mda_27\NNP\0|,_2 (r_conj) tnfalpha_25\NNP\0|NONE_0 (r_pobj) of_24\IN\0|the_21|increased_17 (r_prep) levels_23\NNS\4916342|NONE_0 (r_dobj) counteracted_20\VBD\2367363|as_52|it_49|inhibition_33|and_4 (r_conj) prevented_13\VBD\0|in_74|,_61|induction_56|toxicity_15|._161 (r_advcl) halts_5\VBZ\14010148|NONE_0 (l_dobj) toxicity_10\NN\13576101|in_59|,_46|induction_41|prevented_15|._176
D005978_D064420 NONE gsh_17\NNP\0|NONE_0 (r_compound) depletion_18\NN\351638|gr_22|and_8 (r_conj) inhibition_15\NN\1068773|as_19|it_16|and_29|counteracted_33 (r_dobj) prevented_13\VBD\0|in_74|,_61|induction_56|toxicity_15|._161 (r_advcl) halts_5\VBZ\14010148|NONE_0 (l_dobj) toxicity_10\NN\13576101|in_59|,_46|induction_41|prevented_15|._176
D005978_D007859 NONE glutathione_47\NN\0|decreased_22|hippocampal_12|activity_27 (r_compound) reductase_48\NN\14732946|NONE_0 (r_pobj) with_44\IN\0|NONE_0 (r_prep) accompanied_43\VBN\0|as_44|by_32|,_2 (r_conj) measured_35\VBN\697589|that_95|administration_85|in_61|,_5 (r_advcl) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D005978_D007859 NONE glutathione_55\NN\0|(_12|gsh_13 (r_nmod) content_59\NN\7951464|(_44|gr_43|)_41|and_30 (r_conj) activity_52\NN\30358|decreased_49|hippocampal_39|glutathione_27 (r_appos) reductase_48\NN\14732946|NONE_0 (r_pobj) with_44\IN\0|NONE_0 (r_prep) accompanied_43\VBN\0|as_44|by_32|,_2 (r_conj) measured_35\VBN\697589|that_95|administration_85|in_61|,_5 (r_advcl) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D005978_D007859 NONE gsh_57\NNP\0|glutathione_13|(_1 (r_nmod) content_59\NN\7951464|(_44|gr_43|)_41|and_30 (r_conj) activity_52\NN\30358|decreased_49|hippocampal_39|glutathione_27 (r_appos) reductase_48\NN\14732946|NONE_0 (r_pobj) with_44\IN\0|NONE_0 (r_prep) accompanied_43\VBN\0|as_44|by_32|,_2 (r_conj) measured_35\VBN\697589|that_95|administration_85|in_61|,_5 (r_advcl) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D002330_D009336 NONE bcnu_2\NNP\0|NONE_0 (r_compound) administration_3\NN\1133281|also_11|,_7|contents_112|._190 (r_nsubj) increased_4\VBD\169651|NONE_0 (l_dobj) contents_22\NNS\6481320|also_123|,_119|administration_112|._78 (l_nmod) factor_8\NN\7326557|(_60|mda_61|)_64|as_83|activity_96 (l_compound) necrosis_7\NN\11444117|-_15|alpha_16
D008315_D009369 NONE malondialdehyde_18\NN\0|hippocampal_19|and_4 (r_conj) mt_16\NNP\14622893|tnfalpha_23|,_14 (r_appos) alpha_10\NN\6828818|necrosis_16|-_1 (r_appos) factor_8\NN\7326557|(_60|mda_61|)_64|as_83|activity_96 (l_compound) necrosis_7\NN\11444117|-_15|alpha_16 (l_compound) tumor_6\NN\14234074|NONE_0
D008315_D009369 NONE mda_20\NNP\0|factor_61|(_1|)_3|as_22|activity_35 (r_nmod) contents_22\NNS\6481320|also_123|,_119|administration_112|._78 (l_nmod) factor_8\NN\7326557|(_60|mda_61|)_64|as_83|activity_96 (l_compound) necrosis_7\NN\11444117|-_15|alpha_16 (l_compound) tumor_6\NN\14234074|NONE_0
D008315_D009336 NONE malondialdehyde_18\NN\0|hippocampal_19|and_4 (r_conj) mt_16\NNP\14622893|tnfalpha_23|,_14 (r_appos) alpha_10\NN\6828818|necrosis_16|-_1 (r_appos) factor_8\NN\7326557|(_60|mda_61|)_64|as_83|activity_96 (l_compound) necrosis_7\NN\11444117|-_15|alpha_16
D008315_D009336 NONE mda_20\NNP\0|factor_61|(_1|)_3|as_22|activity_35 (r_nmod) contents_22\NNS\6481320|also_123|,_119|administration_112|._78 (l_nmod) factor_8\NN\7326557|(_60|mda_61|)_64|as_83|activity_96 (l_compound) necrosis_7\NN\11444117|-_15|alpha_16
D002330_D007859 CID bcnu_1\NNP\0|then_5|after_27|data_52|resulted_91|._314 (r_nsubj) revealed_16\VBD\2137132|NONE_0 (l_ccomp) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D002330_D007859 CID bcnu_18\NNP\0|NONE_0 (r_compound) administration_19\NN\1133281|that_10|in_24|,_80|measured_85 (r_nsubj) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D008668_D003072 NONE mt_9\NNP\14622893|on_13 (r_compound) induction_10\NN\7450842|NONE_0 (l_prep) on_11\IN\0|mt_13 (l_pobj) carmustine_12\NN\0|NONE_0 (l_appos) dysfunction_17\NN\14204950|NONE_0
D008668_D064420 NONE mt_3\NNP\14622893|NONE_0 (r_compound) induction_4\NN\7450842|in_18|,_5|toxicity_41|prevented_56|._217 (r_nsubj) halts_5\VBZ\14010148|NONE_0 (l_dobj) toxicity_10\NN\13576101|in_59|,_46|induction_41|prevented_15|._176
D008668_D009369 NONE mt_16\NNP\14622893|tnfalpha_23|,_14 (r_appos) alpha_10\NN\6828818|necrosis_16|-_1 (r_appos) factor_8\NN\7326557|(_60|mda_61|)_64|as_83|activity_96 (l_compound) necrosis_7\NN\11444117|-_15|alpha_16 (l_compound) tumor_6\NN\14234074|NONE_0
D002330_D009369 NONE bcnu_2\NNP\0|NONE_0 (r_compound) administration_3\NN\1133281|also_11|,_7|contents_112|._190 (r_nsubj) increased_4\VBD\169651|NONE_0 (l_dobj) contents_22\NNS\6481320|also_123|,_119|administration_112|._78 (l_nmod) factor_8\NN\7326557|(_60|mda_61|)_64|as_83|activity_96 (l_compound) necrosis_7\NN\11444117|-_15|alpha_16 (l_compound) tumor_6\NN\14234074|NONE_0
D008668_D009336 NONE mt_16\NNP\14622893|tnfalpha_23|,_14 (r_appos) alpha_10\NN\6828818|necrosis_16|-_1 (r_appos) factor_8\NN\7326557|(_60|mda_61|)_64|as_83|activity_96 (l_compound) necrosis_7\NN\11444117|-_15|alpha_16
D002330_D064420 NONE bcnu_6\NNP\0|-_4 (r_npadvmod) induced_8\VBN\1627355|hippocampal_8 (r_amod) toxicity_10\NN\13576101|in_59|,_46|induction_41|prevented_15|._176
D005978_D008569 NONE glutathione_47\NN\0|decreased_22|hippocampal_12|activity_27 (r_compound) reductase_48\NN\14732946|NONE_0 (r_pobj) with_44\IN\0|NONE_0 (r_prep) accompanied_43\VBN\0|as_44|by_32|,_2 (r_conj) measured_35\VBN\697589|that_95|administration_85|in_61|,_5 (r_advcl) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D005978_D008569 NONE glutathione_55\NN\0|(_12|gsh_13 (r_nmod) content_59\NN\7951464|(_44|gr_43|)_41|and_30 (r_conj) activity_52\NN\30358|decreased_49|hippocampal_39|glutathione_27 (r_appos) reductase_48\NN\14732946|NONE_0 (r_pobj) with_44\IN\0|NONE_0 (r_prep) accompanied_43\VBN\0|as_44|by_32|,_2 (r_conj) measured_35\VBN\697589|that_95|administration_85|in_61|,_5 (r_advcl) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D005978_D008569 NONE gsh_57\NNP\0|glutathione_13|(_1 (r_nmod) content_59\NN\7951464|(_44|gr_43|)_41|and_30 (r_conj) activity_52\NN\30358|decreased_49|hippocampal_39|glutathione_27 (r_appos) reductase_48\NN\14732946|NONE_0 (r_pobj) with_44\IN\0|NONE_0 (r_prep) accompanied_43\VBN\0|as_44|by_32|,_2 (r_conj) measured_35\VBN\697589|that_95|administration_85|in_61|,_5 (r_advcl) resulted_20\VBD\2633881|then_96|bcnu_91|after_64|data_39|._223 (l_prep) in_21\IN\13603305|that_34|administration_24|,_56|measured_61 (l_pobj) deterioration_22\NN\14560612|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) learning_24\NN\5701944|NONE_0 (l_conj) memory_29\NN\5926676|and_15
D002330_D003072 CID carmustine_12\NN\0|NONE_0 (l_appos) dysfunction_17\NN\14204950|NONE_0
D002330_D003072 CID bcnu)-induced_14\VBN\0|(_1|hippocampal_14|cognitive_26|in_48 (r_amod) dysfunction_17\NN\14204950|NONE_0
24438483
D015742_D066126 NONE propofol_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|the_18|lipid_14 (r_prep) content_17\NN\7951464|may_20|cardiotoxicity_54|._68 (r_nsubj) alleviate_21\VB\205885|treatment_125|has_94|been_90|increase_76|,_40|and_38 (l_dobj) cardiotoxicity_25\NN\0|content_54|may_34|._14
D015742_D066126 NONE propofol_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) intralipid_13\NN\0|NONE_0 (l_conj) emulsions_16\NNS\14588219|or_14 (l_prep) on_17\IN\0|medialipid_21 (l_pobj) cardiotoxicity_21\NN\0|NONE_0
D015742_D066126 NONE propofol_7\NN\0|we_36|delayed_72|induced_105|._177 (r_dobj) conclude_1\VBP\628491|NONE_0 (l_conj) induced_25\VBN\1627355|we_141|propofol_105|delayed_33|._72 (l_dobj) effects_27\NNS\13245626|-_21 (l_amod) cardiotoxic_26\JJ\0|as_28|levels_58
D015742_D066126 NONE propofol_13\NN\0|NONE_0 (r_pcomp) with_12\IN\0|NONE_0 (r_prep) compared_11\VBN\644583|that_48|with_29|in_15|,_2 (r_prep) propofol_7\NN\0|we_36|delayed_72|induced_105|._177 (r_dobj) conclude_1\VBP\628491|NONE_0 (l_conj) induced_25\VBN\1627355|we_141|propofol_105|delayed_33|._72 (l_dobj) effects_27\NNS\13245626|-_21 (l_amod) cardiotoxic_26\JJ\0|as_28|levels_58
D002045_D066126 CID bupivacaine_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|lethal_13 (r_prep) doses_10\NNS\3740161|to_19 (r_dobj) increase_8\VB\13576355|treatment_49|has_18|been_14|,_36|and_38|alleviate_76 (r_xcomp) shown_6\VBN\2137132|NONE_0 (l_conj) alleviate_21\VB\205885|treatment_125|has_94|been_90|increase_76|,_40|and_38 (l_dobj) cardiotoxicity_25\NN\0|content_54|may_34|._14
D002045_D066126 CID bupivacaine_22\NN\0|-_11 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_25\NN\0|content_54|may_34|._14
D002045_D066126 CID bupivacaine_18\NN\0|-_11 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_21\NN\0|NONE_0
D002045_D066126 CID bupivacaine_23\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_10 (r_prep) onset_21\NN\7325190|,_14 (r_dobj) delayed_19\VBD\439958|we_108|propofol_72|induced_33|._105 (r_conj) conclude_1\VBP\628491|NONE_0 (l_conj) induced_25\VBN\1627355|we_141|propofol_105|delayed_33|._72 (l_dobj) effects_27\NNS\13245626|-_21 (l_amod) cardiotoxic_26\JJ\0|as_28|levels_58
D002045_D066126 CID bupivacaine_33\NN\0|NONE_0 (r_compound) levels_34\NNS\4916342|cardiotoxic_58|as_30 (r_conj) effects_27\NNS\13245626|-_21 (l_amod) cardiotoxic_26\JJ\0|as_28|levels_58
D002045_D002318 NONE bupivacaine_4\NN\0|-_11 (r_npadvmod) induced_6\VBN\1627355|cardiovascular_8 (r_amod) depression_8\NN\14373582|NONE_0
D002045_D001145 NONE bupivacaine_37\NN\0|NONE_0 (r_compound) consumption_38\NN\13440063|NONE_0 (r_pobj) of_36\IN\0|total_13 (r_prep) amount_35\NN\13329641|asystole_19 (r_conj) time_30\NN\7308889|mean_28|arterial_23|,_6|and_4 (r_conj) pressure_27\NN\11419404|respective_83|to_66|and_18 (r_conj) times_9\NNS\15113229|we_61|time_49|to_44|,_13|._146 (r_npadvmod) recorded_1\VBD\2225492|NONE_0 (l_prep) to_3\IN\0|we_17|time_5|,_31|times_44|._190 (l_pobj) occurrence_6\NN\29378|NONE_0 (l_amod) dysrhythmia_5\NN\0|first_6
D002045_D006323 CID bupivacaine_37\NN\0|NONE_0 (r_compound) consumption_38\NN\13440063|NONE_0 (r_pobj) of_36\IN\0|total_13 (r_prep) amount_35\NN\13329641|asystole_19 (r_conj) time_30\NN\7308889|mean_28|arterial_23|,_6|and_4 (l_relcl) asystole_32\NN\14204950|amount_19
D015742_D002318 NONE propofol_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|different_29|lipid_19 (r_prep) formulations_12\NNS\14818238|treatment_81|._24 (r_dobj) using_9\VBG\418025|NONE_0 (l_nsubj) treatment_2\NN\654885|formulations_81|._105 (l_prep) of_3\IN\0|pre_14|-_11 (l_pobj) depression_8\NN\14373582|NONE_0
6695685
D014700_D002637 NONE verapamil_8\NN\2938514|in_47|,_2|neither_10|frequency_32|nor_64|suppressed_68|._155 (r_nsubj) increased_10\VBD\169651|NONE_0 (l_prep) in_0\IN\13603305|,_45|verapamil_47|neither_57|frequency_79|nor_111|suppressed_115|._202 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) syndromes_6\NNS\5870365|NONE_0 (l_compound) pain_5\NN\14299637|various_14|chest_6
D014700_D001145 CID verapamil_5\NN\2938514|oral_5 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) during_3\IN\0|accelerated_31|junctional_19|._29 (r_prep) rhythms_2\NNS\15122011|NONE_0
D014700_D001145 CID verapamil_20\NN\2938514|NONE_0 (r_dobj) receiving_18\VBG\2210855|59_12 (r_acl) patients_17\NNS\9898892|NONE_0 (r_pobj) in_15\IN\13603305|rhythms_8 (r_prep) accelerated_12\VBD\226566|study_71|frequency_52|and_4|._70 (l_dobj) rhythms_14\NNS\15122011|in_8
7176945
D013390_D010146 CID suxamethonium_2\NN\0|in_20|._49 (r_compound) pains_3\NNS\786195|NONE_0
D013390_D010146 CID scoline_8\JJ\0|NONE_0 (r_amod) pain_9\NN\14299637|contrary_48|,_10|in_12|._30
D013390_D010146 CID scoline_9\JJ\0|NONE_0 (r_amod) pain_10\NN\14299637|%_40|compared_8|._53
D013390_D010146 CID scoline_20\JJ\0|NONE_0 (r_amod) pain_21\NN\14299637|NONE_0
D013390_D010146 CID suxamethonium_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_21|salt_17 (r_prep) preparation_14\NN\407535|neither_75|the_67|of_58|nor_13|,_55 (r_conj) type_2\NN\5839024|incidence_133|._158 (r_nsubj) affected_24\VBD\126264|NONE_0 (l_dobj) incidence_26\NN\13821570|type_133|._25 (l_prep) of_27\IN\0|the_14 (l_pobj) pain_29\NN\14299637|NONE_0
D013390_D010146 CID scoline_28\JJ\0|NONE_0 (r_amod) pain_29\NN\14299637|NONE_0
D000530_D010146 NONE althesin_7\NNP\0|induction_17|(_1|)_23 (r_appos) agent_5\NN\7347|NONE_0 (r_pobj) of_3\IN\0|neither_17|the_9|nor_45|preparation_58|,_113 (r_prep) type_2\NN\5839024|incidence_133|._158 (r_nsubj) affected_24\VBD\126264|NONE_0 (l_dobj) incidence_26\NN\13821570|type_133|._25 (l_prep) of_27\IN\0|the_14 (l_pobj) pain_29\NN\14299637|NONE_0
D013390_D005207 CID scoline_20\JJ\0|NONE_0 (r_amod) pain_21\NN\14299637|NONE_0 (r_pobj) of_19\IN\0|the_15 (r_prep) occurrence_18\NN\29378|abolition_92|did_22|not_18|._26 (r_dobj) influence_16\VB\5190804|NONE_0 (l_nsubj) abolition_1\NN\209943|did_70|not_74|occurrence_92|._118 (l_prep) of_2\IN\0|the_14|dose_40 (l_pobj) fasciculations_4\NNS\14361664|NONE_0
C084773_D005207 NONE fazadinium_12\NNP\0|NONE_0 (r_pobj) of_11\IN\0|(_20|by_19|kg_8|)_13 (r_prep) dose_10\NN\3740161|the_54|of_40 (r_appos) abolition_1\NN\209943|did_70|not_74|occurrence_92|._118 (l_prep) of_2\IN\0|the_14|dose_40 (l_pobj) fasciculations_4\NNS\14361664|NONE_0
D002712_D010146 NONE chloride_19\NN\14818238|NONE_0 (r_oprd) used_17\VBN\0|NONE_0 (r_acl) suxamethonium_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_21|salt_17 (r_prep) preparation_14\NN\407535|neither_75|the_67|of_58|nor_13|,_55 (r_conj) type_2\NN\5839024|incidence_133|._158 (r_nsubj) affected_24\VBD\126264|NONE_0 (l_dobj) incidence_26\NN\13821570|type_133|._25 (l_prep) of_27\IN\0|the_14 (l_pobj) pain_29\NN\14299637|NONE_0
C084773_D010146 NONE fazadinium_12\NNP\0|NONE_0 (r_pobj) of_11\IN\0|(_20|by_19|kg_8|)_13 (r_prep) dose_10\NN\3740161|the_54|of_40 (r_appos) abolition_1\NN\209943|did_70|not_74|occurrence_92|._118 (r_nsubj) influence_16\VB\5190804|NONE_0 (l_dobj) occurrence_18\NN\29378|abolition_92|did_22|not_18|._26 (l_prep) of_19\IN\0|the_15 (l_pobj) pain_21\NN\14299637|NONE_0
D001965_D010146 NONE bromide_21\NN\14904359|(_13|or_3|)_7 (r_conj) chloride_19\NN\14818238|NONE_0 (r_oprd) used_17\VBN\0|NONE_0 (r_acl) suxamethonium_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_21|salt_17 (r_prep) preparation_14\NN\407535|neither_75|the_67|of_58|nor_13|,_55 (r_conj) type_2\NN\5839024|incidence_133|._158 (r_nsubj) affected_24\VBD\126264|NONE_0 (l_dobj) incidence_26\NN\13821570|type_133|._25 (l_prep) of_27\IN\0|the_14 (l_pobj) pain_29\NN\14299637|NONE_0
D013874_D010146 NONE thiopentone_9\NNP\0|or_3 (r_conj) althesin_7\NNP\0|induction_17|(_1|)_23 (r_appos) agent_5\NN\7347|NONE_0 (r_pobj) of_3\IN\0|neither_17|the_9|nor_45|preparation_58|,_113 (r_prep) type_2\NN\5839024|incidence_133|._158 (r_nsubj) affected_24\VBD\126264|NONE_0 (l_dobj) incidence_26\NN\13821570|type_133|._25 (l_prep) of_27\IN\0|the_14 (l_pobj) pain_29\NN\14299637|NONE_0
26033014
C051786_D008113 CID metolachlor_0\NNP\0|is_38|as_52|by_76|based_120|._169 (r_nsubjpass) classified_8\VBN\7249426|NONE_0 (l_prep) based_20\VBN\0|metolachlor_120|is_82|as_68|by_44|._49 (l_prep) on_21\IN\0|NONE_0 (l_pobj) neoplasms_24\NNS\14234074|NONE_0
C051786_D008113 CID metolachlor_6\NN\0|liver_16|among_29 (r_nmod) cancer_9\NN\14239425|NONE_0
C051786_D008113 CID metolachlor_6\NN\0|liver_16|among_29 (r_nmod) cancer_9\NN\14239425|NONE_0 (r_pobj) between_5\IN\0|an_15 (r_prep) association_4\NN\8008335|NONE_0 (r_pobj) of_2\IN\0|this_16 (r_prep) suggestion_1\NN\5833840|finding_105|._187 (r_nsubj) is_13\VBZ\0|NONE_0 (l_attr) finding_16\NN\43195|suggestion_105|._82 (l_conj) echoes_18\VBZ\5010627|a_20|novel_18|and_4 (l_dobj) observation_19\NN\996969|in_41 (l_prep) of_20\IN\0|NONE_0 (l_pobj) neoplasms_23\NNS\14234074|NONE_0
C051786_D008113 CID metolachlor_21\JJ\0|from_16 (r_amod) use_22\NN\407535|NONE_0 (r_pobj) of_20\IN\0|differentiate_22 (r_prep) effects_19\NNS\13245626|NONE_0 (r_pobj) to_16\TO\0|warrant_18|follow_10|-_4 (r_prep) up_15\NN\153263|both_62|liver_57|and_44 (r_conj) cancer_7\NN\14239425|NONE_0
C051786_D009369 NONE metolachlor_3\JJ\0|in_16 (r_amod) use_4\NN\407535|cancer_33|and_16 (r_conj) incidence_1\NN\13821570|:_62|an_64|._73 (l_compound) cancer_0\NN\14239425|and_17|use_33
C051786_D009369 NONE metolachlor_22\NN\0|ever_11 (r_dobj) using_21\VBG\418025|%_24 (r_xcomp) reported_19\VBD\831651|we_92|incidence_72|through_62|for_36|._31 (r_advcl) evaluated_1\VBD\670261|NONE_0 (l_dobj) incidence_3\NN\13821570|we_20|through_10|for_36|reported_72|._103 (l_compound) cancer_2\NN\14239425|NONE_0
C051786_D009369 NONE metolachlor_11\JJ\0|NONE_0 (r_amod) use_12\NN\407535|NONE_0 (r_pobj) of_10\IN\0|two_12|(_19|days_29|)_67|and_69|incidence_80 (r_prep) metrics_9\NNS\6169932|NONE_0 (l_conj) incidence_25\NN\13821570|two_92|of_80|(_61|days_51|)_13|and_11 (l_compound) cancer_24\NN\14239425|NONE_0
C051786_D009369 NONE metolachlor_5\JJ\0|and_16|incidence_20|5,701_59 (r_amod) use_6\NN\407535|NONE_0 (l_conj) incidence_8\NN\13821570|metolachlor_20|and_4|5,701_39 (l_prep) of_9\IN\0|NONE_0 (l_pobj) cancers_11\NNS\14239425|NONE_0
C051786_D009369 NONE metolachlor_5\JJ\0|and_16|incidence_20|5,701_59 (r_amod) use_6\NN\407535|NONE_0 (r_pobj) between_4\IN\0|no_15|with_73 (r_prep) association_3\NN\8008335|we_10|._133 (l_prep) with_17\IN\0|no_88|between_73 (l_pobj) lag_20\NN\1066163|NONE_0 (l_conj) cancers_27\NNS\14239425|a_36|5-year_34|)_24|or_22
C051786_D008175 NONE metolachlor_12\JJ\0|in_16 (r_amod) use_13\NN\407535|NONE_0 (r_pobj) of_11\IN\0|high_12 (r_prep) levels_10\NNS\4916342|NONE_0 (r_pobj) at_8\IN\14622893|increased_27|cancer_12 (r_prep) risk_7\NN\14541044|NONE_0 (l_compound) cancer_6\NN\14239425|increased_15|at_12
C051786_D008223 NONE metolachlor_21\JJ\0|from_16 (r_amod) use_22\NN\407535|NONE_0 (r_pobj) of_20\IN\0|differentiate_22 (r_prep) effects_19\NNS\13245626|NONE_0 (r_pobj) to_16\TO\0|warrant_18|follow_10|-_4 (r_prep) up_15\NN\153263|both_62|liver_57|and_44 (l_compound) warrant_12\NN\6552984|follow_8|-_14|to_18 (l_compound) lymphoma_11\NN\14239918|NONE_0
3895875
D008012_D009203 NONE lidocaine_1\NN\3681148|NONE_0 (l_prep) in_2\IN\13603305|prophylactic_23|._53 (l_pobj) phase_5\NN\15113229|NONE_0 (l_prep) of_6\IN\0|the_16|early_12 (l_pobj) infarction_9\NN\14204950|NONE_0
D008012_D009203 NONE lidocaine_25\NN\3681148|NONE_0 (r_pobj) of_24\IN\0|a_32|blind_23|randomized_17 (r_prep) trial_23\NN\786195|patients_125|._29 (r_dobj) entered_17\VBD\0|NONE_0 (l_nsubj) patients_3\NNS\9898892|trial_125|._154 (l_prep) with_4\IN\0|two_13 (l_pobj) infarction_7\NN\14204950|NONE_0
D008012_D009203 NONE lidocaine_3\NN\3681148|the_19|average_15|after_27 (r_compound) level_4\NN\4916342|higher_101|for_118|._155 (l_prep) after_7\IN\0|the_46|average_42|lidocaine_27 (l_pobj) administration_8\NN\1133281|minutes_14 (l_prep) for_9\IN\0|NONE_0 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) without_11\IN\0|NONE_0 (l_pobj) infarction_14\NN\14204950|NONE_0
D008012_D009203 NONE lidocaine_7\NN\3681148|NONE_0 (r_pobj) of_6\IN\0|the_19 (r_prep) administration_5\NN\1133281|we_23|can_20|not_17|prophylactically_28|in_45|._98 (r_dobj) advocate_3\VB\7846|NONE_0 (l_prep) in_9\IN\13603305|we_68|can_65|not_62|administration_45|prophylactically_17|._53 (l_pobj) hours_12\NNS\15118228|NONE_0 (l_prep) of_13\IN\0|the_16|early_12 (l_pobj) infarction_16\NN\14204950|NONE_0
D008012_D007238 NONE lidocaine_3\NN\3681148|the_19|average_15|after_27 (r_compound) level_4\NN\4916342|higher_101|for_118|._155 (r_nsubj) was_15\VBD\0|NONE_0 (l_prep) for_20\IN\0|level_118|higher_17|._37 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|NONE_0 (l_pobj) infarction_25\NN\14204950|NONE_0
D008012_D006323 NONE lidocaine_19\NN\3681148|the_4 (r_compound) group_20\NN\2137|NONE_0 (r_pobj) in_17\IN\13603305|significantly_22 (r_prep) greater_16\JJR\0|during_103|,_73|incidence_67 (r_acomp) was_14\VBD\0|,_48|hypotension_50|in_71|,_122|and_124|died_142 (r_ccomp) occurred_23\VBD\0|NONE_0 (l_conj) died_38\VBD\146138|was_142|,_94|hypotension_92|in_71|,_20|and_18 (l_prep) from_39\IN\0|patients_14|,_13|had_33|._46 (l_pobj) asystole_40\NN\14204950|NONE_0
D008012_D006323 NONE lidocaine_33\NN\3681148|nine_26|had_13 (r_dobj) received_32\VBN\2210855|11_30|,_19 (r_relcl) patients_26\NNS\9898892|NONE_0 (r_pobj) in_24\IN\13603305|was_71|,_23|hypotension_21|,_51|and_53|died_71 (r_prep) occurred_23\VBD\0|NONE_0 (l_conj) died_38\VBD\146138|was_142|,_94|hypotension_92|in_71|,_20|and_18 (l_prep) from_39\IN\0|patients_14|,_13|had_33|._46 (l_pobj) asystole_40\NN\14204950|NONE_0
D008012_D006323 NONE lidocaine_47\NN\3681148|three_22|had_8 (r_dobj) had_46\VBN\0|patients_47|from_33|,_20|._13 (r_conj) died_38\VBD\146138|was_142|,_94|hypotension_92|in_71|,_20|and_18 (l_prep) from_39\IN\0|patients_14|,_13|had_33|._46 (l_pobj) asystole_40\NN\14204950|NONE_0
D008012_D017180 NONE lidocaine_0\NN\3681148|,_9|given_11|,_82|did_84|not_88|tachycardia_122|,_133|was_150|)_310|._311 (r_nsubj) prevent_17\VB\0|NONE_0 (l_dobj) tachycardia_20\NN\14110674|lidocaine_122|,_113|given_111|,_40|did_38|not_34|,_11|was_28|)_188|._189
D008012_D017180 NONE lidocaine_45\NN\3681148|NONE_0 (r_pobj) of_44\IN\0|the_19|0.05_26 (r_prep) administration_43\NN\1133281|minutes_18 (r_pobj) after_41\IN\0|although_120|there_111|reduction_87 (r_prep) was_24\VBD\0|lidocaine_150|,_141|given_139|,_68|did_66|not_62|tachycardia_28|,_17|)_160|._161 (r_advcl) prevent_17\VB\0|NONE_0 (l_dobj) tachycardia_20\NN\14110674|lidocaine_122|,_113|given_111|,_40|did_38|not_34|,_11|was_28|)_188|._189
D008012_D001145 NONE lidocaine_0\NN\3681148|,_9|given_11|,_82|did_84|not_88|tachycardia_122|,_133|was_150|)_310|._311 (r_nsubj) prevent_17\VB\0|NONE_0 (l_advcl) was_24\VBD\0|lidocaine_150|,_141|given_139|,_68|did_66|not_62|tachycardia_28|,_17|)_160|._161 (l_attr) reduction_27\NN\351485|although_33|there_24|after_87 (l_prep) in_28\IN\13603305|a_24|significant_22 (l_pobj) number_30\NN\5107765|NONE_0 (l_prep) of_31\IN\0|the_11 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|NONE_0 (l_pcomp) warning_34\VBG\7212190|NONE_0 (l_dobj) arrhythmias_35\NNS\14103288|NONE_0
D008012_D001145 NONE lidocaine_45\NN\3681148|NONE_0 (r_pobj) of_44\IN\0|the_19|0.05_26 (r_prep) administration_43\NN\1133281|minutes_18 (r_pobj) after_41\IN\0|although_120|there_111|reduction_87 (r_prep) was_24\VBD\0|lidocaine_150|,_141|given_139|,_68|did_66|not_62|tachycardia_28|,_17|)_160|._161 (l_attr) reduction_27\NN\351485|although_33|there_24|after_87 (l_prep) in_28\IN\13603305|a_24|significant_22 (l_pobj) number_30\NN\5107765|NONE_0 (l_prep) of_31\IN\0|the_11 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|NONE_0 (l_pcomp) warning_34\VBG\7212190|NONE_0 (l_dobj) arrhythmias_35\NNS\14103288|NONE_0
D008012_D007022 CID lidocaine_19\NN\3681148|the_4 (r_compound) group_20\NN\2137|NONE_0 (r_pobj) in_17\IN\13603305|significantly_22 (r_prep) greater_16\JJR\0|during_103|,_73|incidence_67 (r_acomp) was_14\VBD\0|,_48|hypotension_50|in_71|,_122|and_124|died_142 (r_ccomp) occurred_23\VBD\0|NONE_0 (l_nsubj) hypotension_22\NN\14057371|was_50|,_2|in_21|,_72|and_74|died_92
D008012_D007022 CID lidocaine_33\NN\3681148|nine_26|had_13 (r_dobj) received_32\VBN\2210855|11_30|,_19 (r_relcl) patients_26\NNS\9898892|NONE_0 (r_pobj) in_24\IN\13603305|was_71|,_23|hypotension_21|,_51|and_53|died_71 (r_prep) occurred_23\VBD\0|NONE_0 (l_nsubj) hypotension_22\NN\14057371|was_50|,_2|in_21|,_72|and_74|died_92
D008012_D007022 CID lidocaine_47\NN\3681148|three_22|had_8 (r_dobj) had_46\VBN\0|patients_47|from_33|,_20|._13 (r_conj) died_38\VBD\146138|was_142|,_94|hypotension_92|in_71|,_20|and_18 (r_conj) occurred_23\VBD\0|NONE_0 (l_nsubj) hypotension_22\NN\14057371|was_50|,_2|in_21|,_72|and_74|died_92
16880771
D004298_D020521 NONE dopamine_3\NN\14807737|NONE_0 (r_compound) precursor_4\NN\14580897|the_13 (r_compound) levodopa_5\NN\14604959|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|learning_59|._107 (r_nsubj) enhances_6\VBZ\227165|NONE_0 (l_dobj) learning_7\VBG\5701944|administration_59|._48 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) subjects_10\NNS\6598915|NONE_0 (l_conj) patients_13\NNS\9898892|healthy_28|and_11 (l_compound) stroke_12\NN\556313|NONE_0
D004298_D020521 NONE dopamine_12\NN\14807737|by_9|learning_30 (r_nsubj) enhances_13\VBZ\227165|the_41|critical_37 (l_dobj) learning_15\NN\5701944|by_39|dopamine_30 (l_prep) in_16\IN\13603305|associative_21 (l_pobj) subjects_18\NNS\6598915|NONE_0 (l_conj) patients_21\NNS\9898892|healthy_28|and_11 (l_compound) stroke_20\NN\556313|NONE_0
D007980_D020521 NONE levodopa_5\NN\14604959|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|learning_59|._107 (r_nsubj) enhances_6\VBZ\227165|NONE_0 (l_dobj) learning_7\VBG\5701944|administration_59|._48 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) subjects_10\NNS\6598915|NONE_0 (l_conj) patients_13\NNS\9898892|healthy_28|and_11 (l_compound) stroke_12\NN\556313|NONE_0
D004298_D007859 NONE dopamine_1\NN\14807737|the_4 (r_compound) agonist_2\NN\0|significantly_8 (r_nsubj) impaired_4\JJ\258857|word_15|compared_29|._48 (r_amod) learning_7\NN\5701944|NONE_0
7248895
D003520_D006869 NONE cyclophosphamide_23\NN\0|NONE_0 (r_pobj) wtih_22\IN\0|being_29|for_15|for_22 (r_prep) treated_18\VBN\2376958|NONE_0 (r_pcomp) after_16\IN\0|woman_102|hematuria_10|._80 (r_prep) had_13\VBD\0|NONE_0 (l_nsubj) woman_4\NN\9605289|hematuria_92|after_102|._182 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) hydroureteronephrosis_7\NN\0|NONE_0
D003520_D006869 NONE cyclophosphamide_21\NN\0|NONE_0 (r_pobj) to_20\IN\0|upper_31|urinary_25|tract_17 (r_prep) epithelium_19\NN\5267548|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) exposure_14\NN\5042871|NONE_0 (r_dobj) intensified_13\VBN\153263|that_26|stasis_21|and_4 (r_conj) prolonged_11\VBN\317700|association_85|._88 (r_ccomp) suggests_8\VBZ\1010118|NONE_0 (l_nsubj) association_1\NN\8008335|prolonged_85|._173 (l_prep) with_5\IN\0|the_29|of_13 (l_pobj) hydroureteronephrosis_7\NN\0|NONE_0
D003520_D006417 CID cyclophosphamide_23\NN\0|NONE_0 (r_pobj) wtih_22\IN\0|being_29|for_15|for_22 (r_prep) treated_18\VBN\2376958|NONE_0 (r_pcomp) after_16\IN\0|woman_102|hematuria_10|._80 (r_prep) had_13\VBD\0|NONE_0 (l_dobj) hematuria_15\NN\14299637|woman_92|after_10|._90
D003520_D020293 NONE cyclophosphamide_23\NN\0|NONE_0 (r_pobj) wtih_22\IN\0|being_29|for_15|for_22 (r_prep) treated_18\VBN\2376958|NONE_0 (l_prep) for_24\IN\0|being_51|for_37|wtih_22 (l_pobj) vasculitis_26\NN\14336539|NONE_0
D003520_D014571 NONE cyclophosphamide_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_12|cause_23 (r_prep) ability_2\NN\4723816|although_13|known_144 (r_nsubj) is_18\VBZ\0|,_13|it_15 (r_advcl) is_23\VBZ\0|widely_8|associated_43|._89 (r_auxpass) appreciated_26\VBN\892467|NONE_0 (l_ccomp) associated_31\VBN\628491|is_43|widely_35|._46 (l_prep) with_32\IN\0|that_27|it_22|is_19|also_16 (l_pobj) carcinoma_33\NN\14239918|NONE_0 (l_prep) of_34\IN\0|NONE_0 (l_pobj) tract_37\NN\8574314|NONE_0
D003520_D014571 NONE cyclophosphamide_11\JJ\0|for_27 (r_compound) treatment_12\NN\654885|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) association_9\NN\8008335|NONE_0 (r_pobj) in_8\IN\13603305|NONE_0 (r_prep) reported_7\VBN\831651|the_31|third_27|urinary_21|tract_13 (r_acl) cancer_6\NN\14239425|it_30|._87
D003520_-1 NONE cyclophosphamide_8\NN\0|term_5 (r_compound) treatment_9\NN\654885|NONE_0 (r_pobj) for_4\IN\0|NONE_0 (r_prep) candidates_3\NNS\10450303|who_8 (r_attr) are_2\VBP\13600404|NONE_0 (r_relcl) patients_0\NNS\9898892|should_69|be_76|routinely_79|for_99|._123 (r_nsubjpass) evaluated_13\VBN\670261|NONE_0 (l_prep) for_14\IN\0|patients_99|should_30|be_23|routinely_20|._24 (l_pobj) uropathy_16\NN\14204950|NONE_0
D003520_D010386 NONE cyclophosphamide_7\NN\0|NONE_0 (r_compound) therapy_8\NN\657604|for_8 (r_dobj) following_6\VBG\8180190|the_17|renal_13 (r_prep) pelvis_5\NN\5578911|NONE_0
D003520_D010386 NONE cyclophosphamide_15\NN\0|NONE_0 (r_compound) treatment_16\NN\654885|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) association_13\NN\8008335|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) reported_11\VBD\831651|the_17|renal_13 (r_acl) pelvis_10\NN\5578911|NONE_0
D003520_D006470 NONE cyclophosphamide_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_12|cause_23 (r_prep) ability_2\NN\4723816|although_13|known_144 (l_acl) cause_6\VB\7323922|the_35|of_23 (l_dobj) cystitis_8\NN\14566129|to_21|and_9|urine_13
D003520_D002277 CID cyclophosphamide_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_12|cause_23 (r_prep) ability_2\NN\4723816|although_13|known_144 (l_acl) cause_6\VB\7323922|the_35|of_23 (l_conj) urine_10\NN\14853947|to_34|cystitis_13|and_4 (l_dobj) abnormalities_12\NNS\14034177|NONE_0 (l_amod) indistinguishable_13\JJ\0|cytologic_24 (l_prep) from_14\IN\0|NONE_0 (l_pobj) carcinoma_17\NN\14239918|NONE_0
D003520_D003556 NONE cyclophosphamide_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_12|cause_23 (r_prep) ability_2\NN\4723816|although_13|known_144 (l_acl) cause_6\VB\7323922|the_35|of_23 (l_dobj) cystitis_8\NN\14566129|to_21|and_9|urine_13
D003520_D009369 NONE cyclophosphamide_21\NN\0|NONE_0 (r_pobj) to_20\IN\0|upper_31|urinary_25|tract_17 (r_prep) epithelium_19\NN\5267548|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) exposure_14\NN\5042871|NONE_0 (r_dobj) intensified_13\VBN\153263|that_26|stasis_21|and_4 (r_conj) prolonged_11\VBN\317700|association_85|._88 (r_ccomp) suggests_8\VBZ\1010118|NONE_0 (l_nsubj) association_1\NN\8008335|prolonged_85|._173 (l_prep) of_2\IN\0|the_16|with_13 (l_pobj) tumor_4\NN\14234074|NONE_0
24345882
D008727_D054198 NONE methotrexate_20\JJ\2722166|a_2 (r_compound) consequence_21\NN\34213|(_106|standard_105|)_92|and_90|p9201_86|protocols_37|:_17 (r_appos) risk_3\NN\14541044|?_107 (l_appos) protocols_14\NNS\6652242|(_69|standard_68|)_55|and_53|p9201_49|:_20|consequence_37 (l_compound) leukemia_13\NN\14239918|acute_20|lymphoblastic_14|(_19|accl0131_20|)_28
D008727_D054198 NONE methotrexate_5\NN\2722166|mtx_14|in_33 (r_nmod) neurotoxicity_9\NN\0|NONE_0 (r_pobj) about_1\IN\0|NONE_0 (r_prep) concerns_0\NNS\5682950|to_75|._230 (r_nsubj) led_13\VBD\3202760|NONE_0 (l_prep) to_14\IN\0|concerns_75|._155 (l_pobj) modifications_15\NNS\191142|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) therapy_21\NN\657604|NONE_0 (l_conj) rescue_24\NN\45907|intrathecal_37|(_25|it_24|)_22|,_13 (l_conj) frequency_27\NN\15286249|leucovorin_23|,_6|and_4 (l_prep) in_32\IN\13603305|of_31 (l_pobj) children_33\NNS\9622049|NONE_0 (l_prep) with_34\IN\0|NONE_0 (l_pobj) leukemia_37\NN\14239918|NONE_0
D008727_D054198 NONE mtx_7\NNP\0|methotrexate_14|in_19 (r_nmod) neurotoxicity_9\NN\0|NONE_0 (r_pobj) about_1\IN\0|NONE_0 (r_prep) concerns_0\NNS\5682950|to_75|._230 (r_nsubj) led_13\VBD\3202760|NONE_0 (l_prep) to_14\IN\0|concerns_75|._155 (l_pobj) modifications_15\NNS\191142|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) therapy_21\NN\657604|NONE_0 (l_conj) rescue_24\NN\45907|intrathecal_37|(_25|it_24|)_22|,_13 (l_conj) frequency_27\NN\15286249|leucovorin_23|,_6|and_4 (l_prep) in_32\IN\13603305|of_31 (l_pobj) children_33\NNS\9622049|NONE_0 (l_prep) with_34\IN\0|NONE_0 (l_pobj) leukemia_37\NN\14239918|NONE_0
D008727_D054198 NONE mtx_30\NNP\0|systemic_9 (r_compound) administration_31\NN\1133281|NONE_0 (r_pobj) of_28\IN\0|in_31 (r_prep) frequency_27\NN\15286249|leucovorin_23|,_6|and_4 (l_prep) in_32\IN\13603305|of_31 (l_pobj) children_33\NNS\9622049|NONE_0 (l_prep) with_34\IN\0|NONE_0 (l_pobj) leukemia_37\NN\14239918|NONE_0
D008727_D020258 NONE methotrexate_5\NN\2722166|mtx_14|in_33 (r_nmod) neurotoxicity_9\NN\0|NONE_0
D008727_D020258 NONE mtx_7\NNP\0|methotrexate_14|in_19 (r_nmod) neurotoxicity_9\NN\0|NONE_0
D008727_D020258 NONE mtx_30\NNP\0|systemic_9 (r_compound) administration_31\NN\1133281|NONE_0 (r_pobj) of_28\IN\0|in_31 (r_prep) frequency_27\NN\15286249|leucovorin_23|,_6|and_4 (r_conj) rescue_24\NN\45907|intrathecal_37|(_25|it_24|)_22|,_13 (r_conj) therapy_21\NN\657604|NONE_0 (r_pobj) in_16\IN\13603305|NONE_0 (r_prep) modifications_15\NNS\191142|NONE_0 (r_pobj) to_14\IN\0|concerns_75|._155 (r_prep) led_13\VBD\3202760|NONE_0 (l_nsubj) concerns_0\NNS\5682950|to_75|._230 (l_prep) about_1\IN\0|NONE_0 (l_pobj) neurotoxicity_9\NN\0|NONE_0
18945509
D005913_D003324 NONE glipizide_36\NN\2719105|NONE_0 (r_pobj) with_35\IN\0|0.9_18|,_11|p=0.099_9|)_2|;_14|2.9-fold_16|and_57|was_61 (r_prep) 2-fold_27\JJ\0|the_133|of_122|associated_95|;_2|._115 (r_appos) hazard_1\NN\14541044|NONE_0 (l_prep) of_2\IN\0|the_11|associated_27|;_120|2-fold_122|._237 (l_pcomp) developing_3\VBG\13541167|NONE_0 (l_dobj) cad_4\NNP\10753546|NONE_0
D005913_D003324 NONE glipizide_9\NN\2719105|or_3 (r_conj) glibenclamide_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|2_11 (r_prep) diabetes_5\NNS\14075199|treatment_20 (r_dobj) initiating_0\VBG\1617192|is_72|with_86|._155 (r_csubjpass) associated_11\VBN\628491|NONE_0 (l_prep) with_12\IN\0|initiating_86|is_14|._69 (l_pobj) risk_14\NN\14541044|NONE_0 (l_prep) of_15\IN\0|increased_15|in_7 (l_pobj) cad_16\NNP\10753546|NONE_0
D005907_D003324 NONE gliclazide_20\VB\0|NONE_0 (r_pobj) to_19\TO\0|NONE_0 (r_prep) comparison_18\NN\635850|NONE_0 (r_pobj) in_17\IN\13603305|increased_22|of_7 (r_prep) risk_14\NN\14541044|NONE_0 (l_prep) of_15\IN\0|increased_15|in_7 (l_pobj) cad_16\NNP\10753546|NONE_0
-1_D003924 NONE sulphonylurea_8\JJ\0|initial_8|of_24 (r_compound) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|initial_32|sulphonylurea_24 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) diabetes_15\NNS\14075199|NONE_0
-1_D003924 NONE sulphonylureas_25\NNS\0|NONE_0 (r_pobj) with_23\IN\0|2_11 (r_prep) diabetes_22\NNS\14075199|disease_58
C057619_D003924 NONE glimepiride_22\NN\0|or_3 (r_conj) gliclazide_20\VB\0|NONE_0 (r_pobj) to_19\TO\0|NONE_0 (r_prep) comparison_18\NN\635850|NONE_0 (r_pobj) in_17\IN\13603305|increased_22|of_7 (r_prep) risk_14\NN\14541044|NONE_0 (r_pobj) with_12\IN\0|initiating_86|is_14|._69 (r_prep) associated_11\VBN\628491|NONE_0 (l_csubjpass) initiating_0\VBG\1617192|is_72|with_86|._155 (l_dobj) diabetes_5\NNS\14075199|treatment_20
D005907_D003924 NONE gliclazide_20\VB\0|NONE_0 (r_pobj) to_19\TO\0|NONE_0 (r_prep) comparison_18\NN\635850|NONE_0 (r_pobj) in_17\IN\13603305|increased_22|of_7 (r_prep) risk_14\NN\14541044|NONE_0 (r_pobj) with_12\IN\0|initiating_86|is_14|._69 (r_prep) associated_11\VBN\628491|NONE_0 (l_csubjpass) initiating_0\VBG\1617192|is_72|with_86|._155 (l_dobj) diabetes_5\NNS\14075199|treatment_20
-1_D003324 NONE sulphonylurea_8\JJ\0|initial_8|of_24 (r_compound) treatment_9\NN\654885|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|coronary_24|artery_15 (r_acl) disease_4\NN\14061805|NONE_0
-1_D003324 NONE sulphonylureas_25\NNS\0|NONE_0 (r_pobj) with_23\IN\0|2_11 (r_prep) diabetes_22\NNS\14075199|disease_58 (r_dobj) developing_8\VBG\13541167|NONE_0 (l_dobj) disease_11\NN\14061805|diabetes_58
-1_D003324 NONE sulphonylureas_25\NNS\0|NONE_0 (r_pobj) with_23\IN\0|2_11 (r_prep) diabetes_22\NNS\14075199|disease_58 (r_dobj) developing_8\VBG\13541167|NONE_0 (l_dobj) disease_11\NN\14061805|diabetes_58 (l_appos) cad_13\NNP\10753546|coronary_25|artery_16|(_1|)_3|associated_5
D005905_D003324 CID glibenclamide_25\NN\0|NONE_0 (r_pobj) with_24\IN\0|by_31 (r_prep) increased_14\VBN\169651|initial_18 (r_acl) treatment_13\NN\654885|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) associated_10\VBN\628491|the_38|of_27|;_93|2-fold_95|._210 (r_acl) hazard_1\NN\14541044|NONE_0 (l_prep) of_2\IN\0|the_11|associated_27|;_120|2-fold_122|._237 (l_pcomp) developing_3\VBG\13541167|NONE_0 (l_dobj) cad_4\NNP\10753546|NONE_0
D005905_D003324 CID glibenclamide_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|2_11 (r_prep) diabetes_5\NNS\14075199|treatment_20 (r_dobj) initiating_0\VBG\1617192|is_72|with_86|._155 (r_csubjpass) associated_11\VBN\628491|NONE_0 (l_prep) with_12\IN\0|initiating_86|is_14|._69 (l_pobj) risk_14\NN\14541044|NONE_0 (l_prep) of_15\IN\0|increased_15|in_7 (l_pobj) cad_16\NNP\10753546|NONE_0
C057619_D003324 NONE glimepiride_22\NN\0|or_3 (r_conj) gliclazide_20\VB\0|NONE_0 (r_pobj) to_19\TO\0|NONE_0 (r_prep) comparison_18\NN\635850|NONE_0 (r_pobj) in_17\IN\13603305|increased_22|of_7 (r_prep) risk_14\NN\14541044|NONE_0 (l_prep) of_15\IN\0|increased_15|in_7 (l_pobj) cad_16\NNP\10753546|NONE_0
D005913_D003924 NONE glipizide_9\NN\2719105|or_3 (r_conj) glibenclamide_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|2_11 (r_prep) diabetes_5\NNS\14075199|treatment_20
D005905_D003924 NONE glibenclamide_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|2_11 (r_prep) diabetes_5\NNS\14075199|treatment_20
D008687_D003324 NONE metformin_53\NN\2719105|NONE_0 (r_pobj) with_52\IN\0|NONE_0 (r_prep) unchanged_51\JJ\0|NONE_0 (r_acomp) was_50\VBD\0|0.9_79|,_72|p=0.099_70|)_63|with_61|;_47|2.9-fold_45|and_4 (r_conj) 2-fold_27\JJ\0|the_133|of_122|associated_95|;_2|._115 (r_appos) hazard_1\NN\14541044|NONE_0 (l_prep) of_2\IN\0|the_11|associated_27|;_120|2-fold_122|._237 (l_pcomp) developing_3\VBG\13541167|NONE_0 (l_dobj) cad_4\NNP\10753546|NONE_0
15627798
D005839_D005355 NONE gentamicin_3\NN\2716866|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) treated_1\VBN\2376958|NONE_0 (r_acl) animals_0\NNS\4475|can_32|areas_50|._100 (r_nsubj) show_5\VB\429048|NONE_0 (l_dobj) areas_7\NNS\8630985|animals_50|can_18|._50 (l_prep) of_8\IN\0|residual_15|in_25 (l_pobj) fibrosis_10\NN\14204950|NONE_0
D005839_D009395 CID gentamicin_12\NN\2716866|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|tubulointerstitial_29 (r_acl) nephritis_9\NN\14113228|inhibition_77|._31
D005839_D009395 CID gentamicin_15\NN\2716866|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|that_80|inhibition_75|nephritis_10 (r_advcl) attenuates_10\VBZ\224901|data_50|._61 (l_dobj) nephritis_12\NN\14113228|that_70|inhibition_65|induced_10
16731636
D007545_D006332 CID isoproterenol_1\NN\3740161|-_13 (r_npadvmod) induced_3\VBN\1627355|enhanced_23|cardiac_8|in_28|._77 (r_amod) hypertrophy_5\NN\14365950|NONE_0
D007545_D006332 CID iso_4\NNP\0|NONE_0 (r_compound) treatment_5\NN\654885|NONE_0 (r_pobj) by_3\IN\0|hypertrophy_20 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubj) hypertrophy_1\NN\14365950|by_20
6985498
D008733_D041881 NONE methoxyflurane_10\NN\0|developed_26 (r_compound) anesthesia_11\NN\14034177|NONE_0 (r_pobj) under_9\IN\0|for_24 (r_prep) operated_5\VBN\2439501|a_18|old_8|._150 (l_prep) for_6\IN\0|under_24 (l_pobj) cholecystitis_8\NN\14336539|NONE_0
D008733_D056486 CID methoxyflurane_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) anesthesia_6\NN\14034177|NONE_0 (r_pobj) after_5\IN\0|renal_23|tubular_17 (r_prep) acidosis_4\NN\14204950|and_18|._45 (r_conj) hepatitis_0\NNP\14127211|NONE_0
D008733_D000141 CID methoxyflurane_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) anesthesia_6\NN\14034177|NONE_0 (r_pobj) after_5\IN\0|renal_23|tubular_17 (r_prep) acidosis_4\NN\14204950|and_18|._45
D008733_D000141 CID methoxyflurane_10\NN\0|developed_26 (r_compound) anesthesia_11\NN\14034177|NONE_0 (l_acl) developed_12\VBD\1753788|methoxyflurane_26 (l_dobj) syndrome_17\NN\5870365|postoperatively_40 (l_conj) acidosis_21\NN\14204950|a_51|insufficiency_41|and_18
D008733_D048550 NONE methoxyflurane_10\NN\0|developed_26 (r_compound) anesthesia_11\NN\14034177|NONE_0 (l_acl) developed_12\VBD\1753788|methoxyflurane_26 (l_dobj) syndrome_17\NN\5870365|postoperatively_40
8819482
C082828_D023921 NONE cd-832_7\NNP\0|NONE_0 (r_punct) ,_8\,\0|of_35|on_2|._85 (r_punct) effects_0\NNS\13245626|NONE_0 (l_prep) on_9\IN\0|of_37|,_2|._83 (l_pobj) ischemia_14\NN\14195315|NONE_0 (l_prep) in_15\IN\13603305|induced_28|myocardial_20 (l_pobj) dogs_16\NNS\2083346|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) stenosis_20\NN\14204950|NONE_0
C082828_D023921 NONE cd-832_2\NNP\0|NONE_0 (r_pobj) of_1\IN\0|on_10 (r_prep) effects_0\NNS\13245626|ischemia_60|were_69|in_82|compared_178|._225 (r_nsubjpass) studied_10\VBN\0|NONE_0 (l_prep) in_11\IN\13603305|effects_82|ischemia_22|were_13|compared_96|._143 (l_pobj) dogs_12\NNS\2083346|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) stenosis_16\NN\14204950|NONE_0
D007545_D017202 CID isoproterenol_10\NN\3740161|-_13 (r_npadvmod) induced_12\VBN\1627355|myocardial_8|in_28 (r_amod) ischemia_14\NN\14195315|NONE_0
D007545_D017202 CID isoproterenol_4\NN\3740161|NONE_0 (r_pobj) on_3\IN\0|of_10 (r_prep) effects_0\NNS\13245626|ischemia_60|were_69|in_82|compared_178|._225 (r_nsubjpass) studied_10\VBN\0|NONE_0 (l_nsubjpass) ischemia_8\NN\14195315|effects_60|were_9|in_22|compared_118|._165
D007545_D017202 CID iso)-induced_6\VBN\0|myocardial_13 (r_nmod) ischemia_8\NN\14195315|effects_60|were_9|in_22|compared_118|._165
D007545_D017202 CID iso_9\NN\0|with_13 (r_compound) infusion_10\NN\14589223|NONE_0 (r_pobj) during_8\IN\0|that_41|cd-832_36|ischemia_9|and_34|suggest_38 (r_prep) improves_5\VBZ\126264|data_22|._179 (l_dobj) ischemia_7\NN\14195315|that_32|cd-832_27|during_9|and_43|suggest_47
D007545_D023921 NONE isoproterenol_10\NN\3740161|-_13 (r_npadvmod) induced_12\VBN\1627355|myocardial_8|in_28 (r_amod) ischemia_14\NN\14195315|NONE_0 (l_prep) in_15\IN\13603305|induced_28|myocardial_20 (l_pobj) dogs_16\NNS\2083346|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) stenosis_20\NN\14204950|NONE_0
D007545_D023921 NONE isoproterenol_4\NN\3740161|NONE_0 (r_pobj) on_3\IN\0|of_10 (r_prep) effects_0\NNS\13245626|ischemia_60|were_69|in_82|compared_178|._225 (r_nsubjpass) studied_10\VBN\0|NONE_0 (l_prep) in_11\IN\13603305|effects_82|ischemia_22|were_13|compared_96|._143 (l_pobj) dogs_12\NNS\2083346|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) stenosis_16\NN\14204950|NONE_0
D007545_D023921 NONE iso)-induced_6\VBN\0|myocardial_13 (r_nmod) ischemia_8\NN\14195315|effects_60|were_9|in_22|compared_118|._165 (r_nsubjpass) studied_10\VBN\0|NONE_0 (l_prep) in_11\IN\13603305|effects_82|ischemia_22|were_13|compared_96|._143 (l_pobj) dogs_12\NNS\2083346|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) stenosis_16\NN\14204950|NONE_0
D007545_D023921 NONE iso_12\NNP\0|intracoronary_14 (r_compound) infusion_13\NN\14589223|NONE_0 (r_pobj) of_10\IN\0|3-min_14|min_40 (r_prep) periods_9\NNS\13575869|in_51|,_8|rate_69|._250 (r_nsubj) increased_22\VBN\169651|NONE_0 (l_prep) in_0\IN\13603305|,_43|periods_51|rate_120|._301 (l_pobj) presence_2\NN\13954253|NONE_0 (l_prep) of_3\IN\0|the_13 (l_pobj) stenosis_6\NN\14204950|NONE_0
D007545_D003251 NONE iso_3\NN\0|with_13 (r_compound) infusion_4\NN\14589223|after_22|was_23|,_36|doses_54|cd-832_63 (l_prep) with_5\IN\0|iso_13 (l_pobj) stenosis_6\NN\14204950|NONE_0
D007545_D003251 NONE iso_64\NN\0|with_13 (r_compound) infusion_65\NN\14589223|NONE_0 (l_prep) with_66\IN\0|iso_13 (l_pobj) stenosis_67\NN\14204950|NONE_0
D007545_D003251 NONE iso_60\NN\0|with_13 (r_compound) infusion_61\NN\14589223|NONE_0 (l_prep) with_62\IN\0|iso_13 (l_pobj) stenosis_63\NN\14204950|NONE_0
D007545_D003251 NONE iso_9\NN\0|with_13 (r_compound) infusion_10\NN\14589223|NONE_0 (l_prep) with_11\IN\0|iso_13 (l_pobj) stenosis_12\NN\14204950|NONE_0
D004110_D003251 NONE diltiazem_0\NNP\2938514|(_10|micrograms_14|also_33|decrease_52|to_112|and_157|elevation_172|._271 (r_nsubj) prevented_10\VBD\0|NONE_0 (l_conj) elevation_40\NN\7445480|diltiazem_172|(_162|micrograms_158|also_139|decrease_120|to_60|and_15|._99 (l_prep) from_41\IN\0|segment_18 (l_prep) at_56\IN\14622893|mv_31|to_28 (l_pobj) min_58\NN\15154774|NONE_0 (l_prep) after_59\IN\0|3_6 (l_pobj) infusion_61\NN\14589223|NONE_0 (l_prep) with_62\IN\0|iso_13 (l_pobj) stenosis_63\NN\14204950|NONE_0
D009543_D023921 NONE nifedipine_30\NN\2938514|NONE_0 (r_pobj) for_29\IN\0|NONE_0 (r_prep) those_28\DT\0|NONE_0 (r_pobj) with_27\IN\0|were_14 (r_prep) compared_26\VBN\644583|effects_178|ischemia_118|were_109|in_96|._47 (r_prep) studied_10\VBN\0|NONE_0 (l_prep) in_11\IN\13603305|effects_82|ischemia_22|were_13|compared_96|._143 (l_pobj) dogs_12\NNS\2083346|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) stenosis_16\NN\14204950|NONE_0
C082828_D017202 NONE cd-832_7\NNP\0|NONE_0 (r_punct) ,_8\,\0|of_35|on_2|._85 (r_punct) effects_0\NNS\13245626|NONE_0 (l_prep) on_9\IN\0|of_37|,_2|._83 (l_pobj) ischemia_14\NN\14195315|NONE_0
C082828_D017202 NONE cd-832_2\NNP\0|NONE_0 (r_pobj) of_1\IN\0|on_10 (r_prep) effects_0\NNS\13245626|ischemia_60|were_69|in_82|compared_178|._225 (r_nsubjpass) studied_10\VBN\0|NONE_0 (l_nsubjpass) ischemia_8\NN\14195315|effects_60|were_9|in_22|compared_118|._165
C082828_D017202 NONE cd-832_4\NNP\0|that_5|ischemia_27|during_36|and_70|suggest_74 (r_nsubj) improves_5\VBZ\126264|data_22|._179 (l_dobj) ischemia_7\NN\14195315|that_32|cd-832_27|during_9|and_43|suggest_47
C082828_D017202 NONE cd-832_21\NNP\0|that_43|property_12|role_21|in_26 (r_punct) plays_22\VBZ\7007684|NONE_0 (r_ccomp) suggest_14\VBP\1010118|that_79|cd-832_74|ischemia_47|during_38|and_4 (r_conj) improves_5\VBZ\126264|data_22|._179 (l_dobj) ischemia_7\NN\14195315|that_32|cd-832_27|during_9|and_43|suggest_47
C082828_D017202 NONE cd-832_31\NNP\0|NONE_0 (r_pobj) of_30\IN\0|the_23|beneficial_19 (r_prep) effects_29\NNS\13245626|NONE_0 (r_pobj) in_26\IN\13603305|that_69|property_38|cd-832_26|role_5 (r_prep) plays_22\VBZ\7007684|NONE_0 (r_ccomp) suggest_14\VBP\1010118|that_79|cd-832_74|ischemia_47|during_38|and_4 (r_conj) improves_5\VBZ\126264|data_22|._179 (l_dobj) ischemia_7\NN\14195315|that_32|cd-832_27|during_9|and_43|suggest_47
D009543_D017202 NONE nifedipine_30\NN\2938514|NONE_0 (r_pobj) for_29\IN\0|NONE_0 (r_prep) those_28\DT\0|NONE_0 (r_pobj) with_27\IN\0|were_14 (r_prep) compared_26\VBN\644583|effects_178|ischemia_118|were_109|in_96|._47 (r_prep) studied_10\VBN\0|NONE_0 (l_nsubjpass) ischemia_8\NN\14195315|effects_60|were_9|in_22|compared_118|._165
C082828_D003251 NONE cd-832_13\NNP\0|after_85|infusion_63|was_40|,_27|doses_9 (r_punct) performed_8\VBN\0|NONE_0 (l_nsubjpass) infusion_4\NN\14589223|after_22|was_23|,_36|doses_54|cd-832_63 (l_prep) with_5\IN\0|iso_13 (l_pobj) stenosis_6\NN\14204950|NONE_0
C082828_D003251 NONE cd-832_5\NNP\0|in_27|,_2|decrease_44|and_150|elevation_165|._264 (r_nsubj) prevented_14\VBD\0|NONE_0 (l_conj) elevation_44\NN\7445480|in_192|,_167|cd-832_165|decrease_121|and_15|._99 (l_prep) at_60\IN\14622893|segment_66|from_48|to_28 (l_pobj) min_62\NN\15154774|NONE_0 (l_prep) after_63\IN\0|3_6 (l_pobj) infusion_65\NN\14589223|NONE_0 (l_prep) with_66\IN\0|iso_13 (l_pobj) stenosis_67\NN\14204950|NONE_0
C082828_D003251 NONE cd-832_4\NNP\0|that_5|ischemia_27|during_36|and_70|suggest_74 (r_nsubj) improves_5\VBZ\126264|data_22|._179 (l_prep) during_8\IN\0|that_41|cd-832_36|ischemia_9|and_34|suggest_38 (l_pobj) infusion_10\NN\14589223|NONE_0 (l_prep) with_11\IN\0|iso_13 (l_pobj) stenosis_12\NN\14204950|NONE_0
C082828_D003251 NONE cd-832_21\NNP\0|that_43|property_12|role_21|in_26 (r_punct) plays_22\VBZ\7007684|NONE_0 (r_ccomp) suggest_14\VBP\1010118|that_79|cd-832_74|ischemia_47|during_38|and_4 (r_conj) improves_5\VBZ\126264|data_22|._179 (l_prep) during_8\IN\0|that_41|cd-832_36|ischemia_9|and_34|suggest_38 (l_pobj) infusion_10\NN\14589223|NONE_0 (l_prep) with_11\IN\0|iso_13 (l_pobj) stenosis_12\NN\14204950|NONE_0
C082828_D003251 NONE cd-832_31\NNP\0|NONE_0 (r_pobj) of_30\IN\0|the_23|beneficial_19 (r_prep) effects_29\NNS\13245626|NONE_0 (r_pobj) in_26\IN\13603305|that_69|property_38|cd-832_26|role_5 (r_prep) plays_22\VBZ\7007684|NONE_0 (r_ccomp) suggest_14\VBP\1010118|that_79|cd-832_74|ischemia_47|during_38|and_4 (r_conj) improves_5\VBZ\126264|data_22|._179 (l_prep) during_8\IN\0|that_41|cd-832_36|ischemia_9|and_34|suggest_38 (l_pobj) infusion_10\NN\14589223|NONE_0 (l_prep) with_11\IN\0|iso_13 (l_pobj) stenosis_12\NN\14204950|NONE_0
D004110_D017202 NONE diltiazem_32\NN\2938514|or_3 (r_conj) nifedipine_30\NN\2938514|NONE_0 (r_pobj) for_29\IN\0|NONE_0 (r_prep) those_28\DT\0|NONE_0 (r_pobj) with_27\IN\0|were_14 (r_prep) compared_26\VBN\644583|effects_178|ischemia_118|were_109|in_96|._47 (r_prep) studied_10\VBN\0|NONE_0 (l_nsubjpass) ischemia_8\NN\14195315|effects_60|were_9|in_22|compared_118|._165
D009543_D003251 NONE nifedipine_3\NN\2938514|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) contrast_1\NN\13854649|NONE_0 (r_pobj) in_0\IN\13603305|,_25|cd-832_27|decrease_71|and_177|elevation_192|._291 (r_prep) prevented_14\VBD\0|NONE_0 (l_conj) elevation_44\NN\7445480|in_192|,_167|cd-832_165|decrease_121|and_15|._99 (l_prep) at_60\IN\14622893|segment_66|from_48|to_28 (l_pobj) min_62\NN\15154774|NONE_0 (l_prep) after_63\IN\0|3_6 (l_pobj) infusion_65\NN\14589223|NONE_0 (l_prep) with_66\IN\0|iso_13 (l_pobj) stenosis_67\NN\14204950|NONE_0
D002118_D023921 NONE calcium_4\NN\14625458|a_6|new_4|,_18 (r_compound) antagonist_5\NN\7846|NONE_0 (r_pobj) of_1\IN\0|,_35|on_37|._120 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) on_9\IN\0|of_37|,_2|._83 (l_pobj) ischemia_14\NN\14195315|NONE_0 (l_prep) in_15\IN\13603305|induced_28|myocardial_20 (l_pobj) dogs_16\NNS\2083346|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) stenosis_20\NN\14204950|NONE_0
D004110_D023921 NONE diltiazem_32\NN\2938514|or_3 (r_conj) nifedipine_30\NN\2938514|NONE_0 (r_pobj) for_29\IN\0|NONE_0 (r_prep) those_28\DT\0|NONE_0 (r_pobj) with_27\IN\0|were_14 (r_prep) compared_26\VBN\644583|effects_178|ischemia_118|were_109|in_96|._47 (r_prep) studied_10\VBN\0|NONE_0 (l_prep) in_11\IN\13603305|effects_82|ischemia_22|were_13|compared_96|._143 (l_pobj) dogs_12\NNS\2083346|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) stenosis_16\NN\14204950|NONE_0
D002118_D017202 NONE calcium_4\NN\14625458|a_6|new_4|,_18 (r_compound) antagonist_5\NN\7846|NONE_0 (r_pobj) of_1\IN\0|,_35|on_37|._120 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) on_9\IN\0|of_37|,_2|._83 (l_pobj) ischemia_14\NN\14195315|NONE_0
12165618
D019469_D015658 NONE indinavir_18\NNS\4013993|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) treated_16\VBN\2376958|1-infected_20 (r_acl) children_15\NNS\9622049|leukocyturia_104|is_91|with_77|._31 (l_amod) 1-infected_14\VBN\0|treated_20
D019469_D015658 NONE indinavir_5\NNS\4013993|-_9 (r_npadvmod) related_7\VBN\628491|NONE_0 (r_amod) nephrotoxicity_8\NN\0|to_29|in_15 (r_dobj) monitor_4\VB\10676877|a_23|prospective_21|._135 (l_prep) in_9\IN\13603305|to_44|nephrotoxicity_15 (l_pobj) cohort_11\NN\8184861|NONE_0 (l_prep) of_12\IN\0|a_9 (l_pobj) children_19\NNS\9622049|NONE_0 (l_amod) 1-infected_18\VBN\0|type_5|treated_20
D019469_D015658 NONE indinavir_22\NNS\4013993|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) treated_20\VBN\2376958|type_25|1-infected_20 (r_acl) children_19\NNS\9622049|NONE_0 (l_amod) 1-infected_18\VBN\0|type_5|treated_20
D019469_-1 NONE indinavir_18\NNS\4013993|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) treated_16\VBN\2376958|1-infected_20 (r_acl) children_15\NNS\9622049|leukocyturia_104|is_91|with_77|._31 (r_dobj) associated_4\VBN\628491|NONE_0 (l_nsubjpass) leukocyturia_2\NN\0|is_13|with_27|children_104|._135
D019469_-1 NONE indinavir_30\NNS\4013993|NONE_0 (r_pobj) of_29\IN\0|a_19|peak_17|serum_12 (r_prep) level_28\NN\4916342|19_28|mg_25|/_23|x_20|h_18|or_16 (r_conj) l_21\NN\13616054|NONE_0 (r_appos) >_17\XX\0|incidence_88|was_51|in_41 (r_meta) found_8\VBN\13279262|NONE_0 (l_nsubjpass) incidence_3\NN\13821570|was_37|in_47|>_88 (l_prep) of_4\IN\0|a_30|higher_28|cumulative_21 (l_pobj) leukocyturia_6\NN\0|NONE_0
D019469_-1 NONE indinavir_3\NNS\4013993|NONE_0 (r_pobj) with_2\IN\0|children_17 (r_prep) treated_1\VBN\2376958|incidence_46|._90 (r_csubj) have_4\VBP\7846|NONE_0 (l_dobj) incidence_8\NN\13821570|treated_46|._44 (l_prep) of_9\IN\0|a_28|high_26|cumulative_21 (l_pobj) leukocyturia_12\NN\0|NONE_0
D019469_-1 NONE indinavir_0\NNP\4013993|-_9 (r_npadvmod) associated_2\VBN\628491|NONE_0 (r_amod) nephrotoxicity_3\NN\0|must_15|be_20|closely_33|,_40|in_53|age_124 (r_nsubjpass) monitored_6\VBN\2169352|NONE_0 (l_prep) in_10\IN\13603305|nephrotoxicity_53|must_38|be_33|closely_20|,_13|age_71 (l_pobj) children_11\NNS\9622049|especially_14 (l_prep) with_12\IN\0|NONE_0 (l_pobj) factors_14\NNS\7326557|NONE_0 (l_prep) as_16\IN\14622893|risk_18 (l_pobj) leukocyturia_19\NN\0|such_27
D019469_-1 NONE indinavir_32\NNS\4013993|NONE_0 (r_pobj) of_31\IN\0|the_10 (r_prep) curve_30\NN\13863771|NONE_0 (r_pobj) under_28\IN\0|an_8 (r_prep) area_27\NN\8630985|<_15|years_10|,_5 (r_appos) age_21\NN\4916342|nephrotoxicity_124|must_109|be_104|closely_91|,_84|in_71 (r_appos) monitored_6\VBN\2169352|NONE_0 (l_prep) in_10\IN\13603305|nephrotoxicity_53|must_38|be_33|closely_20|,_13|age_71 (l_pobj) children_11\NNS\9622049|especially_14 (l_prep) with_12\IN\0|NONE_0 (l_pobj) factors_14\NNS\7326557|NONE_0 (l_prep) as_16\IN\14622893|risk_18 (l_pobj) leukocyturia_19\NN\0|such_27
D003404_-1 NONE creatinine_15\NN\0|albumin_8 (r_compound) ratio_16\NN\13815152|the_29 (r_appos) urine_12\NN\14853947|and_31|by_35 (r_pobj) in_10\IN\13603305|a_16|mild_14 (r_prep) increase_9\NN\13576355|NONE_0 (r_pobj) with_6\IN\0|leukocyturia_39|was_26|frequently_22|._87 (r_prep) associated_5\VBN\628491|NONE_0 (l_nsubjpass) leukocyturia_2\NN\0|was_13|frequently_17|with_39|._126
D003404_-1 NONE creatinine_9\JJ\0|serum_6|of_18 (r_compound) levels_10\NNS\4916342|children_83|frequently_32|without_47|._86 (r_dobj) had_7\VBD\0|NONE_0 (l_nsubj) children_0\NNS\9622049|frequently_51|levels_83|without_130|._169 (l_prep) with_1\IN\0|NONE_0 (l_pobj) leukocyturia_4\NN\0|NONE_0
D003404_-1 NONE creatinine_9\JJ\0|serum_6|of_18 (r_compound) levels_10\NNS\4916342|children_83|frequently_32|without_47|._86 (r_dobj) had_7\VBD\0|NONE_0 (l_prep) without_19\IN\0|children_130|frequently_79|levels_47|._39 (l_pobj) leukocyturia_22\NN\0|NONE_0
D003404_-1 NONE creatinine_4\NN\0|the_10|serum_6 (r_compound) levels_5\NNS\4916342|subsequently_35|,_23|,_16|returned_54 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_conj) returned_14\VBD\1835496|subsequently_89|,_77|levels_54|,_38 (l_conj) disappeared_21\VBD\0|ratios_46|to_30|,_23|and_21 (l_nsubj) leukocyturia_20\NN\0|within_25|._40
D003404_-1 NONE creatinine_12\NN\0|urine_14|albumin_8 (r_compound) ratios_13\NNS\13815152|to_16|,_23|and_25|disappeared_46 (r_nsubj) returned_14\VBD\1835496|subsequently_89|,_77|levels_54|,_38 (l_conj) disappeared_21\VBD\0|ratios_46|to_30|,_23|and_21 (l_nsubj) leukocyturia_20\NN\0|within_25|._40
D003404_-1 NONE creatinine_12\NN\0|serum_6|of_18 (r_compound) levels_13\NNS\4916342|NONE_0 (r_pobj) in_10\IN\13603305|an_12|above_35 (r_prep) increase_9\NN\13576355|children_69|frequently_18|._56 (r_dobj) had_7\VBD\0|NONE_0 (l_nsubj) children_0\NNS\9622049|frequently_51|increase_69|._125 (l_prep) with_1\IN\0|NONE_0 (l_pobj) leukocyturia_4\NN\0|NONE_0
D003404_D006417 NONE creatinine_15\NN\0|albumin_8 (r_compound) ratio_16\NN\13815152|the_29 (r_appos) urine_12\NN\14853947|and_31|by_35 (r_pobj) in_10\IN\13603305|a_16|mild_14 (l_conj) by_18\IN\0|urine_35|and_4 (l_pobj) hematuria_20\NN\14299637|NONE_0
D019469_D007674 CID indinavir_18\NNS\4013993|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) treated_16\VBN\2376958|1-infected_20 (r_acl) children_15\NNS\9622049|leukocyturia_104|is_91|with_77|._31 (r_dobj) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|leukocyturia_27|is_14|children_77|._108 (l_pobj) function_8\NN\13783581|NONE_0
D019469_D007674 CID indinavir_5\NNS\4013993|-_9 (r_npadvmod) related_7\VBN\628491|NONE_0 (r_amod) nephrotoxicity_8\NN\0|to_29|in_15
D019469_D007674 CID indinavir_22\NNS\4013993|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) treated_20\VBN\2376958|type_25|1-infected_20 (r_acl) children_19\NNS\9622049|NONE_0 (r_pobj) of_12\IN\0|a_9 (r_prep) cohort_11\NN\8184861|NONE_0 (r_pobj) in_9\IN\13603305|to_44|nephrotoxicity_15 (r_prep) monitor_4\VB\10676877|a_23|prospective_21|._135 (l_dobj) nephrotoxicity_8\NN\0|to_29|in_15
D019469_D007674 CID indinavir_4\NNS\4013993|in_15|,_2|was_10|of_35|._52 (r_nsubjpass) discontinued_6\VBN\0|NONE_0 (l_prep) of_8\IN\0|in_50|,_37|indinavir_35|was_25|._17 (l_pobj) nephrotoxicity_9\NN\0|because_11
D019469_D007674 CID indinavir_0\NNP\4013993|-_9 (r_npadvmod) associated_2\VBN\628491|NONE_0 (r_amod) nephrotoxicity_3\NN\0|must_15|be_20|closely_33|,_40|in_53|age_124
D019469_D007674 CID indinavir_32\NNS\4013993|NONE_0 (r_pobj) of_31\IN\0|the_10 (r_prep) curve_30\NN\13863771|NONE_0 (r_pobj) under_28\IN\0|an_8 (r_prep) area_27\NN\8630985|<_15|years_10|,_5 (r_appos) age_21\NN\4916342|nephrotoxicity_124|must_109|be_104|closely_91|,_84|in_71 (r_appos) monitored_6\VBN\2169352|NONE_0 (l_nsubjpass) nephrotoxicity_3\NN\0|must_15|be_20|closely_33|,_40|in_53|age_124
16083708
D019980_D056486 CID clavulanate_2\NNP\0|out_19|as_23|._62 (r_nsubj) stands_3\VBZ\4359589|NONE_0 (l_prep) as_5\IN\14622893|clavulanate_23|out_4|._39 (l_pobj) drug_9\NN\14778436|NONE_0 (l_acl) related_10\VBN\628491|the_21|common_12 (l_prep) to_11\IN\0|NONE_0 (l_pobj) dili_12\NNP\0|NONE_0
D001663_D017114 NONE bilirubin_54\NN\14756039|higher_23|plasma_7|ci_32 (r_compound) value_55\NN\5856066|p_48|<_46|)_40|,_39|and_37 (r_conj) .009_47\CD\0|factors_177|sex_96|1.6_12|;_6|._91 (r_appos) were_9\VBD\0|NONE_0 (l_nsubj) factors_0\NNS\7326557|sex_81|1.6_165|;_171|.009_177|._268 (l_acl) associated_1\VBN\628491|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) development_4\NN\248977|NONE_0 (l_prep) of_5\IN\0|the_16 (l_pobj) failure_8\NN\66216|NONE_0
23872883
D007545_D066126 CID isoproterenol_18\NN\3740161|-_13 (r_npadvmod) induced_20\VBN\1627355|in_23 (r_amod) cardiotoxicity_21\NN\0|NONE_0
3833372
D013999_D006973 NONE maleate_23\NN\2718811|NONE_0 (r_pobj) of_21\IN\0|10_6|and_19|mg_26 (r_prep) mg_20\NN\13717155|NONE_0 (r_dobj) containing_18\VBG\2632940|a_26|ratio_18|,_68|administered_70 (r_acl) combination_17\NN\7951464|NONE_0 (l_acl) administered_30\VBN\2436349|a_96|ratio_88|containing_70|,_2 (l_prep) to_36\IN\0|daily_20|for_14 (l_pobj) patients_38\NNS\9898892|NONE_0 (l_amod) hypertensive_37\JJ\10405694|NONE_0
D006852_D006973 NONE hydrochlorothiazide_28\NN\4423288|NONE_0 (r_pobj) of_27\IN\0|25_6 (r_prep) mg_26\NN\13717155|10_32|of_26|and_7 (r_conj) mg_20\NN\13717155|NONE_0 (r_dobj) containing_18\VBG\2632940|a_26|ratio_18|,_68|administered_70 (r_acl) combination_17\NN\7951464|NONE_0 (l_acl) administered_30\VBN\2436349|a_96|ratio_88|containing_70|,_2 (l_prep) to_36\IN\0|daily_20|for_14 (l_pobj) patients_38\NNS\9898892|NONE_0 (l_amod) hypertensive_37\JJ\10405694|NONE_0
25041770
D017291_D012206 CID clarithromycin_9\NN\0|NONE_0 (r_pobj) in_8\IN\13603305|simvastatin_33 (r_prep) increment_7\NN\29677|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) association_2\NN\8008335|NONE_0 (r_pobj) in_1\IN\13603305|._70 (r_prep) rhabdomyolysis_0\NNP\0|NONE_0
D017291_D012206 CID clarithromycin_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|the_9 (r_prep) dose_15\NN\3740161|NONE_0 (r_pobj) in_13\IN\13603305|an_12 (r_prep) increase_12\NN\13576355|NONE_0 (r_pobj) after_10\IN\0|only_14 (r_prep) occurred_9\VBD\0|case_43|of_35|._56 (r_advcl) is_3\VBZ\0|NONE_0 (l_prep) of_4\IN\0|case_8|occurred_35|._91 (l_pobj) interest_5\NN\5682570|NONE_0 (l_prep) as_6\IN\14622893|NONE_0 (l_pobj) rhabdomyolysis_7\NN\0|NONE_0
D019821_D012206 CID simvastatin_4\NN\3676175|in_33 (r_nmod) increment_7\NN\29677|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) association_2\NN\8008335|NONE_0 (r_pobj) in_1\IN\13603305|._70 (r_prep) rhabdomyolysis_0\NNP\0|NONE_0
D019821_D012206 CID statin_10\NN\3740161|NONE_0 (r_pobj) with_9\IN\0|that_44|elevation_30|could_20|be_14|induced_12|,_34|warrant_46 (r_prep) associated_8\VBN\628491|case_47|._80 (l_conj) induced_11\VBN\1627355|that_56|elevation_42|could_32|be_26|with_12|,_22|warrant_34 (l_dobj) rhabdomyolysis_12\NN\0|NONE_0
11835460
D007980_D015835 CID levodopa_0\NNP\14604959|-_8|dyskinesias_24|._58 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dyskinesias_4\NNS\14084880|levodopa_24|-_16|._34
D007980_D015835 CID levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|ocular_8 (r_amod) dyskinesias_4\NNS\14084880|uncommon_21|._29
D007980_D015835 CID levodopa_17\NN\14604959|NONE_0 (r_pobj) of_16\IN\0|the_16|peak_12 (r_prep) effect_15\NN\34213|NONE_0 (r_pobj) during_12\IN\0|we_67|on_57|,_34|and_36|hypothesize_40|._186 (r_prep) report_1\VBP\6470073|NONE_0 (l_conj) hypothesize_20\VB\719734|we_107|on_97|during_40|,_6|and_4|._146 (l_ccomp) needed_31\VBN\0|NONE_0 (l_prep) for_32\IN\0|that_72|denervation_45|is_10 (l_pobj) appearance_34\NN\4723816|NONE_0 (l_prep) of_35\IN\0|the_15 (l_pobj) dyskinesias_41\NNS\14084880|NONE_0
D007980_D015835 CID levodopa_37\NN\14604959|-_8 (r_npadvmod) induce_39\VB\1627355|these_15|ocular_7 (r_amod) dyskinesias_41\NNS\14084880|NONE_0
D007980_D010300 NONE levodopa_0\NNP\14604959|-_8|dyskinesias_24|._58 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dyskinesias_4\NNS\14084880|levodopa_24|-_16|._34 (l_prep) in_5\IN\13603305|ocular_19 (l_pobj) disease_8\NN\14061805|NONE_0
9759693
D018170_D017091 CID sumatriptan_3\JJ\0|NONE_0 (r_amod) use_4\NN\407535|ischemic_33|and_16|._3 (r_conj) colitis_1\NN\14336539|NONE_0
D018170_D017091 CID sumatriptan_18\NNP\0|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) treated_16\VBN\2376958|NONE_0 (r_acl) migraine_15\NN\14326607|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) patients_13\NNS\9898892|NONE_0 (r_pobj) in_12\IN\13603305|the_55|of_39 (r_prep) development_4\NN\248977|NONE_0 (l_prep) of_5\IN\0|the_16|in_39 (l_pobj) cases_8\NNS\7283608|NONE_0 (l_prep) of_9\IN\0|8_16|serious_14 (l_pobj) colitis_11\NN\14336539|NONE_0
D018170_D017202 NONE sumatriptan_16\JJ\0|NONE_0 (r_compound) use_17\NN\407535|NONE_0 (r_pobj) after_15\IN\0|NONE_0 (r_prep) occurring_14\VBG\0|myocardial_22 (r_acl) infarction_13\NN\14204950|myocardial_36|,_17|and_15 (r_conj) ischemia_9\NN\14195315|coronary_31|,_13
D018170_D009203 NONE sumatriptan_16\JJ\0|NONE_0 (r_compound) use_17\NN\407535|NONE_0 (r_pobj) after_15\IN\0|NONE_0 (r_prep) occurring_14\VBG\0|myocardial_22 (r_acl) infarction_13\NN\14204950|myocardial_36|,_17|and_15
D018170_D008881 NONE sumatriptan_18\NNP\0|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) treated_16\VBN\2376958|NONE_0 (r_acl) migraine_15\NN\14326607|NONE_0
D018170_D003329 NONE sumatriptan_16\JJ\0|NONE_0 (r_compound) use_17\NN\407535|NONE_0 (r_pobj) after_15\IN\0|NONE_0 (r_prep) occurring_14\VBG\0|myocardial_22 (r_acl) infarction_13\NN\14204950|myocardial_36|,_17|and_15 (r_conj) ischemia_9\NN\14195315|coronary_31|,_13 (r_conj) vasospasm_6\NN\0|NONE_0
9382023
D004280_D006973 CID dobutamine_3\NN\0|NONE_0 (r_compound) stress_4\NN\7083732|NONE_0 (r_compound) echocardiography_5\RB\177127|NONE_0 (r_pobj) during_2\IN\0|hypertensive_22|._41 (r_prep) response_1\NN\11410625|NONE_0 (l_amod) hypertensive_0\JJ\10405694|during_22|._63
D004280_D006973 CID dobutamine_2\NN\0|NONE_0 (r_compound) stress_3\NN\7083732|NONE_0 (r_compound) echocardiographic_4\JJ\0|3,129_24 (r_amod) studies_5\NNS\635850|NONE_0 (r_pobj) among_0\IN\0|,_55|a_57|hypertensive_59|,_80|defined_82|or_124 (r_prep) response_9\NN\11410625|NONE_0 (l_amod) hypertensive_8\JJ\10405694|among_59|,_4|a_2|,_21|defined_23|or_65
D004280_D006973 CID dobutamine_20\NN\0|NONE_0 (r_compound) infusion_21\NN\14589223|NONE_0 (r_pobj) before_19\IN\0|bp_3 (r_prep) had_12\VBD\0|patients_73|often_40|history_28|and_4|._71 (r_conj) had_6\VBD\0|NONE_0 (l_dobj) history_8\NN\15120823|patients_45|often_12|and_24|had_28|._99 (l_prep) of_9\IN\0|a_10 (l_pobj) hypertension_10\NN\14057371|NONE_0
9125676
D013015_D002311 NONE sotalol_32\NN\0|patients_174|prevent_11|._63 (r_dobj) received_26\VBD\2210855|NONE_0 (l_nsubj) patients_4\NNS\9898892|sotalol_174|prevent_185|._237 (l_appos) 54_6\CD\0|one_26|consecutive_22|(_1|with_69 (l_conj) 20_13\CD\13745420|with_34|,_6|and_4 (l_prep) with_14\IN\0|)_27 (l_pobj) cardiomyopathy_16\NN\14103288|NONE_0
D013015_D016171 CID sotalol_32\NN\0|d_4 (r_pobj) with_27\IN\0|NONE_0 (r_prep) treated_26\VBN\2376958|NONE_0 (r_acl) patients_25\NNS\9898892|NONE_0 (r_pobj) in_24\IN\13603305|torsades_20|de_11 (r_prep) pointes_23\FW\831651|NONE_0 (r_pobj) for_20\IN\0|the_28|presumable_24|risk_13 (r_prep) factors_19\NNS\7326557|the_62|of_48|,_26|and_24 (r_conj) incidence_9\NN\13821570|the_27|clinical_23|,_6 (l_prep) of_10\IN\0|the_14|,_22|and_24|factors_48 (l_pobj) pointes_13\FW\831651|NONE_0
D013015_D016171 CID sotalol_32\NN\0|d_4 (r_pobj) with_27\IN\0|NONE_0 (r_prep) treated_26\VBN\2376958|NONE_0 (r_acl) patients_25\NNS\9898892|NONE_0 (r_pobj) in_24\IN\13603305|torsades_20|de_11 (r_prep) pointes_23\FW\831651|NONE_0
D013015_D016171 CID sotalol_21\NN\0|NONE_0 (r_pobj) with_16\IN\0|the_27|initial_23|oral_15 (r_prep) treatment_15\NN\654885|NONE_0 (r_pobj) during_11\IN\0|patients_38|from_25|._50 (r_prep) had_6\VBD\0|NONE_0 (l_prep) from_7\IN\0|patients_13|during_25|._75 (l_pobj) pointes_10\FW\831651|NONE_0
D013015_D016171 CID sotalol_10\NN\0|however_30|,_23|dose_12|,_3|lower_26|in_32|._115 (r_nsubj) was_11\VBD\0|NONE_0 (l_prep) in_14\IN\13603305|however_62|,_55|dose_44|,_35|sotalol_32|lower_6|._83 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) pointes_19\FW\831651|NONE_0
D013015_D016171 CID sotalol_23\NN\0|NONE_0 (r_pobj) with_18\IN\0|successful_21 (r_prep) treatment_17\NN\654885|NONE_0 (r_pobj) of_15\IN\0|2_8 (r_prep) years_14\NNS\15144371|NONE_0 (r_pobj) after_12\IN\0|patient_70|pointes_8|._54 (r_prep) had_7\VBD\0|NONE_0 (l_dobj) pointes_11\NNS\831651|patient_62|after_8|._62
D013015_D016171 CID sotalol_17\NN\0|NONE_0 (r_pobj) of_11\IN\0|low_10 (r_prep) doses_10\NNS\3740161|even_14 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treatment_6\NN\654885|NONE_0 (r_pobj) during_5\IN\0|pointes_23|early_6|._56 (r_prep) occurred_3\VBD\0|NONE_0 (l_nsubj) pointes_2\NNS\831651|early_17|during_23|._79
D013015_D016171 CID sotalol_26\NN\0|pronounced_102|d_4|,_3|might_8|subgroup_25|._92 (r_nsubj) identify_28\VB\699815|NONE_0 (l_dobj) subgroup_30\NN\31264|pronounced_127|d_29|,_28|sotalol_25|might_17|._67 (l_prep) of_31\IN\0|a_11 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|NONE_0 (l_pobj) risk_36\NN\14541044|NONE_0 (l_prep) for_37\IN\0|an_18|increased_15 (l_pobj) pointes_40\FW\831651|NONE_0
D013015_D016171 CID sotalol_11\NN\0|parameters_41|,_3|did_8|not_12|patients_25|at_34|._75 (r_nsubj) identify_14\VB\699815|NONE_0 (l_prep) at_16\IN\14622893|parameters_75|,_37|sotalol_34|did_26|not_22|patients_9|._41 (l_pobj) risk_18\NN\14541044|NONE_0 (l_prep) for_19\IN\0|increased_15 (l_pobj) pointes_22\FW\831651|NONE_0
D013015_D014693 NONE sotalol_32\NN\0|patients_174|prevent_11|._63 (r_dobj) received_26\VBD\2210855|NONE_0 (l_nsubj) patients_4\NNS\9898892|sotalol_174|prevent_185|._237 (l_prep) with_18\IN\0|one_95|consecutive_91|(_70|54_69 (l_pobj) tachycardia_22\NN\14110674|NONE_0 (l_conj) fibrillation_25\NN\14361664|inducible_59|sustained_49|ventricular_39|or_15
D013015_D014693 NONE sotalol_8\NN\0|in_12|,_3|induction_18 (r_nsubj) prevented_9\VBN\0|those_35 (l_dobj) induction_10\NN\7450842|in_30|,_21|sotalol_18 (l_prep) of_11\IN\0|NONE_0 (l_pobj) tachycardia_13\NN\14110674|NONE_0 (l_conj) fibrillation_16\NN\14361664|ventricular_39|or_15
D013015_-1 NONE sotalol_11\NN\0|d_4 (r_pobj) of_6\IN\0|the_8 (r_prep) use_5\NN\407535|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) proarrhythmia_2\NN\0|and_4|._84
D013015_D006331 NONE sotalol_23\NN\0|NONE_0 (r_pobj) with_18\IN\0|successful_21 (r_prep) treatment_17\NN\654885|NONE_0 (r_pobj) of_15\IN\0|2_8 (r_prep) years_14\NNS\15144371|NONE_0 (r_pobj) after_12\IN\0|patient_70|pointes_8|._54 (r_prep) had_7\VBD\0|NONE_0 (l_nsubj) patient_2\NN\9898892|pointes_62|after_70|._124 (l_prep) with_3\IN\0|one_19|female_15 (l_pobj) disease_6\NN\14061805|NONE_0
D013015_D003324 NONE sotalol_32\NN\0|patients_174|prevent_11|._63 (r_dobj) received_26\VBD\2210855|NONE_0 (l_nsubj) patients_4\NNS\9898892|sotalol_174|prevent_185|._237 (l_appos) 54_6\CD\0|one_26|consecutive_22|(_1|with_69 (l_prep) with_7\IN\0|,_28|and_30|20_34 (l_pobj) disease_10\NN\14061805|NONE_0
D013015_D017180 NONE sotalol_11\NN\0|d_4 (l_prep) for_12\IN\0|,_11|l_10|-_9 (l_pobj) tachyarrhythmias_15\NNS\0|NONE_0
D013015_D017180 NONE sotalol_32\NN\0|d_4 (l_prep) for_33\IN\0|,_11|l_10|-_9 (l_pobj) tachyarrhythmias_36\NNS\0|NONE_0
D013015_D017180 NONE sotalol_32\NN\0|patients_174|prevent_11|._63 (r_dobj) received_26\VBD\2210855|NONE_0 (l_nsubj) patients_4\NNS\9898892|sotalol_174|prevent_185|._237 (l_prep) with_18\IN\0|one_95|consecutive_91|(_70|54_69 (l_pobj) tachycardia_22\NN\14110674|NONE_0
D013015_D017180 NONE sotalol_32\NN\0|patients_174|prevent_11|._63 (r_dobj) received_26\VBD\2210855|NONE_0 (l_advcl) prevent_34\VB\0|patients_185|sotalol_11|._52 (l_dobj) induction_35\NN\7450842|to_11 (l_prep) of_36\IN\0|NONE_0 (l_pobj) tachyarrhythmia_39\NN\0|NONE_0
D013015_D017180 NONE sotalol_8\NN\0|in_12|,_3|induction_18 (r_nsubj) prevented_9\VBN\0|those_35 (l_dobj) induction_10\NN\7450842|in_30|,_21|sotalol_18 (l_prep) of_11\IN\0|NONE_0 (l_pobj) tachycardia_13\NN\14110674|NONE_0
D013015_D017180 NONE sotalol_13\NN\0|d_4|,_3|;_28|tachyarrhythmia_46|inducible_71|in_81 (r_dep) remained_25\VBD\2604760|induction_133|was_88|by_74|;_39|and_41|tolerate_73 (r_conj) prevented_6\VBN\0|NONE_0 (l_nsubjpass) induction_0\NN\7450842|was_45|by_59|remained_133|;_172|and_174|tolerate_206 (l_prep) of_1\IN\0|NONE_0 (l_pobj) tachyarrhythmia_4\NN\0|NONE_0
D013015_D017180 NONE sotalol_13\NN\0|d_4|,_3|;_28|tachyarrhythmia_46|inducible_71|in_81 (r_dep) remained_25\VBD\2604760|induction_133|was_88|by_74|;_39|and_41|tolerate_73 (l_nsubj) tachyarrhythmia_24\NN\0|d_50|,_49|sotalol_46|;_18|inducible_25|in_35
D013015_D017180 NONE sotalol_53\NN\0|d_4 (r_pobj) of_48\IN\0|40_6 (r_prep) mg_47\NN\13717155|patients_34|did_25|not_21|daily_23|._28 (r_dobj) tolerate_44\VB\802318|induction_206|was_161|by_147|remained_73|;_34|and_32 (r_conj) prevented_6\VBN\0|NONE_0 (l_nsubjpass) induction_0\NN\7450842|was_45|by_59|remained_133|;_172|and_174|tolerate_206 (l_prep) of_1\IN\0|NONE_0 (l_pobj) tachyarrhythmia_4\NN\0|NONE_0
D013015_D017180 NONE sotalol_53\NN\0|d_4 (r_pobj) of_48\IN\0|40_6 (r_prep) mg_47\NN\13717155|patients_34|did_25|not_21|daily_23|._28 (r_dobj) tolerate_44\VB\802318|induction_206|was_161|by_147|remained_73|;_34|and_32 (r_conj) prevented_6\VBN\0|NONE_0 (l_conj) remained_25\VBD\2604760|induction_133|was_88|by_74|;_39|and_41|tolerate_73 (l_nsubj) tachyarrhythmia_24\NN\0|d_50|,_49|sotalol_46|;_18|inducible_25|in_35
1735570
D014294_D007022 CID trimethaphan_1\RB\0|-_12 (r_npadvmod) induced_3\VBN\1627355|the_17 (r_amod) hypotension_4\NN\14057371|was_12|by_28|._181
D014294_D001919 NONE trimethaphan_1\RB\0|-_12 (r_npadvmod) induced_3\VBN\1627355|the_17 (r_amod) hypotension_4\NN\14057371|was_12|by_28|._181 (r_nsubjpass) accompanied_6\VBN\0|NONE_0 (l_agent) by_7\IN\0|hypotension_28|was_16|._153 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D014294_D013610 CID trimethaphan_1\RB\0|-_12 (r_npadvmod) induced_3\VBN\1627355|the_17 (r_amod) hypotension_4\NN\14057371|was_12|by_28|._181 (r_nsubjpass) accompanied_6\VBN\0|NONE_0 (l_agent) by_7\IN\0|hypotension_28|was_16|._153 (l_pobj) bradycardia_10\NN\14110674|NONE_0 (l_prep) in_11\IN\13603305|a_26|significant_24 (l_pobj) rats_13\NNS\2329401|NONE_0 (l_appos) beats_18\NNS\8289449|lesioned_26|(_12|-32_11 (l_conj) tachycardia_24\NN\14110674|+/-_31|13_27|per_18|)_8|but_6
20169779
D007980_D001523 NONE levodopa_1\RB\14604959|-_8 (r_npadvmod) treated_3\VBN\2376958|the_13|lesioned_13 (r_amod) marmoset_7\NN\2489589|was_9|as_18|._72 (r_nsubjpass) used_9\VBN\0|NONE_0 (l_prep) as_10\IN\14622893|marmoset_18|was_9|._54 (l_pobj) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|a_8 (l_pobj) symptoms_15\NNS\5823932|NONE_0
D007980_D001523 NONE levodopa_7\NN\14604959|-_8 (r_npadvmod) induced_9\VBN\1627355|motor_8|and_27|behaviors_53 (r_amod) fluctuations_11\NNS\7345593|NONE_0 (l_conj) behaviors_16\NNS\407535|induced_53|motor_45|and_26
D007980_D001523 NONE levodopa_27\VB\14604959|NONE_0 (r_pobj) to_26\IN\0|(_7|)_11|and_13|on_17 (r_prep) prior_25\RB\10675876|analysis_83|,_110|blind_112 (r_advmod) hoc_45\FW\0|animals_217|were_209|for_194|on_85|._63 (r_prep) evaluated_2\VBN\670261|NONE_0 (l_prep) for_3\IN\0|animals_23|were_15|on_109|hoc_194|._257 (l_pobj) disability_5\NN\14547369|NONE_0 (l_conj) dyskinesia_7\JJ\14084880|parkinsonian_25|,_2 (l_conj) behaviors_20\NNS\407535|and_59|on_55|(_47|fluctuations_40|)_28|and_26
D007980_D001523 NONE levodopa_3\RB\14604959|-_8 (r_npadvmod) induced_5\VBN\1627355|like_25 (r_amod) behaviors_9\NNS\407535|in_52|,_41|present_15|and_54|correlate_81
D007980_D001523 NONE levodopa_16\JJ\14604959|NONE_0 (r_compound) treatment_17\NN\654885|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) 1_14\CD\13741022|NONE_0 (r_nummod) day_13\NN\15154774|NONE_0 (r_pobj) on_12\IN\0|NONE_0 (r_prep) present_11\JJ\28270|in_67|,_56|behaviors_15|and_39|correlate_66 (r_acomp) were_10\VBD\0|NONE_0 (l_nsubj) behaviors_9\NNS\407535|in_52|,_41|present_15|and_54|correlate_81
D007980_D001523 NONE levodopa_14\NN\14604959|NONE_0 (r_pobj) between_13\IN\0|an_15|than_39 (r_prep) interaction_12\NN\37396|that_57|disorders_35|likely_10|therapy_112 (r_attr) are_8\VBP\13600404|data_51|._138 (l_nsubj) disorders_5\NNS\14034177|that_22|likely_25|interaction_35|therapy_147
D015632_D001523 NONE mptp_4\NNP\0|-_4 (r_npadvmod) lesioned_6\VBN\0|the_26|treated_13 (r_amod) marmoset_7\NN\2489589|was_9|as_18|._72 (r_nsubjpass) used_9\VBN\0|NONE_0 (l_prep) as_10\IN\14622893|marmoset_18|was_9|._54 (l_pobj) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|a_8 (l_pobj) symptoms_15\NNS\5823932|NONE_0
D015632_D010302 NONE mptp_4\NNP\0|the_4|marmoset_5|of_20 (r_nmod) model_6\NN\5888929|NONE_0 (l_prep) of_7\IN\0|the_24|mptp_20|marmoset_15 (l_pobj) disease_10\NN\14061805|NONE_0
D015632_D010302 NONE mptp_4\NNP\0|-_4 (r_npadvmod) lesioned_6\VBN\0|the_26|treated_13 (r_amod) marmoset_7\NN\2489589|was_9|as_18|._72 (r_nsubjpass) used_9\VBN\0|NONE_0 (l_prep) as_10\IN\14622893|marmoset_18|was_9|._54 (l_pobj) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|a_8 (l_pobj) symptoms_15\NNS\5823932|NONE_0 (l_prep) in_16\IN\13603305|neuropsychiatric_26 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_compound) pd_17\NNP\14625458|NONE_0
D015632_D010302 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_3\CD\0|marmosets_28|were_18|s.c._56|)_60|for_62|,_75|resulting_77|._109 (r_oprd) administered_2\VBN\2436349|NONE_0 (l_advcl) resulting_13\VBG\2633881|marmosets_105|were_95|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_77|s.c._21|)_17|for_15|,_2|._32 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) parkinsonism_16\NN\14085708|NONE_0
D007980_D020734 NONE levodopa_27\VB\14604959|NONE_0 (r_pobj) to_26\IN\0|(_7|)_11|and_13|on_17 (r_prep) prior_25\RB\10675876|analysis_83|,_110|blind_112 (r_advmod) hoc_45\FW\0|animals_217|were_209|for_194|on_85|._63 (r_prep) evaluated_2\VBN\670261|NONE_0 (l_prep) for_3\IN\0|animals_23|were_15|on_109|hoc_194|._257 (l_pobj) disability_5\NN\14547369|NONE_0
D007980_D004409 CID levodopa_27\VB\14604959|NONE_0 (r_pobj) to_26\IN\0|(_7|)_11|and_13|on_17 (r_prep) prior_25\RB\10675876|analysis_83|,_110|blind_112 (r_advmod) hoc_45\FW\0|animals_217|were_209|for_194|on_85|._63 (r_prep) evaluated_2\VBN\670261|NONE_0 (l_prep) for_3\IN\0|animals_23|were_15|on_109|hoc_194|._257 (l_pobj) disability_5\NN\14547369|NONE_0 (l_conj) dyskinesia_7\JJ\14084880|parkinsonian_25|,_2
D007980_D004409 CID levodopa_9\NN\14604959|-_8 (r_npadvmod) induced_11\VBN\1627355|motor_8|,_26|dyskinesia_28 (r_amod) fluctuations_13\NNS\7345593|NONE_0 (l_conj) dyskinesia_15\JJ\14084880|induced_28|motor_20|,_2
D007980_D004409 CID levodopa_27\NN\14604959|NONE_0 (r_compound) therapy_28\NN\657604|NONE_0 (r_pobj) of_26\IN\0|the_13 (r_prep) duration_25\NN\15113229|NONE_0 (r_pobj) with_23\IN\0|that_16 (r_prep) correlated_22\VBD\2657219|a_96|progressive_94|in_73 (r_relcl) increase_7\NN\13576355|anticipated_45|,_34|animals_32|,_75|._130 (l_prep) in_8\IN\13603305|a_23|progressive_21|correlated_73 (l_pobj) fluctuations_13\NNS\7345593|NONE_0 (l_conj) dyskinesia_15\JJ\14084880|induced_28|motor_20|,_2
D007980_D010302 NONE levodopa_1\RB\14604959|-_8 (r_npadvmod) treated_3\VBN\2376958|the_13|lesioned_13 (r_amod) marmoset_7\NN\2489589|was_9|as_18|._72 (r_nsubjpass) used_9\VBN\0|NONE_0 (l_prep) as_10\IN\14622893|marmoset_18|was_9|._54 (l_pobj) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|a_8 (l_pobj) symptoms_15\NNS\5823932|NONE_0 (l_prep) in_16\IN\13603305|neuropsychiatric_26 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_compound) pd_17\NNP\14625458|NONE_0
D007980_D010302 NONE levodopa_14\NN\14604959|NONE_0 (r_pobj) between_13\IN\0|an_15|than_39 (r_prep) interaction_12\NN\37396|that_57|disorders_35|likely_10|therapy_112 (r_attr) are_8\VBP\13600404|data_51|._138 (l_nsubj) disorders_5\NNS\14034177|that_22|likely_25|interaction_35|therapy_147 (l_prep) in_6\IN\13603305|neuropsychiatric_27 (l_pobj) pd_7\NNP\14625458|NONE_0
24641119
D007654_-1 NONE ketoconazole_4\NN\0|NONE_0 (r_pobj) by_3\IN\0|syndrome_17|._15 (r_prep) induced_2\VBN\1627355|NONE_0 (l_nsubj) syndrome_1\NN\5870365|by_17|._32
D007654_-1 NONE ketoconazole_21\NN\0|NONE_0 (r_pobj) to_19\IN\0|prior_18 (r_prep) sensitivity_18\NN\5651971|which_21 (r_dobj) included_16\VBD\0|his_19|,_8 (r_relcl) history_13\NN\15120823|NONE_0 (r_pobj) on_11\IN\0|NONE_0 (r_prep) based_10\VBN\0|induced_24|baboon_16 (r_acl) syndrome_9\NN\5870365|NONE_0
D007654_-1 NONE ketoconazole_14\RB\0|-_12 (r_npadvmod) induced_16\VBN\1627355|baboon_8|in_24 (r_amod) syndrome_18\NN\5870365|NONE_0
D007654_D003875 CID ketoconazole_20\RB\0|NONE_0 (r_dobj) using_18\VBG\418025|NONE_0 (r_pcomp) after_17\IN\0|patient_83|with_65|._29 (r_prep) presented_6\VBN\2137132|NONE_0 (l_prep) with_7\IN\0|patient_18|after_65|._94 (l_pobj) eruption_10\NN\7307754|NONE_0
24840785
D002118_D011041 NONE ca(2_10\NNP\0|NONE_0 (r_pobj) of_9\IN\0|the_9 (r_prep) role_8\NN\719494|NONE_0 (r_pobj) on_6\IN\0|NONE_0 (r_prep) available_5\JJ\0|however_24|,_17|reports_12|+_29|)_30|in_32|._54 (r_acomp) are_4\VBP\13600404|NONE_0 (l_prep) in_13\IN\13603305|however_56|,_49|reports_44|available_32|+_3|)_2|._22 (l_pobj) poisoning_15\NN\14034177|NONE_0
D002118_D011041 NONE ca(2_10\NNP\0|NONE_0 (r_pobj) of_8\IN\0|the_15 (r_prep) importance_7\NN\5138488|in_31|,_18|we_16|)_32|signaling_34|._87 (r_dobj) explored_5\VBD\789138|NONE_0 (l_advcl) signaling_13\NN\33020|in_65|,_52|we_50|importance_34|)_2|._53 (l_prep) in_14\IN\13603305|in_23 (l_pobj) poisoning_16\NN\14034177|NONE_0
D000157_D011041 CID aconitine_14\NN\0|NONE_0 (r_compound) poisoning_15\NN\14034177|NONE_0
D000157_D011041 CID aconitine_15\NN\0|NONE_0 (r_compound) poisoning_16\NN\14034177|NONE_0
D012964_D066126 NONE na(+_7\NN\0|voltage_18|-_11 (r_cc) dependent_6\JJ\9627906|)_14 (r_nmod) channels_9\NNS\6251781|that_29|roles_22|in_28 (r_nsubj) have_10\VBP\7846|evidence_57|._53 (l_prep) in_13\IN\13603305|that_57|channels_28|roles_6 (l_pobj) cardiotoxicity_15\NN\0|NONE_0
D000157_D064420 NONE aconitine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|on_13 (r_prep) effects_2\NNS\13245626|to_15 (r_dobj) investigate_1\VB\644583|,_53|we_55|assay_81|._259 (r_advcl) performed_10\VBD\0|NONE_0 (l_dobj) assay_12\NN\5733583|investigate_81|,_28|we_26|._178 (l_compound) cytotoxicity_11\NN\13583478|in_19|,_63|as_73|level_107
D002118_D001145 NONE ca2_3\NN\0|arrhythmia_21|and_32|apoptosis_45|._97 (r_nsubj) causes_6\NNS\7323922|NONE_0 (l_dobj) arrhythmia_7\NN\14103288|ca2_21|and_11|apoptosis_24|._76
D002118_D001145 NONE ca(2_3\NNP\0|that_5|accelerated_24|and_85|caused_89 (r_nsubj) lead_7\NN\5155821|we_30|._122 (l_conj) caused_18\VBD\1617192|that_94|ca(2_89|accelerated_65|and_4 (l_dobj) arrhythmia_19\NN\14103288|in_11
D002118_D001145 NONE ca(2_9\NNP\0|)_5|and_16|causes_20 (r_nmod) overload_12\NN\3679986|aconitine_42|significantly_32|and_31|promotes_43 (l_conj) causes_14\VBZ\7323922|ca(2_20|)_15|and_4 (l_dobj) arrhythmia_15\NN\14103288|NONE_0
D019344_D064420 NONE lactate_26\NN\14850483|NONE_0 (r_compound) dehydrogenase_27\NN\0|measured_17|in_20 (r_compound) level_28\NN\4916342|cytotoxicity_107|in_88|,_44|as_34 (r_conj) assay_12\NN\5733583|investigate_81|,_28|we_26|._178 (l_compound) cytotoxicity_11\NN\13583478|in_19|,_63|as_73|level_107
D019344_D009202 NONE lactate_26\NN\14850483|NONE_0 (r_compound) dehydrogenase_27\NN\0|measured_17|in_20 (r_compound) level_28\NN\4916342|cytotoxicity_107|in_88|,_44|as_34 (r_conj) assay_12\NN\5733583|investigate_81|,_28|we_26|._178 (r_dobj) performed_10\VBD\0|NONE_0 (l_advcl) investigate_1\VB\644583|,_53|we_55|assay_81|._259 (l_dobj) effects_2\NNS\13245626|to_15 (l_prep) on_5\IN\0|of_13 (l_pobj) injury_7\NN\14052046|NONE_0
D000157_D001145 CID aconitine_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|+_11|overload_13 (r_amod) ca2_3\NN\0|arrhythmia_21|and_32|apoptosis_45|._97 (r_nsubj) causes_6\NNS\7323922|NONE_0 (l_dobj) arrhythmia_7\NN\14103288|ca2_21|and_11|apoptosis_24|._76
D000157_D001145 CID aconitine_6\NN\0|significantly_10|overload_42|and_73|promotes_85 (r_nsubj) aggravates_8\VBZ\126264|hence_56|,_51|results_45|._151 (l_dobj) overload_12\NN\3679986|aconitine_42|significantly_32|and_31|promotes_43 (l_conj) causes_14\VBZ\7323922|ca(2_20|)_15|and_4 (l_dobj) arrhythmia_15\NN\14103288|NONE_0
D000157_D066126 CID aconitine_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|the_19 (r_prep) cardiotoxicity_15\NN\0|NONE_0
D000157_D009202 NONE aconitine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|on_13 (r_prep) effects_2\NNS\13245626|to_15 (l_prep) on_5\IN\0|of_13 (l_pobj) injury_7\NN\14052046|NONE_0
D000157_D009202 NONE aconitine_4\NN\0|that_5|in_19|and_40|reduced_44 (r_nsubj) resulted_5\VBD\2633881|results_30|._74 (l_prep) in_6\IN\13603305|that_24|aconitine_19|and_21|reduced_25 (l_pobj) injury_8\NN\14052046|NONE_0
24975837
D014508_D058186 NONE urea_33\NN\14727670|and_4 (r_conj) creatinine_31\NN\0|NONE_0 (r_pobj) of_30\IN\0|serum_13 (r_prep) levels_29\NNS\4916342|,_29|increase_31 (r_dobj) augment_27\VBP\153263|adopted_135|;_105|however_103|,_96|drug_89|can_84|injury_60|due_53|,_2|._136 (r_conj) induce_14\VB\1627355|NONE_0 (l_dobj) injury_17\NN\14052046|adopted_75|;_45|however_43|,_36|drug_29|can_24|due_7|,_58|augment_60|._196
D002945_D007674 NONE cisplatin_15\NN\0|NONE_0 (r_amod) therapy_16\NN\657604|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|NONE_0 (r_acl) nephrotoxicity_12\NN\0|NONE_0
D003404_D007683 NONE creatinine_31\NN\0|NONE_0 (r_pobj) of_30\IN\0|serum_13 (r_prep) levels_29\NNS\4916342|,_29|increase_31 (r_dobj) augment_27\VBP\153263|adopted_135|;_105|however_103|,_96|drug_89|can_84|injury_60|due_53|,_2|._136 (l_conj) increase_35\VB\13576355|levels_31|,_2 (l_dobj) score_40\NN\5736149|NONE_0 (l_compound) necrosis_39\NN\11444117|the_18|acute_14|tubular_8|and_15|cytokines_31
D003404_D058186 NONE creatinine_31\NN\0|NONE_0 (r_pobj) of_30\IN\0|serum_13 (r_prep) levels_29\NNS\4916342|,_29|increase_31 (r_dobj) augment_27\VBP\153263|adopted_135|;_105|however_103|,_96|drug_89|can_84|injury_60|due_53|,_2|._136 (r_conj) induce_14\VB\1627355|NONE_0 (l_dobj) injury_17\NN\14052046|adopted_75|;_45|however_43|,_36|drug_29|can_24|due_7|,_58|augment_60|._196
D002945_D058186 CID cisplatin_7\RB\0|-_9 (r_npadvmod) induced_9\VBN\1627355|acute_8|renal_14 (r_amod) injury_12\NN\14052046|deletion_64|._6
D002945_D058186 CID cisplatin_0\NNP\0|NONE_0 (r_compound) treatment_1\NN\654885|has_10|been_14|in_27 (r_nsubjpass) adopted_4\VBN\674607|;_30|however_32|,_39|drug_46|can_51|injury_75|due_82|,_133|augment_135|._271 (r_ccomp) induce_14\VB\1627355|NONE_0 (l_dobj) injury_17\NN\14052046|adopted_75|;_45|however_43|,_36|drug_29|can_24|due_7|,_58|augment_60|._196
D002945_D058186 CID cisplatin_10\NN\0|-_9 (r_advmod) induced_12\VBN\1627355|acute_8|kidney_14 (r_amod) injury_15\NN\14052046|NONE_0
D002945_D058186 CID cisplatin_25\NN\0|NONE_0 (r_pobj) with_24\IN\0|examine_132|mice_21|were_16|._14 (r_prep) challenged_23\VBN\869596|NONE_0 (l_advcl) examine_1\VB\0|mice_111|were_116|with_132|._146 (l_dobj) role_3\NN\719494|to_15 (l_prep) of_4\IN\0|the_9 (l_pobj) kinin_6\NN\14744841|NONE_0 (l_appos) receptor_8\NN\5225602|the_13|,_49|kinin_51 (l_prep) in_9\IN\13603305|b2_12 (l_pobj) injury_15\NN\14052046|NONE_0
D002945_D058186 CID cisplatin_13\NN\0|-_9 (r_advmod) induced_15\VBN\1627355|acute_8|kidney_14 (r_amod) injury_18\NN\14052046|NONE_0
D002945_D007683 CID cisplatin_0\NNP\0|NONE_0 (r_compound) treatment_1\NN\654885|has_10|been_14|in_27 (r_nsubjpass) adopted_4\VBN\674607|;_30|however_32|,_39|drug_46|can_51|injury_75|due_82|,_133|augment_135|._271 (r_ccomp) induce_14\VB\1627355|NONE_0 (l_conj) augment_27\VBP\153263|adopted_135|;_105|however_103|,_96|drug_89|can_84|injury_60|due_53|,_2|._136 (l_conj) increase_35\VB\13576355|levels_31|,_2 (l_dobj) score_40\NN\5736149|NONE_0 (l_compound) necrosis_39\NN\11444117|the_18|acute_14|tubular_8|and_15|cytokines_31
D014508_D007683 NONE urea_33\NN\14727670|and_4 (r_conj) creatinine_31\NN\0|NONE_0 (r_pobj) of_30\IN\0|serum_13 (r_prep) levels_29\NNS\4916342|,_29|increase_31 (r_dobj) augment_27\VBP\153263|adopted_135|;_105|however_103|,_96|drug_89|can_84|injury_60|due_53|,_2|._136 (l_conj) increase_35\VB\13576355|levels_31|,_2 (l_dobj) score_40\NN\5736149|NONE_0 (l_compound) necrosis_39\NN\11444117|the_18|acute_14|tubular_8|and_15|cytokines_31
D002945_D009336 NONE cisplatin_13\NN\0|-_9 (r_advmod) induced_15\VBN\1627355|acute_8|kidney_14 (r_amod) injury_18\NN\14052046|NONE_0 (r_pobj) in_12\IN\13603305|that_39|kinin_30|is_12|by_41 (r_prep) involved_11\VBN\2676054|thus_53|,_49|data_43|._171 (l_prep) by_19\IN\0|that_80|kinin_71|is_53|in_41 (l_pcomp) mediating_20\VBG\761713|NONE_0 (l_dobj) process_23\NN\407535|,_52|resulting_59 (l_amod) necrotic_22\JJ\0|the_4|and_17|expression_25
1556529
D015215_D056486 CID zidovudine_0\RB\3834836|-_10 (r_npadvmod) induced_2\VBN\1627355|._17 (r_amod) hepatitis_3\NN\14127211|NONE_0
D015215_D056486 CID zidovudine_7\NNP\3834836|NONE_0 (r_pobj) by_6\IN\0|in_14 (r_agent) induced_5\VBN\1627355|a_26|of_19 (r_acl) case_1\NN\7283608|is_81|._93 (l_prep) of_2\IN\0|a_7|induced_19 (l_pobj) hepatitis_4\NN\14127211|NONE_0
D015215_D000163 NONE zidovudine_7\NNP\3834836|NONE_0 (r_pobj) by_6\IN\0|in_14 (r_agent) induced_5\VBN\1627355|a_26|of_19 (l_prep) in_8\IN\13603305|by_14 (l_pobj) patient_13\NN\9898892|NONE_0 (l_prep) with_14\IN\0|a_22|old_12 (l_pobj) aids_15\NNP\13974317|NONE_0
8667442
D009853_D051437 NONE omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (r_pobj) with_1\IN\0|,_69|frequency_75|has_109|significantly_123|,_136 (r_advcl) decreased_23\VBN\169651|triad_37|hallmark_105|._129 (r_ccomp) remains_37\VBZ\2684|NONE_0 (l_nsubj) triad_28\NN\13741022|decreased_37|hallmark_68|._92 (l_prep) of_29\IN\0|the_18|classic_14 (l_pobj) hypercalcemia_30\NN\14299637|NONE_0 (l_conj) alkalosis_32\NN\14204950|,_2 (l_conj) impairment_36\NN\7296428|,_12|and_10
D002118_D010437 NONE calcium_24\NN\14625458|NONE_0 (r_pobj) of_23\IN\0|large_14 (r_prep) amounts_22\NNS\13329641|NONE_0 (r_pobj) with_20\IN\0|the_38|of_24 (r_prep) treatment_15\NN\654885|NONE_0 (l_prep) of_16\IN\0|the_14|with_24 (l_pobj) disease_19\NN\14061805|NONE_0
D013392_D014456 NONE sucralfate_12\JJ\3740161|,_6|and_4 (r_conj) omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (l_compound) ulcer_3\NN\14211294|current_8|(_14|h-2_15|blockers_19
D002118_D006934 CID calcium_24\NN\14625458|NONE_0 (r_pobj) of_23\IN\0|large_14 (r_prep) amounts_22\NNS\13329641|NONE_0 (r_pobj) with_20\IN\0|the_38|of_24 (r_prep) treatment_15\NN\654885|NONE_0 (r_pobj) of_13\IN\0|the_12 (r_prep) context_12\NN\6284777|NONE_0 (r_pobj) in_10\IN\13603305|syndrome_42|was_33|first_29|ago_4|._96 (r_prep) described_6\VBN\1001294|NONE_0 (l_nsubjpass) syndrome_3\NN\5870365|was_9|first_13|ago_38|in_42|._138
D009853_D000471 NONE omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (r_pobj) with_1\IN\0|,_69|frequency_75|has_109|significantly_123|,_136 (r_advcl) decreased_23\VBN\169651|triad_37|hallmark_105|._129 (r_ccomp) remains_37\VBZ\2684|NONE_0 (l_nsubj) triad_28\NN\13741022|decreased_37|hallmark_68|._92 (l_prep) of_29\IN\0|the_18|classic_14 (l_pobj) hypercalcemia_30\NN\14299637|NONE_0 (l_conj) alkalosis_32\NN\14204950|,_2
D013392_D000471 NONE sucralfate_12\JJ\3740161|,_6|and_4 (r_conj) omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (r_pobj) with_1\IN\0|,_69|frequency_75|has_109|significantly_123|,_136 (r_advcl) decreased_23\VBN\169651|triad_37|hallmark_105|._129 (r_ccomp) remains_37\VBZ\2684|NONE_0 (l_nsubj) triad_28\NN\13741022|decreased_37|hallmark_68|._92 (l_prep) of_29\IN\0|the_18|classic_14 (l_pobj) hypercalcemia_30\NN\14299637|NONE_0 (l_conj) alkalosis_32\NN\14204950|,_2
D002119_D007011 NONE carbonate_12\NN\15010703|NONE_0 (r_pobj) with_10\IN\0|who_16|was_12|resulting_38 (r_prep) treated_9\VBN\2376958|NONE_0 (r_relcl) hypoparathyroidism_6\NN\14059928|NONE_0
D009853_D006934 NONE omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (r_pobj) with_1\IN\0|,_69|frequency_75|has_109|significantly_123|,_136 (r_advcl) decreased_23\VBN\169651|triad_37|hallmark_105|._129 (l_nsubj) frequency_16\NN\15286249|with_75|,_6|has_34|significantly_48|,_61 (l_prep) of_17\IN\0|the_14 (l_pobj) syndrome_21\NN\5870365|NONE_0
D009853_D006934 NONE omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (r_pobj) with_1\IN\0|,_69|frequency_75|has_109|significantly_123|,_136 (r_advcl) decreased_23\VBN\169651|triad_37|hallmark_105|._129 (r_ccomp) remains_37\VBZ\2684|NONE_0 (l_nsubj) triad_28\NN\13741022|decreased_37|hallmark_68|._92 (l_prep) of_29\IN\0|the_18|classic_14 (l_pobj) hypercalcemia_30\NN\14299637|NONE_0
C019248_D006934 NONE pamidronate_3\NN\0|this_29|._104 (l_advcl) presents_14\VBZ\28270|intravenous_81|as_57 (l_nsubj) syndrome_13\NN\5870365|when_17|as_18
C019248_D006934 NONE pamidronate_3\NN\0|this_29|._104 (l_advcl) presents_14\VBZ\28270|intravenous_81|as_57 (l_prep) as_15\IN\14622893|when_35|syndrome_18 (l_pobj) emergency_17\NN\7417644|NONE_0
D002119_D006934 CID carbonate_12\NN\15010703|NONE_0 (r_pobj) with_10\IN\0|who_16|was_12|resulting_38 (r_prep) treated_9\VBN\2376958|NONE_0 (l_advcl) resulting_15\VBG\2633881|who_54|was_50|with_38 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) admissions_18\NNS\49003|NONE_0 (l_prep) for_22\IN\0|two_31|to_16 (l_pobj) syndrome_26\NN\5870365|NONE_0
D002117_D006934 CID 1,25(oh)2d_6\CD\0|NONE_0 (r_pobj) by_5\IN\0|in_14 (r_agent) induced_4\VBN\1627355|alkali_16|._58 (r_acl) syndrome_3\NN\5870365|NONE_0
D002117_D006934 CID calcitriol_14\NN\0|calcium_22|and_4 (r_conj) carbonate_12\NN\15010703|NONE_0 (r_pobj) with_10\IN\0|who_16|was_12|resulting_38 (r_prep) treated_9\VBN\2376958|NONE_0 (l_advcl) resulting_15\VBG\2633881|who_54|was_50|with_38 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) admissions_18\NNS\49003|NONE_0 (l_prep) for_22\IN\0|two_31|to_16 (l_pobj) syndrome_26\NN\5870365|NONE_0
D000468_D006934 CID alkali_26\NN\14818238|and_4 (r_conj) calcium_24\NN\14625458|NONE_0 (r_pobj) of_23\IN\0|large_14 (r_prep) amounts_22\NNS\13329641|NONE_0 (r_pobj) with_20\IN\0|the_38|of_24 (r_prep) treatment_15\NN\654885|NONE_0 (r_pobj) of_13\IN\0|the_12 (r_prep) context_12\NN\6284777|NONE_0 (r_pobj) in_10\IN\13603305|syndrome_42|was_33|first_29|ago_4|._96 (r_prep) described_6\VBN\1001294|NONE_0 (l_nsubjpass) syndrome_3\NN\5870365|was_9|first_13|ago_38|in_42|._138
D013392_D006934 NONE sucralfate_12\JJ\3740161|,_6|and_4 (r_conj) omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (r_pobj) with_1\IN\0|,_69|frequency_75|has_109|significantly_123|,_136 (r_advcl) decreased_23\VBN\169651|triad_37|hallmark_105|._129 (l_nsubj) frequency_16\NN\15286249|with_75|,_6|has_34|significantly_48|,_61 (l_prep) of_17\IN\0|the_14 (l_pobj) syndrome_21\NN\5870365|NONE_0
D013392_D006934 NONE sucralfate_12\JJ\3740161|,_6|and_4 (r_conj) omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (r_pobj) with_1\IN\0|,_69|frequency_75|has_109|significantly_123|,_136 (r_advcl) decreased_23\VBN\169651|triad_37|hallmark_105|._129 (r_ccomp) remains_37\VBZ\2684|NONE_0 (l_nsubj) triad_28\NN\13741022|decreased_37|hallmark_68|._92 (l_prep) of_29\IN\0|the_18|classic_14 (l_pobj) hypercalcemia_30\NN\14299637|NONE_0
D009853_D014456 NONE omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (l_compound) ulcer_3\NN\14211294|current_8|(_14|h-2_15|blockers_19
D002117_D007011 NONE 1,25(oh)2d_6\CD\0|NONE_0 (r_pobj) by_5\IN\0|in_14 (r_agent) induced_4\VBN\1627355|alkali_16|._58 (l_prep) in_7\IN\13603305|by_14 (l_pobj) patient_9\NN\9898892|NONE_0 (l_prep) with_10\IN\0|a_10 (l_pobj) hypoparathyroidism_11\NN\14059928|NONE_0
D002117_D007011 NONE calcitriol_14\NN\0|calcium_22|and_4 (r_conj) carbonate_12\NN\15010703|NONE_0 (r_pobj) with_10\IN\0|who_16|was_12|resulting_38 (r_prep) treated_9\VBN\2376958|NONE_0 (r_relcl) hypoparathyroidism_6\NN\14059928|NONE_0
D013392_D051437 NONE sucralfate_12\JJ\3740161|,_6|and_4 (r_conj) omeprazole_9\NN\14778019|,_2|)_26 (r_conj) blockers_7\NNS\10101634|current_27|ulcer_19|(_5|h-2_4 (r_conj) therapy_4\NN\657604|although_28 (r_pobj) with_1\IN\0|,_69|frequency_75|has_109|significantly_123|,_136 (r_advcl) decreased_23\VBN\169651|triad_37|hallmark_105|._129 (r_ccomp) remains_37\VBZ\2684|NONE_0 (l_nsubj) triad_28\NN\13741022|decreased_37|hallmark_68|._92 (l_prep) of_29\IN\0|the_18|classic_14 (l_pobj) hypercalcemia_30\NN\14299637|NONE_0 (l_conj) alkalosis_32\NN\14204950|,_2 (l_conj) impairment_36\NN\7296428|,_12|and_10
D000468_D010437 NONE alkali_26\NN\14818238|and_4 (r_conj) calcium_24\NN\14625458|NONE_0 (r_pobj) of_23\IN\0|large_14 (r_prep) amounts_22\NNS\13329641|NONE_0 (r_pobj) with_20\IN\0|the_38|of_24 (r_prep) treatment_15\NN\654885|NONE_0 (l_prep) of_16\IN\0|the_14|with_24 (l_pobj) disease_19\NN\14061805|NONE_0
10986547
C076029_D015430 CID olanzapine_2\RB\0|-_10 (r_npadvmod) treated_4\VBN\2376958|NONE_0 (r_amod) patients_5\NNS\9898892|however_28|,_21|mean_49|._256 (r_nsubj) had_6\VBD\0|NONE_0 (l_dobj) mean_11\JJ\6021761|however_77|,_70|patients_49|._207 (l_appos) gain_17\NN\13576355|a_57|significant_41|greater_29|(_16
C076029_D001714 NONE olanzapine_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_14|:_36|study_73|._78 (r_prep) efficacy_0\NN\5199286|NONE_0 (l_prep) in_3\IN\13603305|of_14|:_22|study_59|._64 (l_pobj) mania_6\NN\9180259|NONE_0
C076029_D001714 NONE olanzapine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_24|and_11|safety_7|for_25 (r_prep) efficacy_3\NN\5199286|we_16|._85 (l_prep) for_10\IN\0|the_49|and_36|safety_32|of_25 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) mania_16\NN\9180259|NONE_0
C076029_D001714 NONE olanzapine_22\NN\0|total_102|,_21|were_19|._54 (r_xcomp) randomized_20\VBN\278117|NONE_0 (l_nsubjpass) total_1\NN\3553|,_81|were_83|olanzapine_102|._156 (l_prep) of_2\IN\0|a_8 (l_pobj) patients_4\NNS\9898892|NONE_0 (l_prep) with_5\IN\0|115_13 (l_pobj) diagnosis_10\NN\152018|NONE_0 (l_prep) of_11\IN\0|a_19|iv_13 (l_pobj) disorder_13\NN\14034177|NONE_0
C076029_D001714 NONE olanzapine_22\NN\0|total_102|,_21|were_19|._54 (r_xcomp) randomized_20\VBN\278117|NONE_0 (l_nsubjpass) total_1\NN\3553|,_81|were_83|olanzapine_102|._156 (l_prep) of_2\IN\0|a_8 (l_pobj) patients_4\NNS\9898892|NONE_0 (l_prep) with_5\IN\0|115_13 (l_pobj) diagnosis_10\NN\152018|NONE_0 (l_prep) of_11\IN\0|a_19|iv_13 (l_pobj) disorder_13\NN\14034177|NONE_0 (l_amod) manic_15\JJ\0|bipolar_18|,_2
C076029_D001714 NONE olanzapine_0\NNP\0|efficacy_32|and_94|tolerated_117|._126 (r_nsubj) demonstrated_1\VBD\2137132|NONE_0 (l_dobj) efficacy_3\NN\5199286|olanzapine_32|and_62|tolerated_85|._94 (l_prep) than_4\IN\0|greater_17 (l_pobj) placebo_5\NN\3740161|NONE_0 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) mania_12\NN\9180259|NONE_0
C076029_D006970 CID olanzapine_2\RB\0|-_10 (r_npadvmod) treated_4\VBN\2376958|NONE_0 (r_amod) patients_5\NNS\9898892|however_28|,_21|mean_49|._256 (r_nsubj) had_6\VBD\0|NONE_0 (l_dobj) mean_11\JJ\6021761|however_77|,_70|patients_49|._207 (l_appos) gain_17\NN\13576355|a_57|significant_41|greater_29|(_16 (l_conj) experienced_37\VBD\2108377|+/-_106|sd_102|)_100|weight_98|than_86|and_9 (l_dobj) somnolence_42\NN\14015731|also_41
17356399
D003561_D006212 CID cytarabine_35\NN\0|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) after_30\IN\0|diffuse_61|cerebral_53|on_34 (r_prep) vasospasm_25\NN\0|NONE_0 (r_pobj) with_22\IN\0|sided_15 (r_prep) weakness_21\NN\14462666|visual_39|,_18|and_16 (r_conj) hallucinations_15\NNS\14376855|,_9
C042705_D054198 NONE asparaginase_11\NN\2722458|NONE_0 (r_pobj) including_8\VBG\0|NONE_0 (r_prep) chemotherapy_7\NN\661091|encephalopathy_55|after_17|for_67|._116 (r_dobj) multiagent_6\JJ\0|NONE_0 (l_prep) for_15\IN\0|encephalopathy_122|after_84|chemotherapy_67|._49 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) leukemia_21\NN\14239918|NONE_0
C042705_D020803 NONE asparaginase_11\NN\2722458|NONE_0 (r_pobj) including_8\VBG\0|NONE_0 (r_prep) chemotherapy_7\NN\661091|encephalopathy_55|after_17|for_67|._116 (r_dobj) multiagent_6\JJ\0|NONE_0 (l_nsubj) encephalopathy_1\JJ\14084880|after_38|chemotherapy_55|for_122|._171
C042705_D020301 CID asparaginase_11\NN\2722458|NONE_0 (r_pobj) including_8\VBG\0|NONE_0 (r_prep) chemotherapy_7\NN\661091|encephalopathy_55|after_17|for_67|._116 (r_dobj) multiagent_6\JJ\0|NONE_0 (l_nsubj) encephalopathy_1\JJ\14084880|after_38|chemotherapy_55|for_122|._171 (l_conj) vasospasm_4\NN\0|acute_34|and_13
D003561_D018908 CID cytarabine_35\NN\0|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) after_30\IN\0|diffuse_61|cerebral_53|on_34 (r_prep) vasospasm_25\NN\0|NONE_0 (r_pobj) with_22\IN\0|sided_15 (r_prep) weakness_21\NN\14462666|visual_39|,_18|and_16
D003561_D001037 CID cytarabine_35\NN\0|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) after_30\IN\0|diffuse_61|cerebral_53|on_34 (r_prep) vasospasm_25\NN\0|NONE_0 (r_pobj) with_22\IN\0|sided_15 (r_prep) weakness_21\NN\14462666|visual_39|,_18|and_16 (r_conj) hallucinations_15\NNS\14376855|,_9 (r_conj) incontinence_12\NN\13473097|,_2 (r_conj) aphasia_10\NN\14085708|behavioral_20|,_2
D003561_D020803 NONE cytarabine_14\NN\0|peg_33|-_30|and_16 (r_conj) asparaginase_11\NN\2722458|NONE_0 (r_pobj) including_8\VBG\0|NONE_0 (r_prep) chemotherapy_7\NN\661091|encephalopathy_55|after_17|for_67|._116 (r_dobj) multiagent_6\JJ\0|NONE_0 (l_nsubj) encephalopathy_1\JJ\14084880|after_38|chemotherapy_55|for_122|._171
D003561_D020803 NONE cytarabine_35\NN\0|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) after_30\IN\0|diffuse_61|cerebral_53|on_34 (r_prep) vasospasm_25\NN\0|NONE_0 (r_pobj) with_22\IN\0|sided_15 (r_prep) weakness_21\NN\14462666|visual_39|,_18|and_16 (r_conj) hallucinations_15\NNS\14376855|,_9 (r_conj) incontinence_12\NN\13473097|,_2 (r_conj) aphasia_10\NN\14085708|behavioral_20|,_2 (r_conj) changes_8\NNS\7283608|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) evidenced_5\VBN\1015244|acute_21 (r_acl) encephalopathy_4\NN\14084880|patient_24|._235
D003561_D014549 CID cytarabine_35\NN\0|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) after_30\IN\0|diffuse_61|cerebral_53|on_34 (r_prep) vasospasm_25\NN\0|NONE_0 (r_pobj) with_22\IN\0|sided_15 (r_prep) weakness_21\NN\14462666|visual_39|,_18|and_16 (r_conj) hallucinations_15\NNS\14376855|,_9 (r_conj) incontinence_12\NN\13473097|,_2
D003561_D020301 CID cytarabine_14\NN\0|peg_33|-_30|and_16 (r_conj) asparaginase_11\NN\2722458|NONE_0 (r_pobj) including_8\VBG\0|NONE_0 (r_prep) chemotherapy_7\NN\661091|encephalopathy_55|after_17|for_67|._116 (r_dobj) multiagent_6\JJ\0|NONE_0 (l_nsubj) encephalopathy_1\JJ\14084880|after_38|chemotherapy_55|for_122|._171 (l_conj) vasospasm_4\NN\0|acute_34|and_13
D003561_D020301 CID cytarabine_35\NN\0|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) after_30\IN\0|diffuse_61|cerebral_53|on_34 (r_prep) vasospasm_25\NN\0|NONE_0
D003561_D054198 NONE cytarabine_14\NN\0|peg_33|-_30|and_16 (r_conj) asparaginase_11\NN\2722458|NONE_0 (r_pobj) including_8\VBG\0|NONE_0 (r_prep) chemotherapy_7\NN\661091|encephalopathy_55|after_17|for_67|._116 (r_dobj) multiagent_6\JJ\0|NONE_0 (l_prep) for_15\IN\0|encephalopathy_122|after_84|chemotherapy_67|._49 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) leukemia_21\NN\14239918|NONE_0
3533179
D003520_D007153 NONE cya_4\NNP\0|the_4 (r_compound) cardiotoxicity_5\NN\0|that_13|with_26|calculated_45|,_76|and_78|prepared_159 (r_nsubj) correlates_6\VBZ\5857459|we_40|._322 (l_conj) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_nsubjpass) patients_19\NNS\9898892|that_5|can_53|be_57|effectively_60|for_81 (l_prep) with_20\IN\0|NONE_0 (l_pobj) anemia_22\NN\14189204|NONE_0 (l_conj) immunodeficiencies_24\NNS\13973990|aplastic_20|and_4
D003520_D007153 NONE cya_8\NNP\0|NONE_0 (r_compound) dosage_9\NN\13576355|NONE_0 (r_pobj) with_7\IN\0|that_39|cardiotoxicity_26|calculated_19|,_50|and_52|prepared_133 (r_prep) correlates_6\VBZ\5857459|we_40|._322 (l_conj) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_nsubjpass) patients_19\NNS\9898892|that_5|can_53|be_57|effectively_60|for_81 (l_prep) with_20\IN\0|NONE_0 (l_pobj) anemia_22\NN\14189204|NONE_0 (l_conj) immunodeficiencies_24\NNS\13973990|aplastic_20|and_4
D003520_D007153 NONE cya_35\NNP\0|a_2|of_9 (r_compound) dose_36\NN\3740161|NONE_0 (r_pobj) at_33\IN\14622893|marrow_16|with_43 (r_prep) grafting_32\VBG\379422|NONE_0 (r_pobj) for_29\IN\0|that_86|patients_81|can_28|be_24|effectively_21 (r_prep) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_nsubjpass) patients_19\NNS\9898892|that_5|can_53|be_57|effectively_60|for_81 (l_prep) with_20\IN\0|NONE_0 (l_pobj) anemia_22\NN\14189204|NONE_0 (l_conj) immunodeficiencies_24\NNS\13973990|aplastic_20|and_4
D003520_D007153 NONE cya_54\NNP\0|whose_6 (r_compound) dosage_55\NN\13576355|is_7|based_21 (r_nsubjpass) calculated_57\VBN\632627|NONE_0 (r_relcl) patients_52\NNS\9898892|NONE_0 (r_pobj) than_51\IN\0|NONE_0 (r_prep) cardiotoxicity_50\NN\0|NONE_0 (r_pobj) of_49\IN\0|a_18|lower_16 (r_prep) incidence_48\NN\13821570|NONE_0 (r_pobj) with_45\IN\0|marrow_59|at_43 (r_prep) grafting_32\VBG\379422|NONE_0 (r_pobj) for_29\IN\0|that_86|patients_81|can_28|be_24|effectively_21 (r_prep) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_nsubjpass) patients_19\NNS\9898892|that_5|can_53|be_57|effectively_60|for_81 (l_prep) with_20\IN\0|NONE_0 (l_pobj) anemia_22\NN\14189204|NONE_0 (l_conj) immunodeficiencies_24\NNS\13973990|aplastic_20|and_4
D003520_D014923 NONE cya_6\NNP\0|to_11 (r_dobj) receive_5\VB\2210855|who_12 (r_xcomp) were_3\VBD\0|eighty_20 (r_relcl) patients_1\NNS\9898892|d_42|for_44|total_105|,_148|syndrome_166|._220 (r_nsubj) underwent_21\VBD\109660|NONE_0 (l_conj) syndrome_34\NN\5870365|patients_166|d_124|for_122|total_61|,_18|._54
D003520_D016511 NONE cya_6\NNP\0|to_11 (r_dobj) receive_5\VB\2210855|who_12 (r_xcomp) were_3\VBD\0|eighty_20 (r_relcl) patients_1\NNS\9898892|d_42|for_44|total_105|,_148|syndrome_166|._220 (r_nsubj) underwent_21\VBD\109660|NONE_0 (l_conj) syndrome_34\NN\5870365|patients_166|d_124|for_122|total_61|,_18|._54 (l_conj) syndrome_40\NN\5870365|aldrich_54|,_38|or_36
D003520_D000741 NONE cya_6\NNP\0|to_11 (r_dobj) receive_5\VB\2210855|who_12 (r_xcomp) were_3\VBD\0|eighty_20 (r_relcl) patients_1\NNS\9898892|d_42|for_44|total_105|,_148|syndrome_166|._220 (r_nsubj) underwent_21\VBD\109660|NONE_0 (l_dobj) total_23\NN\3553|patients_105|d_63|for_61|,_43|syndrome_61|._115 (l_prep) of_24\IN\0|a_8 (l_pobj) transplants_26\NNS\5267548|NONE_0 (l_prep) for_27\IN\0|84_15 (l_pobj) anemia_29\NN\14189204|NONE_0
D003520_D000741 NONE cya_4\NNP\0|the_4 (r_compound) cardiotoxicity_5\NN\0|that_13|with_26|calculated_45|,_76|and_78|prepared_159 (r_nsubj) correlates_6\VBZ\5857459|we_40|._322 (l_conj) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_nsubjpass) patients_19\NNS\9898892|that_5|can_53|be_57|effectively_60|for_81 (l_prep) with_20\IN\0|NONE_0 (l_pobj) anemia_22\NN\14189204|NONE_0
D003520_D000741 NONE cya_8\NNP\0|NONE_0 (r_compound) dosage_9\NN\13576355|NONE_0 (r_pobj) with_7\IN\0|that_39|cardiotoxicity_26|calculated_19|,_50|and_52|prepared_133 (r_prep) correlates_6\VBZ\5857459|we_40|._322 (l_conj) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_nsubjpass) patients_19\NNS\9898892|that_5|can_53|be_57|effectively_60|for_81 (l_prep) with_20\IN\0|NONE_0 (l_pobj) anemia_22\NN\14189204|NONE_0
D003520_D000741 NONE cya_35\NNP\0|a_2|of_9 (r_compound) dose_36\NN\3740161|NONE_0 (r_pobj) at_33\IN\14622893|marrow_16|with_43 (r_prep) grafting_32\VBG\379422|NONE_0 (r_pobj) for_29\IN\0|that_86|patients_81|can_28|be_24|effectively_21 (r_prep) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_nsubjpass) patients_19\NNS\9898892|that_5|can_53|be_57|effectively_60|for_81 (l_prep) with_20\IN\0|NONE_0 (l_pobj) anemia_22\NN\14189204|NONE_0
D003520_D000741 NONE cya_54\NNP\0|whose_6 (r_compound) dosage_55\NN\13576355|is_7|based_21 (r_nsubjpass) calculated_57\VBN\632627|NONE_0 (r_relcl) patients_52\NNS\9898892|NONE_0 (r_pobj) than_51\IN\0|NONE_0 (r_prep) cardiotoxicity_50\NN\0|NONE_0 (r_pobj) of_49\IN\0|a_18|lower_16 (r_prep) incidence_48\NN\13821570|NONE_0 (r_pobj) with_45\IN\0|marrow_59|at_43 (r_prep) grafting_32\VBG\379422|NONE_0 (r_pobj) for_29\IN\0|that_86|patients_81|can_28|be_24|effectively_21 (r_prep) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_nsubjpass) patients_19\NNS\9898892|that_5|can_53|be_57|effectively_60|for_81 (l_prep) with_20\IN\0|NONE_0 (l_pobj) anemia_22\NN\14189204|NONE_0
D003520_D064420 NONE cya_19\NNP\0|NONE_0 (r_pobj) of_18\IN\0|the_9|in_7 (r_prep) dose_17\NN\3740161|correlates_78|,_36|we_34|retrospectively_31|determine_59|._159 (r_dobj) calculated_15\VBD\632627|NONE_0 (l_advcl) correlates_5\VBZ\5857459|,_42|we_44|retrospectively_47|dose_78|determine_137|._237 (l_nsubj) toxicity_3\NN\13576101|since_29|generally_9|with_30
D003520_D064420 NONE cya_32\NNP\0|NONE_0 (r_compound) cardiotoxicity_33\NN\0|NONE_0 (r_pobj) of_31\IN\0|the_14 (r_prep) incidence_30\NN\13821570|whether_12|with_43 (r_nsubj) correlated_34\VBN\2657219|to_57 (r_ccomp) determine_27\VB\0|correlates_137|,_95|we_93|retrospectively_90|dose_59|._100 (r_advcl) calculated_15\VBD\632627|NONE_0 (l_advcl) correlates_5\VBZ\5857459|,_42|we_44|retrospectively_47|dose_78|determine_137|._237 (l_nsubj) toxicity_3\NN\13576101|since_29|generally_9|with_30
D003520_D066126 NONE cyclophosphamide_0\NNP\0|:_31|analysis_36|._71 (r_compound) cardiotoxicity_1\NN\0|NONE_0
D003520_D066126 NONE cya_5\NNP\0|NONE_0 (r_pobj) of_4\IN\0|these_17|high_11 (r_prep) doses_3\NNS\3740161|NONE_0 (r_pobj) at_0\IN\14622893|,_26|cardiotoxicity_36|may_51|,_60|but_62|described_147 (r_prep) occur_10\VB\0|NONE_0 (l_nsubj) cardiotoxicity_8\NN\0|at_36|,_10|may_15|,_24|but_26|described_111
D003520_D066126 NONE cya_5\NNP\0|NONE_0 (r_pobj) of_4\IN\0|these_17|high_11 (r_prep) doses_3\NNS\3740161|NONE_0 (r_pobj) at_0\IN\14622893|,_26|cardiotoxicity_36|may_51|,_60|but_62|described_147 (r_prep) occur_10\VB\0|NONE_0 (l_conj) described_25\VBN\1001294|at_147|,_121|cardiotoxicity_111|may_96|,_87|but_85 (l_nsubjpass) factors_15\NNS\7326557|have_51|not_56|been_60|._74 (l_prep) for_16\IN\0|definitive_24|risk_13 (l_pobj) development_18\NN\248977|NONE_0 (l_prep) of_19\IN\0|the_16 (l_pobj) cardiotoxicity_21\NN\0|NONE_0
D003520_D066126 NONE cya_19\NNP\0|NONE_0 (r_pobj) of_18\IN\0|the_9|in_7 (r_prep) dose_17\NN\3740161|correlates_78|,_36|we_34|retrospectively_31|determine_59|._159 (r_dobj) calculated_15\VBD\632627|NONE_0 (l_advcl) determine_27\VB\0|correlates_137|,_95|we_93|retrospectively_90|dose_59|._100 (l_ccomp) correlated_34\VBN\2657219|to_57 (l_nsubj) incidence_30\NN\13821570|whether_12|with_43 (l_prep) of_31\IN\0|the_14 (l_pobj) cardiotoxicity_33\NN\0|NONE_0
D003520_D066126 NONE cya_32\NNP\0|NONE_0 (r_compound) cardiotoxicity_33\NN\0|NONE_0
D003520_D066126 NONE cya_14\NNP\0|NONE_0 (r_compound) cardiotoxicity_15\NN\0|NONE_0
D003520_D066126 NONE cya_26\NNP\0|NONE_0 (r_pobj) of_25\IN\0|4_8 (r_prep) doses_24\NNS\3740161|NONE_0 (r_dobj) receiving_20\VBG\2210855|NONE_0 (r_pcomp) of_19\IN\0|ten_9 (r_prep) days_18\NNS\15140892|NONE_0 (r_pobj) within_16\IN\0|patients_67|symptoms_54|._48 (r_prep) had_8\VBD\0|NONE_0 (l_dobj) symptoms_9\NNS\5823932|patients_13|within_54|._102 (l_amod) consistent_12\JJ\0|and_10|signs_6 (l_prep) with_13\IN\0|NONE_0 (l_pobj) cardiotoxicity_15\NN\0|NONE_0
D003520_D066126 NONE cya_8\NNP\0|NONE_0 (r_pobj) to_7\IN\0|to_14|be_11 (r_prep) related_6\VBN\628491|that_23|was_18 (r_xcomp) thought_3\VBN\5809192|NONE_0 (r_relcl) cardiotoxicity_0\NN\0|in_62|._156
D003520_D066126 NONE cya_4\NNP\0|the_4 (r_compound) cardiotoxicity_5\NN\0|that_13|with_26|calculated_45|,_76|and_78|prepared_159
D003520_D066126 NONE cya_4\NNP\0|the_4 (r_compound) cardiotoxicity_5\NN\0|that_13|with_26|calculated_45|,_76|and_78|prepared_159 (r_nsubj) correlates_6\VBZ\5857459|we_40|._322 (l_conj) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_prep) for_29\IN\0|that_86|patients_81|can_28|be_24|effectively_21 (l_pobj) grafting_32\VBG\379422|NONE_0 (l_prep) with_45\IN\0|marrow_59|at_43 (l_pobj) incidence_48\NN\13821570|NONE_0 (l_prep) of_49\IN\0|a_18|lower_16 (l_pobj) cardiotoxicity_50\NN\0|NONE_0
D003520_D066126 NONE cya_8\NNP\0|NONE_0 (r_compound) dosage_9\NN\13576355|NONE_0 (r_pobj) with_7\IN\0|that_39|cardiotoxicity_26|calculated_19|,_50|and_52|prepared_133 (r_prep) correlates_6\VBZ\5857459|we_40|._322 (l_nsubj) cardiotoxicity_5\NN\0|that_13|with_26|calculated_45|,_76|and_78|prepared_159
D003520_D066126 NONE cya_8\NNP\0|NONE_0 (r_compound) dosage_9\NN\13576355|NONE_0 (r_pobj) with_7\IN\0|that_39|cardiotoxicity_26|calculated_19|,_50|and_52|prepared_133 (r_prep) correlates_6\VBZ\5857459|we_40|._322 (l_conj) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (l_prep) for_29\IN\0|that_86|patients_81|can_28|be_24|effectively_21 (l_pobj) grafting_32\VBG\379422|NONE_0 (l_prep) with_45\IN\0|marrow_59|at_43 (l_pobj) incidence_48\NN\13821570|NONE_0 (l_prep) of_49\IN\0|a_18|lower_16 (l_pobj) cardiotoxicity_50\NN\0|NONE_0
D003520_D066126 NONE cya_35\NNP\0|a_2|of_9 (r_compound) dose_36\NN\3740161|NONE_0 (r_pobj) at_33\IN\14622893|marrow_16|with_43 (r_prep) grafting_32\VBG\379422|NONE_0 (r_pobj) for_29\IN\0|that_86|patients_81|can_28|be_24|effectively_21 (r_prep) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (r_conj) correlates_6\VBZ\5857459|we_40|._322 (l_nsubj) cardiotoxicity_5\NN\0|that_13|with_26|calculated_45|,_76|and_78|prepared_159
D003520_D066126 NONE cya_35\NNP\0|a_2|of_9 (r_compound) dose_36\NN\3740161|NONE_0 (r_pobj) at_33\IN\14622893|marrow_16|with_43 (r_prep) grafting_32\VBG\379422|NONE_0 (l_prep) with_45\IN\0|marrow_59|at_43 (l_pobj) incidence_48\NN\13821570|NONE_0 (l_prep) of_49\IN\0|a_18|lower_16 (l_pobj) cardiotoxicity_50\NN\0|NONE_0
D003520_D066126 NONE cya_54\NNP\0|whose_6 (r_compound) dosage_55\NN\13576355|is_7|based_21 (r_nsubjpass) calculated_57\VBN\632627|NONE_0 (r_relcl) patients_52\NNS\9898892|NONE_0 (r_pobj) than_51\IN\0|NONE_0 (r_prep) cardiotoxicity_50\NN\0|NONE_0 (r_pobj) of_49\IN\0|a_18|lower_16 (r_prep) incidence_48\NN\13821570|NONE_0 (r_pobj) with_45\IN\0|marrow_59|at_43 (r_prep) grafting_32\VBG\379422|NONE_0 (r_pobj) for_29\IN\0|that_86|patients_81|can_28|be_24|effectively_21 (r_prep) prepared_28\VBN\126264|that_172|cardiotoxicity_159|with_133|calculated_114|,_83|and_81 (r_conj) correlates_6\VBZ\5857459|we_40|._322 (l_nsubj) cardiotoxicity_5\NN\0|that_13|with_26|calculated_45|,_76|and_78|prepared_159
D003520_D066126 NONE cya_54\NNP\0|whose_6 (r_compound) dosage_55\NN\13576355|is_7|based_21 (r_nsubjpass) calculated_57\VBN\632627|NONE_0 (r_relcl) patients_52\NNS\9898892|NONE_0 (r_pobj) than_51\IN\0|NONE_0 (r_prep) cardiotoxicity_50\NN\0|NONE_0
20589632
D014295_D000743 CID trimethoprim_0\NNP\0|-_12 (r_npadvmod) induced_2\VBN\1627355|immune_8|hemolytic_15|in_32|._117 (r_amod) anemia_5\NN\14189204|NONE_0
15018178
D015662_D000743 CID sulfomethoxazole_24\NN\0|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) induced_20\VBN\1627355|a_45|installing_35|hemolytic_24|anemia_14 (r_acl) crisis_19\NN\14411243|who_46 (l_compound) anemia_18\NN\14189204|a_31|installing_21|hemolytic_10|induced_14
D015662_D002534 NONE sulfomethoxazole_24\NN\0|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) induced_20\VBN\1627355|a_45|installing_35|hemolytic_24|anemia_14 (r_acl) crisis_19\NN\14411243|who_46 (r_dobj) had_13\VBD\0|a_22|old_13 (r_relcl) girl_11\NN\10787470|NONE_0 (r_pobj) of_6\IN\0|imaging_17 (r_prep) findings_5\NNS\7951464|we_38|,_123|resulting_125|._181 (r_dobj) present_1\VBP\28270|NONE_0 (l_advcl) resulting_26\VBG\2633881|we_163|findings_125|,_2|._56 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) anoxia_29\NN\14041256|NONE_0
23666265
D003520_D010146 CID cyp_7\NNP\0|NONE_0 (r_pobj) of_6\IN\0|the_19 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) following_3\VBG\8180190|spontaneous_27|pain_15 (r_prep) behaviors_2\NNS\407535|were_46|._59 (l_compound) pain_1\NN\14299637|spontaneous_12|following_15
D003520_D010146 CID cyclophosphamide_0\NNP\0|NONE_0 (r_compound) treatment_1\NN\654885|scores_51|._57 (r_nsubj) increased_2\VBD\169651|NONE_0 (l_dobj) scores_7\NNS\13757724|treatment_51|._6 (l_compound) behaviors_6\NNS\407535|NONE_0 (l_compound) pain_5\NN\14299637|the_16|spontaneous_12
D003520_D003556 CID cyclophosphamide_10\NN\0|-_16 (r_npadvmod) induced_12\VBN\1627355|in_17 (r_amod) cystitis_13\NN\14566129|NONE_0
D003520_D003556 CID cyclophosphamide_17\NN\0|NONE_0 (r_pobj) on_16\IN\0|p2x3_35|(_20|cystitis_34 (r_prep) antagonists_15\NNS\7846|NONE_0 (l_appos) cystitis_20\NN\14566129|p2x3_69|on_34|(_14
D003520_D003556 CID cyp)-induced_19\VBN\0|in_22 (r_amod) cystitis_20\NN\14566129|p2x3_69|on_34|(_14
D003520_D003556 CID cyp_1\NNP\0|-_3 (r_npadvmod) induced_3\VBN\1627355|,_16|expression_22|increased_59 (r_amod) cystitis_4\NN\14566129|._95
9578276
15366550
D008094_D018500 CID lithium_0\NN\14625458|is_8|in_22|,_52|and_54|changed_155 (r_nsubjpass) implicated_2\VBN\2677097|NONE_0 (l_prep) in_3\IN\13603305|lithium_22|is_14|,_30|and_32|changed_133 (l_pobj) di_8\NNP\0|NONE_0
D008094_D018500 CID lithium_0\NN\14625458|is_8|in_22|,_52|and_54|changed_155 (r_nsubjpass) implicated_2\VBN\2677097|NONE_0 (l_conj) changed_27\VBD\0|lithium_155|is_147|in_133|,_103|and_101 (l_advcl) focus_29\VB\5704266|received_80|,_27|treatment_21|._23 (l_prep) on_30\IN\0|to_9 (l_pobj) di_32\NNP\0|NONE_0
D008094_D018500 CID lithium_17\NN\14625458|because_37|patient_25|had_17|not_13|since_8 (r_dobj) received_16\VBN\2210855|,_53|treatment_59|focus_80|._103 (r_advcl) changed_27\VBD\0|lithium_155|is_147|in_133|,_103|and_101 (r_conj) implicated_2\VBN\2677097|NONE_0 (l_prep) in_3\IN\13603305|lithium_22|is_14|,_30|and_32|changed_133 (l_pobj) di_8\NNP\0|NONE_0
D008094_D018500 CID lithium_17\NN\14625458|because_37|patient_25|had_17|not_13|since_8 (r_dobj) received_16\VBN\2210855|,_53|treatment_59|focus_80|._103 (r_advcl) changed_27\VBD\0|lithium_155|is_147|in_133|,_103|and_101 (l_advcl) focus_29\VB\5704266|received_80|,_27|treatment_21|._23 (l_prep) on_30\IN\0|to_9 (l_pobj) di_32\NNP\0|NONE_0
D008094_D018500 CID lithium_32\NN\14625458|-_7 (r_npadvmod) induced_34\VBN\1627355|his_12|nephrogenic_8 (r_amod) di_36\NNP\0|been_51|self_46|-_42|and_3|developed_7
D008094_D018500 CID lithium_32\NN\14625458|-_7 (r_npadvmod) induced_34\VBN\1627355|his_12|nephrogenic_8 (r_amod) di_36\NNP\0|been_51|self_46|-_42|and_3|developed_7 (r_dobj) treating_30\VBG\2376958|by_183|,_69|team_49|._97 (l_conj) developed_38\VBN\1753788|been_58|self_53|-_49|di_7|and_4 (l_dobj) di_40\NNP\0|brain_16
D008094_D001930 NONE lithium_32\NN\14625458|-_7 (r_npadvmod) induced_34\VBN\1627355|his_12|nephrogenic_8 (r_amod) di_36\NNP\0|been_51|self_46|-_42|and_3|developed_7 (r_dobj) treating_30\VBG\2376958|by_183|,_69|team_49|._97 (l_conj) developed_38\VBN\1753788|been_58|self_53|-_49|di_7|and_4 (l_advcl) brain_43\NN\5462674|di_16 (l_dobj) trauma_44\NN\14052046|to_9
D008094_D059606 NONE lithium_24\NN\14625458|standing_9 (r_compound) use_25\NN\407535|and_26 (r_conj) polydipsia_19\NN\14040660|NONE_0
10713017
D005277_D006976 CID fenfluramines_9\NNS\0|however_47|,_40|of_38|,_11|association_45|compared_69|._170 (r_nsubj) had_10\VBD\0|NONE_0 (l_dobj) association_14\NN\8008335|however_92|,_85|of_83|,_56|fenfluramines_45|compared_24|._125 (l_prep) with_15\IN\0|a_39|significant_37|preferential_25 (l_pobj) pph_16\NNP\0|NONE_0
D005277_D006976 CID fenfluramines_22\NNS\0|NONE_0 (r_pobj) for_21\IN\0|the_16 (r_prep) specificity_20\NN\4762633|the_95|with_79|and_8 (r_conj) association_4\NN\8008335|NONE_0 (l_prep) with_5\IN\0|the_16|and_71|specificity_79 (l_pobj) pph_6\NNP\0|NONE_0
D005277_D006976 CID fenfluramines_22\NNS\0|NONE_0 (r_pobj) for_21\IN\0|the_16 (r_prep) specificity_20\NN\4762633|the_95|with_79|and_8 (r_conj) association_4\NN\8008335|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) magnitude_1\NN\4916342|consistent_142|._232 (r_nsubj) are_23\VBP\13600404|NONE_0 (l_acomp) consistent_24\JJ\0|magnitude_142|._90 (l_prep) with_25\IN\0|NONE_0 (l_pobj) studies_27\NNS\635850|NONE_0 (l_acl) indicating_28\VBG\952524|previous_17 (l_ccomp) related_33\VBN\628491|NONE_0 (l_prep) to_34\IN\0|that_40|fenfluramines_35|are_21|causally_17 (l_pobj) pph_35\NNP\0|NONE_0
D005277_D006976 CID fenfluramines_30\NNS\0|that_5|are_14|causally_18|to_35 (r_nsubjpass) related_33\VBN\628491|NONE_0 (r_ccomp) indicating_28\VBG\952524|previous_17 (r_acl) studies_27\NNS\635850|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) consistent_24\JJ\0|magnitude_142|._90 (r_acomp) are_23\VBP\13600404|NONE_0 (l_nsubj) magnitude_1\NN\4916342|consistent_142|._232 (l_prep) of_2\IN\0|the_14 (l_pobj) association_4\NN\8008335|NONE_0 (l_prep) with_5\IN\0|the_16|and_71|specificity_79 (l_pobj) pph_6\NNP\0|NONE_0
D005277_D006976 CID fenfluramines_30\NNS\0|that_5|are_14|causally_18|to_35 (r_nsubjpass) related_33\VBN\628491|NONE_0 (l_prep) to_34\IN\0|that_40|fenfluramines_35|are_21|causally_17 (l_pobj) pph_35\NNP\0|NONE_0
2818777
D010672_D056486 NONE phenytoin_0\NNP\3550533|injury_32|._38 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) injury_4\NN\14052046|phenytoin_32|._6
D010672_D017093 CID phenytoin_10\NN\3550533|NONE_0 (r_compound) administration_11\NN\1133281|NONE_0 (r_pobj) after_9\IN\0|a_53|old_43|female_39|developed_32|fatal_22|hepatic_16|._30 (r_prep) failure_8\NN\66216|NONE_0
25986755
D003404_D005355 NONE creatinine_26\NN\0|NONE_0 (r_nmod) protein_29\NN\14944888|NONE_0 (r_pobj) of_24\IN\0|elevated_16 (r_prep) levels_23\NNS\4916342|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) accompanied_20\VBN\0|that_113|kidneys_88|glomerulosclerosis_53 (r_advcl) exhibited_12\VBD\2632167|results_67|._131 (l_dobj) glomerulosclerosis_13\NN\0|that_60|kidneys_35|accompanied_53 (l_conj) fibrosis_18\NN\14204950|as_16
D003404_D005921 NONE creatinine_26\NN\0|NONE_0 (r_nmod) protein_29\NN\14944888|NONE_0 (r_pobj) of_24\IN\0|elevated_16 (r_prep) levels_23\NNS\4916342|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) accompanied_20\VBN\0|that_113|kidneys_88|glomerulosclerosis_53 (r_advcl) exhibited_12\VBD\2632167|results_67|._131 (l_dobj) glomerulosclerosis_13\NN\0|that_60|kidneys_35|accompanied_53
D002110_D005317 CID caffeine_7\NN\14712692|pce_19 (r_compound) exposure_8\NN\5042871|that_23|could_15|retardation_48 (r_nsubj) induce_13\VB\1627355|study_64|has_58|._58 (l_dobj) retardation_16\NN\7296428|that_71|exposure_48|could_33
D002110_D005317 CID caffeine_7\NN\14712692|pce_19 (r_compound) exposure_8\NN\5042871|that_23|could_15|retardation_48 (r_nsubj) induce_13\VB\1627355|study_64|has_58|._58 (l_dobj) retardation_16\NN\7296428|that_71|exposure_48|could_33 (l_appos) iugr_18\NNP\0|intrauterine_33|growth_20
D002110_D005921 NONE caffeine_18\NN\14712692|NONE_0 (r_compound) exposure_19\NN\5042871|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|adult_16 (r_acl) offspring_14\NN\10235549|NONE_0 (r_pobj) in_12\IN\13603305|programming_82|origin_29|._56 (r_prep) mediates_6\VBZ\761713|NONE_0 (l_dobj) origin_9\NN\8620061|programming_53|in_29|._85 (l_prep) of_10\IN\0|the_25|developmental_21 (l_pobj) glomerulosclerosis_11\NN\0|NONE_0
2217015
D008528_D051437 CID acid_1\NN\14818238|-_4|neutropenia_13|._81 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (l_dobj) neutropenia_4\NN\14196405|acid_13|-_9|._68 (l_conj) failure_7\NN\66216|and_10|in_8|with_27
D008528_D051437 CID acid_3\NN\14818238|-_4 (r_npadvmod) induced_5\VBN\1627355|mefenamic_15|oliguric_12|renal_21|and_35|occurring_58 (r_amod) failure_10\NN\66216|we_52|._78
D008528_D009503 CID acid_1\NN\14818238|-_4|neutropenia_13|._81 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (l_dobj) neutropenia_4\NN\14196405|acid_13|-_9|._68
D008528_D009503 CID acid_3\NN\14818238|-_4 (r_npadvmod) induced_5\VBN\1627355|mefenamic_15|oliguric_12|renal_21|and_35|occurring_58 (r_amod) failure_10\NN\66216|we_52|._78 (l_conj) occurring_14\VBG\0|mefenamic_73|induced_58|oliguric_46|renal_37|and_23 (l_compound) neutropenia_13\NN\14196405|simultaneously_22|in_37
D008528_D007037 NONE acid_1\NN\14818238|-_4|neutropenia_13|._81 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (l_dobj) neutropenia_4\NN\14196405|acid_13|-_9|._68 (l_prep) with_11\IN\0|and_37|failure_27|in_19 (l_pobj) hypothyroidism_12\NN\14059928|NONE_0
D008528_D007037 NONE acid_10\NN\14818238|not_21|to_17|in_5|corrected_63 (r_dobj) use_8\VB\407535|however_38|,_31|it_29|would_26|prudent_15|._86 (l_prep) in_11\IN\13603305|not_26|to_22|acid_5|corrected_58 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_amod) hypothyroid_12\JJ\0|NONE_0
D008528_D007037 NONE acid_10\NN\14818238|not_21|to_17|in_5|corrected_63 (r_dobj) use_8\VB\407535|however_38|,_31|it_29|would_26|prudent_15|._86 (l_advcl) corrected_19\VBN\138508|not_84|to_80|acid_63|in_58 (l_nsubjpass) hypothyroidism_16\NN\14059928|until_10|has_15|been_19
15609701
D013015_D002311 NONE sotalol_0\NNP\0|-_7|spasm_25|in_31|._121 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_prep) in_5\IN\13603305|sotalol_31|-_24|spasm_6|._90 (l_pobj) patient_7\NN\9898892|NONE_0 (l_prep) with_8\IN\0|a_10 (l_pobj) cardiomyopathy_10\NN\14103288|NONE_0
C076259_D017180 NONE hydrochloride_5\NN\14817592|NONE_0 (r_pobj) of_3\IN\0|the_19 (r_prep) administration_2\NN\1133281|after_10|,_42|vt_54|was_57|._71 (r_nsubjpass) terminated_10\VBN\126264|NONE_0 (l_nsubjpass) vt_8\NNP\0|after_64|administration_54|,_12|was_3|._17
D013015_D003329 CID sotalol_0\NNP\0|-_7|spasm_25|in_31|._121 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) spasm_4\NN\14299637|sotalol_25|-_18|in_6|._96
D013015_D003329 CID sotalol_15\NN\0|NONE_0 (r_pobj) of_14\IN\0|the_43|selective_35|blocking_20 (r_prep) properties_13\NNS\32613|NONE_0 (r_pobj) by_5\IN\0|vasospasm_25|may_15|be_11|._56 (r_agent) induced_4\VBN\1627355|NONE_0 (l_nsubjpass) vasospasm_1\NN\0|may_10|be_14|by_25|._81
D013015_D017180 NONE sotalol_0\NNP\0|-_7|spasm_25|in_31|._121 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_prep) in_5\IN\13603305|sotalol_31|-_24|spasm_6|._90 (l_pobj) patient_7\NN\9898892|NONE_0 (l_prep) with_8\IN\0|a_10 (l_pobj) cardiomyopathy_10\NN\14103288|NONE_0 (l_acl) associated_11\VBN\628491|dilated_23 (l_prep) with_12\IN\0|NONE_0 (l_pobj) tachycardia_15\NN\14110674|NONE_0
D013015_D017180 NONE sotalol_6\NN\0|an_30|alternate_27|class_17|iii_11|,_2 (r_appos) agent_4\NN\7347|,_14|also_20|effective_25|._59 (r_nsubj) was_8\VBD\0|NONE_0 (l_acomp) effective_10\JJ\0|agent_25|,_11|also_5|._34 (l_prep) for_11\IN\0|NONE_0 (l_pobj) prevention_13\NN\1073995|NONE_0 (l_prep) of_14\IN\0|the_15 (l_pobj) vt_15\NNP\0|NONE_0
23433219
D008694_D000987 CID methamphetamine_39\NN\2704153|heavy_6 (r_compound) uses_40\NNS\407535|antisocial_90|personality_79|(_58|or=12.619_57|and_26 (r_conj) disorder_28\NN\14034177|morbid_137|major_130|depressive_124|(_104|or=7.18_103|,_75|disorder_65|,_25
D008694_D000987 CID methamphetamine_46\NN\2704153|-_15 (r_npadvmod) induced_48\VBN\1627355|lifetime_25 (r_amod) psychosis_49\NN\14380140|NONE_0 (r_pobj) with_44\IN\0|disorder_215|were_30|significantly_25|adjusted_54|._80 (r_prep) associated_43\VBN\628491|NONE_0 (l_nsubjpass) disorder_5\NN\14034177|were_185|significantly_190|with_215|adjusted_269|._295 (l_appos) disorder_28\NN\14034177|morbid_137|major_130|depressive_124|(_104|or=7.18_103|,_75|disorder_65|,_25
D008694_D000987 CID methamphetamine_15\NN\2704153|heavy_6 (r_compound) use_16\NN\407535|antisocial_50|,_28|and_26 (r_conj) personality_11\NN\24264|morbid_38|affective_31|,_13
D008694_D019964 NONE methamphetamine_15\NN\2704153|heavy_6 (r_compound) use_16\NN\407535|antisocial_50|,_28|and_26 (r_conj) personality_11\NN\24264|morbid_38|affective_31|,_13 (r_conj) disorder_8\NN\14034177|NONE_0
D008694_D011605 CID methamphetamine_6\NN\2704153|in_26 (r_compound) psychosis_7\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_9\NN\2704153|-_15 (r_npadvmod) dependent_11\JJ\9627906|in_19 (r_amod) patients_12\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|methamphetamine_26 (r_prep) psychosis_7\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_14\NN\2704153|-_15 (r_npadvmod) induced_16\VBN\1627355|current_24 (r_amod) psychosis_17\NN\14380140|and_36|in_10
D008694_D011605 CID methamphetamine_21\NN\2704153|NONE_0 (r_compound) dependence_22\NN\24720|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) patients_19\NNS\9898892|NONE_0 (r_pobj) in_18\IN\13603305|and_46|psychosis_10 (r_prep) lifetime_11\NN\15113229|NONE_0 (l_conj) psychosis_17\NN\14380140|and_36|in_10
D008694_D011605 CID methamphetamine_8\NN\2704153|NONE_0 (r_punct) -_9\HYPH\0|morbidity_29 (r_punct) induced_10\VBN\1627355|NONE_0 (r_amod) psychosis_11\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_5\NN\2704153|NONE_0 (r_pobj) of_4\IN\0|the_14 (r_prep) diagnosis_3\NN\152018|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) patients_0\NNS\9898892|were_63|using_80 (r_nsubjpass) interviewed_12\VBN\964694|NONE_0 (l_advcl) using_13\VBG\418025|patients_80|were_17 (l_prep) for_22\IN\0|interview_21 (l_pobj) psychosis_26\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_23\NN\2704153|-_15 (r_npadvmod) induced_25\VBN\1627355|and_18|axis_28 (r_amod) psychosis_26\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_39\NN\2704153|heavy_6 (r_compound) uses_40\NNS\407535|antisocial_90|personality_79|(_58|or=12.619_57|and_26 (r_conj) disorder_28\NN\14034177|morbid_137|major_130|depressive_124|(_104|or=7.18_103|,_75|disorder_65|,_25 (r_appos) disorder_5\NN\14034177|were_185|significantly_190|with_215|adjusted_269|._295 (r_nsubjpass) associated_43\VBN\628491|NONE_0 (l_prep) with_44\IN\0|disorder_215|were_30|significantly_25|adjusted_54|._80 (l_pobj) psychosis_49\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_46\NN\2704153|-_15 (r_npadvmod) induced_48\VBN\1627355|lifetime_25 (r_amod) psychosis_49\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_10\NN\2704153|NONE_0 (r_compound) dependence_11\NN\24720|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) patients_8\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|a_25|high_23|of_13 (r_prep) risk_4\NN\14541044|there_17|._61 (l_prep) of_5\IN\0|a_12|high_10|in_13 (l_pobj) psychosis_6\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_7\NN\2704153|NONE_0 (r_compound) dependence_8\NN\24720|NONE_0 (r_pobj) of_6\IN\0|all_10 (r_prep) cases_5\NNS\7283608|that_9|should_36|be_43|for_55 (r_nsubjpass) screened_11\VBN\2533282|it_73|is_70|._31 (l_prep) for_12\IN\0|that_64|cases_55|should_19|be_12 (l_pobj) symptoms_14\NNS\5823932|NONE_0
D008694_D003866 NONE methamphetamine_39\NN\2704153|heavy_6 (r_compound) uses_40\NNS\407535|antisocial_90|personality_79|(_58|or=12.619_57|and_26 (r_conj) disorder_28\NN\14034177|morbid_137|major_130|depressive_124|(_104|or=7.18_103|,_75|disorder_65|,_25 (r_appos) disorder_5\NN\14034177|were_185|significantly_190|with_215|adjusted_269|._295
D008694_D003866 NONE methamphetamine_46\NN\2704153|-_15 (r_npadvmod) induced_48\VBN\1627355|lifetime_25 (r_amod) psychosis_49\NN\14380140|NONE_0 (r_pobj) with_44\IN\0|disorder_215|were_30|significantly_25|adjusted_54|._80 (r_prep) associated_43\VBN\628491|NONE_0 (l_nsubjpass) disorder_5\NN\14034177|were_185|significantly_190|with_215|adjusted_269|._295
D008694_D001714 CID methamphetamine_39\NN\2704153|heavy_6 (r_compound) uses_40\NNS\407535|antisocial_90|personality_79|(_58|or=12.619_57|and_26 (r_conj) disorder_28\NN\14034177|morbid_137|major_130|depressive_124|(_104|or=7.18_103|,_75|disorder_65|,_25 (r_appos) disorder_5\NN\14034177|were_185|significantly_190|with_215|adjusted_269|._295 (l_appos) disorder_16\NN\14034177|morbid_72|major_65|depressive_59|(_39|or=7.18_38|,_10|,_40|disorder_65
D008694_D001714 CID methamphetamine_46\NN\2704153|-_15 (r_npadvmod) induced_48\VBN\1627355|lifetime_25 (r_amod) psychosis_49\NN\14380140|NONE_0 (r_pobj) with_44\IN\0|disorder_215|were_30|significantly_25|adjusted_54|._80 (r_prep) associated_43\VBN\628491|NONE_0 (l_nsubjpass) disorder_5\NN\14034177|were_185|significantly_190|with_215|adjusted_269|._295 (l_appos) disorder_16\NN\14034177|morbid_72|major_65|depressive_59|(_39|or=7.18_38|,_10|,_40|disorder_65
16112787
C048498_-1 NONE erdosteine_33\NN\0|the_4 (r_amod) groups_34\NNS\2137|the_31|and_19 (r_conj) control_30\NN\5190804|NONE_0 (r_pobj) of_28\IN\0|NONE_0 (r_prep) those_27\DT\0|NONE_0 (r_pobj) than_26\IN\0|NONE_0 (r_prep) more_25\JJR\0|a_141|significant_139|of_116|,_99|vacuolization_71 (r_amod) dilatation_4\NN\14034177|there_25|._183 (l_conj) vacuolization_12\NN\13920835|a_70|significant_68|of_45|,_28|more_71 (l_conj) atrophy_14\NN\14299637|extensive_41|epithelial_31|cell_20|,_2|in_36 (l_conj) desquamation_16\NN\11418750|,_2
D014640_D009336 NONE vcm_21\NNP\0|-_3 (r_npadvmod) treated_23\VBN\2376958|NONE_0 (r_amod) rats_24\NNS\2329401|NONE_0 (r_pobj) in_20\IN\13603305|extensive_77|epithelial_67|cell_56|,_38|atrophy_36 (r_prep) vacuolization_12\NN\13920835|a_70|significant_68|of_45|,_28|more_71 (l_conj) atrophy_14\NN\14299637|extensive_41|epithelial_31|cell_20|,_2|in_36 (l_conj) desquamation_16\NN\11418750|,_2 (l_conj) necrosis_19\NN\11444117|,_6|and_4
D014640_D007674 CID vancomycin_12\NNP\2716866|-_10 (r_npadvmod) induced_14\VBN\1627355|:_22|protection_24 (r_amod) nephrotoxicity_15\NN\0|NONE_0
D014640_D007674 CID vancomycin_8\NNP\2716866|(_11|vcm)-induced_12|oxidative_25|promotes_47|and_100 (r_det) stress_12\NN\7083732|to_46|investigate_72 (r_dobj) examine_7\VB\0|aims_27|._286 (l_advcl) investigate_25\VB\644583|to_118|stress_72 (l_dobj) role_27\NN\719494|to_19 (l_appos) agent_33\NN\7347|the_39|of_30|,_17 (l_prep) on_41\IN\0|an_61|expectorant_58|,_41|has_33|,_2 (l_pobj) tissue_43\NN\5220461|NONE_0 (l_prep) against_44\IN\0|kidney_14 (l_pobj) impairment_51\NN\7296428|NONE_0
D014640_D007674 CID vcm)-induced_10\VBN\0|vancomycin_12|(_1|oxidative_13|promotes_35|and_88 (r_amod) stress_12\NN\7083732|to_46|investigate_72 (r_dobj) examine_7\VB\0|aims_27|._286 (l_advcl) investigate_25\VB\644583|to_118|stress_72 (l_dobj) role_27\NN\719494|to_19 (l_appos) agent_33\NN\7347|the_39|of_30|,_17 (l_prep) on_41\IN\0|an_61|expectorant_58|,_41|has_33|,_2 (l_pobj) tissue_43\NN\5220461|NONE_0 (l_prep) against_44\IN\0|kidney_14 (l_pobj) impairment_51\NN\7296428|NONE_0
D014640_D007674 CID vcm_47\NN\0|-_3 (r_npadvmod) induced_49\VBN\1627355|the_17|possible_13|renal_8|in_25 (r_amod) impairment_51\NN\7296428|NONE_0
D014640_D007674 CID vcm_0\NN\0|NONE_0 (r_compound) administration_1\NN\1133281|to_15|rats_26|malondialdehyde_61|but_177|decreased_181|._247 (r_nsubj) control_3\VB\5190804|NONE_0 (l_dobj) malondialdehyde_8\NN\0|administration_61|to_46|rats_35|but_116|decreased_120|._186 (l_appos) excretion_33\NN\13466586|increased_122|renal_112|(_90|mda_89 (l_nmod) glucosaminidase_22\NN\0|NONE_0 (l_appos) nag_24\NN\9631463|urinary_41|beta_24|-_20|d_19|-_18|(_1|)_37 (l_appos) marker_27\NN\21939|,_4 (l_prep) of_28\IN\0|a_9 (l_pobj) injury_31\NN\14052046|NONE_0
D014640_D007674 CID vcm_5\NNP\0|-_3 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) nephrotoxicity_8\NN\0|NONE_0
D014640_D007674 CID vcm_13\NNP\0|-_3 (r_npadvmod) induced_15\VBN\1627355|the_8 (r_amod) nephrotoxicity_16\NN\0|NONE_0
D014640_D007674 CID vcm_13\NNP\0|-_3 (r_npadvmod) induced_15\VBN\1627355|the_8 (r_amod) nephrotoxicity_16\NN\0|NONE_0 (r_pobj) in_11\IN\13603305|an_18|important_15|and_34|modulation_42 (r_prep) role_10\NN\719494|that_49|damage_26 (r_dobj) plays_7\VBZ\7007684|it_46|is_43|reduces_113|._198 (r_ccomp) concluded_2\VBN\628491|NONE_0 (l_conj) reduces_25\VBZ\441445|it_159|is_156|plays_113|._85 (l_dobj) damage_31\NN\7296428|NONE_0
D014640_D007674 CID vcm_27\NNP\0|-_3 (r_npadvmod) induced_29\VBN\1627355|the_8|kidney_8|at_27 (r_amod) damage_31\NN\7296428|NONE_0 (r_dobj) reduces_25\VBZ\441445|it_159|is_156|plays_113|._85 (r_conj) concluded_2\VBN\628491|NONE_0 (l_ccomp) plays_7\VBZ\7007684|it_46|is_43|reduces_113|._198 (l_dobj) role_10\NN\719494|that_49|damage_26 (l_prep) in_11\IN\13603305|an_18|important_15|and_34|modulation_42 (l_pobj) nephrotoxicity_16\NN\0|NONE_0
D014640_D007674 CID vcm_27\NNP\0|-_3 (r_npadvmod) induced_29\VBN\1627355|the_8|kidney_8|at_27 (r_amod) damage_31\NN\7296428|NONE_0
C048498_D007674 NONE erdosteine_19\NN\0|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_prep) protection_17\NN\407535|induced_24|:_2 (r_appos) nephrotoxicity_15\NN\0|NONE_0
C048498_D007674 NONE erdosteine_29\NN\0|NONE_0 (r_pobj) of_28\IN\0|the_9|,_13|agent_30 (r_prep) role_27\NN\719494|to_19 (l_appos) agent_33\NN\7347|the_39|of_30|,_17 (l_prep) on_41\IN\0|an_61|expectorant_58|,_41|has_33|,_2 (l_pobj) tissue_43\NN\5220461|NONE_0 (l_prep) against_44\IN\0|kidney_14 (l_pobj) impairment_51\NN\7296428|NONE_0
C048498_D007674 NONE erdosteine_0\NNP\0|protection_36|._81 (r_nsubj) showed_1\VBD\2137132|NONE_0 (l_dobj) protection_3\NN\407535|erdosteine_36|._45 (l_prep) against_4\IN\0|histopathological_29 (l_pobj) nephrotoxicity_8\NN\0|NONE_0
C048498_D007674 NONE erdosteine_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|the_35|of_20 (r_prep) modulation_19\NN\7044917|an_60|important_57|in_42|and_8 (r_conj) role_10\NN\719494|that_49|damage_26 (l_prep) in_11\IN\13603305|an_18|important_15|and_34|modulation_42 (l_pobj) nephrotoxicity_16\NN\0|NONE_0
C048498_D007674 NONE erdosteine_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|the_35|of_20 (r_prep) modulation_19\NN\7044917|an_60|important_57|in_42|and_8 (r_conj) role_10\NN\719494|that_49|damage_26 (r_dobj) plays_7\VBZ\7007684|it_46|is_43|reduces_113|._198 (r_ccomp) concluded_2\VBN\628491|NONE_0 (l_conj) reduces_25\VBZ\441445|it_159|is_156|plays_113|._85 (l_dobj) damage_31\NN\7296428|NONE_0
C048498_D009336 NONE erdosteine_33\NN\0|the_4 (r_amod) groups_34\NNS\2137|the_31|and_19 (r_conj) control_30\NN\5190804|NONE_0 (r_pobj) of_28\IN\0|NONE_0 (r_prep) those_27\DT\0|NONE_0 (r_pobj) than_26\IN\0|NONE_0 (r_prep) more_25\JJR\0|a_141|significant_139|of_116|,_99|vacuolization_71 (r_amod) dilatation_4\NN\14034177|there_25|._183 (l_conj) vacuolization_12\NN\13920835|a_70|significant_68|of_45|,_28|more_71 (l_conj) atrophy_14\NN\14299637|extensive_41|epithelial_31|cell_20|,_2|in_36 (l_conj) desquamation_16\NN\11418750|,_2 (l_conj) necrosis_19\NN\11444117|,_6|and_4
D014640_-1 NONE vcm_21\NNP\0|-_3 (r_npadvmod) treated_23\VBN\2376958|NONE_0 (r_amod) rats_24\NNS\2329401|NONE_0 (r_pobj) in_20\IN\13603305|extensive_77|epithelial_67|cell_56|,_38|atrophy_36 (r_prep) vacuolization_12\NN\13920835|a_70|significant_68|of_45|,_28|more_71 (l_conj) atrophy_14\NN\14299637|extensive_41|epithelial_31|cell_20|,_2|in_36 (l_conj) desquamation_16\NN\11418750|,_2
D010100_D007674 NONE oxygen_18\NN\14622893|reactive_9|(_15|ros_16|)_19 (r_compound) species_19\NNS\7992450|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) production_15\NN\30358|that_14 (r_dobj) promotes_14\VBZ\2556126|vancomycin_47|(_36|vcm)-induced_35|oxidative_22|and_53 (r_relcl) stress_12\NN\7083732|to_46|investigate_72 (r_dobj) examine_7\VB\0|aims_27|._286 (l_advcl) investigate_25\VB\644583|to_118|stress_72 (l_dobj) role_27\NN\719494|to_19 (l_appos) agent_33\NN\7347|the_39|of_30|,_17 (l_prep) on_41\IN\0|an_61|expectorant_58|,_41|has_33|,_2 (l_pobj) tissue_43\NN\5220461|NONE_0 (l_prep) against_44\IN\0|kidney_14 (l_pobj) impairment_51\NN\7296428|NONE_0
D008315_D007674 NONE malondialdehyde_8\NN\0|administration_61|to_46|rats_35|but_116|decreased_120|._186 (l_appos) excretion_33\NN\13466586|increased_122|renal_112|(_90|mda_89 (l_nmod) glucosaminidase_22\NN\0|NONE_0 (l_appos) nag_24\NN\9631463|urinary_41|beta_24|-_20|d_19|-_18|(_1|)_37 (l_appos) marker_27\NN\21939|,_4 (l_prep) of_28\IN\0|a_9 (l_pobj) injury_31\NN\14052046|NONE_0
D008315_D007674 NONE mda_10\NNP\0|increased_33|renal_23|(_1|excretion_89 (r_appos) malondialdehyde_8\NN\0|administration_61|to_46|rats_35|but_116|decreased_120|._186 (l_appos) excretion_33\NN\13466586|increased_122|renal_112|(_90|mda_89 (l_nmod) glucosaminidase_22\NN\0|NONE_0 (l_appos) nag_24\NN\9631463|urinary_41|beta_24|-_20|d_19|-_18|(_1|)_37 (l_appos) marker_27\NN\21939|,_4 (l_prep) of_28\IN\0|a_9 (l_pobj) injury_31\NN\14052046|NONE_0
D013481_D007674 NONE superoxide_36\NN\14971519|(_21|sod_22|)_25|and_27|activities_46 (r_amod) dismutase_37\NN\0|NONE_0 (r_dobj) decreased_35\VBD\169651|administration_181|to_166|rats_155|malondialdehyde_120|but_4|._66 (r_conj) control_3\VB\5190804|NONE_0 (l_dobj) malondialdehyde_8\NN\0|administration_61|to_46|rats_35|but_116|decreased_120|._186 (l_appos) excretion_33\NN\13466586|increased_122|renal_112|(_90|mda_89 (l_nmod) glucosaminidase_22\NN\0|NONE_0 (l_appos) nag_24\NN\9631463|urinary_41|beta_24|-_20|d_19|-_18|(_1|)_37 (l_appos) marker_27\NN\21939|,_4 (l_prep) of_28\IN\0|a_9 (l_pobj) injury_31\NN\14052046|NONE_0
D014640_D001284 NONE vcm_21\NNP\0|-_3 (r_npadvmod) treated_23\VBN\2376958|NONE_0 (r_amod) rats_24\NNS\2329401|NONE_0 (r_pobj) in_20\IN\13603305|extensive_77|epithelial_67|cell_56|,_38|atrophy_36 (r_prep) vacuolization_12\NN\13920835|a_70|significant_68|of_45|,_28|more_71 (l_conj) atrophy_14\NN\14299637|extensive_41|epithelial_31|cell_20|,_2|in_36
C048498_D001284 NONE erdosteine_33\NN\0|the_4 (r_amod) groups_34\NNS\2137|the_31|and_19 (r_conj) control_30\NN\5190804|NONE_0 (r_pobj) of_28\IN\0|NONE_0 (r_prep) those_27\DT\0|NONE_0 (r_pobj) than_26\IN\0|NONE_0 (r_prep) more_25\JJR\0|a_141|significant_139|of_116|,_99|vacuolization_71 (r_amod) dilatation_4\NN\14034177|there_25|._183 (l_conj) vacuolization_12\NN\13920835|a_70|significant_68|of_45|,_28|more_71 (l_conj) atrophy_14\NN\14299637|extensive_41|epithelial_31|cell_20|,_2|in_36
11439380
D013792_D011471 NONE thalidomide_0\NNP\4166841|in_23|._73 (r_compound) neuropathy_1\NN\14204950|NONE_0 (l_prep) in_2\IN\13603305|thalidomide_23|._50 (l_pobj) patients_3\NNS\9898892|NONE_0 (l_acl) treated_4\VBN\2376958|NONE_0 (l_prep) for_5\IN\0|NONE_0 (l_pobj) cancer_8\NN\14239425|NONE_0
D013792_D011471 NONE thalidomide_19\NN\4166841|NONE_0 (r_pobj) of_17\IN\0|an_20|label_12 (r_prep) trial_16\NN\786195|NONE_0 (r_pobj) in_11\IN\13603305|seven_63|with_53 (r_prep) men_3\NNS\8208016|examinations_121|to_175|._219 (l_prep) with_4\IN\0|seven_10|in_53 (l_pobj) cancer_10\NN\14239425|NONE_0
D013792_D009422 NONE thalidomide_0\NNP\4166841|in_23|._73 (r_compound) neuropathy_1\NN\14204950|NONE_0
D013792_D009422 NONE thalidomide_3\NN\4166841|-_11 (r_npadvmod) induced_5\VBN\1627355|using_19 (r_amod) neuropathy_6\NN\14204950|we_47|prospectively_44|._42
D013792_D009422 NONE thalidomide_8\NN\4166841|NONE_0 (r_pobj) of_7\IN\0|a_22|common_20|in_15 (r_prep) complication_6\NN\1073995|neuropathy_32|may_21|thus_17|._45 (r_attr) be_3\VB\14625458|NONE_0 (l_nsubj) neuropathy_0\NNP\14204950|may_11|thus_15|complication_32|._77
D000728_D011471 NONE androgen_6\JJ\14745635|-_8 (r_npadvmod) independent_8\JJ\9619824|metastatic_20|prostate_12 (r_amod) cancer_10\NN\14239425|NONE_0
24842192
D000667_D009203 NONE amp_20\NNP\13633375|-_3 (r_npadvmod) activated_22\VBN\1641914|protein_10|ampk_26 (r_amod) kinase_24\NN\14732946|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) activation_18\NN\13561719|to_3 (r_pobj) due_16\JJ\5174653|treatment_115|effect_73|._56 (r_prep) has_4\VBZ\13888491|NONE_0 (l_dobj) effect_7\NN\34213|treatment_42|due_73|._129 (l_prep) in_8\IN\13603305|a_20|protective_18|by_25 (l_pobj) infarction_10\NN\14204950|NONE_0
D007545_D009369 NONE isoproterenol_3\NN\3740161|-_13 (r_npadvmod) induced_5\VBN\1627355|in_18 (r_amod) elevation_6\NN\7445480|metfromin_49|markedly_39|,_36|myeloid_38|._164 (r_dobj) lowered_2\VBD\1850315|NONE_0 (l_advcl) myeloid_14\NN\0|metfromin_87|markedly_77|elevation_38|,_2|._126 (l_dobj) protein_16\NN\14944888|in_82 (l_appos) factor_24\NN\7326557|differentiation_51|88_27|myd88_23|,_17|)_45 (l_compound) necrosis_23\NN\11444117|-_15|alpha_16|,_29|and_31|interleukin_35 (l_compound) tumor_22\NN\14234074|NONE_0
D007545_D009203 CID isoproterenol_0\NNP\3740161|was_25|subcutaneously_38|on_53|induce_82|._116 (r_nsubjpass) injected_7\VBN\81072|NONE_0 (l_advcl) induce_16\VB\1627355|isoproterenol_82|was_57|subcutaneously_44|on_29|._34 (l_dobj) infarction_19\NN\14204950|to_27
D008687_D018487 NONE metformin_3\NN\2719105|NONE_0 (r_pobj) with_2\IN\0|chronic_18 (r_prep) treatment_1\NN\654885|receptor_46|and_67|attenuates_71|left_82|._142 (r_nsubj) suppresses_4\VBZ\2510337|NONE_0 (l_conj) left_13\VBN\8621598|treatment_82|receptor_36|and_15|attenuates_11|._60 (l_dobj) dysfunction_15\NN\14204950|NONE_0
D008687_D018487 NONE metformin_18\NN\2719105|NONE_0 (r_pobj) of_17\IN\0|25_15|/_4 (r_prep) kg_16\NNS\13717155|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) treated_10\VBN\2376958|the_11 (r_acl) groups_9\NNS\2137|NONE_0 (r_pobj) in_7\IN\13603305|dysfunction_36|lower_6|._54 (r_prep) was_4\VBD\0|NONE_0 (l_nsubj) dysfunction_3\NN\14204950|lower_30|in_36|._90
D008687_D006331 NONE metformin_13\NN\2719105|(_58|tlr4_59|)_63|following_76 (l_prep) on_14\IN\0|in_73|,_53|effect_47|with_15 (l_pobj) dysfunction_16\NN\14204950|NONE_0
D008687_D009203 NONE metformin_3\NN\2719105|NONE_0 (r_pobj) with_2\IN\0|chronic_18 (r_prep) treatment_1\NN\654885|receptor_46|and_67|attenuates_71|left_82|._142 (r_nsubj) suppresses_4\VBZ\2510337|NONE_0 (l_conj) left_13\VBN\8621598|treatment_82|receptor_36|and_15|attenuates_11|._60 (l_dobj) dysfunction_15\NN\14204950|NONE_0 (l_prep) following_16\VBG\8180190|ventricular_24 (l_pobj) infarction_18\NN\14204950|NONE_0
D008687_D009203 NONE metformin_3\NN\2719105|NONE_0 (r_pobj) with_2\IN\0|acute_16 (r_prep) treatment_1\NN\654885|effect_42|due_115|._171 (r_nsubj) has_4\VBZ\13888491|NONE_0 (l_dobj) effect_7\NN\34213|treatment_42|due_73|._129 (l_prep) in_8\IN\13603305|a_20|protective_18|by_25 (l_pobj) infarction_10\NN\14204950|NONE_0
D008687_D009203 NONE metformin_13\NN\2719105|(_58|tlr4_59|)_63|following_76 (r_nmod) activities_26\NNS\30358|were_72|._85 (l_acl) following_27\VBG\8180190|metformin_76|(_18|tlr4_17|)_13 (l_pobj) infarction_29\NN\14204950|NONE_0
D008687_D009203 NONE metformin_5\NN\2719105|dysfunction_53|and_65|suppresses_69|._150 (r_nsubj) reduces_6\VBZ\441445|NONE_0 (l_dobj) dysfunction_12\NN\14204950|metformin_53|and_12|suppresses_16|._97 (l_nmod) infarction_10\NN\14204950|myocardial_11|cardiac_11
D007545_D009336 NONE isoproterenol_3\NN\3740161|-_13 (r_npadvmod) induced_5\VBN\1627355|in_18 (r_amod) elevation_6\NN\7445480|metfromin_49|markedly_39|,_36|myeloid_38|._164 (r_dobj) lowered_2\VBD\1850315|NONE_0 (l_advcl) myeloid_14\NN\0|metfromin_87|markedly_77|elevation_38|,_2|._126 (l_dobj) protein_16\NN\14944888|in_82 (l_appos) factor_24\NN\7326557|differentiation_51|88_27|myd88_23|,_17|)_45 (l_compound) necrosis_23\NN\11444117|-_15|alpha_16|,_29|and_31|interleukin_35
9646784
D006493_D013923 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|,_24|thromboembolism_38|._96 (r_amod) thrombocytopenia_3\NN\14189204|NONE_0 (l_conj) thromboembolism_6\NN\14100769|induced_38|,_14|._58
D006493_D013923 CID heparin_13\JJ\2718259|NONE_0 (r_compound) therapy_14\NN\657604|NONE_0 (r_pobj) of_12\IN\0|other_19|side_13 (r_prep) effects_11\NNS\13245626|paradoxical_44|,_17|and_15 (r_conj) thromboembolism_6\NN\14100769|induced_38|,_14|._58
D006493_D000505 CID heparin_4\JJ\2718259|including_16 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) including_6\VBG\0|heparin_16 (l_pobj) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11 (l_amod) other_24\JJ\0|allergic_19 (l_prep) than_25\IN\0|NONE_0 (l_pobj) thrombocytopenia_26\JJ\14189204|NONE_0 (l_conj) alopecia_28\NN\14457041|and_4
D006493_D000505 CID heparin_7\NN\2718259|-_7 (r_npadvmod) induced_9\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11 (l_amod) other_24\JJ\0|allergic_19 (l_prep) than_25\IN\0|NONE_0 (l_pobj) thrombocytopenia_26\JJ\14189204|NONE_0 (l_conj) alopecia_28\NN\14457041|and_4
D006493_D000505 CID heparin_12\NN\2718259|-_7 (r_npadvmod) associated_14\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11 (l_amod) other_24\JJ\0|allergic_19 (l_prep) than_25\IN\0|NONE_0 (l_pobj) thrombocytopenia_26\JJ\14189204|NONE_0 (l_conj) alopecia_28\NN\14457041|and_4
D006493_D010024 CID heparin_4\JJ\2718259|including_16 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) including_6\VBG\0|heparin_16 (l_pobj) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21
D006493_D010024 CID heparin_7\NN\2718259|-_7 (r_npadvmod) induced_9\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21
D006493_D010024 CID heparin_12\NN\2718259|-_7 (r_npadvmod) associated_14\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_15\NN\14204950|induced_45|,_21
D006493_D012871 CID heparin_4\JJ\2718259|including_16 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) including_6\VBG\0|heparin_16 (l_pobj) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7
D006493_D012871 CID heparin_7\NN\2718259|-_7 (r_npadvmod) induced_9\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7
D006493_D012871 CID heparin_12\NN\2718259|-_7 (r_npadvmod) associated_14\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|,_24|thromboembolism_38|._96 (r_amod) thrombocytopenia_3\NN\14189204|NONE_0
D006493_D013921 CID heparin_13\JJ\2718259|NONE_0 (r_compound) therapy_14\NN\657604|NONE_0 (r_pobj) of_12\IN\0|other_19|side_13 (r_prep) effects_11\NNS\13245626|paradoxical_44|,_17|and_15 (r_conj) thromboembolism_6\NN\14100769|induced_38|,_14|._58 (r_conj) thrombocytopenia_3\NN\14189204|NONE_0
D006493_D013921 CID heparin_4\JJ\2718259|including_16 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) including_6\VBG\0|heparin_16 (l_pobj) thrombocytopenia_10\NN\14189204|NONE_0
D006493_D013921 CID heparin_4\JJ\2718259|including_16 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) including_6\VBG\0|heparin_16 (l_pobj) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11 (l_amod) other_24\JJ\0|allergic_19 (l_prep) than_25\IN\0|NONE_0 (l_pobj) thrombocytopenia_26\JJ\14189204|NONE_0
D006493_D013921 CID heparin_7\NN\2718259|-_7 (r_npadvmod) induced_9\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_10\NN\14189204|NONE_0
D006493_D013921 CID heparin_7\NN\2718259|-_7 (r_npadvmod) induced_9\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11 (l_amod) other_24\JJ\0|allergic_19 (l_prep) than_25\IN\0|NONE_0 (l_pobj) thrombocytopenia_26\JJ\14189204|NONE_0
D006493_D013921 CID heparin_12\NN\2718259|-_7 (r_npadvmod) associated_14\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_15\NN\14204950|induced_45|,_21 (r_conj) thrombocytopenia_10\NN\14189204|NONE_0
D006493_D013921 CID heparin_12\NN\2718259|-_7 (r_npadvmod) associated_14\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11 (l_amod) other_24\JJ\0|allergic_19 (l_prep) than_25\IN\0|NONE_0 (l_pobj) thrombocytopenia_26\JJ\14189204|NONE_0
D006493_D004342 CID heparin_4\JJ\2718259|including_16 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) including_6\VBG\0|heparin_16 (l_pobj) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11
D006493_D004342 CID heparin_7\NN\2718259|-_7 (r_npadvmod) induced_9\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11
D006493_D004342 CID heparin_12\NN\2718259|-_7 (r_npadvmod) associated_14\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2 (l_conj) reactions_20\NNS\13446390|,_7 (l_conj) reactions_23\NNS\13446390|skin_25|,_11
D006493_D004802 CID heparin_4\JJ\2718259|including_16 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) including_6\VBG\0|heparin_16 (l_pobj) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2
D006493_D004802 CID heparin_7\NN\2718259|-_7 (r_npadvmod) induced_9\VBN\1627355|,_24|osteoporosis_45 (r_amod) thrombocytopenia_10\NN\14189204|NONE_0 (l_conj) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2
D006493_D004802 CID heparin_12\NN\2718259|-_7 (r_npadvmod) associated_14\VBN\628491|,_23|eosinophilia_25 (r_amod) osteoporosis_15\NN\14204950|induced_45|,_21 (l_conj) eosinophilia_17\NN\14299637|associated_25|,_2
24582773
C069541_D011595 CID quetiapine_11\NN\0|add_18|high_11|-_7|in_11 (r_amod) doses_10\NNS\3740161|NONE_0 (r_pobj) by_4\IN\0|agitation_18|._60 (r_prep) induced_3\VBN\1627355|NONE_0 (l_nsubj) agitation_2\NN\14373582|by_18|._78
C069541_D011595 CID quetiapine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|the_25|gradual_21|(_14|day_28|)_31 (r_prep) introduction_7\NN\235435|NONE_0 (r_pobj) following_4\VBG\8180190|the_9|48_5 (r_prep) h_3\NN\14622893|NONE_0 (r_pobj) within_0\IN\0|,_83|patient_89|agitation_114|without_124|,_160|contrasting_162|._245 (r_prep) presented_21\VBD\2137132|NONE_0 (l_dobj) agitation_23\NN\14373582|within_114|,_31|patient_25|without_10|,_46|contrasting_48|._131
C069541_D011595 CID quetiapine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_27|gradual_23|later_22|,_27|led_35|,_66 (r_prep) reintroduction_5\NN\7217349|the_31|and_16 (l_relcl) led_13\VBD\3202760|the_62|gradual_58|of_35|later_13|,_8|,_31 (l_prep) to_14\IN\0|which_10 (l_pobj) agitation_17\NN\14373582|NONE_0
C069541_D011595 CID quetiapine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_27|gradual_23|later_22|,_27|led_35|,_66 (r_prep) reintroduction_5\NN\7217349|the_31|and_16 (r_conj) withdrawal_1\NN\7206096|us_118|attribute_124|._174 (r_nsubj) enabled_19\VBD\126264|NONE_0 (l_xcomp) attribute_22\VB\5835747|withdrawal_124|us_6|._50 (l_dobj) agitation_24\NN\14373582|to_17|to_23
C069541_D011595 CID quetiapine_27\NN\0|specifically_16 (r_pobj) to_26\IN\0|to_40|agitation_23 (r_prep) attribute_22\VB\5835747|withdrawal_124|us_6|._50 (r_xcomp) enabled_19\VBD\126264|NONE_0 (l_nsubj) withdrawal_1\NN\7206096|us_118|attribute_124|._174 (l_conj) reintroduction_5\NN\7217349|the_31|and_16 (l_relcl) led_13\VBD\3202760|the_62|gradual_58|of_35|later_13|,_8|,_31 (l_prep) to_14\IN\0|which_10 (l_pobj) agitation_17\NN\14373582|NONE_0
C069541_D011595 CID quetiapine_27\NN\0|specifically_16 (r_pobj) to_26\IN\0|to_40|agitation_23 (r_prep) attribute_22\VB\5835747|withdrawal_124|us_6|._50 (l_dobj) agitation_24\NN\14373582|to_17|to_23
D008094_D011618 NONE lithium_41\NN\14625458|day_9|and_4 (r_conj) zuclopenthixol_33\NN\0|generation_27|,_2 (r_appos) antipsychotics_31\NNS\4470232|NONE_0 (r_pobj) of_27\IN\0|a_14 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) by_24\IN\0|serum_108 (r_agent) treated_23\VBN\2376958|the_102|of_93|since_27|,_2 (r_acl) case_3\NN\7283608|we_14|._239 (l_prep) of_4\IN\0|the_9|since_66|,_91|treated_93 (l_pobj) suffering_10\NN\14322699|NONE_0 (l_prep) from_11\IN\0|a_32|old_22|patient_18 (l_pobj) disorder_15\NN\14034177|NONE_0
D008094_D011618 NONE lithium=0.85_50\NN\0|(_7|l_17|)_18 (r_punct) serum_49\NN\5397468|by_108 (r_parataxis) treated_23\VBN\2376958|the_102|of_93|since_27|,_2 (r_acl) case_3\NN\7283608|we_14|._239 (l_prep) of_4\IN\0|the_9|since_66|,_91|treated_93 (l_pobj) suffering_10\NN\14322699|NONE_0 (l_prep) from_11\IN\0|a_32|old_22|patient_18 (l_pobj) disorder_15\NN\14034177|NONE_0
C069541_D010554 NONE quetiapine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|the_25|gradual_21|(_14|day_28|)_31 (r_prep) introduction_7\NN\235435|NONE_0 (r_pobj) following_4\VBG\8180190|the_9|48_5 (r_prep) h_3\NN\14622893|NONE_0 (r_pobj) within_0\IN\0|,_83|patient_89|agitation_114|without_124|,_160|contrasting_162|._245 (r_prep) presented_21\VBD\2137132|NONE_0 (l_advcl) contrasting_29\VBG\650353|within_162|,_79|patient_73|agitation_48|without_38|,_2|._83 (l_prep) with_30\IN\0|NONE_0 (l_pobj) absence_32\NN\14449405|NONE_0 (l_prep) of_33\IN\0|the_12 (l_pobj) history_35\NN\15120823|NONE_0 (l_prep) of_36\IN\0|a_10 (l_pobj) aggressiveness_37\NN\4835724|NONE_0
C069541_D010554 NONE quetiapine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|the_25|gradual_21|(_14|day_28|)_31 (r_prep) introduction_7\NN\235435|NONE_0 (r_pobj) following_4\VBG\8180190|the_9|48_5 (r_prep) h_3\NN\14622893|NONE_0 (r_pobj) within_0\IN\0|,_83|patient_89|agitation_114|without_124|,_160|contrasting_162|._245 (r_prep) presented_21\VBD\2137132|NONE_0 (l_advcl) contrasting_29\VBG\650353|within_162|,_79|patient_73|agitation_48|without_38|,_2|._83 (l_prep) with_30\IN\0|NONE_0 (l_pobj) absence_32\NN\14449405|NONE_0 (l_prep) of_33\IN\0|the_12 (l_pobj) history_35\NN\15120823|NONE_0 (l_prep) of_36\IN\0|a_10 (l_pobj) aggressiveness_37\NN\4835724|NONE_0 (l_conj) disorder_40\NN\14034177|or_15
C069541_D011618 NONE quetiapine_11\NN\0|add_18|high_11|-_7|in_11 (r_amod) doses_10\NNS\3740161|NONE_0 (l_prep) in_12\IN\13603305|add_29|high_22|-_18|quetiapine_11 (l_pobj) disorder_16\NN\14034177|NONE_0
D003006_D011618 NONE zuclopenthixol_33\NN\0|generation_27|,_2 (r_appos) antipsychotics_31\NNS\4470232|NONE_0 (r_pobj) of_27\IN\0|a_14 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) by_24\IN\0|serum_108 (r_agent) treated_23\VBN\2376958|the_102|of_93|since_27|,_2 (r_acl) case_3\NN\7283608|we_14|._239 (l_prep) of_4\IN\0|the_9|since_66|,_91|treated_93 (l_pobj) suffering_10\NN\14322699|NONE_0 (l_prep) from_11\IN\0|a_32|old_22|patient_18 (l_pobj) disorder_15\NN\14034177|NONE_0
24459006
D015725_D013921 CID fluconazole_0\NNP\0|agranulocytosis_23|._59 (r_nsubj) associated_1\VBD\628491|NONE_0 (l_dobj) agranulocytosis_2\NN\14189204|fluconazole_23|._36 (l_conj) thrombocytopenia_4\NN\14189204|and_4
D015725_D013921 CID fluconazole_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|second_12 (r_prep) case_4\NN\7283608|we_21|agranulocytosis_31|._113 (r_dobj) describe_1\VBP\1001294|NONE_0 (l_dobj) agranulocytosis_8\NN\14189204|we_52|case_31|._82 (l_prep) with_9\IN\0|associated_27 (l_pobj) thrombocytopenia_10\NN\14189204|NONE_0
D015725_D013921 CID fluconazole_21\NN\0|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) therapy_19\NN\657604|NONE_0 (r_pobj) of_18\IN\0|a_9 (r_prep) result_17\NN\34213|NONE_0 (r_pobj) as_15\IN\14622893|that_65|agranulocytosis_46 (r_prep) occurred_14\VBD\0|the_71 (l_nsubj) agranulocytosis_11\NN\14189204|that_19|as_46 (l_conj) thrombocytopenia_13\NN\14189204|patient_30|and_4
D015725_D001855 NONE fluconazole_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_15|and_15|abatement_23 (r_prep) initiation_11\NN\7450842|NONE_0 (r_pobj) to_9\IN\0|the_53|temporal_49|of_27 (r_prep) relationship_4\NN\31921|particular_24|._162 (l_prep) of_5\IN\0|the_26|temporal_22|to_27 (l_pobj) suppression_8\NN\13489037|NONE_0
D015725_D000380 CID fluconazole_0\NNP\0|agranulocytosis_23|._59 (r_nsubj) associated_1\VBD\628491|NONE_0 (l_dobj) agranulocytosis_2\NN\14189204|fluconazole_23|._36
D015725_D000380 CID fluconazole_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|second_12 (r_prep) case_4\NN\7283608|we_21|agranulocytosis_31|._113 (r_dobj) describe_1\VBP\1001294|NONE_0 (l_dobj) agranulocytosis_8\NN\14189204|we_52|case_31|._82
D015725_D000380 CID fluconazole_21\NN\0|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) therapy_19\NN\657604|NONE_0 (r_pobj) of_18\IN\0|a_9 (r_prep) result_17\NN\34213|NONE_0 (r_pobj) as_15\IN\14622893|that_65|agranulocytosis_46 (r_prep) occurred_14\VBD\0|the_71 (l_nsubj) agranulocytosis_11\NN\14189204|that_19|as_46
24234943
C086816_D001008 CID desvenlafaxine_3\NN\0|medications_21|,_14|and_16|included_29 (r_dobj) included_2\VBD\0|NONE_0 (l_conj) included_7\VBD\0|medications_50|desvenlafaxine_29|,_15|and_13 (l_dobj) nausea_8\NN\14299637|symptoms_18|._29 (l_conj) anxiety_10\NN\14373582|,_2
C086816_D007177 CID desvenlafaxine_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|inappropriate_45|antidiuretic_31|hormone_18 (r_acl) secretion_5\NN\13526110|NONE_0 (l_compound) hormone_4\NN\5404728|inappropriate_27|antidiuretic_13|associated_18
C086816_D007177 CID desvenlafaxine_18\NN\0|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) associated_16\VBN\628491|inappropriate_54|hormone_26|(_18|siadh_17|)_12 (r_acl) secretion_15\NN\13526110|NONE_0 (l_nmod) hormone_11\NN\5404728|inappropriate_28|(_8|siadh_9|)_14|associated_26
C086816_D007177 CID desvenlafaxine_18\NN\0|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) associated_16\VBN\628491|inappropriate_54|hormone_26|(_18|siadh_17|)_12 (r_acl) secretion_15\NN\13526110|NONE_0 (l_nmod) siadh_13\NNP\0|inappropriate_37|hormone_9|(_1|)_5|associated_17
C086816_D009325 CID desvenlafaxine_3\NN\0|medications_21|,_14|and_16|included_29 (r_dobj) included_2\VBD\0|NONE_0 (l_conj) included_7\VBD\0|medications_50|desvenlafaxine_29|,_15|and_13 (l_dobj) nausea_8\NN\14299637|symptoms_18|._29
C086816_D003221 CID desvenlafaxine_3\NN\0|medications_21|,_14|and_16|included_29 (r_dobj) included_2\VBD\0|NONE_0 (l_conj) included_7\VBD\0|medications_50|desvenlafaxine_29|,_15|and_13 (l_dobj) nausea_8\NN\14299637|symptoms_18|._29 (l_conj) anxiety_10\NN\14373582|,_2 (l_conj) confusion_12\NN\13972797|and_4
C086816_D007010 CID desvenlafaxine_5\NN\0|that_5|might_15|hyponatremia_50 (r_nsubj) cause_7\VB\7323922|report_42|._41 (l_dobj) hyponatremia_10\NN\14299637|that_55|desvenlafaxine_50|might_35
D012964_D007177 NONE sodium_2\NN\14625458|l_33 (r_nsubj) was_6\VBD\0|,_14|osmolality_22|mosmol_41|._147 (r_ccomp) was_14\VBD\0|NONE_0 (l_attr) mosmol_16\NN\0|was_41|,_27|osmolality_19|._106 (l_amod) consistent_34\JJ\0|263_74|/_64|kg_63|,_61|osmolality_53|,_2 (l_prep) with_35\IN\0|NONE_0 (l_pobj) diagnosis_37\NN\152018|NONE_0 (l_prep) of_38\IN\0|a_12 (l_pobj) siadh_39\NNP\0|NONE_0
D012964_D007177 NONE sodium_28\NN\14625458|mosmol_20|/_14|and_10|l_15 (r_conj) kg_25\NNS\13717155|urine_28 (r_appos) osmolality_21\NN\0|263_21|/_11|kg_10|,_8|,_51|consistent_53 (r_appos) mosmol_16\NN\0|was_41|,_27|osmolality_19|._106 (l_amod) consistent_34\JJ\0|263_74|/_64|kg_63|,_61|osmolality_53|,_2 (l_prep) with_35\IN\0|NONE_0 (l_pobj) diagnosis_37\NN\152018|NONE_0 (l_prep) of_38\IN\0|a_12 (l_pobj) siadh_39\NNP\0|NONE_0
8829135
D001058_D000647 CID apomorphine_5\NN\3786417|-_11 (r_npadvmod) induced_7\VBN\1627355|of_16 (r_amod) amnesia_8\NN\5669934|nefiracetam_51
D001058_D000647 CID apomorphine_2\NN\3786417|NONE_0 (r_pobj) given_0\VBN\5892096|retention_50|given_65 (r_prep) inhibits_3\VBZ\2510337|,_107|we_109|ability_126|._201 (r_ccomp) evaluated_24\VBD\670261|NONE_0 (l_dobj) ability_26\NN\4723816|inhibits_126|,_19|we_17|._75 (l_acl) attenuate_30\VB\224901|the_30|of_18 (l_dobj) amnesia_31\NN\5669934|to_13
D001058_D000647 CID apomorphine_13\NN\3786417|NONE_0 (r_pobj) by_12\IN\0|at_15 (r_agent) induced_11\VBN\1627355|the_12 (r_acl) amnesia_10\NN\5669934|however_79|,_72|administration_70|completely_24|and_61|was_78
D011760_D007859 NONE pyrrolidone_4\NN\0|a_8|novel_6|attenuates_29 (r_compound) derivative_5\NN\5802185|nefiracetam_35|._97 (l_relcl) attenuates_7\VBZ\224901|a_37|novel_35|pyrrolidone_29 (l_dobj) learning_11\NN\5701944|which_37 (l_conj) deficits_17\NNS\5113133|induced_49|and_32
C058876_D007859 NONE nefiracetam_0\NNP\0|derivative_35|._132 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) derivative_5\NN\5802185|nefiracetam_35|._97 (l_relcl) attenuates_7\VBZ\224901|a_37|novel_35|pyrrolidone_29 (l_dobj) learning_11\NN\5701944|which_37 (l_conj) deficits_17\NNS\5113133|induced_49|and_32
D012601_D007859 CID scopolamine_8\NN\14712692|-_11 (r_npadvmod) induced_10\VBN\1627355|and_17|deficits_49 (r_amod) learning_11\NN\5701944|which_37 (l_conj) deficits_17\NNS\5113133|induced_49|and_32
C058876_D000647 NONE nefiracetam_0\NNP\0|amnesia_51 (r_nsubj) reverses_4\VBZ\13854649|:_68|emergence_78|._119 (l_dobj) amnesia_8\NN\5669934|nefiracetam_51
C058876_D000647 NONE dm-9384_2\NNP\0|(_1|)_7 (r_appos) nefiracetam_0\NNP\0|amnesia_51 (r_nsubj) reverses_4\VBZ\13854649|:_68|emergence_78|._119 (l_dobj) amnesia_8\NN\5669934|nefiracetam_51
C058876_D000647 NONE nefiracetam_28\NN\0|NONE_0 (r_pobj) of_27\IN\0|the_12|attenuate_18 (r_prep) ability_26\NN\4723816|inhibits_126|,_19|we_17|._75 (l_acl) attenuate_30\VB\224901|the_30|of_18 (l_dobj) amnesia_31\NN\5669934|to_13
C058876_D000647 NONE nefiracetam_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|during_15 (r_prep) administration_2\NN\1133281|however_9|,_2|completely_46|amnesia_70|and_131|was_148 (r_nsubj) reversed_8\VBD\109660|NONE_0 (l_dobj) amnesia_10\NN\5669934|however_79|,_72|administration_70|completely_24|and_61|was_78
24709919
C035054_D006930 NONE ginsenosides_15\NNS\0|NONE_0 (l_prep) on_23\IN\0|re_68|,_39|components_23|,_2 (l_pobj) oih_24\NNP\0|NONE_0
C035054_D006930 NONE ginsenosides_6\NNS\0|however_25|,_18|prevent_23|._49 (r_nsubj) failed_7\VBD\0|NONE_0 (l_xcomp) prevent_9\VB\0|however_48|,_41|ginsenosides_23|._26 (l_dobj) oih_10\NNP\0|to_11|in_4
C035054_D006930 NONE rg1_2\NNP\0|furthermore_13|,_2|tendency_13|._79 (r_nsubj) showed_3\VBD\2137132|NONE_0 (l_dobj) tendency_5\NN\6193203|furthermore_26|,_15|rg1_13|._66 (l_acl) aggravate_7\VB\126264|a_14 (l_dobj) oih_8\NNP\0|to_13|in_4
C035054_D006930 NONE rg1_10\NN\0|the_28|re_12|but_8 (r_conj) ginsenoside_5\NN\0|that_9|,_34|may_36|toward_51 (r_nsubj) contribute_15\VB\126264|data_64|._33 (l_prep) toward_16\IN\0|that_60|ginsenoside_51|,_17|may_15 (l_pobj) reversal_17\NN\199130|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) oih_19\NNP\0|NONE_0
D009020_D006930 CID morphine_9\NN\2707683|NONE_0 (r_pobj) of_8\IN\0|subcutaneous_28 (r_prep) administration_7\NN\1133281|NONE_0 (r_pobj) after_5\IN\0|oih_25|was_21|in_8|for_46|._88 (r_prep) achieved_2\VBN\2524171|NONE_0 (l_nsubjpass) oih_0\NNP\0|was_4|in_17|after_25|for_71|._113
D036145_D006930 NONE ginsenosides_2\NNS\0|NONE_0 (l_prep) on_3\IN\0|NONE_0 (l_pobj) hyperalgesia_7\NN\0|NONE_0
C049864_D006930 NONE ginsenosides_15\NNS\0|NONE_0 (l_prep) on_23\IN\0|re_68|,_39|components_23|,_2 (l_pobj) oih_24\NNP\0|NONE_0
C049864_D006930 NONE re_0\IN\14625458|NONE_0 (l_appos) mg/kg_3\NNS\0|(_5|._99 (l_dobj) oih_6\NNP\0|300_21|in_4
C049864_D006930 NONE re_6\IN\14625458|the_16|but_4|rg1_12 (r_prep) ginsenoside_5\NN\0|that_9|,_34|may_36|toward_51 (r_nsubj) contribute_15\VB\126264|data_64|._33 (l_prep) toward_16\IN\0|that_60|ginsenoside_51|,_17|may_15 (l_pobj) reversal_17\NN\199130|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) oih_19\NNP\0|NONE_0
D019342_D006930 NONE acid_16\NN\14818238|-_4|writhing_13 (r_npadvmod) induced_18\VBN\1627355|the_16 (r_advcl) acetic_15\JJ\0|both_42|the_37|sensitivity_25|and_8 (r_conj) test_12\NN\5798043|NONE_0 (r_pobj) in_7\IN\13603305|300_25|oih_4 (r_prep) mg/kg_3\NNS\0|(_5|._99 (l_dobj) oih_6\NNP\0|300_21|in_4
D019342_D006930 NONE acid_12\NN\14818238|the_11|acetic_7|-_4 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) writhing_15\VBG\1831531|NONE_0 (r_compound) test_16\NN\5798043|NONE_0 (r_pobj) in_9\IN\13603305|to_17|oih_4 (r_prep) aggravate_7\VB\126264|a_14 (l_dobj) oih_8\NNP\0|to_13|in_4
C442759_D006930 NONE ginsenosides_15\NNS\0|NONE_0 (l_prep) on_23\IN\0|re_68|,_39|components_23|,_2 (l_pobj) oih_24\NNP\0|NONE_0
C442759_D006930 NONE ginsenosides_6\NNS\0|however_25|,_18|prevent_23|._49 (r_nsubj) failed_7\VBD\0|NONE_0 (l_xcomp) prevent_9\VB\0|however_48|,_41|ginsenosides_23|._26 (l_dobj) oih_10\NNP\0|to_11|in_4
C442759_D006930 NONE rb1_12\NN\0|not_11|or_3 (r_conj) rg1_10\NN\0|the_28|re_12|but_8 (r_conj) ginsenoside_5\NN\0|that_9|,_34|may_36|toward_51 (r_nsubj) contribute_15\VB\126264|data_64|._33 (l_prep) toward_16\IN\0|that_60|ginsenoside_51|,_17|may_15 (l_pobj) reversal_17\NN\199130|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) oih_19\NNP\0|NONE_0
689020
D005280_D014202 CID hydrobromide_6\NN\0|NONE_0 (r_compound) infusion_7\NN\14589223|NONE_0 (r_pobj) of_3\IN\0|the_8 (r_prep) end_2\NN\8568978|NONE_0 (r_pobj) after_0\IN\0|,_48|amplitudes_57|faster_92|._141 (r_prep) decreased_11\VBD\169651|NONE_0 (l_nsubj) amplitudes_10\NNS\7444668|after_57|,_9|faster_35|._84 (l_compound) tremor_9\NN\345926|NONE_0
D012312_D014202 CID hcl_19\NN\0|NONE_0 (r_compound) infusion_20\NN\14589223|NONE_0 (r_pobj) following_16\VBG\8180190|NONE_0 (r_acl) those_15\DT\0|NONE_0 (r_pobj) than_14\IN\0|significantly_21 (r_prep) faster_13\RBR\0|after_92|,_44|amplitudes_35|._49 (r_advmod) decreased_11\VBD\169651|NONE_0 (l_nsubj) amplitudes_10\NNS\7444668|after_57|,_9|faster_35|._84 (l_compound) tremor_9\NN\345926|NONE_0
19392810
D003932_D012206 CID heroin_7\NN\3492717|-_6 (r_npadvmod) dependent_9\JJ\9627906|a_9 (r_amod) male_10\NN\15388|NONE_0 (r_pobj) in_5\IN\13603305|rhabdomyolysis_41|ischemic_16|under_27|._62 (r_prep) stroke_4\NN\556313|NONE_0 (l_nmod) rhabdomyolysis_0\NNP\0|ischemic_25|in_41|under_68|._103
D003932_D012206 CID heroin_14\NN\3492717|NONE_0 (r_pobj) after_12\IN\0|man_63|with_49|._24 (r_prep) presented_5\VBN\2137132|NONE_0 (l_prep) with_6\IN\0|man_14|after_49|._73 (l_pobj) rhabdomyolysis_7\NN\0|NONE_0
D003932_D012206 CID heroin_4\NN\3492717|and_4 (r_conj) methadone_2\NN\3808564|simultaneously_21 (r_dobj) using_1\VBG\418025|NONE_0 (r_acl) those_0\DT\0|may_48|risk_61|._103 (r_nsubj) increase_7\VB\13576355|NONE_0 (l_dobj) risk_8\NN\14541044|those_61|may_13|._42 (l_prep) of_9\IN\0|NONE_0 (l_pobj) rhabdomyolysis_10\NN\0|NONE_0
D003932_D012206 CID heroin_2\NN\3492717|-_6 (r_npadvmod) related_4\VBN\628491|and_23|stroke_27 (r_amod) rhabdomyolysis_5\NN\0|NONE_0
D003932_D012206 CID heroin_9\NN\3492717|NONE_0 (r_compound) abusers_10\NNS\9633969|NONE_0 (r_pobj) in_8\IN\13603305|NONE_0 (r_prep) stroke_7\NN\556313|related_27|and_4 (r_conj) rhabdomyolysis_5\NN\0|NONE_0
D003932_D002544 NONE heroin_7\NN\3492717|-_6 (r_npadvmod) dependent_9\JJ\9627906|a_9 (r_amod) male_10\NN\15388|NONE_0 (r_pobj) in_5\IN\13603305|rhabdomyolysis_41|ischemic_16|under_27|._62 (r_prep) stroke_4\NN\556313|NONE_0
D003932_D002544 NONE heroin_14\NN\3492717|NONE_0 (r_pobj) after_12\IN\0|man_63|with_49|._24 (r_prep) presented_5\VBN\2137132|NONE_0 (l_prep) with_6\IN\0|man_14|after_49|._73 (l_pobj) rhabdomyolysis_7\NN\0|NONE_0 (l_conj) stroke_11\NN\556313|and_22
D003932_D002544 NONE heroin_4\NN\3492717|and_4 (r_conj) methadone_2\NN\3808564|simultaneously_21 (r_dobj) using_1\VBG\418025|NONE_0 (r_acl) those_0\DT\0|may_48|risk_61|._103 (r_nsubj) increase_7\VB\13576355|NONE_0 (l_dobj) risk_8\NN\14541044|those_61|may_13|._42 (l_prep) of_9\IN\0|NONE_0 (l_pobj) rhabdomyolysis_10\NN\0|NONE_0 (l_conj) stroke_13\NN\556313|and_13
D008691_D012206 CID methadone_12\NN\3808564|maintenance_10 (r_compound) therapy_14\NN\657604|NONE_0 (r_pobj) under_11\IN\0|rhabdomyolysis_68|ischemic_43|in_27|._35 (r_prep) stroke_4\NN\556313|NONE_0 (l_nmod) rhabdomyolysis_0\NNP\0|ischemic_25|in_41|under_68|._103
D008691_D012206 CID methadone_2\NN\3808564|simultaneously_21 (r_dobj) using_1\VBG\418025|NONE_0 (r_acl) those_0\DT\0|may_48|risk_61|._103 (r_nsubj) increase_7\VB\13576355|NONE_0 (l_dobj) risk_8\NN\14541044|those_61|may_13|._42 (l_prep) of_9\IN\0|NONE_0 (l_pobj) rhabdomyolysis_10\NN\0|NONE_0
D003932_D020521 CID heroin_2\NN\3492717|-_6 (r_npadvmod) related_4\VBN\628491|and_23|stroke_27 (r_amod) rhabdomyolysis_5\NN\0|NONE_0 (l_conj) stroke_7\NN\556313|related_27|and_4
D003932_D020521 CID heroin_9\NN\3492717|NONE_0 (r_compound) abusers_10\NNS\9633969|NONE_0 (r_pobj) in_8\IN\13603305|NONE_0 (r_prep) stroke_7\NN\556313|related_27|and_4
D008691_D002544 NONE methadone_12\NN\3808564|maintenance_10 (r_compound) therapy_14\NN\657604|NONE_0 (r_pobj) under_11\IN\0|rhabdomyolysis_68|ischemic_43|in_27|._35 (r_prep) stroke_4\NN\556313|NONE_0
D008691_D002544 NONE methadone_2\NN\3808564|simultaneously_21 (r_dobj) using_1\VBG\418025|NONE_0 (r_acl) those_0\DT\0|may_48|risk_61|._103 (r_nsubj) increase_7\VB\13576355|NONE_0 (l_dobj) risk_8\NN\14541044|those_61|may_13|._42 (l_prep) of_9\IN\0|NONE_0 (l_pobj) rhabdomyolysis_10\NN\0|NONE_0 (l_conj) stroke_13\NN\556313|and_13
24451297
C065180_D056486 CID fluvastatin_10\NNP\3676175|NONE_0 (r_compound) therapy_11\NNP\657604|NONE_0 (r_pobj) after_9\IN\0|12_9 (r_prep) hours_8\NNS\15118228|NONE_0 (r_pobj) within_6\IN\0|induced_27|acute_19|liver_13|._41 (r_prep) injury_5\NN\14052046|NONE_0
C065180_D056486 CID fluvastatin_19\NN\3676175|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treatment_17\NN\654885|NONE_0 (r_dobj) beginning_16\VBG\7283608|hours_12 (r_pcomp) after_15\IN\0|which_24 (r_prep) appeared_12\VBD\2604760|liver_20|,_8 (r_relcl) damage_9\NN\7296428|NONE_0
D019161_D056486 NONE statins_1\NNS\3740161|although_9|generally_12|drugs_37 (r_nsubj) are_2\VBP\13600404|,_34|cases_43|have_104|been_109|._122 (r_advcl) reported_23\VBN\831651|NONE_0 (l_nsubjpass) cases_10\NNS\7283608|are_43|,_9|have_61|been_66|._79 (l_prep) of_11\IN\0|recent_13|associated_29 (l_pobj) injury_16\NN\14052046|NONE_0
15229250
D008694_D006984 NONE ma_3\NNP\10332385|NONE_0 (r_compound) abusers_4\NNS\9633969|on_15|,_5|volumes_37|0.05_105|._168 (r_nsubj) had_5\VBD\0|NONE_0 (l_dobj) 0.05_29\CD\0|on_120|,_110|abusers_105|volumes_68|._63 (l_conj) hypertrophy_36\NN\14365950|;_64|0.01_52|;_48|right_46|,_41|p_39|<_37|)_31|and_29
D008694_D008659 NONE ma_7\NNP\10332385|who_14|have_10 (r_dobj) used_6\VBN\0|human_24 (r_relcl) subjects_3\NNS\6598915|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) studies_0\NNS\635850|chronically_43|have_55|deficits_69|._155 (r_nsubj) revealed_10\VBN\2137132|NONE_0 (l_dobj) deficits_11\NNS\5113133|studies_69|chronically_26|have_14|._86 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) systems_16\NNS\3575240|NONE_0 (l_conj) abnormalities_20\NNS\14034177|dopaminergic_61|and_23
D008694_D008569 CID methamphetamine_7\NN\2704153|chronic_8 (r_compound) abuse_8\NN\418025|that_29|pattern_25 (r_nsubj) causes_9\VBZ\7323922|maps_48|._100 (l_dobj) pattern_12\NN\5726345|that_54|abuse_25 (l_prep) of_13\IN\0|a_20|selective_18 (l_pobj) deterioration_15\NN\14560612|NONE_0 (l_relcl) contributes_17\VBZ\126264|cerebral_28 (l_prep) to_18\IN\0|that_17 (l_pobj) performance_21\NN\6619065|NONE_0
D008694_D003072 NONE ma_26\NNP\10332385|chronic_8|in_9 (r_compound) abuse_27\NN\418025|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) associated_23\VBN\628491|structural_29|brain_18 (r_acl) alterations_22\NNS\7283608|NONE_0 (r_pobj) of_19\IN\0|the_12 (r_prep) pattern_18\NN\5726345|using_105|,_20|we_18|and_91|related_95|._141 (r_dobj) determined_16\VBD\0|NONE_0 (l_conj) related_32\VBD\628491|using_200|,_115|we_113|pattern_95|and_4|._46 (l_prep) to_35\IN\0|deficits_9 (l_pobj) impairment_37\NN\7296428|NONE_0
D008694_D001930 CID methamphetamine_20\NN\2704153|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_16|human_12 (r_acl) brain_16\NN\5462674|NONE_0
D008694_D001930 CID ma_22\NNP\10332385|(_1|)_2 (r_nmod) abuse_24\NN\418025|chronic_29 (r_appos) methamphetamine_20\NN\2704153|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_16|human_12 (r_acl) brain_16\NN\5462674|NONE_0
D008694_D001930 CID ma_34\NNP\10332385|who_9 (r_dobj) used_33\VBD\0|22_22|human_19 (r_relcl) subjects_31\NNS\6598915|NONE_0 (r_pobj) in_28\IN\13603305|NONE_0 (r_prep) ventricles_27\NNS\5303402|white_18|,_6|and_4
D008694_D001930 CID ma_10\NNP\10332385|NONE_0 (r_compound) abuse_11\NN\418025|NONE_0 (r_pobj) of_9\IN\0|the_13 (r_prep) symptoms_8\NNS\5823932|NONE_0 (r_pobj) for_6\IN\0|NONE_0 (r_prep) account_5\VB\6647206|substrates_20|may_9|,_36|providing_38|._97 (r_xcomp) help_4\VB\407535|NONE_0 (l_advcl) providing_13\VBG\2199590|substrates_58|may_47|account_38|,_2|._59 (l_dobj) targets_15\NNS\7258332|NONE_0 (l_prep) for_16\IN\0|therapeutic_20 (l_pobj) injury_21\NN\14052046|NONE_0
16867246
D002746_D012559 NONE chlorpromazine_5\NN\3713736|-_14 (r_npadvmod) induced_7\VBN\1627355|drd2_38|and_19 (r_conj) polymorphisms_3\NNS\11418750|extrapyramidal_41|in_65 (r_nmod) syndrome_9\NN\5870365|NONE_0 (l_prep) in_10\IN\13603305|polymorphisms_65|extrapyramidal_24 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_amod) schizophrenic_12\JJ\10490141|chinese_8
D002746_D012559 NONE chlorpromazine_11\NN\3713736|-_14 (r_npadvmod) induced_13\VBN\1627355|in_12 (r_amod) eps_14\NNP\0|NONE_0 (l_prep) in_15\IN\13603305|induced_12 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_amod) schizophrenic_16\JJ\10490141|NONE_0
D002746_D012559 NONE chlorpromazine_38\NN\3713736|NONE_0 (r_pobj) with_37\IN\0|taqib_178|,_173|rs6275_153|after_20|._33 (r_prep) treated_36\VBN\2376958|NONE_0 (l_nsubj) rs6275_6\ADD\0|taqib_25|,_20|with_153|after_173|._186 (l_prep) in_12\IN\13603305|ser311cys_37|,_28|,_20|rs6277_18|)_2 (l_pobj) gene_15\NN\8459252|NONE_0 (l_prep) in_16\IN\13603305|the_14|drd2_10 (l_pobj) inpatients_19\NNS\10405694|NONE_0 (l_amod) schizophrenic_18\JJ\10490141|146_4|(_25|59_26|according_57
D002746_D012559 NONE chlorpromazine_30\NN\3713736|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|the_41|variable_24|adverse_15 (r_acl) effect_27\NN\34213|NONE_0 (r_pobj) in_22\IN\13603305|that_63|variation_46|role_5|,_69|in_80 (r_prep) plays_18\VBZ\7007684|the_53 (l_prep) in_34\IN\13603305|that_143|variation_126|role_85|in_80|,_11 (l_pobj) patients_36\NNS\9898892|least_17 (l_prep) with_37\IN\0|chinese_17 (l_pobj) schizophrenia_38\NN\14398067|NONE_0
D002746_D001480 CID chlorpromazine_5\NN\3713736|-_14 (r_npadvmod) induced_7\VBN\1627355|drd2_38|and_19 (r_conj) polymorphisms_3\NNS\11418750|extrapyramidal_41|in_65 (r_nmod) syndrome_9\NN\5870365|NONE_0
D002746_D001480 CID chlorpromazine_11\NN\3713736|-_14 (r_npadvmod) induced_13\VBN\1627355|in_12 (r_amod) eps_14\NNP\0|NONE_0
D002746_D001480 CID chlorpromazine_38\NN\3713736|NONE_0 (r_pobj) with_37\IN\0|taqib_178|,_173|rs6275_153|after_20|._33 (r_prep) treated_36\VBN\2376958|NONE_0 (l_nsubj) rs6275_6\ADD\0|taqib_25|,_20|with_153|after_173|._186 (l_prep) in_12\IN\13603305|ser311cys_37|,_28|,_20|rs6277_18|)_2 (l_pobj) gene_15\NN\8459252|NONE_0 (l_prep) in_16\IN\13603305|the_14|drd2_10 (l_pobj) inpatients_19\NNS\10405694|NONE_0 (l_appos) 59_21\CD\0|146_30|schizophrenic_26|(_1|according_31 (l_prep) with_22\IN\0|and_9|87_13 (l_pobj) eps_23\NNP\0|NONE_0
D002746_D001480 CID chlorpromazine_38\NN\3713736|NONE_0 (r_pobj) with_37\IN\0|taqib_178|,_173|rs6275_153|after_20|._33 (r_prep) treated_36\VBN\2376958|NONE_0 (l_nsubj) rs6275_6\ADD\0|taqib_25|,_20|with_153|after_173|._186 (l_prep) in_12\IN\13603305|ser311cys_37|,_28|,_20|rs6277_18|)_2 (l_pobj) gene_15\NN\8459252|NONE_0 (l_prep) in_16\IN\13603305|the_14|drd2_10 (l_pobj) inpatients_19\NNS\10405694|NONE_0 (l_appos) 59_21\CD\0|146_30|schizophrenic_26|(_1|according_31 (l_conj) 87_25\CD\0|with_13|and_4 (l_prep) without_26\IN\0|NONE_0 (l_pobj) eps_27\NNP\0|NONE_0
611664
D009638_D004342 NONE norepinephrine_27\NN\14807929|NONE_0 (r_pobj) of_25\IN\0|the_20|pressor_16 (r_prep) effects_24\NNS\13245626|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_prep) hypersensitivity_20\NN\14531772|had_11
D002395_D004342 NONE catecholamines_6\NNS\5407119|they_43|and_81|marked_89|._161 (r_dobj) exhibited_2\VBD\2632167|NONE_0 (l_conj) marked_19\VBN\1296462|they_132|catecholamines_89|and_8|._72 (l_dobj) hypersensitivity_20\NN\14531772|had_11
D011433_D006973 CID propranolol_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|in_46|,_34|hypertension_25|was_12|and_15|had_28 (r_agent) induced_7\VBN\1627355|NONE_0 (l_nsubjpass) hypertension_5\NN\14057371|in_21|,_9|was_13|by_25|and_40|had_53
D011433_C544351 NONE propranolol_2\NN\0|NONE_0 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) treatment_5\NN\654885|NONE_0 (l_prep) of_6\IN\0|the_14 (l_pobj) hypotension_9\NN\14057371|NONE_0
D011433_C544351 NONE propranolol_4\NN\0|that_5|drug_24 (r_nsubj) is_5\VBZ\0|studies_33|._84 (l_attr) drug_8\NN\14778436|that_29|propranolol_24 (l_prep) in_9\IN\13603305|a_14|useful_12 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|selected_18 (l_pobj) hypotension_16\NN\14057371|NONE_0
20513036
C542870_D010243 NONE botox_3\JJ\14587688|for_16 (r_compound) injection_4\NN\320852|NONE_0 (r_pobj) after_2\IN\0|abductor_19|._54 (r_prep) paralysis_1\NN\14557898|NONE_0
C542870_D010243 NONE botox_10\NNP\14587688|for_17|,_25|complication_29 (r_compound) injections_11\NNS\320852|NONE_0 (r_pobj) following_9\VBG\8180190|here_62|we_57|cases_38|._73 (r_prep) report_2\VBP\6470073|NONE_0 (l_dobj) cases_4\NNS\7283608|here_24|we_19|following_38|._111 (l_prep) of_5\IN\0|multiple_15 (l_pobj) paralysis_8\NN\14557898|NONE_0
C542870_D010243 NONE botox_12\NNP\14587688|paralytic_10|,_10|dose_24 (r_compound) dose_13\NN\3740161|,_18 (r_conj) sex_9\NN\13440063|,_2 (r_conj) age_7\NN\4916342|bilateral_30|abductor_20|,_2 (r_conj) paralysis_5\NN\14557898|NONE_0
C542870_D010243 NONE botox_12\NNP\14587688|paralytic_10|,_10|dose_24 (r_compound) dose_13\NN\3740161|,_18 (l_conj) dose_17\NN\3740161|paralytic_34|botox_24|,_14 (l_conj) paralysis_22\NN\14557898|prior_39|botox_33|,_23|and_21|course_17
C542870_D010243 NONE botox_16\NNP\14587688|prior_6|,_10|and_12|course_16|paralysis_33 (r_compound) dose_17\NN\3740161|paralytic_34|botox_24|,_14 (r_conj) dose_13\NN\3740161|,_18 (r_conj) sex_9\NN\13440063|,_2 (r_conj) age_7\NN\4916342|bilateral_30|abductor_20|,_2 (r_conj) paralysis_5\NN\14557898|NONE_0
C542870_D010243 NONE botox_16\NNP\14587688|prior_6|,_10|and_12|course_16|paralysis_33 (r_compound) dose_17\NN\3740161|paralytic_34|botox_24|,_14 (l_conj) paralysis_22\NN\14557898|prior_39|botox_33|,_23|and_21|course_17
C542870_D010243 NONE botox_6\NNP\14587688|for_16 (r_compound) injection_7\NN\320852|NONE_0 (r_pobj) after_5\IN\0|the_36|of_22 (r_prep) incidence_1\NN\13821570|%_71|._72 (l_prep) of_2\IN\0|the_14|after_22 (l_pobj) paralysis_4\NN\14557898|NONE_0
C542870_D010243 NONE botox_8\NNP\14587688|for_17 (r_compound) injections_9\NNS\320852|NONE_0 (r_pobj) of_7\IN\0|a_20|rare_18 (r_prep) complication_6\NN\1073995|paralysis_20|,_41|causing_43|._90 (r_attr) is_3\VBZ\0|NONE_0 (l_nsubj) paralysis_2\NN\14557898|complication_20|,_61|causing_63|._110
C542870_D010243 NONE botox_8\NNP\14587688|NONE_0 (r_pobj) of_7\IN\0|around_9 (r_prep) diffusion_6\NN\13518963|mechanism_26|._103 (r_attr) is_5\VBZ\0|NONE_0 (l_nsubj) mechanism_2\NN\13446390|diffusion_26|._129 (l_prep) of_3\IN\0|the_21|likely_17 (l_pobj) paralysis_4\NN\14557898|NONE_0
C542870_D055154 NONE botox_5\NNP\14587688|NONE_0 (r_compound) injections_6\NNS\320852|that_20|for_11 (r_dobj) received_4\VBD\2210855|NONE_0 (l_prep) for_7\IN\0|that_31|injections_11 (l_pobj) dysphonia_9\NN\14400677|NONE_0
C542870_D014826 CID botox_3\JJ\14587688|for_16 (r_compound) injection_4\NN\320852|NONE_0 (l_prep) for_5\IN\0|botox_16 (l_pobj) dysphonia_8\NN\14400677|NONE_0
C542870_D014826 CID botox_3\NNP\14587688|botulinum_17|(_1|)_5|injections_7 (r_appos) toxin_1\NN\15032376|standard_73|._129 (r_nsubj) are_10\VBP\13600404|NONE_0 (l_attr) standard_13\NN\13577171|toxin_73|._56 (l_prep) for_16\IN\0|the_29|current_25|of_8 (l_pobj) dysphonia_19\NN\14400677|NONE_0
C542870_D014826 CID botox_3\NNP\14587688|botulinum_17|(_1|)_5|injections_7 (r_appos) toxin_1\NN\15032376|standard_73|._129 (r_nsubj) are_10\VBP\13600404|NONE_0 (l_attr) standard_13\NN\13577171|toxin_73|._56 (l_prep) for_16\IN\0|the_29|current_25|of_8 (l_pobj) dysphonia_19\NN\14400677|NONE_0 (l_appos) adsd_21\NNP\0|adductor_30|spasmodic_21|(_1|)_4
C542870_D014826 CID botox_10\NNP\14587688|for_17|,_25|complication_29 (r_compound) injections_11\NNS\320852|NONE_0 (l_prep) for_12\IN\0|botox_17|,_8|complication_12 (l_pobj) adsd_13\NNP\0|NONE_0
C542870_D014826 CID botox_7\NNP\14587688|NONE_0 (r_dobj) receiving_6\VBG\2210855|452_13 (r_acl) patients_5\NNS\9898892|NONE_0 (r_pobj) of_3\IN\0|a_11 (r_prep) database_2\NN\6634376|NONE_0 (r_pobj) from_0\IN\0|,_47|patients_53|had_62|been_66|with_81|._90 (r_prep) diagnosed_13\VBN\644583|NONE_0 (l_prep) with_14\IN\0|from_81|,_34|patients_28|had_19|been_15|._9 (l_pobj) adsd_15\NNP\0|NONE_0
C542870_D014826 CID botox_6\NNP\14587688|for_16 (r_compound) injection_7\NN\320852|NONE_0 (l_prep) for_8\IN\0|botox_16 (l_pobj) adsd_9\NNP\0|NONE_0
C542870_D014826 CID botox_8\NNP\14587688|for_17 (r_compound) injections_9\NNS\320852|NONE_0 (l_prep) for_10\IN\0|botox_17 (l_pobj) adsd_11\NNP\0|NONE_0
2614930
D009543_D009422 NONE nifedipine_0\NNP\2938514|bradycardia_19|in_31|._69 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_prep) in_3\IN\13603305|nifedipine_31|bradycardia_12|._38 (l_pobj) patient_5\NN\9898892|NONE_0 (l_prep) with_6\IN\0|a_10 (l_pobj) neuropathy_8\NN\14204950|NONE_0
D009543_D013610 CID nifedipine_10\NN\2938514|that_5|tachycardia_19|in_31 (r_nsubj) induces_11\VBZ\1627355|the_45|established_36 (l_dobj) tachycardia_12\VBG\14110674|that_24|nifedipine_19|in_12
D009543_D001919 CID nifedipine_0\NNP\2938514|bradycardia_19|in_31|._69 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) bradycardia_2\NNP\14110674|nifedipine_19|in_12|._50
D009543_D001282 NONE nifedipine_21\NN\2938514|which_36|down_23|to_18 (r_advcl) slowed_14\VBD\151689|a_35|ventricular_33|of_16 (r_relcl) rate_10\NN\13815152|NONE_0 (r_pobj) at_7\IN\14622893|to_23|flutter_8 (r_prep) have_4\VB\7846|he_16|was_13|._172 (l_dobj) flutter_6\NN\331950|to_15|at_8
24614773
D014635_D020325 NONE valproate_25\NN\0|had_20|been_16|on_3 (l_prep) for_26\IN\0|NONE_0 (l_pobj) migraine_29\NN\14326607|NONE_0
D014635_D010291 NONE valproate_25\NN\0|had_20|been_16|on_3 (r_conj) started_23\VBN\0|in_134|,_111|patient_105|number_91|,_15|and_13|._53 (r_conj) had_7\VBD\0|NONE_0 (l_dobj) number_9\NN\5107765|in_43|,_20|patient_14|,_76|and_78|started_91|._144 (l_prep) of_10\IN\0|a_9 (l_pobj) admissions_11\NNS\49003|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) hemiparesis_15\NN\0|NONE_0
D014635_D001927 NONE valproate_4\VBP\0|normoammonemic_38|:_9|?_40 (r_acl) encephalopathy_1\NN\14084880|NONE_0
D014635_D001927 NONE valproate_4\NN\0|-_9 (r_npadvmod) induced_6\VBN\1627355|and_23|encephalitis_52 (r_amod) encephalopathy_7\JJ\14084880|NONE_0
D016202_D004660 NONE nmda_9\NNP\0|associated_14 (r_nmod) encephalitis_13\NN\14336539|induced_52|and_29
D016202_D001927 NONE aspartate_20\NNP\0|low_21|titre_17|receptor_17 (r_nmod) antibodies_25\NNS\14728724|,_53|and_51 (r_conj) encephalopathy_9\JJ\14084880|NONE_0
D016202_D001927 NONE nmda_22\NNP\0|(_1|)_4 (r_nmod) receptor_24\NN\5225602|low_38|titre_34|aspartate_17 (r_compound) antibodies_25\NNS\14728724|,_53|and_51 (r_conj) encephalopathy_9\JJ\14084880|NONE_0
D016202_D001927 NONE nmda_9\NNP\0|associated_14 (r_nmod) encephalitis_13\NN\14336539|induced_52|and_29 (r_conj) encephalopathy_7\JJ\14084880|NONE_0
D014635_D004660 NONE valproate_4\NN\0|-_9 (r_npadvmod) induced_6\VBN\1627355|and_23|encephalitis_52 (r_amod) encephalopathy_7\JJ\14084880|NONE_0 (l_conj) encephalitis_13\NN\14336539|induced_52|and_29
17042797
D010862_D013226 CID pilocarpine_14\NN\14712692|-_11 (r_npadvmod) induced_16\VBN\1627355|epilepticus_15 (r_amod) status_17\NN\24720|NONE_0 (l_acl) epilepticus_18\NN\0|induced_15
D010862_D013226 CID pilocarpine_22\NN\14712692|-_11 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_amod) status_25\NN\24720|NONE_0 (r_nsubj) epilepticus_26\NN\0|NONE_0
D010862_D004833 CID pilocarpine_16\NN\14712692|the_4|of_18 (r_amod) model_17\NN\5888929|NONE_0 (l_prep) of_18\IN\0|the_22|pilocarpine_18 (l_pobj) epilepsy_21\NN\14085708|NONE_0
7378868
D010197_D014313 NONE pancuronium_21\NN\0|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) pretreatment_19\NN\0|NONE_0 (r_pobj) despite_18\IN\7501545|in_41 (r_prep) suxamethonium_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|that_50|rigidity_31|may_10 (r_prep) occur_10\VB\0|case_55|._104 (l_nsubj) rigidity_6\NN\5023233|that_19|may_21|after_31
D013390_D063806 CID suxamethonium_0\NN\0|-_13 (r_npadvmod) induced_2\VBN\1627355|jaw_8|and_22|myalgia_26|associated_34 (r_amod) stiffness_4\NN\5023233|:_61|case_63|._74 (l_conj) myalgia_6\NN\14322699|induced_26|jaw_18|and_4|associated_8
D013390_D063806 CID suxamethonium_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|that_50|rigidity_31|may_10 (r_prep) occur_10\VB\0|case_55|._104 (l_nsubj) rigidity_6\NN\5023233|that_19|may_21|after_31 (l_conj) myalgia_8\NN\14322699|prolonged_27|jaw_17|and_4
D013390_D014313 CID suxamethonium_0\NN\0|-_13 (r_npadvmod) induced_2\VBN\1627355|jaw_8|and_22|myalgia_26|associated_34 (r_amod) stiffness_4\NN\5023233|:_61|case_63|._74
D013390_D014313 CID suxamethonium_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|that_50|rigidity_31|may_10 (r_prep) occur_10\VB\0|case_55|._104 (l_nsubj) rigidity_6\NN\5023233|that_19|may_21|after_31
D010197_D063806 NONE pancuronium_21\NN\0|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) pretreatment_19\NN\0|NONE_0 (r_pobj) despite_18\IN\7501545|in_41 (r_prep) suxamethonium_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|that_50|rigidity_31|may_10 (r_prep) occur_10\VB\0|case_55|._104 (l_nsubj) rigidity_6\NN\5023233|that_19|may_21|after_31 (l_conj) myalgia_8\NN\14322699|prolonged_27|jaw_17|and_4
9869655
D004997_D002780 CID ethinylestradiol_6\NNP\0|that_13|is_63|with_77 (l_appos) cholestasis_10\NN\14052403|17alpha_51|-_44
D004997_D002780 CID ee)-induced_8\VBN\0|(_1|intrahepatic_12|in_37 (r_nmod) cholestasis_10\NN\14052403|17alpha_51|-_44
D001647_D002780 NONE salt_24\NN\14818238|bs_6 (r_nmod) synthesis_28\NN\13446390|NONE_0 (r_pobj) of_22\IN\0|the_20|neutral_16 (r_prep) pathway_21\NN\5483677|NONE_0 (r_pobj) of_18\IN\0|selective_21 (r_prep) inhibition_17\NN\1068773|NONE_0 (r_pobj) with_15\IN\0|that_90|ethinylestradiol_77|is_14 (r_prep) associated_14\VBN\628491|study_91|._87 (l_nsubjpass) ethinylestradiol_6\NNP\0|that_13|is_63|with_77 (l_appos) cholestasis_10\NN\14052403|17alpha_51|-_44
D001647_D002780 NONE bs_26\NN\6698252|salt_6 (r_nmod) synthesis_28\NN\13446390|NONE_0 (r_pobj) of_22\IN\0|the_20|neutral_16 (r_prep) pathway_21\NN\5483677|NONE_0 (r_pobj) of_18\IN\0|selective_21 (r_prep) inhibition_17\NN\1068773|NONE_0 (r_pobj) with_15\IN\0|that_90|ethinylestradiol_77|is_14 (r_prep) associated_14\VBN\628491|study_91|._87 (l_nsubjpass) ethinylestradiol_6\NNP\0|that_13|is_63|with_77 (l_appos) cholestasis_10\NN\14052403|17alpha_51|-_44
11366874
D019888_D001145 NONE viracept_0\NNP\4013993|heartbeat_23|._40 (r_amod) warning_4\NN\7212190|NONE_0 (l_compound) heartbeat_3\NN\7296190|viracept_23|._17
D019888_D001145 NONE viracept_11\NNP\4013993|that_28|may_9|beat_38 (r_nsubj) cause_13\VB\7323922|group_73|._71 (l_ccomp) beat_17\VBD\8616311|that_66|viracept_38|may_29
D019888_D001919 CID viracept_11\NNP\4013993|that_28|may_9|beat_38 (r_nsubj) cause_13\VB\7323922|group_73|._71 (l_ccomp) beat_17\VBD\8616311|that_66|viracept_38|may_29 (l_advcl) known_19\VBN\0|heart_12|,_2|,_20|in_22 (l_prep) as_20\IN\14622893|NONE_0 (l_pobj) bradycardia_21\NNP\14110674|NONE_0
D019888_D001919 CID viracept_11\NNP\4013993|who_8 (r_attr) was_10\VBD\0|a_31|old_21|male_17 (r_relcl) patient_8\NN\9898892|NONE_0 (r_pobj) in_2\IN\13603305|bradycardia_21|._87 (r_prep) occurred_1\VBD\0|NONE_0 (l_nsubj) bradycardia_0\NNS\14110674|in_21|._108
11423811
D003042_D002637 CID cocaine_17\NN\3492717|-_7 (r_npadvmod) associated_19\VBN\628491|chest_11 (r_amod) pain_21\NN\14299637|NONE_0
D003042_D002637 CID cocaine_9\NN\3492717|NONE_0 (r_compound) use_10\NN\407535|NONE_0 (r_pobj) of_8\IN\0|the_12 (r_prep) setting_7\NN\8567235|NONE_0 (r_pobj) in_5\IN\13603305|chest_11 (r_prep) pain_4\NN\14299637|dilemma_54
D003042_D002637 CID cocaine_13\NN\3492717|NONE_0 (r_compound) use_14\NN\407535|NONE_0 (r_pobj) of_12\IN\0|the_12 (r_prep) setting_11\NN\8567235|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) dobutamine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) administration_6\NN\1133281|NONE_0 (r_pobj) regarding_5\VBG\689344|the_24|theoretical_20 (r_prep) concern_4\NN\5682950|of_19 (r_pobj) because_0\IN\0|,_103|we_105|study_126|._227 (r_prep) conducted_17\VBD\2436349|NONE_0 (l_dobj) study_20\NN\635850|because_126|,_23|we_21|._101 (l_relcl) assess_22\VB\5220461|a_17|pilot_15 (l_dobj) safety_24\NN\13920835|to_14 (l_prep) in_27\IN\13603305|the_18|of_7 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_prep) with_31\IN\0|department_20 (l_pobj) pain_36\NN\14299637|NONE_0
D003042_D002637 CID cocaine_32\NN\3492717|-_7 (r_npadvmod) associated_34\VBN\628491|chest_11 (r_amod) pain_36\NN\14299637|NONE_0
D003042_D002637 CID cocaine_9\NN\3492717|if_17|they_14|had_9|within_8|preceding_24|and_58|had_62 (r_dobj) used_8\VBN\0|patients_43|eligible_29|._104 (l_advcl) preceding_13\VBG\0|if_41|they_38|had_33|cocaine_24|within_16|and_34|had_38 (l_dobj) onset_15\NN\7325190|NONE_0 (l_prep) of_16\IN\0|the_10 (l_pobj) pain_18\NN\14299637|NONE_0
D003042_D002637 CID cocaine_13\NN\3492717|-_7 (r_npadvmod) related_15\VBN\628491|chest_8 (r_amod) pain_17\NN\14299637|NONE_0
D004280_D002637 NONE dobutamine_8\NN\0|echocardiography_18 (r_compound) stress_9\NN\7083732|NONE_0 (l_dobj) echocardiography_10\RB\177127|dobutamine_18 (l_prep) in_11\IN\13603305|NONE_0 (l_pobj) evaluation_15\NN\874067|NONE_0 (l_prep) of_16\IN\0|the_36|department_22 (l_pobj) pain_21\NN\14299637|NONE_0
D004280_D002637 NONE dobutamine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) administration_6\NN\1133281|NONE_0 (r_pobj) regarding_5\VBG\689344|the_24|theoretical_20 (r_prep) concern_4\NN\5682950|of_19 (r_pobj) because_0\IN\0|,_103|we_105|study_126|._227 (r_prep) conducted_17\VBD\2436349|NONE_0 (l_dobj) study_20\NN\635850|because_126|,_23|we_21|._101 (l_relcl) assess_22\VB\5220461|a_17|pilot_15 (l_dobj) safety_24\NN\13920835|to_14 (l_prep) in_27\IN\13603305|the_18|of_7 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_prep) with_31\IN\0|department_20 (l_pobj) pain_36\NN\14299637|NONE_0
D004280_D002637 NONE dobutamine_7\NN\0|when_5|was_11|to_28 (r_nsubjpass) administered_9\VBN\2436349|response_42|was_33|._56 (l_prep) to_10\IN\0|when_33|dobutamine_28|was_17 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) pain_17\NN\14299637|NONE_0
D004280_D007511 NONE dobutamine_0\NNP\0|echocardiography_18 (r_nsubj) stress_1\NN\7083732|test_66|._102 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) test_12\NN\5798043|stress_66|._36 (l_prep) for_13\IN\0|a_38|available_29 (l_pcomp) evaluating_14\VBG\670261|NONE_0 (l_dobj) ischemia_16\NN\14195315|NONE_0
D003042_D064420 NONE cocaine_5\NN\3492717|continuing_11 (r_compound) toxicity_6\NN\13576101|NONE_0
17255138
D000082_D006471 NONE acetaminophen_24\RB\2707683|ns_14|-_12|and_4 (r_conj) nsaids_22\NNPS\2721538|cox-2_21|,_5 (r_conj) inhibitors_18\NNS\20090|NONE_0 (r_dobj) using_16\VBG\418025|elderly_17 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) among_13\IN\0|NONE_0 (r_prep) bleeding_12\VBG\14285662|the_44|of_34
D009288_D006471 CID naproxen_7\NN\3828465|among_28|,_2|carry_19|._61 (r_nsubj) seemed_8\VBD\2604760|NONE_0 (l_xcomp) carry_10\VB\315986|among_47|,_21|naproxen_19|._42 (l_dobj) risk_13\NN\14541044|to_21 (l_prep) for_14\IN\0|the_17|highest_13 (l_pobj) bleeding_18\NN\14285662|NONE_0
C105934_D064420 NONE celecoxib_6\NN\3124700|NONE_0 (r_pobj) of_5\IN\0|the_20|gi_12 (r_prep) toxicity_4\NN\13576101|similar_26|and_59|seemed_63|._120
D007052_D009203 NONE ibuprofen_66\NNP\3828465|1.17_22|and_4 (r_conj) diclofenac_58\NN\0|1.59_19|,_2 (r_conj) naproxen_50\NN\3828465|1.27_48|(_43|1.13_42|)_32|,_31|celecoxib_29|,_2 (r_appos) rofecoxib_34\XX\3124700|among_162|,_136|group_12|:_2|._146 (r_nsubj) were_32\VBD\0|NONE_0 (l_nsubj) group_31\NN\2137|among_150|,_124|:_10|rofecoxib_12|._158 (l_nmod) ratios_10\NNS\13815152|NONE_0 (l_appos) interval_15\NN\33615|the_43|adjusted_39|hazard_30|)_77 (l_prep) of_17\IN\0|(_26|%_23|confidence_21|)_2 (l_pobj) hospitalization_18\NN\15113229|NONE_0 (l_prep) for_19\IN\0|NONE_0 (l_pobj) gi_22\NNP\13634615|NONE_0 (l_nmod) ami_20\NNP\0|/_3|vs_7|with_29
D052246_D006471 NONE inhibitors_18\NNS\20090|NONE_0 (r_dobj) using_16\VBG\418025|elderly_17 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) among_13\IN\0|NONE_0 (r_prep) bleeding_12\VBG\14285662|the_44|of_34
D000082_D064420 NONE acetaminophen_12\RB\2707683|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) that_10\DT\0|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) similar_8\JJ\0|toxicity_26|and_33|seemed_37|._94 (r_acomp) was_7\VBD\0|NONE_0 (l_nsubj) toxicity_4\NN\13576101|similar_26|and_59|seemed_63|._120
D001241_D006471 NONE aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|non_10|-_7 (r_prep) users_3\NNS\7846|NONE_0 (r_punct) ,_6\,\0|among_26|naproxen_2|carry_21|._63 (r_punct) seemed_8\VBD\2604760|NONE_0 (l_xcomp) carry_10\VB\315986|among_47|,_21|naproxen_19|._42 (l_dobj) risk_13\NN\14541044|to_21 (l_prep) for_14\IN\0|the_17|highest_13 (l_pobj) bleeding_18\NN\14285662|NONE_0
D001241_D009203 NONE aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|non_10|-_7 (r_prep) users_3\NNS\7846|NONE_0 (r_punct) ,_6\,\0|among_26|group_124|:_134|rofecoxib_136|._282 (r_punct) were_32\VBD\0|NONE_0 (l_nsubj) group_31\NN\2137|among_150|,_124|:_10|rofecoxib_12|._158 (l_nmod) ratios_10\NNS\13815152|NONE_0 (l_appos) interval_15\NN\33615|the_43|adjusted_39|hazard_30|)_77 (l_prep) of_17\IN\0|(_26|%_23|confidence_21|)_2 (l_pobj) hospitalization_18\NN\15113229|NONE_0 (l_prep) for_19\IN\0|NONE_0 (l_pobj) gi_22\NNP\13634615|NONE_0 (l_nmod) ami_20\NNP\0|/_3|vs_7|with_29
D001241_D009203 NONE aspirin_29\NN\2707683|(_9 (r_pobj) with_27\IN\0|ami_29|/_26|vs_22 (r_parataxis) gi_22\NNP\13634615|NONE_0 (l_nmod) ami_20\NNP\0|/_3|vs_7|with_29
D001241_D009203 NONE aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|non_10|-_7 (r_prep) users_3\NNS\7846|NONE_0 (r_punct) ,_6\,\0|among_26|naproxen_2|carry_21|._63 (r_punct) seemed_8\VBD\2604760|NONE_0 (l_xcomp) carry_10\VB\315986|among_47|,_21|naproxen_19|._42 (l_dobj) risk_13\NN\14541044|to_21 (l_prep) for_14\IN\0|the_17|highest_13 (l_pobj) bleeding_18\NN\14285662|NONE_0 (l_compound) gi_17\NNP\13634615|NONE_0 (l_nmod) ami_15\NNP\0|/_3
C116926_D009203 CID rofecoxib_34\XX\3124700|among_162|,_136|group_12|:_2|._146 (r_nsubj) were_32\VBD\0|NONE_0 (l_nsubj) group_31\NN\2137|among_150|,_124|:_10|rofecoxib_12|._158 (l_nmod) ratios_10\NNS\13815152|NONE_0 (l_appos) interval_15\NN\33615|the_43|adjusted_39|hazard_30|)_77 (l_prep) of_17\IN\0|(_26|%_23|confidence_21|)_2 (l_pobj) hospitalization_18\NN\15113229|NONE_0 (l_prep) for_19\IN\0|NONE_0 (l_pobj) gi_22\NNP\13634615|NONE_0 (l_nmod) ami_20\NNP\0|/_3|vs_7|with_29
C116926_D009203 CID rofecoxib_21\NN\3124700|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) those_19\DT\0|NONE_0 (r_pobj) than_18\IN\0|NONE_0 (r_prep) better_17\JJR\5142180|to_6 (r_acomp) be_16\VB\14625458|NONE_0 (r_xcomp) seemed_14\VBD\2604760|toxicity_63|similar_37|and_4|._57 (r_conj) was_7\VBD\0|NONE_0 (l_nsubj) toxicity_4\NN\13576101|similar_26|and_59|seemed_63|._120 (l_compound) gi_3\NNP\13634615|the_8|of_12 (l_nmod) ami_1\NNP\0|/_3
D009288_D009203 CID naproxen_50\NN\3828465|1.27_48|(_43|1.13_42|)_32|,_31|celecoxib_29|,_2 (r_appos) rofecoxib_34\XX\3124700|among_162|,_136|group_12|:_2|._146 (r_nsubj) were_32\VBD\0|NONE_0 (l_nsubj) group_31\NN\2137|among_150|,_124|:_10|rofecoxib_12|._158 (l_nmod) ratios_10\NNS\13815152|NONE_0 (l_appos) interval_15\NN\33615|the_43|adjusted_39|hazard_30|)_77 (l_prep) of_17\IN\0|(_26|%_23|confidence_21|)_2 (l_pobj) hospitalization_18\NN\15113229|NONE_0 (l_prep) for_19\IN\0|NONE_0 (l_pobj) gi_22\NNP\13634615|NONE_0 (l_nmod) ami_20\NNP\0|/_3|vs_7|with_29
D009288_D009203 CID naproxen_7\NN\3828465|among_28|,_2|carry_19|._61 (r_nsubj) seemed_8\VBD\2604760|NONE_0 (l_xcomp) carry_10\VB\315986|among_47|,_21|naproxen_19|._42 (l_dobj) risk_13\NN\14541044|to_21 (l_prep) for_14\IN\0|the_17|highest_13 (l_pobj) bleeding_18\NN\14285662|NONE_0 (l_compound) gi_17\NNP\13634615|NONE_0 (l_nmod) ami_15\NNP\0|/_3
C116926_D064420 NONE rofecoxib_21\NN\3124700|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) those_19\DT\0|NONE_0 (r_pobj) than_18\IN\0|NONE_0 (r_prep) better_17\JJR\5142180|to_6 (r_acomp) be_16\VB\14625458|NONE_0 (r_xcomp) seemed_14\VBD\2604760|toxicity_63|similar_37|and_4|._57 (r_conj) was_7\VBD\0|NONE_0 (l_nsubj) toxicity_4\NN\13576101|similar_26|and_59|seemed_63|._120
C105934_D009203 NONE celecoxib_42\NN\3124700|1.27_19|(_14|1.13_13|)_3|,_2|,_27|naproxen_29 (r_conj) rofecoxib_34\XX\3124700|among_162|,_136|group_12|:_2|._146 (r_nsubj) were_32\VBD\0|NONE_0 (l_nsubj) group_31\NN\2137|among_150|,_124|:_10|rofecoxib_12|._158 (l_nmod) ratios_10\NNS\13815152|NONE_0 (l_appos) interval_15\NN\33615|the_43|adjusted_39|hazard_30|)_77 (l_prep) of_17\IN\0|(_26|%_23|confidence_21|)_2 (l_pobj) hospitalization_18\NN\15113229|NONE_0 (l_prep) for_19\IN\0|NONE_0 (l_pobj) gi_22\NNP\13634615|NONE_0 (l_nmod) ami_20\NNP\0|/_3|vs_7|with_29
C105934_D009203 NONE celecoxib_6\NN\3124700|NONE_0 (r_pobj) of_5\IN\0|the_20|gi_12 (r_prep) toxicity_4\NN\13576101|similar_26|and_59|seemed_63|._120 (l_compound) gi_3\NNP\13634615|the_8|of_12 (l_nmod) ami_1\NNP\0|/_3
D000082_D009203 NONE acetaminophen_24\RB\2707683|ns_14|-_12|and_4 (r_conj) nsaids_22\NNPS\2721538|cox-2_21|,_5 (r_conj) inhibitors_18\NNS\20090|NONE_0 (r_dobj) using_16\VBG\418025|elderly_17 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) among_13\IN\0|NONE_0 (r_prep) bleeding_12\VBG\14285662|the_44|of_34 (r_acl) risks_5\NNS\14541044|to_15 (l_prep) of_6\IN\0|the_10|bleeding_34 (l_pobj) hospitalization_7\NN\15113229|NONE_0 (l_prep) for_8\IN\0|NONE_0 (l_pobj) ami_9\NNP\0|NONE_0
D000082_D009203 NONE acetaminophen_25\NN\2707683|NONE_0 (r_pobj) vs_23\IN\13634784|ami_7|/_4|with_22 (r_prep) gi_22\NNP\13634615|NONE_0 (l_nmod) ami_20\NNP\0|/_3|vs_7|with_29
D000082_D009203 NONE acetaminophen_12\RB\2707683|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) that_10\DT\0|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) similar_8\JJ\0|toxicity_26|and_33|seemed_37|._94 (r_acomp) was_7\VBD\0|NONE_0 (l_nsubj) toxicity_4\NN\13576101|similar_26|and_59|seemed_63|._120 (l_compound) gi_3\NNP\13634615|the_8|of_12 (l_nmod) ami_1\NNP\0|/_3
D052246_D009203 CID inhibitors_11\NNS\20090|NONE_0 (r_pobj) with_9\IN\0|acute_34|myocardial_28|(_6|ami_5|)_2 (r_prep) infarction_5\NN\14204950|NONE_0
D052246_D009203 CID inhibitors_11\NNS\20090|NONE_0 (r_pobj) with_9\IN\0|acute_34|myocardial_28|(_6|ami_5|)_2 (r_prep) infarction_5\NN\14204950|NONE_0 (l_appos) ami_7\NNP\0|acute_29|myocardial_23|(_1|)_3|with_5
D052246_D009203 CID inhibitors_18\NNS\20090|NONE_0 (r_dobj) using_16\VBG\418025|elderly_17 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) among_13\IN\0|NONE_0 (r_prep) bleeding_12\VBG\14285662|the_44|of_34 (r_acl) risks_5\NNS\14541044|to_15 (l_prep) of_6\IN\0|the_10|bleeding_34 (l_pobj) hospitalization_7\NN\15113229|NONE_0 (l_prep) for_8\IN\0|NONE_0 (l_pobj) ami_9\NNP\0|NONE_0
D000894_D009203 CID drugs_34\NNS\14778436|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) compared_20\VBN\644583|risk_111|may_47|benefit_8|._79 (r_prep) offset_13\VB\15180528|NONE_0 (l_nsubj) risk_1\NN\14541044|may_64|benefit_103|compared_111|._190 (l_prep) of_2\IN\0|the_9 (l_pobj) infarction_5\NN\14204950|NONE_0
D000894_D009203 CID drugs_34\NNS\14778436|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) compared_20\VBN\644583|risk_111|may_47|benefit_8|._79 (r_prep) offset_13\VB\15180528|NONE_0 (l_nsubj) risk_1\NN\14541044|may_64|benefit_103|compared_111|._190 (l_prep) of_2\IN\0|the_9 (l_pobj) infarction_5\NN\14204950|NONE_0 (l_appos) ami_7\NNP\0|acute_29|myocardial_23|(_1|)_3|with_5
D004008_D009203 NONE diclofenac_58\NN\0|1.59_19|,_2 (r_conj) naproxen_50\NN\3828465|1.27_48|(_43|1.13_42|)_32|,_31|celecoxib_29|,_2 (r_appos) rofecoxib_34\XX\3124700|among_162|,_136|group_12|:_2|._146 (r_nsubj) were_32\VBD\0|NONE_0 (l_nsubj) group_31\NN\2137|among_150|,_124|:_10|rofecoxib_12|._158 (l_nmod) ratios_10\NNS\13815152|NONE_0 (l_appos) interval_15\NN\33615|the_43|adjusted_39|hazard_30|)_77 (l_prep) of_17\IN\0|(_26|%_23|confidence_21|)_2 (l_pobj) hospitalization_18\NN\15113229|NONE_0 (l_prep) for_19\IN\0|NONE_0 (l_pobj) gi_22\NNP\13634615|NONE_0 (l_nmod) ami_20\NNP\0|/_3|vs_7|with_29
15953230
C012052_D062787 NONE amisulpride_3\JJ\0|NONE_0 (r_amod) overdose_4\NN\84738|NONE_0
C012052_D011041 NONE amisulpride_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|3.6_6|,_14|respectively_16 (r_prep) g_12\NN\13717155|deliberate_43|self_32|-_28|with_17|and_8 (r_conj) poisoning_6\NN\14034177|NONE_0
D002125_D008133 NONE gluconate_11\VBN\0|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) administration_7\NN\1133281|NONE_0 (r_pobj) to_6\IN\0|to_11 (r_prep) respond_5\VB\2367363|prolongation_25|._51 (r_xcomp) appeared_3\VBD\2604760|NONE_0 (l_nsubj) prolongation_2\NN\1017987|respond_25|._76
C012052_D008133 CID amisulpride_3\JJ\0|NONE_0 (r_amod) overdose_4\NN\84738|NONE_0 (r_pobj) of_2\IN\0|two_10|:_23|cause_27|._58 (r_prep) cases_1\NNS\7283608|NONE_0 (l_appos) cause_7\NN\7323922|two_37|of_27|:_4|._31 (l_prep) for_8\IN\0|a_8 (l_pobj) syndrome_11\NN\5870365|NONE_0
12498738
C043211_D009202 NONE carvedilol_0\NNP\2832168|against_20|._76 (r_nsubj) protects_1\VBZ\1127795|NONE_0 (l_prep) against_2\IN\0|carvedilol_20|._56 (l_pobj) cardiomyopathy_7\NN\14103288|NONE_0
C043211_D009202 NONE carvedilol_7\NN\2832168|NONE_0 (r_pobj) by_6\IN\0|this_16 (r_prep) protection_5\NN\407535|that_10|may_90|advantage_122|in_132 (r_nsubj) afford_18\VB\2267060|it_120|is_117|._180 (l_prep) in_22\IN\13603305|that_142|protection_132|may_42|advantage_10 (l_pcomp) minimizing_23\VBG\441445|NONE_0 (l_dobj) dysfunction_29\NN\14204950|NONE_0 (l_conj) cardiomyopathy_31\NN\14103288|the_48|limiting_39|mitochondrial_30|and_4|accompanies_20
C043211_D028361 NONE carvedilol_7\NN\2832168|NONE_0 (r_pobj) by_6\IN\0|this_16 (r_prep) protection_5\NN\407535|that_10|may_90|advantage_122|in_132 (r_nsubj) afford_18\VB\2267060|it_120|is_117|._180 (l_prep) in_22\IN\13603305|that_142|protection_132|may_42|advantage_10 (l_pcomp) minimizing_23\VBG\441445|NONE_0 (l_dobj) dysfunction_29\NN\14204950|NONE_0
D004317_D028361 NONE doxorubicin_37\NN\2716866|term_5 (r_compound) therapy_38\NN\657604|that_39|in_8 (r_dobj) accompanies_33\VBZ\0|the_68|limiting_59|mitochondrial_50|and_24|cardiomyopathy_20 (r_relcl) dysfunction_29\NN\14204950|NONE_0
D004317_D064420 NONE doxorubicin_37\JJ\2716866|subchronic_11 (r_compound) toxicity_38\NN\13576101|NONE_0
D004317_D009202 CID doxorubicin_3\RB\2716866|-_11 (r_npadvmod) induced_5\VBN\1627355|mitochondrial_8 (r_amod) cardiomyopathy_7\NN\14103288|NONE_0
D004317_D009202 CID doxorubicin_18\NN\2716866|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) caused_16\VBN\1617192|the_61|limiting_52|cumulative_43 (r_acl) cardiomyopathy_15\NN\14103288|to_57
D004317_D009202 CID doxorubicin_37\NN\2716866|term_5 (r_compound) therapy_38\NN\657604|that_39|in_8 (r_dobj) accompanies_33\VBZ\0|the_68|limiting_59|mitochondrial_50|and_24|cardiomyopathy_20 (r_relcl) dysfunction_29\NN\14204950|NONE_0 (l_conj) cardiomyopathy_31\NN\14103288|the_48|limiting_39|mitochondrial_30|and_4|accompanies_20
C043211_D009369 NONE carvedilol_7\NN\2832168|NONE_0 (r_pobj) by_6\IN\0|this_16 (r_prep) protection_5\NN\407535|that_10|may_90|advantage_122|in_132 (r_nsubj) afford_18\VB\2267060|it_120|is_117|._180 (l_prep) in_22\IN\13603305|that_142|protection_132|may_42|advantage_10 (l_pcomp) minimizing_23\VBG\441445|NONE_0 (l_dobj) dysfunction_29\NN\14204950|NONE_0 (l_relcl) accompanies_33\VBZ\0|the_68|limiting_59|mitochondrial_50|and_24|cardiomyopathy_20 (l_prep) in_39\IN\13603305|that_47|therapy_8 (l_pobj) patients_41\NNS\9898892|NONE_0 (l_compound) cancer_40\NN\14239425|NONE_0
D004317_D009369 NONE doxorubicin_37\NN\2716866|term_5 (r_compound) therapy_38\NN\657604|that_39|in_8 (r_dobj) accompanies_33\VBZ\0|the_68|limiting_59|mitochondrial_50|and_24|cardiomyopathy_20 (l_prep) in_39\IN\13603305|that_47|therapy_8 (l_pobj) patients_41\NNS\9898892|NONE_0 (l_compound) cancer_40\NN\14239425|NONE_0
C043211_D064420 NONE carvedilol_11\NN\2832168|against_108 (r_nsubj) protects_25\VBZ\1127795|the_119 (l_prep) against_26\IN\0|carvedilol_108 (l_pobj) dysfunction_33\NN\14204950|NONE_0 (l_acl) associated_34\VBN\628491|the_63|cardiac_59|mitochondrial_39|bioenergetic_25 (l_prep) with_35\IN\0|NONE_0 (l_pobj) toxicity_38\NN\13576101|NONE_0
19515070
D019343_D064420 NONE citrate_6\NN\14850483|unsafe_20|regional_9|in_24 (r_compound) anticoagulation_7\NN\657604|anticoagulation_47|carries_53|._89 (r_attr) is_2\VBZ\0|NONE_0 (l_conj) carries_15\VBZ\315986|anticoagulation_100|anticoagulation_53|._36 (l_dobj) risk_17\NN\14541044|NONE_0 (l_prep) of_18\IN\0|the_9 (l_pobj) toxicity_20\NN\13576101|NONE_0
D019343_D064420 NONE citrate_19\JJ\14850483|NONE_0 (r_compound) toxicity_20\NN\13576101|NONE_0
D019343_D064420 NONE citrate_10\JJ\14850483|NONE_0 (r_compound) toxicity_11\NN\13576101|NONE_0
D000082_D017114 CID acetaminophen_11\RB\2707683|-_13 (r_advmod) induced_13\VBN\1627355|fulminant_8|liver_18|with_32 (r_amod) failure_16\NN\66216|NONE_0
D019343_D017114 NONE citrate_30\NN\14850483|NONE_0 (r_compound) dialysate_31\NN\0|NONE_0 (r_pobj) with_29\IN\0|during_23 (r_prep) anticoagulated_28\VBN\0|liver_22 (r_acl) transplantation_27\NN\671351|NONE_0 (r_pobj) during_25\IN\0|who_46|support_8 (r_prep) underwent_21\VBD\109660|associated_19 (r_relcl) aki_19\NNP\0|NONE_0 (r_pobj) with_17\IN\0|induced_32|fulminant_24|liver_14 (r_prep) failure_16\NN\66216|NONE_0
D019343_D017114 NONE citrate_0\NNP\14850483|NONE_0 (r_compound) dialysate_1\NN\0|alternative_20|._109 (r_nsubj) is_2\VBZ\0|NONE_0 (l_attr) alternative_5\NN\5788149|dialysate_20|._89 (l_prep) for_6\IN\0|a_19|safe_17 (l_pobj) support_8\NN\407535|NONE_0 (l_prep) in_12\IN\13603305|intradialytic_47|of_25 (l_pobj) failure_15\NN\66216|NONE_0
D000082_D058186 CID acetaminophen_11\RB\2707683|-_13 (r_advmod) induced_13\VBN\1627355|fulminant_8|liver_18|with_32 (r_amod) failure_16\NN\66216|NONE_0 (l_prep) with_17\IN\0|induced_32|fulminant_24|liver_14 (l_pobj) aki_19\NNP\0|NONE_0
D019343_D058186 NONE citrate_30\NN\14850483|NONE_0 (r_compound) dialysate_31\NN\0|NONE_0 (r_pobj) with_29\IN\0|during_23 (r_prep) anticoagulated_28\VBN\0|liver_22 (r_acl) transplantation_27\NN\671351|NONE_0 (r_pobj) during_25\IN\0|who_46|support_8 (r_prep) underwent_21\VBD\109660|associated_19 (r_relcl) aki_19\NNP\0|NONE_0
9889429
D009543_D005885 CID nifedipine_10\NN\2938514|cyclosporin_18|and_4 (r_conj) a_8\NN\13649268|NONE_0 (r_pobj) with_6\IN\0|combined_17 (r_prep) therapy_5\NN\657604|NONE_0 (r_pobj) during_3\IN\0|the_19|adverse_15 (r_prep) events_2\NNS\23100|increase_77|._203 (r_nsubj) included_11\VBD\0|NONE_0 (l_dobj) increase_13\NN\13576355|events_77|._126 (l_prep) in_19\IN\13603305|an_42|in_30|in_64 (l_pobj) 9_20\CD\13741022|NONE_0 (l_prep) of_21\IN\0|NONE_0 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) of_27\IN\0|the_32|13_28|and_16|development_12 (l_pobj) hyperplasia_29\NN\14365950|NONE_0
D009543_D005885 CID nifedipine_7\NN\2938514|useful_14|for_21|,_101|but_103|monitored_137 (r_nsubj) is_8\VBZ\0|findings_52|._160 (l_conj) monitored_29\VBN\2169352|nifedipine_137|useful_123|for_116|,_36|but_34 (l_prep) for_30\IN\0|that_40|patients_29|should_20|be_13 (l_pobj) hyperplasia_32\NN\14365950|NONE_0
D016572_D011565 NONE a_15\NNP\13649268|-_1 (r_npadvmod) induced_17\VBN\1627355|in_21 (r_amod) hypertension_18\NN\14057371|NONE_0 (l_prep) in_19\IN\13603305|induced_21 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) psoriasis_22\NN\14219661|NONE_0
D016572_D011565 NONE a_10\NNP\13649268|NONE_0 (r_det) therapy_11\NN\657604|cyclosporin_14 (r_pobj) of_8\IN\0|the_11 (r_prep) course_7\NN\883297|NONE_0 (r_pobj) during_5\IN\0|thirteen_46|psoriatic_37|with_18 (r_prep) patients_2\NNS\9898892|were_70|for_83|with_97|,_127|nifedipine_147|,_157|study_162|._257 (l_amod) psoriatic_1\JJ\0|thirteen_9|with_19|during_37
D016572_D011565 NONE a_21\NN\13649268|NONE_0 (r_pobj) with_19\IN\0|term_15 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) under_14\IN\0|hypertensive_32|psoriatic_19 (r_prep) patients_13\NNS\9898892|NONE_0 (l_amod) psoriatic_12\JJ\0|hypertensive_13|under_19
D016572_D006973 CID a_15\NNP\13649268|-_1 (r_npadvmod) induced_17\VBN\1627355|in_21 (r_amod) hypertension_18\NN\14057371|NONE_0
D016572_D006973 CID a_10\NNP\13649268|NONE_0 (r_det) therapy_11\NN\657604|cyclosporin_14 (r_pobj) of_8\IN\0|the_11 (r_prep) course_7\NN\883297|NONE_0 (r_pobj) during_5\IN\0|thirteen_46|psoriatic_37|with_18 (r_prep) patients_2\NNS\9898892|were_70|for_83|with_97|,_127|nifedipine_147|,_157|study_162|._257 (l_prep) with_3\IN\0|thirteen_28|psoriatic_19|during_18 (l_pobj) hypertension_4\NN\14057371|NONE_0
D016572_D006973 CID a_13\NNP\13649268|NONE_0 (r_det) therapy_14\NN\657604|NONE_0 (r_dobj) cyclosporin_12\NN\0|NONE_0 (r_pcomp) before_11\IN\0|seven_72|had_47|state_6|._28 (r_prep) exhibited_6\VBN\2632167|NONE_0 (l_dobj) state_10\NN\8491826|seven_66|had_41|before_6|._34 (l_amod) hypertensive_9\JJ\10405694|a_14|subclinical_12
D016572_D006973 CID a_21\NN\13649268|NONE_0 (r_pobj) with_19\IN\0|term_15 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) under_14\IN\0|hypertensive_32|psoriatic_19 (r_prep) patients_13\NNS\9898892|NONE_0 (l_amod) hypertensive_11\JJ\10405694|psoriatic_13|under_32
D001806_D005885 NONE nitrogen_17\NN\14622893|urea_5 (r_compound) levels_18\NNS\4916342|NONE_0 (r_pobj) in_14\IN\13603305|an_12|in_30|in_94 (r_prep) increase_13\NN\13576355|events_77|._126 (l_prep) in_19\IN\13603305|an_42|in_30|in_64 (l_pobj) 9_20\CD\13741022|NONE_0 (l_prep) of_21\IN\0|NONE_0 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) of_27\IN\0|the_32|13_28|and_16|development_12 (l_pobj) hyperplasia_29\NN\14365950|NONE_0
D002118_D011565 NONE calcium_19\NN\14625458|NONE_0 (r_compound) channel_20\NN\6251781|a_10 (r_compound) blocker_21\NN\10101634|NONE_0 (r_pobj) with_17\IN\0|patients_97|were_27|for_14|,_30|nifedipine_50|,_60|study_65|._160 (r_prep) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_2\NNS\9898892|were_70|for_83|with_97|,_127|nifedipine_147|,_157|study_162|._257 (l_amod) psoriatic_1\JJ\0|thirteen_9|with_19|during_37
D009543_D011565 NONE nifedipine_8\JJ\2938514|release_21|for_37 (r_amod) tablets_12\NNS\4233405|NONE_0 (l_prep) for_13\IN\0|nifedipine_37|release_16 (l_pobj) cyclosporin_14\NN\0|NONE_0 (l_dobj) hypertension_18\NN\14057371|NONE_0 (l_prep) in_19\IN\13603305|induced_21 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) psoriasis_22\NN\14219661|NONE_0
D009543_D011565 NONE nifedipine_26\NN\2938514|patients_147|were_77|for_64|with_50|,_20|,_10|study_15|._110 (r_dobj) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_2\NNS\9898892|were_70|for_83|with_97|,_127|nifedipine_147|,_157|study_162|._257 (l_amod) psoriatic_1\JJ\0|thirteen_9|with_19|during_37
D009543_D011565 NONE nifedipine_7\NN\2938514|useful_14|for_21|,_101|but_103|monitored_137 (r_nsubj) is_8\VBZ\0|findings_52|._160 (l_prep) for_10\IN\0|nifedipine_21|useful_7|,_80|but_82|monitored_116 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_amod) psoriatic_12\JJ\0|hypertensive_13|under_19
D009543_D006973 NONE nifedipine_8\JJ\2938514|release_21|for_37 (r_amod) tablets_12\NNS\4233405|NONE_0 (l_prep) for_13\IN\0|nifedipine_37|release_16 (l_pobj) cyclosporin_14\NN\0|NONE_0 (l_dobj) hypertension_18\NN\14057371|NONE_0
D009543_D006973 NONE nifedipine_26\NN\2938514|patients_147|were_77|for_64|with_50|,_20|,_10|study_15|._110 (r_dobj) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_2\NNS\9898892|were_70|for_83|with_97|,_127|nifedipine_147|,_157|study_162|._257 (l_prep) with_3\IN\0|thirteen_28|psoriatic_19|during_18 (l_pobj) hypertension_4\NN\14057371|NONE_0
D009543_D006973 NONE nifedipine_7\NN\2938514|useful_14|for_21|,_101|but_103|monitored_137 (r_nsubj) is_8\VBZ\0|findings_52|._160 (l_prep) for_10\IN\0|nifedipine_21|useful_7|,_80|but_82|monitored_116 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_amod) hypertensive_11\JJ\10405694|psoriatic_13|under_32
D002118_D006973 NONE calcium_19\NN\14625458|NONE_0 (r_compound) channel_20\NN\6251781|a_10 (r_compound) blocker_21\NN\10101634|NONE_0 (r_pobj) with_17\IN\0|patients_97|were_27|for_14|,_30|nifedipine_50|,_60|study_65|._160 (r_prep) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_2\NNS\9898892|were_70|for_83|with_97|,_127|nifedipine_147|,_157|study_162|._257 (l_prep) with_3\IN\0|thirteen_28|psoriatic_19|during_18 (l_pobj) hypertension_4\NN\14057371|NONE_0
D016572_D005885 CID a_8\NN\13649268|NONE_0 (r_pobj) with_6\IN\0|combined_17 (r_prep) therapy_5\NN\657604|NONE_0 (r_pobj) during_3\IN\0|the_19|adverse_15 (r_prep) events_2\NNS\23100|increase_77|._203 (r_nsubj) included_11\VBD\0|NONE_0 (l_dobj) increase_13\NN\13576355|events_77|._126 (l_prep) in_19\IN\13603305|an_42|in_30|in_64 (l_pobj) 9_20\CD\13741022|NONE_0 (l_prep) of_21\IN\0|NONE_0 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) of_27\IN\0|the_32|13_28|and_16|development_12 (l_pobj) hyperplasia_29\NN\14365950|NONE_0
D016572_D005885 CID a_21\NN\13649268|NONE_0 (r_pobj) with_19\IN\0|term_15 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) under_14\IN\0|hypertensive_32|psoriatic_19 (r_prep) patients_13\NNS\9898892|NONE_0 (r_pobj) for_10\IN\0|nifedipine_21|useful_7|,_80|but_82|monitored_116 (r_prep) is_8\VBZ\0|findings_52|._160 (l_conj) monitored_29\VBN\2169352|nifedipine_137|useful_123|for_116|,_36|but_34 (l_prep) for_30\IN\0|that_40|patients_29|should_20|be_13 (l_pobj) hyperplasia_32\NN\14365950|NONE_0
17554526
D003042_D001925 CID cocaine_6\NN\3492717|regular_21 (r_compound) users_7\NNS\7846|NONE_0 (r_pobj) in_3\IN\13603305|impaired_26|fear_17|._37 (r_prep) recognition_2\NN\13932421|NONE_0
D003042_D001925 CID cocaine_21\NN\3492717|NONE_0 (r_pobj) of_20\IN\0|the_21|subacute_17 (r_prep) effects_19\NNS\13245626|NONE_0 (r_pobj) by_16\IN\0|deficit_84|can_20|not_17|be_13|,_46|were_118|._141 (r_agent) explained_15\VBN\831651|NONE_0 (l_nsubjpass) deficit_2\NN\5113133|can_64|not_67|be_71|by_84|,_130|were_202|._225 (l_prep) in_3\IN\13603305|the_22|selective_18 (l_pobj) accuracy_6\NN\4723816|fear_17 (l_compound) recognition_5\NN\13932421|manifested_21
D018817_D001925 NONE ecstasy_24\NN\13985818|,_5|or_3 (r_conj) cocaine_21\NN\3492717|NONE_0 (r_pobj) of_20\IN\0|the_21|subacute_17 (r_prep) effects_19\NNS\13245626|NONE_0 (r_pobj) by_16\IN\0|deficit_84|can_20|not_17|be_13|,_46|were_118|._141 (r_agent) explained_15\VBN\831651|NONE_0 (l_nsubjpass) deficit_2\NN\5113133|can_64|not_67|be_71|by_84|,_130|were_202|._225 (l_prep) in_3\IN\13603305|the_22|selective_18 (l_pobj) accuracy_6\NN\4723816|fear_17 (l_compound) recognition_5\NN\13932421|manifested_21
920167
D014859_-1 NONE warfarin_3\RB\2718259|-_8 (r_npadvmod) induced_5\VBN\1627355|with_20 (r_amod) embryopathy_6\JJ\0|baby_29|._84 (l_prep) with_7\IN\0|induced_20 (l_pobj) hypoplasia_9\NN\14365950|NONE_0
D014859_-1 NONE warfarin_19\NN\2718259|NONE_0 (r_pobj) with_18\IN\0|during_14 (r_prep) treated_17\VBN\2376958|NONE_0 (r_acl) mothers_16\NNS\10399491|NONE_0 (r_pobj) to_15\IN\0|NONE_0 (r_prep) born_14\VBN\0|11_11 (r_acl) infants_13\NNS\9918248|NONE_0 (r_pobj) in_11\IN\13603305|hypoplasia_68|has_22|now_18|been_14|,_78|and_80|is_105 (r_prep) reported_10\VBN\831651|NONE_0 (l_nsubjpass) hypoplasia_1\NN\14365950|has_46|now_50|been_54|in_68|,_146|and_148|is_173
D014859_D005315 NONE warfarin_3\RB\2718259|-_8 (r_npadvmod) induced_5\VBN\1627355|with_20 (r_amod) embryopathy_6\JJ\0|baby_29|._84
D014859_D002806 CID warfarin_3\RB\2718259|-_8 (r_npadvmod) induced_5\VBN\1627355|with_20 (r_amod) embryopathy_6\JJ\0|baby_29|._84 (l_prep) with_7\IN\0|induced_20 (l_pobj) hypoplasia_9\NN\14365950|NONE_0 (l_conj) epiphyses_12\NNS\5275651|nasal_30|and_13
D014859_D002806 CID warfarin_3\RB\2718259|-_8 (r_npadvmod) induced_5\VBN\1627355|with_20 (r_amod) embryopathy_6\JJ\0|baby_29|._84 (l_prep) with_7\IN\0|induced_20 (l_pobj) hypoplasia_9\NN\14365950|NONE_0 (l_conj) epiphyses_12\NNS\5275651|nasal_30|and_13 (l_appos) punctata_15\NN\0|stippled_37|(_18|)_8
D014859_D002806 CID warfarin_19\NN\2718259|NONE_0 (r_pobj) with_18\IN\0|during_14 (r_prep) treated_17\VBN\2376958|NONE_0 (r_acl) mothers_16\NNS\10399491|NONE_0 (r_pobj) to_15\IN\0|NONE_0 (r_prep) born_14\VBN\0|11_11 (r_acl) infants_13\NNS\9918248|NONE_0 (r_pobj) in_11\IN\13603305|hypoplasia_68|has_22|now_18|been_14|,_78|and_80|is_105 (r_prep) reported_10\VBN\831651|NONE_0 (l_nsubjpass) hypoplasia_1\NN\14365950|has_46|now_50|been_54|in_68|,_146|and_148|is_173 (l_prep) with_2\IN\0|nasal_17 (l_conj) without_4\IN\0|or_3 (l_pobj) epiphyses_6\NNS\5275651|NONE_0
25054547
C049430_C537417 CID mivacurium_16\NN\0|or_3 (r_conj) suxamethonium_14\NN\0|muscle_18|(_1|)_27 (r_appos) relaxants_12\NNS\3247620|NONE_0 (r_pobj) of_10\IN\0|the_8|in_50 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) after_7\IN\0|deficiency_47|is_36|by_19|._111 (r_prep) characterized_3\VBN\609683|NONE_0 (l_nsubjpass) deficiency_1\NN\14449126|is_11|by_28|after_47|._158
D013390_C537417 CID suxamethonium_14\NN\0|muscle_18|(_1|)_27 (r_appos) relaxants_12\NNS\3247620|NONE_0 (r_pobj) of_10\IN\0|the_8|in_50 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) after_7\IN\0|deficiency_47|is_36|by_19|._111 (r_prep) characterized_3\VBN\609683|NONE_0 (l_nsubjpass) deficiency_1\NN\14449126|is_11|by_28|after_47|._158
D013390_D001049 CID suxamethonium_25\NN\0|NONE_0 (r_pobj) with_24\IN\0|prolonged_16 (r_prep) apnea_23\NN\14299637|of_26|and_14
D013390_D001049 CID suxamethonium_14\NN\0|muscle_18|(_1|)_27 (r_appos) relaxants_12\NNS\3247620|NONE_0 (r_pobj) of_10\IN\0|the_8|in_50 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) after_7\IN\0|deficiency_47|is_36|by_19|._111 (r_prep) characterized_3\VBN\609683|NONE_0 (l_agent) by_4\IN\0|deficiency_28|is_17|after_19|._130 (l_pobj) apnea_6\NN\14299637|NONE_0
C049430_D001049 CID mivacurium_16\NN\0|or_3 (r_conj) suxamethonium_14\NN\0|muscle_18|(_1|)_27 (r_appos) relaxants_12\NNS\3247620|NONE_0 (r_pobj) of_10\IN\0|the_8|in_50 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) after_7\IN\0|deficiency_47|is_36|by_19|._111 (r_prep) characterized_3\VBN\609683|NONE_0 (l_agent) by_4\IN\0|deficiency_28|is_17|after_19|._130 (l_pobj) apnea_6\NN\14299637|NONE_0
10677406
D004280_D017202 NONE dobutamine_13\NN\0|NONE_0 (r_pobj) after_11\IN\0|ischaemia_54 (r_mark) induced_16\VBN\1627355|dysfunction_95|in_76|._28 (l_dobj) ischaemia_18\NN\14195315|after_54
D004280_D003324 NONE dobutamine_13\NN\0|NONE_0 (r_pobj) after_11\IN\0|ischaemia_54 (r_mark) induced_16\VBN\1627355|dysfunction_95|in_76|._28 (r_advcl) occurs_4\VBZ\0|NONE_0 (l_prep) in_5\IN\13603305|dysfunction_19|induced_76|._104 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disease_10\NN\14061805|NONE_0
D004280_D003324 NONE dobutamine_7\NN\0|in_42|,_2|results_29|in_37|,_89|presumed_91|._162 (r_nsubj) induced_8\VBN\1627355|NONE_0 (l_prep) in_0\IN\13603305|,_40|dobutamine_42|results_71|in_79|,_131|presumed_133|._204 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) disease_5\NN\14061805|NONE_0
D004280_D003324 NONE dobutamine_0\NNP\0|ischaemia_19 (r_nsubj) induced_1\VBD\1627355|could_18|therefore_24|be_34|study_45|._138 (r_csubjpass) used_6\VBN\0|NONE_0 (l_xcomp) study_8\VB\635850|induced_45|could_27|therefore_21|be_11|._93 (l_prep) in_15\IN\13603305|to_56|pathophysiology_43|further_8 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) disease_20\NN\14061805|NONE_0
D004280_D007511 NONE dobutamine_17\NN\0|and_4 (r_conj) exercise_15\NN\621627|NONE_0 (r_pobj) after_14\IN\0|a_98|randomised_96|crossover_85|of_69 (r_prep) study_3\NN\635850|ischaemia_113|._122 (r_nsubj) induced_18\VBN\1627355|NONE_0 (l_dobj) ischaemia_19\NN\14195315|study_113|._9
D004280_D007511 NONE dobutamine_7\NN\0|in_42|,_2|results_29|in_37|,_89|presumed_91|._162 (r_nsubj) induced_8\VBN\1627355|NONE_0 (l_dobj) results_10\NNS\34213|in_71|,_31|dobutamine_29|in_8|,_60|presumed_62|._133 (l_compound) ischaemia_9\NN\14195315|NONE_0
D004280_D007511 NONE dobutamine_0\NNP\0|ischaemia_19 (r_nsubj) induced_1\VBD\1627355|could_18|therefore_24|be_34|study_45|._138 (l_dobj) ischaemia_2\NN\14195315|dobutamine_19
D004280_D018487 CID dobutamine_13\NN\0|NONE_0 (r_pobj) after_11\IN\0|ischaemia_54 (r_mark) induced_16\VBN\1627355|dysfunction_95|in_76|._28 (r_advcl) occurs_4\VBZ\0|NONE_0 (l_nsubj) dysfunction_3\NN\14204950|in_19|induced_95|._123
D004280_D018487 CID dobutamine_7\NN\0|in_42|,_2|results_29|in_37|,_89|presumed_91|._162 (r_nsubj) induced_8\VBN\1627355|NONE_0 (l_prep) in_11\IN\13603305|in_79|,_39|dobutamine_37|results_8|,_52|presumed_54|._125 (l_pobj) dysfunction_16\NN\14204950|NONE_0
D004280_D017682 CID dobutamine_7\NN\0|in_42|,_2|results_29|in_37|,_89|presumed_91|._162 (r_nsubj) induced_8\VBN\1627355|NONE_0 (l_conj) presumed_18\VBN\719734|in_133|,_93|dobutamine_91|results_62|in_54|,_2|._71 (l_xcomp) be_20\VB\14625458|NONE_0 (l_acomp) similar_24\JJ\0|to_27 (l_amod) stunning_22\JJ\269140|myocardial_11|to_18
1361574
D007538_D012640 CID isoniazid_22\NN\2716205|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) induced_20\VBN\1627355|the_16 (r_acl) convulsions_19\NNS\14081375|moreover_103|,_95|mg/kg_88|markedly_51|increase_38|and_8|._49
D002243_D012640 NONE carboline_8\NN\0|NONE_0 (r_pobj) of_4\IN\0|0.05_11 (r_prep) mg/kg_3\NNS\0|moreover_15|,_7|markedly_37|increase_50|and_80|convulsions_88|._137 (r_nsubj) reduced_9\VBD\441445|NONE_0 (l_conj) convulsions_19\NNS\14081375|moreover_103|,_95|mg/kg_88|markedly_51|increase_38|and_8|._49
C037476_D012640 NONE 35s]tbps_15\NNP\0|[_1 (r_nummod) binding_16\NN\4688246|NONE_0 (r_pobj) of_13\IN\0|the_13 (r_prep) increase_12\NN\13576355|moreover_65|,_57|mg/kg_50|markedly_13|and_30|convulsions_38|._87 (r_dobj) reduced_9\VBD\441445|NONE_0 (l_conj) convulsions_19\NNS\14081375|moreover_103|,_95|mg/kg_88|markedly_51|increase_38|and_8|._49
6687006
D000661_D020258 NONE amphetamine_3\NN\3248958|NONE_0 (r_compound) hyperactivity_4\NN\14052403|NONE_0 (r_pobj) of_2\IN\0|the_14|induced_29 (r_prep) reduction_1\NN\351485|was_55|by_67|._186 (r_nsubjpass) blocked_9\VBN\1476483|NONE_0 (l_agent) by_10\IN\0|reduction_67|was_12|._119 (l_pobj) pretreatment_11\NN\0|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) agent_18\NN\7347|NONE_0 (l_relcl) prevents_23\VBZ\0|the_60|uptake_42|blocking_35|,_21|desipramine_19|,_8 (l_dobj) action_26\NN\30358|which_30 (l_amod) neurotoxic_25\JJ\0|the_4|of_18
D003913_D006948 CID amphetamine_6\NN\3248958|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|the_18|)_37 (r_acl) hyperactivity_1\NN\14052403|was_53|significantly_57|by_79|._99
C012102_D019956 NONE dsp4_17\NNP\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) pretreatment_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|however_90|,_83|rearings_67|were_17|not_12|._25 (r_agent) blocked_13\VBN\1476483|NONE_0 (l_nsubjpass) rearings_4\NNS\4921754|however_23|,_16|were_50|not_55|by_67|._92 (l_conj) stereotypies_10\NNS\0|the_51|increased_47|and_28
D009638_D020258 NONE noradrenaline_14\NN\14807929|-_13 (r_amod) uptake_16\NN\13440063|the_18|blocking_7|,_21|desipramine_23|,_34|prevents_42 (r_compound) agent_18\NN\7347|NONE_0 (l_relcl) prevents_23\VBZ\0|the_60|uptake_42|blocking_35|,_21|desipramine_19|,_8 (l_dobj) action_26\NN\30358|which_30 (l_amod) neurotoxic_25\JJ\0|the_4|of_18
D000661_D006948 NONE amphetamine_3\NN\3248958|NONE_0 (r_compound) hyperactivity_4\NN\14052403|NONE_0
C012102_D020258 NONE dsp4_7\NNP\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|the_43|of_29 (r_acl) reduction_1\NN\351485|was_55|by_67|._186 (r_nsubjpass) blocked_9\VBN\1476483|NONE_0 (l_agent) by_10\IN\0|reduction_67|was_12|._119 (l_pobj) pretreatment_11\NN\0|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) agent_18\NN\7347|NONE_0 (l_relcl) prevents_23\VBZ\0|the_60|uptake_42|blocking_35|,_21|desipramine_19|,_8 (l_dobj) action_26\NN\30358|which_30 (l_amod) neurotoxic_25\JJ\0|the_4|of_18
C012102_D020258 NONE dsp4_28\NNP\0|NONE_0 (r_pobj) of_27\IN\0|the_22|neurotoxic_18 (r_prep) action_26\NN\30358|which_30 (l_amod) neurotoxic_25\JJ\0|the_4|of_18
D003891_D006948 NONE desipramine_20\NN\4482543|the_41|uptake_23|blocking_16|,_2|,_11|prevents_19 (r_appos) agent_18\NN\7347|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) pretreatment_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|reduction_67|was_12|._119 (r_agent) blocked_9\VBN\1476483|NONE_0 (l_nsubjpass) reduction_1\NN\351485|was_55|by_67|._186 (l_prep) of_2\IN\0|the_14|induced_29 (l_pobj) hyperactivity_4\NN\14052403|NONE_0
D003891_D020258 NONE desipramine_20\NN\4482543|the_41|uptake_23|blocking_16|,_2|,_11|prevents_19 (r_appos) agent_18\NN\7347|NONE_0 (l_relcl) prevents_23\VBZ\0|the_60|uptake_42|blocking_35|,_21|desipramine_19|,_8 (l_dobj) action_26\NN\30358|which_30 (l_amod) neurotoxic_25\JJ\0|the_4|of_18
C012102_D006948 NONE dsp4_17\NNP\0|NONE_0 (r_compound) pretreatment_18\NN\0|NONE_0 (r_pobj) by_16\IN\0|hyperactivity_79|was_26|significantly_22|._20 (r_agent) reduced_15\VBN\441445|NONE_0 (l_nsubjpass) hyperactivity_1\NN\14052403|was_53|significantly_57|by_79|._99
C012102_D006948 NONE dsp4_7\NNP\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|the_43|of_29 (r_acl) reduction_1\NN\351485|was_55|by_67|._186 (l_prep) of_2\IN\0|the_14|induced_29 (l_pobj) hyperactivity_4\NN\14052403|NONE_0
C012102_D006948 NONE dsp4_28\NNP\0|NONE_0 (r_pobj) of_27\IN\0|the_22|neurotoxic_18 (r_prep) action_26\NN\30358|which_30 (r_dobj) prevents_23\VBZ\0|the_60|uptake_42|blocking_35|,_21|desipramine_19|,_8 (r_relcl) agent_18\NN\7347|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) pretreatment_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|reduction_67|was_12|._119 (r_agent) blocked_9\VBN\1476483|NONE_0 (l_nsubjpass) reduction_1\NN\351485|was_55|by_67|._186 (l_prep) of_2\IN\0|the_14|induced_29 (l_pobj) hyperactivity_4\NN\14052403|NONE_0
D009638_D006948 NONE noradrenaline_14\NN\14807929|-_13 (r_amod) uptake_16\NN\13440063|the_18|blocking_7|,_21|desipramine_23|,_34|prevents_42 (r_compound) agent_18\NN\7347|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) pretreatment_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|reduction_67|was_12|._119 (r_agent) blocked_9\VBN\1476483|NONE_0 (l_nsubjpass) reduction_1\NN\351485|was_55|by_67|._186 (l_prep) of_2\IN\0|the_14|induced_29 (l_pobj) hyperactivity_4\NN\14052403|NONE_0
D000661_D019956 NONE amphetamine_7\NN\3248958|-_11 (r_npadvmod) induced_9\VBN\1627355|the_16 (r_amod) stereotypies_10\NNS\0|the_51|increased_47|and_28
10770468
D008094_D001714 NONE lithium_8\NN\14625458|developed_20 (r_compound) therapy_9\NN\657604|NONE_0 (r_dobj) receiving_6\VBG\2210855|a_18|bipolar_16 (r_acl) patient_5\NN\9898892|NONE_0 (l_amod) bipolar_4\JJ\0|a_2|receiving_16
D008094_D001714 NONE lithium_8\NN\14625458|developed_20 (r_compound) therapy_9\NN\657604|NONE_0 (r_dobj) receiving_6\VBG\2210855|a_18|bipolar_16 (r_acl) patient_5\NN\9898892|NONE_0 (r_pobj) in_2\IN\13603305|recent_16 (r_prep) findings_1\NNS\7951464|authors_136|conduct_147|._234 (r_nsubj) prompted_16\VBD\1645601|NONE_0 (l_xcomp) conduct_20\VB\407535|findings_147|authors_11|._87 (l_dobj) study_23\NN\635850|to_27 (l_prep) of_24\IN\0|a_22|retrospective_20|with_20 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_amod) bipolar_25\JJ\0|NONE_0
D008094_D001714 NONE lithium_28\NN\14625458|-_7 (r_npadvmod) associated_30\VBN\628491|NONE_0 (r_amod) hypercalcemia_31\NN\14299637|NONE_0 (r_pobj) with_27\IN\0|a_42|retrospective_40|of_20 (r_prep) study_23\NN\635850|to_27 (r_dobj) conduct_20\VB\407535|findings_147|authors_11|._87 (r_xcomp) prompted_16\VBD\1645601|NONE_0 (l_nsubj) findings_1\NNS\7951464|authors_136|conduct_147|._234 (l_prep) in_2\IN\13603305|recent_16 (l_pobj) patient_5\NN\9898892|NONE_0 (l_amod) bipolar_4\JJ\0|a_2|receiving_16
D008094_D001714 NONE lithium_28\NN\14625458|-_7 (r_npadvmod) associated_30\VBN\628491|NONE_0 (r_amod) hypercalcemia_31\NN\14299637|NONE_0 (r_pobj) with_27\IN\0|a_42|retrospective_40|of_20 (r_prep) study_23\NN\635850|to_27 (l_prep) of_24\IN\0|a_22|retrospective_20|with_20 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_amod) bipolar_25\JJ\0|NONE_0
D008094_D001714 NONE lithium_18\NN\14625458|-_7 (r_npadvmod) treated_20\VBN\2376958|age-_32|comparable_19|bipolar_8|normocalcemic_16 (r_amod) patients_23\NNS\9898892|which_77 (l_amod) bipolar_21\JJ\0|age-_40|comparable_27|treated_8|normocalcemic_8
D008094_D001714 NONE lithium_18\NN\14625458|-_7 (r_npadvmod) treated_20\VBN\2376958|age-_32|comparable_19|bipolar_8|normocalcemic_16 (r_amod) patients_23\NNS\9898892|which_77 (r_dobj) included_12\VBD\0|:_18|group_16|,_8|,_79|and_81|c2_91 (r_relcl) c1_9\NN\0|thus_47|,_43|groups_29|were_22|._195 (l_conj) c2_27\NNP\0|:_109|group_107|,_99|included_91|,_12|and_10 (l_relcl) included_30\VBD\0|group_16|,_8 (l_dobj) patients_33\NNS\9898892|which_37 (l_amod) bipolar_31\JJ\0|normocalcemic_8|treated_31
D008094_D001714 NONE lithium_11\NN\14625458|-_7 (r_npadvmod) associated_13\VBN\628491|NONE_0 (r_amod) hypercalcemia_14\NN\14299637|NONE_0 (r_pobj) with_10\IN\0|medical_38|and_21|patients_9 (r_prep) diseases_6\NNS\14061805|NONE_0 (l_conj) patients_9\NNS\9898892|medical_29|and_12|with_9 (l_amod) bipolar_8\JJ\0|NONE_0
D008094_D006934 CID lithium_8\NN\14625458|developed_20 (r_compound) therapy_9\NN\657604|NONE_0 (l_relcl) developed_11\VBD\1753788|lithium_20 (l_dobj) hypercalcemia_12\NN\14299637|who_14
D008094_D006934 CID lithium_8\NN\14625458|developed_20 (r_compound) therapy_9\NN\657604|NONE_0 (r_dobj) receiving_6\VBG\2210855|a_18|bipolar_16 (r_acl) patient_5\NN\9898892|NONE_0 (r_pobj) in_2\IN\13603305|recent_16 (r_prep) findings_1\NNS\7951464|authors_136|conduct_147|._234 (r_nsubj) prompted_16\VBD\1645601|NONE_0 (l_xcomp) conduct_20\VB\407535|findings_147|authors_11|._87 (l_dobj) study_23\NN\635850|to_27 (l_prep) with_27\IN\0|a_42|retrospective_40|of_20 (l_pobj) hypercalcemia_31\NN\14299637|NONE_0
D008094_D006934 CID lithium_28\NN\14625458|-_7 (r_npadvmod) associated_30\VBN\628491|NONE_0 (r_amod) hypercalcemia_31\NN\14299637|NONE_0 (r_pobj) with_27\IN\0|a_42|retrospective_40|of_20 (r_prep) study_23\NN\635850|to_27 (r_dobj) conduct_20\VB\407535|findings_147|authors_11|._87 (r_xcomp) prompted_16\VBD\1645601|NONE_0 (l_nsubj) findings_1\NNS\7951464|authors_136|conduct_147|._234 (l_prep) in_2\IN\13603305|recent_16 (l_pobj) patient_5\NN\9898892|NONE_0 (l_acl) receiving_6\VBG\2210855|a_18|bipolar_16 (l_dobj) therapy_9\NN\657604|NONE_0 (l_relcl) developed_11\VBD\1753788|lithium_20 (l_dobj) hypercalcemia_12\NN\14299637|who_14
D008094_D006934 CID lithium_28\NN\14625458|-_7 (r_npadvmod) associated_30\VBN\628491|NONE_0 (r_amod) hypercalcemia_31\NN\14299637|NONE_0
D008094_D006934 CID lithium_17\NN\14625458|-_7 (r_npadvmod) treated_19\VBN\2376958|18_15|with_17|and_100|patients_107 (r_amod) patients_20\NNS\9898892|after_133|,_48|authors_42|._155 (r_dobj) identified_13\VBD\699815|NONE_0 (l_prep) after_0\IN\0|,_85|authors_91|patients_133|._288 (l_pcomp) eliminating_1\VBG\1619929|NONE_0 (l_dobj) hypercalcemias_3\NNS\14299637|NONE_0
D008094_D006934 CID lithium_17\NN\14625458|-_7 (r_npadvmod) treated_19\VBN\2376958|18_15|with_17|and_100|patients_107 (r_amod) patients_20\NNS\9898892|after_133|,_48|authors_42|._155 (l_prep) with_21\IN\0|18_32|treated_17|and_83|patients_90 (l_pobj) hypercalcemias_22\NNS\14299637|NONE_0
D008094_D006934 CID lithium_17\NN\14625458|-_7 (r_npadvmod) treated_19\VBN\2376958|18_15|with_17|and_100|patients_107 (r_amod) patients_20\NNS\9898892|after_133|,_48|authors_42|._155 (l_conj) patients_36\NNS\9898892|18_122|treated_107|with_90|and_7 (l_prep) with_37\IN\0|12_12 (l_pobj) hypercalcemia_41\NN\14299637|NONE_0
D008094_D006934 CID lithium_38\NN\14625458|-_7 (r_npadvmod) associated_40\VBN\628491|(_25|b_32|)_33 (r_amod) hypercalcemia_41\NN\14299637|NONE_0 (r_pobj) with_37\IN\0|12_12 (r_prep) patients_36\NNS\9898892|18_122|treated_107|with_90|and_7 (r_conj) patients_20\NNS\9898892|after_133|,_48|authors_42|._155 (r_dobj) identified_13\VBD\699815|NONE_0 (l_prep) after_0\IN\0|,_85|authors_91|patients_133|._288 (l_pcomp) eliminating_1\VBG\1619929|NONE_0 (l_dobj) hypercalcemias_3\NNS\14299637|NONE_0
D008094_D006934 CID lithium_38\NN\14625458|-_7 (r_npadvmod) associated_40\VBN\628491|(_25|b_32|)_33 (r_amod) hypercalcemia_41\NN\14299637|NONE_0 (r_pobj) with_37\IN\0|12_12 (r_prep) patients_36\NNS\9898892|18_122|treated_107|with_90|and_7 (r_conj) patients_20\NNS\9898892|after_133|,_48|authors_42|._155 (l_prep) with_21\IN\0|18_32|treated_17|and_83|patients_90 (l_pobj) hypercalcemias_22\NNS\14299637|NONE_0
D008094_D006934 CID lithium_38\NN\14625458|-_7 (r_npadvmod) associated_40\VBN\628491|(_25|b_32|)_33 (r_amod) hypercalcemia_41\NN\14299637|NONE_0
D008094_D006934 CID lithium_11\NN\14625458|-_7 (r_npadvmod) associated_13\VBN\628491|NONE_0 (r_amod) hypercalcemia_14\NN\14299637|NONE_0 (r_pobj) with_10\IN\0|medical_38|and_21|patients_9 (r_prep) diseases_6\NNS\14061805|NONE_0 (r_pobj) from_4\IN\0|NONE_0 (r_prep) resulting_3\VBG\2633881|NONE_0 (r_acl) hypercalcemia_2\NN\14299637|NONE_0
D008094_D006934 CID lithium_11\NN\14625458|-_7 (r_npadvmod) associated_13\VBN\628491|NONE_0 (r_amod) hypercalcemia_14\NN\14299637|NONE_0
D008094_D001919 NONE lithium_8\NN\14625458|developed_20 (r_compound) therapy_9\NN\657604|NONE_0 (l_relcl) developed_11\VBD\1753788|lithium_20 (l_dobj) hypercalcemia_12\NN\14299637|who_14 (l_conj) bradyarrhythmia_15\NN\0|and_11
D008094_D001919 NONE lithium_28\NN\14625458|-_7 (r_npadvmod) associated_30\VBN\628491|NONE_0 (r_amod) hypercalcemia_31\NN\14299637|NONE_0 (r_pobj) with_27\IN\0|a_42|retrospective_40|of_20 (r_prep) study_23\NN\635850|to_27 (r_dobj) conduct_20\VB\407535|findings_147|authors_11|._87 (r_xcomp) prompted_16\VBD\1645601|NONE_0 (l_nsubj) findings_1\NNS\7951464|authors_136|conduct_147|._234 (l_prep) in_2\IN\13603305|recent_16 (l_pobj) patient_5\NN\9898892|NONE_0 (l_acl) receiving_6\VBG\2210855|a_18|bipolar_16 (l_dobj) therapy_9\NN\657604|NONE_0 (l_relcl) developed_11\VBD\1753788|lithium_20 (l_dobj) hypercalcemia_12\NN\14299637|who_14 (l_conj) bradyarrhythmia_15\NN\0|and_11
D008094_D009369 NONE lithium_17\NN\14625458|-_7 (r_npadvmod) treated_19\VBN\2376958|18_15|with_17|and_100|patients_107 (r_amod) patients_20\NNS\9898892|after_133|,_48|authors_42|._155 (l_prep) with_21\IN\0|18_32|treated_17|and_83|patients_90 (l_pobj) hypercalcemias_22\NNS\14299637|NONE_0 (l_acl) related_23\VBN\628491|NONE_0 (l_prep) to_24\IN\0|NONE_0 (l_pobj) malignancies_25\NNS\14070360|NONE_0
D008094_D009369 NONE lithium_38\NN\14625458|-_7 (r_npadvmod) associated_40\VBN\628491|(_25|b_32|)_33 (r_amod) hypercalcemia_41\NN\14299637|NONE_0 (r_pobj) with_37\IN\0|12_12 (r_prep) patients_36\NNS\9898892|18_122|treated_107|with_90|and_7 (r_conj) patients_20\NNS\9898892|after_133|,_48|authors_42|._155 (l_prep) with_21\IN\0|18_32|treated_17|and_83|patients_90 (l_pobj) hypercalcemias_22\NNS\14299637|NONE_0 (l_acl) related_23\VBN\628491|NONE_0 (l_prep) to_24\IN\0|NONE_0 (l_pobj) malignancies_25\NNS\14070360|NONE_0
18025637
D005473_D012170 CID fluoxetine_5\NN\4169152|branch_34|vein_19|and_4|._10 (r_conj) occlusion_3\NN\14081375|NONE_0
D005473_D012170 CID fluoxetine_9\NN\4169152|-_10 (r_advmod) induced_11\VBN\1627355|secondary_8 (r_amod) hypertension_13\NN\14057371|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) associated_7\VBN\628491|branch_30|vein_15 (r_acl) occlusion_6\NN\14081375|NONE_0
D005473_D006973 CID fluoxetine_9\NN\4169152|-_10 (r_advmod) induced_11\VBN\1627355|secondary_8 (r_amod) hypertension_13\NN\14057371|NONE_0
D012701_D006973 NONE serotonin_6\NN\14807737|selective_10|reuptake_10|inhibitor_19 (r_compound) therapy_9\NN\657604|NONE_0 (r_pobj) of_4\IN\0|an_27|infrequent_24 (r_prep) complication_3\NN\1073995|NONE_0 (r_pobj) although_0\IN\0|,_85|it_87|important_93|are_125|._224 (r_prep) is_12\VBZ\0|NONE_0 (l_ccomp) are_16\VBP\13600404|although_125|,_40|it_38|important_32|._99 (l_acomp) aware_17\JJ\0|that_26|ophthalmologists_21 (l_ccomp) cause_22\VB\7323922|NONE_0 (l_dobj) hypertension_23\NN\14057371|that_28|agents_17|can_10|prescribed_51
16309808
D004298_D012148 NONE dopamine_14\NN\14807737|levodopa_13 (r_compound) agonists_15\NNS\0|NONE_0 (r_pobj) by_11\IN\0|for_62|,_51|symptoms_45|can_29|be_25|dramatically_22|,_33|induce_88|._120 (r_agent) improved_10\VBN\126264|NONE_0 (l_nsubjpass) symptoms_4\NNS\5823932|for_17|,_6|can_16|be_20|dramatically_23|by_45|,_78|induce_133|._165 (l_prep) of_5\IN\0|the_13 (l_pobj) rls_6\NNP\0|NONE_0
D004298_D012148 NONE dopamine_14\NN\14807737|levodopa_13 (r_compound) agonists_15\NNS\0|NONE_0 (r_pobj) by_11\IN\0|for_62|,_51|symptoms_45|can_29|be_25|dramatically_22|,_33|induce_88|._120 (r_agent) improved_10\VBN\126264|NONE_0 (l_advcl) induce_24\VB\1627355|for_150|,_139|symptoms_133|can_117|be_113|dramatically_110|by_88|,_55|._32 (l_conj) aggravate_26\VB\126264|whereas_63|antagonists_26|can_14|or_3 (l_dobj) symptoms_28\NNS\5823932|NONE_0 (l_compound) rls_27\NNP\0|NONE_0
D004298_D012148 NONE dopamine_19\NN\14807737|receptor_12 (r_compound) antagonists_22\NNS\7846|whereas_37|can_12|or_23|aggravate_26 (r_nsubj) induce_24\VB\1627355|for_150|,_139|symptoms_133|can_117|be_113|dramatically_110|by_88|,_55|._32 (r_advcl) improved_10\VBN\126264|NONE_0 (l_nsubjpass) symptoms_4\NNS\5823932|for_17|,_6|can_16|be_20|dramatically_23|by_45|,_78|induce_133|._165 (l_prep) of_5\IN\0|the_13 (l_pobj) rls_6\NNP\0|NONE_0
D004298_D012148 NONE dopamine_19\NN\14807737|receptor_12 (r_compound) antagonists_22\NNS\7846|whereas_37|can_12|or_23|aggravate_26 (r_nsubj) induce_24\VB\1627355|for_150|,_139|symptoms_133|can_117|be_113|dramatically_110|by_88|,_55|._32 (l_conj) aggravate_26\VB\126264|whereas_63|antagonists_26|can_14|or_3 (l_dobj) symptoms_28\NNS\5823932|NONE_0 (l_compound) rls_27\NNP\0|NONE_0
D004298_D012148 NONE dopamine_15\NN\14807737|a_13|d2_9|receptor_12 (r_compound) antagonist_18\NN\7846|,_36 (r_appos) domperidone_11\NN\0|whether_8|,_57|can_59|also_63|or_75|aggravate_78 (r_nsubj) induce_22\VB\1627355|NONE_0 (l_conj) aggravate_24\VBP\126264|whether_86|domperidone_78|,_21|can_19|also_15|or_3 (l_dobj) symptoms_25\NNS\5823932|NONE_0 (l_prep) of_26\IN\0|NONE_0 (l_pobj) rls_27\NNP\0|NONE_0
D004298_D012148 NONE dopamine_24\NN\14807737|concomitant_12|receptor_12 (r_compound) antagonists_27\NNS\7846|NONE_0 (r_dobj) receiving_22\VBG\2210855|especially_17 (r_acl) those_21\DT\0|the_92|associated_52|,_13 (r_appos) possibility_8\NN\5944958|NONE_0 (l_acl) associated_13\VBN\628491|the_40|,_39|those_52 (l_prep) with_14\IN\0|that_35|mirtazapine_30|can_18|be_14|in_9 (l_pobj) rls_15\NNP\0|NONE_0
D007980_D012148 NONE levodopa_12\NN\14604959|dopamine_13 (r_nmod) agonists_15\NNS\0|NONE_0 (r_pobj) by_11\IN\0|for_62|,_51|symptoms_45|can_29|be_25|dramatically_22|,_33|induce_88|._120 (r_agent) improved_10\VBN\126264|NONE_0 (l_nsubjpass) symptoms_4\NNS\5823932|for_17|,_6|can_16|be_20|dramatically_23|by_45|,_78|induce_133|._165 (l_prep) of_5\IN\0|the_13 (l_pobj) rls_6\NNP\0|NONE_0
D007980_D012148 NONE levodopa_12\NN\14604959|dopamine_13 (r_nmod) agonists_15\NNS\0|NONE_0 (r_pobj) by_11\IN\0|for_62|,_51|symptoms_45|can_29|be_25|dramatically_22|,_33|induce_88|._120 (r_agent) improved_10\VBN\126264|NONE_0 (l_advcl) induce_24\VB\1627355|for_150|,_139|symptoms_133|can_117|be_113|dramatically_110|by_88|,_55|._32 (l_conj) aggravate_26\VB\126264|whereas_63|antagonists_26|can_14|or_3 (l_dobj) symptoms_28\NNS\5823932|NONE_0 (l_compound) rls_27\NNP\0|NONE_0
D004294_D012148 NONE domperidone_1\NN\0|does_5|syndrome_60|?_68 (r_nsubj) potentiate_2\VB\229605|NONE_0 (l_dobj) syndrome_8\NN\5870365|does_65|domperidone_60|?_8
D004294_D012148 NONE domperidone_11\NN\0|whether_8|,_57|can_59|also_63|or_75|aggravate_78 (r_nsubj) induce_22\VB\1627355|NONE_0 (l_conj) aggravate_24\VBP\126264|whether_86|domperidone_78|,_21|can_19|also_15|or_3 (l_dobj) symptoms_25\NNS\5823932|NONE_0 (l_prep) of_26\IN\0|NONE_0 (l_pobj) rls_27\NNP\0|NONE_0
D004294_D012148 NONE domperidone_21\NN\0|his_4 (r_compound) therapy_22\NN\657604|NONE_0 (r_pobj) to_19\IN\0|had_15|been_11 (r_prep) added_18\VBN\156601|authors_122|here_107|comorbid_82|._32 (r_ccomp) report_2\VBP\6470073|NONE_0 (l_dobj) comorbid_7\JJ\0|authors_40|here_25|added_82|._114 (l_prep) with_8\IN\0|a_29|depressed_27|patient_17 (l_pobj) dyspepsia_10\NN\14299637|NONE_0 (l_relcl) developed_12\VBD\1753788|postprandial_27 (l_dobj) rls_13\NNP\0|who_14|after_4
D004294_D012148 NONE domperione_24\NN\0|NONE_0 (r_pobj) of_23\IN\0|a_22|potentiating_20 (r_prep) effect_22\NN\34213|relationship_114|did_31|not_27|._50 (r_dobj) support_19\VB\407535|NONE_0 (l_nsubj) relationship_3\NN\31921|did_83|not_87|effect_114|._164 (l_prep) between_4\IN\0|such_29|a_24|temporal_22 (l_pobj) use_6\NN\407535|NONE_0 (l_conj) symptoms_11\NNS\5823932|the_31|of_23|and_8 (l_prep) of_12\IN\0|the_13|in_7 (l_pobj) rls_13\NNP\0|NONE_0
D004294_D012148 NONE domperione_24\NN\0|NONE_0 (l_prep) on_25\IN\0|NONE_0 (l_pobj) rls_29\NNP\0|NONE_0
D004294_D004415 NONE domperidone_21\NN\0|his_4 (r_compound) therapy_22\NN\657604|NONE_0 (r_pobj) to_19\IN\0|had_15|been_11 (r_prep) added_18\VBN\156601|authors_122|here_107|comorbid_82|._32 (r_ccomp) report_2\VBP\6470073|NONE_0 (l_dobj) comorbid_7\JJ\0|authors_40|here_25|added_82|._114 (l_prep) with_8\IN\0|a_29|depressed_27|patient_17 (l_pobj) dyspepsia_10\NN\14299637|NONE_0
C035133_D004415 NONE mirtazapine_15\RB\0|NONE_0 (r_pobj) after_14\IN\0|who_18|rls_4 (r_prep) developed_12\VBD\1753788|postprandial_27 (r_relcl) dyspepsia_10\NN\14299637|NONE_0
C035133_D012148 CID mirtazapine_3\RB\0|-_11 (r_advmod) associated_5\VBN\628491|legs_20 (r_amod) syndrome_8\NN\5870365|does_65|domperidone_60|?_8
C035133_D012148 CID mirtazapine_0\NNP\0|has_87|been_91|with_107|in_116|._146 (r_nsubjpass) associated_15\VBN\628491|NONE_0 (l_prep) with_16\IN\0|mirtazapine_107|has_20|been_16|in_9|._39 (l_pobj) rls_17\NNP\0|NONE_0
C035133_D012148 CID mirtazapine_15\RB\0|NONE_0 (r_pobj) after_14\IN\0|who_18|rls_4 (r_prep) developed_12\VBD\1753788|postprandial_27 (l_dobj) rls_13\NNP\0|who_14|after_4
C035133_D012148 CID mirtazapine_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|only_31|after_26|he_20|had_17|been_13 (r_prep) treated_13\VBN\2376958|to_47|symptoms_39 (r_advcl) have_4\VB\7846|patient_19|,_68|and_70|resolved_91 (l_dobj) symptoms_5\NNS\5823932|to_8|treated_39 (l_prep) of_6\IN\0|NONE_0 (l_pobj) rls_7\NNP\0|NONE_0
C035133_D012148 CID mirtazapine_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|only_31|after_26|he_20|had_17|been_13 (r_prep) treated_13\VBN\2376958|to_47|symptoms_39 (r_advcl) have_4\VB\7846|patient_19|,_68|and_70|resolved_91 (r_xcomp) started_2\VBD\0|NONE_0 (l_conj) resolved_21\VBD\352826|patient_110|have_91|,_23|and_21 (l_nsubj) symptoms_20\NNS\5823932|completely_18|upon_29|._68 (l_compound) rls_19\NNP\0|his_4
C035133_D012148 CID mirtazapine_27\NN\0|NONE_0 (r_pobj) of_25\IN\0|NONE_0 (r_prep) discontinuation_24\NN\209943|NONE_0 (r_pobj) upon_23\IN\0|symptoms_29|completely_11|._39 (r_prep) resolved_21\VBD\352826|patient_110|have_91|,_23|and_21 (r_conj) started_2\VBD\0|NONE_0 (l_xcomp) have_4\VB\7846|patient_19|,_68|and_70|resolved_91 (l_dobj) symptoms_5\NNS\5823932|to_8|treated_39 (l_prep) of_6\IN\0|NONE_0 (l_pobj) rls_7\NNP\0|NONE_0
C035133_D012148 CID mirtazapine_27\NN\0|NONE_0 (r_pobj) of_25\IN\0|NONE_0 (r_prep) discontinuation_24\NN\209943|NONE_0 (r_pobj) upon_23\IN\0|symptoms_29|completely_11|._39 (r_prep) resolved_21\VBD\352826|patient_110|have_91|,_23|and_21 (l_nsubj) symptoms_20\NNS\5823932|completely_18|upon_29|._68 (l_compound) rls_19\NNP\0|his_4
C035133_D012148 CID mirtazapine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_8|and_15|symptoms_23 (r_prep) use_6\NN\407535|NONE_0 (l_conj) symptoms_11\NNS\5823932|the_31|of_23|and_8 (l_prep) of_12\IN\0|the_13|in_7 (l_pobj) rls_13\NNP\0|NONE_0
C035133_D012148 CID mirtazapine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_8|and_15|symptoms_23 (r_prep) use_6\NN\407535|NONE_0 (r_pobj) between_4\IN\0|such_29|a_24|temporal_22 (r_prep) relationship_3\NN\31921|did_83|not_87|effect_114|._164 (r_nsubj) support_19\VB\407535|NONE_0 (l_dobj) effect_22\NN\34213|relationship_114|did_31|not_27|._50 (l_prep) of_23\IN\0|a_22|potentiating_20 (l_pobj) domperione_24\NN\0|NONE_0 (l_prep) on_25\IN\0|NONE_0 (l_pobj) rls_29\NNP\0|NONE_0
C035133_D012148 CID mirtazapine_26\RB\0|-_11 (r_npadvmod) associated_28\VBN\628491|NONE_0 (r_amod) rls_29\NNP\0|NONE_0 (r_pobj) on_25\IN\0|NONE_0 (r_prep) domperione_24\NN\0|NONE_0 (r_pobj) of_23\IN\0|a_22|potentiating_20 (r_prep) effect_22\NN\34213|relationship_114|did_31|not_27|._50 (r_dobj) support_19\VB\407535|NONE_0 (l_nsubj) relationship_3\NN\31921|did_83|not_87|effect_114|._164 (l_prep) between_4\IN\0|such_29|a_24|temporal_22 (l_pobj) use_6\NN\407535|NONE_0 (l_conj) symptoms_11\NNS\5823932|the_31|of_23|and_8 (l_prep) of_12\IN\0|the_13|in_7 (l_pobj) rls_13\NNP\0|NONE_0
C035133_D012148 CID mirtazapine_26\RB\0|-_11 (r_npadvmod) associated_28\VBN\628491|NONE_0 (r_amod) rls_29\NNP\0|NONE_0
C035133_D012148 CID mirtazapine_10\NN\0|that_5|can_12|be_16|with_30|in_39 (r_nsubjpass) associated_13\VBN\628491|the_40|,_39|those_52 (l_prep) with_14\IN\0|that_35|mirtazapine_30|can_18|be_14|in_9 (l_pobj) rls_15\NNP\0|NONE_0
3832950
D002998_D013036 NONE clonazepam_23\NN\0|NONE_0 (r_pobj) with_22\IN\0|patients_107|were_13|._15 (r_prep) treated_21\VBN\2376958|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_94|with_107|._122 (l_prep) with_12\IN\0|sixty_49|(_34|range_29|)_2 (l_pobj) types_14\NNS\5839024|NONE_0 (l_prep) than_17\IN\0|other_24|of_12 (l_pobj) spasms_19\NNS\14299637|NONE_0
D002998_D004827 NONE clonazepam_0\NNP\0|for_23|in_36|._48 (r_compound) monotherapy_1\NN\0|NONE_0 (l_prep) for_2\IN\0|clonazepam_23|in_13|._25 (l_pobj) epilepsy_3\NN\14085708|NONE_0
D002998_D004827 NONE clonazepam_23\NN\0|NONE_0 (r_pobj) with_22\IN\0|patients_107|were_13|._15 (r_prep) treated_21\VBN\2376958|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_94|with_107|._122 (l_prep) with_12\IN\0|sixty_49|(_34|range_29|)_2 (l_pobj) types_14\NNS\5839024|NONE_0 (l_prep) of_15\IN\0|other_12|than_12 (l_pobj) epilepsy_16\NN\14085708|NONE_0
4010471
D004229_D012640 NONE dithiothreitol_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treatment_13\NN\654885|NONE_0 (r_pobj) by_12\IN\0|sites_70|were_22|equally_17|._49 (r_agent) affected_11\VBN\126264|NONE_0 (l_nsubjpass) sites_2\NNS\8673395|were_48|equally_53|by_70|._119 (l_prep) from_3\IN\0|the_18|binding_14 (l_pobj) mice_8\NNS\2329401|NONE_0 (l_amod) sensitive_5\JJ\10488309|NONE_0 (l_npadvmod) seizure_4\NN\14081375|and_18|resistant_22
D009538_D012640 CID nicotine_2\NN\14712692|-_8 (r_npadvmod) induced_4\VBN\1627355|and_17|receptors_43 (r_amod) seizures_5\NNS\14081375|NONE_0
D009538_D012640 CID nicotine_15\NN\14712692|-_8 (r_npadvmod) induced_17\VBN\1627355|and_17|concentration_59 (r_amod) seizures_18\NNS\14081375|NONE_0
D009538_D012640 CID nicotine_7\NN\14712692|NONE_0 (r_pobj) of_6\IN\0|the_23|convulsant_19 (r_prep) effects_5\NNS\13245626|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) sensitive_1\JJ\10488309|NONE_0 (r_amod) mice_0\NNS\2329401|binding_84|._140 (r_nsubj) had_8\VBD\0|NONE_0 (l_dobj) binding_13\NN\4688246|mice_84|._56 (l_prep) than_17\IN\0|greater_54|bungarotoxin_40|in_19 (l_pobj) mice_20\NNS\2329401|NONE_0 (l_nmod) seizure_18\NN\14081375|insensitive_8
7644931
D017239_D006402 CID paclitaxel_14\NN\0|/_10 (r_nmod) carboplatin_16\NN\0|the_15 (r_compound) combination_17\NN\7951464|could_12|be_18|weeks_35|._40 (r_nsubjpass) dosed_20\VBN\515154|carboplatin_126|did_114|not_110|add_96|,_54|and_52 (r_conj) appear_3\VB\2604760|NONE_0 (l_xcomp) add_5\VB\14304060|carboplatin_30|did_18|not_14|,_42|and_44|dosed_96 (l_prep) to_6\IN\0|to_7 (l_pobj) toxicities_9\NNS\13576101|NONE_0
D017239_D064420 NONE paclitaxel_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|i_8|alone_14 (r_prep) trial_12\NN\786195|toxicities_64|were_53|with_39|._50 (r_dobj) compared_2\VBN\644583|NONE_0 (l_nsubjpass) toxicities_0\NNS\13576101|were_11|with_25|trial_64|._114
D017239_D002289 NONE paclitaxel_0\NNP\0|was_83|with_96|in_113|._187 (r_nsubjpass) combined_18\VBN\2630189|NONE_0 (l_prep) in_21\IN\13603305|paclitaxel_113|was_30|with_17|._74 (l_pobj) phase_23\NN\15113229|NONE_0 (l_acl) directed_28\VBN\746718|a_19 (l_prep) to_29\IN\0|study_15 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_prep) with_31\IN\0|NONE_0 (l_pobj) cancer_37\NN\14239425|NONE_0
D017239_D002289 NONE taxol_2\NNP\0|company_28 (r_appos) paclitaxel_0\NNP\0|was_83|with_96|in_113|._187 (r_nsubjpass) combined_18\VBN\2630189|NONE_0 (l_prep) in_21\IN\13603305|paclitaxel_113|was_30|with_17|._74 (l_pobj) phase_23\NN\15113229|NONE_0 (l_acl) directed_28\VBN\746718|a_19 (l_prep) to_29\IN\0|study_15 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_prep) with_31\IN\0|NONE_0 (l_pobj) cancer_37\NN\14239425|NONE_0
D016190_D002289 NONE carboplatin_20\NN\0|NONE_0 (r_pobj) with_19\IN\0|paclitaxel_96|was_13|in_17|._91 (r_prep) combined_18\VBN\2630189|NONE_0 (l_prep) in_21\IN\13603305|paclitaxel_113|was_30|with_17|._74 (l_pobj) phase_23\NN\15113229|NONE_0 (l_acl) directed_28\VBN\746718|a_19 (l_prep) to_29\IN\0|study_15 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_prep) with_31\IN\0|NONE_0 (l_pobj) cancer_37\NN\14239425|NONE_0
D016190_D006402 NONE carboplatin_0\NNP\0|did_12|not_16|add_30|,_72|and_74|dosed_126 (r_nsubj) appear_3\VB\2604760|NONE_0 (l_xcomp) add_5\VB\14304060|carboplatin_30|did_18|not_14|,_42|and_44|dosed_96 (l_prep) to_6\IN\0|to_7 (l_pobj) toxicities_9\NNS\13576101|NONE_0
D016190_D006402 NONE carboplatin_16\NN\0|the_15 (r_compound) combination_17\NN\7951464|could_12|be_18|weeks_35|._40 (r_nsubjpass) dosed_20\VBN\515154|carboplatin_126|did_114|not_110|add_96|,_54|and_52 (r_conj) appear_3\VB\2604760|NONE_0 (l_xcomp) add_5\VB\14304060|carboplatin_30|did_18|not_14|,_42|and_44|dosed_96 (l_prep) to_6\IN\0|to_7 (l_pobj) toxicities_9\NNS\13576101|NONE_0
1280054
D014750_D007049 CID vincristine_0\NNP\3917455|was_12|accidentally_16|intrathecally_35|to_49|,_74|producing_76|._152 (r_nsubjpass) given_3\VBN\5892096|NONE_0 (l_advcl) producing_11\VBG\1617192|vincristine_76|was_64|accidentally_60|intrathecally_41|to_27|,_2|._76 (l_dobj) dysfunction_15\NN\14204950|NONE_0
D014750_D001927 CID vincristine_5\NN\3917455|intrathecal_12 (r_compound) administration_6\NN\1133281|to_27 (r_pobj) due_2\IN\5174653|fatal_26|._45 (r_prep) myeloencephalopathy_1\NN\0|NONE_0
D014750_D001927 CID vincristine_0\NNP\3917455|was_12|accidentally_16|intrathecally_35|to_49|,_74|producing_76|._152 (r_nsubjpass) given_3\VBN\5892096|NONE_0 (l_advcl) producing_11\VBG\1617192|vincristine_76|was_64|accidentally_60|intrathecally_41|to_27|,_2|._76 (l_dobj) dysfunction_15\NN\14204950|NONE_0 (l_acl) followed_16\VBN\1835496|sensory_30 (l_agent) by_17\IN\0|NONE_0 (l_pobj) encephalopathy_18\JJ\14084880|NONE_0
D014750_D007938 NONE vincristine_0\NNP\3917455|was_12|accidentally_16|intrathecally_35|to_49|,_74|producing_76|._152 (r_nsubjpass) given_3\VBN\5892096|NONE_0 (l_dative) to_5\IN\0|vincristine_49|was_37|accidentally_33|intrathecally_14|,_25|producing_27|._103 (l_pobj) child_7\NN\9622049|NONE_0 (l_prep) with_8\IN\0|a_8 (l_pobj) leukaemia_9\NN\14239918|NONE_0
895432
D007545_D009203 CID isoproterenol_7\NN\3740161|-_13 (r_npadvmod) induced_9\VBN\1627355|myocardial_8 (r_amod) infarction_11\NN\14204950|NONE_0
D007545_D009203 CID isoproterenol_8\NN\3740161|-_13 (r_npadvmod) induced_10\VBN\1627355|myocardial_8 (r_amod) infarction_12\NN\14204950|NONE_0
D007545_D007238 NONE isoproterenol_16\NN\3740161|NONE_0 (r_pobj) of_15\IN\0|large_14 (r_prep) dosages_14\NNS\13576355|NONE_0 (r_pobj) of_12\IN\0|the_12 (r_prep) effects_11\NNS\13245626|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) associated_8\VBN\628491|the_14 (r_acl) mortality_7\NN\5054863|that_26|exercise_21|but_72|had_76 (r_dobj) reduced_5\VBD\441445|results_32|._132 (l_conj) had_18\VBD\0|that_102|exercise_97|mortality_76|but_4 (l_prep) on_20\IN\0|little_7 (l_pobj) severity_22\NN\5036394|NONE_0 (l_prep) of_23\IN\0|the_13 (l_pobj) infarction_25\NN\14204950|NONE_0
19815465
D020888_D014786 CID vigabatrin_8\NN\0|NONE_0 (r_pobj) to_7\TO\0|NONE_0 (r_prep) specific_6\JJ\5817396|defects_16|not_4|._22 (r_acomp) are_4\VBP\13600404|NONE_0 (l_nsubj) defects_3\NNS\14462666|not_12|specific_16|._38
D020888_D014786 CID vigabatrin_11\NN\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|the_19|visual_15 (r_acl) defects_5\NNS\14462666|study_30|._63
D020888_D014786 CID vgb_13\NNP\0|the_35|antiepileptic_31|drug_17|(_1|)_3 (r_appos) vigabatrin_11\NN\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|the_19|visual_15 (r_acl) defects_5\NNS\14462666|study_30|._63
D020888_D004827 NONE vgb_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|current_34|no_12 (r_prep) exposure_22\NN\5042871|antiepileptic_53|drug_39|(_26|)_15 (r_appos) therapy_14\NN\657604|NONE_0 (r_pobj) of_11\IN\0|the_10 (r_prep) basis_10\NN\13790712|NONE_0 (r_pobj) on_8\IN\0|people_34|were_13|._85 (r_prep) grouped_7\VBN\654625|NONE_0 (l_nsubjpass) people_3\NNS\31264|were_21|on_34|._119 (l_prep) with_4\IN\0|four_12 (l_pobj) epilepsy_5\NN\14085708|NONE_0
D020888_D012164 CID vgb_19\NNP\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|retinal_17 (r_acl) toxicity_16\NN\13576101|to_29|reliably_26
16565833
C522803_D066126 NONE monoher_7\NN\0|NONE_0 (r_pobj) between_6\IN\0|the_18|time_14 (r_prep) interval_5\NN\33615|NONE_0 (r_pobj) of_2\IN\0|the_14|and_37|administration_53|._136 (r_prep) influence_1\NN\5190804|NONE_0 (l_conj) administration_10\NN\1133281|the_67|of_53|and_16|._83 (l_prep) on_11\IN\0|doxorubicin_27 (l_pobj) protection_13\NN\407535|NONE_0 (l_prep) against_14\IN\0|the_15 (l_pobj) cardiotoxicity_18\NN\0|NONE_0
C522803_D066126 NONE monohydroxyethylrutoside_3\NN\0|cardioprotection_42|._154 (r_nsubj) showed_7\VBD\2137132|NONE_0 (l_dobj) cardioprotection_8\NN\0|monohydroxyethylrutoside_42|._112 (l_prep) against_9\IN\0|NONE_0 (l_pobj) cardiotoxicity_13\NN\0|NONE_0
C522803_D066126 NONE monoher_5\NN\0|the_54|semisynthetic_50|flavonoid_36|(_1|)_7 (r_appos) monohydroxyethylrutoside_3\NN\0|cardioprotection_42|._154 (r_nsubj) showed_7\VBD\2137132|NONE_0 (l_dobj) cardioprotection_8\NN\0|monohydroxyethylrutoside_42|._112 (l_prep) against_9\IN\0|NONE_0 (l_pobj) cardiotoxicity_13\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_9\NN\2716866|on_27 (r_compound) administration_10\NN\1133281|the_67|of_53|and_16|._83 (l_prep) on_11\IN\0|doxorubicin_27 (l_pobj) protection_13\NN\407535|NONE_0 (l_prep) against_14\IN\0|the_15 (l_pobj) cardiotoxicity_18\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_15\NN\2716866|-_11 (r_npadvmod) induced_17\VBN\1627355|in_23 (r_amod) cardiotoxicity_18\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_9\NN\2716866|be_31|._85 (l_prep) despite_0\IN\7501545|,_37|anthracyclin_43|dox_69 (l_pobj) cardiotoxicity_5\NN\0|NONE_0
D004317_D066126 NONE dox_11\NNP\0|despite_69|,_32|anthracyclin_26 (r_appos) doxorubicin_9\NN\2716866|be_31|._85 (l_prep) despite_0\IN\7501545|,_37|anthracyclin_43|dox_69 (l_pobj) cardiotoxicity_5\NN\0|NONE_0
D004317_D066126 NONE dox_10\NNP\0|-_3 (r_npadvmod) induced_12\VBN\1627355|through_23 (r_amod) cardiotoxicity_13\NN\0|NONE_0
D007501_D066126 NONE iron_19\NN\14625458|NONE_0 (r_compound) chelating_20\VBG\2621395|scavenging_20 (r_compound) properties_21\NNS\32613|NONE_0 (r_pobj) through_14\IN\0|induced_23 (r_prep) cardiotoxicity_13\NN\0|NONE_0
D004317_D006331 NONE dox_0\NNP\0|-_3 (r_npadvmod) induced_2\VBN\1627355|cardiac_8 (r_amod) damage_4\NN\7296428|presumably_7|from_26|._68
D004317_D006331 NONE dox_14\NNP\0|NONE_0 (r_pobj) by_13\IN\0|free_14 (r_prep) radicals_12\NNS\9465459|NONE_0 (r_pobj) of_10\IN\0|the_14 (r_prep) formation_9\NN\7938773|NONE_0 (r_pobj) from_7\IN\0|damage_26|presumably_19|._42 (r_prep) results_6\VBZ\34213|NONE_0 (l_nsubj) damage_4\NN\7296428|presumably_7|from_26|._68
D004317_D006331 NONE dox_6\NNP\0|NONE_0 (r_pobj) with_5\IN\0|alone_9 (r_prep) treatment_4\NN\654885|that_5|damage_53 (r_nsubj) induced_8\VBD\1627355|evaluation_50|._86 (l_dobj) damage_11\NN\7296428|that_58|treatment_53
D005419_D066126 NONE flavonoid_2\NN\14983143|the_18|semisynthetic_14|(_35|monoher_36|)_43 (r_compound) monohydroxyethylrutoside_3\NN\0|cardioprotection_42|._154 (r_nsubj) showed_7\VBD\2137132|NONE_0 (l_dobj) cardioprotection_8\NN\0|monohydroxyethylrutoside_42|._112 (l_prep) against_9\IN\0|NONE_0 (l_pobj) cardiotoxicity_13\NN\0|NONE_0
20682692
D013311_D003920 NONE streptozotocin_28\JJ\0|(_15|stz)-induced_16 (r_nmod) diabetes_31\NNS\14075199|NONE_0
D013311_D003920 NONE stz)-induced_30\VBN\0|streptozotocin_16|(_1 (r_amod) diabetes_31\NNS\14075199|NONE_0
D013311_D003928 CID streptozotocin_15\NNS\0|-_14 (r_npadvmod) induced_17\VBN\1627355|diabetic_8 (r_amod) nephropathy_19\NN\14573196|NONE_0
D013311_D003928 CID stz_22\NNP\0|-_3 (r_npadvmod) induced_24\VBN\1627355|diabetic_8|in_29 (r_amod) nephropathy_26\NN\14573196|NONE_0
D013311_D003928 CID stz_20\NNP\0|-_3 (r_npadvmod) induced_22\VBN\1627355|diabetic_8 (r_amod) nephropathy_24\NN\14573196|NONE_0
D000804_D003928 NONE angiotensin_13\NN\4522421|the_10 (r_compound) system_14\NN\3575240|NONE_0 (r_pobj) of_9\IN\0|early_15|in_32 (r_prep) blockade_8\NN\952963|that_11|did_95|not_99|progression_114|,_140|suggesting_142 (r_nsubj) retard_25\VB\10599354|trial_127|._159 (l_advcl) suggesting_31\VBG\1010118|that_153|blockade_142|did_47|not_43|progression_28|,_2 (l_ccomp) involved_37\VBN\2676054|NONE_0 (l_prep) in_38\IN\13603305|that_37|mechanism(s_26|)_15|are_13 (l_pobj) pathogenesis_40\NN\13533470|NONE_0 (l_prep) of_41\IN\0|the_17 (l_pobj) nephropathy_44\NN\14573196|NONE_0
D000804_D003928 NONE angiotensin_13\NN\4522421|the_10 (r_compound) system_14\NN\3575240|NONE_0 (r_pobj) of_9\IN\0|early_15|in_32 (r_prep) blockade_8\NN\952963|that_11|did_95|not_99|progression_114|,_140|suggesting_142 (r_nsubj) retard_25\VB\10599354|trial_127|._159 (l_advcl) suggesting_31\VBG\1010118|that_153|blockade_142|did_47|not_43|progression_28|,_2 (l_ccomp) involved_37\VBN\2676054|NONE_0 (l_prep) in_38\IN\13603305|that_37|mechanism(s_26|)_15|are_13 (l_pobj) pathogenesis_40\NN\13533470|NONE_0 (l_prep) of_41\IN\0|the_17 (l_pobj) nephropathy_44\NN\14573196|NONE_0 (l_appos) nephropathy_47\NN\14573196|early_37|diabetic_31|(_10|)_11
D013311_D005355 NONE streptozotocin_28\JJ\0|(_15|stz)-induced_16 (r_nmod) diabetes_31\NNS\14075199|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) mice_26\NNS\2329401|NONE_0 (r_pobj) in_25\IN\13603305|the_87|early_83|of_65|of_20 (r_prep) development_17\NN\248977|NONE_0 (l_prep) of_18\IN\0|the_22|early_18|of_45|in_65 (l_pobj) fibrosis_21\NN\14204950|NONE_0
D013311_D005355 NONE stz)-induced_30\VBN\0|streptozotocin_16|(_1 (r_amod) diabetes_31\NNS\14075199|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) mice_26\NNS\2329401|NONE_0 (r_pobj) in_25\IN\13603305|the_87|early_83|of_65|of_20 (r_prep) development_17\NN\248977|NONE_0 (l_prep) of_18\IN\0|the_22|early_18|of_45|in_65 (l_pobj) fibrosis_21\NN\14204950|NONE_0
D000804_D007674 NONE angiotensin_13\NN\4522421|the_10 (r_compound) system_14\NN\3575240|NONE_0 (r_pobj) of_9\IN\0|early_15|in_32 (r_prep) blockade_8\NN\952963|that_11|did_95|not_99|progression_114|,_140|suggesting_142 (r_nsubj) retard_25\VB\10599354|trial_127|._159 (l_dobj) progression_27\NN\8457976|that_125|blockade_114|did_19|not_15|,_26|suggesting_28 (l_prep) of_28\IN\0|the_16 (l_pobj) nephropathy_29\NN\14573196|NONE_0
D000804_D003922 NONE angiotensin_13\NN\4522421|the_10 (r_compound) system_14\NN\3575240|NONE_0 (r_pobj) of_9\IN\0|early_15|in_32 (r_prep) blockade_8\NN\952963|that_11|did_95|not_99|progression_114|,_140|suggesting_142 (l_prep) in_15\IN\13603305|early_47|of_32 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) diabetes_20\NNS\14075199|NONE_0
18189308
D014443_D003556 NONE tyrosine_9\NN\14601829|kinase_9|(_26|trks_27|)_31 (r_det) receptors_11\NNS\5225602|NONE_0 (r_pobj) of_8\IN\0|the_30|and_15|regulation_11 (r_prep) expression_5\NN\4679549|studies_26|have_18|in_62|._119 (r_dobj) examined_3\VBN\0|NONE_0 (l_prep) in_15\IN\13603305|studies_88|have_80|expression_62|._57 (l_pobj) reflexes_17\NNS\859001|NONE_0 (l_prep) with_18\IN\0|micturition_21 (l_pobj) inflammation_21\NN\14299637|NONE_0
D003520_D003556 CID cyclophosphamide_12\NN\0|-_16 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) cystitis_15\NN\14566129|NONE_0
D003520_D003556 CID cyclophosphamide_27\NN\0|NONE_0 (r_pobj) by_26\IN\0|NONE_0 (r_agent) induced_25\VBN\1627355|various_42|of_24 (r_acl) durations_21\NNS\15113229|NONE_0 (l_prep) of_22\IN\0|various_18|induced_24 (l_pobj) inflammation_24\NN\14299637|NONE_0
D003520_D003556 CID cyp_29\NNP\0|NONE_0 (r_appos) cyclophosphamide_27\NN\0|NONE_0 (r_pobj) by_26\IN\0|NONE_0 (r_agent) induced_25\VBN\1627355|various_42|of_24 (r_acl) durations_21\NNS\15113229|NONE_0 (l_prep) of_22\IN\0|various_18|induced_24 (l_pobj) inflammation_24\NN\14299637|NONE_0
D003520_D003556 CID cyp_0\NNP\0|-_3 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) cystitis_3\NN\14566129|(_19|expression_45|._140
D003520_D003556 CID cyp_27\NNP\0|-_3 (r_npadvmod) induced_29\VBN\1627355|(_17|acute_18|)_50 (r_amod) cystitis_30\NN\14566129|NONE_0
D003520_D003556 CID cyp_7\NNP\0|intermediate_25|-_3 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) cystitis_10\NN\14566129|NONE_0
9428298
D000420_D001249 NONE albuterol_2\NN\2905612|NONE_0 (l_prep) in_3\IN\13603305|nebulized_20|:_43|study_63|._68 (l_pobj) exacerbations_5\NNS\374224|NONE_0 (l_prep) of_6\IN\0|severe_21|in_10 (l_pobj) asthma_7\NN\14145095|NONE_0
D000420_D001249 NONE albuterol_25\NN\2905612|nebulized_10|(_10|)_14 (r_nmod) cna_27\NNP\0|who_47|versus_5 (r_dobj) received_22\VBD\2210855|severe_35|of_14 (r_relcl) exacerbations_18\NNS\374224|NONE_0 (l_prep) of_19\IN\0|severe_21|received_14 (l_pobj) asthma_20\NN\14145095|NONE_0
D000420_D001249 NONE albuterol_31\NN\2905612|intermittent_13|(_10|ina_11|)_14 (r_nmod) treatments_35\NNS\654885|NONE_0 (r_pobj) versus_29\IN\0|who_52|cna_5 (r_prep) received_22\VBD\2210855|severe_35|of_14 (r_relcl) exacerbations_18\NNS\374224|NONE_0 (l_prep) of_19\IN\0|severe_21|received_14 (l_pobj) asthma_20\NN\14145095|NONE_0
16369751
C032348_D002637 NONE fbal_34\NNP\0|serum_6|of_19 (r_compound) concentration_35\NN\4916342|NONE_0 (r_pobj) with_30\IN\0|during_83|pain_59|concomitantly_14 (r_prep) occurred_28\VBD\0|a_117|continuous_115|intravenous_104|of_83|,_62 (l_nsubj) pain_22\NN\14299637|during_24|concomitantly_45|with_59
C032348_D002037 NONE fbal_34\NNP\0|serum_6|of_19 (r_compound) concentration_35\NN\4916342|NONE_0 (r_pobj) with_30\IN\0|during_83|pain_59|concomitantly_14 (r_prep) occurred_28\VBD\0|a_117|continuous_115|intravenous_104|of_83|,_62 (l_nsubj) pain_22\NN\14299637|during_24|concomitantly_45|with_59 (l_prep) with_23\IN\0|precordial_16 (l_pobj) block_27\NN\21939|NONE_0
C032348_D066126 NONE alanine_10\NN\14601829|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|5-fluorouracil_30|._36 (r_acl) cardiotoxicity_1\NN\0|NONE_0
C032348_D066126 NONE alanine_30\NN\14601829|NONE_0 (r_pobj) of_23\IN\0|a_19|high_17|serum_12 (r_prep) level_22\NN\4916342|in_21|(_35|)_40|was_42 (r_nsubjpass) observed_35\VBN\2163746|induced_91|,_69 (r_relcl) cardiotoxicity_15\NN\0|NONE_0
C032348_D066126 NONE fbal_32\NNP\0|NONE_0 (r_preconj) (_31\-LRB-\0|in_56|level_35|)_5|was_7 (r_punct) observed_35\VBN\2163746|induced_91|,_69 (r_relcl) cardiotoxicity_15\NN\0|NONE_0
C032348_D066126 NONE fbal_16\NNP\0|that_5|is_5|to_16 (r_nsubjpass) related_18\VBN\628491|experience_89|,_24|._38 (l_prep) to_19\IN\0|that_21|fbal_16|is_11 (l_pobj) cardiotoxicity_23\NN\0|NONE_0
D005472_D002037 CID 5-fu_11\CD\0|NONE_0 (r_pobj) of_10\IN\0|a_34|continuous_32|intravenous_21|,_21|occurred_83 (r_prep) infusion_9\NN\14589223|after_63|,_48|patient_42|._165 (l_relcl) occurred_28\VBD\0|a_117|continuous_115|intravenous_104|of_83|,_62 (l_nsubj) pain_22\NN\14299637|during_24|concomitantly_45|with_59 (l_prep) with_23\IN\0|precordial_16 (l_pobj) block_27\NN\21939|NONE_0
D005472_D009369 NONE 5-fu_1\CD\0|(_1|)_4|for_16|._32 (r_nummod) treatment_3\NN\654885|NONE_0 (l_prep) for_4\IN\0|(_17|5-fu_16|)_12|._16 (l_pobj) malignancies_5\NNS\14070360|NONE_0
D005472_D066126 NONE 5-fluorouracil_0\CD\0|induced_30|._66 (r_punct) cardiotoxicity_1\NN\0|NONE_0
D005472_D066126 NONE 5-fluorouracil_7\CD\0|cardiotoxicity_55|complication_30 (r_punct) is_1\VBZ\0|NONE_0 (l_nsubj) cardiotoxicity_0\NNP\0|complication_25|5-fluorouracil_55
D005472_D066126 NONE 5-fu_12\CD\0|-_4 (r_npadvmod) induced_14\VBN\1627355|,_22|observed_91 (r_amod) cardiotoxicity_15\NN\0|NONE_0
D005472_D066126 NONE 5-fu_14\CD\0|-_4 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_17\NN\0|NONE_0
D005472_D066126 NONE 5-fu_22\CD\0|NONE_0 (r_pobj) of_21\IN\0|the_19 (r_prep) administration_20\NN\1133281|considered_64|,_6|was_23|._36 (r_nsubjpass) abandoned_24\VBN\2222318|NONE_0 (l_advcl) considered_8\VBN\689344|,_58|administration_64|was_87|._100 (l_xcomp) been_11\VBN\0|as_62|pain_44|was_23 (l_acomp) due_12\JJ\5174653|to_13|have_10 (l_prep) to_13\IN\0|NONE_0 (l_pobj) cardiotoxicity_17\NN\0|NONE_0
D005472_D066126 NONE 5-fu_20\CD\0|-_4 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_23\NN\0|NONE_0
D005472_D066126 NONE 5-fu_8\CD\0|-_4 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_11\NN\0|NONE_0
D005472_D002637 CID 5-fu_11\CD\0|NONE_0 (r_pobj) of_10\IN\0|a_34|continuous_32|intravenous_21|,_21|occurred_83 (r_prep) infusion_9\NN\14589223|after_63|,_48|patient_42|._165 (l_relcl) occurred_28\VBD\0|a_117|continuous_115|intravenous_104|of_83|,_62 (l_nsubj) pain_22\NN\14299637|during_24|concomitantly_45|with_59
D005472_D002637 CID 5-fu_14\CD\0|NONE_0 (r_pobj) of_13\IN\0|the_20 (r_prep) discontinuation_12\NN\209943|NONE_0 (r_pobj) after_10\IN\0|pain_68|spontaneously_14|._33 (r_prep) disappeared_8\VBD\0|NONE_0 (l_nsubj) pain_3\NN\14299637|spontaneously_54|after_68|._101
D005472_D002637 CID 5-fu_14\CD\0|-_4 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_17\NN\0|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) due_12\JJ\5174653|to_13|have_10 (r_acomp) been_11\VBN\0|as_62|pain_44|was_23 (r_xcomp) considered_8\VBN\689344|,_58|administration_64|was_87|._100 (l_nsubjpass) pain_3\NN\14299637|as_18|was_21|been_44
D005472_D002637 CID 5-fu_22\CD\0|NONE_0 (r_pobj) of_21\IN\0|the_19 (r_prep) administration_20\NN\1133281|considered_64|,_6|was_23|._36 (r_nsubjpass) abandoned_24\VBN\2222318|NONE_0 (l_advcl) considered_8\VBN\689344|,_58|administration_64|was_87|._100 (l_nsubjpass) pain_3\NN\14299637|as_18|was_21|been_44
3708328
D005680_D012640 NONE acid_16\NN\14818238|NONE_0 (r_pobj) of_11\IN\0|the_13 (r_prep) activity_10\NN\30358|NONE_0 (r_dobj) manipulating_8\VBG\2536557|NONE_0 (r_pcomp) of_7\IN\0|the_12|inhibition_85 (r_prep) effects_6\NNS\13245626|in_26|,_6|,_175|were_177|._194 (l_appos) inhibition_20\NN\1068773|the_97|of_85 (l_prep) on_25\IN\0|(_64|gaba)-mediated_63|synaptic_48|within_28 (l_pobj) seizures_26\NNS\14081375|NONE_0
D005680_D012640 NONE gaba)-mediated_18\VBN\0|(_1|synaptic_15|within_35|on_63 (r_amod) inhibition_20\NN\1068773|the_97|of_85 (l_prep) on_25\IN\0|(_64|gaba)-mediated_63|synaptic_48|within_28 (l_pobj) seizures_26\NNS\14081375|NONE_0
D005680_D012640 NONE gaba_17\NNP\14601829|-_4 (r_npadvmod) synthesizing_19\VBG\193486|the_9|,_19|decarboxylase_37|,_50|into_52 (r_amod) enzyme_20\NN\14723628|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) activity_14\NN\30358|NONE_0 (r_pobj) of_13\IN\0|an_13 (r_prep) inhibitor_12\NN\20090|150_19|,_5 (r_appos) micrograms_9\NNS\13717155|of_18|,_6 (r_conj) microinjections_4\NNS\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) pretreated_2\VBN\0|NONE_0 (r_acl) animals_1\NNS\4475|NONE_0 (r_pobj) in_0\IN\13603305|doses_239|in_289|._343 (r_prep) resulted_52\VBD\2633881|NONE_0 (l_prep) in_53\IN\13603305|in_289|doses_50|._54 (l_pobj) seizures_57\NNS\14081375|NONE_0
D005680_D012640 NONE gaba_20\NNP\14601829|-_4 (r_npadvmod) mediated_22\VBN\761713|the_9|synaptic_9|within_29 (r_amod) inhibition_24\NN\1068773|NONE_0 (r_pobj) of_18\IN\0|the_15 (r_prep) regulation_17\NN\6652242|NONE_0 (r_pobj) to_15\IN\0|that_73|threshold_64|is_13 (r_prep) subjected_14\VBN\137313|results_83|._96 (l_nsubjpass) threshold_5\NN\15265518|that_9|is_51|to_64 (l_prep) for_6\IN\0|the_14 (l_pobj) seizures_10\NNS\14081375|NONE_0
D007538_D013226 NONE isoniazid_6\NN\2716205|NONE_0 (r_pobj) of_5\IN\0|,_12|micrograms_18 (r_prep) microinjections_4\NNS\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) pretreated_2\VBN\0|NONE_0 (r_acl) animals_1\NNS\4475|NONE_0 (r_pobj) in_0\IN\13603305|doses_239|in_289|._343 (r_prep) resulted_52\VBD\2633881|NONE_0 (l_prep) in_53\IN\13603305|in_289|doses_50|._54 (l_pobj) seizures_57\NNS\14081375|NONE_0 (l_conj) epilepticus_60\NN\0|severe_40|motor_33|limbic_27|and_11
D010862_D013226 NONE pilocarpine_45\NN\14712692|NONE_0 (r_pobj) of_44\IN\0|-_18|convulsant_17|,_14|mg/kg_28|,_33 (r_prep) doses_43\NNS\3740161|in_239|in_50|._104 (r_nsubj) resulted_52\VBD\2633881|NONE_0 (l_prep) in_53\IN\13603305|in_289|doses_50|._54 (l_pobj) seizures_57\NNS\14081375|NONE_0 (l_conj) epilepticus_60\NN\0|severe_40|motor_33|limbic_27|and_11
D020888_D012640 NONE gaba_17\NNP\14601829|or_15 (r_conj) isoniazid_11\NN\2716205|NONE_0 (r_pobj) of_10\IN\0|into_33 (r_prep) microinjection_9\NN\0|NONE_0 (r_pobj) after_8\IN\0|NONE_0 (r_prep) rats_7\NNS\2329401|NONE_0 (r_pobj) in_6\IN\13603305|by_15 (r_prep) produced_3\VBN\1617192|NONE_0 (r_acl) seizures_2\NNS\14081375|NONE_0
D020888_D012640 NONE acid_6\NN\14818238|,_23|,_5|micrograms_9|,_19|into_21 (r_appos) d_1\NNP\15089472|(_1|,_57|bilaterally_59|,_70|appearance_87|,_163|mg/kg_169|._174 (r_nsubj) suppressed_18\VBD\2510337|NONE_0 (l_dobj) appearance_20\NN\4723816|(_88|d_87|,_30|bilaterally_28|,_17|,_76|mg/kg_82|._87 (l_prep) of_21\IN\0|the_15 (l_pobj) seizures_25\NNS\14081375|NONE_0
D020888_D012640 NONE gaba_6\NNP\14601829|NONE_0 (r_pobj) of_1\IN\0|into_35 (r_prep) microinjections_0\NNS\0|,_75|bilaterally_77|,_88|prevent_100|,_162|mg/kg_168|._173 (r_nsubj) failed_18\VBD\0|NONE_0 (l_xcomp) prevent_20\VB\0|microinjections_100|,_25|bilaterally_23|,_12|,_62|mg/kg_68|._73 (l_dobj) development_22\NN\248977|to_15 (l_prep) of_23\IN\0|the_16 (l_pobj) convulsions_24\NNS\14081375|NONE_0
D018698_D012640 NONE acid_25\NN\14818238|glutamic_9 (r_compound) decarboxylase_26\NN\14732946|the_46|synthesizing_37|,_18|,_13|into_15 (r_appos) enzyme_20\NN\14723628|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) activity_14\NN\30358|NONE_0 (r_pobj) of_13\IN\0|an_13 (r_prep) inhibitor_12\NN\20090|150_19|,_5 (r_appos) micrograms_9\NNS\13717155|of_18|,_6 (r_conj) microinjections_4\NNS\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) pretreated_2\VBN\0|NONE_0 (r_acl) animals_1\NNS\4475|NONE_0 (r_pobj) in_0\IN\13603305|doses_239|in_289|._343 (r_prep) resulted_52\VBD\2633881|NONE_0 (l_prep) in_53\IN\13603305|in_289|doses_50|._54 (l_pobj) seizures_57\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_5\NN\14712692|NONE_0 (r_pobj) by_4\IN\0|in_15 (r_agent) produced_3\VBN\1617192|NONE_0 (r_acl) seizures_2\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_0\NNP\14712692|,_11|given_13|,_44|sequelae_79|and_114|provides_118|._302 (r_nsubj) reproduces_7\VBZ\1621555|NONE_0 (l_conj) provides_16\VBZ\2199590|pilocarpine_118|,_107|given_105|,_74|sequelae_39|and_4|._184 (l_dobj) model_20\NN\5888929|NONE_0 (l_prep) for_21\IN\0|a_24|relevant_22|animal_13 (l_pcomp) studying_22\VBG\5808794|NONE_0 (l_dobj) mechanisms_23\NNS\13446390|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) buildup_25\NN\372013|NONE_0 (l_prep) of_26\IN\0|NONE_0 (l_pobj) activity_28\NN\30358|NONE_0 (l_amod) convulsive_27\JJ\0|and_20|pathways_24|operative_33
D010862_D012640 CID pilocarpine_0\NNP\14712692|,_11|given_13|,_44|sequelae_79|and_114|provides_118|._302 (r_nsubj) reproduces_7\VBZ\1621555|NONE_0 (l_conj) provides_16\VBZ\2199590|pilocarpine_118|,_107|given_105|,_74|sequelae_39|and_4|._184 (l_dobj) model_20\NN\5888929|NONE_0 (l_prep) for_21\IN\0|a_24|relevant_22|animal_13 (l_pcomp) studying_22\VBG\5808794|NONE_0 (l_dobj) mechanisms_23\NNS\13446390|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) buildup_25\NN\372013|NONE_0 (l_prep) of_26\IN\0|NONE_0 (l_pobj) activity_28\NN\30358|NONE_0 (l_amod) operative_31\JJ\9777353|convulsive_33|and_13|pathways_9 (l_prep) in_32\IN\13603305|NONE_0 (l_pobj) generalization_34\NN\5764197|NONE_0 (l_prep) of_37\IN\0|the_35|and_16|propagation_12 (l_pobj) seizures_38\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_29\NN\14712692|NONE_0 (r_pobj) by_28\IN\0|in_15 (r_agent) produced_27\VBN\1617192|NONE_0 (r_acl) seizures_26\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_45\NN\14712692|NONE_0 (r_pobj) of_44\IN\0|-_18|convulsant_17|,_14|mg/kg_28|,_33 (r_prep) doses_43\NNS\3740161|in_239|in_50|._104 (r_nsubj) resulted_52\VBD\2633881|NONE_0 (l_prep) in_53\IN\13603305|in_289|doses_50|._54 (l_pobj) seizures_57\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_12\NN\14712692|-_11 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) convulsions_15\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_36\NN\14712692|NONE_0 (r_pobj) with_35\IN\0|which_28|is_22|typically_19|in_17 (r_prep) observed_34\VBN\2163746|the_116|hippocampal_112|,_91|thalamus_89|,_21 (r_relcl) formation_17\NN\7938773|NONE_0 (r_pobj) to_14\IN\0|related_15 (r_prep) damage_13\NN\7296428|analysis_86|._180 (l_amod) related_12\VBN\628491|to_15 (l_npadvmod) seizure_10\NN\14081375|-_7
D010862_D012640 CID pilocarpine_11\NN\14712692|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) produced_9\VBN\1617192|,_23|mg/kg_29 (r_acl) seizures_8\NNS\14081375|injections_40|did_16|not_12|._43
D010862_D012640 CID pilocarpine_28\NN\14712692|NONE_0 (r_pobj) by_27\IN\0|NONE_0 (r_agent) produced_26\VBN\1617192|electrographic_39 (r_acl) seizures_25\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_27\NN\14712692|NONE_0 (r_pobj) by_26\IN\0|NONE_0 (r_agent) produced_25\VBN\1617192|NONE_0 (r_acl) convulsions_24\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_7\NN\14712692|-_11 (r_npadvmod) induced_9\VBN\1627355|in_17 (r_amod) seizures_10\NNS\14081375|NONE_0
D010862_D004833 NONE pilocarpine_0\NNP\14712692|,_11|given_13|,_44|sequelae_79|and_114|provides_118|._302 (r_nsubj) reproduces_7\VBZ\1621555|NONE_0 (l_dobj) sequelae_10\NNS\14501726|pilocarpine_79|,_68|given_66|,_35|and_35|provides_39|._223 (l_prep) of_11\IN\0|the_31|neuropathological_27 (l_pobj) epilepsy_14\NN\14085708|NONE_0
D007538_D012640 NONE isoniazid_11\NN\2716205|NONE_0 (r_pobj) of_10\IN\0|into_33 (r_prep) microinjection_9\NN\0|NONE_0 (r_pobj) after_8\IN\0|NONE_0 (r_prep) rats_7\NNS\2329401|NONE_0 (r_pobj) in_6\IN\13603305|by_15 (r_prep) produced_3\VBN\1617192|NONE_0 (r_acl) seizures_2\NNS\14081375|NONE_0
D007538_D012640 NONE isoniazid_6\NN\2716205|NONE_0 (r_pobj) of_5\IN\0|,_12|micrograms_18 (r_prep) microinjections_4\NNS\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) pretreated_2\VBN\0|NONE_0 (r_acl) animals_1\NNS\4475|NONE_0 (r_pobj) in_0\IN\13603305|doses_239|in_289|._343 (r_prep) resulted_52\VBD\2633881|NONE_0 (l_prep) in_53\IN\13603305|in_289|doses_50|._54 (l_pobj) seizures_57\NNS\14081375|NONE_0
D007538_D012640 NONE isoniazid_4\NN\2716205|NONE_0 (r_pobj) of_3\IN\0|bilateral_35|intrastriatal_25 (r_prep) injections_2\NNS\320852|did_24|not_28|seizures_40|._83 (r_nsubj) augment_7\VB\153263|NONE_0 (l_dobj) seizures_8\NNS\14081375|injections_40|did_16|not_12|._43
D018698_D013226 NONE acid_25\NN\14818238|glutamic_9 (r_compound) decarboxylase_26\NN\14732946|the_46|synthesizing_37|,_18|,_13|into_15 (r_appos) enzyme_20\NN\14723628|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) activity_14\NN\30358|NONE_0 (r_pobj) of_13\IN\0|an_13 (r_prep) inhibitor_12\NN\20090|150_19|,_5 (r_appos) micrograms_9\NNS\13717155|of_18|,_6 (r_conj) microinjections_4\NNS\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) pretreated_2\VBN\0|NONE_0 (r_acl) animals_1\NNS\4475|NONE_0 (r_pobj) in_0\IN\13603305|doses_239|in_289|._343 (r_prep) resulted_52\VBD\2633881|NONE_0 (l_prep) in_53\IN\13603305|in_289|doses_50|._54 (l_pobj) seizures_57\NNS\14081375|NONE_0 (l_conj) epilepticus_60\NN\0|severe_40|motor_33|limbic_27|and_11
D005680_D013226 NONE gaba_17\NNP\14601829|-_4 (r_npadvmod) synthesizing_19\VBG\193486|the_9|,_19|decarboxylase_37|,_50|into_52 (r_amod) enzyme_20\NN\14723628|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) activity_14\NN\30358|NONE_0 (r_pobj) of_13\IN\0|an_13 (r_prep) inhibitor_12\NN\20090|150_19|,_5 (r_appos) micrograms_9\NNS\13717155|of_18|,_6 (r_conj) microinjections_4\NNS\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) pretreated_2\VBN\0|NONE_0 (r_acl) animals_1\NNS\4475|NONE_0 (r_pobj) in_0\IN\13603305|doses_239|in_289|._343 (r_prep) resulted_52\VBD\2633881|NONE_0 (l_prep) in_53\IN\13603305|in_289|doses_50|._54 (l_pobj) seizures_57\NNS\14081375|NONE_0 (l_conj) epilepticus_60\NN\0|severe_40|motor_33|limbic_27|and_11
4082466
D009020_D012640 CID morphine_0\NNP\2707683|-_8 (r_npadvmod) induced_2\VBN\1627355|in_17|._35 (r_amod) seizures_3\NNS\14081375|NONE_0
D009020_D012640 CID sulfate_12\NN\15010703|NONE_0 (r_pobj) of_9\IN\0|the_11 (r_prep) course_8\NN\883297|NONE_0 (r_pobj) during_6\IN\0|neonates_44|from_26|._78 (r_prep) suffered_2\VBD\2110220|NONE_0 (l_prep) from_3\IN\0|neonates_18|during_26|._104 (l_pobj) seizures_5\NNS\14081375|NONE_0
D009020_D012640 CID morphine_18\NN\2707683|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) cessation_16\NN\7365849|hours_12 (r_pobj) after_15\IN\0|convulsions_32|and_28|reoccur_40|._74 (r_prep) stopped_11\VBD\0|reasons_56|were_35|out_24|and_20 (r_conj) ruled_6\VBN\2441022|NONE_0 (l_nsubjpass) reasons_2\NNS\9178821|were_21|out_32|and_36|stopped_56 (l_prep) for_3\IN\0|other_20|known_14 (l_pobj) seizures_4\NNS\14081375|NONE_0
D009020_D012640 CID morphine_18\NN\2707683|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) cessation_16\NN\7365849|hours_12 (r_pobj) after_15\IN\0|convulsions_32|and_28|reoccur_40|._74 (r_prep) stopped_11\VBD\0|reasons_56|were_35|out_24|and_20 (l_nsubj) convulsions_10\NNS\14081375|after_32|and_60|reoccur_72|._106
2933998
D017265_D014202 CID procaterol_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|both_44|asthmatic_34 (r_prep) effects_6\NNS\13245626|related_32|._39 (l_amod) asthmatic_3\JJ\7846|both_10|of_34 (l_conj) tremorgenic_5\JJ\0|-_15|and_4
D013726_D001249 NONE terbutaline_2\NN\0|and_4|._31 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) asthma_5\NN\14145095|NONE_0
D017265_D001249 NONE procaterol_0\NNP\0|NONE_0 (l_conj) terbutaline_2\NN\0|and_4|._31 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) asthma_5\NN\14145095|NONE_0
D017265_D001249 NONE procaterol_0\NNP\0|was_49|in_61|._150 (r_nsubjpass) studied_9\VBN\0|NONE_0 (l_prep) in_10\IN\13603305|procaterol_61|was_12|._89 (l_pobj) trial_23\NN\786195|NONE_0 (l_prep) in_24\IN\13603305|a_53|blind_44|,_39|controlled_29|,_19|cross_17 (l_pobj) patients_25\NNS\9898892|NONE_0 (l_prep) with_26\IN\0|NONE_0 (l_pobj) asthma_28\NN\14145095|NONE_0
D017265_D001249 NONE procaterol_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|both_44|asthmatic_34 (r_prep) effects_6\NNS\13245626|related_32|._39 (l_amod) asthmatic_3\JJ\7846|both_10|of_34
24778426
D008353_D007674 NONE mannitol_22\NN\3214670|NONE_0 (r_pobj) without_21\IN\0|and_4 (r_conj) with_19\IN\0|NONE_0 (r_prep) cisplatin_18\NN\0|agent_6 (r_dobj) receiving_14\VBG\2210855|cancer_16 (r_acl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|induced_23 (r_prep) nephrotoxicity_10\NN\0|NONE_0
D008353_D007674 NONE mannitol_5\NN\3214670|who_20|did_16|not_12 (r_dobj) receive_4\VB\2210855|NONE_0 (r_relcl) patients_0\NNS\9898892|likely_48|ratio_87|._140 (r_nsubj) were_6\VBD\0|NONE_0 (l_acomp) likely_8\JJ\0|patients_48|ratio_39|._92 (l_xcomp) develop_10\VB\1753788|more_15 (l_dobj) nephrotoxicity_11\NN\0|to_11
D008353_D007674 NONE mannitol_4\NNS\3214670|NONE_0 (r_pobj) of_3\IN\0|limited_19 (r_prep) quantities_2\NNS\2137|when_13|available_27 (r_nsubj) are_5\VBP\13600404|,_13|it_15|should_18|preferentially_25|be_40|to_49|._104 (r_advcl) given_12\VBN\5892096|NONE_0 (l_dative) to_13\IN\0|are_49|,_36|it_34|should_31|preferentially_24|be_9|._55 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) at_15\IN\14622893|NONE_0 (l_pobj) risk_18\NN\14541044|NONE_0 (l_prep) of_19\IN\0|high_10 (l_pobj) nephrotoxicity_20\NN\0|NONE_0
D008353_D007674 NONE mannitol_38\NN\3214670|NONE_0 (r_pobj) of_37\IN\0|the_13 (r_prep) addition_36\NN\3081021|NONE_0 (r_pobj) from_34\IN\0|would_14 (r_prep) benefit_33\VB\13278375|weeks_87|at_49|and_10 (r_conj) are_24\VBP\13600404|that_117|patients_106 (l_prep) at_25\IN\14622893|weeks_38|and_39|benefit_49 (l_pobj) risk_28\NN\14541044|NONE_0 (l_prep) of_29\IN\0|the_18|greatest_14 (l_pobj) nephrotoxicity_30\NN\0|NONE_0
D002945_D007674 NONE cisplatin_6\JJ\0|NONE_0 (r_amod) use_7\NN\407535|NONE_0 (r_pobj) of_5\IN\0|the_24|major_20 (r_prep) complications_4\NNS\1073995|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) one_0\CD\13741022|nephrotoxicity_65|._79 (r_nsubj) is_8\VBZ\0|NONE_0 (l_attr) nephrotoxicity_12\NN\0|one_65|._14
D002945_D007674 NONE cisplatin_7\NN\0|-_9 (r_advmod) induced_9\VBN\1627355|in_23 (r_amod) nephrotoxicity_10\NN\0|NONE_0
D002945_D007674 NONE cisplatin_18\NN\0|agent_6 (r_dobj) receiving_14\VBG\2210855|cancer_16 (r_acl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|induced_23 (r_prep) nephrotoxicity_10\NN\0|NONE_0
D002945_D007674 NONE cisplatin_16\NN\0|analysis_83|._142 (l_advcl) are_24\VBP\13600404|that_117|patients_106 (l_prep) at_25\IN\14622893|weeks_38|and_39|benefit_49 (l_pobj) risk_28\NN\14541044|NONE_0 (l_prep) of_29\IN\0|the_18|greatest_14 (l_pobj) nephrotoxicity_30\NN\0|NONE_0
D008353_D064420 NONE mannitol_13\NN\3214670|NONE_0 (r_pobj) of_12\IN\0|the_8|as_12 (r_prep) use_11\NN\407535|NONE_0 (r_pobj) including_9\VBG\0|to_26|toxicity_10|,_2 (r_prep) prevent_5\VB\0|many_19 (l_dobj) toxicity_7\NN\13576101|to_16|,_8|including_10
D002945_D009369 NONE cisplatin_7\NN\0|-_9 (r_advmod) induced_9\VBN\1627355|in_23 (r_amod) nephrotoxicity_10\NN\0|NONE_0 (l_prep) in_11\IN\13603305|induced_23 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_compound) cancer_12\NN\14239425|receiving_16
D002945_D009369 NONE cisplatin_18\NN\0|agent_6 (r_dobj) receiving_14\VBG\2210855|cancer_16 (r_acl) patients_13\NNS\9898892|NONE_0 (l_compound) cancer_12\NN\14239425|receiving_16
D002945_D009369 NONE cisplatin_11\NN\0|as_10 (r_dobj) receiving_7\VBG\2210855|cancer_16 (r_acl) patients_6\NNS\9898892|NONE_0 (l_compound) cancer_5\NN\14239425|receiving_16
D002945_D009369 NONE cisplatin_10\NN\0|who_26 (r_dobj) received_6\VBD\2210855|143_17 (r_relcl) patients_4\NNS\9898892|:_19|we_17 (r_dobj) evaluated_2\VBD\670261|;_58|%_64|cancer_96|as_103|._130 (r_ccomp) had_16\VBD\0|NONE_0 (l_prep) as_21\IN\14622893|evaluated_103|;_45|%_39|cancer_7|._27 (l_pobj) malignancy_24\NN\14070360|NONE_0
D002945_D006973 NONE cisplatin_16\NN\0|analysis_83|._142 (l_advcl) are_24\VBP\13600404|that_117|patients_106 (l_nsubj) weeks_19\NNS\15113229|at_38|and_77|benefit_87 (l_conj) those_21\DT\0|every_18|3_12|and_4 (l_prep) with_22\IN\0|NONE_0 (l_pobj) hypertension_23\NN\14057371|NONE_0
D002945_D006258 NONE cisplatin_10\NN\0|who_26 (r_dobj) received_6\VBD\2210855|143_17 (r_relcl) patients_4\NNS\9898892|:_19|we_17 (r_dobj) evaluated_2\VBD\670261|;_58|%_64|cancer_96|as_103|._130 (r_ccomp) had_16\VBD\0|NONE_0 (l_dobj) cancer_20\NN\14239425|evaluated_96|;_38|%_32|as_7|._34
D008353_D009369 NONE mannitol_22\NN\3214670|NONE_0 (r_pobj) without_21\IN\0|and_4 (r_conj) with_19\IN\0|NONE_0 (r_prep) cisplatin_18\NN\0|agent_6 (r_dobj) receiving_14\VBG\2210855|cancer_16 (r_acl) patients_13\NNS\9898892|NONE_0 (l_compound) cancer_12\NN\14239425|receiving_16
D008353_D006973 NONE mannitol_38\NN\3214670|NONE_0 (r_pobj) of_37\IN\0|the_13 (r_prep) addition_36\NN\3081021|NONE_0 (r_pobj) from_34\IN\0|would_14 (r_prep) benefit_33\VB\13278375|weeks_87|at_49|and_10 (r_conj) are_24\VBP\13600404|that_117|patients_106 (l_nsubj) weeks_19\NNS\15113229|at_38|and_77|benefit_87 (l_conj) those_21\DT\0|every_18|3_12|and_4 (l_prep) with_22\IN\0|NONE_0 (l_pobj) hypertension_23\NN\14057371|NONE_0
20447294
C401121_D003929 NONE cnsb002_9\NNP\0|and_4 (r_conj) morphine_7\NN\2707683|NONE_0 (r_pobj) of_6\IN\0|nonsedating_18 (r_prep) doses_5\NNS\3740161|NONE_0 (r_pobj) for_3\IN\0|response_16|given_46 (r_prep) curves_2\VBZ\13863771|were_112|for_129 (r_nsubjpass) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (r_ccomp) inflammation_38\NN\14299637|NONE_0 (l_appos) neuropathy_44\NN\14204950|constructed_182|:_81|induced_67|paw_59|and_42|streptozotocin_38|._10
C401121_D007249 NONE cnsb002_9\NNP\0|and_4 (r_conj) morphine_7\NN\2707683|NONE_0 (r_pobj) of_6\IN\0|nonsedating_18 (r_prep) doses_5\NNS\3740161|NONE_0 (r_pobj) for_3\IN\0|response_16|given_46 (r_prep) curves_2\VBZ\13863771|were_112|for_129 (r_nsubjpass) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (r_ccomp) inflammation_38\NN\14299637|NONE_0
D013311_D007249 NONE streptozotocin_40\JJ\0|constructed_144|:_43|induced_29|paw_21|and_4|neuropathy_38|._48 (r_conj) inflammation_38\NN\14299637|NONE_0
D013311_D007249 NONE stz)-induced_42\VBN\0|(_1|diabetic_13 (r_amod) neuropathy_44\NN\14204950|constructed_182|:_81|induced_67|paw_59|and_42|streptozotocin_38|._10 (r_appos) inflammation_38\NN\14299637|NONE_0
C401121_D006930 NONE cnsb002_45\NNP\0|NONE_0 (r_pobj) for_44\IN\0|the_33|induced_25|neuropathy_17 (r_prep) model_43\NN\5888929|NONE_0 (r_pobj) in_37\IN\13603305|(_81|1.81_80|)_76|and_74|4.83_70|,_60|sem_89|)_92 (r_prep) 7.54_14\CD\0|doses_67|._179 (r_attr) were_13\VBD\0|NONE_0 (l_nsubj) doses_1\NNS\3740161|7.54_67|._246 (l_acl) calculated_2\VBN\632627|the_10|(_49|ed50_50|)_54 (l_advcl) cause_4\VB\7323922|NONE_0 (l_dobj) reversal_7\NN\199130|to_13 (l_prep) of_8\IN\0|%_11 (l_pobj) hyperalgesia_9\NN\0|NONE_0
C401121_D006930 NONE cnsb002_15\NNP\0|administration_20 (r_pobj) with_14\IN\0|28.0_18|to_33|and_42|reversal_52 (r_punct) from_16\IN\0|antinociception_91|was_48|._212 (l_conj) reversal_26\NN\199130|with_52|28.0_34|to_19|and_10 (l_prep) of_27\IN\0|%_11|in_16|,_58|respectively_60|(_73|p_74 (l_pobj) hyperalgesia_28\NN\0|NONE_0
C401121_D010146 NONE cnsb002_9\NNP\0|and_4 (r_conj) morphine_7\NN\2707683|NONE_0 (r_pobj) of_6\IN\0|nonsedating_18 (r_prep) doses_5\NNS\3740161|NONE_0 (r_pobj) for_3\IN\0|response_16|given_46 (r_prep) curves_2\VBZ\13863771|were_112|for_129 (r_nsubjpass) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (l_prep) for_19\IN\0|curves_129|were_17 (l_pobj) effect_21\NN\34213|NONE_0 (l_acl) using_22\VBG\418025|antihyperalgesic_24 (l_prep) in_28\IN\13603305|withdrawal_29 (l_pobj) models_32\NNS\5888929|NONE_0 (l_compound) pain_31\NN\14299637|two_8|rat_4
C401121_D009437 NONE cnsb002_12\NNP\0|a_32|novel_30|channel_17|,_2 (r_appos) blocker_10\NN\10101634|and_27 (r_conj) morphine_4\NN\2707683|NONE_0 (r_pobj) between_3\IN\0|NONE_0 (r_prep) synergy_2\NN\13518963|NONE_0 (r_pobj) of_1\IN\0|,_71|in_73|._123 (r_prep) studies_0\NNS\635850|NONE_0 (l_prep) in_14\IN\13603305|of_73|,_2|._50 (l_pobj) models_16\NNS\5888929|NONE_0 (l_prep) of_17\IN\0|rat_11 (l_pobj) pain_21\NN\14299637|NONE_0
C401121_D009437 NONE cnsb002_9\NNP\0|NONE_0 (l_appos) blocker_14\NN\10101634|,_19 (l_prep) with_15\IN\0|a_25|channel_16 (l_conj) in_21\IN\13603305|properties_27|and_4 (l_pobj) combinations_22\NNS\7951464|NONE_0 (l_prep) in_25\IN\13603305|with_14 (l_pobj) models_27\NNS\5888929|NONE_0 (l_prep) of_28\IN\0|rat_11 (l_pobj) pain_32\NN\14299637|NONE_0
D002351_D010146 NONE carrageenan_34\NN\14898470|-_11 (r_npadvmod) induced_36\VBN\1627355|constructed_115|:_14|paw_8|and_25|streptozotocin_29|neuropathy_67|._77 (r_amod) inflammation_38\NN\14299637|NONE_0 (l_ccomp) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (l_prep) for_19\IN\0|curves_129|were_17 (l_pobj) effect_21\NN\34213|NONE_0 (l_acl) using_22\VBG\418025|antihyperalgesic_24 (l_prep) in_28\IN\13603305|withdrawal_29 (l_pobj) models_32\NNS\5888929|NONE_0 (l_compound) pain_31\NN\14299637|two_8|rat_4
D013311_D009422 NONE stz_39\NNP\0|-_3 (r_npadvmod) induced_41\VBN\1627355|the_8|neuropathy_8|for_25 (r_amod) model_43\NN\5888929|NONE_0 (l_compound) neuropathy_42\NN\14204950|the_16|induced_8|for_17
D009020_D010146 NONE morphine_7\NN\2707683|NONE_0 (r_pobj) of_6\IN\0|nonsedating_18 (r_prep) doses_5\NNS\3740161|NONE_0 (r_pobj) for_3\IN\0|response_16|given_46 (r_prep) curves_2\VBZ\13863771|were_112|for_129 (r_nsubjpass) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (l_prep) for_19\IN\0|curves_129|were_17 (l_pobj) effect_21\NN\34213|NONE_0 (l_acl) using_22\VBG\418025|antihyperalgesic_24 (l_prep) in_28\IN\13603305|withdrawal_29 (l_pobj) models_32\NNS\5888929|NONE_0 (l_compound) pain_31\NN\14299637|two_8|rat_4
D002351_D006930 CID carrageenan_25\NN\14898470|the_4 (r_compound) model_26\NN\5888929|NONE_0 (r_pobj) in_23\IN\13603305|1.54_6|and_25|44.18_29|1.37_36|and_42|9.14_46 (r_prep) 4.83_19\CD\0|(_11|1.81_10|)_6|and_4|in_70|,_130|sem_159|)_162 (r_conj) 7.54_14\CD\0|doses_67|._179 (r_attr) were_13\VBD\0|NONE_0 (l_nsubj) doses_1\NNS\3740161|7.54_67|._246 (l_acl) calculated_2\VBN\632627|the_10|(_49|ed50_50|)_54 (l_advcl) cause_4\VB\7323922|NONE_0 (l_dobj) reversal_7\NN\199130|to_13 (l_prep) of_8\IN\0|%_11 (l_pobj) hyperalgesia_9\NN\0|NONE_0
D009020_D009437 NONE morphine_4\NN\2707683|NONE_0 (r_pobj) between_3\IN\0|NONE_0 (r_prep) synergy_2\NN\13518963|NONE_0 (r_pobj) of_1\IN\0|,_71|in_73|._123 (r_prep) studies_0\NNS\635850|NONE_0 (l_prep) in_14\IN\13603305|of_73|,_2|._50 (l_pobj) models_16\NNS\5888929|NONE_0 (l_prep) of_17\IN\0|rat_11 (l_pobj) pain_21\NN\14299637|NONE_0
D009020_D009437 NONE morphine_24\NN\2707683|NONE_0 (r_pobj) with_23\IN\0|in_14 (r_prep) combinations_22\NNS\7951464|NONE_0 (l_prep) in_25\IN\13603305|with_14 (l_pobj) models_27\NNS\5888929|NONE_0 (l_prep) of_28\IN\0|rat_11 (l_pobj) pain_32\NN\14299637|NONE_0
D002351_D003929 NONE carrageenan_34\NN\14898470|-_11 (r_npadvmod) induced_36\VBN\1627355|constructed_115|:_14|paw_8|and_25|streptozotocin_29|neuropathy_67|._77 (r_amod) inflammation_38\NN\14299637|NONE_0 (l_appos) neuropathy_44\NN\14204950|constructed_182|:_81|induced_67|paw_59|and_42|streptozotocin_38|._10
D013311_D006930 CID stz_39\NNP\0|-_3 (r_npadvmod) induced_41\VBN\1627355|the_8|neuropathy_8|for_25 (r_amod) model_43\NN\5888929|NONE_0 (r_pobj) in_37\IN\13603305|(_81|1.81_80|)_76|and_74|4.83_70|,_60|sem_89|)_92 (r_prep) 7.54_14\CD\0|doses_67|._179 (r_attr) were_13\VBD\0|NONE_0 (l_nsubj) doses_1\NNS\3740161|7.54_67|._246 (l_acl) calculated_2\VBN\632627|the_10|(_49|ed50_50|)_54 (l_advcl) cause_4\VB\7323922|NONE_0 (l_dobj) reversal_7\NN\199130|to_13 (l_prep) of_8\IN\0|%_11 (l_pobj) hyperalgesia_9\NN\0|NONE_0
D002351_D009422 NONE carrageenan_25\NN\14898470|the_4 (r_compound) model_26\NN\5888929|NONE_0 (r_pobj) in_23\IN\13603305|1.54_6|and_25|44.18_29|1.37_36|and_42|9.14_46 (r_prep) 4.83_19\CD\0|(_11|1.81_10|)_6|and_4|in_70|,_130|sem_159|)_162 (r_conj) 7.54_14\CD\0|doses_67|._179 (l_prep) in_37\IN\13603305|(_81|1.81_80|)_76|and_74|4.83_70|,_60|sem_89|)_92 (l_pobj) model_43\NN\5888929|NONE_0 (l_compound) neuropathy_42\NN\14204950|the_16|induced_8|for_17
D002351_D009422 NONE carrageenan_29\NN\14898470|the_4 (r_compound) model_30\NN\5888929|NONE_0 (r_pobj) in_27\IN\13603305|the_42|maximum_38|nonsedating_30|1.55_6 (r_prep) dose_21\NN\3740161|NONE_0 (r_pobj) than_17\IN\0|and_72|1.37_76 (r_prep) less_16\JJR\14187378|values_74|._135 (l_conj) 1.37_32\CD\0|than_76|and_4 (l_prep) in_36\IN\13603305|1.23_6 (l_pobj) model_39\NN\5888929|sem_20 (l_compound) neuropathy_38\NN\14204950|the_4
C401121_D009422 NONE cnsb002_45\NNP\0|NONE_0 (r_pobj) for_44\IN\0|the_33|induced_25|neuropathy_17 (r_prep) model_43\NN\5888929|NONE_0 (l_compound) neuropathy_42\NN\14204950|the_16|induced_8|for_17
C401121_D009422 NONE cnsb002_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) combination_8\NN\7951464|NONE_0 (r_pobj) in_7\IN\13603305|when_11|mg/kg_31 (r_prep) given_6\VBN\5892096|the_34|ed50_30|for_18 (r_advcl) values_2\NNS\5941423|less_74|._209 (r_nsubj) were_15\VBD\0|NONE_0 (l_acomp) less_16\JJR\14187378|values_74|._135 (l_conj) 1.37_32\CD\0|than_76|and_4 (l_prep) in_36\IN\13603305|1.23_6 (l_pobj) model_39\NN\5888929|sem_20 (l_compound) neuropathy_38\NN\14204950|the_4
C401121_D009422 NONE cnsb002_15\NNP\0|administration_20 (r_pobj) with_14\IN\0|28.0_18|to_33|and_42|reversal_52 (r_punct) from_16\IN\0|antinociception_91|was_48|._212 (l_conj) reversal_26\NN\199130|with_52|28.0_34|to_19|and_10 (l_prep) in_29\IN\13603305|%_27|of_16|,_42|respectively_44|(_57|p_58 (l_pobj) models_34\NNS\5888929|NONE_0 (l_amod) inflammatory_31\JJ\0|the_4 (l_conj) neuropathic_33\JJ\0|and_4
D013311_D003929 CID streptozotocin_40\JJ\0|constructed_144|:_43|induced_29|paw_21|and_4|neuropathy_38|._48 (r_conj) inflammation_38\NN\14299637|NONE_0 (l_appos) neuropathy_44\NN\14204950|constructed_182|:_81|induced_67|paw_59|and_42|streptozotocin_38|._10
D013311_D003929 CID stz)-induced_42\VBN\0|(_1|diabetic_13 (r_amod) neuropathy_44\NN\14204950|constructed_182|:_81|induced_67|paw_59|and_42|streptozotocin_38|._10
D009020_D006930 NONE morphine_47\NN\2707683|and_4 (r_conj) cnsb002_45\NNP\0|NONE_0 (r_pobj) for_44\IN\0|the_33|induced_25|neuropathy_17 (r_prep) model_43\NN\5888929|NONE_0 (r_pobj) in_37\IN\13603305|(_81|1.81_80|)_76|and_74|4.83_70|,_60|sem_89|)_92 (r_prep) 7.54_14\CD\0|doses_67|._179 (r_attr) were_13\VBD\0|NONE_0 (l_nsubj) doses_1\NNS\3740161|7.54_67|._246 (l_acl) calculated_2\VBN\632627|the_10|(_49|ed50_50|)_54 (l_advcl) cause_4\VB\7323922|NONE_0 (l_dobj) reversal_7\NN\199130|to_13 (l_prep) of_8\IN\0|%_11 (l_pobj) hyperalgesia_9\NN\0|NONE_0
D009020_D006930 NONE morphine_3\NN\2707683|NONE_0 (r_pobj) after_2\IN\0|the_20|(_15|mg/kg_20|)_25 (r_prep) antinociception_1\NN\0|was_43|from_91|._303 (r_nsubjpass) increased_9\VBN\169651|NONE_0 (l_prep) from_16\IN\0|antinociception_91|was_48|._212 (l_conj) reversal_26\NN\199130|with_52|28.0_34|to_19|and_10 (l_prep) of_27\IN\0|%_11|in_16|,_58|respectively_60|(_73|p_74 (l_pobj) hyperalgesia_28\NN\0|NONE_0
D013311_D010146 NONE streptozotocin_40\JJ\0|constructed_144|:_43|induced_29|paw_21|and_4|neuropathy_38|._48 (r_conj) inflammation_38\NN\14299637|NONE_0 (l_ccomp) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (l_prep) for_19\IN\0|curves_129|were_17 (l_pobj) effect_21\NN\34213|NONE_0 (l_acl) using_22\VBG\418025|antihyperalgesic_24 (l_prep) in_28\IN\13603305|withdrawal_29 (l_pobj) models_32\NNS\5888929|NONE_0 (l_compound) pain_31\NN\14299637|two_8|rat_4
D013311_D010146 NONE stz)-induced_42\VBN\0|(_1|diabetic_13 (r_amod) neuropathy_44\NN\14204950|constructed_182|:_81|induced_67|paw_59|and_42|streptozotocin_38|._10 (r_appos) inflammation_38\NN\14299637|NONE_0 (l_ccomp) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (l_prep) for_19\IN\0|curves_129|were_17 (l_pobj) effect_21\NN\34213|NONE_0 (l_acl) using_22\VBG\418025|antihyperalgesic_24 (l_prep) in_28\IN\13603305|withdrawal_29 (l_pobj) models_32\NNS\5888929|NONE_0 (l_compound) pain_31\NN\14299637|two_8|rat_4
D012964_D009437 NONE sodium_8\NN\14625458|NONE_0 (r_compound) channel_9\NN\6251781|a_15|novel_13|,_15|cnsb002_17 (r_compound) blocker_10\NN\10101634|and_27 (r_conj) morphine_4\NN\2707683|NONE_0 (r_pobj) between_3\IN\0|NONE_0 (r_prep) synergy_2\NN\13518963|NONE_0 (r_pobj) of_1\IN\0|,_71|in_73|._123 (r_prep) studies_0\NNS\635850|NONE_0 (l_prep) in_14\IN\13603305|of_73|,_2|._50 (l_pobj) models_16\NNS\5888929|NONE_0 (l_prep) of_17\IN\0|rat_11 (l_pobj) pain_21\NN\14299637|NONE_0
D012964_D009437 NONE sodium_12\NN\14625458|NONE_0 (r_compound) channel_13\NN\6251781|a_9|with_16 (r_compound) blocker_14\NN\10101634|,_19 (l_prep) with_15\IN\0|a_25|channel_16 (l_conj) in_21\IN\13603305|properties_27|and_4 (l_pobj) combinations_22\NNS\7951464|NONE_0 (l_prep) in_25\IN\13603305|with_14 (l_pobj) models_27\NNS\5888929|NONE_0 (l_prep) of_28\IN\0|rat_11 (l_pobj) pain_32\NN\14299637|NONE_0
D009020_D009422 NONE morphine_47\NN\2707683|and_4 (r_conj) cnsb002_45\NNP\0|NONE_0 (r_pobj) for_44\IN\0|the_33|induced_25|neuropathy_17 (r_prep) model_43\NN\5888929|NONE_0 (l_compound) neuropathy_42\NN\14204950|the_16|induced_8|for_17
D009020_D009422 NONE morphine_4\NN\2707683|NONE_0 (r_pobj) for_3\IN\0|the_16|ed50_12|given_18 (r_prep) values_2\NNS\5941423|less_74|._209 (r_nsubj) were_15\VBD\0|NONE_0 (l_acomp) less_16\JJR\14187378|values_74|._135 (l_conj) 1.37_32\CD\0|than_76|and_4 (l_prep) in_36\IN\13603305|1.23_6 (l_pobj) model_39\NN\5888929|sem_20 (l_compound) neuropathy_38\NN\14204950|the_4
D009020_D009422 NONE morphine_3\NN\2707683|NONE_0 (r_pobj) after_2\IN\0|the_20|(_15|mg/kg_20|)_25 (r_prep) antinociception_1\NN\0|was_43|from_91|._303 (r_nsubjpass) increased_9\VBN\169651|NONE_0 (l_prep) from_16\IN\0|antinociception_91|was_48|._212 (l_conj) reversal_26\NN\199130|with_52|28.0_34|to_19|and_10 (l_prep) in_29\IN\13603305|%_27|of_16|,_42|respectively_44|(_57|p_58 (l_pobj) models_34\NNS\5888929|NONE_0 (l_amod) inflammatory_31\JJ\0|the_4 (l_conj) neuropathic_33\JJ\0|and_4
D009020_D007249 NONE morphine_7\NN\2707683|NONE_0 (r_pobj) of_6\IN\0|nonsedating_18 (r_prep) doses_5\NNS\3740161|NONE_0 (r_pobj) for_3\IN\0|response_16|given_46 (r_prep) curves_2\VBZ\13863771|were_112|for_129 (r_nsubjpass) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (r_ccomp) inflammation_38\NN\14299637|NONE_0
D009020_D003929 NONE morphine_7\NN\2707683|NONE_0 (r_pobj) of_6\IN\0|nonsedating_18 (r_prep) doses_5\NNS\3740161|NONE_0 (r_pobj) for_3\IN\0|response_16|given_46 (r_prep) curves_2\VBZ\13863771|were_112|for_129 (r_nsubjpass) constructed_18\VBN\1617192|:_101|induced_115|paw_123|and_140|streptozotocin_144|neuropathy_182|._192 (r_ccomp) inflammation_38\NN\14299637|NONE_0 (l_appos) neuropathy_44\NN\14204950|constructed_182|:_81|induced_67|paw_59|and_42|streptozotocin_38|._10
D002351_D007249 CID carrageenan_34\NN\14898470|-_11 (r_npadvmod) induced_36\VBN\1627355|constructed_115|:_14|paw_8|and_25|streptozotocin_29|neuropathy_67|._77 (r_amod) inflammation_38\NN\14299637|NONE_0
22836123
D016559_D012595 CID tacrolimus_13\NN\0|in_15 (r_compound) use_14\NN\407535|NONE_0 (l_prep) in_15\IN\13603305|tacrolimus_15 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) ssc_18\NNS\0|NONE_0
D016572_D012595 NONE cyclosporine_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) ssc_15\NNS\0|NONE_0
D000305_D007674 NONE corticosteroid_4\NN\14745635|high_10|dose_5 (r_compound) use_5\NN\407535|NONE_0 (r_pobj) to_1\IN\0|NONE_0 (r_prep) moderate_0\JJ\9605289|is_41|as_55|._85 (r_nsubjpass) recognized_7\VBN\686447|NONE_0 (l_prep) as_8\IN\14622893|moderate_55|is_14|._30 (l_pobj) factor_12\NN\7326557|NONE_0 (l_prep) for_13\IN\0|a_20|major_18|risk_12 (l_pobj) src_14\NNP\0|NONE_0
D000305_D007674 NONE corticosteroids_14\NNS\14745635|and_4 (r_conj) tacrolimus_12\NNS\0|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|a_19|with_9 (r_acl) patient_7\NN\9898892|in_29|,_14|we_12|._58 (l_prep) with_8\IN\0|a_10|induced_9 (l_pobj) src_9\NNP\0|NONE_0
D016572_D057049 CID cyclosporine_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) precipitated_9\VBN\1642924|thrombotic_27 (r_acl) microangiopathy_8\NN\0|NONE_0
D011239_D007674 NONE prednisolone_10\NN\2721538|and_4 (r_conj) tacrolimus_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|crisis_15 (r_agent) induced_6\VBN\1627355|:_38|a_40|case_42|._53 (l_nsubj) crisis_5\NN\14411243|by_15
D016559_D007674 NONE tacrolimus_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|crisis_15 (r_agent) induced_6\VBN\1627355|:_38|a_40|case_42|._53 (l_nsubj) crisis_5\NN\14411243|by_15
D016559_D007674 NONE tacrolimus_12\NNS\0|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|a_19|with_9 (r_acl) patient_7\NN\9898892|in_29|,_14|we_12|._58 (l_prep) with_8\IN\0|a_10|induced_9 (l_pobj) src_9\NNP\0|NONE_0
12559315
D007213_D008415 CID indomethacin_0\NNP\3828465|in_22|._141 (r_nsubj) resulted_1\VBD\2633881|NONE_0 (l_prep) in_2\IN\13603305|indomethacin_22|._119 (l_pobj) findings_4\NNS\7951464|NONE_0 (l_amod) typical_5\JJ\0|histopathologic_25 (l_prep) of_6\IN\0|NONE_0 (l_pobj) cystitis_8\NN\14566129|NONE_0 (l_prep) as_11\IN\14622893|interstitial_28|,_7 (l_pobj) epithelium_14\NN\5267548|such_22 (l_conj) mastocytosis_17\NN\0|leaky_37|bladder_31|and_12
D007213_D018856 CID indomethacin_0\NNP\3828465|in_22|._141 (r_nsubj) resulted_1\VBD\2633881|NONE_0 (l_prep) in_2\IN\13603305|indomethacin_22|._119 (l_pobj) findings_4\NNS\7951464|NONE_0 (l_amod) typical_5\JJ\0|histopathologic_25 (l_prep) of_6\IN\0|NONE_0 (l_pobj) cystitis_8\NN\14566129|NONE_0
753803
D008696_D009135 NONE dianabol_29\NNP\0|one_23|anabolizing_19|(_1|)_14 (r_appos) agent_27\NN\7347|NONE_0 (r_pobj) of_24\IN\0|the_23|beneficial_19|at_42 (r_prep) effects_23\NNS\13245626|to_30 (r_dobj) investigate_20\VB\644583|results_137|have_31|authors_11|e._149 (r_xcomp) encouraged_16\VBN\2556126|NONE_0 (l_nsubj) results_2\NNS\34213|have_106|authors_126|investigate_137|e._286 (l_acl) obtained_3\VBN\2210855|the_24|encouraging_20 (l_prep) in_4\IN\13603305|by_59 (l_pobj) departments_7\NNS\8220714|NONE_0 (l_prep) in_8\IN\13603305|various_34|authoratative_26 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) myopathic_9\JJ\0|NONE_0
D008696_D009135 NONE dianabol_29\NNP\0|one_23|anabolizing_19|(_1|)_14 (r_appos) agent_27\NN\7347|NONE_0 (r_pobj) of_24\IN\0|the_23|beneficial_19|at_42 (r_prep) effects_23\NNS\13245626|to_30 (l_prep) at_33\IN\14622893|the_65|beneficial_61|of_42 (l_pobj) doses_35\NNS\3740161|NONE_0 (l_prep) in_36\IN\13603305|high_11 (l_pobj) rats_37\NNS\2329401|NONE_0 (l_acl) rendered_38\VBN\120316|NONE_0 (l_oprd) myopathic_39\JJ\0|by_10
D014810_D009136 CID e._15\NNP\0|NONE_0 (r_pobj) in_13\IN\13603305|NONE_0 (r_prep) lacking_12\VBG\0|a_7 (r_acl) diet_11\NN\7560652|it_5 (r_dobj) giving_8\VBG\1085793|NONE_0 (r_pcomp) by_7\IN\0|authors_40|myodystrophy_24 (r_prep) induced_2\VBD\1627355|NONE_0 (l_dobj) myodystrophy_3\NN\0|authors_16|by_24
-1_D009135 NONE ciba_31\NNP\0|,_2 (r_appos) dianabol_29\NNP\0|one_23|anabolizing_19|(_1|)_14 (r_appos) agent_27\NN\7347|NONE_0 (r_pobj) of_24\IN\0|the_23|beneficial_19|at_42 (r_prep) effects_23\NNS\13245626|to_30 (r_dobj) investigate_20\VB\644583|results_137|have_31|authors_11|e._149 (r_xcomp) encouraged_16\VBN\2556126|NONE_0 (l_nsubj) results_2\NNS\34213|have_106|authors_126|investigate_137|e._286 (l_acl) obtained_3\VBN\2210855|the_24|encouraging_20 (l_prep) in_4\IN\13603305|by_59 (l_pobj) departments_7\NNS\8220714|NONE_0 (l_prep) in_8\IN\13603305|various_34|authoratative_26 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) myopathic_9\JJ\0|NONE_0
-1_D009135 NONE ciba_31\NNP\0|,_2 (r_appos) dianabol_29\NNP\0|one_23|anabolizing_19|(_1|)_14 (r_appos) agent_27\NN\7347|NONE_0 (r_pobj) of_24\IN\0|the_23|beneficial_19|at_42 (r_prep) effects_23\NNS\13245626|to_30 (l_prep) at_33\IN\14622893|the_65|beneficial_61|of_42 (l_pobj) doses_35\NNS\3740161|NONE_0 (l_prep) in_36\IN\13603305|high_11 (l_pobj) rats_37\NNS\2329401|NONE_0 (l_acl) rendered_38\VBN\120316|NONE_0 (l_oprd) myopathic_39\JJ\0|by_10
D013256_D009135 NONE steroids_14\NNS\14727670|NONE_0 (r_dobj) using_12\VBG\418025|NONE_0 (r_pcomp) by_11\IN\0|in_59 (r_prep) obtained_3\VBN\2210855|the_24|encouraging_20 (l_prep) in_4\IN\13603305|by_59 (l_pobj) departments_7\NNS\8220714|NONE_0 (l_prep) in_8\IN\13603305|various_34|authoratative_26 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) myopathic_9\JJ\0|NONE_0
D013256_D009135 NONE steroids_14\NNS\14727670|NONE_0 (r_dobj) using_12\VBG\418025|NONE_0 (r_pcomp) by_11\IN\0|in_59 (r_prep) obtained_3\VBN\2210855|the_24|encouraging_20 (r_acl) results_2\NNS\34213|have_106|authors_126|investigate_137|e._286 (r_nsubj) encouraged_16\VBN\2556126|NONE_0 (l_xcomp) investigate_20\VB\644583|results_137|have_31|authors_11|e._149 (l_dobj) effects_23\NNS\13245626|to_30 (l_prep) at_33\IN\14622893|the_65|beneficial_61|of_42 (l_pobj) doses_35\NNS\3740161|NONE_0 (l_prep) in_36\IN\13603305|high_11 (l_pobj) rats_37\NNS\2329401|NONE_0 (l_acl) rendered_38\VBN\120316|NONE_0 (l_oprd) myopathic_39\JJ\0|by_10
D013256_D009135 NONE steroids_11\NNS\14727670|NONE_0 (r_pobj) of_8\IN\0|the_23|undoubted_19|in_28 (r_prep) efficacy_7\NN\5199286|NONE_0 (l_prep) in_12\IN\13603305|the_51|undoubted_47|of_28 (l_pobj) disease_15\NN\14061805|NONE_0
D014810_D009135 NONE e_6\NNS\14724645|NONE_0 (r_pobj) of_4\IN\0|induced_26 (r_prep) lack_3\NN\14449126|to_3 (r_pobj) due_1\IN\5174653|NONE_0 (r_amod) myopathy_0\NNP\14204950|much_79|anatomically_94|with_126|._145
D014810_D009135 NONE e_6\NNS\14724645|NONE_0 (l_conj) myopathy_8\NNS\14204950|vitamin_14|and_4
D014810_D009135 NONE e._46\NNP\0|results_286|have_180|authors_160|investigate_149 (r_punct) encouraged_16\VBN\2556126|NONE_0 (l_nsubj) results_2\NNS\34213|have_106|authors_126|investigate_137|e._286 (l_acl) obtained_3\VBN\2210855|the_24|encouraging_20 (l_prep) in_4\IN\13603305|by_59 (l_pobj) departments_7\NNS\8220714|NONE_0 (l_prep) in_8\IN\13603305|various_34|authoratative_26 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) myopathic_9\JJ\0|NONE_0
D014810_D009135 NONE e._46\NNP\0|results_286|have_180|authors_160|investigate_149 (r_punct) encouraged_16\VBN\2556126|NONE_0 (l_xcomp) investigate_20\VB\644583|results_137|have_31|authors_11|e._149 (l_dobj) effects_23\NNS\13245626|to_30 (l_prep) at_33\IN\14622893|the_65|beneficial_61|of_42 (l_pobj) doses_35\NNS\3740161|NONE_0 (l_prep) in_36\IN\13603305|high_11 (l_pobj) rats_37\NNS\2329401|NONE_0 (l_acl) rendered_38\VBN\120316|NONE_0 (l_oprd) myopathic_39\JJ\0|by_10
D014810_D009135 NONE e_91\NN\14724645|NONE_0 (r_pobj) of_89\IN\0|the_9|but_13|something_17 (r_prep) lack_88\NN\14449126|finally_68|because_60|agent_27|certainly_18|not_8 (r_attr) is_84\VBZ\0|because_170|injury_151|often_140|at_127|;_53|and_51 (r_conj) occurs_58\VBZ\0|they_216|reservations_206|;_38|._201 (r_advcl) have_19\VBP\7846|authors_125|by_108|,_11|but_9 (r_conj) conclude_2\VBP\628491|NONE_0 (l_prep) by_3\IN\0|authors_17|,_97|but_99|have_108 (l_pcomp) affirming_4\VBG\0|NONE_0 (l_dobj) efficacy_7\NN\5199286|NONE_0 (l_prep) in_12\IN\13603305|the_51|undoubted_47|of_28 (l_pobj) disease_15\NN\14061805|NONE_0
1760851
D004317_D066126 CID doxorubicin_3\NN\2716866|NONE_0 (r_pobj) of_2\IN\0|reduced_23|:_80|and_82|study_99|._115 (r_prep) cardiotoxicity_1\NN\0|NONE_0
D004317_D066126 CID doxorubicin_18\NN\2716866|NONE_0 (r_pobj) of_15\IN\0|the_24|late_20 (r_prep) cardiotoxicity_14\NN\0|the_40|general_36|acute_28|and_13
D004317_D066126 CID dox_20\NNP\0|mg/kg_19 (r_appos) doxorubicin_18\NN\2716866|NONE_0 (r_pobj) of_15\IN\0|the_24|late_20 (r_prep) cardiotoxicity_14\NN\0|the_40|general_36|acute_28|and_13
D004317_D066126 CID dox_21\NNP\0|that_26 (r_dobj) received_18\VBD\2210855|NONE_0 (r_relcl) animals_16\NNS\4475|only_8 (r_pobj) in_15\IN\13603305|throughout_85|,_54|deaths_52|were_19 (r_prep) observed_13\VBN\2163746|;_100|in_102|,_116|investigations_131|changes_162|._235 (l_nsubjpass) deaths_8\NNS\7296428|throughout_33|,_2|were_33|in_52 (l_acl) related_9\VBN\628491|NONE_0 (l_prep) to_10\IN\0|NONE_0 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
D004317_D066126 CID dox_21\NNP\0|that_26 (r_dobj) received_18\VBD\2210855|NONE_0 (r_relcl) animals_16\NNS\4475|only_8 (r_pobj) in_15\IN\13603305|throughout_85|,_54|deaths_52|were_19 (r_prep) observed_13\VBN\2163746|;_100|in_102|,_116|investigations_131|changes_162|._235 (r_ccomp) revealed_38\VBD\2137132|NONE_0 (l_dobj) changes_40\NNS\7283608|observed_162|;_62|in_60|,_46|investigations_31|._73 (l_relcl) were_45\VBD\0|marked_33|in_18 (l_acomp) consistent_46\JJ\0|that_10 (l_prep) with_47\IN\0|NONE_0 (l_pobj) cardiotoxicity_51\NN\0|NONE_0
D004317_D066126 CID dox_30\NNP\0|hpma_24|and_9 (r_conj) copolymer_27\NN\14994328|NONE_0 (r_pobj) of_25\IN\0|the_12 (r_prep) mixture_24\NN\19613|free_16|or_7 (r_conj) dox_21\NNP\0|that_26 (r_dobj) received_18\VBD\2210855|NONE_0 (r_relcl) animals_16\NNS\4475|only_8 (r_pobj) in_15\IN\13603305|throughout_85|,_54|deaths_52|were_19 (r_prep) observed_13\VBN\2163746|;_100|in_102|,_116|investigations_131|changes_162|._235 (l_nsubjpass) deaths_8\NNS\7296428|throughout_33|,_2|were_33|in_52 (l_acl) related_9\VBN\628491|NONE_0 (l_prep) to_10\IN\0|NONE_0 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
D004317_D066126 CID dox_30\NNP\0|hpma_24|and_9 (r_conj) copolymer_27\NN\14994328|NONE_0 (r_pobj) of_25\IN\0|the_12 (r_prep) mixture_24\NN\19613|free_16|or_7 (r_conj) dox_21\NNP\0|that_26 (r_dobj) received_18\VBD\2210855|NONE_0 (r_relcl) animals_16\NNS\4475|only_8 (r_pobj) in_15\IN\13603305|throughout_85|,_54|deaths_52|were_19 (r_prep) observed_13\VBN\2163746|;_100|in_102|,_116|investigations_131|changes_162|._235 (r_ccomp) revealed_38\VBD\2137132|NONE_0 (l_dobj) changes_40\NNS\7283608|observed_162|;_62|in_60|,_46|investigations_31|._73 (l_relcl) were_45\VBD\0|marked_33|in_18 (l_acomp) consistent_46\JJ\0|that_10 (l_prep) with_47\IN\0|NONE_0 (l_pobj) cardiotoxicity_51\NN\0|NONE_0
D004317_D066126 CID dox_48\NNP\0|-_3 (r_npadvmod) induced_50\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_51\NN\0|NONE_0 (r_pobj) with_47\IN\0|NONE_0 (r_prep) consistent_46\JJ\0|that_10 (r_acomp) were_45\VBD\0|marked_33|in_18 (r_relcl) changes_40\NNS\7283608|observed_162|;_62|in_60|,_46|investigations_31|._73 (r_dobj) revealed_38\VBD\2137132|NONE_0 (l_ccomp) observed_13\VBN\2163746|;_100|in_102|,_116|investigations_131|changes_162|._235 (l_nsubjpass) deaths_8\NNS\7296428|throughout_33|,_2|were_33|in_52 (l_acl) related_9\VBN\628491|NONE_0 (l_prep) to_10\IN\0|NONE_0 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
D004317_D066126 CID dox_48\NNP\0|-_3 (r_npadvmod) induced_50\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_51\NN\0|NONE_0
C032976_D064420 NONE n-(2-hydroxypropyl)methacrylamide_33\NN\0|three_6|copolymer_41 (r_nmod) conjugates_38\NNS\14589223|NONE_0 (r_pobj) of_31\IN\0|the_9 (r_prep) form_30\NN\6286395|NONE_0 (r_pobj) in_28\IN\13603305|either_23|drug_8|or_3 (r_conj) as_24\IN\14622893|NONE_0 (r_prep) given_22\VBN\5892096|model_111|was_105|evaluate_93|._111 (r_prep) used_4\VBN\0|NONE_0 (l_xcomp) evaluate_6\VB\670261|model_18|was_12|given_93|._204 (l_dobj) toxicity_10\NN\13576101|to_30
C032976_D064420 NONE hpma_35\NNP\0|(_1|)_4 (r_nmod) copolymer_37\NN\14994328|three_47|n-(2-hydroxypropyl)methacrylamide_41 (r_compound) conjugates_38\NNS\14589223|NONE_0 (r_pobj) of_31\IN\0|the_9 (r_prep) form_30\NN\6286395|NONE_0 (r_pobj) in_28\IN\13603305|either_23|drug_8|or_3 (r_conj) as_24\IN\14622893|NONE_0 (r_prep) given_22\VBN\5892096|model_111|was_105|evaluate_93|._111 (r_prep) used_4\VBN\0|NONE_0 (l_xcomp) evaluate_6\VB\670261|model_18|was_12|given_93|._204 (l_dobj) toxicity_10\NN\13576101|to_30
D004317_D064420 NONE doxorubicin_18\NN\2716866|NONE_0 (r_pobj) of_15\IN\0|the_24|late_20 (r_prep) cardiotoxicity_14\NN\0|the_40|general_36|acute_28|and_13 (r_conj) toxicity_10\NN\13576101|to_30
D004317_D064420 NONE dox_20\NNP\0|mg/kg_19 (r_appos) doxorubicin_18\NN\2716866|NONE_0 (r_pobj) of_15\IN\0|the_24|late_20 (r_prep) cardiotoxicity_14\NN\0|the_40|general_36|acute_28|and_13 (r_conj) toxicity_10\NN\13576101|to_30
C032976_D066126 NONE n-(2-hydroxypropyl)methacrylamide_9\JJ\0|NONE_0 (r_compound) conjugates_10\NNS\14589223|NONE_0 (r_pobj) of_8\IN\0|the_9 (r_prep) form_7\NN\6286395|NONE_0 (r_pobj) in_5\IN\13603305|NONE_0 (r_prep) given_4\VBN\5892096|NONE_0 (r_acl) doxorubicin_3\NN\2716866|NONE_0 (r_pobj) of_2\IN\0|reduced_23|:_80|and_82|study_99|._115 (r_prep) cardiotoxicity_1\NN\0|NONE_0
C032976_D066126 NONE n-(2-hydroxypropyl)methacrylamide_33\NN\0|three_6|copolymer_41 (r_nmod) conjugates_38\NNS\14589223|NONE_0 (r_pobj) of_31\IN\0|the_9 (r_prep) form_30\NN\6286395|NONE_0 (r_pobj) in_28\IN\13603305|either_23|drug_8|or_3 (r_conj) as_24\IN\14622893|NONE_0 (r_prep) given_22\VBN\5892096|model_111|was_105|evaluate_93|._111 (r_prep) used_4\VBN\0|NONE_0 (l_xcomp) evaluate_6\VB\670261|model_18|was_12|given_93|._204 (l_dobj) toxicity_10\NN\13576101|to_30 (l_conj) cardiotoxicity_14\NN\0|the_40|general_36|acute_28|and_13
C032976_D066126 NONE hpma_35\NNP\0|(_1|)_4 (r_nmod) copolymer_37\NN\14994328|three_47|n-(2-hydroxypropyl)methacrylamide_41 (r_compound) conjugates_38\NNS\14589223|NONE_0 (r_pobj) of_31\IN\0|the_9 (r_prep) form_30\NN\6286395|NONE_0 (r_pobj) in_28\IN\13603305|either_23|drug_8|or_3 (r_conj) as_24\IN\14622893|NONE_0 (r_prep) given_22\VBN\5892096|model_111|was_105|evaluate_93|._111 (r_prep) used_4\VBN\0|NONE_0 (l_xcomp) evaluate_6\VB\670261|model_18|was_12|given_93|._204 (l_dobj) toxicity_10\NN\13576101|to_30 (l_conj) cardiotoxicity_14\NN\0|the_40|general_36|acute_28|and_13
C032976_D066126 NONE hpma_26\NNP\0|and_15|dox_24 (r_compound) copolymer_27\NN\14994328|NONE_0 (r_pobj) of_25\IN\0|the_12 (r_prep) mixture_24\NN\19613|free_16|or_7 (r_conj) dox_21\NNP\0|that_26 (r_dobj) received_18\VBD\2210855|NONE_0 (r_relcl) animals_16\NNS\4475|only_8 (r_pobj) in_15\IN\13603305|throughout_85|,_54|deaths_52|were_19 (r_prep) observed_13\VBN\2163746|;_100|in_102|,_116|investigations_131|changes_162|._235 (l_nsubjpass) deaths_8\NNS\7296428|throughout_33|,_2|were_33|in_52 (l_acl) related_9\VBN\628491|NONE_0 (l_prep) to_10\IN\0|NONE_0 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
C032976_D066126 NONE hpma_26\NNP\0|and_15|dox_24 (r_compound) copolymer_27\NN\14994328|NONE_0 (r_pobj) of_25\IN\0|the_12 (r_prep) mixture_24\NN\19613|free_16|or_7 (r_conj) dox_21\NNP\0|that_26 (r_dobj) received_18\VBD\2210855|NONE_0 (r_relcl) animals_16\NNS\4475|only_8 (r_pobj) in_15\IN\13603305|throughout_85|,_54|deaths_52|were_19 (r_prep) observed_13\VBN\2163746|;_100|in_102|,_116|investigations_131|changes_162|._235 (r_ccomp) revealed_38\VBD\2137132|NONE_0 (l_dobj) changes_40\NNS\7283608|observed_162|;_62|in_60|,_46|investigations_31|._73 (l_relcl) were_45\VBD\0|marked_33|in_18 (l_acomp) consistent_46\JJ\0|that_10 (l_prep) with_47\IN\0|NONE_0 (l_pobj) cardiotoxicity_51\NN\0|NONE_0
17879217
D012293_D014376 NONE rifampicin_9\NNS\0|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) of_8\IN\0|in_22 (r_prep) complication_7\NN\1073995|NONE_0 (l_prep) in_11\IN\13603305|of_22 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_acl) receiving_13\VBG\2210855|NONE_0 (l_dobj) treatment_14\NN\654885|NONE_0 (l_prep) for_15\IN\0|NONE_0 (l_pobj) tuberculosis_16\NN\14127211|NONE_0
D012293_D058186 CID rifampicin_25\NNS\0|NONE_0 (r_pobj) with_24\IN\0|while_20|being_14 (r_prep) treated_23\VBN\2376958|who_102|failure_76|,_23|and_25|review_29 (r_advcl) developed_11\VBD\1753788|staphylococcal_22 (l_dobj) failure_14\NN\66216|who_26|treated_76|,_99|and_101|review_105
D012293_D058186 CID rifampicin_35\NNS\0|NONE_0 (r_compound) therapy_36\NN\657604|NONE_0 (r_pobj) of_34\IN\0|this_18 (r_prep) complication_33\NN\1073995|NONE_0 (r_pobj) regarding_31\VBG\689344|literature_11 (r_prep) review_28\VB\5733583|who_131|failure_105|treated_29|,_6|and_4 (r_conj) developed_11\VBD\1753788|staphylococcal_22 (l_dobj) failure_14\NN\66216|who_26|treated_76|,_99|and_101|review_105
D012293_D013203 NONE rifampicin_0\NNS\0|-_10 (r_npadvmod) associated_2\VBN\628491|necrotizing_21|in_52|._82 (r_amod) glomerulonephritis_5\NN\14113798|NONE_0 (l_prep) in_6\IN\13603305|associated_52|necrotizing_31|._30 (l_pobj) endocarditis_8\NN\14338942|NONE_0
D012293_D013203 NONE rifampicin_20\NNS\0|NONE_0 (l_prep) for_21\IN\0|NONE_0 (l_pobj) infections_23\NNS\14052046|NONE_0
D012293_D013203 NONE rifampicin_25\NNS\0|NONE_0 (r_pobj) with_24\IN\0|while_20|being_14 (r_prep) treated_23\VBN\2376958|who_102|failure_76|,_23|and_25|review_29 (r_advcl) developed_11\VBD\1753788|staphylococcal_22 (r_relcl) ie_9\NNP\0|NONE_0
D012293_D013203 NONE rifampicin_35\NNS\0|NONE_0 (r_compound) therapy_36\NN\657604|NONE_0 (r_pobj) of_34\IN\0|this_18 (r_prep) complication_33\NN\1073995|NONE_0 (r_pobj) regarding_31\VBG\689344|literature_11 (r_prep) review_28\VB\5733583|who_131|failure_105|treated_29|,_6|and_4 (r_conj) developed_11\VBD\1753788|staphylococcal_22 (r_relcl) ie_9\NNP\0|NONE_0
D012293_D005921 CID rifampicin_0\NNS\0|-_10 (r_npadvmod) associated_2\VBN\628491|necrotizing_21|in_52|._82 (r_amod) glomerulonephritis_5\NN\14113798|NONE_0
D012293_D005921 CID rifampicin_9\NNS\0|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) of_8\IN\0|in_22 (r_prep) complication_7\NN\1073995|NONE_0 (r_pobj) as_6\IN\14622893|glomerulonephritis_37|has_18|been_14|._86 (r_prep) reported_5\VBN\831651|NONE_0 (l_nsubjpass) glomerulonephritis_2\NN\14113798|has_19|been_23|as_37|._123
D012293_D005921 CID rifampicin_25\NNS\0|NONE_0 (r_pobj) with_24\IN\0|while_20|being_14 (r_prep) treated_23\VBN\2376958|who_102|failure_76|,_23|and_25|review_29 (r_advcl) developed_11\VBD\1753788|staphylococcal_22 (l_dobj) failure_14\NN\66216|who_26|treated_76|,_99|and_101|review_105 (l_amod) secondary_15\JJ\8426461|acute_20|renal_14 (l_prep) to_16\IN\0|NONE_0 (l_pobj) glomerulonephritis_20\NN\14113798|NONE_0
D012293_D005921 CID rifampicin_35\NNS\0|NONE_0 (r_compound) therapy_36\NN\657604|NONE_0 (r_pobj) of_34\IN\0|this_18 (r_prep) complication_33\NN\1073995|NONE_0 (r_pobj) regarding_31\VBG\689344|literature_11 (r_prep) review_28\VB\5733583|who_131|failure_105|treated_29|,_6|and_4 (r_conj) developed_11\VBD\1753788|staphylococcal_22 (l_dobj) failure_14\NN\66216|who_26|treated_76|,_99|and_101|review_105 (l_amod) secondary_15\JJ\8426461|acute_20|renal_14 (l_prep) to_16\IN\0|NONE_0 (l_pobj) glomerulonephritis_20\NN\14113798|NONE_0
D012293_D007239 NONE rifampicin_20\NNS\0|NONE_0 (r_pobj) of_19\IN\0|the_8 (r_prep) use_18\NN\407535|NONE_0 (r_pobj) in_16\IN\13603305|an_12 (r_prep) increase_15\NN\13576355|NONE_0 (r_pobj) to_13\IN\0|changing_80|has_8|._69 (r_prep) led_12\VBN\3202760|NONE_0 (l_csubj) changing_0\VBG\0|has_72|to_80|._149 (l_dobj) epidemiology_1\NN\6043075|NONE_0 (l_prep) of_2\IN\0|NONE_0 (l_pobj) infections_3\NNS\14052046|NONE_0
D012293_D004696 NONE rifampicin_0\NNS\0|-_10 (r_npadvmod) associated_2\VBN\628491|necrotizing_21|in_52|._82 (r_amod) glomerulonephritis_5\NN\14113798|NONE_0 (l_prep) in_6\IN\13603305|associated_52|necrotizing_31|._30 (l_pobj) endocarditis_8\NN\14338942|NONE_0
D012293_D004696 NONE rifampicin_20\NNS\0|NONE_0 (r_pobj) of_19\IN\0|the_8 (r_prep) use_18\NN\407535|NONE_0 (r_pobj) in_16\IN\13603305|an_12 (r_prep) increase_15\NN\13576355|NONE_0 (r_pobj) to_13\IN\0|changing_80|has_8|._69 (r_prep) led_12\VBN\3202760|NONE_0 (l_csubj) changing_0\VBG\0|has_72|to_80|._149 (l_dobj) epidemiology_1\NN\6043075|NONE_0 (l_prep) of_2\IN\0|NONE_0 (l_pobj) infections_3\NNS\14052046|NONE_0 (l_prep) as_5\IN\14622893|NONE_0 (l_pobj) endocarditis_7\NN\14338942|such_18
D012293_D004696 NONE rifampicin_20\NNS\0|NONE_0 (r_pobj) of_19\IN\0|the_8 (r_prep) use_18\NN\407535|NONE_0 (r_pobj) in_16\IN\13603305|an_12 (r_prep) increase_15\NN\13576355|NONE_0 (r_pobj) to_13\IN\0|changing_80|has_8|._69 (r_prep) led_12\VBN\3202760|NONE_0 (l_csubj) changing_0\VBG\0|has_72|to_80|._149 (l_dobj) epidemiology_1\NN\6043075|NONE_0 (l_prep) of_2\IN\0|NONE_0 (l_pobj) infections_3\NNS\14052046|NONE_0 (l_prep) as_5\IN\14622893|NONE_0 (l_pobj) endocarditis_7\NN\14338942|such_18 (l_appos) ie_9\NNP\0|infective_24|(_1|)_2
D012293_D004696 NONE rifampicin_25\NNS\0|NONE_0 (r_pobj) with_24\IN\0|while_20|being_14 (r_prep) treated_23\VBN\2376958|who_102|failure_76|,_23|and_25|review_29 (r_advcl) developed_11\VBD\1753788|staphylococcal_22 (r_relcl) ie_9\NNP\0|NONE_0
D012293_D004696 NONE rifampicin_35\NNS\0|NONE_0 (r_compound) therapy_36\NN\657604|NONE_0 (r_pobj) of_34\IN\0|this_18 (r_prep) complication_33\NN\1073995|NONE_0 (r_pobj) regarding_31\VBG\689344|literature_11 (r_prep) review_28\VB\5733583|who_131|failure_105|treated_29|,_6|and_4 (r_conj) developed_11\VBD\1753788|staphylococcal_22 (r_relcl) ie_9\NNP\0|NONE_0
8957205
D000324_D006935 NONE corticotropin_1\NN\5407119|-_13 (r_npadvmod) releasing_3\VBG\0|human_20|and_18 (r_amod) hormone_4\NN\5404728|releasing_24 (r_nmod) hormone_9\NN\5404728|response_45|._63 (r_nsubj) modulate_10\VBP\1724459|NONE_0 (l_dobj) response_14\NN\11410625|hormone_45|._18 (l_amod) hypercapnic_12\JJ\0|the_4|ventilatory_12|in_33
D013972_D006935 NONE thyrotropin_6\NN\5407119|-_11 (r_npadvmod) releasing_8\VBG\0|hormone_24 (r_amod) hormone_9\NN\5404728|response_45|._63 (r_nsubj) modulate_10\VBP\1724459|NONE_0 (l_dobj) response_14\NN\11410625|hormone_45|._18 (l_amod) hypercapnic_12\JJ\0|the_4|ventilatory_12|in_33
24816962
D008795_D001927 CID metronidazole_0\NNP\2723292|-_13 (r_npadvmod) induced_2\VBN\1627355|:_22|scenario_36|._44 (r_amod) encephalopathy_3\NN\14084880|NONE_0
D008795_D001927 CID metronidazole_13\NN\2723292|prolonged_10 (r_compound) intake_14\NN\13440063|NONE_0 (r_pobj) following_11\VBG\8180190|where_53|a_47|patient_45|developed_37|of_18 (r_prep) features_8\NNS\5849040|a_33 (l_prep) of_9\IN\0|where_35|a_29|patient_27|developed_19|following_18 (l_pobj) encephalopathy_10\JJ\14084880|NONE_0
D008795_D064420 NONE metronidazole_3\JJ\2723292|NONE_0 (r_amod) toxicity_4\NN\13576101|NONE_0
12950111
D006024_D006261 CID glycopyrrolate_17\NN\0|2_15|(_4|)_14 (r_appos) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|a_14|sore_12 (r_prep) throat_10\NN\5548726|a_30|dry_21|and_11|,_40|headache_50 (r_conj) mouth_6\NN\5610008|effects_30|._110 (l_appos) headache_22\NN\5829480|a_80|dry_71|and_61|throat_50|,_10
D006024_D006261 CID glycopyrrolate_29\NN\0|a_36|light_34|in_19 (r_parataxis) headache_22\NN\5829480|a_80|dry_71|and_61|throat_50|,_10
D006024_D010612 CID glycopyrrolate_17\NN\0|2_15|(_4|)_14 (r_appos) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|a_14|sore_12 (r_prep) throat_10\NN\5548726|a_30|dry_21|and_11|,_40|headache_50
D006024_D010612 CID glycopyrrolate_29\NN\0|a_36|light_34|in_19 (r_parataxis) headache_22\NN\5829480|a_80|dry_71|and_61|throat_50|,_10 (r_appos) mouth_6\NN\5610008|effects_30|._110 (l_conj) throat_10\NN\5548726|a_30|dry_21|and_11|,_40|headache_50
D006024_D014987 NONE glycopyrrolate_17\NN\0|2_15|(_4|)_14 (r_appos) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|a_14|sore_12 (r_prep) throat_10\NN\5548726|a_30|dry_21|and_11|,_40|headache_50 (r_conj) mouth_6\NN\5610008|effects_30|._110
D006024_D014987 NONE glycopyrrolate_29\NN\0|a_36|light_34|in_19 (r_parataxis) headache_22\NN\5829480|a_80|dry_71|and_61|throat_50|,_10 (r_appos) mouth_6\NN\5610008|effects_30|._110
D006024_D013547 NONE glycopyrrolate_7\NN\0|NONE_0 (r_pobj) with_5\IN\0|compensatory_37|gustatory_24 (r_prep) hyperhidrosis_4\NN\13535261|NONE_0
D006024_D013547 NONE glycopyrrolate_3\NN\0|NONE_0 (r_dobj) applying_1\VBG\0|NONE_0 (r_pcomp) after_0\IN\0|,_37|effect_54|excellent_65|sweating_79|._194 (r_prep) was_8\VBD\0|NONE_0 (l_parataxis) sweating_12\NN\13440063|after_79|,_42|effect_25|excellent_14|._115
D006024_D013547 NONE glycopyrrolate_3\NN\0|NONE_0 (r_dobj) applying_1\VBG\0|NONE_0 (r_pcomp) after_0\IN\0|,_37|effect_54|excellent_65|sweating_79|._194 (r_prep) was_8\VBD\0|NONE_0 (l_parataxis) sweating_12\NN\13440063|after_79|,_42|effect_25|excellent_14|._115 (l_conj) sweating_32\NN\13440063|(_90|no_89|after_77|)_50|in_48|,_28|and_26
D006024_D013547 NONE glycopyrrolate_5\JJ\0|a_2 (r_compound) pad_6\NN\14974264|NONE_0 (r_pobj) of_3\IN\0|the_24|topical_20|method_91 (r_prep) application_2\NN\947128|be_48|tolerated_75|._278 (l_appos) method_20\NN\5616786|the_115|topical_111|of_91 (l_prep) to_25\TO\0|a_46|convenient_44|of_26|in_46|,_119|with_121 (l_pobj) symptoms_27\NNS\5823932|NONE_0 (l_prep) of_28\IN\0|severe_16 (l_pobj) hyperhidrosis_30\NN\13535261|NONE_0
20024739
D000431_D003866 CID alcohol_5\NN\7881800|and_20|depression_24 (r_compound) consumption_6\NN\13440063|NONE_0 (l_conj) depression_8\NN\14373582|alcohol_24|and_4
D000431_D003866 CID alcohol_39\NN\7881800|NONE_0 (r_compound) use_40\NN\407535|at_15|,_28|and_30|semiannually_34|._63 (r_compound) assessment_41\NN\5732756|participants_245|examination_219|(_93|using_92|,_18|and_16 (r_conj) had_2\VBD\0|NONE_0 (l_dobj) examination_4\NN\633864|participants_26|(_126|using_127|,_201|and_203|assessment_219 (l_appos) measurement_19\NN\407535|physical_100|,_80|extraction_63 (l_prep) of_20\IN\0|NONE_0 (l_pobj) symptoms_22\NNS\5823932|NONE_0 (l_compound) depression_21\NN\14373582|NONE_0
D000431_D003866 CID alcohol_39\NN\7881800|NONE_0 (r_compound) use_40\NN\407535|at_15|,_28|and_30|semiannually_34|._63 (r_compound) assessment_41\NN\5732756|participants_245|examination_219|(_93|using_92|,_18|and_16 (r_conj) had_2\VBD\0|NONE_0 (l_advcl) using_24\VBG\418025|participants_153|examination_127|(_1|,_74|and_76|assessment_92 (l_dobj) center_29\NNP\8497294|)_51 (l_prep) for_30\IN\0|the_23|report_14 (l_pobj) scale_35\NNP\7260623|NONE_0 (l_compound) depression_34\NNP\14373582|epidemiological_24
D000431_D003866 CID alcohol_3\NN\7881800|and_20|depression_24 (r_compound) consumption_4\NN\13440063|NONE_0 (l_conj) depression_6\NN\14373582|alcohol_24|and_4
D000431_D003866 CID alcohol_4\NN\7881800|NONE_0 (r_compound) consumption_5\NN\13440063|that_13|association_25 (r_nsubj) has_6\VBZ\13888491|findings_42|._40 (l_dobj) association_9\NN\8008335|that_38|consumption_25 (l_prep) with_10\IN\0|a_21|direct_19 (l_pobj) depression_11\NN\14373582|NONE_0
D000431_D015658 NONE alcohol_3\NN\7881800|with_12 (r_compound) use_4\NN\407535|NONE_0 (l_prep) with_5\IN\0|alcohol_12 (l_pobj) progression_8\NN\8457976|NONE_0 (l_compound) disease_7\NN\14061805|and_20|health_38
D000431_D015658 NONE alcohol_5\NN\7881800|and_20|depression_24 (r_compound) consumption_6\NN\13440063|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) association_3\NN\8008335|we_17|,_49|and_51|effects_61|._116 (r_dobj) evaluated_1\VBD\670261|NONE_0 (l_conj) effects_12\NNS\13245626|we_78|association_61|,_12|and_10|._55 (l_prep) on_13\IN\0|their_14 (l_pobj) progression_16\NN\8457976|NONE_0 (l_compound) disease_15\NN\14061805|among_20
24717468
D015742_D007022 CID propofol_16\NN\0|who_31|dexmedetomidine_19|or_3 (r_conj) receive_13\VBP\2210855|neurocritical_32|care_18 (r_relcl) patients_11\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|similar_19 (r_prep) prevalence_7\NN\4764412|NONE_0 (r_pobj) at_5\IN\14622893|hypotension_34|._92 (r_prep) occur_4\VBP\0|NONE_0 (l_nsubj) hypotension_1\NN\14057371|at_34|._126
D020927_D001919 CID dexmedetomidine_14\NN\0|who_12|or_16|propofol_19 (r_dobj) receive_13\VBP\2210855|neurocritical_32|care_18 (r_relcl) patients_11\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|similar_19 (r_prep) prevalence_7\NN\4764412|NONE_0 (r_pobj) at_5\IN\14622893|hypotension_34|._92 (r_prep) occur_4\VBP\0|NONE_0 (l_nsubj) hypotension_1\NN\14057371|at_34|._126 (l_conj) bradycardia_3\NN\14110674|severe_23|and_4
D015742_D001919 CID propofol_16\NN\0|who_31|dexmedetomidine_19|or_3 (r_conj) receive_13\VBP\2210855|neurocritical_32|care_18 (r_relcl) patients_11\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|similar_19 (r_prep) prevalence_7\NN\4764412|NONE_0 (r_pobj) at_5\IN\14622893|hypotension_34|._92 (r_prep) occur_4\VBP\0|NONE_0 (l_nsubj) hypotension_1\NN\14057371|at_34|._126 (l_conj) bradycardia_3\NN\14110674|severe_23|and_4
D020927_D007022 CID dexmedetomidine_14\NN\0|who_12|or_16|propofol_19 (r_dobj) receive_13\VBP\2210855|neurocritical_32|care_18 (r_relcl) patients_11\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|similar_19 (r_prep) prevalence_7\NN\4764412|NONE_0 (r_pobj) at_5\IN\14622893|hypotension_34|._92 (r_prep) occur_4\VBP\0|NONE_0 (l_nsubj) hypotension_1\NN\14057371|at_34|._126
8985298
D019259_D006509 NONE lamivudine_0\NNP\3834836|effective_14|._136 (r_nsubj) is_1\VBZ\0|NONE_0 (l_acomp) effective_2\JJ\0|lamivudine_14|._122 (l_prep) in_3\IN\13603305|NONE_0 (l_pcomp) suppressing_4\VBG\2510337|NONE_0 (l_dobj) dna_8\NN\14994328|NONE_0 (l_compound) virus_7\NN\9312843|in_10|:_57|trial_80 (l_compound) b_6\NNP\1355326|NONE_0
D019259_D006509 NONE lamivudine_0\NNP\3834836|analogue_45|._142 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) analogue_6\NN\4743605|lamivudine_45|._97 (l_relcl) has_8\VBZ\13888491|a_45|novel_43|2',3'-dideoxy_37|cytosine_23 (l_dobj) effects_11\NNS\13245626|that_27|in_41 (l_prep) on_12\IN\0|potent_26|inhibitory_19 (l_pobj) replication_16\NN\1019524|NONE_0 (l_compound) virus_15\NN\9312843|NONE_0 (l_compound) b_14\NN\1355326|NONE_0
D019259_D006509 NONE cytosine_5\NN\14999913|a_22|novel_20|2',3'-dideoxy_14|has_23 (r_compound) analogue_6\NN\4743605|lamivudine_45|._97 (l_relcl) has_8\VBZ\13888491|a_45|novel_43|2',3'-dideoxy_37|cytosine_23 (l_dobj) effects_11\NNS\13245626|that_27|in_41 (l_prep) on_12\IN\0|potent_26|inhibitory_19 (l_pobj) replication_16\NN\1019524|NONE_0 (l_compound) virus_15\NN\9312843|NONE_0 (l_compound) b_14\NN\1355326|NONE_0
D019259_D006509 NONE lamivudine_4\NN\3834836|NONE_0 (r_dobj) receiving_3\VBG\2210855|all_16|36_12 (r_acl) patients_2\NNS\9898892|decrease_36|compared_101|)_122|._123 (r_nsubj) had_5\VBD\0|NONE_0 (l_dobj) decrease_7\NN\7296428|patients_36|compared_65|)_86|._87 (l_prep) in_8\IN\13603305|a_11 (l_pobj) virus_11\NN\9312843|NONE_0 (l_compound) b_10\NN\1355326|(_8|values_18|(_33|p_34
D006514_D006509 CID antigen_14\NN\20090|chinese_28|b_10 (r_compound) carriers_15\NNS\9629752|NONE_0 (r_pobj) in_9\IN\13603305|virus_10|:_47|trial_70 (r_prep) dna_8\NN\14994328|NONE_0 (l_compound) virus_7\NN\9312843|in_10|:_57|trial_80 (l_compound) b_6\NNP\1355326|NONE_0
24927617
D019821_D012206 CID simvastatin_12\NN\3676175|with_20|and_4 (r_conj) treated_8\VBN\2376958|infected_17 (r_acl) patient_7\NN\9898892|in_32|._47 (r_appos) rhabdomyolysis_0\NNP\0|NONE_0
D019821_D009135 CID simvastatin_0\NNP\3676175|NONE_0 (r_compound) plasma_1\NN\5398023|NONE_0 (r_compound) concentration_2\NN\4916342|times_27|in_33|induced_60|._138 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_advcl) induced_11\VBD\1627355|concentration_60|times_33|in_27|._78 (l_ccomp) related_15\VBN\628491|NONE_0 (l_nsubjpass) toxicity_13\NN\13576101|is_9|to_20
D019821_D009135 CID statin_10\NN\3740161|this_17|and_4 (r_conj) patient_8\NN\9898892|NONE_0 (r_pobj) in_6\IN\13603305|concentration_33|times_6|induced_27|._105 (r_prep) increased_3\VBD\169651|NONE_0 (l_advcl) induced_11\VBD\1627355|concentration_60|times_33|in_27|._78 (l_ccomp) related_15\VBN\628491|NONE_0 (l_nsubjpass) toxicity_13\NN\13576101|is_9|to_20
D019821_D009135 CID statin_21\NN\3740161|NONE_0 (r_pobj) of_19\IN\0|the_18 (r_prep) concentration_18\NN\4916342|NONE_0 (r_pobj) to_16\IN\0|toxicity_20|is_11 (r_prep) related_15\VBN\628491|NONE_0 (l_nsubjpass) toxicity_13\NN\13576101|is_9|to_20
D019821_D064420 NONE simvastatin_2\NN\3676175|admission_10 (l_conj) discontinued_8\VBN\0|and_29 (l_advcl) suspected_19\VBN\916909|drugs_76|were_70|._9 (l_nsubjpass) toxicity_10\NN\13576101|because_8|was_40
D019821_D006526 NONE simvastatin_12\NN\3676175|with_20|and_4 (r_conj) treated_8\VBN\2376958|infected_17 (r_acl) patient_7\NN\9898892|in_32|._47 (l_amod) infected_6\VBN\2316868|treated_17
C486464_D012206 CID telaprevir_10\NNS\0|NONE_0 (r_pobj) with_9\IN\0|and_16|simvastatin_20 (r_prep) treated_8\VBN\2376958|infected_17 (r_acl) patient_7\NN\9898892|in_32|._47 (r_appos) rhabdomyolysis_0\NNP\0|NONE_0
C417083_D006526 NONE interferon_18\NN\2725367|NONE_0 (r_dobj) pegylated_17\VBN\0|man_87|therapy_24|with_16|,_2|._35 (r_conj) received_11\VBD\2210855|NONE_0 (l_nsubj) man_3\NN\9605289|therapy_63|with_71|,_85|pegylated_87|._122 (l_prep) with_4\IN\0|a_18|46-year_16|old_8 (l_pobj) infection_10\NN\14052046|NONE_0
D012254_D006526 NONE ribavirin_15\RB\2725367|NONE_0 (r_pobj) with_14\IN\0|man_71|therapy_8|,_14|pegylated_16|._51 (r_prep) received_11\VBD\2210855|NONE_0 (l_nsubj) man_3\NN\9605289|therapy_63|with_71|,_85|pegylated_87|._122 (l_prep) with_4\IN\0|a_18|46-year_16|old_8 (l_pobj) infection_10\NN\14052046|NONE_0
C486464_D006526 NONE telaprevir_10\NNS\0|NONE_0 (r_pobj) with_9\IN\0|and_16|simvastatin_20 (r_prep) treated_8\VBN\2376958|infected_17 (r_acl) patient_7\NN\9898892|in_32|._47 (l_amod) infected_6\VBN\2316868|treated_17
C486464_D006526 NONE telaprevir_20\NNS\0|and_4 (r_conj) interferon_18\NN\2725367|NONE_0 (r_dobj) pegylated_17\VBN\0|man_87|therapy_24|with_16|,_2|._35 (r_conj) received_11\VBD\2210855|NONE_0 (l_nsubj) man_3\NN\9605289|therapy_63|with_71|,_85|pegylated_87|._122 (l_prep) with_4\IN\0|a_18|46-year_16|old_8 (l_pobj) infection_10\NN\14052046|NONE_0
11474137
D000617_D006311 NONE aminoglycoside_7\NN\0|-_14 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) ototoxicity_10\NN\0|NONE_0
D000617_D006311 NONE aminoglycoside_7\NN\0|-_14 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) ototoxicity_10\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|reactive_24|oxygen_15 (r_prep) species_5\NNS\7992450|NONE_0 (r_pobj) of_2\IN\0|the_18 (r_prep) participation_1\NN\1080366|has_79|been_83|from_96|._255 (r_nsubjpass) deduced_13\VBN\634472|NONE_0 (l_prep) from_14\IN\0|participation_96|has_17|been_13|._159 (l_pobj) observations_15\NNS\996969|NONE_0 (l_acl) catalyze_21\VBP\146138|NONE_0 (l_conj) attenuate_32\VBP\224901|that_112|complexes_87|formation_64|and_22 (l_dobj) ototoxicity_33\NN\0|that_28|antioxidants_23
D000617_D006311 NONE aminoglycoside_17\NN\0|-_14 (r_compound) iron_19\NN\14625458|NONE_0 (r_compound) complexes_20\NNS\5869584|that_25|formation_23|and_65|attenuate_87 (r_nsubj) catalyze_21\VBP\146138|NONE_0 (r_acl) observations_15\NNS\996969|NONE_0 (r_pobj) from_14\IN\0|participation_96|has_17|been_13|._159 (r_prep) deduced_13\VBN\634472|NONE_0 (l_nsubjpass) participation_1\NN\1080366|has_79|been_83|from_96|._255 (l_prep) of_2\IN\0|the_18 (l_pobj) species_5\NNS\7992450|NONE_0 (l_prep) in_6\IN\13603305|reactive_24|oxygen_15 (l_pobj) ototoxicity_10\NN\0|NONE_0
D000617_D006311 NONE aminoglycoside_17\NN\0|-_14 (r_compound) iron_19\NN\14625458|NONE_0 (r_compound) complexes_20\NNS\5869584|that_25|formation_23|and_65|attenuate_87 (r_nsubj) catalyze_21\VBP\146138|NONE_0 (l_conj) attenuate_32\VBP\224901|that_112|complexes_87|formation_64|and_22 (l_dobj) ototoxicity_33\NN\0|that_28|antioxidants_23
D000617_D006311 NONE aminoglycoside_18\NN\0|-_14 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) ototoxicity_21\NN\0|NONE_0
D003300_D034381 NONE copper_2\NN\14821043|/_6|zinc_7|-_11 (r_npadvmod) superoxide_6\NN\14971519|NONE_0 (r_amod) dismutase_7\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) overexpression_0\NN\0|from_60|._95 (r_nsubj) protects_8\VBZ\1127795|NONE_0 (l_prep) from_9\IN\0|overexpression_60|._35 (l_pobj) loss_14\NN\13252973|NONE_0
D007612_D034381 CID kanamycin_10\NN\2716866|-_9 (r_npadvmod) induced_12\VBN\1627355|hearing_8 (r_amod) loss_14\NN\13252973|NONE_0
D015032_D006311 NONE zn_8\NNP\14625458|-_2 (r_compound) superoxide_10\NN\14971519|cu_6|/_4|(_21|sod1_24|)_28 (r_amod) dismutase_11\NN\0|NONE_0 (r_pobj) of_5\IN\0|that_20 (r_prep) overexpression_4\NN\0|should_54|mice_80|from_85 (r_nsubj) protect_18\VB\1127795|we_92|therefore_89|._40 (l_prep) from_21\IN\0|overexpression_85|should_31|mice_5 (l_pobj) ototoxicity_22\NN\0|NONE_0
D003300_D006311 NONE cu_6\NNP\14821043|/_2|superoxide_6|(_27|sod1_30|)_34 (r_nmod) dismutase_11\NN\0|NONE_0 (r_pobj) of_5\IN\0|that_20 (r_prep) overexpression_4\NN\0|should_54|mice_80|from_85 (r_nsubj) protect_18\VB\1127795|we_92|therefore_89|._40 (l_prep) from_21\IN\0|overexpression_85|should_31|mice_5 (l_pobj) ototoxicity_22\NN\0|NONE_0
D013481_D034381 NONE superoxide_6\NN\14971519|NONE_0 (r_amod) dismutase_7\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) overexpression_0\NN\0|from_60|._95 (r_nsubj) protects_8\VBZ\1127795|NONE_0 (l_prep) from_9\IN\0|overexpression_60|._35 (l_pobj) loss_14\NN\13252973|NONE_0
D015032_D034381 NONE zinc_4\NN\14625458|copper_7|/_1|-_4 (r_npadvmod) superoxide_6\NN\14971519|NONE_0 (r_amod) dismutase_7\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) overexpression_0\NN\0|from_60|._95 (r_nsubj) protects_8\VBZ\1127795|NONE_0 (l_prep) from_9\IN\0|overexpression_60|._35 (l_pobj) loss_14\NN\13252973|NONE_0
D010100_D006311 NONE oxygen_4\NN\14622893|reactive_9|in_15 (r_compound) species_5\NNS\7992450|NONE_0 (l_prep) in_6\IN\13603305|reactive_24|oxygen_15 (l_pobj) ototoxicity_10\NN\0|NONE_0
D010100_D006311 NONE oxygen_4\NN\14622893|reactive_9|in_15 (r_compound) species_5\NNS\7992450|NONE_0 (r_pobj) of_2\IN\0|the_18 (r_prep) participation_1\NN\1080366|has_79|been_83|from_96|._255 (r_nsubjpass) deduced_13\VBN\634472|NONE_0 (l_prep) from_14\IN\0|participation_96|has_17|been_13|._159 (l_pobj) observations_15\NNS\996969|NONE_0 (l_acl) catalyze_21\VBP\146138|NONE_0 (l_conj) attenuate_32\VBP\224901|that_112|complexes_87|formation_64|and_22 (l_dobj) ototoxicity_33\NN\0|that_28|antioxidants_23
D013481_D006311 NONE superoxide_25\JJ\14971519|in_20 (r_amod) radicals_26\NNS\9465459|NONE_0 (r_pobj) of_24\IN\0|the_14 (r_prep) formation_23\NN\7938773|that_48|complexes_23|and_42|attenuate_64 (r_dobj) catalyze_21\VBP\146138|NONE_0 (r_acl) observations_15\NNS\996969|NONE_0 (r_pobj) from_14\IN\0|participation_96|has_17|been_13|._159 (r_prep) deduced_13\VBN\634472|NONE_0 (l_nsubjpass) participation_1\NN\1080366|has_79|been_83|from_96|._255 (l_prep) of_2\IN\0|the_18 (l_pobj) species_5\NNS\7992450|NONE_0 (l_prep) in_6\IN\13603305|reactive_24|oxygen_15 (l_pobj) ototoxicity_10\NN\0|NONE_0
D013481_D006311 NONE superoxide_25\JJ\14971519|in_20 (r_amod) radicals_26\NNS\9465459|NONE_0 (r_pobj) of_24\IN\0|the_14 (r_prep) formation_23\NN\7938773|that_48|complexes_23|and_42|attenuate_64 (r_dobj) catalyze_21\VBP\146138|NONE_0 (l_conj) attenuate_32\VBP\224901|that_112|complexes_87|formation_64|and_22 (l_dobj) ototoxicity_33\NN\0|that_28|antioxidants_23
D013481_D006311 NONE superoxide_10\NN\14971519|cu_6|/_4|(_21|sod1_24|)_28 (r_amod) dismutase_11\NN\0|NONE_0 (r_pobj) of_5\IN\0|that_20 (r_prep) overexpression_4\NN\0|should_54|mice_80|from_85 (r_nsubj) protect_18\VB\1127795|we_92|therefore_89|._40 (l_prep) from_21\IN\0|overexpression_85|should_31|mice_5 (l_pobj) ototoxicity_22\NN\0|NONE_0
D013481_D006311 NONE superoxide_5\NN\14971519|NONE_0 (r_amod) dismutase_6\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) overexpression_3\NN\0|NONE_0 (r_pobj) by_2\IN\0|the_15 (r_prep) protection_1\NN\407535|hypothesis_66|._159 (r_nsubj) supports_7\VBZ\407535|NONE_0 (l_dobj) hypothesis_9\NN\7162194|protection_66|._93 (l_acl) plays_13\VBZ\7007684|the_35 (l_dobj) role_16\NN\719494|that_40|stress_27 (l_prep) in_17\IN\13603305|a_19|significant_17 (l_pobj) ototoxicity_21\NN\0|NONE_0
D007501_D006311 NONE iron_19\NN\14625458|NONE_0 (r_compound) complexes_20\NNS\5869584|that_25|formation_23|and_65|attenuate_87 (r_nsubj) catalyze_21\VBP\146138|NONE_0 (r_acl) observations_15\NNS\996969|NONE_0 (r_pobj) from_14\IN\0|participation_96|has_17|been_13|._159 (r_prep) deduced_13\VBN\634472|NONE_0 (l_nsubjpass) participation_1\NN\1080366|has_79|been_83|from_96|._255 (l_prep) of_2\IN\0|the_18 (l_pobj) species_5\NNS\7992450|NONE_0 (l_prep) in_6\IN\13603305|reactive_24|oxygen_15 (l_pobj) ototoxicity_10\NN\0|NONE_0
D007501_D006311 NONE iron_19\NN\14625458|NONE_0 (r_compound) complexes_20\NNS\5869584|that_25|formation_23|and_65|attenuate_87 (r_nsubj) catalyze_21\VBP\146138|NONE_0 (l_conj) attenuate_32\VBP\224901|that_112|complexes_87|formation_64|and_22 (l_dobj) ototoxicity_33\NN\0|that_28|antioxidants_23
24897009
D004977_D011115 CID ethambutol_0\NNP\0|is_11|cause_23|and_46|polyneuropathy_71 (r_nsubjpass) known_2\VBN\0|NONE_0 (l_conj) polyneuropathy_13\NN\0|ethambutol_71|is_60|cause_48|and_25
D004977_D064420 NONE ethambutol_15\VB\0|case_103|vulnerability_71|._19 (l_dobj) toxicity_16\NN\13576101|to_14
D004977_D009901 CID ethambutol_0\NNP\0|is_11|cause_23|and_46|polyneuropathy_71 (r_nsubjpass) known_2\VBN\0|NONE_0 (l_xcomp) cause_4\VB\7323922|ethambutol_23|is_12|and_23|polyneuropathy_48 (l_dobj) neuropathy_6\NN\14204950|to_15
D004977_D010292 CID ethambutol_32\NN\0|NONE_0 (r_pobj) of_31\IN\0|a_24|supratherapeutic_22 (r_prep) dose_30\NN\3740161|NONE_0 (r_pobj) to_27\IN\0|NONE_0 (r_prep) exposure_26\NN\5042871|NONE_0 (r_pobj) of_25\IN\0|11_9 (r_prep) weeks_24\NNS\15113229|NONE_0 (r_pobj) after_22\IN\0|who_43|loss_22 (r_prep) developed_17\VBD\1753788|a_22|old_12 (l_dobj) loss_19\NN\13252973|who_21|after_22 (l_conj) paresthesias_21\NNS\14299637|visual_16|and_4
D004977_D014786 CID ethambutol_32\NN\0|NONE_0 (r_pobj) of_31\IN\0|a_24|supratherapeutic_22 (r_prep) dose_30\NN\3740161|NONE_0 (r_pobj) to_27\IN\0|NONE_0 (r_prep) exposure_26\NN\5042871|NONE_0 (r_pobj) of_25\IN\0|11_9 (r_prep) weeks_24\NNS\15113229|NONE_0 (r_pobj) after_22\IN\0|who_43|loss_22 (r_prep) developed_17\VBD\1753788|a_22|old_12 (l_dobj) loss_19\NN\13252973|who_21|after_22
D004977_D010523 NONE ethambutol_6\NN\0|NONE_0 (r_amod) overtreatment_7\NN\0|to_14 (r_pobj) due_4\IN\5174653|and_26|neuropathy_11|._31 (r_prep) optochiasmatic_0\JJ\0|NONE_0 (l_conj) neuropathy_3\NN\14204950|and_15|due_11|._42
25071004
C039726_D000740 NONE artesunate_6\NN\0|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) treatment_3\NN\654885|NONE_0 (r_pobj) after_2\IN\0|anemia_7|:_82|issue_97|._102 (r_prep) delayed_0\JJ\439958|NONE_0 (l_dobj) anemia_1\NN\14189204|after_7|:_89|issue_104|._109
C039726_D008288 NONE artesunate_12\NN\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treatment_9\NN\654885|NONE_0 (r_pobj) after_8\IN\0|cases_54|have_20|been_15|,_42|organization_69 (r_prep) described_7\VBN\1001294|NONE_0 (l_appos) organization_18\NNP\7950920|cases_123|have_89|been_84|after_69|,_27 (l_parataxis) who)-recommended_20\VBN\0|the_39|current_35|world_27|health_21 (l_dobj) drug_24\NN\14778436|(_29|._40 (l_prep) for_25\IN\0|line_10 (l_pobj) treatment_27\NN\654885|NONE_0 (l_prep) of_28\IN\0|the_14 (l_pobj) malaria_30\NN\14178913|NONE_0
C039726_D008288 NONE artesunate_36\NN\0|NONE_0 (l_prep) for_37\IN\0|injectable_22 (l_pobj) malaria_39\NN\14178913|NONE_0
C039726_D000743 CID artesunate_12\NN\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treatment_9\NN\654885|NONE_0 (r_pobj) after_8\IN\0|cases_54|have_20|been_15|,_42|organization_69 (r_prep) described_7\VBN\1001294|NONE_0 (l_nsubjpass) cases_0\NNS\7283608|have_34|been_39|after_54|,_96|organization_123 (l_prep) of_1\IN\0|NONE_0 (l_pobj) anemia_4\NN\14189204|NONE_0
19914299
D005473_D008569 NONE fluoxetine_0\NNP\4169152|deficits_31|5-fluorouracil_73|._87 (r_nsubj) improves_1\VBZ\126264|NONE_0 (l_dobj) deficits_4\NNS\5113133|fluoxetine_31|5-fluorouracil_42|._56
D005472_D008569 CID 5-fluorouracil_10\CD\0|fluoxetine_73|deficits_42|._14 (r_punct) improves_1\VBZ\126264|NONE_0 (l_dobj) deficits_4\NNS\5113133|fluoxetine_31|5-fluorouracil_42|._56
11745287
D004317_D002294 NONE doxorubicin_7\NN\2716866|in_12 (r_dobj) liposomal_6\JJ\0|ii_28|of_19|and_4|._86 (l_prep) in_8\IN\13603305|doxorubicin_12 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) carcinoma_14\NN\14239918|NONE_0 (l_prep) of_15\IN\0|recurrent_34|cell_15 (l_pobj) cervix_17\NN\5225090|NONE_0
D004317_D002294 NONE doxorubicin_18\NN\2716866|combination_87|;_18 (r_dobj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_prep) to_37\IN\0|liposomal_102|dose_63|was_45|intravenously_28|days_5|determine_66|._115 (l_pobj) patients_39\NNS\9898892|NONE_0 (l_prep) with_40\IN\0|37_12 (l_pobj) carcinoma_45\NN\14239918|NONE_0
D004317_D002294 NONE doxil_20\NNS\0|NONE_0 (r_appos) doxorubicin_18\NN\2716866|combination_87|;_18 (r_dobj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_prep) to_37\IN\0|liposomal_102|dose_63|was_45|intravenously_28|days_5|determine_66|._115 (l_pobj) patients_39\NNS\9898892|NONE_0 (l_prep) with_40\IN\0|37_12 (l_pobj) carcinoma_45\NN\14239918|NONE_0
D004317_D064420 NONE doxorubicin_18\NN\2716866|combination_87|;_18 (r_dobj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_advcl) determine_47\VB\0|liposomal_168|dose_129|was_111|intravenously_94|days_71|to_66|._49 (l_dobj) activity_49\NN\30358|to_23 (l_conj) profile_52\NN\6999802|antitumor_32|and_13 (l_compound) toxicity_51\NN\13576101|NONE_0
D004317_D064420 NONE doxil_20\NNS\0|NONE_0 (r_appos) doxorubicin_18\NN\2716866|combination_87|;_18 (r_dobj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_advcl) determine_47\VB\0|liposomal_168|dose_129|was_111|intravenously_94|days_71|to_66|._49 (l_dobj) activity_49\NN\30358|to_23 (l_conj) profile_52\NN\6999802|antitumor_32|and_13 (l_compound) toxicity_51\NN\13576101|NONE_0
D016190_D064420 NONE carboplatin_3\NN\0|(_12|under_18 (r_nmod) area_5\NN\8630985|NONE_0 (r_pobj) of_2\IN\0|the_16 (r_prep) combination_1\NN\7951464|doxorubicin_87|;_105 (r_nsubj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_advcl) determine_47\VB\0|liposomal_168|dose_129|was_111|intravenously_94|days_71|to_66|._49 (l_dobj) activity_49\NN\30358|to_23 (l_conj) profile_52\NN\6999802|antitumor_32|and_13 (l_compound) toxicity_51\NN\13576101|NONE_0
D016190_D002294 NONE carboplatin_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|ii_9|and_15|liposomal_19|._105 (r_prep) study_2\NN\635850|NONE_0 (l_conj) liposomal_6\JJ\0|ii_28|of_19|and_4|._86 (l_prep) in_8\IN\13603305|doxorubicin_12 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) carcinoma_14\NN\14239918|NONE_0 (l_prep) of_15\IN\0|recurrent_34|cell_15 (l_pobj) cervix_17\NN\5225090|NONE_0
D016190_D002294 NONE carboplatin_3\NN\0|(_12|under_18 (r_nmod) area_5\NN\8630985|NONE_0 (r_pobj) of_2\IN\0|the_16 (r_prep) combination_1\NN\7951464|doxorubicin_87|;_105 (r_nsubj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_prep) to_37\IN\0|liposomal_102|dose_63|was_45|intravenously_28|days_5|determine_66|._115 (l_pobj) patients_39\NNS\9898892|NONE_0 (l_prep) with_40\IN\0|37_12 (l_pobj) carcinoma_45\NN\14239918|NONE_0
D016190_D002583 NONE carboplatin_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|ii_9|and_15|liposomal_19|._105 (r_prep) study_2\NN\635850|NONE_0 (l_conj) liposomal_6\JJ\0|ii_28|of_19|and_4|._86 (l_prep) in_8\IN\13603305|doxorubicin_12 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) carcinoma_14\NN\14239918|NONE_0 (l_prep) of_15\IN\0|recurrent_34|cell_15 (l_pobj) cervix_17\NN\5225090|NONE_0
D016190_D002583 NONE carboplatin_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_16 (r_prep) combination_4\NN\7951464|NONE_0 (r_pobj) of_2\IN\0|the_13 (r_prep) activity_1\NN\30358|was_69|in_80|._145 (r_nsubjpass) tested_11\VBN\670261|NONE_0 (l_prep) in_12\IN\13603305|activity_80|was_11|._65 (l_pobj) study_16\NN\635850|NONE_0 (l_prep) of_17\IN\0|a_17|ii_9 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) carcinoma_22\NN\14239918|NONE_0
D016190_D002583 NONE carboplatin_3\NN\0|(_12|under_18 (r_nmod) area_5\NN\8630985|NONE_0 (r_pobj) of_2\IN\0|the_16 (r_prep) combination_1\NN\7951464|doxorubicin_87|;_105 (r_nsubj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_prep) to_37\IN\0|liposomal_102|dose_63|was_45|intravenously_28|days_5|determine_66|._115 (l_pobj) patients_39\NNS\9898892|NONE_0 (l_prep) with_40\IN\0|37_12 (l_pobj) carcinoma_45\NN\14239918|NONE_0
D016190_D002583 NONE carboplatin_3\NN\0|doxorubicin_26 (r_pobj) of_2\IN\0|the_16 (r_prep) combination_1\NN\7951464|activity_64|._118 (r_nsubj) has_7\VBZ\13888491|NONE_0 (l_dobj) activity_9\NN\30358|combination_64|._54 (l_prep) in_10\IN\13603305|modest_16 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) carcinoma_15\NN\14239918|NONE_0
D004317_D002583 NONE doxorubicin_7\NN\2716866|in_12 (r_dobj) liposomal_6\JJ\0|ii_28|of_19|and_4|._86 (l_prep) in_8\IN\13603305|doxorubicin_12 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) carcinoma_14\NN\14239918|NONE_0 (l_prep) of_15\IN\0|recurrent_34|cell_15 (l_pobj) cervix_17\NN\5225090|NONE_0
D004317_D002583 NONE doxorubicin_9\NN\2716866|and_14 (r_conj) carboplatin_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_16 (r_prep) combination_4\NN\7951464|NONE_0 (r_pobj) of_2\IN\0|the_13 (r_prep) activity_1\NN\30358|was_69|in_80|._145 (r_nsubjpass) tested_11\VBN\670261|NONE_0 (l_prep) in_12\IN\13603305|activity_80|was_11|._65 (l_pobj) study_16\NN\635850|NONE_0 (l_prep) of_17\IN\0|a_17|ii_9 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) carcinoma_22\NN\14239918|NONE_0
D004317_D002583 NONE doxorubicin_18\NN\2716866|combination_87|;_18 (r_dobj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_prep) to_37\IN\0|liposomal_102|dose_63|was_45|intravenously_28|days_5|determine_66|._115 (l_pobj) patients_39\NNS\9898892|NONE_0 (l_prep) with_40\IN\0|37_12 (l_pobj) carcinoma_45\NN\14239918|NONE_0
D004317_D002583 NONE doxil_20\NNS\0|NONE_0 (r_appos) doxorubicin_18\NN\2716866|combination_87|;_18 (r_dobj) liposomal_17\JJ\0|dose_39|was_57|intravenously_74|days_97|to_102|determine_168|._217 (r_ccomp) administered_32\VBN\2436349|NONE_0 (l_prep) to_37\IN\0|liposomal_102|dose_63|was_45|intravenously_28|days_5|determine_66|._115 (l_pobj) patients_39\NNS\9898892|NONE_0 (l_prep) with_40\IN\0|37_12 (l_pobj) carcinoma_45\NN\14239918|NONE_0
D004317_D002583 NONE doxorubicin_6\NN\2716866|carboplatin_26 (r_pobj) of_2\IN\0|the_16 (r_prep) combination_1\NN\7951464|activity_64|._118 (r_nsubj) has_7\VBZ\13888491|NONE_0 (l_dobj) activity_9\NN\30358|combination_64|._54 (l_prep) in_10\IN\13603305|modest_16 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) carcinoma_15\NN\14239918|NONE_0
10510854
D006220_D002375 CID haloperidol_9\NN\3713736|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|a_29|high_27|of_13|indicating_23 (r_acl) reversal_4\NN\199130|7e_19|._89 (l_prep) of_5\IN\0|a_16|high_14|induced_13|indicating_36 (l_pobj) catalepsy_6\NN\14023236|NONE_0
1943082
D005978_D015427 NONE glutathione_8\NN\0|NONE_0 (r_pobj) in_4\IN\13603305|no_10|following_36 (r_prep) change_3\NN\7283608|there_13|._91 (l_prep) following_9\VBG\8180190|no_46|in_36 (l_pobj) injury_14\NN\14052046|NONE_0
D005978_D007511 NONE glutathione_8\NN\0|NONE_0 (r_pobj) in_4\IN\13603305|no_10|following_36 (r_prep) change_3\NN\7283608|there_13|._91 (l_prep) following_9\VBG\8180190|no_46|in_36 (l_pobj) injury_14\NN\14052046|NONE_0 (l_compound) reperfusion_13\NN\0|intestinal_20 (l_compound) ischemia_11\NN\14195315|-_8
3074291
C017590_D014839 NONE oxitropium_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|side_13 (r_prep) effects_4\NNS\13245626|subject_22|,_21|compared_26|._110 (r_dobj) reported_2\VBN\831651|NONE_0 (l_advcl) compared_9\VBN\644583|subject_48|effects_26|,_5|._84 (l_prep) to_10\IN\0|as_12 (l_pobj) subjects_12\NNS\6598915|NONE_0 (l_acl) reporting_13\VBG\6681177|three_15 (l_dobj) nausea_14\NN\14299637|after_29 (l_conj) vomiting_16\VBG\116687|,_2
D013806_D009325 CID theophylline_20\NN\2905612|NONE_0 (r_pobj) after_19\IN\0|nausea_29 (r_prep) reporting_13\VBG\6681177|three_15 (l_dobj) nausea_14\NN\14299637|after_29
C017590_D009325 NONE oxitropium_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|side_13 (r_prep) effects_4\NNS\13245626|subject_22|,_21|compared_26|._110 (r_dobj) reported_2\VBN\831651|NONE_0 (l_advcl) compared_9\VBN\644583|subject_48|effects_26|,_5|._84 (l_prep) to_10\IN\0|as_12 (l_pobj) subjects_12\NNS\6598915|NONE_0 (l_acl) reporting_13\VBG\6681177|three_15 (l_dobj) nausea_14\NN\14299637|after_29
D013806_D001249 NONE theophylline_12\NN\2905612|NONE_0 (l_prep) on_13\IN\0|release_21 (l_pobj) asthma_15\NN\14145095|NONE_0
D013806_D001249 NONE theophylline_18\NN\2905612|a_15|release_8|upon_25 (r_amod) preparation_19\NN\407535|NONE_0 (l_prep) upon_20\IN\0|a_40|release_33|theophylline_25 (l_pobj) asthma_22\NN\14145095|NONE_0
D013806_D001249 NONE theophylline_8\NN\2905612|NONE_0 (r_pobj) to_7\IN\0|a_23|valuable_21|in_16 (r_prep) alternative_6\NN\5788149|to_17 (l_prep) in_9\IN\13603305|a_39|valuable_37|to_16 (l_pobj) asthma_11\NN\14145095|NONE_0
C017590_D001249 NONE bromide_6\NN\14904359|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) effect_3\NN\34213|NONE_0 (r_pobj) of_1\IN\0|and_36|of_40|._88 (r_prep) comparison_0\NN\635850|NONE_0 (l_conj) of_8\IN\0|of_40|and_4|._48 (l_pobj) theophylline_12\NN\2905612|NONE_0 (l_prep) on_13\IN\0|release_21 (l_pobj) asthma_15\NN\14145095|NONE_0
C017590_D001249 NONE bromide_10\NN\14904359|a_46|new_44|inhaled_40|antimuscarinic_32|,_13 (r_appos) drug_7\NN\14778436|and_26|of_30 (r_pobj) of_2\IN\0|the_12 (l_conj) of_13\IN\0|drug_30|and_4 (l_pobj) preparation_19\NN\407535|NONE_0 (l_prep) upon_20\IN\0|a_40|release_33|theophylline_25 (l_pobj) asthma_22\NN\14145095|NONE_0
C017590_D001249 NONE oxitropium_0\NNP\0|be_21|,_82|is_93|._162 (r_nsubj) proves_1\VBZ\9759069|NONE_0 (l_xcomp) be_3\VB\14625458|oxitropium_21|,_61|is_72|._141 (l_attr) alternative_6\NN\5788149|to_17 (l_prep) in_9\IN\13603305|a_39|valuable_37|to_16 (l_pobj) asthma_11\NN\14145095|NONE_0
D013806_D014202 CID theophylline_20\NN\2905612|NONE_0 (r_pobj) after_19\IN\0|nausea_29 (r_prep) reporting_13\VBG\6681177|three_15 (l_dobj) nausea_14\NN\14299637|after_29 (l_conj) vomiting_16\VBG\116687|,_2 (l_conj) tremors_18\NNS\345926|and_4
C017590_D014202 NONE oxitropium_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|side_13 (r_prep) effects_4\NNS\13245626|subject_22|,_21|compared_26|._110 (r_dobj) reported_2\VBN\831651|NONE_0 (l_advcl) compared_9\VBN\644583|subject_48|effects_26|,_5|._84 (l_prep) to_10\IN\0|as_12 (l_pobj) subjects_12\NNS\6598915|NONE_0 (l_acl) reporting_13\VBG\6681177|three_15 (l_dobj) nausea_14\NN\14299637|after_29 (l_conj) vomiting_16\VBG\116687|,_2 (l_conj) tremors_18\NNS\345926|and_4
D013806_D014839 CID theophylline_20\NN\2905612|NONE_0 (r_pobj) after_19\IN\0|nausea_29 (r_prep) reporting_13\VBG\6681177|three_15 (l_dobj) nausea_14\NN\14299637|after_29 (l_conj) vomiting_16\VBG\116687|,_2
19263707
D002231_D014657 NONE carbimazole_12\NN\0|who_28 (r_dobj) developed_9\VBD\1753788|graves_20 (r_relcl) disease_7\NN\14061805|NONE_0 (r_pobj) with_4\IN\0|a_10 (r_prep) patient_3\NN\9898892|vasculitis_77 (r_nsubj) induced_13\VBD\1627355|we_81|._18 (l_dobj) vasculitis_14\NN\14336539|patient_77
D002231_D014657 NONE carbimazole_12\NN\0|to_61|this_32|._55 (l_acl) induced_13\VBD\1627355|the_36|first_32|anca_26|positive_21 (l_dobj) case_15\NN\7283608|NONE_0 (l_compound) vasculitis_14\JJ\14336539|reported_16
D002231_D006980 NONE carbimazole_6\NN\0|NONE_0 (r_pobj) like_5\IN\5839024|thyroid_15|,_2 (r_prep) drugs_3\NNS\14778436|are_51|commonly_55|for_75|._111 (r_nsubjpass) prescribed_14\VBN\748282|NONE_0 (l_prep) for_15\IN\0|drugs_75|are_24|commonly_20|._36 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) hyperthyroidism_19\NN\14059928|NONE_0
D013956_D006980 NONE drugs_3\NNS\14778436|are_51|commonly_55|for_75|._111 (r_nsubjpass) prescribed_14\VBN\748282|NONE_0 (l_prep) for_15\IN\0|drugs_75|are_24|commonly_20|._36 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) hyperthyroidism_19\NN\14059928|NONE_0
D002231_D056648 CID carbimazole_0\NNS\0|vasculitis_34|._44 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) vasculitis_4\NN\14336539|carbimazole_34|._10
D002231_D006111 NONE carbimazole_12\NN\0|who_28 (r_dobj) developed_9\VBD\1753788|graves_20 (r_relcl) disease_7\NN\14061805|NONE_0
D013956_D056648 CID antithyroidmedications_15\NNS\0|NONE_0 (r_pobj) of_14\IN\0|a_46|threatening_27|adverse_15 (r_prep) effect_13\NN\34213|antibody_81|._32 (r_attr) is_6\VBZ\0|NONE_0 (l_nsubj) antibody_2\NN\14728724|effect_81|._113 (l_appos) vasculitis_5\NN\14336539|antineutrophil_55|cytoplasmic_40
D011441_D006980 NONE propylthiouracil_8\NN\14727670|and_4|ptu_18 (r_conj) carbimazole_6\NN\0|NONE_0 (r_pobj) like_5\IN\5839024|thyroid_15|,_2 (r_prep) drugs_3\NNS\14778436|are_51|commonly_55|for_75|._111 (r_nsubjpass) prescribed_14\VBN\748282|NONE_0 (l_prep) for_15\IN\0|drugs_75|are_24|commonly_20|._36 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) hyperthyroidism_19\NN\14059928|NONE_0
D011441_D006980 NONE ptu_10\NNP\0|and_22|propylthiouracil_18 (r_appos) carbimazole_6\NN\0|NONE_0 (r_pobj) like_5\IN\5839024|thyroid_15|,_2 (r_prep) drugs_3\NNS\14778436|are_51|commonly_55|for_75|._111 (r_nsubjpass) prescribed_14\VBN\748282|NONE_0 (l_prep) for_15\IN\0|drugs_75|are_24|commonly_20|._36 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) hyperthyroidism_19\NN\14059928|NONE_0
816141
D002512_D007674 NONE cephalothin_13\JJ\2996840|NONE_0 (r_compound) therapy_14\NN\657604|while_28 (r_dobj) receiving_12\VBG\2210855|patient_76|anemia_13|._29 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_nsubj) patient_1\NN\9898892|anemia_63|receiving_76|._105 (l_prep) with_2\IN\0|a_10 (l_pobj) disease_4\NN\14061805|NONE_0
D002512_D000743 CID cephalothin_0\NNP\2996840|-_11 (r_npadvmod) induced_2\VBN\1627355|immune_8|hemolytic_15|._31 (r_amod) anemia_5\NN\14189204|NONE_0
D002512_D000743 CID cephalothin_13\JJ\2996840|NONE_0 (r_compound) therapy_14\NN\657604|while_28 (r_dobj) receiving_12\VBG\2210855|patient_76|anemia_13|._29 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_dobj) anemia_10\NN\14189204|patient_63|receiving_13|._42
10960401
D009020_D009759 CID morphine_10\NN\2707683|NONE_0 (r_pobj) of_9\IN\0|intravenous_46|controlled_26 (r_prep) administration_8\NN\1133281|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|downbeat_19|._73 (r_acl) nystagmus_1\NN\337486|NONE_0
D009020_D009759 CID morphine_23\NN\2707683|NONE_0 (r_pobj) of_17\IN\0|a_24|large_11 (r_prep) dose_16\NN\3740161|while_35 (r_dobj) receiving_12\VBG\2210855|who_57|dizziness_43|with_33 (r_advcl) developed_6\VBD\1753788|a_14 (l_prep) with_8\IN\0|who_24|dizziness_10|receiving_33 (l_pobj) nystagmus_10\NN\337486|NONE_0
D009020_D004244 CID morphine_23\NN\2707683|NONE_0 (r_pobj) of_17\IN\0|a_24|large_11 (r_prep) dose_16\NN\3740161|while_35 (r_dobj) receiving_12\VBG\2210855|who_57|dizziness_43|with_33 (r_advcl) developed_6\VBD\1753788|a_14 (l_dobj) dizziness_7\NN\14299637|who_14|with_10|receiving_43
891494
D010672_D012640 NONE phenytoin_3\NNP\3550533|(_10|dph_11|)_14|with_31 (r_nmod) encephalopathy_7\JJ\14084880|NONE_0 (l_prep) with_8\IN\0|phenytoin_31|(_21|dph_20|)_17 (l_pobj) seizures_10\NNS\14081375|NONE_0
D010672_D012640 NONE dph_5\NNP\6702458|phenytoin_11|(_1|)_3|with_20 (r_nmod) encephalopathy_7\JJ\14084880|NONE_0 (l_prep) with_8\IN\0|phenytoin_31|(_21|dph_20|)_17 (l_pobj) seizures_10\NNS\14081375|NONE_0
D010672_D012640 NONE dph_8\NNP\6702458|NONE_0 (r_compound) treatment_9\NN\654885|NONE_0 (r_dobj) starting_7\VBG\457382|a_10 (r_acl) patient_6\NN\9898892|increase_45 (r_pobj) in_4\IN\13603305|that_5|,_124|should_126|physician_143|to_153|,_222|are_254 (l_pobj) increase_12\NN\13576355|patient_45 (l_prep) in_13\IN\13603305|an_23|unexpected_20|,_11|with_13 (l_pobj) seizures_14\NNS\14081375|NONE_0
D010672_D012640 NONE dph_34\NNP\6702458|from_4 (r_dobj) eliminating_33\VBG\1619929|NONE_0 (r_pcomp) for_32\IN\0|the_18|possible_14 (r_prep) need_31\NN\13920835|NONE_0 (r_pobj) to_28\IN\0|that_158|in_153|,_29|should_27|physician_10|,_69|are_101 (r_prep) alert_25\VB\14031108|authors_155|._128 (l_prep) in_4\IN\13603305|that_5|,_124|should_126|physician_143|to_153|,_222|are_254 (l_pobj) increase_12\NN\13576355|patient_45 (l_prep) in_13\IN\13603305|an_23|unexpected_20|,_11|with_13 (l_pobj) seizures_14\NNS\14081375|NONE_0
D010672_D005076 NONE dph_6\NNP\6702458|NONE_0 (r_pobj) of_4\IN\0|the_18 (r_prep) concentration_3\NN\4916342|in_12|normal_30 (r_nsubj) was_7\VBD\0|,_10|patient_16|rash_58|during_63 (r_ccomp) presented_12\VBD\2137132|,_59|protidogram_65|normal_81|,_87|and_89|had_122 (l_dobj) rash_16\JJ\14321469|was_58|,_48|patient_42|during_5
D010672_D005076 NONE dph_18\NNP\6702458|NONE_0 (r_compound) treatment_19\NN\654885|NONE_0 (r_pobj) during_17\IN\0|was_63|,_53|patient_47|rash_5 (r_prep) presented_12\VBD\2137132|,_59|protidogram_65|normal_81|,_87|and_89|had_122 (l_dobj) rash_16\JJ\14321469|was_58|,_48|patient_42|during_5
D010672_D005076 NONE dph_29\NNP\6702458|an_15|intradermic_12 (r_compound) injection_30\NN\320852|effect_23|._29 (r_nsubj) had_31\VBD\0|presented_122|,_63|protidogram_57|normal_41|,_35|and_33 (r_conj) was_23\VBD\0|NONE_0 (l_ccomp) presented_12\VBD\2137132|,_59|protidogram_65|normal_81|,_87|and_89|had_122 (l_dobj) rash_16\JJ\14321469|was_58|,_48|patient_42|during_5
D010672_D001927 CID phenytoin_0\NNP\3550533|as_25|:_59|report_66|._72 (r_compound) encephalopathy_1\NNP\14084880|NONE_0
D010672_D001927 CID phenytoin_3\NNP\3550533|(_10|dph_11|)_14|with_31 (r_nmod) encephalopathy_7\JJ\14084880|NONE_0
D010672_D001927 CID dph_5\NNP\6702458|phenytoin_11|(_1|)_3|with_20 (r_nmod) encephalopathy_7\JJ\14084880|NONE_0
11915580
D009569_D004412 NONE no_19\JJ\7204911|an_3 (r_det) donor_20\NN\9608709|glyceryl_33|(_13|gtn_12|)_9|,_8|,_5 (r_appos) trinitrate_13\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_13 (r_prep) efficacy_10\NN\5199286|to_17|in_52 (r_dobj) determine_8\VB\0|aim_32|._143 (l_prep) in_22\IN\13603305|to_69|efficacy_52 (l_pobj) resolution_24\NN\6470073|NONE_0 (l_prep) of_25\IN\0|the_15|in_24 (l_pobj) dysmenorrhea_27\NN\14322699|NONE_0
D005996_D006261 CID gtn_5\NNP\0|but_4|not_8 (r_pobj) by_4\IN\0|headache_37|was_28|significantly_24|by_15|._21 (r_agent) increased_3\VBN\169651|NONE_0 (l_nsubjpass) headache_0\NNP\5829480|was_9|significantly_13|by_37|by_52|._58
D005996_D006261 CID gtn_4\NNP\0|NONE_0 (r_dobj) using_3\VBG\418025|patients_17|became_51|._69 (r_xcomp) stopped_2\VBD\0|NONE_0 (l_advcl) became_13\VBD\146138|patients_68|using_51|._18 (l_nsubj) headache_6\NN\5829480|because_8|intolerable_40
D004008_D006261 NONE dcf_9\NNP\0|NONE_0 (r_pobj) by_8\IN\0|headache_52|was_43|significantly_39|by_15|._6 (r_prep) increased_3\VBN\169651|NONE_0 (l_nsubjpass) headache_0\NNP\5829480|was_9|significantly_13|by_37|by_52|._58
D004008_D004412 NONE diclofenac_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|glyceryl_20|for_16 (r_prep) trinitrate_4\NN\0|NONE_0 (l_prep) for_7\IN\0|glyceryl_36|with_16 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_14 (l_pobj) dysmenorrhea_12\NN\14322699|NONE_0
D004008_D004412 NONE diclofenac_31\NNP\0|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) comparison_29\NN\635850|NONE_0 (r_pobj) in_28\IN\13603305|the_39|of_24 (r_prep) resolution_24\NN\6470073|NONE_0 (l_prep) of_25\IN\0|the_15|in_24 (l_pobj) dysmenorrhea_27\NN\14322699|NONE_0
D004008_D004412 NONE dcf_33\NNP\0|NONE_0 (r_appos) diclofenac_31\NNP\0|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) comparison_29\NN\635850|NONE_0 (r_pobj) in_28\IN\13603305|the_39|of_24 (r_prep) resolution_24\NN\6470073|NONE_0 (l_prep) of_25\IN\0|the_15|in_24 (l_pobj) dysmenorrhea_27\NN\14322699|NONE_0
D004008_D004412 NONE dcf_14\NNP\0|NONE_0 (r_pobj) with_13\IN\0|in_9 (r_prep) comparison_12\NN\635850|NONE_0 (l_prep) in_15\IN\13603305|with_9 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) dysmenorrhea_20\NN\14322699|NONE_0
D005996_D004412 NONE trinitrate_4\NN\0|NONE_0 (l_prep) for_7\IN\0|glyceryl_36|with_16 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_14 (l_pobj) dysmenorrhea_12\NN\14322699|NONE_0
D005996_D004412 NONE trinitrate_13\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_13 (r_prep) efficacy_10\NN\5199286|to_17|in_52 (r_dobj) determine_8\VB\0|aim_32|._143 (l_prep) in_22\IN\13603305|to_69|efficacy_52 (l_pobj) resolution_24\NN\6470073|NONE_0 (l_prep) of_25\IN\0|the_15|in_24 (l_pobj) dysmenorrhea_27\NN\14322699|NONE_0
D005996_D004412 NONE gtn_15\NNP\0|glyceryl_21|(_1|)_3|,_4|donor_12|,_17 (r_appos) trinitrate_13\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_13 (r_prep) efficacy_10\NN\5199286|to_17|in_52 (r_dobj) determine_8\VB\0|aim_32|._143 (l_prep) in_22\IN\13603305|to_69|efficacy_52 (l_pobj) resolution_24\NN\6470073|NONE_0 (l_prep) of_25\IN\0|the_15|in_24 (l_pobj) dysmenorrhea_27\NN\14322699|NONE_0
D005996_D004412 NONE gtn_4\NNP\0|that_5|efficacy_18|by_44 (r_nsubj) has_5\VBZ\13888491|findings_27|._103 (l_prep) by_11\IN\0|that_49|gtn_44|efficacy_26 (l_pobj) comparison_12\NN\635850|NONE_0 (l_prep) in_15\IN\13603305|with_9 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) dysmenorrhea_20\NN\14322699|NONE_0
D011453_D004412 NONE prostaglandins_16\NNS\5414534|NONE_0 (r_pobj) of_14\IN\0|a_17 (r_prep) hypersecretion_13\NN\13553916|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) caused_10\VBN\1617192|painful_30|uterine_22 (r_acl) contractility_9\NN\5200169|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) characterized_5\VBN\609683|a_11 (r_acl) syndrome_4\NN\5870365|dysmenorrhea_18|are_152|._190 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) dysmenorrhea_1\NN\14322699|syndrome_18|are_170|._208
D004008_D017699 NONE dcf_2\NNP\0|however_9|,_2|be_17|,_67|remained_88|._306 (r_nsubj) continued_3\VBD\2367363|NONE_0 (l_xcomp) be_5\VB\14625458|however_26|,_19|dcf_17|,_50|remained_71|._289 (l_acomp) effective_6\JJ\0|to_6 (l_prep) in_7\IN\13603305|NONE_0 (l_pcomp) reducing_8\VBG\13447361|NONE_0 (l_dobj) pain_10\NN\14299637|for_5
D005996_D017699 NONE gtn_16\NNP\0|NONE_0 (r_compound) scores_17\NNS\13757724|whereas_12|stable_29|after_36|and_49|higher_67|(_93|after_94|:_108|gtn_110 (r_nsubj) remained_18\VBD\2604760|however_97|,_90|dcf_88|be_71|,_21|._218 (r_advcl) continued_3\VBD\2367363|NONE_0 (l_xcomp) be_5\VB\14625458|however_26|,_19|dcf_17|,_50|remained_71|._289 (l_acomp) effective_6\JJ\0|to_6 (l_prep) in_7\IN\13603305|NONE_0 (l_pcomp) reducing_8\VBG\13447361|NONE_0 (l_dobj) pain_10\NN\14299637|for_5
D005996_D017699 NONE gtn_38\NNP\0|whereas_122|scores_110|stable_81|after_74|and_61|higher_43|(_17|after_16|:_2 (r_npadvmod) remained_18\VBD\2604760|however_97|,_90|dcf_88|be_71|,_21|._218 (r_advcl) continued_3\VBD\2367363|NONE_0 (l_xcomp) be_5\VB\14625458|however_26|,_19|dcf_17|,_50|remained_71|._289 (l_acomp) effective_6\JJ\0|to_6 (l_prep) in_7\IN\13603305|NONE_0 (l_pcomp) reducing_8\VBG\13447361|NONE_0 (l_dobj) pain_10\NN\14299637|for_5
D005996_D017699 NONE gtn_54\NNP\0|,_59|-12.8_57|+/-_51|;_43|dfc_41|-18.9_36|16.6_26|after_17|:_2|-23.7_5|20.5_15|;_19|dfc_21 (r_appos) gtn_38\NNP\0|whereas_122|scores_110|stable_81|after_74|and_61|higher_43|(_17|after_16|:_2 (r_npadvmod) remained_18\VBD\2604760|however_97|,_90|dcf_88|be_71|,_21|._218 (r_advcl) continued_3\VBD\2367363|NONE_0 (l_xcomp) be_5\VB\14625458|however_26|,_19|dcf_17|,_50|remained_71|._289 (l_acomp) effective_6\JJ\0|to_6 (l_prep) in_7\IN\13603305|NONE_0 (l_pcomp) reducing_8\VBG\13447361|NONE_0 (l_dobj) pain_10\NN\14299637|for_5
24190587
D018817_D008107 NONE ecstasy_0\NNP\13985818|drug_36|._107 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) drug_7\NN\14778436|ecstasy_36|._71 (l_relcl) associated_11\VBN\628491|a_45|psychostimulant_43 (l_prep) with_12\IN\0|which_33|is_27|increasingly_24 (l_pobj) dysfunction_14\NN\14204950|NONE_0
D018817_D008107 NONE mdma_2\NNP\3054098|NONE_0 (r_appos) ecstasy_0\NNP\13985818|drug_36|._107 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) drug_7\NN\14778436|ecstasy_36|._71 (l_relcl) associated_11\VBN\628491|a_45|psychostimulant_43 (l_prep) with_12\IN\0|which_33|is_27|increasingly_24 (l_pobj) dysfunction_14\NN\14204950|NONE_0
D018817_D003866 CID ecstasy_14\NN\13985818|-_7 (r_npadvmod) polydrug_16\NN\0|recreational_21 (r_compound) users_17\NNS\7846|NONE_0 (r_pobj) in_12\IN\13603305|previous_22 (r_prep) observations_11\NNS\996969|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) line_8\NN\8426461|NONE_0 (r_pobj) in_7\IN\13603305|increases_40|._73 (r_prep) are_6\VBP\13600404|NONE_0 (l_nsubj) increases_1\NNS\13576355|in_40|._113 (l_prep) in_2\IN\13603305|the_14 (l_pobj) anxiety_3\NN\14373582|NONE_0 (l_conj) depression_5\NN\14373582|and_4
D018817_D001008 NONE ecstasy_14\NN\13985818|-_7 (r_npadvmod) polydrug_16\NN\0|recreational_21 (r_compound) users_17\NNS\7846|NONE_0 (r_pobj) in_12\IN\13603305|previous_22 (r_prep) observations_11\NNS\996969|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) line_8\NN\8426461|NONE_0 (r_pobj) in_7\IN\13603305|increases_40|._73 (r_prep) are_6\VBP\13600404|NONE_0 (l_nsubj) increases_1\NNS\13576355|in_40|._113 (l_prep) in_2\IN\13603305|the_14 (l_pobj) anxiety_3\NN\14373582|NONE_0
35781
D010423_D002375 NONE pentazocine_18\NN\2707683|and_4 (r_conj) fentanyl_16\NN\2707683|,_2 (r_conj) codeine_14\NN\2707683|,_2 (r_conj) morphine_12\NN\2707683|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) analgesia_9\NN\14034177|NONE_0 (r_pobj) on_8\IN\0|NONE_0 (r_prep) xylometazoline_7\NN\0|and_4|,_82 (r_conj) naphazoline_5\NN\3809939|,_2 (r_conj) clonidine_3\NN\2721160|and_111|on_115 (r_pobj) of_2\IN\0|the_11 (l_conj) on_21\IN\0|clonidine_115|and_4 (l_pobj) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D003000_D002375 CID clonidine_3\NN\2721160|and_111|on_115 (r_pobj) of_2\IN\0|the_11 (l_conj) on_21\IN\0|clonidine_115|and_4 (l_pobj) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D003000_D002375 CID clonidine_5\NN\2721160|NONE_0 (r_pobj) by_4\IN\0|catalepsy_24|was_14|and_13|decreased_17|._60 (r_agent) increased_3\VBN\169651|NONE_0 (l_nsubjpass) catalepsy_1\NN\14023236|was_10|by_24|and_37|decreased_41|._84
D009638_D002375 NONE na_8\NNP\14625458|central_8 (r_compound) receptors_9\NNS\5225602|NONE_0 (r_dobj) stimulating_6\VBG\137313|three_12 (r_acl) drugs_5\NNS\14778436|that_11|affect_49|and_105|enhanced_114 (r_nsubj) failed_10\VBD\0|it_63|was_60|._126 (l_conj) enhanced_22\VBD\227165|that_125|drugs_114|affect_65|and_9 (l_dobj) catalepsy_23\NN\14023236|they_14
D003061_D002375 CID codeine_14\NN\2707683|,_2 (r_conj) morphine_12\NN\2707683|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) analgesia_9\NN\14034177|NONE_0 (r_pobj) on_8\IN\0|NONE_0 (r_prep) xylometazoline_7\NN\0|and_4|,_82 (r_conj) naphazoline_5\NN\3809939|,_2 (r_conj) clonidine_3\NN\2721160|and_111|on_115 (r_pobj) of_2\IN\0|the_11 (l_conj) on_21\IN\0|clonidine_115|and_4 (l_pobj) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D003061_D002375 CID codine_27\NN\0|,_2 (r_conj) morphine_25\NN\2707683|NONE_0 (r_pobj) of_24\IN\0|cataleptic_18 (r_prep) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D003061_D002375 CID codeine_0\NNP\2707683|NONE_0 (r_compound) catalepsy_1\NN\14023236|was_10|by_24|and_37|decreased_41|._84
C009695_D002375 CID xylometazoline_7\NN\0|and_4|,_82 (r_conj) naphazoline_5\NN\3809939|,_2 (r_conj) clonidine_3\NN\2721160|and_111|on_115 (r_pobj) of_2\IN\0|the_11 (l_conj) on_21\IN\0|clonidine_115|and_4 (l_pobj) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
C009695_D002375 CID xylometazoline_11\NN\0|and_4 (r_conj) naphazoline_9\NN\3809939|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_prep) decreased_7\VBD\169651|catalepsy_41|was_31|by_17|and_4|._43 (r_conj) increased_3\VBN\169651|NONE_0 (l_nsubjpass) catalepsy_1\NN\14023236|was_10|by_24|and_37|decreased_41|._84
D009020_D002375 CID morphine_12\NN\2707683|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) analgesia_9\NN\14034177|NONE_0 (r_pobj) on_8\IN\0|NONE_0 (r_prep) xylometazoline_7\NN\0|and_4|,_82 (r_conj) naphazoline_5\NN\3809939|,_2 (r_conj) clonidine_3\NN\2721160|and_111|on_115 (r_pobj) of_2\IN\0|the_11 (l_conj) on_21\IN\0|clonidine_115|and_4 (l_pobj) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D009020_D002375 CID morphine_25\NN\2707683|NONE_0 (r_pobj) of_24\IN\0|cataleptic_18 (r_prep) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D009020_D002375 CID morphine_26\NN\2707683|NONE_0 (r_pobj) by_25\IN\0|NONE_0 (r_agent) induced_24\VBN\1627355|NONE_0 (r_acl) catalepsy_23\NN\14023236|they_14
D009278_D002375 CID naphazoline_5\NN\3809939|,_2 (r_conj) clonidine_3\NN\2721160|and_111|on_115 (r_pobj) of_2\IN\0|the_11 (l_conj) on_21\IN\0|clonidine_115|and_4 (l_pobj) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D009278_D002375 CID naphazoline_9\NN\3809939|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_prep) decreased_7\VBD\169651|catalepsy_41|was_31|by_17|and_4|._43 (r_conj) increased_3\VBN\169651|NONE_0 (l_nsubjpass) catalepsy_1\NN\14023236|was_10|by_24|and_37|decreased_41|._84
D005283_D002375 CID fentanyl_16\NN\2707683|,_2 (r_conj) codeine_14\NN\2707683|,_2 (r_conj) morphine_12\NN\2707683|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|NONE_0 (r_acl) analgesia_9\NN\14034177|NONE_0 (r_pobj) on_8\IN\0|NONE_0 (r_prep) xylometazoline_7\NN\0|and_4|,_82 (r_conj) naphazoline_5\NN\3809939|,_2 (r_conj) clonidine_3\NN\2721160|and_111|on_115 (r_pobj) of_2\IN\0|the_11 (l_conj) on_21\IN\0|clonidine_115|and_4 (l_pobj) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D005283_D002375 CID fentanyl_29\NN\2707683|and_4 (r_conj) codine_27\NN\0|,_2 (r_conj) morphine_25\NN\2707683|NONE_0 (r_pobj) of_24\IN\0|cataleptic_18 (r_prep) effect_23\NN\34213|NONE_0 (l_amod) cataleptic_22\JJ\10490141|of_18
D005283_D002375 CID fentanyl_28\NN\2707683|and_4 (r_conj) morphine_26\NN\2707683|NONE_0 (r_pobj) by_25\IN\0|NONE_0 (r_agent) induced_24\VBN\1627355|NONE_0 (r_acl) catalepsy_23\NN\14023236|they_14
6310832
D016572_D016470 NONE cyclosporine_3\NN\0|NONE_0 (r_pobj) on_2\IN\0|renal_15 (r_prep) patients_1\NNS\9898892|bacteremias_40|._51 (r_nsubj) had_4\VBD\0|NONE_0 (l_dobj) bacteremias_7\NNS\14204950|patients_40|._11
D001379_D013203 NONE aza_0\NNP\0|NONE_0 (r_compound) patients_1\NNS\9898892|infections_47|,_110|and_112|occurred_143 (r_nsubj) had_2\VBD\0|NONE_0 (l_dobj) infections_6\NNS\14052046|patients_47|,_63|and_65|occurred_96
D016572_D003586 NONE cyclosporine_2\JJ\0|the_4 (r_compound) patients_3\NNS\9898892|NONE_0 (r_pobj) of_0\IN\0|15_30 (r_prep) %_6\NN\0|,_4|symptoms_6|._39 (r_nsubj) had_7\VBD\0|NONE_0 (l_dobj) symptoms_8\NNS\5823932|,_10|%_6|._33 (l_acl) related_9\VBN\628491|NONE_0 (l_prep) to_10\IN\0|NONE_0 (l_pobj) infection_12\NN\14052046|NONE_0
D016572_D007239 CID cyclosporine_12\NN\0|NONE_0 (r_pobj) on_11\IN\0|transplant_22 (r_prep) recipients_10\NNS\9764201|,_23|and_21 (r_conj) heart_5\NN\5919034|,_2 (r_conj) kidney_3\NN\5333259|NONE_0 (r_pobj) in_2\IN\13603305|early_17|._65 (r_prep) infections_1\NNS\14052046|NONE_0
D016572_D007239 CID cyclosporine_27\NN\0|the_15|randomized_11 (r_compound) patients_28\NNS\9898892|NONE_0 (r_pobj) than_24\IN\0|patients_104|infections_78|._41 (r_prep) had_4\VBD\0|NONE_0 (l_dobj) infections_7\NNS\14052046|patients_26|than_78|._119
D016572_D007239 CID cyclosporine_27\NN\0|the_15|randomized_11 (r_compound) patients_28\NNS\9898892|NONE_0 (r_pobj) than_24\IN\0|patients_104|infections_78|._41 (r_prep) had_4\VBD\0|NONE_0 (l_dobj) infections_7\NNS\14052046|patients_26|than_78|._119 (l_appos) p_9\NN\14622893|overall_20|(_1|(_47|p_48|)_64 (l_conj) infections_17\NNS\14052046|0.05_24|)_20|and_18
D016572_D007239 CID cyclosporine_8\JJ\0|renal_13 (r_nmod) patients_10\NNS\9898892|NONE_0 (r_pobj) than_7\IN\0|more_16|but_33|infections_43 (r_prep) infections_6\NNS\14052046|patients_18|._92
D016572_D007239 CID cyclosporine_8\JJ\0|renal_13 (r_nmod) patients_10\NNS\9898892|NONE_0 (r_pobj) than_7\IN\0|more_16|but_33|infections_43 (r_prep) infections_6\NNS\14052046|patients_18|._92 (l_conj) infections_13\NNS\14052046|more_59|than_43|but_10
D016572_D007239 CID cyclosporine_10\NN\0|NONE_0 (r_pobj) on_9\IN\0|renal_26|transplant_20 (r_prep) patients_8\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|no_21|infectious_18 (r_prep) deaths_4\NNS\7296428|there_25|,_58|but_60|played_74 (r_attr) were_1\VBD\0|NONE_0 (l_conj) played_16\VBD\1072262|there_99|deaths_74|,_16|but_14 (l_nsubj) infection_15\NN\14052046|role_25|in_30|out_35|out_79|._111
D016572_D007239 CID cyclosporine_6\NN\0|-_12 (r_npadvmod) treated_8\VBN\2376958|renal_8 (r_amod) patients_10\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|infections_28|common_7|than_39|._86 (r_prep) were_2\VBD\0|NONE_0 (l_nsubj) infections_1\NNS\14052046|common_21|in_28|than_67|._114
D016572_D020031 NONE cyclosporine_14\NN\0|65_3|studied_22 (r_compound) patients_15\NNS\9898892|NONE_0 (r_pobj) of_12\IN\0|20_4 (r_prep) %_11\NN\0|NONE_0 (r_pobj) in_9\IN\13603305|evidence_52|was_10|._42 (r_prep) found_8\VBN\13279262|NONE_0 (l_nsubjpass) evidence_1\NN\5816287|was_42|in_52|._94 (l_prep) for_2\IN\0|serological_21 (l_pobj) infection_6\NN\14052046|NONE_0
D001379_D009181 NONE aza_0\NNP\0|NONE_0 (r_compound) patients_1\NNS\9898892|infections_47|,_110|and_112|occurred_143 (r_nsubj) had_2\VBD\0|NONE_0 (l_conj) occurred_23\VBD\0|patients_143|infections_96|,_33|and_31 (l_nsubj) infections_22\NNS\14052046|in_25|._54
D001379_D007239 CID aza_2\NNP\0|the_15|randomized_11 (r_compound) patients_3\NNS\9898892|infections_26|than_104|._145 (r_nsubj) had_4\VBD\0|NONE_0 (l_dobj) infections_7\NNS\14052046|patients_26|than_78|._119
D001379_D007239 CID aza_2\NNP\0|the_15|randomized_11 (r_compound) patients_3\NNS\9898892|infections_26|than_104|._145 (r_nsubj) had_4\VBD\0|NONE_0 (l_dobj) infections_7\NNS\14052046|patients_26|than_78|._119 (l_appos) p_9\NN\14622893|overall_20|(_1|(_47|p_48|)_64 (l_conj) infections_17\NNS\14052046|0.05_24|)_20|and_18
D001379_D007239 CID aza_16\NNP\0|the_4|renal_4 (r_nmod) patients_18\NNS\9898892|NONE_0 (r_pobj) than_14\IN\0|fewer_17 (r_prep) infections_13\NNS\14052046|more_59|than_43|but_10 (r_conj) infections_6\NNS\14052046|patients_18|._92
D001379_D007239 CID aza_16\NNP\0|the_4|renal_4 (r_nmod) patients_18\NNS\9898892|NONE_0 (r_pobj) than_14\IN\0|fewer_17 (r_prep) infections_13\NNS\14052046|more_59|than_43|but_10
D001379_D007239 CID aza_12\NNP\0|or_3 (r_conj) cyclosporine_10\NN\0|NONE_0 (r_pobj) on_9\IN\0|renal_26|transplant_20 (r_prep) patients_8\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|no_21|infectious_18 (r_prep) deaths_4\NNS\7296428|there_25|,_58|but_60|played_74 (r_attr) were_1\VBD\0|NONE_0 (l_conj) played_16\VBD\1072262|there_99|deaths_74|,_16|but_14 (l_nsubj) infection_15\NN\14052046|role_25|in_30|out_35|out_79|._111
D001379_D007239 CID aza_13\NNP\0|-_3 (r_npadvmod) treated_15\VBN\2376958|(_17|p_18|)_34 (r_amod) patients_16\NNS\9898892|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) than_11\IN\0|infections_67|common_46|in_39|._47 (r_prep) were_2\VBD\0|NONE_0 (l_nsubj) infections_1\NNS\14052046|common_21|in_28|than_67|._114
8096565
D018170_D003027 NONE sumatriptan_15\NNP\0|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) after_12\IN\0|an_31|acute_28|myocardial_22|subcutaneously_41|for_56 (r_prep) infarction_11\NN\14204950|NONE_0 (l_prep) for_19\IN\0|an_87|acute_84|myocardial_78|after_56|subcutaneously_15 (l_pobj) headache_21\NN\5829480|NONE_0
D018170_D009203 CID sumatriptan_4\NNP\0|NONE_0 (r_pobj) with_3\IN\0|transmural_33|myocardial_22|._16 (r_prep) infarction_2\NN\14204950|NONE_0
D018170_D009203 CID sumatriptan_15\NNP\0|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) after_12\IN\0|an_31|acute_28|myocardial_22|subcutaneously_41|for_56 (r_prep) infarction_11\NN\14204950|NONE_0
16876986
D010862_D012640 CID pilocarpine_6\NN\14712692|-_11 (r_npadvmod) induced_8\VBN\1627355|subsequent_23|in_17 (r_amod) seizures_9\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_6\NN\14712692|in_23 (r_amod) injections_7\NNS\320852|NONE_0 (r_pobj) by_5\IN\0|thereafter_34|,_24|seizures_22|were_13|._67 (r_agent) induced_4\VBN\1627355|NONE_0 (l_nsubjpass) seizures_2\NNS\14081375|thereafter_12|,_2|were_9|by_22|._89
946593
D008727_D002493 NONE methothexate_34\NN\0|elevated_29|cerebrospinal_20|related_27|;_191|presence_197 (r_compound) concentration_35\NN\4916342|abnormal_170|cerebrospinal_161|related_138|,_80|and_78|leakage_51|;_44 (r_appos) dynamics_15\NNS\6100236|the_107|following_103 (l_acl) related_16\VBN\628491|abnormal_32|cerebrospinal_23|,_58|and_60|leakage_87|;_94|concentration_138 (l_prep) to_17\IN\0|NONE_0 (l_pobj) presence_19\NN\13954253|NONE_0 (l_prep) of_20\IN\0|the_13 (l_pobj) leukemia_24\NN\14239918|NONE_0
D008727_D002493 NONE methotrexate_46\NN\2722166|high_5|based_19 (r_compound) doses_47\NNS\3740161|NONE_0 (r_pobj) to_43\TO\0|to_45|and_4 (r_conj) related_36\VBN\628491|elevated_56|cerebrospinal_47|methothexate_27|;_164|presence_170 (r_acl) concentration_35\NN\4916342|abnormal_170|cerebrospinal_161|related_138|,_80|and_78|leakage_51|;_44 (r_appos) dynamics_15\NNS\6100236|the_107|following_103 (l_acl) related_16\VBN\628491|abnormal_32|cerebrospinal_23|,_58|and_60|leakage_87|;_94|concentration_138 (l_prep) to_17\IN\0|NONE_0 (l_pobj) presence_19\NN\13954253|NONE_0 (l_prep) of_20\IN\0|the_13 (l_pobj) leukemia_24\NN\14239918|NONE_0
D008727_D002493 NONE methotrexate_68\NN\2722166|available_10|and_26|diluents_30 (r_compound) preparations_69\NNS\407535|NONE_0 (r_pobj) in_65\IN\13603305|the_41|of_28|;_64|and_66|use_74 (r_prep) presence_61\NN\13954253|elevated_226|cerebrospinal_217|methothexate_197|related_170|;_6 (r_conj) concentration_35\NN\4916342|abnormal_170|cerebrospinal_161|related_138|,_80|and_78|leakage_51|;_44 (r_appos) dynamics_15\NNS\6100236|the_107|following_103 (l_acl) related_16\VBN\628491|abnormal_32|cerebrospinal_23|,_58|and_60|leakage_87|;_94|concentration_138 (l_prep) to_17\IN\0|NONE_0 (l_pobj) presence_19\NN\13954253|NONE_0 (l_prep) of_20\IN\0|the_13 (l_pobj) leukemia_24\NN\14239918|NONE_0
D008727_D002493 NONE methotrexate_77\NN\2722166|of_22 (r_compound) diluents_78\NNS\14778436|NONE_0 (r_pobj) of_76\IN\0|the_8 (r_prep) use_75\NN\407535|the_115|of_102|in_74|;_10|and_8 (r_conj) presence_61\NN\13954253|elevated_226|cerebrospinal_217|methothexate_197|related_170|;_6 (r_conj) concentration_35\NN\4916342|abnormal_170|cerebrospinal_161|related_138|,_80|and_78|leakage_51|;_44 (r_appos) dynamics_15\NNS\6100236|the_107|following_103 (l_acl) related_16\VBN\628491|abnormal_32|cerebrospinal_23|,_58|and_60|leakage_87|;_94|concentration_138 (l_prep) to_17\IN\0|NONE_0 (l_pobj) presence_19\NN\13954253|NONE_0 (l_prep) of_20\IN\0|the_13 (l_pobj) leukemia_24\NN\14239918|NONE_0
D008727_D002493 NONE methotrexate_12\NNP\2722166|NONE_0 (r_pobj) of_11\IN\0|lower_12 (r_prep) doses_10\NNS\3740161|in_22|,_72|in_74 (r_dobj) employing_8\VBG\0|NONE_0 (l_prep) in_13\IN\13603305|doses_22|,_50|in_52 (l_pobj) presence_15\NN\13954253|NONE_0 (l_prep) of_16\IN\0|the_13 (l_pobj) leukemia_20\NN\14239918|NONE_0
D008727_D020258 NONE methothexate_34\NN\0|elevated_29|cerebrospinal_20|related_27|;_191|presence_197 (r_compound) concentration_35\NN\4916342|abnormal_170|cerebrospinal_161|related_138|,_80|and_78|leakage_51|;_44 (l_conj) presence_61\NN\13954253|elevated_226|cerebrospinal_217|methothexate_197|related_170|;_6 (l_prep) of_62\IN\0|the_13|in_28|;_92|and_94|use_102 (l_pobj) preservatives_64\NNS\14818238|NONE_0 (l_amod) neurotoxic_63\JJ\0|NONE_0
D008727_D020258 NONE methotrexate_46\NN\2722166|high_5|based_19 (r_compound) doses_47\NNS\3740161|NONE_0 (r_pobj) to_43\TO\0|to_45|and_4 (r_conj) related_36\VBN\628491|elevated_56|cerebrospinal_47|methothexate_27|;_164|presence_170 (r_acl) concentration_35\NN\4916342|abnormal_170|cerebrospinal_161|related_138|,_80|and_78|leakage_51|;_44 (l_conj) presence_61\NN\13954253|elevated_226|cerebrospinal_217|methothexate_197|related_170|;_6 (l_prep) of_62\IN\0|the_13|in_28|;_92|and_94|use_102 (l_pobj) preservatives_64\NNS\14818238|NONE_0 (l_amod) neurotoxic_63\JJ\0|NONE_0
D008727_D020258 NONE methotrexate_68\NN\2722166|available_10|and_26|diluents_30 (r_compound) preparations_69\NNS\407535|NONE_0 (r_pobj) in_65\IN\13603305|the_41|of_28|;_64|and_66|use_74 (r_prep) presence_61\NN\13954253|elevated_226|cerebrospinal_217|methothexate_197|related_170|;_6 (l_prep) of_62\IN\0|the_13|in_28|;_92|and_94|use_102 (l_pobj) preservatives_64\NNS\14818238|NONE_0 (l_amod) neurotoxic_63\JJ\0|NONE_0
D008727_D020258 NONE methotrexate_77\NN\2722166|of_22 (r_compound) diluents_78\NNS\14778436|NONE_0 (r_pobj) of_76\IN\0|the_8 (r_prep) use_75\NN\407535|the_115|of_102|in_74|;_10|and_8 (r_conj) presence_61\NN\13954253|elevated_226|cerebrospinal_217|methothexate_197|related_170|;_6 (l_prep) of_62\IN\0|the_13|in_28|;_92|and_94|use_102 (l_pobj) preservatives_64\NNS\14818238|NONE_0 (l_amod) neurotoxic_63\JJ\0|NONE_0
D008727_D020258 NONE methotrexate_12\NNP\2722166|NONE_0 (r_pobj) of_11\IN\0|lower_12 (r_prep) doses_10\NNS\3740161|in_22|,_72|in_74 (r_dobj) employing_8\VBG\0|NONE_0 (r_pcomp) by_7\IN\0|incidence_42|may_15|be_11|._162 (r_prep) reduced_6\VBN\441445|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|may_27|be_31|by_42|._204 (l_prep) of_2\IN\0|the_14 (l_pobj) neurotoxicity_3\NN\0|NONE_0
D008727_D020258 NONE methotrexate_5\NNP\2722166|cerebruspinal_20 (r_compound) levels_6\NNS\4916342|NONE_0 (r_pobj) of_2\IN\0|periodic_20 (r_prep) monitoring_1\NN\879759|may_54|predictive_61|._115 (r_nsubj) be_8\VB\14625458|NONE_0 (l_acomp) predictive_9\JJ\0|monitoring_61|may_7|._54 (l_prep) of_10\IN\0|NONE_0 (l_pobj) development_12\NN\248977|NONE_0 (l_prep) of_13\IN\0|the_16 (l_pobj) neurotoxicity_15\NN\0|NONE_0
D008727_D064420 NONE methotrexate_3\NNP\2722166|,_25|deficiency_40 (r_compound) contaminants_4\NNS\14580897|NONE_0 (r_pobj) of_2\IN\0|the_9|in_79 (r_prep) role_1\NN\719494|unclear_144|._151 (l_prep) in_13\IN\13603305|the_88|of_79 (l_pobj) pathogenesis_15\NN\13533470|NONE_0 (l_prep) of_16\IN\0|the_17 (l_pobj) toxicity_19\NN\13576101|NONE_0
D008727_D064420 NONE methotrexate_18\NNP\2722166|intrathecal_12 (r_compound) toxicity_19\NN\13576101|NONE_0
D008727_D010264 CID methotrexate_3\NN\2722166|NONE_0 (r_dobj) following_1\VBG\8180190|report_36 (r_prep) paraplegia_0\NNP\14558226|NONE_0
D008727_D010264 CID methotrexate_10\NNP\2722166|NONE_0 (r_pobj) of_9\IN\0|the_29|intrathecal_25 (r_prep) instillation_8\NN\320852|NONE_0 (r_pobj) following_5\VBG\8180190|who_25|paraplegia_11 (r_prep) developed_3\VBD\1753788|a_14 (l_dobj) paraplegia_4\NNS\14558226|who_14|following_11
D008727_C536409 NONE methotrexate_3\NNP\2722166|,_25|deficiency_40 (r_compound) contaminants_4\NNS\14580897|NONE_0 (l_conj) deficiency_8\NN\14449126|methotrexate_40|,_15
D008727_C536409 NONE methotrexate_18\NNP\2722166|intrathecal_12 (r_compound) toxicity_19\NN\13576101|NONE_0 (r_pobj) of_16\IN\0|the_17 (r_prep) pathogenesis_15\NN\13533470|NONE_0 (r_pobj) in_13\IN\13603305|the_88|of_79 (r_prep) role_1\NN\719494|unclear_144|._151 (l_prep) of_2\IN\0|the_9|in_79 (l_pobj) contaminants_4\NNS\14580897|NONE_0 (l_conj) deficiency_8\NN\14449126|methotrexate_40|,_15
16034922
D004967_D020521 CID oestrogen_3\NN\14745635|term_5 (r_compound) ht_6\NNP\0|also_3|significantly_8|risk_36|._74 (r_nsubj) increased_9\VBD\169651|NONE_0 (l_dobj) risk_11\NN\14541044|ht_36|also_33|significantly_28|._38 (l_prep) of_12\IN\0|the_9 (l_pobj) disease_16\NN\14061805|NONE_0 (l_nmod) stroke_13\NN\556313|NONE_0
D004967_D005705 CID oestrogen_3\NN\14745635|term_5 (r_compound) ht_6\NNP\0|also_3|significantly_8|risk_36|._74 (r_nsubj) increased_9\VBD\169651|NONE_0 (l_dobj) risk_11\NN\14541044|ht_36|also_33|significantly_28|._38 (l_prep) of_12\IN\0|the_9 (l_pobj) disease_16\NN\14061805|NONE_0
17445520
D002110_D003865 NONE caffeine_51\NN\14712692|NONE_0 (r_compound) challenge_52\NN\13927383|an_17|oral_14 (r_compound) test_53\NN\5798043|NONE_0 (r_pobj) by_48\IN\0|panic_14 (r_prep) attacks_47\NNS\955060|NONE_0 (r_pobj) of_45\IN\0|the_14 (r_prep) induction_44\NN\7450842|NONE_0 (r_pobj) to_42\IN\0|a_14|similar_12 (r_prep) way_41\NN\4916342|NONE_0 (r_pobj) in_38\IN\13603305|if_186|patients_183 (r_prep) respond_37\VBP\2367363|to_189 (l_nsubj) patients_6\NNS\9898892|if_3|in_183 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disorder_9\NN\14034177|NONE_0 (l_conj) patients_14\NNS\9898892|panic_24|(_9|pd_8|)_6|and_4 (l_prep) with_15\IN\0|NONE_0 (l_pobj) depression_17\NN\14373582|NONE_0
D002110_D003865 NONE caffeine_51\NN\14712692|NONE_0 (r_compound) challenge_52\NN\13927383|an_17|oral_14 (r_compound) test_53\NN\5798043|NONE_0 (r_pobj) by_48\IN\0|panic_14 (r_prep) attacks_47\NNS\955060|NONE_0 (r_pobj) of_45\IN\0|the_14 (r_prep) induction_44\NN\7450842|NONE_0 (r_pobj) to_42\IN\0|a_14|similar_12 (r_prep) way_41\NN\4916342|NONE_0 (r_pobj) in_38\IN\13603305|if_186|patients_183 (r_prep) respond_37\VBP\2367363|to_189 (l_nsubj) patients_6\NNS\9898892|if_3|in_183 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disorder_9\NN\14034177|NONE_0 (l_conj) patients_14\NNS\9898892|panic_24|(_9|pd_8|)_6|and_4 (l_prep) with_15\IN\0|NONE_0 (l_pobj) depression_17\NN\14373582|NONE_0 (l_prep) with_18\IN\0|major_17 (l_pobj) attacks_20\NNS\955060|NONE_0 (l_appos) mdp_22\NNP\0|panic_15|(_1|)_3|(_5|diagnostic_6|)_84
D002110_D003865 NONE caffeine_56\NN\14712692|the_11|480-mg_7|challenge_9|(_24|chi(2)(3_25|)_33|16.22_37|,_42|p_44|)_52 (r_compound) test_58\NN\5798043|NONE_0 (r_pobj) after_53\IN\0|total_172|attack_7|._70 (r_prep) had_49\VBD\0|NONE_0 (l_nsubj) total_1\NN\3553|attack_165|after_172|._242 (l_prep) of_2\IN\0|a_8 (l_pobj) %_4\NN\0|NONE_0 (l_prep) of_22\IN\0|58.6_51|(_45|n_44|17_40|)_38|of_36|,_17|%_11|)_2|,_20|%_26|)_34|of_36|,_55|and_57|%_64 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_prep) with_24\IN\0|NONE_0 (l_pobj) mdp_25\NNP\0|NONE_0
D002110_D003865 NONE caffeine_56\NN\14712692|the_11|480-mg_7|challenge_9|(_24|chi(2)(3_25|)_33|16.22_37|,_42|p_44|)_52 (r_compound) test_58\NN\5798043|NONE_0 (r_pobj) after_53\IN\0|total_172|attack_7|._70 (r_prep) had_49\VBD\0|NONE_0 (l_nsubj) total_1\NN\3553|attack_165|after_172|._242 (l_prep) of_2\IN\0|a_8 (l_pobj) %_4\NN\0|NONE_0 (l_prep) of_34\IN\0|58.6_87|(_81|n_80|17_76|)_74|of_72|,_53|%_47|)_38|of_36|,_16|%_10|)_2|,_19|and_21|%_28 (l_pobj) patients_35\NNS\9898892|NONE_0 (l_prep) with_36\IN\0|NONE_0 (l_pobj) md_37\NNP\14622893|NONE_0
D002110_D003865 NONE caffeine_10\NN\14712692|NONE_0 (r_pobj) to_9\IN\0|more_15|were_17 (r_prep) sensitive_8\JJ\10488309|patients_35|._71 (r_acomp) were_6\VBD\0|NONE_0 (l_nsubj) patients_1\NNS\9898892|sensitive_35|._106 (l_prep) with_2\IN\0|the_13 (l_pobj) pd_3\NNP\14625458|NONE_0 (l_conj) mdp_5\NNP\0|and_4
D002110_D003865 NONE caffeine_10\NN\14712692|NONE_0 (r_pobj) to_9\IN\0|more_15|were_17 (r_prep) sensitive_8\JJ\10488309|patients_35|._71 (l_advcl) were_12\VBD\0|more_32|to_17 (l_nsubj) patients_13\NNS\9898892|than_10 (l_prep) with_14\IN\0|NONE_0 (l_pobj) md_15\NNP\14622893|NONE_0
D002110_D003865 NONE caffeine_26\NN\14712692|NONE_0 (r_compound) challenge_27\NN\13927383|an_17|oral_14 (r_compound) test_28\NN\5798043|NONE_0 (r_pobj) to_23\IN\0|NONE_0 (r_prep) hyperreactivity_22\NN\0|that_96|there_91|association_79|matter_41|associated_31|,_6|and_4 (r_conj) is_5\VBZ\0|data_24|._135 (l_advcl) associated_15\VBN\628491|that_65|there_60|association_48|matter_10|,_25|and_27|hyperreactivity_31 (l_prep) with_16\IN\0|if_14 (l_pobj) pd_17\NNP\14625458|NONE_0 (l_conj) mdp_19\NNP\0|or_3
D002110_D003866 NONE caffeine_0\NN\14712692|challenge_9|in_24|._75 (r_amod) test_2\NN\5798043|NONE_0 (l_prep) in_3\IN\13603305|caffeine_24|challenge_15|._51 (l_pobj) disorder_5\NN\14034177|NONE_0 (l_conj) depression_7\NN\14373582|panic_19|and_4
D002110_D001008 NONE caffeine_17\NN\14712692|in_86|,_9|were_48|in_66|applied_107|._141 (r_nsubjpass) administered_28\VBN\2436349|NONE_0 (l_prep) in_29\IN\13603305|in_152|,_75|caffeine_66|were_18|applied_41|._75 (l_pobj) scales_35\NNS\7260623|NONE_0 (l_nmod) form_32\NN\6286395|a_9 (l_conj) anxiety_34\NN\14373582|coffee_16|and_4
D002110_D001008 NONE caffeine_20\NN\14712692|-_8 (r_npadvmod) free_22\JJ\7942152|a_11|(_5|placebo_6|)_13 (r_amod) solution_26\NN\14586258|mg_42|and_30 (r_conj) caffeine_17\NN\14712692|in_86|,_9|were_48|in_66|applied_107|._141 (r_nsubjpass) administered_28\VBN\2436349|NONE_0 (l_prep) in_29\IN\13603305|in_152|,_75|caffeine_66|were_18|applied_41|._75 (l_pobj) scales_35\NNS\7260623|NONE_0 (l_nmod) form_32\NN\6286395|a_9 (l_conj) anxiety_34\NN\14373582|coffee_16|and_4
D002110_D016584 CID caffeine_0\NN\14712692|challenge_9|in_24|._75 (r_amod) test_2\NN\5798043|NONE_0 (l_prep) in_3\IN\13603305|caffeine_24|challenge_15|._51 (l_pobj) disorder_5\NN\14034177|NONE_0
D002110_D016584 CID caffeine_0\NN\14712692|challenge_9|in_24|._75 (r_amod) test_2\NN\5798043|NONE_0 (l_prep) in_3\IN\13603305|caffeine_24|challenge_15|._51 (l_pobj) disorder_5\NN\14034177|NONE_0 (l_conj) depression_7\NN\14373582|panic_19|and_4 (l_prep) with_8\IN\0|NONE_0 (l_pobj) attacks_10\NNS\955060|NONE_0
D002110_D016584 CID caffeine_51\NN\14712692|NONE_0 (r_compound) challenge_52\NN\13927383|an_17|oral_14 (r_compound) test_53\NN\5798043|NONE_0 (r_pobj) by_48\IN\0|panic_14 (r_prep) attacks_47\NNS\955060|NONE_0 (r_pobj) of_45\IN\0|the_14 (r_prep) induction_44\NN\7450842|NONE_0 (r_pobj) to_42\IN\0|a_14|similar_12 (r_prep) way_41\NN\4916342|NONE_0 (r_pobj) in_38\IN\13603305|if_186|patients_183 (r_prep) respond_37\VBP\2367363|to_189 (l_nsubj) patients_6\NNS\9898892|if_3|in_183 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disorder_9\NN\14034177|NONE_0
D002110_D016584 CID caffeine_51\NN\14712692|NONE_0 (r_compound) challenge_52\NN\13927383|an_17|oral_14 (r_compound) test_53\NN\5798043|NONE_0 (r_pobj) by_48\IN\0|panic_14 (r_prep) attacks_47\NNS\955060|NONE_0 (r_pobj) of_45\IN\0|the_14 (r_prep) induction_44\NN\7450842|NONE_0 (r_pobj) to_42\IN\0|a_14|similar_12 (r_prep) way_41\NN\4916342|NONE_0 (r_pobj) in_38\IN\13603305|if_186|patients_183 (r_prep) respond_37\VBP\2367363|to_189 (l_nsubj) patients_6\NNS\9898892|if_3|in_183 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disorder_9\NN\14034177|NONE_0 (l_appos) pd_11\NNP\14625458|panic_16|(_1|)_2|and_4|patients_8
D002110_D016584 CID caffeine_51\NN\14712692|NONE_0 (r_compound) challenge_52\NN\13927383|an_17|oral_14 (r_compound) test_53\NN\5798043|NONE_0 (r_pobj) by_48\IN\0|panic_14 (r_prep) attacks_47\NNS\955060|NONE_0 (r_pobj) of_45\IN\0|the_14 (r_prep) induction_44\NN\7450842|NONE_0 (r_pobj) to_42\IN\0|a_14|similar_12 (r_prep) way_41\NN\4916342|NONE_0 (r_pobj) in_38\IN\13603305|if_186|patients_183 (r_prep) respond_37\VBP\2367363|to_189 (l_nsubj) patients_6\NNS\9898892|if_3|in_183 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disorder_9\NN\14034177|NONE_0 (l_conj) patients_14\NNS\9898892|panic_24|(_9|pd_8|)_6|and_4 (l_prep) with_15\IN\0|NONE_0 (l_pobj) depression_17\NN\14373582|NONE_0 (l_prep) with_18\IN\0|major_17 (l_pobj) attacks_20\NNS\955060|NONE_0
D002110_D016584 CID caffeine_51\NN\14712692|NONE_0 (r_compound) challenge_52\NN\13927383|an_17|oral_14 (r_compound) test_53\NN\5798043|NONE_0 (r_pobj) by_48\IN\0|panic_14 (r_prep) attacks_47\NNS\955060|NONE_0
D002110_D016584 CID caffeine_56\NN\14712692|the_11|480-mg_7|challenge_9|(_24|chi(2)(3_25|)_33|16.22_37|,_42|p_44|)_52 (r_compound) test_58\NN\5798043|NONE_0 (r_pobj) after_53\IN\0|total_172|attack_7|._70 (r_prep) had_49\VBD\0|NONE_0 (l_nsubj) total_1\NN\3553|attack_165|after_172|._242 (l_prep) of_2\IN\0|a_8 (l_pobj) %_4\NN\0|NONE_0 (l_prep) of_10\IN\0|58.6_15|(_9|n_8|17_4|)_2|,_19|%_25|)_34|of_36|,_56|%_62|)_70|of_72|,_91|and_93|%_100 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) pd_13\NNP\14625458|NONE_0
D002110_D016584 CID caffeine_56\NN\14712692|the_11|480-mg_7|challenge_9|(_24|chi(2)(3_25|)_33|16.22_37|,_42|p_44|)_52 (r_compound) test_58\NN\5798043|NONE_0 (r_pobj) after_53\IN\0|total_172|attack_7|._70 (r_prep) had_49\VBD\0|NONE_0 (l_dobj) attack_52\NN\955060|total_165|after_7|._77
D002110_D016584 CID caffeine_10\NN\14712692|NONE_0 (r_pobj) to_9\IN\0|more_15|were_17 (r_prep) sensitive_8\JJ\10488309|patients_35|._71 (r_acomp) were_6\VBD\0|NONE_0 (l_nsubj) patients_1\NNS\9898892|sensitive_35|._106 (l_prep) with_2\IN\0|the_13 (l_pobj) pd_3\NNP\14625458|NONE_0
D002110_D016584 CID caffeine_7\NN\14712692|-_8 (r_npadvmod) free_9\JJ\7942152|the_13|solution_5 (r_amod) intake_11\NN\13440063|NONE_0 (r_pobj) after_5\IN\0|attack_20|was_13|._39 (r_prep) observed_4\VBN\2163746|NONE_0 (l_nsubjpass) attack_2\NN\955060|was_7|after_20|._59
D002110_D016584 CID caffeine_26\NN\14712692|NONE_0 (r_compound) challenge_27\NN\13927383|an_17|oral_14 (r_compound) test_28\NN\5798043|NONE_0 (r_pobj) to_23\IN\0|NONE_0 (r_prep) hyperreactivity_22\NN\0|that_96|there_91|association_79|matter_41|associated_31|,_6|and_4 (r_conj) is_5\VBZ\0|data_24|._135 (l_attr) association_7\NN\8008335|that_17|there_12|matter_38|associated_48|,_73|and_75|hyperreactivity_79 (l_prep) between_8\IN\0|an_15|,_21 (l_pobj) attacks_10\NNS\955060|NONE_0
D002110_D016584 CID caffeine_26\NN\14712692|NONE_0 (r_compound) challenge_27\NN\13927383|an_17|oral_14 (r_compound) test_28\NN\5798043|NONE_0 (r_pobj) to_23\IN\0|NONE_0 (r_prep) hyperreactivity_22\NN\0|that_96|there_91|association_79|matter_41|associated_31|,_6|and_4 (r_conj) is_5\VBZ\0|data_24|._135 (l_advcl) associated_15\VBN\628491|that_65|there_60|association_48|matter_10|,_25|and_27|hyperreactivity_31 (l_prep) with_16\IN\0|if_14 (l_pobj) pd_17\NNP\14625458|NONE_0
D002110_D016584 NONE caffeine_51\NN\14712692|NONE_0 (r_compound) challenge_52\NN\13927383|an_17|oral_14 (r_compound) test_53\NN\5798043|NONE_0 (r_pobj) by_48\IN\0|panic_14 (r_prep) attacks_47\NNS\955060|NONE_0 (r_pobj) of_45\IN\0|the_14 (r_prep) induction_44\NN\7450842|NONE_0 (r_pobj) to_42\IN\0|a_14|similar_12 (r_prep) way_41\NN\4916342|NONE_0 (r_pobj) in_38\IN\13603305|if_186|patients_183 (r_prep) respond_37\VBP\2367363|to_189 (l_nsubj) patients_6\NNS\9898892|if_3|in_183 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disorder_9\NN\14034177|NONE_0 (l_conj) patients_14\NNS\9898892|panic_24|(_9|pd_8|)_6|and_4 (l_prep) with_15\IN\0|NONE_0 (l_pobj) depression_17\NN\14373582|NONE_0 (l_prep) with_18\IN\0|major_17 (l_pobj) attacks_20\NNS\955060|NONE_0 (l_appos) mdp_22\NNP\0|panic_15|(_1|)_3|(_5|diagnostic_6|)_84
D002110_D016584 NONE caffeine_56\NN\14712692|the_11|480-mg_7|challenge_9|(_24|chi(2)(3_25|)_33|16.22_37|,_42|p_44|)_52 (r_compound) test_58\NN\5798043|NONE_0 (r_pobj) after_53\IN\0|total_172|attack_7|._70 (r_prep) had_49\VBD\0|NONE_0 (l_nsubj) total_1\NN\3553|attack_165|after_172|._242 (l_prep) of_2\IN\0|a_8 (l_pobj) %_4\NN\0|NONE_0 (l_prep) of_22\IN\0|58.6_51|(_45|n_44|17_40|)_38|of_36|,_17|%_11|)_2|,_20|%_26|)_34|of_36|,_55|and_57|%_64 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_prep) with_24\IN\0|NONE_0 (l_pobj) mdp_25\NNP\0|NONE_0
D002110_D016584 NONE caffeine_10\NN\14712692|NONE_0 (r_pobj) to_9\IN\0|more_15|were_17 (r_prep) sensitive_8\JJ\10488309|patients_35|._71 (r_acomp) were_6\VBD\0|NONE_0 (l_nsubj) patients_1\NNS\9898892|sensitive_35|._106 (l_prep) with_2\IN\0|the_13 (l_pobj) pd_3\NNP\14625458|NONE_0 (l_conj) mdp_5\NNP\0|and_4
D002110_D016584 NONE caffeine_26\NN\14712692|NONE_0 (r_compound) challenge_27\NN\13927383|an_17|oral_14 (r_compound) test_28\NN\5798043|NONE_0 (r_pobj) to_23\IN\0|NONE_0 (r_prep) hyperreactivity_22\NN\0|that_96|there_91|association_79|matter_41|associated_31|,_6|and_4 (r_conj) is_5\VBZ\0|data_24|._135 (l_advcl) associated_15\VBN\628491|that_65|there_60|association_48|matter_10|,_25|and_27|hyperreactivity_31 (l_prep) with_16\IN\0|if_14 (l_pobj) pd_17\NNP\14625458|NONE_0 (l_conj) mdp_19\NNP\0|or_3
D002110_D001523 NONE caffeine_51\NN\14712692|NONE_0 (r_compound) challenge_52\NN\13927383|an_17|oral_14 (r_compound) test_53\NN\5798043|NONE_0 (r_pobj) by_48\IN\0|panic_14 (r_prep) attacks_47\NNS\955060|NONE_0 (r_pobj) of_45\IN\0|the_14 (r_prep) induction_44\NN\7450842|NONE_0 (r_pobj) to_42\IN\0|a_14|similar_12 (r_prep) way_41\NN\4916342|NONE_0 (r_pobj) in_38\IN\13603305|if_186|patients_183 (r_prep) respond_37\VBP\2367363|to_189 (l_nsubj) patients_6\NNS\9898892|if_3|in_183 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disorder_9\NN\14034177|NONE_0 (l_conj) patients_14\NNS\9898892|panic_24|(_9|pd_8|)_6|and_4 (l_prep) with_15\IN\0|NONE_0 (l_pobj) depression_17\NN\14373582|NONE_0 (l_prep) with_18\IN\0|major_17 (l_pobj) attacks_20\NNS\955060|NONE_0 (l_appos) diagnostic_25\NNP\0|panic_21|(_7|mdp_6|)_3|(_1|)_78 (l_conj) manual_28\NNP\6421301|and_16|,_26|criteria_43 (l_prep) of_29\IN\0|statistical_19 (l_pobj) disorders_31\NNP\14034177|NONE_0
10462057
D017330_D000741 CID remoxipride_4\NN\0|in_24|and_32|cells_77 (r_compound) metabolites_5\NNS\20090|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) apoptosis_2\NN\11486178|NONE_0 (r_pobj) of_1\IN\0|:_98|relevance_110|._158 (r_prep) induction_0\NN\7450842|NONE_0 (l_appos) relevance_17\NN\13791389|of_110|:_12|._48 (l_prep) to_18\IN\0|potential_20 (l_pobj) anemia_23\NN\14189204|NONE_0
D017330_D000741 CID remoxipride_19\NN\0|-_11 (r_npadvmod) induced_21\VBN\1627355|aplastic_8 (r_amod) anemia_23\NN\14189204|NONE_0
D017330_D000741 CID remoxipride_4\NN\0|has_89|been_93|with_109|._138 (r_nsubjpass) associated_14\VBN\628491|NONE_0 (l_prep) with_15\IN\0|remoxipride_109|has_20|been_16|._29 (l_pobj) anemia_18\NN\14189204|NONE_0
D017330_D000741 CID amide_10\NN\14727670|agent_89|,_84|[_70|(_69|]_5 (r_appos) remoxipride_4\NN\0|has_89|been_93|with_109|._138 (r_nsubjpass) associated_14\VBN\628491|NONE_0 (l_prep) with_15\IN\0|remoxipride_109|has_20|been_16|._29 (l_pobj) anemia_18\NN\14189204|NONE_0
D017330_D000741 CID remoxipride_3\NN\0|that_5|may_24|anemia_44|via_51|and_98|apoptosis_150 (r_nsubj) induce_7\VB\1627355|we_44|contribute_150|._255 (l_dobj) anemia_9\NN\14189204|that_49|remoxipride_44|may_20|via_7|and_54|apoptosis_106
D017330_D000741 CID remoxipride_3\NN\0|that_5|may_24|anemia_44|via_51|and_98|apoptosis_150 (r_nsubj) induce_7\VB\1627355|we_44|contribute_150|._255 (r_ccomp) propose_1\VBP\1010118|NONE_0 (l_conj) contribute_31\VB\126264|we_194|induce_150|._105 (l_prep) to_32\IN\0|may_15 (l_pobj) anemia_38\NN\14189204|NONE_0
D017330_D000741 CID remoxipride_44\NN\0|NONE_0 (r_pobj) with_43\IN\0|that_25|has_20|been_16 (r_prep) associated_42\VBN\628491|mechanism_60|underlying_50|acquired_39|aplastic_30 (r_relcl) anemia_38\NN\14189204|NONE_0 (r_pobj) to_32\IN\0|may_15 (r_prep) contribute_31\VB\126264|we_194|induce_150|._105 (r_conj) propose_1\VBP\1010118|NONE_0 (l_ccomp) induce_7\VB\1627355|we_44|contribute_150|._255 (l_dobj) anemia_9\NN\14189204|that_49|remoxipride_44|may_20|via_7|and_54|apoptosis_106
D017330_D000741 CID remoxipride_44\NN\0|NONE_0 (r_pobj) with_43\IN\0|that_25|has_20|been_16 (r_prep) associated_42\VBN\628491|mechanism_60|underlying_50|acquired_39|aplastic_30 (r_relcl) anemia_38\NN\14189204|NONE_0
C084325_D009336 NONE ncq436_8\NNP\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) treated_6\VBN\2376958|NONE_0 (r_acl) cells_5\NNS\3080309|NONE_0 (r_pobj) in_4\IN\13603305|necrosis_22|was_13|but_29|had_40 (r_prep) observed_3\VBN\2163746|NONE_0 (l_nsubjpass) necrosis_1\NN\11444117|was_9|in_22|but_51|had_62
C084325_D009336 NONE ncq436_8\NNP\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) treated_6\VBN\2376958|NONE_0 (r_acl) cells_5\NNS\3080309|NONE_0 (r_pobj) in_4\IN\13603305|necrosis_22|was_13|but_29|had_40 (r_prep) observed_3\VBN\2163746|NONE_0 (l_conj) had_11\VBD\0|necrosis_62|was_53|in_40|but_11 (l_advcl) inducing_20\VBG\42311|ncq344_49|effect_27|,_2|._80 (l_advmod) apoptosis_21\NN\11486178|NONE_0 (l_prep) at_22\IN\14622893|NONE_0 (l_pobj) concentrations_24\NNS\4916342|NONE_0 (l_conj) necrosis_26\NN\11444117|lower_25|and_4|at_9
C112341_D009336 NONE ncq344_10\NNP\0|effect_22|,_47|inducing_49|._129 (r_nsubj) had_11\VBD\0|necrosis_62|was_53|in_40|but_11 (r_conj) observed_3\VBN\2163746|NONE_0 (l_nsubjpass) necrosis_1\NN\11444117|was_9|in_22|but_51|had_62
C112341_D009336 NONE ncq344_10\NNP\0|effect_22|,_47|inducing_49|._129 (r_nsubj) had_11\VBD\0|necrosis_62|was_53|in_40|but_11 (l_advcl) inducing_20\VBG\42311|ncq344_49|effect_27|,_2|._80 (l_advmod) apoptosis_21\NN\11486178|NONE_0 (l_prep) at_22\IN\14622893|NONE_0 (l_pobj) concentrations_24\NNS\4916342|NONE_0 (l_conj) necrosis_26\NN\11444117|lower_25|and_4|at_9
D001554_D000741 CID benzene_5\NN\14767996|and_4 (r_conj) remoxipride_3\NN\0|that_5|may_24|anemia_44|via_51|and_98|apoptosis_150 (r_nsubj) induce_7\VB\1627355|we_44|contribute_150|._255 (l_dobj) anemia_9\NN\14189204|that_49|remoxipride_44|may_20|via_7|and_54|apoptosis_106
D001554_D000741 CID benzene_5\NN\14767996|and_4 (r_conj) remoxipride_3\NN\0|that_5|may_24|anemia_44|via_51|and_98|apoptosis_150 (r_nsubj) induce_7\VB\1627355|we_44|contribute_150|._255 (r_ccomp) propose_1\VBP\1010118|NONE_0 (l_conj) contribute_31\VB\126264|we_194|induce_150|._105 (l_prep) to_32\IN\0|may_15 (l_pobj) anemia_38\NN\14189204|NONE_0
C084325_D000741 NONE ncq436_21\NNP\0|NONE_0 (r_pobj) of_20\IN\0|the_12|induce_24 (r_prep) ability_19\NN\4723816|that_9|in_49 (r_nsubj) apoptosis_26\NN\11486178|that_155|remoxipride_150|may_126|anemia_106|via_99|and_52 (r_conj) induce_7\VB\1627355|we_44|contribute_150|._255 (l_dobj) anemia_9\NN\14189204|that_49|remoxipride_44|may_20|via_7|and_54|apoptosis_106
C084325_D000741 NONE ncq436_21\NNP\0|NONE_0 (r_pobj) of_20\IN\0|the_12|induce_24 (r_prep) ability_19\NN\4723816|that_9|in_49 (r_nsubj) apoptosis_26\NN\11486178|that_155|remoxipride_150|may_126|anemia_106|via_99|and_52 (r_conj) induce_7\VB\1627355|we_44|contribute_150|._255 (r_ccomp) propose_1\VBP\1010118|NONE_0 (l_conj) contribute_31\VB\126264|we_194|induce_150|._105 (l_prep) to_32\IN\0|may_15 (l_pobj) anemia_38\NN\14189204|NONE_0
C112341_D000741 NONE ncq344_23\NNP\0|and_4 (r_conj) ncq436_21\NNP\0|NONE_0 (r_pobj) of_20\IN\0|the_12|induce_24 (r_prep) ability_19\NN\4723816|that_9|in_49 (r_nsubj) apoptosis_26\NN\11486178|that_155|remoxipride_150|may_126|anemia_106|via_99|and_52 (r_conj) induce_7\VB\1627355|we_44|contribute_150|._255 (l_dobj) anemia_9\NN\14189204|that_49|remoxipride_44|may_20|via_7|and_54|apoptosis_106
C112341_D000741 NONE ncq344_23\NNP\0|and_4 (r_conj) ncq436_21\NNP\0|NONE_0 (r_pobj) of_20\IN\0|the_12|induce_24 (r_prep) ability_19\NN\4723816|that_9|in_49 (r_nsubj) apoptosis_26\NN\11486178|that_155|remoxipride_150|may_126|anemia_106|via_99|and_52 (r_conj) induce_7\VB\1627355|we_44|contribute_150|._255 (r_ccomp) propose_1\VBP\1010118|NONE_0 (l_conj) contribute_31\VB\126264|we_194|induce_150|._105 (l_prep) to_32\IN\0|may_15 (l_pobj) anemia_38\NN\14189204|NONE_0
6627074
D013390_D020879 NONE succinylcholine_15\NN\3800001|NONE_0 (r_pobj) of_14\IN\0|the_19 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) following_11\VBG\8180190|prolonged_33|neuromuscular_23 (r_prep) blockade_10\NN\952963|to_38
D013390_D001049 CID succinylcholine_0\NN\3800001|:_22|attempted_24|._67 (r_compound) apnoea_1\NN\0|NONE_0
D013390_D001049 CID succinylcholine_14\NN\3800001|NONE_0 (r_compound) apnoea_15\NN\0|NONE_0
3323599
D011479_D064420 NONE ps_9\NNP\6763273|NONE_0 (r_pobj) of_8\IN\0|the_19 (r_prep) administration_7\NN\1133281|that_9|toxicity_34|and_69|produces_81 (r_nsubj) enhances_10\VBZ\227165|therefore_57|,_48|it_46|is_43|._134 (l_dobj) toxicity_12\NN\13576101|that_43|administration_34|and_35|produces_47
D011692_D007676 CID amns_14\NNP\0|NONE_0 (r_pobj) of_13\IN\0|the_13|on_8 (r_prep) toxicity_12\NN\13576101|that_43|administration_34|and_35|produces_47 (r_dobj) enhances_10\VBZ\227165|therefore_57|,_48|it_46|is_43|._134 (l_conj) produces_20\VBZ\7555863|that_90|administration_81|toxicity_47|and_12 (l_dobj) fsgs_22\NNS\0|readily_29 (l_prep) in_23\IN\13603305|progressive_17 (l_pobj) rats_24\NNS\2329401|NONE_0 (l_acl) resulting_25\VBG\2633881|NONE_0 (l_prep) in_26\IN\13603305|NONE_0 (l_pobj) disease_32\NN\14061805|NONE_0
D011692_D064420 NONE amns_14\NNP\0|NONE_0 (r_pobj) of_13\IN\0|the_13|on_8 (r_prep) toxicity_12\NN\13576101|that_43|administration_34|and_35|produces_47
D011479_D007676 NONE ps_9\NNP\6763273|NONE_0 (r_pobj) of_8\IN\0|the_19 (r_prep) administration_7\NN\1133281|that_9|toxicity_34|and_69|produces_81 (r_nsubj) enhances_10\VBZ\227165|therefore_57|,_48|it_46|is_43|._134 (l_conj) produces_20\VBZ\7555863|that_90|administration_81|toxicity_47|and_12 (l_dobj) fsgs_22\NNS\0|readily_29 (l_prep) in_23\IN\13603305|progressive_17 (l_pobj) rats_24\NNS\2329401|NONE_0 (l_acl) resulting_25\VBG\2633881|NONE_0 (l_prep) in_26\IN\13603305|NONE_0 (l_pobj) disease_32\NN\14061805|NONE_0
D011692_D009401 NONE aminonucleoside_3\JJ\0|NONE_0 (r_amod) nephrosis_4\NN\14304060|NONE_0
D011692_D005923 CID aminonucleoside_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_28|combined_24 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|model_75|was_22|in_8|._93 (r_agent) developed_12\VBN\1753788|NONE_0 (l_nsubjpass) model_2\NN\5888929|was_53|in_67|by_75|._168 (l_prep) of_3\IN\0|an_22|experimental_19|(_40|fsgs_41|)_45 (l_pobj) sclerosis_7\NN\14204950|NONE_0
D011692_D005923 CID aminonucleoside_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_28|combined_24 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|model_75|was_22|in_8|._93 (r_agent) developed_12\VBN\1753788|NONE_0 (l_nsubjpass) model_2\NN\5888929|was_53|in_67|by_75|._168 (l_appos) fsgs_9\NNP\0|an_63|experimental_60|of_41|(_1|)_4
D011692_D005923 CID amns_24\NNP\0|puromycin_27|-_18 (r_appos) aminonucleoside_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_28|combined_24 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|model_75|was_22|in_8|._93 (r_agent) developed_12\VBN\1753788|NONE_0 (l_nsubjpass) model_2\NN\5888929|was_53|in_67|by_75|._168 (l_prep) of_3\IN\0|an_22|experimental_19|(_40|fsgs_41|)_45 (l_pobj) sclerosis_7\NN\14204950|NONE_0
D011692_D005923 CID amns_24\NNP\0|puromycin_27|-_18 (r_appos) aminonucleoside_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_28|combined_24 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|model_75|was_22|in_8|._93 (r_agent) developed_12\VBN\1753788|NONE_0 (l_nsubjpass) model_2\NN\5888929|was_53|in_67|by_75|._168 (l_appos) fsgs_9\NNP\0|an_63|experimental_60|of_41|(_1|)_4
D011692_D005923 CID amns_14\NNP\0|NONE_0 (r_pobj) of_13\IN\0|the_13|on_8 (r_prep) toxicity_12\NN\13576101|that_43|administration_34|and_35|produces_47 (r_dobj) enhances_10\VBZ\227165|therefore_57|,_48|it_46|is_43|._134 (l_conj) produces_20\VBZ\7555863|that_90|administration_81|toxicity_47|and_12 (l_dobj) fsgs_22\NNS\0|readily_29
D011479_D005923 NONE sulfate_28\NN\15010703|)_11 (r_dobj) protamine_27\NN\14736972|(_11|)_6|and_4 (r_conj) amns_24\NNP\0|puromycin_27|-_18 (r_appos) aminonucleoside_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_28|combined_24 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|model_75|was_22|in_8|._93 (r_agent) developed_12\VBN\1753788|NONE_0 (l_nsubjpass) model_2\NN\5888929|was_53|in_67|by_75|._168 (l_prep) of_3\IN\0|an_22|experimental_19|(_40|fsgs_41|)_45 (l_pobj) sclerosis_7\NN\14204950|NONE_0
D011479_D005923 NONE sulfate_28\NN\15010703|)_11 (r_dobj) protamine_27\NN\14736972|(_11|)_6|and_4 (r_conj) amns_24\NNP\0|puromycin_27|-_18 (r_appos) aminonucleoside_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_28|combined_24 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|model_75|was_22|in_8|._93 (r_agent) developed_12\VBN\1753788|NONE_0 (l_nsubjpass) model_2\NN\5888929|was_53|in_67|by_75|._168 (l_appos) fsgs_9\NNP\0|an_63|experimental_60|of_41|(_1|)_4
D011479_D005923 NONE ps_30\NNP\6763273|NONE_0 (r_appos) sulfate_28\NN\15010703|)_11 (r_dobj) protamine_27\NN\14736972|(_11|)_6|and_4 (r_conj) amns_24\NNP\0|puromycin_27|-_18 (r_appos) aminonucleoside_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_28|combined_24 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|model_75|was_22|in_8|._93 (r_agent) developed_12\VBN\1753788|NONE_0 (l_nsubjpass) model_2\NN\5888929|was_53|in_67|by_75|._168 (l_prep) of_3\IN\0|an_22|experimental_19|(_40|fsgs_41|)_45 (l_pobj) sclerosis_7\NN\14204950|NONE_0
D011479_D005923 NONE ps_30\NNP\6763273|NONE_0 (r_appos) sulfate_28\NN\15010703|)_11 (r_dobj) protamine_27\NN\14736972|(_11|)_6|and_4 (r_conj) amns_24\NNP\0|puromycin_27|-_18 (r_appos) aminonucleoside_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_28|combined_24 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|model_75|was_22|in_8|._93 (r_agent) developed_12\VBN\1753788|NONE_0 (l_nsubjpass) model_2\NN\5888929|was_53|in_67|by_75|._168 (l_appos) fsgs_9\NNP\0|an_63|experimental_60|of_41|(_1|)_4
D011479_D005923 NONE ps_9\NNP\6763273|NONE_0 (r_pobj) of_8\IN\0|the_19 (r_prep) administration_7\NN\1133281|that_9|toxicity_34|and_69|produces_81 (r_nsubj) enhances_10\VBZ\227165|therefore_57|,_48|it_46|is_43|._134 (l_conj) produces_20\VBZ\7555863|that_90|administration_81|toxicity_47|and_12 (l_dobj) fsgs_22\NNS\0|readily_29
24658375
D014212_D009220 CID acid_4\NN\14818238|-_4 (r_npadvmod) induced_6\VBN\1627355|trans_20|retinoic_14|inflammatory_8|in_30|._76 (r_amod) myositis_8\NN\14336539|NONE_0
D014212_D009220 CID atra_6\NNP\0|-_4 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) myositis_9\NN\14336539|NONE_0
D014212_D015473 NONE acid_4\NN\14818238|-_4 (r_npadvmod) induced_6\VBN\1627355|trans_20|retinoic_14|inflammatory_8|in_30|._76 (r_amod) myositis_8\NN\14336539|NONE_0 (l_prep) in_9\IN\13603305|trans_50|retinoic_44|induced_30|inflammatory_22|._46 (l_pobj) patient_11\NN\9898892|NONE_0 (l_prep) with_12\IN\0|a_10 (l_pobj) leukemia_15\NN\14239918|NONE_0
D014212_D015473 NONE acid_4\NN\14818238|is_85|with_99|._230 (l_appos) component_10\NN\5867413|trans_30|retinoic_24|atra_9|,_4|,_68 (l_prep) for_14\IN\0|a_32|of_20 (l_pobj) leukemia_17\NN\14239918|NONE_0
D014212_D015473 NONE acid_4\NN\14818238|is_85|with_99|._230 (l_appos) component_10\NN\5867413|trans_30|retinoic_24|atra_9|,_4|,_68 (l_prep) for_14\IN\0|a_32|of_20 (l_pobj) leukemia_17\NN\14239918|NONE_0 (l_appos) apl_19\NNP\0|acute_30|promyelocytic_24|(_1|)_3
D014212_D015473 NONE atra_6\NNP\0|trans_21|retinoic_15|,_5|component_9|,_77 (r_appos) acid_4\NN\14818238|is_85|with_99|._230 (l_appos) component_10\NN\5867413|trans_30|retinoic_24|atra_9|,_4|,_68 (l_prep) for_14\IN\0|a_32|of_20 (l_pobj) leukemia_17\NN\14239918|NONE_0
D014212_D015473 NONE atra_6\NNP\0|trans_21|retinoic_15|,_5|component_9|,_77 (r_appos) acid_4\NN\14818238|is_85|with_99|._230 (l_appos) component_10\NN\5867413|trans_30|retinoic_24|atra_9|,_4|,_68 (l_prep) for_14\IN\0|a_32|of_20 (l_pobj) leukemia_17\NN\14239918|NONE_0 (l_appos) apl_19\NNP\0|acute_30|promyelocytic_24|(_1|)_3
12535818
D000638_D001919 CID amiodarone_0\NN\2715941|NONE_0 (l_conj) risk_3\NN\14541044|and_8|._130 (l_prep) of_4\IN\0|the_9|requiring_19 (l_pobj) bradyarrhythmia_5\JJ\0|NONE_0
D000638_D001919 CID amiodarone_14\NN\2715941|NONE_0 (r_pobj) of_13\IN\0|the_8 (r_prep) use_12\NN\407535|whether_12|)_58|risk_74 (r_nsubj) increases_23\VBZ\13576355|to_85 (l_dobj) risk_25\NN\14541044|whether_86|use_74|)_16 (l_prep) of_26\IN\0|the_9|requiring_19 (l_pobj) bradyarrhythmia_27\NNS\0|NONE_0
D000638_D001919 CID amiodarone_5\NN\2715941|NONE_0 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) during_4\IN\0|severe_23 (r_prep) bradyarrhythmia_3\NN\0|NONE_0
D000638_D001919 CID amiodarone_7\NN\2715941|NONE_0 (r_pobj) of_6\IN\0|the_8|and_42|mi_57 (r_prep) use_5\NN\407535|that_9|risk_78 (r_nsubj) increases_17\VBZ\13576355|study_88|._69 (l_dobj) risk_19\NN\14541044|that_87|use_78 (l_prep) of_20\IN\0|the_9|requiring_19 (l_pobj) bradyarrhythmia_21\NNS\0|NONE_0
D000638_D001145 NONE amiodarone_5\NN\2715941|NONE_0 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) during_4\IN\0|severe_23 (r_prep) bradyarrhythmia_3\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) reports_0\NNS\6470073|infrequent_64|._184 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_acomp) infrequent_8\JJ\0|reports_64|._120 (l_conj) limited_10\VBN\4019101|and_4 (l_prep) to_11\IN\0|NONE_0 (l_pobj) studies_12\NNS\635850|NONE_0 (l_acl) assessing_13\VBG\670261|NONE_0 (l_dobj) use_17\NN\407535|NONE_0 (l_prep) in_18\IN\13603305|therapy_14 (l_pobj) management_20\NN\1123598|NONE_0 (l_prep) of_21\IN\0|the_15 (l_pobj) patients_22\NNS\9898892|NONE_0 (l_prep) with_23\IN\0|NONE_0 (l_pobj) arrhythmias_25\NNS\14103288|NONE_0
D000638_D009203 NONE amiodarone_0\NN\2715941|NONE_0 (l_conj) risk_3\NN\14541044|and_8|._130 (l_acl) requiring_6\VBG\0|the_28|of_19 (l_dobj) pacemaker_8\NN\5925366|NONE_0 (l_prep) in_9\IN\13603305|permanent_20 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|elderly_17 (l_pobj) fibrillation_14\NN\14361664|NONE_0 (l_conj) infarction_18\NN\14204950|atrial_41|and_21
D000638_D009203 NONE amiodarone_7\NN\2715941|NONE_0 (r_pobj) of_6\IN\0|the_8|and_42|mi_57 (r_prep) use_5\NN\407535|that_9|risk_78 (l_conj) mi_16\NNP\14207561|the_65|of_57|and_15
D000638_D001281 NONE amiodarone_0\NN\2715941|NONE_0 (l_conj) risk_3\NN\14541044|and_8|._130 (l_acl) requiring_6\VBG\0|the_28|of_19 (l_dobj) pacemaker_8\NN\5925366|NONE_0 (l_prep) in_9\IN\13603305|permanent_20 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|elderly_17 (l_pobj) fibrillation_14\NN\14361664|NONE_0
D000638_D001281 NONE amiodarone_14\NN\2715941|NONE_0 (l_prep) in_15\IN\13603305|NONE_0 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) fibrillation_19\NN\14361664|NONE_0
D000638_D001281 NONE amiodarone_14\NN\2715941|NONE_0 (l_prep) in_15\IN\13603305|NONE_0 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) fibrillation_19\NN\14361664|NONE_0 (l_appos) af_21\NNP\0|atrial_21|(_1
D000638_D001281 NONE amiodarone_7\NN\2715941|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|elderly_17 (l_pobj) af_12\NNP\0|NONE_0
2429800
D014403_D007022 CID tubocurarine_5\NN\14712692|-_12 (r_advmod) induced_7\VBN\1627355|d_15|in_20 (r_amod) hypotension_8\NN\14057371|histamine_49|and_27|._40
D006632_D007022 NONE histamine_0\NN\14739004|and_22|hypotension_49|._89 (r_amod) antagonists_1\NNS\7846|NONE_0 (l_conj) hypotension_8\NN\14057371|histamine_49|and_27|._40
2765447
D019793_D012640 NONE fluorescein_3\NN\14598383|intravenous_12 (r_amod) angiography_4\NN\904623|NONE_0 (r_dobj) following_1\VBG\8180190|._45 (r_prep) convulsion_0\NNP\14081375|NONE_0
D019793_D004830 CID fluorescein_6\NN\14598383|intravenous_12|for_22|in_45 (r_amod) injection_7\NN\320852|seizures_42|._54 (r_dobj) followed_4\VBD\1835496|NONE_0 (l_nsubj) seizures_3\NNS\14081375|injection_42|._96
3685052
D004986_D007035 NONE ether_1\NN\14840755|hypothermia_15 (r_nsubj) produced_2\VBD\1617192|;_81|however_83|,_90|relationship_96|unclear_149|._156 (l_dobj) hypothermia_3\NN\14034177|ether_15
D004986_D007035 NONE ether_1\NN\14840755|hypothermia_15 (r_nsubj) produced_2\VBD\1617192|;_81|however_83|,_90|relationship_96|unclear_149|._156 (r_ccomp) was_23\VBD\0|NONE_0 (l_nsubj) relationship_17\NN\31921|produced_96|;_15|however_13|,_6|unclear_53|._60 (l_prep) of_18\IN\0|the_17|to_15 (l_pobj) hypothermia_19\NN\14034177|NONE_0
D009270_D012640 NONE naloxone_1\NN\3808977|(_9|mg/kg_12|)_17 (r_nmod) challenge_6\NN\13927383|also_14|ineffective_19|in_31|._103 (r_nsubj) was_7\VBD\0|NONE_0 (l_prep) in_10\IN\13603305|challenge_31|also_17|ineffective_12|._72 (l_pcomp) altering_11\VBG\692130|NONE_0 (l_dobj) thresholds_14\NNS\15265518|NONE_0 (l_compound) seizure_13\NN\14081375|the_4|of_19
D005481_D012640 NONE flurothyl_0\JJ\0|seizure_10|in_29 (r_compound) thresholds_2\NNS\15265518|neonatally_27|with_38|:_91|evaluation_93|._159 (l_compound) seizure_1\NN\14081375|flurothyl_10|in_19
D005481_D012640 NONE flurothyl_0\JJ\0|seizure_10|in_29 (r_compound) thresholds_2\NNS\15265518|neonatally_27|with_38|:_91|evaluation_93|._159 (r_nsubj) treated_5\VBD\2376958|NONE_0 (l_dobj) evaluation_18\NN\874067|thresholds_93|neonatally_66|with_55|:_2|._66 (l_prep) of_19\IN\0|NONE_0 (l_pobj) parameters_21\NNS\5858936|NONE_0 (l_prep) in_22\IN\13603305|experimental_24 (l_pobj) testing_25\NN\639556|NONE_0 (l_compound) seizure_24\NN\14081375|flurothyl_10
D005481_D012640 NONE flurothyl_23\JJ\0|seizure_10 (r_compound) testing_25\NN\639556|NONE_0 (r_pobj) in_22\IN\13603305|experimental_24 (r_prep) parameters_21\NNS\5858936|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) evaluation_18\NN\874067|thresholds_93|neonatally_66|with_55|:_2|._66 (r_dobj) treated_5\VBD\2376958|NONE_0 (l_nsubj) thresholds_2\NNS\15265518|neonatally_27|with_38|:_91|evaluation_93|._159 (l_compound) seizure_1\NN\14081375|flurothyl_10|in_19
D005481_D012640 NONE flurothyl_23\JJ\0|seizure_10 (r_compound) testing_25\NN\639556|NONE_0 (l_compound) seizure_24\NN\14081375|flurothyl_10
D005481_D012640 NONE flurothyl_1\JJ\0|a_2|ether_10|screening_24 (r_nmod) technique_5\NN\5660268|was_10|evaluate_22|)_127|._128 (l_compound) screening_4\NN\6887726|a_26|flurothyl_24|ether_14 (l_compound) seizure_3\NN\14081375|NONE_0
D005481_D012640 NONE flurothyl_1\JJ\0|a_2|ether_10|screening_24 (r_nmod) technique_5\NN\5660268|was_10|evaluate_22|)_127|._128 (r_nsubjpass) used_7\VBN\0|NONE_0 (l_xcomp) evaluate_9\VB\670261|technique_22|was_12|)_105|._106 (l_dobj) susceptibility_11\NN\13920835|to_20 (l_compound) seizure_10\NN\14081375|in_23|received_42
D005481_D012640 NONE flurothyl_0\NNP\0|NONE_0 (r_compound) ether_1\NN\14840755|hypothermia_15 (r_nsubj) produced_2\VBD\1617192|;_81|however_83|,_90|relationship_96|unclear_149|._156 (r_ccomp) was_23\VBD\0|NONE_0 (l_nsubj) relationship_17\NN\31921|produced_96|;_15|however_13|,_6|unclear_53|._60 (l_prep) to_20\IN\0|the_32|of_15 (l_pobj) induction_22\NN\7450842|NONE_0 (l_compound) seizure_21\NN\14081375|NONE_0
D005481_D012640 NONE flurothyl_11\JJ\0|NONE_0 (r_compound) exposure_12\NN\5042871|NONE_0 (r_pobj) of_10\IN\0|the_13 (r_prep) duration_9\NN\15113229|NONE_0 (r_pobj) with_7\IN\0|which_21|was_15 (r_prep) correlated_6\VBN\2657219|NONE_0 (r_relcl) hypothermia_3\NN\14034177|ether_15 (r_dobj) produced_2\VBD\1617192|;_81|however_83|,_90|relationship_96|unclear_149|._156 (r_ccomp) was_23\VBD\0|NONE_0 (l_nsubj) relationship_17\NN\31921|produced_96|;_15|however_13|,_6|unclear_53|._60 (l_prep) to_20\IN\0|the_32|of_15 (l_pobj) induction_22\NN\7450842|NONE_0 (l_compound) seizure_21\NN\14081375|NONE_0
D005481_D012640 NONE flurothyl_0\JJ\0|seizure_10 (r_compound) testing_2\NN\639556|be_18|._97 (l_compound) seizure_1\NN\14081375|flurothyl_10
D005481_D012640 NONE flurothyl_0\JJ\0|seizure_10 (r_compound) testing_2\NN\639556|be_18|._97 (r_nsubj) proved_3\VBD\2604760|NONE_0 (l_xcomp) be_5\VB\14625458|testing_18|._79 (l_attr) technique_10\NN\5660268|to_27 (l_relcl) evaluate_14\VB\670261|a_45|rapid_43 (l_dobj) susceptibility_16\NN\13920835|with_31|to_20 (l_compound) seizure_15\NN\14081375|NONE_0
D005481_D007035 CID flurothyl_0\NNP\0|NONE_0 (r_compound) ether_1\NN\14840755|hypothermia_15 (r_nsubj) produced_2\VBD\1617192|;_81|however_83|,_90|relationship_96|unclear_149|._156 (l_dobj) hypothermia_3\NN\14034177|ether_15
D005481_D007035 CID flurothyl_0\NNP\0|NONE_0 (r_compound) ether_1\NN\14840755|hypothermia_15 (r_nsubj) produced_2\VBD\1617192|;_81|however_83|,_90|relationship_96|unclear_149|._156 (r_ccomp) was_23\VBD\0|NONE_0 (l_nsubj) relationship_17\NN\31921|produced_96|;_15|however_13|,_6|unclear_53|._60 (l_prep) of_18\IN\0|the_17|to_15 (l_pobj) hypothermia_19\NN\14034177|NONE_0
D005481_D007035 CID flurothyl_11\JJ\0|NONE_0 (r_compound) exposure_12\NN\5042871|NONE_0 (r_pobj) of_10\IN\0|the_13 (r_prep) duration_9\NN\15113229|NONE_0 (r_pobj) with_7\IN\0|which_21|was_15 (r_prep) correlated_6\VBN\2657219|NONE_0 (r_relcl) hypothermia_3\NN\14034177|ether_15
D005481_D007035 CID flurothyl_11\JJ\0|NONE_0 (r_compound) exposure_12\NN\5042871|NONE_0 (r_pobj) of_10\IN\0|the_13 (r_prep) duration_9\NN\15113229|NONE_0 (r_pobj) with_7\IN\0|which_21|was_15 (r_prep) correlated_6\VBN\2657219|NONE_0 (r_relcl) hypothermia_3\NN\14034177|ether_15 (r_dobj) produced_2\VBD\1617192|;_81|however_83|,_90|relationship_96|unclear_149|._156 (r_ccomp) was_23\VBD\0|NONE_0 (l_nsubj) relationship_17\NN\31921|produced_96|;_15|however_13|,_6|unclear_53|._60 (l_prep) of_18\IN\0|the_17|to_15 (l_pobj) hypothermia_19\NN\14034177|NONE_0
D012970_D012640 NONE glutamate_13\NN\15010703|NONE_0 (r_pobj) of_11\IN\0|a_19|single_17 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) with_7\IN\0|thresholds_38|neonatally_11|:_53|evaluation_55|._121 (r_prep) treated_5\VBD\2376958|NONE_0 (l_nsubj) thresholds_2\NNS\15265518|neonatally_27|with_38|:_91|evaluation_93|._159 (l_compound) seizure_1\NN\14081375|flurothyl_10|in_19
D012970_D012640 NONE glutamate_13\NN\15010703|NONE_0 (r_pobj) of_11\IN\0|a_19|single_17 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) with_7\IN\0|thresholds_38|neonatally_11|:_53|evaluation_55|._121 (r_prep) treated_5\VBD\2376958|NONE_0 (l_dobj) evaluation_18\NN\874067|thresholds_93|neonatally_66|with_55|:_2|._66 (l_prep) of_19\IN\0|NONE_0 (l_pobj) parameters_21\NNS\5858936|NONE_0 (l_prep) in_22\IN\13603305|experimental_24 (l_pobj) testing_25\NN\639556|NONE_0 (l_compound) seizure_24\NN\14081375|flurothyl_10
D012970_D012640 NONE msg_15\NNP\7809368|monosodium_22 (r_appos) glutamate_13\NN\15010703|NONE_0 (r_pobj) of_11\IN\0|a_19|single_17 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) with_7\IN\0|thresholds_38|neonatally_11|:_53|evaluation_55|._121 (r_prep) treated_5\VBD\2376958|NONE_0 (l_nsubj) thresholds_2\NNS\15265518|neonatally_27|with_38|:_91|evaluation_93|._159 (l_compound) seizure_1\NN\14081375|flurothyl_10|in_19
D012970_D012640 NONE msg_15\NNP\7809368|monosodium_22 (r_appos) glutamate_13\NN\15010703|NONE_0 (r_pobj) of_11\IN\0|a_19|single_17 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) with_7\IN\0|thresholds_38|neonatally_11|:_53|evaluation_55|._121 (r_prep) treated_5\VBD\2376958|NONE_0 (l_dobj) evaluation_18\NN\874067|thresholds_93|neonatally_66|with_55|:_2|._66 (l_prep) of_19\IN\0|NONE_0 (l_pobj) parameters_21\NNS\5858936|NONE_0 (l_prep) in_22\IN\13603305|experimental_24 (l_pobj) testing_25\NN\639556|NONE_0 (l_compound) seizure_24\NN\14081375|flurothyl_10
D012970_D012640 NONE glutamate_1\NN\15010703|(_10|msg_11|)_14|to_31 (r_nmod) administration_5\NN\1133281|convulsions_44|in_68|._115 (r_nsubj) produces_9\VBZ\7555863|NONE_0 (l_dobj) convulsions_10\NNS\14081375|administration_44|in_24|._71
D012970_D012640 NONE msg_3\NNP\7809368|glutamate_11|(_1|)_3|to_20 (r_nmod) administration_5\NN\1133281|convulsions_44|in_68|._115 (r_nsubj) produces_9\VBZ\7555863|NONE_0 (l_dobj) convulsions_10\NNS\14081375|administration_44|in_24|._71
D012970_D012640 NONE msg_10\NNP\7809368|NONE_0 (r_pobj) of_9\IN\0|neonatal_24 (r_prep) administration_8\NN\1133281|if_12|alterations_41 (r_nsubj) produced_11\VBD\1617192|to_47 (l_dobj) alterations_13\NNS\7283608|if_53|administration_41 (l_prep) in_14\IN\13603305|permanent_22 (l_pobj) susceptibility_16\NN\13920835|NONE_0 (l_compound) seizure_15\NN\14081375|NONE_0
D012970_D012640 NONE msg_20\NNP\7809368|NONE_0 (r_pobj) of_19\IN\0|neonatal_20|g_13 (r_prep) injections_18\NNS\320852|that_23 (r_dobj) received_16\VBD\2210855|seizure_42|in_19 (r_relcl) susceptibility_11\NN\13920835|to_20 (r_dobj) evaluate_9\VB\670261|technique_22|was_12|)_105|._106 (r_xcomp) used_7\VBN\0|NONE_0 (l_nsubjpass) technique_5\NN\5660268|was_10|evaluate_22|)_127|._128 (l_compound) screening_4\NN\6887726|a_26|flurothyl_24|ether_14 (l_compound) seizure_3\NN\14081375|NONE_0
D012970_D012640 NONE msg_20\NNP\7809368|NONE_0 (r_pobj) of_19\IN\0|neonatal_20|g_13 (r_prep) injections_18\NNS\320852|that_23 (r_dobj) received_16\VBD\2210855|seizure_42|in_19 (r_relcl) susceptibility_11\NN\13920835|to_20 (l_compound) seizure_10\NN\14081375|in_23|received_42
D012970_D012640 NONE msg_0\NNP\7809368|NONE_0 (r_compound) treatment_1\NN\654885|in_19|but_67|alter_79|._102 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_conj) alter_13\VB\0|treatment_79|in_60|but_12|._23 (l_dobj) threshold_15\NN\15265518|did_22|not_18 (l_compound) seizure_14\NN\14081375|NONE_0
D012970_D012640 NONE msg_19\NNP\7809368|-_3 (r_npadvmod) treated_21\VBN\2376958|NONE_0 (r_amod) mice_22\NNS\2329401|NONE_0 (r_pobj) of_18\IN\0|either_15 (r_prep) control_17\NN\5190804|NONE_0 (r_pobj) of_15\IN\0|the_23|seizure_19 (r_prep) thresholds_14\NNS\15265518|NONE_0 (l_compound) seizure_13\NN\14081375|the_4|of_19
D004986_D012640 NONE ether_2\NN\14840755|a_12|flurothyl_10|screening_14 (r_compound) technique_5\NN\5660268|was_10|evaluate_22|)_127|._128 (l_compound) screening_4\NN\6887726|a_26|flurothyl_24|ether_14 (l_compound) seizure_3\NN\14081375|NONE_0
D004986_D012640 NONE ether_2\NN\14840755|a_12|flurothyl_10|screening_14 (r_compound) technique_5\NN\5660268|was_10|evaluate_22|)_127|._128 (r_nsubjpass) used_7\VBN\0|NONE_0 (l_xcomp) evaluate_9\VB\670261|technique_22|was_12|)_105|._106 (l_dobj) susceptibility_11\NN\13920835|to_20 (l_compound) seizure_10\NN\14081375|in_23|received_42
D004986_D012640 NONE ether_1\NN\14840755|hypothermia_15 (r_nsubj) produced_2\VBD\1617192|;_81|however_83|,_90|relationship_96|unclear_149|._156 (r_ccomp) was_23\VBD\0|NONE_0 (l_nsubj) relationship_17\NN\31921|produced_96|;_15|however_13|,_6|unclear_53|._60 (l_prep) to_20\IN\0|the_32|of_15 (l_pobj) induction_22\NN\7450842|NONE_0 (l_compound) seizure_21\NN\14081375|NONE_0
1360900
D005680_D012640 NONE acid_34\NN\14818238|NONE_0 (r_pobj) of_30\IN\0|the_14 (r_prep) synthesis_29\NN\13446390|NONE_0 (r_dobj) suppressed_27\VBD\2510337|injection_141|turnover_43|)_6|but_4|._84 (r_conj) accelerated_16\VBD\226566|NONE_0 (l_nsubj) injection_1\NN\320852|turnover_98|)_135|but_137|suppressed_141|._225 (l_prep) of_2\IN\0|intracerebroventricular_34|mouse_55 (l_pobj) acid_4\NN\14818238|NONE_0 (l_appos) dose_9\NN\3740161|ethacrynic_32 (l_amod) convulsive_8\JJ\0|(_5|%_2
D012701_D012640 NONE 5-hydroxytryptamine_22\CD\14807737|NONE_0 (r_pobj) of_21\IN\0|the_23|synthesis_19|/_10 (r_prep) turnover_20\NN\13819207|injection_98|)_37|but_39|suppressed_43|._127 (r_dobj) accelerated_16\VBD\226566|NONE_0 (l_nsubj) injection_1\NN\320852|turnover_98|)_135|but_137|suppressed_141|._225 (l_prep) of_2\IN\0|intracerebroventricular_34|mouse_55 (l_pobj) acid_4\NN\14818238|NONE_0 (l_appos) dose_9\NN\3740161|ethacrynic_32 (l_amod) convulsive_8\JJ\0|(_5|%_2
D012701_D012640 NONE 5-ht_24\CD\0|NONE_0 (r_appos) 5-hydroxytryptamine_22\CD\14807737|NONE_0 (r_pobj) of_21\IN\0|the_23|synthesis_19|/_10 (r_prep) turnover_20\NN\13819207|injection_98|)_37|but_39|suppressed_43|._127 (r_dobj) accelerated_16\VBD\226566|NONE_0 (l_nsubj) injection_1\NN\320852|turnover_98|)_135|but_137|suppressed_141|._225 (l_prep) of_2\IN\0|intracerebroventricular_34|mouse_55 (l_pobj) acid_4\NN\14818238|NONE_0 (l_appos) dose_9\NN\3740161|ethacrynic_32 (l_amod) convulsive_8\JJ\0|(_5|%_2
D004976_D012640 CID acid_1\NN\14818238|-_4 (r_npadvmod) induced_3\VBN\1627355|ethacrynic_16|and_20|neurotransmitters_30|in_48|._55 (r_amod) convulsions_4\NNS\14081375|NONE_0
D004976_D012640 CID acid_4\NN\14818238|NONE_0 (l_appos) dose_9\NN\3740161|ethacrynic_32 (l_amod) convulsive_8\JJ\0|(_5|%_2
D004976_D012640 CID acid_2\NN\14818238|-_4 (r_npadvmod) induced_4\VBN\1627355|ethacrynic_16 (r_amod) convulsions_5\NNS\14081375|NONE_0
D000109_D012640 NONE acetylcholine_36\NN\14807558|aminobutyric_22|and_4 (r_conj) acid_34\NN\14818238|NONE_0 (r_pobj) of_30\IN\0|the_14 (r_prep) synthesis_29\NN\13446390|NONE_0 (r_dobj) suppressed_27\VBD\2510337|injection_141|turnover_43|)_6|but_4|._84 (r_conj) accelerated_16\VBD\226566|NONE_0 (l_nsubj) injection_1\NN\320852|turnover_98|)_135|but_137|suppressed_141|._225 (l_prep) of_2\IN\0|intracerebroventricular_34|mouse_55 (l_pobj) acid_4\NN\14818238|NONE_0 (l_appos) dose_9\NN\3740161|ethacrynic_32 (l_amod) convulsive_8\JJ\0|(_5|%_2
11026989
D014331_D015878 CID tropicamide_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|pupil_15 (r_prep) dilation_4\NN\7138085|NONE_0
D014331_D015878 CID tropicamide_28\NN\0|guttae_7 (r_advmod) using_26\VBG\418025|pupil_15 (r_acl) dilation_25\NN\7138085|NONE_0
24729111
D000638_D007035 CID amiodarone_20\NN\2715941|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|for_22 (r_prep) initiation_18\NN\7450842|weeks_12 (r_pobj) after_17\IN\0|to_65|bradycardia_57 (r_prep) have_8\VB\7846|man_17|was_13|._124 (l_dobj) bradycardia_9\VBN\14110674|to_8|after_57 (l_conj) hypothermia_11\NN\14034177|,_2
D000638_D003128 CID amiodarone_0\NN\2715941|-_10 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) myxoedema_3\NN\14121276|._14 (r_compound) coma_4\NN\5678932|NONE_0
D000638_D003128 CID amiodarone_5\NN\2715941|-_10 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) myxoedema_8\NN\14121276|in_15 (r_compound) coma_9\NN\5678932|NONE_0
D000638_D003128 CID amiodarone_9\NN\2715941|-_10 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) myxoedema_12\NN\14121276|with_15 (r_compound) coma_13\NN\5678932|NONE_0
D000638_D012131 CID amiodarone_20\NN\2715941|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|for_22 (r_prep) initiation_18\NN\7450842|weeks_12 (r_pobj) after_17\IN\0|to_65|bradycardia_57 (r_prep) have_8\VB\7846|man_17|was_13|._124 (l_dobj) bradycardia_9\VBN\14110674|to_8|after_57 (l_conj) hypothermia_11\NN\14034177|,_2 (l_conj) failure_14\NN\66216|and_16
D000638_D013959 NONE amiodarone_9\NN\2715941|-_10 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) myxoedema_12\NN\14121276|with_15 (r_compound) coma_13\NN\5678932|NONE_0 (l_prep) with_14\IN\0|myxoedema_15 (l_pobj) history_16\NN\15120823|NONE_0 (l_amod) significant_17\JJ\0|a_10 (l_prep) for_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0
D000638_D001919 CID amiodarone_20\NN\2715941|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|for_22 (r_prep) initiation_18\NN\7450842|weeks_12 (r_pobj) after_17\IN\0|to_65|bradycardia_57 (r_prep) have_8\VB\7846|man_17|was_13|._124 (l_dobj) bradycardia_9\VBN\14110674|to_8|after_57
D000638_D001281 NONE amiodarone_20\NN\2715941|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|for_22 (r_prep) initiation_18\NN\7450842|weeks_12 (l_prep) for_22\IN\0|of_22 (l_pobj) fibrillation_24\NN\14361664|NONE_0
D000638_D007037 CID amiodarone_0\NN\2715941|-_10 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) myxoedema_3\NN\14121276|._14 (r_compound) coma_4\NN\5678932|NONE_0
D000638_D007037 CID amiodarone_5\NN\2715941|-_10 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) myxoedema_8\NN\14121276|in_15 (r_compound) coma_9\NN\5678932|NONE_0
D000638_D007037 CID amiodarone_9\NN\2715941|-_10 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) myxoedema_12\NN\14121276|with_15 (r_compound) coma_13\NN\5678932|NONE_0
15282950
D007545_D009202 CID isoproterenol_11\NN\3740161|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|effect_68|against_39|._24 (r_advcl) chebula_4\NN\0|NONE_0 (l_prep) against_5\IN\0|effect_29|induced_39|._63 (l_pobj) injury_8\NN\14052046|NONE_0
D007545_D009202 CID isoproterenol_18\NN\3740161|NONE_0 (r_pobj) in_17\IN\13603305|effect_90|was_13|body_28|induced_37|._70 (r_prep) examined_16\VBN\0|NONE_0 (l_conj) induced_25\VBN\1627355|effect_127|was_50|in_37|body_9|._33 (l_dobj) damage_27\NN\7296428|NONE_0
D010936_D009202 NONE chebula_4\NN\0|NONE_0 (l_prep) against_5\IN\0|effect_29|induced_39|._63 (l_pobj) injury_8\NN\14052046|NONE_0
D010936_D009202 NONE fruits_8\NNS\11675842|NONE_0 (r_pobj) of_5\IN\0|ethanolic_18 (r_prep) extract_4\NN\14589223|NONE_0 (r_pobj) of_2\IN\0|cardioprotective_24 (r_prep) effect_1\NN\34213|was_77|in_90|body_118|induced_127|._160 (r_nsubjpass) examined_16\VBN\0|NONE_0 (l_conj) induced_25\VBN\1627355|effect_127|was_50|in_37|body_9|._33 (l_dobj) damage_27\NN\7296428|NONE_0
11105626
D015474_D065817 CID isotretinoin_21\VB\0|NONE_0 (r_pobj) to_20\IN\0|within_16 (r_prep) exposure_19\NN\5042871|to_3 (r_pobj) due_17\IN\5174653|we_101|infant_81|._58 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) infant_4\NN\9918248|we_20|due_81|._139 (l_prep) with_5\IN\0|a_17|newborn_15 (l_pobj) anomalies_8\NNS\14501726|NONE_0 (l_appos) anotia_10\NN\0|multiple_31|congenital_22|(_1|)_36
D015474_D004310 CID isotretinoin_21\VB\0|NONE_0 (r_pobj) to_20\IN\0|within_16 (r_prep) exposure_19\NN\5042871|to_3 (r_pobj) due_17\IN\5174653|we_101|infant_81|._58 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) infant_4\NN\9918248|we_20|due_81|._139 (l_prep) with_5\IN\0|a_17|newborn_15 (l_pobj) anomalies_8\NNS\14501726|NONE_0 (l_appos) anotia_10\NN\0|multiple_31|congenital_22|(_1|)_36 (l_conj) malformation_15\NN\14213199|and_17
1420650
D003024_D020258 NONE clozapine_29\NN\3713736|or_3 (r_conj) lithium_27\NN\14625458|NONE_0 (r_pobj) as_26\IN\14622893|certain_14 (r_prep) drugs_25\NNS\14778436|if_11|are_30|in_39 (r_nsubjpass) used_31\VBN\0|we_172|be_147|,_47|._28 (r_advcl) consider_1\VBP\689344|NONE_0 (l_ccomp) be_4\VB\14625458|we_25|,_100|used_147|._175 (l_attr) sign_8\NN\6643763|asterixis_37|to_27 (l_prep) of_9\IN\0|an_26|overlooked_16 (l_pobj) neurotoxicity_10\NN\0|NONE_0
D002220_D020820 NONE carbamazepine_3\NN\0|NONE_0 (r_compound) therapy_4\NN\657604|NONE_0 (r_pobj) by_2\IN\0|asterixis_18|._24 (r_agent) induced_1\VBN\1627355|NONE_0 (l_nsubj) asterixis_0\NNS\0|by_18|._42
D002220_D020820 NONE carbamazepine_24\NN\0|to_20 (r_dobj) adding_23\VBG\156601|either_10 (r_pcomp) by_22\IN\0|in_39|asterixis_31|was_21 (r_prep) triggered_20\VBN\1641914|different_52|psychotropic_42|,_24 (l_nsubjpass) asterixis_18\NNS\0|in_8|was_10|by_31
D002220_D020820 NONE cbz_26\NNP\0|(_1|)_3 (r_appos) carbamazepine_24\NN\0|to_20 (r_dobj) adding_23\VBG\156601|either_10 (r_pcomp) by_22\IN\0|in_39|asterixis_31|was_21 (r_prep) triggered_20\VBN\1641914|different_52|psychotropic_42|,_24 (l_nsubjpass) asterixis_18\NNS\0|in_8|was_10|by_31
D002220_D020820 NONE cbz_35\NN\0|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) combination_33\NN\7951464|NONE_0 (r_pobj) in_32\IN\13603305|if_50|drugs_39|are_9 (r_prep) used_31\VBN\0|we_172|be_147|,_47|._28 (r_advcl) consider_1\VBP\689344|NONE_0 (l_ccomp) be_4\VB\14625458|we_25|,_100|used_147|._175 (l_nsubj) asterixis_2\NNS\0|to_10|sign_37
D008094_D020820 CID lithium_27\NN\14625458|NONE_0 (r_pobj) as_26\IN\14622893|certain_14 (r_prep) drugs_25\NNS\14778436|if_11|are_30|in_39 (r_nsubjpass) used_31\VBN\0|we_172|be_147|,_47|._28 (r_advcl) consider_1\VBP\689344|NONE_0 (l_ccomp) be_4\VB\14625458|we_25|,_100|used_147|._175 (l_nsubj) asterixis_2\NNS\0|to_10|sign_37
D002220_D020258 NONE cbz_35\NN\0|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) combination_33\NN\7951464|NONE_0 (r_pobj) in_32\IN\13603305|if_50|drugs_39|are_9 (r_prep) used_31\VBN\0|we_172|be_147|,_47|._28 (r_advcl) consider_1\VBP\689344|NONE_0 (l_ccomp) be_4\VB\14625458|we_25|,_100|used_147|._175 (l_attr) sign_8\NN\6643763|asterixis_37|to_27 (l_prep) of_9\IN\0|an_26|overlooked_16 (l_pobj) neurotoxicity_10\NN\0|NONE_0
D003024_D020820 CID clozapine_29\NN\3713736|or_3 (r_conj) lithium_27\NN\14625458|NONE_0 (r_pobj) as_26\IN\14622893|certain_14 (r_prep) drugs_25\NNS\14778436|if_11|are_30|in_39 (r_nsubjpass) used_31\VBN\0|we_172|be_147|,_47|._28 (r_advcl) consider_1\VBP\689344|NONE_0 (l_ccomp) be_4\VB\14625458|we_25|,_100|used_147|._175 (l_nsubj) asterixis_2\NNS\0|to_10|sign_37
D008094_D020258 NONE lithium_27\NN\14625458|NONE_0 (r_pobj) as_26\IN\14622893|certain_14 (r_prep) drugs_25\NNS\14778436|if_11|are_30|in_39 (r_nsubjpass) used_31\VBN\0|we_172|be_147|,_47|._28 (r_advcl) consider_1\VBP\689344|NONE_0 (l_ccomp) be_4\VB\14625458|we_25|,_100|used_147|._175 (l_attr) sign_8\NN\6643763|asterixis_37|to_27 (l_prep) of_9\IN\0|an_26|overlooked_16 (l_pobj) neurotoxicity_10\NN\0|NONE_0
3746148
D004176_D003324 NONE dipyridamole_14\NN\0|NONE_0 (r_compound) infusion_15\NN\14589223|NONE_0 (r_pobj) after_13\IN\0|invasive_91|of_72|by_45|._27 (r_prep) detection_3\NN\5708432|NONE_0 (l_prep) of_4\IN\0|invasive_19|by_27|after_72|._99 (l_pobj) disease_7\NN\14061805|NONE_0
D004176_D003324 NONE dipyridamole_3\NN\0|NONE_0 (r_compound) infusion_4\NN\14589223|NONE_0 (r_pobj) after_2\IN\0|electrocardiographic_29|min_43 (r_prep) changes_1\NNS\7283608|were_56|in_69|and_113|compared_117|._217 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_prep) in_14\IN\13603305|changes_69|were_13|and_44|compared_48|._148 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|41_12 (l_pobj) disease_20\NN\14061805|NONE_0
D004176_D003324 NONE dipyridamole_4\NN\0|the_4|ecg_13 (r_compound) test_6\NN\5798043|that_26|useful_11 (r_nsubj) is_7\VBZ\0|we_43|._83 (l_acomp) useful_9\JJ\0|that_37|test_11 (l_prep) as_10\IN\14622893|as_10 (l_pobj) test_14\NN\5798043|NONE_0 (l_prep) for_15\IN\0|the_22|ecg_9 (l_pobj) assessment_17\NN\5732756|NONE_0 (l_prep) of_18\IN\0|the_15 (l_pobj) disease_21\NN\14061805|NONE_0
D004176_D009203 NONE dipyridamole_1\NN\0|NONE_0 (r_pobj) after_0\IN\0|,_18|depression_40|mv_57|was_69|in_82|._190 (r_prep) observed_15\VBN\2163746|NONE_0 (l_prep) in_16\IN\13603305|after_82|,_64|depression_42|mv_25|was_13|._108 (l_pobj) %_18\NN\0|NONE_0 (l_prep) of_19\IN\0|84_4|,_19|%_23 (l_pobj) group_24\NN\2137|NONE_0 (l_compound) mi_23\NNP\14207561|the_8
D004176_D017202 CID dipyridamole_5\NN\0|-_12 (r_npadvmod) induced_7\VBN\1627355|the_17|myocardial_8 (r_amod) ischemia_9\NN\14195315|that_41|is_9|by_19
D004176_D003866 NONE dipyridamole_1\NN\0|NONE_0 (r_pobj) after_0\IN\0|,_18|depression_40|mv_57|was_69|in_82|._190 (r_prep) observed_15\VBN\2163746|NONE_0 (l_nsubjpass) depression_7\NN\14373582|after_40|,_22|mv_17|was_29|in_42|._150
D004176_D007511 NONE dipyridamole_1\NN\0|NONE_0 (r_pobj) after_0\IN\0|,_18|depression_40|mv_57|was_69|in_82|._190 (r_prep) observed_15\VBN\2163746|NONE_0 (l_nsubjpass) depression_7\NN\14373582|after_40|,_22|mv_17|was_29|in_42|._150 (l_amod) ischemic_3\JJ\0|segment_12
D004176_D056989 NONE dipyridamole_1\NN\0|NONE_0 (r_pobj) after_0\IN\0|,_18|depression_40|mv_57|was_69|in_82|._190 (r_prep) observed_15\VBN\2163746|NONE_0 (l_prep) in_16\IN\13603305|after_82|,_64|depression_42|mv_25|was_13|._108 (l_pobj) %_18\NN\0|NONE_0 (l_appos) %_27\NN\0|84_27|of_23|,_4 (l_appos) %_36\NN\0|29_27|of_23|,_4 (l_prep) of_37\IN\0|63_4|and_20|%_26 (l_pobj) group_42\NN\2137|NONE_0 (l_compound) mi_41\NNP\14207561|the_8
D004176_D056988 NONE dipyridamole_1\NN\0|NONE_0 (r_pobj) after_0\IN\0|,_18|depression_40|mv_57|was_69|in_82|._190 (r_prep) observed_15\VBN\2163746|NONE_0 (l_prep) in_16\IN\13603305|after_82|,_64|depression_42|mv_25|was_13|._108 (l_pobj) %_18\NN\0|NONE_0 (l_appos) %_27\NN\0|84_27|of_23|,_4 (l_prep) of_28\IN\0|29_4|,_19|%_23 (l_pobj) group_33\NN\2137|NONE_0 (l_compound) mi_32\NNP\14207561|the_8
24055495
D005690_D003072 CID galactose_4\NN\15062778|term_10 (r_compound) treatment_5\NN\654885|deficits_29|._111 (r_nsubj) prevents_6\VBZ\0|NONE_0 (l_dobj) deficits_8\NNS\5113133|treatment_29|._82
D005690_D003072 CID galactose_9\NN\15062778|NONE_0 (l_appos) treatment_18\NN\654885|continuous_48|daily_37|oral_31 (l_prep) on_19\IN\0|(_26|kg_18|)_12|in_22 (l_pobj) deficits_21\NNS\5113133|NONE_0
D005690_D003072 CID galactose_4\NN\15062778|oral_5 (r_compound) treatment_5\NN\654885|NONE_0 (r_pobj) of_2\IN\0|one_10 (r_prep) month_1\NN\15113229|immediately_44|after_56|,_88|prevented_103|._166 (r_nsubj) initiated_6\VBD\1617192|NONE_0 (l_conj) prevented_16\VBN\0|month_103|immediately_59|after_47|,_15|._63 (l_dobj) development_17\NN\248977|successfully_23 (l_prep) of_18\IN\0|NONE_0 (l_pobj) deficits_26\NNS\5113133|NONE_0
D005690_D003072 CID galactose_1\NN\15062778|oral_5 (r_compound) exposure_2\NN\5042871|might_9|effects_31|and_70|be_80|._185 (r_nsubj) have_4\VB\7846|NONE_0 (l_conj) be_14\VB\14625458|exposure_80|might_71|effects_49|and_10|._105 (l_acomp) worth_15\JJ\13576355|could_9 (l_xcomp) investigating_16\VBG\575741|NONE_0 (l_prep) for_17\IN\0|NONE_0 (l_pobj) improvement_18\NN\7359599|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) deficits_21\NNS\5113133|NONE_0
D005690_D008569 NONE galactose_5\NN\15062778|NONE_0 (r_pobj) of_4\IN\0|exclusively_40|parenteral_28|daily_17 (r_prep) injections_3\NNS\320852|deterioration_38|and_63|used_71|,_106|but_108|tested_191 (r_nsubj) induce_6\VBP\1627355|NONE_0 (l_dobj) deterioration_8\NN\14560612|injections_38|and_25|used_33|,_68|but_70|tested_153
D005690_D008569 NONE galactose_25\NN\15062778|oral_5|on_20 (r_compound) treatment_26\NN\654885|NONE_0 (r_pobj) of_23\IN\0|the_12 (r_prep) effects_22\NNS\13245626|have_59|never_64|been_70|._81 (r_nsubjpass) tested_33\VBN\670261|injections_191|deterioration_153|and_128|used_120|,_85|but_83 (r_conj) induce_6\VBP\1627355|NONE_0 (l_dobj) deterioration_8\NN\14560612|injections_38|and_25|used_33|,_68|but_70|tested_153
D005947_D000544 CID glucose_33\NN\14710501|decreased_10|via_18|and_48|metabolism_70 (r_compound) transport_34\NN\3575240|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_agent) followed_30\VBN\1835496|of_36 (r_acl) dysfunction_20\NN\14204950|NONE_0 (r_pobj) with_19\IN\0|that_71|dementia_66|is_14 (r_prep) associated_18\VBN\628491|research_86|has_77|._181 (l_nsubjpass) dementia_7\NN\14395018|that_5|is_52|with_66 (l_prep) of_8\IN\0|NONE_0 (l_pobj) type_16\NN\5839024|NONE_0 (l_nmod) disease_12\NN\14061805|(_8|sad_9|)_12
D005947_D000544 CID glucose_36\NN\14710501|transporter_8 (r_compound) glut4_38\NNPS\0|NONE_0 (r_pobj) via_35\IN\0|decreased_28|glucose_18|and_30|metabolism_52 (r_prep) transport_34\NN\3575240|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_agent) followed_30\VBN\1835496|of_36 (r_acl) dysfunction_20\NN\14204950|NONE_0 (r_pobj) with_19\IN\0|that_71|dementia_66|is_14 (r_prep) associated_18\VBN\628491|research_86|has_77|._181 (l_nsubjpass) dementia_7\NN\14395018|that_5|is_52|with_66 (l_prep) of_8\IN\0|NONE_0 (l_pobj) type_16\NN\5839024|NONE_0 (l_nmod) disease_12\NN\14061805|(_8|sad_9|)_12
D005947_D000544 CID glucose_41\NN\14710501|decreased_10|in_19 (r_compound) metabolism_42\NN\13526110|decreased_80|glucose_70|via_52|and_22 (r_conj) transport_34\NN\3575240|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_agent) followed_30\VBN\1835496|of_36 (r_acl) dysfunction_20\NN\14204950|NONE_0 (r_pobj) with_19\IN\0|that_71|dementia_66|is_14 (r_prep) associated_18\VBN\628491|research_86|has_77|._181 (l_nsubjpass) dementia_7\NN\14395018|that_5|is_52|with_66 (l_prep) of_8\IN\0|NONE_0 (l_pobj) type_16\NN\5839024|NONE_0 (l_nmod) disease_12\NN\14061805|(_8|sad_9|)_12
D013311_D003072 CID streptozotocin_16\NNS\0|NONE_0 (r_pobj) with_15\IN\0|intracerebroventricularly_26 (r_prep) treated_13\VBD\2376958|cognitive_39|in_20 (r_acl) deficits_8\NNS\5113133|treatment_29|._82
D013311_D003072 CID streptozotocin_23\NNS\0|-_14 (r_npadvmod) induced_25\VBN\1627355|(_8|icv_13|)_16|rat_18|of_28|,_34|tested_36 (r_amod) model_32\NN\5888929|NONE_0 (r_pobj) in_22\IN\13603305|(_48|kg_40|)_34|on_22 (r_prep) treatment_18\NN\654885|continuous_48|daily_37|oral_31 (l_prep) on_19\IN\0|(_26|kg_18|)_12|in_22 (l_pobj) deficits_21\NNS\5113133|NONE_0
D013311_D003072 CID stz_27\NNP\0|-_3 (r_nmod) icv_29\NN\0|induced_13|(_5|)_3|rat_5|of_15|,_21|tested_23 (r_nmod) model_32\NN\5888929|NONE_0 (r_pobj) in_22\IN\13603305|(_48|kg_40|)_34|on_22 (r_prep) treatment_18\NN\654885|continuous_48|daily_37|oral_31 (l_prep) on_19\IN\0|(_26|kg_18|)_12|in_22 (l_pobj) deficits_21\NNS\5113133|NONE_0
D013311_D003072 CID stz_10\NNP\0|-_3 (r_compound) icv_12\NN\0|the_8 (r_compound) administration_13\NN\1133281|NONE_0 (r_pobj) after_8\IN\0|month_56|immediately_12|,_32|prevented_47|._110 (r_prep) initiated_6\VBD\1617192|NONE_0 (l_conj) prevented_16\VBN\0|month_103|immediately_59|after_47|,_15|._63 (l_dobj) development_17\NN\248977|successfully_23 (l_prep) of_18\IN\0|NONE_0 (l_pobj) deficits_26\NNS\5113133|NONE_0
D013311_D003072 CID stz_20\NNP\0|-_3 (r_compound) icv_22\NN\0|-_3 (r_npadvmod) induced_24\VBN\1627355|the_12|cognitive_8 (r_amod) deficits_26\NNS\5113133|NONE_0
D005947_D003704 NONE glucose_33\NN\14710501|decreased_10|via_18|and_48|metabolism_70 (r_compound) transport_34\NN\3575240|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_agent) followed_30\VBN\1835496|of_36 (r_acl) dysfunction_20\NN\14204950|NONE_0 (r_pobj) with_19\IN\0|that_71|dementia_66|is_14 (r_prep) associated_18\VBN\628491|research_86|has_77|._181 (l_nsubjpass) dementia_7\NN\14395018|that_5|is_52|with_66
D005947_D003704 NONE glucose_36\NN\14710501|transporter_8 (r_compound) glut4_38\NNPS\0|NONE_0 (r_pobj) via_35\IN\0|decreased_28|glucose_18|and_30|metabolism_52 (r_prep) transport_34\NN\3575240|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_agent) followed_30\VBN\1835496|of_36 (r_acl) dysfunction_20\NN\14204950|NONE_0 (r_pobj) with_19\IN\0|that_71|dementia_66|is_14 (r_prep) associated_18\VBN\628491|research_86|has_77|._181 (l_nsubjpass) dementia_7\NN\14395018|that_5|is_52|with_66
D005947_D003704 NONE glucose_41\NN\14710501|decreased_10|in_19 (r_compound) metabolism_42\NN\13526110|decreased_80|glucose_70|via_52|and_22 (r_conj) transport_34\NN\3575240|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_agent) followed_30\VBN\1835496|of_36 (r_acl) dysfunction_20\NN\14204950|NONE_0 (r_pobj) with_19\IN\0|that_71|dementia_66|is_14 (r_prep) associated_18\VBN\628491|research_86|has_77|._181 (l_nsubjpass) dementia_7\NN\14395018|that_5|is_52|with_66
D005690_D000544 NONE galactose_1\NN\15062778|oral_5 (r_compound) exposure_2\NN\5042871|might_9|effects_31|and_70|be_80|._185 (r_nsubj) have_4\VB\7846|NONE_0 (l_conj) be_14\VB\14625458|exposure_80|might_71|effects_49|and_10|._105 (l_acomp) worth_15\JJ\13576355|could_9 (l_xcomp) investigating_16\VBG\575741|NONE_0 (l_prep) for_17\IN\0|NONE_0 (l_pobj) improvement_18\NN\7359599|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) deficits_21\NNS\5113133|NONE_0 (l_acl) associated_22\VBN\628491|cognitive_19 (l_prep) with_23\IN\0|NONE_0 (l_pobj) hypometabolism_25\NN\0|NONE_0 (l_prep) in_26\IN\13603305|glucose_23 (l_pobj) ad_27\NN\7247071|NONE_0
D005690_D018149 NONE galactose_1\NN\15062778|oral_5 (r_compound) exposure_2\NN\5042871|might_9|effects_31|and_70|be_80|._185 (r_nsubj) have_4\VB\7846|NONE_0 (l_conj) be_14\VB\14625458|exposure_80|might_71|effects_49|and_10|._105 (l_acomp) worth_15\JJ\13576355|could_9 (l_xcomp) investigating_16\VBG\575741|NONE_0 (l_prep) for_17\IN\0|NONE_0 (l_pobj) improvement_18\NN\7359599|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) deficits_21\NNS\5113133|NONE_0 (l_acl) associated_22\VBN\628491|cognitive_19 (l_prep) with_23\IN\0|NONE_0 (l_pobj) hypometabolism_25\NN\0|NONE_0
24220752
D003287_D009369 NONE contrast_2\NN\13854649|-_8 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) nephropathy_5\NN\14573196|NONE_0 (r_pobj) of_1\IN\0|in_32|._68 (r_prep) incidence_0\NN\13821570|NONE_0 (l_prep) in_6\IN\13603305|of_32|._36 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|hospitalised_22 (l_pobj) cancer_10\NN\14239425|NONE_0
D003287_D009369 NONE contrast_10\NN\13854649|-_8 (r_npadvmod) induced_12\VBN\1627355|(_20|cin_21|)_24 (r_amod) nephropathy_13\NN\14573196|NONE_0 (r_pobj) to_9\IN\0|in_38 (r_prep) related_8\VBN\628491|possible_17 (l_prep) in_17\IN\13603305|to_38 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|hospitalised_22 (l_pobj) cancer_21\NN\14239425|NONE_0
C051890_D006973 NONE irinotecan_9\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|more_11|and_50|in_54 (r_pobj) after_4\IN\0|cin_27|._101 (l_conj) in_16\IN\13603305|more_65|treatment_54|and_4 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) hypertension_19\NN\14057371|NONE_0
C051890_D006973 NONE irinotecan_7\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) combination_3\NN\7951464|and_8 (r_conj) hypertension_0\NN\14057371|may_59|factors_82|._109
-1_D006973 NONE bevacizumab_7\NN\0|/_11|(_23|p_24 (r_amod) irinotecan_9\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|more_11|and_50|in_54 (r_pobj) after_4\IN\0|cin_27|._101 (l_conj) in_16\IN\13603305|more_65|treatment_54|and_4 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) hypertension_19\NN\14057371|NONE_0
-1_D006973 NONE bevacizumab_5\NN\0|/_11 (r_amod) irinotecan_7\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) combination_3\NN\7951464|and_8 (r_conj) hypertension_0\NN\14057371|may_59|factors_82|._109
-1_D006973 NONE bevacizumab_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) treatment_2\NN\654885|and_4 (r_conj) hypertension_0\NN\14057371|be_54|._80
D003287_D007674 CID contrast_2\NN\13854649|-_8 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) nephropathy_5\NN\14573196|NONE_0
D003287_D007674 CID contrast_10\NN\13854649|-_8 (r_npadvmod) induced_12\VBN\1627355|(_20|cin_21|)_24 (r_amod) nephropathy_13\NN\14573196|NONE_0
D003287_D007674 CID contrast_0\RB\13854649|-_8 (r_npadvmod) induced_2\VBN\1627355|is_26 (r_amod) nephropathy_3\NN\14573196|NONE_0
17069550
D005702_D019958 NONE galantamine_5\NN\0|in_20|,_2|tolerated_21|and_31|appeared_35|._192 (r_nsubj) was_6\VBD\0|NONE_0 (l_conj) appeared_11\VBD\2604760|in_55|,_37|galantamine_35|tolerated_14|and_4|._157 (l_xcomp) be_13\VB\14625458|NONE_0 (l_acomp) beneficial_14\JJ\0|to_6 (l_prep) for_15\IN\0|NONE_0 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pcomp) interfering_19\VBG\2451370|NONE_0 (l_dobj) behaviors_20\NNS\407535|NONE_0 (l_prep) in_21\IN\13603305|NONE_0 (l_pobj) children_22\NNS\9622049|NONE_0 (l_prep) with_23\IN\0|NONE_0 (l_pobj) autism_24\NN\14304060|NONE_0 (l_appos) aggression_27\NN\4657876|,_15 (l_conj) dyscontrol_30\NN\0|particularly_36|,_13 (l_conj) inattention_33\NN\5701944|behavioral_27|,_6|and_4
D005702_D001523 NONE galantamine_5\NN\0|in_20|,_2|tolerated_21|and_31|appeared_35|._192 (r_nsubj) was_6\VBD\0|NONE_0 (l_conj) appeared_11\VBD\2604760|in_55|,_37|galantamine_35|tolerated_14|and_4|._157 (l_xcomp) be_13\VB\14625458|NONE_0 (l_acomp) beneficial_14\JJ\0|to_6 (l_prep) for_15\IN\0|NONE_0 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pcomp) interfering_19\VBG\2451370|NONE_0 (l_dobj) behaviors_20\NNS\407535|NONE_0 (l_prep) in_21\IN\13603305|NONE_0 (l_pobj) children_22\NNS\9622049|NONE_0 (l_prep) with_23\IN\0|NONE_0 (l_pobj) autism_24\NN\14304060|NONE_0 (l_appos) aggression_27\NN\4657876|,_15
D005702_D001321 NONE galantamine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_32|prospective_30|,_19|label_12|in_15|._35 (r_prep) trial_6\NN\786195|NONE_0 (l_prep) in_9\IN\13603305|a_47|prospective_45|,_34|label_27|of_15|._20 (l_pobj) disorder_11\NN\14034177|NONE_0
D005702_D001321 NONE galantamine_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_8|in_84 (r_prep) use_9\NN\407535|to_14 (l_prep) in_21\IN\13603305|the_92|of_84 (l_pobj) treatment_23\NN\654885|NONE_0 (l_prep) of_24\IN\0|the_14 (l_pcomp) interfering_25\VBG\2451370|NONE_0 (l_dobj) behaviors_26\NNS\407535|NONE_0 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) children_28\NNS\9622049|NONE_0 (l_prep) with_29\IN\0|NONE_0 (l_pobj) autism_30\NN\14304060|NONE_0
D005702_D001321 NONE galantamine_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|a_28|12-week_26|,_19|label_12 (r_prep) trial_24\NN\786195|NONE_0 (r_pobj) in_17\IN\13603305|children_64|._45 (r_prep) participated_16\VBD\2367363|NONE_0 (l_nsubj) children_4\NNS\9622049|in_64|._109 (l_prep) with_5\IN\0|thirteen_34|free_14|)_40 (l_pobj) autism_6\NN\14304060|NONE_0
D005702_D001321 NONE galantamine_5\NN\0|in_20|,_2|tolerated_21|and_31|appeared_35|._192 (r_nsubj) was_6\VBD\0|NONE_0 (l_conj) appeared_11\VBD\2604760|in_55|,_37|galantamine_35|tolerated_14|and_4|._157 (l_xcomp) be_13\VB\14625458|NONE_0 (l_acomp) beneficial_14\JJ\0|to_6 (l_prep) for_15\IN\0|NONE_0 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pcomp) interfering_19\VBG\2451370|NONE_0 (l_dobj) behaviors_20\NNS\407535|NONE_0 (l_prep) in_21\IN\13603305|NONE_0 (l_pobj) children_22\NNS\9622049|NONE_0 (l_prep) with_23\IN\0|NONE_0 (l_pobj) autism_24\NN\14304060|NONE_0
D005702_D006261 CID galantamine_2\NN\0|overall_9|,_2|tolerated_21|,_30|with_32|._103 (r_nsubj) was_3\VBD\0|NONE_0 (l_prep) with_8\IN\0|overall_41|,_34|galantamine_32|tolerated_11|,_2|._71 (l_pobj) effects_12\NNS\13245626|NONE_0 (l_advmod) apart_13\RB\0|no_31|significant_28|adverse_16 (l_prep) from_14\IN\0|NONE_0 (l_pobj) headaches_15\NNS\5829480|NONE_0
D005702_D002653 NONE galantamine_5\NN\0|in_20|,_2|tolerated_21|and_31|appeared_35|._192 (r_nsubj) was_6\VBD\0|NONE_0 (l_conj) appeared_11\VBD\2604760|in_55|,_37|galantamine_35|tolerated_14|and_4|._157 (l_xcomp) be_13\VB\14625458|NONE_0 (l_acomp) beneficial_14\JJ\0|to_6 (l_prep) for_15\IN\0|NONE_0 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pcomp) interfering_19\VBG\2451370|NONE_0 (l_dobj) behaviors_20\NNS\407535|NONE_0 (l_prep) in_21\IN\13603305|NONE_0 (l_pobj) children_22\NNS\9622049|NONE_0 (l_prep) with_23\IN\0|NONE_0 (l_pobj) autism_24\NN\14304060|NONE_0 (l_appos) aggression_27\NN\4657876|,_15 (l_conj) dyscontrol_30\NN\0|particularly_36|,_13
20595935
D014700_-1 NONE verapamil_7\NN\2938514|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) unresponsiveness_5\NN\4723816|that_5|as_38 (r_nsubj) defined_8\VBN\2604760|analysis_53|,_18|discriminated_20|._245 (r_ccomp) revealed_3\VBD\2137132|NONE_0 (l_conj) discriminated_15\VBD\650353|analysis_73|defined_20|,_2|._225 (l_npadvmod) sensitivity_22\NN\5651971|effect_8|respectively_160 (l_acl) associated_46\VBN\628491|(_83|:_71|%_67|)_2|,_76 (l_prep) with_47\IN\0|NONE_0 (l_pobj) pseudoprolactinoma_48\NN\0|NONE_0
D018967_D006966 CID risperidone_25\NN\0|-_11 (r_npadvmod) induced_27\VBN\1627355|prl_34|._42 (r_amod) hyperprolactinemia_28\NN\0|(_93|n._92|,_87|:_82|%_77|)_76|,_75|but_73|in_65|prl_36|,_26|and_24
D018967_D006966 CID risperidone_50\NN\0|-_11 (r_npadvmod) induced_52\VBN\1627355|NONE_0 (r_amod) hyperprolactinemia_53\NN\0|or_23
D014700_D015175 NONE verapamil_12\NN\2938514|NONE_0 (r_pobj) of_11\IN\0|the_21|diagnostic_17|in_13 (r_prep) value_10\NN\5856066|here_48|,_44|we_42|._79 (l_prep) in_13\IN\13603305|the_34|diagnostic_30|of_13 (l_pobj) population_15\NN\7942152|NONE_0 (l_relcl) screened_19\VBN\2533282|a_26 (l_prep) for_20\IN\0|who_22|were_18|all_13 (l_pobj) macroprolactinemia_21\NN\0|NONE_0
D014700_D015175 NONE verapamil_1\NNP\2938514|:_2|significantly_10|levels_38|in_45|macroprolactinoma_84 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_advcl) macroprolactinoma_19\NN\0|:_86|verapamil_84|significantly_74|levels_46|in_39
D014700_D015175 NONE verapamil_1\NNP\2938514|:_2|significantly_10|levels_38|in_45|macroprolactinoma_84 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_advcl) macroprolactinoma_19\NN\0|:_86|verapamil_84|significantly_74|levels_46|in_39 (l_appos) prl_24\NN\0|NONE_0 (l_conj) microprolactinoma_30\NN\0|(_17|n._16|,_12|:_7|%_4|)_3|,_2|,_35|macroprolactinemia_37
D014700_D015175 NONE verapamil_1\NNP\2938514|:_2|significantly_10|levels_38|in_45|macroprolactinoma_84 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_advcl) macroprolactinoma_19\NN\0|:_86|verapamil_84|significantly_74|levels_46|in_39 (l_appos) prl_24\NN\0|NONE_0 (l_appos) macroprolactinemia_41\JJ\0|(_54|n._53|,_49|:_44|%_41|)_40|,_39|microprolactinoma_37|,_2
D018967_-1 NONE risperidone_25\NN\0|-_11 (r_npadvmod) induced_27\VBN\1627355|prl_34|._42 (r_amod) hyperprolactinemia_28\NN\0|(_93|n._92|,_87|:_82|%_77|)_76|,_75|but_73|in_65|prl_36|,_26|and_24 (r_conj) prl_4\NN\0|NONE_0 (l_conj) in_12\IN\13603305|(_28|n._27|,_22|:_17|%_12|)_11|,_10|but_8|prl_29|,_39|and_41|hyperprolactinemia_65 (l_pobj) pseudoprolactinoma_13\NN\0|not_7
D018967_-1 NONE risperidone_50\NN\0|-_11 (r_npadvmod) induced_52\VBN\1627355|NONE_0 (r_amod) hyperprolactinemia_53\NN\0|or_23 (r_conj) pseudoprolactinoma_48\NN\0|NONE_0
D014700_D006966 NONE verapamil_0\NNP\2938514|stimulation_10|in_27|:_48|loss_50|._115 (r_compound) test_2\NN\5798043|NONE_0 (l_prep) in_3\IN\13603305|verapamil_27|stimulation_17|:_21|loss_23|._88 (l_pobj) hyperprolactinemia_4\NN\0|NONE_0
D014700_D006966 NONE verapamil_0\NNP\2938514|stimulation_10 (r_compound) test_2\NN\5798043|was_5|previously_9|as_33|,_91|but_93|with_97|._121 (r_nsubjpass) investigated_5\VBN\644583|NONE_0 (l_prep) as_6\IN\14622893|test_33|was_28|previously_24|,_58|but_60|with_64|._88 (l_pobj) tool_8\NN\3563967|NONE_0 (l_prep) for_9\IN\0|a_7 (l_pobj) diagnosis_11\NN\152018|NONE_0 (l_prep) of_12\IN\0|differential_23 (l_pobj) hyperprolactinemia_13\NN\0|NONE_0
D014700_D006966 NONE verapamil_3\NN\2938514|NONE_0 (r_pobj) to_2\IN\0|prolactin_20|in_13|with_61 (r_prep) responses_1\NNS\11410625|were_95|in_107|._151 (l_prep) with_16\IN\0|prolactin_81|to_61|in_48 (l_pobj) hyperprolactinemia_17\NN\0|NONE_0
D014700_D006966 NONE verapamil_7\NN\2938514|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) unresponsiveness_5\NN\4723816|that_5|as_38 (r_nsubj) defined_8\VBN\2604760|analysis_53|,_18|discriminated_20|._245 (r_ccomp) revealed_3\VBD\2137132|NONE_0 (l_conj) discriminated_15\VBD\650353|analysis_73|defined_20|,_2|._225 (l_npadvmod) sensitivity_22\NN\5651971|effect_8|respectively_160 (l_acl) associated_46\VBN\628491|(_83|:_71|%_67|)_2|,_76 (l_prep) with_47\IN\0|NONE_0 (l_pobj) pseudoprolactinoma_48\NN\0|NONE_0 (l_conj) hyperprolactinemia_53\NN\0|or_23
D014700_D006966 NONE verapamil_0\NNP\2938514|NONE_0 (r_compound) responsiveness_1\NN\5652926|not_18|finding_33|._93 (r_nsubj) is_2\VBZ\0|NONE_0 (l_attr) finding_6\NN\43195|responsiveness_33|not_15|._60 (l_prep) for_7\IN\0|a_19|reliable_17 (l_pobj) diagnosis_10\NN\152018|NONE_0 (l_prep) of_11\IN\0|the_27|differential_23 (l_pobj) hyperprolactinemia_12\NN\0|NONE_0
D014700_D006966 NONE verapamil_2\NN\2938514|NONE_0 (r_compound) unresponsiveness_3\NN\4723816|however_19|,_12|effect_37|._188 (r_nsubj) discriminates_4\VBZ\650353|NONE_0 (l_dobj) effect_6\NN\34213|however_56|,_49|unresponsiveness_37|._151 (l_parataxis) inhibited_13\JJ\2510337|stalk_49 (l_prep) from_17\IN\0|(_66|i.e._65|,_61|anatomically_59|functionally_43|tonus_7|)_2 (l_pobj) causes_19\NNS\7323922|NONE_0 (l_prep) of_20\IN\0|other_13|with_22 (l_pobj) hyperprolactinemia_21\NN\0|NONE_0
3339945
D013806_D020258 NONE theophylline_0\NNP\2905612|in_27|._43 (r_amod) neurotoxicity_1\NN\0|NONE_0
D013806_D020258 NONE theophylline_12\NN\2905612|NONE_0 (r_pobj) of_11\IN\0|the_18 (r_prep) neurotoxicity_10\NN\0|whether_12|is_30|in_41
D013806_D020258 NONE theophylline_15\NN\2905612|NONE_0 (r_pobj) to_14\IN\0|the_24|neurotoxic_20|in_16 (r_prep) response_13\NN\11410625|NONE_0 (l_amod) neurotoxic_12\JJ\0|the_4|to_20|in_36
D000628_D012640 CID aminophylline_21\NN\2905612|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) infusions_19\NNS\14589223|rats_89|until_27|._110 (r_dobj) received_18\VBD\2210855|NONE_0 (l_prep) until_22\IN\0|rats_116|infusions_27|._83 (l_pobj) onset_23\NN\7325190|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) seizures_26\NNS\14081375|NONE_0
6893265
D011441_D056486 CID propylthiouracil_0\NNP\14727670|-_16 (r_npadvmod) induced_2\VBN\1627355|hepatic_8|._22 (r_amod) damage_4\NN\7296428|NONE_0
D011441_D056486 CID propylthiouracil_3\NN\14727670|-_16 (r_npadvmod) induced_5\VBN\1627355|liver_8 (r_amod) damage_7\NN\7296428|NONE_0
16810074
D018738_D006973 NONE hexamethonium_5\NN\0|NONE_0 (r_pobj) with_4\IN\0|ganglionic_20 (r_prep) blockade_3\NN\952963|similarly_22|,_13|fall_59|compared_107|._151 (r_nsubj) caused_6\VBD\1617192|NONE_0 (l_dobj) fall_10\NN\15236475|similarly_81|,_72|blockade_59|compared_48|._92 (l_prep) in_11\IN\13603305|a_29|greater_13 (l_pobj) rats_14\NNS\2329401|NONE_0 (l_amod) hypertensive_13\JJ\10405694|lnna_5|(_18|hg_31|)_33
D019335_D006973 NONE arginine_21\NN\14605787|lnna_10|)_14|through_29 (r_nmod) hypertension_25\NN\14057371|NONE_0
D019335_D006973 NONE lnna_23\NNP\0|arginine_10|)_4|through_19 (r_nmod) hypertension_25\NN\14057371|NONE_0
D019335_D006973 NONE lnna_17\NNP\0|NONE_0 (r_compound) hypertension_18\NN\14057371|NONE_0
D019335_D006973 NONE lnna_25\NNP\0|weeks_12 (r_pobj) after_24\IN\0|pressure_102|an_92|in_89|,_56|was_54|not_50|in_37|at_16|._10 (r_prep) elevated_15\VBN\4048568|NONE_0 (l_prep) in_16\IN\13603305|pressure_65|an_55|in_52|,_19|was_17|not_13|at_21|after_37|._47 (l_pobj) hypertension_18\NN\14057371|NONE_0
D019335_D006973 NONE lnna_12\NNS\0|hypertensive_5|(_23|hg_36|)_38 (r_nmod) rats_14\NNS\2329401|NONE_0 (l_amod) hypertensive_13\JJ\10405694|lnna_5|(_18|hg_31|)_33
D009569_D006973 CID oxide_6\NN\14818238|(_6|no_7|)_9 (r_nmod) deficiency_10\NN\14449126|NONE_0 (r_pobj) by_4\IN\0|mechanisms_35 (r_agent) induced_3\VBN\1627355|:_39|on_47|._65 (l_nsubj) mechanisms_0\NNS\13446390|by_35 (l_prep) of_1\IN\0|NONE_0 (l_pobj) hypertension_2\NN\14057371|NONE_0
D009569_D006973 CID no_8\NNP\7204911|oxide_7|(_1|)_2 (r_intj) deficiency_10\NN\14449126|NONE_0 (r_pobj) by_4\IN\0|mechanisms_35 (r_agent) induced_3\VBN\1627355|:_39|on_47|._65 (l_nsubj) mechanisms_0\NNS\13446390|by_35 (l_prep) of_1\IN\0|NONE_0 (l_pobj) hypertension_2\NN\14057371|NONE_0
D009569_D006973 CID oxide_7\NN\14818238|NONE_0 (l_prep) in_11\IN\13603305|endothelial_43|derived_26|nitric_18|(_5|no_4 (l_pobj) hypertension_12\NN\14057371|NONE_0
D009569_D006973 CID no_9\NNP\7204911|endothelial_39|derived_22|nitric_14|(_1|in_4 (r_appos) oxide_7\NN\14818238|NONE_0 (l_prep) in_11\IN\13603305|endothelial_43|derived_26|nitric_18|(_5|no_4 (l_pobj) hypertension_12\NN\14057371|NONE_0
D009569_D006973 CID no_7\UH\7204911|NONE_0 (r_pobj) of_6\IN\0|the_12 (r_prep) removal_5\NN\383606|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) created_2\VBN\0|experimental_26 (r_acl) hypertension_1\NN\14057371|,_41|however_43|,_50|mechanisms_61|decreased_87|._126
D009569_D006973 CID no_5\DT\7204911|NONE_0 (r_det) deficiency_6\NN\14449126|while_9|stress_31|in_63 (r_nsubj) increases_7\VBZ\13576355|that_25|,_87|impact_93|does_109|not_114|contribution_131 (r_advcl) make_26\VB\5839024|data_156|._54 (l_dobj) contribution_29\NN\786195|that_156|increases_131|,_44|impact_38|does_22|not_17 (l_prep) to_30\IN\0|a_21|major_19 (l_pobj) form_32\NN\6286395|NONE_0 (l_prep) of_33\IN\0|this_10 (l_pobj) hypertension_34\NN\14057371|NONE_0
D009569_D018754 NONE oxide_7\NN\14818238|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) loss_0\NN\13252973|hallmark_72|._104 (r_nsubj) is_13\VBZ\0|NONE_0 (l_attr) hallmark_15\NN\4731497|loss_72|._32 (l_prep) of_16\IN\0|a_11 (l_pobj) dysfunction_18\NN\14204950|NONE_0
D009569_D018754 NONE no_9\NNP\7204911|endothelial_39|derived_22|nitric_14|(_1|in_4 (r_appos) oxide_7\NN\14818238|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) loss_0\NN\13252973|hallmark_72|._104 (r_nsubj) is_13\VBZ\0|NONE_0 (l_attr) hallmark_15\NN\4731497|loss_72|._32 (l_prep) of_16\IN\0|a_11 (l_pobj) dysfunction_18\NN\14204950|NONE_0
1563460
D014859_D020758 CID coumadin_4\NN\2718259|anticoagulant_9 (r_amod) therapy_6\NN\657604|NONE_0 (r_pobj) to_3\IN\0|thoracic_32|secondary_10|:_33|report_42|._48 (r_prep) hematomyelia_1\NNS\0|NONE_0
6529939
D011433_D019955 NONE propranolol_6\NN\0|being_12 (r_pcomp) for_5\IN\0|NONE_0 (l_pcomp) being_7\VBG\24720|propranolol_12 (l_attr) cause_9\NN\7323922|NONE_0 (l_prep) of_10\IN\0|the_10 (l_pobj) disorder_13\NN\14034177|NONE_0
D011433_D000787 NONE propranolol_28\NN\0|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) angina_24\NN\14171682|NONE_0
D011433_D001146 CID propranolol_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|rhythm_41|._22 (r_xcomp) alternating_0\VBG\123170|NONE_0 (l_dobj) rhythm_2\NN\15122011|induced_41|._63
D011433_D001146 CID propranolol_28\NN\0|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) angina_24\NN\14171682|NONE_0 (r_pobj) for_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) under_21\IN\0|alternating_102|block_43|was_37|in_24|,_2|._55 (r_prep) observed_13\VBN\2163746|NONE_0 (l_advcl) alternating_0\VBG\123170|block_59|was_65|in_78|,_100|under_102|._157 (l_dobj) rhythm_2\NN\15122011|NONE_0
D011433_D012848 CID propranolol_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|rhythm_41|._22 (r_xcomp) alternating_0\VBG\123170|NONE_0 (l_dobj) rhythm_2\NN\15122011|induced_41|._63 (l_conj) block_6\NN\21939|sinus_41|and_28
D011433_D012848 CID propranolol_28\NN\0|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) angina_24\NN\14171682|NONE_0 (r_pobj) for_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) under_21\IN\0|alternating_102|block_43|was_37|in_24|,_2|._55 (r_prep) observed_13\VBN\2163746|NONE_0 (l_nsubjpass) block_11\NN\21939|alternating_59|was_6|in_19|,_41|under_43|._98
D011433_D012848 CID propranolol_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_15|and_15 (r_prep) withdrawal_6\NN\7206096|NONE_0 (r_pobj) with_4\IN\0|rhythm_19 (r_prep) disappeared_3\VBD\0|restarted_69|block_89|was_95|._103 (r_ccomp) seen_22\VBN\2106506|NONE_0 (l_nsubjpass) block_20\NN\21939|disappeared_89|restarted_20|was_6|._14
24812279
D004317_D066126 NONE doxorubicin_2\NNP\2716866|therapeutic_46|,_57|but_59|associated_66 (r_nsubj) is_6\VBZ\0|:_20|._104 (l_conj) associated_16\VBN\628491|doxorubicin_66|therapeutic_20|,_9|but_7 (l_prep) with_17\IN\0|is_14 (l_pobj) cardiotoxicity_24\NN\0|NONE_0
D004317_D066126 NONE dox_4\NNP\0|)_3 (r_appos) doxorubicin_2\NNP\2716866|therapeutic_46|,_57|but_59|associated_66 (r_nsubj) is_6\VBZ\0|:_20|._104 (l_conj) associated_16\VBN\628491|doxorubicin_66|therapeutic_20|,_9|but_7 (l_prep) with_17\IN\0|is_14 (l_pobj) cardiotoxicity_24\NN\0|NONE_0
D004317_D066126 NONE dox_13\NNP\0|stage_6 (r_compound) cardiotoxicity_14\NN\0|NONE_0
D004317_D006333 CID dox_5\NNP\0|-_3 (r_npadvmod) induced_7\VBN\1627355|heart_8 (r_amod) failure_9\NN\66216|NONE_0
D004317_D009369 NONE doxorubicin_2\NNP\2716866|therapeutic_46|,_57|but_59|associated_66 (r_nsubj) is_6\VBZ\0|:_20|._104 (l_attr) therapeutic_12\NN\3740161|doxorubicin_46|,_11|but_13|associated_20 (l_compound) cancer_11\NN\14239425|an_18|effective_15
D004317_D009369 NONE dox_4\NNP\0|)_3 (r_appos) doxorubicin_2\NNP\2716866|therapeutic_46|,_57|but_59|associated_66 (r_nsubj) is_6\VBZ\0|:_20|._104 (l_attr) therapeutic_12\NN\3740161|doxorubicin_46|,_11|but_13|associated_20 (l_compound) cancer_11\NN\14239425|an_18|effective_15
D018943_D066126 NONE anthracycline_6\NN\0|stage_6 (r_amod) cardiotoxicity_7\NN\0|inhibition_48|._14
3538855
D000617_D008107 NONE aminoglycoside_13\NN\0|therapy_16 (r_compound) levels_14\NNS\4916342|NONE_0 (r_pobj) of_9\IN\0|the_13|,_40|disease_48|gender_137 (r_prep) duration_8\NN\15113229|that_9|all_153|risk_170 (l_appos) disease_17\NN\14061805|the_61|of_48|,_8|gender_89
D000617_D058186 NONE aminoglycosides_3\NNS\0|NONE_0 (r_pobj) of_2\IN\0|clinical_16|in_19 (r_prep) trials_1\NNS\786195|ranges_134|._198 (r_nsubj) indicate_8\VBP\952524|NONE_0 (l_ccomp) ranges_20\VBZ\5123416|trials_134|._64 (l_nsubj) risk_12\NN\14541044|that_18|from_62|and_75|is_106 (l_prep) for_13\IN\0|the_18|relative_14 (l_pcomp) developing_14\VBG\13541167|NONE_0 (l_dobj) failure_17\NN\66216|during_8
D000617_D007674 CID aminoglycoside_5\NN\0|NONE_0 (r_compound) nephrotoxicity_6\NN\0|NONE_0
D000617_D007674 CID aminoglycoside_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_17 (r_prep) epidemiology_1\NN\6043075|-_30 (r_nsubj) induced_5\VBN\1627355|NONE_0 (r_amod) nephrotoxicity_6\NN\0|is_15|not_18|fully_22|._38
D000617_D007674 CID aminoglycosides_7\NNS\0|studies_45|cause_16|._124 (r_dobj) indicate_6\VBP\952524|NONE_0 (l_conj) cause_8\VBP\7323922|studies_61|aminoglycosides_16|._108 (l_conj) cause_22\VB\7323922|damage_46|,_23|but_21 (l_dobj) dysfunction_26\NN\14204950|rarely_45|,_39|ever_34|,_30
D000617_D007674 CID aminoglycoside_13\NN\0|therapy_16 (r_compound) levels_14\NNS\4916342|NONE_0 (r_pobj) of_9\IN\0|the_13|,_40|disease_48|gender_137 (r_prep) duration_8\NN\15113229|that_9|all_153|risk_170 (r_nsubj) increase_34\VBP\13576355|analysis_198|._36 (l_dobj) risk_36\NN\14541044|that_179|duration_170|all_17 (l_prep) for_37\IN\0|the_9 (l_pobj) nephrotoxicity_38\NN\0|NONE_0
D000617_D007674 CID aminoglycoside_13\NN\0|-_14 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) nephrotoxicity_16\NN\0|NONE_0
D003404_D007674 NONE creatinine_25\NN\0|high_23|initial_18|estimated_10|and_21|,_24|possibly_26 (r_compound) clearance_26\NN\5089947|advanced_48|,_36 (r_conj) age_20\NN\4916342|liver_24|,_11 (r_conj) disease_17\NN\14061805|the_61|of_48|,_8|gender_89 (r_appos) duration_8\NN\15113229|that_9|all_153|risk_170 (r_nsubj) increase_34\VBP\13576355|analysis_198|._36 (l_dobj) risk_36\NN\14541044|that_179|duration_170|all_17 (l_prep) for_37\IN\0|the_9 (l_pobj) nephrotoxicity_38\NN\0|NONE_0
D003404_D008107 NONE creatinine_25\NN\0|high_23|initial_18|estimated_10|and_21|,_24|possibly_26 (r_compound) clearance_26\NN\5089947|advanced_48|,_36 (r_conj) age_20\NN\4916342|liver_24|,_11 (r_conj) disease_17\NN\14061805|the_61|of_48|,_8|gender_89
15817013
D014859_D001281 NONE warfarin_8\NN\2718259|NONE_0 (r_pobj) on_7\IN\0|atrial_20 (r_prep) fibrillation_6\NN\14361664|NONE_0
D014859_D001281 NONE warfarin_22\NN\2718259|NONE_0 (r_pobj) on_18\IN\0|atrial_20 (r_prep) fibrillation_17\NN\14361664|NONE_0
D014859_D001281 NONE warfarin_32\NN\2718259|NONE_0 (r_pobj) on_31\IN\0|atrial_20 (r_prep) fibrillation_30\NN\14361664|NONE_0
D014859_D006470 CID warfarin_8\NN\2718259|NONE_0 (r_pobj) on_7\IN\0|atrial_20 (r_prep) fibrillation_6\NN\14361664|NONE_0 (r_pobj) in_4\IN\13603305|over_8 (r_prep) 75_3\CD\0|NONE_0 (r_dobj) aged_1\VBN\7943480|:_47|rate_53|._132 (r_acl) people_0\NNS\31264|NONE_0 (l_appos) rate_11\NN\13815152|aged_53|:_6|._79 (l_prep) of_12\IN\0|the_9 (l_pobj) hemorrhage_14\NN\14285662|NONE_0
D014859_D006470 CID warfarin_22\NN\2718259|NONE_0 (r_pobj) on_18\IN\0|atrial_20 (r_prep) fibrillation_17\NN\14361664|NONE_0 (r_pobj) with_15\IN\0|76_13 (r_prep) aged_11\VBN\7943480|admitted_96 (r_acl) people_10\NNS\31264|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) stroke_8\NN\556313|major_21|and_4 (r_conj) hemorrhage_6\NN\14285662|NONE_0
D014859_D006470 CID warfarin_9\JJ\2718259|NONE_0 (r_compound) use_10\NN\407535|,_15|and_13 (r_conj) strokes_6\NNS\556313|major_25|bleeding_19|,_2 (r_conj) episodes_4\NNS\7283608|NONE_0 (l_compound) bleeding_3\VBG\14285662|major_6|,_17|strokes_19
D014859_D006470 CID warfarin_31\NN\2718259|NONE_0 (r_pobj) on_30\IN\0|the_16|stroke_12 (r_prep) rate_29\NN\13815152|low_21|,_24 (r_nsubj) was_32\VBD\0|,_69|in_58|demonstrating_9|._58 (r_ccomp) resulted_18\VBD\2633881|rate_86|high_57|in_52|,_28|but_26|excluding_22 (r_conj) was_5\VBD\0|NONE_0 (l_nsubj) rate_1\NN\13815152|high_29|in_34|,_58|but_60|excluding_64|resulted_86 (l_prep) of_2\IN\0|the_9 (l_pobj) hemorrhage_4\NN\14285662|NONE_0
D014859_D006470 CID warfarin_38\JJ\2718259|NONE_0 (r_compound) treatment_39\NN\654885|effective_19 (r_nsubj) is_40\VBZ\0|NONE_0 (r_ccomp) demonstrating_35\VBG\2137132|,_78|in_67|was_9|._49 (r_advcl) resulted_18\VBD\2633881|rate_86|high_57|in_52|,_28|but_26|excluding_22 (r_conj) was_5\VBD\0|NONE_0 (l_nsubj) rate_1\NN\13815152|high_29|in_34|,_58|but_60|excluding_64|resulted_86 (l_prep) of_2\IN\0|the_9 (l_pobj) hemorrhage_4\NN\14285662|NONE_0
D014859_D020521 NONE warfarin_8\NN\2718259|NONE_0 (r_pobj) on_7\IN\0|atrial_20 (r_prep) fibrillation_6\NN\14361664|NONE_0 (r_pobj) in_4\IN\13603305|over_8 (r_prep) 75_3\CD\0|NONE_0 (r_dobj) aged_1\VBN\7943480|:_47|rate_53|._132 (r_acl) people_0\NNS\31264|NONE_0 (l_appos) rate_11\NN\13815152|aged_53|:_6|._79 (l_prep) of_12\IN\0|the_9 (l_pobj) hemorrhage_14\NN\14285662|NONE_0 (l_conj) stroke_16\NN\556313|major_21|and_4
D014859_D020521 NONE warfarin_22\NN\2718259|NONE_0 (r_pobj) on_18\IN\0|atrial_20 (r_prep) fibrillation_17\NN\14361664|NONE_0 (r_pobj) with_15\IN\0|76_13 (r_prep) aged_11\VBN\7943480|admitted_96 (r_acl) people_10\NNS\31264|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) stroke_8\NN\556313|major_21|and_4
D014859_D020521 NONE warfarin_9\JJ\2718259|NONE_0 (r_compound) use_10\NN\407535|,_15|and_13 (r_conj) strokes_6\NNS\556313|major_25|bleeding_19|,_2
D014859_D020521 NONE warfarin_7\NN\2718259|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) initiation_5\NN\7450842|NONE_0 (r_pobj) after_4\IN\0|the_23|annual_19|stroke_12 (r_prep) rate_3\NN\13815152|%_41|._42 (l_compound) stroke_2\NN\556313|the_11|annual_7|after_12
D014859_D020521 NONE warfarin_31\NN\2718259|NONE_0 (r_pobj) on_30\IN\0|the_16|stroke_12 (r_prep) rate_29\NN\13815152|low_21|,_24 (l_compound) stroke_28\NN\556313|the_4|on_12
D014859_D020521 NONE warfarin_38\JJ\2718259|NONE_0 (r_compound) treatment_39\NN\654885|effective_19 (r_nsubj) is_40\VBZ\0|NONE_0 (r_ccomp) demonstrating_35\VBG\2137132|,_78|in_67|was_9|._49 (r_advcl) resulted_18\VBD\2633881|rate_86|high_57|in_52|,_28|but_26|excluding_22 (l_ccomp) was_32\VBD\0|,_69|in_58|demonstrating_9|._58 (l_nsubj) rate_29\NN\13815152|low_21|,_24 (l_compound) stroke_28\NN\556313|the_4|on_12
19178808
D015742_D006470 NONE propofol_54\NN\0|-_8 (r_compound) remifentanil_56\NN\0|NONE_0 (r_compound) total_57\JJ\3553|i.v._6|(_22|tiva_23|)_27 (r_amod) anesthesia_59\NN\14034177|NONE_0 (r_pobj) by_53\IN\0|NONE_0 (r_agent) induced_52\VBN\1627355|controlled_34|hypotension_23 (r_acl) anesthesia_51\NN\14034177|NONE_0 (r_dobj) maintaining_48\VBG\0|NONE_0 (r_pcomp) in_47\IN\13603305|airway_46|versus_31 (r_prep) using_32\VBG\418025|to_172|conditions_152|during_50 (r_advcl) compare_7\VB\4744814|purpose_29|._366 (l_dobj) conditions_9\NNS\14512817|to_20|during_102|using_152 (l_prep) including_11\VBG\0|surgical_21|,_2|,_88 (l_pobj) amount_13\NN\13329641|NONE_0 (l_prep) of_14\IN\0|the_11 (l_pobj) bleeding_16\NN\14285662|NONE_0
C071741_D006470 NONE remifentanil_56\NN\0|NONE_0 (r_compound) total_57\JJ\3553|i.v._6|(_22|tiva_23|)_27 (r_amod) anesthesia_59\NN\14034177|NONE_0 (r_pobj) by_53\IN\0|NONE_0 (r_agent) induced_52\VBN\1627355|controlled_34|hypotension_23 (r_acl) anesthesia_51\NN\14034177|NONE_0 (r_dobj) maintaining_48\VBG\0|NONE_0 (r_pcomp) in_47\IN\13603305|airway_46|versus_31 (r_prep) using_32\VBG\418025|to_172|conditions_152|during_50 (r_advcl) compare_7\VB\4744814|purpose_29|._366 (l_dobj) conditions_9\NNS\14512817|to_20|during_102|using_152 (l_prep) including_11\VBG\0|surgical_21|,_2|,_88 (l_pobj) amount_13\NN\13329641|NONE_0 (l_prep) of_14\IN\0|the_11 (l_pobj) bleeding_16\NN\14285662|NONE_0
D015742_D007022 CID propofol_54\NN\0|-_8 (r_compound) remifentanil_56\NN\0|NONE_0 (r_compound) total_57\JJ\3553|i.v._6|(_22|tiva_23|)_27 (r_amod) anesthesia_59\NN\14034177|NONE_0 (r_pobj) by_53\IN\0|NONE_0 (r_agent) induced_52\VBN\1627355|controlled_34|hypotension_23 (r_acl) anesthesia_51\NN\14034177|NONE_0 (l_compound) hypotension_50\NN\14057371|controlled_11|induced_23
D015742_D007022 CID propofol_19\JJ\0|-_8|remifentanil_9|-_21 (r_compound) tiva_23\NNP\0|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) caused_17\VBN\1617192|controlled_34|hypotension_23 (r_acl) anesthesia_16\NN\14034177|NONE_0 (l_compound) hypotension_15\NN\14057371|controlled_11|caused_23
C071741_D007022 CID remifentanil_56\NN\0|NONE_0 (r_compound) total_57\JJ\3553|i.v._6|(_22|tiva_23|)_27 (r_amod) anesthesia_59\NN\14034177|NONE_0 (r_pobj) by_53\IN\0|NONE_0 (r_agent) induced_52\VBN\1627355|controlled_34|hypotension_23 (r_acl) anesthesia_51\NN\14034177|NONE_0 (l_compound) hypotension_50\NN\14057371|controlled_11|induced_23
C071741_D007022 CID remifentanil_21\NN\0|propofol_9|-_1|-_12 (r_compound) tiva_23\NNP\0|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) caused_17\VBN\1617192|controlled_34|hypotension_23 (r_acl) anesthesia_16\NN\14034177|NONE_0 (l_compound) hypotension_15\NN\14057371|controlled_11|caused_23
C071741_D007022 CID remifentanil_15\NN\0|NONE_0 (r_compound) infusion_16\NN\14589223|NONE_0 (r_pobj) of_14\IN\0|lower_12 (r_prep) rates_13\NNS\13308999|and_31 (r_dobj) using_11\VBG\418025|mask_5 (r_xcomp) using_8\VBG\418025|a_17|shorter_15 (r_acl) period_7\NN\13575869|NONE_0 (r_pobj) within_4\IN\0|hypotension_25|was_13|dose_104|._124 (r_prep) achieved_3\VBN\2524171|NONE_0 (l_nsubjpass) hypotension_1\NN\14057371|was_12|within_25|dose_129|._149
C071741_D007022 CID remifentanil_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|lower_17|total_11 (r_prep) dose_20\NN\3740161|hypotension_129|was_117|within_104|._20 (r_dobj) achieved_3\VBN\2524171|NONE_0 (l_nsubjpass) hypotension_1\NN\14057371|was_12|within_25|dose_129|._149
C071741_D007022 CID remifentanil_39\NN\0|NONE_0 (r_pobj) of_38\IN\0|low_10 (r_prep) doses_37\NNS\3740161|NONE_0 (r_pobj) with_35\IN\0|convenient_31|induced_20|during_31|in_43 (r_prep) hypotension_34\NN\14057371|NONE_0 (r_pobj) for_31\IN\0|NONE_0 (r_prep) allowed_30\VBN\0|management_158|frlma_141|during_135|and_4 (r_conj) using_9\VBG\418025|in_56|,_46|results_40|._260 (l_prep) during_11\IN\0|management_23|frlma_6|and_131|allowed_135 (l_pobj) anesthesia_14\NN\14034177|NONE_0 (l_compound) hypotension_13\NN\14057371|controlled_11|provided_23
C071741_D007022 CID remifentanil_39\NN\0|NONE_0 (r_pobj) of_38\IN\0|low_10 (r_prep) doses_37\NNS\3740161|NONE_0 (r_pobj) with_35\IN\0|convenient_31|induced_20|during_31|in_43 (r_prep) hypotension_34\NN\14057371|NONE_0
7121659
D012293_D006461 CID rifampicin_18\NNS\0|NONE_0 (r_pobj) of_17\IN\0|the_19 (r_prep) reintroduction_16\NN\7217349|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|5_72|with_61|3_35 (r_acl) patients_1\NNS\9898892|are_114|._127 (l_appos) 3_7\CD\13741022|5_37|with_26|induced_35 (l_prep) with_8\IN\0|(_3|)_31 (l_pobj) thrombopenia_9\NN\14189204|NONE_0 (l_conj) hemolysis_11\NN\13509528|and_4
D012293_D013921 CID rifampicin_18\NNS\0|NONE_0 (r_pobj) of_17\IN\0|the_19 (r_prep) reintroduction_16\NN\7217349|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|5_72|with_61|3_35 (r_acl) patients_1\NNS\9898892|are_114|._127 (l_appos) 3_7\CD\13741022|5_37|with_26|induced_35 (l_prep) with_8\IN\0|(_3|)_31 (l_pobj) thrombopenia_9\NN\14189204|NONE_0
D012293_D058186 NONE rifampicin_18\NNS\0|NONE_0 (r_pobj) of_17\IN\0|the_19 (r_prep) reintroduction_16\NN\7217349|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|5_72|with_61|3_35 (r_acl) patients_1\NNS\9898892|are_114|._127 (l_prep) with_2\IN\0|5_11|3_26|induced_61 (l_pobj) failure_5\NN\66216|NONE_0
D012293_D051437 NONE rifampicin_4\NN\0|-_10 (r_npadvmod) associated_6\VBN\628491|acute_17|renal_11 (r_amod) failure_8\NN\66216|NONE_0
12644816
D013792_D019337 NONE thalidomide_4\NN\4166841|NONE_0 (r_pobj) of_3\IN\0|the_27|antiangiogenic_23 (r_prep) effects_2\NNS\13245626|have_23|been_28|in_42|._123 (r_nsubjpass) assessed_7\VBN\670261|NONE_0 (l_prep) in_8\IN\13603305|effects_42|have_19|been_14|._81 (l_pobj) trials_10\NNS\786195|NONE_0 (l_prep) in_11\IN\13603305|clinical_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) malignancies_18\NNS\14070360|NONE_0
D013792_D011471 NONE thalidomide_11\NN\4166841|NONE_0 (l_prep) in_12\IN\13603305|dose_17 (l_pobj) cancer_17\NN\14239425|NONE_0
D013792_D011471 NONE thalidomide_8\NN\4166841|daily_24|for_30 (r_dobj) using_7\VBG\418025|an_20|label_12 (l_prep) for_13\IN\0|thalidomide_30|daily_6 (l_pobj) months_17\NNS\15113229|NONE_0 (l_prep) in_18\IN\13603305|6_9 (l_pobj) men_20\NNS\8208016|NONE_0 (l_prep) with_21\IN\0|20_7 (l_pobj) cancer_26\NN\14239425|NONE_0
D013792_D010523 CID thalidomide_9\NN\4166841|NONE_0 (r_pobj) on_8\IN\0|who_25|months_7 (r_prep) completed_5\VBD\352826|the_18|seven_14 (r_relcl) men_3\NNS\8208016|NONE_0 (r_pobj) in_0\IN\13603305|evidence_70|was_104|in_114|,_138|but_140|in_144|._174 (r_prep) found_17\VBN\13279262|NONE_0 (l_nsubjpass) evidence_12\NN\5816287|in_70|was_34|in_44|,_68|but_70|in_74|._104 (l_prep) of_13\IN\0|subclinical_21 (l_pobj) neuropathy_15\NN\14204950|NONE_0
D013792_D010523 CID thalidomide_4\NN\4166841|that_5|may_12|option_22|,_80 (r_nsubj) be_6\VB\14625458|findings_39|provided_66|._145 (r_ccomp) indicate_2\VBP\952524|NONE_0 (l_ccomp) provided_19\VBD\2199590|findings_105|be_66|._79 (l_dobj) maintained_25\VBN\0|NONE_0 (l_prep) for_26\IN\0|up_17|is_14 (l_pobj) development_27\NN\248977|NONE_0 (l_prep) of_28\IN\0|NONE_0 (l_pobj) neuropathy_30\NN\14204950|NONE_0
D000728_D011471 NONE androgen_13\JJ\14745635|-_8 (r_npadvmod) independent_15\JJ\9619824|prostate_12 (r_amod) cancer_17\NN\14239425|NONE_0
D000728_D011471 NONE androgen_22\JJ\14745635|-_8 (r_npadvmod) independent_24\JJ\9619824|prostate_12 (r_amod) cancer_26\NN\14239425|NONE_0
3990093
D011692_D009401 NONE aminonucleoside_8\JJ\0|NONE_0 (r_amod) nephrosis_9\NN\14304060|NONE_0
D011692_D009401 NONE pan_7\NNP\3101986|NONE_0 (r_compound) nephrosis_8\NN\14304060|NONE_0
D011692_D007674 NONE aminonucleoside_8\JJ\0|NONE_0 (r_amod) nephrosis_9\NN\14304060|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) rats_6\NNS\2329401|NONE_0 (r_pobj) in_5\IN\13603305|glomerular_21 (r_prep) sclerosis_4\NN\14204950|mesangial_34|and_15|._48
D011692_D007674 NONE aminonucleoside_16\NN\0|(_16|pan_17|)_20 (r_nmod) model_20\NN\5888929|relationship_134|was_51|in_39|._5 (r_advcl) studied_12\VBN\0|NONE_0 (l_nsubjpass) relationship_2\NN\31921|was_83|in_95|model_134|._139 (l_prep) between_3\IN\0|the_26|possible_22 (l_pobj) dysfunction_5\NN\14204950|NONE_0
D011692_D007674 NONE aminonucleoside_16\NN\0|(_16|pan_17|)_20 (r_nmod) model_20\NN\5888929|relationship_134|was_51|in_39|._5 (r_advcl) studied_12\VBN\0|NONE_0 (l_nsubjpass) relationship_2\NN\31921|was_83|in_95|model_134|._139 (l_prep) between_3\IN\0|the_26|possible_22 (l_pobj) dysfunction_5\NN\14204950|NONE_0 (l_prep) of_8\IN\0|mesangial_38|and_16|development_12 (l_pobj) sclerosis_10\NN\14204950|NONE_0
D011692_D007674 NONE pan_18\NNP\3101986|aminonucleoside_17|(_1|)_3 (r_nmod) model_20\NN\5888929|relationship_134|was_51|in_39|._5 (r_advcl) studied_12\VBN\0|NONE_0 (l_nsubjpass) relationship_2\NN\31921|was_83|in_95|model_134|._139 (l_prep) between_3\IN\0|the_26|possible_22 (l_pobj) dysfunction_5\NN\14204950|NONE_0
D011692_D007674 NONE pan_18\NNP\3101986|aminonucleoside_17|(_1|)_3 (r_nmod) model_20\NN\5888929|relationship_134|was_51|in_39|._5 (r_advcl) studied_12\VBN\0|NONE_0 (l_nsubjpass) relationship_2\NN\31921|was_83|in_95|model_134|._139 (l_prep) between_3\IN\0|the_26|possible_22 (l_pobj) dysfunction_5\NN\14204950|NONE_0 (l_prep) of_8\IN\0|mesangial_38|and_16|development_12 (l_pobj) sclerosis_10\NN\14204950|NONE_0
D011692_D007674 NONE pan_16\NNP\3101986|NONE_0 (r_compound) rats_17\NNS\2329401|NONE_0 (r_pobj) of_15\IN\0|the_14 (r_prep) glomeruli_14\NN\5425910|NONE_0 (r_pobj) of_12\IN\0|7.6_13|+/-_9|3.4_5 (r_prep) %_11\NN\0|NONE_0 (r_pobj) in_7\IN\13603305|at_43|sclerosis_20|was_10|;_44|were_72 (r_prep) found_6\VBN\13279262|NONE_0 (l_nsubjpass) sclerosis_4\NN\14204950|at_23|was_10|in_20|;_64|were_92
D011692_D007674 NONE pan_7\NNP\3101986|NONE_0 (r_compound) nephrosis_8\NN\14304060|NONE_0 (r_pobj) in_6\IN\13603305|the_25|remnant_21|kidney_13 (r_prep) model_5\NN\5888929|NONE_0 (r_pobj) to_1\IN\0|NONE_0 (r_prep) similar_0\JJ\0|development_57|may_93|be_97|to_108|._133|"_134 (r_nsubjpass) related_16\VBN\628491|NONE_0 (l_nsubjpass) development_10\NN\248977|similar_57|may_36|be_40|to_51|._76|"_77 (l_prep) of_11\IN\0|the_16 (l_pobj) sclerosis_13\NN\14204950|NONE_0
D011692_D011507 CID pan_4\NNP\3101986|the_4 (r_compound) rats_5\NNS\2329401|NONE_0 (r_nsubj) were_6\VBD\0|after_27|severely_5|hr_44|,_47|and_49|given_67 (r_auxpass) proteinuric_8\JJ\0|NONE_0
D002244_D011507 NONE carbon_23\NN\14622893|rats_26|were_21|intravenously_12|._25 (r_dobj) given_21\VBN\5892096|after_94|were_67|severely_62|hr_23|,_20|and_18 (r_conj) proteinuric_8\JJ\0|NONE_0
D011692_D012598 NONE pan_12\NNP\3101986|chronic_8 (r_compound) treatment_13\NN\654885|NONE_0 (r_pobj) during_10\IN\0|since_63|clearance_44|did_15|not_11 (r_prep) change_9\VB\7283608|,_35|we_37|caused_110|._237 (r_advcl) conclude_16\VBP\628491|NONE_0 (l_ccomp) caused_26\VBN\1617192|change_110|,_75|we_73|._127 (l_agent) by_27\IN\0|that_68|localization_42|is_10 (l_pobj) uptake_31\NN\13440063|NONE_0 (l_prep) after_33\IN\0|an_31|increased_28|cc_18 (l_pobj) injection_34\NN\320852|shortly_14 (l_prep) in_35\IN\13603305|NONE_0 (l_pobj) areas_38\NNS\8630985|NONE_0 (l_relcl) develop_42\VB\1753788|apparent_47|vulnerable_38 (l_nsubj) sclerosis_40\NN\14204950|where_6|will_10|subsequently_23
17346443
D003300_D001523 NONE copper_10\NN\14821043|hepatic_8 (r_compound) metabolism_11\NN\13526110|NONE_0 (r_pobj) of_8\IN\0|an_32|autosomal_29|recessive_19|with_29 (r_prep) disorder_7\NN\14034177|disease_34|._163 (l_prep) with_12\IN\0|an_61|autosomal_58|recessive_48|of_29 (l_pobj) accumulation_15\NN\13497135|NONE_0 (l_prep) in_18\IN\13603305|consequent_44|copper_33|and_13|toxicity_9 (l_pobj) tissues_20\NNS\5220461|NONE_0 (l_conj) disorders_28\NNS\14034177|many_64|and_51
D003300_D001523 NONE copper_14\NN\14821043|consequent_11|and_20|toxicity_24|in_33 (r_compound) accumulation_15\NN\13497135|NONE_0 (l_prep) in_18\IN\13603305|consequent_44|copper_33|and_13|toxicity_9 (l_pobj) tissues_20\NNS\5220461|NONE_0 (l_conj) disorders_28\NNS\14034177|many_64|and_51
D010396_D017512 CID penicillamine_0\NN\3740161|-_13 (r_npadvmod) related_2\VBN\628491|lichenoid_8|and_29|utility_33|in_57|._143 (r_amod) dermatitis_4\NN\14226056|NONE_0
D010396_D017512 CID penicillamine_9\NN\3740161|during_37|,_2|was_14|after_30|,_76|and_78|permitted_95 (r_nsubjpass) interrupted_11\VBN\362348|NONE_0 (l_prep) after_12\IN\0|during_67|,_32|penicillamine_30|was_16|,_46|and_48|permitted_65 (l_pobj) appearance_14\NN\4723816|NONE_0 (l_prep) of_15\IN\0|the_15 (l_pobj) dermatitis_18\NN\14226056|NONE_0
D010396_D006527 NONE penicillamine_0\NN\3740161|-_13 (r_npadvmod) related_2\VBN\628491|lichenoid_8|and_29|utility_33|in_57|._143 (r_amod) dermatitis_4\NN\14226056|NONE_0 (l_prep) in_10\IN\13603305|related_57|lichenoid_49|and_28|utility_24|._86 (l_pobj) patient_14\JJ\9898892|NONE_0 (l_compound) disease_13\NN\14061805|a_9|with_16
D010396_D006527 NONE penicillamine_20\NN\3740161|-_13 (r_npadvmod) related_22\VBN\628491|side_8 (r_amod) effects_24\NNS\13245626|in_36 (r_nsubj) appeared_25\VBD\2604760|an_98|effective_95|for_75 (r_relcl) treatment_11\NN\654885|in_67|therapy_51|._93 (l_prep) for_12\IN\0|an_23|effective_20|appeared_75 (l_pobj) patient_17\NN\9898892|NONE_0 (l_compound) disease_16\NN\14061805|wilson_9
D010396_D006527 NONE penicillamine_6\NN\3740161|-_13 (r_npadvmod) treated_8\VBN\2376958|wilson_31|disease_22 (r_amod) patients_9\NNS\9898892|NONE_0 (l_nmod) disease_5\NN\14061805|wilson_9|treated_22
D019345_D001008 NONE acetate_9\NN\15010703|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) utility_6\NN\8186047|related_33|lichenoid_25|and_4|in_24|._110 (r_conj) dermatitis_4\NN\14226056|NONE_0 (l_prep) in_10\IN\13603305|related_57|lichenoid_49|and_28|utility_24|._86 (l_pobj) patient_14\JJ\9898892|NONE_0 (l_prep) with_15\IN\0|a_25|disease_16 (l_pobj) presentation_17\NN\1027379|NONE_0 (l_conj) anxiety_19\NN\14373582|hepatic_22|,_2
D010396_D012871 NONE penicillamine_6\NN\3740161|-_13 (r_npadvmod) treated_8\VBN\2376958|wilson_31|disease_22 (r_amod) patients_9\NNS\9898892|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) most_1\JJS\0|since_6|do_56|not_59|develop_71 (r_nsubj) seem_12\VB\2604760|,_32|it_34|could_37|conceivable_46|involved_92|._117 (l_xcomp) develop_14\VB\1753788|since_77|most_71|do_15|not_12 (l_dobj) lesion_17\NN\14204950|to_21
D010396_D001008 NONE penicillamine_0\NN\3740161|-_13 (r_npadvmod) related_2\VBN\628491|lichenoid_8|and_29|utility_33|in_57|._143 (r_amod) dermatitis_4\NN\14226056|NONE_0 (l_prep) in_10\IN\13603305|related_57|lichenoid_49|and_28|utility_24|._86 (l_pobj) patient_14\JJ\9898892|NONE_0 (l_prep) with_15\IN\0|a_25|disease_16 (l_pobj) presentation_17\NN\1027379|NONE_0 (l_conj) anxiety_19\NN\14373582|hepatic_22|,_2
D003300_D056486 NONE copper_10\NN\14821043|hepatic_8 (r_compound) metabolism_11\NN\13526110|NONE_0 (r_pobj) of_8\IN\0|an_32|autosomal_29|recessive_19|with_29 (r_prep) disorder_7\NN\14034177|disease_34|._163 (l_prep) with_12\IN\0|an_61|autosomal_58|recessive_48|of_29 (l_pobj) accumulation_15\NN\13497135|NONE_0 (l_prep) in_18\IN\13603305|consequent_44|copper_33|and_13|toxicity_9 (l_pobj) tissues_20\NNS\5220461|NONE_0 (l_conj) disorders_28\NNS\14034177|many_64|and_51
D003300_D056486 NONE copper_14\NN\14821043|consequent_11|and_20|toxicity_24|in_33 (r_compound) accumulation_15\NN\13497135|NONE_0 (l_prep) in_18\IN\13603305|consequent_44|copper_33|and_13|toxicity_9 (l_pobj) tissues_20\NNS\5220461|NONE_0 (l_conj) disorders_28\NNS\14034177|many_64|and_51
D003300_D006527 NONE copper_10\NN\14821043|hepatic_8 (r_compound) metabolism_11\NN\13526110|NONE_0 (r_pobj) of_8\IN\0|an_32|autosomal_29|recessive_19|with_29 (r_prep) disorder_7\NN\14034177|disease_34|._163 (r_attr) is_3\VBZ\0|NONE_0 (l_nsubj) disease_2\NN\14061805|disorder_34|._197
D003300_D006527 NONE copper_14\NN\14821043|consequent_11|and_20|toxicity_24|in_33 (r_compound) accumulation_15\NN\13497135|NONE_0 (r_pobj) with_12\IN\0|an_61|autosomal_58|recessive_48|of_29 (r_prep) disorder_7\NN\14034177|disease_34|._163 (r_attr) is_3\VBZ\0|NONE_0 (l_nsubj) disease_2\NN\14061805|disorder_34|._197
D003300_D009422 NONE copper_10\NN\14821043|hepatic_8 (r_compound) metabolism_11\NN\13526110|NONE_0 (r_pobj) of_8\IN\0|an_32|autosomal_29|recessive_19|with_29 (r_prep) disorder_7\NN\14034177|disease_34|._163 (l_prep) with_12\IN\0|an_61|autosomal_58|recessive_48|of_29 (l_pobj) accumulation_15\NN\13497135|NONE_0 (l_prep) in_18\IN\13603305|consequent_44|copper_33|and_13|toxicity_9 (l_pobj) tissues_20\NNS\5220461|NONE_0 (l_conj) disorders_28\NNS\14034177|many_64|and_51
D003300_D009422 NONE copper_14\NN\14821043|consequent_11|and_20|toxicity_24|in_33 (r_compound) accumulation_15\NN\13497135|NONE_0 (l_prep) in_18\IN\13603305|consequent_44|copper_33|and_13|toxicity_9 (l_pobj) tissues_20\NNS\5220461|NONE_0 (l_conj) disorders_28\NNS\14034177|many_64|and_51
D019345_D017512 NONE acetate_9\NN\15010703|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) utility_6\NN\8186047|related_33|lichenoid_25|and_4|in_24|._110 (r_conj) dermatitis_4\NN\14226056|NONE_0
D019345_D017512 NONE acetate_22\NN\15010703|continue_21|._90 (r_nsubj) permitted_23\VBD\797697|during_132|,_97|penicillamine_95|was_81|after_65|,_19|and_17 (r_conj) interrupted_11\VBN\362348|NONE_0 (l_prep) after_12\IN\0|during_67|,_32|penicillamine_30|was_16|,_46|and_48|permitted_65 (l_pobj) appearance_14\NN\4723816|NONE_0 (l_prep) of_15\IN\0|the_15 (l_pobj) dermatitis_18\NN\14226056|NONE_0
D019345_D006527 NONE acetate_9\NN\15010703|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) utility_6\NN\8186047|related_33|lichenoid_25|and_4|in_24|._110 (r_conj) dermatitis_4\NN\14226056|NONE_0 (l_prep) in_10\IN\13603305|related_57|lichenoid_49|and_28|utility_24|._86 (l_pobj) patient_14\JJ\9898892|NONE_0 (l_compound) disease_13\NN\14061805|a_9|with_16
D019345_D006527 NONE acetate_7\NN\15010703|NONE_0 (r_pobj) with_5\IN\0|the_12 (r_prep) therapy_4\NN\657604|in_16|treatment_51|._144 (r_nsubj) represented_8\VBD\2664769|NONE_0 (l_dobj) treatment_11\NN\654885|in_67|therapy_51|._93 (l_prep) for_12\IN\0|an_23|effective_20|appeared_75 (l_pobj) patient_17\NN\9898892|NONE_0 (l_compound) disease_16\NN\14061805|wilson_9
D019345_D006527 NONE acetate_5\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) safety_1\NN\13920835|avoid_41 (r_nsubj) allowed_6\VBD\0|;_59|observation_66|in_81|._179 (r_ccomp) is_18\VBZ\0|NONE_0 (l_prep) in_19\IN\13603305|allowed_81|;_22|observation_15|._98 (l_pobj) line_20\NN\8426461|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) evidence_24\NN\5816287|NONE_0 (l_prep) on_25\IN\0|the_21|growing_17 (l_pobj) efficacy_27\NN\5199286|NONE_0 (l_prep) of_28\IN\0|the_13 (l_pobj) drug_30\NN\14778436|NONE_0 (l_prep) in_31\IN\13603305|the_9 (l_pobj) treatment_33\NN\654885|NONE_0 (l_prep) of_34\IN\0|the_14 (l_pobj) disease_37\NN\14061805|NONE_0
D003300_D064420 NONE copper_10\NN\14821043|hepatic_8 (r_compound) metabolism_11\NN\13526110|NONE_0 (r_pobj) of_8\IN\0|an_32|autosomal_29|recessive_19|with_29 (r_prep) disorder_7\NN\14034177|disease_34|._163 (l_prep) with_12\IN\0|an_61|autosomal_58|recessive_48|of_29 (l_pobj) accumulation_15\NN\13497135|NONE_0 (l_conj) toxicity_17\NN\13576101|consequent_35|copper_24|and_4|in_9
D003300_D064420 NONE copper_14\NN\14821043|consequent_11|and_20|toxicity_24|in_33 (r_compound) accumulation_15\NN\13497135|NONE_0 (l_conj) toxicity_17\NN\13576101|consequent_35|copper_24|and_4|in_9
3975902
C024986_D004342 NONE chloride_11\NN\14818238|chronic_15 (r_compound) ingestion_12\NN\13440063|NONE_0 (r_pobj) by_8\IN\0|dysfunction_65|._36 (r_agent) induced_7\VBN\1627355|NONE_0 (l_nsubj) dysfunction_1\NN\14204950|by_65|._101 (l_conj) hypersensitivity_3\NN\14531772|cardiovascular_31|and_4|pentobarbital_27
D001464_D006973 NONE barium_0\NN\14625458|-_6 (r_npadvmod) supplemented_2\VBN\182406|evans_18|hooded_24 (r_amod) rats_7\NNS\2329401|were_5|by_24|._147 (r_nsubjpass) characterized_9\VBN\609683|NONE_0 (l_agent) by_10\IN\0|rats_24|were_19|._123 (l_pobj) hypertension_13\NN\14057371|NONE_0
D001464_D006973 NONE barium_21\NN\14625458|NONE_0 (r_pobj) of_20\IN\0|1_8|treatment_54 (r_prep) month_19\NN\15113229|NONE_0 (r_pobj) after_17\IN\0|that_17|evident_8 (r_prep) was_15\VBD\0|a_31|persistent_29 (r_relcl) hypertension_13\NN\14057371|NONE_0
D001464_D009202 NONE barium_37\NN\14625458|chronic_8 (r_compound) exposure_38\NN\5042871|NONE_0 (r_pobj) by_35\IN\0|NONE_0 (r_agent) induced_34\VBN\1627355|a_50|undescribed_37|cardiomyopathic_25 (r_acl) disorder_33\NN\14034177|NONE_0
D001464_D002318 NONE barium_18\NN\14625458|-_6 (r_npadvmod) induced_20\VBN\1627355|other_25|significant_19|within_21 (r_amod) disturbances_21\NNS\407535|analysis_145|._45 (l_prep) within_22\IN\0|other_46|significant_40|induced_21 (l_pobj) system_25\NN\3575240|NONE_0
D001464_D008659 NONE barium_37\NN\14625458|chronic_8 (r_compound) exposure_38\NN\5042871|NONE_0 (r_pobj) by_35\IN\0|NONE_0 (r_agent) induced_34\VBN\1627355|a_50|undescribed_37|cardiomyopathic_25 (r_acl) disorder_33\NN\14034177|NONE_0 (r_pobj) of_28\IN\0|the_14 (r_prep) existence_27\NN\24720|overall_206|,_199|contractility_177|._97 (r_dobj) suggest_25\VBP\1010118|NONE_0 (l_nsubj) contractility_5\NN\5200169|overall_29|,_22|existence_177|._274 (l_conj) disturbances_13\NNS\407535|the_93|altered_89|cardiac_81|and_59|characteristics_42|,_27|pentobarbital_78
D010424_D004342 NONE pentobarbital_6\NN\2792049|cardiovascular_58|and_31|hypersensitivity_27 (r_amod) dysfunction_1\NN\14204950|by_65|._101 (l_conj) hypersensitivity_3\NN\14531772|cardiovascular_31|and_4|pentobarbital_27
D010424_D004342 NONE pentobarbital_18\NN\2792049|a_71|demonstrated_69|of_39|to_10 (r_amod) hypersensitivity_11\NN\14531772|aspect_47|._69
D010424_D004342 NONE pentobarbital_24\NN\2792049|the_171|altered_167|cardiac_159|and_137|characteristics_120|,_105|disturbances_78 (r_appos) contractility_5\NN\5200169|overall_29|,_22|existence_177|._274 (l_conj) disturbances_13\NNS\407535|the_93|altered_89|cardiac_81|and_59|characteristics_42|,_27|pentobarbital_78 (l_conj) hypersensitivity_17\NN\14531772|the_47|myocardial_43|metabolic_32|,_10|and_8
D010424_D002318 NONE pentobarbital_6\NN\2792049|cardiovascular_58|and_31|hypersensitivity_27 (r_amod) dysfunction_1\NN\14204950|by_65|._101
D010424_D008659 NONE pentobarbital_24\NN\2792049|the_171|altered_167|cardiac_159|and_137|characteristics_120|,_105|disturbances_78 (r_appos) contractility_5\NN\5200169|overall_29|,_22|existence_177|._274 (l_conj) disturbances_13\NNS\407535|the_93|altered_89|cardiac_81|and_59|characteristics_42|,_27|pentobarbital_78
D010424_D009202 NONE pentobarbital_24\NN\2792049|the_171|altered_167|cardiac_159|and_137|characteristics_120|,_105|disturbances_78 (r_appos) contractility_5\NN\5200169|overall_29|,_22|existence_177|._274 (r_nsubj) suggest_25\VBP\1010118|NONE_0 (l_dobj) existence_27\NN\24720|overall_206|,_199|contractility_177|._97 (l_prep) of_28\IN\0|the_14 (l_pobj) disorder_33\NN\14034177|NONE_0
D001464_D004342 NONE barium_6\NN\14625458|the_4 (r_compound) effect_7\NN\34213|NONE_0 (r_pobj) of_4\IN\0|the_28|distinctive_19 (r_prep) aspect_3\NN\5849789|hypersensitivity_47|._116 (r_nsubj) was_8\VBD\0|NONE_0 (l_attr) hypersensitivity_11\NN\14531772|aspect_47|._69
D001464_D004342 NONE barium_37\NN\14625458|chronic_8 (r_compound) exposure_38\NN\5042871|NONE_0 (r_pobj) by_35\IN\0|NONE_0 (r_agent) induced_34\VBN\1627355|a_50|undescribed_37|cardiomyopathic_25 (r_acl) disorder_33\NN\14034177|NONE_0 (r_pobj) of_28\IN\0|the_14 (r_prep) existence_27\NN\24720|overall_206|,_199|contractility_177|._97 (r_dobj) suggest_25\VBP\1010118|NONE_0 (l_nsubj) contractility_5\NN\5200169|overall_29|,_22|existence_177|._274 (l_conj) disturbances_13\NNS\407535|the_93|altered_89|cardiac_81|and_59|characteristics_42|,_27|pentobarbital_78 (l_conj) hypersensitivity_17\NN\14531772|the_47|myocardial_43|metabolic_32|,_10|and_8
C024986_D002318 NONE chloride_11\NN\14818238|chronic_15 (r_compound) ingestion_12\NN\13440063|NONE_0 (r_pobj) by_8\IN\0|dysfunction_65|._36 (r_agent) induced_7\VBN\1627355|NONE_0 (l_nsubj) dysfunction_1\NN\14204950|by_65|._101
17379047
C081489_D006973 NONE valsartan_2\JJ\2712393|hydrochlorothiazide_10|combination_30 (r_nmod) therapy_6\NN\657604|NONE_0 (r_pobj) of_1\IN\0|at_53|:_96|study_133|._203 (r_prep) comparison_0\NN\635850|NONE_0 (l_appos) study_24\NN\635850|of_133|at_80|:_37|._70 (l_acl) followed_25\VBN\1835496|a_41|blind_32|,_27|controlled_17 (l_agent) by_26\IN\0|NONE_0 (l_pobj) therapy_31\NN\657604|NONE_0 (l_prep) in_32\IN\13603305|term_25|combination_20 (l_pobj) adults_34\NNS\7846|NONE_0 (l_amod) hypertensive_33\JJ\10405694|NONE_0
C081489_C562386 NONE valsartan_10\JJ\2712393|NONE_0 (l_appos) hctz)-monotherapy_17\NN\0|val_29|(_1 (l_conj) combinations_22\NNS\7951464|and_16 (l_prep) in_23\IN\13603305|dose_18 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) hypertension_27\NN\14057371|NONE_0
C081489_C562386 NONE val_12\NNP\0|(_28|hctz)-monotherapy_29 (r_appos) valsartan_10\JJ\2712393|NONE_0 (l_appos) hctz)-monotherapy_17\NN\0|val_29|(_1 (l_conj) combinations_22\NNS\7951464|and_16 (l_prep) in_23\IN\13603305|dose_18 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) hypertension_27\NN\14057371|NONE_0
C081489_C562386 NONE val_34\NNP\0|8_20|treatment_18|:_2 (r_appos) groups_32\NNS\2137|NONE_0 (r_pobj) to_27\IN\0|patients_120|mean_82|sitting_77|were_16|._120 (r_prep) randomized_26\VBN\278117|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|mean_38|sitting_43|were_104|to_120|._240 (l_prep) with_1\IN\0|NONE_0 (l_pobj) hypertension_3\NN\14057371|NONE_0
C081489_C562386 NONE val_46\NNP\0|/_3|160/12.5_9|,_17|320/12.5_19|;_41|or_43|placebo_46 (r_nmod) hctz_48\NNP\0|160_39|mg_28|;_26|hctz_24|;_6 (r_appos) val_34\NNP\0|8_20|treatment_18|:_2 (r_appos) groups_32\NNS\2137|NONE_0 (r_pobj) to_27\IN\0|patients_120|mean_82|sitting_77|were_16|._120 (r_prep) randomized_26\VBN\278117|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|mean_38|sitting_43|were_104|to_120|._240 (l_prep) with_1\IN\0|NONE_0 (l_pobj) hypertension_3\NN\14057371|NONE_0
D006852_D007008 CID hctz_9\NNP\0|(_18|%_27|)_28 (r_compound) combinations_10\NNS\7951464|NONE_0 (r_pobj) with_6\IN\0|than_39 (r_prep) lower_5\JJR\2831724|incidence_29|._86 (r_acomp) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|lower_29|._115 (l_prep) of_2\IN\0|the_14 (l_pobj) hypokalemia_3\NN\14299637|NONE_0
D006852_D007008 CID hctz_17\NNP\0|(_19|%_29|)_30 (r_compound) monotherapies_18\NNS\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) than_15\IN\0|with_39 (r_prep) lower_5\JJR\2831724|incidence_29|._86 (r_acomp) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|lower_29|._115 (l_prep) of_2\IN\0|the_14 (l_pobj) hypokalemia_3\NN\14299637|NONE_0
D006852_D007008 CID hctz_10\NNP\0|NONE_0 (r_pobj) with_7\IN\0|combination_22 (r_prep) therapies_6\NNS\657604|in_38|,_14|were_24|with_40|,_113|tolerated_125|._193 (r_nsubjpass) associated_12\VBN\628491|NONE_0 (l_conj) tolerated_25\VBN\802318|in_163|,_139|therapies_125|were_101|with_85|,_12|._68 (l_conj) associated_29\VBN\628491|were_30|well_25|,_11|and_9 (l_prep) with_30\IN\0|were_16 (l_pobj) hypokalemia_32\NN\14299637|NONE_0
D006852_D007008 CID hctz_34\NNP\0|NONE_0 (r_pobj) than_33\IN\0|less_17 (r_prep) hypokalemia_32\NN\14299637|NONE_0
D006852_D006973 NONE hydrochlorothiazide_4\JJ\4423288|valsartan_10|combination_20 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) of_1\IN\0|at_53|:_96|study_133|._203 (r_prep) comparison_0\NN\635850|NONE_0 (l_appos) study_24\NN\635850|of_133|at_80|:_37|._70 (l_acl) followed_25\VBN\1835496|a_41|blind_32|,_27|controlled_17 (l_agent) by_26\IN\0|NONE_0 (l_pobj) therapy_31\NN\657604|NONE_0 (l_prep) in_32\IN\13603305|term_25|combination_20 (l_pobj) adults_34\NNS\7846|NONE_0 (l_amod) hypertensive_33\JJ\10405694|NONE_0
C081489_D007008 NONE val_7\NNP\0|/_3 (r_nmod) hctz_9\NNP\0|(_18|%_27|)_28 (r_compound) combinations_10\NNS\7951464|NONE_0 (r_pobj) with_6\IN\0|than_39 (r_prep) lower_5\JJR\2831724|incidence_29|._86 (r_acomp) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|lower_29|._115 (l_prep) of_2\IN\0|the_14 (l_pobj) hypokalemia_3\NN\14299637|NONE_0
C081489_D007008 NONE val_8\NNP\0|/_3 (r_nmod) hctz_10\NNP\0|NONE_0 (r_pobj) with_7\IN\0|combination_22 (r_prep) therapies_6\NNS\657604|in_38|,_14|were_24|with_40|,_113|tolerated_125|._193 (r_nsubjpass) associated_12\VBN\628491|NONE_0 (l_conj) tolerated_25\VBN\802318|in_163|,_139|therapies_125|were_101|with_85|,_12|._68 (l_conj) associated_29\VBN\628491|were_30|well_25|,_11|and_9 (l_prep) with_30\IN\0|were_16 (l_pobj) hypokalemia_32\NN\14299637|NONE_0
D006852_C562386 NONE hydrochlorothiazide_15\NN\4423288|(_9|)_5|or_3 (r_conj) val_12\NNP\0|(_28|hctz)-monotherapy_29 (r_appos) valsartan_10\JJ\2712393|NONE_0 (l_appos) hctz)-monotherapy_17\NN\0|val_29|(_1 (l_conj) combinations_22\NNS\7951464|and_16 (l_prep) in_23\IN\13603305|dose_18 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) hypertension_27\NN\14057371|NONE_0
D006852_C562386 NONE hctz)-monotherapy_17\NN\0|val_29|(_1 (l_conj) combinations_22\NNS\7951464|and_16 (l_prep) in_23\IN\13603305|dose_18 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) hypertension_27\NN\14057371|NONE_0
D006852_C562386 NONE hctz_40\NNP\0|160_15|mg_4|;_2|;_18|hctz_24 (r_appos) val_34\NNP\0|8_20|treatment_18|:_2 (r_appos) groups_32\NNS\2137|NONE_0 (r_pobj) to_27\IN\0|patients_120|mean_82|sitting_77|were_16|._120 (r_prep) randomized_26\VBN\278117|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|mean_38|sitting_43|were_104|to_120|._240 (l_prep) with_1\IN\0|NONE_0 (l_pobj) hypertension_3\NN\14057371|NONE_0
D006852_C562386 NONE hctz_48\NNP\0|160_39|mg_28|;_26|hctz_24|;_6 (r_appos) val_34\NNP\0|8_20|treatment_18|:_2 (r_appos) groups_32\NNS\2137|NONE_0 (r_pobj) to_27\IN\0|patients_120|mean_82|sitting_77|were_16|._120 (r_prep) randomized_26\VBN\278117|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|mean_38|sitting_43|were_104|to_120|._240 (l_prep) with_1\IN\0|NONE_0 (l_pobj) hypertension_3\NN\14057371|NONE_0
24068571
D015742_D003693 NONE propofol_19\NN\0|NONE_0 (r_pcomp) to_18\IN\0|df_51 (r_prep) compared_17\VBN\644583|use_92|was_73|significantly_69|with_44|._84 (r_prep) associated_6\VBN\628491|NONE_0 (l_prep) with_7\IN\0|use_48|was_29|significantly_25|compared_44|._128 (l_pobj) risk_14\NN\14541044|NONE_0 (l_prep) for_15\IN\0|an_26|higher_12 (l_pobj) delirium_16\NN\14391660|NONE_0
D013874_D003693 CID thiopentone_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_8 (r_prep) use_1\NN\407535|was_19|significantly_23|with_48|compared_92|._176 (r_nsubjpass) associated_6\VBN\628491|NONE_0 (l_prep) with_7\IN\0|use_48|was_29|significantly_25|compared_44|._128 (l_pobj) risk_14\NN\14541044|NONE_0 (l_prep) for_15\IN\0|an_26|higher_12 (l_pobj) delirium_16\NN\14391660|NONE_0
10933650
C059765_D007683 CID amb_11\VBN\0|-_3 (r_dep) treated_13\VBN\2376958|d_6 (r_amod) rats_14\NNS\2329401|NONE_0 (r_pobj) in_8\IN\13603305|tubular_17 (r_prep) necrosis_7\NN\11444117|examination_41|but_31|change_38|._67
D000666_D064420 NONE b_7\NN\1355326|nanosphere_38 (r_dobj) incorporating_5\VBG\1461328|a_19 (r_acl) lipid_3\NN\14944888|ns-718_10|,_4|,_45|effective_50|and_85|has_89|._105 (r_nsubj) is_9\VBZ\0|NONE_0 (l_conj) has_15\VBZ\13888491|ns-718_99|,_93|lipid_89|,_44|effective_39|and_4|._16 (l_dobj) toxicity_17\NN\13576101|NONE_0
D000666_D064420 NONE fungizone_9\NNP\0|(_10|sodium_26 (r_nmod) deoxycholate_15\NN\0|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) that_7\DT\0|ns-718_12 (r_pobj) with_6\IN\0|NONE_0 (r_punct) ;_16\:\0|amb_4|cultures_35|and_44|in_48|by_56|following_163 (r_punct) using_23\VBG\418025|we_111|toxicity_95|._202 (r_advcl) compared_1\VBD\644583|NONE_0 (l_dobj) toxicity_3\NN\13576101|we_16|using_95|._297
D000666_D064420 NONE b_44\NNP\1355326|NONE_0 (r_pobj) of_42\IN\0|pharmacokinetic_22 (r_prep) study_41\NN\635850|the_31|and_20 (r_conj) kidney_38\NN\5333259|NONE_0 (r_pobj) of_36\IN\0|histopathological_24 (r_prep) study_35\NN\635850|biochemical_40|,_20 (r_appos) analysis_32\NN\633864|NONE_0 (r_pobj) by_30\IN\0|;_56|amb_52|cultures_21|and_12|in_8|following_107 (r_prep) using_23\VBG\418025|we_111|toxicity_95|._202 (r_advcl) compared_1\VBD\644583|NONE_0 (l_dobj) toxicity_3\NN\13576101|we_16|using_95|._297
C059765_D064420 NONE deoxycholate_15\NN\0|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) that_7\DT\0|ns-718_12 (r_pobj) with_6\IN\0|NONE_0 (r_punct) ;_16\:\0|amb_4|cultures_35|and_44|in_48|by_56|following_163 (r_punct) using_23\VBG\418025|we_111|toxicity_95|._202 (r_advcl) compared_1\VBD\644583|NONE_0 (l_dobj) toxicity_3\NN\13576101|we_16|using_95|._297
C059765_D064420 NONE amb_19\NNP\0|;_4|cultures_31|and_40|in_44|by_52|following_159 (r_nsubj) using_23\VBG\418025|we_111|toxicity_95|._202 (r_advcl) compared_1\VBD\644583|NONE_0 (l_dobj) toxicity_3\NN\13576101|we_16|using_95|._297
D000666_D007674 NONE b._13\NNP\0|of_82|by_64 (r_appos) attenuation_0\NN\7427337|NONE_0 (l_prep) of_1\IN\0|by_18|b._82 (l_pobj) nephrotoxicity_2\NN\0|NONE_0
D000666_D007674 NONE b_12\NNP\1355326|NONE_0 (r_pobj) of_10\IN\0|into_18 (r_prep) incorporation_9\NN\1237415|that_5|ns-718_58|nephrotoxicity_80 (r_nsubj) attenuates_18\VBZ\224901|in_107 (l_dobj) nephrotoxicity_20\NN\0|that_85|incorporation_80|ns-718_22
D000666_D007674 NONE b._23\NNP\0|NONE_0 (r_pobj) of_21\IN\0|the_19 (r_prep) nephrotoxicity_20\NN\0|that_85|incorporation_80|ns-718_22
9881641
D019806_D007022 CID levcromakalim_14\RB\0|-_13 (r_npadvmod) produced_16\VBN\1617192|a_16|in_18 (r_amod) decrease_17\NN\7296428|which_41 (r_dobj) abolished_12\VBD\0|,_8 (r_relcl) glibenclamide_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|hypotension_66|was_29|significantly_25|._94 (r_agent) attenuated_7\VBN\224901|NONE_0 (l_nsubjpass) hypotension_0\NN\14057371|was_37|significantly_41|by_66|._160
C040442_D007022 CID helodermin_6\NN\0|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) produced_4\VBN\1617192|sensitive_22|._42 (r_acl) hypotension_3\NN\14057371|NONE_0
C040442_D007022 CID helodermin_0\NNP\0|hypotension_20|._113 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) hypotension_2\NN\14057371|helodermin_20|._93
C040442_D007022 CID helodermin_4\NN\0|-_10 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypotension_7\NN\14057371|oxyhemoglobin_48|did_34|not_30|,_11|shortened_24|._90
C040442_D007022 CID helodermin_4\NN\0|-_10 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypotension_7\NN\14057371|oxyhemoglobin_48|did_34|not_30|,_11|shortened_24|._90 (r_dobj) affect_3\VB\26192|NONE_0 (l_advcl) shortened_11\VBD\429060|oxyhemoglobin_72|did_58|not_54|hypotension_24|,_13|._66 (l_dobj) duration_13\NN\15113229|whereas_25|it_17 (l_prep) of_14\IN\0|the_13 (l_pobj) acetylcholine_15\NN\14807558|NONE_0 (l_appos) hypotension_18\NN\14057371|NONE_0
C040442_D007022 CID helodermin_4\NN\0|-_10 (r_npadvmod) produced_6\VBN\1617192|NONE_0 (r_amod) hypotension_7\NN\14057371|that_25|attributable_22
D011188_D007022 NONE k+_18\NNP\0|sensitive_10|channels_20|,_29|exist_48 (r_amod) channels_19\NNS\6251781|NONE_0 (r_pobj) of_14\IN\0|the_15 (r_prep) activation_13\NN\13561719|NONE_0 (r_pobj) to_11\IN\0|partly_20 (r_prep) attributable_10\JJ\0|that_47|hypotension_22 (r_acomp) is_8\VBZ\0|findings_54|._153 (l_nsubj) hypotension_7\NN\14057371|that_25|attributable_22
D011188_D007022 NONE k(atp_21\NNP\0|(_1|)_5|)_15 (r_nmod) channels_23\NNS\6251781|sensitive_30|k+_20|,_9|exist_28 (r_appos) channels_19\NNS\6251781|NONE_0 (r_pobj) of_14\IN\0|the_15 (r_prep) activation_13\NN\13561719|NONE_0 (r_pobj) to_11\IN\0|partly_20 (r_prep) attributable_10\JJ\0|that_47|hypotension_22 (r_acomp) is_8\VBZ\0|findings_54|._153 (l_nsubj) hypotension_7\NN\14057371|that_25|attributable_22
D005905_D007022 NONE glibenclamide_0\NN\0|-_13 (r_npadvmod) sensitive_2\JJ\10488309|produced_22|._64 (r_amod) hypotension_3\NN\14057371|NONE_0
D005905_D007022 NONE glibenclamide_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|hypotension_66|was_29|significantly_25|._94 (r_agent) attenuated_7\VBN\224901|NONE_0 (l_nsubjpass) hypotension_0\NN\14057371|was_37|significantly_41|by_66|._160
D005905_D007022 NONE glibenclamide_15\NN\0|-_13 (r_npadvmod) sensitive_17\JJ\10488309|k+_10|channels_30|,_39|exist_58 (r_amod) channels_19\NNS\6251781|NONE_0 (r_pobj) of_14\IN\0|the_15 (r_prep) activation_13\NN\13561719|NONE_0 (r_pobj) to_11\IN\0|partly_20 (r_prep) attributable_10\JJ\0|that_47|hypotension_22 (r_acomp) is_8\VBZ\0|findings_54|._153 (l_nsubj) hypotension_7\NN\14057371|that_25|attributable_22
D000109_D007022 CID acetylcholine_15\NN\14807558|NONE_0 (r_pobj) of_14\IN\0|the_13 (r_prep) duration_13\NN\15113229|whereas_25|it_17 (r_dobj) shortened_11\VBD\429060|oxyhemoglobin_72|did_58|not_54|hypotension_24|,_13|._66 (r_advcl) affect_3\VB\26192|NONE_0 (l_dobj) hypotension_7\NN\14057371|oxyhemoglobin_48|did_34|not_30|,_11|shortened_24|._90
D000109_D007022 CID acetylcholine_15\NN\14807558|NONE_0 (l_appos) hypotension_18\NN\14057371|NONE_0
D000109_D007022 CID ach)-produced_17\JJ\0|(_1 (r_amod) hypotension_18\NN\14057371|NONE_0 (r_appos) acetylcholine_15\NN\14807558|NONE_0 (r_pobj) of_14\IN\0|the_13 (r_prep) duration_13\NN\15113229|whereas_25|it_17 (r_dobj) shortened_11\VBD\429060|oxyhemoglobin_72|did_58|not_54|hypotension_24|,_13|._66 (r_advcl) affect_3\VB\26192|NONE_0 (l_dobj) hypotension_7\NN\14057371|oxyhemoglobin_48|did_34|not_30|,_11|shortened_24|._90
D000109_D007022 CID ach)-produced_17\JJ\0|(_1 (r_amod) hypotension_18\NN\14057371|NONE_0
D009569_D007022 NONE oxide_7\NN\14818238|NONE_0 (r_dobj) relaxing_5\VBG\146138|endothelium_20|-_9 (r_xcomp) derived_4\VBN\634472|(_13 (r_acl) edrf_0\NN\0|does_56|not_61|play_73|._131 (r_nsubj) seem_10\VB\2604760|NONE_0 (l_xcomp) play_12\VB\7007684|edrf_73|does_17|not_12|._58 (l_dobj) role_15\NN\719494|to_21 (l_prep) in_16\IN\13603305|an_18|important_15 (l_pobj) hypotension_21\NN\14057371|NONE_0
D000255_D007022 NONE k(atp_21\NNP\0|(_1|)_5|)_15 (r_nmod) channels_23\NNS\6251781|sensitive_30|k+_20|,_9|exist_28 (r_appos) channels_19\NNS\6251781|NONE_0 (r_pobj) of_14\IN\0|the_15 (r_prep) activation_13\NN\13561719|NONE_0 (r_pobj) to_11\IN\0|partly_20 (r_prep) attributable_10\JJ\0|that_47|hypotension_22 (r_acomp) is_8\VBZ\0|findings_54|._153 (l_nsubj) hypotension_7\NN\14057371|that_25|attributable_22
1158089
D013752_D003866 NONE tetracycline_23\NN\2716205|NONE_0 (r_pobj) of_22\IN\0|and_16|accumulation_25 (r_prep) dose_21\NN\3740161|NONE_0 (l_conj) accumulation_26\NN\13497135|of_25|and_9 (l_prep) of_27\IN\0|both_18|by_70 (l_pobj) triglyceride_28\NN\14885088|NONE_0 (l_prep) in_29\IN\13603305|NONE_0 (l_pobj) liver_31\NN\5298729|NONE_0 (l_conj) depression_33\NN\14373582|the_14|and_4|of_11
D013752_D003866 NONE tetracycline_19\NN\2716205|NONE_0 (r_pobj) of_18\IN\0|the_12|on_16 (r_prep) effects_17\NNS\13245626|NONE_0 (l_prep) on_20\IN\0|the_28|of_16 (l_pobj) depression_21\NN\14373582|NONE_0
D019301_D003866 NONE acid_5\NN\14818238|NONE_0 (r_pobj) of_2\IN\0|as_23 (r_prep) provision_1\NN\6755568|NONE_0 (r_pobj) with_0\IN\0|,_84|relationship_95|was_108|between_121|._277 (r_prep) observed_19\VBN\2163746|NONE_0 (l_prep) between_20\IN\0|with_121|,_37|relationship_26|was_13|._156 (l_pobj) dose_21\NN\3740161|NONE_0 (l_conj) accumulation_26\NN\13497135|of_25|and_9 (l_prep) of_27\IN\0|both_18|by_70 (l_pobj) triglyceride_28\NN\14885088|NONE_0 (l_prep) in_29\IN\13603305|NONE_0 (l_pobj) liver_31\NN\5298729|NONE_0 (l_conj) depression_33\NN\14373582|the_14|and_4|of_11
D013752_D005234 CID tetracycline_4\NN\2716205|NONE_0 (r_pobj) by_3\IN\0|in_16 (r_agent) induced_2\VBN\1627355|fatty_12|._34 (r_acl) liver_1\NN\5298729|NONE_0
D013752_D005234 CID tetracycline_18\NN\2716205|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|response_100|,_78|mechanisms_64 (r_acl) relationships_3\NNS\31921|were_115|in_128|._195 (l_conj) mechanisms_6\NNS\13446390|response_36|,_14|induced_64 (l_conj) differences_10\NNS\4723816|biochemical_32|,_10|and_8 (l_prep) in_11\IN\13603305|sex_16 (l_pobj) liver_15\NN\5298729|NONE_0
D013752_D005234 CID tetracycline_37\NN\2716205|NONE_0 (r_pobj) to_36\IN\0|NONE_0 (r_prep) response_35\NN\11410625|NONE_0 (r_pobj) in_34\IN\13603305|the_52|of_37 (r_prep) production_26\NN\30358|NONE_0 (l_prep) of_27\IN\0|the_15|in_37 (l_pobj) liver_33\NN\5298729|NONE_0
D014280_D005234 NONE triglyceride_4\NN\14885088|NONE_0 (r_pobj) of_3\IN\0|depressed_28|hepatic_18 (r_prep) secretion_2\NN\13526110|%_53|,_90|indicating_92|._229 (r_nsubj) accounted_5\VBD\2604760|NONE_0 (l_advcl) indicating_17\VBG\952524|secretion_92|%_39|,_2|._137 (l_ccomp) involved_23\VBN\2676054|NONE_0 (l_prep) in_24\IN\13603305|that_44|mechanisms_28|must_17|be_12 (l_pobj) production_26\NN\30358|NONE_0 (l_prep) of_27\IN\0|the_15|in_37 (l_pobj) liver_33\NN\5298729|NONE_0
D014280_D005234 NONE triglyceride_15\NN\14885088|NONE_0 (r_pobj) of_12\IN\0|50_4 (r_prep) %_11\NN\0|secretion_53|,_37|indicating_39|._176 (r_dobj) accounted_5\VBD\2604760|NONE_0 (l_advcl) indicating_17\VBG\952524|secretion_92|%_39|,_2|._137 (l_ccomp) involved_23\VBN\2676054|NONE_0 (l_prep) in_24\IN\13603305|that_44|mechanisms_28|must_17|be_12 (l_pobj) production_26\NN\30358|NONE_0 (l_prep) of_27\IN\0|the_15|in_37 (l_pobj) liver_33\NN\5298729|NONE_0
D014280_D005234 NONE triglyceride_29\NN\14885088|-_12 (r_npadvmod) rich_31\JJ\7942152|the_17|fatty_5 (r_amod) liver_33\NN\5298729|NONE_0
D014280_D003866 NONE triglyceride_28\NN\14885088|NONE_0 (l_prep) in_29\IN\13603305|NONE_0 (l_pobj) liver_31\NN\5298729|NONE_0 (l_conj) depression_33\NN\14373582|the_14|and_4|of_11
D014280_D003866 NONE triglyceride_37\NN\14885088|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) output_35\NN\4007894|NONE_0 (r_pobj) of_34\IN\0|the_25|and_15|depression_11 (r_prep) liver_31\NN\5298729|NONE_0 (l_conj) depression_33\NN\14373582|the_14|and_4|of_11
D014280_D003866 NONE triglyceride_25\NN\14885088|NONE_0 (r_pobj) of_24\IN\0|NONE_0 (r_prep) output_23\NN\4007894|NONE_0 (r_pobj) of_22\IN\0|under_26 (r_prep) depression_21\NN\14373582|NONE_0
1289188
D003676_D058186 NONE desferrioxamine_6\NN\0|intravenous_12 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) during_4\IN\0|NONE_0 (r_prep) occurring_3\VBG\0|acute_20|renal_14|:_52|recovery_54|._82 (r_acl) failure_2\NN\66216|NONE_0
D003676_D058186 NONE desferrioxamine_24\NN\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) caused_22\VBN\1617192|progressive_32|acute_20|renal_14 (r_acl) failure_21\NN\66216|NONE_0
D003676_D013789 NONE desferrioxamine_11\NN\0|patient_79|was_32|because_71|._139 (r_dobj) undergoing_8\VBG\109660|NONE_0 (l_nsubj) patient_1\NN\9898892|was_47|desferrioxamine_79|because_150|._218 (l_prep) with_2\IN\0|a_10 (l_pobj) thalassemia_6\NN\14165544|NONE_0
D003676_D013789 NONE dfx_13\NNP\0|(_1|)_3|by_15 (r_nmod) treatment_15\NN\654885|home_39|intravenous_34 (r_appos) desferrioxamine_11\NN\0|patient_79|was_32|because_71|._139 (r_dobj) undergoing_8\VBG\109660|NONE_0 (l_nsubj) patient_1\NN\9898892|was_47|desferrioxamine_79|because_150|._218 (l_prep) with_2\IN\0|a_10 (l_pobj) thalassemia_6\NN\14165544|NONE_0
24309294
D012844_D000647 NONE cck-8_5\NNP\0|that_5|significantly_6|amnesia_48|and_56|reversed_60|decreases_83 (r_punct) alleviated_7\VBN\205885|we_53|have_50|previously_45|._137 (l_dobj) amnesia_11\NN\5669934|that_53|cck-8_48|significantly_42|and_8|reversed_12|decreases_35
D009020_D000647 CID morphine_8\NN\2707683|-_8 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) amnesia_11\NN\5669934|that_53|cck-8_48|significantly_42|and_8|reversed_12|decreases_35
D009020_D000647 CID morphine_25\NN\2707683|-_8 (r_npadvmod) treated_27\VBN\2376958|NONE_0 (r_amod) animals_28\NNS\4475|NONE_0 (r_pobj) in_24\IN\13603305|the_34|ca1_30|of_19 (r_prep) region_20\NN\27167|NONE_0 (r_pobj) in_17\IN\13603305|NONE_0 (r_prep) decreases_16\VBZ\7296428|that_88|cck-8_83|significantly_77|amnesia_35|and_27|reversed_23 (r_conj) alleviated_7\VBN\205885|we_53|have_50|previously_45|._137 (l_dobj) amnesia_11\NN\5669934|that_53|cck-8_48|significantly_42|and_8|reversed_12|decreases_35
D009020_D008569 NONE morphine_10\NN\2707683|NONE_0 (r_pobj) of_9\IN\0|the_11|on_12|through_31 (r_prep) effect_8\NN\34213|that_26|cck-8_21|and_61|suggest_65 (r_dobj) attenuates_6\VBZ\224901|results_31|._159 (l_conj) suggest_18\VBP\1010118|that_91|cck-8_86|effect_65|and_4 (l_dobj) function_21\NN\13783581|NONE_0 (l_prep) on_24\IN\0|an_34|ameliorative_31|of_9 (l_pobj) impairment_29\NN\7296428|cck-8_33
D009020_D008569 NONE morphine_25\NN\2707683|-_8 (r_npadvmod) induced_27\VBN\1627355|memory_8 (r_amod) impairment_29\NN\7296428|cck-8_33
D012844_D008569 NONE cck-8_5\NNP\0|that_5|effect_21|and_82|suggest_86 (r_nsubj) attenuates_6\VBZ\224901|results_31|._159 (l_conj) suggest_18\VBP\1010118|that_91|cck-8_86|effect_65|and_4 (l_dobj) function_21\NN\13783581|NONE_0 (l_prep) on_24\IN\0|an_34|ameliorative_31|of_9 (l_pobj) impairment_29\NN\7296428|cck-8_33
D012844_D008569 NONE cck-8_23\NNP\0|impairment_33 (r_punct) on_24\IN\0|an_34|ameliorative_31|of_9 (l_pobj) impairment_29\NN\7296428|cck-8_33
15630069
D018967_D011618 NONE risperidone_25\NN\0|,_5|or_3 (r_conj) olanzapine_22\NN\0|either_18|,_2 (r_conj) clozapine_20\NN\3713736|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|by_23|and_4 (r_conj) matched_11\VBN\2664769|six_70|nonobese_66|with_48|,_2|,_88 (r_acl) subjects_4\NNS\6598915|were_147|in_161|._176 (l_prep) with_5\IN\0|six_22|nonobese_18|,_46|matched_48|,_136 (l_pobj) schizophrenia_6\NN\14398067|NONE_0 (l_conj) disorder_9\NN\14034177|or_19
D003024_D012559 NONE clozapine_20\NN\3713736|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|by_23|and_4 (r_conj) matched_11\VBN\2664769|six_70|nonobese_66|with_48|,_2|,_88 (r_acl) subjects_4\NNS\6598915|were_147|in_161|._176 (l_prep) with_5\IN\0|six_22|nonobese_18|,_46|matched_48|,_136 (l_pobj) schizophrenia_6\NN\14398067|NONE_0
D005947_D012559 NONE glucose_0\NN\14710501|in_19|:_92|test_145|._176 (r_nsubj) metabolism_1\NN\13526110|NONE_0 (l_prep) in_2\IN\13603305|glucose_19|:_73|test_126|._157 (l_pobj) patients_3\NNS\9898892|NONE_0 (l_prep) with_4\IN\0|NONE_0 (l_pobj) schizophrenia_5\NN\14398067|NONE_0
D005947_D012559 NONE glucose_16\NN\14710501|NONE_0 (r_compound) tolerance_17\NN\5032565|a_41|sampled_28|intravenous_20|and_15|analysis_33 (r_compound) test_18\NN\5798043|glucose_145|in_126|:_53|._31 (r_appos) metabolism_1\NN\13526110|NONE_0 (l_prep) in_2\IN\13603305|glucose_19|:_73|test_126|._157 (l_pobj) patients_3\NNS\9898892|NONE_0 (l_prep) with_4\IN\0|NONE_0 (l_pobj) schizophrenia_5\NN\14398067|NONE_0
D005947_D012559 NONE glucose_32\NN\14710501|NONE_0 (r_compound) metabolism_33\NN\13526110|whether_55|agents_38|are_31|directly_27|or_11|increasing_21 (r_dobj) affecting_31\VBG\126264|increasing_150|,_58|it_56|unclear_45|._81 (r_ccomp) remains_24\VBZ\2684|NONE_0 (l_advcl) increasing_11\VBG\169651|,_92|it_94|unclear_105|affecting_150|._231 (l_prep) in_12\IN\13603305|while_69|incidence_59|may_18|be_14 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) schizophrenia_15\NN\14398067|NONE_0
D005947_D012559 NONE glucose_18\NN\14710501|NONE_0 (r_compound) tolerance_19\NN\5032565|a_41|sampled_28|intravenous_20|and_15|analysis_45 (r_compound) test_20\NN\5798043|NONE_0 (r_dobj) using_13\VBG\418025|NONE_0 (r_advcl) evaluated_12\VBD\670261|NONE_0 (r_acl) schizophrenia_11\NN\14398067|NONE_0
C076029_D012559 NONE olanzapine_22\NN\0|either_18|,_2 (r_conj) clozapine_20\NN\3713736|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|by_23|and_4 (r_conj) matched_11\VBN\2664769|six_70|nonobese_66|with_48|,_2|,_88 (r_acl) subjects_4\NNS\6598915|were_147|in_161|._176 (l_prep) with_5\IN\0|six_22|nonobese_18|,_46|matched_48|,_136 (l_pobj) schizophrenia_6\NN\14398067|NONE_0
D003024_D007333 CID clozapine_20\NN\3713736|(_1|<_9|olanzapine_10|<_20|)_32 (r_nmod) risperidone_24\NNP\0|)_24|,_12|with_14 (r_appos) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (r_appos) was_1\VBD\0|NONE_0 (l_attr) difference_4\NN\4723816|there_24|;_67|p<.001_69|=_297 (l_prep) in_5\IN\13603305|a_25|significant_23|among_29 (l_pobj) index_8\NN\13850304|NONE_0 (l_compound) sensitivity_7\NN\5651971|NONE_0
D003024_D007333 CID clozapine_20\NN\3713736|(_1|<_9|olanzapine_10|<_20|)_32 (r_nmod) risperidone_24\NNP\0|)_24|,_12|with_14 (r_appos) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (l_prep) with_27\IN\0|)_38|risperidone_14|,_2 (l_pobj) subjects_28\NNS\6598915|NONE_0 (l_acl) exhibiting_34\VBG\2632167|received_34 (l_dobj) resistance_37\NN\37396|compared_11
D003024_D007333 CID clozapine_31\NN\3713736|who_13 (r_dobj) received_30\VBD\2210855|exhibiting_34 (r_relcl) subjects_28\NNS\6598915|NONE_0 (r_pobj) with_27\IN\0|)_38|risperidone_14|,_2 (r_prep) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (r_appos) was_1\VBD\0|NONE_0 (l_attr) difference_4\NN\4723816|there_24|;_67|p<.001_69|=_297 (l_prep) in_5\IN\13603305|a_25|significant_23|among_29 (l_pobj) index_8\NN\13850304|NONE_0 (l_compound) sensitivity_7\NN\5651971|NONE_0
D003024_D007333 CID clozapine_31\NN\3713736|who_13 (r_dobj) received_30\VBD\2210855|exhibiting_34 (r_relcl) subjects_28\NNS\6598915|NONE_0 (l_acl) exhibiting_34\VBG\2632167|received_34 (l_dobj) resistance_37\NN\37396|compared_11
D003024_D007333 CID clozapine_47\NN\3713736|NONE_0 (r_appos) risperidone_45\NN\0|NONE_0 (r_pobj) with_44\IN\0|who_17|were_13 (r_prep) treated_43\VBN\2376958|NONE_0 (r_relcl) subjects_40\NNS\6598915|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) compared_38\VBN\644583|resistance_11 (r_prep) exhibiting_34\VBG\2632167|received_34 (r_acl) subjects_28\NNS\6598915|NONE_0 (r_pobj) with_27\IN\0|)_38|risperidone_14|,_2 (r_prep) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (r_appos) was_1\VBD\0|NONE_0 (l_attr) difference_4\NN\4723816|there_24|;_67|p<.001_69|=_297 (l_prep) in_5\IN\13603305|a_25|significant_23|among_29 (l_pobj) index_8\NN\13850304|NONE_0 (l_compound) sensitivity_7\NN\5651971|NONE_0
D003024_D007333 CID clozapine_47\NN\3713736|NONE_0 (r_appos) risperidone_45\NN\0|NONE_0 (r_pobj) with_44\IN\0|who_17|were_13 (r_prep) treated_43\VBN\2376958|NONE_0 (r_relcl) subjects_40\NNS\6598915|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) compared_38\VBN\644583|resistance_11 (r_prep) exhibiting_34\VBG\2632167|received_34 (l_dobj) resistance_37\NN\37396|compared_11
D003024_D007333 CID clozapine-_2\NN\0|treated_26 (r_nmod) groups_7\NNS\2137|resistance_37|compared_88|._130 (r_nsubj) displayed_8\VBD\2137132|NONE_0 (l_dobj) resistance_11\NN\37396|groups_37|compared_51|._93
D003024_D007333 CID clozapine_2\NN\3713736|and_10|olanzapine_14 (r_dobj) taking_1\VBG\37396|NONE_0 (r_acl) patients_0\NNS\9898892|must_41|be_46|for_58|._101 (r_nsubjpass) examined_7\VBN\0|NONE_0 (l_prep) for_8\IN\0|patients_58|must_17|be_12|._43 (l_pobj) resistance_10\NN\37396|NONE_0
C076029_D007333 CID olanzapine_22\RB\0|(_11|clozapine_10|<_1|<_10|)_22 (r_nmod) risperidone_24\NNP\0|)_24|,_12|with_14 (r_appos) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (r_appos) was_1\VBD\0|NONE_0 (l_attr) difference_4\NN\4723816|there_24|;_67|p<.001_69|=_297 (l_prep) in_5\IN\13603305|a_25|significant_23|among_29 (l_pobj) index_8\NN\13850304|NONE_0 (l_compound) sensitivity_7\NN\5651971|NONE_0
C076029_D007333 CID olanzapine_22\RB\0|(_11|clozapine_10|<_1|<_10|)_22 (r_nmod) risperidone_24\NNP\0|)_24|,_12|with_14 (r_appos) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (l_prep) with_27\IN\0|)_38|risperidone_14|,_2 (l_pobj) subjects_28\NNS\6598915|NONE_0 (l_acl) exhibiting_34\VBG\2632167|received_34 (l_dobj) resistance_37\NN\37396|compared_11
C076029_D007333 CID olanzapine_33\RB\0|and_4 (r_conj) clozapine_31\NN\3713736|who_13 (r_dobj) received_30\VBD\2210855|exhibiting_34 (r_relcl) subjects_28\NNS\6598915|NONE_0 (r_pobj) with_27\IN\0|)_38|risperidone_14|,_2 (r_prep) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (r_appos) was_1\VBD\0|NONE_0 (l_attr) difference_4\NN\4723816|there_24|;_67|p<.001_69|=_297 (l_prep) in_5\IN\13603305|a_25|significant_23|among_29 (l_pobj) index_8\NN\13850304|NONE_0 (l_compound) sensitivity_7\NN\5651971|NONE_0
C076029_D007333 CID olanzapine_33\RB\0|and_4 (r_conj) clozapine_31\NN\3713736|who_13 (r_dobj) received_30\VBD\2210855|exhibiting_34 (r_relcl) subjects_28\NNS\6598915|NONE_0 (l_acl) exhibiting_34\VBG\2632167|received_34 (l_dobj) resistance_37\NN\37396|compared_11
C076029_D007333 CID olanzapine_4\RB\0|-_10 (r_npadvmod) treated_6\VBN\2376958|clozapine-_26 (r_amod) groups_7\NNS\2137|resistance_37|compared_88|._130 (r_nsubj) displayed_8\VBD\2137132|NONE_0 (l_dobj) resistance_11\NN\37396|groups_37|compared_51|._93
C076029_D007333 CID olanzapine_4\NN\0|clozapine_14|and_4 (r_conj) taking_1\VBG\37396|NONE_0 (r_acl) patients_0\NNS\9898892|must_41|be_46|for_58|._101 (r_nsubjpass) examined_7\VBN\0|NONE_0 (l_prep) for_8\IN\0|patients_58|must_17|be_12|._43 (l_pobj) resistance_10\NN\37396|NONE_0
D005947_D007333 NONE glucose_6\NN\14710501|and_8|fasting_12|,_40|index_62 (r_dobj) fasting_4\VBG\1068773|main_23|outcome_18|:_2|._161 (l_conj) index_15\NN\13850304|glucose_62|and_54|fasting_50|,_22 (l_compound) sensitivity_14\NN\5651971|,_17|assessment_37
D005947_D007333 NONE glucose_6\NN\14710501|and_8|fasting_12|,_40|index_62 (r_dobj) fasting_4\VBG\1068773|main_23|outcome_18|:_2|._161 (l_conj) index_15\NN\13850304|glucose_62|and_54|fasting_50|,_22 (l_conj) assessment_19\NN\5732756|sensitivity_37|,_20 (l_prep) of_20\IN\0|model_17|,_21|and_23|effectiveness_35 (l_pobj) resistance_22\NN\37396|NONE_0
D005947_D007333 NONE glucose_25\NN\14710501|NONE_0 (r_compound) effectiveness_26\NN\5190804|model_52|of_35|,_14|and_12 (r_conj) assessment_19\NN\5732756|sensitivity_37|,_20 (r_conj) index_15\NN\13850304|glucose_62|and_54|fasting_50|,_22 (l_compound) sensitivity_14\NN\5651971|,_17|assessment_37
D005947_D007333 NONE glucose_25\NN\14710501|NONE_0 (r_compound) effectiveness_26\NN\5190804|model_52|of_35|,_14|and_12 (r_conj) assessment_19\NN\5732756|sensitivity_37|,_20 (l_prep) of_20\IN\0|model_17|,_21|and_23|effectiveness_35 (l_pobj) resistance_22\NN\37396|NONE_0
D005947_D007333 NONE glucose_15\NN\14710501|NONE_0 (r_compound) effectiveness_16\NN\5190804|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) impairment_13\NN\7296428|significant_35|insulin_23|and_4 (r_conj) resistance_11\NN\37396|groups_37|compared_51|._93
D018967_D012559 NONE risperidone_25\NN\0|,_5|or_3 (r_conj) olanzapine_22\NN\0|either_18|,_2 (r_conj) clozapine_20\NN\3713736|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|by_23|and_4 (r_conj) matched_11\VBN\2664769|six_70|nonobese_66|with_48|,_2|,_88 (r_acl) subjects_4\NNS\6598915|were_147|in_161|._176 (l_prep) with_5\IN\0|six_22|nonobese_18|,_46|matched_48|,_136 (l_pobj) schizophrenia_6\NN\14398067|NONE_0
D005947_D003920 NONE glucose_32\NN\14710501|NONE_0 (r_compound) metabolism_33\NN\13526110|whether_55|agents_38|are_31|directly_27|or_11|increasing_21 (r_dobj) affecting_31\VBG\126264|increasing_150|,_58|it_56|unclear_45|._81 (r_ccomp) remains_24\VBZ\2684|NONE_0 (l_advcl) increasing_11\VBG\169651|,_92|it_94|unclear_105|affecting_150|._231 (l_nsubj) incidence_2\NN\13821570|while_10|may_41|be_45|in_59 (l_prep) of_3\IN\0|the_14 (l_pobj) mellitus_8\NN\0|NONE_0
D005947_D003920 NONE glucose_32\NN\14710501|NONE_0 (r_compound) metabolism_33\NN\13526110|whether_55|agents_38|are_31|directly_27|or_11|increasing_21 (r_dobj) affecting_31\VBG\126264|increasing_150|,_58|it_56|unclear_45|._81 (l_conj) increasing_36\VBG\169651|whether_76|agents_59|are_52|directly_48|metabolism_21|or_10 (l_dobj) factors_39\NNS\7326557|simply_29 (l_prep) for_40\IN\0|known_19|risk_13 (l_pobj) diabetes_41\NNS\14075199|NONE_0
C076029_D011618 NONE olanzapine_22\NN\0|either_18|,_2 (r_conj) clozapine_20\NN\3713736|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|by_23|and_4 (r_conj) matched_11\VBN\2664769|six_70|nonobese_66|with_48|,_2|,_88 (r_acl) subjects_4\NNS\6598915|were_147|in_161|._176 (l_prep) with_5\IN\0|six_22|nonobese_18|,_46|matched_48|,_136 (l_pobj) schizophrenia_6\NN\14398067|NONE_0 (l_conj) disorder_9\NN\14034177|or_19
D018967_D007333 NONE risperidone_24\NNP\0|)_24|,_12|with_14 (r_appos) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (r_appos) was_1\VBD\0|NONE_0 (l_attr) difference_4\NN\4723816|there_24|;_67|p<.001_69|=_297 (l_prep) in_5\IN\13603305|a_25|significant_23|among_29 (l_pobj) index_8\NN\13850304|NONE_0 (l_compound) sensitivity_7\NN\5651971|NONE_0
D018967_D007333 NONE risperidone_24\NNP\0|)_24|,_12|with_14 (r_appos) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (l_prep) with_27\IN\0|)_38|risperidone_14|,_2 (l_pobj) subjects_28\NNS\6598915|NONE_0 (l_acl) exhibiting_34\VBG\2632167|received_34 (l_dobj) resistance_37\NN\37396|compared_11
D018967_D007333 NONE risperidone_45\NN\0|NONE_0 (r_pobj) with_44\IN\0|who_17|were_13 (r_prep) treated_43\VBN\2376958|NONE_0 (r_relcl) subjects_40\NNS\6598915|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) compared_38\VBN\644583|resistance_11 (r_prep) exhibiting_34\VBG\2632167|received_34 (r_acl) subjects_28\NNS\6598915|NONE_0 (r_pobj) with_27\IN\0|)_38|risperidone_14|,_2 (r_prep) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (r_appos) was_1\VBD\0|NONE_0 (l_attr) difference_4\NN\4723816|there_24|;_67|p<.001_69|=_297 (l_prep) in_5\IN\13603305|a_25|significant_23|among_29 (l_pobj) index_8\NN\13850304|NONE_0 (l_compound) sensitivity_7\NN\5651971|NONE_0
D018967_D007333 NONE risperidone_45\NN\0|NONE_0 (r_pobj) with_44\IN\0|who_17|were_13 (r_prep) treated_43\VBN\2376958|NONE_0 (r_relcl) subjects_40\NNS\6598915|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) compared_38\VBN\644583|resistance_11 (r_prep) exhibiting_34\VBG\2632167|received_34 (l_dobj) resistance_37\NN\37396|compared_11
D018967_D007333 NONE risperidone_49\NN\0|NONE_0 (r_pobj) vs_48\IN\13634784|(_11|)_20 (r_prep) clozapine_47\NN\3713736|NONE_0 (r_appos) risperidone_45\NN\0|NONE_0 (r_pobj) with_44\IN\0|who_17|were_13 (r_prep) treated_43\VBN\2376958|NONE_0 (r_relcl) subjects_40\NNS\6598915|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) compared_38\VBN\644583|resistance_11 (r_prep) exhibiting_34\VBG\2632167|received_34 (r_acl) subjects_28\NNS\6598915|NONE_0 (r_pobj) with_27\IN\0|)_38|risperidone_14|,_2 (r_prep) p<.001_17\NNP\0|there_93|difference_69|;_2|=_228 (r_appos) was_1\VBD\0|NONE_0 (l_attr) difference_4\NN\4723816|there_24|;_67|p<.001_69|=_297 (l_prep) in_5\IN\13603305|a_25|significant_23|among_29 (l_pobj) index_8\NN\13850304|NONE_0 (l_compound) sensitivity_7\NN\5651971|NONE_0
D018967_D007333 NONE risperidone_49\NN\0|NONE_0 (r_pobj) vs_48\IN\13634784|(_11|)_20 (r_prep) clozapine_47\NN\3713736|NONE_0 (r_appos) risperidone_45\NN\0|NONE_0 (r_pobj) with_44\IN\0|who_17|were_13 (r_prep) treated_43\VBN\2376958|NONE_0 (r_relcl) subjects_40\NNS\6598915|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) compared_38\VBN\644583|resistance_11 (r_prep) exhibiting_34\VBG\2632167|received_34 (l_dobj) resistance_37\NN\37396|compared_11
D018967_D007333 NONE risperidone_19\NN\0|-_11 (r_npadvmod) treated_21\VBN\2376958|NONE_0 (r_amod) subjects_22\NNS\6598915|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) compared_17\VBN\644583|groups_88|resistance_51|._42 (r_prep) displayed_8\VBD\2137132|NONE_0 (l_dobj) resistance_11\NN\37396|groups_37|compared_51|._93
D003024_D011618 NONE clozapine_20\NN\3713736|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|by_23|and_4 (r_conj) matched_11\VBN\2664769|six_70|nonobese_66|with_48|,_2|,_88 (r_acl) subjects_4\NNS\6598915|were_147|in_161|._176 (l_prep) with_5\IN\0|six_22|nonobese_18|,_46|matched_48|,_136 (l_pobj) schizophrenia_6\NN\14398067|NONE_0 (l_conj) disorder_9\NN\14034177|or_19
19841052
D016578_D006679 CID cocaine_13\NN\3492717|crack_6 (r_pobj) of_11\IN\0|daily_14 (r_prep) smokers_10\NNS\9612848|NONE_0 (r_pobj) among_8\IN\0|hiv_19 (r_prep) seroconversion_7\NN\0|NONE_0
D016578_D006679 CID cocaine_22\NN\3492717|NONE_0 (r_dobj) crack_21\VB\9379111|NONE_0 (r_pcomp) of_20\IN\0|daily_14 (r_prep) smokers_19\NNS\9612848|who_15 (r_attr) were_17\VBD\0|NONE_0 (r_relcl) participants_15\NNS\9816771|NONE_0 (r_pobj) among_14\IN\0|hiv_19 (r_prep) seroconversion_13\NN\0|NONE_0
D016578_D006679 CID cocaine_3\NN\3492717|crack_6 (r_pobj) of_1\IN\0|NONE_0 (r_prep) smoking_0\NN\831191|was_25|be_38|._133 (r_nsubjpass) found_5\VBN\13279262|NONE_0 (l_xcomp) be_7\VB\14625458|smoking_38|was_13|._95 (l_attr) factor_11\NN\7326557|to_26 (l_prep) for_12\IN\0|an_27|independent_24|risk_12 (l_pobj) seroconversion_14\NN\0|NONE_0
D016578_D015658 NONE cocaine_3\NN\3492717|as_8 (r_dobj) crack_2\VB\9379111|NONE_0 (l_prep) as_4\IN\14622893|cocaine_8 (l_pobj) factor_7\NN\7326557|NONE_0 (l_prep) for_8\IN\0|a_14|risk_12 (l_pobj) infection_10\NN\14052046|NONE_0
D016578_D015658 NONE cocaine_10\NN\3492717|that_19|smoking_14 (r_dobj) crack_9\VBP\9379111|the_31|possible_27|has_14 (r_relcl) role_6\NN\719494|NONE_0 (l_acl) has_11\VBZ\13888491|the_45|possible_41|crack_14 (l_prep) on_12\IN\0|NONE_0 (l_pobj) incidence_14\NN\13821570|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) infection_17\NN\14052046|NONE_0
D016578_D015658 NONE cocaine_6\NN\3492717|NONE_0 (r_pobj) of_4\IN\0|the_19|increasing_15 (r_prep) use_3\NN\407535|NONE_0 (r_pobj) given_0\VBN\5892096|,_41|we_43|examine_56|._139 (r_prep) sought_9\VBD\1825237|NONE_0 (l_xcomp) examine_11\VB\0|given_56|,_15|we_13|._83 (l_ccomp) become_19\VBN\146138|to_48 (l_attr) factor_22\NN\7326557|whether_51|use_43|has_18 (l_prep) for_23\IN\0|a_14|risk_12 (l_pobj) infection_25\NN\14052046|NONE_0
851038
D011188_D007008 NONE potassium_11\NN\14625458|NONE_0 (r_pobj) of_10\IN\0|the_20|renal_16 (r_prep) excretion_9\NN\13466586|NONE_0 (r_pobj) on_6\IN\0|l_7|-_6 (r_prep) dopa_5\NN\14601829|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) influence_1\NN\5190804|was_56|in_68|._307 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_prep) in_14\IN\13603305|influence_68|was_12|._239 (l_pobj) patients_16\NNS\9898892|and_26|in_30 (l_prep) with_17\IN\0|3_11 (l_pobj) hypokalemia_18\NN\14299637|NONE_0
D011188_D007008 NONE potassium_38\NN\14625458|NONE_0 (r_pobj) of_37\IN\0|plasma_21 (r_prep) concentration_36\NN\4916342|glomerular_35|filtration_24|,_9 (r_conj) rate_33\NN\13815152|renal_41|plasma_35|,_24 (r_conj) flow_29\NN\7311115|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) determination_25\NN\43195|NONE_0 (r_pobj) by_24\IN\0|5_24|normokalemic_22 (r_prep) patients_23\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|patients_30|and_4 (r_conj) in_14\IN\13603305|influence_68|was_12|._239 (l_pobj) patients_16\NNS\9898892|and_26|in_30 (l_prep) with_17\IN\0|3_11 (l_pobj) hypokalemia_18\NN\14299637|NONE_0
D011188_D007008 NONE potassium_47\NN\14625458|NONE_0 (r_pobj) of_46\IN\0|urinary_18 (r_prep) excretion_45\NN\13466586|and_30|sodium_26|as_11 (r_conj) potassium_38\NN\14625458|NONE_0 (r_pobj) of_37\IN\0|plasma_21 (r_prep) concentration_36\NN\4916342|glomerular_35|filtration_24|,_9 (r_conj) rate_33\NN\13815152|renal_41|plasma_35|,_24 (r_conj) flow_29\NN\7311115|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) determination_25\NN\43195|NONE_0 (r_pobj) by_24\IN\0|5_24|normokalemic_22 (r_prep) patients_23\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|patients_30|and_4 (r_conj) in_14\IN\13603305|influence_68|was_12|._239 (l_pobj) patients_16\NNS\9898892|and_26|in_30 (l_prep) with_17\IN\0|3_11 (l_pobj) hypokalemia_18\NN\14299637|NONE_0
D000450_D007008 NONE aldosterone_51\NN\14751863|and_4 (r_conj) sodium_49\NN\14625458|,_2 (r_conj) potassium_47\NN\14625458|NONE_0 (r_pobj) of_46\IN\0|urinary_18 (r_prep) excretion_45\NN\13466586|and_30|sodium_26|as_11 (r_conj) potassium_38\NN\14625458|NONE_0 (r_pobj) of_37\IN\0|plasma_21 (r_prep) concentration_36\NN\4916342|glomerular_35|filtration_24|,_9 (r_conj) rate_33\NN\13815152|renal_41|plasma_35|,_24 (r_conj) flow_29\NN\7311115|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) determination_25\NN\43195|NONE_0 (r_pobj) by_24\IN\0|5_24|normokalemic_22 (r_prep) patients_23\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|patients_30|and_4 (r_conj) in_14\IN\13603305|influence_68|was_12|._239 (l_pobj) patients_16\NNS\9898892|and_26|in_30 (l_prep) with_17\IN\0|3_11 (l_pobj) hypokalemia_18\NN\14299637|NONE_0
D012964_D007008 NONE sodium_40\NN\14625458|and_4|as_15|excretion_26 (r_conj) potassium_38\NN\14625458|NONE_0 (r_pobj) of_37\IN\0|plasma_21 (r_prep) concentration_36\NN\4916342|glomerular_35|filtration_24|,_9 (r_conj) rate_33\NN\13815152|renal_41|plasma_35|,_24 (r_conj) flow_29\NN\7311115|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) determination_25\NN\43195|NONE_0 (r_pobj) by_24\IN\0|5_24|normokalemic_22 (r_prep) patients_23\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|patients_30|and_4 (r_conj) in_14\IN\13603305|influence_68|was_12|._239 (l_pobj) patients_16\NNS\9898892|and_26|in_30 (l_prep) with_17\IN\0|3_11 (l_pobj) hypokalemia_18\NN\14299637|NONE_0
D012964_D007008 NONE sodium_49\NN\14625458|,_2 (r_conj) potassium_47\NN\14625458|NONE_0 (r_pobj) of_46\IN\0|urinary_18 (r_prep) excretion_45\NN\13466586|and_30|sodium_26|as_11 (r_conj) potassium_38\NN\14625458|NONE_0 (r_pobj) of_37\IN\0|plasma_21 (r_prep) concentration_36\NN\4916342|glomerular_35|filtration_24|,_9 (r_conj) rate_33\NN\13815152|renal_41|plasma_35|,_24 (r_conj) flow_29\NN\7311115|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) determination_25\NN\43195|NONE_0 (r_pobj) by_24\IN\0|5_24|normokalemic_22 (r_prep) patients_23\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|patients_30|and_4 (r_conj) in_14\IN\13603305|influence_68|was_12|._239 (l_pobj) patients_16\NNS\9898892|and_26|in_30 (l_prep) with_17\IN\0|3_11 (l_pobj) hypokalemia_18\NN\14299637|NONE_0
D007980_D007008 CID dopa_11\NN\14601829|-_4 (r_npadvmod) treated_13\VBN\2376958|some_12|parkinsonian_8 (r_amod) patients_15\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|hypokalemia_44|was_13|._44 (r_prep) observed_6\VBN\2163746|NONE_0 (l_nsubjpass) hypokalemia_0\NNP\14299637|was_31|in_44|._88
D007980_D007008 CID dopa_5\NN\14601829|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) influence_1\NN\5190804|was_56|in_68|._307 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_prep) in_14\IN\13603305|influence_68|was_12|._239 (l_pobj) patients_16\NNS\9898892|and_26|in_30 (l_prep) with_17\IN\0|3_11 (l_pobj) hypokalemia_18\NN\14299637|NONE_0
D007980_D010300 NONE dopa_5\NN\14601829|in_15 (r_compound) treatment_6\NN\654885|NONE_0 (l_prep) in_7\IN\13603305|dopa_15 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_amod) parkinsonian_8\JJ\0|NONE_0
D007980_D010300 NONE dopa_11\NN\14601829|-_4 (r_npadvmod) treated_13\VBN\2376958|some_12|parkinsonian_8 (r_amod) patients_15\NNS\9898892|NONE_0 (l_amod) parkinsonian_14\JJ\0|some_20|treated_8
20129423
D002220_D004802 CID carbamazepine_1\NN\0|hypersensitivity_46|._209 (r_nsubj) induced_2\VBD\1627355|NONE_0 (l_dobj) hypersensitivity_6\NN\14531772|carbamazepine_46|._163 (l_amod) eosinophilic_4\JJ\0|fulminant_10|(_13|)_30|myocarditis_32|emphasis_45
D002220_D009205 CID carbamazepine_1\NN\0|hypersensitivity_46|._209 (r_nsubj) induced_2\VBD\1627355|NONE_0 (l_dobj) hypersensitivity_6\NN\14531772|carbamazepine_46|._163 (l_amod) myocarditis_8\NN\14338942|fulminant_42|eosinophilic_32|(_19|)_2|emphasis_13
D002220_D009205 CID carbamazepine_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|rare_17|side_12 (r_prep) effect_8\NN\34213|fatal_40|,_35|although_33|is_24|myocarditis_71|._82 (r_nsubj) necrotizing_12\VBG\0|NONE_0 (l_oprd) myocarditis_17\NN\14338942|fatal_111|,_106|although_104|effect_71|is_47|._11
D002220_D009205 CID carbamazepine_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) to_8\IN\0|myocarditis_22 (r_prep) secondary_7\JJ\8426461|NONE_0 (l_advmod) myocarditis_6\NN\14338942|to_22
D002220_D009205 CID carbamazepine_12\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_16|second_12|induced_23 (r_prep) case_9\NN\7283608|to_44|this_19|._78 (l_acl) induced_13\VBN\1627355|the_39|second_35|of_23 (l_dobj) myocarditis_14\NN\14338942|NONE_0
D002220_D004342 CID carbamazepine_1\NN\0|hypersensitivity_46|._209 (r_nsubj) induced_2\VBD\1627355|NONE_0 (l_dobj) hypersensitivity_6\NN\14531772|carbamazepine_46|._163
D002220_D004342 CID carbamazepine_1\NN\0|hypersensitivity_46|._209 (r_nsubj) induced_2\VBD\1627355|NONE_0 (l_dobj) hypersensitivity_6\NN\14531772|carbamazepine_46|._163 (l_appos) emphasis_10\NN\14434681|fulminant_55|eosinophilic_45|(_32|)_15|myocarditis_13 (l_prep) on_11\IN\0|NONE_0 (l_pobj) characteristics_15\NNS\5849040|NONE_0 (l_prep) of_20\IN\0|anatomical_69|,_26|mechanisms_24 (l_pobj) hypersensitivity_22\NN\14531772|NONE_0
D002220_D004342 CID carbamazepine_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|rare_17|side_12 (r_prep) effect_8\NN\34213|fatal_40|,_35|although_33|is_24|myocarditis_71|._82 (r_nsubj) necrotizing_12\VBG\0|NONE_0 (l_oprd) myocarditis_17\NN\14338942|fatal_111|,_106|although_104|effect_71|is_47|._11 (l_nmod) hypersensitivity_15\NN\14531772|eosinophilic_14
D002220_D004342 CID carbamazepine_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) to_8\IN\0|myocarditis_22 (r_prep) secondary_7\JJ\8426461|NONE_0 (r_amod) hypersensitivity_5\NN\14531772|NONE_0
10327032
D000644_D001424 NONE ammonium_2\NN\14743582|higher_14|and_16|onset_31 (r_compound) levels_3\NNS\4916342|were_46|in_56|and_132|in_136|._246 (r_nsubjpass) seen_11\VBN\2106506|NONE_0 (l_prep) in_12\IN\13603305|levels_56|were_10|and_76|in_80|._190 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|18_12 (l_pobj) infections_17\NNS\14052046|NONE_0
D005472_D007239 NONE 5-fluorouracil_13\CD\0|complication_24 (r_punct) with_14\IN\0|who_51|infusion_27 (l_pobj) complication_16\NN\1073995|5-fluorouracil_24 (l_prep) of_17\IN\0|the_17 (l_pobj) dehydration_18\NN\14536438|NONE_0 (l_conj) infection_20\NN\14052046|and_4
D005472_D009369 NONE 5-fluorouracil_13\CD\0|complication_24 (r_punct) with_14\IN\0|who_51|infusion_27 (r_prep) received_9\VBD\2210855|cancer_20 (r_relcl) patients_7\NNS\9898892|NONE_0 (l_compound) cancer_6\NN\14239425|received_20
D005472_D009369 NONE 5-fluorouracil_21\CD\0|(_15 (r_punct) 5-fu_23\CD\0|NONE_0 (r_pobj) of_20\IN\0|continuous_20 (r_prep) infusion_19\NN\14589223|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) related_16\VBN\628491|transient_40|hyperammonemic_30 (r_acl) encephalopathy_15\NN\14084880|NONE_0 (r_pobj) of_12\IN\0|32_12 (r_prep) episodes_11\NNS\7283608|who_11 (r_dobj) had_9\VBD\0|29_23|cancer_20|)_113 (r_relcl) patients_7\NNS\9898892|from_29|,_12|were_128|._143 (l_compound) cancer_6\NN\14239425|29_3|had_20|)_133
D005472_D009369 NONE 5-fu_23\CD\0|NONE_0 (r_pobj) of_20\IN\0|continuous_20 (r_prep) infusion_19\NN\14589223|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) related_16\VBN\628491|transient_40|hyperammonemic_30 (r_acl) encephalopathy_15\NN\14084880|NONE_0 (r_pobj) of_12\IN\0|32_12 (r_prep) episodes_11\NNS\7283608|who_11 (r_dobj) had_9\VBD\0|29_23|cancer_20|)_113 (r_relcl) patients_7\NNS\9898892|from_29|,_12|were_128|._143 (l_compound) cancer_6\NN\14239425|29_3|had_20|)_133
D005472_D003681 NONE 5-fluorouracil_13\CD\0|complication_24 (r_punct) with_14\IN\0|who_51|infusion_27 (l_pobj) complication_16\NN\1073995|5-fluorouracil_24 (l_prep) of_17\IN\0|the_17 (l_pobj) dehydration_18\NN\14536438|NONE_0
D000644_D022124 NONE ammonium_2\NN\14743582|higher_14|and_16|onset_31 (r_compound) levels_3\NNS\4916342|were_46|in_56|and_132|in_136|._246 (l_conj) onset_7\NN\7325190|higher_45|ammonium_31|and_15 (l_prep) of_8\IN\0|rapid_12 (l_pobj) hyperammonemia_9\NN\0|NONE_0
D005472_D022124 CID 5-fluorouracil_13\CD\0|complication_24 (r_punct) with_14\IN\0|who_51|infusion_27 (r_prep) received_9\VBD\2210855|cancer_20 (r_relcl) patients_7\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|transient_40|hyperammonemic_30 (r_prep) encephalopathy_4\NN\14084880|NONE_0
D005472_D022124 CID 5-fluorouracil_21\CD\0|(_15 (r_punct) 5-fu_23\CD\0|NONE_0 (r_pobj) of_20\IN\0|continuous_20 (r_prep) infusion_19\NN\14589223|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) related_16\VBN\628491|transient_40|hyperammonemic_30 (r_acl) encephalopathy_15\NN\14084880|NONE_0
D005472_D022124 CID 5-fu_23\CD\0|NONE_0 (r_pobj) of_20\IN\0|continuous_20 (r_prep) infusion_19\NN\14589223|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) related_16\VBN\628491|transient_40|hyperammonemic_30 (r_acl) encephalopathy_15\NN\14084880|NONE_0
D005472_D022124 CID 5-fu_42\CD\0|NONE_0 (r_pobj) of_41\IN\0|high_38|daily_33|(_21|m2_4|)_2 (r_prep) doses_32\NNS\3740161|respectively_59 (r_dobj) receiving_29\VBG\2210855|nine_14 (r_acl) patients_28\NNS\9898892|)_101 (r_pobj) in_26\IN\13603305|levels_136|were_90|in_80|and_4|._110 (r_prep) seen_11\VBN\2106506|NONE_0 (l_nsubjpass) levels_3\NNS\4916342|were_46|in_56|and_132|in_136|._246 (l_conj) onset_7\NN\7325190|higher_45|ammonium_31|and_15 (l_prep) of_8\IN\0|rapid_12 (l_pobj) hyperammonemia_9\NN\0|NONE_0
D005472_D022124 CID 5-fu_13\CD\0|NONE_0 (r_pobj) of_12\IN\0|continuous_20 (r_prep) infusion_11\NN\14589223|NONE_0 (r_dobj) receiving_9\VBG\2210855|NONE_0 (r_acl) patients_8\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|in_55|,_42|encephalopathy_25|can_10|._49 (r_prep) occur_6\VB\0|NONE_0 (l_nsubj) encephalopathy_4\NN\14084880|in_30|,_17|can_15|in_25|._74
D005472_D001424 NONE 5-fu_42\CD\0|NONE_0 (r_pobj) of_41\IN\0|high_38|daily_33|(_21|m2_4|)_2 (r_prep) doses_32\NNS\3740161|respectively_59 (r_dobj) receiving_29\VBG\2210855|nine_14 (r_acl) patients_28\NNS\9898892|)_101 (r_pobj) in_26\IN\13603305|levels_136|were_90|in_80|and_4|._110 (r_prep) seen_11\VBN\2106506|NONE_0 (l_prep) in_12\IN\13603305|levels_56|were_10|and_76|in_80|._190 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|18_12 (l_pobj) infections_17\NNS\14052046|NONE_0
D005472_D001927 CID 5-fluorouracil_13\CD\0|complication_24 (r_punct) with_14\IN\0|who_51|infusion_27 (r_prep) received_9\VBD\2210855|cancer_20 (r_relcl) patients_7\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|transient_40|hyperammonemic_30 (r_prep) encephalopathy_4\NN\14084880|NONE_0
D005472_D001927 CID 5-fluorouracil_21\CD\0|(_15 (r_punct) 5-fu_23\CD\0|NONE_0 (r_pobj) of_20\IN\0|continuous_20 (r_prep) infusion_19\NN\14589223|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) related_16\VBN\628491|transient_40|hyperammonemic_30 (r_acl) encephalopathy_15\NN\14084880|NONE_0
D005472_D001927 CID 5-fu_23\CD\0|NONE_0 (r_pobj) of_20\IN\0|continuous_20 (r_prep) infusion_19\NN\14589223|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) related_16\VBN\628491|transient_40|hyperammonemic_30 (r_acl) encephalopathy_15\NN\14084880|NONE_0
D005472_D001927 CID 5-fu_13\CD\0|NONE_0 (r_pobj) of_12\IN\0|continuous_20 (r_prep) infusion_11\NN\14589223|NONE_0 (r_dobj) receiving_9\VBG\2210855|NONE_0 (r_acl) patients_8\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|in_55|,_42|encephalopathy_25|can_10|._49 (r_prep) occur_6\VB\0|NONE_0 (l_nsubj) encephalopathy_4\NN\14084880|in_30|,_17|can_15|in_25|._74
3109094
D015080_D001745 NONE mesna_20\NN\0|NONE_0 (r_pobj) by_19\IN\0|their_17 (r_prep) prevention_18\NN\1073995|the_81|induced_60|of_44|and_10 (r_conj) lesions_8\NNS\14204950|NONE_0 (l_prep) of_9\IN\0|the_37|induced_16|and_34|prevention_44 (l_pobj) bladder_12\NN\5515670|NONE_0
D003520_D004487 NONE cyclophosphamide_2\NN\0|-_16 (r_npadvmod) induced_4\VBN\1627355|developed_27 (r_amod) cystitis_5\NN\14566129|is_9|by_26|edema_93|._165 (r_nsubjpass) characterized_7\VBN\609683|NONE_0 (l_dobj) edema_18\NN\14315192|cystitis_93|is_84|by_67|._72
D003520_D003556 NONE cyclophosphamide_2\NN\0|-_16 (r_npadvmod) induced_4\VBN\1627355|developed_27 (r_amod) cystitis_5\NN\14566129|is_9|by_26|edema_93|._165
D003520_D001745 CID cyclophosphamide_5\NN\0|-_16 (r_npadvmod) induced_7\VBN\1627355|the_21|of_16|and_50|prevention_60 (r_amod) lesions_8\NNS\14204950|NONE_0 (l_prep) of_9\IN\0|the_37|induced_16|and_34|prevention_44 (l_pobj) bladder_12\NN\5515670|NONE_0
D003520_D009336 NONE cyclophosphamide_2\NN\0|-_16 (r_npadvmod) induced_4\VBN\1627355|developed_27 (r_amod) cystitis_5\NN\14566129|is_9|by_26|edema_93|._165 (r_nsubjpass) characterized_7\VBN\609683|NONE_0 (l_dobj) edema_18\NN\14315192|cystitis_93|is_84|by_67|._72 (l_acl) owing_19\VBG\0|,_26|severe_24|submucosal_17 (l_prep) to_20\IN\0|NONE_0 (l_pobj) damage_21\NN\7296428|NONE_0 (l_prep) to_22\IN\0|NONE_0 (l_pobj) bed_25\NN\2821943|NONE_0 (l_conj) necroses_29\NNS\93775|the_39|microvascular_35|and_17
11380496
D011441_D019226 CID ptu_36\NNP\0|NONE_0 (r_compound) therapy_37\NN\657604|NONE_0 (r_dobj) stopping_35\VBG\3323703|weeks_12 (r_pcomp) after_34\IN\0|symptoms_26|,_26|and_28|decreased_51 (r_prep) resolved_31\VBD\352826|she_79|fever_56|,_19|but_17 (r_conj) developed_18\VBD\1753788|in_71|,_51|titre_36|to_20|and_8 (l_dobj) fever_21\NN\14299637|she_23|,_37|but_39|resolved_56 (l_conj) ulcers_24\NNS\14211294|a_21|higher_19|,_7
D011441_D019226 CID ptu_56\NNP\0|NONE_0 (r_dobj) discontinuing_55\VBG\0|NONE_0 (r_pcomp) after_54\IN\0|titre_41|to_25|by_12|._23 (r_prep) decreased_45\VBD\169651|symptoms_77|after_51|,_25|and_23 (r_conj) resolved_31\VBD\352826|she_79|fever_56|,_19|but_17 (r_conj) developed_18\VBD\1753788|in_71|,_51|titre_36|to_20|and_8 (l_dobj) fever_21\NN\14299637|she_23|,_37|but_39|resolved_56 (l_conj) ulcers_24\NNS\14211294|a_21|higher_19|,_7
D011441_D018771 CID ptu_36\NNP\0|NONE_0 (r_compound) therapy_37\NN\657604|NONE_0 (r_dobj) stopping_35\VBG\3323703|weeks_12 (r_pcomp) after_34\IN\0|symptoms_26|,_26|and_28|decreased_51 (r_prep) resolved_31\VBD\352826|she_79|fever_56|,_19|but_17 (r_conj) developed_18\VBD\1753788|in_71|,_51|titre_36|to_20|and_8 (l_dobj) fever_21\NN\14299637|she_23|,_37|but_39|resolved_56 (l_conj) ulcers_24\NNS\14211294|a_21|higher_19|,_7 (l_conj) polyarthralgia_26\NN\0|oral_16|and_4
D011441_D018771 CID ptu_56\NNP\0|NONE_0 (r_dobj) discontinuing_55\VBG\0|NONE_0 (r_pcomp) after_54\IN\0|titre_41|to_25|by_12|._23 (r_prep) decreased_45\VBD\169651|symptoms_77|after_51|,_25|and_23 (r_conj) resolved_31\VBD\352826|she_79|fever_56|,_19|but_17 (r_conj) developed_18\VBD\1753788|in_71|,_51|titre_36|to_20|and_8 (l_dobj) fever_21\NN\14299637|she_23|,_37|but_39|resolved_56 (l_conj) ulcers_24\NNS\14211294|a_21|higher_19|,_7 (l_conj) polyarthralgia_26\NN\0|oral_16|and_4
D011441_D005334 CID ptu_36\NNP\0|NONE_0 (r_compound) therapy_37\NN\657604|NONE_0 (r_dobj) stopping_35\VBG\3323703|weeks_12 (r_pcomp) after_34\IN\0|symptoms_26|,_26|and_28|decreased_51 (r_prep) resolved_31\VBD\352826|she_79|fever_56|,_19|but_17 (r_conj) developed_18\VBD\1753788|in_71|,_51|titre_36|to_20|and_8 (l_dobj) fever_21\NN\14299637|she_23|,_37|but_39|resolved_56
D011441_D005334 CID ptu_56\NNP\0|NONE_0 (r_dobj) discontinuing_55\VBG\0|NONE_0 (r_pcomp) after_54\IN\0|titre_41|to_25|by_12|._23 (r_prep) decreased_45\VBD\169651|symptoms_77|after_51|,_25|and_23 (r_conj) resolved_31\VBD\352826|she_79|fever_56|,_19|but_17 (r_conj) developed_18\VBD\1753788|in_71|,_51|titre_36|to_20|and_8 (l_dobj) fever_21\NN\14299637|she_23|,_37|but_39|resolved_56
D011441_D006111 NONE propylthiouracil_21\NN\14727670|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) treated_19\VBN\2376958|graves_25|disease_17 (r_acl) patients_18\NNS\9898892|NONE_0 (l_compound) disease_17\NN\14061805|graves_8|treated_17
D011441_D006111 NONE propylthiouracil_22\NN\14727670|NONE_0 (r_pobj) with_21\IN\0|who_17|were_13 (r_prep) treated_20\VBN\2376958|graves_25 (r_relcl) disease_17\NN\14061805|NONE_0
D011441_D006111 NONE ptu_24\NNP\0|NONE_0 (r_appos) propylthiouracil_22\NN\14727670|NONE_0 (r_pobj) with_21\IN\0|who_17|were_13 (r_prep) treated_20\VBN\2376958|graves_25 (r_relcl) disease_17\NN\14061805|NONE_0
D011441_D006111 NONE ptu_21\NNP\0|NONE_0 (r_compound) therapy_22\NN\657604|NONE_0 (r_pobj) during_20\IN\0|the_42|of_27 (r_prep) appearance_13\NN\4723816|NONE_0 (r_pobj) between_11\IN\0|the_26|temporal_22 (r_prep) relationship_10\NN\31921|NONE_0 (r_pobj) on_7\IN\0|no_11 (r_prep) studies_6\NNS\635850|nevertheless_33|,_21|there_19|have_13|,_105|or_107|on_110|._176 (r_attr) been_4\VBN\0|NONE_0 (l_conj) on_25\IN\0|nevertheless_143|,_131|there_129|have_123|studies_110|,_5|or_3|._66 (l_pobj) anca_31\NNP\0|incidence_17|-_1 (l_prep) in_32\IN\13603305|NONE_0 (l_pobj) patients_37\NNS\9898892|NONE_0 (l_compound) disease_36\NN\14061805|graves_8
D011441_D006111 NONE ptu_27\NNP\0|NONE_0 (r_compound) therapy_28\NN\657604|NONE_0 (r_dobj) starting_26\VBG\457382|NONE_0 (r_pcomp) after_25\IN\0|the_27|development_23 (r_prep) vasculitis_24\NN\14336539|NONE_0 (r_pobj) for_21\IN\0|we_117|patients_87|due_57|,_6|and_4|._57 (r_conj) investigated_1\VBD\644583|NONE_0 (l_prep) due_7\IN\5174653|we_60|patients_30|,_51|and_53|for_57|._114 (l_pobj) disease_11\NN\14061805|to_11
D011441_D014652 NONE ptu_24\NNP\0|continued_10 (r_compound) therapy_25\NN\657604|NONE_0 (r_pobj) despite_22\IN\7501545|in_95|,_81|titres_66|transiently_59|to_37|,_16|respectively_14|,_2|,_29|but_31|developed_59 (r_prep) increased_11\VBD\169651|NONE_0 (l_conj) developed_31\VBD\1753788|in_154|,_140|titres_125|transiently_118|to_96|,_75|respectively_73|,_61|despite_59|,_30|but_28 (l_nsubj) disorders_30\NNS\14034177|._19
D011441_D014657 NONE propylthiouracil_22\NN\14727670|NONE_0 (r_pobj) with_21\IN\0|who_17|were_13 (r_prep) treated_20\VBN\2376958|graves_25 (r_relcl) disease_17\NN\14061805|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) patients_13\NNS\9898892|NONE_0 (r_pobj) in_12\IN\13603305|vasculitis_29|has_18|been_14|._77 (r_prep) reported_11\VBN\831651|NONE_0 (l_nsubjpass) vasculitis_8\NN\14336539|has_11|been_15|in_29|._106
D011441_D014657 NONE ptu_24\NNP\0|NONE_0 (r_appos) propylthiouracil_22\NN\14727670|NONE_0 (r_pobj) with_21\IN\0|who_17|were_13 (r_prep) treated_20\VBN\2376958|graves_25 (r_relcl) disease_17\NN\14061805|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) patients_13\NNS\9898892|NONE_0 (r_pobj) in_12\IN\13603305|vasculitis_29|has_18|been_14|._77 (r_prep) reported_11\VBN\831651|NONE_0 (l_nsubjpass) vasculitis_8\NN\14336539|has_11|been_15|in_29|._106
D011441_D014657 NONE ptu_21\NNP\0|NONE_0 (r_compound) therapy_22\NN\657604|NONE_0 (r_pobj) during_20\IN\0|the_42|of_27 (r_prep) appearance_13\NN\4723816|NONE_0 (l_prep) of_14\IN\0|the_15|during_27 (l_pobj) mpo_15\NNP\0|NONE_0 (l_appos) anca_17\NNP\0|-_1 (l_conj) vasculitis_19\NN\14336539|and_4
D011441_D014657 NONE ptu_27\NNP\0|NONE_0 (r_compound) therapy_28\NN\657604|NONE_0 (r_dobj) starting_26\VBG\457382|NONE_0 (r_pcomp) after_25\IN\0|the_27|development_23 (r_prep) vasculitis_24\NN\14336539|NONE_0
D011441_D006980 NONE ptu_27\NNP\0|NONE_0 (r_compound) therapy_28\NN\657604|NONE_0 (r_dobj) starting_26\VBG\457382|NONE_0 (r_pcomp) after_25\IN\0|the_27|development_23 (r_prep) vasculitis_24\NN\14336539|NONE_0 (r_pobj) for_21\IN\0|we_117|patients_87|due_57|,_6|and_4|._57 (r_conj) investigated_1\VBD\644583|NONE_0 (l_dobj) patients_4\NNS\9898892|we_30|due_30|,_81|and_83|for_87|._144 (l_prep) with_5\IN\0|102_23|untreated_19 (l_pobj) hyperthyroidism_6\NN\14059928|NONE_0
11176729
D017706_D006333 NONE lisinopril_15\NN\2673637|NONE_0 (l_prep) in_16\IN\13603305|dose_16 (l_pobj) chf_17\NNP\0|NONE_0
D000806_D006947 NONE inhibitor_8\NN\20090|not_32|previously_28 (r_dobj) receiving_5\VBG\2210855|405_28 (r_acl) patients_2\NNS\9898892|NONE_0 (r_pobj) of_0\IN\0|,_57|doses_59|could_78|not_84|be_88|to_100|because_147|or_206|because_209|._260 (r_prep) titrated_18\VBN\489837|NONE_0 (l_conj) because_38\IN\0|of_209|,_152|doses_150|could_131|not_125|be_121|to_109|because_62|or_3|._51 (l_pobj) dysfunction_41\NN\14204950|of_9 (l_conj) hyperkalemia_43\NN\14299637|renal_21|or_3|(_13|%_17|)_18
D000806_D007022 NONE inhibitor_8\NN\20090|not_32|previously_28 (r_dobj) receiving_5\VBG\2210855|405_28 (r_acl) patients_2\NNS\9898892|NONE_0 (r_pobj) of_0\IN\0|,_57|doses_59|could_78|not_84|be_88|to_100|because_147|or_206|because_209|._260 (r_prep) titrated_18\VBN\489837|NONE_0 (l_prep) because_26\IN\0|of_147|,_90|doses_88|could_69|not_63|be_59|to_47|or_59|because_62|._113 (l_pobj) symptoms_28\NNS\5823932|of_3 (l_acl) related_30\VBD\628491|NONE_0 (l_prep) to_31\IN\0|possibly_17 (l_pobj) hypotension_32\NN\14057371|NONE_0
D000806_D006333 NONE inhibitors_9\NNS\20090|NONE_0 (r_pobj) of_4\IN\0|high_11 (r_prep) doses_3\NNS\3740161|NONE_0 (r_pobj) of_1\IN\0|in_58|:_96|results_98|._126 (r_prep) toleration_0\NN\4637923|NONE_0 (l_prep) in_10\IN\13603305|of_58|:_38|results_40|._68 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) failure_15\NN\66216|NONE_0
D000806_D006333 NONE inhibitors_9\NNS\20090|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|mortality_70|,_138|but_140|receiving_175 (r_nsubj) reduces_10\VBZ\441445|NONE_0 (l_dobj) mortality_11\NN\5054863|treatment_70|,_68|but_70|receiving_105 (l_prep) in_14\IN\13603305|and_14|morbidity_10 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) failure_19\NN\66216|NONE_0
D000806_D006333 NONE inhibitors_9\NNS\20090|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|mortality_70|,_138|but_140|receiving_175 (r_nsubj) reduces_10\VBZ\441445|NONE_0 (l_dobj) mortality_11\NN\5054863|treatment_70|,_68|but_70|receiving_105 (l_prep) in_14\IN\13603305|and_14|morbidity_10 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) failure_19\NN\66216|NONE_0 (l_appos) chf_21\NNP\0|chronic_23|heart_15
D000806_D006333 NONE inhibitor_5\NN\20090|ace_4|in_18 (r_compound) therapy_6\NN\657604|that_19|can_34|be_38|successfully_41|to_63|and_66|maintained_70|,_94|and_96|warranted_144 (l_prep) in_7\IN\13603305|ace_22|inhibitor_18 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|most_14 (l_pobj) chf_11\NNP\0|NONE_0
D000806_D007674 NONE inhibitor_8\NN\20090|not_32|previously_28 (r_dobj) receiving_5\VBG\2210855|405_28 (r_acl) patients_2\NNS\9898892|NONE_0 (r_pobj) of_0\IN\0|,_57|doses_59|could_78|not_84|be_88|to_100|because_147|or_206|because_209|._260 (r_prep) titrated_18\VBN\489837|NONE_0 (l_conj) because_38\IN\0|of_209|,_152|doses_150|could_131|not_125|be_121|to_109|because_62|or_3|._51 (l_pobj) dysfunction_41\NN\14204950|of_9
2383364
C048279_D010146 CID chp_6\NNP\0|and_18|ratings_32 (r_compound) concentration_7\NN\4916342|NONE_0 (l_conj) ratings_11\NNS\5733583|chp_32|and_14 (l_prep) of_12\IN\0|patients_18|on_8 (l_pobj) pain_13\NN\14299637|NONE_0
C048279_D010146 CID chp_4\NNP\0|the_18|0.25_14|cent_5 (r_compound) cream_5\NN\8386555|closest_10|in_26 (r_nsubj) was_6\VBD\0|;_37|however_39|,_46|none_48|statistically_80|from_94|._122 (l_prep) in_10\IN\13603305|cream_26|closest_16 (l_pobj) tolerance_12\NN\5032565|NONE_0 (l_compound) pain_11\NN\14299637|NONE_0
C048279_D002056 NONE diphosphanilate_6\NN\0|NONE_0 (r_pobj) of_3\IN\0|tolerance_16|:_40|agent_56|._71 (r_prep) study_2\NN\635850|NONE_0 (l_appos) agent_11\NN\7347|tolerance_72|of_56|:_16|._15 (l_prep) for_12\IN\0|a_20|new_18|topical_14 (l_pobj) burns_13\NNS\0|NONE_0
C048279_D002056 NONE phosphanilate_1\NN\0|has_63|been_67|as_82|,_128|but_130|reported_162 (r_nsubjpass) evaluated_16\VBN\670261|NONE_0 (l_prep) as_17\IN\14622893|phosphanilate_82|has_19|been_15|,_46|but_48|reported_80 (l_pobj) wound_21\NN\14285662|NONE_0 (l_compound) burn_20\NN\14322699|a_10|topical_8|dressing_11
C048279_D002056 NONE chp_3\NNP\0|chlorhexidine_29|,_4|agent_41|,_46 (r_appos) phosphanilate_1\NN\0|has_63|been_67|as_82|,_128|but_130|reported_162 (r_nsubjpass) evaluated_16\VBN\670261|NONE_0 (l_prep) as_17\IN\14622893|phosphanilate_82|has_19|been_15|,_46|but_48|reported_80 (l_pobj) wound_21\NN\14285662|NONE_0 (l_compound) burn_20\NN\14322699|a_10|topical_8|dressing_11
C048279_D002056 NONE chp_10\NNP\0|four_15|different_10 (r_compound) concentrations_11\NNS\4916342|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) each_6\DT\0|NONE_0 (r_pobj) with_5\IN\0|site_17|was_12|,_46|from_48|,_80|vehicle_88|._222 (r_prep) treated_4\VBN\2376958|NONE_0 (l_nsubjpass) site_2\NN\8673395|was_5|with_17|,_63|from_65|,_97|vehicle_105|._239 (l_compound) burn_1\NN\14322699|one_4
C048279_D002056 NONE chp_10\NNP\0|four_15|different_10 (r_compound) concentrations_11\NNS\4916342|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) each_6\DT\0|NONE_0 (r_pobj) with_5\IN\0|site_17|was_12|,_46|from_48|,_80|vehicle_88|._222 (r_prep) treated_4\VBN\2376958|NONE_0 (l_dobj) vehicle_23\NN\3100490|site_105|was_100|with_88|,_42|from_40|,_8|._134 (l_conj) cream_34\NN\8386555|their_58|,_45|and_43 (l_appos) agent_38\NN\7347|1_63|sulphadiazine_45|(_31|agsd_30|)_26|,_19 (l_acl) used_40\VBN\0|an_34|antimicrobial_31 (l_prep) for_41\IN\0|frequently_16 (l_pobj) treatment_43\NN\654885|NONE_0 (l_prep) of_44\IN\0|topical_18 (l_pobj) wounds_46\NNS\14285662|NONE_0 (l_compound) burn_45\NN\14322699|NONE_0
D012837_D010146 NONE agsd_9\NNP\0|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) closest_7\JJS\0|cream_10|in_16 (r_acomp) was_6\VBD\0|;_37|however_39|,_46|none_48|statistically_80|from_94|._122 (l_prep) in_10\IN\13603305|cream_26|closest_16 (l_pobj) tolerance_12\NN\5032565|NONE_0 (l_compound) pain_11\NN\14299637|NONE_0
D012837_D010146 NONE agsd_23\NNP\0|or_5|from_8 (r_pobj) from_22\IN\0|was_94|;_57|however_55|,_48|none_46|statistically_14|._28 (r_prep) differed_20\VBD\0|NONE_0 (l_ccomp) was_6\VBD\0|;_37|however_39|,_46|none_48|statistically_80|from_94|._122 (l_prep) in_10\IN\13603305|cream_26|closest_16 (l_pobj) tolerance_12\NN\5032565|NONE_0 (l_compound) pain_11\NN\14299637|NONE_0
D012837_D002056 NONE sulphadiazine_30\NN\0|1_18|(_14|agsd_15|)_19|,_26|agent_45 (r_nmod) cream_34\NN\8386555|their_58|,_45|and_43 (r_conj) vehicle_23\NN\3100490|site_105|was_100|with_88|,_42|from_40|,_8|._134 (r_dobj) treated_4\VBN\2376958|NONE_0 (l_nsubjpass) site_2\NN\8673395|was_5|with_17|,_63|from_65|,_97|vehicle_105|._239 (l_compound) burn_1\NN\14322699|one_4
D012837_D002056 NONE sulphadiazine_30\NN\0|1_18|(_14|agsd_15|)_19|,_26|agent_45 (r_nmod) cream_34\NN\8386555|their_58|,_45|and_43 (l_appos) agent_38\NN\7347|1_63|sulphadiazine_45|(_31|agsd_30|)_26|,_19 (l_acl) used_40\VBN\0|an_34|antimicrobial_31 (l_prep) for_41\IN\0|frequently_16 (l_pobj) treatment_43\NN\654885|NONE_0 (l_prep) of_44\IN\0|topical_18 (l_pobj) wounds_46\NNS\14285662|NONE_0 (l_compound) burn_45\NN\14322699|NONE_0
D012837_D002056 NONE agsd_32\NNP\0|1_33|sulphadiazine_15|(_1|)_4|,_11|agent_30 (r_nmod) cream_34\NN\8386555|their_58|,_45|and_43 (r_conj) vehicle_23\NN\3100490|site_105|was_100|with_88|,_42|from_40|,_8|._134 (r_dobj) treated_4\VBN\2376958|NONE_0 (l_nsubjpass) site_2\NN\8673395|was_5|with_17|,_63|from_65|,_97|vehicle_105|._239 (l_compound) burn_1\NN\14322699|one_4
D012837_D002056 NONE agsd_32\NNP\0|1_33|sulphadiazine_15|(_1|)_4|,_11|agent_30 (r_nmod) cream_34\NN\8386555|their_58|,_45|and_43 (l_appos) agent_38\NN\7347|1_63|sulphadiazine_45|(_31|agsd_30|)_26|,_19 (l_acl) used_40\VBN\0|an_34|antimicrobial_31 (l_prep) for_41\IN\0|frequently_16 (l_pobj) treatment_43\NN\654885|NONE_0 (l_prep) of_44\IN\0|topical_18 (l_pobj) wounds_46\NNS\14285662|NONE_0 (l_compound) burn_45\NN\14322699|NONE_0
9725303
D019469_D015658 NONE indinavir_17\NNS\4013993|NONE_0 (r_dobj) receiving_16\VBG\2210855|six_26|infected_18 (r_acl) patients_15\NNS\9898892|NONE_0 (l_amod) infected_14\VBN\2316868|six_8|receiving_18
D019469_D015658 NONE indinavir_25\NNS\4013993|NONE_0 (r_compound) therapy_26\NN\657604|who_22 (r_dobj) receive_24\VBP\2210855|with_23 (r_relcl) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|receive_23 (l_pobj) infection_22\NN\14052046|NONE_0
D019469_D014514 CID indinavir_17\NNS\4013993|NONE_0 (r_dobj) receiving_16\VBG\2210855|six_26|infected_18 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) in_10\IN\13603305|:_57|we_55|features_29|,_48|inhibitor_86|._160 (r_prep) describe_2\VBP\1001294|NONE_0 (l_dobj) features_6\NNS\5849040|:_28|we_26|in_29|,_77|inhibitor_115|._189 (l_prep) of_7\IN\0|the_23|unique_19|ct_12 (l_pobj) calculi_9\NNS\9416076|NONE_0
D019469_D014514 NONE indinavir_25\NNS\4013993|NONE_0 (r_compound) therapy_26\NN\657604|who_22 (r_dobj) receive_24\VBP\2210855|with_23 (r_relcl) patients_19\NNS\9898892|NONE_0 (r_pobj) in_18\IN\13603305|ureteric_31|or_15|obstruction_12 (r_prep) stones_15\NNS\19128|NONE_0 (l_conj) obstruction_17\NN\4341686|ureteric_19|or_3|in_12
D019469_D052878 NONE indinavir_17\NNS\4013993|NONE_0 (r_dobj) receiving_16\VBG\2210855|six_26|infected_18 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) in_10\IN\13603305|:_57|we_55|features_29|,_48|inhibitor_86|._160 (r_prep) describe_2\VBP\1001294|NONE_0 (l_dobj) inhibitor_25\NN\20090|:_143|we_141|features_115|in_86|,_38|._74 (l_relcl) associated_29\VBN\628491|the_56|used_38|protease_29|,_11 (l_prep) with_30\IN\0|which_20|is_14 (l_pobj) incidence_33\NN\13821570|NONE_0 (l_prep) of_34\IN\0|an_23|increased_20 (l_pobj) urolithiasis_35\NN\0|NONE_0
D019469_D014517 NONE indinavir_11\NNS\4013993|NONE_0 (r_compound) therapy_12\NN\657604|NONE_0 (r_dobj) undergoing_10\VBG\109660|with_9 (r_acl) patients_7\NNS\9898892|NONE_0 (r_pobj) in_6\IN\13603305|obstruction_12 (r_prep) causing_3\VBG\30358|crystal_19|._78 (l_dobj) obstruction_5\NN\4341686|in_12
D019469_D014517 NONE indinavir_5\JJ\4013993|precipitated_13 (r_compound) crystals_6\NNS\15046900|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|ureteric_21 (r_acl) obstruction_1\NN\4341686|may_54|difficult_61|._101
D019469_D014517 NONE indinavir_25\NNS\4013993|NONE_0 (r_compound) therapy_26\NN\657604|who_22 (r_dobj) receive_24\VBP\2210855|with_23 (r_relcl) patients_19\NNS\9898892|NONE_0 (r_pobj) in_18\IN\13603305|ureteric_31|or_15|obstruction_12 (r_prep) stones_15\NNS\19128|NONE_0 (l_conj) obstruction_17\NN\4341686|ureteric_19|or_3|in_12
10401555
D012601_D008569 CID scopolamine_13\NN\14712692|NONE_0 (r_pobj) by_12\IN\0|in_15 (r_agent) induced_11\VBN\1627355|learning_31 (r_acl) impairment_10\NN\7296428|NONE_0
D012601_D008569 CID scopolamine_23\NN\14712692|NONE_0 (r_pobj) by_22\IN\0|NONE_0 (r_agent) induced_21\VBN\1627355|of_23 (r_acl) impairment_16\NN\7296428|whether_61|fq_33|could_15|using_104 (l_prep) of_17\IN\0|induced_23 (l_pobj) learning_18\NN\5701944|NONE_0 (l_conj) memory_20\NN\5926676|and_4
D012601_D007859 CID scopolamine_13\NN\14712692|NONE_0 (r_pobj) by_12\IN\0|in_15 (r_agent) induced_11\VBN\1627355|learning_31 (r_acl) impairment_10\NN\7296428|NONE_0
D012601_D007859 CID scopolamine_23\NN\14712692|NONE_0 (r_pobj) by_22\IN\0|NONE_0 (r_agent) induced_21\VBN\1627355|of_23 (r_acl) impairment_16\NN\7296428|whether_61|fq_33|could_15|using_104 (l_prep) of_17\IN\0|induced_23 (l_pobj) learning_18\NN\5701944|NONE_0 (l_conj) memory_20\NN\5926676|and_4
C111148_D006930 NONE nocistatin_5\NN\0|on_19|,_2|is_11|recently_14|from_32|._126 (r_advmod) isolated_8\VBN\2512305|NONE_0 (l_prep) from_9\IN\0|on_51|,_34|nocistatin_32|is_21|recently_18|._94 (l_pobj) precursor_12\NN\14580897|NONE_0 (l_prep) as_13\IN\14622893|the_19|same_15 (l_pobj) allodynia_20\NN\0|nociceptin_41
C111148_D006930 NONE nocistatin_5\NN\0|on_19|,_2|is_11|recently_14|from_32|._126 (r_advmod) isolated_8\VBN\2512305|NONE_0 (l_prep) from_9\IN\0|on_51|,_34|nocistatin_32|is_21|recently_18|._94 (l_pobj) precursor_12\NN\14580897|NONE_0 (l_prep) as_13\IN\14622893|the_19|same_15 (l_pobj) allodynia_20\NN\0|nociceptin_41 (l_conj) hyperalgesia_22\NN\0|induced_22|and_4
C096012_D007859 NONE nociceptin_0\NNP\0|/_10 (r_nmod) orphanin_2\NN\0|and_12|nocistatin_16|._91 (r_compound) fq_3\NNP\0|NONE_0 (l_conj) nocistatin_5\NNS\0|orphanin_16|and_4|._75 (l_prep) on_6\IN\0|NONE_0 (l_pobj) impairment_10\NN\7296428|NONE_0
C096012_D007859 NONE fq_3\NNP\0|NONE_0 (l_conj) nocistatin_5\NNS\0|orphanin_16|and_4|._75 (l_prep) on_6\IN\0|NONE_0 (l_pobj) impairment_10\NN\7296428|NONE_0
C096012_D007859 NONE nociceptin_8\NN\0|/_10 (r_nmod) orphanin_10\VB\0|and_12|nocistatin_16 (r_compound) fq_11\NNP\0|whether_28|could_18|impairment_33|using_137 (r_nsubj) modulate_15\VB\1724459|to_67 (l_dobj) impairment_16\NN\7296428|whether_61|fq_33|could_15|using_104 (l_prep) of_17\IN\0|induced_23 (l_pobj) learning_18\NN\5701944|NONE_0 (l_conj) memory_20\NN\5926676|and_4
C096012_D007859 NONE fq_11\NNP\0|whether_28|could_18|impairment_33|using_137 (r_nsubj) modulate_15\VB\1724459|to_67 (l_dobj) impairment_16\NN\7296428|whether_61|fq_33|could_15|using_104 (l_prep) of_17\IN\0|induced_23 (l_pobj) learning_18\NN\5701944|NONE_0 (l_conj) memory_20\NN\5926676|and_4
C111148_D007859 NONE nocistatin_5\NNS\0|orphanin_16|and_4|._75 (l_prep) on_6\IN\0|NONE_0 (l_pobj) impairment_10\NN\7296428|NONE_0
C111148_D007859 NONE nocistatin_13\NN\0|orphanin_16|and_4 (r_conj) fq_11\NNP\0|whether_28|could_18|impairment_33|using_137 (r_nsubj) modulate_15\VB\1724459|to_67 (l_dobj) impairment_16\NN\7296428|whether_61|fq_33|could_15|using_104 (l_prep) of_17\IN\0|induced_23 (l_pobj) learning_18\NN\5701944|NONE_0 (l_conj) memory_20\NN\5926676|and_4
C096012_D008569 NONE nociceptin_0\NNP\0|/_10 (r_nmod) orphanin_2\NN\0|and_12|nocistatin_16|._91 (r_compound) fq_3\NNP\0|NONE_0 (l_conj) nocistatin_5\NNS\0|orphanin_16|and_4|._75 (l_prep) on_6\IN\0|NONE_0 (l_pobj) impairment_10\NN\7296428|NONE_0
C096012_D008569 NONE fq_3\NNP\0|NONE_0 (l_conj) nocistatin_5\NNS\0|orphanin_16|and_4|._75 (l_prep) on_6\IN\0|NONE_0 (l_pobj) impairment_10\NN\7296428|NONE_0
C096012_D008569 NONE nociceptin_8\NN\0|/_10 (r_nmod) orphanin_10\VB\0|and_12|nocistatin_16 (r_compound) fq_11\NNP\0|whether_28|could_18|impairment_33|using_137 (r_nsubj) modulate_15\VB\1724459|to_67 (l_dobj) impairment_16\NN\7296428|whether_61|fq_33|could_15|using_104 (l_prep) of_17\IN\0|induced_23 (l_pobj) learning_18\NN\5701944|NONE_0 (l_conj) memory_20\NN\5926676|and_4
C096012_D008569 NONE fq_11\NNP\0|whether_28|could_18|impairment_33|using_137 (r_nsubj) modulate_15\VB\1724459|to_67 (l_dobj) impairment_16\NN\7296428|whether_61|fq_33|could_15|using_104 (l_prep) of_17\IN\0|induced_23 (l_pobj) learning_18\NN\5701944|NONE_0 (l_conj) memory_20\NN\5926676|and_4
C111148_D008569 NONE nocistatin_5\NNS\0|orphanin_16|and_4|._75 (l_prep) on_6\IN\0|NONE_0 (l_pobj) impairment_10\NN\7296428|NONE_0
C111148_D008569 NONE nocistatin_13\NN\0|orphanin_16|and_4 (r_conj) fq_11\NNP\0|whether_28|could_18|impairment_33|using_137 (r_nsubj) modulate_15\VB\1724459|to_67 (l_dobj) impairment_16\NN\7296428|whether_61|fq_33|could_15|using_104 (l_prep) of_17\IN\0|induced_23 (l_pobj) learning_18\NN\5701944|NONE_0 (l_conj) memory_20\NN\5926676|and_4
C096012_D006930 NONE nociceptin_14\NN\0|allodynia_41 (r_amod) as_13\IN\14622893|the_19|same_15 (l_pobj) allodynia_20\NN\0|nociceptin_41
C096012_D006930 NONE nociceptin_14\NN\0|allodynia_41 (r_amod) as_13\IN\14622893|the_19|same_15 (l_pobj) allodynia_20\NN\0|nociceptin_41 (l_conj) hyperalgesia_22\NN\0|induced_22|and_4
C096012_D006930 NONE nociceptin_17\RB\0|-_10 (r_advmod) induced_19\VBN\1627355|and_18|hyperalgesia_22 (r_amod) allodynia_20\NN\0|nociceptin_41
C096012_D006930 NONE nociceptin_17\RB\0|-_10 (r_advmod) induced_19\VBN\1627355|and_18|hyperalgesia_22 (r_amod) allodynia_20\NN\0|nociceptin_41 (l_conj) hyperalgesia_22\NN\0|induced_22|and_4
3323259
D009553_D008881 NONE nimodipine_6\RB\0|potentially_11|in_30 (r_nsubj) useful_8\JJ\0|selectivity_69|._91 (l_prep) in_9\IN\13603305|nimodipine_30|potentially_19 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_14 (l_pobj) hemorrhage_14\NN\14285662|NONE_0 (l_conj) headache_17\NN\5829480|subarachnoid_34|,_11
C038806_D006973 NONE dihydropyridine_3\NN\0|as_13|the_10|first_6|for_26 (r_advmod) available_4\JJ\0|,_38|nifedipine_40|angina_60|._127 (r_advcl) controls_13\NNS\5190804|NONE_0 (l_dobj) angina_14\NN\14171682|available_60|,_22|nifedipine_20|._67 (l_conj) hypertension_16\NN\14057371|and_4|with_13
D015737_D000787 NONE nisoldipine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_37|coronary_33|vasodilating_24 (r_prep) properties_3\NNS\32613|have_26|to_35|._87 (r_nsubj) led_7\VBN\3202760|NONE_0 (l_prep) to_8\IN\0|properties_35|have_9|._52 (l_pobj) investigation_10\NN\5797597|NONE_0 (l_prep) for_14\IN\0|the_32|of_14 (l_pobj) use_15\NN\407535|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) angina_17\NN\14171682|NONE_0
D009543_D000787 NONE nifedipine_12\NN\2938514|available_40|,_2|angina_20|._87 (r_amod) controls_13\NNS\5190804|NONE_0 (l_dobj) angina_14\NN\14171682|available_60|,_22|nifedipine_20|._67
C038806_D005483 NONE dihydropyridine_4\JJ\0|NONE_0 (r_compound) calcium_5\NN\14625458|the_20 (r_compound) channel_6\NN\6251781|NONE_0 (r_compound) blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9
C038806_D004244 NONE dihydropyridine_4\JJ\0|NONE_0 (r_compound) calcium_5\NN\14625458|the_20 (r_compound) channel_6\NN\6251781|NONE_0 (r_compound) blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2 (l_conj) edema_21\NN\14315192|,_2 (l_conj) nausea_23\NN\14299637|,_2 (l_conj) anorexia_25\NN\14055623|,_2 (l_conj) dizziness_28\NN\14299637|,_6|and_4
D009553_D013345 NONE nimodipine_6\RB\0|potentially_11|in_30 (r_nsubj) useful_8\JJ\0|selectivity_69|._91 (l_prep) in_9\IN\13603305|nimodipine_30|potentially_19 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_14 (l_pobj) hemorrhage_14\NN\14285662|NONE_0
D002121_D004487 CID blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2 (l_conj) edema_21\NN\14315192|,_2
D002121_D005483 CID blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9
D009553_D003704 NONE nimodipine_6\RB\0|potentially_11|in_30 (r_nsubj) useful_8\JJ\0|selectivity_69|._91 (l_prep) in_9\IN\13603305|nimodipine_30|potentially_19 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_14 (l_pobj) hemorrhage_14\NN\14285662|NONE_0 (l_conj) headache_17\NN\5829480|subarachnoid_34|,_11 (l_conj) dementia_19\NN\14395018|migraine_19|,_2
C038806_D006261 NONE dihydropyridine_4\JJ\0|NONE_0 (r_compound) calcium_5\NN\14625458|the_20 (r_compound) channel_6\NN\6251781|NONE_0 (r_compound) blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80
D009568_D006973 NONE nitrendipine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|once_36|daily_22|possible_9 (r_prep) dosage_4\NN\13576355|schedule_85|._167 (r_nsubj) offers_10\VBZ\7160883|NONE_0 (l_dobj) schedule_14\NN\5898568|dosage_85|._82 (l_relcl) encourages_17\VBZ\2556126|a_44|convenient_42|administration_31|,_8 (l_dobj) compliance_19\NN\1202904|which_25 (l_prep) in_20\IN\13603305|patient_19 (l_pobj) therapy_24\NN\657604|NONE_0 (l_prep) of_25\IN\0|term_13 (l_pobj) hypertension_26\NN\14057371|NONE_0
D002121_D006261 CID blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80
C038806_D000855 NONE dihydropyridine_4\JJ\0|NONE_0 (r_compound) calcium_5\NN\14625458|the_20 (r_compound) channel_6\NN\6251781|NONE_0 (r_compound) blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2 (l_conj) edema_21\NN\14315192|,_2 (l_conj) nausea_23\NN\14299637|,_2 (l_conj) anorexia_25\NN\14055623|,_2
D015737_D006973 NONE nisoldipine_9\NN\0|and_4 (r_conj) nitrendipine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|once_36|daily_22|possible_9 (r_prep) dosage_4\NN\13576355|schedule_85|._167 (r_nsubj) offers_10\VBZ\7160883|NONE_0 (l_dobj) schedule_14\NN\5898568|dosage_85|._82 (l_relcl) encourages_17\VBZ\2556126|a_44|convenient_42|administration_31|,_8 (l_dobj) compliance_19\NN\1202904|which_25 (l_prep) in_20\IN\13603305|patient_19 (l_pobj) therapy_24\NN\657604|NONE_0 (l_prep) of_25\IN\0|term_13 (l_pobj) hypertension_26\NN\14057371|NONE_0
D009553_D020521 NONE nimodipine_6\RB\0|potentially_11|in_30 (r_nsubj) useful_8\JJ\0|selectivity_69|._91 (l_prep) in_9\IN\13603305|nimodipine_30|potentially_19 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_14 (l_pobj) hemorrhage_14\NN\14285662|NONE_0 (l_conj) headache_17\NN\5829480|subarachnoid_34|,_11 (l_conj) dementia_19\NN\14395018|migraine_19|,_2 (l_conj) stroke_22\NN\556313|,_6|and_4
D002121_D000855 CID blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2 (l_conj) edema_21\NN\14315192|,_2 (l_conj) nausea_23\NN\14299637|,_2 (l_conj) anorexia_25\NN\14055623|,_2
D002121_-1 NONE blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2
D009543_D006973 NONE nifedipine_12\NN\2938514|available_40|,_2|angina_20|._87 (r_amod) controls_13\NNS\5190804|NONE_0 (l_dobj) angina_14\NN\14171682|available_60|,_22|nifedipine_20|._67 (l_conj) hypertension_16\NN\14057371|and_4|with_13
D002121_D009325 CID blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2 (l_conj) edema_21\NN\14315192|,_2 (l_conj) nausea_23\NN\14299637|,_2
C038806_-1 NONE dihydropyridine_4\JJ\0|NONE_0 (r_compound) calcium_5\NN\14625458|the_20 (r_compound) channel_6\NN\6251781|NONE_0 (r_compound) blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2
C038806_D009325 NONE dihydropyridine_4\JJ\0|NONE_0 (r_compound) calcium_5\NN\14625458|the_20 (r_compound) channel_6\NN\6251781|NONE_0 (r_compound) blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2 (l_conj) edema_21\NN\14315192|,_2 (l_conj) nausea_23\NN\14299637|,_2
D002121_D004244 CID blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2 (l_conj) edema_21\NN\14315192|,_2 (l_conj) nausea_23\NN\14299637|,_2 (l_conj) anorexia_25\NN\14055623|,_2 (l_conj) dizziness_28\NN\14299637|,_6|and_4
D002118_D002318 NONE calcium_6\NN\14625458|NONE_0 (r_pobj) of_5\IN\0|the_15|in_11 (r_prep) importance_4\NN\5138488|NONE_0 (l_prep) in_7\IN\13603305|the_26|of_11 (l_pobj) pathogenesis_9\NN\13533470|NONE_0 (l_prep) of_10\IN\0|the_17 (l_pobj) disease_12\NN\14061805|NONE_0
D002118_D002318 NONE calcium_6\NN\14625458|NONE_0 (r_pobj) of_5\IN\0|the_15|in_11 (r_prep) importance_4\NN\5138488|NONE_0 (r_pobj) of_2\IN\0|increasing_23 (r_prep) recognition_1\NN\13932421|has_87|research_102|into_111|._212 (r_nsubj) stimulated_14\VBN\137313|NONE_0 (l_prep) into_16\IN\0|recognition_111|has_24|research_9|._101 (l_pobj) use_18\NN\407535|NONE_0 (l_acl) blocking_22\VBG\562280|the_27|of_19 (l_prep) for_24\IN\0|agents_7 (l_pobj) treatment_25\NN\654885|NONE_0 (l_prep) of_26\IN\0|NONE_0 (l_pobj) variety_28\NN\7951464|NONE_0 (l_prep) of_29\IN\0|a_10 (l_pobj) diseases_31\NNS\14061805|NONE_0
C038806_D004487 NONE dihydropyridine_4\JJ\0|NONE_0 (r_compound) calcium_5\NN\14625458|the_20 (r_compound) channel_6\NN\6251781|NONE_0 (r_compound) blockers_7\NNS\10101634|in_48|,_38|are_9|usually_13|well_21|,_35|with_37|._159 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_prep) with_13\IN\0|in_85|,_75|blockers_37|are_28|usually_24|well_16|,_2|._122 (l_pobj) headache_14\NN\5829480|being_80 (l_conj) flushing_17\NN\281101|,_9 (l_conj) palpitations_19\NNS\14299637|facial_17|,_2 (l_conj) edema_21\NN\14315192|,_2
C038806_D000787 NONE dihydropyridine_3\NN\0|as_13|the_10|first_6|for_26 (r_advmod) available_4\JJ\0|,_38|nifedipine_40|angina_60|._127 (r_advcl) controls_13\NNS\5190804|NONE_0 (l_dobj) angina_14\NN\14171682|available_60|,_22|nifedipine_20|._67
D002121_D002318 NONE agents_23\NNS\7347|for_7 (r_dobj) blocking_22\VBG\562280|the_27|of_19 (r_acl) use_18\NN\407535|NONE_0 (r_pobj) into_16\IN\0|recognition_111|has_24|research_9|._101 (r_prep) stimulated_14\VBN\137313|NONE_0 (l_nsubj) recognition_1\NN\13932421|has_87|research_102|into_111|._212 (l_prep) of_2\IN\0|increasing_23 (l_pobj) importance_4\NN\5138488|NONE_0 (l_prep) in_7\IN\13603305|the_26|of_11 (l_pobj) pathogenesis_9\NN\13533470|NONE_0 (l_prep) of_10\IN\0|the_17 (l_pobj) disease_12\NN\14061805|NONE_0
D002121_D002318 NONE agents_23\NNS\7347|for_7 (r_dobj) blocking_22\VBG\562280|the_27|of_19 (l_prep) for_24\IN\0|agents_7 (l_pobj) treatment_25\NN\654885|NONE_0 (l_prep) of_26\IN\0|NONE_0 (l_pobj) variety_28\NN\7951464|NONE_0 (l_prep) of_29\IN\0|a_10 (l_pobj) diseases_31\NNS\14061805|NONE_0
2884595
D006632_D001927 NONE histamine_2\NN\14739004|h1_10 (r_compound) receptors_4\NNS\5225602|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) blockade_0\NN\952963|may_35|mortality_46|._112 (r_nsubj) reduce_6\VB\441445|NONE_0 (l_dobj) mortality_7\NN\5054863|blockade_46|may_11|._66 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) encephalopathy_13\NN\14084880|NONE_0
D006632_D014917 NONE histamine_2\NN\14739004|h1_10 (r_compound) receptors_4\NNS\5225602|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) blockade_0\NN\952963|may_35|mortality_46|._112 (r_nsubj) reduce_6\VB\441445|NONE_0 (l_dobj) mortality_7\NN\5054863|blockade_46|may_11|._66 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) encephalopathy_13\NN\14084880|NONE_0 (l_compound) pertussis_9\NN\14127211|induced_23|in_46
2710809
D009116_D001919 NONE muscarine_25\NN\0|NONE_0 (r_compound) receptors_26\NNS\5225602|NONE_0 (r_pobj) on_24\IN\0|a_50|related_43|dual_35|of_23 (r_prep) effect_18\NN\34213|NONE_0 (r_pobj) to_12\IN\0|speed_23|and_4 (r_conj) to_6\IN\0|bradycardia_47|is_14|._105 (r_prep) attributed_5\VBN\670261|NONE_0 (l_nsubjpass) bradycardia_0\NNS\14110674|is_33|to_47|._152
D001285_D001919 NONE atropine_20\NN\14712692|-_8 (r_npadvmod) like_22\JJ\5839024|NONE_0 (r_amod) drugs_23\NNS\14778436|NONE_0 (r_pobj) of_19\IN\0|a_27|related_20|dual_12|on_23 (r_prep) effect_18\NN\34213|NONE_0 (r_pobj) to_12\IN\0|speed_23|and_4 (r_conj) to_6\IN\0|bradycardia_47|is_14|._105 (r_prep) attributed_5\VBN\670261|NONE_0 (l_nsubjpass) bradycardia_0\NNS\14110674|is_33|to_47|._152
C036432_D014277 NONE lactate_21\NN\14850483|NONE_0 (r_pobj) of_17\IN\0|intravenous_24 (r_prep) application_16\NN\947128|in_101|,_14|to_43|._150 (r_nsubj) led_22\VBD\3202760|NONE_0 (l_prep) in_0\IN\13603305|,_87|application_101|to_144|._251 (l_pobj) patient_6\NN\9898892|NONE_0 (l_acl) suffering_7\NN\14322699|a_27|old_17|male_13 (l_prep) from_8\IN\0|NONE_0 (l_pobj) neuralgia_13\NN\14322699|NONE_0
C036432_D006562 NONE lactate_21\NN\14850483|NONE_0 (r_pobj) of_17\IN\0|intravenous_24 (r_prep) application_16\NN\947128|in_101|,_14|to_43|._150 (r_nsubj) led_22\VBD\3202760|NONE_0 (l_prep) in_0\IN\13603305|,_87|application_101|to_144|._251 (l_pobj) patient_6\NN\9898892|NONE_0 (l_acl) suffering_7\NN\14322699|a_27|old_17|male_13 (l_prep) from_8\IN\0|NONE_0 (l_pobj) neuralgia_13\NN\14322699|NONE_0 (l_nmod) postzosteric_11\JJ\0|a_9|severe_7|trigeminal_13
C036432_D004401 NONE lactate_21\NN\14850483|NONE_0 (r_pobj) of_17\IN\0|intravenous_24 (r_prep) application_16\NN\947128|in_101|,_14|to_43|._150 (r_nsubj) led_22\VBD\3202760|NONE_0 (l_prep) to_23\IN\0|in_144|,_57|application_43|._107 (l_pobj) reaction_29\NN\13446390|NONE_0 (l_acl) characterized_30\VBN\609683|a_36|lasting_29|paradoxical_21 (l_agent) by_31\IN\0|NONE_0 (l_pobj) bradycardia_33\NN\14110674|NONE_0 (l_conj) dysarthria_35\NN\14400677|considerable_26|,_2
C036432_D001919 NONE lactate_21\NN\14850483|NONE_0 (r_pobj) of_17\IN\0|intravenous_24 (r_prep) application_16\NN\947128|in_101|,_14|to_43|._150 (r_nsubj) led_22\VBD\3202760|NONE_0 (l_prep) to_23\IN\0|in_144|,_57|application_43|._107 (l_pobj) reaction_29\NN\13446390|NONE_0 (l_acl) characterized_30\VBN\609683|a_36|lasting_29|paradoxical_21 (l_agent) by_31\IN\0|NONE_0 (l_pobj) bradycardia_33\NN\14110674|NONE_0
C036432_D003680 NONE lactate_21\NN\14850483|NONE_0 (r_pobj) of_17\IN\0|intravenous_24 (r_prep) application_16\NN\947128|in_101|,_14|to_43|._150 (r_nsubj) led_22\VBD\3202760|NONE_0 (l_prep) to_23\IN\0|in_144|,_57|application_43|._107 (l_pobj) reaction_29\NN\13446390|NONE_0 (l_acl) characterized_30\VBN\609683|a_36|lasting_29|paradoxical_21 (l_agent) by_31\IN\0|NONE_0 (l_pobj) bradycardia_33\NN\14110674|NONE_0 (l_conj) dysarthria_35\NN\14400677|considerable_26|,_2 (l_conj) dysphagia_38\NN\14052403|,_6|and_4
D001712_D001919 CID biperiden_3\VBN\0|NONE_0 (l_nsubj) bradycardia_0\NNS\14110674|._28
D001712_D001919 CID biperiden_3\VBN\0|NONE_0 (r_pobj) by_2\IN\0|NONE_0 (r_agent) induced_1\VBN\1627355|NONE_0 (r_acl) bradycardia_0\NNS\14110674|is_33|to_47|._152
12865514
D007980_D009127 NONE levodopa_29\RB\14604959|-_8 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) dyskinesias_32\NNS\14084880|,_23|and_21 (r_conj) rigidity_26\NN\5023233|particularly_27|,_2
D007980_D018476 NONE levodopa_29\RB\14604959|-_8 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) dyskinesias_32\NNS\14084880|,_23|and_21 (r_conj) rigidity_26\NN\5023233|particularly_27|,_2 (r_conj) bradykinesia_24\JJ\0|stages_56|)_20|and_18|,_15
D007980_D004409 CID levodopa_29\RB\14604959|-_8 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) dyskinesias_32\NNS\14084880|,_23|and_21
D007980_D004409 CID levodopa_4\JJ\14604959|the_4 (r_compound) dose_5\NN\3740161|NONE_0 (r_pobj) in_2\IN\13603305|the_14 (r_prep) reduction_1\NN\351485|useful_34|._80 (r_nsubj) is_6\VBZ\0|NONE_0 (l_acomp) useful_7\JJ\0|reduction_34|._46 (l_prep) in_8\IN\13603305|NONE_0 (l_pcomp) controlling_9\VBG\0|NONE_0 (l_dobj) dyskinesias_13\NNS\14084880|NONE_0
D007980_D010300 NONE levodopa_29\RB\14604959|-_8 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) dyskinesias_32\NNS\14084880|,_23|and_21 (r_conj) rigidity_26\NN\5023233|particularly_27|,_2 (r_conj) bradykinesia_24\JJ\0|stages_56|)_20|and_18|,_15 (r_conj) scale_19\NN\7260623|three_89|suffering_74 (r_appos) patients_3\NNS\9898892|implantation_185|._222 (l_acl) suffering_4\VBG\14322699|three_15|scale_74 (l_prep) from_5\IN\0|NONE_0 (l_pobj) disease_9\NN\14061805|NONE_0
16323982
D004967_D050171 NONE estrogen_47\NN\14745635|NONE_0 (r_pobj) by_46\IN\0|NONE_0 (r_agent) caused_45\VBN\1617192|the_40|known_31|hyperglyceridemic_25 (r_acl) effect_44\NN\34213|NONE_0
D004967_D003324 NONE estrogen_47\NN\14745635|NONE_0 (r_pobj) by_46\IN\0|NONE_0 (r_agent) caused_45\VBN\1617192|the_40|known_31|hyperglyceridemic_25 (r_acl) effect_44\NN\34213|NONE_0 (r_pobj) than_38\IN\0|i_33 (r_prep) other_37\JJ\0|arteriosclerosis_165|is_81|through_69|,_35|._69 (r_conj) mediated_17\VBN\761713|NONE_0 (l_nsubjpass) arteriosclerosis_2\NN\14110411|is_84|through_96|,_130|other_165|._234
D002784_D003324 NONE cholesterol_22\NN\15058310|NONE_0 (r_pobj) in_20\IN\13603305|NONE_0 (r_prep) changes_19\NNS\7283608|NONE_0 (r_pobj) through_18\IN\0|arteriosclerosis_96|is_12|,_34|other_69|._138 (r_prep) mediated_17\VBN\761713|NONE_0 (l_nsubjpass) arteriosclerosis_2\NN\14110411|is_84|through_96|,_130|other_165|._234
D002784_D050171 NONE cholesterol_22\NN\15058310|NONE_0 (r_pobj) in_20\IN\13603305|NONE_0 (r_prep) changes_19\NNS\7283608|NONE_0 (r_pobj) through_18\IN\0|arteriosclerosis_96|is_12|,_34|other_69|._138 (r_prep) mediated_17\VBN\761713|NONE_0 (l_conj) other_37\JJ\0|arteriosclerosis_165|is_81|through_69|,_35|._69 (l_prep) than_38\IN\0|i_33 (l_pobj) effect_44\NN\34213|NONE_0
D017373_D050171 CID cpa_14\NN\9761403|prolonged_10 (r_compound) therapy_15\NN\657604|NONE_0 (r_pobj) by_12\IN\0|as_10 (r_agent) caused_11\VBN\1617192|ischaemic_71|coronary_61|with_35 (r_advcl) arteriosclerosis_2\NN\14110411|is_84|through_96|,_130|other_165|._234 (r_nsubjpass) mediated_17\VBN\761713|NONE_0 (l_conj) other_37\JJ\0|arteriosclerosis_165|is_81|through_69|,_35|._69 (l_prep) than_38\IN\0|i_33 (l_pobj) effect_44\NN\34213|NONE_0
D017373_D003324 CID cpa_14\NN\9761403|prolonged_10 (r_compound) therapy_15\NN\657604|NONE_0 (r_pobj) by_12\IN\0|as_10 (r_agent) caused_11\VBN\1617192|ischaemic_71|coronary_61|with_35 (r_advcl) arteriosclerosis_2\NN\14110411|is_84|through_96|,_130|other_165|._234
D017373_D003327 NONE cpa_7\NN\9761403|NONE_0 (r_compound) treatment_8\NN\654885|NONE_0 (r_pobj) on_6\IN\0|2.5_10 (r_prep) years_5\NNS\15144371|NONE_0 (r_pobj) of_3\IN\0|a_9 (r_prep) period_2\NN\13575869|NONE_0 (r_pobj) after_0\IN\0|,_44|patients_51|were_79|affected_96|._130 (r_prep) found_18\VBN\13279262|NONE_0 (l_xcomp) affected_21\VBN\126264|after_96|,_52|patients_45|were_17|._34 (l_agent) by_22\IN\0|to_15|be_12 (l_pobj) disease_25\NN\14061805|NONE_0
16723784
D015764_D001282 NONE bepridil_6\NN\0|NONE_0 (r_amod) administration_7\NN\1133281|NONE_0 (r_pobj) during_5\IN\0|adverse_16|for_31 (r_prep) effects_4\NNS\13245626|NONE_0 (l_prep) for_8\IN\0|adverse_47|during_31 (l_pobj) fibrillation_10\NN\14361664|NONE_0 (l_conj) flutter_12\JJ\331950|atrial_24|and_4
D015764_D001282 NONE hydrochloride_1\NN\14817592|bepridil_9|has_20|attention_34|as_44|._118 (r_nsubj) attracted_6\VBN\1448100|NONE_0 (l_prep) as_8\IN\14622893|bepridil_53|hydrochloride_44|has_24|attention_10|._74 (l_pobj) drug_11\NN\14778436|NONE_0 (l_prep) for_12\IN\0|an_18|effective_15 (l_pobj) fibrillation_14\NN\14361664|NONE_0 (l_conj) flutter_20\NN\331950|atrial_36|(_16|af_15
D015764_D001282 NONE hydrochloride_1\NN\14817592|bepridil_9|has_20|attention_34|as_44|._118 (r_nsubj) attracted_6\VBN\1448100|NONE_0 (l_prep) as_8\IN\14622893|bepridil_53|hydrochloride_44|has_24|attention_10|._74 (l_pobj) drug_11\NN\14778436|NONE_0 (l_prep) for_12\IN\0|an_18|effective_15 (l_pobj) fibrillation_14\NN\14361664|NONE_0 (l_conj) flutter_20\NN\331950|atrial_36|(_16|af_15 (l_appos) afl_22\NNP\8303504|atrial_16|(_1|)_3
D015764_D001282 NONE bpd_3\NNP\0|NONE_0 (r_appos) hydrochloride_1\NN\14817592|bepridil_9|has_20|attention_34|as_44|._118 (r_nsubj) attracted_6\VBN\1448100|NONE_0 (l_prep) as_8\IN\14622893|bepridil_53|hydrochloride_44|has_24|attention_10|._74 (l_pobj) drug_11\NN\14778436|NONE_0 (l_prep) for_12\IN\0|an_18|effective_15 (l_pobj) fibrillation_14\NN\14361664|NONE_0 (l_conj) flutter_20\NN\331950|atrial_36|(_16|af_15
D015764_D001282 NONE bpd_3\NNP\0|NONE_0 (r_appos) hydrochloride_1\NN\14817592|bepridil_9|has_20|attention_34|as_44|._118 (r_nsubj) attracted_6\VBN\1448100|NONE_0 (l_prep) as_8\IN\14622893|bepridil_53|hydrochloride_44|has_24|attention_10|._74 (l_pobj) drug_11\NN\14778436|NONE_0 (l_prep) for_12\IN\0|an_18|effective_15 (l_pobj) fibrillation_14\NN\14361664|NONE_0 (l_conj) flutter_20\NN\331950|atrial_36|(_16|af_15 (l_appos) afl_22\NNP\8303504|atrial_16|(_1|)_3
D015764_D001282 NONE bpd_0\NNP\0|was_4|to_21|._102 (r_nsubjpass) administered_2\VBN\2436349|NONE_0 (l_prep) to_3\IN\0|bpd_21|was_17|._81 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_acl) comprising_14\VBG\2604760|459_44|(_31|males_26|)_2 (l_dobj) cases_20\NNS\7283608|NONE_0 (l_compound) afl_19\NNP\8303504|378_14|af_10|81_3
D015764_D001281 NONE bepridil_6\NN\0|NONE_0 (r_amod) administration_7\NN\1133281|NONE_0 (r_pobj) during_5\IN\0|adverse_16|for_31 (r_prep) effects_4\NNS\13245626|NONE_0 (l_prep) for_8\IN\0|adverse_47|during_31 (l_pobj) fibrillation_10\NN\14361664|NONE_0 (l_conj) flutter_12\JJ\331950|atrial_24|and_4
D015764_D001281 NONE hydrochloride_1\NN\14817592|bepridil_9|has_20|attention_34|as_44|._118 (r_nsubj) attracted_6\VBN\1448100|NONE_0 (l_prep) as_8\IN\14622893|bepridil_53|hydrochloride_44|has_24|attention_10|._74 (l_pobj) drug_11\NN\14778436|NONE_0 (l_prep) for_12\IN\0|an_18|effective_15 (l_pobj) fibrillation_14\NN\14361664|NONE_0
D015764_D001281 NONE hydrochloride_1\NN\14817592|bepridil_9|has_20|attention_34|as_44|._118 (r_nsubj) attracted_6\VBN\1448100|NONE_0 (l_prep) as_8\IN\14622893|bepridil_53|hydrochloride_44|has_24|attention_10|._74 (l_pobj) drug_11\NN\14778436|NONE_0 (l_prep) for_12\IN\0|an_18|effective_15 (l_pobj) fibrillation_14\NN\14361664|NONE_0 (l_appos) af_16\NNP\0|atrial_21|(_1|flutter_15
D015764_D001281 NONE bpd_3\NNP\0|NONE_0 (r_appos) hydrochloride_1\NN\14817592|bepridil_9|has_20|attention_34|as_44|._118 (r_nsubj) attracted_6\VBN\1448100|NONE_0 (l_prep) as_8\IN\14622893|bepridil_53|hydrochloride_44|has_24|attention_10|._74 (l_pobj) drug_11\NN\14778436|NONE_0 (l_prep) for_12\IN\0|an_18|effective_15 (l_pobj) fibrillation_14\NN\14361664|NONE_0
D015764_D001281 NONE bpd_3\NNP\0|NONE_0 (r_appos) hydrochloride_1\NN\14817592|bepridil_9|has_20|attention_34|as_44|._118 (r_nsubj) attracted_6\VBN\1448100|NONE_0 (l_prep) as_8\IN\14622893|bepridil_53|hydrochloride_44|has_24|attention_10|._74 (l_pobj) drug_11\NN\14778436|NONE_0 (l_prep) for_12\IN\0|an_18|effective_15 (l_pobj) fibrillation_14\NN\14361664|NONE_0 (l_appos) af_16\NNP\0|atrial_21|(_1|flutter_15
D015764_D001281 NONE bpd_0\NNP\0|was_4|to_21|._102 (r_nsubjpass) administered_2\VBN\2436349|NONE_0 (l_prep) to_3\IN\0|bpd_21|was_17|._81 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_acl) comprising_14\VBG\2604760|459_44|(_31|males_26|)_2 (l_dobj) cases_20\NNS\7283608|NONE_0 (l_nmod) af_16\NNP\0|378_4|81_7|afl_10
15321332
D004329_D001008 CID droperidol_9\NN\0|to_12 (r_pobj) due_5\IN\5174653|a_32|of_25|._65 (r_prep) case_1\NN\7283608|NONE_0 (l_prep) of_2\IN\0|a_7|due_25|._90 (l_pobj) anxiety_4\NN\14373582|NONE_0
D004329_D001008 CID droperidol_3\NN\0|-_10 (r_npadvmod) induced_5\VBN\1627355|psychological_8 (r_amod) disturbance_7\NN\407535|NONE_0
19920070
D010634_D006529 CID phenobarbital_21\JJ\2792049|NONE_0 (r_amod) administration_22\NN\1133281|NONE_0 (r_pobj) after_20\IN\0|NONE_0 (r_prep) hepatomegaly_19\NN\14501726|specific_109|of_91|and_4|._47
6806735
D006585_D005767 NONE hmm_0\UH\0|gastrointestinal_4 (r_compound) toxicity_2\NN\13576101|discontinuation_22|._63
C034868_D010051 NONE cpdd_20\NNP\0|NONE_0 (r_appos) cisplatinum_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|a_14 (r_prep) combination_16\NN\7951464|NONE_0 (r_pobj) with_14\IN\0|during_74|,_47|patients_42|were_13|,_40|m2_48|._169 (r_prep) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_8\NNS\9898892|during_32|,_5|were_29|with_42|,_82|m2_90|._211 (l_prep) with_9\IN\0|38_12 (l_pobj) cancer_11\NN\14239425|NONE_0
D006585_D010051 NONE hexamethylmelamine_16\NN\0|and_4 (r_conj) cyclophosphamide_14\NN\0|platinum_22|,_14|,_2 (r_conj) adriamycin_12\NNS\0|NONE_0 (r_pobj) of_7\IN\0|a_14 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) with_4\IN\0|of_18|._87 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|with_18|._105 (l_pobj) cancer_3\NN\14239425|NONE_0
D006585_D010051 NONE hexamethylmelamine_47\NN\0|50_75|mg_72|/_70|,_67|adriamycin_65|,_27|m2_18|,_16|on_14|;_6|and_4 (r_conj) m2_26\NN\13357178|during_122|,_95|patients_90|were_61|with_48|,_8|._121 (r_npadvmod) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_8\NNS\9898892|during_32|,_5|were_29|with_42|,_82|m2_90|._211 (l_prep) with_9\IN\0|38_12 (l_pobj) cancer_11\NN\14239425|NONE_0
D006585_D010051 NONE hmm_49\NNP\0|,_4|daily_14|,_19|for_21 (r_appos) hexamethylmelamine_47\NN\0|50_75|mg_72|/_70|,_67|adriamycin_65|,_27|m2_18|,_16|on_14|;_6|and_4 (r_conj) m2_26\NN\13357178|during_122|,_95|patients_90|were_61|with_48|,_8|._121 (r_npadvmod) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_8\NNS\9898892|during_32|,_5|were_29|with_42|,_82|m2_90|._211 (l_prep) with_9\IN\0|38_12 (l_pobj) cancer_11\NN\14239425|NONE_0
D004317_D010051 NONE adriamycin_12\NNS\0|NONE_0 (r_pobj) of_7\IN\0|a_14 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) with_4\IN\0|of_18|._87 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|with_18|._105 (l_pobj) cancer_3\NN\14239425|NONE_0
D004317_D010051 NONE adriamycin_28\NNS\0|50_10|mg_7|/_5|,_2|,_38|m2_47|,_49|on_51|;_59|and_61|hexamethylmelamine_65 (r_amod) m2_26\NN\13357178|during_122|,_95|patients_90|were_61|with_48|,_8|._121 (r_npadvmod) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_8\NNS\9898892|during_32|,_5|were_29|with_42|,_82|m2_90|._211 (l_prep) with_9\IN\0|38_12 (l_pobj) cancer_11\NN\14239425|NONE_0
D003520_D010051 NONE cyclophosphamide_14\NN\0|platinum_22|,_14|,_2 (r_conj) adriamycin_12\NNS\0|NONE_0 (r_pobj) of_7\IN\0|a_14 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) with_4\IN\0|of_18|._87 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|with_18|._105 (l_pobj) cancer_3\NN\14239425|NONE_0
D003520_D010051 NONE cyclophosphamide_35\NN\0|30_10|mg_7|/_5|,_2 (r_conj) m2_33\NN\13357178|,_8 (r_conj) adriamycin_28\NNS\0|50_10|mg_7|/_5|,_2|,_38|m2_47|,_49|on_51|;_59|and_61|hexamethylmelamine_65 (r_amod) m2_26\NN\13357178|during_122|,_95|patients_90|were_61|with_48|,_8|._121 (r_npadvmod) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_8\NNS\9898892|during_32|,_5|were_29|with_42|,_82|m2_90|._211 (l_prep) with_9\IN\0|38_12 (l_pobj) cancer_11\NN\14239425|NONE_0
D002945_D010051 NONE platinum_10\NN\14627081|,_8|,_20|cyclophosphamide_22 (r_nmod) adriamycin_12\NNS\0|NONE_0 (r_pobj) of_7\IN\0|a_14 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) with_4\IN\0|of_18|._87 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|with_18|._105 (l_pobj) cancer_3\NN\14239425|NONE_0
D002945_D010051 NONE cisplatinum_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|a_14 (r_prep) combination_16\NN\7951464|NONE_0 (r_pobj) with_14\IN\0|during_74|,_47|patients_42|were_13|,_40|m2_48|._169 (r_prep) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) patients_8\NNS\9898892|during_32|,_5|were_29|with_42|,_82|m2_90|._211 (l_prep) with_9\IN\0|38_12 (l_pobj) cancer_11\NN\14239425|NONE_0
24275640
D004317_D066126 CID doxorubicin_12\NN\2716866|NONE_0 (r_pobj) of_11\IN\0|single_26 (r_prep) doses_10\NNS\3740161|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) after_4\IN\0|NONE_0 (r_prep) cardiotoxicity_3\NN\0|NONE_0
D004317_D066126 CID doxorubicin_3\NN\2716866|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) mechanism_1\NN\13446390|cardiotoxicity_39|controversial_62|._75 (r_nsubj) remains_7\VBZ\2684|NONE_0 (l_nsubj) cardiotoxicity_6\NN\0|mechanism_39|controversial_23|._36
D004317_D066126 CID dox)-induced_5\JJ\0|(_1 (r_amod) cardiotoxicity_6\NN\0|mechanism_39|controversial_23|._36
D004317_D066126 CID dox_17\NNP\0|NONE_0 (r_pobj) of_16\IN\0|a_14|single_12 (r_prep) dose_15\NN\3740161|NONE_0 (r_pobj) by_12\IN\0|only_24 (r_agent) induced_11\VBN\1627355|acute_21 (r_acl) cardiotoxicity_10\NN\0|NONE_0
D004317_D006331 NONE dox_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|single_12 (r_prep) dose_1\NN\3740161|was_12|with_27|._155 (r_nsubjpass) associated_5\VBN\628491|NONE_0 (l_prep) with_6\IN\0|dose_27|was_15|._128 (l_pobj) disarrangement_9\NN\14499262|NONE_0
D004317_D009336 CID dox_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|single_12 (r_prep) dose_1\NN\3740161|was_12|with_27|._155 (r_nsubjpass) associated_5\VBN\628491|NONE_0 (l_prep) with_6\IN\0|dose_27|was_15|._128 (l_pobj) disarrangement_9\NN\14499262|NONE_0 (l_conj) necrosis_11\NN\11444117|increased_34|cardiac_24|,_2
3409843
D002220_D004827 NONE carbamazepine_8\NN\0|in_24 (r_compound) treatment_9\NN\654885|to_17 (l_prep) in_10\IN\13603305|carbamazepine_24 (l_pobj) woman_13\NN\9605289|NONE_0 (l_amod) epileptic_12\JJ\10595647|an_3
D002220_D001855 NONE carbamazepine_9\NN\0|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_pcomp) due_7\IN\5174653|of_30 (r_prep) concerns_1\NNS\5682950|NONE_0 (l_prep) of_2\IN\0|due_30 (l_pobj) toxicity_6\NN\13576101|NONE_0
D002220_D000741 CID carbamazepine_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) treated_6\VBN\2376958|a_10 (r_acl) patient_5\NN\9898892|NONE_0 (r_pobj) in_3\IN\13603305|fatal_22|aplastic_16|._39 (r_prep) anemia_2\NN\14189204|NONE_0
D002220_D000741 CID carbamazepine_8\NN\0|in_24 (r_compound) treatment_9\NN\654885|to_17 (r_pobj) due_6\IN\5174653|a_32|of_25 (r_amod) case_1\NN\7283608|is_83|._94 (l_prep) of_2\IN\0|a_7|due_25 (l_pobj) anemia_5\NN\14189204|NONE_0
2021990
D002927_D007022 CID cimetidine_15\NN\14778019|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) caused_12\VBN\1617192|NONE_0 (r_acl) hypotension_11\NN\14057371|NONE_0
D002927_D007022 CID cimetidine_22\NN\14778019|NONE_0 (r_pobj) of_21\IN\0|the_26|vasodilating_22 (r_prep) activity_20\NN\30358|since_23|is_23|,_34|in_36|,_43|through_45 (r_nsubjpass) mediated_24\VBN\761713|that_136|antagonist_125|may_114|useful_107|,_51 (r_advcl) be_7\VB\14625458|we_38|._152 (l_acomp) useful_8\JJ\0|that_29|antagonist_18|may_7|,_56|mediated_107 (l_prep) in_9\IN\13603305|NONE_0 (l_pcomp) preventing_10\VBG\0|NONE_0 (l_dobj) hypotension_11\NN\14057371|NONE_0
8996419
D003276_D020246 NONE ocs_11\NNS\0|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) use_8\NN\407535|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|the_20|83_16|of_7 (r_acl) cases_3\NNS\7283608|NONE_0 (r_pobj) of_0\IN\0|,_58|43_60|were_63|as_77|and_130|five_134|._183 (r_prep) recorded_15\VBN\2225492|NONE_0 (l_prep) as_16\IN\14622893|of_77|,_19|43_17|were_14|and_53|five_57|._106 (l_pobj) thrombosis_20\NN\14100769|NONE_0
D003276_D020246 NONE ocs_11\NNS\0|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) use_8\NN\407535|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|the_20|83_16|of_7 (r_acl) cases_3\NNS\7283608|NONE_0 (r_pobj) of_0\IN\0|,_58|43_60|were_63|as_77|and_130|five_134|._183 (r_prep) recorded_15\VBN\2225492|NONE_0 (l_conj) five_28\CD\13741022|of_134|,_76|43_74|were_71|as_57|and_4|._49 (l_prep) as_29\IN\14622893|NONE_0 (l_pobj) thrombosis_31\NN\14100769|NONE_0
D011372_D054556 NONE progestagen_15\NN\0|NONE_0 (r_nmod) ocs_18\NNS\0|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) users_13\NNS\7846|two_17 (r_attr) were_12\VBD\0|,_14 (r_relcl) vte_7\NNP\0|NONE_0
C033273_D054556 NONE gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0
C033273_D054556 NONE gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0 (l_appos) vte_16\NNP\0|venous_24|(_1|)_3
C033273_D054556 NONE gestodene_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|with_28 (r_prep) users_24\NNS\7846|NONE_0 (r_pobj) in_23\IN\13603305|NONE_0 (r_prep) than_22\IN\0|among_125|,_81|risk_75|higher_59|in_52|._69 (r_prep) was_12\VBD\0|NONE_0 (l_nsubj) risk_9\NN\14541044|among_50|,_6|higher_16|in_23|than_75|._144 (l_prep) of_10\IN\0|the_9 (l_pobj) vte_11\NNP\0|NONE_0
D004997_D054556 NONE ethinyloestradiol_21\NN\0|NONE_0 (r_pobj) with_18\IN\0|of_15 (r_prep) users_15\NNS\7846|NONE_0 (r_pobj) in_14\IN\13603305|among_73|,_29|risk_23|higher_7|than_52|._121 (r_prep) was_12\VBD\0|NONE_0 (l_nsubj) risk_9\NN\14541044|among_50|,_6|higher_16|in_23|than_75|._144 (l_prep) of_10\IN\0|the_9 (l_pobj) vte_11\NNP\0|NONE_0
D004997_D054556 NONE ethinyloestradiol_32\NN\0|NONE_0 (r_pobj) with_29\IN\0|of_28 (r_prep) users_24\NNS\7846|NONE_0 (r_pobj) in_23\IN\13603305|NONE_0 (r_prep) than_22\IN\0|among_125|,_81|risk_75|higher_59|in_52|._69 (r_prep) was_12\VBD\0|NONE_0 (l_nsubj) risk_9\NN\14541044|among_50|,_6|higher_16|in_23|than_75|._144 (l_prep) of_10\IN\0|the_9 (l_pobj) vte_11\NNP\0|NONE_0
D004997_D054556 NONE ethinyloestradiol_27\NN\0|plus_10 (r_appos) desogestrel_23\NN\0|NONE_0 (r_pobj) for_22\IN\0|10.12_7|)_2 (r_prep) 3.49_16\CD\0|with_78|,_31|ratios_20|for_83|._126 (r_attr) were_15\VBD\0|NONE_0 (l_nsubj) ratios_12\NNS\13815152|with_58|,_11|3.49_20|for_103|._146 (l_prep) for_13\IN\0|the_16|odds_12 (l_pobj) vte_14\NNP\0|NONE_0
D003276_D054556 CID contraceptives_13\NNS\3183080|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|venous_23 (r_acl) thromboembolism_8\NN\14100769|NONE_0
D003276_D054556 CID contraceptives_25\NNS\3183080|who_14 (r_dobj) used_23\VBD\0|NONE_0 (r_relcl) women_21\NNS\9605289|NONE_0 (r_pobj) in_20\IN\13603305|NONE_0 (r_prep) higher_19\JJR\0|that_55|incidence_46|containing_51 (r_acomp) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0
D003276_D054556 CID contraceptives_25\NNS\3183080|who_14 (r_dobj) used_23\VBD\0|NONE_0 (r_relcl) women_21\NNS\9605289|NONE_0 (r_pobj) in_20\IN\13603305|NONE_0 (r_prep) higher_19\JJR\0|that_55|incidence_46|containing_51 (r_acomp) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0 (l_appos) vte_16\NNP\0|venous_24|(_1|)_3
D003276_D054556 CID ocs_27\NNP\0|oral_21|(_1|)_3 (r_appos) contraceptives_25\NNS\3183080|who_14 (r_dobj) used_23\VBD\0|NONE_0 (r_relcl) women_21\NNS\9605289|NONE_0 (r_pobj) in_20\IN\13603305|NONE_0 (r_prep) higher_19\JJR\0|that_55|incidence_46|containing_51 (r_acomp) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0
D003276_D054556 CID ocs_27\NNP\0|oral_21|(_1|)_3 (r_appos) contraceptives_25\NNS\3183080|who_14 (r_dobj) used_23\VBD\0|NONE_0 (r_relcl) women_21\NNS\9605289|NONE_0 (r_pobj) in_20\IN\13603305|NONE_0 (r_prep) higher_19\JJR\0|that_55|incidence_46|containing_51 (r_acomp) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0 (l_appos) vte_16\NNP\0|venous_24|(_1|)_3
D003276_D054556 CID ocs_42\NNS\0|NONE_0 (r_pobj) of_41\IN\0|NONE_0 (r_prep) users_40\NNS\7846|NONE_0 (r_pobj) in_39\IN\13603305|NONE_0 (r_prep) than_38\IN\0|the_59|generation_49|progestagens_38|or_15|desogestrel_12 (r_prep) gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0
D003276_D054556 CID ocs_42\NNS\0|NONE_0 (r_pobj) of_41\IN\0|NONE_0 (r_prep) users_40\NNS\7846|NONE_0 (r_pobj) in_39\IN\13603305|NONE_0 (r_prep) than_38\IN\0|the_59|generation_49|progestagens_38|or_15|desogestrel_12 (r_prep) gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0 (l_appos) vte_16\NNP\0|venous_24|(_1|)_3
D003276_D054556 CID oc_17\NNP\0|and_4 (r_conj) vte_15\NNP\0|with_15
D003276_D054556 CID oc_17\NNP\0|the_9|main_5 (r_compound) preparations_18\NNS\407535|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) users_13\NNS\7846|NONE_0 (r_pobj) in_12\IN\13603305|incidence_17 (r_prep) compare_8\VB\4744814|to_16|and_4 (l_dobj) incidence_9\NN\13821570|in_17 (l_prep) of_10\IN\0|NONE_0 (l_pobj) vte_11\NNP\0|NONE_0
D003276_D054556 CID oc_17\NNP\0|the_9|main_5 (r_compound) preparations_18\NNS\407535|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) users_13\NNS\7846|NONE_0 (r_pobj) in_12\IN\13603305|incidence_17 (r_prep) compare_8\VB\4744814|to_16|and_4 (r_conj) estimate_6\VB\5802185|a_21|cohort_19 (r_relcl) analysis_4\NN\633864|we_16|,_86|and_88|study_114|._252 (r_dobj) did_1\VBD\0|NONE_0 (l_conj) study_26\NN\635850|we_130|analysis_114|,_28|and_26|._138 (l_acl) calculate_28\VB\632627|a_31|nested_29|control_17|,_77|after_79 (l_dobj) ratios_31\NNS\13815152|to_22 (l_prep) of_32\IN\0|the_16|odds_12|associated_7 (l_pobj) vte_33\NNP\0|NONE_0
D003276_D054556 CID oc_41\NNP\0|NONE_0 (r_pobj) of_40\IN\0|different_16 (r_prep) types_39\NNS\5839024|NONE_0 (r_pobj) of_37\IN\0|NONE_0 (r_prep) use_36\NN\407535|NONE_0 (r_pobj) with_35\IN\0|NONE_0 (r_prep) associated_34\VBN\628491|the_23|odds_19|of_7 (r_acl) ratios_31\NNS\13815152|to_22 (r_dobj) calculate_28\VB\632627|a_31|nested_29|control_17|,_77|after_79 (r_acl) study_26\NN\635850|we_130|analysis_114|,_28|and_26|._138 (r_conj) did_1\VBD\0|NONE_0 (l_dobj) analysis_4\NN\633864|we_16|,_86|and_88|study_114|._252 (l_relcl) estimate_6\VB\5802185|a_21|cohort_19 (l_conj) compare_8\VB\4744814|to_16|and_4 (l_dobj) incidence_9\NN\13821570|in_17 (l_prep) of_10\IN\0|NONE_0 (l_pobj) vte_11\NNP\0|NONE_0
D003276_D054556 CID oc_41\NNP\0|NONE_0 (r_pobj) of_40\IN\0|different_16 (r_prep) types_39\NNS\5839024|NONE_0 (r_pobj) of_37\IN\0|NONE_0 (r_prep) use_36\NN\407535|NONE_0 (r_pobj) with_35\IN\0|NONE_0 (r_prep) associated_34\VBN\628491|the_23|odds_19|of_7 (r_acl) ratios_31\NNS\13815152|to_22 (l_prep) of_32\IN\0|the_16|odds_12|associated_7 (l_pobj) vte_33\NNP\0|NONE_0
D003276_D054556 CID ocs_18\NNS\0|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) users_13\NNS\7846|two_17 (r_attr) were_12\VBD\0|,_14 (r_relcl) vte_7\NNP\0|NONE_0
D003276_D054556 CID ocs_11\NNS\0|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) use_8\NN\407535|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|the_20|83_16|of_7 (r_acl) cases_3\NNS\7283608|NONE_0 (l_prep) of_4\IN\0|the_13|83_9|associated_7 (l_pobj) vte_5\NNP\0|NONE_0
D003276_D054556 CID oc_17\NNP\0|NONE_0 (r_pobj) of_15\IN\0|current_14 (r_prep) users_14\NNS\7846|NONE_0 (r_pobj) in_12\IN\13603305|,_26|3.10_28 (r_prep) 4.10_11\CD\0|rate_39|._123 (r_attr) was_10\VBD\0|NONE_0 (l_nsubj) rate_2\NN\13815152|4.10_39|._162 (l_prep) of_3\IN\0|the_15|crude_11|per_7 (l_pobj) vte_4\NNP\0|NONE_0
D003276_D054556 CID ocs_26\NNS\0|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) users_21\NNS\7846|NONE_0 (r_pobj) in_20\IN\13603305|,_33|and_35|4.96_39 (r_prep) 3.10_19\CD\0|in_28|,_2 (r_appos) 4.10_11\CD\0|rate_39|._123 (r_attr) was_10\VBD\0|NONE_0 (l_nsubj) rate_2\NN\13815152|4.10_39|._162 (l_prep) of_3\IN\0|the_15|crude_11|per_7 (l_pobj) vte_4\NNP\0|NONE_0
D003276_D054556 CID ocs_21\NNS\0|NONE_0 (r_pobj) to_17\IN\0|generation_20 (r_prep) relative_16\JJ\7846|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) users_11\NNS\7846|NONE_0 (r_pobj) in_10\IN\13603305|the_22|rate_18|of_7 (r_prep) ratio_7\NN\13815152|after_35|,_11|%_88|._103 (l_prep) of_8\IN\0|the_15|rate_11|in_7 (l_pobj) vte_9\NNP\0|NONE_0
D003276_D054556 CID ocs_21\NNS\0|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) users_12\NNS\7846|NONE_0 (r_pobj) between_11\IN\0|the_16|of_7 (r_prep) risk_8\NN\14541044|NONE_0 (l_prep) of_9\IN\0|the_9|between_7 (l_pobj) vte_10\NNP\0|NONE_0
D003276_D054556 CID ocs_5\NNS\0|NONE_0 (r_pobj) with_0\IN\0|,_47|ratios_58|3.49_78|for_161|._204 (r_prep) were_15\VBD\0|NONE_0 (l_nsubj) ratios_12\NNS\13815152|with_58|,_11|3.49_20|for_103|._146 (l_prep) for_13\IN\0|the_16|odds_12 (l_pobj) vte_14\NNP\0|NONE_0
D017135_D054556 NONE desogestrel_37\NN\0|the_47|generation_37|progestagens_26|or_3|than_12 (r_conj) gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0
D017135_D054556 NONE desogestrel_37\NN\0|the_47|generation_37|progestagens_26|or_3|than_12 (r_conj) gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0 (l_appos) vte_16\NNP\0|venous_24|(_1|)_3
D017135_D054556 NONE desogestrel_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|with_15 (r_prep) users_15\NNS\7846|NONE_0 (r_pobj) in_14\IN\13603305|among_73|,_29|risk_23|higher_7|than_52|._121 (r_prep) was_12\VBD\0|NONE_0 (l_nsubj) risk_9\NN\14541044|among_50|,_6|higher_16|in_23|than_75|._144 (l_prep) of_10\IN\0|the_9 (l_pobj) vte_11\NNP\0|NONE_0
D017135_D054556 NONE desogestrel_28\NN\0|or_3 (r_conj) gestodene_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|with_28 (r_prep) users_24\NNS\7846|NONE_0 (r_pobj) in_23\IN\13603305|NONE_0 (r_prep) than_22\IN\0|among_125|,_81|risk_75|higher_59|in_52|._69 (r_prep) was_12\VBD\0|NONE_0 (l_nsubj) risk_9\NN\14541044|among_50|,_6|higher_16|in_23|than_75|._144 (l_prep) of_10\IN\0|the_9 (l_pobj) vte_11\NNP\0|NONE_0
D017135_D054556 NONE desogestrel_23\NN\0|NONE_0 (r_pobj) for_22\IN\0|10.12_7|)_2 (r_prep) 3.49_16\CD\0|with_78|,_31|ratios_20|for_83|._126 (r_attr) were_15\VBD\0|NONE_0 (l_nsubj) ratios_12\NNS\13815152|with_58|,_11|3.49_20|for_103|._146 (l_prep) for_13\IN\0|the_16|odds_12 (l_pobj) vte_14\NNP\0|NONE_0
D011374_D054556 NONE progestagens_34\NNS\0|the_21|generation_11|or_23|desogestrel_26|than_38 (r_compound) gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0
D011374_D054556 NONE progestagens_34\NNS\0|the_21|generation_11|or_23|desogestrel_26|than_38 (r_compound) gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0 (l_appos) vte_16\NNP\0|venous_24|(_1|)_3
D011374_D054556 NONE progestagens_47\NNS\0|NONE_0 (r_dobj) containing_43\VBG\2632940|NONE_0 (r_acl) ocs_42\NNS\0|NONE_0 (r_pobj) of_41\IN\0|NONE_0 (r_prep) users_40\NNS\7846|NONE_0 (r_pobj) in_39\IN\13603305|NONE_0 (r_prep) than_38\IN\0|the_59|generation_49|progestagens_38|or_15|desogestrel_12 (r_prep) gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0
D011374_D054556 NONE progestagens_47\NNS\0|NONE_0 (r_dobj) containing_43\VBG\2632940|NONE_0 (r_acl) ocs_42\NNS\0|NONE_0 (r_pobj) of_41\IN\0|NONE_0 (r_prep) users_40\NNS\7846|NONE_0 (r_pobj) in_39\IN\13603305|NONE_0 (r_prep) than_38\IN\0|the_59|generation_49|progestagens_38|or_15|desogestrel_12 (r_prep) gestodene_35\NN\0|NONE_0 (r_dobj) containing_29\VBG\2632940|that_106|incidence_97|higher_51 (r_advcl) was_18\VBD\0|studies_100|._187 (l_nsubj) incidence_11\NN\13821570|that_9|higher_46|containing_97 (l_prep) of_12\IN\0|the_14 (l_pobj) thromboembolism_14\NN\14100769|NONE_0 (l_appos) vte_16\NNP\0|venous_24|(_1|)_3
D011374_D054556 NONE progestagens_6\NNS\0|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) users_1\NNS\7846|NONE_0 (r_pobj) among_0\IN\0|,_44|risk_50|higher_66|in_73|than_125|._194 (r_prep) was_12\VBD\0|NONE_0 (l_nsubj) risk_9\NN\14541044|among_50|,_6|higher_16|in_23|than_75|._144 (l_prep) of_10\IN\0|the_9 (l_pobj) vte_11\NNP\0|NONE_0
D011374_D054556 NONE progestagens_41\NNS\0|NONE_0 (r_pobj) for_35\IN\0|with_161|,_114|ratios_103|3.49_83|._43 (r_prep) were_15\VBD\0|NONE_0 (l_nsubj) ratios_12\NNS\13815152|with_58|,_11|3.49_20|for_103|._146 (l_prep) for_13\IN\0|the_16|odds_12 (l_pobj) vte_14\NNP\0|NONE_0
D003276_D013927 NONE ocs_11\NNS\0|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) use_8\NN\407535|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|the_20|83_16|of_7 (r_acl) cases_3\NNS\7283608|NONE_0 (r_pobj) of_0\IN\0|,_58|43_60|were_63|as_77|and_130|five_134|._183 (r_prep) recorded_15\VBN\2225492|NONE_0 (l_prep) as_16\IN\14622893|of_77|,_19|43_17|were_14|and_53|five_57|._106 (l_pobj) thrombosis_20\NN\14100769|NONE_0 (l_appos) 35_22\CD\0|vein_17|,_2|,_26 (l_prep) as_23\IN\14622893|NONE_0 (l_pobj) thrombosis_25\NN\14100769|NONE_0
18422462
D018119_D010523 CID t_21\NN\14999913|d4_2 (r_compound) therapy_22\NN\657604|rash_13|and_8|with_8 (r_conj) developing_17\VBG\13541167|NONE_0 (l_prep) with_23\IN\0|rash_21|and_16|therapy_8 (l_pcomp) developing_24\VBG\13541167|0.05_38 (l_dobj) neuropathy_26\NN\14204950|NONE_0
D000409_D000740 NONE alanine_32\NN\14601829|NONE_0 (r_compound) aminotransferase_33\FW\15077571|NONE_0 (r_pobj) with_31\IN\0|(_19|clinical_18 (r_prep) jaundice_30\NN\14299637|>_39 (r_appos) hepatitis_27\NN\14127211|5_61|upper_69|of_82|)_91|in_93|cd4_114 (r_nsubj) limits_38\NNS\5123416|anemia_164|was_136|in_123|and_79|._61 (r_conj) observed_12\VBN\2163746|NONE_0 (l_nsubjpass) anemia_2\NN\14189204|was_28|in_41|and_85|limits_164|._225
D019829_D005076 CID nvp_11\NNP\0|NONE_0 (r_compound) therapy_12\NN\657604|among_49|,_6|was_8|significantly_12|with_37|._122 (r_nsubjpass) associated_15\VBN\628491|NONE_0 (l_prep) with_16\IN\0|among_86|,_43|therapy_37|was_29|significantly_25|._85 (l_pcomp) developing_17\VBG\13541167|NONE_0 (l_dobj) rash_18\NN\14321469|and_5|therapy_13|with_21
D019829_D010523 NONE nvp_11\NNP\0|NONE_0 (r_compound) therapy_12\NN\657604|among_49|,_6|was_8|significantly_12|with_37|._122 (r_nsubjpass) associated_15\VBN\628491|NONE_0 (l_prep) with_16\IN\0|among_86|,_43|therapy_37|was_29|significantly_25|._85 (l_pcomp) developing_17\VBG\13541167|NONE_0 (l_prep) with_23\IN\0|rash_21|and_16|therapy_8 (l_pcomp) developing_24\VBG\13541167|0.05_38 (l_dobj) neuropathy_26\NN\14204950|NONE_0
D018119_D005076 NONE t_21\NN\14999913|d4_2 (r_compound) therapy_22\NN\657604|rash_13|and_8|with_8 (r_conj) developing_17\VBG\13541167|NONE_0 (l_dobj) rash_18\NN\14321469|and_5|therapy_13|with_21
D000409_D007565 NONE alanine_32\NN\14601829|NONE_0 (r_compound) aminotransferase_33\FW\15077571|NONE_0 (r_pobj) with_31\IN\0|(_19|clinical_18 (r_prep) jaundice_30\NN\14299637|>_39
D000409_D056486 NONE alanine_32\NN\14601829|NONE_0 (r_compound) aminotransferase_33\FW\15077571|NONE_0 (r_pobj) with_31\IN\0|(_19|clinical_18 (r_prep) jaundice_30\NN\14299637|>_39 (r_appos) hepatitis_27\NN\14127211|5_61|upper_69|of_82|)_91|in_93|cd4_114
18450790
D013792_D008178 NONE thalidomide_30\NN\4166841|NONE_0 (r_pobj) with_29\IN\0|(_14|cle_13|and_17|use_21|._170 (r_prep) treated_28\VBN\2376958|aims_152|measure_139|amplitude_74 (r_parataxis) were_4\VBD\0|NONE_0 (l_punct) amplitude_17\VBP\7444668|aims_78|measure_65|treated_74 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) erythematosus_24\NN\0|NONE_0
D013792_D008178 NONE thalidomide_30\NN\4166841|NONE_0 (r_pobj) with_29\IN\0|(_14|cle_13|and_17|use_21|._170 (r_prep) treated_28\VBN\2376958|aims_152|measure_139|amplitude_74 (l_nsubj) cle_26\NNP\0|(_1|with_13|and_30|use_34|._183
D013792_D008178 NONE thalidomide_41\NN\4166841|NONE_0 (r_pobj) of_40\IN\0|the_25|neurotoxic_21 (r_prep) potential_39\NN\14481929|to_27 (r_dobj) identify_36\VB\699815|findings_12 (r_xcomp) use_32\VB\407535|(_35|cle_34|with_21|and_4|._149 (r_conj) treated_28\VBN\2376958|aims_152|measure_139|amplitude_74 (r_parataxis) were_4\VBD\0|NONE_0 (l_punct) amplitude_17\VBP\7444668|aims_78|measure_65|treated_74 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) erythematosus_24\NN\0|NONE_0
D013792_D008178 NONE thalidomide_41\NN\4166841|NONE_0 (r_pobj) of_40\IN\0|the_25|neurotoxic_21 (r_prep) potential_39\NN\14481929|to_27 (r_dobj) identify_36\VB\699815|findings_12 (r_xcomp) use_32\VB\407535|(_35|cle_34|with_21|and_4|._149 (r_conj) treated_28\VBN\2376958|aims_152|measure_139|amplitude_74 (l_nsubj) cle_26\NNP\0|(_1|with_13|and_30|use_34|._183
D013792_D008178 NONE thalidomide_17\NN\4166841|and_12 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treatment_15\NN\654885|NONE_0 (r_pobj) during_14\IN\0|clinical_70|in_31 (r_prep) data_7\NNS\7951464|patients_56|months_83|after_90|discontinuation_96|were_125|._138 (l_prep) in_8\IN\13603305|clinical_39|during_31 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|12_19|female_16 (l_pobj) cle_13\NNP\0|NONE_0
D013792_D010523 CID thalidomide_0\NNP\4166841|NONE_0 (l_conj) neurotoxicity_3\NN\0|and_12|:_13|study_36|._41
D013792_D010523 CID thalidomide_17\NN\4166841|NONE_0 (r_pobj) of_16\IN\0|different_16 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) treated_12\VBN\2376958|NONE_0 (r_acl) patients_11\NNS\9898892|NONE_0 (r_pobj) in_10\IN\13603305|a_46|high_44|of_29 (r_prep) incidence_5\NN\13821570|studies_25|._94 (l_prep) of_6\IN\0|a_17|high_15|in_29 (l_pobj) neuropathy_9\NN\14204950|NONE_0
D013792_D020258 NONE thalidomide_30\NN\4166841|NONE_0 (r_pobj) with_29\IN\0|(_14|cle_13|and_17|use_21|._170 (r_prep) treated_28\VBN\2376958|aims_152|measure_139|amplitude_74 (l_conj) use_32\VB\407535|(_35|cle_34|with_21|and_4|._149 (l_xcomp) identify_36\VB\699815|findings_12 (l_dobj) potential_39\NN\14481929|to_27 (l_amod) neurotoxic_38\JJ\0|the_4|of_21
D013792_D020258 NONE thalidomide_41\NN\4166841|NONE_0 (r_pobj) of_40\IN\0|the_25|neurotoxic_21 (r_prep) potential_39\NN\14481929|to_27 (l_amod) neurotoxic_38\JJ\0|the_4|of_21
D013792_D020258 NONE thalidomide_10\NN\4166841|NONE_0 (r_pobj) of_9\IN\0|subclinical_33|neurotoxic_21 (r_prep) potential_8\NN\14481929|NONE_0 (l_amod) neurotoxic_7\JJ\0|subclinical_12|of_21
24894748
D008790_D003324 NONE metoprolol_8\NN\2832168|was_57|course_81|day_115|._136 (l_prep) for_13\IN\0|man_29|day_4 (l_pobj) disease_17\NN\14061805|NONE_0
C041359_D003221 NONE terbinafine_5\NN\2720201|NONE_0 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) of_4\IN\0|the_13|49th_9 (r_prep) day_3\NN\15154774|NONE_0 (r_pobj) on_0\IN\0|,_38|he_40|was_43|to_55|for_77|._140 (r_prep) brought_10\VBN\1449974|NONE_0 (l_prep) for_15\IN\0|on_77|,_39|he_37|was_34|to_22|._63 (l_pobj) decrease_17\NN\7296428|NONE_0 (l_prep) of_18\IN\0|a_11 (l_pobj) status_22\NN\24720|NONE_0 (l_conj) confusion_24\NN\13972797|his_26|global_22|health_15|,_2
C041359_D014009 NONE terbinafine_25\NN\2720201|NONE_0 (r_pobj) of_23\IN\0|a_16|90-day_14 (r_prep) course_22\NN\883297|metoprolol_81|was_24|day_34|._55 (r_dobj) prescribed_19\VBN\748282|NONE_0 (l_npadvmod) day_29\NN\15154774|metoprolol_115|was_58|course_34|._21 (l_prep) for_30\IN\0|250_11|mg_7|/_5 (l_pobj) onychomycosis_31\NN\0|NONE_0
C041359_D001919 CID terbinafine_3\NN\2720201|a_13 (r_compound) combination_4\NN\7951464|bradycardia_20|._31 (r_nsubj) induced_5\VBN\1627355|NONE_0 (l_dobj) bradycardia_6\NN\14110674|combination_20|._11
C041359_D064420 NONE terbinafine_29\NN\2720201|and_4 (r_conj) metoprolol_27\NN\2832168|NONE_0 (r_pobj) between_26\IN\0|the_21|drug_17 (r_prep) interaction_25\NN\37396|sinus_31|and_13 (r_conj) bradycardia_21\NNP\14110674|NONE_0 (r_pobj) between_16\IN\0|a_24|probable_22 (r_prep) relationship_15\NN\31921|score_87|._112 (r_dobj) indicates_12\VBZ\952524|NONE_0 (l_nsubj) score_1\NN\5736149|relationship_87|._199 (l_prep) on_4\IN\0|a_13|of_5 (l_pobj) scale_11\NN\7260623|NONE_0 (l_compound) probability_10\NN\33615|the_34|naranjo_30 (l_compound) reaction_9\NN\13446390|NONE_0
D008790_D064420 NONE metoprolol_27\NN\2832168|NONE_0 (r_pobj) between_26\IN\0|the_21|drug_17 (r_prep) interaction_25\NN\37396|sinus_31|and_13 (r_conj) bradycardia_21\NNP\14110674|NONE_0 (r_pobj) between_16\IN\0|a_24|probable_22 (r_prep) relationship_15\NN\31921|score_87|._112 (r_dobj) indicates_12\VBZ\952524|NONE_0 (l_nsubj) score_1\NN\5736149|relationship_87|._199 (l_prep) on_4\IN\0|a_13|of_5 (l_pobj) scale_11\NN\7260623|NONE_0 (l_compound) probability_10\NN\33615|the_34|naranjo_30 (l_compound) reaction_9\NN\13446390|NONE_0
D008790_D001919 CID metoprolol_1\NN\2832168|NONE_0 (r_compound) terbinafine_3\NN\2720201|a_13 (r_compound) combination_4\NN\7951464|bradycardia_20|._31 (r_nsubj) induced_5\VBN\1627355|NONE_0 (l_dobj) bradycardia_6\NN\14110674|combination_20|._11
D008790_D012804 NONE metoprolol_7\NN\2832168|NONE_0 (r_pobj) by_6\IN\0|report_35|._70 (r_agent) induced_5\VBN\1627355|NONE_0 (l_advcl) report_1\VB\6470073|by_35|._105 (l_dobj) bradycardia_4\NN\14110674|to_18|sinus_6
D008790_D012804 NONE metoprolol_27\NN\2832168|NONE_0 (r_pobj) between_26\IN\0|the_21|drug_17 (r_prep) interaction_25\NN\37396|sinus_31|and_13 (r_conj) bradycardia_21\NNP\14110674|NONE_0
D008790_D012804 NONE metoprolol_10\NN\2832168|NONE_0 (r_poss) clearance_12\NN\5089947|by_78|,_41|terbinafine_39|had_27|,_9|leading_11|._108 (r_dobj) decreased_9\VBN\169651|NONE_0 (l_advcl) leading_14\VBG\4339291|by_89|,_52|terbinafine_50|had_38|clearance_11|,_2|._97 (l_prep) in_15\IN\13603305|NONE_0 (l_pobj) accumulation_17\NN\13497135|NONE_0 (l_relcl) resulted_20\VBN\2633881|metoprolol_34 (l_prep) in_21\IN\13603305|which_19|has_13 (l_pobj) bradycardia_25\NN\14110674|NONE_0
D008790_D012804 NONE metoprolol_16\NN\2832168|resulted_34 (r_compound) accumulation_17\NN\13497135|NONE_0 (l_relcl) resulted_20\VBN\2633881|metoprolol_34 (l_prep) in_21\IN\13603305|which_19|has_13 (l_pobj) bradycardia_25\NN\14110674|NONE_0
D008790_D014009 NONE metoprolol_8\NN\2832168|was_57|course_81|day_115|._136 (r_nsubjpass) prescribed_19\VBN\748282|NONE_0 (l_npadvmod) day_29\NN\15154774|metoprolol_115|was_58|course_34|._21 (l_prep) for_30\IN\0|250_11|mg_7|/_5 (l_pobj) onychomycosis_31\NN\0|NONE_0
C041359_D003324 NONE terbinafine_25\NN\2720201|NONE_0 (r_pobj) of_23\IN\0|a_16|90-day_14 (r_prep) course_22\NN\883297|metoprolol_81|was_24|day_34|._55 (r_dobj) prescribed_19\VBN\748282|NONE_0 (l_nsubjpass) metoprolol_8\NN\2832168|was_57|course_81|day_115|._136 (l_prep) for_13\IN\0|man_29|day_4 (l_pobj) disease_17\NN\14061805|NONE_0
C041359_D012804 NONE terbinafine_9\NN\2720201|drug_17|and_34|management_42 (r_compound) interaction_13\NN\37396|and_26 (r_conj) metoprolol_7\NN\2832168|NONE_0 (r_pobj) by_6\IN\0|report_35|._70 (r_agent) induced_5\VBN\1627355|NONE_0 (l_advcl) report_1\VB\6470073|by_35|._105 (l_dobj) bradycardia_4\NN\14110674|to_18|sinus_6
C041359_D012804 NONE terbinafine_29\NN\2720201|and_4 (r_conj) metoprolol_27\NN\2832168|NONE_0 (r_pobj) between_26\IN\0|the_21|drug_17 (r_prep) interaction_25\NN\37396|sinus_31|and_13 (r_conj) bradycardia_21\NNP\14110674|NONE_0
C041359_D012804 NONE terbinafine_7\NN\2720201|by_39|,_2|had_12|clearance_39|,_48|leading_50|._147 (r_nsubj) decreased_9\VBN\169651|NONE_0 (l_advcl) leading_14\VBG\4339291|by_89|,_52|terbinafine_50|had_38|clearance_11|,_2|._97 (l_prep) in_15\IN\13603305|NONE_0 (l_pobj) accumulation_17\NN\13497135|NONE_0 (l_relcl) resulted_20\VBN\2633881|metoprolol_34 (l_prep) in_21\IN\13603305|which_19|has_13 (l_pobj) bradycardia_25\NN\14110674|NONE_0
19715529
12051122
D014750_D007010 CID vincristine_14\NNP\3917455|NONE_0 (r_pobj) of_13\IN\0|the_8 (r_prep) use_12\NN\407535|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) reported_9\VBN\831651|inappropriate_36|-_18|diuretic_17 (r_acl) hormone_8\NN\5404728|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) syndrome_2\NN\5870365|and_4|?_118 (r_conj) hyponatremia_0\NNP\14299637|NONE_0
D014750_D007010 CID vincristine_32\NN\3917455|-_11 (r_npadvmod) treated_34\VBN\2376958|NONE_0 (r_amod) patients_35\NNS\9898892|NONE_0 (r_pobj) among_31\IN\0|(_8|)_2 (r_prep) siadh_29\NNP\0|-_19|diuretic_18 (r_appos) hormone_27\NN\5404728|NONE_0 (r_pobj) of_23\IN\0|inappropriate_24 (r_prep) secretion_22\NN\13526110|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) syndrome_19\NN\5870365|and/or_7 (r_conj) hyponatremia_17\NN\14299637|NONE_0
D014750_D007010 CID vincristine_33\NN\3917455|NONE_0 (r_pobj) of_32\IN\0|the_8 (r_prep) use_31\NN\407535|NONE_0 (r_pobj) during_29\IN\0|that_23|had_18|been_14 (r_prep) reported_28\VBN\831651|the_152|eli_148|and_138|database_97 (r_relcl) lilly_4\NNP\0|we_20|as_108|._182 (l_conj) database_11\NN\6634376|the_55|eli_51|and_41|reported_97 (l_prep) for_12\IN\0|company_46|computerized_36|event_15 (l_pobj) cases_15\NNS\7283608|NONE_0 (l_prep) of_16\IN\0|all_19|reported_15 (l_pobj) hyponatremia_17\NN\14299637|NONE_0
D014750_D007010 CID vincristine_11\NN\3917455|NONE_0 (r_compound) use_12\NN\407535|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBD\628491|a_49|of_41 (r_acl) total_1\NN\3553|were_79|._94 (l_prep) of_2\IN\0|a_8|associated_41 (l_pobj) cases_4\NNS\7283608|NONE_0 (l_prep) of_5\IN\0|76_9 (l_pobj) hyponatremia_6\NN\14299637|NONE_0
D014750_D007010 CID vincristine_17\NN\3917455|NONE_0 (r_compound) use_18\NN\407535|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) associated_15\VBD\628491|increased_44|of_29 (r_acl) risk_10\NN\14541044|NONE_0 (l_prep) of_11\IN\0|increased_15|associated_29 (l_pobj) hyponatremia_12\NN\14299637|NONE_0
D014750_D007177 CID vincristine_14\NNP\3917455|NONE_0 (r_pobj) of_13\IN\0|the_8 (r_prep) use_12\NN\407535|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) reported_9\VBN\831651|inappropriate_36|-_18|diuretic_17 (r_acl) hormone_8\NN\5404728|NONE_0
D014750_D007177 CID vincristine_32\NN\3917455|-_11 (r_npadvmod) treated_34\VBN\2376958|NONE_0 (r_amod) patients_35\NNS\9898892|NONE_0 (r_pobj) among_31\IN\0|(_8|)_2 (r_prep) siadh_29\NNP\0|-_19|diuretic_18 (r_appos) hormone_27\NN\5404728|NONE_0
D014750_D007177 CID vincristine_32\NN\3917455|-_11 (r_npadvmod) treated_34\VBN\2376958|NONE_0 (r_amod) patients_35\NNS\9898892|NONE_0 (r_pobj) among_31\IN\0|(_8|)_2 (r_prep) siadh_29\NNP\0|-_19|diuretic_18
D014750_D007177 CID vincristine_33\NN\3917455|NONE_0 (r_pobj) of_32\IN\0|the_8 (r_prep) use_31\NN\407535|NONE_0 (r_pobj) during_29\IN\0|that_23|had_18|been_14 (r_prep) reported_28\VBN\831651|the_152|eli_148|and_138|database_97 (r_relcl) lilly_4\NNP\0|we_20|as_108|._182 (l_conj) database_11\NN\6634376|the_55|eli_51|and_41|reported_97 (l_prep) for_12\IN\0|company_46|computerized_36|event_15 (l_pobj) cases_15\NNS\7283608|NONE_0 (l_prep) of_16\IN\0|all_19|reported_15 (l_pobj) hyponatremia_17\NN\14299637|NONE_0 (l_conj) siadh_19\NNP\0|and/or_7
D014750_D007177 CID vincristine_11\NN\3917455|NONE_0 (r_compound) use_12\NN\407535|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBD\628491|a_49|of_41 (r_acl) total_1\NN\3553|were_79|._94 (l_prep) of_2\IN\0|a_8|associated_41 (l_pobj) cases_4\NNS\7283608|NONE_0 (l_prep) of_5\IN\0|76_9 (l_pobj) hyponatremia_6\NN\14299637|NONE_0 (l_conj) siadh_8\NNP\0|and/or_7
D014750_D007177 CID vincristine_17\NN\3917455|NONE_0 (r_compound) use_18\NN\407535|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) associated_15\VBD\628491|increased_44|of_29 (r_acl) risk_10\NN\14541044|NONE_0 (l_prep) of_11\IN\0|increased_15|associated_29 (l_pobj) hyponatremia_12\NN\14299637|NONE_0 (l_conj) siadh_14\NNP\0|and/or_7
D014750_D007177 CID vincristine_9\NN\3917455|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) associated_7\VBN\628491|the_35|overall_31|reported_23|of_9 (r_acl) rate_4\NN\13815152|although_30|low_50 (l_prep) of_5\IN\0|the_26|overall_22|reported_14|associated_9 (l_pobj) siadh_6\NNP\0|NONE_0
15605432
D010100_D066126 NONE oxygen_12\NN\14622893|if_21|be_48 (r_nsubj) reported_19\VBD\831651|to_70 (r_ccomp) determine_8\VB\0|purpose_36|adriamycin_93|resulted_142|._334 (r_xcomp) was_6\VBD\0|NONE_0 (l_conj) resulted_29\VBD\2633881|purpose_178|determine_142|adriamycin_49|._192 (l_nsubj) cardiotoxicity_27\NN\0|actually_15|in_33|,_76|and_78|determine_100
D004317_D066126 NONE adriamycin_24\NNS\0|purpose_129|determine_93|resulted_49|._241 (r_acomp) was_6\VBD\0|NONE_0 (l_conj) resulted_29\VBD\2633881|purpose_178|determine_142|adriamycin_49|._192 (l_nsubj) cardiotoxicity_27\NN\0|actually_15|in_33|,_76|and_78|determine_100
D004317_D066126 NONE adr)-induced_26\JJ\0|(_1 (r_compound) cardiotoxicity_27\NN\0|actually_15|in_33|,_76|and_78|determine_100
D004317_D028361 CID adriamycin_6\NNS\0|-_10 (r_npadvmod) induced_8\VBN\1627355|cardiac_8|mitochondrial_16 (r_amod) injury_11\NN\14052046|NONE_0
D004317_D028361 CID adr_3\NNP\0|adducts_25|at_49 (r_nsubj) induced_4\VBD\1627355|data_16|._115 (l_prep) at_11\IN\14622893|adr_49|adducts_24 (l_pobj) point_15\NN\5868954|NONE_0 (l_prep) as_16\IN\14622893|the_20|same_16|time_11 (l_pcomp) appeared_21\VBD\2604760|NONE_0 (l_nsubj) injury_19\NN\14052046|when_19|initially_7
D009584_D066126 NONE ros)/nitrogen_14\NN\0|(_1|(_22|rns_23|)_26 (r_compound) species_15\NNS\7992450|elevated_40|reactive_31 (r_appos) oxygen_12\NN\14622893|if_21|be_48 (r_nsubj) reported_19\VBD\831651|to_70 (r_ccomp) determine_8\VB\0|purpose_36|adriamycin_93|resulted_142|._334 (r_xcomp) was_6\VBD\0|NONE_0 (l_conj) resulted_29\VBD\2633881|purpose_178|determine_142|adriamycin_49|._192 (l_nsubj) cardiotoxicity_27\NN\0|actually_15|in_33|,_76|and_78|determine_100
C027576_D028361 NONE 4hne_5\CD\0|-_4 (r_compound) protein_7\NN\14944888|in_16 (r_compound) adducts_8\NNS\14818238|adr_25|at_24 (r_dobj) induced_4\VBD\1627355|data_16|._115 (l_prep) at_11\IN\14622893|adr_49|adducts_24 (l_pobj) point_15\NN\5868954|NONE_0 (l_prep) as_16\IN\14622893|the_20|same_16|time_11 (l_pcomp) appeared_21\VBD\2604760|NONE_0 (l_nsubj) injury_19\NN\14052046|when_19|initially_7
8184922
D007545_D006332 CID isoproterenol_17\NN\3740161|-_13 (r_npadvmod) induced_19\VBN\1627355|cardiac_8 (r_amod) hypertrophy_21\NN\14365950|NONE_0
20959502
D017576_D008581 NONE daptomycin_7\NN\0|NONE_0 (l_prep) in_8\IN\13603305|dose_16 (l_pobj) meningitis_12\NN\14127211|NONE_0
D017576_D008581 NONE daptomycin_23\NN\0|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBD\2376958|suspected_26|mssa_16 (r_acl) meningitis_17\NN\14127211|NONE_0
D017576_D008581 NONE daptomycin_4\JJ\0|nafcillin_31|was_21|and_4|initiated_29|._117 (r_conj) discontinued_2\VBN\0|NONE_0 (l_conj) initiated_9\VBN\1617192|nafcillin_60|was_50|and_33|daptomycin_29|._88 (l_prep) for_10\IN\0|was_14|and_25|continued_33 (l_pobj) meningitis_12\NN\14127211|NONE_0
D017576_D016470 NONE daptomycin_23\NN\0|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBD\2376958|suspected_26|mssa_16 (r_acl) meningitis_17\NN\14127211|NONE_0 (r_pobj) with_14\IN\0|(_18|mssa_17|)_13 (r_prep) bacteremia_13\XX\14204950|sensitive_39|staphylococcus_29
D017576_D016470 NONE daptomycin_0\NNP\0|was_11|in_25|nephritis_99|._133 (r_nsubjpass) initiated_2\VBN\1617192|NONE_0 (l_dobj) nephritis_14\NN\14113228|daptomycin_99|was_88|in_74|._34 (l_conj) relapsing_16\VBG\66636|induced_41|acute_33|interstitial_27|and_4 (l_dobj) bacteremia_17\NN\14204950|NONE_0
D017576_D016470 NONE daptomycin_3\NN\0|may_11|option_33|._152 (r_nsubj) be_5\VB\14625458|NONE_0 (l_attr) option_8\NN\6480506|daptomycin_33|may_22|._119 (l_prep) for_9\IN\0|an_22|alternative_19 (l_pobj) bacteremia_11\VBG\14204950|NONE_0
D009254_D016470 NONE nafcillin_9\NN\3910417|-_9 (r_npadvmod) induced_11\VBN\1627355|acute_8|interstitial_14|and_37|relapsing_41 (r_amod) nephritis_14\NN\14113228|daptomycin_99|was_88|in_74|._34 (l_conj) relapsing_16\VBG\66636|induced_41|acute_33|interstitial_27|and_4 (l_dobj) bacteremia_17\NN\14204950|NONE_0
D008712_D016470 NONE methicillin_5\NN\3910033|-_11 (r_npadvmod) sensitive_7\JJ\10488309|staphylococcus_10|bacteremia_39 (r_amod) aureus_9\NNP\0|NONE_0 (l_appos) bacteremia_13\XX\14204950|sensitive_39|staphylococcus_29
D009254_D008581 NONE nafcillin_0\NNP\3910417|was_10|and_27|daptomycin_31|initiated_60|._148 (r_nsubjpass) discontinued_2\VBN\0|NONE_0 (l_conj) initiated_9\VBN\1617192|nafcillin_60|was_50|and_33|daptomycin_29|._88 (l_prep) for_10\IN\0|was_14|and_25|continued_33 (l_pobj) meningitis_12\NN\14127211|NONE_0
D008712_D008581 NONE methicillin_5\NN\3910033|-_11 (r_npadvmod) sensitive_7\JJ\10488309|staphylococcus_10|bacteremia_39 (r_amod) aureus_9\NNP\0|NONE_0 (l_appos) bacteremia_13\XX\14204950|sensitive_39|staphylococcus_29 (l_prep) with_14\IN\0|(_18|mssa_17|)_13 (l_pobj) meningitis_17\NN\14127211|NONE_0
D003404_D058186 NONE creatinine_12\JJ\0|acute_27|renal_21|(_7|,_20 (r_appos) failure_9\NN\66216|from_47|)_105
D017576_D009395 NONE daptomycin_0\NNP\0|was_11|in_25|nephritis_99|._133 (r_nsubjpass) initiated_2\VBN\1617192|NONE_0 (l_dobj) nephritis_14\NN\14113228|daptomycin_99|was_88|in_74|._34
D009254_D009395 CID nafcillin_9\NN\3910417|-_9 (r_npadvmod) induced_11\VBN\1627355|acute_8|interstitial_14|and_37|relapsing_41 (r_amod) nephritis_14\NN\14113228|daptomycin_99|was_88|in_74|._34
89511
D004967_D004714 NONE oestrogen_4\NN\14745635|cyclical_18|dose_5|with_18 (r_compound) therapy_5\NN\657604|does_39|not_44|increase_56|._113 (r_nsubj) seem_15\VB\2604760|NONE_0 (l_xcomp) increase_17\VB\13576355|therapy_56|does_17|not_12|._57 (l_dobj) risk_19\NN\14541044|to_16 (l_prep) of_20\IN\0|the_9 (l_pobj) hyperplasia_22\NN\14365950|NONE_0
D004967_D009369 NONE oestrogen_16\NN\14745635|inappropriate_41|unopposed_10|and_18|difficulty_26 (r_compound) therapy_17\NN\657604|NONE_0 (l_conj) difficulty_20\NN\621627|inappropriate_67|unopposed_36|oestrogen_26|and_8 (l_prep) in_21\IN\13603305|the_15 (l_pcomp) distinguishing_22\VBG\618878|NONE_0 (l_prep) from_25\IN\0|hyperplasia_12 (l_pobj) malignancy_26\NN\14070360|NONE_0
D004967_D014591 NONE oestrogen_10\NN\14745635|NONE_0 (r_compound) therapy_11\NN\657604|NONE_0 (r_dobj) receiving_9\VBG\2210855|climacteric_18 (r_acl) women_8\NNS\9605289|NONE_0 (r_pobj) in_6\IN\13603305|and_37|treatment_33|of_23|._48 (r_prep) prevention_0\NN\1073995|NONE_0 (l_prep) of_3\IN\0|and_14|treatment_10|in_23|._71 (l_pobj) disease_5\NN\14061805|NONE_0
D004967_D014591 NONE oestrogen_16\NN\14745635|NONE_0 (r_compound) therapy_17\NN\657604|NONE_0 (r_dobj) receiving_15\VBG\2210855|850_22|climacteric_18 (r_acl) women_14\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|regimens_63|are_54|in_40|._55 (r_prep) described_4\VBN\1001294|NONE_0 (l_prep) in_5\IN\13603305|regimens_23|are_14|among_40|._95 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|74_12 (l_pobj) disease_10\NN\14061805|NONE_0
D011372_D004714 NONE progestagen_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|-13_9 (r_prep) days_10\NNS\15140892|NONE_0 (r_pobj) with_6\IN\0|cyclical_36|dose_23|oestrogen_18 (r_prep) therapy_5\NN\657604|does_39|not_44|increase_56|._113 (r_nsubj) seem_15\VB\2604760|NONE_0 (l_xcomp) increase_17\VB\13576355|therapy_56|does_17|not_12|._57 (l_dobj) risk_19\NN\14541044|to_16 (l_prep) of_20\IN\0|the_9 (l_pobj) hyperplasia_22\NN\14365950|NONE_0
D004967_D002277 NONE oestrogen_4\NN\14745635|cyclical_18|dose_5|with_18 (r_compound) therapy_5\NN\657604|does_39|not_44|increase_56|._113 (r_nsubj) seem_15\VB\2604760|NONE_0 (l_xcomp) increase_17\VB\13576355|therapy_56|does_17|not_12|._57 (l_dobj) risk_19\NN\14541044|to_16 (l_prep) of_20\IN\0|the_9 (l_pobj) hyperplasia_22\NN\14365950|NONE_0 (l_conj) carcinoma_24\NN\14239918|endometrial_27|or_3
D009640_D006965 NONE norethisterone_8\NN\0|5_5 (r_amod) mg_7\NN\13717155|NONE_0 (r_pobj) of_5\IN\0|21_8 (r_prep) days_4\NNS\15140892|NONE_0 (r_pobj) of_2\IN\0|two_12 (r_prep) courses_1\NNS\883297|reversion_55|and_113|6_117|._157 (r_nsubj) caused_10\VBN\1617192|NONE_0 (l_dobj) reversion_11\NN\13286801|courses_55|and_58|6_62|._102 (l_prep) in_14\IN\13603305|to_10 (l_pobj) cases_17\NNS\7283608|NONE_0 (l_prep) of_18\IN\0|all_13|57_9 (l_pobj) hyperplasia_20\NN\14365950|NONE_0
D009640_D006965 NONE norethisterone_8\NN\0|5_5 (r_amod) mg_7\NN\13717155|NONE_0 (r_pobj) of_5\IN\0|21_8 (r_prep) days_4\NNS\15140892|NONE_0 (r_pobj) of_2\IN\0|two_12 (r_prep) courses_1\NNS\883297|reversion_55|and_113|6_117|._157 (r_nsubj) caused_10\VBN\1617192|NONE_0 (l_conj) 6_22\CD\13741022|courses_117|reversion_62|and_4|._40 (l_prep) of_23\IN\0|NONE_0 (l_pobj) cases_26\NNS\7283608|NONE_0 (l_prep) of_27\IN\0|the_12|8_8 (l_pobj) hyperplasia_29\NN\14365950|NONE_0
D004967_D006965 CID oestrogen_6\NN\14745635|unopposed_10 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) with_4\IN\0|hyperplasia_27|was_15|without_33|._52 (r_prep) associated_3\VBN\628491|NONE_0 (l_nsubjpass) hyperplasia_1\NN\14365950|was_12|with_27|without_60|._79
D004967_D006965 CID oestrogen_16\NN\14745635|inappropriate_41|unopposed_10|and_18|difficulty_26 (r_compound) therapy_17\NN\657604|NONE_0 (l_conj) difficulty_20\NN\621627|inappropriate_67|unopposed_36|oestrogen_26|and_8 (l_prep) in_21\IN\13603305|the_15 (l_pcomp) distinguishing_22\VBG\618878|NONE_0 (l_dobj) hyperplasia_24\NN\14365950|from_12
D004967_D016889 NONE oestrogen_16\NN\14745635|inappropriate_41|unopposed_10|and_18|difficulty_26 (r_compound) therapy_17\NN\657604|NONE_0 (r_pobj) of_11\IN\0|the_13 (r_prep) problems_10\NNS\14408086|referred_41|._142 (r_dobj) demonstrated_8\VBD\2137132|NONE_0 (l_csubj) referred_5\VBD\730052|problems_41|._183 (l_nsubj) cases_1\NNS\7283608|from_40 (l_prep) of_2\IN\0|4_8 (l_pobj) carcinoma_4\NN\14239918|NONE_0
D011372_D006965 NONE progestagen_9\NN\0|NONE_0 (r_pobj) without_8\IN\0|hyperplasia_60|was_48|with_33|._19 (r_prep) associated_3\VBN\628491|NONE_0 (l_nsubjpass) hyperplasia_1\NN\14365950|was_12|with_27|without_60|._79
D011372_D002277 NONE progestagen_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|-13_9 (r_prep) days_10\NNS\15140892|NONE_0 (r_pobj) with_6\IN\0|cyclical_36|dose_23|oestrogen_18 (r_prep) therapy_5\NN\657604|does_39|not_44|increase_56|._113 (r_nsubj) seem_15\VB\2604760|NONE_0 (l_xcomp) increase_17\VB\13576355|therapy_56|does_17|not_12|._57 (l_dobj) risk_19\NN\14541044|to_16 (l_prep) of_20\IN\0|the_9 (l_pobj) hyperplasia_22\NN\14365950|NONE_0 (l_conj) carcinoma_24\NN\14239918|endometrial_27|or_3
8748050
D000639_D003866 NONE amitriptyline_12\NN\4482543|NONE_0 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) of_11\IN\0|the_11 (r_prep) course_10\NN\883297|NONE_0 (r_pobj) in_8\IN\13603305|NONE_0 (r_prep) developed_7\VBN\1753788|NONE_0 (r_acl) encephalopathy_6\NN\14084880|NONE_0 (r_pobj) of_5\IN\0|a_7 (r_prep) case_4\NN\7283608|report_19|,_71|during_73|._114 (r_dobj) describes_2\VBZ\1001294|NONE_0 (l_prep) during_15\IN\0|report_92|case_73|,_2|._41 (l_pobj) remission_17\NN\7368256|NONE_0 (l_prep) of_18\IN\0|a_12 (l_pobj) depression_20\NN\14373582|NONE_0
D000639_D020230 NONE amitriptyline_2\NN\4482543|NONE_0 (r_compound) therapy_3\NN\657604|NONE_0 (r_pobj) during_1\IN\0|NONE_0 (r_prep) encephalopathy_0\VBG\14084880|:_43|syndrome_71|?_121 (r_nsubj) are_5\VBP\13600404|NONE_0 (l_attr) syndrome_8\NN\5870365|encephalopathy_71|:_28|?_50 (l_conj) disorders_13\NNS\14034177|neuroleptic_63|malignant_51|and_32 (l_compound) syndrome_11\NN\5870365|serotonin_10|spectrum_9
D000639_D001927 CID amitriptyline_2\NN\4482543|NONE_0 (r_compound) therapy_3\NN\657604|NONE_0 (r_pobj) during_1\IN\0|NONE_0 (r_prep) encephalopathy_0\VBG\14084880|:_43|syndrome_71|?_121
D000639_D001927 CID amitriptyline_12\NN\4482543|NONE_0 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) of_11\IN\0|the_11 (r_prep) course_10\NN\883297|NONE_0 (r_pobj) in_8\IN\13603305|NONE_0 (r_prep) developed_7\VBN\1753788|NONE_0 (r_acl) encephalopathy_6\NN\14084880|NONE_0
D000639_D009459 NONE amitriptyline_2\NN\4482543|NONE_0 (r_compound) therapy_3\NN\657604|NONE_0 (r_pobj) during_1\IN\0|NONE_0 (r_prep) encephalopathy_0\VBG\14084880|:_43|syndrome_71|?_121 (r_nsubj) are_5\VBP\13600404|NONE_0 (l_attr) syndrome_8\NN\5870365|encephalopathy_71|:_28|?_50
24535067
D005045_D009069 NONE etomidate_19\NN\0|according_58|during_27 (r_advcl) graded_9\VBN\670261|which_24|were_18|and_4 (r_conj) observed_7\VBN\2163746|movements_36|are_26|,_13|._97 (r_advcl) evaluated_3\VBN\670261|NONE_0 (l_nsubjpass) movements_1\NNS\191142|are_10|,_23|observed_36|._133
D008874_D009207 NONE midazolam_13\NN\2830852|,_2 (r_appos) fentanyl_11\NN\2707683|induced_38|:_21|is_13|:_2 (r_appos) myoclonus_5\NN\14360459|NONE_0
D008874_D009207 NONE midazolam_15\NN\2830852|,_2 (r_conj) fentanyl_13\NN\2707683|NONE_0 (r_pobj) of_12\IN\0|the_18|combination_30 (r_prep) effectiveness_11\NN\5190804|to_15 (l_conj) combination_19\NN\7951464|the_48|of_30 (l_relcl) prevent_25\VB\0|a_43|of_29 (l_dobj) myoclonus_29\NN\14360459|to_29
D008874_D009207 NONE midazolam_23\NN\2830852|and_4 (r_conj) fentanyl_21\NN\2707683|NONE_0 (r_pobj) of_20\IN\0|a_14|prevent_29 (r_prep) combination_19\NN\7951464|the_48|of_30 (l_relcl) prevent_25\VB\0|a_43|of_29 (l_dobj) myoclonus_29\NN\14360459|to_29
D008874_D009207 NONE midazolam_11\NN\2830852|and_4 (r_conj) fentanyl_9\NN\2707683|NONE_0 (r_pobj) of_8\IN\0|or_15|combination_12 (r_prep) fentanyl_5\NN\2707683|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) pretreatment_3\NN\0|that_5|effective_72 (r_nsubj) was_12\VBD\0|we_85|._55 (l_acomp) effective_13\JJ\0|that_77|pretreatment_72 (l_prep) in_14\IN\13603305|NONE_0 (l_pcomp) preventing_15\VBG\0|NONE_0 (l_dobj) myoclonus_19\NN\14360459|NONE_0
D005045_D009207 CID etomidate_2\NN\0|-_9 (r_npadvmod) induced_4\VBN\1627355|:_17|is_25|:_36|fentanyl_38 (r_amod) myoclonus_5\NN\14360459|NONE_0
D005045_D009207 CID etomidate_26\NN\0|-_9 (r_npadvmod) induced_28\VBN\1627355|NONE_0 (r_amod) myoclonus_29\NN\14360459|to_29
D005045_D009207 CID etomidate_16\NN\0|-_9 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) myoclonus_19\NN\14360459|NONE_0
D005045_D010146 NONE etomidate_6\NN\0|NONE_0 (r_xcomp) due_4\IN\5174653|the_21|of_8 (r_prep) severity_1\NN\5036394|,_43|pressure_59 (l_prep) of_2\IN\0|the_13|due_8 (l_pobj) pain_3\NN\14299637|NONE_0
D005283_D009207 NONE fentanyl_11\NN\2707683|induced_38|:_21|is_13|:_2 (r_appos) myoclonus_5\NN\14360459|NONE_0
D005283_D009207 NONE fentanyl_13\NN\2707683|NONE_0 (r_pobj) of_12\IN\0|the_18|combination_30 (r_prep) effectiveness_11\NN\5190804|to_15 (l_conj) combination_19\NN\7951464|the_48|of_30 (l_relcl) prevent_25\VB\0|a_43|of_29 (l_dobj) myoclonus_29\NN\14360459|to_29
D005283_D009207 NONE fentanyl_21\NN\2707683|NONE_0 (r_pobj) of_20\IN\0|a_14|prevent_29 (r_prep) combination_19\NN\7951464|the_48|of_30 (l_relcl) prevent_25\VB\0|a_43|of_29 (l_dobj) myoclonus_29\NN\14360459|to_29
D005283_D009207 NONE fentanyl_5\NN\2707683|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) pretreatment_3\NN\0|that_5|effective_72 (r_nsubj) was_12\VBD\0|we_85|._55 (l_acomp) effective_13\JJ\0|that_77|pretreatment_72 (l_prep) in_14\IN\13603305|NONE_0 (l_pcomp) preventing_15\VBG\0|NONE_0 (l_dobj) myoclonus_19\NN\14360459|NONE_0
D005283_D009207 NONE fentanyl_9\NN\2707683|NONE_0 (r_pobj) of_8\IN\0|or_15|combination_12 (r_prep) fentanyl_5\NN\2707683|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) pretreatment_3\NN\0|that_5|effective_72 (r_nsubj) was_12\VBD\0|we_85|._55 (l_acomp) effective_13\JJ\0|that_77|pretreatment_72 (l_prep) in_14\IN\13603305|NONE_0 (l_pcomp) preventing_15\VBG\0|NONE_0 (l_dobj) myoclonus_19\NN\14360459|NONE_0
24802403
D010433_D003072 CID pentylenetetrazole_23\NN\0|-_18 (r_npadvmod) induced_25\VBN\1627355|kindling_8 (r_amod) animals_27\NNS\4475|NONE_0 (r_pobj) in_22\IN\13603305|NONE_0 (r_prep) observed_21\VBN\2163746|the_107|ameliorative_103|of_82|on_69 (r_acl) effects_8\NNS\13245626|to_29 (l_prep) on_11\IN\0|the_38|ameliorative_34|of_13|observed_69 (l_pobj) seizures_12\NNS\14081375|NONE_0 (l_conj) impairment_15\NN\7296428|,_12
D008687_D012640 NONE metformin_0\NNP\2719105|against_19|._144 (r_nsubj) protects_1\VBZ\1127795|NONE_0 (l_prep) against_2\IN\0|metformin_19|._125 (l_pobj) seizures_3\NNS\14081375|NONE_0
D008687_D012640 NONE metformin_10\NN\2719105|NONE_0 (r_pobj) of_9\IN\0|the_25|ameliorative_21|on_13|observed_82 (r_prep) effects_8\NNS\13245626|to_29 (l_prep) on_11\IN\0|the_38|ameliorative_34|of_13|observed_69 (l_pobj) seizures_12\NNS\14081375|NONE_0
D008687_D012640 NONE metformin_6\NN\2719105|that_5|may_10|agent_29 (r_nsubj) be_8\VB\14625458|thus_52|study_35|._132 (l_attr) agent_11\NN\7347|that_34|metformin_29|may_19 (l_prep) for_12\IN\0|a_18|potential_16 (l_pobj) treatment_14\NN\654885|NONE_0 (l_conj) medicine_22\NN\6045562|the_50|of_36|as_16 (l_acl) induced_26\VBN\1627355|a_51|protective_49|against_29 (l_agent) by_27\IN\0|NONE_0 (l_pobj) seizures_28\NNS\14081375|NONE_0
D008687_D003072 NONE metformin_10\NN\2719105|NONE_0 (r_pobj) of_9\IN\0|the_25|ameliorative_21|on_13|observed_82 (r_prep) effects_8\NNS\13245626|to_29 (l_prep) on_11\IN\0|the_38|ameliorative_34|of_13|observed_69 (l_pobj) seizures_12\NNS\14081375|NONE_0 (l_conj) impairment_15\NN\7296428|,_12
D008687_D003072 NONE metformin_3\NN\2719105|that_5|progression_25|,_48|ameliorated_50 (r_nsubj) suppressed_4\VBD\2510337|we_24|._113 (l_conj) ameliorated_10\VBD\126264|that_55|metformin_50|progression_25|,_2 (l_dobj) impairment_13\NN\7296428|and_11|decreased_15
D008687_D003072 NONE metformin_6\NN\2719105|that_5|may_10|agent_29 (r_nsubj) be_8\VB\14625458|thus_52|study_35|._132 (l_attr) agent_11\NN\7347|that_34|metformin_29|may_19 (l_prep) for_12\IN\0|a_18|potential_16 (l_pobj) treatment_14\NN\654885|NONE_0 (l_conj) medicine_22\NN\6045562|the_50|of_36|as_16 (l_prep) against_23\IN\0|a_22|protective_20|induced_29 (l_pobj) impairment_25\NN\7296428|NONE_0
D010433_D008569 CID pentylenetetrazole_14\NN\0|-_18 (r_npadvmod) induced_16\VBN\1627355|in_17 (r_amod) kindling_17\NN\15101361|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|and_21|damage_7 (r_acl) impairments_8\NNS\7296428|,_22|learning_20
D008687_D007859 NONE metformin_0\NNP\2719105|against_19|._144 (r_nsubj) protects_1\VBZ\1127795|NONE_0 (l_prep) against_2\IN\0|metformin_19|._125 (l_pobj) seizures_3\NNS\14081375|NONE_0 (l_conj) impairments_8\NNS\7296428|,_22|learning_20
D010433_D007859 CID pentylenetetrazole_14\NN\0|-_18 (r_npadvmod) induced_16\VBN\1627355|in_17 (r_amod) kindling_17\NN\15101361|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|and_21|damage_7 (r_acl) impairments_8\NNS\7296428|,_22|learning_20
D008687_D008569 NONE metformin_0\NNP\2719105|against_19|._144 (r_nsubj) protects_1\VBZ\1127795|NONE_0 (l_prep) against_2\IN\0|metformin_19|._125 (l_pobj) seizures_3\NNS\14081375|NONE_0 (l_conj) impairments_8\NNS\7296428|,_22|learning_20
D010433_D012640 CID pentylenetetrazole_14\NN\0|-_18 (r_npadvmod) induced_16\VBN\1627355|in_17 (r_amod) kindling_17\NN\15101361|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|and_21|damage_7 (r_acl) impairments_8\NNS\7296428|,_22|learning_20 (r_conj) seizures_3\NNS\14081375|NONE_0
D010433_D012640 CID pentylenetetrazole_23\NN\0|-_18 (r_npadvmod) induced_25\VBN\1627355|kindling_8 (r_amod) animals_27\NNS\4475|NONE_0 (r_pobj) in_22\IN\13603305|NONE_0 (r_prep) observed_21\VBN\2163746|the_107|ameliorative_103|of_82|on_69 (r_acl) effects_8\NNS\13245626|to_29 (l_prep) on_11\IN\0|the_38|ameliorative_34|of_13|observed_69 (l_pobj) seizures_12\NNS\14081375|NONE_0
D008687_D004827 NONE metformin_6\NN\2719105|that_5|may_10|agent_29 (r_nsubj) be_8\VB\14625458|thus_52|study_35|._132 (l_attr) agent_11\NN\7347|that_34|metformin_29|may_19 (l_prep) for_12\IN\0|a_18|potential_16 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_14|as_20|medicine_36 (l_pobj) epilepsy_16\NN\14085708|NONE_0
25006369
D013390_D005207 CID succinylcholine_11\NN\3800001|NONE_0 (r_compound) administration_12\NN\1133281|NONE_0 (r_pobj) following_10\VBG\8180190|to_38|fasciculation_26 (r_prep) decrease_6\VB\7296428|optimal_44|precurarizing_36|of_17|._75 (l_dobj) fasciculation_7\NN\14361664|to_12|following_26
D013390_D005207 CID succinylcholine_0\NNP\3800001|commonly_16|effects_51|._102 (r_nsubj) produces_2\VBZ\7555863|NONE_0 (l_dobj) effects_5\NNS\13245626|succinylcholine_51|commonly_35|._51 (l_prep) including_7\VBG\0|frequent_26|adverse_17|,_2 (l_pobj) fasciculation_9\NN\14361664|NONE_0
D013390_D005207 CID succinylcholine_11\NN\3800001|-_15 (r_npadvmod) induced_13\VBN\1627355|and_22|myalgia_26 (r_amod) fasciculation_14\NN\14361664|to_35
D013390_D005207 CID succinylcholine_30\NN\3800001|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) produced_28\VBN\1617192|NONE_0 (r_acl) onset_27\NN\7325190|NONE_0 (r_pobj) of_26\IN\0|the_10 (r_prep) speed_25\NN\15286249|NONE_0 (r_pobj) on_23\IN\0|NONE_0 (r_prep) rocuronium_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|the_14 (r_prep) influence_20\NN\5190804|NONE_0 (r_dobj) evaluated_18\VBD\670261|study_113|dose_84|prevent_62|and_4|._87 (r_conj) identified_3\VBD\699815|NONE_0 (l_advcl) prevent_10\VB\0|study_51|dose_22|and_58|evaluated_62|._149 (l_dobj) fasciculation_14\NN\14361664|to_35
D013390_D005207 CID succinylcholine_3\NN\3800001|patients_18|,_64|and_66|assessed_75|._182 (r_dobj) received_2\VBD\2210855|NONE_0 (l_conj) assessed_15\VBN\670261|patients_93|succinylcholine_75|,_11|and_9|._107 (l_dobj) incidence_17\NN\13821570|were_18|,_40|assessed_60 (l_prep) of_20\IN\0|the_27|and_13|severity_9 (l_pobj) fasciculations_21\NNS\14361664|NONE_0
D013390_D063806 CID succinylcholine_11\NN\3800001|NONE_0 (r_compound) administration_12\NN\1133281|NONE_0 (r_pobj) following_10\VBG\8180190|to_38|fasciculation_26 (r_prep) decrease_6\VB\7296428|optimal_44|precurarizing_36|of_17|._75 (l_dobj) fasciculation_7\NN\14361664|to_12|following_26 (l_conj) myalgia_9\NN\14322699|and_4
D013390_D063806 CID succinylcholine_0\NNP\3800001|commonly_16|effects_51|._102 (r_nsubj) produces_2\VBZ\7555863|NONE_0 (l_dobj) effects_5\NNS\13245626|succinylcholine_51|commonly_35|._51 (l_prep) including_7\VBG\0|frequent_26|adverse_17|,_2 (l_pobj) fasciculation_9\NN\14361664|NONE_0 (l_conj) myalgia_11\NN\14322699|muscle_25|and_4
D013390_D063806 CID succinylcholine_11\NN\3800001|-_15 (r_npadvmod) induced_13\VBN\1627355|and_22|myalgia_26 (r_amod) fasciculation_14\NN\14361664|to_35 (l_conj) myalgia_16\NN\14322699|induced_26|and_4
D013390_D063806 CID succinylcholine_30\NN\3800001|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) produced_28\VBN\1617192|NONE_0 (r_acl) onset_27\NN\7325190|NONE_0 (r_pobj) of_26\IN\0|the_10 (r_prep) speed_25\NN\15286249|NONE_0 (r_pobj) on_23\IN\0|NONE_0 (r_prep) rocuronium_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|the_14 (r_prep) influence_20\NN\5190804|NONE_0 (r_dobj) evaluated_18\VBD\670261|study_113|dose_84|prevent_62|and_4|._87 (r_conj) identified_3\VBD\699815|NONE_0 (l_advcl) prevent_10\VB\0|study_51|dose_22|and_58|evaluated_62|._149 (l_dobj) fasciculation_14\NN\14361664|to_35 (l_conj) myalgia_16\NN\14322699|induced_26|and_4
D013390_D063806 CID succinylcholine_3\NN\3800001|patients_18|,_64|and_66|assessed_75|._182 (r_dobj) received_2\VBD\2210855|NONE_0 (l_conj) assessed_15\VBN\670261|patients_93|succinylcholine_75|,_11|and_9|._107 (l_advcl) assessed_26\VBN\670261|were_78|incidence_60|,_20 (l_nsubjpass) myalgia_24\NN\14322699|while_6|was_8|at_21
C061870_D063806 NONE rocuronium_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|optimal_27|precurarizing_19|decrease_17|._92 (r_prep) dose_2\NN\3740161|NONE_0 (l_acl) decrease_6\VB\7296428|optimal_44|precurarizing_36|of_17|._75 (l_dobj) fasciculation_7\NN\14361664|to_12|following_26 (l_conj) myalgia_9\NN\14322699|and_4
C061870_D063806 NONE rocuronium_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_17|optimal_13 (r_prep) dose_6\NN\3740161|study_29|prevent_22|and_80|evaluated_84|._171 (r_dobj) identified_3\VBD\699815|NONE_0 (l_advcl) prevent_10\VB\0|study_51|dose_22|and_58|evaluated_62|._149 (l_dobj) fasciculation_14\NN\14361664|to_35 (l_conj) myalgia_16\NN\14322699|induced_26|and_4
C061870_D063806 NONE rocuronium_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|the_14 (r_prep) influence_20\NN\5190804|NONE_0 (r_dobj) evaluated_18\VBD\670261|study_113|dose_84|prevent_62|and_4|._87 (r_conj) identified_3\VBD\699815|NONE_0 (l_advcl) prevent_10\VB\0|study_51|dose_22|and_58|evaluated_62|._149 (l_dobj) fasciculation_14\NN\14361664|to_35 (l_conj) myalgia_16\NN\14322699|induced_26|and_4
C061870_D063806 NONE rocuronium_15\NN\0|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) dose_13\NN\3740161|NONE_0 (r_dobj) precurarizing_12\VBG\0|NONE_0 (r_pcomp) of_11\IN\0|the_11 (r_prep) amount_10\NN\13329641|NONE_0 (r_dobj) increasing_8\VBG\169651|NONE_0 (r_pcomp) to_7\IN\0|NONE_0 (r_prep) according_6\VBG\2657219|to_12 (r_prep) decrease_5\VB\7296428|those_25|,_79|but_81|was_91 (r_xcomp) tend_3\VBP\2604760|NONE_0 (l_nsubj) those_0\DT\0|decrease_25|,_104|but_106|was_116 (l_prep) of_1\IN\0|NONE_0 (l_pobj) myalgia_2\NN\14322699|NONE_0
C061870_D063806 NONE rocuronium_4\NN\0|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) precurarization_0\NN\0|dose_59|,_175|and_177|precurarization_204|._219 (r_nsubj) was_5\VBD\0|NONE_0 (l_attr) dose_8\NN\3740161|precurarization_59|,_116|and_118|precurarization_145|._160 (l_acl) considering_9\VBG\689344|the_17|optimal_13 (l_dobj) reduction_11\NN\351485|NONE_0 (l_prep) in_12\IN\13603305|the_14 (l_pobj) incidence_14\NN\13821570|NONE_0 (l_prep) of_17\IN\0|the_27|and_13|severity_9 (l_pobj) fasciculation_18\NN\14361664|NONE_0 (l_conj) myalgia_20\NN\14322699|and_4
C061870_D005207 NONE rocuronium_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|optimal_27|precurarizing_19|decrease_17|._92 (r_prep) dose_2\NN\3740161|NONE_0 (l_acl) decrease_6\VB\7296428|optimal_44|precurarizing_36|of_17|._75 (l_dobj) fasciculation_7\NN\14361664|to_12|following_26
C061870_D005207 NONE rocuronium_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_17|optimal_13 (r_prep) dose_6\NN\3740161|study_29|prevent_22|and_80|evaluated_84|._171 (r_dobj) identified_3\VBD\699815|NONE_0 (l_advcl) prevent_10\VB\0|study_51|dose_22|and_58|evaluated_62|._149 (l_dobj) fasciculation_14\NN\14361664|to_35
C061870_D005207 NONE rocuronium_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|the_14 (r_prep) influence_20\NN\5190804|NONE_0 (r_dobj) evaluated_18\VBD\670261|study_113|dose_84|prevent_62|and_4|._87 (r_conj) identified_3\VBD\699815|NONE_0 (l_advcl) prevent_10\VB\0|study_51|dose_22|and_58|evaluated_62|._149 (l_dobj) fasciculation_14\NN\14361664|to_35
C061870_D005207 NONE rocuronium_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) dose_17\NN\3740161|NONE_0 (r_dobj) precurarizing_16\VBG\0|NONE_0 (r_pcomp) of_15\IN\0|the_11|(_36|p_37|)_46 (r_prep) amount_14\NN\13329641|NONE_0 (r_dobj) increasing_12\VBG\169651|NONE_0 (r_pcomp) with_11\IN\0|significantly_19 (r_prep) less_10\JJR\14187378|incidence_73|._79 (r_acomp) was_8\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|less_73|._152 (l_prep) of_4\IN\0|the_27|and_13|severity_9 (l_pobj) fasciculation_7\NN\14361664|NONE_0
C061870_D005207 NONE rocuronium_4\NN\0|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) precurarization_0\NN\0|dose_59|,_175|and_177|precurarization_204|._219 (r_nsubj) was_5\VBD\0|NONE_0 (l_attr) dose_8\NN\3740161|precurarization_59|,_116|and_118|precurarization_145|._160 (l_acl) considering_9\VBG\689344|the_17|optimal_13 (l_dobj) reduction_11\NN\351485|NONE_0 (l_prep) in_12\IN\13603305|the_14 (l_pobj) incidence_14\NN\13821570|NONE_0 (l_prep) of_17\IN\0|the_27|and_13|severity_9 (l_pobj) fasciculation_18\NN\14361664|NONE_0
8188982
D009599_D007022 CID nitroprusside_42\NN\0|phenylephrine_52|hypertension_24|(_14|sn)-induced_15 (r_amod) hypotension_45\NN\14057371|NONE_0
D009599_D007022 CID sn)-induced_44\JJ\0|phenylephrine_67|hypertension_39|nitroprusside_15|(_1 (r_amod) hypotension_45\NN\14057371|NONE_0
D009599_D007022 CID sn_13\NNP\14625458|-_2 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) hypotension_16\NN\14057371|NONE_0
D001127_D006973 CID avp_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|central_31|cardiovascular_23|in_15|._66 (r_prep) effects_2\NNS\13245626|NONE_0 (l_prep) in_7\IN\13603305|central_46|cardiovascular_38|of_15|._51 (l_pobj) rats_12\NNS\2329401|NONE_0 (l_amod) hypertensive_11\JJ\10405694|normotensive_31
D001127_D006973 CID vasopressin_13\NN\5407119|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) influence_9\NN\5190804|to_11|and_48|of_52|on_88|and_174|rats_211 (r_dobj) compare_8\VB\4744814|purpose_36|._223 (l_conj) rats_51\NNS\2329401|to_222|influence_211|and_163|of_159|on_123|and_37 (l_amod) hypertensive_47\JJ\10405694|(_13|shr_14|)_17
D001127_D006973 CID avp_15\NNP\0|central_30|arginine_22|(_1|)_3 (r_appos) vasopressin_13\NN\5407119|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) influence_9\NN\5190804|to_11|and_48|of_52|on_88|and_174|rats_211 (r_dobj) compare_8\VB\4744814|purpose_36|._223 (l_conj) rats_51\NNS\2329401|to_222|influence_211|and_163|of_159|on_123|and_37 (l_amod) hypertensive_47\JJ\10405694|(_13|shr_14|)_17
D010656_D007022 NONE phenylephrine_36\NN\2682038|hypertension_28|nitroprusside_52|(_66|sn)-induced_67 (r_nmod) hypotension_45\NN\14057371|NONE_0
D010656_D007022 NONE phe)-induced_38\VBN\0|(_1|and_26|sodium_30 (r_amod) hypertension_39\NN\14057371|phenylephrine_28|nitroprusside_24|(_38|sn)-induced_39 (r_nmod) hypotension_45\NN\14057371|NONE_0
D010656_D006973 CID phenylephrine_36\NN\2682038|hypertension_28|nitroprusside_52|(_66|sn)-induced_67 (r_nmod) hypotension_45\NN\14057371|NONE_0 (l_nmod) hypertension_39\NN\14057371|phenylephrine_28|nitroprusside_24|(_38|sn)-induced_39
D010656_D006973 CID phe)-induced_38\VBN\0|(_1|and_26|sodium_30 (r_amod) hypertension_39\NN\14057371|phenylephrine_28|nitroprusside_24|(_38|sn)-induced_39
D009599_D006973 NONE nitroprusside_42\NN\0|phenylephrine_52|hypertension_24|(_14|sn)-induced_15 (r_amod) hypotension_45\NN\14057371|NONE_0 (l_nmod) hypertension_39\NN\14057371|phenylephrine_28|nitroprusside_24|(_38|sn)-induced_39
D009599_D006973 NONE sn)-induced_44\JJ\0|phenylephrine_67|hypertension_39|nitroprusside_15|(_1 (r_amod) hypotension_45\NN\14057371|NONE_0 (l_nmod) hypertension_39\NN\14057371|phenylephrine_28|nitroprusside_24|(_38|sn)-induced_39
D001127_D007022 NONE avp_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|lv_18 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) after_7\IN\0|ccb_31|was_27|in_15|during_31|._60 (r_prep) reduced_2\VBN\441445|NONE_0 (l_prep) during_12\IN\0|ccb_62|was_58|in_46|after_31|._29 (l_pobj) hypotension_16\NN\14057371|NONE_0
23892921
C467567_D009101 NONE lenalidomide_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_24|and_11|safety_7 (r_prep) efficacy_8\NN\5199286|NONE_0 (r_pobj) on_6\IN\0|"_18|world_12|"_7|in_61|:_175|study_179|._217 (r_prep) data_5\NNS\7951464|NONE_0 (l_prep) in_15\IN\13603305|"_79|world_73|"_68|on_61|:_114|study_118|._156 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) myeloma_22\NN\14239425|NONE_0
C467567_D009101 NONE lenalidomide_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_24|and_11|safety_7 (r_prep) efficacy_8\NN\5199286|NONE_0 (r_pobj) on_6\IN\0|"_18|world_12|"_7|in_61|:_175|study_179|._217 (r_prep) data_5\NNS\7951464|NONE_0 (l_appos) study_34\NN\635850|"_197|world_191|"_186|on_179|in_118|:_4|._38 (l_prep) of_35\IN\0|a_8 (l_pobj) group_40\NNP\2137|NONE_0 (l_compound) myeloma_38\NNP\14239425|the_10|greek_6|study_8
C467567_D009101 NONE lenalidomide_0\NNP\0|standard_41|,_105|but_107|is_117 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) standard_8\NN\13577171|lenalidomide_41|,_64|but_66|is_76 (l_prep) for_11\IN\0|a_19|of_8 (l_pobj) myeloma_16\NN\14239425|NONE_0
C467567_D009101 NONE lenalidomide_0\NNP\0|standard_41|,_105|but_107|is_117 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) standard_8\NN\13577171|lenalidomide_41|,_64|but_66|is_76 (l_prep) for_11\IN\0|a_19|of_8 (l_pobj) myeloma_16\NN\14239425|NONE_0 (l_appos) rrmm_18\NNP\0|relapsed_38|refractory_29|multiple_18
C467567_D009101 NONE rd_4\NNP\0|NONE_0 (r_appos) dexamethasone_2\NN\2721538|and_4 (r_conj) lenalidomide_0\NNP\0|standard_41|,_105|but_107|is_117 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) standard_8\NN\13577171|lenalidomide_41|,_64|but_66|is_76 (l_prep) for_11\IN\0|a_19|of_8 (l_pobj) myeloma_16\NN\14239425|NONE_0
C467567_D009101 NONE rd_4\NNP\0|NONE_0 (r_appos) dexamethasone_2\NN\2721538|and_4 (r_conj) lenalidomide_0\NNP\0|standard_41|,_105|but_107|is_117 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) standard_8\NN\13577171|lenalidomide_41|,_64|but_66|is_76 (l_prep) for_11\IN\0|a_19|of_8 (l_pobj) myeloma_16\NN\14239425|NONE_0 (l_appos) rrmm_18\NNP\0|relapsed_38|refractory_29|multiple_18
C467567_D009101 NONE rd_7\NNP\0|who_13|in_3 (r_dobj) received_6\VBD\2210855|212_22|rrmm_18 (r_relcl) patients_4\NNS\9898892|we_20|._30 (l_compound) rrmm_3\NNP\0|212_4|received_18
C467567_D009101 NONE rd_4\NNP\0|that_5|effective_6|in_33 (r_nsubj) is_5\VBZ\0|study_23 (l_acomp) effective_6\JJ\0|that_11|rd_6|in_27 (l_conj) safe_8\JJ\4340750|and_4 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) rrmm_10\NNP\0|NONE_0
D003907_D009101 NONE dexamethasone_14\NN\2721538|and_4 (r_conj) lenalidomide_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_24|and_11|safety_7 (r_prep) efficacy_8\NN\5199286|NONE_0 (r_pobj) on_6\IN\0|"_18|world_12|"_7|in_61|:_175|study_179|._217 (r_prep) data_5\NNS\7951464|NONE_0 (l_prep) in_15\IN\13603305|"_79|world_73|"_68|on_61|:_114|study_118|._156 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) myeloma_22\NN\14239425|NONE_0
D003907_D009101 NONE dexamethasone_14\NN\2721538|and_4 (r_conj) lenalidomide_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_24|and_11|safety_7 (r_prep) efficacy_8\NN\5199286|NONE_0 (r_pobj) on_6\IN\0|"_18|world_12|"_7|in_61|:_175|study_179|._217 (r_prep) data_5\NNS\7951464|NONE_0 (l_appos) study_34\NN\635850|"_197|world_191|"_186|on_179|in_118|:_4|._38 (l_prep) of_35\IN\0|a_8 (l_pobj) group_40\NNP\2137|NONE_0 (l_compound) myeloma_38\NNP\14239425|the_10|greek_6|study_8
D003907_D009101 NONE dexamethasone_2\NN\2721538|and_4 (r_conj) lenalidomide_0\NNP\0|standard_41|,_105|but_107|is_117 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) standard_8\NN\13577171|lenalidomide_41|,_64|but_66|is_76 (l_prep) for_11\IN\0|a_19|of_8 (l_pobj) myeloma_16\NN\14239425|NONE_0
D003907_D009101 NONE dexamethasone_2\NN\2721538|and_4 (r_conj) lenalidomide_0\NNP\0|standard_41|,_105|but_107|is_117 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) standard_8\NN\13577171|lenalidomide_41|,_64|but_66|is_76 (l_prep) for_11\IN\0|a_19|of_8 (l_pobj) myeloma_16\NN\14239425|NONE_0 (l_appos) rrmm_18\NNP\0|relapsed_38|refractory_29|multiple_18
D003907_D009101 NONE rd_4\NNP\0|NONE_0 (r_appos) dexamethasone_2\NN\2721538|and_4 (r_conj) lenalidomide_0\NNP\0|standard_41|,_105|but_107|is_117 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) standard_8\NN\13577171|lenalidomide_41|,_64|but_66|is_76 (l_prep) for_11\IN\0|a_19|of_8 (l_pobj) myeloma_16\NN\14239425|NONE_0
D003907_D009101 NONE rd_4\NNP\0|NONE_0 (r_appos) dexamethasone_2\NN\2721538|and_4 (r_conj) lenalidomide_0\NNP\0|standard_41|,_105|but_107|is_117 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) standard_8\NN\13577171|lenalidomide_41|,_64|but_66|is_76 (l_prep) for_11\IN\0|a_19|of_8 (l_pobj) myeloma_16\NN\14239425|NONE_0 (l_appos) rrmm_18\NNP\0|relapsed_38|refractory_29|multiple_18
D003907_D009101 NONE rd_7\NNP\0|who_13|in_3 (r_dobj) received_6\VBD\2210855|212_22|rrmm_18 (r_relcl) patients_4\NNS\9898892|we_20|._30 (l_compound) rrmm_3\NNP\0|212_4|received_18
D003907_D009101 NONE rd_4\NNP\0|that_5|effective_6|in_33 (r_nsubj) is_5\VBZ\0|study_23 (l_acomp) effective_6\JJ\0|that_11|rd_6|in_27 (l_conj) safe_8\JJ\4340750|and_4 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) rrmm_10\NNP\0|NONE_0
12359538
D003042_D009336 NONE cocaine_19\NN\3492717|-_7 (r_npadvmod) associated_21\VBN\628491|chest_11|and_22|mi_36 (r_amod) pain_23\NN\14299637|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) patients_17\NNS\9898892|NONE_0 (r_pobj) in_16\IN\13603305|NONE_0 (r_prep) necrosis_15\NN\11444117|NONE_0
D003042_D002637 NONE cocaine_7\NN\3492717|-_7 (r_npadvmod) associated_9\VBN\628491|chest_11 (r_amod) pain_11\NN\14299637|NONE_0
D003042_D002637 NONE cocaine_24\NN\3492717|-_7 (r_npadvmod) associated_26\VBN\628491|chest_11 (r_amod) pain_28\NN\14299637|NONE_0
D003042_D002637 NONE cocaine_10\NN\3492717|NONE_0 (r_compound) chest_11\NN\5220461|NONE_0 (r_compound) pain_12\NN\14299637|NONE_0
D003042_D002637 NONE cocaine_19\NN\3492717|-_7 (r_npadvmod) associated_21\VBN\628491|chest_11|and_22|mi_36 (r_amod) pain_23\NN\14299637|NONE_0
D003042_D009203 CID cocaine_24\NN\3492717|-_7 (r_npadvmod) associated_26\VBN\628491|chest_11 (r_amod) pain_28\NN\14299637|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) patients_22\NNS\9898892|NONE_0 (r_pobj) in_21\IN\13603305|NONE_0 (r_prep) difficult_20\JJ\0|abnormalities_130|diagnosis_40|._56 (r_ccomp) make_11\VBP\5839024|NONE_0 (l_dobj) diagnosis_13\NN\152018|abnormalities_90|difficult_40|._96 (l_prep) of_14\IN\0|accurate_19 (l_pobj) infarction_16\NN\14204950|NONE_0
D003042_D009203 CID cocaine_24\NN\3492717|-_7 (r_npadvmod) associated_26\VBN\628491|chest_11 (r_amod) pain_28\NN\14299637|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) patients_22\NNS\9898892|NONE_0 (r_pobj) in_21\IN\13603305|NONE_0 (r_prep) difficult_20\JJ\0|abnormalities_130|diagnosis_40|._56 (r_ccomp) make_11\VBP\5839024|NONE_0 (l_dobj) diagnosis_13\NN\152018|abnormalities_90|difficult_40|._96 (l_prep) of_14\IN\0|accurate_19 (l_pobj) infarction_16\NN\14204950|NONE_0 (l_appos) mi_18\NNP\14207561|myocardial_23|(_1|)_2
D003042_D009203 CID cocaine_10\NN\3492717|NONE_0 (r_compound) chest_11\NN\5220461|NONE_0 (r_compound) pain_12\NN\14299637|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) patients_8\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|troponin_20|admitted_36 (r_prep) positivity_6\NN\13856574|NONE_0 (l_acl) admitted_13\VBD\822367|troponin_56|in_36 (l_prep) for_14\IN\0|NONE_0 (l_pobj) exclusion_15\NN\13927383|NONE_0 (l_prep) of_16\IN\0|NONE_0 (l_pobj) mi_17\NNP\14207561|NONE_0
D003042_D009203 CID cocaine_10\NN\3492717|NONE_0 (r_compound) use_11\NN\407535|NONE_0 (r_pobj) after_9\IN\0|for_16 (r_prep) admitted_5\VBN\822367|NONE_0 (l_prep) for_6\IN\0|after_16 (l_pobj) mi_8\NNP\14207561|NONE_0
D003042_D009203 CID cocaine_19\NN\3492717|-_7 (r_npadvmod) associated_21\VBN\628491|chest_11|and_22|mi_36 (r_amod) pain_23\NN\14299637|NONE_0 (l_conj) mi_26\NNP\14207561|associated_36|chest_25|and_14
D003042_D009202 NONE cocaine_24\NN\3492717|-_7 (r_npadvmod) associated_26\VBN\628491|chest_11 (r_amod) pain_28\NN\14299637|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) patients_22\NNS\9898892|NONE_0 (r_pobj) in_21\IN\13603305|NONE_0 (r_prep) difficult_20\JJ\0|abnormalities_130|diagnosis_40|._56 (r_ccomp) make_11\VBP\5839024|NONE_0 (l_nsubj) abnormalities_2\NNS\14034177|diagnosis_90|difficult_130|._186 (l_acl) associated_7\VBN\628491|baseline_67|electrocardiogram_58|and_26|elevations_15 (l_prep) with_8\IN\0|not_15 (l_pobj) necrosis_10\NN\11444117|NONE_0
25080425
D001622_D017202 NONE betaine_11\NN\14712692|NONE_0 (r_pobj) of_10\IN\0|the_29|cardioprotective_25|on_11|induced_40 (r_prep) effects_9\NNS\13245626|to_36 (l_prep) on_12\IN\0|the_40|cardioprotective_36|of_11|induced_29 (l_pobj) ischemia_15\NN\14195315|NONE_0
D001622_D017202 NONE betaine_7\NN\14712692|NONE_0 (r_compound) pretreatment_8\NN\0|NONE_0 (r_nsubj) attenuated_9\VBD\224901|that_26|induced_25|acute_33|myocardial_39|via_59 (r_amod) ischemia_15\NN\14195315|in_107|,_97|results_91|._59
D001622_D020257 NONE betaine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|oral_20|mg/kg_24 (r_prep) administration_1\NN\1133281|significantly_46|level_72|and_116|prevented_120|._157 (r_nsubj) reduced_11\VBD\441445|NONE_0 (l_conj) prevented_22\VBN\0|administration_120|significantly_74|level_48|and_4|._37 (l_dobj) remodeling_25\NN\126264|NONE_0
D007545_D009202 NONE isoproterenol_15\NN\3740161|-_13 (r_npadvmod) induced_17\VBN\1627355|acute_8|myocardial_14|in_32 (r_amod) injury_20\NN\14052046|regulation_149|._14
D001622_D009202 NONE betaine_13\NN\14712692|NONE_0 (r_pobj) by_12\IN\0|of_77 (r_prep) regulation_0\NN\6652242|injury_149|._163 (r_nsubj) attenuates_14\VBZ\224901|NONE_0 (l_dobj) injury_20\NN\14052046|regulation_149|._14
D001622_D009202 NONE betaine_4\NN\14712692|NONE_0 (l_prep) on_5\IN\0|NONE_0 (l_pobj) damage_7\NN\7296428|NONE_0
D007545_D017202 CID isoproterenol_12\NN\3740161|NONE_0 (r_pobj) of_11\IN\0|subcutaneous_23|(_17|mg/kg_21|)_26 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) by_8\IN\0|injury_27|was_20|in_8|,_53|for_55|._79 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) injury_3\NN\14052046|was_7|in_19|by_27|,_80|for_82|._106
D007545_D017202 CID isoproterenol_10\NN\3740161|-_13 (r_npadvmod) induced_12\VBN\1627355|that_51|attenuated_25|acute_8|myocardial_14|via_34 (r_amod) ischemia_15\NN\14195315|in_107|,_97|results_91|._59
15614572
D006220_D009062 NONE haloperidol_19\NN\3713736|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|NONE_0 (r_acl) catalepsy_16\NN\14023236|NONE_0 (r_pobj) on_15\IN\0|effect_100|,_2|,_70|on_72|was_164|in_176|._183 (r_prep) studied_47\VBN\0|NONE_0 (l_nsubjpass) effect_1\NN\34213|,_98|on_100|,_170|on_172|was_264|in_276|._283 (l_prep) of_2\IN\0|the_11 (l_pobj) pretreatment_3\NN\0|NONE_0 (l_prep) on_6\IN\0|with_15 (l_pobj) stereotypies_13\NNS\0|NONE_0
D001058_D002375 CID apomorphine_9\NN\3786417|and_4 (r_conj) dexamphetamine-_7\FW\0|-_31 (r_npadvmod) induced_11\VBN\1627355|oral_8 (r_amod) stereotypies_13\NNS\0|NONE_0 (r_pobj) on_6\IN\0|with_15 (r_prep) pretreatment_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|,_98|on_100|,_170|on_172|was_264|in_276|._283 (r_nsubjpass) studied_47\VBN\0|NONE_0 (l_prep) on_15\IN\0|effect_100|,_2|,_70|on_72|was_164|in_176|._183 (l_pobj) catalepsy_16\NN\14023236|NONE_0
D001058_D002375 CID apomorphine_21\NN\3786417|and_4|mg/kg_18 (r_conj) haloperidol_19\NN\3713736|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|NONE_0 (r_acl) catalepsy_16\NN\14023236|NONE_0
D001058_D002375 CID apomorphine_16\NN\3786417|did_19|not_15|catalepsy_78 (r_dobj) antagonize_15\VB\1787955|trazodone_69|did_38|not_34|catalepsy_23|,_14|and_12|._98 (r_conj) induce_9\VB\1627355|NONE_0 (l_dobj) catalepsy_10\NN\14023236|trazodone_46|did_15|not_11|,_9|and_11|antagonize_23|._121
D001058_D002375 CID apomorphine_16\NN\3786417|did_19|not_15|catalepsy_78 (r_dobj) antagonize_15\VB\1787955|trazodone_69|did_38|not_34|catalepsy_23|,_14|and_12|._98 (l_dobj) catalepsy_31\NN\14023236|did_97|not_93|apomorphine_78
D001058_D002375 CID apomorphine_25\NN\3786417|(_33|mg/kg_22|)_17|and_4 (r_conj) stereotypy_23\NN\0|kg)-induced_36 (r_nmod) catalepsy_31\NN\14023236|did_97|not_93|apomorphine_78 (r_dobj) antagonize_15\VB\1787955|trazodone_69|did_38|not_34|catalepsy_23|,_14|and_12|._98 (r_conj) induce_9\VB\1627355|NONE_0 (l_dobj) catalepsy_10\NN\14023236|trazodone_46|did_15|not_11|,_9|and_11|antagonize_23|._121
D001058_D002375 CID apomorphine_25\NN\3786417|(_33|mg/kg_22|)_17|and_4 (r_conj) stereotypy_23\NN\0|kg)-induced_36 (r_nmod) catalepsy_31\NN\14023236|did_97|not_93|apomorphine_78
D001058_D002375 CID apomorphine_13\NN\3786417|NONE_0 (r_dobj) antagonized_12\VBN\1787955|trazodone_60|,_45|mg/kg_33|i.p._27|catalepsy_14|and_4|._55 (r_conj) induced_9\VBN\1627355|NONE_0 (l_dobj) catalepsy_10\NN\14023236|trazodone_46|,_31|mg/kg_19|i.p._13|and_10|antagonized_14|._69
D001058_D009062 NONE apomorphine_9\NN\3786417|and_4 (r_conj) dexamphetamine-_7\FW\0|-_31 (r_npadvmod) induced_11\VBN\1627355|oral_8 (r_amod) stereotypies_13\NNS\0|NONE_0
D001058_D009062 NONE apomorphine_21\NN\3786417|and_4|mg/kg_18 (r_conj) haloperidol_19\NN\3713736|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|NONE_0 (r_acl) catalepsy_16\NN\14023236|NONE_0 (r_pobj) on_15\IN\0|effect_100|,_2|,_70|on_72|was_164|in_176|._183 (r_prep) studied_47\VBN\0|NONE_0 (l_nsubjpass) effect_1\NN\34213|,_98|on_100|,_170|on_172|was_264|in_276|._283 (l_prep) of_2\IN\0|the_11 (l_pobj) pretreatment_3\NN\0|NONE_0 (l_prep) on_6\IN\0|with_15 (l_pobj) stereotypies_13\NNS\0|NONE_0
D014196_D002375 NONE trazodone_5\NN\3829085|NONE_0 (r_pobj) with_4\IN\0|on_15 (r_prep) pretreatment_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|,_98|on_100|,_170|on_172|was_264|in_276|._283 (r_nsubjpass) studied_47\VBN\0|NONE_0 (l_prep) on_15\IN\0|effect_100|,_2|,_70|on_72|was_164|in_176|._183 (l_pobj) catalepsy_16\NN\14023236|NONE_0
D014196_D002375 NONE trazodone_4\NN\3829085|whether_8|catalepsy_18|in_28 (r_nsubj) induces_5\VBZ\1627355|we_39|also_36|._25 (l_dobj) catalepsy_6\NN\14023236|whether_26|trazodone_18|in_10
D014196_D002375 NONE trazodone_0\NNP\3829085|did_31|not_35|catalepsy_46|,_55|and_57|antagonize_69|._167 (r_nsubj) induce_9\VB\1627355|NONE_0 (l_dobj) catalepsy_10\NN\14023236|trazodone_46|did_15|not_11|,_9|and_11|antagonize_23|._121
D014196_D002375 NONE trazodone_0\NNP\3829085|did_31|not_35|catalepsy_46|,_55|and_57|antagonize_69|._167 (r_nsubj) induce_9\VB\1627355|NONE_0 (l_conj) antagonize_15\VB\1787955|trazodone_69|did_38|not_34|catalepsy_23|,_14|and_12|._98 (l_dobj) catalepsy_31\NN\14023236|did_97|not_93|apomorphine_78
D014196_D002375 NONE trazodone_11\NNP\3829085|,_23|i.p._5|enhanced_10|dexamphetamine_19 (r_nmod) stereotypy_14\NN\0|5_58 (r_pobj) with_3\IN\0|however_22|,_15|,_73|and_75|antagonized_79|._186 (r_prep) pretreatment_2\NN\0|NONE_0 (l_conj) antagonized_17\VBD\1787955|however_101|,_94|with_79|,_6|and_4|._107 (l_dobj) catalepsy_19\NN\14023236|NONE_0
D014196_D002375 NONE trazodone_0\NNP\3829085|,_15|mg/kg_27|i.p._33|catalepsy_46|and_56|antagonized_60|._115 (r_nsubj) induced_9\VBN\1627355|NONE_0 (l_dobj) catalepsy_10\NN\14023236|trazodone_46|,_31|mg/kg_19|i.p._13|and_10|antagonized_14|._69
D014196_D002375 NONE trazodone_3\NNP\3829085|that_5|,_65|neurons_102|,_146|and_148|potentiates_160 (r_nsubj) releases_20\VBZ\3748886|we_83|._168 (l_conj) potentiates_34\VBZ\229605|that_165|trazodone_160|,_95|neurons_58|,_14|and_12 (l_conj) antagonizes_38\VBZ\1787955|thereby_50|stereotypy_15|and_4 (l_dobj) catalepsy_40\NN\14023236|NONE_0
D014196_D009062 NONE trazodone_5\NN\3829085|NONE_0 (r_pobj) with_4\IN\0|on_15 (r_prep) pretreatment_3\NN\0|NONE_0 (l_prep) on_6\IN\0|with_15 (l_pobj) stereotypies_13\NNS\0|NONE_0
D012701_D002375 NONE 5-ht_16\CD\0|NONE_0 (r_compound) 2c_17\NNP\0|the_9 (r_compound) receptors_18\NNS\5225602|NONE_0 (r_dobj) blocking_14\VBG\562280|NONE_0 (r_pcomp) by_13\IN\0|mg/kg_8|,_2 (r_prep) trazodone_3\NNP\3829085|that_5|,_65|neurons_102|,_146|and_148|potentiates_160 (r_nsubj) releases_20\VBZ\3748886|we_83|._168 (l_conj) potentiates_34\VBZ\229605|that_165|trazodone_160|,_95|neurons_58|,_14|and_12 (l_conj) antagonizes_38\VBZ\1787955|thereby_50|stereotypy_15|and_4 (l_dobj) catalepsy_40\NN\14023236|NONE_0
D012701_D002375 NONE 5-ht_30\CD\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) caused_28\VBN\1617192|tonic_17 (r_acl) inhibition_27\NN\1068773|NONE_0 (r_pobj) from_25\IN\0|the_34|nigrostriatal_30|daergic_16 (r_prep) neurons_24\NNS\5430628|that_107|trazodone_102|,_37|,_44|and_46|potentiates_58 (r_dobj) releases_20\VBZ\3748886|we_83|._168 (l_conj) potentiates_34\VBZ\229605|that_165|trazodone_160|,_95|neurons_58|,_14|and_12 (l_conj) antagonizes_38\VBZ\1787955|thereby_50|stereotypy_15|and_4 (l_dobj) catalepsy_40\NN\14023236|NONE_0
D003913_D009062 NONE dexamphetamine-_7\FW\0|-_31 (r_npadvmod) induced_11\VBN\1627355|oral_8 (r_amod) stereotypies_13\NNS\0|NONE_0
D006220_D002375 CID haloperidol_19\NN\3713736|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|NONE_0 (r_acl) catalepsy_16\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_18\NN\3713736|,_21|behavior_47 (r_det) catalepsy_19\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_39\NN\3713736|NONE_0 (r_det) catalepsy_40\NN\14023236|NONE_0
D004874_D002375 NONE ergometrine_30\NN\0|-_11 (r_advmod) induced_32\VBN\1627355|shake_16|(_22|wds_23|)_26|and_37|erections_67 (r_amod) behavior_39\NN\407535|NONE_0 (r_pobj) on_29\IN\0|effect_172|,_74|on_72|,_2|was_92|in_104|._111 (r_prep) studied_47\VBN\0|NONE_0 (l_prep) on_15\IN\0|effect_100|,_2|,_70|on_72|was_164|in_176|._183 (l_pobj) catalepsy_16\NN\14023236|NONE_0
D004874_D002375 NONE ergometrine_21\NN\0|-_11 (r_advmod) induced_23\VBN\1627355|wds_8|and_21|erections_51 (r_amod) behavior_25\NN\407535|haloperidol_47|,_26 (r_conj) catalepsy_19\NN\14023236|NONE_0
D003913_D002375 NONE dexamphetamine-_7\FW\0|-_31 (r_npadvmod) induced_11\VBN\1627355|oral_8 (r_amod) stereotypies_13\NNS\0|NONE_0 (r_pobj) on_6\IN\0|with_15 (r_prep) pretreatment_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|,_98|on_100|,_170|on_172|was_264|in_276|._283 (r_nsubjpass) studied_47\VBN\0|NONE_0 (l_prep) on_15\IN\0|effect_100|,_2|,_70|on_72|was_164|in_176|._183 (l_pobj) catalepsy_16\NN\14023236|NONE_0
D003913_D002375 NONE dexamphetamine_13\NN\0|,_42|i.p._24|trazodone_19|enhanced_9 (r_compound) stereotypy_14\NN\0|5_58 (r_pobj) with_3\IN\0|however_22|,_15|,_73|and_75|antagonized_79|._186 (r_prep) pretreatment_2\NN\0|NONE_0 (l_conj) antagonized_17\VBD\1787955|however_101|,_94|with_79|,_6|and_4|._107 (l_dobj) catalepsy_19\NN\14023236|NONE_0
D003913_D002375 NONE dexamphetamine_15\NN\0|NONE_0 (r_compound) stereotypies_16\NNS\0|and_19 (r_conj) apomorphine_13\NN\3786417|NONE_0 (r_dobj) antagonized_12\VBN\1787955|trazodone_60|,_45|mg/kg_33|i.p._27|catalepsy_14|and_4|._55 (r_conj) induced_9\VBN\1627355|NONE_0 (l_dobj) catalepsy_10\NN\14023236|trazodone_46|,_31|mg/kg_19|i.p._13|and_10|antagonized_14|._69
D003913_D002375 NONE dexamphetamine_35\NN\0|NONE_0 (r_compound) stereotypy_36\NN\0|thereby_35|and_11|antagonizes_15 (r_dobj) potentiates_34\VBZ\229605|that_165|trazodone_160|,_95|neurons_58|,_14|and_12 (l_conj) antagonizes_38\VBZ\1787955|thereby_50|stereotypy_15|and_4 (l_dobj) catalepsy_40\NN\14023236|NONE_0
D004874_D009062 NONE ergometrine_30\NN\0|-_11 (r_advmod) induced_32\VBN\1627355|shake_16|(_22|wds_23|)_26|and_37|erections_67 (r_amod) behavior_39\NN\407535|NONE_0 (r_pobj) on_29\IN\0|effect_172|,_74|on_72|,_2|was_92|in_104|._111 (r_prep) studied_47\VBN\0|NONE_0 (l_nsubjpass) effect_1\NN\34213|,_98|on_100|,_170|on_172|was_264|in_276|._283 (l_prep) of_2\IN\0|the_11 (l_pobj) pretreatment_3\NN\0|NONE_0 (l_prep) on_6\IN\0|with_15 (l_pobj) stereotypies_13\NNS\0|NONE_0
D005473_D009062 NONE fluoxetine_41\NN\4169152|-_10 (r_advmod) induced_43\VBN\1627355|penile_8 (r_amod) erections_45\NNS\14037619|induced_67|shake_51|(_45|wds_44|)_41|and_30 (r_conj) behavior_39\NN\407535|NONE_0 (r_pobj) on_29\IN\0|effect_172|,_74|on_72|,_2|was_92|in_104|._111 (r_prep) studied_47\VBN\0|NONE_0 (l_nsubjpass) effect_1\NN\34213|,_98|on_100|,_170|on_172|was_264|in_276|._283 (l_prep) of_2\IN\0|the_11 (l_pobj) pretreatment_3\NN\0|NONE_0 (l_prep) on_6\IN\0|with_15 (l_pobj) stereotypies_13\NNS\0|NONE_0
D005473_D002375 NONE fluoxetine_41\NN\4169152|-_10 (r_advmod) induced_43\VBN\1627355|penile_8 (r_amod) erections_45\NNS\14037619|induced_67|shake_51|(_45|wds_44|)_41|and_30 (r_conj) behavior_39\NN\407535|NONE_0 (r_pobj) on_29\IN\0|effect_172|,_74|on_72|,_2|was_92|in_104|._111 (r_prep) studied_47\VBN\0|NONE_0 (l_prep) on_15\IN\0|effect_100|,_2|,_70|on_72|was_164|in_176|._183 (l_pobj) catalepsy_16\NN\14023236|NONE_0
D005473_D002375 NONE fluoxetine_27\NN\4169152|-_10 (r_advmod) induced_29\VBN\1627355|penile_8 (r_amod) erections_31\NNS\14037619|induced_51|wds_43|and_30 (r_conj) behavior_25\NN\407535|haloperidol_47|,_26 (r_conj) catalepsy_19\NN\14023236|NONE_0
11425091
D003042_D006470 NONE cocaine_1\NN\3492717|NONE_0 (r_compound) exposure_2\NN\5042871|has_9|been_13|with_25|._147 (r_nsubjpass) linked_5\VBN\628491|NONE_0 (l_prep) with_6\IN\0|exposure_25|has_16|been_12|._122 (l_pobj) hemorrhage_8\NN\14285662|NONE_0
D003042_D019970 NONE cocaine_5\NN\3492717|-_7 (r_npadvmod) exposed_7\VBN\2110927|the_12 (r_amod) group_8\NN\2137|NONE_0 (r_pobj) to_3\IN\0|infants_22|were_14|was_38|._184 (r_prep) assigned_2\VBN\2475922|NONE_0 (l_advcl) was_11\VBD\0|infants_60|were_52|to_38|._146 (l_attr) history_14\NN\15120823|if_24|there_21|were_94 (l_prep) of_15\IN\0|a_19|maternal_17|or_34 (l_pobj) abuse_17\NN\418025|NONE_0
D003042_D003560 CID cocaine_1\NN\3492717|NONE_0 (r_compound) exposure_2\NN\5042871|has_9|been_13|with_25|._147 (r_nsubjpass) linked_5\VBN\628491|NONE_0 (l_prep) with_6\IN\0|exposure_25|has_16|been_12|._122 (l_pobj) hemorrhage_8\NN\14285662|NONE_0 (l_conj) formation_11\NN\7938773|subependymal_32|and_8 (l_prep) of_12\IN\0|the_14|are_14 (l_pobj) cysts_13\NNS\14204950|NONE_0
D003042_D003560 CID cocaine_6\NN\3492717|NONE_0 (r_compound) exposure_7\NN\5042871|if_20|incidence_23 (r_nsubj) increases_8\VBZ\13576355|to_42 (l_dobj) incidence_10\NN\13821570|if_43|exposure_23 (l_prep) of_11\IN\0|the_14 (l_pobj) cysts_13\NNS\14204950|NONE_0
D003042_D003560 CID cocaine_9\NN\3492717|NONE_0 (r_pobj) to_8\IN\0|prenatally_11 (r_prep) exposed_7\VBN\2110927|NONE_0 (r_acl) infants_6\NNS\9918248|NONE_0 (r_pobj) in_5\IN\13603305|subependymal_19 (r_prep) cysts_4\NNS\14204950|NONE_0
D003042_D003560 CID cocaine_16\NN\3492717|NONE_0 (r_pobj) to_15\IN\0|who_17|were_13 (r_prep) exposed_14\VBN\2110927|preterm_25 (r_relcl) infants_11\NNS\9918248|NONE_0 (r_pobj) in_9\IN\13603305|subependymal_28|cyst_15 (r_prep) formation_8\NN\7938773|NONE_0 (l_compound) cyst_7\NN\14204950|subependymal_13|in_15
D003042_D007235 CID cocaine_1\NN\3492717|and_17|findings_41|in_50|._68 (r_compound) exposure_2\NN\5042871|NONE_0 (l_prep) in_7\IN\13603305|cocaine_50|and_33|findings_9|._18 (l_pobj) infants_9\NNS\9918248|NONE_0
D003042_D007235 CID cocaine_6\NN\3492717|NONE_0 (r_compound) exposure_7\NN\5042871|if_20|incidence_23 (r_nsubj) increases_8\VBZ\13576355|to_42 (l_dobj) incidence_10\NN\13821570|if_43|exposure_23 (l_prep) of_11\IN\0|the_14 (l_pobj) cysts_13\NNS\14204950|NONE_0 (l_prep) in_14\IN\13603305|subependymal_19 (l_pobj) infants_16\NNS\9918248|NONE_0
D003042_D007235 CID cocaine_16\NN\3492717|NONE_0 (r_pobj) to_15\IN\0|who_17|were_13 (r_prep) exposed_14\VBN\2110927|preterm_25 (r_relcl) infants_11\NNS\9918248|NONE_0
D003042_D001927 CID cocaine_6\NN\3492717|NONE_0 (r_compound) exposure_7\NN\5042871|if_20|incidence_23 (r_nsubj) increases_8\VBZ\13576355|to_42 (l_dobj) incidence_10\NN\13821570|if_43|exposure_23 (l_prep) of_11\IN\0|the_14 (l_pobj) cysts_13\NNS\14204950|NONE_0
D003042_D001927 CID cocaine_9\NN\3492717|NONE_0 (r_pobj) to_8\IN\0|prenatally_11 (r_prep) exposed_7\VBN\2110927|NONE_0 (r_acl) infants_6\NNS\9918248|NONE_0 (r_pobj) in_5\IN\13603305|subependymal_19 (r_prep) cysts_4\NNS\14204950|NONE_0
D003042_D001927 CID cocaine_16\NN\3492717|NONE_0 (r_pobj) to_15\IN\0|who_17|were_13 (r_prep) exposed_14\VBN\2110927|preterm_25 (r_relcl) infants_11\NNS\9918248|NONE_0 (r_pobj) in_9\IN\13603305|subependymal_28|cyst_15 (r_prep) formation_8\NN\7938773|NONE_0 (l_compound) cyst_7\NN\14204950|subependymal_13|in_15
17954033
D019259_D006509 NONE lamivudine_20\NN\3834836|-_10 (r_npadvmod) untreated_22\VBN\0|chronic_10|b_28 (r_amod) patients_26\NNS\9898892|NONE_0 (r_pobj) in_19\IN\13603305|natural_27|genome_19 (r_prep) variability_18\NN\4733640|NONE_0 (r_pobj) as_15\IN\14622893|that_64|mutants_44 (r_prep) occur_14\VBP\0|studies_71|._88 (l_nsubj) mutants_7\NNS\4475|that_20|as_44 (l_appos) virus_12\NN\9312843|the_46|motif_37|(_23|)_5 (l_compound) b_11\NNP\1355326|resistant_20
D019259_D019694 NONE lamivudine_6\NN\3834836|-_10 (r_npadvmod) untreated_8\VBN\0|iranian_10|with_27 (r_amod) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|untreated_27|iranian_17 (l_pobj) infection_16\NN\14052046|NONE_0
D019259_D019694 NONE lamivudine_0\NNP\3834836|is_11|for_19|._68 (r_nsubjpass) used_2\VBN\0|NONE_0 (l_prep) for_3\IN\0|lamivudine_19|is_8|._49 (l_pobj) treatment_5\NN\654885|NONE_0 (l_prep) of_6\IN\0|the_14 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_compound) b_9\NNP\1355326|chronic_18
D019259_D019694 NONE lamivudine_20\NN\3834836|-_10 (r_npadvmod) untreated_22\VBN\0|chronic_10|b_28 (r_amod) patients_26\NNS\9898892|NONE_0 (l_compound) b_25\NNP\1355326|untreated_28|chronic_18
D019259_D019694 NONE lamivudine_14\NN\3834836|-_10 (r_npadvmod) untreated_16\VBN\0|chronic_10|b_28|in_39 (r_amod) patients_20\NNS\9898892|NONE_0 (l_compound) b_19\NNP\1355326|untreated_28|chronic_18|in_11
D019259_D019694 NONE lamivudine_14\NN\3834836|NONE_0 (r_pobj) with_13\IN\0|who_25|had_21|not_17|been_13 (r_prep) treated_12\VBN\2376958|77_49|chronic_46|b_28 (r_relcl) patients_7\NNS\9898892|NONE_0 (l_compound) b_6\NNP\1355326|77_21|chronic_18|treated_28
D019259_D019694 NONE lamivudine_9\NN\3834836|-_10 (r_npadvmod) untreated_11\VBN\0|with_19 (r_amod) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|untreated_19 (l_pobj) b_16\NNP\1355326|NONE_0
D019259_D019694 NONE lamivudine_9\NN\3834836|-_10 (r_npadvmod) untreated_11\VBN\0|with_19 (r_amod) patients_12\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|ymdd_19|motif_14 (r_prep) mutants_7\NNS\4475|NONE_0 (r_pobj) of_4\IN\0|the_23|natural_19 (r_prep) occurrence_3\NN\29378|although_21|has_91|been_95 (r_nsubjpass) reported_19\VBN\831651|,_8|mutants_16|were_24|not_29|in_42|._102 (r_advcl) detected_25\VBN\2163746|NONE_0 (l_prep) in_26\IN\13603305|reported_42|,_34|mutants_26|were_18|not_13|._60 (l_pobj) patients_34\NNS\9898892|NONE_0 (l_compound) b_33\NNP\1355326|iranian_47|untreated_28|chronic_18
D019259_D019694 NONE lamivudine_28\NN\3834836|-_10 (r_npadvmod) untreated_30\VBN\0|iranian_19|chronic_10|b_28 (r_amod) patients_34\NNS\9898892|NONE_0 (r_pobj) in_26\IN\13603305|reported_42|,_34|mutants_26|were_18|not_13|._60 (r_prep) detected_25\VBN\2163746|NONE_0 (l_advcl) reported_19\VBN\831651|,_8|mutants_16|were_24|not_29|in_42|._102 (l_nsubjpass) occurrence_3\NN\29378|although_21|has_91|been_95 (l_prep) of_4\IN\0|the_23|natural_19 (l_pobj) mutants_7\NNS\4475|NONE_0 (l_prep) in_8\IN\13603305|ymdd_19|motif_14 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|untreated_19 (l_pobj) b_16\NNP\1355326|NONE_0
D019259_D019694 NONE lamivudine_28\NN\3834836|-_10 (r_npadvmod) untreated_30\VBN\0|iranian_19|chronic_10|b_28 (r_amod) patients_34\NNS\9898892|NONE_0 (l_compound) b_33\NNP\1355326|iranian_47|untreated_28|chronic_18
2484903
D008713_D047508 CID methimazole_13\NN\0|-_11 (r_npadvmod) associated_15\VBN\628491|fatal_18|hepatocellular_11 (r_amod) necrosis_17\NN\11444117|NONE_0
D008713_D056486 NONE methimazole_13\NN\0|-_11 (r_npadvmod) associated_15\VBN\628491|fatal_18|hepatocellular_11 (r_amod) necrosis_17\NN\11444117|NONE_0 (r_pobj) of_11\IN\0|one_9|and_56|case_64 (r_prep) case_10\NN\7283608|two_62|of_52|,_6 (r_appos) cases_1\NNS\7283608|are_183|._196 (l_prep) of_2\IN\0|two_10|,_46|case_52 (l_pobj) hepatitis_7\NN\14127211|NONE_0
D011441_D047508 NONE propylthiouracil_3\NN\14727670|-_16 (r_npadvmod) associated_5\VBN\628491|acute_11 (r_amod) hepatitis_7\NN\14127211|NONE_0 (r_pobj) of_2\IN\0|two_10|,_46|case_52 (r_prep) cases_1\NNS\7283608|are_183|._196 (l_appos) case_10\NN\7283608|two_62|of_52|,_6 (l_prep) of_11\IN\0|one_9|and_56|case_64 (l_pobj) necrosis_17\NN\11444117|NONE_0
D011441_D047508 NONE propylthiouracil_22\NN\14727670|-_16 (r_npadvmod) associated_24\VBN\628491|like_17 (r_amod) syndrome_28\NN\5870365|NONE_0 (r_pobj) of_21\IN\0|one_9 (r_prep) case_20\NN\7283608|one_73|of_64|and_8 (r_conj) case_10\NN\7283608|two_62|of_52|,_6 (l_prep) of_11\IN\0|one_9|and_56|case_64 (l_pobj) necrosis_17\NN\11444117|NONE_0
D011441_D056486 CID propylthiouracil_3\NN\14727670|-_16 (r_npadvmod) associated_5\VBN\628491|acute_11 (r_amod) hepatitis_7\NN\14127211|NONE_0
D011441_D056486 CID propylthiouracil_22\NN\14727670|-_16 (r_npadvmod) associated_24\VBN\628491|like_17 (r_amod) syndrome_28\NN\5870365|NONE_0 (r_pobj) of_21\IN\0|one_9 (r_prep) case_20\NN\7283608|one_73|of_64|and_8 (r_conj) case_10\NN\7283608|two_62|of_52|,_6 (r_appos) cases_1\NNS\7283608|are_183|._196 (l_prep) of_2\IN\0|two_10|,_46|case_52 (l_pobj) hepatitis_7\NN\14127211|NONE_0
D011441_D008180 CID propylthiouracil_3\NN\14727670|-_16 (r_npadvmod) associated_5\VBN\628491|acute_11 (r_amod) hepatitis_7\NN\14127211|NONE_0 (r_pobj) of_2\IN\0|two_10|,_46|case_52 (r_prep) cases_1\NNS\7283608|are_183|._196 (l_appos) case_10\NN\7283608|two_62|of_52|,_6 (l_conj) case_20\NN\7283608|one_73|of_64|and_8 (l_prep) of_21\IN\0|one_9 (l_pobj) syndrome_28\NN\5870365|NONE_0
D011441_D008180 CID propylthiouracil_22\NN\14727670|-_16 (r_npadvmod) associated_24\VBN\628491|like_17 (r_amod) syndrome_28\NN\5870365|NONE_0
D008713_D008180 NONE methimazole_13\NN\0|-_11 (r_npadvmod) associated_15\VBN\628491|fatal_18|hepatocellular_11 (r_amod) necrosis_17\NN\11444117|NONE_0 (r_pobj) of_11\IN\0|one_9|and_56|case_64 (r_prep) case_10\NN\7283608|two_62|of_52|,_6 (l_conj) case_20\NN\7283608|one_73|of_64|and_8 (l_prep) of_21\IN\0|one_9 (l_pobj) syndrome_28\NN\5870365|NONE_0
17484470
D011433_D008944 NONE propranolol_6\NN\0|NONE_0 (r_pobj) by_5\IN\0|failure_20|was_12 (r_agent) induced_4\VBN\1627355|;_83|absence_88|was_102|by_116|._135 (r_ccomp) confirmed_21\VBN\0|NONE_0 (l_nsubjpass) absence_17\NN\14449405|induced_88|;_5|was_14|by_28|._47 (l_prep) of_18\IN\0|an_11 (l_pobj) mr_19\NNP\6339416|NONE_0
D011433_D006333 CID propranolol_6\NN\0|NONE_0 (r_pobj) by_5\IN\0|failure_20|was_12 (r_agent) induced_4\VBN\1627355|;_83|absence_88|was_102|by_116|._135 (l_nsubjpass) failure_2\NN\66216|was_8|by_20
23535177
D007980_D004409 CID levodopa_19\RB\14604959|-_8 (r_npadvmod) induced_21\VBN\1627355|(_20|lids_21|)_25 (r_amod) dyskinesias_22\NNS\14084880|parkinson_46|(_26|pd_25|)_23|and_21
D007980_D004409 CID levodopa_19\RB\14604959|-_8 (r_npadvmod) induced_21\VBN\1627355|(_20|lids_21|)_25 (r_amod) dyskinesias_22\NNS\14084880|parkinson_46|(_26|pd_25|)_23|and_21 (l_appos) lids_24\NNPS\5313679|induced_21|(_1|)_4
D007980_D010300 NONE levodopa_19\RB\14604959|-_8 (r_npadvmod) induced_21\VBN\1627355|(_20|lids_21|)_25 (r_amod) dyskinesias_22\NNS\14084880|parkinson_46|(_26|pd_25|)_23|and_21 (r_conj) disease_14\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_19\RB\14604959|-_8 (r_npadvmod) induced_21\VBN\1627355|(_20|lids_21|)_25 (r_amod) dyskinesias_22\NNS\14084880|parkinson_46|(_26|pd_25|)_23|and_21 (r_conj) disease_14\NN\14061805|NONE_0 (l_appos) pd_16\NNP\14625458|parkinson_21|(_1|)_2|and_4|dyskinesias_25
6585590
D004317_D066126 NONE doxorubicin_8\NN\2716866|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) nephrotoxicity_6\NN\0|,_6|and_4|in_30 (r_conj) cardiotoxicity_3\NN\0|antitumor_18|,_2|._101
D004317_D066126 NONE doxorubicin_9\NN\2716866|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|NONE_0 (r_acl) nephrotoxicity_6\NN\0|,_6|and_4 (r_conj) cardiotoxicity_3\NN\0|antitumor_20|,_2
D004317_D066126 NONE doxorubicin_17\NN\2716866|mg_3|/_11 (r_nmod) kg_19\NNS\13717155|NONE_0 (r_pobj) of_14\IN\0|a_7 (r_prep) dose_13\NN\3740161|NONE_0 (r_pobj) at_11\IN\14622893|scored_38|was_18|only_14|._34 (r_prep) observed_10\VBN\2163746|NONE_0 (l_ccomp) scored_4\VBD\1111028|was_20|only_24|at_38|._72 (l_nsubj) evidence_1\NN\5816287|as_34 (l_prep) of_2\IN\0|histologic_20 (l_pobj) cardiotoxicity_3\NN\0|NONE_0
D004317_D000419 CID doxorubicin_14\NN\2716866|mg_3|/_11 (r_nmod) kg_16\NNS\13717155|NONE_0 (r_pobj) of_11\IN\0|a_7|,_24|resulted_32 (r_prep) dose_10\NN\3740161|NONE_0 (l_relcl) resulted_19\VBD\2633881|a_39|of_32|,_8 (l_prep) in_20\IN\13603305|which_15 (l_pobj) albuminuria_21\NN\14299637|NONE_0
D004317_D009369 NONE doxorubicin_18\NN\2716866|NONE_0 (r_pobj) of_17\IN\0|iv_14 (r_prep) injections_16\NNS\320852|NONE_0 (r_pobj) with_14\IN\0|animals_62|were_13|on_34|,_55|followed_57|body_129|)_136|._137 (r_prep) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) animals_0\NNS\4475|were_49|with_62|on_96|,_117|followed_119|body_191|)_198|._199 (l_prep) with_1\IN\0|,_22|+/-_29|)_39 (l_pobj) tumor_3\NN\14234074|NONE_0
D004317_D009369 NONE doxorubicin_7\NN\2716866|mg_3|/_11 (r_nmod) kg_9\NNS\13717155|NONE_0 (r_pobj) with_4\IN\0|regression_24|was_13|._26 (r_prep) observed_3\VBN\2163746|NONE_0 (l_nsubjpass) regression_1\NN\14501726|was_11|with_24|._50 (l_compound) tumor_0\NN\14234074|NONE_0
D004317_D009369 NONE doxorubicin_10\NN\2716866|mg_3|/_11 (r_nmod) kg_12\NNS\13717155|NONE_0 (r_pobj) with_7\IN\0|disappearance_39|was_12|._26 (r_prep) induced_6\VBN\1627355|NONE_0 (l_nsubjpass) disappearance_1\NN\42757|was_27|with_39|._65 (l_prep) of_2\IN\0|complete_23 (l_pobj) tumor_4\NN\14234074|NONE_0
D004317_D007674 NONE doxorubicin_8\NN\2716866|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) nephrotoxicity_6\NN\0|,_6|and_4|in_30
D004317_D007674 NONE doxorubicin_9\NN\2716866|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|NONE_0 (r_acl) nephrotoxicity_6\NN\0|,_6|and_4
D004317_D007674 NONE doxorubicin_14\NN\2716866|mg_3|/_11 (r_nmod) kg_16\NNS\13717155|NONE_0 (r_pobj) of_11\IN\0|a_7|,_24|resulted_32 (r_prep) dose_10\NN\3740161|NONE_0 (r_pobj) above_8\IN\6392001|evidence_34|was_9|._102 (r_prep) seen_7\VBN\2106506|NONE_0 (l_nsubjpass) evidence_2\NN\5816287|was_25|above_34|._136 (l_prep) of_3\IN\0|light_27|microscopic_21 (l_pobj) damage_5\NN\7296428|NONE_0
D004317_-1 NONE doxorubicin_8\NN\2716866|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) nephrotoxicity_6\NN\0|,_6|and_4|in_30 (r_conj) cardiotoxicity_3\NN\0|antitumor_18|,_2|._101 (l_prep) in_9\IN\13603305|,_36|and_34|nephrotoxicity_30 (l_pobj) rat_21\NN\2329401|NONE_0 (l_amod) bearing_15\VBG\13795489|the_27|igm_23|solid_19|wsl_14 (l_compound) immunocytoma_13\NN\0|-_12
D004317_-1 NONE doxorubicin_9\NN\2716866|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|NONE_0 (r_acl) nephrotoxicity_6\NN\0|,_6|and_4 (r_conj) cardiotoxicity_3\NN\0|antitumor_20|,_2 (r_conj) activity_1\NN\30358|were_68|in_81|bearing_111|._158 (r_nsubjpass) studied_11\VBN\0|NONE_0 (l_advcl) bearing_21\VBG\13795489|activity_111|were_43|in_30|._47 (l_dobj) immunocytoma_26\NN\0|each_40
2650911
D004958_D009369 NONE estradiol_10\NN\14749794|NONE_0 (r_pobj) of_7\IN\0|the_22|in_18|vivo_15 (r_prep) injection_6\NN\320852|NONE_0 (r_pobj) following_2\VBG\8180190|radiolabelling_16|,_2|,_55|was_57|over_76 (r_prep) increased_13\VBN\169651|;_45|analysis_59|concentration_104|._184 (l_prep) over_15\IN\5867413|radiolabelling_92|,_78|following_76|,_21|was_19 (l_pobj) nuclei_17\NNS\5445668|only_14 (l_prep) of_18\IN\0|the_11 (l_pobj) cells_20\NNS\3080309|NONE_0 (l_compound) tumor_19\NN\14234074|NONE_0
D004054_D002292 CID diethylstilbesterol_9\NN\15058023|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) nuclei_7\NNS\5445668|NONE_0 (r_pobj) in_6\IN\13603305|estrogen_23|binding_14 (r_prep) sites_5\NNS\8673395|NONE_0 (r_pobj) of_2\IN\0|autoradiographic_26 (r_prep) evidence_1\NN\5816287|carcinomas_90|._100 (r_nsubj) induced_10\VBN\1627355|NONE_0 (l_dobj) carcinomas_13\NNS\14239918|evidence_90|._10
D004054_D002292 CID diethylstilbesterol_13\NN\15058023|NONE_0 (r_pobj) in_7\IN\13603305|NONE_0 (r_prep) autoradiography_6\NN\13545382|NONE_0 (r_pobj) by_5\IN\0|sites_24|were_18|induced_78|._120 (r_agent) demonstrated_4\VBN\2137132|NONE_0 (l_conj) induced_14\VBD\1627355|sites_102|were_96|by_78|._42 (l_dobj) carcinomas_16\NNS\14239918|in_11
D004967_D002292 NONE estrogen_3\NN\14745635|binding_9|in_23 (r_nmod) sites_5\NNS\8673395|NONE_0 (r_pobj) of_2\IN\0|autoradiographic_26 (r_prep) evidence_1\NN\5816287|carcinomas_90|._100 (r_nsubj) induced_10\VBN\1627355|NONE_0 (l_dobj) carcinomas_13\NNS\14239918|evidence_90|._10
D004967_D002292 NONE estrogen_0\NN\14745635|binding_9 (r_nmod) sites_2\NNS\8673395|were_6|by_24|induced_102|._144 (r_nsubjpass) demonstrated_4\VBN\2137132|NONE_0 (l_conj) induced_14\VBD\1627355|sites_102|were_96|by_78|._42 (l_dobj) carcinomas_16\NNS\14239918|in_11
D004967_D002292 NONE estrogen_13\NN\14745635|NONE_0 (r_pobj) of_12\IN\0|vivo_13 (r_prep) binding_11\NN\4688246|NONE_0 (r_pobj) in_9\IN\13603305|the_17 (r_prep) preferential_8\NN\0|to_41 (r_dobj) documenting_6\VBG\1000214|the_27|first_23|published_17|induced_88 (r_acl) report_5\NN\6470073|this_28|._127 (l_acl) induced_20\VBD\1627355|the_115|first_111|published_105|documenting_88 (l_dobj) carcinomas_23\NNS\14239918|NONE_0
D004967_D002292 NONE estrogen_19\NN\14745635|NONE_0 (r_pobj) in_18\IN\13603305|NONE_0 (r_prep) cells_17\NNS\3080309|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) nuclei_15\NNS\5445668|NONE_0 (r_pobj) to_14\IN\0|preferential_41 (r_prep) documenting_6\VBG\1000214|the_27|first_23|published_17|induced_88 (r_acl) report_5\NN\6470073|this_28|._127 (l_acl) induced_20\VBD\1627355|the_115|first_111|published_105|documenting_88 (l_dobj) carcinomas_23\NNS\14239918|NONE_0
D012834_D009369 NONE silver_33\NN\14821043|reduced_8|over_14|than_26 (r_compound) grains_34\NNS\14585519|NONE_0 (r_pobj) of_31\IN\0|a_41|6.7-times_31|higher_21 (r_prep) concentration_30\NN\4916342|increased_104|;_59|analysis_45|._80 (r_dobj) revealed_24\VBD\2137132|NONE_0 (l_ccomp) increased_13\VBN\169651|;_45|analysis_59|concentration_104|._184 (l_prep) over_15\IN\5867413|radiolabelling_92|,_78|following_76|,_21|was_19 (l_pobj) nuclei_17\NNS\5445668|only_14 (l_prep) of_18\IN\0|the_11 (l_pobj) cells_20\NNS\3080309|NONE_0 (l_compound) tumor_19\NN\14234074|NONE_0
17297207
D011803_D007565 NONE quinine_25\NN\2721948|NONE_0 (r_compound) infusion_26\NN\14589223|was_9 (r_nsubjpass) reported_28\VBN\831651|while_35 (r_ccomp) getting_24\VBG\30358|that_134|there_129|case_117|)_8 (r_advcl) was_5\VBD\0|it_27|was_24|._160 (l_attr) case_7\NN\7283608|that_17|there_12|)_109|getting_117 (l_prep) of_8\IN\0|a_7|contraction_93 (l_pobj) patient_11\NN\9898892|NONE_0 (l_prep) with_12\IN\0|severe_23|malaria_16 (l_pobj) jaundice_13\NN\14299637|NONE_0
D011803_D007565 NONE quinine_11\NN\2721948|in_17 (r_compound) infusion_12\NN\14589223|%_22 (r_dobj) got_10\VBD\0|patient_58|was_50|as_36|and_4|._49 (r_conj) diagnosed_3\VBN\644583|NONE_0 (l_prep) as_4\IN\14622893|patient_22|was_14|and_32|got_36|._85 (l_pobj) malaria_6\NN\14178913|NONE_0 (l_prep) with_7\IN\0|severe_15 (l_pobj) jaundice_8\NN\14299637|NONE_0
D011803_D016778 NONE quinine_0\NN\2721948|-_7 (r_npadvmod) induced_2\VBN\1627355|in_19|._51 (r_amod) arrhythmia_3\NN\14103288|NONE_0 (l_prep) in_4\IN\13603305|induced_19|._32 (l_pobj) patient_6\NN\9898892|NONE_0 (l_prep) with_7\IN\0|a_10 (l_pobj) malaria_9\NN\14178913|NONE_0
D011803_D016778 NONE quinine_25\NN\2721948|NONE_0 (r_compound) infusion_26\NN\14589223|was_9 (r_nsubjpass) reported_28\VBN\831651|while_35 (r_ccomp) getting_24\VBG\30358|that_134|there_129|case_117|)_8 (r_advcl) was_5\VBD\0|it_27|was_24|._160 (l_attr) case_7\NN\7283608|that_17|there_12|)_109|getting_117 (l_prep) of_8\IN\0|a_7|contraction_93 (l_pobj) patient_11\NN\9898892|NONE_0 (l_compound) malaria_10\NN\14178913|severe_7|with_16
D011803_D016778 NONE quinine_11\NN\2721948|in_17 (r_compound) infusion_12\NN\14589223|%_22 (r_dobj) got_10\VBD\0|patient_58|was_50|as_36|and_4|._49 (r_conj) diagnosed_3\VBN\644583|NONE_0 (l_prep) as_4\IN\14622893|patient_22|was_14|and_32|got_36|._85 (l_pobj) malaria_6\NN\14178913|NONE_0
D011803_D001145 NONE quinine_0\NN\2721948|-_7 (r_npadvmod) induced_2\VBN\1627355|in_19|._51 (r_amod) arrhythmia_3\NN\14103288|NONE_0
D011803_D001145 NONE quinine_25\NN\2721948|NONE_0 (r_compound) infusion_26\NN\14589223|was_9 (r_nsubjpass) reported_28\VBN\831651|while_35 (r_ccomp) getting_24\VBG\30358|that_134|there_129|case_117|)_8 (r_advcl) was_5\VBD\0|it_27|was_24|._160 (l_attr) case_7\NN\7283608|that_17|there_12|)_109|getting_117 (l_prep) of_8\IN\0|a_7|contraction_93 (l_pobj) patient_11\NN\9898892|NONE_0 (l_prep) with_12\IN\0|severe_23|malaria_16 (l_pobj) jaundice_13\NN\14299637|NONE_0 (l_relcl) presented_15\VBD\2137132|NONE_0 (l_prep) with_16\IN\0|who_14 (l_pobj) arrhythmia_17\NN\14103288|NONE_0
D011803_D001145 NONE quinine_0\NN\2721948|,_7|like_9|,_23|alkaloid_39|,_81|arrhythmic_104|._199 (r_nsubj) is_5\VBZ\0|NONE_0 (l_attr) alkaloid_8\NN\14727670|quinine_39|,_32|like_30|,_16|,_42|arrhythmic_65|._160 (l_relcl) has_10\VBZ\13888491|a_25|chincona_23 (l_dobj) property_14\NN\32613|that_25 (l_amod) arrhythmic_13\JJ\0|NONE_0
D011803_D001145 NONE quinine_0\NN\2721948|,_7|like_9|,_23|alkaloid_39|,_81|arrhythmic_104|._199 (r_nsubj) is_5\VBZ\0|NONE_0 (l_advcl) arrhythmic_21\JJ\0|quinine_104|,_97|like_95|,_81|alkaloid_65|,_23|._95
D011803_D001145 NONE quinine_0\NN\2721948|,_7|like_9|,_23|alkaloid_39|,_81|arrhythmic_104|._199 (r_nsubj) is_5\VBZ\0|NONE_0 (l_advcl) arrhythmic_21\JJ\0|quinine_104|,_97|like_95|,_81|alkaloid_65|,_23|._95 (l_ccomp) cause_24\VB\7323922|although_41|it_32|also_29|-_21 (l_dobj) arrhythmias_26\NNS\14103288|that_23|can_18
D011803_D001145 NONE quinine_0\NN\2721948|,_7|like_9|,_23|alkaloid_39|,_81|arrhythmic_104|._199 (r_nsubj) is_5\VBZ\0|NONE_0 (l_advcl) arrhythmic_21\JJ\0|quinine_104|,_97|like_95|,_81|alkaloid_65|,_23|._95 (l_ccomp) cause_24\VB\7323922|although_41|it_32|also_29|-_21 (l_dobj) arrhythmias_26\NNS\14103288|that_23|can_18 (l_prep) including_28\VBG\0|various_21|,_2 (l_pobj) arrhythmia_30\NN\14103288|NONE_0
D011803_D001145 NONE quinine_3\NN\2721948|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|must_37|be_42|carefully_50|and_60|with_64|because_86|._301 (r_nsubjpass) done_6\VBN\0|NONE_0 (l_prep) because_12\IN\0|administration_86|must_49|be_44|carefully_36|and_26|with_22|._215 (l_pobj) effect_18\NN\34213|of_22 (l_amod) arrhythmic_17\JJ\0|its_8|,_17|in_30
D011803_-1 NONE quinine_4\NN\2721948|NONE_0 (r_compound) infusion_5\NN\14589223|NONE_0 (r_pobj) of_3\IN\0|30_9 (r_prep) hours_2\NNS\15118228|NONE_0 (r_pobj) after_0\IN\0|patient_39|palpitation_52|showed_104 (r_prep) felt_8\VBD\3309808|NONE_0 (l_dobj) palpitation_9\NN\14299637|after_52|patient_13|showed_52
D011803_D014839 NONE quinine_3\NN\2721948|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|must_37|be_42|carefully_50|and_60|with_64|because_86|._301 (r_nsubjpass) done_6\VBN\0|NONE_0 (l_prep) because_12\IN\0|administration_86|must_49|be_44|carefully_36|and_26|with_22|._215 (l_pobj) effect_18\NN\34213|of_22 (l_prep) in_21\IN\13603305|its_38|arrhythmic_30|,_13 (l_pobj) patients_23\NNS\9898892|especially_20 (l_relcl) have_25\VBP\7846|older_19 (l_dobj) diseases_27\NNS\14061805|who_15 (l_conj) patients_29\NNS\9898892|heart_18|or_3 (l_prep) with_30\IN\0|NONE_0 (l_pobj) disorder_32\NN\14034177|NONE_0 (l_relcl) occurs_38\VBZ\0|electrolyte_52|(_31|hypokalemia_30|)_19 (l_advcl) vomiting_41\NN\116687|which_31|frequently_25|due_7
D011803_D008288 NONE quinine_3\NN\2721948|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|must_37|be_42|carefully_50|and_60|with_64|because_86|._301 (r_nsubjpass) done_6\VBN\0|NONE_0 (l_prep) because_12\IN\0|administration_86|must_49|be_44|carefully_36|and_26|with_22|._215 (l_pobj) effect_18\NN\34213|of_22 (l_prep) in_21\IN\13603305|its_38|arrhythmic_30|,_13 (l_pobj) patients_23\NNS\9898892|especially_20 (l_relcl) have_25\VBP\7846|older_19 (l_dobj) diseases_27\NNS\14061805|who_15 (l_conj) patients_29\NNS\9898892|heart_18|or_3 (l_prep) with_30\IN\0|NONE_0 (l_pobj) disorder_32\NN\14034177|NONE_0 (l_relcl) occurs_38\VBZ\0|electrolyte_52|(_31|hypokalemia_30|)_19 (l_advcl) vomiting_41\NN\116687|which_31|frequently_25|due_7 (l_conj) diarrhea_44\NN\14299637|and_7|or_3 (l_prep) in_45\IN\13603305|NONE_0 (l_pobj) cases_47\NNS\7283608|NONE_0 (l_compound) malaria_46\NN\14178913|NONE_0
D005947_D007565 NONE dextrose_14\NN\14884120|NONE_0 (r_pobj) in_13\IN\13603305|quinine_17 (r_prep) infusion_12\NN\14589223|%_22 (r_dobj) got_10\VBD\0|patient_58|was_50|as_36|and_4|._49 (r_conj) diagnosed_3\VBN\644583|NONE_0 (l_prep) as_4\IN\14622893|patient_22|was_14|and_32|got_36|._85 (l_pobj) malaria_6\NN\14178913|NONE_0 (l_prep) with_7\IN\0|severe_15 (l_pobj) jaundice_8\NN\14299637|NONE_0
D011802_D018879 NONE quinidine_3\NN\2715941|NONE_0 (r_pobj) like_2\IN\5839024|quinine_9|,_2|,_14|alkaloid_30|,_72|arrhythmic_95|._190 (r_prep) is_5\VBZ\0|NONE_0 (l_advcl) arrhythmic_21\JJ\0|quinine_104|,_97|like_95|,_81|alkaloid_65|,_23|._95 (l_ccomp) cause_24\VB\7323922|although_41|it_32|also_29|-_21 (l_dobj) arrhythmias_26\NNS\14103288|that_23|can_18 (l_prep) including_28\VBG\0|various_21|,_2 (l_pobj) arrhythmia_30\NN\14103288|NONE_0 (l_prep) as_32\IN\14622893|severe_23 (l_pobj) pvc_34\NN\15088440|such_17
D011803_D018879 CID quinine_25\NN\2721948|NONE_0 (r_compound) infusion_26\NN\14589223|was_9 (r_nsubjpass) reported_28\VBN\831651|while_35 (r_ccomp) getting_24\VBG\30358|that_134|there_129|case_117|)_8 (r_advcl) was_5\VBD\0|it_27|was_24|._160 (l_attr) case_7\NN\7283608|that_17|there_12|)_109|getting_117 (l_appos) contraction_21\NN\358931|a_100|of_93
D011803_D018879 CID quinine_4\NN\2721948|NONE_0 (r_compound) infusion_5\NN\14589223|NONE_0 (r_pobj) of_3\IN\0|30_9 (r_prep) hours_2\NNS\15118228|NONE_0 (r_pobj) after_0\IN\0|patient_39|palpitation_52|showed_104 (r_prep) felt_8\VBD\3309808|NONE_0 (l_parataxis) showed_16\VBD\2137132|after_104|patient_65|palpitation_52 (l_dobj) contraction_19\NN\358931|(_45|recording_39|wave_87|._91
D011803_D018879 CID quinine_4\NN\2721948|NONE_0 (r_compound) infusion_5\NN\14589223|NONE_0 (r_pobj) of_3\IN\0|30_9 (r_prep) hours_2\NNS\15118228|NONE_0 (r_pobj) after_0\IN\0|patient_39|palpitation_52|showed_104 (r_prep) felt_8\VBD\3309808|NONE_0 (l_parataxis) showed_16\VBD\2137132|after_104|patient_65|palpitation_52 (l_dobj) contraction_19\NN\358931|(_45|recording_39|wave_87|._91 (l_appos) pvc_21\NN\15088440|premature_35|ventricular_25|>_5
D011803_D018879 CID quinine_0\NN\2721948|,_7|like_9|,_23|alkaloid_39|,_81|arrhythmic_104|._199 (r_nsubj) is_5\VBZ\0|NONE_0 (l_advcl) arrhythmic_21\JJ\0|quinine_104|,_97|like_95|,_81|alkaloid_65|,_23|._95 (l_ccomp) cause_24\VB\7323922|although_41|it_32|also_29|-_21 (l_dobj) arrhythmias_26\NNS\14103288|that_23|can_18 (l_prep) including_28\VBG\0|various_21|,_2 (l_pobj) arrhythmia_30\NN\14103288|NONE_0 (l_prep) as_32\IN\14622893|severe_23 (l_pobj) pvc_34\NN\15088440|such_17
D005947_D016778 NONE dextrose_14\NN\14884120|NONE_0 (r_pobj) in_13\IN\13603305|quinine_17 (r_prep) infusion_12\NN\14589223|%_22 (r_dobj) got_10\VBD\0|patient_58|was_50|as_36|and_4|._49 (r_conj) diagnosed_3\VBN\644583|NONE_0 (l_prep) as_4\IN\14622893|patient_22|was_14|and_32|got_36|._85 (l_pobj) malaria_6\NN\14178913|NONE_0
D011803_D006331 NONE quinine_3\NN\2721948|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|must_37|be_42|carefully_50|and_60|with_64|because_86|._301 (r_nsubjpass) done_6\VBN\0|NONE_0 (l_prep) because_12\IN\0|administration_86|must_49|be_44|carefully_36|and_26|with_22|._215 (l_pobj) effect_18\NN\34213|of_22 (l_prep) in_21\IN\13603305|its_38|arrhythmic_30|,_13 (l_pobj) patients_23\NNS\9898892|especially_20 (l_relcl) have_25\VBP\7846|older_19 (l_dobj) diseases_27\NNS\14061805|who_15
D011803_D007008 NONE quinine_3\NN\2721948|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|must_37|be_42|carefully_50|and_60|with_64|because_86|._301 (r_nsubjpass) done_6\VBN\0|NONE_0 (l_prep) because_12\IN\0|administration_86|must_49|be_44|carefully_36|and_26|with_22|._215 (l_pobj) effect_18\NN\34213|of_22 (l_prep) in_21\IN\13603305|its_38|arrhythmic_30|,_13 (l_pobj) patients_23\NNS\9898892|especially_20 (l_relcl) have_25\VBP\7846|older_19 (l_dobj) diseases_27\NNS\14061805|who_15 (l_conj) patients_29\NNS\9898892|heart_18|or_3 (l_prep) with_30\IN\0|NONE_0 (l_pobj) disorder_32\NN\14034177|NONE_0 (l_appos) hypokalemia_34\NN\14299637|electrolyte_22|(_1|)_11|occurs_30
D011803_D003967 NONE quinine_3\NN\2721948|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|must_37|be_42|carefully_50|and_60|with_64|because_86|._301 (r_nsubjpass) done_6\VBN\0|NONE_0 (l_prep) because_12\IN\0|administration_86|must_49|be_44|carefully_36|and_26|with_22|._215 (l_pobj) effect_18\NN\34213|of_22 (l_prep) in_21\IN\13603305|its_38|arrhythmic_30|,_13 (l_pobj) patients_23\NNS\9898892|especially_20 (l_relcl) have_25\VBP\7846|older_19 (l_dobj) diseases_27\NNS\14061805|who_15 (l_conj) patients_29\NNS\9898892|heart_18|or_3 (l_prep) with_30\IN\0|NONE_0 (l_pobj) disorder_32\NN\14034177|NONE_0 (l_relcl) occurs_38\VBZ\0|electrolyte_52|(_31|hypokalemia_30|)_19 (l_advcl) vomiting_41\NN\116687|which_31|frequently_25|due_7 (l_conj) diarrhea_44\NN\14299637|and_7|or_3
D011803_D014883 NONE quinine_3\NN\2721948|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|must_37|be_42|carefully_50|and_60|with_64|because_86|._301 (r_nsubjpass) done_6\VBN\0|NONE_0 (l_prep) because_12\IN\0|administration_86|must_49|be_44|carefully_36|and_26|with_22|._215 (l_pobj) effect_18\NN\34213|of_22 (l_prep) in_21\IN\13603305|its_38|arrhythmic_30|,_13 (l_pobj) patients_23\NNS\9898892|especially_20 (l_relcl) have_25\VBP\7846|older_19 (l_dobj) diseases_27\NNS\14061805|who_15 (l_conj) patients_29\NNS\9898892|heart_18|or_3 (l_prep) with_30\IN\0|NONE_0 (l_pobj) disorder_32\NN\14034177|NONE_0
D011803_D012848 NONE quinine_4\NN\2721948|NONE_0 (r_compound) infusion_5\NN\14589223|NONE_0 (r_pobj) of_3\IN\0|30_9 (r_prep) hours_2\NNS\15118228|NONE_0 (r_pobj) after_0\IN\0|patient_39|palpitation_52|showed_104 (r_prep) felt_8\VBD\3309808|NONE_0 (l_parataxis) showed_16\VBD\2137132|after_104|patient_65|palpitation_52 (l_ccomp) wave_39\VBP\7309781|(_132|recording_126|contraction_87|._4 (l_nmod) block_35\NN\21939|,_5|positive_7|u_16
D011188_D018879 NONE potassium_29\NN\14625458|NONE_0 (r_compound) level_30\NN\4916342|reduced_73|,_12|meq/_15 (r_nsubj) was_31\VBD\0|NONE_0 (l_ccomp) reduced_12\VBN\441445|,_61|level_73|meq/_88 (l_nsubj) frequency_9\NN\15286249|felt_17|,_6|to_25|was_68 (l_prep) of_10\IN\0|the_14 (l_pobj) pvc_11\NNP\15088440|NONE_0
D011802_D001145 NONE quinidine_3\NN\2715941|NONE_0 (r_pobj) like_2\IN\5839024|quinine_9|,_2|,_14|alkaloid_30|,_72|arrhythmic_95|._190 (r_prep) is_5\VBZ\0|NONE_0 (l_attr) alkaloid_8\NN\14727670|quinine_39|,_32|like_30|,_16|,_42|arrhythmic_65|._160 (l_relcl) has_10\VBZ\13888491|a_25|chincona_23 (l_dobj) property_14\NN\32613|that_25 (l_amod) arrhythmic_13\JJ\0|NONE_0
D011802_D001145 NONE quinidine_3\NN\2715941|NONE_0 (r_pobj) like_2\IN\5839024|quinine_9|,_2|,_14|alkaloid_30|,_72|arrhythmic_95|._190 (r_prep) is_5\VBZ\0|NONE_0 (l_advcl) arrhythmic_21\JJ\0|quinine_104|,_97|like_95|,_81|alkaloid_65|,_23|._95
D011802_D001145 NONE quinidine_3\NN\2715941|NONE_0 (r_pobj) like_2\IN\5839024|quinine_9|,_2|,_14|alkaloid_30|,_72|arrhythmic_95|._190 (r_prep) is_5\VBZ\0|NONE_0 (l_advcl) arrhythmic_21\JJ\0|quinine_104|,_97|like_95|,_81|alkaloid_65|,_23|._95 (l_ccomp) cause_24\VB\7323922|although_41|it_32|also_29|-_21 (l_dobj) arrhythmias_26\NNS\14103288|that_23|can_18
D011802_D001145 NONE quinidine_3\NN\2715941|NONE_0 (r_pobj) like_2\IN\5839024|quinine_9|,_2|,_14|alkaloid_30|,_72|arrhythmic_95|._190 (r_prep) is_5\VBZ\0|NONE_0 (l_advcl) arrhythmic_21\JJ\0|quinine_104|,_97|like_95|,_81|alkaloid_65|,_23|._95 (l_ccomp) cause_24\VB\7323922|although_41|it_32|also_29|-_21 (l_dobj) arrhythmias_26\NNS\14103288|that_23|can_18 (l_prep) including_28\VBG\0|various_21|,_2 (l_pobj) arrhythmia_30\NN\14103288|NONE_0
3084231
D014635_D022124 CID acid_25\NN\14818238|NONE_0 (r_pobj) of_23\IN\0|toxic_13 (r_prep) effect_22\NN\34213|a_44|direct_42|central_35|nervous_27|(_12|cns_11|)_8|;_23|effect_53 (r_appos) system_17\NN\3575240|mechanisms_88|:_27|._188 (l_appos) effect_30\NN\34213|a_97|direct_95|central_88|nervous_80|(_65|cns_64|)_61|effect_53|;_30 (l_conj) effect_41\NN\34213|a_84|paradoxical_82|epileptogenic_70|secondary_49|;_28|and_26 (l_acl) mediated_42\VBN\761713|an_29|indirect_26|cns_17|toxic_13 (l_prep) through_43\IN\0|NONE_0 (l_pobj) hyperammonemia_48\NN\0|NONE_0
D014635_D022124 CID acid_45\NN\14818238|-_4 (r_npadvmod) induced_47\VBN\1627355|valproic_14 (r_amod) hyperammonemia_48\NN\0|NONE_0
D014635_D003704 CID acid_2\NN\14818238|-_4 (r_npadvmod) induced_4\VBN\1627355|reversible_25|valproic_14|:_16|report_25|._31 (r_amod) dementia_5\NN\14395018|NONE_0
D014635_D003704 CID acid_2\NN\14818238|-_4 (r_npadvmod) induced_4\VBN\1627355|reversible_25|valproic_14 (r_amod) dementia_5\NN\14395018|was_9|in_24|._194
D014635_D004827 NONE acid_2\NN\14818238|-_4 (r_npadvmod) induced_4\VBN\1627355|reversible_25|valproic_14 (r_amod) dementia_5\NN\14395018|was_9|in_24|._194 (r_nsubjpass) documented_7\VBN\1000214|NONE_0 (l_prep) in_8\IN\13603305|dementia_24|was_15|._170 (l_pobj) man_13\NN\9605289|NONE_0 (l_prep) with_14\IN\0|a_18|old_8|had_18 (l_pobj) epilepsy_15\NN\14085708|NONE_0
2083961
D012293_D014839 NONE rifampicin_0\NNP\0|was_11|thrice_28|as_35|and_66|developed_83 (r_nsubjpass) administered_2\VBN\2436349|NONE_0 (l_conj) developed_17\VBD\1753788|rifampicin_83|was_72|thrice_55|as_48|and_17 (l_dobj) effects_20\NNS\13245626|time_32|he_27|._62 (l_prep) like_21\IN\5839024|untoward_22|side_13 (l_pobj) nausea_22\NN\14299637|NONE_0 (l_conj) vomiting_24\NN\116687|,_2
D012293_D005334 NONE rifampicin_0\NNP\0|was_11|thrice_28|as_35|and_66|developed_83 (r_nsubjpass) administered_2\VBN\2436349|NONE_0 (l_conj) developed_17\VBD\1753788|rifampicin_83|was_72|thrice_55|as_48|and_17 (l_dobj) effects_20\NNS\13245626|time_32|he_27|._62 (l_prep) like_21\IN\5839024|untoward_22|side_13 (l_pobj) nausea_22\NN\14299637|NONE_0 (l_conj) vomiting_24\NN\116687|,_2 (l_conj) fever_26\NN\14299637|and_4
D012293_D058186 CID rifampicin_5\NNS\0|to_3 (r_pobj) due_3\IN\5174653|acute_20|renal_14|._17 (r_prep) failure_2\NN\66216|NONE_0
D012293_D009325 NONE rifampicin_0\NNP\0|was_11|thrice_28|as_35|and_66|developed_83 (r_nsubjpass) administered_2\VBN\2436349|NONE_0 (l_conj) developed_17\VBD\1753788|rifampicin_83|was_72|thrice_55|as_48|and_17 (l_dobj) effects_20\NNS\13245626|time_32|he_27|._62 (l_prep) like_21\IN\5839024|untoward_22|side_13 (l_pobj) nausea_22\NN\14299637|NONE_0
23949582
D007069_D030342 NONE ifo_3\NNP\0|NONE_0 (r_poss) genotoxicity_5\NN\0|mesna_34|significantly_28|,_12|acts_64|._130
D015080_D030342 NONE mesna_0\NNP\0|significantly_6|genotoxicity_34|,_46|acts_98|._164 (r_nsubj) reduces_2\VBZ\441445|NONE_0 (l_dobj) genotoxicity_5\NN\0|mesna_34|significantly_28|,_12|acts_64|._130
19154241
D008094_D006934 CID lithium_6\NN\14625458|-_7 (r_npadvmod) treated_8\VBN\2376958|a_10|had_20 (r_amod) patient_9\NN\9898892|NONE_0 (l_relcl) had_11\VBD\0|a_30|treated_20 (l_dobj) hypercalcemia_13\NN\14299637|who_18|understand_24
D008094_D006934 CID lithium_6\NN\14625458|-_7 (r_npadvmod) treated_8\VBN\2376958|NONE_0 (r_amod) patients_9\NNS\9898892|NONE_0 (r_pobj) of_5\IN\0|15_4 (r_prep) %_4\NN\0|hypercalcemic_37|._50 (r_nsubj) become_10\VBP\146138|NONE_0 (l_acomp) hypercalcemic_11\JJ\0|%_37|._13
D008094_D049950 NONE lithium_16\NN\14625458|term_5 (r_compound) therapy_17\NN\657604|NONE_0 (r_pobj) of_12\IN\0|a_52|rare_50|side_12 (r_prep) effect_11\NN\34213|hyperparathyroidism_68|._35 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) hyperparathyroidism_1\NN\14059928|effect_68|._103
D008094_D006961 CID lithium_3\NN\14625458|leading_16 (r_compound) therapy_4\NN\657604|:_38|a_40|case_42|._53 (l_acl) leading_5\VBG\4339291|lithium_16 (l_prep) to_6\IN\0|NONE_0 (l_pobj) hyperparathyroidism_7\NN\14059928|NONE_0
8318674
D003561_D011654 CID c_10\NN\13714184|NONE_0 (r_pobj) after_4\IN\0|pulmonary_26|and_10|shock_6|;_40|role_51|._76 (r_prep) edema_1\NN\14315192|NONE_0
D003561_D012128 NONE c_29\NNP\13714184|that_19|may_2|be_6|with_20 (r_nsubjpass) associated_32\VBN\628491|thought_142|,_45|we_43|._32 (r_ccomp) hypothesize_22\VBP\719734|NONE_0 (l_advcl) thought_5\VBN\5809192|,_97|we_99|associated_142|._174 (l_xcomp) involved_8\VBN\2676054|as_33|tnf_30|are_18 (l_prep) in_9\IN\13603305|to_15|be_12 (l_pobj) development_11\NN\248977|NONE_0 (l_prep) of_12\IN\0|the_16 (l_pobj) shock_14\NN\7510495|NONE_0 (l_conj) syndrome_19\NN\5870365|septic_44|and_31
D003561_D012769 CID c_10\NN\13714184|NONE_0 (r_pobj) after_4\IN\0|pulmonary_26|and_10|shock_6|;_40|role_51|._76 (r_prep) edema_1\NN\14315192|NONE_0 (l_conj) shock_3\NN\7510495|pulmonary_20|and_4|after_6|;_46|role_57|._82
D003561_D012769 CID c_29\NNP\13714184|that_19|may_2|be_6|with_20 (r_nsubjpass) associated_32\VBN\628491|thought_142|,_45|we_43|._32 (r_ccomp) hypothesize_22\VBP\719734|NONE_0 (l_advcl) thought_5\VBN\5809192|,_97|we_99|associated_142|._174 (l_xcomp) involved_8\VBN\2676054|as_33|tnf_30|are_18 (l_prep) in_9\IN\13603305|to_15|be_12 (l_pobj) development_11\NN\248977|NONE_0 (l_prep) of_12\IN\0|the_16 (l_pobj) shock_14\NN\7510495|NONE_0
D003561_D008223 NONE c_10\NN\13714184|NONE_0 (l_prep) for_11\IN\0|dose_17|aracytine_12|-_3 (l_pobj) lymphoma_12\NN\14239918|NONE_0
D003561_D008223 NONE c_13\NNP\13714184|NONE_0 (r_pobj) with_7\IN\0|for_21|in_35 (r_prep) treated_6\VBN\2376958|23_24|consecutive_21 (l_prep) for_14\IN\0|with_21|in_14 (l_pobj) lymphomas_15\NNS\14239918|NONE_0
19338378
C031942_D013921 NONE argatroban_9\JJ\0|in_19 (r_amod) therapy_10\NN\657604|NONE_0 (l_prep) in_11\IN\13603305|argatroban_19 (l_pobj) thrombocytopenia_15\NN\14189204|NONE_0
C031942_D013921 NONE argatroban_0\NNP\0|inhibitor_57|and_157|for_161|._248 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) inhibitor_8\NN\20090|argatroban_57|and_100|for_104|._191 (l_acl) used_9\VBN\0|a_53|metabolized_39|,_28|direct_26|thrombin_19 (l_prep) in_16\IN\13603305|for_43 (l_pobj) thrombocytopenia_20\NN\14189204|NONE_0
C031942_D013921 NONE argatroban_0\NNP\0|inhibitor_57|and_157|for_161|._248 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) inhibitor_8\NN\20090|argatroban_57|and_100|for_104|._191 (l_acl) used_9\VBN\0|a_53|metabolized_39|,_28|direct_26|thrombin_19 (l_prep) in_16\IN\13603305|for_43 (l_pobj) thrombocytopenia_20\NN\14189204|NONE_0 (l_appos) hit_22\NNP\36762|induced_26|(_1|)_3
C031942_D013921 NONE argatroban_0\NNP\0|inhibitor_57|and_157|for_161|._248 (r_nsubj) is_1\VBZ\0|NONE_0 (l_conj) for_25\IN\0|argatroban_161|inhibitor_104|and_4|._87 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_prep) with_27\IN\0|undergoing_23 (l_conj) at_29\IN\14622893|or_3 (l_pobj) risk_30\NN\14541044|NONE_0 (l_prep) of_31\IN\0|NONE_0 (l_pobj) hit_32\NNP\36762|NONE_0
C031942_D013921 NONE argatroban_11\JJ\0|in_19 (r_amod) therapy_12\NN\657604|NONE_0 (l_prep) in_13\IN\13603305|argatroban_19 (l_pobj) hit_14\NNP\36762|NONE_0
C031942_D013921 NONE argatroban_5\JJ\0|recommended_12|in_16 (r_amod) dose_6\NN\3740161|min_27|(_164 (l_prep) in_7\IN\13603305|recommended_28|argatroban_16 (l_pobj) hit_8\NNP\36762|NONE_0
C031942_D013921 NONE argatroban_6\JJ\0|in_19|,_25|including_27 (r_amod) therapy_7\NN\657604|NONE_0 (l_prep) in_8\IN\13603305|argatroban_19|,_6|including_8 (l_pobj) hit_9\NNP\36762|NONE_0
C031942_D013921 NONE argatroban_6\JJ\0|in_19|,_25|including_27 (r_amod) therapy_7\NN\657604|NONE_0 (r_pobj) with_5\IN\0|improved_49|of_28 (r_prep) familiarity_1\NN\5816287|,_119|may_121|reduction_136|._256 (r_nsubj) facilitate_20\VB\2547586|NONE_0 (l_dobj) reduction_21\NN\351485|familiarity_136|,_17|may_15|._120 (l_prep) of_22\IN\0|NONE_0 (l_pobj) harm_23\NN\14052046|NONE_0 (l_acl) associated_24\VBN\628491|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) thromboses_30\NNS\146138|NONE_0 (l_nmod) hit_26\NNP\36762|(_4|fewer_10|)_26|or_28|treatment_35
C031942_D013921 NONE argatroban_38\JJ\0|fewer_6|medication_11 (r_amod) errors_40\NNS\66216|its_48|(_34|)_6 (r_appos) treatment_34\NN\654885|hit_35|(_31|fewer_25|)_9|or_7 (r_conj) thromboses_30\NNS\146138|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) associated_24\VBN\628491|NONE_0 (r_acl) harm_23\NN\14052046|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) reduction_21\NN\351485|familiarity_136|,_17|may_15|._120 (r_dobj) facilitate_20\VB\2547586|NONE_0 (l_nsubj) familiarity_1\NN\5816287|,_119|may_121|reduction_136|._256 (l_prep) with_5\IN\0|improved_49|of_28 (l_pobj) therapy_7\NN\657604|NONE_0 (l_prep) in_8\IN\13603305|argatroban_19|,_6|including_8 (l_pobj) hit_9\NNP\36762|NONE_0
C031942_D013921 NONE argatroban_38\JJ\0|fewer_6|medication_11 (r_amod) errors_40\NNS\66216|its_48|(_34|)_6 (r_appos) treatment_34\NN\654885|hit_35|(_31|fewer_25|)_9|or_7 (r_conj) thromboses_30\NNS\146138|NONE_0 (l_nmod) hit_26\NNP\36762|(_4|fewer_10|)_26|or_28|treatment_35
D006493_D013927 NONE heparin_17\NN\2718259|-_7 (r_npadvmod) induced_19\VBN\1627355|(_25|hit_26|)_29 (r_amod) thrombocytopenia_20\NN\14189204|NONE_0 (r_pobj) in_16\IN\13603305|for_43 (r_prep) used_9\VBN\0|a_53|metabolized_39|,_28|direct_26|thrombin_19 (l_prep) for_10\IN\0|in_43 (l_pobj) prophylaxis_11\NN\1077350|NONE_0 (l_conj) treatment_13\NN\654885|or_3 (l_prep) of_14\IN\0|NONE_0 (l_pobj) thrombosis_15\NN\14100769|NONE_0
C031942_D006470 CID argatroban_3\NN\0|NONE_0 (r_amod) with_2\IN\0|NONE_0 (r_prep) bleeding_1\VBG\14285662|NONE_0
C031942_D008107 NONE argatroban_5\JJ\0|recommended_12|in_16 (r_amod) dose_6\NN\3740161|min_27|(_164 (r_nsubj) is_9\VBZ\0|NONE_0 (l_attr) min_15\NN\15154774|dose_27|(_137 (l_acl) reduced_17\VBN\441445|2_17|microg_15|kg_8|/_6|(_1|)_70|,_71|adjusted_73 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) impairment_22\NN\7296428|and_11|in_15
D006493_D013921 NONE heparin_12\NN\2718259|-_7 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_15\NN\14189204|NONE_0
D006493_D013921 NONE heparin_17\NN\2718259|-_7 (r_npadvmod) induced_19\VBN\1627355|(_25|hit_26|)_29 (r_amod) thrombocytopenia_20\NN\14189204|NONE_0
D006493_D013921 NONE heparin_17\NN\2718259|-_7 (r_npadvmod) induced_19\VBN\1627355|(_25|hit_26|)_29 (r_amod) thrombocytopenia_20\NN\14189204|NONE_0 (l_appos) hit_22\NNP\36762|induced_26|(_1|)_3
D006493_D013921 NONE heparin_17\NN\2718259|-_7 (r_npadvmod) induced_19\VBN\1627355|(_25|hit_26|)_29 (r_amod) thrombocytopenia_20\NN\14189204|NONE_0 (r_pobj) in_16\IN\13603305|for_43 (r_prep) used_9\VBN\0|a_53|metabolized_39|,_28|direct_26|thrombin_19 (r_acl) inhibitor_8\NN\20090|argatroban_57|and_100|for_104|._191 (r_attr) is_1\VBZ\0|NONE_0 (l_conj) for_25\IN\0|argatroban_161|inhibitor_104|and_4|._87 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_prep) with_27\IN\0|undergoing_23 (l_conj) at_29\IN\14622893|or_3 (l_pobj) risk_30\NN\14541044|NONE_0 (l_prep) of_31\IN\0|NONE_0 (l_pobj) hit_32\NNP\36762|NONE_0
C031942_D009765 NONE argatroban_3\NN\0|for_9|,_2|has_11|not_15|been_19|in_37 (r_advmod) investigated_7\VBN\644583|;_45|adjustment_52|unnecessary_66|,_123|and_125|be_146 (r_ccomp) is_15\VBZ\0|NONE_0 (l_acomp) unnecessary_16\JJ\0|investigated_66|;_21|adjustment_14|,_57|and_59|be_80 (l_prep) for_17\IN\0|NONE_0 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|adult_11|,_2 (l_conj) ethnicity_25\NN\4723816|,_7 (l_conj) obesity_27\NN\4999401|race_18|/_14|or_3
C031942_D013927 NONE argatroban_0\NNP\0|inhibitor_57|and_157|for_161|._248 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) inhibitor_8\NN\20090|argatroban_57|and_100|for_104|._191 (l_acl) used_9\VBN\0|a_53|metabolized_39|,_28|direct_26|thrombin_19 (l_prep) for_10\IN\0|in_43 (l_pobj) prophylaxis_11\NN\1077350|NONE_0 (l_conj) treatment_13\NN\654885|or_3 (l_prep) of_14\IN\0|NONE_0 (l_pobj) thrombosis_15\NN\14100769|NONE_0
12948256
D004977_D014388 NONE ethambutol_10\NN\0|NONE_0 (l_prep) for_11\IN\0|NONE_0 (l_pobj) tuberculosis_12\NN\14127211|NONE_0 (l_prep) of_13\IN\0|NONE_0 (l_pobj) node_18\NN\13870805|NONE_0
D004977_D014397 NONE ethambutol_10\NN\0|NONE_0 (l_prep) for_11\IN\0|NONE_0 (l_pobj) tuberculosis_12\NN\14127211|NONE_0 (l_prep) of_13\IN\0|NONE_0 (l_pobj) node_18\NN\13870805|NONE_0
D004977_D009901 CID ethambutol_0\NNP\0|._31 (r_nmod) neuropathy_3\NN\14204950|NONE_0
D004977_D009901 CID ethambutol_5\NN\0|NONE_0 (r_amod) neuropathy_8\NN\14204950|NONE_0
D004977_D009901 CID ethambutol_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|being_14 (r_prep) treated_8\VBN\2376958|NONE_0 (r_pcomp) after_6\IN\0|who_31|neuropathy_11 (r_prep) developed_3\VBD\1753788|thirteen_22 (l_dobj) neuropathy_5\NN\14204950|who_20|after_11
D004977_D009901 CID ethambutol_19\NN\0|NONE_0 (r_amod) therapy_20\NN\657604|at_8 (r_dobj) starting_18\VBG\457382|NONE_0 (r_pcomp) after_17\IN\0|:_78|patients_72|neuropathy_53|)_2|._99 (r_prep) had_3\VBD\0|NONE_0 (l_dobj) neuropathy_5\NN\14204950|:_25|patients_19|)_51|after_53|._152
D004977_D009901 CID ethambutol_11\NN\0|NONE_0 (r_amod) therapy_12\NN\657604|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) patients_9\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|recognition_53|should_21|be_14|._35 (r_prep) considered_7\VBN\689344|NONE_0 (l_nsubjpass) recognition_1\NN\13932421|should_32|be_39|in_53|._88 (l_prep) of_2\IN\0|early_18 (l_pobj) neuropathy_4\NN\14204950|NONE_0
8312343
D004317_D002311 NONE doxorubicin_49\NN\2716866|congenital_157|heart_146|(_132|%_129|)_128|with_126|(_96|%_93|)_70|,_69|cardiomyopathy_54|,_35|disease_18|,_6|and_4 (r_conj) disease_13\NN\14061805|for_75 (r_appos) indications_0\NNS\33020|cardiomyopathy_48|,_68|._258 (r_nsubj) were_3\VBD\0|NONE_0 (l_attr) cardiomyopathy_5\NN\14103288|indications_48|,_20|._210
D004317_D006349 NONE doxorubicin_49\NN\2716866|congenital_157|heart_146|(_132|%_129|)_128|with_126|(_96|%_93|)_70|,_69|cardiomyopathy_54|,_35|disease_18|,_6|and_4 (r_conj) disease_13\NN\14061805|for_75 (l_appos) disease_42\NN\14061805|congenital_139|heart_128|(_114|%_111|)_110|with_108|(_78|%_75|)_52|,_51|cardiomyopathy_36|,_17|,_12|and_14|doxorubicin_18
D004317_D009202 CID doxorubicin_49\NN\2716866|congenital_157|heart_146|(_132|%_129|)_128|with_126|(_96|%_93|)_70|,_69|cardiomyopathy_54|,_35|disease_18|,_6|and_4 (l_appos) cardiomyopathy_50\NN\14103288|%_17
D004317_D006331 NONE doxorubicin_49\NN\2716866|congenital_157|heart_146|(_132|%_129|)_128|with_126|(_96|%_93|)_70|,_69|cardiomyopathy_54|,_35|disease_18|,_6|and_4 (r_conj) disease_13\NN\14061805|for_75
D004317_D002312 NONE doxorubicin_49\NN\2716866|congenital_157|heart_146|(_132|%_129|)_128|with_126|(_96|%_93|)_70|,_69|cardiomyopathy_54|,_35|disease_18|,_6|and_4 (r_conj) disease_13\NN\14061805|for_75 (l_conj) cardiomyopathy_34\NN\14103288|congenital_103|heart_92|(_78|%_75|)_74|with_72|(_42|%_39|)_16|,_15|,_19|disease_36|,_48|and_50|doxorubicin_54
D015774_D003586 NONE ganciclovir_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|infections_37|were_26|successfully_13|._31 (r_prep) treated_3\VBN\2376958|NONE_0 (l_nsubjpass) infections_1\NNS\14052046|were_11|successfully_24|with_37|._68
11401944
C086123_D016171 NONE azimilide_34\NN\0|dl_15|-_13|and_4 (r_conj) sotalol_32\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|qt_16 (r_acl) prolongation_27\NN\1017987|NONE_0 (r_pobj) with_25\IN\0|to_37|pointes_14 (r_prep) initiate_18\VB\9632274|a_13 (l_dobj) pointes_21\FW\831651|to_23|with_14
C086123_D016171 NONE azimilide_34\NN\0|dl_15|-_13|and_4 (r_conj) sotalol_32\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|qt_16 (r_acl) prolongation_27\NN\1017987|NONE_0 (r_pobj) with_25\IN\0|to_37|pointes_14 (r_prep) initiate_18\VB\9632274|a_13 (l_dobj) pointes_21\FW\831651|to_23|with_14 (l_appos) tdp_23\NN\0|torsade_20|de_12|(_1|)_3
D013015_D016171 CID sotalol_32\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|qt_16 (r_acl) prolongation_27\NN\1017987|NONE_0 (r_pobj) with_25\IN\0|to_37|pointes_14 (r_prep) initiate_18\VB\9632274|a_13 (l_dobj) pointes_21\FW\831651|to_23|with_14
D013015_D016171 CID sotalol_32\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|qt_16 (r_acl) prolongation_27\NN\1017987|NONE_0 (r_pobj) with_25\IN\0|to_37|pointes_14 (r_prep) initiate_18\VB\9632274|a_13 (l_dobj) pointes_21\FW\831651|to_23|with_14 (l_appos) tdp_23\NN\0|torsade_20|de_12|(_1|)_3
D013015_D016171 CID sotalol_7\NN\0|NONE_0 (r_pobj) by_4\IN\0|an_19|in_7 (r_prep) increase_1\NN\13576355|propagation_53|._157 (r_nsubj) facilitated_8\VBN\2547586|NONE_0 (l_dobj) propagation_10\NN\6253140|increase_53|._104 (l_relcl) initiated_14\VBD\1617192|transmural_36|of_13 (l_dobj) episodes_16\NNS\7283608|that_24|in_28 (l_prep) of_17\IN\0|multiple_18 (l_pobj) tdp_19\NN\0|NONE_0
C086123_D008133 NONE azimilide_34\NN\0|dl_15|-_13|and_4 (r_conj) sotalol_32\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|qt_16 (r_acl) prolongation_27\NN\1017987|NONE_0
C086123_D008133 NONE azimilide_6\NN\0|both_20|dl_15|-_13|and_4 (r_conj) sotalol_4\NNS\0|although_17|rarely_22|eads_37 (r_nsubj) induced_8\VBD\1627355|,_38|they_40|eads_63|in_68|,_78|pronounced_94|._129 (r_advcl) produced_16\VBD\1617192|NONE_0 (l_relcl) pronounced_25\VBN\0|induced_94|,_56|they_54|eads_31|in_26|,_16|._35 (l_ccomp) seen_29\VBN\2106506|in_45|more_36 (l_nsubjpass) prolongation_27\NN\1017987|was_13
D013015_D008133 CID sotalol_32\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|qt_16 (r_acl) prolongation_27\NN\1017987|NONE_0
D013015_D008133 CID sotalol_2\NNP\0|preferentially_8|duration_50|in_65|,_114|leading_116|._165 (r_nsubj) prolonged_4\VBD\317700|NONE_0 (l_advcl) leading_26\VBG\4339291|sotalol_116|preferentially_108|duration_66|in_51|,_2|._49 (l_prep) to_27\IN\0|NONE_0 (l_pobj) prolongation_29\NN\1017987|NONE_0
D013015_D008133 CID sotalol_4\NNS\0|although_17|rarely_22|eads_37 (r_nsubj) induced_8\VBD\1627355|,_38|they_40|eads_63|in_68|,_78|pronounced_94|._129 (r_advcl) produced_16\VBD\1617192|NONE_0 (l_relcl) pronounced_25\VBN\0|induced_94|,_56|they_54|eads_31|in_26|,_16|._35 (l_ccomp) seen_29\VBN\2106506|in_45|more_36 (l_nsubjpass) prolongation_27\NN\1017987|was_13
6517710
D011796_D013927 NONE hydrochloride_8\NN\14817592|ppm_15 (r_appos) quinacrine_7\NN\2721948|percent_30|simultaneously_54|in_69 (r_dobj) given_4\VBN\5892096|thrombosis_99|,_135|have_193|._215 (r_csubj) had_18\VBD\0|NONE_0 (l_dobj) thrombosis_19\NN\14100769|given_99|,_36|have_94|._116
D012977_D003328 NONE nitrite_13\NN\14621446|and_21 (r_conj) hydrochloride_8\NN\14817592|ppm_15 (r_appos) quinacrine_7\NN\2721948|percent_30|simultaneously_54|in_69 (r_dobj) given_4\VBN\5892096|thrombosis_99|,_135|have_193|._215 (r_csubj) had_18\VBD\0|NONE_0 (l_advcl) have_36\VB\7846|given_193|thrombosis_94|,_58|._22 (l_dobj) thrombosis_38\NN\14100769|while_68|rats_44|did_20|not_16
D011796_D003328 CID hydrochloride_10\NN\14817592|NONE_0 (r_dobj) ingesting_8\VBG\0|f-344_11 (r_acl) rats_7\NNS\2329401|NONE_0 (r_pobj) of_5\IN\0|the_10 (r_prep) heart_4\NN\5919034|NONE_0 (r_dobj) involving_2\VBG\2676054|atrial_18|._68 (r_acl) thrombosis_1\NN\14100769|NONE_0
D011796_D003328 CID hydrochloride_6\NN\14817592|ppm_15|in_14 (r_appos) quinacrine_5\NN\2721948|NONE_0 (r_pobj) with_2\IN\0|rats_13|developed_54|._106 (r_prep) treated_1\VBD\2376958|NONE_0 (l_conj) developed_11\VBD\1753788|rats_67|with_54|._52 (l_dobj) incidence_14\NN\13821570|all_21 (l_prep) of_15\IN\0|a_17|high_15 (l_pobj) thrombosis_18\NN\14100769|NONE_0
D011796_D003328 CID hydrochloride_8\NN\14817592|ppm_15 (r_appos) quinacrine_7\NN\2721948|percent_30|simultaneously_54|in_69 (r_dobj) given_4\VBN\5892096|thrombosis_99|,_135|have_193|._215 (r_csubj) had_18\VBD\0|NONE_0 (l_advcl) have_36\VB\7846|given_193|thrombosis_94|,_58|._22 (l_dobj) thrombosis_38\NN\14100769|while_68|rats_44|did_20|not_16
D012977_D013927 NONE nitrite_13\NN\14621446|and_21 (r_conj) hydrochloride_8\NN\14817592|ppm_15 (r_appos) quinacrine_7\NN\2721948|percent_30|simultaneously_54|in_69 (r_dobj) given_4\VBN\5892096|thrombosis_99|,_135|have_193|._215 (r_csubj) had_18\VBD\0|NONE_0 (l_dobj) thrombosis_19\NN\14100769|given_99|,_36|have_94|._116
7661171
D007213_D005355 NONE indomethacin_8\NN\3828465|-_12 (r_npadvmod) induced_10\VBN\1627355|renal_8|in_26 (r_amod) dysfunction_12\NN\14204950|NONE_0 (l_prep) in_13\IN\13603305|induced_26|renal_18 (l_pobj) cirrhosis_16\NN\14116321|NONE_0
D007213_D005355 NONE indomethacin_12\NN\3828465|-_12 (r_npadvmod) induced_14\VBN\1627355|the_17|renal_8|in_26 (r_amod) dysfunction_16\NN\14204950|to_53|acutely_50 (l_prep) in_17\IN\13603305|the_43|induced_26|renal_18 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_amod) cirrhotic_20\JJ\0|compensated_12
D007213_D005355 NONE indomethacin_31\NN\3828465|NONE_0 (r_pobj) of_30\IN\0|50_6|and_16|doses_28 (r_prep) mg_29\NN\13717155|NONE_0 (r_pobj) of_27\IN\0|an_20|oral_17 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) after_23\IN\0|and_4 (r_conj) before_21\RB\0|parameters_151|were_80|by_66|in_42|._94 (r_prep) assessed_11\VBN\670261|NONE_0 (l_prep) in_15\IN\13603305|parameters_109|were_38|by_24|before_42|._136 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_amod) cirrhotic_19\JJ\0|26_20|compensated_12
D007213_D005355 NONE indomethacin_17\NN\3828465|NONE_0 (r_pobj) of_16\IN\0|the_20|adverse_16 (r_prep) effects_15\NNS\13245626|to_23 (r_dobj) prevent_12\VB\0|this_58|apparent_53|of_36 (r_acl) ability_5\NN\4723816|however_29|,_22|until_20|is_106|with_119 (r_nsubjpass) confirmed_22\VBN\0|,_38|it_40|would_43|prudent_52|avoid_63|._134 (r_advcl) be_30\VB\14625458|NONE_0 (l_xcomp) avoid_33\VB\0|confirmed_63|,_25|it_23|would_20|prudent_11|._71 (l_dobj) therapy_38\NN\657604|to_40 (l_prep) in_39\IN\13603305|nonsteroidal_39|inflammatory_21 (l_pobj) patients_40\NNS\9898892|NONE_0 (l_prep) with_41\IN\0|NONE_0 (l_pobj) cirrhosis_42\NN\14116321|NONE_0
D016595_D005355 NONE misoprostol_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_26|dependent_17|on_15|._86 (r_prep) effect_4\NN\34213|NONE_0 (l_prep) on_7\IN\0|the_41|dependent_32|of_15|._71 (l_pobj) dysfunction_12\NN\14204950|NONE_0 (l_prep) in_13\IN\13603305|induced_26|renal_18 (l_pobj) cirrhosis_16\NN\14116321|NONE_0
D016595_D005355 NONE misoprostol_0\NNP\0|has_29|been_33|counteract_55|._147 (r_nsubjpass) shown_7\VBN\2137132|NONE_0 (l_xcomp) counteract_10\VB\2367363|misoprostol_55|has_26|been_22|._92 (l_dobj) dysfunction_16\NN\14204950|to_53|acutely_50 (l_prep) in_17\IN\13603305|the_43|induced_26|renal_18 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_amod) cirrhotic_20\JJ\0|compensated_12
D016595_D005355 NONE misoprostol_36\NN\0|NONE_0 (r_pobj) of_35\IN\0|various_14 (r_prep) doses_34\NNS\3740161|50_34|of_28|and_12 (r_conj) mg_29\NN\13717155|NONE_0 (r_pobj) of_27\IN\0|an_20|oral_17 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) after_23\IN\0|and_4 (r_conj) before_21\RB\0|parameters_151|were_80|by_66|in_42|._94 (r_prep) assessed_11\VBN\670261|NONE_0 (l_prep) in_15\IN\13603305|parameters_109|were_38|by_24|before_42|._136 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_amod) cirrhotic_19\JJ\0|26_20|compensated_12
D016595_D005355 NONE misoprostol_10\NNP\0|NONE_0 (r_pobj) of_9\IN\0|200_15 (r_prep) micrograms_8\NNS\13717155|NONE_0 (r_pobj) of_6\IN\0|this_22|apparent_17|prevent_36 (r_prep) ability_5\NN\4723816|however_29|,_22|until_20|is_106|with_119 (r_nsubjpass) confirmed_22\VBN\0|,_38|it_40|would_43|prudent_52|avoid_63|._134 (r_advcl) be_30\VB\14625458|NONE_0 (l_xcomp) avoid_33\VB\0|confirmed_63|,_25|it_23|would_20|prudent_11|._71 (l_dobj) therapy_38\NN\657604|to_40 (l_prep) in_39\IN\13603305|nonsteroidal_39|inflammatory_21 (l_pobj) patients_40\NNS\9898892|NONE_0 (l_prep) with_41\IN\0|NONE_0 (l_pobj) cirrhosis_42\NN\14116321|NONE_0
D016595_D007674 NONE misoprostol_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_26|dependent_17|on_15|._86 (r_prep) effect_4\NN\34213|NONE_0 (l_prep) on_7\IN\0|the_41|dependent_32|of_15|._71 (l_pobj) dysfunction_12\NN\14204950|NONE_0
D016595_D007674 NONE misoprostol_0\NNP\0|has_29|been_33|counteract_55|._147 (r_nsubjpass) shown_7\VBN\2137132|NONE_0 (l_xcomp) counteract_10\VB\2367363|misoprostol_55|has_26|been_22|._92 (l_dobj) dysfunction_16\NN\14204950|to_53|acutely_50
D012964_D005355 NONE sodium_6\NN\14625458|renal_31|and_12 (r_conj) hemodynamics_3\NNS\6080522|NONE_0 (r_pobj) of_1\IN\0|handling_51 (r_prep) parameters_0\NNS\5858936|were_71|by_85|in_109|before_151|._245 (r_nsubjpass) assessed_11\VBN\670261|NONE_0 (l_prep) in_15\IN\13603305|parameters_109|were_38|by_24|before_42|._136 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_amod) cirrhotic_19\JJ\0|26_20|compensated_12
D007213_D007674 CID indomethacin_8\NN\3828465|-_12 (r_npadvmod) induced_10\VBN\1627355|renal_8|in_26 (r_amod) dysfunction_12\NN\14204950|NONE_0
D007213_D007674 CID indomethacin_12\NN\3828465|-_12 (r_npadvmod) induced_14\VBN\1627355|the_17|renal_8|in_26 (r_amod) dysfunction_16\NN\14204950|to_53|acutely_50
11385188
D003042_D009202 CID cocaine_18\NN\3492717|young_27|asymptomatic_21|chronic_8 (r_compound) users_19\NNS\7846|NONE_0 (r_pobj) in_14\IN\13603305|%_3 (r_prep) common_9\JJ\8673395|that_46|disease_11 (r_acomp) is_8\VBZ\0|we_55|._59 (l_nsubj) disease_7\NN\14061805|that_35|common_11
D003042_D003324 CID cocaine_18\NN\3492717|young_27|asymptomatic_21|chronic_8 (r_compound) users_19\NNS\7846|NONE_0 (r_pobj) in_14\IN\13603305|%_3 (r_prep) common_9\JJ\8673395|that_46|disease_11 (r_acomp) is_8\VBZ\0|we_55|._59 (l_nsubj) disease_7\NN\14061805|that_35|common_11
D003042_D006331 NONE cocaine_7\NN\3492717|asymptomatic_21|chronic_8 (r_compound) users_8\NNS\7846|NONE_0 (r_pobj) in_4\IN\13603305|of_17|._37 (r_prep) prevalence_0\NN\4764412|NONE_0 (l_prep) of_1\IN\0|in_17|._54 (l_pobj) disease_3\NN\14061805|NONE_0
D003042_D006331 NONE cocaine_12\NN\3492717|young_27|asymptomatic_21|chronic_8 (r_compound) users_13\NNS\7846|NONE_0 (r_pobj) in_7\IN\13603305|heart_14 (r_prep) disease_6\NN\14061805|NONE_0
D003042_D006331 NONE cocaine_16\NN\3492717|35_3|and_14|controls_33 (r_compound) users_17\NNS\7846|the_99|of_84|,_13 (r_conj) prevalence_3\NN\4764412|to_17 (l_prep) of_4\IN\0|the_15|,_71|users_84 (l_pobj) disease_6\NN\14061805|NONE_0
24091473
C476513_D066126 NONE levobupivacaine_9\NN\0|-_15 (r_npadvmod) induced_11\VBN\1627355|cardiac_8|in_25 (r_amod) toxicity_13\NN\13576101|NONE_0
D004837_D066126 NONE epinephrine_4\NN\14807929|,_2 (l_conj) both_7\DT\0|,_5|or_3 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) toxicity_13\NN\13576101|NONE_0
D004837_D064420 NONE epinephrine_8\NN\14807929|lipid_16|,_2 (r_conj) emulsion_6\NN\14588219|NONE_0 (r_pobj) of_4\IN\0|the_28|optimal_24|dosing_16 (r_prep) regimens_3\NNS\5898568|are_49|not_53|yet_57|in_72|._138 (r_nsubjpass) determined_15\VBN\0|NONE_0 (l_prep) in_16\IN\13603305|regimens_72|are_23|not_19|yet_15|._66 (l_pobj) neonates_17\NNS\9827683|NONE_0 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) cases_19\NNS\7283608|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) toxicity_24\NN\13576101|NONE_0
C476513_D002318 CID levobupivacaine_3\PRP\0|piglets_17|occurred_46|._54 (r_dobj) received_2\VBD\2210855|NONE_0 (l_advcl) occurred_7\VBD\0|piglets_63|levobupivacaine_46|._8 (l_nsubj) collapse_6\NN\14061805|until_21
16911931
D019259_D006509 NONE lamivudine_7\NN\3834836|NONE_0 (r_pobj) with_6\IN\0|after_56 (r_prep) combined_5\VBN\2630189|intramuscular_42|b_18|immune_16|._92 (r_acl) globulin_4\NN\14736972|NONE_0 (l_compound) b_2\NNP\1355326|intramuscular_24|immune_2|combined_18|._110
D019259_D006509 NONE lamivudine_7\NN\3834836|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) prevention_9\NN\1073995|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) recurrence_13\NN\7342049|NONE_0 (l_compound) b_12\NNP\1355326|NONE_0
D019259_D006509 NONE lamivudine_9\NN\3834836|)_6|and_4 (r_conj) hbig_6\NNP\0|combined_38|b_19|immune_17|(_1|after_69 (r_appos) globulin_4\NN\14736972|has_107|significantly_111|survival_138|._173 (l_compound) b_2\NNP\1355326|combined_19|immune_2|(_18|hbig_19|after_88
D019259_D006509 NONE lamivudine_9\NN\3834836|)_6|and_4 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) prophylaxis_11\NN\1077350|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) recurrence_14\NN\7342049|NONE_0 (l_prep) of_15\IN\0|the_15 (l_pobj) b_17\NNP\1355326|NONE_0
D006514_D006509 NONE hbsag_27\JJ\0|positive_6 (r_nmod) patients_29\NNS\9898892|NONE_0 (r_pobj) of_26\IN\0|the_13 (r_prep) survival_25\NN\13961642|globulin_138|has_31|significantly_27|._35 (r_dobj) improved_23\VBN\126264|NONE_0 (l_nsubj) globulin_4\NN\14736972|has_107|significantly_111|survival_138|._173 (l_compound) b_2\NNP\1355326|combined_19|immune_2|(_18|hbig_19|after_88
D006514_D006509 NONE hbsag_27\JJ\0|positive_6 (r_nmod) patients_29\NNS\9898892|NONE_0 (r_pobj) of_26\IN\0|the_13 (r_prep) survival_25\NN\13961642|globulin_138|has_31|significantly_27|._35 (r_dobj) improved_23\VBN\126264|NONE_0 (l_nsubj) globulin_4\NN\14736972|has_107|significantly_111|survival_138|._173 (l_appos) hbig_6\NNP\0|combined_38|b_19|immune_17|(_1|after_69 (l_conj) lamivudine_9\NN\3834836|)_6|and_4 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) prophylaxis_11\NN\1077350|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) recurrence_14\NN\7342049|NONE_0 (l_prep) of_15\IN\0|the_15 (l_pobj) b_17\NNP\1355326|NONE_0
20034406
D010862_D013226 CID pilocarpine_12\NN\14712692|-_11 (r_npadvmod) induced_14\VBN\1627355|epilepticus_15 (r_amod) status_15\NN\24720|NONE_0 (l_amod) epilepticus_16\NN\0|induced_15
D010862_D013226 CID pilocarpine_17\NN\14712692|NONE_0 (r_amod) injection_18\NN\320852|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|status_24|epilepticus_17|(_5|)_2 (r_acl) se_13\NNP\14724645|NONE_0 (l_nmod) epilepticus_11\NN\0|status_7|(_12|)_15|induced_17
D010862_D013226 CID pilocarpine_17\NN\14712692|NONE_0 (r_amod) injection_18\NN\320852|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|status_24|epilepticus_17|(_5|)_2 (r_acl) se_13\NNP\14724645|NONE_0
D010862_D013226 CID pilocarpine_4\NN\14712692|NONE_0 (r_amod) injection_5\NN\320852|NONE_0 (r_pobj) by_3\IN\0|se_15|was_12|._24 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) se_0\NNP\14724645|was_3|by_15|._39
D010862_D013226 CID pilocarpine_15\NN\14712692|-_11 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) se_18\NNP\14724645|NONE_0
6985297
D015764_D001919 CID bepridil_6\NN\0|NONE_0 (r_pcomp) by_5\IN\0|studies_35|._11 (r_prep) induced_4\VBN\1627355|NONE_0 (l_nsubj) studies_0\NNS\635850|by_35|._46 (l_prep) on_1\IN\0|NONE_0 (l_pobj) bradycardia_3\NN\14110674|NONE_0
D015764_D001919 CID bepridil_0\NN\0|,_8|compound_25|,_79|bradycardia_100 (r_advmod) induced_13\VBD\1627355|,_74|mechanisms_80|were_100|in_118|._138 (l_dobj) bradycardia_15\NNS\14110674|bepridil_100|,_92|compound_75|,_21
D015764_D013610 NONE bepridil_0\NN\0|,_8|compound_25|,_79|bradycardia_100 (r_advmod) induced_13\VBD\1627355|,_74|mechanisms_80|were_100|in_118|._138 (l_dobj) bradycardia_15\NNS\14110674|bepridil_100|,_92|compound_75|,_21 (l_conj) effect_24\NN\34213|persistent_60|and_37 (l_amod) tachycardial_23\JJ\0|a_20
D015764_D000787 NONE bepridil_0\NN\0|,_8|compound_25|,_79|bradycardia_100 (r_advmod) induced_13\VBD\1627355|,_74|mechanisms_80|were_100|in_118|._138 (l_nsubj) compound_5\NN\5869584|bepridil_25|,_17|,_54|bradycardia_75 (l_prep) for_6\IN\0|a_24|novel_22|active_16 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|prophylactic_23 (l_pobj) attacks_11\NNS\955060|NONE_0
7949506
D013148_D006929 NONE spironolactone_16\CD\2721160|woman_70|was_40|with_28|d_6|and_4|._23 (r_conj) treated_8\VBN\2376958|NONE_0 (l_nsubjpass) woman_4\NN\9605289|was_30|with_42|d_64|and_66|spironolactone_70|._93 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) hyperaldosteronism_6\NN\14059928|NONE_0
D003000_D007022 CID clonidine_10\NN\2721160|NONE_0 (r_pobj) between_9\IN\0|a_31|possible_29|adverse_20|resulting_32 (r_prep) interaction_8\NN\37396|NONE_0 (l_acl) resulting_13\VBG\2633881|a_63|possible_61|adverse_52|between_32 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) block_19\NN\21939|NONE_0 (l_prep) in_20\IN\13603305|atrioventricular_28|(_11|av_10|)_8 (l_pobj) patients_22\NNS\9898892|NONE_0 (l_conj) hypotension_25\NN\14057371|both_25|and_11
D003000_D007022 CID clonidine_8\NN\2721160|NONE_0 (r_pobj) of_7\IN\0|a_15|minimal_13|bid_22 (r_prep) dose_6\NN\3740161|NONE_0 (r_pobj) of_3\IN\0|the_13 (r_prep) addition_2\NN\3081021|NONE_0 (r_pobj) after_0\IN\0|,_63|she_65|block_91 (r_prep) developed_16\VBD\1753788|NONE_0 (l_dobj) block_19\NN\21939|after_91|,_28|she_26 (l_conj) hypotension_22\NN\14057371|complete_29|av_20|and_11|,_11|resolved_19
D003000_D054537 CID clonidine_10\NN\2721160|NONE_0 (r_pobj) between_9\IN\0|a_31|possible_29|adverse_20|resulting_32 (r_prep) interaction_8\NN\37396|NONE_0 (l_acl) resulting_13\VBG\2633881|a_63|possible_61|adverse_52|between_32 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) block_19\NN\21939|NONE_0
D003000_D054537 CID clonidine_8\NN\2721160|NONE_0 (r_pobj) of_7\IN\0|a_15|minimal_13|bid_22 (r_prep) dose_6\NN\3740161|NONE_0 (r_pobj) of_3\IN\0|the_13 (r_prep) addition_2\NN\3081021|NONE_0 (r_pobj) after_0\IN\0|,_63|she_65|block_91 (r_prep) developed_16\VBD\1753788|NONE_0 (l_dobj) block_19\NN\21939|after_91|,_28|she_26
D003000_D054537 CID clonidine_4\JJ\2721160|NONE_0 (r_pobj) of_3\IN\0|the_13 (r_prep) addition_2\NN\3081021|bid_30 (r_pobj) after_0\IN\0|she_44|block_70|._121 (r_prep) developed_9\VBD\1753788|NONE_0 (l_dobj) block_12\NN\21939|after_70|she_26|._51
D014700_D054537 CID verapamil_12\NN\2938514|and_4 (r_conj) clonidine_10\NN\2721160|NONE_0 (r_pobj) between_9\IN\0|a_31|possible_29|adverse_20|resulting_32 (r_prep) interaction_8\NN\37396|NONE_0 (l_acl) resulting_13\VBG\2633881|a_63|possible_61|adverse_52|between_32 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) block_19\NN\21939|NONE_0
D014700_D007022 CID verapamil_12\NN\2938514|and_4 (r_conj) clonidine_10\NN\2721160|NONE_0 (r_pobj) between_9\IN\0|a_31|possible_29|adverse_20|resulting_32 (r_prep) interaction_8\NN\37396|NONE_0 (l_acl) resulting_13\VBG\2633881|a_63|possible_61|adverse_52|between_32 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) block_19\NN\21939|NONE_0 (l_prep) in_20\IN\13603305|atrioventricular_28|(_11|av_10|)_8 (l_pobj) patients_22\NNS\9898892|NONE_0 (l_conj) hypotension_25\NN\14057371|both_25|and_11
D014700_D006929 NONE verapamil_10\NN\2938514|NONE_0 (r_pobj) with_9\IN\0|woman_42|was_12|d_22|and_24|spironolactone_28|._51 (r_prep) treated_8\VBN\2376958|NONE_0 (l_nsubjpass) woman_4\NN\9605289|was_30|with_42|d_64|and_66|spironolactone_70|._93 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) hyperaldosteronism_6\NN\14059928|NONE_0
11135381
D008729_D014550 NONE methoxamine_2\NN\0|NONE_0 (l_prep) on_3\IN\0|NONE_0 (l_pobj) pressure_6\NN\11419404|NONE_0 (l_prep) with_9\IN\0|maximum_35|urethral_27|in_9 (l_pobj) incontinence_12\NN\13473097|NONE_0
D008729_D014550 NONE methoxamine_6\NN\0|NONE_0 (r_pobj) of_4\IN\0|incremental_18|(_38|saline_39|)_45 (r_prep) doses_3\NNS\3740161|half_21 (r_dobj) log_1\NN\15098161|were_69|to_87|measuring_146|._245 (r_csubjpass) administered_13\VBN\2436349|NONE_0 (l_prep) to_14\IN\0|log_87|were_18|measuring_59|._158 (l_pobj) group_16\NN\2137|NONE_0 (l_prep) with_19\IN\0|a_17|of_9 (l_pobj) incontinence_22\NN\13473097|NONE_0
D008729_D006973 CID methoxamine_0\NNP\0|increases_35|but_81|caused_85|._190 (r_nsubj) evoked_1\VBD\1617192|NONE_0 (l_conj) caused_13\VBD\1617192|methoxamine_85|increases_50|but_4|._105 (l_dobj) rise_16\NN\7324673|NONE_0 (l_prep) in_17\IN\13603305|a_19|significant_17|and_27|fall_43 (l_pobj) pressure_20\NN\11419404|NONE_0
3191389
D010862_D013226 CID pilocarpine_4\NN\14712692|in_20|followed_60|._106 (r_nsubj) induces_5\VBZ\1627355|NONE_0 (l_prep) in_6\IN\13603305|pilocarpine_20|followed_40|._86 (l_pobj) seizures_8\NNS\14081375|NONE_0 (l_conj) epilepticus_11\NN\0|rats_25|and_11
D007213_D012640 NONE indomethacin_24\NN\3828465|,_2 (r_conj) phenylbutazone_22\NN\2721538|sodium_19|,_2 (r_appos) salicylate_20\NN\3828465|5_48|steroidal_42|inflammatory_27|,_9|,_70 (r_conj) drugs_17\NNS\14778436|NONE_0 (r_pobj) of_9\IN\0|the_11|on_123 (r_prep) effect_8\NN\34213|to_19 (l_prep) on_31\IN\0|the_134|of_123 (l_pobj) seizures_32\NNS\14081375|NONE_0
D007213_D012640 NONE indomethacin_0\NNP\3828465|modulate_65|._106 (r_nsubj) failed_15\VBD\0|NONE_0 (l_xcomp) modulate_17\VB\1724459|indomethacin_65|._41 (l_dobj) seizures_18\NNS\14081375|to_12
D012980_D012640 CID salicylate_20\NN\3828465|5_48|steroidal_42|inflammatory_27|,_9|,_70 (r_conj) drugs_17\NNS\14778436|NONE_0 (r_pobj) of_9\IN\0|the_11|on_123 (r_prep) effect_8\NN\34213|to_19 (l_prep) on_31\IN\0|the_134|of_123 (l_pobj) seizures_32\NNS\14081375|NONE_0
D010862_D001930 NONE pilocarpine_24\NN\14712692|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|related_21|brain_13 (r_acl) damage_21\NN\7296428|NONE_0
D010862_D012640 CID pilocarpine_14\NN\14712692|NONE_0 (r_pobj) by_13\IN\0|in_15 (r_agent) produced_12\VBN\1617192|NONE_0 (r_acl) seizures_11\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_4\NN\14712692|in_20|followed_60|._106 (r_nsubj) induces_5\VBZ\1627355|NONE_0 (l_prep) in_6\IN\13603305|pilocarpine_20|followed_40|._86 (l_pobj) seizures_8\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_35\NN\14712692|NONE_0 (r_pobj) by_34\IN\0|NONE_0 (r_agent) produced_33\VBN\1617192|NONE_0 (r_acl) seizures_32\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_21\NN\14712692|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) produced_19\VBN\1617192|NONE_0 (r_acl) seizures_18\NNS\14081375|to_12
D010862_D012640 CID pilocarpine_24\NN\14712692|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|related_21|brain_13 (r_acl) damage_21\NN\7296428|NONE_0 (r_pobj) from_16\IN\0|and_19|rats_5|,_56|mg/kg_62 (r_prep) seizures_12\NNS\14081375|acid_34|._95
D010862_D012640 CID pilocarpine_24\NN\14712692|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|related_21|brain_13 (r_acl) damage_21\NN\7296428|NONE_0 (l_amod) related_19\VBN\628491|brain_8|induced_21 (l_npadvmod) seizure_17\NN\14081375|-_7
D010862_D012640 CID pilocarpine_16\NN\14712692|-_11 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) seizures_19\NNS\14081375|NONE_0
D008528_D012640 NONE acid_29\NN\14818238|and_14 (r_conj) ibuprofen_26\NNP\3828465|,_2 (r_conj) indomethacin_24\NN\3828465|,_2 (r_conj) phenylbutazone_22\NN\2721538|sodium_19|,_2 (r_appos) salicylate_20\NN\3828465|5_48|steroidal_42|inflammatory_27|,_9|,_70 (r_conj) drugs_17\NNS\14778436|NONE_0 (r_pobj) of_9\IN\0|the_11|on_123 (r_prep) effect_8\NN\34213|to_19 (l_prep) on_31\IN\0|the_134|of_123 (l_pobj) seizures_32\NNS\14081375|NONE_0
D008528_D012640 NONE acid_1\NN\14818238|seizures_34|._129 (r_nsubj) prevented_11\VBN\0|NONE_0 (l_dobj) seizures_12\NNS\14081375|acid_34|._95
D008528_D012640 NONE acid_1\NN\14818238|seizures_34|._129 (r_nsubj) prevented_11\VBN\0|NONE_0 (l_dobj) seizures_12\NNS\14081375|acid_34|._95 (l_prep) from_16\IN\0|and_19|rats_5|,_56|mg/kg_62 (l_pobj) damage_21\NN\7296428|NONE_0 (l_amod) related_19\VBN\628491|brain_8|induced_21 (l_npadvmod) seizure_17\NN\14081375|-_7
D007052_D012640 NONE ibuprofen_26\NNP\3828465|,_2 (r_conj) indomethacin_24\NN\3828465|,_2 (r_conj) phenylbutazone_22\NN\2721538|sodium_19|,_2 (r_appos) salicylate_20\NN\3828465|5_48|steroidal_42|inflammatory_27|,_9|,_70 (r_conj) drugs_17\NNS\14778436|NONE_0 (r_pobj) of_9\IN\0|the_11|on_123 (r_prep) effect_8\NN\34213|to_19 (l_prep) on_31\IN\0|the_134|of_123 (l_pobj) seizures_32\NNS\14081375|NONE_0
D007052_D012640 NONE ibuprofen_8\NNP\3828465|1_16|,_6|and_4 (r_conj) mg/kg_5\NN\0|,_7|,_20|mg/kg_29|,_34 (r_conj) indomethacin_0\NNP\3828465|modulate_65|._106 (r_nsubj) failed_15\VBD\0|NONE_0 (l_xcomp) modulate_17\VB\1724459|indomethacin_65|._41 (l_dobj) seizures_18\NNS\14081375|to_12
D008528_D001930 NONE acid_1\NN\14818238|seizures_34|._129 (r_nsubj) prevented_11\VBN\0|NONE_0 (l_dobj) seizures_12\NNS\14081375|acid_34|._95 (l_prep) from_16\IN\0|and_19|rats_5|,_56|mg/kg_62 (l_pobj) damage_21\NN\7296428|NONE_0
D010653_D012640 CID phenylbutazone_22\NN\2721538|sodium_19|,_2 (r_appos) salicylate_20\NN\3828465|5_48|steroidal_42|inflammatory_27|,_9|,_70 (r_conj) drugs_17\NNS\14778436|NONE_0 (r_pobj) of_9\IN\0|the_11|on_123 (r_prep) effect_8\NN\34213|to_19 (l_prep) on_31\IN\0|the_134|of_123 (l_pobj) seizures_32\NNS\14081375|NONE_0
7147232
D009599_D007022 CID nitroprusside_10\NN\0|NONE_0 (l_nsubj) effects_1\NNS\13245626|on_82|._112 (l_prep) of_2\IN\0|cardiovascular_23|induced_15 (l_pobj) hypotension_3\NN\14057371|NONE_0
D009599_D007022 CID nitroprusside_7\NN\0|are_20|to_37|induce_52|._100 (r_nsubjpass) administered_12\VBN\2436349|NONE_0 (l_advcl) induce_16\VB\1627355|nitroprusside_52|are_32|to_15|._48 (l_conj) control_18\VB\5190804|to_14|and_4 (l_dobj) hypotension_19\NN\14057371|NONE_0
D009599_D007022 CID snp_9\NNP\11493266|triphosphate_45 (r_appos) nitroprusside_7\NN\0|are_20|to_37|induce_52|._100 (r_nsubjpass) administered_12\VBN\2436349|NONE_0 (l_advcl) induce_16\VB\1627355|nitroprusside_52|are_32|to_15|._48 (l_conj) control_18\VB\5190804|to_14|and_4 (l_dobj) hypotension_19\NN\14057371|NONE_0
D009599_D007022 CID snp_4\NNP\11493266|similar_4 (r_nmod) decreases_6\NNS\7296428|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) produced_2\VBN\1617192|NONE_0 (r_acl) hypotension_1\NN\14057371|NONE_0
D010100_D007022 NONE oxygen_66\NN\14622893|body_5|(_19|0.05_32|)_36|,_37|and_39|rate_49 (r_compound) consumption_67\NN\13440063|total_110|peripheral_104|(_82|0.001_69|)_64|,_63|product_47|,_20 (r_conj) resistance_46\NN\37396|accompanied_217|,_125|pressure_108|pressure_47|,_19 (r_dobj) left_31\VBD\8621598|;_237|variables_249|normal_268|within_275|stopped_303|._310 (l_ccomp) accompanied_5\VBN\0|,_92|pressure_109|pressure_170|,_198|resistance_217 (l_nsubjpass) hypotension_0\NN\14057371|was_27|by_43
D010100_D007022 NONE oxygen_65\NN\14622893|content_7|between_26|0.05_79|)_83 (r_compound) difference_67\NN\4723816|pressure_57|(_40|0.001_27|)_22|,_21|and_19 (r_conj) product_56\NN\3076708|total_63|peripheral_57|(_35|0.001_22|)_17|,_16|,_117|increased_199 (r_conj) resistance_46\NN\37396|during_245|were_192|in_178|p_36|,_19|._254 (r_appos) observed_8\VBN\2163746|NONE_0 (l_prep) during_0\IN\0|were_53|in_67|p_209|,_226|resistance_245|._499 (l_pobj) hypotension_1\NN\14057371|NONE_0
D000255_D007022 CID triphosphate_7\NN\0|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) induced_4\VBN\1627355|cardiovascular_38|of_15 (r_acl) effects_1\NNS\13245626|on_82|._112 (l_prep) of_2\IN\0|cardiovascular_23|induced_15 (l_pobj) hypotension_3\NN\14057371|NONE_0
D000255_D007022 CID triphosphate_1\NN\0|snp_45 (r_nsubj) nitroprusside_7\NN\0|are_20|to_37|induce_52|._100 (r_nsubjpass) administered_12\VBN\2436349|NONE_0 (l_advcl) induce_16\VB\1627355|nitroprusside_52|are_32|to_15|._48 (l_conj) control_18\VB\5190804|to_14|and_4 (l_dobj) hypotension_19\NN\14057371|NONE_0
D000255_D007022 CID atp_3\NNP\14964590|adenosine_24|(_1|)_3|and_5|sodium_9 (r_appos) triphosphate_1\NN\0|snp_45 (r_nsubj) nitroprusside_7\NN\0|are_20|to_37|induce_52|._100 (r_nsubjpass) administered_12\VBN\2436349|NONE_0 (l_advcl) induce_16\VB\1627355|nitroprusside_52|are_32|to_15|._48 (l_conj) control_18\VB\5190804|to_14|and_4 (l_dobj) hypotension_19\NN\14057371|NONE_0
D000255_D007022 CID atp_3\NNP\14964590|NONE_0 (r_pobj) by_2\IN\0|NONE_0 (r_agent) induced_1\VBN\1627355|NONE_0 (r_acl) hypotension_0\NN\14057371|was_27|by_43
D000255_D007022 CID atp_94\NNP\14964590|after_6|was_4 (r_nsubjpass) stopped_96\VBN\0|left_303|;_66|variables_54|normal_35|within_28|._7 (r_advcl) returned_88\VBD\1835496|NONE_0 (l_ccomp) left_31\VBD\8621598|;_237|variables_249|normal_268|within_275|stopped_303|._310 (l_ccomp) accompanied_5\VBN\0|,_92|pressure_109|pressure_170|,_198|resistance_217 (l_nsubjpass) hypotension_0\NN\14057371|was_27|by_43
24665854
D014635_D022124 CID valproate_0\NNP\0|-_9|encephalopathy_33|._79 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) encephalopathy_4\NN\14084880|valproate_33|-_24|._46 (l_det) hyperammonemic_3\JJ\0|in_30
D014635_D022124 CID valproate_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|hyperammonemic_8 (r_amod) encephalopathy_4\NN\14084880|effect_42|._71 (l_det) hyperammonemic_3\JJ\0|induced_8
D014635_D022124 CID valproate_12\NN\0|NONE_0 (r_amod) treatment_13\NN\654885|NONE_0 (r_pobj) of_11\IN\0|an_31|uncommon_28 (r_prep) effect_10\NN\34213|encephalopathy_42|._29 (r_attr) is_5\VBZ\0|NONE_0 (l_nsubj) encephalopathy_4\NN\14084880|effect_42|._71 (l_det) hyperammonemic_3\JJ\0|induced_8
D014635_D022124 CID valproate_21\NN\0|the_67|of_58 (l_conj) revealed_26\VBN\2137132|due_20|and_4 (l_dobj) consciousness_28\NN\5669934|after_42 (l_prep) with_29\IN\0|impaired_23 (l_pobj) hyperammonemia_30\NN\0|NONE_0
D014635_D003244 CID valproate_21\NN\0|the_67|of_58 (l_conj) revealed_26\VBN\2137132|due_20|and_4 (l_dobj) consciousness_28\NN\5669934|after_42
D014635_D001927 NONE valproate_0\NNP\0|-_9|encephalopathy_33|._79 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) encephalopathy_4\NN\14084880|valproate_33|-_24|._46
D014635_D001927 NONE valproate_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|hyperammonemic_8 (r_amod) encephalopathy_4\NN\14084880|effect_42|._71
D014635_D001927 NONE valproate_12\NN\0|NONE_0 (r_amod) treatment_13\NN\654885|NONE_0 (r_pobj) of_11\IN\0|an_31|uncommon_28 (r_prep) effect_10\NN\34213|encephalopathy_42|._29 (r_attr) is_5\VBZ\0|NONE_0 (l_nsubj) encephalopathy_4\NN\14084880|effect_42|._71
D014635_D004827 NONE valproate_21\NN\0|the_67|of_58 (l_prep) due_22\JJ\5174653|and_16|revealed_20 (l_prep) to_23\IN\0|NONE_0 (l_pobj) epilepsy_24\NN\14085708|NONE_0
8603459
D004317_D066126 CID doxorubicin_0\NNP\2716866|-_11 (r_npadvmod) induced_2\VBN\1627355|monitored_23|._61 (r_amod) cardiotoxicity_3\NN\0|NONE_0
D004317_D066126 CID doxorubicin_11\RB\2716866|-_11 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_14\NN\0|to_29
D004317_D066126 CID doxorubicin_13\NN\2716866|-_11 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_16\NN\0|NONE_0
D064730_D064420 NONE icrf-187_16\NNP\0|NONE_0 (r_pobj) of_15\IN\0|the_15 (r_prep) protection_14\NN\407535|exerted_72|,_6|was_23|using_38|)_165|._166 (r_nsubjpass) determined_18\VBN\0|NONE_0 (l_advcl) exerted_3\VBD\1158872|,_66|protection_72|was_95|using_110|)_237|._238 (l_dobj) toxicity_5\NN\13576101|as_30|schedule_22
D064730_D064420 NONE icrf-187_16\NNP\0|NONE_0 (r_pobj) of_15\IN\0|the_15 (r_prep) protection_14\NN\407535|exerted_72|,_6|was_23|using_38|)_165|._166 (r_nsubjpass) determined_18\VBN\0|NONE_0 (l_xcomp) using_19\VBG\418025|exerted_110|,_44|protection_38|was_15|)_127|._128 (l_dobj) schedule_22\NN\5898568|NONE_0 (l_prep) with_23\IN\0|a_16|dose_14 (l_pobj) toxicity_26\NN\13576101|NONE_0
D004317_D064420 NONE doxorubicin_34\NN\2716866|lower_50|general_44|(_27|doses_17 (r_punct) toxicity_26\NN\13576101|NONE_0 (r_pobj) with_23\IN\0|a_16|dose_14 (r_prep) schedule_22\NN\5898568|NONE_0 (r_dobj) using_19\VBG\418025|exerted_110|,_44|protection_38|was_15|)_127|._128 (r_xcomp) determined_18\VBN\0|NONE_0 (l_advcl) exerted_3\VBD\1158872|,_66|protection_72|was_95|using_110|)_237|._238 (l_dobj) toxicity_5\NN\13576101|as_30|schedule_22
D004317_D064420 NONE doxorubicin_34\NN\2716866|lower_50|general_44|(_27|doses_17 (r_punct) toxicity_26\NN\13576101|NONE_0
D064730_D066126 NONE icrf-187_24\NNP\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) provided_22\VBN\2199590|the_15 (r_acl) protection_21\NN\407535|NONE_0 (r_pobj) by_19\IN\0|testing_81|as_16 (r_agent) demonstrated_18\VBN\2137132|that_84 (l_nsubj) testing_9\NN\639556|as_65|by_81 (l_prep) of_10\IN\0|the_12 (l_pobj) protectors_11\NNS\10466918|NONE_0 (l_prep) against_12\IN\0|NONE_0 (l_pobj) cardiotoxicity_16\NN\0|NONE_0
D004317_D006984 NONE doxorubicin_5\RB\2716866|-_11 (r_npadvmod) treated_7\VBN\2376958|NONE_0 (r_amod) animals_8\NNS\4475|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) hearts_3\NNS\496167|NONE_0 (r_dobj) sacrifice_1\NN\30358|NONE_0 (r_pcomp) after_0\IN\0|were_58|and_72|were_86 (r_prep) enlarged_10\VBN\153263|NONE_0 (l_conj) were_14\VBD\0|after_86|were_28|and_14 (l_acomp) hypertrophic_15\JJ\0|atria_11|._12
21195121
D005680_D012640 NONE gaba(a_8\NNP\0|)_6 (r_nmod) receptors_10\NNS\5225602|NONE_0 (r_pobj) of_7\IN\0|the_13 (r_prep) blockage_6\NN\14034177|convulsions_30|mainly_18 (r_dobj) trough_4\VB\9366017|it_29|._40 (l_nsubj) convulsions_2\NNS\14081375|mainly_12|blockage_30
D009569_D004827 NONE oxide_1\NN\14818238|role_55|in_60|due_79|,_149|and_151|observed_178 (r_nsubj) has_9\VBZ\13888491|NONE_0 (l_conj) observed_39\VBN\2163746|oxide_178|role_123|in_118|due_99|,_29|and_27 (l_prep) in_40\IN\13603305|name_30|._28 (l_pobj) models_43\NNS\5888929|NONE_0 (l_compound) epilepsy_42\NN\14085708|different_10
D009569_D004827 NONE no_3\NNP\7204911|nitric_14|(_1|)_2|,_3|neurotransmitter_13|,_29 (r_intj) oxide_1\NN\14818238|role_55|in_60|due_79|,_149|and_151|observed_178 (r_nsubj) has_9\VBZ\13888491|NONE_0 (l_conj) observed_39\VBN\2163746|oxide_178|role_123|in_118|due_99|,_29|and_27 (l_prep) in_40\IN\13603305|name_30|._28 (l_pobj) models_43\NNS\5888929|NONE_0 (l_compound) epilepsy_42\NN\14085708|different_10
D009569_D004827 NONE no_25\DT\7204911|nos_14 (r_det) syntheses_26\NNS\13446390|NONE_0 (r_pobj) of_24\IN\0|arginine_20 (r_prep) precursor_23\NN\14580897|NONE_0 (r_pobj) of_18\IN\0|opposite_17 (r_prep) effects_17\NNS\13245626|to_12 (r_pobj) due_14\IN\5174653|oxide_79|role_24|in_19|,_70|and_72|observed_99 (r_prep) has_9\VBZ\13888491|NONE_0 (l_conj) observed_39\VBN\2163746|oxide_178|role_123|in_118|due_99|,_29|and_27 (l_prep) in_40\IN\13603305|name_30|._28 (l_pobj) models_43\NNS\5888929|NONE_0 (l_compound) epilepsy_42\NN\14085708|different_10
D009569_D004827 NONE no_12\DT\7204911|NONE_0 (r_pobj) of_11\IN\0|the_12|on_6 (r_prep) effects_10\NNS\13245626|to_17 (l_prep) on_13\IN\0|the_18|of_6 (l_pobj) characteristics_18\NNS\5849040|NONE_0 (l_prep) of_19\IN\0|the_39|behavioral_35|in_28 (l_pobj) epilepsy_23\NN\14085708|NONE_0
D001556_D004827 NONE lindane_20\NN\14919948|-_7 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) epilepsy_23\NN\14085708|NONE_0
D009569_D012640 NONE oxide_4\NN\14818238|NONE_0 (r_pobj) of_2\IN\0|the_9|in_16|induced_31|._57 (r_prep) role_1\NN\719494|NONE_0 (l_prep) in_5\IN\13603305|the_25|of_16|induced_15|._41 (l_pobj) convulsions_6\NNS\14081375|NONE_0
D009569_D012640 NONE no_6\DT\7204911|that_5|role_11 (r_nsubj) plays_7\VBZ\7007684|the_23 (l_dobj) role_9\NN\719494|that_16|no_11 (l_prep) in_13\IN\13603305|a_32|of_25 (l_pobj) model_15\NN\5888929|NONE_0 (l_prep) of_16\IN\0|rat_10 (l_pobj) seizures_18\NNS\14081375|NONE_0
D019331_D012640 NONE name_8\NNP\6284225|NONE_0 (r_pobj) with_5\IN\0|mg/kg_30 (r_prep) pretreatment_4\NN\0|on_17|,_2|incidence_77|following_141|._210 (r_nsubj) decreased_19\VBD\169651|NONE_0 (l_npadvmod) incidence_21\NN\13821570|on_94|,_79|pretreatment_77|following_64|._133 (l_compound) convulsion_20\NN\14081375|and_21|severity_25|and_34|time_56
D019331_D012640 NONE name_8\NNP\6284225|NONE_0 (r_pobj) with_5\IN\0|mg/kg_30 (r_prep) pretreatment_4\NN\0|on_17|,_2|incidence_77|following_141|._210 (r_nsubj) decreased_19\VBD\169651|NONE_0 (l_npadvmod) incidence_21\NN\13821570|on_94|,_79|pretreatment_77|following_64|._133 (l_conj) time_27\NN\7308889|convulsion_56|and_35|severity_31|and_22 (l_prep) to_28\IN\0|prolonged_23|latency_13 (l_pobj) convulsion_29\NN\14081375|NONE_0
D019331_D012640 NONE name_8\NNP\6284225|NONE_0 (r_pobj) with_5\IN\0|mg/kg_30 (r_prep) pretreatment_4\NN\0|on_17|,_2|incidence_77|following_141|._210 (r_nsubj) decreased_19\VBD\169651|NONE_0 (l_prep) following_30\VBG\8180190|on_158|,_143|pretreatment_141|incidence_64|._69 (l_pobj) injection_31\NN\320852|NONE_0 (l_prep) with_32\IN\0|NONE_0 (l_pobj) dose_35\NN\3740161|NONE_0 (l_amod) convulsive_34\JJ\0|a_2|of_16|(_27|mg/kg_30|)_41
D001120_D012640 NONE arginine_5\NN\14605787|NONE_0 (r_pobj) of_2\IN\0|the_19|mg/kg_33|,_38|i.p._40|)_44|in_46 (r_prep) administration_1\NN\1133281|significantly_86|incidence_121|and_144|shortened_148|._237 (r_nsubj) increased_22\VBD\169651|NONE_0 (l_dobj) incidence_24\NN\13821570|administration_121|significantly_35|and_23|shortened_27|._116 (l_compound) convulsion_23\NN\14081375|and_21|severity_25
D001120_D012640 NONE arginine_5\NN\14605787|NONE_0 (r_pobj) of_2\IN\0|the_19|mg/kg_33|,_38|i.p._40|)_44|in_46 (r_prep) administration_1\NN\1133281|significantly_86|incidence_121|and_144|shortened_148|._237 (r_nsubj) increased_22\VBD\169651|NONE_0 (l_conj) shortened_28\VBN\429060|administration_148|significantly_62|incidence_27|and_4|._89 (l_prep) to_31\IN\0|time_5 (l_pobj) convulsion_33\NN\14081375|NONE_0
D001556_D012640 CID lindane_9\NN\14919948|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|the_40|of_31|in_15|._26 (r_acl) role_1\NN\719494|NONE_0 (l_prep) in_5\IN\13603305|the_25|of_16|induced_15|._41 (l_pobj) convulsions_6\NNS\14081375|NONE_0
D001556_D012640 CID lindane_37\NN\14919948|lower_6|mg/kg_16 (r_compound) dose_38\NN\3740161|NONE_0 (r_pobj) by_35\IN\0|NONE_0 (r_agent) elicited_34\VBN\1617192|first_17 (r_acl) convulsion_33\NN\14081375|NONE_0 (r_pobj) to_31\IN\0|time_5 (r_prep) shortened_28\VBN\429060|administration_148|significantly_62|incidence_27|and_4|._89 (r_conj) increased_22\VBD\169651|NONE_0 (l_dobj) incidence_24\NN\13821570|administration_121|significantly_35|and_23|shortened_27|._116 (l_compound) convulsion_23\NN\14081375|and_21|severity_25
D001556_D012640 CID lindane_37\NN\14919948|lower_6|mg/kg_16 (r_compound) dose_38\NN\3740161|NONE_0 (r_pobj) by_35\IN\0|NONE_0 (r_agent) elicited_34\VBN\1617192|first_17 (r_acl) convulsion_33\NN\14081375|NONE_0
D001556_D012640 CID lindane_37\NN\14919948|NONE_0 (r_pobj) of_36\IN\0|a_18|convulsive_16|(_11|mg/kg_14|)_25 (r_prep) dose_35\NN\3740161|NONE_0 (r_pobj) with_32\IN\0|NONE_0 (r_prep) injection_31\NN\320852|NONE_0 (r_pobj) following_30\VBG\8180190|on_158|,_143|pretreatment_141|incidence_64|._69 (r_prep) decreased_19\VBD\169651|NONE_0 (l_npadvmod) incidence_21\NN\13821570|on_94|,_79|pretreatment_77|following_64|._133 (l_compound) convulsion_20\NN\14081375|and_21|severity_25|and_34|time_56
D001556_D012640 CID lindane_37\NN\14919948|NONE_0 (r_pobj) of_36\IN\0|a_18|convulsive_16|(_11|mg/kg_14|)_25 (r_prep) dose_35\NN\3740161|NONE_0 (r_pobj) with_32\IN\0|NONE_0 (r_prep) injection_31\NN\320852|NONE_0 (r_pobj) following_30\VBG\8180190|on_158|,_143|pretreatment_141|incidence_64|._69 (r_prep) decreased_19\VBD\169651|NONE_0 (l_npadvmod) incidence_21\NN\13821570|on_94|,_79|pretreatment_77|following_64|._133 (l_conj) time_27\NN\7308889|convulsion_56|and_35|severity_31|and_22 (l_prep) to_28\IN\0|prolonged_23|latency_13 (l_pobj) convulsion_29\NN\14081375|NONE_0
D001556_D012640 CID lindane_37\NN\14919948|NONE_0 (r_pobj) of_36\IN\0|a_18|convulsive_16|(_11|mg/kg_14|)_25 (r_prep) dose_35\NN\3740161|NONE_0 (l_amod) convulsive_34\JJ\0|a_2|of_16|(_27|mg/kg_30|)_41
D001556_D012640 CID lindane_17\NN\14919948|NONE_0 (r_compound) seizures_18\NNS\14081375|NONE_0
D019331_D004827 NONE name_34\NNP\6284225|in_30|._58 (r_nsubj) observed_39\VBN\2163746|oxide_178|role_123|in_118|due_99|,_29|and_27 (l_prep) in_40\IN\13603305|name_30|._28 (l_pobj) models_43\NNS\5888929|NONE_0 (l_compound) epilepsy_42\NN\14085708|different_10
D001120_D004827 NONE arginine_21\NN\14605787|of_20 (r_nmod) precursor_23\NN\14580897|NONE_0 (r_pobj) of_18\IN\0|opposite_17 (r_prep) effects_17\NNS\13245626|to_12 (r_pobj) due_14\IN\5174653|oxide_79|role_24|in_19|,_70|and_72|observed_99 (r_prep) has_9\VBZ\13888491|NONE_0 (l_conj) observed_39\VBN\2163746|oxide_178|role_123|in_118|due_99|,_29|and_27 (l_prep) in_40\IN\13603305|name_30|._28 (l_pobj) models_43\NNS\5888929|NONE_0 (l_compound) epilepsy_42\NN\14085708|different_10
3864191
D012459_D007674 NONE salicylate_0\NNP\3828465|in_23|:_38|role_50|._72 (r_compound) nephropathy_1\NN\14573196|NONE_0
D011453_D007674 NONE prostaglandins_10\NNS\5414534|NONE_0 (r_pobj) of_9\IN\0|potential_15 (r_prep) role_8\NN\719494|salicylate_50|in_27|:_12|._22 (r_appos) nephropathy_1\NN\14573196|NONE_0
D011453_D007674 NONE prostaglandins_6\NNS\5414534|NONE_0 (r_pobj) of_5\IN\0|the_19|potential_15|in_18 (r_prep) role_4\NN\719494|we_26|._92 (l_prep) in_7\IN\13603305|the_37|potential_33|of_18 (l_pobj) development_9\NN\248977|NONE_0 (l_prep) of_10\IN\0|the_16|in_25 (l_pobj) nephropathy_12\NN\14573196|NONE_0
D011453_D007674 NONE prostaglandin_4\NN\5414534|renal_6 (r_amod) synthesis_5\NN\13446390|NONE_0 (r_pobj) in_2\IN\13603305|the_12 (r_prep) changes_1\NNS\7283608|were_41|by_58|._386 (r_nsubjpass) accompanied_7\VBN\0|NONE_0 (l_agent) by_8\IN\0|changes_58|were_17|._328 (l_pobj) evidence_9\NN\5816287|NONE_0 (l_prep) of_10\IN\0|but_38|rats_49 (l_pobj) damage_12\NN\7296428|NONE_0
D011453_D007674 NONE prostaglandin_5\NN\5414534|enhanced_9 (r_amod) synthesis_6\NN\13446390|that_28|to_22|,_82|and_84|lead_135 (r_nsubj) contributes_7\VBZ\126264|results_54|._205 (l_conj) lead_24\VB\5155821|that_163|synthesis_135|to_113|,_53|and_51 (l_prep) to_25\IN\0|that_52|inhibition_47|may_9 (l_pobj) lesions_29\NNS\14204950|NONE_0 (l_conj) deterioration_31\NN\14560612|pathological_41|renal_28|medullary_22|and_4 (l_prep) of_32\IN\0|NONE_0 (l_pobj) function_34\NN\13783581|NONE_0
D011453_D007674 NONE prostaglandin_21\JJ\5414534|NONE_0 (r_amod) synthesis_22\NN\13446390|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) inhibition_19\NN\1068773|that_5|may_38|to_47 (r_nsubj) lead_24\VB\5155821|that_163|synthesis_135|to_113|,_53|and_51 (l_prep) to_25\IN\0|that_52|inhibition_47|may_9 (l_pobj) lesions_29\NNS\14204950|NONE_0 (l_conj) deterioration_31\NN\14560612|pathological_41|renal_28|medullary_22|and_4 (l_prep) of_32\IN\0|NONE_0 (l_pobj) function_34\NN\13783581|NONE_0
D011453_D006417 NONE prostaglandin_4\NN\5414534|renal_6 (r_amod) synthesis_5\NN\13446390|NONE_0 (r_pobj) in_2\IN\13603305|the_12 (r_prep) changes_1\NNS\7283608|were_41|by_58|._386 (r_nsubjpass) accompanied_7\VBN\0|NONE_0 (l_agent) by_8\IN\0|changes_58|were_17|._328 (l_pobj) evidence_9\NN\5816287|NONE_0 (l_conj) rats_21\NNS\2329401|of_49|but_11 (l_conj) incidence_27\NN\13821570|jj_35|evidenced_24|:_12|;_54|creatinine_72 (l_prep) of_30\IN\0|increased_33|and_13|severity_9|p_14 (l_pobj) hematuria_31\NN\14299637|NONE_0
D003404_D007674 NONE creatinine_41\NN\0|jj_107|evidenced_96|:_84|incidence_72|;_18 (r_conj) rats_21\NNS\2329401|of_49|but_11 (r_conj) evidence_9\NN\5816287|NONE_0 (l_prep) of_10\IN\0|but_38|rats_49 (l_pobj) damage_12\NN\7296428|NONE_0
D001241_D006417 NONE aspirin_14\NN\2707683|-_7 (r_npadvmod) treated_16\VBN\2376958|NONE_0 (r_amod) jj_17\UH\0|NONE_0 (r_pobj) in_13\IN\13603305|renal_13 (r_prep) damage_12\NN\7296428|NONE_0 (r_pobj) of_10\IN\0|but_38|rats_49 (r_prep) evidence_9\NN\5816287|NONE_0 (l_conj) rats_21\NNS\2329401|of_49|but_11 (l_conj) incidence_27\NN\13821570|jj_35|evidenced_24|:_12|;_54|creatinine_72 (l_prep) of_30\IN\0|increased_33|and_13|severity_9|p_14 (l_pobj) hematuria_31\NN\14299637|NONE_0
D001241_D006417 NONE aspirin_69\NN\2707683|-_7 (r_npadvmod) treated_71\VBN\2376958|NONE_0 (r_amod) jj_72\NNP\0|either_42|treated_30|or_19 (r_conj) jj_67\NNS\0|NONE_0 (r_pobj) to_62\IN\0|NONE_0 (r_prep) compared_61\VBN\644583|0.005_6|)_56 (r_prep) p_57\XX\14622893|in_44|(_1 (r_appos) increase_50\VB\13576355|increased_51|serum_41|(_24|0.05_11|)_7|;_6|and_4 (r_conj) creatinine_41\NN\0|jj_107|evidenced_96|:_84|incidence_72|;_18 (r_conj) rats_21\NNS\2329401|of_49|but_11 (l_conj) incidence_27\NN\13821570|jj_35|evidenced_24|:_12|;_54|creatinine_72 (l_prep) of_30\IN\0|increased_33|and_13|severity_9|p_14 (l_pobj) hematuria_31\NN\14299637|NONE_0
D001663_D006932 NONE bilirubin_18\NN\14756039|marked_7|in_21 (r_amod) deposition_19\NN\13424865|NONE_0 (r_pobj) to_16\IN\0|NONE_0 (r_prep) leading_15\VBG\4339291|rats_88|hyperbilirubinemia_65|,_2|._67 (r_advcl) have_4\VBP\7846|NONE_0 (l_dobj) hyperbilirubinemia_6\NN\14204950|rats_23|,_63|leading_65|._132
-1_D006932 NONE glucuronyl_12\NN\0|NONE_0 (r_compound) transferase_13\NN\14732946|NONE_0 (r_pobj) of_11\IN\0|the_12 (r_prep) absence_10\NN\14449405|to_7 (r_pobj) due_7\IN\5174653|unconjugated_32 (r_amod) hyperbilirubinemia_6\NN\14204950|rats_23|,_63|leading_65|._132
D001241_D007674 CID aspirin_14\NN\2707683|-_7 (r_npadvmod) treated_16\VBN\2376958|NONE_0 (r_amod) jj_17\UH\0|NONE_0 (r_pobj) in_13\IN\13603305|renal_13 (r_prep) damage_12\NN\7296428|NONE_0
D001241_D007674 CID aspirin_69\NN\2707683|-_7 (r_npadvmod) treated_71\VBN\2376958|NONE_0 (r_amod) jj_72\NNP\0|either_42|treated_30|or_19 (r_conj) jj_67\NNS\0|NONE_0 (r_pobj) to_62\IN\0|NONE_0 (r_prep) compared_61\VBN\644583|0.005_6|)_56 (r_prep) p_57\XX\14622893|in_44|(_1 (r_appos) increase_50\VB\13576355|increased_51|serum_41|(_24|0.05_11|)_7|;_6|and_4 (r_conj) creatinine_41\NN\0|jj_107|evidenced_96|:_84|incidence_72|;_18 (r_conj) rats_21\NNS\2329401|of_49|but_11 (r_conj) evidence_9\NN\5816287|NONE_0 (l_prep) of_10\IN\0|but_38|rats_49 (l_pobj) damage_12\NN\7296428|NONE_0
D003404_D006417 NONE creatinine_41\NN\0|jj_107|evidenced_96|:_84|incidence_72|;_18 (r_conj) rats_21\NNS\2329401|of_49|but_11 (l_conj) incidence_27\NN\13821570|jj_35|evidenced_24|:_12|;_54|creatinine_72 (l_prep) of_30\IN\0|increased_33|and_13|severity_9|p_14 (l_pobj) hematuria_31\NN\14299637|NONE_0
D011453_D058186 NONE prostaglandin_5\NN\5414534|enhanced_9 (r_amod) synthesis_6\NN\13446390|that_28|to_22|,_82|and_84|lead_135 (r_nsubj) contributes_7\VBZ\126264|results_54|._205 (l_conj) lead_24\VB\5155821|that_163|synthesis_135|to_113|,_53|and_51 (l_prep) to_25\IN\0|that_52|inhibition_47|may_9 (l_pobj) lesions_29\NNS\14204950|NONE_0
D011453_D058186 NONE prostaglandin_21\JJ\5414534|NONE_0 (r_amod) synthesis_22\NN\13446390|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) inhibition_19\NN\1068773|that_5|may_38|to_47 (r_nsubj) lead_24\VB\5155821|that_163|synthesis_135|to_113|,_53|and_51 (l_prep) to_25\IN\0|that_52|inhibition_47|may_9 (l_pobj) lesions_29\NNS\14204950|NONE_0
15815446
C009591_D001930 NONE chloride_18\NN\14818238|NONE_0 (r_dobj) using_16\VBG\418025|tissue_7 (r_advcl) staining_14\VBG\275424|NONE_0 (r_pcomp) by_13\IN\0|a_59|,_58|for_56|was_14 (r_prep) evaluated_12\VBN\670261|was_81|by_95|._113 (l_prep) for_3\IN\0|a_3|,_2|was_42|by_56 (l_pobj) rats_5\NNS\2329401|NONE_0 (l_prep) in_6\IN\13603305|eight_11 (l_pobj) injury_10\NN\14052046|NONE_0
D010656_D001930 NONE phenylephrine_17\NN\2682038|-_13 (r_npadvmod) induced_19\VBN\1627355|on_21 (r_amod) hypertension_20\NN\14057371|NONE_0 (l_prep) on_21\IN\0|induced_21 (l_pobj) injury_24\NN\14052046|NONE_0
D010656_D006973 CID phenylephrine_8\NN\2682038|-_13 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hypertension_11\NN\14057371|NONE_0
D010656_D006973 CID phenylephrine_17\NN\2682038|-_13 (r_npadvmod) induced_19\VBN\1627355|on_21 (r_amod) hypertension_20\NN\14057371|NONE_0 (r_pobj) of_16\IN\0|the_11 (r_prep) effect_15\NN\34213|after_100|,_6 (r_nsubj) was_31\VBD\0|._14 (l_prep) after_0\IN\0|,_94|effect_100 (l_pobj) min_2\NN\15154774|NONE_0 (l_prep) of_3\IN\0|180_8 (l_pobj) occlusion_8\NN\14081375|NONE_0 (l_prep) in_9\IN\13603305|temporary_43|middle_33|cerebral_26|artery_17 (l_pobj) rats_12\NNS\2329401|NONE_0 (l_amod) hypertensive_11\JJ\10405694|NONE_0
D010656_D006973 CID phenylephrine_17\NN\2682038|-_13 (r_npadvmod) induced_19\VBN\1627355|on_21 (r_amod) hypertension_20\NN\14057371|NONE_0
D005070_D006973 NONE blue_1\NNP\4959672|greater_35|._180 (r_nsubj) was_9\VBD\0|NONE_0 (l_acomp) greater_10\JJR\0|blue_35|._145 (l_prep) in_11\IN\13603305|NONE_0 (l_pobj) group_14\NN\2137|NONE_0 (l_nummod) 90/htn_13\CD\0|the_4|(_13|6.0_23|)_26|versus_28|(_53|+/-_59|)_66|,_67|was_75
D005070_D006973 NONE blue_1\NNP\4959672|greater_35|._180 (r_nsubj) was_9\VBD\0|NONE_0 (l_acomp) greater_10\JJR\0|blue_35|._145 (l_prep) in_11\IN\13603305|NONE_0 (l_pobj) group_14\NN\2137|NONE_0 (l_relcl) was_31\VBD\0|the_79|90/htn_75|(_62|6.0_52|)_49|versus_47|(_22|+/-_16|)_9|,_8 (l_acomp) greater_34\JJR\0|which_18|in_8 (l_prep) than_35\IN\0|NONE_0 (l_pobj) group_38\NN\2137|NONE_0 (l_compound) 15/htn_37\CD\0|the_4|(_13|+/-_18|)_25
D010656_D002545 NONE phenylephrine_8\NN\2682038|-_13 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hypertension_11\NN\14057371|NONE_0 (r_pobj) of_7\IN\0|during_38 (r_prep) effect_6\NN\34213|focal_33|cerebral_27|in_9|:_2|._63 (r_appos) ischemia_2\NN\14195315|NONE_0
D010656_D020244 NONE phenylephrine_17\NN\2682038|-_13 (r_npadvmod) induced_19\VBN\1627355|on_21 (r_amod) hypertension_20\NN\14057371|NONE_0 (r_pobj) of_16\IN\0|the_11 (r_prep) effect_15\NN\34213|after_100|,_6 (r_nsubj) was_31\VBD\0|._14 (l_prep) after_0\IN\0|,_94|effect_100 (l_pobj) min_2\NN\15154774|NONE_0 (l_prep) of_3\IN\0|180_8 (l_pobj) occlusion_8\NN\14081375|NONE_0
C009591_D004487 NONE chloride_18\NN\14818238|NONE_0 (l_conj) edema_20\NN\14315192|2,3,5-triphenyltetrazolium_40|and_4
15276093
C451780_D050171 NONE lovastatin_5\NN\3676175|NONE_0 (r_appos) niacin_0\NNP\15090742|product_56|._141 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) product_10\NN\3076708|niacin_56|._85 (l_acl) approved_11\VBN\803325|a_26|new_24|combination_20 (l_prep) for_12\IN\0|NONE_0 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|NONE_0 (l_pobj) hypercholesterolemia_16\NN\14299637|NONE_0 (l_conj) dyslipidemia_19\NN\0|primary_39|and_10
C451780_D050171 NONE lovastatin_30\NN\3676175|and_28|niacin_24 (r_conj) dyslipidemia_23\NN\0|NONE_0
C451780_D006937 NONE lovastatin_5\NN\3676175|NONE_0 (r_appos) niacin_0\NNP\15090742|product_56|._141 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) product_10\NN\3076708|niacin_56|._85 (l_acl) approved_11\VBN\803325|a_26|new_24|combination_20 (l_prep) for_12\IN\0|NONE_0 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|NONE_0 (l_pobj) hypercholesterolemia_16\NN\14299637|NONE_0
D003401_D009135 NONE creatine_3\NN\14601829|NONE_0 (r_compound) phosphokinase_4\NN\0|NONE_0 (r_pobj) of_2\IN\0|an_12|to_26 (r_prep) increase_1\NN\13576355|limit_57|in_82|,_102|and_104|observed_147 (r_nsubj) occurred_14\VBD\0|NONE_0 (l_conj) observed_30\VBN\2163746|increase_147|limit_90|in_65|,_45|and_43 (l_nsubjpass) cases_23\NNS\7283608|were_31|._44 (l_prep) of_24\IN\0|no_9 (l_pobj) myopathy_28\NNS\14204950|NONE_0
7479194
D014295_D064420 NONE trimethoprim_14\NN\0|trimethoprim_31|-_19|,_2 (r_conj) sulfamethoxazole_12\NN\4352070|NONE_0 (r_pobj) of_9\IN\0|a_41|large_39|based_22|up_9|for_63|._97 (r_prep) study_8\NN\635850|NONE_0 (l_prep) for_18\IN\0|a_104|large_102|based_85|up_72|of_63|._34 (l_pobj) toxicity_22\NN\13576101|NONE_0
D002506_D007674 NONE cephalexin_34\NN\2996840|,_64|266,951_62|trimethoprim_43|,_25|and_23 (r_conj) prescribed_27\VBD\748282|we_142|study_93|estimate_69|._206 (r_conj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D008107 CID smz_15\NNP\0|(_4|)_16 (r_nmod) 5.2/100,000_17\CD\0|NONE_0 (r_dobj) prescribed_12\VBN\748282|NONE_0 (r_acl) persons_11\NNS\7347|NONE_0 (r_pobj) for_10\IN\0|NONE_0 (r_prep) similar_9\JJ\0|risk_58|and_53|trimethoprim_74 (r_acomp) was_8\VBD\0|NONE_0 (l_nsubj) risk_1\NN\14541044|similar_58|and_111|trimethoprim_132 (l_prep) of_2\IN\0|the_9 (l_pobj) disease_7\NN\14061805|NONE_0
D015662_D008107 NONE sulfamethoxazole_19\NN\4352070|(_17|tmp_18|-_21|)_25 (r_compound) smz_23\NNP\0|who_55|were_51 (r_dobj) prescribed_16\VBN\748282|232,390_24 (r_relcl) people_13\NNS\31264|NONE_0 (r_pobj) of_11\IN\0|a_42|based_29|45-day_23|follow_16 (r_prep) study_10\NN\635850|we_49|prescribed_93|estimate_162|._299 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D008107 NONE smz_23\NNP\0|who_55|were_51 (r_dobj) prescribed_16\VBN\748282|232,390_24 (r_relcl) people_13\NNS\31264|NONE_0 (r_pobj) of_11\IN\0|a_42|based_29|45-day_23|follow_16 (r_prep) study_10\NN\635850|we_49|prescribed_93|estimate_162|._299 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D002506_D012871 NONE cephalexin_34\NN\2996840|,_64|266,951_62|trimethoprim_43|,_25|and_23 (r_conj) prescribed_27\VBD\748282|we_142|study_93|estimate_69|._206 (r_conj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D014295_D012871 NONE trimethoprim_28\NN\0|,_21|266,951_19|,_18|and_20|cephalexin_43 (r_dobj) prescribed_27\VBD\748282|we_142|study_93|estimate_69|._206 (r_conj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D004892 NONE smz_15\NNP\0|NONE_0 (r_pobj) to_12\IN\0|one_24|was_12 (r_prep) exposed_11\VBN\2110927|blood_33|,_18|;_18|of_20 (r_relcl) disorders_5\NNS\14034177|patients_27 (l_prep) of_17\IN\0|blood_53|,_38|exposed_20|;_2 (l_pobj) seven_18\CD\13741022|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) multiforme_21\NNS\0|NONE_0
D015662_D004892 NONE smz_34\NNP\0|NONE_0 (r_pobj) to_31\IN\0|experienced_147|,_20|four_18|were_13|._10 (r_prep) exposed_30\VBN\2110927|NONE_0 (l_ccomp) experienced_3\VBD\2108377|,_127|four_129|were_134|to_147|._157 (l_dobj) disorders_5\NNS\14034177|patients_27 (l_prep) of_17\IN\0|blood_53|,_38|exposed_20|;_2 (l_pobj) seven_18\CD\13741022|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) multiforme_21\NNS\0|NONE_0
D014295_D008107 CID trimethoprim_22\NN\0|risk_132|similar_74|and_21 (r_conj) was_8\VBD\0|NONE_0 (l_nsubj) risk_1\NN\14541044|similar_58|and_111|trimethoprim_132 (l_prep) of_2\IN\0|the_9 (l_pobj) disease_7\NN\14061805|NONE_0
D014295_D008107 NONE trimethoprim_28\NN\0|,_21|266,951_19|,_18|and_20|cephalexin_43 (r_dobj) prescribed_27\VBD\748282|we_142|study_93|estimate_69|._206 (r_conj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D064420 NONE sulfamethoxazole_12\NN\4352070|NONE_0 (r_pobj) of_9\IN\0|a_41|large_39|based_22|up_9|for_63|._97 (r_prep) study_8\NN\635850|NONE_0 (l_prep) for_18\IN\0|a_104|large_102|based_85|up_72|of_63|._34 (l_pobj) toxicity_22\NN\13576101|NONE_0
D014295_D007674 NONE trimethoprim_28\NN\0|,_21|266,951_19|,_18|and_20|cephalexin_43 (r_dobj) prescribed_27\VBD\748282|we_142|study_93|estimate_69|._206 (r_conj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D007674 NONE sulfamethoxazole_19\NN\4352070|(_17|tmp_18|-_21|)_25 (r_compound) smz_23\NNP\0|who_55|were_51 (r_dobj) prescribed_16\VBN\748282|232,390_24 (r_relcl) people_13\NNS\31264|NONE_0 (r_pobj) of_11\IN\0|a_42|based_29|45-day_23|follow_16 (r_prep) study_10\NN\635850|we_49|prescribed_93|estimate_162|._299 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D007674 NONE smz_23\NNP\0|who_55|were_51 (r_dobj) prescribed_16\VBN\748282|232,390_24 (r_relcl) people_13\NNS\31264|NONE_0 (r_pobj) of_11\IN\0|a_42|based_29|45-day_23|follow_16 (r_prep) study_10\NN\635850|we_49|prescribed_93|estimate_162|._299 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D013262 CID smz_15\NNP\0|NONE_0 (r_pobj) to_12\IN\0|one_24|was_12 (r_prep) exposed_11\VBN\2110927|blood_33|,_18|;_18|of_20 (r_relcl) disorders_5\NNS\14034177|patients_27 (l_prep) of_17\IN\0|blood_53|,_38|exposed_20|;_2 (l_pobj) seven_18\CD\13741022|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) multiforme_21\NNS\0|NONE_0 (l_conj) syndrome_26\NN\5870365|erythema_40|and_20
D015662_D013262 CID smz_34\NNP\0|NONE_0 (r_pobj) to_31\IN\0|experienced_147|,_20|four_18|were_13|._10 (r_prep) exposed_30\VBN\2110927|NONE_0 (l_ccomp) experienced_3\VBD\2108377|,_127|four_129|were_134|to_147|._157 (l_dobj) disorders_5\NNS\14034177|patients_27 (l_prep) of_17\IN\0|blood_53|,_38|exposed_20|;_2 (l_pobj) seven_18\CD\13741022|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) multiforme_21\NNS\0|NONE_0 (l_conj) syndrome_26\NN\5870365|erythema_40|and_20
D002506_D008107 NONE cephalexin_34\NN\2996840|,_64|266,951_62|trimethoprim_43|,_25|and_23 (r_conj) prescribed_27\VBD\748282|we_142|study_93|estimate_69|._206 (r_conj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D002506_D006402 NONE cephalexin_34\NN\2996840|,_64|266,951_62|trimethoprim_43|,_25|and_23 (r_conj) prescribed_27\VBD\748282|we_142|study_93|estimate_69|._206 (r_conj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D012871 NONE sulfamethoxazole_19\NN\4352070|(_17|tmp_18|-_21|)_25 (r_compound) smz_23\NNP\0|who_55|were_51 (r_dobj) prescribed_16\VBN\748282|232,390_24 (r_relcl) people_13\NNS\31264|NONE_0 (r_pobj) of_11\IN\0|a_42|based_29|45-day_23|follow_16 (r_prep) study_10\NN\635850|we_49|prescribed_93|estimate_162|._299 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D012871 NONE smz_23\NNP\0|who_55|were_51 (r_dobj) prescribed_16\VBN\748282|232,390_24 (r_relcl) people_13\NNS\31264|NONE_0 (r_pobj) of_11\IN\0|a_42|based_29|45-day_23|follow_16 (r_prep) study_10\NN\635850|we_49|prescribed_93|estimate_162|._299 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D002506_D013262 CID cephalexin_13\NN\2996840|who_9 (r_dobj) took_12\VBD\2367363|a_14 (r_relcl) patient_10\NN\9898892|NONE_0 (r_pobj) in_8\IN\13603305|case_44|._32 (r_prep) occurred_7\VBD\0|NONE_0 (l_nsubj) case_2\NN\7283608|in_44|._76 (l_prep) of_3\IN\0|the_13|one_9 (l_pobj) necrolysis_6\NN\13509528|NONE_0
D002506_D064420 NONE cephalexin_17\NN\2996840|,_6|and_4 (r_conj) trimethoprim_14\NN\0|trimethoprim_31|-_19|,_2 (r_conj) sulfamethoxazole_12\NN\4352070|NONE_0 (r_pobj) of_9\IN\0|a_41|large_39|based_22|up_9|for_63|._97 (r_prep) study_8\NN\635850|NONE_0 (l_prep) for_18\IN\0|a_104|large_102|based_85|up_72|of_63|._34 (l_pobj) toxicity_22\NN\13576101|NONE_0
D014295_D006402 NONE trimethoprim_28\NN\0|,_21|266,951_19|,_18|and_20|cephalexin_43 (r_dobj) prescribed_27\VBD\748282|we_142|study_93|estimate_69|._206 (r_conj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D006402 NONE sulfamethoxazole_19\NN\4352070|(_17|tmp_18|-_21|)_25 (r_compound) smz_23\NNP\0|who_55|were_51 (r_dobj) prescribed_16\VBN\748282|232,390_24 (r_relcl) people_13\NNS\31264|NONE_0 (r_pobj) of_11\IN\0|a_42|based_29|45-day_23|follow_16 (r_prep) study_10\NN\635850|we_49|prescribed_93|estimate_162|._299 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
D015662_D006402 NONE smz_23\NNP\0|who_55|were_51 (r_dobj) prescribed_16\VBN\748282|232,390_24 (r_relcl) people_13\NNS\31264|NONE_0 (r_pobj) of_11\IN\0|a_42|based_29|45-day_23|follow_16 (r_prep) study_10\NN\635850|we_49|prescribed_93|estimate_162|._299 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_advcl) estimate_37\VB\5802185|we_211|study_162|prescribed_69|._137 (l_dobj) risk_39\NN\14541044|to_16 (l_prep) of_40\IN\0|the_9 (l_pobj) liver_42\NN\5298729|NONE_0 (l_conj) blood_44\NN\5397468|serious_15|,_2 (l_conj) skin_46\NN\5237755|,_2 (l_conj) disorders_50\NNS\14034177|,_12|and_10
8511251
D003042_D017202 CID cocaine_0\NN\3492717|ischemia_27|._35 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) ischemia_3\NN\14195315|cocaine_27|._8
D003042_D017202 CID cocaine_9\NN\3492717|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|a_30|of_23 (r_acl) case_3\NN\7283608|we_12|._46 (l_prep) of_4\IN\0|a_7|induced_23 (l_pobj) ischemia_6\NN\14195315|NONE_0
D005996_D007511 NONE nitroglycerin_11\NN\15015501|NONE_0 (r_pobj) by_10\IN\0|was_13 (r_agent) reversed_9\VBN\109660|ischemia_55|probably_46|by_29|._53 (r_conj) induced_3\VBN\1627355|NONE_0 (l_nsubj) ischemia_1\NN\14195315|probably_9|by_26|reversed_55|._108
D002118_D007511 NONE calcium_13\NN\14625458|NONE_0 (r_npadvmod) blocking_14\VBG\562280|NONE_0 (r_amod) agents_15\NNS\7347|and_21 (r_conj) nitroglycerin_11\NN\15015501|NONE_0 (r_pobj) by_10\IN\0|was_13 (r_agent) reversed_9\VBN\109660|ischemia_55|probably_46|by_29|._53 (r_conj) induced_3\VBN\1627355|NONE_0 (l_nsubj) ischemia_1\NN\14195315|probably_9|by_26|reversed_55|._108
D002118_D003329 NONE calcium_13\NN\14625458|NONE_0 (r_npadvmod) blocking_14\VBG\562280|NONE_0 (r_amod) agents_15\NNS\7347|and_21 (r_conj) nitroglycerin_11\NN\15015501|NONE_0 (r_pobj) by_10\IN\0|was_13 (r_agent) reversed_9\VBN\109660|ischemia_55|probably_46|by_29|._53 (r_conj) induced_3\VBN\1627355|NONE_0 (l_agent) by_4\IN\0|ischemia_26|probably_17|reversed_29|._82 (l_pobj) spasm_7\NN\14299637|NONE_0
D005996_D003329 NONE nitroglycerin_11\NN\15015501|NONE_0 (r_pobj) by_10\IN\0|was_13 (r_agent) reversed_9\VBN\109660|ischemia_55|probably_46|by_29|._53 (r_conj) induced_3\VBN\1627355|NONE_0 (l_agent) by_4\IN\0|ischemia_26|probably_17|reversed_29|._82 (l_pobj) spasm_7\NN\14299637|NONE_0
19447152
D012964_D001714 NONE na(+)/k(+)-atpase_10\NNP\0|a_2 (r_compound) inhibitor_11\NN\20090|(_53|icv_52|)_49|of_32|(_21|)_9|in_11 (r_appos) administration_5\NN\1133281|the_34 (r_appos) intracerebroventricular_1\JJ\0|has_96|been_100|mimic_118|._160 (r_nsubjpass) suggested_17\VBN\1010118|NONE_0 (l_xcomp) mimic_19\VB\10200365|intracerebroventricular_118|has_22|been_18|._42 (l_dobj) symptoms_21\NNS\5823932|to_14 (l_prep) of_22\IN\0|some_14 (l_pobj) mania_25\NN\9180259|NONE_0
D010042_D009069 NONE ouabain_4\NN\0|that_5|hyperlocomotion_38 (r_nsubj) induced_10\VBN\1627355|findings_57|,_31|and_33|remained_51 (l_dobj) hyperlocomotion_11\NN\0|that_43|ouabain_38
D011188_D001714 NONE na(+)/k(+)-atpase_10\NNP\0|a_2 (r_compound) inhibitor_11\NN\20090|(_53|icv_52|)_49|of_32|(_21|)_9|in_11 (r_appos) administration_5\NN\1133281|the_34 (r_appos) intracerebroventricular_1\JJ\0|has_96|been_100|mimic_118|._160 (r_nsubjpass) suggested_17\VBN\1010118|NONE_0 (l_xcomp) mimic_19\VB\10200365|intracerebroventricular_118|has_22|been_18|._42 (l_dobj) symptoms_21\NNS\5823932|to_14 (l_prep) of_22\IN\0|some_14 (l_pobj) mania_25\NN\9180259|NONE_0
D010042_D001714 CID ouabain_6\NN\0|NONE_0 (r_pobj) by_5\IN\0|model_23|:_10|evidence_12|._87 (r_prep) induced_4\VBN\1627355|NONE_0 (l_nsubj) model_1\NN\5888929|by_23|:_33|evidence_35|._110 (l_prep) of_2\IN\0|animal_13 (l_pobj) mania_3\NN\9180259|NONE_0
D010042_D001714 CID ouabain_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|(_21|icv_20|)_17|(_11|inhibitor_32|)_41|in_43 (r_prep) administration_5\NN\1133281|the_34 (r_appos) intracerebroventricular_1\JJ\0|has_96|been_100|mimic_118|._160 (r_nsubjpass) suggested_17\VBN\1010118|NONE_0 (l_xcomp) mimic_19\VB\10200365|intracerebroventricular_118|has_22|been_18|._42 (l_dobj) symptoms_21\NNS\5823932|to_14 (l_prep) of_22\IN\0|some_14 (l_pobj) mania_25\NN\9180259|NONE_0
D010042_D001714 CID ouabain_3\NN\0|-_7 (r_npadvmod) induced_5\VBN\1627355|mania_8 (r_amod) behavior_9\NN\407535|in_42|,_29|may_9|model_37|._124 (l_nmod) mania_6\NN\9180259|induced_8
D010042_D001714 CID ouabain_3\NN\0|-_7 (r_npadvmod) induced_5\VBN\1627355|mania_8 (r_amod) behavior_9\NN\407535|in_42|,_29|may_9|model_37|._124 (r_nsubj) provide_11\VB\2199590|NONE_0 (l_dobj) model_15\NN\5888929|in_79|,_66|behavior_37|may_28|._87 (l_relcl) test_17\VB\5798043|a_25|useful_23|animal_16 (l_dobj) hypothesis_19\NN\7162194|to_12 (l_prep) of_20\IN\0|the_15 (l_pobj) involvement_22\NN\1080366|NONE_0 (l_prep) of_23\IN\0|the_16 (l_pobj) stress_25\NN\7083732|NONE_0 (l_prep) in_26\IN\13603305|oxidative_17 (l_pobj) disorder_28\NN\14034177|NONE_0
733189
C000873_D015356 CID acetate_24\NN\15010703|NONE_0 (r_pobj) with_22\IN\0|head_36|tissue_17|in_32 (r_prep) injection_21\NN\320852|NONE_0 (r_dobj) following_14\VBG\8180190|NONE_0 (r_prep) blindness_13\NN\14552802|NONE_0 (r_pobj) with_12\IN\0|choriocapillaris_28 (r_prep) occlusions_11\NNS\14081375|bilateral_46|retinal_36|and_21
D010406_D015356 NONE penicillin_33\NN\2716866|,_5|or_3 (r_conj) epinephrine_30\NN\14807929|,_2 (r_conj) lidocaine_28\NN\3681148|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) in_25\IN\13603305|head_68|tissue_49|with_32 (r_prep) injection_21\NN\320852|NONE_0 (r_dobj) following_14\VBG\8180190|NONE_0 (r_prep) blindness_13\NN\14552802|NONE_0 (r_pobj) with_12\IN\0|choriocapillaris_28 (r_prep) occlusions_11\NNS\14081375|bilateral_46|retinal_36|and_21
D004837_D015356 NONE epinephrine_30\NN\14807929|,_2 (r_conj) lidocaine_28\NN\3681148|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) in_25\IN\13603305|head_68|tissue_49|with_32 (r_prep) injection_21\NN\320852|NONE_0 (r_dobj) following_14\VBG\8180190|NONE_0 (r_prep) blindness_13\NN\14552802|NONE_0 (r_pobj) with_12\IN\0|choriocapillaris_28 (r_prep) occlusions_11\NNS\14081375|bilateral_46|retinal_36|and_21
D004837_D001766 NONE epinephrine_30\NN\14807929|,_2 (r_conj) lidocaine_28\NN\3681148|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) in_25\IN\13603305|head_68|tissue_49|with_32 (r_prep) injection_21\NN\320852|NONE_0 (r_dobj) following_14\VBG\8180190|NONE_0 (r_prep) blindness_13\NN\14552802|NONE_0
D008012_D015356 NONE lidocaine_28\NN\3681148|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) in_25\IN\13603305|head_68|tissue_49|with_32 (r_prep) injection_21\NN\320852|NONE_0 (r_dobj) following_14\VBG\8180190|NONE_0 (r_prep) blindness_13\NN\14552802|NONE_0 (r_pobj) with_12\IN\0|choriocapillaris_28 (r_prep) occlusions_11\NNS\14081375|bilateral_46|retinal_36|and_21
D008012_D001766 NONE lidocaine_28\NN\3681148|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) in_25\IN\13603305|head_68|tissue_49|with_32 (r_prep) injection_21\NN\320852|NONE_0 (r_dobj) following_14\VBG\8180190|NONE_0 (r_prep) blindness_13\NN\14552802|NONE_0
D010406_D001766 NONE penicillin_33\NN\2716866|,_5|or_3 (r_conj) epinephrine_30\NN\14807929|,_2 (r_conj) lidocaine_28\NN\3681148|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) combination_26\NN\7951464|NONE_0 (r_pobj) in_25\IN\13603305|head_68|tissue_49|with_32 (r_prep) injection_21\NN\320852|NONE_0 (r_dobj) following_14\VBG\8180190|NONE_0 (r_prep) blindness_13\NN\14552802|NONE_0
D000305_D015356 NONE corticosteroid_13\NN\14745635|acting_7|in_27 (r_compound) suspensions_14\NNS\14586258|NONE_0 (r_pobj) of_9\IN\0|the_14 (r_prep) injection_8\NN\320852|NONE_0 (r_pobj) following_6\VBG\8180190|bilateral_56|retinal_46|and_31|occlusion_10|:_97|studies_111|._118 (r_prep) artery_2\NN\5417975|NONE_0 (l_conj) occlusion_5\NN\14081375|bilateral_46|retinal_36|and_21|following_10|:_107|studies_121|._128
C000873_D001766 NONE acetate_24\NN\15010703|NONE_0 (r_pobj) with_22\IN\0|head_36|tissue_17|in_32 (r_prep) injection_21\NN\320852|NONE_0 (r_dobj) following_14\VBG\8180190|NONE_0 (r_prep) blindness_13\NN\14552802|NONE_0
20566328
C476756_D006331 NONE mitoq._15\NNP\0|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_prep) prevention_10\NN\1073995|mitochondrial_77 (r_appos) impairment_1\NN\7296428|to_23|:_61 (r_nsubj) contributes_2\VBZ\126264|NONE_0 (l_prep) to_3\IN\0|impairment_23|:_38 (l_pobj) dysfunction_8\NN\14204950|NONE_0
C476756_D006331 NONE mitoq_0\NNP\0|was_45|prevent_69|._254 (r_nsubjpass) shown_9\VBN\2137132|NONE_0 (l_xcomp) prevent_12\VB\0|mitoq_69|was_24|._185 (l_dobj) abnormalities_15\NNS\14034177|to_42|completely_39 (l_conj) dysfunction_20\NN\14204950|these_53|mitochondrial_47|as_11
C476756_-1 NONE mitoq_0\NNP\0|was_45|prevent_69|._254 (r_nsubjpass) shown_9\VBN\2137132|NONE_0 (l_xcomp) prevent_12\VB\0|mitoq_69|was_24|._185 (l_dobj) abnormalities_15\NNS\14034177|to_42|completely_39 (l_conj) dysfunction_20\NN\14204950|these_53|mitochondrial_47|as_11 (l_acl) characterized_21\VBN\609683|cardiac_20 (l_agent) by_23\IN\0|here_5 (l_pobj) dysfunction_26\NN\14204950|NONE_0
D003042_D028361 NONE cocaine_4\NN\3492717|-_7 (r_npadvmod) induced_6\VBN\1627355|cardiac_8 (r_amod) dysfunction_8\NN\14204950|NONE_0 (r_pobj) to_3\IN\0|impairment_23|:_38 (r_prep) contributes_2\VBZ\126264|NONE_0 (l_nsubj) impairment_1\NN\7296428|to_23|:_61
D003042_D028361 NONE cocaine_15\NN\3492717|NONE_0 (r_pobj) to_14\IN\0|term_14 (r_prep) exposure_13\NN\5042871|NONE_0 (r_pobj) after_9\IN\0|effect_55|not_15|detectable_11|,_36|suggesting_38|._167 (r_prep) was_6\VBD\0|NONE_0 (l_advcl) suggesting_17\VBG\1010118|effect_93|not_53|detectable_49|after_38|,_2|._129 (l_ccomp) were_22\VBD\0|NONE_0 (l_nsubj) abnormalities_21\NNS\14034177|that_25|event_48
D003042_D028361 NONE cocaine_35\NN\3492717|NONE_0 (r_pobj) to_34\IN\0|the_26|pathological_22 (r_prep) response_33\NN\11410625|NONE_0 (r_pobj) in_30\IN\13603305|a_35|late_33|a_16|primary_14 (r_prep) event_29\NN\23100|that_73|abnormalities_48 (r_attr) were_22\VBD\0|NONE_0 (l_nsubj) abnormalities_21\NNS\14034177|that_25|event_48
D003042_D028361 NONE cocaine_11\NN\3492717|-_7 (r_npadvmod) induced_13\VBN\1627355|cardiac_8 (r_amod) dysfunction_15\NN\14204950|that_29|may_12|due_19 (r_nsubj) be_17\VB\14625458|NONE_0 (l_acomp) due_18\JJ\5174653|that_48|dysfunction_19|may_7 (l_prep) to_19\IN\0|NONE_0 (l_pobj) defect_22\NN\14462666|NONE_0
D003042_D006331 CID cocaine_4\NN\3492717|-_7 (r_npadvmod) induced_6\VBN\1627355|cardiac_8 (r_amod) dysfunction_8\NN\14204950|NONE_0
D003042_D006331 CID cocaine_18\NN\3492717|-_7 (r_npadvmod) induced_20\VBN\1627355|cardiac_8 (r_amod) dysfunction_22\NN\14204950|NONE_0
D003042_D006331 CID cocaine_11\NN\3492717|-_7 (r_npadvmod) induced_13\VBN\1627355|cardiac_8 (r_amod) dysfunction_15\NN\14204950|that_29|may_12|due_19
C476756_D028361 NONE mitoq._15\NNP\0|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_prep) prevention_10\NN\1073995|mitochondrial_77 (r_appos) impairment_1\NN\7296428|to_23|:_61
C476756_D028361 NONE mitoq_0\NNP\0|was_45|prevent_69|._254 (r_nsubjpass) shown_9\VBN\2137132|NONE_0 (l_xcomp) prevent_12\VB\0|mitoq_69|was_24|._185 (l_dobj) abnormalities_15\NNS\14034177|to_42|completely_39
8308951
D014859_D001778 NONE warfarin_7\RB\2718259|-_8 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) coagulopathy_10\NN\0|to_20
D014859_D001778 NONE warfarin_3\JJ\2718259|NONE_0 (r_pobj) of_2\IN\0|percutaneous_24|causing_12 (r_prep) absorption_1\NN\13558490|,_43|times_60|in_66|,_77|is_79|._153 (l_acl) causing_4\VBG\30358|percutaneous_36|of_12 (l_dobj) coagulopathy_5\NN\0|NONE_0
D014859_D002543 CID warfarin_3\VB\2718259|-_8 (r_npadvmod) like_5\JJ\5839024|NONE_0 (r_amod) anticoagulant_6\NN\3740161|NONE_0 (r_pobj) to_2\IN\0|cutaneous_19|causing_31|:_66|report_75|._81 (r_prep) exposure_1\NN\5042871|NONE_0 (l_acl) causing_7\VBG\30358|cutaneous_50|to_31|:_35|report_44|._50 (l_dobj) hemorrhage_10\NN\14285662|NONE_0
D010894_D001778 NONE piroxicam_5\NN\3828465|NONE_0 (r_pobj) with_4\IN\0|an_28|adverse_25|drug_17|,_14|took_26 (r_prep) interaction_3\NN\37396|,_55|may_57|have_61|coagulopathy_82|._94 (r_nsubj) exacerbated_14\VBN\126264|NONE_0 (l_dobj) coagulopathy_16\NN\0|interaction_82|,_27|may_25|have_21|._12
D014859_D006406 NONE warfarin_7\RB\2718259|-_8 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) coagulopathy_10\NN\0|to_20 (r_pobj) due_5\IN\5174653|a_33|of_26 (r_prep) case_1\NN\7283608|is_68|._80 (l_prep) of_2\IN\0|a_7|due_26 (l_pobj) hematoma_4\NN\14317720|NONE_0
2718706
D006221_D007022 CID halothane_6\NN\3570838|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) labetalol_4\NN\2721160|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|deliberate_23|._83 (r_acl) hypotension_1\NN\14057371|NONE_0
D006221_D007022 CID halothane_25\NN\3570838|inhalation_25|(_1|)_34 (r_appos) anaesthetics_23\NNS\3247620|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) combination_20\NN\7951464|NONE_0 (r_pobj) in_19\IN\13603305|a_20|hypotensive_18 (r_prep) agent_18\NN\7347|NONE_0 (l_amod) hypotensive_17\JJ\10405694|a_2|in_18
D006221_D007022 CID h_2\NN\14622893|the_9|mean_5|during_16|concentration_91 (r_compound) concentration_3\NN\4916342|+/-_64|,_76 (l_prep) during_4\IN\0|the_25|mean_21|h_16|concentration_75 (l_pobj) hypotension_5\NN\14057371|NONE_0
D004737_D007022 CID enflurane_8\NN\3299929|,_2 (r_conj) halothane_6\NN\3570838|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) labetalol_4\NN\2721160|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|deliberate_23|._83 (r_acl) hypotension_1\NN\14057371|NONE_0
D004737_D007022 CID enflurane_27\NN\3299929|,_2 (r_conj) halothane_25\NN\3570838|inhalation_25|(_1|)_34 (r_appos) anaesthetics_23\NNS\3247620|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) combination_20\NN\7951464|NONE_0 (r_pobj) in_19\IN\13603305|a_20|hypotensive_18 (r_prep) agent_18\NN\7347|NONE_0 (l_amod) hypotensive_17\JJ\10405694|a_2|in_18
D004737_D007022 CID e_18\NN\14724645|the_9|mean_5|1.6_16|+/-_20|,_32|and_34|mean_42 (r_compound) concentration_19\NN\4916342|the_100|mean_96|h_91|during_75 (r_appos) concentration_3\NN\4916342|+/-_64|,_76 (l_prep) during_4\IN\0|the_25|mean_21|h_16|concentration_75 (l_pobj) hypotension_5\NN\14057371|NONE_0
D003404_D007022 NONE creatinine_5\NN\0|the_10|serum_6 (r_compound) concentration_6\NN\4916342|during_41|,_23|significantly_19|in_33|before_63|and_82|returned_86|._180 (r_nsubj) rose_7\VBD\13112664|NONE_0 (l_prep) during_0\IN\0|,_18|concentration_41|significantly_60|in_74|before_104|and_123|returned_127|._221 (l_pobj) hypotension_1\NN\14057371|NONE_0
D003404_D007022 NONE creatinine_5\NN\0|the_10|serum_6 (r_compound) concentration_6\NN\4916342|during_41|,_23|significantly_19|in_33|before_63|and_82|returned_86|._180 (r_nsubj) rose_7\VBD\13112664|NONE_0 (l_prep) before_15\IN\0|during_104|,_86|concentration_63|significantly_44|in_30|and_19|returned_23|._117 (l_pobj) hypotension_16\NN\14057371|NONE_0
D007741_D007022 CID labetalol_4\NN\2721160|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|deliberate_23|._83 (r_acl) hypotension_1\NN\14057371|NONE_0
D007741_D007022 CID labetalol_4\NN\2721160|as_57 (r_dobj) using_3\VBG\418025|NONE_0 (l_prep) as_15\IN\14622893|labetalol_57 (l_pobj) agent_18\NN\7347|NONE_0 (l_amod) hypotensive_17\JJ\10405694|a_2|in_18
D007741_D007022 CID labetalol_4\NN\2721160|that_5|hypotension_36 (r_nsubj) induces_5\VBZ\1627355|results_32|._95 (l_dobj) hypotension_8\NN\14057371|that_41|labetalol_36
D007741_D006973 NONE labetalol_4\NN\2721160|that_5|hypotension_36 (r_nsubj) induces_5\VBZ\1627355|results_32|._95 (l_dobj) hypotension_8\NN\14057371|that_41|labetalol_36 (l_conj) hypertension_14\NN\14057371|adjustable_68|without_45|and_12
D007741_D013610 NONE labetalol_4\NN\2721160|that_5|hypotension_36 (r_nsubj) induces_5\VBZ\1627355|results_32|._95 (l_dobj) hypotension_8\NN\14057371|that_41|labetalol_36 (l_prep) without_9\IN\0|adjustable_23|and_33|hypertension_45 (l_pobj) tachycardia_11\NNS\14110674|NONE_0
D007530_D007022 CID isoflurane_10\RB\3570838|or_3 (r_conj) enflurane_8\NN\3299929|,_2 (r_conj) halothane_6\NN\3570838|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) labetalol_4\NN\2721160|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|deliberate_23|._83 (r_acl) hypotension_1\NN\14057371|NONE_0
D007530_D007022 CID isoflurane_29\RB\3570838|or_3 (r_conj) enflurane_27\NN\3299929|,_2 (r_conj) halothane_25\NN\3570838|inhalation_25|(_1|)_34 (r_appos) anaesthetics_23\NNS\3247620|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) combination_20\NN\7951464|NONE_0 (r_pobj) in_19\IN\13603305|a_20|hypotensive_18 (r_prep) agent_18\NN\7347|NONE_0 (l_amod) hypotensive_17\JJ\10405694|a_2|in_18
D007530_D007022 CID isoflurane_31\JJ\3570838|the_4 (r_amod) group_32\NN\2137|NONE_0 (r_pobj) except_29\IN\807461|postoperatively_58|to_42|,_2 (r_prep) returned_18\VBD\1835496|during_127|,_109|concentration_86|significantly_67|in_53|before_23|and_4|._94 (r_conj) rose_7\VBD\13112664|NONE_0 (l_prep) during_0\IN\0|,_18|concentration_41|significantly_60|in_74|before_104|and_123|returned_127|._221 (l_pobj) hypotension_1\NN\14057371|NONE_0
D007530_D007022 CID isoflurane_31\JJ\3570838|the_4 (r_amod) group_32\NN\2137|NONE_0 (r_pobj) except_29\IN\807461|postoperatively_58|to_42|,_2 (r_prep) returned_18\VBD\1835496|during_127|,_109|concentration_86|significantly_67|in_53|before_23|and_4|._94 (r_conj) rose_7\VBD\13112664|NONE_0 (l_prep) before_15\IN\0|during_104|,_86|concentration_63|significantly_44|in_30|and_19|returned_23|._117 (l_pobj) hypotension_16\NN\14057371|NONE_0
2400986
D002998_D002493 NONE clonazepam_33\NN\0|NONE_0 (r_pobj) with_32\IN\0|m2_12 (r_prep) busulfan_31\NNS\0|NONE_0 (r_pobj) under_26\IN\0|a_137|gas_135|mass_115|spectrometry_110|in_91|without_39 (r_prep) assay_11\NN\5733583|NONE_0 (l_prep) without_21\IN\0|a_98|gas_96|mass_76|spectrometry_71|in_52|under_39 (l_pobj) disease_25\NN\14061805|NONE_0
D002066_D002493 NONE busulfan_0\NNS\0|NONE_0 (r_compound) levels_1\NNS\4916342|were_7|by_21|was_244 (r_nsubjpass) measured_3\VBN\697589|NONE_0 (l_agent) by_4\IN\0|levels_21|were_14|was_223 (l_pobj) assay_11\NN\5733583|NONE_0 (l_prep) without_21\IN\0|a_98|gas_96|mass_76|spectrometry_71|in_52|under_39 (l_pobj) disease_25\NN\14061805|NONE_0
D002066_D002493 NONE busulfan_31\NNS\0|NONE_0 (r_pobj) under_26\IN\0|a_137|gas_135|mass_115|spectrometry_110|in_91|without_39 (r_prep) assay_11\NN\5733583|NONE_0 (l_prep) without_21\IN\0|a_98|gas_96|mass_76|spectrometry_71|in_52|under_39 (l_pobj) disease_25\NN\14061805|NONE_0
D002066_D002493 NONE busulfan_35\NNS\0|cerebrospinal_9|fluid_23|:_28|plasma_29 (r_amod) ratio_40\NN\13815152|1.39_10|._14 (r_nsubj) was_41\VBD\0|levels_244|were_237|by_223 (r_conj) measured_3\VBN\697589|NONE_0 (l_agent) by_4\IN\0|levels_21|were_14|was_223 (l_pobj) assay_11\NN\5733583|NONE_0 (l_prep) without_21\IN\0|a_98|gas_96|mass_76|spectrometry_71|in_52|under_39 (l_pobj) disease_25\NN\14061805|NONE_0
D002998_D020258 NONE clonazepam_16\NN\0|NONE_0 (r_pobj) by_15\IN\0|efficiently_22 (r_agent) prevented_14\VBN\0|that_74|neurotoxicity_60|dependent_38|and_16 (r_conj) is_6\VBZ\0|study_40|._69 (l_nsubj) neurotoxicity_5\NN\0|that_14|dependent_22|and_44|prevented_60
D002066_D001932 NONE busulfan_20\NNS\0|before_34 (r_dobj) receiving_16\VBG\2210855|a_62|retrospective_60|of_40 (r_acl) study_5\NN\635850|we_31|here_21|,_161|excluded_176 (r_dobj) report_1\VBP\6470073|NONE_0 (l_conj) excluded_35\VBD\471711|we_207|here_197|study_176|,_15 (l_nsubj) tumors_34\NNS\14234074|._15
D002066_D012640 CID busulfan_23\NNS\0|the_4 (r_amod) course_24\NN\883297|NONE_0 (r_pobj) of_21\IN\0|the_11|4_7|or_23|within_26 (r_prep) days_20\NNS\15140892|NONE_0 (r_pobj) during_17\IN\0|given_62|;_30|%_22|seizures_9|._77 (r_prep) developed_15\VBN\1753788|NONE_0 (l_dobj) seizures_16\NNS\14081375|given_53|;_21|%_13|during_9|._86
D002998_D009461 NONE clonazepam_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|continuous_25|i.v._14 (r_prep) infusion_16\NN\14589223|NONE_0 (r_pobj) with_13\IN\0|a_32|busulfan_20|total_11 (r_prep) dose_12\NN\3740161|patients_47|were_38 (r_dobj) given_5\VBN\5892096|;_81|none_83|symptoms_109|._117 (r_ccomp) had_21\VBD\0|NONE_0 (l_dobj) symptoms_24\NNS\5823932|given_109|;_28|none_26|._8
D002066_D020258 NONE busulfan_8\NNS\0|NONE_0 (r_pobj) of_4\IN\0|dependent_24|:_33|study_66|._71 (r_prep) neurotoxicity_3\NN\0|NONE_0
D002066_D020258 NONE busulfan_0\NNPS\0|is_9|be_21|,_56|but_58|remains_86 (r_nsubjpass) known_2\VBN\0|NONE_0 (l_xcomp) be_4\VB\14625458|busulfan_21|is_12|,_35|but_37|remains_65 (l_acomp) neurotoxic_5\JJ\0|to_6
D002066_D020258 NONE busulfan_0\NNPS\0|is_9|be_21|,_56|but_58|remains_86 (r_nsubjpass) known_2\VBN\0|NONE_0 (l_conj) remains_15\VBZ\2684|busulfan_86|is_77|be_65|,_30|but_28 (l_nsubj) neurotoxicity_14\NN\0|characterized_29|._54
D002066_D020258 NONE busulfan_3\NNS\0|the_10|total_6 (r_compound) dose_4\NN\3740161|when_24|was_5|into_15 (r_nsubjpass) taken_6\VBN\2367363|,_18|there_20|difference_44|._201 (r_advcl) was_11\VBD\0|NONE_0 (l_attr) difference_14\NN\4723816|taken_44|,_26|there_24|._157 (l_prep) in_15\IN\13603305|a_25|significant_23|and_82|patients_86 (l_pobj) terms_16\NNS\13945919|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) incidence_19\JJ\13821570|NONE_0 (l_compound) neurotoxicity_18\NN\0|among_24
D002066_D020258 NONE busulfan_4\NNS\0|NONE_0 (r_amod) neurotoxicity_5\NN\0|that_14|dependent_22|and_44|prevented_60
D002066_D020258 NONE busulfan_1\NNS\0|a_2|calculated_14|,_58|resulting_60|,_103 (r_compound) dose_2\NN\3740161|was_96|by_109|,_135|close_137|observed_170|._188 (r_nsubjpass) followed_21\VBN\1835496|NONE_0 (l_agent) by_22\IN\0|dose_109|was_13|,_26|close_28|observed_61|._79 (l_pobj) neurotoxicity_24\NN\0|NONE_0
D002066_D020258 NONE busulfan_1\NNS\0|a_2|calculated_14|,_58|resulting_60|,_103 (r_compound) dose_2\NN\3740161|was_96|by_109|,_135|close_137|observed_170|._188 (r_nsubjpass) followed_21\VBN\1835496|NONE_0 (l_advmod) close_26\JJ\15266911|dose_137|was_41|by_28|,_2|observed_33|._51 (l_prep) to_27\IN\0|NONE_0 (l_pobj) incidence_29\NN\13821570|NONE_0 (l_compound) neurotoxicity_28\NN\0|NONE_0
D002066_D009461 NONE busulfan_10\NNS\0|a_12|total_9|with_20 (r_nmod) dose_12\NN\3740161|patients_47|were_38 (r_dobj) given_5\VBN\5892096|;_81|none_83|symptoms_109|._117 (r_ccomp) had_21\VBD\0|NONE_0 (l_dobj) symptoms_24\NNS\5823932|given_109|;_28|none_26|._8
D002066_D009369 NONE busulfan_20\NNS\0|before_34 (r_dobj) receiving_16\VBG\2210855|a_62|retrospective_60|of_40 (l_prep) before_24\IN\0|busulfan_34 (l_pobj) transplantation_27\NN\671351|NONE_0 (l_prep) for_28\IN\0|bone_28|marrow_23 (l_pobj) tumors_31\NNS\14234074|NONE_0
9782254
D007980_D009127 NONE dopa_28\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) dyskinesias_31\NNS\14084880|,_21|and_19 (r_conj) rigidity_23\NN\5023233|,_2
D007980_D018476 NONE dopa_28\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) dyskinesias_31\NNS\14084880|,_21|and_19 (r_conj) rigidity_23\NN\5023233|,_2 (r_conj) bradykinesia_21\NN\0|NONE_0
D007980_D004409 CID dopa_28\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) dyskinesias_31\NNS\14084880|,_21|and_19
D007980_D010300 NONE dopa_28\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) dyskinesias_31\NNS\14084880|,_21|and_19 (r_conj) rigidity_23\NN\5023233|,_2 (r_conj) bradykinesia_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) treatment_19\NN\654885|NONE_0 (r_pobj) for_18\IN\0|patients_142|pallidotomy_50|between_38|._71 (r_prep) underwent_8\VBD\109660|NONE_0 (l_nsubj) patients_1\NNS\9898892|pallidotomy_92|between_104|for_142|._213 (l_prep) with_2\IN\0|51_12 (l_pobj) disease_7\NN\14061805|NONE_0
25907210
D010755_D009369 NONE organophosphate_10\NN\14919948|the_4|insecticide_16|in_37 (r_amod) diazinon_12\NN\0|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) exposed_7\VBN\2110927|pesticide_22 (r_acl) applicators_6\NNS\3183080|NONE_0 (r_pobj) among_4\IN\0|solid_14 (r_prep) tumours_3\NNS\14234074|NONE_0
D010755_D009369 NONE organophosphate_4\NN\14919948|a_9|common_7|with_28 (r_compound) insecticide_5\NN\14980215|,_27|,_37 (r_appos) diazinon_0\NNP\0|was_74|previously_78|with_100 (r_nsubjpass) associated_12\VBN\628491|studies_105|have_113|risk_154|._158 (r_ccomp) examined_32\VBN\0|NONE_0 (l_dobj) risk_37\NN\14541044|associated_154|studies_49|have_41|._4 (l_compound) cancer_36\NN\14239425|associated_11
D010755_D008175 NONE organophosphate_4\NN\14919948|a_9|common_7|with_28 (r_compound) insecticide_5\NN\14980215|,_27|,_37 (r_appos) diazinon_0\NNP\0|was_74|previously_78|with_100 (r_nsubjpass) associated_12\VBN\628491|studies_105|have_113|risk_154|._158 (l_prep) with_13\IN\0|diazinon_100|was_26|previously_22 (l_pobj) cancer_15\NN\14239425|NONE_0
D003976_D009369 NONE diazinon_12\NN\0|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) exposed_7\VBN\2110927|pesticide_22 (r_acl) applicators_6\NNS\3183080|NONE_0 (r_pobj) among_4\IN\0|solid_14 (r_prep) tumours_3\NNS\14234074|NONE_0
D003976_D009369 NONE diazinon_0\NNP\0|was_74|previously_78|with_100 (r_nsubjpass) associated_12\VBN\628491|studies_105|have_113|risk_154|._158 (r_ccomp) examined_32\VBN\0|NONE_0 (l_dobj) risk_37\NN\14541044|associated_154|studies_49|have_41|._4 (l_compound) cancer_36\NN\14239425|associated_11
D003976_D009369 NONE diazinon_33\NN\0|-_8 (r_npadvmod) associated_35\VBN\628491|cancer_11 (r_amod) risk_37\NN\14541044|associated_154|studies_49|have_41|._4 (l_compound) cancer_36\NN\14239425|associated_11
D003976_D009369 NONE diazinon_3\NN\0|updated_8|and_18|information_39 (r_compound) exposure_4\NN\5042871|we_25|evaluate_45|._82 (l_conj) information_8\NN\6598915|updated_47|diazinon_39|and_21 (l_compound) cancer_6\NN\14239425|incidence_7
D003976_D009369 NONE diazinon_3\NN\0|updated_8|and_18|information_39 (r_compound) exposure_4\NN\5042871|we_25|evaluate_45|._82 (r_dobj) used_1\VBD\0|NONE_0 (l_xcomp) evaluate_10\VB\670261|we_70|exposure_45|._37 (l_dobj) risk_13\NN\14541044|to_25|in_5 (l_compound) tumour_12\NN\14234074|solid_6
D003976_D009369 NONE diazinon_10\NN\0|at_13 (r_compound) use_11\NN\407535|applicators_66 (r_dobj) reported_8\VBD\831651|;_81|incidence_90|was_100|through_113|)_151|._152 (r_ccomp) assessed_32\VBN\670261|NONE_0 (l_nsubjpass) incidence_30\NN\13821570|reported_90|;_9|was_10|through_23|)_61|._62 (l_compound) cancer_29\NN\14239425|NONE_0
D003976_D008175 CID diazinon_0\NNP\0|was_74|previously_78|with_100 (r_nsubjpass) associated_12\VBN\628491|studies_105|have_113|risk_154|._158 (l_prep) with_13\IN\0|diazinon_100|was_26|previously_22 (l_pobj) cancer_15\NN\14239425|NONE_0
D003976_D008175 CID diazinon_33\NN\0|-_8 (r_npadvmod) associated_35\VBN\628491|cancer_11 (r_amod) risk_37\NN\14541044|associated_154|studies_49|have_41|._4 (r_dobj) examined_32\VBN\0|NONE_0 (l_ccomp) associated_12\VBN\628491|studies_105|have_113|risk_154|._158 (l_prep) with_13\IN\0|diazinon_100|was_26|previously_22 (l_pobj) cancer_15\NN\14239425|NONE_0
D003976_D008175 CID diazinon_34\NN\0|NONE_0 (r_compound) use_35\NN\407535|NONE_0 (r_pobj) of_33\IN\0|iw_8|(_16|rr=1.41_17|;_24 (r_prep) days_32\NNS\15140892|)_9|and_7 (r_conj) ptrend=0.02_28\LS\0|%_19|1.11_14|to_9|;_2|%_53 (r_appos) ci_23\NNP\13635336|:_112|we_110|risks_77|;_6|._101 (r_npadvmod) observed_2\VBD\2163746|NONE_0 (l_dobj) risks_6\NNS\14541044|:_35|we_33|;_71|ci_77|._178 (l_compound) cancer_5\NN\14239425|elevated_14|(_13|n=283_14|)_19|among_21
D003976_D008175 CID diazinon_4\NNS\0|NONE_0 (r_pobj) of_3\IN\0|our_23|updated_19 (r_prep) evaluation_2\NN\874067|evidence_43|._91 (r_nsubj) provides_5\VBZ\2199590|NONE_0 (l_dobj) evidence_7\NN\5816287|evaluation_43|._48 (l_prep) of_8\IN\0|additional_20 (l_pobj) association_10\NN\8008335|NONE_0 (l_prep) with_11\IN\0|an_15 (l_pobj) risk_14\NN\14541044|NONE_0 (l_compound) cancer_13\NN\14239425|NONE_0
2173761
D018727_D013610 NONE blockade_25\VBP\952963|NONE_0 (l_conj) tachycardia_30\NN\14110674|prior_82|combined_76|beta_67|receptors_36|but_17
D020110_D007022 CID pinacidil_13\NN\0|and_4 (r_conj) cromakalim_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|of_52 (r_acl) vasodilation_0\NN\365995|were_101|not_106|by_119|abolished_220|._229 (l_prep) of_1\IN\0|induced_52 (l_pobj) vessels_6\NNS\5246511|NONE_0 (l_conj) hypotension_8\NN\14057371|large_37|coronary_21|and_4
D019806_D007022 CID cromakalim_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|of_52 (r_acl) vasodilation_0\NN\365995|were_101|not_106|by_119|abolished_220|._229 (l_prep) of_1\IN\0|induced_52 (l_pobj) vessels_6\NNS\5246511|NONE_0 (l_conj) hypotension_8\NN\14057371|large_37|coronary_21|and_4
D000319_D013610 NONE blockade_25\VBP\952963|NONE_0 (l_conj) tachycardia_30\NN\14110674|prior_82|combined_76|beta_67|receptors_36|but_17
D018727_D007022 NONE blockade_25\VBP\952963|NONE_0 (r_pobj) by_17\IN\0|vasodilation_119|were_18|not_13|abolished_101|._110 (r_agent) affected_16\VBN\126264|NONE_0 (l_nsubjpass) vasodilation_0\NN\365995|were_101|not_106|by_119|abolished_220|._229 (l_prep) of_1\IN\0|induced_52 (l_pobj) vessels_6\NNS\5246511|NONE_0 (l_conj) hypotension_8\NN\14057371|large_37|coronary_21|and_4
D019806_D013610 CID cromakalim_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|of_52 (r_acl) vasodilation_0\NN\365995|were_101|not_106|by_119|abolished_220|._229 (r_nsubjpass) affected_16\VBN\126264|NONE_0 (l_agent) by_17\IN\0|vasodilation_119|were_18|not_13|abolished_101|._110 (l_pobj) blockade_25\VBP\952963|NONE_0 (l_conj) tachycardia_30\NN\14110674|prior_82|combined_76|beta_67|receptors_36|but_17
D020110_D013610 CID pinacidil_13\NN\0|and_4 (r_conj) cromakalim_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|of_52 (r_acl) vasodilation_0\NN\365995|were_101|not_106|by_119|abolished_220|._229 (r_nsubjpass) affected_16\VBN\126264|NONE_0 (l_agent) by_17\IN\0|vasodilation_119|were_18|not_13|abolished_101|._110 (l_pobj) blockade_25\VBP\952963|NONE_0 (l_conj) tachycardia_30\NN\14110674|prior_82|combined_76|beta_67|receptors_36|but_17
D000319_D007022 NONE blockade_25\VBP\952963|NONE_0 (r_pobj) by_17\IN\0|vasodilation_119|were_18|not_13|abolished_101|._110 (r_agent) affected_16\VBN\126264|NONE_0 (l_nsubjpass) vasodilation_0\NN\365995|were_101|not_106|by_119|abolished_220|._229 (l_prep) of_1\IN\0|induced_52 (l_pobj) vessels_6\NNS\5246511|NONE_0 (l_conj) hypotension_8\NN\14057371|large_37|coronary_21|and_4
10390729
D011803_D006948 NONE quinine-_33\JJ\0|-_28 (r_npadvmod) sensitive_37\JJ\10488309|NONE_0 (r_amod) k(+)-channels_38\NNPS\0|NONE_0 (r_pobj) to_31\IN\0|to_16|be_13 (r_prep) connected_30\VBN\0|whereas_51|hyperactivity_26 (r_xcomp) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (l_nsubj) hyperactivity_26\NN\14052403|whereas_25|connected_26
D011803_D009069 NONE quinine-_33\JJ\0|-_28 (r_npadvmod) sensitive_37\JJ\10488309|NONE_0 (r_amod) k(+)-channels_38\NNPS\0|NONE_0 (r_pobj) to_31\IN\0|to_16|be_13 (r_prep) connected_30\VBN\0|whereas_51|hyperactivity_26 (r_xcomp) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (r_advcl) is_13\VBZ\0|it_84|is_81|also_78|._180 (l_acomp) sufficient_15\JJ\0|that_70|blockade_61|not_4|seems_91 (l_xcomp) prevent_17\VB\0|NONE_0 (l_dobj) hypoactivity_21\NN\0|to_28
D009020_D006948 CID morphine_18\NN\2707683|-_8 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) hypoactivity_21\NN\0|in_129|neither_63|,_12|but_14|prevented_45 (r_dobj) affected_17\VBD\126264|NONE_0 (l_conj) prevented_27\VBD\0|in_174|neither_108|hypoactivity_45|,_33|but_31 (l_dobj) hyperactivity_32\NN\14052403|blockers_46|._13
D009020_D006948 CID morphine_28\NN\2707683|-_8 (r_npadvmod) induced_30\VBN\1627355|secondary_8 (r_amod) hyperactivity_32\NN\14052403|blockers_46|._13
D009020_D006948 CID morphine_18\NN\2707683|-_8 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) hypoactivity_21\NN\0|to_28 (r_dobj) prevent_17\VB\0|NONE_0 (r_xcomp) sufficient_15\JJ\0|that_70|blockade_61|not_4|seems_91 (r_acomp) is_13\VBZ\0|it_84|is_81|also_78|._180 (l_advcl) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (l_nsubj) hyperactivity_26\NN\14052403|whereas_25|connected_26
D009020_D006948 CID morphine_23\NN\2707683|-_8 (r_npadvmod) induced_25\VBN\1627355|NONE_0 (r_amod) hyperactivity_26\NN\14052403|whereas_25|connected_26
D009020_D009069 NONE morphine_18\NN\2707683|-_8 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) hypoactivity_21\NN\0|in_129|neither_63|,_12|but_14|prevented_45
D009020_D009069 NONE morphine_28\NN\2707683|-_8 (r_npadvmod) induced_30\VBN\1627355|secondary_8 (r_amod) hyperactivity_32\NN\14052403|blockers_46|._13 (r_dobj) prevented_27\VBD\0|in_174|neither_108|hypoactivity_45|,_33|but_31 (r_conj) affected_17\VBD\126264|NONE_0 (l_dobj) hypoactivity_21\NN\0|in_129|neither_63|,_12|but_14|prevented_45
D009020_D009069 NONE morphine_18\NN\2707683|-_8 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) hypoactivity_21\NN\0|to_28
D009020_D009069 NONE morphine_23\NN\2707683|-_8 (r_npadvmod) induced_25\VBN\1627355|NONE_0 (r_amod) hyperactivity_26\NN\14052403|whereas_25|connected_26 (r_nsubj) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (r_advcl) is_13\VBZ\0|it_84|is_81|also_78|._180 (l_acomp) sufficient_15\JJ\0|that_70|blockade_61|not_4|seems_91 (l_xcomp) prevent_17\VB\0|NONE_0 (l_dobj) hypoactivity_21\NN\0|to_28
D011188_D006948 NONE k(+)-channel_15\NNP\0|the_4 (r_compound) blockers_16\NNS\10101634|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) neither_12\DT\0|in_66|hypoactivity_63|,_75|but_77|prevented_108 (r_nsubj) affected_17\VBD\126264|NONE_0 (l_conj) prevented_27\VBD\0|in_174|neither_108|hypoactivity_45|,_33|but_31 (l_dobj) hyperactivity_32\NN\14052403|blockers_46|._13
D011188_D006948 NONE k(+)-channel_25\NNP\0|both_5 (r_compound) blockers_26\NNS\10101634|hyperactivity_46|._59 (r_nsubj) prevented_27\VBD\0|in_174|neither_108|hypoactivity_45|,_33|but_31 (l_dobj) hyperactivity_32\NN\14052403|blockers_46|._13
D011188_D006948 NONE k(+)-channels_8\NNPS\0|NONE_0 (r_pobj) of_7\IN\0|the_13 (r_prep) blockade_6\NN\952963|that_9|not_57|sufficient_61|seems_152 (r_nsubj) is_13\VBZ\0|it_84|is_81|also_78|._180 (l_advcl) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (l_nsubj) hyperactivity_26\NN\14052403|whereas_25|connected_26
D011188_D006948 NONE k(+)-channels_38\NNPS\0|NONE_0 (r_pobj) to_31\IN\0|to_16|be_13 (r_prep) connected_30\VBN\0|whereas_51|hyperactivity_26 (r_xcomp) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (l_nsubj) hyperactivity_26\NN\14052403|whereas_25|connected_26
D015761_D006948 NONE 4-aminopyridine_35\CD\0|NONE_0 (r_punct) -_36\HYPH\0|quinine-_28 (r_punct) sensitive_37\JJ\10488309|NONE_0 (r_amod) k(+)-channels_38\NNPS\0|NONE_0 (r_pobj) to_31\IN\0|to_16|be_13 (r_prep) connected_30\VBN\0|whereas_51|hyperactivity_26 (r_xcomp) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (l_nsubj) hyperactivity_26\NN\14052403|whereas_25|connected_26
D011188_D009069 NONE k(+)-channel_15\NNP\0|the_4 (r_compound) blockers_16\NNS\10101634|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) neither_12\DT\0|in_66|hypoactivity_63|,_75|but_77|prevented_108 (r_nsubj) affected_17\VBD\126264|NONE_0 (l_dobj) hypoactivity_21\NN\0|in_129|neither_63|,_12|but_14|prevented_45
D011188_D009069 NONE k(+)-channel_25\NNP\0|both_5 (r_compound) blockers_26\NNS\10101634|hyperactivity_46|._59 (r_nsubj) prevented_27\VBD\0|in_174|neither_108|hypoactivity_45|,_33|but_31 (r_conj) affected_17\VBD\126264|NONE_0 (l_dobj) hypoactivity_21\NN\0|in_129|neither_63|,_12|but_14|prevented_45
D011188_D009069 NONE k(+)-channels_8\NNPS\0|NONE_0 (r_pobj) of_7\IN\0|the_13 (r_prep) blockade_6\NN\952963|that_9|not_57|sufficient_61|seems_152 (r_nsubj) is_13\VBZ\0|it_84|is_81|also_78|._180 (l_acomp) sufficient_15\JJ\0|that_70|blockade_61|not_4|seems_91 (l_xcomp) prevent_17\VB\0|NONE_0 (l_dobj) hypoactivity_21\NN\0|to_28
D011188_D009069 NONE k(+)-channels_38\NNPS\0|NONE_0 (r_pobj) to_31\IN\0|to_16|be_13 (r_prep) connected_30\VBN\0|whereas_51|hyperactivity_26 (r_xcomp) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (r_advcl) is_13\VBZ\0|it_84|is_81|also_78|._180 (l_acomp) sufficient_15\JJ\0|that_70|blockade_61|not_4|seems_91 (l_xcomp) prevent_17\VB\0|NONE_0 (l_dobj) hypoactivity_21\NN\0|to_28
D015761_D009069 NONE 4-aminopyridine_35\CD\0|NONE_0 (r_punct) -_36\HYPH\0|quinine-_28 (r_punct) sensitive_37\JJ\10488309|NONE_0 (r_amod) k(+)-channels_38\NNPS\0|NONE_0 (r_pobj) to_31\IN\0|to_16|be_13 (r_prep) connected_30\VBN\0|whereas_51|hyperactivity_26 (r_xcomp) seems_27\VBZ\2604760|that_161|blockade_152|not_95|sufficient_91 (r_advcl) is_13\VBZ\0|it_84|is_81|also_78|._180 (l_acomp) sufficient_15\JJ\0|that_70|blockade_61|not_4|seems_91 (l_xcomp) prevent_17\VB\0|NONE_0 (l_dobj) hypoactivity_21\NN\0|to_28
25119790
D003474_D007674 NONE curcumin_0\NN\0|nephrotoxicity_34 (r_nsubj) prevents_1\VBZ\0|NONE_0 (l_dobj) nephrotoxicity_5\NN\0|curcumin_34
D003474_D007674 NONE curcumin_8\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_32|potential_28|protective_18|against_63 (r_prep) effect_3\NN\34213|was_114|._127 (l_prep) against_20\IN\0|the_95|potential_91|protective_81|of_63 (l_pobj) injury_23\NN\14052046|NONE_0
D003474_D007674 NONE curcumin_4\NN\0|that_5|able_12 (r_nsubj) is_5\VBZ\0|it_30|is_27|._81 (l_acomp) able_6\JJ\0|that_17|curcumin_12 (l_xcomp) attenuate_8\VB\224901|NONE_0 (l_prep) in_9\IN\13603305|to_13 (l_pobj) nephropathy_14\NN\14573196|and_12|in_16
D005947_D007674 NONE glucose_20\NN\14710501|total_15|,_2 (r_conj) protein_18\NN\14944888|NONE_0 (r_pobj) of_16\IN\0|the_22|urinary_18 (r_prep) excretion_15\NN\13466586|NONE_0 (r_pobj) in_12\IN\13603305|in_33|and_4 (r_conj) increase_6\NN\13576355|injury_16|,_190|determined_375 (r_dobj) included_5\VBD\0|NONE_0 (l_nsubj) injury_4\NN\14052046|increase_16|,_206|determined_391
D005947_D007674 NONE glucose_20\NN\14710501|total_15|,_2 (r_conj) protein_18\NN\14944888|NONE_0 (r_pobj) of_16\IN\0|the_22|urinary_18 (r_prep) excretion_15\NN\13466586|NONE_0 (r_pobj) in_12\IN\13603305|in_33|and_4 (r_conj) increase_6\NN\13576355|injury_16|,_190|determined_375 (r_dobj) included_5\VBD\0|NONE_0 (l_conj) determined_75\VBN\0|injury_391|increase_375|,_185 (l_nsubjpass) upregulation_45\NN\0|was_179|by_194|._279 (l_prep) of_46\IN\0|decrease_35 (l_pobj) molecule_49\NN\9465459|NONE_0 (l_compound) injury_48\NN\14052046|kidney_7
D005947_D009336 NONE glucose_20\NN\14710501|total_15|,_2 (r_conj) protein_18\NN\14944888|NONE_0 (r_pobj) of_16\IN\0|the_22|urinary_18 (r_prep) excretion_15\NN\13466586|NONE_0 (r_pobj) in_12\IN\13603305|in_33|and_4 (r_conj) increase_6\NN\13576355|injury_16|,_190|determined_375 (r_dobj) included_5\VBD\0|NONE_0 (l_conj) determined_75\VBN\0|injury_391|increase_375|,_185 (l_nsubjpass) upregulation_45\NN\0|was_179|by_194|._279 (l_parataxis) decrease_53\NN\7296428|of_35 (l_prep) besides_61\IN\0|(_63|kim)-1_62|,_56|in_45|and_20|apoptosis_24 (l_prep) of_62\IN\0|NONE_0 (l_pobj) necrosis_63\NN\11444117|NONE_0
C030272_D011507 CID maleate_12\NN\2718811|NONE_0 (r_pobj) of_11\IN\0|a_19|single_17|in_23 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) by_7\IN\0|proteinuria_46|were_13|._52 (r_agent) induced_6\VBN\1627355|NONE_0 (l_nsubjpass) proteinuria_1\NN\14299637|were_33|by_46|._98
D010100_D007674 NONE oxygen_16\NN\14622893|mitochondrial_14|and_19|activity_23|of_32 (r_compound) consumption_17\NN\13440063|oxidative_39|,_23 (r_conj) stress_13\NN\7083732|hemodynamic_35|,_12 (r_conj) alterations_10\NNS\7283608|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) relation_7\NN\2137|induced_24|:_2 (r_appos) nephrotoxicity_5\NN\0|curcumin_34
D012964_D009336 NONE sodium_22\NN\14625458|,_2 (r_conj) glucose_20\NN\14710501|total_15|,_2 (r_conj) protein_18\NN\14944888|NONE_0 (r_pobj) of_16\IN\0|the_22|urinary_18 (r_prep) excretion_15\NN\13466586|NONE_0 (r_pobj) in_12\IN\13603305|in_33|and_4 (r_conj) increase_6\NN\13576355|injury_16|,_190|determined_375 (r_dobj) included_5\VBD\0|NONE_0 (l_conj) determined_75\VBN\0|injury_391|increase_375|,_185 (l_nsubjpass) upregulation_45\NN\0|was_179|by_194|._279 (l_parataxis) decrease_53\NN\7296428|of_35 (l_prep) besides_61\IN\0|(_63|kim)-1_62|,_56|in_45|and_20|apoptosis_24 (l_prep) of_62\IN\0|NONE_0 (l_pobj) necrosis_63\NN\11444117|NONE_0
C030272_D007674 CID maleate_2\NN\2718811|-_7 (r_npadvmod) induced_4\VBN\1627355|:_22|relation_24 (r_amod) nephrotoxicity_5\NN\0|curcumin_34
C030272_D007674 CID maleate_26\NN\2718811|NONE_0 (r_pobj) by_25\IN\0|NONE_0 (r_agent) induced_24\VBN\1627355|the_17|renal_13 (r_acl) injury_23\NN\14052046|NONE_0
C030272_D007674 CID maleate_0\NNP\2718811|-_7 (r_npadvmod) induced_2\VBN\1627355|renal_8 (r_amod) injury_4\NN\14052046|increase_16|,_206|determined_391
C030272_D007674 CID maleate_0\NNP\2718811|-_7 (r_npadvmod) induced_2\VBN\1627355|renal_8 (r_amod) injury_4\NN\14052046|increase_16|,_206|determined_391 (r_nsubj) included_5\VBD\0|NONE_0 (l_conj) determined_75\VBN\0|injury_391|increase_375|,_185 (l_nsubjpass) upregulation_45\NN\0|was_179|by_194|._279 (l_prep) of_46\IN\0|decrease_35 (l_pobj) molecule_49\NN\9465459|NONE_0 (l_compound) injury_48\NN\14052046|kidney_7
C030272_D007674 CID maleate_11\NN\2718811|-_7 (r_npadvmod) induced_13\VBN\1627355|vivo_13 (r_amod) nephropathy_14\NN\14573196|and_12|in_16
C030272_D009336 CID maleate_0\NNP\2718811|-_7 (r_npadvmod) induced_2\VBN\1627355|renal_8 (r_amod) injury_4\NN\14052046|increase_16|,_206|determined_391 (r_nsubj) included_5\VBD\0|NONE_0 (l_conj) determined_75\VBN\0|injury_391|increase_375|,_185 (l_nsubjpass) upregulation_45\NN\0|was_179|by_194|._279 (l_parataxis) decrease_53\NN\7296428|of_35 (l_prep) besides_61\IN\0|(_63|kim)-1_62|,_56|in_45|and_20|apoptosis_24 (l_prep) of_62\IN\0|NONE_0 (l_pobj) necrosis_63\NN\11444117|NONE_0
D012964_D007674 NONE sodium_22\NN\14625458|,_2 (r_conj) glucose_20\NN\14710501|total_15|,_2 (r_conj) protein_18\NN\14944888|NONE_0 (r_pobj) of_16\IN\0|the_22|urinary_18 (r_prep) excretion_15\NN\13466586|NONE_0 (r_pobj) in_12\IN\13603305|in_33|and_4 (r_conj) increase_6\NN\13576355|injury_16|,_190|determined_375 (r_dobj) included_5\VBD\0|NONE_0 (l_nsubj) injury_4\NN\14052046|increase_16|,_206|determined_391
D012964_D007674 NONE sodium_22\NN\14625458|,_2 (r_conj) glucose_20\NN\14710501|total_15|,_2 (r_conj) protein_18\NN\14944888|NONE_0 (r_pobj) of_16\IN\0|the_22|urinary_18 (r_prep) excretion_15\NN\13466586|NONE_0 (r_pobj) in_12\IN\13603305|in_33|and_4 (r_conj) increase_6\NN\13576355|injury_16|,_190|determined_375 (r_dobj) included_5\VBD\0|NONE_0 (l_conj) determined_75\VBN\0|injury_391|increase_375|,_185 (l_nsubjpass) upregulation_45\NN\0|was_179|by_194|._279 (l_prep) of_46\IN\0|decrease_35 (l_pobj) molecule_49\NN\9465459|NONE_0 (l_compound) injury_48\NN\14052046|kidney_7
24434397
D014148_D051437 NONE acid_1\NN\14818238|induced_16|generalized_24|in_44|._60 (r_compound) seizure_6\NN\14081375|NONE_0 (l_prep) in_7\IN\13603305|acid_44|induced_28|generalized_20|._16 (l_pobj) failure_9\NN\66216|NONE_0
D014148_D012640 NONE acid_1\NN\14818238|induced_16|generalized_24|in_44|._60 (r_compound) seizure_6\NN\14081375|NONE_0
D014148_D012640 NONE tna_14\NNP\0|NONE_0 (r_pobj) of_13\IN\0|an_12 (r_prep) overdose_12\NN\84738|to_9 (r_attr) be_10\VB\14625458|thus_61|,_57|cause_37|was_16|._21 (r_xcomp) believed_8\VBN\686447|NONE_0 (l_nsubjpass) cause_4\NN\7323922|thus_24|,_20|was_21|be_37|._58 (l_prep) of_5\IN\0|the_24|precipitating_20 (l_pobj) convulsions_6\NNS\14081375|NONE_0
D014148_D004830 CID tna_7\NNP\0|NONE_0 (r_pobj) of_6\IN\0|the_15|sixth_11 (r_prep) dose_5\NN\3740161|hours_22 (r_pobj) after_2\IN\0|,_27|she_29|episode_40|._87 (r_prep) had_10\VBD\0|NONE_0 (l_dobj) episode_12\NN\7283608|after_40|,_13|she_11|._47 (l_prep) of_13\IN\0|an_11 (l_pobj) convulsions_17\NNS\14081375|NONE_0
D014148_D062787 NONE tna_14\NNP\0|NONE_0 (r_pobj) of_13\IN\0|an_12 (r_prep) overdose_12\NN\84738|to_9
D014148_D006470 NONE acid_1\NN\14818238|8-hourly_15|was_24|to_41|control_51|._79 (r_nsubjpass) administered_9\VBN\2436349|NONE_0 (l_advcl) control_13\VB\5190804|acid_51|8-hourly_36|was_27|to_10|._28 (l_xcomp) bleeding_14\NN\14285662|to_11
D014148_D006470 NONE tna_3\NNP\0|tranexamic_17|g_7 (r_appos) acid_1\NN\14818238|8-hourly_15|was_24|to_41|control_51|._79 (r_nsubjpass) administered_9\VBN\2436349|NONE_0 (l_advcl) control_13\VB\5190804|acid_51|8-hourly_36|was_27|to_10|._28 (l_xcomp) bleeding_14\NN\14285662|to_11
8135424
D003975_D012640 CID diazepam_9\NN\2830852|mixed_14 (r_compound) intoxications_10\NNS\14034177|NONE_0 (r_pobj) in_5\IN\13603305|and_10|death_6 (r_prep) seizures_2\NNS\14081375|flumazenil_19|._58
D003975_D012640 CID diazepam_17\NN\2830852|combined_17 (r_compound) intoxications_18\NNS\14034177|NONE_0 (r_pobj) of_13\IN\0|a_8 (r_prep) model_12\NN\5888929|NONE_0 (r_pobj) in_10\IN\13603305|incidence_19 (r_prep) increase_5\VB\13576355|flumazenil_35|can_24|seizures_13|and_4|._85 (r_conj) unmask_2\VB\853195|NONE_0 (l_dobj) seizures_3\NNS\14081375|flumazenil_22|can_11|and_9|increase_13|._98
D005442_D012640 CID flumazenil_0\NNP\0|seizures_19|._77 (r_nsubj) induces_1\VBZ\1627355|NONE_0 (l_dobj) seizures_2\NNS\14081375|flumazenil_19|._58
D005442_D012640 CID flumazenil_8\JJ\0|of_33 (r_appos) administration_3\NN\1133281|may_59|seizures_70 (r_nsubj) unmask_10\VB\853195|study_81|:_65|._60 (l_dobj) seizures_11\NNS\14081375|administration_70|may_11
D005442_D012640 CID flumazenil_0\NNP\0|can_11|seizures_22|and_31|increase_35|._120 (r_nsubj) unmask_2\VB\853195|NONE_0 (l_dobj) seizures_3\NNS\14081375|flumazenil_22|can_11|and_9|increase_13|._98
D003042_D012640 CID cocaine_7\NN\3492717|-_7 (r_compound) diazepam_9\NN\2830852|mixed_14 (r_compound) intoxications_10\NNS\14034177|NONE_0 (r_pobj) in_5\IN\13603305|and_10|death_6 (r_prep) seizures_2\NNS\14081375|flumazenil_19|._58
D003042_D012640 CID cocaine_14\NN\3492717|-_7 (r_compound) benzodiazepine_16\NN\3771443|mixed_14 (r_amod) intoxication_17\NN\14034177|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) seizures_11\NNS\14081375|administration_70|may_11
D003042_D012640 CID cocaine_15\NN\3492717|-_7 (r_compound) diazepam_17\NN\2830852|combined_17 (r_compound) intoxications_18\NNS\14034177|NONE_0 (r_pobj) of_13\IN\0|a_8 (r_prep) model_12\NN\5888929|NONE_0 (r_pobj) in_10\IN\13603305|incidence_19 (r_prep) increase_5\VB\13576355|flumazenil_35|can_24|seizures_13|and_4|._85 (r_conj) unmask_2\VB\853195|NONE_0 (l_dobj) seizures_3\NNS\14081375|flumazenil_22|can_11|and_9|increase_13|._98
D001569_D012640 NONE benzodiazepine_6\JJ\3771443|the_4 (r_amod) antagonist_7\NN\7846|NONE_0 (r_pobj) of_4\IN\0|flumazenil_33 (r_prep) administration_3\NN\1133281|may_59|seizures_70 (r_nsubj) unmask_10\VB\853195|study_81|:_65|._60 (l_dobj) seizures_11\NNS\14081375|administration_70|may_11
D001569_D012640 NONE benzodiazepine_16\NN\3771443|mixed_14 (r_amod) intoxication_17\NN\14034177|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) seizures_11\NNS\14081375|administration_70|may_11
24333387
D013311_D020258 NONE streptozotocin_12\NNP\0|NONE_0 (r_pobj) in_11\IN\13603305|the_15|key_11 (r_prep) events_10\NNS\23100|impairment_46 (r_nsubj) induced_16\VBN\1627355|glial_89|and_72|neurotoxicity_54|:_41|._33 (r_acl) activation_1\NN\13561719|NONE_0 (l_conj) neurotoxicity_6\NN\0|glial_35|and_18|:_13|induced_54|._87
D013311_D020258 NONE stz_0\NNP\0|NONE_0 (r_compound) treatment_1\NN\654885|expression_26|camkiia_62|and_70|psd-95_74|remains_152 (r_nsubj) showed_2\VBD\2137132|NONE_0 (l_conj) remains_25\VBZ\2684|treatment_152|expression_126|camkiia_90|and_82|psd-95_78 (l_nsubj) neurotoxicity_31\NN\0|,_125|while_123|,_118|expression_116|._13
D013311_D020258 NONE stz_0\NNP\0|activation_18|._95 (r_nsubj) induced_1\VBN\1627355|NONE_0 (l_dobj) activation_3\NN\13561719|stz_18|._77 (l_conj) death_7\NN\7296428|glial_33|,_17 (l_conj) post_9\VB\8621598|apoptotic_25|cell_15|and_4 (l_dobj) neurotoxicity_11\NN\0|NONE_0
D013311_D020258 NONE stz_16\NNP\0|NONE_0 (r_pobj) in_15\IN\13603305|the_16|key_12|induced_7 (r_prep) factors_14\NNS\7326557|that_66|activation_55 (r_attr) are_11\VBP\13600404|study_77|clearly_71|._76 (l_nsubj) activation_6\NN\13561719|that_11|factors_55 (l_conj) post_8\VB\8621598|glial_21|and_4 (l_dobj) neurotoxicity_10\NN\0|NONE_0
D013311_D007249 CID stz_0\NN\0|expression_21|._106 (r_nsubj) causes_1\VBZ\7323922|NONE_0 (l_dobj) expression_3\NN\4679549|stz_21|._85 (l_prep) of_4\IN\0|increased_21 (l_pobj) gfap_5\NNP\0|NONE_0 (l_appos) activation_14\NN\13561719|,_35|cd11b_33|-_20 (l_conj) neuroinflammation_16\NN\0|a_34|indicating_32|glial_21|and_4
D002118_D064420 NONE ca(2_11\NNP\0|,_2 (r_conj) nitrite_9\NN\14621446|,_2 (r_appos) ros_7\NNP\6894544|NONE_0 (r_pobj) of_6\IN\0|the_10 (r_prep) level_5\NN\4916342|stz_37|also_33|significantly_28|)_28|and_30|reduced_34|._152 (r_dobj) increased_3\VBD\169651|NONE_0 (l_conj) reduced_15\VBD\441445|stz_71|also_67|significantly_62|level_34|)_6|and_4|._118 (l_dobj) activity_18\NN\30358|NONE_0 (l_prep) in_19\IN\13603305|the_27|mitochondrial_23 (l_pobj) preparation_21\NN\407535|NONE_0 (l_acl) illustrating_22\VBG\955601|synaptosomal_25 (l_dobj) generation_25\NN\7942152|NONE_0 (l_conj) excitotoxicity_27\NN\0|free_28|radical_23|and_4
D013311_D064420 NONE streptozotocin_15\NNP\0|NONE_0 (r_pobj) in_13\IN\13603305|glial_44|and_27|toxicity_9 (r_prep) activation_8\NN\13561719|NONE_0 (l_conj) toxicity_12\NN\13576101|glial_35|and_18|in_9
D013311_D064420 NONE stz_17\NNP\0|icv_20 (r_appos) streptozotocin_15\NNP\0|NONE_0 (r_pobj) in_13\IN\13603305|glial_44|and_27|toxicity_9 (r_prep) activation_8\NN\13561719|NONE_0 (l_conj) toxicity_12\NN\13576101|glial_35|and_18|in_9
D013311_D064420 NONE stz_0\NNP\0|also_4|significantly_9|level_37|)_65|and_67|reduced_71|._189 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_conj) reduced_15\VBD\441445|stz_71|also_67|significantly_62|level_34|)_6|and_4|._118 (l_dobj) activity_18\NN\30358|NONE_0 (l_prep) in_19\IN\13603305|the_27|mitochondrial_23 (l_pobj) preparation_21\NN\407535|NONE_0 (l_acl) illustrating_22\VBG\955601|synaptosomal_25 (l_dobj) generation_25\NN\7942152|NONE_0 (l_conj) excitotoxicity_27\NN\0|free_28|radical_23|and_4
D009573_D064420 NONE nitrite_9\NN\14621446|,_2 (r_appos) ros_7\NNP\6894544|NONE_0 (r_pobj) of_6\IN\0|the_10 (r_prep) level_5\NN\4916342|stz_37|also_33|significantly_28|)_28|and_30|reduced_34|._152 (r_dobj) increased_3\VBD\169651|NONE_0 (l_conj) reduced_15\VBD\441445|stz_71|also_67|significantly_62|level_34|)_6|and_4|._118 (l_dobj) activity_18\NN\30358|NONE_0 (l_prep) in_19\IN\13603305|the_27|mitochondrial_23 (l_pobj) preparation_21\NN\407535|NONE_0 (l_acl) illustrating_22\VBG\955601|synaptosomal_25 (l_dobj) generation_25\NN\7942152|NONE_0 (l_conj) excitotoxicity_27\NN\0|free_28|radical_23|and_4
D013311_D008569 CID streptozotocin_12\NNP\0|NONE_0 (r_pobj) in_11\IN\13603305|the_15|key_11 (r_prep) events_10\NNS\23100|impairment_46 (r_nsubj) induced_16\VBN\1627355|glial_89|and_72|neurotoxicity_54|:_41|._33 (l_dobj) impairment_18\NN\7296428|events_46
D013311_D008569 CID streptozotocin_15\NNP\0|NONE_0 (r_pobj) in_13\IN\13603305|glial_44|and_27|toxicity_9 (r_prep) activation_8\NN\13561719|NONE_0 (r_pobj) of_6\IN\0|the_9 (r_prep) role_5\NN\719494|the_22|present_18 (r_dobj) study_3\NN\635850|NONE_0 (r_pobj) in_0\IN\13603305|explored_138|._146 (r_prep) induced_19\VBN\1627355|NONE_0 (l_ccomp) explored_24\VBN\789138|in_138|._8 (l_nsubjpass) rats_22\NNS\2329401|was_5 (l_amod) impaired_21\VBN\258857|NONE_0
D013311_D008569 CID stz_17\NNP\0|icv_20 (r_appos) streptozotocin_15\NNP\0|NONE_0 (r_pobj) in_13\IN\13603305|glial_44|and_27|toxicity_9 (r_prep) activation_8\NN\13561719|NONE_0 (r_pobj) of_6\IN\0|the_9 (r_prep) role_5\NN\719494|the_22|present_18 (r_dobj) study_3\NN\635850|NONE_0 (r_pobj) in_0\IN\13603305|explored_138|._146 (r_prep) induced_19\VBN\1627355|NONE_0 (l_ccomp) explored_24\VBN\789138|in_138|._8 (l_nsubjpass) rats_22\NNS\2329401|was_5 (l_amod) impaired_21\VBN\258857|NONE_0
D013311_D008569 CID stz_21\NNP\0|days_11 (r_pobj) after_20\IN\0|in_89|:_67|deficit_58|was_50|in_40|._38 (r_prep) found_9\VBN\13279262|NONE_0 (l_nsubjpass) deficit_7\NN\5113133|in_31|:_9|was_8|in_18|after_58|._96
D013311_D008569 CID stz_16\NNP\0|NONE_0 (r_pobj) in_15\IN\13603305|the_16|key_12|induced_7 (r_prep) factors_14\NNS\7326557|that_66|activation_55 (l_acl) induced_17\VBN\1627355|the_23|key_19|in_7 (l_dobj) impairment_19\NN\7296428|NONE_0
24587916
D006861_D015431 NONE h2o2_11\NNP\0|significantly_42|and_5|increased_9 (r_dobj) reduced_7\VBD\441445|lf_48|loss_23|and_18|._58 (r_conj) prevented_1\VBD\0|NONE_0 (l_dobj) loss_4\NN\13252973|lf_25|and_5|reduced_23|._81
D003907_D006973 CID dexamethasone_6\NN\2721538|-_13 (r_npadvmod) induced_8\VBN\1627355|in_21 (r_amod) hypertension_9\NN\14057371|NONE_0
D003907_D006973 CID dexamethasone-_0\NNP\0|associated_46|._87 (r_nsubj) induced_4\VBN\1627355|NONE_0 (l_ccomp) associated_7\VBN\628491|dexamethasone-_46|._41 (l_nsubjpass) hypertension_5\NN\14057371|is_13|with_27
D003907_D006973 CID dex-_2\NNP\0|NONE_0 (r_appos) dexamethasone-_0\NNP\0|associated_46|._87 (r_nsubj) induced_4\VBN\1627355|NONE_0 (l_ccomp) associated_7\VBN\628491|dexamethasone-_46|._41 (l_nsubjpass) hypertension_5\NN\14057371|is_13|with_27
D003907_D006973 CID dex_19\NNP\0|NONE_0 (r_compound) administration_20\NN\1133281|NONE_0 (r_pobj) upon_18\IN\0|oxidative_34|and_17|hypertension_13 (r_prep) stress_15\NN\7083732|NONE_0 (l_conj) hypertension_17\NN\14057371|oxidative_21|and_4|upon_13
D003907_D006973 CID dex_0\NNP\0|-_3 (r_npadvmod) induced_2\VBN\1627355|._20 (r_amod) hypertension_3\NN\14057371|NONE_0
D003907_D006973 CID dex_18\NNP\0|-_3 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) hypertension_21\NN\14057371|NONE_0
23952588
D007980_D004409 CID levodopa_5\NN\14604959|-_8 (r_npadvmod) induced_7\VBN\1627355|among_19|with_48 (r_amod) dyskinesia_8\NN\14084880|NONE_0
D007980_D004409 CID levodopa_2\NN\14604959|chronic_18|pulsatile_10|for_17 (r_compound) therapy_3\NN\657604|to_43|._98 (r_nsubj) leads_11\VBZ\5155821|NONE_0 (l_prep) to_12\IN\0|therapy_43|._55 (l_pobj) development_14\NN\248977|NONE_0 (l_prep) of_15\IN\0|the_16 (l_pobj) fluctuations_17\NNS\7345593|NONE_0 (l_conj) dyskinesia_19\NN\14084880|motor_23|and_4
D007980_D004409 CID levodopa_7\NN\14604959|-_8 (r_npadvmod) induced_9\VBN\1627355|among_19 (r_amod) dyskinesia_10\NN\14084880|NONE_0
D007980_D004409 CID levodopa_13\NN\14604959|median_7|of_17 (r_compound) therapy_14\NN\657604|NONE_0 (r_pobj) with_11\IN\0|in_16 (r_prep) present_2\JJ\28270|dyskinesia_15|._63 (r_acomp) was_1\VBD\0|NONE_0 (l_nsubj) dyskinesia_0\NNP\14084880|present_15|._78
D007980_D004409 CID levodopa_16\NN\14604959|NONE_0 (r_compound) therapy_17\NN\657604|NONE_0 (r_pobj) of_15\IN\0|longer_16|0.001_26|,_32|duration_49|,_70|dose_100 (r_prep) duration_14\NN\15113229|patients_66|age_25|,_9|._203 (r_dobj) had_3\VBD\0|NONE_0 (l_nsubj) patients_0\NNS\9898892|age_41|,_57|duration_66|._269 (l_prep) with_1\IN\0|NONE_0 (l_pobj) dyskinesia_2\JJ\14084880|NONE_0
D007980_D004409 CID levodopa_16\NN\14604959|NONE_0 (r_compound) therapy_17\NN\657604|NONE_0 (r_pobj) of_15\IN\0|longer_16|0.001_26|,_32|duration_49|,_70|dose_100 (r_prep) duration_14\NN\15113229|patients_66|age_25|,_9|._203 (l_appos) dose_37\NN\3740161|longer_116|of_100|0.001_74|,_68|duration_51|,_30 (l_conj) scores_48\NNS\13757724|higher_70|total_63|levodopa_51|0.001_31|,_25|and_23 (l_appos) p_50\NN\14622893|higher_28|total_21|updrs_15|(_2 (l_prep) than_54\IN\0|0.005_7|)_2 (l_pobj) patients_55\NNS\9898892|NONE_0 (l_prep) without_56\IN\0|NONE_0 (l_pobj) dyskinesia_57\JJ\14084880|NONE_0
D007980_D004409 CID levodopa_36\NN\14604959|higher_19|total_12|0.001_20|,_26|and_28|scores_51 (r_compound) dose_37\NN\3740161|longer_116|of_100|0.001_74|,_68|duration_51|,_30 (r_appos) duration_14\NN\15113229|patients_66|age_25|,_9|._203 (r_dobj) had_3\VBD\0|NONE_0 (l_nsubj) patients_0\NNS\9898892|age_41|,_57|duration_66|._269 (l_prep) with_1\IN\0|NONE_0 (l_pobj) dyskinesia_2\JJ\14084880|NONE_0
D007980_D004409 CID levodopa_36\NN\14604959|higher_19|total_12|0.001_20|,_26|and_28|scores_51 (r_compound) dose_37\NN\3740161|longer_116|of_100|0.001_74|,_68|duration_51|,_30 (l_conj) scores_48\NNS\13757724|higher_70|total_63|levodopa_51|0.001_31|,_25|and_23 (l_appos) p_50\NN\14622893|higher_28|total_21|updrs_15|(_2 (l_prep) than_54\IN\0|0.005_7|)_2 (l_pobj) patients_55\NNS\9898892|NONE_0 (l_prep) without_56\IN\0|NONE_0 (l_pobj) dyskinesia_57\JJ\14084880|NONE_0
D007980_D004409 CID levodopa_9\NN\14604959|,_16|age_24 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) duration_7\NN\15113229|predictors_30|._70 (r_attr) were_6\VBD\0|NONE_0 (l_nsubj) predictors_3\NNS\10756433|duration_30|._100 (l_prep) of_4\IN\0|the_33|three_29|significant_23 (l_pobj) dyskinesia_5\JJ\14084880|NONE_0
D007980_D004409 CID levodopa_18\NN\14604959|total_12|daily_6 (r_compound) dose_19\NN\3740161|onset_36|,_27|and_25 (r_conj) age_13\NN\4916342|levodopa_24|,_8 (r_conj) therapy_10\NN\657604|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) duration_7\NN\15113229|predictors_30|._70 (r_attr) were_6\VBD\0|NONE_0 (l_nsubj) predictors_3\NNS\10756433|duration_30|._100 (l_prep) of_4\IN\0|the_33|three_29|significant_23 (l_pobj) dyskinesia_5\JJ\14084880|NONE_0
D007980_D004409 CID levodopa_3\NN\14604959|-_8 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) dyskinesia_6\NN\14084880|NONE_0
D007980_D010300 NONE levodopa_5\NN\14604959|-_8 (r_npadvmod) induced_7\VBN\1627355|among_19|with_48 (r_amod) dyskinesia_8\NN\14084880|NONE_0 (l_prep) with_12\IN\0|induced_48|among_29 (l_pobj) disease_15\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_2\NN\14604959|chronic_18|pulsatile_10|for_17 (r_compound) therapy_3\NN\657604|to_43|._98 (l_prep) for_4\IN\0|chronic_35|pulsatile_27|levodopa_17 (l_pobj) disease_7\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_2\NN\14604959|chronic_18|pulsatile_10|for_17 (r_compound) therapy_3\NN\657604|to_43|._98 (l_prep) for_4\IN\0|chronic_35|pulsatile_27|levodopa_17 (l_pobj) disease_7\NN\14061805|NONE_0 (l_appos) pd_9\NNP\14625458|parkinson_21|(_1|)_2
D007980_D010300 NONE levodopa_7\NN\14604959|-_8 (r_npadvmod) induced_9\VBN\1627355|among_19 (r_amod) dyskinesia_10\NN\14084880|NONE_0 (l_prep) among_11\IN\0|induced_19 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|multiethnic_31|malaysian_19 (l_pobj) pd_16\NNP\14625458|NONE_0
D007980_D010300 NONE levodopa_14\NN\14604959|uninterrupted_14 (r_compound) therapy_15\NN\657604|NONE_0 (r_pobj) on_12\IN\0|95_20|with_8 (r_prep) patients_9\NNS\9898892|for_51 (l_prep) with_10\IN\0|95_12|on_8 (l_pobj) pd_11\NNP\14625458|NONE_0
24588023
D014148_D012640 CID acid_4\NN\14818238|NONE_0 (l_conj) seizures_7\NNS\14081375|tranexamic_31|and_15 (l_amod) convulsive_6\JJ\0|NONE_0
D014148_D012640 CID acid_4\NN\14818238|NONE_0 (l_conj) seizures_7\NNS\14081375|tranexamic_31|and_15
D014148_D012640 CID acid_37\NN\14818238|NONE_0 (r_pobj) of_30\IN\0|NONE_0 (r_prep) duration_29\NN\15113229|deep_37|hypothermic_32|circulatory_20|,_2 (r_conj) arrest_27\NN\88481|congestive_55|heart_44|,_31 (r_conj) failure_22\NN\66216|of_37|,_19 (r_conj) calcification_15\NN\13446390|cardiac_17|,_2 (r_conj) surgery_13\NN\6045562|NONE_0 (r_dobj) redo_11\VB\1621555|predictors_63|age_17|._169 (r_conj) included_5\VBD\0|NONE_0 (l_nsubj) predictors_1\NNS\10756433|age_46|redo_63|._232 (l_prep) of_2\IN\0|independent_23 (l_pobj) seizures_4\NNS\14081375|NONE_0
D014148_D012640 CID acid_9\NN\14818238|tested_57|,_13|predictor_30|)_88|._89 (r_nsubj) was_10\VBD\0|NONE_0 (l_attr) predictor_14\NN\10756433|tested_87|,_43|acid_30|)_58|._59 (l_prep) of_15\IN\0|a_31|strong_29|independent_22|0.001_43 (l_pobj) seizures_16\NNS\14081375|NONE_0
D014148_D012640 CID acid_2\NN\14818238|as_14|factor_28 (r_nsubj) is_3\VBZ\0|,_29|administration_35|should_97|be_104|against_115|._157 (r_advcl) weighed_22\VBN\2704349|NONE_0 (l_prep) against_23\IN\0|is_115|,_86|administration_80|should_18|be_11|._42 (l_pobj) risk_25\NN\14541044|NONE_0 (l_prep) of_26\IN\0|the_9 (l_pobj) seizures_28\NNS\14081375|NONE_0
D014148_D007035 NONE acid_37\NN\14818238|NONE_0 (r_pobj) of_30\IN\0|NONE_0 (r_prep) duration_29\NN\15113229|deep_37|hypothermic_32|circulatory_20|,_2 (r_conj) arrest_27\NN\88481|congestive_55|heart_44|,_31 (l_amod) hypothermic_25\JJ\0|deep_5|circulatory_12|,_30|duration_32
D014148_D006333 NONE acid_37\NN\14818238|NONE_0 (r_pobj) of_30\IN\0|NONE_0 (r_prep) duration_29\NN\15113229|deep_37|hypothermic_32|circulatory_20|,_2 (r_conj) arrest_27\NN\88481|congestive_55|heart_44|,_31 (r_conj) failure_22\NN\66216|of_37|,_19
24040781
D016559_D011507 NONE tacrolimus_31\NN\0|NONE_0 (r_pobj) from_30\IN\0|NONE_0 (r_prep) conversion_29\NN\7359599|NONE_0 (r_pobj) after_28\IN\0|who_26|proteinuria_12 (r_prep) developed_26\VBD\1753788|undetermined_30 (l_dobj) proteinuria_27\NN\14299637|who_14|after_12
D020123_D011507 NONE rapamycin_13\NNS\0|(_21|i_27|)_28 (r_amod) inhibitors_14\NNS\20090|NONE_0 (r_pobj) of_12\IN\0|mammalian_17 (r_prep) target_11\NN\7258332|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) treated_8\VBN\2376958|an_48|expected_45|in_23 (r_acl) complication_4\NN\1073995|proteinuria_27|._98 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) proteinuria_0\NNP\14299637|complication_27|._125
D016559_D000686 NONE tacrolimus_31\NN\0|NONE_0 (r_pobj) from_30\IN\0|NONE_0 (r_prep) conversion_29\NN\7359599|NONE_0 (r_pobj) after_28\IN\0|who_26|proteinuria_12 (r_prep) developed_26\VBD\1753788|undetermined_30 (r_relcl) significance_24\NN\5168261|NONE_0 (r_pobj) of_22\IN\0|transplant_33|monoclonal_22 (r_prep) gammapathy_21\JJ\0|NONE_0 (r_pobj) with_16\IN\0|a_27|transplant_19 (r_prep) patient_15\NN\9898892|NONE_0 (r_pobj) in_10\IN\13603305|the_40|unexpected_36|of_15 (r_prep) diagnosis_7\NN\152018|in_38|we_25|._198 (l_prep) of_8\IN\0|the_25|unexpected_21|in_15 (l_pobj) amyloidosis_9\NN\14061805|NONE_0
C107135_D011507 CID everolimus_13\NN\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|an_71|unexpected_68|in_47|:_23|amyloidosis_28|._39 (r_acl) diagnosis_2\NN\152018|NONE_0 (l_prep) in_3\IN\13603305|an_24|unexpected_21|treated_47|:_70|amyloidosis_75|._86 (l_pobj) patient_8\NN\9898892|NONE_0 (l_prep) with_9\IN\0|a_27|transplant_19 (l_pobj) proteinuria_10\NN\14299637|NONE_0
C107135_D011507 CID everolimus_33\NN\0|NONE_0 (r_pobj) to_32\IN\0|NONE_0 (r_prep) tacrolimus_31\NN\0|NONE_0 (r_pobj) from_30\IN\0|NONE_0 (r_prep) conversion_29\NN\7359599|NONE_0 (r_pobj) after_28\IN\0|who_26|proteinuria_12 (r_prep) developed_26\VBD\1753788|undetermined_30 (l_dobj) proteinuria_27\NN\14299637|who_14|after_12
C107135_D000686 CID everolimus_13\NN\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|an_71|unexpected_68|in_47|:_23|amyloidosis_28|._39 (r_acl) diagnosis_2\NN\152018|NONE_0 (l_appos) amyloidosis_16\NN\14061805|an_99|unexpected_96|in_75|treated_28|:_5|._11 (l_compound) al_15\NNP\14625458|NONE_0
C107135_D000686 CID everolimus_13\NN\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|an_71|unexpected_68|in_47|:_23|amyloidosis_28|._39 (r_acl) diagnosis_2\NN\152018|NONE_0 (l_appos) amyloidosis_16\NN\14061805|an_99|unexpected_96|in_75|treated_28|:_5|._11
C107135_D000686 CID everolimus_33\NN\0|NONE_0 (r_pobj) to_32\IN\0|NONE_0 (r_prep) tacrolimus_31\NN\0|NONE_0 (r_pobj) from_30\IN\0|NONE_0 (r_prep) conversion_29\NN\7359599|NONE_0 (r_pobj) after_28\IN\0|who_26|proteinuria_12 (r_prep) developed_26\VBD\1753788|undetermined_30 (r_relcl) significance_24\NN\5168261|NONE_0 (r_pobj) of_22\IN\0|transplant_33|monoclonal_22 (r_prep) gammapathy_21\JJ\0|NONE_0 (r_pobj) with_16\IN\0|a_27|transplant_19 (r_prep) patient_15\NN\9898892|NONE_0 (r_pobj) in_10\IN\13603305|the_40|unexpected_36|of_15 (r_prep) diagnosis_7\NN\152018|in_38|we_25|._198 (l_prep) of_8\IN\0|the_25|unexpected_21|in_15 (l_pobj) amyloidosis_9\NN\14061805|NONE_0
6728873
D002110_D012640 CID caffeine_28\NN\14712692|various_8|in_15|under_37 (r_compound) doses_29\NNS\3740161|NONE_0 (r_pobj) at_26\IN\14622893|characteristics_150|were_12|._117 (r_prep) scored_25\VBN\1111028|NONE_0 (l_nsubjpass) characteristics_2\NNS\5849040|were_138|at_150|._267 (l_acl) righting_7\VBG\126264|five_53|phenotypic_48|--_22|activity_10|--_99 (l_dobj) ability_8\NN\4723816|NONE_0 (l_conj) induction_12\NN\7450842|,_17 (l_compound) seizure_11\NN\14081375|,_17|lethality_34
-1_D064420 NONE alkylxanthines_8\NNS\0|NONE_0 (r_pobj) of_7\IN\0|behavioral_28|toxicity_17|in_18 (r_prep) testing_6\NN\639556|that_25|may_51|misleading_58 (l_compound) toxicity_5\NN\13576101|behavioral_11|of_17|in_35
3375885
D005438_D006947 NONE fludrocortisone_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) reversed_7\VBN\109660|hyperkalemia_54|by_33|and_4|._27 (r_conj) induced_1\VBN\1627355|NONE_0 (l_nsubj) hyperkalemia_0\NNP\14299637|by_21|and_50|reversed_54|._81
D005438_D006947 NONE fludrocortisone_13\NN\0|was_71|,_2|was_16|,_25|correcting_27|._111 (r_nsubjpass) added_15\VBN\156601|NONE_0 (l_advcl) correcting_17\VBG\138508|was_98|,_29|fludrocortisone_27|was_11|,_2|._84 (l_dobj) hyperkalemia_19\NN\14299637|and_13|allowing_17
D011453_D007674 NONE prostaglandin_17\JJ\5414534|synthetase_14 (r_amod) inhibitors_19\NNS\20090|NONE_0 (r_pobj) with_16\IN\0|to_34|acidosis_9 (r_prep) type_11\VB\5839024|that_59|disease_36|patient_11 (r_advcl) predisposed_7\VBD\680841|NONE_0 (l_nsubj) disease_6\NN\14061805|that_23|patient_25|type_36
D008528_D006947 NONE acid_14\NN\14818238|mefenamic_10|caused_79 (r_compound) nephropathy_15\NN\14573196|NONE_0 (l_relcl) caused_23\VBN\1617192|mefenamic_89|acid_79 (l_nsubjpass) hyperkalemia_18\NN\14299637|in_8|were_49|by_61|,_94|without_96
D008528_D006994 NONE acid_14\NN\14818238|mefenamic_10|caused_79 (r_compound) nephropathy_15\NN\14573196|NONE_0 (l_relcl) caused_23\VBN\1617192|mefenamic_89|acid_79 (l_nsubjpass) hyperkalemia_18\NN\14299637|in_8|were_49|by_61|,_94|without_96 (l_conj) hypoaldosteronism_21\NN\0|and_18|inappropriate_14
D008528_D007674 CID acid_14\NN\14818238|mefenamic_10|caused_79 (r_compound) nephropathy_15\NN\14573196|NONE_0
D009288_D001172 NONE naproxen_28\NN\3828465|both_22|and_4 (r_conj) indomethacin_26\NN\3828465|NONE_0 (r_pobj) by_24\IN\0|in_69|hyperkalemia_61|were_12|,_33|without_35 (r_agent) caused_23\VBN\1617192|mefenamic_89|acid_79 (r_relcl) nephropathy_15\NN\14573196|NONE_0 (r_pobj) of_12\IN\0|a_10 (r_prep) history_11\NN\15120823|severe_34|rheumatoid_27|and_6 (r_conj) arthritis_8\NN\14171682|NONE_0
D011453_D006994 NONE prostaglandin_17\JJ\5414534|synthetase_14 (r_amod) inhibitors_19\NNS\20090|NONE_0 (r_pobj) with_16\IN\0|to_34|acidosis_9 (r_prep) type_11\VB\5839024|that_59|disease_36|patient_11 (l_dobj) acidosis_15\NN\14204950|to_25|with_9
D009288_D006947 CID naproxen_5\NN\3828465|and_4 (r_conj) indomethacin_3\NN\3828465|NONE_0 (r_pobj) by_2\IN\0|hyperkalemia_21|and_29|reversed_33|._60 (r_prep) induced_1\VBN\1627355|NONE_0 (l_nsubj) hyperkalemia_0\NNP\14299637|by_21|and_50|reversed_54|._81
D009288_D006947 CID naproxen_28\NN\3828465|both_22|and_4 (r_conj) indomethacin_26\NN\3828465|NONE_0 (r_pobj) by_24\IN\0|in_69|hyperkalemia_61|were_12|,_33|without_35 (r_agent) caused_23\VBN\1617192|mefenamic_89|acid_79 (l_nsubjpass) hyperkalemia_18\NN\14299637|in_8|were_49|by_61|,_94|without_96
D007213_D006947 CID indomethacin_3\NN\3828465|NONE_0 (r_pobj) by_2\IN\0|hyperkalemia_21|and_29|reversed_33|._60 (r_prep) induced_1\VBN\1627355|NONE_0 (l_nsubj) hyperkalemia_0\NNP\14299637|by_21|and_50|reversed_54|._81
D007213_D006947 CID indomethacin_26\NN\3828465|NONE_0 (r_pobj) by_24\IN\0|in_69|hyperkalemia_61|were_12|,_33|without_35 (r_agent) caused_23\VBN\1617192|mefenamic_89|acid_79 (l_nsubjpass) hyperkalemia_18\NN\14299637|in_8|were_49|by_61|,_94|without_96
D007213_D006947 CID indomethacin_22\NN\3828465|NONE_0 (r_compound) therapy_23\NN\657604|to_8|be_11|safely_24 (r_nsubjpass) continued_26\VBN\2367363|NONE_0 (r_ccomp) allowing_21\VBG\0|hyperkalemia_17|and_4 (r_conj) correcting_17\VBG\138508|was_98|,_29|fludrocortisone_27|was_11|,_2|._84 (l_dobj) hyperkalemia_19\NN\14299637|and_13|allowing_17
D007213_D007674 NONE indomethacin_26\NN\3828465|NONE_0 (r_pobj) by_24\IN\0|in_69|hyperkalemia_61|were_12|,_33|without_35 (r_agent) caused_23\VBN\1617192|mefenamic_89|acid_79 (r_relcl) nephropathy_15\NN\14573196|NONE_0
D009288_D007674 NONE naproxen_28\NN\3828465|both_22|and_4 (r_conj) indomethacin_26\NN\3828465|NONE_0 (r_pobj) by_24\IN\0|in_69|hyperkalemia_61|were_12|,_33|without_35 (r_agent) caused_23\VBN\1617192|mefenamic_89|acid_79 (r_relcl) nephropathy_15\NN\14573196|NONE_0
D008528_D001172 NONE acid_14\NN\14818238|mefenamic_10|caused_79 (r_compound) nephropathy_15\NN\14573196|NONE_0 (r_pobj) of_12\IN\0|a_10 (r_prep) history_11\NN\15120823|severe_34|rheumatoid_27|and_6 (r_conj) arthritis_8\NN\14171682|NONE_0
D007213_D001172 NONE indomethacin_26\NN\3828465|NONE_0 (r_pobj) by_24\IN\0|in_69|hyperkalemia_61|were_12|,_33|without_35 (r_agent) caused_23\VBN\1617192|mefenamic_89|acid_79 (r_relcl) nephropathy_15\NN\14573196|NONE_0 (r_pobj) of_12\IN\0|a_10 (r_prep) history_11\NN\15120823|severe_34|rheumatoid_27|and_6 (r_conj) arthritis_8\NN\14171682|NONE_0
D007213_D006994 CID indomethacin_26\NN\3828465|NONE_0 (r_pobj) by_24\IN\0|in_69|hyperkalemia_61|were_12|,_33|without_35 (r_agent) caused_23\VBN\1617192|mefenamic_89|acid_79 (l_nsubjpass) hyperkalemia_18\NN\14299637|in_8|were_49|by_61|,_94|without_96 (l_conj) hypoaldosteronism_21\NN\0|and_18|inappropriate_14
D009288_D006994 CID naproxen_28\NN\3828465|both_22|and_4 (r_conj) indomethacin_26\NN\3828465|NONE_0 (r_pobj) by_24\IN\0|in_69|hyperkalemia_61|were_12|,_33|without_35 (r_agent) caused_23\VBN\1617192|mefenamic_89|acid_79 (l_nsubjpass) hyperkalemia_18\NN\14299637|in_8|were_49|by_61|,_94|without_96 (l_conj) hypoaldosteronism_21\NN\0|and_18|inappropriate_14
9538487
D008094_D001714 NONE lithium_15\NN\14625458|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|manic_17 (r_acl) depression_12\NN\14373582|NONE_0
D005947_D018500 NONE glucose_11\NN\14710501|normal_13 (r_compound) concentrations_12\NNS\4916342|NONE_0 (r_pobj) despite_8\IN\7501545|after_57|,_23|he_21|polyuric_9 (r_prep) remained_6\VBD\2604760|;_61|testing_81|insipidus_120|,_129|likely_131|._159 (r_ccomp) indicated_17\VBD\952524|NONE_0 (l_dobj) insipidus_20\NN\0|remained_120|;_59|testing_39|,_9|likely_11|._39
D005947_-1 NONE glucose_11\NN\14710501|normal_13 (r_compound) concentrations_12\NNS\4916342|NONE_0 (r_pobj) despite_8\IN\7501545|after_57|,_23|he_21|polyuric_9 (r_prep) remained_6\VBD\2604760|;_61|testing_81|insipidus_120|,_129|likely_131|._159 (l_prep) after_0\IN\0|,_34|he_36|polyuric_48|despite_57 (l_pobj) recovery_1\NN\7357388|NONE_0 (l_prep) from_2\IN\0|NONE_0 (l_pobj) hyperglycaemia_3\NN\14299637|NONE_0
D008094_D006944 CID lithium_5\NN\14625458|-_7 (r_npadvmod) induced_7\VBN\1627355|diabetes_20 (r_amod) insipidus_10\NN\0|NONE_0 (r_pobj) by_4\IN\0|coma_18|._49 (r_agent) precipitated_3\VBD\1642924|NONE_0 (l_nsubj) coma_2\NN\5678932|by_18|._67
D008094_D006944 CID lithium_15\NN\14625458|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|manic_17 (r_acl) depression_12\NN\14373582|NONE_0 (r_pobj) of_10\IN\0|a_18|10-year_16 (r_prep) history_9\NN\15120823|NONE_0 (r_pobj) with_6\IN\0|man_5|,_2|,_63|was_65|with_78|,_95|coma_108|._112 (r_prep) admitted_18\VBN\822367|NONE_0 (l_npadvmod) coma_23\NN\5678932|man_113|,_110|with_108|,_45|was_43|with_30|,_13|._4
D008094_-1 NONE lithium_25\NN\14625458|-_7 (r_npadvmod) induced_27\VBN\1627355|to_14 (r_acomp) be_24\VB\14625458|NONE_0 (r_xcomp) likely_22\JJ\0|remained_131|;_70|testing_50|insipidus_11|,_2|._28 (r_amod) indicated_17\VBD\952524|NONE_0 (l_ccomp) remained_6\VBD\2604760|;_61|testing_81|insipidus_120|,_129|likely_131|._159 (l_prep) after_0\IN\0|,_34|he_36|polyuric_48|despite_57 (l_pobj) recovery_1\NN\7357388|NONE_0 (l_prep) from_2\IN\0|NONE_0 (l_pobj) hyperglycaemia_3\NN\14299637|NONE_0
D008094_D011141 CID lithium_25\NN\14625458|-_7 (r_npadvmod) induced_27\VBN\1627355|to_14 (r_acomp) be_24\VB\14625458|NONE_0 (r_xcomp) likely_22\JJ\0|remained_131|;_70|testing_50|insipidus_11|,_2|._28 (r_amod) indicated_17\VBD\952524|NONE_0 (l_ccomp) remained_6\VBD\2604760|;_61|testing_81|insipidus_120|,_129|likely_131|._159 (l_acomp) polyuric_7\JJ\0|after_48|,_14|he_12|despite_9
D008094_D018500 CID lithium_5\NN\14625458|-_7 (r_npadvmod) induced_7\VBN\1627355|diabetes_20 (r_amod) insipidus_10\NN\0|NONE_0
D008094_D018500 CID lithium_25\NN\14625458|-_7 (r_npadvmod) induced_27\VBN\1627355|to_14 (r_acomp) be_24\VB\14625458|NONE_0 (r_xcomp) likely_22\JJ\0|remained_131|;_70|testing_50|insipidus_11|,_2|._28 (r_amod) indicated_17\VBD\952524|NONE_0 (l_dobj) insipidus_20\NN\0|remained_120|;_59|testing_39|,_9|likely_11|._39
D005947_D011141 NONE glucose_20\NN\14710501|NONE_0 (r_pobj) for_19\IN\0|NONE_0 (r_prep) negative_18\JJ\7204401|during_38|urinalysis_20|had_9 (r_acomp) been_17\VBN\0|a_81|year_74|of_61|,_35 (r_relcl) history_6\NN\15120823|he_20|._94 (l_prep) of_7\IN\0|a_20|year_13|,_26|been_61 (l_pobj) polyuria_8\NN\14113228|NONE_0
D005947_D011141 NONE glucose_11\NN\14710501|normal_13 (r_compound) concentrations_12\NNS\4916342|NONE_0 (r_pobj) despite_8\IN\7501545|after_57|,_23|he_21|polyuric_9 (r_prep) remained_6\VBD\2604760|;_61|testing_81|insipidus_120|,_129|likely_131|._159 (l_acomp) polyuric_7\JJ\0|after_48|,_14|he_12|despite_9
D005947_D059606 NONE glucose_20\NN\14710501|NONE_0 (r_pobj) for_19\IN\0|NONE_0 (r_prep) negative_18\JJ\7204401|during_38|urinalysis_20|had_9 (r_acomp) been_17\VBN\0|a_81|year_74|of_61|,_35 (r_relcl) history_6\NN\15120823|he_20|._94 (l_prep) of_7\IN\0|a_20|year_13|,_26|been_61 (l_pobj) polyuria_8\NN\14113228|NONE_0 (l_conj) polydipsia_10\NN\14040660|and_4
2239937
D002119_D006934 CID carbonate_8\NN\15010703|calcium_8 (r_compound) therapy_9\NN\657604|NONE_0 (r_pobj) on_6\IN\0|hemodialysis_22 (r_prep) patients_5\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|NONE_0 (r_prep) hypercalcemia_2\NN\14299637|NONE_0
D002119_D006934 CID carbonate_15\NN\15010703|NONE_0 (r_pobj) to_13\IN\0|as_21 (r_prep) switching_12\VBG\191142|NONE_0 (r_pcomp) after_11\IN\0|patients_36|hypercalcemic_14|._72 (r_prep) became_9\VBD\146138|NONE_0 (l_acomp) hypercalcemic_10\JJ\0|patients_22|after_14|._86
D010710_D006934 NONE phosphate_19\NN\15010703|their_16|principal_10 (r_compound) binder_20\NN\3496892|NONE_0 (r_pobj) as_16\IN\14622893|to_21 (r_prep) switching_12\VBG\191142|NONE_0 (r_pcomp) after_11\IN\0|patients_36|hypercalcemic_14|._72 (r_prep) became_9\VBD\146138|NONE_0 (l_acomp) hypercalcemic_10\JJ\0|patients_22|after_14|._86
D002118_D007674 NONE calcium_17\NN\14625458|intestinal_11|and_21|rate_39 (r_compound) reabsorption_18\NN\13526110|NONE_0 (r_pobj) of_15\IN\0|indirect_20|in_58 (r_prep) parameters_14\NNS\5858936|risk_72|associated_59|,_11 (r_appos) factors_5\NNS\7326557|to_17 (r_dobj) identify_3\VB\699815|NONE_0 (r_acl) order_1\NN\7168131|NONE_0 (r_pobj) in_0\IN\13603305|were_183|with_197|._315 (r_prep) compared_28\VBN\644583|NONE_0 (l_prep) with_29\IN\0|in_197|were_14|._118 (l_pobj) results_30\NNS\34213|NONE_0 (l_prep) in_31\IN\13603305|NONE_0 (l_pobj) patients_34\NNS\9898892|NONE_0 (l_acl) matched_35\VBN\2664769|14_23|eucalcemic_20 (l_prep) for_36\IN\0|NONE_0 (l_pobj) age_37\NN\4916342|NONE_0 (l_conj) sex_39\NN\13440063|,_2 (l_conj) length_41\NN\5093581|,_2 (l_conj) etiology_48\NN\7326557|of_25|on_17|,_6|and_4 (l_prep) of_49\IN\0|NONE_0 (l_pobj) disease_51\NN\14061805|NONE_0
D002118_D006934 NONE calcium_17\NN\14625458|intestinal_11|and_21|rate_39 (r_compound) reabsorption_18\NN\13526110|NONE_0 (r_pobj) of_15\IN\0|indirect_20|in_58 (r_prep) parameters_14\NNS\5858936|risk_72|associated_59|,_11 (r_appos) factors_5\NNS\7326557|to_17 (l_acl) associated_6\VBN\628491|risk_13|,_48|parameters_59 (l_prep) with_7\IN\0|NONE_0 (l_pobj) development_9\NN\248977|NONE_0 (l_prep) of_10\IN\0|the_16 (l_pobj) hypercalcemia_11\NN\14299637|NONE_0
D002118_D006934 NONE calcium_8\NN\14625458|peak_5|of_15 (r_compound) values_9\NNS\5941423|NONE_0 (r_pobj) with_6\IN\0|hypercalcemic_23 (r_prep) episodes_5\NNS\7283608|NONE_0 (l_amod) hypercalcemic_4\JJ\0|with_23
D002118_D006934 NONE calcium_8\NN\14625458|peak_5|of_15 (r_compound) values_9\NNS\5941423|NONE_0 (r_pobj) with_6\IN\0|hypercalcemic_23 (r_prep) episodes_5\NNS\7283608|NONE_0 (r_dobj) experiencing_3\VBG\2108377|NONE_0 (r_pcomp) to_2\IN\0|NONE_0 (r_prep) addition_1\NN\3081021|NONE_0 (r_pobj) in_0\IN\13603305|,_117|patients_119|increase_179|._440 (r_prep) exhibited_31\VBD\2632167|NONE_0 (l_nsubj) patients_26\NNS\9898892|in_119|,_2|increase_60|._321 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) group_30\NN\2137|NONE_0 (l_amod) hypercalcemic_29\NN\0|the_4
D002118_D006934 NONE calcium_38\NN\14625458|the_9|mean_5 (r_compound) concentration_39\NN\4916342|NONE_0 (r_pobj) in_35\IN\13603305|a_23|significant_21|obtained_34|,_76|compared_78 (r_prep) increase_34\NN\13576355|in_179|,_62|patients_60|._261 (r_dobj) exhibited_31\VBD\2632167|NONE_0 (l_prep) in_0\IN\13603305|,_117|patients_119|increase_179|._440 (l_pobj) addition_1\NN\3081021|NONE_0 (l_prep) to_2\IN\0|NONE_0 (l_pcomp) experiencing_3\VBG\2108377|NONE_0 (l_dobj) episodes_5\NNS\7283608|NONE_0 (l_amod) hypercalcemic_4\JJ\0|with_23
D002118_D006934 NONE calcium_38\NN\14625458|the_9|mean_5 (r_compound) concentration_39\NN\4916342|NONE_0 (r_pobj) in_35\IN\13603305|a_23|significant_21|obtained_34|,_76|compared_78 (r_prep) increase_34\NN\13576355|in_179|,_62|patients_60|._261 (r_dobj) exhibited_31\VBD\2632167|NONE_0 (l_nsubj) patients_26\NNS\9898892|in_119|,_2|increase_60|._321 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) group_30\NN\2137|NONE_0 (l_amod) hypercalcemic_29\NN\0|the_4
2625524
D000661_D012640 CID amphetamine_4\NN\3248958|-_11 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) seizures_7\NNS\14081375|to_31
D000661_D012640 CID amphetamine_18\NN\3248958|dose_5 (r_compound) exposure_19\NN\5042871|NONE_0 (r_pobj) from_14\IN\0|NONE_0 (r_prep) death_13\NN\7296428|NONE_0 (r_pobj) against_12\IN\0|the_41|dopamine_29|haloperidol_12 (r_prep) blocker_10\NN\10101634|NONE_0 (r_pobj) for_6\IN\0|a_18|protective_16|without_95 (r_prep) role_5\NN\719494|data_26|._142 (l_prep) without_20\IN\0|a_113|protective_111|for_95 (l_pcomp) reducing_21\VBG\13447361|NONE_0 (l_dobj) incidence_23\NN\13821570|NONE_0 (l_prep) of_24\IN\0|the_14 (l_pobj) seizures_25\NNS\14081375|NONE_0
D006220_D012640 NONE haloperidol_0\NNP\3713736|prevent_22|,_58|but_60|lower_68|._113 (r_nsubj) failed_1\VBD\0|NONE_0 (l_xcomp) prevent_3\VB\0|haloperidol_22|,_36|but_38|lower_46|._91 (l_dobj) seizures_7\NNS\14081375|to_31
D006220_D012640 NONE haloperidol_0\NN\3713736|incidence_26|at_64|,_88|but_90|reach_137 (r_nsubj) decreased_1\VBD\169651|NONE_0 (l_dobj) incidence_3\NN\13821570|haloperidol_26|at_38|,_62|but_64|reach_111 (l_prep) of_4\IN\0|the_14 (l_pobj) seizures_8\NNS\14081375|NONE_0
D006220_D012640 NONE haloperidol_11\NN\3713736|the_29|dopamine_17|against_12 (r_appos) blocker_10\NN\10101634|NONE_0 (r_pobj) for_6\IN\0|a_18|protective_16|without_95 (r_prep) role_5\NN\719494|data_26|._142 (l_prep) without_20\IN\0|a_113|protective_111|for_95 (l_pcomp) reducing_21\VBG\13447361|NONE_0 (l_dobj) incidence_23\NN\13821570|NONE_0 (l_prep) of_24\IN\0|the_14 (l_pobj) seizures_25\NNS\14081375|NONE_0
D006220_D012640 NONE haloperidol_3\NN\3713736|in_13|,_2|ability_28|._111 (r_nsubj) demonstrated_4\VBD\2137132|NONE_0 (l_dobj) ability_6\NN\4723816|in_41|,_30|haloperidol_28|._83 (l_acl) reduce_8\VB\441445|an_14 (l_dobj) seizures_12\NNS\14081375|to_26|without_9
D004298_D012640 NONE dopamine_9\NN\14807737|the_12|haloperidol_17|against_29 (r_compound) blocker_10\NN\10101634|NONE_0 (r_pobj) for_6\IN\0|a_18|protective_16|without_95 (r_prep) role_5\NN\719494|data_26|._142 (l_prep) without_20\IN\0|a_113|protective_111|for_95 (l_pcomp) reducing_21\VBG\13447361|NONE_0 (l_dobj) incidence_23\NN\13821570|NONE_0 (l_prep) of_24\IN\0|the_14 (l_pobj) seizures_25\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_5\NN\3492717|-_7 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) seizures_8\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_9\NN\3492717|-_7 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) seizures_12\NNS\14081375|to_26|without_9
11299446
C027429_D010302 CID veralipride_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_8 (r_prep) use_5\NN\407535|NONE_0 (r_pobj) after_3\IN\0|of_16 (r_prep) worsening_0\VBG\13457378|:_81|case_83|._94 (l_prep) of_1\IN\0|after_16 (l_pobj) parkinsonism_2\NN\14085708|NONE_0
C027429_D010302 CID veralipride_27\NN\0|NONE_0 (r_pobj) with_26\IN\0|related_17 (r_prep) symptoms_25\NNS\5823932|of_21 (r_appos) therapy_21\NN\657604|NONE_0 (r_pobj) following_20\VBG\8180190|who_56|has_52|worsening_33 (r_prep) shown_12\VBN\2137132|stable_35|parkinson_28 (r_relcl) disease_9\NN\14061805|NONE_0
3831029
C037293_D001145 NONE denopamine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|these_12 (r_prep) doses_6\NNS\3740161|NONE_0 (r_pobj) by_4\IN\0|arrhythmias_25|were_13|._28 (r_agent) induced_3\VBN\1627355|NONE_0 (l_nsubjpass) arrhythmias_1\NNS\14103288|were_12|by_25|._53
C037293_D006333 NONE denopamine_2\NN\0|NONE_0 (r_pobj) by_1\IN\0|of_23|._97 (r_prep) improvement_0\NN\7359599|NONE_0 (l_prep) of_6\IN\0|by_23|._74 (l_pobj) failure_11\NN\66216|)_35
C037293_D006333 NONE ta-064_4\NNP\0|NONE_0 (r_punct) )_5\-RRB-\0|failure_35 (r_punct) of_6\IN\0|by_23|._74 (l_pobj) failure_11\NN\66216|)_35
C037293_D006333 NONE denopamine_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_13|,_13|agonist_52|,_59 (r_prep) efficacy_1\NN\5199286|in_70|was_99|in_112|._142 (r_nsubjpass) assessed_17\VBN\670261|NONE_0 (l_prep) in_12\IN\13603305|efficacy_70|was_29|in_42|._72 (l_pcomp) improving_13\VBG\126264|NONE_0 (l_dobj) failure_15\NN\66216|NONE_0
C037293_D006333 NONE denopamine_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|clinical_16|in_14 (r_prep) trials_4\NNS\786195|results_25|._56 (l_prep) in_7\IN\13603305|clinical_30|of_14 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_14 (l_pobj) failure_12\NN\66216|NONE_0
D010424_D006333 CID pentobarbital_7\NN\2792049|-_13 (r_npadvmod) induced_9\VBN\1627355|cardiac_8|in_24 (r_amod) failure_11\NN\66216|)_35
2974281
D007545_D006332 CID isoproterenol_8\NN\3740161|-_13 (r_npadvmod) induced_10\VBN\1627355|rat_8|heart_12|in_30 (r_amod) hypertrophy_13\NN\14365950|NONE_0
D007545_D006332 CID isoproterenol_9\NN\3740161|-_13 (r_npadvmod) induced_11\VBN\1627355|heart_8|in_26 (r_amod) hypertrophy_13\NN\14365950|NONE_0
D007545_D006332 CID isoproterenol_24\NN\3740161|to_11|from_14 (r_dobj) prevent_23\VB\0|24/76_26|potency_11 (l_prep) from_25\IN\0|to_25|isoproterenol_14 (l_pcomp) producing_26\VBG\1617192|NONE_0 (l_dobj) hypertrophy_28\NN\14365950|NONE_0
D009952_D006332 NONE ornithine_7\NN\14601829|NONE_0 (r_compound) decarboxylase_8\NN\14732946|the_24|increased_20|with_23 (r_compound) activity_9\NN\30358|to_50 (l_prep) with_10\IN\0|the_47|increased_43|decarboxylase_23 (l_pobj) blockers_14\NNS\10101634|NONE_0 (l_prep) in_15\IN\13603305|both_19|beta_14|-_10 (l_pobj) hearts_17\NNS\496167|NONE_0
D011433_D006332 NONE propranolol_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|subacute_17|on_27|._108 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) on_7\IN\0|subacute_44|of_27|._81 (l_pobj) hypertrophy_13\NN\14365950|NONE_0
D011433_D006332 NONE propranolol_15\NN\0|any_45 (l_conj) have_19\VBP\7846|that_56|blockers_33|and_12 (l_advcl) prevent_23\VB\0|24/76_26|potency_11 (l_prep) from_25\IN\0|to_25|isoproterenol_14 (l_pcomp) producing_26\VBG\1617192|NONE_0 (l_dobj) hypertrophy_28\NN\14365950|NONE_0
D011433_D006984 NONE propranolol_1\NN\0|could_24|changes_39|._124 (r_csubj) stop_6\VB\7291312|NONE_0 (l_dobj) changes_8\NNS\7283608|propranolol_39|could_15|._85 (l_prep) in_9\IN\13603305|the_12 (l_pobj) pattern_14\NN\5726345|myosin_17 (l_prep) of_15\IN\0|isoenzyme_18 (l_pobj) heart_19\NN\5919034|NONE_0 (l_amod) hypertrophied_17\JJ\230746|the_4|rat_14
24100257
C089750_D054549 CID zolmitriptan_10\NNP\0|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) secondary_8\JJ\8426461|ballooning_21|)_2|._25 (r_amod) syndrome_6\NN\5870365|takotsubo_41|(_22|or_21 (r_conj) syndrome_1\NN\5870365|NONE_0
C089750_D054549 CID zolmitriptan_10\NNP\0|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) secondary_8\JJ\8426461|ballooning_21|)_2|._25 (r_amod) syndrome_6\NN\5870365|takotsubo_41|(_22|or_21
C089750_D054549 CID zolmitriptan_12\NN\0|artery_30|secondary_13 (r_advcl) vasospasm_9\NN\0|NONE_0 (r_pobj) of_6\IN\0|multiple_15 (r_prep) cases_5\NNS\7283608|search_25|,_60|but_62|associated_89 (r_dobj) revealed_3\VBD\2137132|NONE_0 (l_conj) associated_20\VBN\628491|search_114|cases_89|,_29|but_27 (l_prep) with_21\IN\0|none_34|were_16|._7 (l_pobj) ts_22\NNP\14999913|NONE_0
C089750_D008881 NONE zolmitriptan_9\NN\0|that_22|patient_13|sparingly_13|had_37 (r_dobj) took_8\VBD\2367363|history_59|retrospectively_42|._55 (l_advcl) had_14\VBD\0|that_59|patient_50|zolmitriptan_37|sparingly_24 (l_dobj) migraines_15\NNS\14326607|only_18|when_13|she_8
C089750_D008881 NONE zolmitriptan_8\JJ\0|but_38|before_34|,_17|she_15|was_11|2_13|daily_23|for_29|because_46|._87 (r_dobj) taking_7\VBG\37396|NONE_0 (l_prep) because_17\IN\0|but_84|before_80|,_63|she_61|was_57|zolmitriptan_46|2_33|daily_23|for_17|._41 (l_pobj) headache_22\NN\5829480|of_25
C089750_D003329 CID zolmitriptan_12\NN\0|artery_30|secondary_13 (r_advcl) vasospasm_9\NN\0|NONE_0
15987266
D010862_D013226 CID pilocarpine_46\NN\14712692|NONE_0 (r_pobj) by_45\IN\0|epilepticus_20 (r_agent) induced_44\VBN\1627355|the_157|(_143|densitometry_142|of_106 (l_amod) epilepticus_43\NN\0|by_20
D010862_D013226 CID pilo_48\NNP\0|NONE_0 (r_appos) pilocarpine_46\NN\14712692|NONE_0 (r_pobj) by_45\IN\0|epilepticus_20 (r_agent) induced_44\VBN\1627355|the_157|(_143|densitometry_142|of_106 (l_amod) epilepticus_43\NN\0|by_20
D003513_D013226 NONE cycloheximide_56\NN\0|not_9 (r_pobj) with_55\IN\0|previously_27|or_7|chx_20 (r_conj) injected_52\VBN\81072|investigate_276|,_213|we_211|intensity_195|,_13|._77 (r_conj) assessed_13\VBD\670261|NONE_0 (l_dobj) intensity_15\NN\5090441|investigate_81|,_18|we_16|,_182|injected_195|._272 (l_acl) induced_44\VBN\1627355|the_157|(_143|densitometry_142|of_106 (l_amod) epilepticus_43\NN\0|by_20
D003513_D013226 NONE chx_58\NNP\0|previously_47|or_27|with_20 (r_appos) injected_52\VBN\81072|investigate_276|,_213|we_211|intensity_195|,_13|._77 (r_conj) assessed_13\VBD\670261|NONE_0 (l_dobj) intensity_15\NN\5090441|investigate_81|,_18|we_16|,_182|injected_195|._272 (l_acl) induced_44\VBN\1627355|the_157|(_143|densitometry_142|of_106 (l_amod) epilepticus_43\NN\0|by_20
D003513_D004827 NONE cycloheximide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|expression_76|._18 (r_prep) treated_14\VBN\2376958|NONE_0 (l_nsubj) expression_5\NN\4679549|with_76|._94 (l_prep) in_6\IN\13603305|protein_22|43_14 (l_pobj) layer_9\NN\21939|NONE_0 (l_prep) of_10\IN\0|hippocampal_28|molecular_16 (l_pobj) rats_13\NNS\2329401|NONE_0 (l_amod) epileptic_12\JJ\10595647|chronic_8
19728177
D000082_D001929 CID acetaminophen_27\NN\2707683|NONE_0 (r_pobj) from_26\IN\0|a_58|care_47|in_33|and_19 (r_prep) facility_17\NN\21939|NONE_0 (r_pobj) in_13\IN\13603305|based_61|from_42|edema_103|._108 (r_prep) observations_3\NNS\996969|NONE_0 (l_conj) edema_31\NN\14315192|based_164|from_145|in_103|._5
D000082_D001929 CID acetaminophen_5\NN\2707683|NONE_0 (l_conj) edema_8\NN\14315192|and_13
D000082_D001929 CID acetaminophen_8\NN\2707683|NONE_0 (r_compound) overdose_9\NN\84738|NONE_0 (r_pobj) from_7\IN\0|cerebral_15 (r_prep) edema_6\NN\14315192|and_13
D000082_D062787 NONE acetaminophen_8\NN\2707683|NONE_0 (r_compound) overdose_9\NN\84738|NONE_0
D000082_D017114 CID acetaminophen_27\NN\2707683|NONE_0 (r_pobj) from_26\IN\0|a_58|care_47|in_33|and_19 (r_prep) facility_17\NN\21939|NONE_0 (l_prep) in_18\IN\13603305|a_25|care_14|from_33|and_52 (l_pobj) female_23\NN\15388|NONE_0 (l_prep) with_24\IN\0|a_21|old_11 (l_pobj) fhf_25\NNP\0|NONE_0
D000082_D017114 CID acetaminophen_5\NN\2707683|NONE_0 (r_pobj) from_4\IN\0|evaluation_25|fhf_4|._37 (r_prep) confirmed_2\VBN\0|NONE_0 (l_dobj) fhf_3\NNP\0|evaluation_21|from_4|._41
D000082_D017114 CID acetaminophen_8\NN\2707683|NONE_0 (r_compound) overdose_9\NN\84738|NONE_0 (r_pobj) from_7\IN\0|cerebral_15 (r_prep) edema_6\NN\14315192|and_13 (r_conj) fhf_3\NNP\0|NONE_0
D000082_D007035 NONE acetaminophen_8\NN\2707683|NONE_0 (r_compound) overdose_9\NN\84738|NONE_0 (r_pobj) from_7\IN\0|cerebral_15 (r_prep) edema_6\NN\14315192|and_13 (r_conj) fhf_3\NNP\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) patients_1\NNS\9898892|NONE_0 (r_pobj) in_0\IN\13603305|,_67|hypothermia_91|could_103|potentially_109|be_121|as_129|._203 (r_prep) used_17\VBN\0|NONE_0 (l_nsubjpass) hypothermia_13\NN\14034177|in_91|,_24|could_12|potentially_18|be_30|as_38|._112
D000082_D064420 NONE acetaminophen_16\NN\2707683|NONE_0 (r_pobj) from_15\IN\0|presumed_18|ingested_29 (r_prep) toxicity_14\NN\13576101|NONE_0
19531695
D005424_D064420 NONE flecainide_5\JJ\2715941|when_5|is_11|with_25 (r_nsubjpass) prescribed_7\VBN\748282|because_46|toxicity_38|may_29 (r_advcl) occur_3\VB\0|should_121|be_128|closely_141|with_149|._187 (l_nsubj) toxicity_1\NN\13576101|because_8|may_9|prescribed_38
D005424_D064420 NONE flecainide_16\JJ\2715941|plasma_11 (r_amod) concentrations_18\NNS\4916342|and_54|inhibitors_30|,_20 (r_conj) paroxetine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|when_30|flecainide_25|is_14 (r_prep) prescribed_7\VBN\748282|because_46|toxicity_38|may_29 (r_advcl) occur_3\VB\0|should_121|be_128|closely_141|with_149|._187 (l_nsubj) toxicity_1\NN\13576101|because_8|may_9|prescribed_38
D017374_D003693 CID paroxetine_18\NN\0|NONE_0 (r_pobj) with_17\IN\0|a_35|pharmacokinetic_33|drug_17 (r_prep) interaction_16\NN\37396|NONE_0 (r_pobj) of_12\IN\0|the_9 (r_prep) role_11\NN\719494|in_62|:_6|._58 (r_appos) delirium_0\NN\14391660|NONE_0
D017374_D003693 CID paroxetine_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_35|pharmacokinetic_33|drug_17 (r_prep) interaction_14\NN\37396|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|induced_17 (r_acl) delirium_8\NN\14391660|NONE_0
D017374_D003693 CID paroxetine_24\NN\0|a_24|cyp2d6_22|,_6|and_4 (l_appos) inhibitor_28\NN\20090|,_11 (l_conj) reports_35\NNS\6470073|a_38|cyp2d6_36|,_20|as_10 (l_prep) of_36\IN\0|3_15|case_13 (l_pobj) delirium_40\NN\14391660|NONE_0
D017374_D003693 CID paroxetine_33\NN\0|and_4 (r_conj) flecainide_31\NN\2715941|NONE_0 (r_pobj) between_30\IN\0|a_44|possible_42|pharmacokinetic_33|drug_17 (r_prep) interaction_29\NN\37396|was_136|;_88|scale_48|._45 (r_dobj) indicates_24\VBZ\952524|NONE_0 (l_ccomp) was_8\VBD\0|;_48|scale_88|interaction_136|._181 (l_attr) cause_11\NN\7323922|according_72|,_30|flecainide_28 (l_prep) of_12\IN\0|the_19|probable_15 (l_pobj) delirium_16\NN\14391660|NONE_0
D012964_D003693 NONE sodium_8\NN\14625458|NONE_0 (r_compound) channels_9\NNS\6251781|NONE_0 (r_pobj) with_7\IN\0|that_14 (r_prep) interact_6\VBP\2367363|flecainide_53 (r_relcl) agents_4\NNS\7347|may_42|delirium_52|._84 (r_nsubj) cause_11\VB\7323922|NONE_0 (l_dobj) delirium_12\NN\14391660|agents_52|may_10|._32
D005424_D001281 NONE flecainide_0\NNP\2715941|had_11|been_15|prior_36|._65 (r_nsubjpass) started_3\VBN\0|NONE_0 (l_advmod) prior_6\RB\10675876|flecainide_36|had_25|been_21|._29 (l_prep) for_7\IN\0|weeks_12 (l_pobj) fibrillation_9\NN\14361664|NONE_0
D017374_D064420 NONE paroxetine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|when_30|flecainide_25|is_14 (r_prep) prescribed_7\VBN\748282|because_46|toxicity_38|may_29 (r_advcl) occur_3\VB\0|should_121|be_128|closely_141|with_149|._187 (l_nsubj) toxicity_1\NN\13576101|because_8|may_9|prescribed_38
D005424_D003693 CID flecainide_6\JJ\2715941|toxic_6|plasma_11 (r_amod) concentrations_8\NNS\4916342|NONE_0 (r_pobj) with_4\IN\0|a_10 (r_prep) patient_3\NN\9898892|NONE_0 (r_pobj) in_1\IN\13603305|:_56|role_62|._120 (r_prep) delirium_0\NN\14391660|NONE_0
D005424_D003693 CID flecainide_5\RB\2715941|-_10 (r_advmod) induced_7\VBN\1627355|associated_17 (r_amod) delirium_8\NN\14391660|NONE_0
D005424_D003693 CID flecainide_0\NNP\2715941|interact_53 (r_amod) agents_4\NNS\7347|may_42|delirium_52|._84 (r_nsubj) cause_11\VB\7323922|NONE_0 (l_dobj) delirium_12\NN\14391660|agents_52|may_10|._32
D005424_D003693 CID flecainide_17\NN\2715941|NONE_0 (r_pobj) between_16\IN\0|the_16 (r_prep) interaction_15\NN\37396|NONE_0 (r_pobj) on_13\IN\0|pharmacokinetic_22|,_37|substrate_48 (r_prep) study_12\NN\635850|search_64|one_28|._157 (l_conj) substrate_21\NN\19613|pharmacokinetic_70|on_48|,_11 (l_conj) paroxetine_24\NN\0|a_24|cyp2d6_22|,_6|and_4 (l_appos) inhibitor_28\NN\20090|,_11 (l_conj) reports_35\NNS\6470073|a_38|cyp2d6_36|,_20|as_10 (l_prep) of_36\IN\0|3_15|case_13 (l_pobj) delirium_40\NN\14391660|NONE_0
D005424_D003693 CID flecainide_37\RB\2715941|-_10 (r_advmod) induced_39\VBN\1627355|NONE_0 (r_amod) delirium_40\NN\14391660|NONE_0
D005424_D003693 CID flecainide_7\NN\2715941|according_44|,_2|cause_28 (r_advmod) was_8\VBD\0|;_48|scale_88|interaction_136|._181 (l_attr) cause_11\NN\7323922|according_72|,_30|flecainide_28 (l_prep) of_12\IN\0|the_19|probable_15 (l_pobj) delirium_16\NN\14391660|NONE_0
D005424_D003693 CID flecainide_31\NN\2715941|NONE_0 (r_pobj) between_30\IN\0|a_44|possible_42|pharmacokinetic_33|drug_17 (r_prep) interaction_29\NN\37396|was_136|;_88|scale_48|._45 (r_dobj) indicates_24\VBZ\952524|NONE_0 (l_ccomp) was_8\VBD\0|;_48|scale_88|interaction_136|._181 (l_attr) cause_11\NN\7323922|according_72|,_30|flecainide_28 (l_prep) of_12\IN\0|the_19|probable_15 (l_pobj) delirium_16\NN\14391660|NONE_0
D005424_D003693 CID flecainide_1\JJ\2715941|supratherapeutic_17|plasma_11 (r_amod) concentrations_3\NNS\4916342|may_15|delirium_25|._33 (r_nsubj) cause_5\VB\7323922|NONE_0 (l_dobj) delirium_6\NN\14391660|concentrations_25|may_10|._8
6631522
D004317_D066126 CID doxorubicin_23\NN\2716866|NONE_0 (r_compound) cardiotoxicity_24\NN\0|NONE_0
C013102_D066126 NONE ha_16\NNP\13888491|that_83|changes_74|i-131_6|not_7|factor_26 (r_nsubj) are_17\VBP\13600404|findings_103|._59 (l_attr) factor_21\NN\7326557|that_109|changes_100|i-131_32|ha_26|not_19 (l_prep) in_22\IN\13603305|the_22|initiating_18 (l_pobj) cardiotoxicity_24\NN\0|NONE_0
25951420
D052638_D010300 CID matter_9\NN\5670710|and_21 (r_conj) ozone_5\NN\14877585|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) associations_3\NNS\8008335|study_16|with_50|._124 (r_dobj) describes_2\VBZ\1001294|NONE_0 (l_prep) with_10\IN\0|study_66|associations_50|._74 (l_pobj) disease_13\NN\14061805|NONE_0
D052638_D010300 CID matter_28\NN\5670710|to_30|)_23|and_21 (r_conj) 0.98_21\CD\0|odds_27|=_16|1.39_14|;_10|ci_4|:_2 (r_appos) ratio_13\NN\13815152|positive_62|of_40|(_6 (r_appos) associations_4\NNS\8008335|:_23|we_21|._192 (l_prep) of_5\IN\0|positive_22|(_34|ratio_40 (l_pobj) disease_8\NN\14061805|NONE_0
D010126_D010300 CID ozone_2\NN\14877585|NONE_0 (r_pobj) of_1\IN\0|with_34|._110 (r_prep) associations_0\NNS\8008335|NONE_0 (l_prep) with_6\IN\0|of_34|._76 (l_pobj) disease_9\NNP\14061805|NONE_0
D010126_D010300 CID ozone_5\NN\14877585|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) associations_3\NNS\8008335|study_16|with_50|._124 (r_dobj) describes_2\VBZ\1001294|NONE_0 (l_prep) with_10\IN\0|study_66|associations_50|._74 (l_pobj) disease_13\NN\14061805|NONE_0
D010126_D010300 CID ozone_10\NN\14877585|NONE_0 (r_pobj) with_9\IN\0|parkinson_20 (r_prep) disease_8\NN\14061805|NONE_0
11395263
D000431_D009203 NONE ethanol_5\NN\14708720|the_4|of_16 (r_compound) extract_6\NN\14589223|NONE_0 (r_pobj) of_3\IN\0|the_28|cardioprotective_24|rhizomes_45|on_69 (r_prep) effect_2\NN\34213|has_190|been_194|._211 (l_prep) on_16\IN\0|the_97|cardioprotective_93|of_69|rhizomes_24 (l_pobj) infarction_21\NN\14204950|NONE_0
D007545_D009203 CID isoproterenol_17\NN\3740161|-_13 (r_npadvmod) induced_19\VBN\1627355|myocardial_8|in_30 (r_amod) infarction_21\NN\14204950|NONE_0
D007545_D009203 CID isoproterenol_9\NN\3740161|-_13 (r_npadvmod) induced_11\VBN\1627355|the_18|myocardial_8 (r_amod) infarction_13\NN\14204950|day(-1_82|significantly_61|and_11|maintained_15|._56
2907577
D003404_D009336 NONE creatinine_10\NN\0|biochemical_29|(_17|plasma_16|and_4|)_10|,_11|analysis_31 (r_conj) urea_8\NN\14727670|NONE_0 (l_conj) analysis_16\NN\633864|biochemical_60|(_48|plasma_47|and_35|creatinine_31|)_21|,_20 (l_conj) degree_31\NN\4916342|functional_103|(_92|urine_91|and_76|clearances_31|and_19|indices_20 (l_prep) of_32\IN\0|morphological_22|(_8|)_11 (l_pobj) necrosis_33\NN\11444117|NONE_0
D014508_D009336 NONE urea_8\NN\14727670|NONE_0 (l_conj) analysis_16\NN\633864|biochemical_60|(_48|plasma_47|and_35|creatinine_31|)_21|,_20 (l_conj) degree_31\NN\4916342|functional_103|(_92|urine_91|and_76|clearances_31|and_19|indices_20 (l_prep) of_32\IN\0|morphological_22|(_8|)_11 (l_pobj) necrosis_33\NN\11444117|NONE_0
D000241_D058186 NONE adenosine_0\NNP\14964367|NONE_0 (r_amod) antagonists_1\NNS\7846|have_12|been_17|previously_22|be_42|._125 (r_nsubjpass) shown_5\VBN\2137132|NONE_0 (l_xcomp) be_7\VB\14625458|antagonists_42|have_30|been_25|previously_20|._83 (l_prep) in_10\IN\13603305|to_17|of_11 (l_pobj) models_15\NNS\5888929|NONE_0 (l_prep) of_16\IN\0|some_38|ischaemic_33 (l_pobj) failure_19\NN\66216|NONE_0
D000241_D058186 NONE adenosine_0\NNP\14964367|NONE_0 (r_amod) antagonists_1\NNS\7846|have_12|been_17|previously_22|be_42|._125 (r_nsubjpass) shown_5\VBN\2137132|NONE_0 (l_xcomp) be_7\VB\14625458|antagonists_42|have_30|been_25|previously_20|._83 (l_prep) in_10\IN\13603305|to_17|of_11 (l_pobj) models_15\NNS\5888929|NONE_0 (l_prep) of_16\IN\0|some_38|ischaemic_33 (l_pobj) failure_19\NN\66216|NONE_0 (l_appos) arf_21\NNP\0|acute_21|renal_15|(_1|)_3
D000241_D058186 NONE adenosine_14\NN\14964367|,_42|theophylline_44 (r_amod) antagonists_15\NNS\7846|NONE_0 (r_pobj) as_13\IN\14622893|different_20 (r_prep) potencies_12\NNS\5196375|NONE_0 (r_pobj) with_10\IN\0|three_21 (r_prep) alkylxanthines_9\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_12 (r_prep) effects_6\NNS\13245626|in_26|,_6|,_133|were_135|in_149|)_239|._240 (r_nsubjpass) examined_23\VBN\0|NONE_0 (l_prep) in_24\IN\13603305|in_175|,_155|effects_149|,_16|were_14|)_90|._91 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_acl) developing_26\VBG\13541167|NONE_0 (l_dobj) failure_29\NN\66216|after_8
D000241_D058186 NONE adenosine_18\NN\14964367|that_5|little_16|,_22|role_51 (r_nsubj) plays_19\VBZ\7007684|NONE_0 (l_dobj) role_26\NN\719494|that_56|adenosine_51|little_35|,_29 (l_prep) in_27\IN\13603305|any_29|,_26|pathophysiological_24 (l_pobj) arf_31\NN\0|NONE_0
D010130_D009336 NONE acid_25\NN\14818238|3h]inulin_35|)_15 (r_compound) clearances_26\NNS\5089947|functional_72|(_61|urine_60|and_45|and_12|degree_31|indices_51 (r_conj) analysis_16\NN\633864|biochemical_60|(_48|plasma_47|and_35|creatinine_31|)_21|,_20 (l_conj) degree_31\NN\4916342|functional_103|(_92|urine_91|and_76|clearances_31|and_19|indices_20 (l_prep) of_32\IN\0|morphological_22|(_8|)_11 (l_pobj) necrosis_33\NN\11444117|NONE_0
D005839_D058186 CID gentamicin_4\NN\2716866|-_10 (r_npadvmod) induced_6\VBN\1627355|acute_8|renal_14|in_28 (r_amod) failure_9\NN\66216|NONE_0
D005839_D058186 CID gentamicin_35\NN\2716866|NONE_0 (r_pobj) of_34\IN\0|4_19|daily_17|(_14|kg-1_22 (r_prep) injections_33\NNS\320852|NONE_0 (r_pobj) after_30\IN\0|failure_8 (r_prep) developing_26\VBG\13541167|NONE_0 (l_dobj) failure_29\NN\66216|after_8
D005839_D058186 CID gentamicin_28\NN\2716866|-_10 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) arf_31\NN\0|NONE_0
D000241_D007674 NONE adenosine_0\NNP\14964367|NONE_0 (r_amod) antagonists_1\NNS\7846|have_12|been_17|previously_22|be_42|._125 (r_nsubjpass) shown_5\VBN\2137132|NONE_0 (l_xcomp) be_7\VB\14625458|antagonists_42|have_30|been_25|previously_20|._83 (l_prep) in_10\IN\13603305|to_17|of_11 (l_pobj) models_15\NNS\5888929|NONE_0 (l_amod) ischaemic_12\JJ\0|some_5|of_33 (l_conj) nephrotoxic_14\JJ\0|and_4
D013806_D058186 NONE theophylline_18\NN\2905612|adenosine_44|,_2 (r_amod) antagonists_15\NNS\7846|NONE_0 (r_pobj) as_13\IN\14622893|different_20 (r_prep) potencies_12\NNS\5196375|NONE_0 (r_pobj) with_10\IN\0|three_21 (r_prep) alkylxanthines_9\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_12 (r_prep) effects_6\NNS\13245626|in_26|,_6|,_133|were_135|in_149|)_239|._240 (r_nsubjpass) examined_23\VBN\0|NONE_0 (l_prep) in_24\IN\13603305|in_175|,_155|effects_149|,_16|were_14|)_90|._91 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_acl) developing_26\VBG\13541167|NONE_0 (l_dobj) failure_29\NN\66216|after_8
C028322_D058186 NONE 8-phenyltheophylline_16\NN\0|NONE_0 (r_punct) ,_17\,\0|adenosine_42|theophylline_2 (r_punct) antagonists_15\NNS\7846|NONE_0 (r_pobj) as_13\IN\14622893|different_20 (r_prep) potencies_12\NNS\5196375|NONE_0 (r_pobj) with_10\IN\0|three_21 (r_prep) alkylxanthines_9\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_12 (r_prep) effects_6\NNS\13245626|in_26|,_6|,_133|were_135|in_149|)_239|._240 (r_nsubjpass) examined_23\VBN\0|NONE_0 (l_prep) in_24\IN\13603305|in_175|,_155|effects_149|,_16|were_14|)_90|._91 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_acl) developing_26\VBG\13541167|NONE_0 (l_dobj) failure_29\NN\66216|after_8
D000241_D007511 NONE adenosine_0\NNP\14964367|NONE_0 (r_amod) antagonists_1\NNS\7846|have_12|been_17|previously_22|be_42|._125 (r_nsubjpass) shown_5\VBN\2137132|NONE_0 (l_xcomp) be_7\VB\14625458|antagonists_42|have_30|been_25|previously_20|._83 (l_prep) in_10\IN\13603305|to_17|of_11 (l_pobj) models_15\NNS\5888929|NONE_0 (l_amod) ischaemic_12\JJ\0|some_5|of_33
-1_D058186 NONE alkylxanthines_2\NNS\0|NONE_0 (l_prep) on_3\IN\0|NONE_0 (l_pobj) failure_9\NN\66216|NONE_0
-1_D058186 NONE alkylxanthines_9\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_12 (r_prep) effects_6\NNS\13245626|in_26|,_6|,_133|were_135|in_149|)_239|._240 (r_nsubjpass) examined_23\VBN\0|NONE_0 (l_prep) in_24\IN\13603305|in_175|,_155|effects_149|,_16|were_14|)_90|._91 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_acl) developing_26\VBG\13541167|NONE_0 (l_dobj) failure_29\NN\66216|after_8
-1_D058186 NONE alkylxanthines_10\NNS\0|NONE_0 (r_pobj) with_8\IN\0|lack_47|indicates_52|._148 (r_prep) noted_7\VBN\1009240|NONE_0 (l_ccomp) indicates_16\VBZ\952524|lack_99|with_52|._96 (l_ccomp) plays_19\VBZ\7007684|NONE_0 (l_dobj) role_26\NN\719494|that_56|adenosine_51|little_35|,_29 (l_prep) in_27\IN\13603305|any_29|,_26|pathophysiological_24 (l_pobj) arf_31\NN\0|NONE_0
C034347_D058186 NONE enprofylline_20\NN\0|and_4 (r_conj) theophylline_18\NN\2905612|adenosine_44|,_2 (r_amod) antagonists_15\NNS\7846|NONE_0 (r_pobj) as_13\IN\14622893|different_20 (r_prep) potencies_12\NNS\5196375|NONE_0 (r_pobj) with_10\IN\0|three_21 (r_prep) alkylxanthines_9\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_12 (r_prep) effects_6\NNS\13245626|in_26|,_6|,_133|were_135|in_149|)_239|._240 (r_nsubjpass) examined_23\VBN\0|NONE_0 (l_prep) in_24\IN\13603305|in_175|,_155|effects_149|,_16|were_14|)_90|._91 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_acl) developing_26\VBG\13541167|NONE_0 (l_dobj) failure_29\NN\66216|after_8
2983630
D000241_D009421 NONE adenosine_4\NN\14964367|an_3|receptor_10 (r_amod) antagonist_6\NN\7846|because_42|caffeine_34 (r_attr) is_2\VBZ\0|,_35|results_43|have_97|._155 (r_advcl) suggest_10\VBP\1010118|NONE_0 (l_ccomp) have_17\VB\7846|is_97|,_62|results_54|._58 (l_dobj) abnormalities_18\NNS\14034177|that_43|patients_18|may_9 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) systems_21\NNS\3575240|NONE_0
D000241_D009421 NONE adenosine_23\NN\14964367|NONE_0 (r_dobj) involving_22\VBG\2676054|neuronal_17 (r_acl) systems_21\NNS\3575240|NONE_0
D008734_D000379 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0
D008734_D000379 NONE mhpg_26\RB\0|(_1|)_4|and_6|cortisol_10 (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0
D006854_D016584 NONE cortisol_29\NN\14751417|(_11|mhpg_10|)_6|and_4 (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) attacks_48\NNS\955060|NONE_0
D006854_D016584 NONE cortisol_29\NN\14751417|(_11|mhpg_10|)_6|and_4 (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) attacks_48\NNS\955060|NONE_0 (l_conj) disorder_51\NN\14034177|panic_23|or_9
D002110_D009421 NONE caffeine_1\NN\14712692|because_8|antagonist_34 (r_nsubj) is_2\VBZ\0|,_35|results_43|have_97|._155 (r_advcl) suggest_10\VBP\1010118|NONE_0 (l_ccomp) have_17\VB\7846|is_97|,_62|results_54|._58 (l_dobj) abnormalities_18\NNS\14034177|that_43|patients_18|may_9 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) systems_21\NNS\3575240|NONE_0
D002110_D009325 CID caffeine_0\NN\14712692|increases_40|compared_159|._189 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) increases_4\NNS\13576355|caffeine_40|compared_119|._149 (l_prep) in_5\IN\13603305|greater_18 (l_pobj) anxiety_9\NN\14373582|NONE_0 (l_conj) nervousness_11\NN\7523905|rated_15|,_2|in_67 (l_conj) fear_13\NN\7480068|,_2 (l_conj) nausea_15\NN\14299637|,_2
D002110_D001008 CID caffeine_0\NN\14712692|increases_40|compared_159|._189 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) increases_4\NNS\13576355|caffeine_40|compared_119|._149 (l_prep) in_5\IN\13603305|greater_18 (l_pobj) anxiety_9\NN\14373582|NONE_0
D002110_D001008 CID caffeine_8\NN\14712692|-_8 (r_npadvmod) containing_10\VBG\2632940|and_17|beverages_21 (r_amod) foods_11\NNS\20090|NONE_0 (r_dobj) avoiding_7\VBG\0|NONE_0 (r_pcomp) by_6\IN\0|patients_44|may_12|._51 (r_prep) benefit_5\VB\13278375|NONE_0 (l_nsubj) patients_0\NNS\9898892|may_32|by_44|._95 (l_prep) with_1\IN\0|NONE_0 (l_pobj) disorders_3\NNS\14034177|NONE_0
D000241_D016584 NONE adenosine_4\NN\14964367|an_3|receptor_10 (r_amod) antagonist_6\NN\7846|because_42|caffeine_34 (r_attr) is_2\VBZ\0|,_35|results_43|have_97|._155 (r_advcl) suggest_10\VBP\1010118|NONE_0 (l_ccomp) have_17\VB\7846|is_97|,_62|results_54|._58 (l_nsubj) patients_15\NNS\9898892|that_25|may_9|abnormalities_18 (l_compound) disorder_14\NN\14034177|some_11
D000241_D016584 NONE adenosine_23\NN\14964367|NONE_0 (r_dobj) involving_22\VBG\2676054|neuronal_17 (r_acl) systems_21\NNS\3575240|NONE_0 (r_pobj) in_19\IN\13603305|NONE_0 (r_prep) abnormalities_18\NNS\14034177|that_43|patients_18|may_9 (r_dobj) have_17\VB\7846|is_97|,_62|results_54|._58 (l_nsubj) patients_15\NNS\9898892|that_25|may_9|abnormalities_18 (l_compound) disorder_14\NN\14034177|some_11
D006854_D000379 NONE cortisol_29\NN\14751417|(_11|mhpg_10|)_6|and_4 (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) attacks_48\NNS\955060|NONE_0
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) attacks_48\NNS\955060|NONE_0 (l_conj) disorder_51\NN\14034177|panic_23|or_9
D008734_D016584 NONE mhpg_26\RB\0|(_1|)_4|and_6|cortisol_10 (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) attacks_48\NNS\955060|NONE_0
D008734_D016584 NONE mhpg_26\RB\0|(_1|)_4|and_6|cortisol_10 (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE_0 (r_pobj) of_23\IN\0|blood_33|and_18|levels_7 (r_prep) pressure_19\NN\11419404|somatic_24|,_8 (r_conj) symptoms_16\NNS\5823932|behavioral_28|,_10 (r_conj) ratings_13\NNS\5733583|NONE_0 (r_pobj) on_11\IN\0|the_58|of_46|(_11|mg/kg_7|)_2 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) attacks_48\NNS\955060|NONE_0 (l_conj) disorder_51\NN\14034177|panic_23|or_9
D002110_-1 NONE caffeine_0\NN\14712692|increases_40|compared_159|._189 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) increases_4\NNS\13576355|caffeine_40|compared_119|._149 (l_prep) in_5\IN\13603305|greater_18 (l_pobj) anxiety_9\NN\14373582|NONE_0 (l_conj) nervousness_11\NN\7523905|rated_15|,_2|in_67 (l_conj) fear_13\NN\7480068|,_2 (l_conj) nausea_15\NN\14299637|,_2 (l_conj) palpitations_17\NNS\14299637|,_2
D002110_D011595 NONE caffeine_0\NN\14712692|increases_40|compared_159|._189 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) increases_4\NNS\13576355|caffeine_40|compared_119|._149 (l_prep) in_5\IN\13603305|greater_18 (l_pobj) anxiety_9\NN\14373582|NONE_0 (l_conj) nervousness_11\NN\7523905|rated_15|,_2|in_67 (l_conj) fear_13\NN\7480068|,_2 (l_conj) nausea_15\NN\14299637|,_2 (l_conj) palpitations_17\NNS\14299637|,_2 (l_conj) restlessness_19\NN\4773351|,_2
D002110_D014202 CID caffeine_0\NN\14712692|increases_40|compared_159|._189 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) increases_4\NNS\13576355|caffeine_40|compared_119|._149 (l_prep) in_5\IN\13603305|greater_18 (l_pobj) anxiety_9\NN\14373582|NONE_0 (l_conj) nervousness_11\NN\7523905|rated_15|,_2|in_67 (l_conj) fear_13\NN\7480068|,_2 (l_conj) nausea_15\NN\14299637|,_2 (l_conj) palpitations_17\NNS\14299637|,_2 (l_conj) restlessness_19\NN\4773351|,_2 (l_conj) tremors_22\NNS\345926|,_6|and_4
D002110_D016584 NONE caffeine_4\NN\14712692|NONE_0 (r_pobj) of_3\IN\0|increased_29|anxiogenic_19|in_12|._30 (r_prep) effects_2\NNS\13245626|NONE_0 (l_prep) in_5\IN\13603305|increased_41|anxiogenic_31|of_12|._18 (l_pobj) disorders_7\NNS\14034177|NONE_0
D002110_D016584 NONE caffeine_6\NN\14712692|NONE_0 (r_pobj) of_5\IN\0|oral_20 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_12|(_35|mg/kg_39|)_44|on_46 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) attacks_48\NNS\955060|NONE_0
D002110_D016584 NONE caffeine_6\NN\14712692|NONE_0 (r_pobj) of_5\IN\0|oral_20 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_12|(_35|mg/kg_39|)_44|on_46 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0 (l_prep) with_46\IN\0|NONE_0 (l_pobj) attacks_48\NNS\955060|NONE_0 (l_conj) disorder_51\NN\14034177|panic_23|or_9
D002110_D016584 NONE caffeine_13\NN\14712692|NONE_0 (r_pobj) of_12\IN\0|the_23|behavioral_19 (r_prep) effects_11\NNS\13245626|that_20|similar_25 (r_nsubj) were_14\VBD\0|percent_73|._54 (l_acomp) similar_15\JJ\0|that_45|effects_25 (l_prep) to_16\IN\0|NONE_0 (l_pobj) those_17\DT\0|NONE_0 (l_acl) experienced_18\VBN\2108377|NONE_0 (l_prep) during_19\IN\0|NONE_0 (l_pobj) attacks_21\NNS\955060|NONE_0
D002110_D016584 NONE caffeine_1\NN\14712692|because_8|antagonist_34 (r_nsubj) is_2\VBZ\0|,_35|results_43|have_97|._155 (r_advcl) suggest_10\VBP\1010118|NONE_0 (l_ccomp) have_17\VB\7846|is_97|,_62|results_54|._58 (l_nsubj) patients_15\NNS\9898892|that_25|may_9|abnormalities_18 (l_compound) disorder_14\NN\14034177|some_11
D002110_D000379 NONE caffeine_6\NN\14712692|NONE_0 (r_pobj) of_5\IN\0|oral_20 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_12|(_35|mg/kg_39|)_44|on_46 (r_prep) effects_1\NNS\13245626|were_189|in_205|meeting_244|._321 (r_nsubjpass) determined_31\VBN\0|NONE_0 (l_advcl) meeting_39\VBG\7975026|effects_244|were_55|in_39|._77 (l_dobj) criteria_43\NNS\13577171|patients_25 (l_prep) for_44\IN\0|iii_13 (l_pobj) agoraphobia_45\NN\14381416|NONE_0
9128918
D004298_D006966 NONE dopamine_5\NN\14807737|NONE_0 (r_compound) neurons_6\NNS\5430628|NONE_0 (r_pobj) in_4\IN\13603305|NONE_0 (r_prep) changes_3\NNS\7283608|chronic_31|and_4|._27 (r_conj) hyperprolactinemia_1\NN\0|NONE_0
D004298_D006966 NONE dopamine_9\NN\14807737|a_2|receptor_9|,_28|and_30|technique_61 (r_compound) antagonist_11\NN\7846|,_22 (r_appos) haloperidol_6\NN\3713736|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) treatment_4\NN\654885|NONE_0 (r_pobj) by_3\IN\0|hyperprolactinemia_31|was_12|used_167|._244 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) hyperprolactinemia_0\NNP\0|was_19|by_31|used_198|._275
D004298_D006966 NONE dopamine_6\NN\14807737|(_9|da_10|)_12|in_29 (r_nmod) concentrations_10\NNS\4916342|after_52|,_16|by_53|over_60|._82 (r_nsubj) increased_18\VBN\169651|NONE_0 (l_prep) after_0\IN\0|,_36|concentrations_52|by_105|over_112|._134 (l_pobj) months_2\NNS\15113229|NONE_0 (l_prep) of_3\IN\0|6_9 (l_pobj) hyperprolactinemia_4\NN\0|NONE_0
D004298_D006966 NONE da_8\NNP\10484858|dopamine_10|(_1|)_2|in_19 (r_nmod) concentrations_10\NNS\4916342|after_52|,_16|by_53|over_60|._82 (r_nsubj) increased_18\VBN\169651|NONE_0 (l_prep) after_0\IN\0|,_36|concentrations_52|by_105|over_112|._134 (l_pobj) months_2\NNS\15113229|NONE_0 (l_prep) of_3\IN\0|6_9 (l_pobj) hyperprolactinemia_4\NN\0|NONE_0
D004298_D006966 NONE da_10\NNP\10484858|in_18 (r_compound) concentrations_11\NNS\4916342|NONE_0 (r_pobj) in_9\IN\13603305|a_15|%_11|over_31 (r_prep) increase_8\NN\13576355|months_44|._62 (r_dobj) produced_4\VBD\1617192|NONE_0 (l_nsubj) months_1\NNS\15113229|increase_44|._106 (l_prep) of_2\IN\0|nine_12 (l_pobj) hyperprolactinemia_3\NN\0|NONE_0
D004298_D006966 NONE da_2\NNP\10484858|NONE_0 (r_compound) response_3\NN\11410625|however_12|,_5|was_9|followed_79|._216 (r_nsubjpass) lost_5\VBN\7942152|NONE_0 (l_advcl) followed_15\VBN\1835496|however_91|,_84|response_79|was_70|._137 (l_nsubjpass) hyperprolactinemia_13\NN\0|if_38|was_19|by_32
D004298_D006966 NONE da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_prep) after_70\IN\0|a_60|in_49|in_10|and_37|increase_44 (l_pobj) 6-months_71\IN\0|NONE_0 (l_prep) of_72\IN\0|NONE_0 (l_pobj) hyperprolactinemia_73\NN\0|NONE_0
D004298_D006966 NONE da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_conj) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (l_prep) after_83\IN\0|an_43|in_31|in_10 (l_pobj) 9-months_84\JJ\0|NONE_0 (l_prep) of_85\IN\0|NONE_0 (l_pobj) hyperprolactinemia_86\NN\0|NONE_0
D004298_D006966 NONE da_78\NNP\10484858|NONE_0 (r_compound) concentrations_79\NNS\4916342|NONE_0 (r_pobj) in_77\IN\13603305|an_12|in_21|after_31 (r_prep) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (r_conj) decrease_60\NN\7296428|NONE_0 (l_prep) after_70\IN\0|a_60|in_49|in_10|and_37|increase_44 (l_pobj) 6-months_71\IN\0|NONE_0 (l_prep) of_72\IN\0|NONE_0 (l_pobj) hyperprolactinemia_73\NN\0|NONE_0
D004298_D006966 NONE da_78\NNP\10484858|NONE_0 (r_compound) concentrations_79\NNS\4916342|NONE_0 (r_pobj) in_77\IN\13603305|an_12|in_21|after_31 (r_prep) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (l_prep) after_83\IN\0|an_43|in_31|in_10 (l_pobj) 9-months_84\JJ\0|NONE_0 (l_prep) of_85\IN\0|NONE_0 (l_pobj) hyperprolactinemia_86\NN\0|NONE_0
D009638_D006966 NONE norepinephrine_10\NN\14807929|,_2|serotonin_21 (r_appos) da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_prep) after_70\IN\0|a_60|in_49|in_10|and_37|increase_44 (l_pobj) 6-months_71\IN\0|NONE_0 (l_prep) of_72\IN\0|NONE_0 (l_pobj) hyperprolactinemia_73\NN\0|NONE_0
D009638_D006966 NONE norepinephrine_10\NN\14807929|,_2|serotonin_21 (r_appos) da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_conj) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (l_prep) after_83\IN\0|an_43|in_31|in_10 (l_pobj) 9-months_84\JJ\0|NONE_0 (l_prep) of_85\IN\0|NONE_0 (l_pobj) hyperprolactinemia_86\NN\0|NONE_0
D009638_D006966 NONE ne_12\NNP\14622893|NONE_0 (r_appos) norepinephrine_10\NN\14807929|,_2|serotonin_21 (r_appos) da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_prep) after_70\IN\0|a_60|in_49|in_10|and_37|increase_44 (l_pobj) 6-months_71\IN\0|NONE_0 (l_prep) of_72\IN\0|NONE_0 (l_pobj) hyperprolactinemia_73\NN\0|NONE_0
D009638_D006966 NONE ne_12\NNP\14622893|NONE_0 (r_appos) norepinephrine_10\NN\14807929|,_2|serotonin_21 (r_appos) da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_conj) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (l_prep) after_83\IN\0|an_43|in_31|in_10 (l_pobj) 9-months_84\JJ\0|NONE_0 (l_prep) of_85\IN\0|NONE_0 (l_pobj) hyperprolactinemia_86\NN\0|NONE_0
D006220_D006966 CID haloperidol_6\NN\3713736|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) treatment_4\NN\654885|NONE_0 (r_pobj) by_3\IN\0|hyperprolactinemia_31|was_12|used_167|._244 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) hyperprolactinemia_0\NNP\0|was_19|by_31|used_198|._275
D006220_D006966 CID haloperidol_10\NN\3713736|-_11 (r_npadvmod) induced_12\VBN\1627355|a_27|long_17 (r_amod) hyperprolactinemia_13\NN\0|if_38|was_19|by_32
D006897_D006966 NONE acid_63\NN\14818238|NONE_0 (r_pobj) in_61\IN\13603305|a_11|in_39|after_49|and_86|increase_93 (r_prep) decrease_60\NN\7296428|NONE_0 (l_prep) after_70\IN\0|a_60|in_49|in_10|and_37|increase_44 (l_pobj) 6-months_71\IN\0|NONE_0 (l_prep) of_72\IN\0|NONE_0 (l_pobj) hyperprolactinemia_73\NN\0|NONE_0
D006897_D006966 NONE acid_63\NN\14818238|NONE_0 (r_pobj) in_61\IN\13603305|a_11|in_39|after_49|and_86|increase_93 (r_prep) decrease_60\NN\7296428|NONE_0 (l_conj) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (l_prep) after_83\IN\0|an_43|in_31|in_10 (l_pobj) 9-months_84\JJ\0|NONE_0 (l_prep) of_85\IN\0|NONE_0 (l_pobj) hyperprolactinemia_86\NN\0|NONE_0
D006897_D006966 NONE 5-hiaa_65\CD\0|5-hydroxyindoleacetic_28|(_1|)_6 (r_appos) acid_63\NN\14818238|NONE_0 (r_pobj) in_61\IN\13603305|a_11|in_39|after_49|and_86|increase_93 (r_prep) decrease_60\NN\7296428|NONE_0 (l_prep) after_70\IN\0|a_60|in_49|in_10|and_37|increase_44 (l_pobj) 6-months_71\IN\0|NONE_0 (l_prep) of_72\IN\0|NONE_0 (l_pobj) hyperprolactinemia_73\NN\0|NONE_0
D006897_D006966 NONE 5-hiaa_65\CD\0|5-hydroxyindoleacetic_28|(_1|)_6 (r_appos) acid_63\NN\14818238|NONE_0 (r_pobj) in_61\IN\13603305|a_11|in_39|after_49|and_86|increase_93 (r_prep) decrease_60\NN\7296428|NONE_0 (l_conj) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (l_prep) after_83\IN\0|an_43|in_31|in_10 (l_pobj) 9-months_84\JJ\0|NONE_0 (l_prep) of_85\IN\0|NONE_0 (l_pobj) hyperprolactinemia_86\NN\0|NONE_0
D012701_D006966 NONE serotonin_15\NN\14807737|,_23|norepinephrine_21 (r_appos) da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_prep) after_70\IN\0|a_60|in_49|in_10|and_37|increase_44 (l_pobj) 6-months_71\IN\0|NONE_0 (l_prep) of_72\IN\0|NONE_0 (l_pobj) hyperprolactinemia_73\NN\0|NONE_0
D012701_D006966 NONE serotonin_15\NN\14807737|,_23|norepinephrine_21 (r_appos) da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_conj) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (l_prep) after_83\IN\0|an_43|in_31|in_10 (l_pobj) 9-months_84\JJ\0|NONE_0 (l_prep) of_85\IN\0|NONE_0 (l_pobj) hyperprolactinemia_86\NN\0|NONE_0
D012701_D006966 NONE 5-ht_17\CD\0|(_1|)_4|,_5|or_7|metabolites_16 (r_appos) serotonin_15\NN\14807737|,_23|norepinephrine_21 (r_appos) da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_prep) after_70\IN\0|a_60|in_49|in_10|and_37|increase_44 (l_pobj) 6-months_71\IN\0|NONE_0 (l_prep) of_72\IN\0|NONE_0 (l_pobj) hyperprolactinemia_73\NN\0|NONE_0
D012701_D006966 NONE 5-ht_17\CD\0|(_1|)_4|,_5|or_7|metabolites_16 (r_appos) serotonin_15\NN\14807737|,_23|norepinephrine_21 (r_appos) da_8\NNP\10484858|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) levels_6\NNS\4916342|NONE_0 (r_pobj) in_4\IN\13603305|no_10 (r_prep) change_3\NN\7283608|there_13|,_143|putamen_153|._404 (r_attr) was_1\VBD\0|NONE_0 (l_attr) putamen_39\NNS\5497363|there_166|change_153|,_10|._251 (l_prep) except_57\IN\807461|caudate_68|cp_51|,_48|nigra_35|,_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) decrease_60\NN\7296428|NONE_0 (l_conj) increase_76\NN\13576355|a_104|in_93|in_54|after_44|and_7 (l_prep) after_83\IN\0|an_43|in_31|in_10 (l_pobj) 9-months_84\JJ\0|NONE_0 (l_prep) of_85\IN\0|NONE_0 (l_pobj) hyperprolactinemia_86\NN\0|NONE_0
11936424
D011692_D006984 NONE aminonucleoside_43\NN\0|(_16|)_20 (r_nmod) pan_45\NNP\3101986|glomerulosclerosis_57|in_38 (r_npadvmod) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (r_conj) inhibited_34\VBD\2510337|to_154 (l_dobj) hypertrophy_36\NN\14365950|whether_162|administration_146|and_12|prevented_16
D011692_D006984 NONE pan_45\NNP\3101986|glomerulosclerosis_57|in_38 (r_npadvmod) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (r_conj) inhibited_34\VBD\2510337|to_154 (l_dobj) hypertrophy_36\NN\14365950|whether_162|administration_146|and_12|prevented_16
C055603_D009404 NONE temocapril_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|chronic_23|,_13|angiotensin_42 (r_prep) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (r_nsubj) inhibited_34\VBD\2510337|to_154 (r_ccomp) determine_8\VB\0|purpose_36|induced_262|._284 (r_xcomp) was_6\VBD\0|NONE_0 (l_conj) induced_48\VBN\1627355|purpose_298|determine_262|._22 (l_dobj) rats_50\NNS\2329401|-_20 (l_amod) nephrotic_49\JJ\0|NONE_0
C055603_D011507 NONE temocapril_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|chronic_23|,_13|angiotensin_42 (r_prep) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (l_appos) angiotensin_23\NN\4522421|chronic_65|of_42|,_29 (l_acl) reduced_31\VBN\441445|a_74|group_53|converting_35|,_2|,_19 (l_dobj) proteinuria_32\NN\14299637|NONE_0
C055603_D011507 NONE temocapril_0\NNP\0|did_11|not_15|proteinuria_29|at_41|,_50|but_52|lower_72 (r_nsubj) attenuate_3\VB\224901|NONE_0 (l_dobj) proteinuria_4\NN\14299637|temocapril_29|did_18|not_14|at_12|,_21|but_23|lower_43
C055603_D005921 NONE temocapril_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|chronic_23|,_13|angiotensin_42 (r_prep) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (r_nsubj) inhibited_34\VBD\2510337|to_154 (l_conj) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (l_dobj) glomerulosclerosis_39\NN\0|in_19|pan_57
D000809_D011507 NONE angiotensin_23\NN\4522421|chronic_65|of_42|,_29 (l_acl) reduced_31\VBN\441445|a_74|group_53|converting_35|,_2|,_19 (l_dobj) proteinuria_32\NN\14299637|NONE_0
D000809_D006984 NONE angiotensin_23\NN\4522421|chronic_65|of_42|,_29 (r_appos) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (r_nsubj) inhibited_34\VBD\2510337|to_154 (l_dobj) hypertrophy_36\NN\14365950|whether_162|administration_146|and_12|prevented_16
D011692_D009401 CID aminonucleoside_21\JJ\0|puromycin_10 (r_amod) nephrosis_22\NN\14304060|NONE_0
D011692_D009401 CID pan_6\NNP\3101986|NONE_0 (r_pobj) of_5\IN\0|in_31 (r_prep) injection_4\NN\320852|NONE_0 (r_pobj) by_3\IN\0|nephrosis_22|was_12|._76 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) nephrosis_0\NNP\14304060|was_10|by_22|._98
D011692_D009401 CID pan_15\NNP\3101986|neprotic_4 (r_compound) rats_17\NNS\2329401|NONE_0 (l_amod) neprotic_16\JJ\0|pan_4
D000809_D009404 NONE angiotensin_23\NN\4522421|chronic_65|of_42|,_29 (r_appos) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (r_nsubj) inhibited_34\VBD\2510337|to_154 (r_ccomp) determine_8\VB\0|purpose_36|induced_262|._284 (r_xcomp) was_6\VBD\0|NONE_0 (l_conj) induced_48\VBN\1627355|purpose_298|determine_262|._22 (l_dobj) rats_50\NNS\2329401|-_20 (l_amod) nephrotic_49\JJ\0|NONE_0
D000809_D007674 NONE angiotensin_10\NN\4522421|,_29|,_39 (r_appos) temocapril_0\NNP\0|injury_101|._154 (r_nsubj) modulates_15\VBZ\1724459|NONE_0 (l_dobj) injury_17\NN\14052046|temocapril_101|._53
C055603_D006984 NONE temocapril_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|chronic_23|,_13|angiotensin_42 (r_prep) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (r_nsubj) inhibited_34\VBD\2510337|to_154 (l_dobj) hypertrophy_36\NN\14365950|whether_162|administration_146|and_12|prevented_16
D000809_D005921 NONE angiotensin_23\NN\4522421|chronic_65|of_42|,_29 (r_appos) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (r_nsubj) inhibited_34\VBD\2510337|to_154 (l_conj) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (l_dobj) glomerulosclerosis_39\NN\0|in_19|pan_57
D011692_D007674 NONE aminonucleoside_21\JJ\0|puromycin_10 (r_amod) nephrosis_22\NN\14304060|NONE_0 (r_pobj) in_18\IN\13603305|glomerular_18 (r_prep) injury_17\NN\14052046|temocapril_101|._53
D011692_D011507 CID aminonucleoside_43\NN\0|(_16|)_20 (r_nmod) pan_45\NNP\3101986|glomerulosclerosis_57|in_38 (r_npadvmod) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (r_conj) inhibited_34\VBD\2510337|to_154 (l_nsubj) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (l_appos) angiotensin_23\NN\4522421|chronic_65|of_42|,_29 (l_acl) reduced_31\VBN\441445|a_74|group_53|converting_35|,_2|,_19 (l_dobj) proteinuria_32\NN\14299637|NONE_0
D011692_D011507 CID pan_45\NNP\3101986|glomerulosclerosis_57|in_38 (r_npadvmod) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (r_conj) inhibited_34\VBD\2510337|to_154 (l_nsubj) administration_11\NN\1133281|whether_16|hypertrophy_146|and_158|prevented_162 (l_appos) angiotensin_23\NN\4522421|chronic_65|of_42|,_29 (l_acl) reduced_31\VBN\441445|a_74|group_53|converting_35|,_2|,_19 (l_dobj) proteinuria_32\NN\14299637|NONE_0
C055603_D009401 NONE temocapril_0\NNP\0|injury_101|._154 (r_nsubj) modulates_15\VBZ\1724459|NONE_0 (l_dobj) injury_17\NN\14052046|temocapril_101|._53 (l_prep) in_18\IN\13603305|glomerular_18 (l_pobj) nephrosis_22\NN\14304060|NONE_0
C055603_D009401 NONE temocapril_3\NN\0|that_5|effective_15 (r_nsubj) was_4\VBD\0|it_27|._94 (l_acomp) effective_5\JJ\0|that_20|temocapril_15 (l_prep) in_6\IN\13603305|NONE_0 (l_pcomp) retarding_7\VBG\438495|NONE_0 (l_conj) protected_11\VBD\1127795|progression_16|and_4 (l_dobj) function_13\NN\13783581|NONE_0 (l_prep) in_14\IN\13603305|renal_15 (l_pobj) rats_17\NNS\2329401|NONE_0 (l_amod) neprotic_16\JJ\0|pan_4
D011692_D009404 NONE aminonucleoside_43\NN\0|(_16|)_20 (r_nmod) pan_45\NNP\3101986|glomerulosclerosis_57|in_38 (r_npadvmod) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (r_conj) inhibited_34\VBD\2510337|to_154 (r_ccomp) determine_8\VB\0|purpose_36|induced_262|._284 (r_xcomp) was_6\VBD\0|NONE_0 (l_conj) induced_48\VBN\1627355|purpose_298|determine_262|._22 (l_dobj) rats_50\NNS\2329401|-_20 (l_amod) nephrotic_49\JJ\0|NONE_0
D011692_D009404 NONE pan_45\NNP\3101986|glomerulosclerosis_57|in_38 (r_npadvmod) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (r_conj) inhibited_34\VBD\2510337|to_154 (r_ccomp) determine_8\VB\0|purpose_36|induced_262|._284 (r_xcomp) was_6\VBD\0|NONE_0 (l_conj) induced_48\VBN\1627355|purpose_298|determine_262|._22 (l_dobj) rats_50\NNS\2329401|-_20 (l_amod) nephrotic_49\JJ\0|NONE_0
C055603_D007674 NONE temocapril_0\NNP\0|injury_101|._154 (r_nsubj) modulates_15\VBZ\1724459|NONE_0 (l_dobj) injury_17\NN\14052046|temocapril_101|._53
D011692_D005921 NONE aminonucleoside_43\NN\0|(_16|)_20 (r_nmod) pan_45\NNP\3101986|glomerulosclerosis_57|in_38 (r_npadvmod) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (l_dobj) glomerulosclerosis_39\NN\0|in_19|pan_57
D011692_D005921 NONE pan_45\NNP\3101986|glomerulosclerosis_57|in_38 (r_npadvmod) prevented_38\VBN\0|whether_178|administration_162|hypertrophy_16|and_4 (l_dobj) glomerulosclerosis_39\NN\0|in_19|pan_57
D011692_D005921 NONE pan_26\NNP\3101986|the_4 (r_compound) group_27\NN\2137|NONE_0 (r_pobj) in_24\IN\13603305|14_16 (r_prep) weeks_23\NNS\15113229|NONE_0 (r_pobj) at_19\IN\14622893|index_71|%_50|at_48|._35 (r_prep) was_6\VBD\0|NONE_0 (l_nsubj) index_2\NN\13850304|%_21|at_23|at_71|._106 (l_compound) glomerulosclerosis_1\NN\0|the_4|(_25|gsi_26|)_29
D000809_D009401 NONE angiotensin_10\NN\4522421|,_29|,_39 (r_appos) temocapril_0\NNP\0|injury_101|._154 (r_nsubj) modulates_15\VBZ\1724459|NONE_0 (l_dobj) injury_17\NN\14052046|temocapril_101|._53 (l_prep) in_18\IN\13603305|glomerular_18 (l_pobj) nephrosis_22\NN\14304060|NONE_0
24923469
7492040
D008012_D014693 NONE lidocaine_5\NN\3681148|who_13|in_10 (r_dobj) received_4\VBD\2210855|29_16 (r_relcl) patients_2\NNS\9898892|,_71|patient_76 (r_nsubj) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (r_ccomp) exhibited_19\VBN\2632167|NONE_0 (l_dobj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (l_conj) tachycardia_23\NN\14110674|,_14|;_40|or_42|seizures_57 (l_conj) fibrillation_27\NN\14361664|ventricular_40|,_17|or_15
D008012_D014693 NONE lidocaine_35\NN\3681148|NONE_0 (r_pobj) of_34\IN\0|interval_29 (r_prep) administration_33\NN\1133281|NONE_0 (r_pobj) after_32\IN\0|experienced_21 (r_prep) seizures_31\NNS\14081375|,_71|tachycardia_57|;_17|or_15 (r_conj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (l_conj) tachycardia_23\NN\14110674|,_14|;_40|or_42|seizures_57 (l_conj) fibrillation_27\NN\14361664|ventricular_40|,_17|or_15
D003042_D017180 NONE cocaine_10\NN\3492717|-_7 (r_npadvmod) associated_12\VBN\628491|NONE_0 (r_amod) mi_13\NNP\14207561|NONE_0 (r_pobj) of_9\IN\0|the_12 (r_prep) setting_8\NN\8567235|NONE_0 (r_pobj) in_6\IN\13603305|who_23|lidocaine_10 (r_prep) received_4\VBD\2210855|29_16 (r_relcl) patients_2\NNS\9898892|,_71|patient_76 (r_nsubj) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (r_ccomp) exhibited_19\VBN\2632167|NONE_0 (l_dobj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (l_conj) tachycardia_23\NN\14110674|,_14|;_40|or_42|seizures_57
D008012_D009203 NONE lidocaine_3\NN\3681148|NONE_0 (r_pobj) of_2\IN\0|clinical_16|in_13|._70 (r_prep) safety_1\NN\13920835|NONE_0 (l_prep) in_4\IN\13603305|clinical_29|of_13|._57 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|NONE_0 (l_pobj) infarction_11\NN\14204950|NONE_0
D008012_D009203 NONE lidocaine_8\NN\3681148|NONE_0 (r_pobj) of_7\IN\0|the_11|in_13 (r_prep) safety_6\NN\13920835|to_16 (l_prep) in_9\IN\13603305|the_24|of_13 (l_pobj) setting_11\NN\8567235|NONE_0 (l_prep) of_12\IN\0|the_12 (l_pobj) infarction_17\NN\14204950|NONE_0
D008012_D009203 NONE lidocaine_8\NN\3681148|NONE_0 (r_pobj) of_7\IN\0|the_11|in_13 (r_prep) safety_6\NN\13920835|to_16 (l_prep) in_9\IN\13603305|the_24|of_13 (l_pobj) setting_11\NN\8567235|NONE_0 (l_prep) of_12\IN\0|the_12 (l_pobj) infarction_17\NN\14204950|NONE_0 (l_appos) mi_19\NNP\14207561|induced_31|myocardial_23|(_1|)_2
D008012_D009203 NONE lidocaine_10\NN\3681148|who_13|in_10 (r_dobj) received_9\VBD\2210855|with_31 (r_relcl) patients_2\NNS\9898892|:_2|._86 (l_prep) with_3\IN\0|received_31 (l_pobj) mi_7\NNP\14207561|NONE_0
D008012_D009203 NONE lidocaine_5\NN\3681148|who_13|in_10 (r_dobj) received_4\VBD\2210855|29_16 (l_prep) in_6\IN\13603305|who_23|lidocaine_10 (l_pobj) setting_8\NN\8567235|NONE_0 (l_prep) of_9\IN\0|the_12 (l_pobj) mi_13\NNP\14207561|NONE_0
D008012_D009203 NONE lidocaine_35\NN\3681148|NONE_0 (r_pobj) of_34\IN\0|interval_29 (r_prep) administration_33\NN\1133281|NONE_0 (r_pobj) after_32\IN\0|experienced_21 (r_prep) seizures_31\NNS\14081375|,_71|tachycardia_57|;_17|or_15 (r_conj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (r_dobj) exhibited_19\VBN\2632167|NONE_0 (l_ccomp) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (l_nsubj) patients_2\NNS\9898892|,_71|patient_76 (l_relcl) received_4\VBD\2210855|29_16 (l_prep) in_6\IN\13603305|who_23|lidocaine_10 (l_pobj) setting_8\NN\8567235|NONE_0 (l_prep) of_9\IN\0|the_12 (l_pobj) mi_13\NNP\14207561|NONE_0
D008012_D009203 NONE lidocaine_4\NN\3681148|that_5|may_10|toxicity_30 (r_nsubj) enhance_6\VB\227165|theoretical_40 (r_acl) concerns_2\NNS\5682950|NONE_0 (r_pobj) despite_0\IN\7501545|,_72|use_78|was_134|not_138|with_153|._219 (r_prep) associated_23\VBN\628491|NONE_0 (l_nsubjpass) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (l_prep) in_14\IN\13603305|the_21|of_13 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) mi_20\NNP\14207561|NONE_0
D008012_D009203 NONE lidocaine_13\NN\3681148|NONE_0 (r_pobj) of_12\IN\0|the_8|in_13 (r_prep) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (l_prep) in_14\IN\13603305|the_21|of_13 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) mi_20\NNP\14207561|NONE_0
D003042_D009203 CID cocaine_7\NN\3492717|-_7 (r_npadvmod) associated_9\VBN\628491|myocardial_11 (r_amod) infarction_11\NN\14204950|NONE_0
D003042_D009203 CID cocaine_13\NN\3492717|-_7 (r_npadvmod) induced_15\VBN\1627355|myocardial_8|(_30|mi_31|)_33 (r_amod) infarction_17\NN\14204950|NONE_0
D003042_D009203 CID cocaine_13\NN\3492717|-_7 (r_npadvmod) induced_15\VBN\1627355|myocardial_8|(_30|mi_31|)_33 (r_amod) infarction_17\NN\14204950|NONE_0 (l_appos) mi_19\NNP\14207561|induced_31|myocardial_23|(_1|)_2
D003042_D009203 CID cocaine_4\NN\3492717|-_7 (r_npadvmod) associated_6\VBN\628491|NONE_0 (r_amod) mi_7\NNP\14207561|NONE_0
D003042_D009203 CID cocaine_10\NN\3492717|-_7 (r_npadvmod) associated_12\VBN\628491|NONE_0 (r_amod) mi_13\NNP\14207561|NONE_0
D003042_D009203 CID cocaine_7\NN\3492717|NONE_0 (r_compound) toxicity_8\NN\13576101|that_35|lidocaine_30|may_20 (r_dobj) enhance_6\VB\227165|theoretical_40 (r_acl) concerns_2\NNS\5682950|NONE_0 (r_pobj) despite_0\IN\7501545|,_72|use_78|was_134|not_138|with_153|._219 (r_prep) associated_23\VBN\628491|NONE_0 (l_nsubjpass) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (l_prep) in_14\IN\13603305|the_21|of_13 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) mi_20\NNP\14207561|NONE_0
D003042_D009203 CID cocaine_17\NN\3492717|-_7 (r_npadvmod) associated_19\VBN\628491|NONE_0 (r_amod) mi_20\NNP\14207561|NONE_0
D008012_D017180 NONE lidocaine_5\NN\3681148|who_13|in_10 (r_dobj) received_4\VBD\2210855|29_16 (r_relcl) patients_2\NNS\9898892|,_71|patient_76 (r_nsubj) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (r_ccomp) exhibited_19\VBN\2632167|NONE_0 (l_dobj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (l_conj) tachycardia_23\NN\14110674|,_14|;_40|or_42|seizures_57
D008012_D017180 NONE lidocaine_35\NN\3681148|NONE_0 (r_pobj) of_34\IN\0|interval_29 (r_prep) administration_33\NN\1133281|NONE_0 (r_pobj) after_32\IN\0|experienced_21 (r_prep) seizures_31\NNS\14081375|,_71|tachycardia_57|;_17|or_15 (r_conj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (l_conj) tachycardia_23\NN\14110674|,_14|;_40|or_42|seizures_57
D003042_D012640 NONE cocaine_10\NN\3492717|-_7 (r_npadvmod) associated_12\VBN\628491|NONE_0 (r_amod) mi_13\NNP\14207561|NONE_0 (r_pobj) of_9\IN\0|the_12 (r_prep) setting_8\NN\8567235|NONE_0 (r_pobj) in_6\IN\13603305|who_23|lidocaine_10 (r_prep) received_4\VBD\2210855|29_16 (r_relcl) patients_2\NNS\9898892|,_71|patient_76 (r_nsubj) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (r_ccomp) exhibited_19\VBN\2632167|NONE_0 (l_dobj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (l_conj) seizures_31\NNS\14081375|,_71|tachycardia_57|;_17|or_15
D008012_D002493 NONE lidocaine_4\NN\3681148|that_5|may_10|toxicity_30 (r_nsubj) enhance_6\VB\227165|theoretical_40 (r_acl) concerns_2\NNS\5682950|NONE_0 (r_pobj) despite_0\IN\7501545|,_72|use_78|was_134|not_138|with_153|._219 (r_prep) associated_23\VBN\628491|NONE_0 (l_prep) with_24\IN\0|despite_153|,_81|use_75|was_19|not_15|._66 (l_pobj) toxicity_31\NN\13576101|NONE_0
D008012_D002493 NONE lidocaine_13\NN\3681148|NONE_0 (r_pobj) of_12\IN\0|the_8|in_13 (r_prep) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (r_nsubjpass) associated_23\VBN\628491|NONE_0 (l_prep) with_24\IN\0|despite_153|,_81|use_75|was_19|not_15|._66 (l_pobj) toxicity_31\NN\13576101|NONE_0
D008012_D012640 NONE lidocaine_5\NN\3681148|who_13|in_10 (r_dobj) received_4\VBD\2210855|29_16 (r_relcl) patients_2\NNS\9898892|,_71|patient_76 (r_nsubj) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (r_ccomp) exhibited_19\VBN\2632167|NONE_0 (l_dobj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (l_conj) seizures_31\NNS\14081375|,_71|tachycardia_57|;_17|or_15
D008012_D012640 NONE lidocaine_35\NN\3681148|NONE_0 (r_pobj) of_34\IN\0|interval_29 (r_prep) administration_33\NN\1133281|NONE_0 (r_pobj) after_32\IN\0|experienced_21 (r_prep) seizures_31\NNS\14081375|,_71|tachycardia_57|;_17|or_15
D008012_D064420 NONE lidocaine_4\NN\3681148|that_5|may_10|toxicity_30 (r_nsubj) enhance_6\VB\227165|theoretical_40 (l_dobj) toxicity_8\NN\13576101|that_35|lidocaine_30|may_20
D008012_D064420 NONE lidocaine_13\NN\3681148|NONE_0 (r_pobj) of_12\IN\0|the_8|in_13 (r_prep) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (r_nsubjpass) associated_23\VBN\628491|NONE_0 (l_prep) despite_0\IN\7501545|,_72|use_78|was_134|not_138|with_153|._219 (l_pobj) concerns_2\NNS\5682950|NONE_0 (l_acl) enhance_6\VB\227165|theoretical_40 (l_dobj) toxicity_8\NN\13576101|that_35|lidocaine_30|may_20
D003042_D002493 NONE cocaine_7\NN\3492717|NONE_0 (r_compound) toxicity_8\NN\13576101|that_35|lidocaine_30|may_20 (r_dobj) enhance_6\VB\227165|theoretical_40 (r_acl) concerns_2\NNS\5682950|NONE_0 (r_pobj) despite_0\IN\7501545|,_72|use_78|was_134|not_138|with_153|._219 (r_prep) associated_23\VBN\628491|NONE_0 (l_prep) with_24\IN\0|despite_153|,_81|use_75|was_19|not_15|._66 (l_pobj) toxicity_31\NN\13576101|NONE_0
D003042_D002493 NONE cocaine_17\NN\3492717|-_7 (r_npadvmod) associated_19\VBN\628491|NONE_0 (r_amod) mi_20\NNP\14207561|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) patients_15\NNS\9898892|NONE_0 (r_pobj) in_14\IN\13603305|the_21|of_13 (r_prep) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (r_nsubjpass) associated_23\VBN\628491|NONE_0 (l_prep) with_24\IN\0|despite_153|,_81|use_75|was_19|not_15|._66 (l_pobj) toxicity_31\NN\13576101|NONE_0
D003042_D014693 NONE cocaine_10\NN\3492717|-_7 (r_npadvmod) associated_12\VBN\628491|NONE_0 (r_amod) mi_13\NNP\14207561|NONE_0 (r_pobj) of_9\IN\0|the_12 (r_prep) setting_8\NN\8567235|NONE_0 (r_pobj) in_6\IN\13603305|who_23|lidocaine_10 (r_prep) received_4\VBD\2210855|29_16 (r_relcl) patients_2\NNS\9898892|,_71|patient_76 (r_nsubj) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (r_ccomp) exhibited_19\VBN\2632167|NONE_0 (l_dobj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167 (l_conj) tachycardia_23\NN\14110674|,_14|;_40|or_42|seizures_57 (l_conj) fibrillation_27\NN\14361664|ventricular_40|,_17|or_15
D008012_D002318 NONE lidocaine_4\NN\3681148|that_5|may_10|toxicity_30 (r_nsubj) enhance_6\VB\227165|theoretical_40 (r_acl) concerns_2\NNS\5682950|NONE_0 (r_pobj) despite_0\IN\7501545|,_72|use_78|was_134|not_138|with_153|._219 (r_prep) associated_23\VBN\628491|NONE_0 (l_prep) with_24\IN\0|despite_153|,_81|use_75|was_19|not_15|._66 (l_pobj) toxicity_31\NN\13576101|NONE_0
D008012_D002318 NONE lidocaine_13\NN\3681148|NONE_0 (r_pobj) of_12\IN\0|the_8|in_13 (r_prep) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (r_nsubjpass) associated_23\VBN\628491|NONE_0 (l_prep) with_24\IN\0|despite_153|,_81|use_75|was_19|not_15|._66 (l_pobj) toxicity_31\NN\13576101|NONE_0
D008012_D001919 NONE lidocaine_5\NN\3681148|who_13|in_10 (r_dobj) received_4\VBD\2210855|29_16 (r_relcl) patients_2\NNS\9898892|,_71|patient_76 (r_nsubj) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (r_ccomp) exhibited_19\VBN\2632167|NONE_0 (l_dobj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167
D008012_D001919 NONE lidocaine_35\NN\3681148|NONE_0 (r_pobj) of_34\IN\0|interval_29 (r_prep) administration_33\NN\1133281|NONE_0 (r_pobj) after_32\IN\0|experienced_21 (r_prep) seizures_31\NNS\14081375|,_71|tachycardia_57|;_17|or_15 (r_conj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167
D003042_D002318 NONE cocaine_7\NN\3492717|NONE_0 (r_compound) toxicity_8\NN\13576101|that_35|lidocaine_30|may_20 (r_dobj) enhance_6\VB\227165|theoretical_40 (r_acl) concerns_2\NNS\5682950|NONE_0 (r_pobj) despite_0\IN\7501545|,_72|use_78|was_134|not_138|with_153|._219 (r_prep) associated_23\VBN\628491|NONE_0 (l_prep) with_24\IN\0|despite_153|,_81|use_75|was_19|not_15|._66 (l_pobj) toxicity_31\NN\13576101|NONE_0
D003042_D002318 NONE cocaine_17\NN\3492717|-_7 (r_npadvmod) associated_19\VBN\628491|NONE_0 (r_amod) mi_20\NNP\14207561|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) patients_15\NNS\9898892|NONE_0 (r_pobj) in_14\IN\13603305|the_21|of_13 (r_prep) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (r_nsubjpass) associated_23\VBN\628491|NONE_0 (l_prep) with_24\IN\0|despite_153|,_81|use_75|was_19|not_15|._66 (l_pobj) toxicity_31\NN\13576101|NONE_0
D003042_D064420 NONE cocaine_7\NN\3492717|NONE_0 (r_compound) toxicity_8\NN\13576101|that_35|lidocaine_30|may_20
D003042_D064420 NONE cocaine_17\NN\3492717|-_7 (r_npadvmod) associated_19\VBN\628491|NONE_0 (r_amod) mi_20\NNP\14207561|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) patients_15\NNS\9898892|NONE_0 (r_pobj) in_14\IN\13603305|the_21|of_13 (r_prep) use_11\NN\407535|despite_78|,_6|was_56|not_60|with_75|._141 (r_nsubjpass) associated_23\VBN\628491|NONE_0 (l_prep) despite_0\IN\7501545|,_72|use_78|was_134|not_138|with_153|._219 (l_pobj) concerns_2\NNS\5682950|NONE_0 (l_acl) enhance_6\VB\227165|theoretical_40 (l_dobj) toxicity_8\NN\13576101|that_35|lidocaine_30|may_20
D003042_D001919 NONE cocaine_10\NN\3492717|-_7 (r_npadvmod) associated_12\VBN\628491|NONE_0 (r_amod) mi_13\NNP\14207561|NONE_0 (r_pobj) of_9\IN\0|the_12 (r_prep) setting_8\NN\8567235|NONE_0 (r_pobj) in_6\IN\13603305|who_23|lidocaine_10 (r_prep) received_4\VBD\2210855|29_16 (r_relcl) patients_2\NNS\9898892|,_71|patient_76 (r_nsubj) died_17\VBD\146138|;_4|bradydysrhythmias_16|._183 (r_ccomp) exhibited_19\VBN\2632167|NONE_0 (l_dobj) bradydysrhythmias_20\NNS\0|died_16|;_12|._167
17035713
-1_D007674 NONE sulfhydryl_3\NN\0|a_2 (r_amod) reagent_4\NN\14779550|NONE_0 (r_pobj) as_1\IN\14622893|:_23|role_29|._84 (r_prep) chloroacetaldehyde_0\NNP\0|NONE_0 (l_appos) role_7\NN\719494|as_29|:_6|._55 (l_prep) of_8\IN\0|the_9 (l_pobj) groups_11\NNS\2137|NONE_0 (l_prep) in_12\IN\13603305|critical_22|thiol_13 (l_pobj) nephropathy_14\NN\14573196|NONE_0
C004656_D009369 NONE chloroacetaldehyde_0\NNP\0|metabolite_30|._163 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) metabolite_6\NN\20090|chloroacetaldehyde_30|._133 (l_conj) responsible_17\JJ\0|a_69|of_56|and_15 (l_prep) for_18\IN\0|putatively_23 (l_pobj) damage_20\NN\7296428|NONE_0 (l_prep) following_21\VBG\8180190|renal_13 (l_pobj) therapy_25\NN\657604|with_8 (l_compound) tumor_24\NN\14234074|NONE_0
C004656_D009369 NONE caa_2\NNP\0|(_1|)_3 (r_appos) chloroacetaldehyde_0\NNP\0|metabolite_30|._163 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) metabolite_6\NN\20090|chloroacetaldehyde_30|._133 (l_conj) responsible_17\JJ\0|a_69|of_56|and_15 (l_prep) for_18\IN\0|putatively_23 (l_pobj) damage_20\NN\7296428|NONE_0 (l_prep) following_21\VBG\8180190|renal_13 (l_pobj) therapy_25\NN\657604|with_8 (l_compound) tumor_24\NN\14234074|NONE_0
C004656_D064420 NONE caa_2\NNP\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) toxicity_0\NN\13576101|was_16|by_31|trypan_77|._127
C004656_D064420 NONE caa_2\NNP\0|thus_6|,_2|directly_4|with_20|,_64|mediating_66|._98 (r_nsubj) reacts_4\VBZ\2367363|NONE_0 (l_advcl) mediating_14\VBG\761713|thus_72|,_68|caa_66|directly_62|with_46|,_2|._32 (l_dobj) toxicity_16\NN\13576101|NONE_0
D007069_D007674 CID ifosfamide_13\JJ\0|NONE_0 (r_amod) nephropathy_14\NN\14573196|NONE_0
D007069_D007674 CID ifosfamide_11\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_13|and_41|responsible_56 (r_prep) metabolite_6\NN\20090|chloroacetaldehyde_30|._133 (l_conj) responsible_17\JJ\0|a_69|of_56|and_15 (l_prep) for_18\IN\0|putatively_23 (l_pobj) damage_20\NN\7296428|NONE_0
D007069_D007674 CID ifo_13\NN\0|the_33|agent_18|(_1|)_3 (r_appos) ifosfamide_11\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_13|and_41|responsible_56 (r_prep) metabolite_6\NN\20090|chloroacetaldehyde_30|._133 (l_conj) responsible_17\JJ\0|a_69|of_56|and_15 (l_prep) for_18\IN\0|putatively_23 (l_pobj) damage_20\NN\7296428|NONE_0
D007069_D007674 CID ifo_27\NN\0|NONE_0 (r_pobj) with_26\IN\0|therapy_8 (r_prep) following_21\VBG\8180190|renal_13 (r_prep) damage_20\NN\7296428|NONE_0
D007069_D007674 CID ifo_10\NN\0|NONE_0 (r_compound) nephropathy_11\NN\14573196|to_15|in_12
D014343_D064420 NONE blue_16\JJ\4959672|NONE_0 (r_amod) exclusion_17\NN\13927383|and_16|activity_30 (r_compound) assay_18\NN\5733583|NONE_0 (r_dobj) trypan_15\NN\0|toxicity_77|was_61|by_46|._50 (r_advcl) determined_4\VBN\0|NONE_0 (l_nsubjpass) toxicity_0\NN\13576101|was_16|by_31|trypan_77|._127
D007069_D009369 NONE ifosfamide_11\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_13|and_41|responsible_56 (r_prep) metabolite_6\NN\20090|chloroacetaldehyde_30|._133 (l_conj) responsible_17\JJ\0|a_69|of_56|and_15 (l_prep) for_18\IN\0|putatively_23 (l_pobj) damage_20\NN\7296428|NONE_0 (l_prep) following_21\VBG\8180190|renal_13 (l_pobj) therapy_25\NN\657604|with_8 (l_compound) tumor_24\NN\14234074|NONE_0
D007069_D009369 NONE ifo_13\NN\0|the_33|agent_18|(_1|)_3 (r_appos) ifosfamide_11\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_13|and_41|responsible_56 (r_prep) metabolite_6\NN\20090|chloroacetaldehyde_30|._133 (l_conj) responsible_17\JJ\0|a_69|of_56|and_15 (l_prep) for_18\IN\0|putatively_23 (l_pobj) damage_20\NN\7296428|NONE_0 (l_prep) following_21\VBG\8180190|renal_13 (l_pobj) therapy_25\NN\657604|with_8 (l_compound) tumor_24\NN\14234074|NONE_0
D007069_D009369 NONE ifo_27\NN\0|NONE_0 (r_pobj) with_26\IN\0|therapy_8 (r_prep) following_21\VBG\8180190|renal_13 (l_pobj) therapy_25\NN\657604|with_8 (l_compound) tumor_24\NN\14234074|NONE_0
D013438_D064420 NONE thiols_12\NNS\0|NONE_0 (r_pobj) with_5\IN\0|thus_26|,_22|caa_20|directly_16|,_44|mediating_46|._78 (r_prep) reacts_4\VBZ\2367363|NONE_0 (l_advcl) mediating_14\VBG\761713|thus_72|,_68|caa_66|directly_62|with_46|,_2|._32 (l_dobj) toxicity_16\NN\13576101|NONE_0
C004656_D009336 NONE caa_0\NNP\0|number_24|,_42|induced_44|._123 (r_nsubj) reduced_1\VBD\441445|NONE_0 (l_conj) induced_8\VBD\1627355|caa_44|number_20|,_2|._79 (l_dobj) loss_10\NN\13252973|NONE_0 (l_conj) increase_17\NN\13576355|a_43|in_36|and_7 (l_prep) in_18\IN\13603305|an_12 (l_pobj) markers_20\NNS\21939|NONE_0 (l_compound) necrosis_19\NN\11444117|NONE_0
C004656_D009336 NONE caa_7\NNP\0|NONE_0 (r_pobj) of_6\IN\0|the_13|with_7 (r_prep) reaction_5\NN\13446390|which_17 (r_dobj) slowed_3\VBD\151689|,_8|,_44 (r_relcl) acidification_0\NN\13518963|could_67|also_73|effects_88|._188 (r_nsubj) attenuate_14\VB\224901|NONE_0 (l_dobj) effects_15\NNS\13245626|acidification_88|could_21|also_15|._100 (l_prep) on_18\IN\0|of_7 (l_pobj) markers_20\NNS\21939|NONE_0 (l_compound) necrosis_19\NN\11444117|,_16|depletion_24
C004656_D009336 NONE caa_17\NNP\0|NONE_0 (r_pobj) of_16\IN\0|on_7 (r_prep) effects_15\NNS\13245626|acidification_88|could_21|also_15|._100 (l_prep) on_18\IN\0|of_7 (l_pobj) markers_20\NNS\21939|NONE_0 (l_compound) necrosis_19\NN\11444117|,_16|depletion_24
D003545_D009336 NONE cysteine_25\NN\14601829|NONE_0 (r_compound) protease_26\NN\14732946|in_20 (r_compound) inhibition_27\NN\1068773|thiol_38|and_22 (r_conj) depletion_23\NN\351638|necrosis_24|,_8 (r_conj) markers_20\NNS\21939|NONE_0 (l_compound) necrosis_19\NN\11444117|,_16|depletion_24
C004656_D007674 NONE chloroacetaldehyde_0\NNP\0|NONE_0 (l_appos) role_7\NN\719494|as_29|:_6|._55 (l_prep) of_8\IN\0|the_9 (l_pobj) groups_11\NNS\2137|NONE_0 (l_prep) in_12\IN\13603305|critical_22|thiol_13 (l_pobj) nephropathy_14\NN\14573196|NONE_0
C004656_D007674 NONE chloroacetaldehyde_0\NNP\0|metabolite_30|._163 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) metabolite_6\NN\20090|chloroacetaldehyde_30|._133 (l_conj) responsible_17\JJ\0|a_69|of_56|and_15 (l_prep) for_18\IN\0|putatively_23 (l_pobj) damage_20\NN\7296428|NONE_0
C004656_D007674 NONE caa_2\NNP\0|(_1|)_3 (r_appos) chloroacetaldehyde_0\NNP\0|metabolite_30|._163 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) metabolite_6\NN\20090|chloroacetaldehyde_30|._133 (l_conj) responsible_17\JJ\0|a_69|of_56|and_15 (l_prep) for_18\IN\0|putatively_23 (l_pobj) damage_20\NN\7296428|NONE_0
D013438_D009336 NONE thiols_14\NNS\0|NONE_0 (r_pobj) in_11\IN\13603305|a_7|and_29|increase_36 (r_prep) loss_10\NN\13252973|NONE_0 (l_conj) increase_17\NN\13576355|a_43|in_36|and_7 (l_prep) in_18\IN\13603305|an_12 (l_pobj) markers_20\NNS\21939|NONE_0 (l_compound) necrosis_19\NN\11444117|NONE_0
D013438_D009336 NONE thiol_9\JJ\0|NONE_0 (r_compound) donors_10\NNS\9608709|NONE_0 (r_pobj) with_8\IN\0|the_20|of_7 (r_prep) reaction_5\NN\13446390|which_17 (r_dobj) slowed_3\VBD\151689|,_8|,_44 (r_relcl) acidification_0\NN\13518963|could_67|also_73|effects_88|._188 (r_nsubj) attenuate_14\VB\224901|NONE_0 (l_dobj) effects_15\NNS\13245626|acidification_88|could_21|also_15|._100 (l_prep) on_18\IN\0|of_7 (l_pobj) markers_20\NNS\21939|NONE_0 (l_compound) necrosis_19\NN\11444117|,_16|depletion_24
D013438_D009336 NONE thiol_22\JJ\0|and_16|inhibition_38 (r_compound) depletion_23\NN\351638|necrosis_24|,_8 (r_conj) markers_20\NNS\21939|NONE_0 (l_compound) necrosis_19\NN\11444117|,_16|depletion_24
D013438_D007674 NONE thiol_10\JJ\0|critical_9|in_13 (r_compound) groups_11\NNS\2137|NONE_0 (l_prep) in_12\IN\13603305|critical_22|thiol_13 (l_pobj) nephropathy_14\NN\14573196|NONE_0
9831002
D008774_D009459 CID methylphenidate_4\NN\4320126|neuroleptic_35|malignant_23|and_4|._15 (r_conj) syndrome_2\NN\5870365|NONE_0
D008774_D009459 CID methylphenidate_13\NN\4320126|NONE_0 (r_pobj) by_12\IN\0|presented_62|probably_16|._18 (r_agent) caused_11\VBN\1617192|NONE_0 (l_nsubj) presented_5\VBN\2137132|probably_46|by_62|._80 (l_prep) with_6\IN\0|female_17 (l_pobj) syndrome_9\NN\5870365|NONE_0
D008774_D009459 CID methylphenidate_13\NN\4320126|NONE_0 (r_pobj) by_12\IN\0|probably_16 (r_agent) caused_11\VBN\1617192|the_72|first_68|reported_62|with_45 (r_acl) patient_5\JJ\9898892|this_27|._78 (l_prep) with_6\IN\0|the_27|first_23|reported_17|caused_45 (l_pobj) syndrome_9\NN\5870365|NONE_0
24072398
D012701_D003866 NONE serotonin_38\NN\14807737|tyrosine_25|and_4 (r_conj) hydroxylase_36\NN\0|and_18|hva_14|,_11 (r_conj) dopac_31\NNP\0|by_42|,_2 (r_conj) indicated_21\VBN\952524|profile_129|was_105|by_89|,_2|,_101|observed_103|._153 (r_advcl) accompanied_9\VBN\0|NONE_0 (l_nsubjpass) profile_4\NN\6999802|was_24|by_40|,_127|indicated_129|,_230|observed_232|._282 (l_amod) like_3\JJ\5839024|this_16|induced_13 (l_npadvmod) depressive_1\JJ\10595647|-_10
D015102_D003866 NONE dopac_31\NNP\0|by_42|,_2 (r_conj) indicated_21\VBN\952524|profile_129|was_105|by_89|,_2|,_101|observed_103|._153 (r_advcl) accompanied_9\VBN\0|NONE_0 (l_nsubjpass) profile_4\NN\6999802|was_24|by_40|,_127|indicated_129|,_230|observed_232|._282 (l_amod) like_3\JJ\5839024|this_16|induced_13 (l_npadvmod) depressive_1\JJ\10595647|-_10
D008694_D003866 CID methamphetamine_5\NN\2704153|NONE_0 (r_pobj) of_4\IN\0|a_25|single_23|neurotoxic_16 (r_prep) dose_3\NN\3740161|behaviour_63|._80 (r_nsubj) induces_6\VBZ\1627355|NONE_0 (l_dobj) behaviour_14\NN\14006945|dose_63|._17 (l_amod) like_13\JJ\5839024|a_26|lasting_19|in_15 (l_amod) depressive_11\JJ\10595647|-_10
D008694_D003866 CID methamphetamine_0\NN\2704153|disruption_34|leads_88|._175 (r_nsubj) triggers_4\VBZ\3659292|NONE_0 (l_conj) leads_14\VBZ\5155821|methamphetamine_88|disruption_54|._87 (l_prep) to_15\IN\0|abuse_12 (l_pobj) states_18\NNS\8491826|NONE_0 (l_prep) including_19\VBG\0|negative_26|emotional_17 (l_pobj) symptoms_21\NNS\5823932|NONE_0
D008694_D003866 CID meth_2\NNP\2704153|(_1|)_4 (r_appos) methamphetamine_0\NN\2704153|disruption_34|leads_88|._175 (r_nsubj) triggers_4\VBZ\3659292|NONE_0 (l_conj) leads_14\VBZ\5155821|methamphetamine_88|disruption_54|._87 (l_prep) to_15\IN\0|abuse_12 (l_pobj) states_18\NNS\8491826|NONE_0 (l_prep) including_19\VBG\0|negative_26|emotional_17 (l_pobj) symptoms_21\NNS\5823932|NONE_0
D008694_D003866 CID meth_12\NNP\2704153|NONE_0 (r_compound) abuse_13\NN\418025|to_12 (r_nsubj) leads_14\VBZ\5155821|methamphetamine_88|disruption_54|._87 (l_prep) to_15\IN\0|abuse_12 (l_pobj) states_18\NNS\8491826|NONE_0 (l_prep) including_19\VBG\0|negative_26|emotional_17 (l_pobj) symptoms_21\NNS\5823932|NONE_0
D008694_D003866 CID meth_12\NNP\2704153|NONE_0 (r_pobj) of_11\IN\0|the_23|acute_19|toxic_13 (r_prep) dosage_10\NN\13576355|if_19|also_15|phenotype_53 (r_nsubj) causes_14\VBZ\7323922|however_72|,_65|it_63|currently_57|unknown_47|._80 (l_dobj) phenotype_20\NN\4933544|if_72|dosage_53|also_38 (l_amod) depressive_19\JJ\10595647|a_15|lasting_8|and_21|deficits_50
D008694_D003866 CID meth_23\NNP\2704153|a_14|single_12|high_5|mg/kg_14 (r_compound) dose_24\NN\3740161|NONE_0 (r_pobj) following_19\VBG\8180190|thus_91|,_87|we_85|now_82|behaviour_49|at_31|._50 (r_prep) assessed_4\VBD\670261|NONE_0 (l_dobj) behaviour_9\NN\14006945|thus_42|,_38|we_36|now_33|at_18|following_49|._99 (l_amod) like_8\JJ\5839024|the_15|in_15 (l_npadvmod) depressive_6\JJ\10595647|-_10
D008694_D003866 CID meth_7\NNP\2704153|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|this_29|like_13 (r_acl) profile_4\NN\6999802|was_24|by_40|,_127|indicated_129|,_230|observed_232|._282 (l_amod) like_3\JJ\5839024|this_16|induced_13 (l_npadvmod) depressive_1\JJ\10595647|-_10
D008694_D003866 CID meth_13\NNP\2704153|NONE_0 (r_pobj) of_12\IN\0|a_19|single_17|high_10 (r_prep) dose_11\NN\3740161|that_19|behaviour_50 (r_nsubj) induces_14\VBZ\1627355|findings_72|for_51|._155 (l_dobj) behaviour_21\NN\14006945|that_69|dose_50 (l_amod) like_20\JJ\5839024|lasting_19|in_15 (l_amod) depressive_18\JJ\10595647|-_10
D006719_D003866 NONE hva_33\NNP\0|and_4|,_3|hydroxylase_14 (r_conj) dopac_31\NNP\0|by_42|,_2 (r_conj) indicated_21\VBN\952524|profile_129|was_105|by_89|,_2|,_101|observed_103|._153 (r_advcl) accompanied_9\VBN\0|NONE_0 (l_nsubjpass) profile_4\NN\6999802|was_24|by_40|,_127|indicated_129|,_230|observed_232|._282 (l_amod) like_3\JJ\5839024|this_16|induced_13 (l_npadvmod) depressive_1\JJ\10595647|-_10
D014443_D003866 NONE tyrosine_35\JJ\14601829|and_21|serotonin_25 (r_compound) hydroxylase_36\NN\0|and_18|hva_14|,_11 (r_conj) dopac_31\NNP\0|by_42|,_2 (r_conj) indicated_21\VBN\952524|profile_129|was_105|by_89|,_2|,_101|observed_103|._153 (r_advcl) accompanied_9\VBN\0|NONE_0 (l_nsubjpass) profile_4\NN\6999802|was_24|by_40|,_127|indicated_129|,_230|observed_232|._282 (l_amod) like_3\JJ\5839024|this_16|induced_13 (l_npadvmod) depressive_1\JJ\10595647|-_10
D008694_D020258 NONE methamphetamine_5\NN\2704153|NONE_0 (r_pobj) of_4\IN\0|a_25|single_23|neurotoxic_16 (r_prep) dose_3\NN\3740161|behaviour_63|._80 (l_amod) neurotoxic_2\JJ\0|a_9|single_7|of_16
D004298_D003866 NONE dopamine_29\NN\14807737|NONE_0 (r_pobj) of_28\IN\0|the_11 (r_prep) levels_27\NNS\4916342|NONE_0 (r_pobj) in_25\IN\13603305|a_12 (r_prep) reduction_24\NN\351485|NONE_0 (r_pobj) by_22\IN\0|,_40|dopac_42 (r_agent) indicated_21\VBN\952524|profile_129|was_105|by_89|,_2|,_101|observed_103|._153 (r_advcl) accompanied_9\VBN\0|NONE_0 (l_nsubjpass) profile_4\NN\6999802|was_24|by_40|,_127|indicated_129|,_230|observed_232|._282 (l_amod) like_3\JJ\5839024|this_16|induced_13 (l_npadvmod) depressive_1\JJ\10595647|-_10
18801087
D000638_D009369 NONE amiodarone_11\NN\2715941|-_10 (r_npadvmod) related_13\VBN\628491|an_14|pulmonary_8|and_25|neoplasm_31 (r_amod) lesion_15\NN\14204950|NONE_0 (l_conj) neoplasm_18\NN\14234074|an_45|related_31|pulmonary_23|and_6
D000638_D009369 NONE amiodarone_36\NN\2715941|NONE_0 (r_compound) treatment_37\NN\654885|NONE_0 (r_pobj) of_35\IN\0|another_30|possible_22 (r_prep) complication_34\NN\1073995|that_61|glomerulonephritis_45|might_26 (r_attr) be_31\VB\14625458|NONE_0 (r_ccomp) suggests_26\VBZ\1010118|case_164|possibility_144|,_6|and_4|._106 (r_conj) highlights_3\VBZ\13809920|NONE_0 (l_dobj) possibility_5\NN\5944958|case_20|,_138|and_140|suggests_144|._250 (l_acl) be_20\VB\14625458|the_110 (l_nsubj) diagnosis_8\NN\152018|that_18|can_72|difficult_84|radiologically_94 (l_prep) between_9\IN\0|differential_23 (l_pobj) lesion_15\NN\14204950|NONE_0 (l_conj) neoplasm_18\NN\14234074|an_45|related_31|pulmonary_23|and_6
D000638_D001145 NONE amiodarone_0\NN\2715941|drug_33|,_70|but_72|reported_110 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) drug_6\NN\14778436|amiodarone_33|,_37|but_39|reported_77 (l_amod) arrhythmic_5\JJ\0|an_8|for_16
D000638_D055370 CID amiodarone_0\NN\2715941|-_10 (r_npadvmod) related_2\VBN\628491|pulmonary_8|and_23|glomerulonephritis_45|in_64|:_104|pitfall_117|._141 (r_amod) mass_4\NN\13575869|NONE_0
D000638_D055370 CID amiodarone_36\NN\2715941|NONE_0 (r_pobj) with_35\IN\0|for_16 (r_prep) treatment_34\NN\654885|NONE_0 (r_pobj) after_33\IN\0|who_76|mass_55 (r_prep) developed_15\VBD\1753788|a_14 (l_dobj) mass_18\NN\13575869|who_21|after_55
D000638_D055370 CID amiodarone_47\NN\2715941|-_10 (r_npadvmod) related_49\VBN\628491|an_14 (r_amod) lesion_50\NN\14204950|that_34|it_29 (r_attr) was_45\VBD\0|NONE_0 (r_ccomp) indicating_42\VBG\952524|histologically_187|lesion_168|was_161|of_148|,_2|._51 (r_advcl) composed_22\VBN\2620587|mass_118|was_113|highly_109|be_89|,_36|but_34 (r_conj) suspected_5\VBN\916909|NONE_0 (l_nsubjpass) mass_2\NN\13575869|was_5|highly_9|be_29|,_82|but_84|composed_118
D000638_D055370 CID amiodarone_11\NN\2715941|-_10 (r_npadvmod) related_13\VBN\628491|an_14|pulmonary_8|and_25|neoplasm_31 (r_amod) lesion_15\NN\14204950|NONE_0
D000638_D055370 CID amiodarone_36\NN\2715941|NONE_0 (r_compound) treatment_37\NN\654885|NONE_0 (r_pobj) of_35\IN\0|another_30|possible_22 (r_prep) complication_34\NN\1073995|that_61|glomerulonephritis_45|might_26 (r_attr) be_31\VB\14625458|NONE_0 (r_ccomp) suggests_26\VBZ\1010118|case_164|possibility_144|,_6|and_4|._106 (r_conj) highlights_3\VBZ\13809920|NONE_0 (l_dobj) possibility_5\NN\5944958|case_20|,_138|and_140|suggests_144|._250 (l_acl) be_20\VB\14625458|the_110 (l_nsubj) diagnosis_8\NN\152018|that_18|can_72|difficult_84|radiologically_94 (l_prep) between_9\IN\0|differential_23 (l_pobj) lesion_15\NN\14204950|NONE_0
D000638_D013610 NONE amiodarone_0\NN\2715941|drug_33|,_70|but_72|reported_110 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) drug_6\NN\14778436|amiodarone_33|,_37|but_39|reported_77 (l_prep) for_7\IN\0|an_24|arrhythmic_16 (l_pobj) tachycardia_11\NN\14110674|NONE_0
D000638_D015433 CID amiodarone_0\NN\2715941|-_10 (r_npadvmod) related_2\VBN\628491|pulmonary_8|and_23|glomerulonephritis_45|in_64|:_104|pitfall_117|._141 (r_amod) mass_4\NN\13575869|NONE_0 (l_conj) glomerulonephritis_8\NN\14113798|related_45|pulmonary_37|and_22|in_19|:_59|pitfall_72|._96
D000638_D015433 CID amiodarone_11\NN\2715941|-_10 (r_npadvmod) related_13\VBN\628491|an_14|pulmonary_8|and_25|neoplasm_31 (r_amod) lesion_15\NN\14204950|NONE_0 (r_pobj) between_9\IN\0|differential_23 (r_prep) diagnosis_8\NN\152018|that_18|can_72|difficult_84|radiologically_94 (r_nsubj) be_20\VB\14625458|the_110 (r_acl) possibility_5\NN\5944958|case_20|,_138|and_140|suggests_144|._250 (r_dobj) highlights_3\VBZ\13809920|NONE_0 (l_conj) suggests_26\VBZ\1010118|case_164|possibility_144|,_6|and_4|._106 (l_ccomp) be_31\VB\14625458|NONE_0 (l_nsubj) glomerulonephritis_29\NN\14113798|that_16|might_19|complication_45
D000638_D015433 CID amiodarone_36\NN\2715941|NONE_0 (r_compound) treatment_37\NN\654885|NONE_0 (r_pobj) of_35\IN\0|another_30|possible_22 (r_prep) complication_34\NN\1073995|that_61|glomerulonephritis_45|might_26 (r_attr) be_31\VB\14625458|NONE_0 (l_nsubj) glomerulonephritis_29\NN\14113798|that_16|might_19|complication_45
D000638_D008175 NONE amiodarone_47\NN\2715941|-_10 (r_npadvmod) related_49\VBN\628491|an_14 (r_amod) lesion_50\NN\14204950|that_34|it_29 (r_attr) was_45\VBD\0|NONE_0 (r_ccomp) indicating_42\VBG\952524|histologically_187|lesion_168|was_161|of_148|,_2|._51 (r_advcl) composed_22\VBN\2620587|mass_118|was_113|highly_109|be_89|,_36|but_34 (r_conj) suspected_5\VBN\916909|NONE_0 (l_xcomp) be_7\VB\14625458|mass_29|was_24|highly_20|,_53|but_55|composed_89 (l_attr) cancer_9\NN\14239425|to_11
D000638_D006349 NONE amiodarone_0\NN\2715941|-_10 (r_npadvmod) related_2\VBN\628491|pulmonary_8|and_23|glomerulonephritis_45|in_64|:_104|pitfall_117|._141 (r_amod) mass_4\NN\13575869|NONE_0 (l_prep) in_9\IN\13603305|related_64|pulmonary_56|and_41|glomerulonephritis_19|:_40|pitfall_53|._77 (l_pobj) patient_11\NN\9898892|NONE_0 (l_prep) with_12\IN\0|a_10 (l_pobj) disease_15\NN\14061805|NONE_0
D000638_D006349 NONE amiodarone_36\NN\2715941|NONE_0 (r_pobj) with_35\IN\0|for_16 (r_prep) treatment_34\NN\654885|NONE_0 (r_pobj) after_33\IN\0|who_76|mass_55 (r_prep) developed_15\VBD\1753788|a_14 (r_relcl) patient_13\NN\9898892|NONE_0 (r_pobj) in_11\IN\13603305|herein_53|is_46|._136 (r_prep) reported_0\VBN\831651|NONE_0 (l_auxpass) is_2\VBZ\0|herein_7|in_46|._182 (l_attr) case_5\NN\7283608|,_30 (l_prep) of_6\IN\0|an_16|autopsy_13 (l_pobj) disease_9\NN\14061805|NONE_0
D000638_D011507 NONE amiodarone_36\NN\2715941|NONE_0 (r_pobj) with_35\IN\0|for_16 (r_prep) treatment_34\NN\654885|NONE_0 (r_pobj) after_33\IN\0|who_76|mass_55 (r_prep) developed_15\VBD\1753788|a_14 (l_dobj) mass_18\NN\13575869|who_21|after_55 (l_appos) cm_21\NNS\13649268|a_17|lung_15|(_5|(_32|day_40|)_43 (l_conj) proteinuria_26\NN\14299637|1.5_24|in_17|)_6|and_4
20927253
D004164_D010024 NONE bisphosphonates_13\NNS\0|,_15|are_17|inhibit_29|._52 (r_nsubjpass) used_16\VBN\0|osteoporosis_96|is_83|by_73|,_27|and_25 (r_conj) caused_2\VBN\1617192|NONE_0 (l_nsubjpass) osteoporosis_0\NN\14204950|is_13|by_23|,_69|and_71|used_96
D004164_D010024 NONE bisphosphonate_11\NN\0|-_14 (r_npadvmod) related_13\VBN\628491|NONE_0 (r_amod) pain_14\NN\14299637|should_5|also_12|be_17|before_31 (r_nsubjpass) considered_18\VBN\689344|that_96|patients_91|can_64|pain_53|and_47 (r_conj) report_7\VB\6470073|we_48|._118 (l_nsubj) patients_3\NNS\9898892|that_5|can_27|pain_38|and_44|considered_91 (l_prep) with_4\IN\0|NONE_0 (l_pobj) osteoporosis_5\NN\14204950|NONE_0
D004164_D010024 NONE bisphosphonate_11\NN\0|-_14 (r_npadvmod) related_13\VBN\628491|NONE_0 (r_amod) pain_14\NN\14299637|should_5|also_12|be_17|before_31 (r_nsubjpass) considered_18\VBN\689344|that_96|patients_91|can_64|pain_53|and_47 (l_prep) before_19\IN\0|pain_31|should_26|also_19|be_14 (l_pcomp) ascribing_20\VBG\670261|NONE_0 (l_prep) to_23\IN\0|complaint_10 (l_pobj) osteoporosis_24\NN\14204950|NONE_0
D019386_D010146 CID alendronate_6\NN\3740161|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) after_3\IN\0|diffuse_22|skeletal_14|._35 (r_prep) pain_2\NN\14299637|NONE_0
D019386_D010146 CID alendronate_20\NN\3740161|NONE_0 (r_pobj) of_19\IN\0|three_33|consecutive_27 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) after_15\IN\0|to_53|with_27 (r_prep) admitted_4\VBN\822367|a_10 (l_prep) with_11\IN\0|to_26|after_27 (l_pobj) pain_14\NN\14299637|NONE_0
D004164_D010146 NONE bisphosphonate_11\NN\0|-_14 (r_npadvmod) related_13\VBN\628491|NONE_0 (r_amod) pain_14\NN\14299637|should_5|also_12|be_17|before_31 (r_nsubjpass) considered_18\VBN\689344|that_96|patients_91|can_64|pain_53|and_47 (r_conj) report_7\VB\6470073|we_48|._118 (l_dobj) pain_8\NN\14299637|that_43|patients_38|can_11|and_6|considered_53
D004164_D010146 NONE bisphosphonate_11\NN\0|-_14 (r_npadvmod) related_13\VBN\628491|NONE_0 (r_amod) pain_14\NN\14299637|should_5|also_12|be_17|before_31
D019386_D010024 NONE alendronate_0\NNP\3740161|effective_33|._120 (r_nsubj) is_5\VBZ\0|NONE_0 (l_acomp) effective_6\JJ\0|alendronate_33|._87 (l_prep) for_7\IN\0|NONE_0 (l_pobj) treatment_10\NN\654885|NONE_0 (l_prep) of_13\IN\0|both_34|the_29|and_15|prevention_11 (l_pobj) osteoporosis_14\NN\14204950|NONE_0
-1_D010024 NONE biphosphonate_3\NN\0|,_4|,_13 (r_appos) alendronate_0\NNP\3740161|effective_33|._120 (r_nsubj) is_5\VBZ\0|NONE_0 (l_acomp) effective_6\JJ\0|alendronate_33|._87 (l_prep) for_7\IN\0|NONE_0 (l_pobj) treatment_10\NN\654885|NONE_0 (l_prep) of_13\IN\0|both_34|the_29|and_15|prevention_11 (l_pobj) osteoporosis_14\NN\14204950|NONE_0
24902786
D013629_D008569 CID tamoxifen_6\NN\2714883|or_3 (r_conj) letrozole_4\NN\0|of_14|,_2 (r_conj) administration_0\NN\1133281|significantly_52|memory_79|,_100|and_102|attenuated_120|._218 (r_nsubj) impaired_8\VBD\258857|NONE_0 (l_dobj) memory_10\NN\5926676|administration_79|significantly_27|,_21|and_23|attenuated_41|._139
D013629_D008569 CID tamoxifen_6\NN\2714883|or_3 (r_conj) letrozole_4\NN\0|of_14|,_2 (r_conj) administration_0\NN\1133281|significantly_52|memory_79|,_100|and_102|attenuated_120|._218 (r_nsubj) impaired_8\VBD\258857|NONE_0 (l_conj) attenuated_17\VBD\224901|administration_120|significantly_68|memory_41|,_20|and_18|._98 (l_dobj) replacement_20\NN\196485|significantly_42 (l_prep) in_21\IN\13603305|the_29|testosterone_25 (l_pcomp) improving_22\VBG\126264|NONE_0 (l_dobj) impairment_29\NN\7296428|NONE_0
D013739_D008569 NONE testosterone_0\NN\14747587|impairment_55|._78 (r_nsubj) ameliorates_1\VBZ\126264|NONE_0 (l_dobj) impairment_6\NN\7296428|testosterone_55|._23
D013739_D008569 NONE testosterone_7\NN\14747587|NONE_0 (r_pobj) of_6\IN\0|the_12|on_16 (r_prep) effects_5\NNS\13245626|to_13 (l_prep) on_8\IN\0|the_28|of_16 (l_pobj) impairment_13\NN\7296428|NONE_0
D013739_D008569 NONE testosterone_19\NN\14747587|the_4|in_25 (r_compound) replacement_20\NN\196485|significantly_42 (r_dobj) attenuated_17\VBD\224901|administration_120|significantly_68|memory_41|,_20|and_18|._98 (r_conj) impaired_8\VBD\258857|NONE_0 (l_dobj) memory_10\NN\5926676|administration_79|significantly_27|,_21|and_23|attenuated_41|._139
D013739_D008569 NONE testosterone_19\NN\14747587|the_4|in_25 (r_compound) replacement_20\NN\196485|significantly_42 (l_prep) in_21\IN\13603305|the_29|testosterone_25 (l_pcomp) improving_22\VBG\126264|NONE_0 (l_dobj) impairment_29\NN\7296428|NONE_0
D013739_D008569 NONE testosterone_0\NN\14747587|NONE_0 (r_compound) administration_1\NN\1133281|impairment_62|._92 (r_nsubj) ameliorates_2\VBZ\126264|NONE_0 (l_dobj) impairment_9\NN\7296428|administration_62|._30
C067431_D008569 CID letrozole_4\NN\0|of_14|,_2 (r_conj) administration_0\NN\1133281|significantly_52|memory_79|,_100|and_102|attenuated_120|._218 (r_nsubj) impaired_8\VBD\258857|NONE_0 (l_dobj) memory_10\NN\5926676|administration_79|significantly_27|,_21|and_23|attenuated_41|._139
C067431_D008569 CID letrozole_4\NN\0|of_14|,_2 (r_conj) administration_0\NN\1133281|significantly_52|memory_79|,_100|and_102|attenuated_120|._218 (r_nsubj) impaired_8\VBD\258857|NONE_0 (l_conj) attenuated_17\VBD\224901|administration_120|significantly_68|memory_41|,_20|and_18|._98 (l_dobj) replacement_20\NN\196485|significantly_42 (l_prep) in_21\IN\13603305|the_29|testosterone_25 (l_pcomp) improving_22\VBG\126264|NONE_0 (l_dobj) impairment_29\NN\7296428|NONE_0
D005485_D008569 CID flutamide_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|,_12|letrozole_14 (r_prep) administration_0\NN\1133281|significantly_52|memory_79|,_100|and_102|attenuated_120|._218 (r_nsubj) impaired_8\VBD\258857|NONE_0 (l_dobj) memory_10\NN\5926676|administration_79|significantly_27|,_21|and_23|attenuated_41|._139
D005485_D008569 CID flutamide_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|,_12|letrozole_14 (r_prep) administration_0\NN\1133281|significantly_52|memory_79|,_100|and_102|attenuated_120|._218 (r_nsubj) impaired_8\VBD\258857|NONE_0 (l_conj) attenuated_17\VBD\224901|administration_120|significantly_68|memory_41|,_20|and_18|._98 (l_dobj) replacement_20\NN\196485|significantly_42 (l_prep) in_21\IN\13603305|the_29|testosterone_25 (l_pcomp) improving_22\VBG\126264|NONE_0 (l_dobj) impairment_29\NN\7296428|NONE_0
D013311_D008569 CID streptozotocin_2\RB\0|-_14 (r_npadvmod) induced_4\VBN\1627355|memory_8|in_26 (r_amod) impairment_6\NN\7296428|testosterone_55|._23
D013311_D008569 CID streptozotocin_9\JJ\0|(_15|memory_29|in_47 (r_nmod) impairment_13\NN\7296428|NONE_0
D013311_D008569 CID stz)-induced_11\VBN\0|NONE_0 (r_amod) memory_12\NN\5926676|streptozotocin_29|(_14|in_18 (r_compound) impairment_13\NN\7296428|NONE_0
D013311_D008569 CID stz-_23\NNP\0|memory_28 (r_nmod) impairment_29\NN\7296428|NONE_0 (r_dobj) improving_22\VBG\126264|NONE_0 (r_pcomp) in_21\IN\13603305|the_29|testosterone_25 (r_prep) replacement_20\NN\196485|significantly_42 (r_dobj) attenuated_17\VBD\224901|administration_120|significantly_68|memory_41|,_20|and_18|._98 (r_conj) impaired_8\VBD\258857|NONE_0 (l_dobj) memory_10\NN\5926676|administration_79|significantly_27|,_21|and_23|attenuated_41|._139
D013311_D008569 CID stz-_23\NNP\0|memory_28 (r_nmod) impairment_29\NN\7296428|NONE_0
D013311_D008569 CID stz-_3\NNP\0|induced_20|memory_28|in_46 (r_nmod) impairment_9\NN\7296428|administration_62|._30
8160791
D006152_D007674 NONE monophosphate_7\NN\0|(_14|cgmp_15|)_19|and_31|increase_49 (r_nmod) excretion_11\NN\13466586|a_79|significant_77|in_55 (r_appos) reduction_2\NN\351485|were_152|also_157|in_171|._197 (r_nsubjpass) observed_25\VBN\2163746|NONE_0 (l_prep) in_26\IN\13603305|reduction_171|were_19|also_14|._26 (l_pobj) nephropathy_30\NN\14573196|NONE_0
D006152_D007674 NONE cgmp_9\NN\0|monophosphate_15|(_1|)_4|and_16|increase_34 (r_nmod) excretion_11\NN\13466586|a_79|significant_77|in_55 (r_appos) reduction_2\NN\351485|were_152|also_157|in_171|._197 (r_nsubjpass) observed_25\VBN\2163746|NONE_0 (l_prep) in_26\IN\13603305|reduction_171|were_19|also_14|._26 (l_pobj) nephropathy_30\NN\14573196|NONE_0
D005839_D007674 CID gentamicin_9\NN\2716866|-_10 (r_npadvmod) mediated_11\VBN\761713|NONE_0 (r_amod) nephropathy_12\NN\14573196|NONE_0
D005839_D007674 CID gentamicin_16\NN\2716866|(_11|gm)-mediated_12 (r_nmod) nephropathy_19\NN\14573196|NONE_0
D005839_D007674 CID gm)-mediated_18\JJ\0|gentamicin_12|(_1 (r_amod) nephropathy_19\NN\14573196|NONE_0
D005839_D007674 CID gm_2\NNP\13717155|NONE_0 (r_pobj) of_1\IN\0|at_6|for_21 (r_prep) administration_0\NN\1133281|reduction_78|damage_167|._173 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) damage_34\NN\7296428|administration_167|reduction_89|._6
D005839_D007674 CID gm_27\NNP\13717155|-_2 (r_npadvmod) mediated_29\VBN\761713|NONE_0 (r_amod) nephropathy_30\NN\14573196|NONE_0
D005839_D007674 CID gm_14\NNP\13717155|-_2 (r_npadvmod) mediated_16\VBN\761713|,_20|2_22|)_23 (r_amod) nephropathy_17\NN\14573196|NONE_0
D005839_D007674 CID gm_43\NNP\13717155|-_2 (r_npadvmod) induced_45\VBN\1627355|renal_8 (r_amod) vasoconstriction_47\NN\1149911|NONE_0 (r_pobj) in_42\IN\13603305|a_16|critical_14 (r_prep) role_41\NN\719494|NONE_0 (r_dobj) play_38\VBP\7007684|that_173|1_168|sod_160|effects_131|differ_50 (r_conj) have_10\VBP\7846|results_42|._204 (l_dobj) effects_12\NNS\13245626|that_42|1_37|sod_29|differ_81|play_131 (l_prep) on_13\IN\0|protective_19 (l_pobj) nephropathy_17\NN\14573196|NONE_0
D013481_D007674 NONE superoxide_36\JJ\14971519|NONE_0 (r_amod) anions_37\NNS\9315159|and_28|dmtu_24|,_20|and_18|3_14 (r_conj) sod_29\NNP\9335240|NONE_0 (r_pobj) for_28\IN\0|mechanisms_45 (r_prep) differ_27\VBP\0|that_123|1_118|sod_110|effects_81|play_50 (r_conj) have_10\VBP\7846|results_42|._204 (l_dobj) effects_12\NNS\13245626|that_42|1_37|sod_29|differ_81|play_131 (l_prep) on_13\IN\0|protective_19 (l_pobj) nephropathy_17\NN\14573196|NONE_0
C038983_D007674 NONE dmtu_3\NNP\0|in_13|,_2|significantly_5|damage_39|,_68|but_70|affect_85 (r_nsubj) reduced_5\VBD\441445|NONE_0 (l_dobj) damage_8\NN\7296428|in_52|,_41|dmtu_39|significantly_34|,_29|but_31|affect_46
C038983_D007674 NONE dmtu_9\NNP\0|both_13|and_4 (r_conj) sod_7\NNP\9335240|that_13|1_8|effects_29|differ_110|play_160 (r_nsubj) have_10\VBP\7846|results_42|._204 (l_dobj) effects_12\NNS\13245626|that_42|1_37|sod_29|differ_81|play_131 (l_prep) on_13\IN\0|protective_19 (l_pobj) nephropathy_17\NN\14573196|NONE_0
C038983_D007674 NONE dmtu_31\NNP\0|and_4|,_4|and_6|3_10|anions_24 (r_conj) sod_29\NNP\9335240|NONE_0 (r_pobj) for_28\IN\0|mechanisms_45 (r_prep) differ_27\VBP\0|that_123|1_118|sod_110|effects_81|play_50 (r_conj) have_10\VBP\7846|results_42|._204 (l_dobj) effects_12\NNS\13245626|that_42|1_37|sod_29|differ_81|play_131 (l_prep) on_13\IN\0|protective_19 (l_pobj) nephropathy_17\NN\14573196|NONE_0
8701013
D015738_D014456 NONE famotidine_0\NNP\3522239|antagonist_38|and_108|showing_115|._168 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) antagonist_5\NN\7846|famotidine_38|and_70|showing_77|._130 (l_acl) used_6\VBD\0|a_35|histamine_33|h2-receptor_23 (l_prep) in_7\IN\13603305|NONE_0 (l_pobj) settings_9\NNS\8567235|NONE_0 (l_prep) for_10\IN\0|inpatient_19 (l_pobj) prevention_11\NN\1073995|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) ulcers_14\NNS\14211294|NONE_0
D015738_D003693 CID famotidine_0\NN\3522239|-_10 (r_npadvmod) associated_2\VBN\628491|._19 (r_amod) delirium_3\NN\14391660|NONE_0
D015738_D003693 CID famotidine_25\NN\3522239|NONE_0 (r_pobj) with_24\IN\0|shown_96|,_58|cases_27|have_21|been_16|._15 (r_prep) associated_23\VBN\628491|NONE_0 (l_advcl) shown_9\VBN\2137132|,_38|cases_69|have_75|been_80|with_96|._111 (l_dobj) propensity_11\NN\7498854|although_79|all_70|have_15 (l_acl) cause_13\VB\7323922|the_18 (l_dobj) delirium_14\NN\14391660|to_9
D015738_D003693 CID famotidine_7\NN\3522239|-_10 (r_npadvmod) associated_9\VBN\628491|in_20 (r_amod) delirium_10\NN\14391660|NONE_0
D015738_D003693 CID famotidine_20\NN\3522239|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) removal_18\NN\383606|NONE_0 (r_pobj) upon_17\IN\0|who_23|completely_11 (r_prep) cleared_15\VBD\126264|hospitalized_26 (r_relcl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|associated_20 (r_prep) delirium_10\NN\14391660|NONE_0
24684312
D018698_D010146 NONE glutamate_3\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|intradermal_23 (r_prep) injections_1\NNS\320852|attractive_42|mimic_129|._178 (r_nsubj) are_6\VBP\13600404|NONE_0 (l_acomp) attractive_7\JJ\0|injections_42|mimic_87|._136 (l_xcomp) use_9\VB\407535|NONE_0 (l_prep) in_10\IN\13603305|to_7 (l_pobj) models_14\NNS\5888929|NONE_0 (l_compound) pain_13\NN\14299637|human_19|experimental_13
D002211_D013001 NONE capsaicin_5\NN\15032661|and_4 (r_conj) glutamate_3\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|intradermal_23 (r_prep) injections_1\NNS\320852|attractive_42|mimic_129|._178 (r_nsubj) are_6\VBP\13600404|NONE_0 (l_advcl) mimic_19\VBP\10200365|injections_129|attractive_87|._49 (l_dobj) aspects_21\NNS\5849789|because_50|hyperalgesia_42 (l_prep) of_22\IN\0|isolated_17 (l_pobj) disorders_25\NNS\14034177|NONE_0
D002211_D010146 NONE capsaicin_5\NN\15032661|and_4 (r_conj) glutamate_3\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|intradermal_23 (r_prep) injections_1\NNS\320852|attractive_42|mimic_129|._178 (r_nsubj) are_6\VBP\13600404|NONE_0 (l_acomp) attractive_7\JJ\0|injections_42|mimic_87|._136 (l_xcomp) use_9\VB\407535|NONE_0 (l_prep) in_10\IN\13603305|to_7 (l_pobj) models_14\NNS\5888929|NONE_0 (l_compound) pain_13\NN\14299637|human_19|experimental_13
D018698_D006930 NONE glutamate_1\NN\15010703|NONE_0 (l_appos) variability_9\NN\4733640|intradermal_75|and_53|injections_39|:_29|._50 (l_prep) of_10\IN\0|intra-_39 (l_pobj) hyperalgesia_12\NN\0|NONE_0
D018698_D006930 NONE glutamate_1\NN\15010703|NONE_0 (l_appos) variability_9\NN\4733640|intradermal_75|and_53|injections_39|:_29|._50 (l_prep) of_10\IN\0|intra-_39 (l_pobj) hyperalgesia_12\NN\0|NONE_0 (l_conj) allodynia_14\NN\0|provoked_26|and_4
D018698_D006930 NONE glutamate_3\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|intradermal_23 (r_prep) injections_1\NNS\320852|attractive_42|mimic_129|._178 (r_nsubj) are_6\VBP\13600404|NONE_0 (l_advcl) mimic_19\VBP\10200365|injections_129|attractive_87|._49 (l_nsubj) hyperalgesia_16\NN\0|because_8|aspects_42
D018698_D006930 NONE glutamate_3\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|intradermal_23 (r_prep) injections_1\NNS\320852|attractive_42|mimic_129|._178 (r_nsubj) are_6\VBP\13600404|NONE_0 (l_advcl) mimic_19\VBP\10200365|injections_129|attractive_87|._49 (l_nsubj) hyperalgesia_16\NN\0|because_8|aspects_42 (l_conj) allodynia_18\NN\0|and_4
D018698_D006930 NONE glutamate_32\NN\15010703|NONE_0 (r_compound) injection_33\NN\320852|NONE_0 (r_pobj) after_31\IN\0|60_25|and_22|g_14|(_12|p_11|)_2 (r_prep) gauges_21\VBZ\3733925|frey_5 (r_pobj) to_18\IN\0|scale_21|(_15|vas_14|)_11 (r_prep) response_17\NN\11410625|NONE_0 (r_pobj) in_9\IN\13603305|a_18|marked_16 (r_prep) increase_8\NN\13576355|NONE_0 (r_pobj) as_5\IN\14622893|hyperalgesia_26|was_13|._134 (r_prep) observed_4\VBN\2163746|NONE_0 (l_nsubjpass) hyperalgesia_2\NN\0|was_13|as_26|._160
D018698_D006930 NONE glutamate_3\NN\15010703|NONE_0 (r_nmod) yield_6\NN\913705|hyperalgesic_19|,_55|and_57|suited_87 (r_nmod) responses_11\NNS\11410625|,_72 (l_amod) hyperalgesic_8\JJ\0|yield_19|,_36|and_38|suited_68
D018698_D006930 NONE glutamate_3\NN\15010703|NONE_0 (r_nmod) yield_6\NN\913705|hyperalgesic_19|,_55|and_57|suited_87 (r_nmod) responses_11\NNS\11410625|,_72 (l_amod) hyperalgesic_8\JJ\0|yield_19|,_36|and_38|suited_68 (l_conj) allodynic_10\JJ\0|reproducible_30|and_4
D002211_D006930 CID capsaicin_3\NN\15032661|NONE_0 (r_compound) injections_4\NNS\320852|intradermal_36|and_14|:_10|variability_39|._89 (r_conj) glutamate_1\NN\15010703|NONE_0 (l_appos) variability_9\NN\4733640|intradermal_75|and_53|injections_39|:_29|._50 (l_prep) of_10\IN\0|intra-_39 (l_pobj) hyperalgesia_12\NN\0|NONE_0
D002211_D006930 CID capsaicin_3\NN\15032661|NONE_0 (r_compound) injections_4\NNS\320852|intradermal_36|and_14|:_10|variability_39|._89 (r_conj) glutamate_1\NN\15010703|NONE_0 (l_appos) variability_9\NN\4733640|intradermal_75|and_53|injections_39|:_29|._50 (l_prep) of_10\IN\0|intra-_39 (l_pobj) hyperalgesia_12\NN\0|NONE_0 (l_conj) allodynia_14\NN\0|provoked_26|and_4
D002211_D006930 CID capsaicin_5\NN\15032661|and_4 (r_conj) glutamate_3\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|intradermal_23 (r_prep) injections_1\NNS\320852|attractive_42|mimic_129|._178 (r_nsubj) are_6\VBP\13600404|NONE_0 (l_advcl) mimic_19\VBP\10200365|injections_129|attractive_87|._49 (l_nsubj) hyperalgesia_16\NN\0|because_8|aspects_42
D002211_D006930 CID capsaicin_5\NN\15032661|and_4 (r_conj) glutamate_3\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|intradermal_23 (r_prep) injections_1\NNS\320852|attractive_42|mimic_129|._178 (r_nsubj) are_6\VBP\13600404|NONE_0 (l_advcl) mimic_19\VBP\10200365|injections_129|attractive_87|._49 (l_nsubj) hyperalgesia_16\NN\0|because_8|aspects_42 (l_conj) allodynia_18\NN\0|and_4
D002211_D006930 CID capsaicin_1\NN\15032661|NONE_0 (r_pobj) for_0\IN\0|,_13|hyperalgesia_34|was_47|with_60|._96 (r_prep) detected_7\VBN\2163746|NONE_0 (l_nsubjpass) hyperalgesia_5\NN\0|for_34|,_21|was_13|with_26|._62
D002211_D006930 CID capsaicin_0\NN\15032661|NONE_0 (r_compound) injection_1\NN\320852|reproducible_14|>_59|and_67|allodynia_71|._93 (r_nsubj) was_2\VBD\0|NONE_0 (l_acomp) reproducible_3\JJ\0|injection_14|>_45|and_53|allodynia_57|._79 (l_prep) for_4\IN\0|NONE_0 (l_pobj) hyperalgesia_6\NN\0|NONE_0
D002211_D006930 CID capsaicin_0\NN\15032661|NONE_0 (r_compound) injection_1\NN\320852|reproducible_14|>_59|and_67|allodynia_71|._93 (r_nsubj) was_2\VBD\0|NONE_0 (l_attr) allodynia_13\NN\0|injection_71|reproducible_57|>_12|and_4|._22
D002211_D006930 CID capsaicin_5\NN\15032661|and_4 (r_conj) glutamate_3\NN\15010703|NONE_0 (r_nmod) yield_6\NN\913705|hyperalgesic_19|,_55|and_57|suited_87 (r_nmod) responses_11\NNS\11410625|,_72 (l_amod) hyperalgesic_8\JJ\0|yield_19|,_36|and_38|suited_68
D002211_D006930 CID capsaicin_5\NN\15032661|and_4 (r_conj) glutamate_3\NN\15010703|NONE_0 (r_nmod) yield_6\NN\913705|hyperalgesic_19|,_55|and_57|suited_87 (r_nmod) responses_11\NNS\11410625|,_72 (l_amod) hyperalgesic_8\JJ\0|yield_19|,_36|and_38|suited_68 (l_conj) allodynic_10\JJ\0|reproducible_30|and_4
D018698_D013001 NONE glutamate_3\NN\15010703|NONE_0 (r_pobj) of_2\IN\0|intradermal_23 (r_prep) injections_1\NNS\320852|attractive_42|mimic_129|._178 (r_nsubj) are_6\VBP\13600404|NONE_0 (l_advcl) mimic_19\VBP\10200365|injections_129|attractive_87|._49 (l_dobj) aspects_21\NNS\5849789|because_50|hyperalgesia_42 (l_prep) of_22\IN\0|isolated_17 (l_pobj) disorders_25\NNS\14034177|NONE_0
3925479
D001285_D002375 NONE atropine_5\NN\14712692|NONE_0 (r_preconj) ,_4\,\0|blocker_7|,_10|catalepsy_42|._51 (r_punct) disrupted_7\VBD\362348|NONE_0 (l_dobj) catalepsy_11\NN\14023236|blocker_49|,_42|,_32|._9
D006220_D002375 CID haloperidol_6\NN\3713736|-_11 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) catalepsy_9\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_19\NN\3713736|the_26|dopaminergic_22|,_2 (r_appos) blocker_17\NN\10101634|NONE_0 (r_pobj) by_14\IN\0|that_17|was_12 (r_agent) induced_13\VBN\1627355|the_23 (r_relcl) catalepsy_10\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_8\NN\3713736|-_11 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) catalepsy_11\NN\14023236|blocker_49|,_42|,_32|._9
D006220_D002375 CID haloperidol_19\NN\3713736|NONE_0 (r_pobj) by_18\IN\0|that_24|is_19|usually_16 (r_agent) induced_17\VBN\1627355|the_30 (r_relcl) catalepsy_13\NN\14023236|injection_80|,_16|._48
D006220_D002375 CID haloperidol_15\NN\3713736|such_8 (r_pobj) as_14\IN\14622893|NONE_0 (r_prep) neuroleptics_12\NNS\4470232|NONE_0 (r_pobj) by_11\IN\0|that_17|is_12 (r_agent) produced_10\VBN\1617192|the_22 (r_relcl) catalepsy_7\NN\14023236|that_9|is_63|actually_66|by_84
D014150_D002375 NONE neuroleptic_25\RB\4470232|-_11 (r_amod) induced_27\VBN\1627355|NONE_0 (r_amod) catalepsy_28\NN\14023236|NONE_0 (r_pobj) of_24\IN\0|full_16 (r_prep) expression_23\NN\4679549|NONE_0 (r_pobj) for_21\IN\0|to_13|intact_7 (r_prep) be_19\VB\14625458|that_36|mechanisms_19 (r_xcomp) need_17\VBP\13920835|that_90|activation_85|catalepsy_42|and_32 (r_conj) promotes_11\VBZ\2556126|previous_57 (l_dobj) catalepsy_12\NN\14023236|that_48|activation_43|and_10|need_42
D014150_D002375 NONE neuroleptic_25\RB\4470232|-_11 (r_amod) induced_27\VBN\1627355|NONE_0 (r_amod) catalepsy_28\NN\14023236|NONE_0
D014150_D002375 NONE neuroleptics_12\NNS\4470232|NONE_0 (r_pobj) by_11\IN\0|that_17|is_12 (r_agent) produced_10\VBN\1617192|the_22 (r_relcl) catalepsy_7\NN\14023236|that_9|is_63|actually_66|by_84
D000109_D002375 NONE acetylcholine_4\NN\14807558|-_13 (r_compound) synthesis_6\NN\13446390|an_17|,_19|hemicholinium_21 (r_compound) inhibitor_7\NN\20090|NONE_0 (r_pobj) of_2\IN\0|intracranial_23 (r_prep) injection_1\NN\320852|,_64|catalepsy_80|._128 (r_nsubj) prevented_11\VBD\0|NONE_0 (l_dobj) catalepsy_13\NN\14023236|injection_80|,_16|._48
D010862_D002375 CID pilocarpine_6\NN\14712692|large_35|of_23|,_2|,_11 (r_appos) doses_1\NNS\3740161|could_42|catalepsy_55|blocked_108|._115 (r_nsubj) induce_9\VB\1627355|NONE_0 (l_dobj) catalepsy_10\NN\14023236|doses_55|could_13|blocked_53|._60
D010862_D002375 CID pilocarpine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|low_10 (r_prep) doses_1\NNS\3740161|enhancement_41|._127 (r_nsubj) caused_4\VBD\1617192|NONE_0 (l_dobj) enhancement_7\NN\248977|doses_41|._86 (l_prep) of_8\IN\0|a_25|pronounced_23 (l_pobj) catalepsy_10\NN\14023236|NONE_0
D006426_D002375 NONE hemicholinium_9\NN\0|an_38|synthesis_21|,_2 (r_appos) inhibitor_7\NN\20090|NONE_0 (r_pobj) of_2\IN\0|intracranial_23 (r_prep) injection_1\NN\320852|,_64|catalepsy_80|._128 (r_nsubj) prevented_11\VBD\0|NONE_0 (l_dobj) catalepsy_13\NN\14023236|injection_80|,_16|._48
25084821
C069541_D008107 NONE quetiapine_23\NN\0|NONE_0 (r_pobj) to_22\IN\0|adverse_17 (r_prep) reaction_21\NN\13446390|NONE_0 (r_pobj) for_19\IN\0|a_20|diagnostic_18 (r_prep) marker_18\NN\21939|fever_26|may_20|._41 (r_attr) be_15\VB\14625458|dysfunction_79|may_67|one_60|,_28|and_26 (r_conj) be_3\VB\14625458|NONE_0 (l_nsubj) dysfunction_1\NN\14204950|may_12|one_19|,_51|and_53|be_79
C069541_D007970 CID quetiapine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|being_14 (r_prep) treated_5\VBN\2376958|NONE_0 (r_pcomp) after_3\IN\0|she_25|leucopenia_11|._35 (r_prep) developed_1\VBD\1753788|NONE_0 (l_dobj) leucopenia_2\JJ\14189204|she_14|after_11|._46
C069541_D006528 NONE quetiapine_0\NNP\0|-_10|neutropenia_19|in_31|._81 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_prep) in_4\IN\13603305|quetiapine_31|-_21|neutropenia_12|._50 (l_pobj) patient_7\NN\9898892|NONE_0 (l_prep) with_8\IN\0|a_18|bipolar_16 (l_pobj) carcinoma_10\NN\14239918|NONE_0
C069541_D006528 NONE quetiapine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) treatment_12\NN\654885|NONE_0 (r_pobj) after_11\IN\0|that_27|neutropenia_12 (r_prep) developed_9\VBD\1753788|a_45|with_35 (r_relcl) patient_4\NN\9898892|NONE_0 (l_prep) with_5\IN\0|a_10|developed_35 (l_pobj) carcinoma_7\NN\14239918|NONE_0
C069541_D005334 CID quetiapine_23\NN\0|NONE_0 (r_pobj) to_22\IN\0|adverse_17 (r_prep) reaction_21\NN\13446390|NONE_0 (r_pobj) for_19\IN\0|a_20|diagnostic_18 (r_prep) marker_18\NN\21939|fever_26|may_20|._41 (r_attr) be_15\VB\14625458|dysfunction_79|may_67|one_60|,_28|and_26 (l_nsubj) fever_13\NN\14299637|may_6|marker_26|._67
C069541_D001714 NONE quetiapine_0\NNP\0|-_10|neutropenia_19|in_31|._81 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_prep) in_4\IN\13603305|quetiapine_31|-_21|neutropenia_12|._50 (l_pobj) patient_7\NN\9898892|NONE_0 (l_amod) bipolar_6\JJ\0|a_2|with_16
C069541_D009503 CID quetiapine_0\NNP\0|-_10|neutropenia_19|in_31|._81 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) neutropenia_3\NN\14196405|quetiapine_19|-_9|in_12|._62
C069541_D009503 CID quetiapine_1\NNP\0|:_2|derivative_34|has_74|._146 (r_nsubj) is_2\VBZ\0|NONE_0 (l_advcl) has_12\VBZ\13888491|:_76|quetiapine_74|derivative_40|._72 (l_dobj) risk_15\NN\14541044|which_22 (l_prep) of_16\IN\0|the_17|highest_13 (l_pcomp) causing_17\VBG\30358|NONE_0 (l_dobj) dyscrasias_19\NNS\14052046|NONE_0 (l_appos) neutropenia_22\NN\14196405|blood_29|,_13
C069541_D009503 CID quetiapine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) treatment_12\NN\654885|NONE_0 (r_pobj) after_11\IN\0|that_27|neutropenia_12 (r_prep) developed_9\VBD\1753788|a_45|with_35 (l_dobj) neutropenia_10\NN\14196405|that_15|after_12
C069541_D009503 CID quetiapine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|a_21|common_19|side_12 (r_prep) effect_7\NN\34213|although_42|neutropenia_33|not_18 (r_attr) is_2\VBZ\0|,_41|physicians_43|should_54|cautious_64|._123 (l_nsubj) neutropenia_1\NN\14196405|although_9|not_15|effect_33
D003024_D009503 NONE clozapine_9\NN\3713736|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) similar_7\JJ\0|a_32|dibenzothiazepine_30|,_2|,_20 (r_amod) derivative_5\JJ\5802185|:_36|quetiapine_34|has_40|._112 (r_attr) is_2\VBZ\0|NONE_0 (l_advcl) has_12\VBZ\13888491|:_76|quetiapine_74|derivative_40|._72 (l_dobj) risk_15\NN\14541044|which_22 (l_prep) of_16\IN\0|the_17|highest_13 (l_pcomp) causing_17\VBG\30358|NONE_0 (l_dobj) dyscrasias_19\NNS\14052046|NONE_0 (l_appos) neutropenia_22\NN\14196405|blood_29|,_13
D003024_D006402 NONE clozapine_9\NN\3713736|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) similar_7\JJ\0|a_32|dibenzothiazepine_30|,_2|,_20 (r_amod) derivative_5\JJ\5802185|:_36|quetiapine_34|has_40|._112 (r_attr) is_2\VBZ\0|NONE_0 (l_advcl) has_12\VBZ\13888491|:_76|quetiapine_74|derivative_40|._72 (l_dobj) risk_15\NN\14541044|which_22 (l_prep) of_16\IN\0|the_17|highest_13 (l_pcomp) causing_17\VBG\30358|NONE_0 (l_dobj) dyscrasias_19\NNS\14052046|NONE_0
C069541_D006402 NONE quetiapine_1\NNP\0|:_2|derivative_34|has_74|._146 (r_nsubj) is_2\VBZ\0|NONE_0 (l_advcl) has_12\VBZ\13888491|:_76|quetiapine_74|derivative_40|._72 (l_dobj) risk_15\NN\14541044|which_22 (l_prep) of_16\IN\0|the_17|highest_13 (l_pcomp) causing_17\VBG\30358|NONE_0 (l_dobj) dyscrasias_19\NNS\14052046|NONE_0
18341442
C026098_C562694 NONE levetiracetam_0\NNP\0|NONE_0 (l_advcl) phenobarbital_5\JJ\2792049|as_17|._66 (l_dobj) treatment_6\NN\654885|to_17 (l_prep) in_7\IN\13603305|NONE_0 (l_pobj) cats_8\NNS\2120997|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) epilepsy_12\NN\14085708|NONE_0
C026098_C562694 NONE levetiracetam_10\NN\0|NONE_0 (l_advcl) phenobarbital_16\JJ\2792049|assess_104|administered_30|._84 (l_dobj) treatment_17\NN\654885|to_17 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) cats_19\NNS\2120997|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) epilepsy_25\NN\14085708|NONE_0
C026098_C562694 NONE levetiracetam_3\NN\0|that_5|is_14|well_17|in_32|and_40|be_48 (r_nsubjpass) tolerated_6\VBN\802318|results_45|._109 (l_conj) be_11\VB\14625458|that_53|levetiracetam_48|is_34|well_31|in_16|and_8 (l_acomp) useful_12\JJ\0|may_7 (l_prep) as_13\IN\14622893|NONE_0 (l_pobj) adjunct_15\NN\9312645|NONE_0 (l_relcl) phenobarbital_17\JJ\2792049|an_14 (l_dobj) treatment_18\NN\654885|to_17 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) cats_20\NNS\2120997|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) epilepsy_23\NN\14085708|NONE_0
C026098_D012640 NONE levetiracetam_7\NN\0|NONE_0 (r_amod) treatment_8\NN\654885|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) initiation_5\NN\7450842|frequencies_29|were_38|,_51|and_53|recorded_78 (r_nsubjpass) compared_10\VBN\644583|NONE_0 (l_nsubjpass) frequencies_1\NNS\15286249|initiation_29|were_67|,_80|and_82|recorded_107 (l_compound) seizure_0\NN\14081375|before_20
C026098_D012640 NONE levetiracetam_7\NN\0|NONE_0 (r_pcomp) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) prior_3\RB\10675876|frequency_10|higher_74|after_111|,_173|and_175|classified_197 (r_advmod) was_14\VBD\0|NONE_0 (l_nsubj) frequency_2\NN\15286249|prior_10|higher_84|after_121|,_183|and_185|classified_207 (l_compound) seizure_1\NN\14081375|median_7
C026098_D012640 NONE levetiracetam_7\NN\0|NONE_0 (l_appos) seizures_10\NNS\14081375|(_5|)_11
C026098_D012640 NONE levetiracetam_7\NN\0|NONE_0 (r_pcomp) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) prior_3\RB\10675876|frequency_10|higher_74|after_111|,_173|and_175|classified_197 (r_advmod) was_14\VBD\0|NONE_0 (l_acomp) higher_16\JJR\0|frequency_84|prior_74|after_37|,_99|and_101|classified_123 (l_prep) than_17\IN\0|significantly_21 (l_pobj) frequency_20\NN\15286249|NONE_0 (l_compound) seizure_19\NN\14081375|median_7
C026098_D012640 NONE levetiracetam_7\NN\0|NONE_0 (r_pcomp) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) prior_3\RB\10675876|frequency_10|higher_74|after_111|,_173|and_175|classified_197 (r_advmod) was_14\VBD\0|NONE_0 (l_prep) after_21\IN\0|frequency_121|prior_111|higher_37|,_62|and_64|classified_86 (l_pobj) initiation_22\NN\7450842|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) treatment_25\NN\654885|NONE_0 (l_appos) seizures_28\NNS\14081375|levetiracetam_30
C026098_D012640 NONE levetiracetam_7\NN\0|NONE_0 (r_pcomp) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) prior_3\RB\10675876|frequency_10|higher_74|after_111|,_173|and_175|classified_197 (r_advmod) was_14\VBD\0|NONE_0 (l_conj) classified_39\VBN\7249426|frequency_207|prior_197|higher_123|after_86|,_24|and_22 (l_prep) as_40\IN\14622893|cats_21|were_16|._94 (l_pcomp) responded_42\VBN\2367363|NONE_0 (l_attr) reduction_49\NN\351485|having_49|levetiracetam_29 (l_prep) in_50\IN\13603305|(_15|ie_14|,_12|)_31 (l_pobj) frequency_52\NN\15286249|NONE_0 (l_compound) seizure_51\NN\14081375|of_18
C026098_D012640 NONE levetiracetam_24\NN\0|seizures_30 (r_amod) treatment_25\NN\654885|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) initiation_22\NN\7450842|NONE_0 (r_pobj) after_21\IN\0|frequency_121|prior_111|higher_37|,_62|and_64|classified_86 (r_prep) was_14\VBD\0|NONE_0 (l_nsubj) frequency_2\NN\15286249|prior_10|higher_84|after_121|,_183|and_185|classified_207 (l_compound) seizure_1\NN\14081375|median_7
C026098_D012640 NONE levetiracetam_24\NN\0|seizures_30 (r_amod) treatment_25\NN\654885|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) initiation_22\NN\7450842|NONE_0 (r_pobj) after_21\IN\0|frequency_121|prior_111|higher_37|,_62|and_64|classified_86 (r_prep) was_14\VBD\0|NONE_0 (l_advmod) prior_3\RB\10675876|frequency_10|higher_74|after_111|,_173|and_175|classified_197 (l_prep) to_4\IN\0|NONE_0 (l_pobj) treatment_5\NN\654885|NONE_0 (l_prep) with_6\IN\0|NONE_0 (l_pcomp) levetiracetam_7\NN\0|NONE_0 (l_appos) seizures_10\NNS\14081375|(_5|)_11
C026098_D012640 NONE levetiracetam_24\NN\0|seizures_30 (r_amod) treatment_25\NN\654885|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) initiation_22\NN\7450842|NONE_0 (r_pobj) after_21\IN\0|frequency_121|prior_111|higher_37|,_62|and_64|classified_86 (r_prep) was_14\VBD\0|NONE_0 (l_acomp) higher_16\JJR\0|frequency_84|prior_74|after_37|,_99|and_101|classified_123 (l_prep) than_17\IN\0|significantly_21 (l_pobj) frequency_20\NN\15286249|NONE_0 (l_compound) seizure_19\NN\14081375|median_7
C026098_D012640 NONE levetiracetam_24\NN\0|seizures_30 (r_amod) treatment_25\NN\654885|NONE_0 (l_appos) seizures_28\NNS\14081375|levetiracetam_30
C026098_D012640 NONE levetiracetam_24\NN\0|seizures_30 (r_amod) treatment_25\NN\654885|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) initiation_22\NN\7450842|NONE_0 (r_pobj) after_21\IN\0|frequency_121|prior_111|higher_37|,_62|and_64|classified_86 (r_prep) was_14\VBD\0|NONE_0 (l_conj) classified_39\VBN\7249426|frequency_207|prior_197|higher_123|after_86|,_24|and_22 (l_prep) as_40\IN\14622893|cats_21|were_16|._94 (l_pcomp) responded_42\VBN\2367363|NONE_0 (l_attr) reduction_49\NN\351485|having_49|levetiracetam_29 (l_prep) in_50\IN\13603305|(_15|ie_14|,_12|)_31 (l_pobj) frequency_52\NN\15286249|NONE_0 (l_compound) seizure_51\NN\14081375|of_18
C026098_D012640 NONE levetiracetam_44\VB\0|having_20|reduction_29 (r_xcomp) responded_42\VBN\2367363|NONE_0 (r_pcomp) as_40\IN\14622893|cats_21|were_16|._94 (r_prep) classified_39\VBN\7249426|frequency_207|prior_197|higher_123|after_86|,_24|and_22 (r_conj) was_14\VBD\0|NONE_0 (l_nsubj) frequency_2\NN\15286249|prior_10|higher_84|after_121|,_183|and_185|classified_207 (l_compound) seizure_1\NN\14081375|median_7
C026098_D012640 NONE levetiracetam_44\VB\0|having_20|reduction_29 (r_xcomp) responded_42\VBN\2367363|NONE_0 (r_pcomp) as_40\IN\14622893|cats_21|were_16|._94 (r_prep) classified_39\VBN\7249426|frequency_207|prior_197|higher_123|after_86|,_24|and_22 (r_conj) was_14\VBD\0|NONE_0 (l_advmod) prior_3\RB\10675876|frequency_10|higher_74|after_111|,_173|and_175|classified_197 (l_prep) to_4\IN\0|NONE_0 (l_pobj) treatment_5\NN\654885|NONE_0 (l_prep) with_6\IN\0|NONE_0 (l_pcomp) levetiracetam_7\NN\0|NONE_0 (l_appos) seizures_10\NNS\14081375|(_5|)_11
C026098_D012640 NONE levetiracetam_44\VB\0|having_20|reduction_29 (r_xcomp) responded_42\VBN\2367363|NONE_0 (r_pcomp) as_40\IN\14622893|cats_21|were_16|._94 (r_prep) classified_39\VBN\7249426|frequency_207|prior_197|higher_123|after_86|,_24|and_22 (r_conj) was_14\VBD\0|NONE_0 (l_acomp) higher_16\JJR\0|frequency_84|prior_74|after_37|,_99|and_101|classified_123 (l_prep) than_17\IN\0|significantly_21 (l_pobj) frequency_20\NN\15286249|NONE_0 (l_compound) seizure_19\NN\14081375|median_7
C026098_D012640 NONE levetiracetam_44\VB\0|having_20|reduction_29 (r_xcomp) responded_42\VBN\2367363|NONE_0 (r_pcomp) as_40\IN\14622893|cats_21|were_16|._94 (r_prep) classified_39\VBN\7249426|frequency_207|prior_197|higher_123|after_86|,_24|and_22 (r_conj) was_14\VBD\0|NONE_0 (l_prep) after_21\IN\0|frequency_121|prior_111|higher_37|,_62|and_64|classified_86 (l_pobj) initiation_22\NN\7450842|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) treatment_25\NN\654885|NONE_0 (l_appos) seizures_28\NNS\14081375|levetiracetam_30
C026098_D012640 NONE levetiracetam_44\VB\0|having_20|reduction_29 (r_xcomp) responded_42\VBN\2367363|NONE_0 (l_attr) reduction_49\NN\351485|having_49|levetiracetam_29 (l_prep) in_50\IN\13603305|(_15|ie_14|,_12|)_31 (l_pobj) frequency_52\NN\15286249|NONE_0 (l_compound) seizure_51\NN\14081375|of_18
D010634_C562694 NONE phenobarbital_5\JJ\2792049|as_17|._66 (l_dobj) treatment_6\NN\654885|to_17 (l_prep) in_7\IN\13603305|NONE_0 (l_pobj) cats_8\NNS\2120997|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) epilepsy_12\NN\14085708|NONE_0
D010634_C562694 NONE phenobarbital_16\JJ\2792049|assess_104|administered_30|._84 (l_dobj) treatment_17\NN\654885|to_17 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) cats_19\NNS\2120997|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) epilepsy_25\NN\14085708|NONE_0
D010634_C562694 NONE phenobarbital_12\JJ\2792049|NONE_0 (r_pobj) with_11\IN\0|that_27|was_22|poorly_18|or_19|had_27 (r_prep) controlled_10\VBN\0|idiopathic_36 (r_relcl) epilepsy_6\NN\14085708|to_19
D010634_C562694 NONE phenobarbital_22\NN\2792049|NONE_0 (r_pobj) with_21\IN\0|when_13 (r_prep) treated_20\VBN\2376958|that_43|effects_13 (r_advcl) had_15\VBD\0|that_54|was_49|poorly_45|with_27|or_8 (r_conj) controlled_10\VBN\0|idiopathic_36 (r_relcl) epilepsy_6\NN\14085708|to_19
D010634_C562694 NONE phenobarbital_17\JJ\2792049|an_14 (l_dobj) treatment_18\NN\654885|to_17 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) cats_20\NNS\2120997|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) epilepsy_23\NN\14085708|NONE_0
24341598
D012965_D007674 NONE chloride_6\NN\14818238|NONE_0 (r_pobj) of_3\IN\0|with_28 (r_prep) effects_2\NNS\13245626|NONE_0 (l_prep) with_7\IN\0|of_28 (l_pobj) diltiazem_8\NN\2938514|NONE_0 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) prevention_10\NN\1073995|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) nephropathy_15\NN\14573196|NONE_0
D003287_D058186 CID contrast_25\NN\13854649|NONE_0 (r_amod) material_26\NN\19613|after_15|was_9|(_22|%_27|)_28 (r_nsubjpass) injected_28\VBN\81072|among_146|,_96|patients_91|failure_60|on_46|._16 (r_advcl) developed_13\VBD\1753788|NONE_0 (l_dobj) failure_16\NN\66216|among_86|,_36|patients_31|on_14|injected_60|._76
D003287_D058186 CID contrast_25\NN\13854649|NONE_0 (r_amod) material_26\NN\19613|after_15|was_9|(_22|%_27|)_28 (r_nsubjpass) injected_28\VBN\81072|among_146|,_96|patients_91|failure_60|on_46|._16 (r_advcl) developed_13\VBD\1753788|NONE_0 (l_dobj) failure_16\NN\66216|among_86|,_36|patients_31|on_14|injected_60|._76 (l_appos) arf_18\NNP\0|acute_21|renal_15|(_1|)_3
D004110_D007674 NONE diltiazem_8\NN\2938514|NONE_0 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) prevention_10\NN\1073995|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) nephropathy_15\NN\14573196|NONE_0
D003287_D007674 NONE contrast_12\NN\13854649|-_8 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) nephropathy_15\NN\14573196|NONE_0
D003287_D007674 NONE contrast_0\RB\13854649|-_8 (r_npadvmod) induced_2\VBN\1627355|cin_21 (r_amod) nephropathy_3\NN\14573196|significantly_18|morbidity_46|._81
17028363
D004008_D058186 CID diclofenac_20\NN\0|a_40|steroidal_34|inflammatory_19|,_2 (r_appos) drug_18\NN\14778436|NONE_0 (r_pobj) of_10\IN\0|the_23|concomitant_19 (r_prep) intake_9\NN\13440063|NONE_0 (r_pobj) by_6\IN\0|injury_31|was_24|probably_20|._79 (r_agent) aggravated_5\VBN\126264|NONE_0 (l_nsubjpass) injury_2\NN\14052046|was_7|probably_11|by_31|._110
D000880_D058186 NONE anthraquinones_11\NNS\0|NONE_0 (r_dobj) containing_10\VBG\2632940|slimming_15 (r_acl) pills_9\NNS\4424218|NONE_0 (r_pobj) of_7\IN\0|prolonged_17 (r_prep) intake_6\NN\13440063|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|acute_20|renal_14|._76 (r_acl) failure_2\NN\66216|NONE_0
D000880_D058186 NONE anthraquinone_24\NN\0|NONE_0 (r_compound) derivatives_25\NNS\5802185|that_29 (r_dobj) contained_23\VBD\2632940|a_48|proprietary_46|chinese_34|herbal_26|slimming_19|,_35 (r_relcl) pill_21\NN\4424218|NONE_0 (r_pobj) of_15\IN\0|prolonged_14|extracted_88 (r_prep) use_14\NN\407535|NONE_0 (r_pobj) following_12\VBG\8180190|who_34|failure_8 (r_prep) developed_8\VBD\1753788|a_24|old_14 (l_dobj) failure_11\NN\66216|who_26|following_8
D000880_D058186 NONE anthraquinone_9\NN\0|-_13 (r_npadvmod) containing_11\VBG\2632940|an_17|herbal_11|and_24|injury_34 (r_amod) agent_13\NN\7347|NONE_0 (l_conj) injury_16\NN\14052046|an_51|containing_34|herbal_23|and_10
D000880_D051437 NONE anthraquinone_9\NN\0|-_13 (r_npadvmod) containing_11\VBG\2632940|an_17|herbal_11|and_24|injury_34 (r_amod) agent_13\NN\7347|NONE_0 (r_pobj) of_7\IN\0|the_8 (r_prep) use_6\NN\407535|NONE_0 (r_pobj) between_4\IN\0|a_22|causal_20 (r_prep) relationship_3\NN\31921|although_18|proven_104 (r_nsubj) remains_17\VBZ\2684|,_20|nephropathy_59|should_71|be_78|in_92|._146 (r_advcl) considered_29\VBN\689344|NONE_0 (l_prep) in_30\IN\13603305|remains_92|,_72|nephropathy_33|should_21|be_14|._54 (l_pobj) patients_31\NNS\9898892|NONE_0 (l_relcl) present_33\VBP\28270|NONE_0 (l_prep) with_34\IN\0|who_12 (l_pobj) failure_37\NN\66216|NONE_0
D034341_D007674 NONE acids_16\NNS\14818238|NONE_0 (r_pobj) of_14\IN\0|the_8 (r_prep) use_13\NN\407535|usually_22 (r_dobj) involving_11\VBG\2676054|nephropathy_74|has_38|previously_34|been_23|,_10|._39 (r_advcl) reported_8\VBN\831651|NONE_0 (l_nsubjpass) nephropathy_0\NNP\14573196|has_36|previously_40|been_51|,_64|involving_74|._113
D004365_D007674 NONE herbs_4\NNS\13083586|NONE_0 (r_pobj) by_2\IN\0|NONE_0 (r_agent) caused_1\VBN\1617192|NONE_0 (r_acl) nephropathy_0\NNP\14573196|has_36|previously_40|been_51|,_64|involving_74|._113
D004365_D058186 CID herbal_19\JJ\7933274|a_22|proprietary_20|chinese_8|slimming_7|contained_26|,_61 (r_amod) pill_21\NN\4424218|NONE_0 (r_pobj) of_15\IN\0|prolonged_14|extracted_88 (r_prep) use_14\NN\407535|NONE_0 (r_pobj) following_12\VBG\8180190|who_34|failure_8 (r_prep) developed_8\VBD\1753788|a_24|old_14 (l_dobj) failure_11\NN\66216|who_26|following_8
D000880_D007674 NONE anthraquinone_9\NN\0|-_13 (r_npadvmod) containing_11\VBG\2632940|an_17|herbal_11|and_24|injury_34 (r_amod) agent_13\NN\7347|NONE_0 (r_pobj) of_7\IN\0|the_8 (r_prep) use_6\NN\407535|NONE_0 (r_pobj) between_4\IN\0|a_22|causal_20 (r_prep) relationship_3\NN\31921|although_18|proven_104 (r_nsubj) remains_17\VBZ\2684|,_20|nephropathy_59|should_71|be_78|in_92|._146 (r_advcl) considered_29\VBN\689344|NONE_0 (l_nsubjpass) nephropathy_26\NN\14573196|remains_59|,_39|should_12|be_19|in_33|._87
24911645
D005680_D012640 NONE acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (l_dobj) effects_8\NNS\13245626|to_20|determine_64 (l_prep) at_9\IN\14622893|the_16|gfc_12 (l_pobj) doses_10\NNS\3740161|NONE_0 (l_prep) on_18\IN\0|of_22 (l_pobj) parameters_20\NNS\5858936|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D005680_D012640 NONE acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (r_xcomp) aimed_3\VBN\1987160|the_18|present_14|)_225 (r_acl) study_2\NN\635850|as_248|on_251|._325 (r_nsubj) levels_47\NNS\4916342|NONE_0 (l_prep) on_51\IN\0|study_251|as_3|._74 (l_pobj) acetylcholinesterase_52\NN\0|NONE_0 (l_appos) activity_56\NN\30358|(_7|ache_6|)_2 (l_prep) in_57\IN\13603305|NONE_0 (l_pobj) hippocampus_59\NN\5462674|NONE_0 (l_prep) after_60\IN\0|mice_17 (l_pobj) seizures_61\NNS\14081375|NONE_0
D005680_D012640 NONE gaba_38\NNP\14601829|(_22|aminobutyric_19|,_5|glutamine_7 (r_appos) acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (l_dobj) effects_8\NNS\13245626|to_20|determine_64 (l_prep) at_9\IN\14622893|the_16|gfc_12 (l_pobj) doses_10\NNS\3740161|NONE_0 (l_prep) on_18\IN\0|of_22 (l_pobj) parameters_20\NNS\5858936|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D005680_D012640 NONE gaba_38\NNP\14601829|(_22|aminobutyric_19|,_5|glutamine_7 (r_appos) acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (r_xcomp) aimed_3\VBN\1987160|the_18|present_14|)_225 (r_acl) study_2\NN\635850|as_248|on_251|._325 (r_nsubj) levels_47\NNS\4916342|NONE_0 (l_prep) on_51\IN\0|study_251|as_3|._74 (l_pobj) acetylcholinesterase_52\NN\0|NONE_0 (l_appos) activity_56\NN\30358|(_7|ache_6|)_2 (l_prep) in_57\IN\13603305|NONE_0 (l_pobj) hippocampus_59\NN\5462674|NONE_0 (l_prep) after_60\IN\0|mice_17 (l_pobj) seizures_61\NNS\14081375|NONE_0
D010862_D013226 CID pilocarpine_16\NN\14712692|-_11 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) status_19\NN\24720|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) installation_14\NN\235435|NONE_0 (r_pobj) of_13\IN\0|the_14 (r_prep) frequency_12\NN\15286249|epilepticus_56|,_67|demonstrated_72 (r_dobj) reduce_10\VB\441445|that_47|gfc_42|can_38|activity_13|and_4 (l_advmod) epilepticus_20\NN\0|frequency_56|,_11|demonstrated_16
D005978_D012640 NONE glutathione_45\NN\0|and_4 (r_conj) aspartate_43\NN\0|,_2 (r_conj) glutamine_41\NN\14601829|(_29|aminobutyric_26|gaba_7|,_2 (r_appos) acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (l_dobj) effects_8\NNS\13245626|to_20|determine_64 (l_prep) at_9\IN\14622893|the_16|gfc_12 (l_pobj) doses_10\NNS\3740161|NONE_0 (l_prep) on_18\IN\0|of_22 (l_pobj) parameters_20\NNS\5858936|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D005978_D012640 NONE glutathione_45\NN\0|and_4 (r_conj) aspartate_43\NN\0|,_2 (r_conj) glutamine_41\NN\14601829|(_29|aminobutyric_26|gaba_7|,_2 (r_appos) acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (r_xcomp) aimed_3\VBN\1987160|the_18|present_14|)_225 (r_acl) study_2\NN\635850|as_248|on_251|._325 (r_nsubj) levels_47\NNS\4916342|NONE_0 (l_prep) on_51\IN\0|study_251|as_3|._74 (l_pobj) acetylcholinesterase_52\NN\0|NONE_0 (l_appos) activity_56\NN\30358|(_7|ache_6|)_2 (l_prep) in_57\IN\13603305|NONE_0 (l_pobj) hippocampus_59\NN\5462674|NONE_0 (l_prep) after_60\IN\0|mice_17 (l_pobj) seizures_61\NNS\14081375|NONE_0
D000596_D012640 NONE acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (l_dobj) effects_8\NNS\13245626|to_20|determine_64 (l_prep) at_9\IN\14622893|the_16|gfc_12 (l_pobj) doses_10\NNS\3740161|NONE_0 (l_prep) on_18\IN\0|of_22 (l_pobj) parameters_20\NNS\5858936|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D000596_D012640 NONE acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (r_xcomp) aimed_3\VBN\1987160|the_18|present_14|)_225 (r_acl) study_2\NN\635850|as_248|on_251|._325 (r_nsubj) levels_47\NNS\4916342|NONE_0 (l_prep) on_51\IN\0|study_251|as_3|._74 (l_pobj) acetylcholinesterase_52\NN\0|NONE_0 (l_appos) activity_56\NN\30358|(_7|ache_6|)_2 (l_prep) in_57\IN\13603305|NONE_0 (l_pobj) hippocampus_59\NN\5462674|NONE_0 (l_prep) after_60\IN\0|mice_17 (l_pobj) seizures_61\NNS\14081375|NONE_0
C573355_D013226 NONE gfc_4\NNP\0|that_5|can_4|activity_29|and_38|reduce_42 (r_nsubj) exert_6\VB\1158872|results_30|._211 (l_conj) reduce_10\VB\441445|that_47|gfc_42|can_38|activity_13|and_4 (l_advmod) epilepticus_20\NN\0|frequency_56|,_11|demonstrated_16
D018698_D012640 NONE glutamine_41\NN\14601829|(_29|aminobutyric_26|gaba_7|,_2 (r_appos) acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (l_dobj) effects_8\NNS\13245626|to_20|determine_64 (l_prep) at_9\IN\14622893|the_16|gfc_12 (l_pobj) doses_10\NNS\3740161|NONE_0 (l_prep) on_18\IN\0|of_22 (l_pobj) parameters_20\NNS\5858936|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D018698_D012640 NONE glutamine_41\NN\14601829|(_29|aminobutyric_26|gaba_7|,_2 (r_appos) acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (r_xcomp) aimed_3\VBN\1987160|the_18|present_14|)_225 (r_acl) study_2\NN\635850|as_248|on_251|._325 (r_nsubj) levels_47\NNS\4916342|NONE_0 (l_prep) on_51\IN\0|study_251|as_3|._74 (l_pobj) acetylcholinesterase_52\NN\0|NONE_0 (l_appos) activity_56\NN\30358|(_7|ache_6|)_2 (l_prep) in_57\IN\13603305|NONE_0 (l_pobj) hippocampus_59\NN\5462674|NONE_0 (l_prep) after_60\IN\0|mice_17 (l_pobj) seizures_61\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_11\NN\14712692|-_11 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_amod) seizures_14\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_16\NN\14712692|-_11 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) status_19\NN\24720|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) installation_14\NN\235435|NONE_0 (r_pobj) of_13\IN\0|the_14 (r_prep) frequency_12\NN\15286249|epilepticus_56|,_67|demonstrated_72 (r_dobj) reduce_10\VB\441445|that_47|gfc_42|can_38|activity_13|and_4 (l_advcl) demonstrated_23\VBN\2137132|frequency_72|epilepticus_16|,_5 (l_agent) by_24\IN\0|as_16 (l_pobj) increase_25\NN\13576355|NONE_0 (l_prep) to_28\IN\0|in_11|and_17|decrease_21 (l_pobj) seizure_30\NN\14081375|NONE_0
C573355_D012640 NONE fc_9\NNP\0|NONE_0 (r_pobj) with_7\IN\0|in_25 (r_prep) pretreated_6\VBN\0|behavioral_45|in_8|._67 (l_prep) in_10\IN\13603305|with_25 (l_pobj) seizures_14\NNS\14081375|NONE_0
C573355_D012640 NONE gfc_7\NNP\0|the_4|at_12 (r_compound) effects_8\NNS\13245626|to_20|determine_64 (l_prep) at_9\IN\14622893|the_16|gfc_12 (l_pobj) doses_10\NNS\3740161|NONE_0 (l_prep) on_18\IN\0|of_22 (l_pobj) parameters_20\NNS\5858936|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
C573355_D012640 NONE gfc_7\NNP\0|the_4|at_12 (r_compound) effects_8\NNS\13245626|to_20|determine_64 (r_dobj) evaluate_5\VB\670261|NONE_0 (r_xcomp) aimed_3\VBN\1987160|the_18|present_14|)_225 (r_acl) study_2\NN\635850|as_248|on_251|._325 (r_nsubj) levels_47\NNS\4916342|NONE_0 (l_prep) on_51\IN\0|study_251|as_3|._74 (l_pobj) acetylcholinesterase_52\NN\0|NONE_0 (l_appos) activity_56\NN\30358|(_7|ache_6|)_2 (l_prep) in_57\IN\13603305|NONE_0 (l_pobj) hippocampus_59\NN\5462674|NONE_0 (l_prep) after_60\IN\0|mice_17 (l_pobj) seizures_61\NNS\14081375|NONE_0
C573355_D012640 NONE gfc_0\NNP\0|latency_26|,_50|at_52|kg_94|._177 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) latency_4\NN\15269513|gfc_26|,_24|at_26|kg_68|._151 (l_prep) to_5\IN\0|an_21|increased_18 (l_pobj) seizure_7\NN\14081375|NONE_0
C573355_D012640 NONE gfc_4\NNP\0|that_5|can_4|activity_29|and_38|reduce_42 (r_nsubj) exert_6\VB\1158872|results_30|._211 (l_conj) reduce_10\VB\441445|that_47|gfc_42|can_38|activity_13|and_4 (l_advcl) demonstrated_23\VBN\2137132|frequency_72|epilepticus_16|,_5 (l_agent) by_24\IN\0|as_16 (l_pobj) increase_25\NN\13576355|NONE_0 (l_prep) to_28\IN\0|in_11|and_17|decrease_21 (l_pobj) seizure_30\NN\14081375|NONE_0
D001224_D012640 NONE aspartate_43\NN\0|,_2 (r_conj) glutamine_41\NN\14601829|(_29|aminobutyric_26|gaba_7|,_2 (r_appos) acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (l_dobj) effects_8\NNS\13245626|to_20|determine_64 (l_prep) at_9\IN\14622893|the_16|gfc_12 (l_pobj) doses_10\NNS\3740161|NONE_0 (l_prep) on_18\IN\0|of_22 (l_pobj) parameters_20\NNS\5858936|NONE_0 (l_compound) seizure_19\NN\14081375|NONE_0
D001224_D012640 NONE aspartate_43\NN\0|,_2 (r_conj) glutamine_41\NN\14601829|(_29|aminobutyric_26|gaba_7|,_2 (r_appos) acid_36\NN\14818238|amino_27 (r_appos) acid_31\NN\14818238|NONE_0 (r_pobj) on_29\IN\0|its_12 (r_prep) effects_28\NNS\13245626|their_38|anticonvulsant_32|and_8 (r_conj) activity_25\NN\30358|to_34 (r_dobj) determine_22\VB\0|to_84|effects_64 (r_advcl) evaluate_5\VB\670261|NONE_0 (r_xcomp) aimed_3\VBN\1987160|the_18|present_14|)_225 (r_acl) study_2\NN\635850|as_248|on_251|._325 (r_nsubj) levels_47\NNS\4916342|NONE_0 (l_prep) on_51\IN\0|study_251|as_3|._74 (l_pobj) acetylcholinesterase_52\NN\0|NONE_0 (l_appos) activity_56\NN\30358|(_7|ache_6|)_2 (l_prep) in_57\IN\13603305|NONE_0 (l_pobj) hippocampus_59\NN\5462674|NONE_0 (l_prep) after_60\IN\0|mice_17 (l_pobj) seizures_61\NNS\14081375|NONE_0
1905439
D016595_D006261 NONE misoprostol_0\NNP\0|has_12|been_16|with_32|._127 (r_nsubjpass) associated_3\VBN\628491|NONE_0 (l_prep) with_4\IN\0|misoprostol_32|has_20|been_16|._95 (l_pobj) reactions_6\NNS\13446390|NONE_0 (l_prep) including_8\VBG\0|adverse_19|,_2 (l_pobj) symptoms_10\NNS\5823932|NONE_0 (l_conj) problems_13\NNS\14408086|gastrointestinal_39|,_14 (l_conj) headache_16\NN\5829480|gynecologic_26|,_6|and_4
D016595_D003693 CID misoprostol_10\NNP\0|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) administration_8\NN\1133281|NONE_0 (r_pobj) with_7\IN\0|possibly_20 (r_prep) associated_6\VBN\628491|an_26|elderly_23 (r_acl) woman_4\NN\9605289|NONE_0 (r_pobj) in_1\IN\13603305|._74 (r_prep) delirium_0\NN\14391660|NONE_0
D016595_D003693 CID misoprostol_5\NNP\0|after_6|was_12|and_29|returned_51 (r_nsubjpass) discontinued_7\VBN\0|delirium_54|significantly_45|._67 (r_advcl) improved_3\VBD\126264|NONE_0 (l_nsubj) delirium_1\NN\14391660|significantly_9|discontinued_54|._121
D016595_D003693 CID misoprostol_20\NNP\0|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) from_19\IN\0|changed_82|,_61|delirium_55|possibly_18|._24 (r_prep) resulted_18\VBD\2633881|NONE_0 (l_nsubj) delirium_12\NN\14391660|changed_27|,_6|possibly_37|from_55|._79
12059909
D003520_D006470 CID cy_1\NNP\0|early_6 (r_compound) toxicity_2\NN\13576101|cystitis_39|._111 (r_nsubj) caused_3\VBD\1617192|NONE_0 (l_dobj) cystitis_7\NN\14566129|toxicity_39|._72 (l_amod) haemorrhagic_6\JJ\0|a_10|typical_8|in_22|repaired_58
D003520_D064420 NONE cyclophosphamide_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) toxicity_1\NN\13576101|on_29|._77
D003520_D064420 NONE cy_1\NNP\0|early_6 (r_compound) toxicity_2\NN\13576101|cystitis_39|._111
D003520_D064420 NONE cy_7\NNP\0|NONE_0 (r_pobj) of_6\IN\0|delayed_17|in_6 (r_prep) toxicity_5\NN\13576101|pathology_53
D003520_D003556 CID cy_1\NNP\0|early_6 (r_compound) toxicity_2\NN\13576101|cystitis_39|._111 (r_nsubj) caused_3\VBD\1617192|NONE_0 (l_dobj) cystitis_7\NN\14566129|toxicity_39|._72
D003520_D003556 CID cy_4\NNP\0|ulcerous_13 (r_compound) injection_5\NN\320852|NONE_0 (r_pobj) of_3\IN\0|30_8 (r_prep) days_2\NNS\15140892|NONE_0 (r_pobj) after_0\IN\0|forms_56|in_91|but_112|%_125|._142 (r_prep) appeared_15\VBD\2604760|NONE_0 (l_nsubj) forms_11\NNS\6286395|after_56|in_35|but_56|%_69|._86 (l_prep) of_12\IN\0|ulcerous_15 (l_pobj) cystitis_14\NN\14566129|NONE_0
26002693
C031763_D015464 NONE 1,3-butadiene_0\CD\0|NONE_0 (l_conj) cml_2\NNP\0|,_2|:_33
C031763_D015464 NONE 1,3-butadiene_3\CD\0|NONE_0 (r_pobj) of_2\IN\0|epidemiological_24 (r_prep) studies_1\NNS\635850|have_25|associated_67|._113 (r_nsubj) suggest_5\VBN\1010118|NONE_0 (l_ccomp) associated_11\VBN\628491|studies_67|have_42|._46 (l_prep) with_12\IN\0|that_40|exposures_35|are_15 (l_pobj) leukemia_15\NN\14239918|NONE_0
C031763_D015464 NONE 1,3-butadiene_3\CD\0|NONE_0 (r_pobj) of_2\IN\0|epidemiological_24 (r_prep) studies_1\NNS\635850|have_25|associated_67|._113 (r_nsubj) suggest_5\VBN\1010118|NONE_0 (l_ccomp) associated_11\VBN\628491|studies_67|have_42|._46 (l_prep) with_12\IN\0|that_40|exposures_35|are_15 (l_pobj) leukemia_15\NN\14239918|NONE_0 (l_appos) cml_17\NNP\0|chronic_26|myeloid_18|(_1|)_3
3289726
D005047_D009422 NONE etoposide_7\NN\0|dose_5|for_18 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) after_3\IN\0|acute_29|neurologic_23|._54 (r_prep) dysfunction_2\NN\14204950|NONE_0
D005047_D009369 NONE etoposide_0\NNP\0|has_22|been_26|in_36|._102 (r_nsubjpass) used_8\VBN\0|NONE_0 (l_prep) in_9\IN\13603305|etoposide_36|has_14|been_10|._66 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_14 (l_pobj) tumors_15\NNS\14234074|NONE_0
D005047_D009369 NONE 213_4\CD\0|vp-16_6 (r_punct) )_5\-RRB-\0|NONE_0 (r_punct) etoposide_0\NNP\0|has_22|been_26|in_36|._102 (r_nsubjpass) used_8\VBN\0|NONE_0 (l_prep) in_9\IN\13603305|etoposide_36|has_14|been_10|._66 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_14 (l_pobj) tumors_15\NNS\14234074|NONE_0
D005047_D064420 NONE etoposide_13\NN\0|dose_5|for_18 (r_compound) therapy_14\NN\657604|NONE_0 (r_pobj) of_9\IN\0|a_27|significant_25|new_13 (r_prep) toxicity_8\NN\13576101|to_31
D005047_D019337 NONE etoposide_0\NNP\0|has_22|been_26|in_36|._102 (r_nsubjpass) used_8\VBN\0|NONE_0 (l_prep) in_9\IN\13603305|etoposide_36|has_14|been_10|._66 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_14 (l_pobj) tumors_15\NNS\14234074|NONE_0 (l_conj) malignancies_18\NNS\14070360|many_34|solid_29|and_16
D005047_D019337 NONE 213_4\CD\0|vp-16_6 (r_punct) )_5\-RRB-\0|NONE_0 (r_punct) etoposide_0\NNP\0|has_22|been_26|in_36|._102 (r_nsubjpass) used_8\VBN\0|NONE_0 (l_prep) in_9\IN\13603305|etoposide_36|has_14|been_10|._66 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|the_14 (l_pobj) tumors_15\NNS\14234074|NONE_0 (l_conj) malignancies_18\NNS\14070360|many_34|solid_29|and_16
D005047_D005910 NONE etoposide_7\NN\0|dose_5|for_18 (r_compound) therapy_8\NN\657604|NONE_0 (l_prep) for_9\IN\0|dose_23|etoposide_18 (l_pobj) glioma_11\NN\14236743|NONE_0
D005047_D005910 NONE etoposide_13\NN\0|dose_5|for_18 (r_compound) therapy_14\NN\657604|NONE_0 (l_prep) for_15\IN\0|dose_23|etoposide_18 (l_pobj) glioma_17\NN\14236743|NONE_0
1615846
D008148_D006949 NONE lovastatin_32\NN\3676175|label_19|in_21 (r_amod) treatment_33\NN\654885|and_82|efficacy_78|of_69|,_37|had_72 (l_prep) in_34\IN\13603305|label_40|lovastatin_21 (l_pobj) patients_36\NNS\9898892|NONE_0 (l_prep) with_37\IN\0|80_12 (l_pobj) hyperlipidemia_40\NN\14299637|NONE_0
D015248_D006949 NONE gemfibrozil_30\NN\3740161|-_11 (r_compound) lovastatin_32\NN\3676175|label_19|in_21 (r_amod) treatment_33\NN\654885|and_82|efficacy_78|of_69|,_37|had_72 (l_prep) in_34\IN\13603305|label_40|lovastatin_21 (l_pobj) patients_36\NNS\9898892|NONE_0 (l_prep) with_37\IN\0|80_12 (l_pobj) hyperlipidemia_40\NN\14299637|NONE_0
D015248_D006951 NONE gemfibrozil_0\NNP\3740161|-_11 (r_compound) lovastatin_2\NN\3676175|for_19|._52 (r_amod) therapy_3\NN\657604|NONE_0 (l_prep) for_4\IN\0|lovastatin_19|._33 (l_pobj) hyperlipoproteinemias_6\NNS\14084502|NONE_0
D008148_D002340 NONE lovastatin_32\NN\3676175|label_19|in_21 (r_amod) treatment_33\NN\654885|and_82|efficacy_78|of_69|,_37|had_72 (r_conj) safety_12\NN\13920835|to_10 (l_relcl) had_46\VBD\0|and_154|efficacy_150|of_141|,_109|treatment_72 (l_dobj) disease_49\NN\14061805|%_39
D015248_D002340 NONE gemfibrozil_30\NN\3740161|-_11 (r_compound) lovastatin_32\NN\3676175|label_19|in_21 (r_amod) treatment_33\NN\654885|and_82|efficacy_78|of_69|,_37|had_72 (r_conj) safety_12\NN\13920835|to_10 (l_relcl) had_46\VBD\0|and_154|efficacy_150|of_141|,_109|treatment_72 (l_dobj) disease_49\NN\14061805|%_39
D008148_D006951 NONE lovastatin_2\NN\3676175|for_19|._52 (r_amod) therapy_3\NN\657604|NONE_0 (l_prep) for_4\IN\0|lovastatin_19|._33 (l_pobj) hyperlipoproteinemias_6\NNS\14084502|NONE_0
D003401_D012206 NONE creatine_28\NN\14601829|concurrent_16 (r_compound) phosphokinase_29\NN\0|NONE_0 (r_pobj) with_25\IN\0|1_3|liter_51 (r_prep) %_24\NN\0|NONE_0 (r_pobj) in_22\IN\13603305|;_63|patients_68|rhabdomyolysis_81|._112 (r_prep) had_39\VBD\0|myositis_198|in_100|,_83|and_81 (l_dobj) rhabdomyolysis_40\NN\0|in_81|;_18|patients_13|._31
D003401_D009212 NONE creatine_28\NN\14601829|concurrent_16 (r_compound) phosphokinase_29\NN\0|NONE_0 (r_pobj) with_25\IN\0|1_3|liter_51 (r_prep) %_24\NN\0|NONE_0 (r_pobj) in_22\IN\13603305|;_63|patients_68|rhabdomyolysis_81|._112 (r_prep) had_39\VBD\0|myositis_198|in_100|,_83|and_81 (l_dobj) rhabdomyolysis_40\NN\0|in_81|;_18|patients_13|._31 (l_conj) myoglobinuria_42\NNS\14299637|or_3
D003401_D009220 NONE creatine_28\NN\14601829|concurrent_16 (r_compound) phosphokinase_29\NN\0|NONE_0 (r_pobj) with_25\IN\0|1_3|liter_51 (r_prep) %_24\NN\0|NONE_0 (r_pobj) in_22\IN\13603305|;_63|patients_68|rhabdomyolysis_81|._112 (r_prep) had_39\VBD\0|myositis_198|in_100|,_83|and_81 (r_conj) occurred_14\VBD\0|NONE_0 (l_nsubj) myositis_0\NNP\14336539|in_98|,_115|and_117|had_198
17384765
D007854_D019958 CID pb_0\NNP\14625458|NONE_0 (r_amod) exposure_1\NN\5042871|impairments_26|paralleling_106|._170 (r_nsubj) produced_2\VBD\1617192|NONE_0 (l_dobj) impairments_4\NNS\7296428|exposure_26|paralleling_80|._144 (l_prep) in_5\IN\13603305|lasting_20 (l_pobj) learning_6\NN\5701944|NONE_0 (l_conj) attention_8\NN\5701944|,_2 (l_conj) control_11\NN\5190804|,_13 (l_conj) regulation_15\NN\6652242|inhibitory_32|,_14|and_12
D007854_D019958 CID pb_24\NNP\14625458|-_2 (r_npadvmod) exposed_26\VBN\2110927|NONE_0 (r_amod) children_27\NNS\9622049|NONE_0 (r_pobj) in_23\IN\13603305|NONE_0 (r_prep) seen_22\VBN\2106506|NONE_0 (r_acl) dysfunction_21\NN\14204950|NONE_0 (r_pobj) of_20\IN\0|the_10 (r_prep) areas_19\NNS\8630985|NONE_0 (r_dobj) paralleling_17\VBG\2657219|exposure_106|impairments_80|._64 (r_advcl) produced_2\VBD\1617192|NONE_0 (l_dobj) impairments_4\NNS\7296428|exposure_26|paralleling_80|._144 (l_prep) in_5\IN\13603305|lasting_20 (l_pobj) learning_6\NN\5701944|NONE_0 (l_conj) attention_8\NN\5701944|,_2 (l_conj) control_11\NN\5190804|,_13 (l_conj) regulation_15\NN\6652242|inhibitory_32|,_14|and_12
D007854_D007855 NONE pb_17\NNP\14625458|and_12|treatment_16|with_26|,_39|agent_65 (r_compound) exposure_18\NN\5042871|model_28 (l_appos) agent_28\NN\7347|pb_65|and_53|treatment_49|with_39|,_26 (l_prep) for_29\IN\0|a_30|used_21|chelating_16 (l_pobj) treatment_31\NN\654885|NONE_0 (l_prep) of_32\IN\0|the_14 (l_pobj) poisoning_34\NN\14034177|NONE_0
D007854_D003072 NONE lead_11\NN\5155821|-_4 (r_npadvmod) exposed_13\VBN\2110927|NONE_0 (r_amod) rats_14\NNS\2329401|NONE_0 (r_pobj) in_10\IN\13603305|arousal_19 (r_prep) regulation_9\NN\6652242|,_14|and_12 (r_conj) attention_5\NN\5701944|,_2 (r_conj) learning_3\VBG\5701944|chelation_19|but_65|produces_69|._138 (r_xcomp) improves_2\VBZ\126264|NONE_0 (l_conj) produces_16\VBZ\7555863|chelation_88|learning_69|but_4|._69 (l_dobj) impairment_19\NN\7296428|in_11
D007854_D003072 NONE lead_24\JJ\5155821|NONE_0 (r_amod) exposure_25\NN\5042871|NONE_0 (r_pobj) of_23\IN\0|the_12 (r_prep) absence_22\NN\14449405|NONE_0 (r_pobj) in_20\IN\13603305|impairment_11 (r_prep) produces_16\VBZ\7555863|chelation_88|learning_69|but_4|._69 (l_dobj) impairment_19\NN\7296428|in_11
D007854_D003072 NONE pb_11\NNP\14625458|NONE_0 (r_pobj) to_10\IN\0|not_23|previously_19 (r_prep) exposed_9\VBN\2110927|succimer_42|of_23 (r_acl) treatment_4\NN\654885|in_22|,_11|dysfunction_102|._188 (r_nsubj) produced_12\VBD\1617192|NONE_0 (l_dobj) dysfunction_19\NN\14204950|in_124|,_113|treatment_102|._86
D007854_D003072 NONE pb_29\NNP\14625458|the_11|higher_7|exposure_3 (r_compound) regimen_31\NN\5898568|NONE_0 (r_pobj) by_26\IN\0|NONE_0 (r_agent) produced_25\VBN\1617192|NONE_0 (r_acl) that_24\DT\0|NONE_0 (r_pobj) to_23\IN\0|NONE_0 (r_prep) magnitude_22\NN\4916342|NONE_0 (r_pobj) in_21\IN\13603305|NONE_0 (r_prep) comparable_20\JJ\0|cognitive_36|affective_22 (r_amod) dysfunction_19\NN\14204950|in_124|,_113|treatment_102|._86
D007854_D003072 NONE pb_24\NNP\14625458|NONE_0 (r_compound) exposure_25\NN\5042871|to_6 (r_pobj) due_22\IN\5174653|can_33|deficits_9 (r_prep) alleviate_19\VB\205885|these_96|data_76|._47 (l_dobj) deficits_21\NNS\5113133|can_24|due_9
D004113_D019964 NONE succimer_3\JJ\0|of_19|exposed_42 (r_amod) treatment_4\NN\654885|in_22|,_11|dysfunction_102|._188 (r_nsubj) produced_12\VBD\1617192|NONE_0 (l_dobj) dysfunction_19\NN\14204950|in_124|,_113|treatment_102|._86
D004113_D007855 NONE succimer_22\NN\0|NONE_0 (r_pobj) with_21\IN\0|pb_26|and_14|treatment_10|,_13|agent_39 (r_prep) exposure_18\NN\5042871|model_28 (l_appos) agent_28\NN\7347|pb_65|and_53|treatment_49|with_39|,_26 (l_prep) for_29\IN\0|a_30|used_21|chelating_16 (l_pobj) treatment_31\NN\654885|NONE_0 (l_prep) of_32\IN\0|the_14 (l_pobj) poisoning_34\NN\14034177|NONE_0
D004113_D003072 CID succimer_0\NNP\0|NONE_0 (r_compound) chelation_1\NN\29677|learning_19|but_84|produces_88|._157 (r_nsubj) improves_2\VBZ\126264|NONE_0 (l_conj) produces_16\VBZ\7555863|chelation_88|learning_69|but_4|._69 (l_dobj) impairment_19\NN\7296428|in_11
D004113_D003072 NONE succimer_3\JJ\0|of_19|exposed_42 (r_amod) treatment_4\NN\654885|in_22|,_11|dysfunction_102|._188 (r_nsubj) produced_12\VBD\1617192|NONE_0 (l_dobj) dysfunction_19\NN\14204950|in_124|,_113|treatment_102|._86
D007854_D007859 CID pb_0\NNP\14625458|NONE_0 (r_amod) exposure_1\NN\5042871|impairments_26|paralleling_106|._170 (r_nsubj) produced_2\VBD\1617192|NONE_0 (l_dobj) impairments_4\NNS\7296428|exposure_26|paralleling_80|._144 (l_prep) in_5\IN\13603305|lasting_20 (l_pobj) learning_6\NN\5701944|NONE_0 (l_conj) attention_8\NN\5701944|,_2 (l_conj) control_11\NN\5190804|,_13 (l_conj) regulation_15\NN\6652242|inhibitory_32|,_14|and_12
D007854_D007859 CID pb_24\NNP\14625458|-_2 (r_npadvmod) exposed_26\VBN\2110927|NONE_0 (r_amod) children_27\NNS\9622049|NONE_0 (r_pobj) in_23\IN\13603305|NONE_0 (r_prep) seen_22\VBN\2106506|NONE_0 (r_acl) dysfunction_21\NN\14204950|NONE_0 (r_pobj) of_20\IN\0|the_10 (r_prep) areas_19\NNS\8630985|NONE_0 (r_dobj) paralleling_17\VBG\2657219|exposure_106|impairments_80|._64 (r_advcl) produced_2\VBD\1617192|NONE_0 (l_dobj) impairments_4\NNS\7296428|exposure_26|paralleling_80|._144 (l_prep) in_5\IN\13603305|lasting_20 (l_pobj) learning_6\NN\5701944|NONE_0 (l_conj) attention_8\NN\5701944|,_2 (l_conj) control_11\NN\5190804|,_13 (l_conj) regulation_15\NN\6652242|inhibitory_32|,_14|and_12
D007854_D019964 NONE pb_11\NNP\14625458|NONE_0 (r_pobj) to_10\IN\0|not_23|previously_19 (r_prep) exposed_9\VBN\2110927|succimer_42|of_23 (r_acl) treatment_4\NN\654885|in_22|,_11|dysfunction_102|._188 (r_nsubj) produced_12\VBD\1617192|NONE_0 (l_dobj) dysfunction_19\NN\14204950|in_124|,_113|treatment_102|._86
D007854_D019964 NONE pb_29\NNP\14625458|the_11|higher_7|exposure_3 (r_compound) regimen_31\NN\5898568|NONE_0 (r_pobj) by_26\IN\0|NONE_0 (r_agent) produced_25\VBN\1617192|NONE_0 (r_acl) that_24\DT\0|NONE_0 (r_pobj) to_23\IN\0|NONE_0 (r_prep) magnitude_22\NN\4916342|NONE_0 (r_pobj) in_21\IN\13603305|NONE_0 (r_prep) comparable_20\JJ\0|cognitive_36|affective_22 (r_amod) dysfunction_19\NN\14204950|in_124|,_113|treatment_102|._86
15625689
D007980_D003680 NONE levodopa_6\NN\14604959|NONE_0 (r_pobj) for_5\IN\0|a_7 (r_prep) role_4\NN\719494|results_18|and_51|confirm_55|._134 (r_dobj) suggest_2\VBP\1010118|NONE_0 (l_conj) confirm_14\VB\0|results_73|role_55|and_4|._79 (l_ccomp) is_17\VBZ\0|NONE_0 (l_nsubj) dysphagia_16\NN\14052403|that_5|not_13|predictor_24
D007980_D004409 CID levodopa_17\NN\14604959|-_8 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) dyskinesia_20\NN\14084880|NONE_0
D007980_D004409 CID levodopa_23\NN\14604959|a_10|greater_8 (r_compound) dose_24\NN\3740161|NONE_0 (r_pobj) of_20\IN\0|the_10 (r_prep) basis_19\NN\13790712|NONE_0 (r_pobj) on_17\IN\0|which_25|could_19|be_13 (r_prep) explained_16\VBN\831651|swallowing_36|,_17 (r_relcl) function_11\NN\13783581|NONE_0 (r_pobj) in_9\IN\13603305|in_59|,_39|patients_26|better_7|._88 (r_prep) performed_7\VBD\0|NONE_0 (l_nsubj) patients_6\NNS\9898892|in_33|,_13|better_19|in_26|._114 (l_amod) dyskinetic_5\JJ\0|NONE_0
D007980_D010300 NONE levodopa_17\NN\14604959|-_8 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) dyskinesia_20\NN\14084880|NONE_0 (r_pobj) without_16\IN\0|and_4 (r_conj) with_14\IN\0|to_58|dynamics_24 (r_prep) characterize_7\VB\609683|aim_25|._99 (l_dobj) dynamics_10\NNS\6100236|to_34|with_24 (l_prep) in_11\IN\13603305|the_27|oropharyngeal_23 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_compound) pd_12\NNP\14625458|NONE_0
D007980_D010300 NONE levodopa_6\NN\14604959|NONE_0 (r_pobj) for_5\IN\0|a_7 (r_prep) role_4\NN\719494|results_18|and_51|confirm_55|._134 (r_dobj) suggest_2\VBP\1010118|NONE_0 (l_conj) confirm_14\VB\0|results_73|role_55|and_4|._79 (l_ccomp) is_17\VBZ\0|NONE_0 (l_attr) predictor_21\NN\10756433|that_29|dysphagia_24|not_11 (l_prep) of_22\IN\0|a_17|good_15 (l_pobj) alterations_24\NNS\7283608|NONE_0 (l_prep) in_25\IN\13603305|deglutition_24 (l_pobj) pd_26\NNP\14625458|NONE_0
448423
D015119_D020767 CID eaca_27\NNP\0|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treated_25\VBN\2376958|fibrinolytic_23 (r_acl) syndromes_24\NNS\5870365|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) patients_21\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|thrombi_8 (r_prep) capillary_17\JJ\4493505|and_4 (r_conj) arteriolar_15\JJ\0|,_2 (r_conj) sah_13\NNP\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) patients_11\NNS\9898892|NONE_0 (r_pobj) in_10\IN\13603305|clinical_60|and_37|thrombosis_11 (r_prep) deterioration_5\NN\14560612|complications_37|have_23|._205 (l_conj) thrombosis_9\NN\14100769|clinical_49|and_26|in_11
D015119_D013923 NONE eaca_27\NNP\0|NONE_0 (l_conj) phenomena_32\NNS\29677|,_26|or_24
D000614_D007674 NONE acid_6\NN\14818238|aminocaproic_13|and_13|thrombosis_36 (r_compound) therapy_7\NN\657604|NONE_0 (l_conj) thrombosis_12\NN\14100769|aminocaproic_49|acid_36|and_23
D000614_D013345 NONE acid_6\NN\14818238|aminocaproic_13|and_13|thrombosis_36 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|recurrent_34|subarachnoid_24|._75 (r_acl) hemorrhage_2\NN\14285662|NONE_0
D015119_D013345 CID acid_2\NN\14818238|has_12|been_16|prevent_29|._94 (r_nsubjpass) used_8\VBN\0|NONE_0 (l_xcomp) prevent_10\VB\0|acid_29|has_17|been_13|._65 (l_dobj) rebleeding_11\NN\0|to_11 (l_prep) with_14\IN\0|in_12 (l_pobj) hemorrhage_16\NN\14285662|NONE_0
D015119_D013345 CID acid_2\NN\14818238|has_12|been_16|prevent_29|._94 (r_nsubjpass) used_8\VBN\0|NONE_0 (l_xcomp) prevent_10\VB\0|acid_29|has_17|been_13|._65 (l_dobj) rebleeding_11\NN\0|to_11 (l_prep) with_14\IN\0|in_12 (l_pobj) hemorrhage_16\NN\14285662|NONE_0 (l_appos) sah_18\NNP\0|subarachnoid_25|(_1|)_3
D015119_D013345 CID eaca_4\NNP\0|epsilon_27|aminocaproic_19 (r_appos) acid_2\NN\14818238|has_12|been_16|prevent_29|._94 (r_nsubjpass) used_8\VBN\0|NONE_0 (l_xcomp) prevent_10\VB\0|acid_29|has_17|been_13|._65 (l_dobj) rebleeding_11\NN\0|to_11 (l_prep) with_14\IN\0|in_12 (l_pobj) hemorrhage_16\NN\14285662|NONE_0
D015119_D013345 CID eaca_4\NNP\0|epsilon_27|aminocaproic_19 (r_appos) acid_2\NN\14818238|has_12|been_16|prevent_29|._94 (r_nsubjpass) used_8\VBN\0|NONE_0 (l_xcomp) prevent_10\VB\0|acid_29|has_17|been_13|._65 (l_dobj) rebleeding_11\NN\0|to_11 (l_prep) with_14\IN\0|in_12 (l_pobj) hemorrhage_16\NN\14285662|NONE_0 (l_appos) sah_18\NNP\0|subarachnoid_25|(_1|)_3
D015119_D013345 CID eaca_27\NNP\0|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treated_25\VBN\2376958|fibrinolytic_23 (r_acl) syndromes_24\NNS\5870365|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) patients_21\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|thrombi_8 (r_prep) capillary_17\JJ\4493505|and_4 (r_conj) arteriolar_15\JJ\0|,_2 (r_conj) sah_13\NNP\0|NONE_0
D015119_D013345 CID eaca_4\NNP\0|in_13 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) in_6\IN\13603305|eaca_13 (l_pobj) patient_8\NN\9898892|NONE_0 (l_prep) with_9\IN\0|a_10 (l_pobj) sah_10\NNP\0|documentation_26
D015119_D013345 CID eaca_4\NNP\0|in_13 (r_compound) therapy_5\NN\657604|NONE_0 (l_prep) in_6\IN\13603305|eaca_13 (l_pobj) patient_8\NN\9898892|NONE_0 (l_prep) with_9\IN\0|a_10 (l_pobj) documentation_13\NN\6650070|sah_26 (l_prep) of_14\IN\0|histopathological_32 (l_pobj) sah_16\NNP\0|NONE_0
D015119_D013927 CID eaca_17\NNP\0|NONE_0 (r_compound) therapy_18\NN\657604|NONE_0 (r_pobj) of_16\IN\0|thrombotic_25 (r_prep) complications_15\NNS\1073995|decrease_80|,_44|reports_34|have_26|._29 (l_amod) thrombotic_14\JJ\0|of_25
D015119_D013927 CID eaca_27\NNP\0|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treated_25\VBN\2376958|fibrinolytic_23 (r_acl) syndromes_24\NNS\5870365|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) patients_21\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|thrombi_8 (r_prep) capillary_17\JJ\4493505|and_4 (l_dobj) thrombi_19\NN\5402091|in_8
D015119_D013927 CID eaca_13\NNP\0|observed_50|,_2|should_5|not_12|be_16|in_30|._160 (r_nsubjpass) implicated_17\VBN\2677097|NONE_0 (l_advcl) observed_6\VBN\2163746|,_48|eaca_50|should_55|not_62|be_66|in_80|._210 (l_nsubjpass) thrombi_3\NN\5402091|since_27|are_8|often_12|in_27
D015119_D013927 CID eaca_13\NNP\0|observed_50|,_2|should_5|not_12|be_16|in_30|._160 (r_nsubjpass) implicated_17\VBN\2677097|NONE_0 (l_prep) in_18\IN\13603305|observed_80|,_32|eaca_30|should_25|not_18|be_14|._130 (l_pobj) pathogenesis_20\NN\13533470|NONE_0 (l_prep) of_21\IN\0|the_17 (l_pobj) thrombi_23\NN\5402091|NONE_0
D015119_D004211 NONE eaca_13\NNP\0|observed_50|,_2|should_5|not_12|be_16|in_30|._160 (r_nsubjpass) implicated_17\VBN\2677097|NONE_0 (l_prep) in_18\IN\13603305|observed_80|,_32|eaca_30|should_25|not_18|be_14|._130 (l_pobj) pathogenesis_20\NN\13533470|NONE_0 (l_prep) of_21\IN\0|the_17 (l_pobj) thrombi_23\NN\5402091|NONE_0 (l_prep) in_24\IN\13603305|fibrin_15 (l_pobj) patients_25\NNS\9898892|NONE_0 (l_prep) with_26\IN\0|NONE_0 (l_pobj) coagulation_29\NN\13518963|NONE_0
D015119_D004211 NONE eaca_13\NNP\0|observed_50|,_2|should_5|not_12|be_16|in_30|._160 (r_nsubjpass) implicated_17\VBN\2677097|NONE_0 (l_prep) in_18\IN\13603305|observed_80|,_32|eaca_30|should_25|not_18|be_14|._130 (l_pobj) pathogenesis_20\NN\13533470|NONE_0 (l_prep) of_21\IN\0|the_17 (l_pobj) thrombi_23\NN\5402091|NONE_0 (l_prep) in_24\IN\13603305|fibrin_15 (l_pobj) patients_25\NNS\9898892|NONE_0 (l_prep) with_26\IN\0|NONE_0 (l_pobj) coagulation_29\NN\13518963|NONE_0 (l_conj) coagulopathies_34\NNS\0|disseminated_61|intravascular_48|or_22
8755612
D004054_D006470 NONE diethylstilbestrol_3\NN\14749794|(_19|des_20|)_23 (r_nmod) treatment_7\NN\654885|NONE_0 (r_pobj) of_2\IN\0|ten_10 (r_prep) weeks_1\NNS\15113229|grow_82|._210 (r_nsubj) caused_8\VBD\1617192|NONE_0 (l_ccomp) grow_14\VB\109660|weeks_82|._128 (l_conj) become_39\VB\146138|pituitaries_118|to_106|to_98|versus_50|,_9|and_7 (l_acomp) hemorrhagic_41\JJ\0|to_17
D004054_D006470 NONE des_5\NNP\14749794|diethylstilbestrol_20|(_1|)_3 (r_nmod) treatment_7\NN\654885|NONE_0 (r_pobj) of_2\IN\0|ten_10 (r_prep) weeks_1\NNS\15113229|grow_82|._210 (r_nsubj) caused_8\VBD\1617192|NONE_0 (l_ccomp) grow_14\VB\109660|weeks_82|._128 (l_conj) become_39\VB\146138|pituitaries_118|to_106|to_98|versus_50|,_9|and_7 (l_acomp) hemorrhagic_41\JJ\0|to_17
D004054_D006470 NONE des_3\NNP\14749794|-_3 (r_npadvmod) induced_5\VBN\1627355|pituitary_8 (r_amod) growth_7\NN\13526110|while_28|inheritance_40 (r_nsubj) exhibited_8\VBD\2632167|however_44|,_37|,_44|phenotype_62|inheritance_103|._114 (r_advcl) exhibited_17\VBD\2632167|NONE_0 (l_nsubj) phenotype_16\NN\4933544|however_106|,_99|exhibited_62|,_18|inheritance_41|._52 (l_amod) hemorrhagic_15\JJ\0|the_4
D004967_D009369 NONE estrogen_10\NN\14745635|-_8 (r_npadvmod) induced_12\VBN\1627355|an_12 (r_amod) tumor_13\NN\14234074|NONE_0 (r_pobj) in_8\IN\13603305|genetic_62|of_43|._28 (r_prep) separation_1\NN\24720|NONE_0 (l_prep) of_2\IN\0|genetic_19|in_43|._71 (l_pobj) growth_4\NN\13526110|NONE_0 (l_compound) tumor_3\NN\14234074|and_13|phenotypes_29
D004967_D009369 NONE estrogen_10\NN\14745635|-_8 (r_npadvmod) induced_12\VBN\1627355|an_12 (r_amod) tumor_13\NN\14234074|NONE_0
D004967_D006470 NONE estrogen_10\NN\14745635|-_8 (r_npadvmod) induced_12\VBN\1627355|an_12 (r_amod) tumor_13\NN\14234074|NONE_0 (r_pobj) in_8\IN\13603305|genetic_62|of_43|._28 (r_prep) separation_1\NN\24720|NONE_0 (l_prep) of_2\IN\0|genetic_19|in_43|._71 (l_pobj) growth_4\NN\13526110|NONE_0 (l_conj) phenotypes_7\NNS\4933544|tumor_29|and_16 (l_amod) hemorrhagic_6\JJ\0|NONE_0
D004967_D006470 NONE estrogen_3\NN\14745635|NONE_0 (r_pobj) of_2\IN\0|chronic_23|to_12 (r_prep) administration_1\NN\1133281|growth_65|._110 (r_nsubj) induces_12\VBZ\1627355|NONE_0 (l_dobj) growth_13\NN\13526110|administration_65|._45 (l_prep) of_14\IN\0|NONE_0 (l_pobj) tumors_19\NNS\14234074|NONE_0 (l_amod) hemorrhagic_17\JJ\0|large_7|,_2|pituitary_12
D004967_D010911 NONE estrogen_3\NN\14745635|NONE_0 (r_pobj) of_2\IN\0|chronic_23|to_12 (r_prep) administration_1\NN\1133281|growth_65|._110 (r_nsubj) induces_12\VBZ\1627355|NONE_0 (l_dobj) growth_13\NN\13526110|administration_65|._45 (l_prep) of_14\IN\0|NONE_0 (l_pobj) tumors_19\NNS\14234074|NONE_0
12452552
D008728_D007676 NONE levomepromazine_21\NN\0|and_4 (r_conj) risperidone_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|neuroleptic_37|malignant_25|nms_5 (r_prep) syndrome_12\NN\5870365|patient_73|._70 (r_dobj) developed_9\VBD\1753788|NONE_0 (l_nsubj) patient_1\NN\9898892|syndrome_73|._143 (l_prep) with_2\IN\0|a_10 (l_pobj) failure_5\NN\66216|NONE_0
D008728_D007676 NONE levomepromazine_21\NN\0|and_4 (r_conj) risperidone_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|neuroleptic_37|malignant_25|nms_5 (r_prep) syndrome_12\NN\5870365|patient_73|._70 (r_dobj) developed_9\VBD\1753788|NONE_0 (l_nsubj) patient_1\NN\9898892|syndrome_73|._143 (l_prep) with_2\IN\0|a_10 (l_pobj) failure_5\NN\66216|NONE_0 (l_appos) crf_7\NNP\0|chronic_23|renal_15|(_1|)_3
D008728_D009459 CID levomepromazine_21\NN\0|and_4 (r_conj) risperidone_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|neuroleptic_37|malignant_25|nms_5 (r_prep) syndrome_12\NN\5870365|patient_73|._70
D008728_D009459 CID levomepromazine_21\NN\0|and_4 (r_conj) risperidone_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|neuroleptic_37|malignant_25|nms_5 (r_prep) syndrome_12\NN\5870365|patient_73|._70 (l_appos) nms_14\NNP\13649268|neuroleptic_32|malignant_20|after_5
D018967_D007676 NONE risperidone_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|neuroleptic_37|malignant_25|nms_5 (r_prep) syndrome_12\NN\5870365|patient_73|._70 (r_dobj) developed_9\VBD\1753788|NONE_0 (l_nsubj) patient_1\NN\9898892|syndrome_73|._143 (l_prep) with_2\IN\0|a_10 (l_pobj) failure_5\NN\66216|NONE_0
D018967_D007676 NONE risperidone_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|neuroleptic_37|malignant_25|nms_5 (r_prep) syndrome_12\NN\5870365|patient_73|._70 (r_dobj) developed_9\VBD\1753788|NONE_0 (l_nsubj) patient_1\NN\9898892|syndrome_73|._143 (l_prep) with_2\IN\0|a_10 (l_pobj) failure_5\NN\66216|NONE_0 (l_appos) crf_7\NNP\0|chronic_23|renal_15|(_1|)_3
D018967_D009459 CID risperidone_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|neuroleptic_37|malignant_25|nms_5 (r_prep) syndrome_12\NN\5870365|patient_73|._70
D018967_D009459 CID risperidone_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|NONE_0 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|neuroleptic_37|malignant_25|nms_5 (r_prep) syndrome_12\NN\5870365|patient_73|._70 (l_appos) nms_14\NNP\13649268|neuroleptic_32|malignant_20|after_5
24126708
D007980_D004409 CID levodopa_0\NNP\14604959|therapy_43|,_74|but_76|lead_102 (r_nsubj) is_1\VBZ\0|NONE_0 (l_conj) lead_17\VB\5155821|levodopa_102|therapy_59|,_28|but_26 (l_prep) to_18\IN\0|use_15|could_11|._93 (l_pobj) outcomes_21\NNS\7291312|NONE_0 (l_prep) as_24\IN\14622893|chronic_31|adverse_23|,_7 (l_pobj) fluctuations_26\NNS\7345593|such_14 (l_conj) dyskinesia_28\JJ\14084880|motor_20|,_2
D007980_D006212 CID levodopa_0\NNP\14604959|therapy_43|,_74|but_76|lead_102 (r_nsubj) is_1\VBZ\0|NONE_0 (l_conj) lead_17\VB\5155821|levodopa_102|therapy_59|,_28|but_26 (l_prep) to_18\IN\0|use_15|could_11|._93 (l_pobj) outcomes_21\NNS\7291312|NONE_0 (l_prep) as_24\IN\14622893|chronic_31|adverse_23|,_7 (l_pobj) fluctuations_26\NNS\7345593|such_14 (l_conj) dyskinesia_28\JJ\14084880|motor_20|,_2 (l_conj) hallucinations_31\NNS\14376855|and_11
D007980_D010300 NONE levodopa_9\JJ\14604959|adverse_9|in_25 (r_amod) effects_11\NNS\13245626|NONE_0 (l_prep) in_12\IN\13603305|levodopa_25|adverse_16 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_compound) disease_15\NN\14061805|parkinson_12
D007980_D010300 NONE levodopa_0\NNP\14604959|therapy_43|,_74|but_76|lead_102 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) therapy_6\NN\657604|levodopa_43|,_31|but_33|lead_59 (l_prep) for_7\IN\0|the_39|effective_30|symptomatic_20 (l_pobj) disease_10\NN\14061805|NONE_0
11708428
D011241_D001008 CID prednisone_0\NNP\2721538|anxiety_19|._61 (r_nsubj) induces_1\VBZ\1627355|NONE_0 (l_dobj) anxiety_2\NN\14373582|prednisone_19|._42
D011241_D001008 CID prednisone_3\NNP\2721538|whether_8|anxiety_26 (r_nsubj) produces_7\VBZ\7555863|to_35|._54 (l_dobj) anxiety_8\NN\14373582|whether_34|prednisone_26
D011241_D001008 CID pdn_5\NNP\0|(_1|)_3 (r_appos) prednisone_3\NNP\2721538|whether_8|anxiety_26 (r_nsubj) produces_7\VBZ\7555863|to_35|._54 (l_dobj) anxiety_8\NN\14373582|whether_34|prednisone_26
D011241_D001008 CID pdn_7\NNP\0|NONE_0 (r_pobj) of_6\IN\0|both_12 (r_prep) groups_5\NNS\2137|NONE_0 (r_pobj) in_3\IN\13603305|anxiety_23|was_15|treated_22|._57 (r_prep) documented_2\VBN\1000214|NONE_0 (l_nsubjpass) anxiety_0\NN\14373582|was_8|in_23|treated_45|._80
D011241_D001008 CID pdn_3\NNP\0|NONE_0 (r_pobj) to_2\IN\0|subacute_18 (r_prep) exposure_1\NN\5042871|anxiety_24|._59 (r_nsubj) induced_4\VBD\1627355|NONE_0 (l_dobj) anxiety_5\NN\14373582|exposure_24|._35
1858969
D004049_D005368 NONE diethylcarbamazine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_dobj) following_4\VBG\8180190|five_27|of_16 (r_prep) cases_1\NNS\7283608|were_72|in_86|with_108|._131 (r_nsubjpass) observed_12\VBN\2163746|NONE_0 (l_prep) with_16\IN\0|cases_108|were_36|in_22|._23 (l_pobj) filariasis_19\NN\14070360|NONE_0
D004049_D005368 NONE dec_9\NNP\15209706|NONE_0 (r_appos) diethylcarbamazine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_dobj) following_4\VBG\8180190|five_27|of_16 (r_prep) cases_1\NNS\7283608|were_72|in_86|with_108|._131 (r_nsubjpass) observed_12\VBN\2163746|NONE_0 (l_prep) with_16\IN\0|cases_108|were_36|in_22|._23 (l_pobj) filariasis_19\NN\14070360|NONE_0
D004049_D008118 NONE diethylcarbamazine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) loiasis_7\NN\0|NONE_0
D004049_D004660 CID diethylcarbamazine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) loiasis_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) during_4\IN\0|five_27|of_16|._51 (r_prep) cases_1\NNS\7283608|NONE_0 (l_prep) of_2\IN\0|five_11|during_16|._67 (l_pobj) encephalitis_3\NN\14336539|NONE_0
D004049_D004660 CID diethylcarbamazine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_dobj) following_4\VBG\8180190|five_27|of_16 (r_prep) cases_1\NNS\7283608|were_72|in_86|with_108|._131 (l_prep) of_2\IN\0|five_11|following_16 (l_pobj) encephalitis_3\NN\14336539|NONE_0
D004049_D004660 CID dec_9\NNP\15209706|NONE_0 (r_appos) diethylcarbamazine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_dobj) following_4\VBG\8180190|five_27|of_16 (r_prep) cases_1\NNS\7283608|were_72|in_86|with_108|._131 (l_prep) of_2\IN\0|five_11|following_16 (l_pobj) encephalitis_3\NN\14336539|NONE_0
6615679
D013999_D007022 CID timolol_6\NN\2832168|eye_24 (r_nmod) drops_10\NNS\13899200|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|NONE_0 (r_acl) hypotension_3\NN\14057371|intraoperative_31|and_4|._61
D013999_D007022 CID maleate_16\NN\2718811|eye_8 (r_amod) drops_18\NNS\13899200|NONE_0 (r_dobj) timolol_15\NN\2832168|pilocarpine_24|and_4 (r_conj) nitrate_13\NN\14818238|NONE_0 (r_pobj) with_11\IN\0|who_35|was_31|concurrently_27|being_14 (r_prep) treated_10\VBN\2376958|a_44|old_36|,_29|,_62 (r_relcl) man_4\NN\9605289|bradycardia_108|and_120|became_124|._171 (r_nsubj) developed_20\VBD\1753788|NONE_0 (l_conj) became_24\VBD\146138|man_124|bradycardia_16|and_4|._47 (l_acomp) hypotensive_25\JJ\10405694|during_12
D010862_D007022 CID pilocarpine_8\VB\14712692|and_4 (r_conj) timolol_6\NN\2832168|eye_24 (r_nmod) drops_10\NNS\13899200|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|NONE_0 (r_acl) hypotension_3\NN\14057371|intraoperative_31|and_4|._61
D010862_D007022 CID nitrate_13\NN\14818238|NONE_0 (r_pobj) with_11\IN\0|who_35|was_31|concurrently_27|being_14 (r_prep) treated_10\VBN\2376958|a_44|old_36|,_29|,_62 (r_relcl) man_4\NN\9605289|bradycardia_108|and_120|became_124|._171 (r_nsubj) developed_20\VBD\1753788|NONE_0 (l_conj) became_24\VBD\146138|man_124|bradycardia_16|and_4|._47 (l_acomp) hypotensive_25\JJ\10405694|during_12
D013999_D001919 CID timolol_6\NN\2832168|eye_24 (r_nmod) drops_10\NNS\13899200|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|NONE_0 (r_acl) hypotension_3\NN\14057371|intraoperative_31|and_4|._61 (r_conj) bradycardia_1\NNP\14110674|NONE_0
D013999_D001919 CID maleate_16\NN\2718811|eye_8 (r_amod) drops_18\NNS\13899200|NONE_0 (r_dobj) timolol_15\NN\2832168|pilocarpine_24|and_4 (r_conj) nitrate_13\NN\14818238|NONE_0 (r_pobj) with_11\IN\0|who_35|was_31|concurrently_27|being_14 (r_prep) treated_10\VBN\2376958|a_44|old_36|,_29|,_62 (r_relcl) man_4\NN\9605289|bradycardia_108|and_120|became_124|._171 (r_nsubj) developed_20\VBD\1753788|NONE_0 (l_dobj) bradycardia_22\NN\14110674|man_108|and_12|became_16|._63
D006221_D001919 NONE halothane_27\NN\3570838|NONE_0 (r_compound) anaesthesia_28\NN\14034177|NONE_0 (r_pobj) during_26\IN\0|hypotensive_12 (r_prep) became_24\VBD\146138|man_124|bradycardia_16|and_4|._47 (r_conj) developed_20\VBD\1753788|NONE_0 (l_dobj) bradycardia_22\NN\14110674|man_108|and_12|became_16|._63
D006221_D001919 NONE halothane_11\NN\3570838|with_22 (r_compound) anaesthesia_12\NN\14034177|NONE_0 (l_prep) with_13\IN\0|halothane_22 (l_pobj) bradycardia_15\NN\14110674|NONE_0
D006221_D007022 NONE halothane_27\NN\3570838|NONE_0 (r_compound) anaesthesia_28\NN\14034177|NONE_0 (r_pobj) during_26\IN\0|hypotensive_12 (r_prep) became_24\VBD\146138|man_124|bradycardia_16|and_4|._47 (l_acomp) hypotensive_25\JJ\10405694|during_12
D006221_D007022 NONE halothane_11\NN\3570838|with_22 (r_compound) anaesthesia_12\NN\14034177|NONE_0 (l_prep) with_13\IN\0|halothane_22 (l_pobj) bradycardia_15\NN\14110674|NONE_0 (l_conj) hypotension_17\NN\14057371|resultant_26|and_4
D010862_D001919 CID pilocarpine_8\VB\14712692|and_4 (r_conj) timolol_6\NN\2832168|eye_24 (r_nmod) drops_10\NNS\13899200|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|NONE_0 (r_acl) hypotension_3\NN\14057371|intraoperative_31|and_4|._61 (r_conj) bradycardia_1\NNP\14110674|NONE_0
D010862_D001919 CID nitrate_13\NN\14818238|NONE_0 (r_pobj) with_11\IN\0|who_35|was_31|concurrently_27|being_14 (r_prep) treated_10\VBN\2376958|a_44|old_36|,_29|,_62 (r_relcl) man_4\NN\9605289|bradycardia_108|and_120|became_124|._171 (r_nsubj) developed_20\VBD\1753788|NONE_0 (l_dobj) bradycardia_22\NN\14110674|man_108|and_12|became_16|._63
24088636
D004977_D054908 NONE ethambutol_22\NN\0|and_4 (l_prep) for_23\IN\0|NONE_0 (l_pobj) tuberculosis_28\NN\14127211|NONE_0
D004977_D054908 NONE ethambutol_22\NN\0|and_4 (l_prep) for_23\IN\0|NONE_0 (l_pobj) tuberculosis_28\NN\14127211|NONE_0 (l_appos) tb_32\NNP\14625458|resistant_28
D004977_D009901 NONE ethambutol_0\NNP\0|-_10 (r_npadvmod) induced_2\VBN\1627355|optic_14 (r_amod) neuropathy_5\NN\14204950|was_11|and_25|withdrawn_51
D004977_D009901 NONE ethambutol_10\NN\0|was_11|._24 (r_nsubjpass) withdrawn_12\VBN\1835496|neuropathy_51|was_40|and_26 (r_conj) suspected_7\VBN\916909|NONE_0 (l_nsubjpass) neuropathy_5\NN\14204950|was_11|and_25|withdrawn_51
C098010_D054908 NONE linezolid_20\NN\0|NONE_0 (l_conj) ethambutol_22\NN\0|and_4 (l_prep) for_23\IN\0|NONE_0 (l_pobj) tuberculosis_28\NN\14127211|NONE_0
C098010_D054908 NONE linezolid_20\NN\0|NONE_0 (l_conj) ethambutol_22\NN\0|and_4 (l_prep) for_23\IN\0|NONE_0 (l_pobj) tuberculosis_28\NN\14127211|NONE_0 (l_appos) tb_32\NNP\14625458|resistant_28
D004977_D015354 NONE ethambutol_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) withdrawal_5\NN\7206096|NONE_0 (r_pobj) despite_4\IN\7501545|deterioration_33|._32 (r_prep) occurred_3\VBD\0|NONE_0 (l_nsubj) deterioration_0\NN\14560612|despite_33|._65 (l_prep) of_1\IN\0|NONE_0 (l_pobj) vision_2\NN\5767733|NONE_0
C098010_D009901 CID linezolid_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|optic_8|._24 (r_amod) neuropathy_4\NN\14204950|NONE_0
D004977_D014786 NONE ethambutol_22\NN\0|and_4 (r_conj) linezolid_20\NN\0|NONE_0 (r_pobj) including_19\VBG\0|multiple_44|line_28|tuberculous_18 (r_prep) drugs_18\NNS\14778436|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treatment_9\NN\654885|NONE_0 (r_pobj) on_8\IN\0|who_8 (r_prep) was_7\VBD\0|a_31|old_21|male_17 (r_relcl) patient_5\NN\9898892|to_176|with_182|._235 (r_nsubj) presented_34\VBN\2137132|NONE_0 (l_prep) with_37\IN\0|patient_182|to_6|._53 (l_pobj) loss_40\NN\13252973|NONE_0 (l_prep) of_41\IN\0|painless_26|progressive_17|in_10 (l_pobj) vision_42\NN\5767733|NONE_0
C098010_D014786 NONE linezolid_11\NN\0|NONE_0 (r_amod) therapy_12\NN\657604|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|NONE_0 (r_acl) vision_8\NN\5767733|NONE_0
C098010_D014786 NONE linezolid_20\NN\0|NONE_0 (r_pobj) including_19\VBG\0|multiple_44|line_28|tuberculous_18 (r_prep) drugs_18\NNS\14778436|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treatment_9\NN\654885|NONE_0 (r_pobj) on_8\IN\0|who_8 (r_prep) was_7\VBD\0|a_31|old_21|male_17 (r_relcl) patient_5\NN\9898892|to_176|with_182|._235 (r_nsubj) presented_34\VBN\2137132|NONE_0 (l_prep) with_37\IN\0|patient_182|to_6|._53 (l_pobj) loss_40\NN\13252973|NONE_0 (l_prep) of_41\IN\0|painless_26|progressive_17|in_10 (l_pobj) vision_42\NN\5767733|NONE_0
24727461
D004317_D066126 NONE doxorubicin_8\NN\2716866|-_11 (r_npadvmod) induced_10\VBN\1627355|in_23 (r_amod) cardiotoxicity_11\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_0\NNP\2716866|cardiotoxicity_31|._129 (r_nsubj) causes_1\VBZ\7323922|NONE_0 (l_dobj) cardiotoxicity_3\NN\0|doxorubicin_31|._98
D004317_D066126 NONE doxorubicin_5\RB\2716866|-_11 (r_npadvmod) associated_7\VBN\628491|chronic_11|cardiac_19 (r_amod) toxicity_10\NN\13576101|whether_47|can_9|be_13|with_28
C005975_D028361 NONE hydroxytyrosol_0\NNP\0|stress_37|in_74|._138 (r_nsubj) ameliorates_1\VBZ\126264|NONE_0 (l_dobj) stress_3\NN\7083732|hydroxytyrosol_37|in_37|._101 (l_conj) dysfunction_6\NN\14204950|oxidative_35|and_18
D004317_D028361 NONE doxorubicin_8\NN\2716866|-_11 (r_npadvmod) induced_10\VBN\1627355|in_23 (r_amod) cardiotoxicity_11\NN\0|NONE_0 (r_pobj) in_7\IN\13603305|hydroxytyrosol_74|stress_37|._64 (r_prep) ameliorates_1\VBZ\126264|NONE_0 (l_dobj) stress_3\NN\7083732|hydroxytyrosol_37|in_37|._101 (l_conj) dysfunction_6\NN\14204950|oxidative_35|and_18
D004317_D028361 NONE doxorubicin_0\NNP\2716866|cardiotoxicity_31|._129 (r_nsubj) causes_1\VBZ\7323922|NONE_0 (l_dobj) cardiotoxicity_3\NN\0|doxorubicin_31|._98 (l_acl) characterized_4\VBN\609683|significant_27 (l_agent) by_5\IN\0|NONE_0 (l_pobj) increases_7\NNS\13576355|NONE_0 (l_prep) in_8\IN\13603305|marked_17 (l_pobj) stress_10\NN\7083732|NONE_0 (l_conj) dysfunction_13\NN\14204950|oxidative_35|and_18
C005975_D006331 NONE hydroxytyrosol_0\NNP\0|disturbances_36|._158 (r_nsubj) improved_1\VBD\126264|NONE_0 (l_dobj) disturbances_4\NNS\407535|hydroxytyrosol_36|._122
C005975_D006331 NONE hydroxytyrosol_4\JJ\0|study_24|decreasing_64|._121 (l_dobj) damage_8\NN\7296428|that_38
C005975_D001943 NONE hydroxytyrosol_0\NNP\0|stress_37|in_74|._138 (r_nsubj) ameliorates_1\VBZ\126264|NONE_0 (l_prep) in_7\IN\13603305|hydroxytyrosol_74|stress_37|._64 (l_pobj) cardiotoxicity_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|induced_23 (l_pobj) rats_13\NNS\2329401|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) cancer_16\NN\14239425|NONE_0
C005975_D001943 NONE hydroxytyrosol_17\NN\0|NONE_0 (l_prep) in_18\IN\13603305|the_31|antioxidant_27 (l_pobj) rats_19\NNS\2329401|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) cancer_22\NN\14239425|NONE_0
C005975_D001943 NONE hydroxytyrosol_17\NN\0|,_2|week_32 (r_conj) control_15\NN\5190804|4_10|:_2|)_45 (r_appos) groups_13\NNS\2137|NONE_0 (r_pobj) into_11\IN\0|induced_32|were_13|,_61|doxorubicin_63|._125 (r_prep) divided_10\VBN\140123|NONE_0 (l_csubjpass) induced_7\VBD\1627355|were_19|into_32|,_93|doxorubicin_95|._157 (l_nsubj) rats_3\NNS\2329401|chemically_35 (l_acl) bearing_4\VBG\13795489|six_9 (l_dobj) tumors_6\NNS\14234074|NONE_0
C005975_D001943 NONE hydroxytyrosol_40\NN\0|plus_5 (r_conj) doxorubicin_38\NN\2716866|week_11|,_6|and_4 (r_conj) doxorubicin_28\NN\2716866|induced_95|were_76|into_63|,_2|._62 (r_appos) divided_10\VBN\140123|NONE_0 (l_csubjpass) induced_7\VBD\1627355|were_19|into_32|,_93|doxorubicin_95|._157 (l_nsubj) rats_3\NNS\2329401|chemically_35 (l_acl) bearing_4\VBG\13795489|six_9 (l_dobj) tumors_6\NNS\14234074|NONE_0
D004317_D001943 NONE doxorubicin_8\NN\2716866|-_11 (r_npadvmod) induced_10\VBN\1627355|in_23 (r_amod) cardiotoxicity_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|induced_23 (l_pobj) rats_13\NNS\2329401|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) cancer_16\NN\14239425|NONE_0
D004317_D001943 NONE doxorubicin_5\RB\2716866|-_11 (r_npadvmod) associated_7\VBN\628491|chronic_11|cardiac_19 (r_amod) toxicity_10\NN\13576101|whether_47|can_9|be_13|with_28 (r_nsubjpass) ameliorated_13\VBN\126264|herein_86|,_80|we_78|._74 (l_prep) with_14\IN\0|whether_75|toxicity_28|can_19|be_15 (l_pobj) hydroxytyrosol_17\NN\0|NONE_0 (l_prep) in_18\IN\13603305|the_31|antioxidant_27 (l_pobj) rats_19\NNS\2329401|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) cancer_22\NN\14239425|NONE_0
D004317_D001943 NONE doxorubicin_28\NN\2716866|induced_95|were_76|into_63|,_2|._62 (r_appos) divided_10\VBN\140123|NONE_0 (l_csubjpass) induced_7\VBD\1627355|were_19|into_32|,_93|doxorubicin_95|._157 (l_nsubj) rats_3\NNS\2329401|chemically_35 (l_acl) bearing_4\VBG\13795489|six_9 (l_dobj) tumors_6\NNS\14234074|NONE_0
D004317_D001943 NONE doxorubicin_38\NN\2716866|week_11|,_6|and_4 (r_conj) doxorubicin_28\NN\2716866|induced_95|were_76|into_63|,_2|._62 (r_appos) divided_10\VBN\140123|NONE_0 (l_csubjpass) induced_7\VBD\1627355|were_19|into_32|,_93|doxorubicin_95|._157 (l_nsubj) rats_3\NNS\2329401|chemically_35 (l_acl) bearing_4\VBG\13795489|six_9 (l_dobj) tumors_6\NNS\14234074|NONE_0
D004317_D009369 NONE doxorubicin_28\NN\2716866|such_8 (r_pobj) as_27\IN\14622893|NONE_0 (r_prep) drugs_25\NNS\14778436|NONE_0 (r_pobj) of_24\IN\0|the_23|therapeutic_19 (r_prep) effect_23\NN\34213|to_30 (r_dobj) potentiate_20\VB\229605|has_18|been_14 (r_xcomp) shown_18\VBN\2137132|stress_105|is_98|in_86|,_15|and_13|._71 (r_conj) involved_3\VBN\2676054|NONE_0 (l_prep) in_4\IN\13603305|stress_19|is_12|,_71|and_73|shown_86|._157 (l_pobj) processes_6\NNS\407535|NONE_0 (l_prep) including_7\VBG\0|several_18 (l_pobj) cancer_8\NN\14239425|NONE_0
C005975_D066126 NONE hydroxytyrosol_0\NNP\0|stress_37|in_74|._138 (r_nsubj) ameliorates_1\VBZ\126264|NONE_0 (l_prep) in_7\IN\13603305|hydroxytyrosol_74|stress_37|._64 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
C005975_D066126 NONE hydroxytyrosol_17\NN\0|NONE_0 (r_pobj) with_14\IN\0|whether_75|toxicity_28|can_19|be_15 (r_prep) ameliorated_13\VBN\126264|herein_86|,_80|we_78|._74 (l_nsubjpass) toxicity_10\NN\13576101|whether_47|can_9|be_13|with_28
D004317_D006331 CID doxorubicin_7\NN\2716866|NONE_0 (r_pobj) by_6\IN\0|by_15 (r_agent) enhanced_5\VBN\227165|the_25|cardiac_21 (r_acl) disturbances_4\NNS\407535|hydroxytyrosol_36|._122
D004317_D006331 CID doxorubicin_11\NN\2716866|damage_33 (r_nmod) decreasing_12\VBG\169651|study_88|hydroxytyrosol_64|._57 (r_advcl) demonstrates_2\VBZ\2137132|NONE_0 (l_ccomp) hydroxytyrosol_4\JJ\0|study_24|decreasing_64|._121 (l_dobj) damage_8\NN\7296428|that_38
D004317_D002318 NONE doxorubicin_28\NN\2716866|such_8 (r_pobj) as_27\IN\14622893|NONE_0 (r_prep) drugs_25\NNS\14778436|NONE_0 (r_pobj) of_24\IN\0|the_23|therapeutic_19 (r_prep) effect_23\NN\34213|to_30 (r_dobj) potentiate_20\VB\229605|has_18|been_14 (r_xcomp) shown_18\VBN\2137132|stress_105|is_98|in_86|,_15|and_13|._71 (r_conj) involved_3\VBN\2676054|NONE_0 (l_prep) in_4\IN\13603305|stress_19|is_12|,_71|and_73|shown_86|._157 (l_pobj) processes_6\NNS\407535|NONE_0 (l_prep) including_7\VBG\0|several_18 (l_pobj) cancer_8\NN\14239425|NONE_0 (l_conj) disease_13\NN\14061805|,_27
1424076
D014750_D007177 CID vincristine_9\NN\3917455|NONE_0 (r_pobj) after_7\IN\0|of_51|._28 (r_prep) syndrome_0\NN\5870365|NONE_0 (l_prep) of_1\IN\0|after_51|._79 (l_pobj) secretion_3\NN\13526110|NONE_0 (l_prep) of_4\IN\0|inappropriate_24 (l_pobj) hormone_6\NN\5404728|NONE_0
D014750_D007177 CID vincristine_16\NN\3917455|the_4 (r_compound) infusion_17\NN\14589223|NONE_0 (r_pobj) to_14\IN\0|which_21|was_15 (r_prep) attributed_13\VBN\670261|antidiuretic_32|,_12 (r_relcl) hormone_9\NN\5404728|NONE_0
D014750_D009101 NONE vincristine_18\NN\3917455|NONE_0 (r_pobj) of_17\IN\0|a_40|4-day_38|continuous_32|intravenous_21|and_15|doxorubicin_19 (r_prep) infusion_16\NN\14589223|NONE_0 (r_pobj) with_11\IN\0|woman_51|was_12|._108 (r_prep) treated_10\VBN\2376958|NONE_0 (l_nsubjpass) woman_4\NN\9605289|was_39|with_51|._159 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) myeloma_8\NN\14239425|NONE_0
D004317_D009101 NONE doxorubicin_20\NN\2716866|a_59|4-day_57|continuous_51|intravenous_40|of_19|and_4 (r_conj) infusion_16\NN\14589223|NONE_0 (r_pobj) with_11\IN\0|woman_51|was_12|._108 (r_prep) treated_10\VBN\2376958|NONE_0 (l_nsubjpass) woman_4\NN\9605289|was_39|with_51|._159 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) myeloma_8\NN\14239425|NONE_0
D003907_D009101 NONE dexamethasone_26\NN\2721538|NONE_0 (r_pobj) of_24\IN\0|4_7 (r_prep) days_23\NNS\15140892|and_6 (r_conj) doxorubicin_20\NN\2716866|a_59|4-day_57|continuous_51|intravenous_40|of_19|and_4 (r_conj) infusion_16\NN\14589223|NONE_0 (r_pobj) with_11\IN\0|woman_51|was_12|._108 (r_prep) treated_10\VBN\2376958|NONE_0 (l_nsubjpass) woman_4\NN\9605289|was_39|with_51|._159 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) myeloma_8\NN\14239425|NONE_0
24554916
D010758_D017114 CID phosphorus_3\NN\14622893|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) poisoning_0\VBG\14034177|classically_33|with_55|._143 (r_nsubj) manifests_5\VBZ\6479665|NONE_0 (l_prep) with_6\IN\0|poisoning_55|classically_22|._88 (l_pobj) hepatitis_8\NN\14127211|NONE_0 (l_acl) leading_9\VBG\4339291|acute_16 (l_prep) to_10\IN\0|NONE_0 (l_pobj) failure_13\NN\66216|NONE_0
D010758_D056486 NONE phosphorus_1\NN\14622893|known_75|._104 (r_nsubj) is_12\VBZ\0|NONE_0 (l_acomp) known_14\JJ\0|phosphorus_75|._29 (l_xcomp) cause_16\VB\7323922|well_14 (l_dobj) hepatotoxicity_17\NN\0|to_9
D010758_D056486 NONE phosphorus_6\NN\14622893|yellow_7|presented_40 (r_compound) poisoning_7\NN\14034177|NONE_0 (l_relcl) presented_12\VBN\2137132|yellow_47|phosphorus_40 (l_advcl) highlighting_19\VBG\4951373|in_74|patient_63|with_45 (l_dobj) fact_21\NN\5816287|NONE_0 (l_acl) be_26\VB\14625458|the_37 (l_attr) feature_29\NN\5849040|that_44|cholestasis_39|can_27|rarely_23 (l_prep) of_30\IN\0|a_21|presenting_19 (l_pobj) hepatotoxicity_33\NN\0|NONE_0
D010758_D056486 NONE phosphorus_32\NN\14622893|NONE_0 (r_compound) hepatotoxicity_33\NN\0|NONE_0
D010758_D011041 NONE phosphorus_4\NN\14622893|yellow_7 (r_compound) poisoning_5\NN\14034177|NONE_0
D010758_D011041 NONE phosphorus_3\NN\14622893|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) poisoning_0\VBG\14034177|classically_33|with_55|._143
D010758_D011041 NONE phosphorus_6\NN\14622893|yellow_7|presented_40 (r_compound) poisoning_7\NN\14034177|NONE_0
D010758_D011041 NONE phosphorus_32\NN\14622893|NONE_0 (r_compound) hepatotoxicity_33\NN\0|NONE_0 (r_pobj) of_30\IN\0|a_21|presenting_19 (r_prep) feature_29\NN\5849040|that_44|cholestasis_39|can_27|rarely_23 (r_attr) be_26\VB\14625458|the_37 (r_acl) fact_21\NN\5816287|NONE_0 (r_dobj) highlighting_19\VBG\4951373|in_74|patient_63|with_45 (r_advcl) presented_12\VBN\2137132|yellow_47|phosphorus_40 (r_relcl) poisoning_7\NN\14034177|NONE_0
D010758_D006505 CID phosphorus_3\NN\14622893|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) poisoning_0\VBG\14034177|classically_33|with_55|._143 (r_nsubj) manifests_5\VBZ\6479665|NONE_0 (l_prep) with_6\IN\0|poisoning_55|classically_22|._88 (l_pobj) hepatitis_8\NN\14127211|NONE_0
D010758_D002779 CID phosphorus_4\NN\14622893|yellow_7 (r_compound) poisoning_5\NN\14034177|NONE_0 (r_pobj) of_2\IN\0|cholestatic_25|._30 (r_prep) presentation_1\NN\1027379|NONE_0 (l_amod) cholestatic_0\JJ\0|of_25|._55
D010758_D002779 CID phosphorus_6\NN\14622893|yellow_7|presented_40 (r_compound) poisoning_7\NN\14034177|NONE_0 (l_relcl) presented_12\VBN\2137132|yellow_47|phosphorus_40 (l_prep) with_13\IN\0|in_29|patient_18|highlighting_45 (l_pobj) features_16\NNS\5849040|NONE_0 (l_prep) of_17\IN\0|florid_25|clinical_18 (l_pobj) cholestasis_18\NN\14052403|NONE_0
D010758_D002779 CID phosphorus_6\NN\14622893|yellow_7|presented_40 (r_compound) poisoning_7\NN\14034177|NONE_0 (l_relcl) presented_12\VBN\2137132|yellow_47|phosphorus_40 (l_advcl) highlighting_19\VBG\4951373|in_74|patient_63|with_45 (l_dobj) fact_21\NN\5816287|NONE_0 (l_acl) be_26\VB\14625458|the_37 (l_nsubj) cholestasis_23\NN\14052403|that_5|can_12|rarely_16|feature_39
D010758_D002779 CID phosphorus_32\NN\14622893|NONE_0 (r_compound) hepatotoxicity_33\NN\0|NONE_0 (r_pobj) of_30\IN\0|a_21|presenting_19 (r_prep) feature_29\NN\5849040|that_44|cholestasis_39|can_27|rarely_23 (r_attr) be_26\VB\14625458|the_37 (r_acl) fact_21\NN\5816287|NONE_0 (r_dobj) highlighting_19\VBG\4951373|in_74|patient_63|with_45 (r_advcl) presented_12\VBN\2137132|yellow_47|phosphorus_40 (l_prep) with_13\IN\0|in_29|patient_18|highlighting_45 (l_pobj) features_16\NNS\5849040|NONE_0 (l_prep) of_17\IN\0|florid_25|clinical_18 (l_pobj) cholestasis_18\NN\14052403|NONE_0
D010758_D002779 CID phosphorus_32\NN\14622893|NONE_0 (r_compound) hepatotoxicity_33\NN\0|NONE_0 (r_pobj) of_30\IN\0|a_21|presenting_19 (r_prep) feature_29\NN\5849040|that_44|cholestasis_39|can_27|rarely_23 (r_attr) be_26\VB\14625458|the_37 (l_nsubj) cholestasis_23\NN\14052403|that_5|can_12|rarely_16|feature_39
24571687
D020927_D001919 CID dexmedetomidine_7\NN\0|NONE_0 (r_dobj) following_5\VBG\8180190|severe_19 (r_prep) bradycardia_4\NNS\14110674|vasovagal_29|and_11|._82
D020927_D001919 CID dexmedetomidine_15\NN\0|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) following_11\VBG\8180190|an_20|old_9 (r_acl) girl_10\NN\10787470|NONE_0 (r_pobj) in_5\IN\13603305|NONE_0 (r_prep) bradycardia_4\NN\14110674|and_4
D020927_D019462 CID dexmedetomidine_7\NN\0|NONE_0 (r_dobj) following_5\VBG\8180190|severe_19 (r_prep) bradycardia_4\NNS\14110674|vasovagal_29|and_11|._82 (r_conj) syncope_1\NN\7478169|NONE_0
D020927_D013575 NONE dexmedetomidine_15\NN\0|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) following_11\VBG\8180190|an_20|old_9 (r_acl) girl_10\NN\10787470|NONE_0 (r_pobj) in_5\IN\13603305|NONE_0 (r_prep) bradycardia_4\NN\14110674|and_4 (r_conj) syncope_2\NN\7478169|we_10|._145
8312983
C036139_D006948 NONE desmethylfluoxetine_22\NN\0|plus_5 (r_conj) fluoxetine_20\NN\4169152|a_31|total_18|fluoxetine_12|(_1|)_35 (r_nmod) concentration_24\NN\4916342|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) connected_12\VBN\0|acute_28|hyperkinetic_22 (r_acl) delirium_11\NN\14391660|NONE_0 (l_amod) hyperkinetic_10\JJ\0|acute_6|connected_22
D015283_D020820 NONE citalopram_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|a_27|high_25|serum_20|l_26|in_29 (r_prep) concentration_7\NN\4916342|in_28|,_15|has_63|been_67|with_83|._134 (r_nsubjpass) associated_22\VBN\628491|NONE_0 (l_prep) with_23\IN\0|in_111|,_98|concentration_83|has_20|been_16|._51 (l_pobj) somnolence_25\NN\14015731|NONE_0 (l_conj) difficulties_28\NNS\621627|increased_34|and_13
D005473_D006948 CID fluoxetine_18\NN\4169152|a_19|total_6|(_11|fluoxetine_12|)_47 (r_nmod) concentration_24\NN\4916342|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) connected_12\VBN\0|acute_28|hyperkinetic_22 (r_acl) delirium_11\NN\14391660|NONE_0 (l_amod) hyperkinetic_10\JJ\0|acute_6|connected_22
D005473_D006948 CID fluoxetine_20\NN\4169152|a_31|total_18|fluoxetine_12|(_1|)_35 (r_nmod) concentration_24\NN\4916342|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) connected_12\VBN\0|acute_28|hyperkinetic_22 (r_acl) delirium_11\NN\14391660|NONE_0 (l_amod) hyperkinetic_10\JJ\0|acute_6|connected_22
C036139_D003693 NONE desmethylfluoxetine_22\NN\0|plus_5 (r_conj) fluoxetine_20\NN\4169152|a_31|total_18|fluoxetine_12|(_1|)_35 (r_nmod) concentration_24\NN\4916342|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) connected_12\VBN\0|acute_28|hyperkinetic_22 (r_acl) delirium_11\NN\14391660|NONE_0
D005473_D003693 CID fluoxetine_2\NN\4169152|NONE_0 (r_amod) treatment_3\NN\654885|NONE_0 (r_pobj) during_1\IN\0|._27 (r_prep) delirium_0\NN\14391660|NONE_0
D005473_D003693 CID fluoxetine_18\NN\4169152|a_19|total_6|(_11|fluoxetine_12|)_47 (r_nmod) concentration_24\NN\4916342|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) connected_12\VBN\0|acute_28|hyperkinetic_22 (r_acl) delirium_11\NN\14391660|NONE_0
D005473_D003693 CID fluoxetine_20\NN\4169152|a_31|total_18|fluoxetine_12|(_1|)_35 (r_nmod) concentration_24\NN\4916342|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) connected_12\VBN\0|acute_28|hyperkinetic_22 (r_acl) delirium_11\NN\14391660|NONE_0
D015283_D006970 NONE citalopram_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|a_27|high_25|serum_20|l_26|in_29 (r_prep) concentration_7\NN\4916342|in_28|,_15|has_63|been_67|with_83|._134 (r_nsubjpass) associated_22\VBN\628491|NONE_0 (l_prep) with_23\IN\0|in_111|,_98|concentration_83|has_20|been_16|._51 (l_pobj) somnolence_25\NN\14015731|NONE_0
12372954
C036067_D012170 NONE lysine_10\NN\14605787|due_7 (r_dobj) bendazac_9\VB\0|before_53|,_37|he_35|had_32|been_28|nicergoline_16|and_4|._74 (l_prep) due_11\IN\5174653|lysine_7 (l_pobj) occlusion_15\NN\14081375|to_16
D009530_D009395 CID nicergoline_5\NN\0|to_3 (r_pobj) due_3\IN\5174653|acute_29|interstitial_23|._28 (r_prep) nephritis_2\NN\14113228|NONE_0
D009530_D009395 CID sermion_7\NN\0|NONE_0 (r_appos) nicergoline_5\NN\0|to_3 (r_pobj) due_3\IN\5174653|acute_29|interstitial_23|._28 (r_prep) nephritis_2\NN\14113228|NONE_0
D009530_D009395 CID nicergoline_13\NN\0|to_3 (r_pobj) due_11\IN\5174653|we_55|case_43|._28 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) case_3\NN\7283608|we_12|due_43|._71 (l_prep) of_4\IN\0|a_7 (l_pobj) nephritis_7\NN\14113228|NONE_0
D009530_D009395 CID nicergoline_13\NN\0|to_3 (r_pobj) due_11\IN\5174653|we_55|case_43|._28 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) case_3\NN\7283608|we_12|due_43|._71 (l_prep) of_4\IN\0|a_7 (l_pobj) nephritis_7\NN\14113228|NONE_0 (l_appos) ain_9\NNP\0|acute_30|interstitial_24|(_1|)_3
D009530_D009395 CID sermion_15\NN\0|NONE_0 (r_appos) nicergoline_13\NN\0|to_3 (r_pobj) due_11\IN\5174653|we_55|case_43|._28 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) case_3\NN\7283608|we_12|due_43|._71 (l_prep) of_4\IN\0|a_7 (l_pobj) nephritis_7\NN\14113228|NONE_0
D009530_D009395 CID sermion_15\NN\0|NONE_0 (r_appos) nicergoline_13\NN\0|to_3 (r_pobj) due_11\IN\5174653|we_55|case_43|._28 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) case_3\NN\7283608|we_12|due_43|._71 (l_prep) of_4\IN\0|a_7 (l_pobj) nephritis_7\NN\14113228|NONE_0 (l_appos) ain_9\NNP\0|acute_30|interstitial_24|(_1|)_3
D009530_D009395 CID nicergoline_10\NN\0|-_11 (r_npadvmod) associated_12\VBN\628491|NONE_0 (r_amod) ain_13\NNP\0|NONE_0
D009530_D012170 NONE nicergoline_7\NN\0|before_37|,_21|he_19|had_16|been_12|and_12|bendazac_16|._90 (r_dobj) taking_6\VBG\37396|NONE_0 (l_conj) bendazac_9\VB\0|before_53|,_37|he_35|had_32|been_28|nicergoline_16|and_4|._74 (l_prep) due_11\IN\5174653|lysine_7 (l_pobj) occlusion_15\NN\14081375|to_16
1564030
D012701_D003866 NONE serotonin_4\NN\14807737|a_12|selective_10|reuptake_10 (r_compound) inhibitor_6\NN\20090|,_33|,_9 (r_appos) fluoxetine_0\NNP\4169152|is_54|acceptance_75|._127 (r_nsubj) gaining_9\VBG\2238085|NONE_0 (l_dobj) acceptance_11\NN\6193203|fluoxetine_75|is_21|._52 (l_prep) in_12\IN\13603305|increased_21 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) depression_17\NN\14373582|NONE_0
D005473_D001714 CID fluoxetine_3\NN\4169152|in_21 (r_amod) treatment_4\NN\654885|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|._51 (r_acl) mania_0\NNP\9180259|NONE_0
D005473_D001714 CID fluoxetine_8\NN\4169152|safe_35|,_2|has_11|been_15|induce_32|._44 (r_nsubjpass) reported_11\VBN\831651|NONE_0 (l_xcomp) induce_13\VB\1627355|safe_67|,_34|fluoxetine_32|has_21|been_17|._12 (l_dobj) mania_14\NN\9180259|to_10
D005473_D001714 CID fluoxetine_20\NN\4169152|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) pharmacotherapy_18\NN\0|NONE_0 (r_pobj) during_17\IN\0|who_20|mania_6 (r_prep) developed_15\VBD\1753788|the_65|of_55|,_26|years_18|,_6|,_54 (l_dobj) mania_16\NN\9180259|who_14|during_6
D005473_D001714 CID fluoxetine_11\NN\4169152|in_27 (r_amod) pharmacotherapy_12\NN\0|NONE_0 (r_pobj) during_10\IN\0|NONE_0 (r_prep) hypomania_9\NN\0|the_28|of_12|or_3 (r_conj) development_5\NN\248977|NONE_0 (l_prep) of_6\IN\0|the_16|or_9|hypomania_12 (l_pobj) mania_7\NN\9180259|NONE_0
D005473_D001714 CID fluoxetine_11\NN\4169152|in_27 (r_amod) pharmacotherapy_12\NN\0|NONE_0 (r_pobj) during_10\IN\0|NONE_0 (r_prep) hypomania_9\NN\0|the_28|of_12|or_3
D005473_D001714 CID fluoxetine_11\NN\4169152|in_27 (r_amod) pharmacotherapy_12\NN\0|NONE_0 (r_pobj) during_10\IN\0|NONE_0 (r_prep) hypomania_9\NN\0|the_28|of_12|or_3 (r_conj) development_5\NN\248977|NONE_0 (r_pobj) for_3\IN\0|apparent_22|risk_13|depression_193 (r_prep) factors_2\NNS\7326557|combination_112|;_193|._341 (l_appos) depression_30\NN\14373582|apparent_215|risk_206|for_193 (l_conj) history_37\NN\15120823|major_51|with_34|;_11 (l_prep) of_38\IN\0|a_17|family_15|;_50|and_52|diagnosis_58 (l_pobj) disorder_40\NN\14034177|NONE_0 (l_appos) disorder_44\NN\14034177|affective_39|,_21
D005473_D001714 CID fluoxetine_11\NN\4169152|in_27 (r_amod) pharmacotherapy_12\NN\0|NONE_0 (r_pobj) during_10\IN\0|NONE_0 (r_prep) hypomania_9\NN\0|the_28|of_12|or_3 (r_conj) development_5\NN\248977|NONE_0 (r_pobj) for_3\IN\0|apparent_22|risk_13|depression_193 (r_prep) factors_2\NNS\7326557|combination_112|;_193|._341 (l_appos) depression_30\NN\14373582|apparent_215|risk_206|for_193 (l_conj) history_37\NN\15120823|major_51|with_34|;_11 (l_conj) diagnosis_48\NN\152018|a_75|family_73|of_58|;_8|and_6 (l_prep) of_49\IN\0|a_12 (l_pobj) disorder_51\NN\14034177|NONE_0
D005473_D001714 CID fluoxetine_19\VB\4169152|NONE_0 (r_advmod) induced_20\VBN\1627355|in_14 (r_amod) mania_21\NN\9180259|NONE_0
D005473_D019964 NONE fluoxetine_11\NN\4169152|in_27 (r_amod) pharmacotherapy_12\NN\0|NONE_0 (r_pobj) during_10\IN\0|NONE_0 (r_prep) hypomania_9\NN\0|the_28|of_12|or_3 (r_conj) development_5\NN\248977|NONE_0 (r_pobj) for_3\IN\0|apparent_22|risk_13|depression_193 (r_prep) factors_2\NNS\7326557|combination_112|;_193|._341 (l_appos) depression_30\NN\14373582|apparent_215|risk_206|for_193 (l_conj) history_37\NN\15120823|major_51|with_34|;_11 (l_prep) of_38\IN\0|a_17|family_15|;_50|and_52|diagnosis_58 (l_pobj) disorder_40\NN\14034177|NONE_0
D005473_D001289 NONE fluoxetine_11\NN\4169152|in_27 (r_amod) pharmacotherapy_12\NN\0|NONE_0 (r_pobj) during_10\IN\0|NONE_0 (r_prep) hypomania_9\NN\0|the_28|of_12|or_3 (r_conj) development_5\NN\248977|NONE_0 (r_pobj) for_3\IN\0|apparent_22|risk_13|depression_193 (r_prep) factors_2\NNS\7326557|combination_112|;_193|._341 (r_nsubj) were_16\VBD\0|NONE_0 (l_attr) combination_18\NN\7951464|factors_112|;_81|._229 (l_prep) of_19\IN\0|the_16 (l_pobj) disorder_24\NN\14034177|NONE_0
D005473_D011618 NONE fluoxetine_11\NN\4169152|in_27 (r_amod) pharmacotherapy_12\NN\0|NONE_0 (r_pobj) during_10\IN\0|NONE_0 (r_prep) hypomania_9\NN\0|the_28|of_12|or_3 (r_conj) development_5\NN\248977|NONE_0 (r_pobj) for_3\IN\0|apparent_22|risk_13|depression_193 (r_prep) factors_2\NNS\7326557|combination_112|;_193|._341 (l_appos) depression_30\NN\14373582|apparent_215|risk_206|for_193 (l_prep) with_31\IN\0|major_17|;_23|history_34 (l_pobj) features_33\NNS\5849040|NONE_0 (l_amod) psychotic_32\JJ\10595647|NONE_0
D005473_D003866 NONE fluoxetine_0\NNP\4169152|is_54|acceptance_75|._127 (r_nsubj) gaining_9\VBG\2238085|NONE_0 (l_dobj) acceptance_11\NN\6193203|fluoxetine_75|is_21|._52 (l_prep) in_12\IN\13603305|increased_21 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) depression_17\NN\14373582|NONE_0
D005473_D003866 NONE fluoxetine_20\NN\4169152|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) pharmacotherapy_18\NN\0|NONE_0 (r_pobj) during_17\IN\0|who_20|mania_6 (r_prep) developed_15\VBD\1753788|the_65|of_55|,_26|years_18|,_6|,_54 (r_relcl) cases_1\NNS\7283608|are_117|here_130|._134 (l_prep) of_2\IN\0|the_10|,_29|years_37|,_49|developed_55|,_109 (l_pobj) adolescents_5\NNS\9622049|NONE_0 (l_amod) depressed_4\JJ\1819147|five_5
D005473_D003866 NONE fluoxetine_11\NN\4169152|in_27 (r_amod) pharmacotherapy_12\NN\0|NONE_0 (r_pobj) during_10\IN\0|NONE_0 (r_prep) hypomania_9\NN\0|the_28|of_12|or_3 (r_conj) development_5\NN\248977|NONE_0 (r_pobj) for_3\IN\0|apparent_22|risk_13|depression_193 (r_prep) factors_2\NNS\7326557|combination_112|;_193|._341 (l_appos) depression_30\NN\14373582|apparent_215|risk_206|for_193
19553912
D020123_D000740 CID sirolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_9 (r_prep) role_4\NN\719494|posttransplant_27|:_6|._17 (r_appos) anemia_1\NN\14189204|NONE_0
D020123_D000740 CID sirolimus_0\NNP\0|has_54|been_58|as_74|._124 (r_nsubjpass) implicated_11\VBN\2677097|NONE_0 (l_prep) as_12\IN\14622893|sirolimus_74|has_20|been_16|._50 (l_pcomp) playing_13\VBG\100253|NONE_0 (l_dobj) role_16\NN\719494|NONE_0 (l_prep) in_17\IN\13603305|a_15|special_13 (l_pobj) anemia_19\NN\14189204|NONE_0
D020123_D000740 CID rapamycin_6\NNS\0|NONE_0 (r_compound) inhibitor_7\NN\20090|NONE_0 (r_pobj) of_5\IN\0|a_19|mammalian_17 (r_prep) target_4\NN\7258332|,_14|,_29 (r_appos) sirolimus_0\NNP\0|has_54|been_58|as_74|._124 (r_nsubjpass) implicated_11\VBN\2677097|NONE_0 (l_prep) as_12\IN\14622893|sirolimus_74|has_20|been_16|._50 (l_pcomp) playing_13\VBG\100253|NONE_0 (l_dobj) role_16\NN\719494|NONE_0 (l_prep) in_17\IN\13603305|a_15|special_13 (l_pobj) anemia_19\NN\14189204|NONE_0
D020123_D000740 CID sirolimus_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|,_25|including_27 (r_acl) anemia_3\NN\14189204|review_17|._88
17496739
C085143_D007676 NONE tazobactam_54\NN\0|progressive_118|mental_106|,_90|and_88|episodes_82 (r_conj) confusion_34\NN\13972797|bizarre_37|,_21 (r_conj) behavior_30\NN\407535|,_10 (r_conj) tremor_27\NN\345926|slurred_16|,_2 (r_conj) speech_25\NN\7160883|who_22 (r_dobj) developed_23\VBD\1753788|continuous_54|ambulatory_43|peritoneal_32|(_12|capd_11|)_7|,_6 (r_relcl) dialysis_17\NN\646833|NONE_0 (r_dobj) receiving_13\VBG\2210855|stage_20|renal_14 (r_acl) disease_12\NN\14061805|NONE_0
C085143_D012640 NONE tazobactam_2\NN\0|piperacillin_13|/_1|-_10 (r_advmod) induced_4\VBN\1627355|NONE_0 (r_amod) seizure_5\NN\14081375|rapidly_8|by_25|in_51|._86
C085143_D060085 NONE tazobactam_54\NN\0|progressive_118|mental_106|,_90|and_88|episodes_82 (r_conj) confusion_34\NN\13972797|bizarre_37|,_21 (r_conj) behavior_30\NN\407535|,_10 (r_conj) tremor_27\NN\345926|slurred_16|,_2 (r_conj) speech_25\NN\7160883|who_22 (r_dobj) developed_23\VBD\1753788|continuous_54|ambulatory_43|peritoneal_32|(_12|capd_11|)_7|,_6 (r_relcl) dialysis_17\NN\646833|NONE_0 (r_dobj) receiving_13\VBG\2210855|stage_20|renal_14 (r_acl) disease_12\NN\14061805|NONE_0 (r_pobj) with_7\IN\0|a_20|old_10 (r_prep) woman_6\NN\9605289|were_293|for_304 (r_nsubjpass) given_61\VBN\5892096|we_322|._49 (l_prep) for_62\IN\0|woman_304|were_11 (l_pobj) bronchiectasis_63\NN\0|NONE_0 (l_prep) with_64\IN\0|NONE_0 (l_pobj) infection_66\NN\14052046|NONE_0
C085143_D004830 CID tazobactam_54\NN\0|progressive_118|mental_106|,_90|and_88|episodes_82 (r_conj) confusion_34\NN\13972797|bizarre_37|,_21 (l_conj) episodes_38\NNS\7283608|progressive_36|mental_24|,_8|and_6|tazobactam_82 (l_prep) of_39\IN\0|2_11|gtcs_37 (l_pobj) seizure_44\NN\14081375|NONE_0
C085143_D004830 CID tazobactam_54\NN\0|progressive_118|mental_106|,_90|and_88|episodes_82 (r_conj) confusion_34\NN\13972797|bizarre_37|,_21 (l_conj) episodes_38\NNS\7283608|progressive_36|mental_24|,_8|and_6|tazobactam_82 (l_parataxis) gtcs_46\NNP\0|2_48|of_37
C085143_D004830 CID tazobactam_18\NN\0|NONE_0 (r_pobj) after_11\IN\0|despite_71|,_32|episode_17|._47 (r_prep) recurred_10\VBD\339934|NONE_0 (l_nsubj) episode_9\NN\7283608|despite_54|,_15|after_17|._64 (l_amod) gtcs_8\NNP\0|another_8
C085143_D014202 CID tazobactam_54\NN\0|progressive_118|mental_106|,_90|and_88|episodes_82 (r_conj) confusion_34\NN\13972797|bizarre_37|,_21 (r_conj) behavior_30\NN\407535|,_10 (r_conj) tremor_27\NN\345926|slurred_16|,_2
C085143_D001987 NONE tazobactam_54\NN\0|progressive_118|mental_106|,_90|and_88|episodes_82 (r_conj) confusion_34\NN\13972797|bizarre_37|,_21 (r_conj) behavior_30\NN\407535|,_10 (r_conj) tremor_27\NN\345926|slurred_16|,_2 (r_conj) speech_25\NN\7160883|who_22 (r_dobj) developed_23\VBD\1753788|continuous_54|ambulatory_43|peritoneal_32|(_12|capd_11|)_7|,_6 (r_relcl) dialysis_17\NN\646833|NONE_0 (r_dobj) receiving_13\VBG\2210855|stage_20|renal_14 (r_acl) disease_12\NN\14061805|NONE_0 (r_pobj) with_7\IN\0|a_20|old_10 (r_prep) woman_6\NN\9605289|were_293|for_304 (r_nsubjpass) given_61\VBN\5892096|we_322|._49 (l_prep) for_62\IN\0|woman_304|were_11 (l_pobj) bronchiectasis_63\NN\0|NONE_0
D010878_D001927 NONE piperacillin_0\NNP\3910033|-_12 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) encephalopathy_3\NN\14084880|should_15|be_22|in_36|._103
D010878_D001927 NONE piperacillin_5\NN\3910033|NONE_0 (r_dobj) removing_4\VBG\0|NONE_0 (r_pcomp) in_3\IN\13603305|NONE_0 (r_prep) inefficient_2\JJ\0|capd_8|,_36|terminate_71|._120 (r_acomp) is_1\VBZ\0|NONE_0 (l_advcl) terminate_11\VB\126264|capd_79|inefficient_71|,_35|._49 (l_dobj) encephalopathy_16\NN\14084880|whereas_68|hemodialysis_60|can_47|rapidly_43
D010878_D001927 NONE piperacillin_13\NN\3910033|-_12 (r_npadvmod) induced_15\VBN\1627355|the_17 (r_amod) encephalopathy_16\NN\14084880|whereas_68|hemodialysis_60|can_47|rapidly_43
C085143_D003221 CID tazobactam_54\NN\0|progressive_118|mental_106|,_90|and_88|episodes_82 (r_conj) confusion_34\NN\13972797|bizarre_37|,_21
D010878_D006463 NONE piperacillin_0\NNP\3910033|-_12 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) encephalopathy_3\NN\14084880|should_15|be_22|in_36|._103 (r_nsubjpass) considered_6\VBN\689344|NONE_0 (l_prep) in_7\IN\13603305|encephalopathy_36|should_21|be_14|._67 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) uremic_9\JJ\0|any_4|with_16
D010878_D020258 NONE piperacillin_4\NN\3910033|NONE_0 (r_pobj) of_3\IN\0|popular_12 (r_prep) use_2\NN\407535|NONE_0 (r_pobj) despite_0\IN\7501545|,_35|neurotoxicity_46|still_89|unrecognized_100|,_112|leading_114|._158 (r_prep) goes_13\VBZ\15291801|NONE_0 (l_nsubj) neurotoxicity_8\NN\0|despite_46|,_11|still_43|unrecognized_54|,_66|leading_68|._112
D010878_D020258 NONE piperacillin_11\NN\3910033|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|the_23|dire_19 (r_acl) neurotoxicity_8\NN\0|despite_46|,_11|still_43|unrecognized_54|,_66|leading_68|._112
D000641_D007964 NONE ammonia_8\NN\14940386|electrolyte_16|but_15|leukocytosis_19 (r_compound) levels_9\NNS\4916342|data_52|._23 (l_conj) leukocytosis_11\NN\14189204|electrolyte_35|ammonia_19|but_4
12119460
D005472_D013274 NONE 5-fluorouracil_3\CD\0|/_15 (r_punct) folinic_5\JJ\0|dose_22|in_13|._101 (r_compound) acid_6\NN\14818238|NONE_0 (l_prep) in_7\IN\13603305|dose_35|folinic_13|._88 (l_pobj) combination_8\NN\7951464|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) c_14\NN\13714184|NONE_0 (l_prep) in_15\IN\13603305|weekly_19|mitomycin_12 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) cancer_21\NN\14239425|NONE_0
D005472_D013274 NONE 5-fluorouracil_5\CD\0|NONE_0 (r_punct) (_6\-LRB-\0|)_5|and_7|folinic_11 (r_punct) 5-fu_7\CD\0|NONE_0 (l_conj) folinic_10\VB\0|(_11|)_6|and_4 (l_prep) as_15\IN\14622893|fa_4|)_2 (l_pobj) part_16\NN\31921|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimens_22\NNS\5898568|NONE_0 (l_prep) in_23\IN\13603305|several_44|new_36|chemotherapy_22 (l_pobj) cancer_26\NN\14239425|NONE_0
D005472_D013274 NONE 5-fluorouracil_5\CD\0|NONE_0 (r_punct) (_6\-LRB-\0|)_5|and_7|folinic_11 (r_punct) 5-fu_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|the_32|24-hour_28|continuous_20 (r_prep) infusion_3\NN\14589223|(_138|agc_139|has_144|be_157|._188 (r_nsubj) shown_31\VBN\2137132|NONE_0 (l_nsubj) agc_28\NNP\0|infusion_139|(_1|has_5|be_18|._49
D005472_D013274 NONE 5-fu_7\CD\0|NONE_0 (l_conj) folinic_10\VB\0|(_11|)_6|and_4 (l_prep) as_15\IN\14622893|fa_4|)_2 (l_pobj) part_16\NN\31921|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimens_22\NNS\5898568|NONE_0 (l_prep) in_23\IN\13603305|several_44|new_36|chemotherapy_22 (l_pobj) cancer_26\NN\14239425|NONE_0
D005472_D013274 NONE 5-fu_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|the_32|24-hour_28|continuous_20 (r_prep) infusion_3\NN\14589223|(_138|agc_139|has_144|be_157|._188 (r_nsubj) shown_31\VBN\2137132|NONE_0 (l_nsubj) agc_28\NNP\0|infusion_139|(_1|has_5|be_18|._49
D005472_D013274 NONE 5-fu_18\CD\0|to_26 (r_dobj) receive_15\VB\2210855|33_24|with_12|preceded_42|)_74 (r_relcl) patients_11\NNS\9898892|from_55|,_23|we_16|for_97|,_108|followed_110|._142 (l_prep) with_12\IN\0|33_12|receive_12|preceded_54|)_86 (l_pobj) agc_13\NNP\0|NONE_0
D005472_D013274 NONE 5-fu_3\CD\0|dose_5|/_4|fa_5|/_7 (r_nmod) mmc_7\NNP\0|regimen_50|._97 (r_nsubj) is_8\VBZ\0|NONE_0 (l_attr) regimen_16\NN\5898568|mmc_50|._47 (l_prep) for_17\IN\0|an_51|effective_48|outpatient_19 (l_pobj) agc_18\NNP\0|NONE_0
D016685_D013274 NONE c_14\NN\13714184|NONE_0 (l_prep) in_15\IN\13603305|weekly_19|mitomycin_12 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) cancer_21\NN\14239425|NONE_0
D016685_D013274 NONE mmc_7\NNP\0|regimen_50|._97 (r_nsubj) is_8\VBZ\0|NONE_0 (l_attr) regimen_16\NN\5898568|mmc_50|._47 (l_prep) for_17\IN\0|an_51|effective_48|outpatient_19 (l_pobj) agc_18\NNP\0|NONE_0
D005472_D064420 NONE 5-fluorouracil_5\CD\0|NONE_0 (r_punct) (_6\-LRB-\0|)_5|and_7|folinic_11 (r_punct) 5-fu_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|the_32|24-hour_28|continuous_20 (r_prep) infusion_3\NN\14589223|(_138|agc_139|has_144|be_157|._188 (r_nsubj) shown_31\VBN\2137132|NONE_0 (l_xcomp) be_33\VB\14625458|infusion_157|(_19|agc_18|has_13|._31 (l_prep) with_36\IN\0|to_17|effective_11|,_2 (l_pobj) toxicity_38\NN\13576101|NONE_0
D005472_D064420 NONE 5-fu_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|the_32|24-hour_28|continuous_20 (r_prep) infusion_3\NN\14589223|(_138|agc_139|has_144|be_157|._188 (r_nsubj) shown_31\VBN\2137132|NONE_0 (l_xcomp) be_33\VB\14625458|infusion_157|(_19|agc_18|has_13|._31 (l_prep) with_36\IN\0|to_17|effective_11|,_2 (l_pobj) toxicity_38\NN\13576101|NONE_0
D002955_D013274 NONE acid_6\NN\14818238|NONE_0 (l_prep) in_7\IN\13603305|dose_35|folinic_13|._88 (l_pobj) combination_8\NN\7951464|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) c_14\NN\13714184|NONE_0 (l_prep) in_15\IN\13603305|weekly_19|mitomycin_12 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) cancer_21\NN\14239425|NONE_0
D002955_D013274 NONE acid_11\NN\14818238|(_5 (r_nmod) fa_13\NNP\6868043|)_2|as_4 (r_dobj) folinic_10\VB\0|(_11|)_6|and_4 (l_prep) as_15\IN\14622893|fa_4|)_2 (l_pobj) part_16\NN\31921|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimens_22\NNS\5898568|NONE_0 (l_prep) in_23\IN\13603305|several_44|new_36|chemotherapy_22 (l_pobj) cancer_26\NN\14239425|NONE_0
D002955_D013274 NONE acid_11\NN\14818238|(_5 (r_nmod) fa_13\NNP\6868043|)_2|as_4 (r_dobj) folinic_10\VB\0|(_11|)_6|and_4 (r_conj) 5-fu_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|the_32|24-hour_28|continuous_20 (r_prep) infusion_3\NN\14589223|(_138|agc_139|has_144|be_157|._188 (r_nsubj) shown_31\VBN\2137132|NONE_0 (l_nsubj) agc_28\NNP\0|infusion_139|(_1|has_5|be_18|._49
D002955_D013274 NONE fa_13\NNP\6868043|)_2|as_4 (r_dobj) folinic_10\VB\0|(_11|)_6|and_4 (l_prep) as_15\IN\14622893|fa_4|)_2 (l_pobj) part_16\NN\31921|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimens_22\NNS\5898568|NONE_0 (l_prep) in_23\IN\13603305|several_44|new_36|chemotherapy_22 (l_pobj) cancer_26\NN\14239425|NONE_0
D002955_D013274 NONE fa_13\NNP\6868043|)_2|as_4 (r_dobj) folinic_10\VB\0|(_11|)_6|and_4 (r_conj) 5-fu_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|the_32|24-hour_28|continuous_20 (r_prep) infusion_3\NN\14589223|(_138|agc_139|has_144|be_157|._188 (r_nsubj) shown_31\VBN\2137132|NONE_0 (l_nsubj) agc_28\NNP\0|infusion_139|(_1|has_5|be_18|._49
D002955_D013274 NONE fa_27\NNP\6868043|2-hour_7|500_3|mg_7|/_9 (r_nmod) m(2_31\NN\0|NONE_0 (r_punct) )_32\-RRB-\0|33_98|with_86|receive_74|preceded_32 (r_punct) patients_11\NNS\9898892|from_55|,_23|we_16|for_97|,_108|followed_110|._142 (l_prep) with_12\IN\0|33_12|receive_12|preceded_54|)_86 (l_pobj) agc_13\NNP\0|NONE_0
D002955_D013274 NONE fa_5\NNP\6868043|dose_10|5-fu_5|/_1|/_2 (r_nmod) mmc_7\NNP\0|regimen_50|._97 (r_nsubj) is_8\VBZ\0|NONE_0 (l_attr) regimen_16\NN\5898568|mmc_50|._47 (l_prep) for_17\IN\0|an_51|effective_48|outpatient_19 (l_pobj) agc_18\NNP\0|NONE_0
D002945_D006463 NONE cisplatin_7\NN\0|-_9 (r_advmod) containing_9\VBG\2632940|NONE_0 (r_amod) regimens_10\NNS\5898568|NONE_0 (r_pobj) to_6\IN\0|an_15 (r_prep) alternative_5\NN\5788149|NONE_0 (r_pobj) as_3\IN\14622893|it_13|may_10 (r_prep) serve_2\VB\566135|;_56|however_58|,_65|it_67|considered_80|._118 (r_ccomp) has_15\VBZ\13888491|NONE_0 (l_xcomp) considered_18\VBN\689344|serve_80|;_24|however_22|,_15|it_13|._38 (l_ccomp) occur_23\VB\0|to_39|be_36 (l_nsubj) hus_21\NNP\0|that_14|possibly_9|may_4
D002955_D064420 NONE acid_11\NN\14818238|(_5 (r_nmod) fa_13\NNP\6868043|)_2|as_4 (r_dobj) folinic_10\VB\0|(_11|)_6|and_4 (r_conj) 5-fu_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|the_32|24-hour_28|continuous_20 (r_prep) infusion_3\NN\14589223|(_138|agc_139|has_144|be_157|._188 (r_nsubj) shown_31\VBN\2137132|NONE_0 (l_xcomp) be_33\VB\14625458|infusion_157|(_19|agc_18|has_13|._31 (l_prep) with_36\IN\0|to_17|effective_11|,_2 (l_pobj) toxicity_38\NN\13576101|NONE_0
D002955_D064420 NONE fa_13\NNP\6868043|)_2|as_4 (r_dobj) folinic_10\VB\0|(_11|)_6|and_4 (r_conj) 5-fu_7\CD\0|NONE_0 (r_pobj) of_4\IN\0|the_32|24-hour_28|continuous_20 (r_prep) infusion_3\NN\14589223|(_138|agc_139|has_144|be_157|._188 (r_nsubj) shown_31\VBN\2137132|NONE_0 (l_xcomp) be_33\VB\14625458|infusion_157|(_19|agc_18|has_13|._31 (l_prep) with_36\IN\0|to_17|effective_11|,_2 (l_pobj) toxicity_38\NN\13576101|NONE_0
12912689
D016190_D005355 CID carboplatin_1\NN\0|NONE_0 (l_ccomp) associated_4\VBN\628491|subtenon_37|._156 (l_prep) with_5\IN\0|chemotherapy_27|is_14|,_49|leading_51 (l_pobj) fibrosis_7\NN\14204950|NONE_0
D016190_D064420 NONE carboplatin_2\NN\0|NONE_0 (l_ccomp) used_7\VBN\0|subtenon_51|._98 (l_prep) as_8\IN\14622893|injections_35|have_24|recently_19|been_10 (l_pobj) adjunct_14\NN\9312645|NONE_0 (l_amod) free_13\JJ\7942152|a_22|to_13 (l_npadvmod) toxicity_11\NN\13576101|presumably_11|-_8
D016190_D064420 NONE carboplatin_1\NN\0|not_15|free_19|,_35|and_37|restricted_57 (r_nsubj) is_2\VBZ\0|NONE_0 (l_acomp) free_4\JJ\7942152|carboplatin_19|not_4|,_16|and_18|restricted_38 (l_prep) of_5\IN\0|NONE_0 (l_pobj) toxicity_6\NN\13576101|NONE_0
D016190_D012175 NONE carboplatin_5\VBP\0|ocular_39|motility_32|._43 (l_prep) for_7\IN\0|after_40|subtenon_34|chemotherapy_13 (l_pobj) retinoblastoma_8\NN\14239425|NONE_0
D016190_D012175 NONE carboplatin_2\NN\0|NONE_0 (l_ccomp) used_7\VBN\0|subtenon_51|._98 (l_prep) as_8\IN\14622893|injections_35|have_24|recently_19|been_10 (l_pobj) adjunct_14\NN\9312645|NONE_0 (l_prep) to_15\IN\0|a_35|free_13 (l_pobj) chemotherapy_17\NN\661091|NONE_0 (l_prep) for_18\IN\0|systemic_22 (l_pobj) retinoblastoma_20\NN\14239425|NONE_0
D016190_D012175 NONE carboplatin_15\NN\0|we_107|motility_82|._11 (r_ccomp) noted_1\VBD\1009240|NONE_0 (l_dobj) motility_4\NN\4773351|we_25|carboplatin_82|._93 (l_prep) in_5\IN\13603305|abnormal_25|ocular_16 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|10_24|consecutive_21 (l_pobj) retinoblastoma_10\NN\14239425|NONE_0
D016190_D012175 NONE carboplatin_24\NN\0|limitation_147|was_117|in_104|._44 (r_advmod) detected_5\VBN\2163746|NONE_0 (l_prep) in_6\IN\13603305|limitation_43|was_13|carboplatin_104|._148 (l_pobj) eyes_9\NNS\5945642|NONE_0 (l_prep) of_10\IN\0|all_12|12_8 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_acl) treated_13\VBN\2376958|10_12 (l_prep) for_14\IN\0|with_31 (l_pobj) retinoblastoma_16\NN\14239425|NONE_0
D016190_D015835 CID carboplatin_14\NN\0|NONE_0 (r_amod) chemotherapy_15\NN\661091|with_26 (r_dobj) treated_11\VBN\2376958|NONE_0 (r_acl) patients_10\NNS\9898892|NONE_0 (r_pobj) in_9\IN\13603305|abnormal_25|ocular_16 (r_prep) motility_8\NN\4773351|NONE_0
D016190_D015835 CID carboplatin_15\NN\0|we_107|motility_82|._11 (r_ccomp) noted_1\VBD\1009240|NONE_0 (l_dobj) motility_4\NN\4773351|we_25|carboplatin_82|._93
9158667
D006493_D013927 NONE heparin_13\NN\2718259|NONE_0 (r_dobj) using_9\VBG\418025|NONE_0 (r_pcomp) by_8\IN\0|events_34|,_28|however_26|,_19|could_17|be_11|._25 (r_prep) avoided_7\VBN\0|NONE_0 (l_nsubjpass) events_1\NNS\23100|,_6|however_8|,_15|could_17|be_23|by_34|._59 (l_amod) thrombotic_0\JJ\0|NONE_0
D014212_D015473 NONE acid_12\NN\14818238|retinoic_9 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) during_6\IN\0|thrombotic_57|in_32|._38 (r_prep) complications_1\NNS\1073995|NONE_0 (l_prep) in_2\IN\13603305|thrombotic_25|during_32|._70 (l_pobj) leukemia_5\NN\14239918|NONE_0
D014212_D015473 NONE acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) in_13\IN\13603305|of_17 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) leukemia_19\NN\14239918|NONE_0
D014212_D015473 NONE acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) in_13\IN\13603305|of_17 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) leukemia_19\NN\14239918|NONE_0 (l_appos) apl_21\NNP\0|acute_30|promyelocytic_24|(_1|)_3
D014212_D015473 NONE atra_32\NNP\0|retinoic_15|and_6|acid_21 (r_appos) acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) in_13\IN\13603305|of_17 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) leukemia_19\NN\14239918|NONE_0
D014212_D015473 NONE atra_32\NNP\0|retinoic_15|and_6|acid_21 (r_appos) acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) in_13\IN\13603305|of_17 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) leukemia_19\NN\14239918|NONE_0 (l_appos) apl_21\NNP\0|acute_30|promyelocytic_24|(_1|)_3
D014212_D015473 NONE atra_14\NNP\0|NONE_0 (r_pobj) with_13\IN\0|alone_10 (r_prep) treated_12\VBN\2376958|an_15|apl_12 (r_acl) patient_11\NN\9898892|NONE_0 (l_compound) apl_10\NNP\0|an_3|treated_12
D014212_D015473 NONE atra_11\NNP\0|in_13 (r_compound) therapy_12\NN\657604|NONE_0 (l_prep) in_13\IN\13603305|atra_13 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_compound) apl_14\NNP\0|NONE_0
D014212_D015473 NONE atra_25\NNP\0|NONE_0 (r_pobj) with_24\IN\0|a_21|treatment_19 (r_prep) protocol_23\NN\6652242|NONE_0 (r_pobj) in_20\IN\13603305|was_13 (r_prep) included_19\VBN\0|patients_81|signs_34|and_8|._42 (r_conj) presented_9\VBD\2137132|NONE_0 (l_dobj) signs_12\NNS\6643763|patients_47|and_26|included_34|._76 (l_prep) of_15\IN\0|all_27|the_23|and_13|symptoms_9 (l_pobj) apl_16\NNP\0|NONE_0
D014212_D015473 NONE atra_3\NNP\0|that_5|choice_28|,_56|corrected_111 (r_nsubj) is_4\VBZ\0|we_22|._115 (l_attr) choice_8\NN\5788149|that_33|atra_28|,_28|corrected_83 (l_prep) for_9\IN\0|a_27|valid_25|therapeutic_19 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) apl_12\NNP\0|NONE_0
D014212_D058186 CID acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_prep) of_2\IN\0|a_7|,_22|due_24|treated_111 (l_pobj) failure_5\NN\66216|NONE_0
D014212_D058186 CID atra_32\NNP\0|retinoic_15|and_6|acid_21 (r_appos) acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_prep) of_2\IN\0|a_7|,_22|due_24|treated_111 (l_pobj) failure_5\NN\66216|NONE_0
D014212_D058186 CID atra_14\NNP\0|NONE_0 (r_pobj) with_13\IN\0|alone_10 (r_prep) treated_12\VBN\2376958|an_15|apl_12 (r_acl) patient_11\NN\9898892|NONE_0 (r_pobj) in_8\IN\13603305|acute_20|renal_14 (r_prep) failure_7\NN\66216|NONE_0
D014212_D013927 CID acid_12\NN\14818238|retinoic_9 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) during_6\IN\0|thrombotic_57|in_32|._38 (r_prep) complications_1\NNS\1073995|NONE_0 (l_amod) thrombotic_0\JJ\0|in_25|during_57|._95
D014148_-1 NONE acid_36\NN\14818238|retinoic_36|atra_21|and_15 (r_conj) acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) of_10\IN\0|in_17 (l_pobj) vessels_12\NNS\5246511|NONE_0
D014148_D015473 NONE acid_36\NN\14818238|retinoic_36|atra_21|and_15 (r_conj) acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) in_13\IN\13603305|of_17 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) leukemia_19\NN\14239918|NONE_0
D014148_D015473 NONE acid_36\NN\14818238|retinoic_36|atra_21|and_15 (r_conj) acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) in_13\IN\13603305|of_17 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) leukemia_19\NN\14239918|NONE_0 (l_appos) apl_21\NNP\0|acute_30|promyelocytic_24|(_1|)_3
D014212_D013923 NONE atra_11\NNP\0|in_13 (r_compound) therapy_12\NN\657604|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|thromboembolic_29 (r_acl) complications_8\NNS\1073995|NONE_0 (l_compound) thromboembolic_7\JJ\0|associated_29
D014212_-1 NONE acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) of_10\IN\0|in_17 (l_pobj) vessels_12\NNS\5246511|NONE_0
D014212_-1 NONE atra_32\NNP\0|retinoic_15|and_6|acid_21 (r_appos) acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_amod) due_7\IN\5174653|a_31|of_24|,_2|treated_87 (l_pobj) occlusion_9\NN\14081375|to_3 (l_prep) of_10\IN\0|in_17 (l_pobj) vessels_12\NNS\5246511|NONE_0
D014148_D058186 NONE acid_36\NN\14818238|retinoic_36|atra_21|and_15 (r_conj) acid_30\NN\14818238|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) treated_23\VBN\2376958|a_118|of_111|,_89|due_87 (r_acl) case_1\NN\7283608|has_180|been_184|recently_199|._207 (l_prep) of_2\IN\0|a_7|,_22|due_24|treated_111 (l_pobj) failure_5\NN\66216|NONE_0
15265979
D000638_D056486 CID amiodarone_0\NNP\2715941|has_65|been_69|cause_86|._123 (r_nsubjpass) reported_12\VBN\831651|NONE_0 (l_xcomp) cause_14\VB\7323922|amiodarone_86|has_21|been_17|._37 (l_dobj) hepatotoxicity_15\NN\0|to_9|in_15
D000638_D056486 CID amiodarone_12\NN\2715941|NONE_0 (r_pobj) of_11\IN\0|the_24|hepatotoxic_20 (r_prep) effects_10\NNS\13245626|NONE_0 (l_amod) hepatotoxic_9\JJ\0|the_4|of_20
D000638_D056486 CID amiodarone_12\NN\2715941|NONE_0 (r_pobj) of_11\IN\0|the_24|hepatotoxic_20 (r_prep) effects_10\NNS\13245626|NONE_0 (r_pobj) regarding_7\VBG\689344|important_38|new_28|mechanistic_24 (r_prep) information_6\NN\6598915|results_42|and_60|indicate_64|._138 (r_dobj) provide_2\VBP\2199590|NONE_0 (l_conj) indicate_14\VBP\952524|results_106|information_64|and_4|._74 (l_ccomp) protects_17\VBZ\1127795|NONE_0 (l_prep) against_18\IN\0|that_24|pparalpha_19 (l_pobj) hepatotoxicity_22\NN\0|NONE_0
D000638_D056486 CID amiodarone_19\NN\2715941|-_10 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) hepatotoxicity_22\NN\0|NONE_0 (r_pobj) against_18\IN\0|that_24|pparalpha_19 (r_prep) protects_17\VBZ\1127795|NONE_0 (r_ccomp) indicate_14\VBP\952524|results_106|information_64|and_4|._74 (r_conj) provide_2\VBP\2199590|NONE_0 (l_dobj) information_6\NN\6598915|results_42|and_60|indicate_64|._138 (l_prep) regarding_7\VBG\689344|important_38|new_28|mechanistic_24 (l_pobj) effects_10\NNS\13245626|NONE_0 (l_amod) hepatotoxic_9\JJ\0|the_4|of_20
D000638_D056486 CID amiodarone_19\NN\2715941|-_10 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) hepatotoxicity_22\NN\0|NONE_0
D014280_D006529 NONE triglycerides_15\NNS\14885088|NONE_0 (r_pobj) in_13\IN\13603305|a_23|significant_21 (r_prep) decrease_12\NN\7296428|amiodarone_97|accumulation_32|,_20|and_18|._43 (r_conj) induced_1\VBD\1627355|NONE_0 (l_dobj) accumulation_7\NN\13497135|amiodarone_65|,_12|and_14|decrease_32|._75 (l_amod) hepatomegaly_2\NN\14501726|,_12|hepatocyte_14|microvesicular_25|lipid_40
D000638_D006529 CID amiodarone_0\NN\2715941|accumulation_65|,_77|and_79|decrease_97|._140 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) accumulation_7\NN\13497135|amiodarone_65|,_12|and_14|decrease_32|._75 (l_amod) hepatomegaly_2\NN\14501726|,_12|hepatocyte_14|microvesicular_25|lipid_40
D005947_D006529 NONE glucose_17\NN\14710501|serum_24|and_4 (r_conj) triglycerides_15\NNS\14885088|NONE_0 (r_pobj) in_13\IN\13603305|a_23|significant_21 (r_prep) decrease_12\NN\7296428|amiodarone_97|accumulation_32|,_20|and_18|._43 (r_conj) induced_1\VBD\1627355|NONE_0 (l_dobj) accumulation_7\NN\13497135|amiodarone_65|,_12|and_14|decrease_32|._75 (l_amod) hepatomegaly_2\NN\14501726|,_12|hepatocyte_14|microvesicular_25|lipid_40
D000638_D006528 NONE amiodarone_3\NN\2715941|NONE_0 (r_pobj) of_2\IN\0|the_14|activate_26 (r_prep) inability_1\NN\23271|transiently_77|in_99 (r_nsubj) expressed_13\VBN\928630|were_114|._127 (l_prep) in_14\IN\13603305|inability_99|transiently_22 (l_pobj) cells_18\NNS\3080309|NONE_0 (l_compound) hepatoma_17\NN\14242337|human_12|hepg2_6
D000638_D006528 NONE amiodarone_24\NN\2715941|NONE_0 (r_pobj) of_23\IN\0|the_12 (r_prep) effects_22\NNS\13245626|that_9|indirect_60 (r_nsubj) were_31\VBD\0|expressed_114|._13 (r_ccomp) indicates_19\VBZ\952524|NONE_0 (l_csubj) expressed_13\VBN\928630|were_114|._127 (l_prep) in_14\IN\13603305|inability_99|transiently_22 (l_pobj) cells_18\NNS\3080309|NONE_0 (l_compound) hepatoma_17\NN\14242337|human_12|hepg2_6
D000638_D015431 NONE amiodarone_12\NN\2715941|NONE_0 (r_pobj) with_11\IN\0|of_21 (r_prep) treatment_7\NN\654885|type_11|,_2 (r_appos) mice_5\NNS\2329401|NONE_0 (r_pobj) to_1\IN\0|NONE_0 (r_prep) compared_0\VBN\644583|in_84|._141 (r_prep) resulted_13\VBD\2633881|NONE_0 (l_prep) in_14\IN\13603305|compared_84|._57 (l_pobj) rate_17\NN\13815152|NONE_0 (l_conj) extent_19\NN\13939892|an_22|increased_19|and_4 (l_prep) of_20\IN\0|NONE_0 (l_pobj) loss_24\NN\13252973|NONE_0
1117341
D015119_D006030 NONE amino_17\JJ\14621446|certain_8|of_18 (r_amod) derivatives_18\NNS\5802185|NONE_0 (r_pobj) of_15\IN\0|small_38|(_24|%_18|)_2 (r_prep) amounts_5\NNS\13329641|NONE_0 (r_pobj) of_3\IN\0|the_20|chronic_16 (r_prep) feeding_2\NN\838098|in_99|._182 (r_nsubj) resulted_21\VBD\2633881|NONE_0 (l_prep) in_22\IN\13603305|feeding_99|._83 (l_pobj) hyperglycemia_23\NN\14299637|NONE_0 (l_appos) curve_29\NN\13863771|,_32 (l_conj) glucosuria_34\NN\14267841|an_55|elevated_52|tolerance_35|and_19|,_16|occasionally_14|,_2
D005947_D006030 NONE glucose_27\NN\14710501|NONE_0 (r_compound) tolerance_28\NN\5032565|an_20|elevated_17|and_16|,_19|occasionally_21|,_33|glucosuria_35 (r_compound) curve_29\NN\13863771|,_32 (l_conj) glucosuria_34\NN\14267841|an_55|elevated_52|tolerance_35|and_19|,_16|occasionally_14|,_2
C037652_D006030 NONE caproate_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|certain_26|amino_18 (r_prep) derivatives_18\NNS\5802185|NONE_0 (r_pobj) of_15\IN\0|small_38|(_24|%_18|)_2 (r_prep) amounts_5\NNS\13329641|NONE_0 (r_pobj) of_3\IN\0|the_20|chronic_16 (r_prep) feeding_2\NN\838098|in_99|._182 (r_nsubj) resulted_21\VBD\2633881|NONE_0 (l_prep) in_22\IN\13603305|feeding_99|._83 (l_pobj) hyperglycemia_23\NN\14299637|NONE_0 (l_appos) curve_29\NN\13863771|,_32 (l_conj) glucosuria_34\NN\14267841|an_55|elevated_52|tolerance_35|and_19|,_16|occasionally_14|,_2
C037652_D006943 NONE caproate_8\NN\0|effect_50|structurally_24|._16 (r_xcomp) related_6\VBN\628491|NONE_0 (l_nsubj) effect_1\NN\34213|structurally_26|caproate_50|._66 (l_amod) hyperglycemic_0\JJ\0|of_21
C037652_D006943 NONE caproate_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|certain_26|amino_18 (r_prep) derivatives_18\NNS\5802185|NONE_0 (r_pobj) of_15\IN\0|small_38|(_24|%_18|)_2 (r_prep) amounts_5\NNS\13329641|NONE_0 (r_pobj) of_3\IN\0|the_20|chronic_16 (r_prep) feeding_2\NN\838098|in_99|._182 (r_nsubj) resulted_21\VBD\2633881|NONE_0 (l_prep) in_22\IN\13603305|feeding_99|._83 (l_pobj) hyperglycemia_23\NN\14299637|NONE_0
D015119_D006943 CID amino_3\JJ\14621446|NONE_0 (r_compound) compounds_4\NNS\5869584|NONE_0 (r_pobj) of_2\IN\0|hyperglycemic_21 (r_prep) effect_1\NN\34213|structurally_26|caproate_50|._66 (l_amod) hyperglycemic_0\JJ\0|of_21
D015119_D006943 CID amino_17\JJ\14621446|certain_8|of_18 (r_amod) derivatives_18\NNS\5802185|NONE_0 (r_pobj) of_15\IN\0|small_38|(_24|%_18|)_2 (r_prep) amounts_5\NNS\13329641|NONE_0 (r_pobj) of_3\IN\0|the_20|chronic_16 (r_prep) feeding_2\NN\838098|in_99|._182 (r_nsubj) resulted_21\VBD\2633881|NONE_0 (l_prep) in_22\IN\13603305|feeding_99|._83 (l_pobj) hyperglycemia_23\NN\14299637|NONE_0
D005947_D006943 NONE glucose_27\NN\14710501|NONE_0 (r_compound) tolerance_28\NN\5032565|an_20|elevated_17|and_16|,_19|occasionally_21|,_33|glucosuria_35 (r_compound) curve_29\NN\13863771|,_32 (r_appos) hyperglycemia_23\NN\14299637|NONE_0
19108278
D011433_D017180 NONE propranolol_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|both_13 (r_prep) isomers_1\NNS\14818238|also_28|capable_33|._126 (r_nsubj) were_4\VBD\0|NONE_0 (l_acomp) capable_6\JJ\0|isomers_33|also_5|._93 (l_prep) of_7\IN\0|NONE_0 (l_pcomp) reversing_8\VBG\109660|NONE_0 (l_dobj) tachycardia_10\NN\14110674|NONE_0
D004837_D001145 CID adrenaline_8\RB\14807929|-_10 (r_advmod) induced_10\VBN\1627355|cardiac_8|in_28 (r_amod) arrhythmias_12\NNS\14103288|NONE_0
D004837_D001145 CID adrenaline.7_13\NNS\0|NONE_0 (r_pobj) of_12\IN\0|the_9 (r_prep) dose_11\NN\3740161|NONE_0 (r_dobj) increasing_9\VBG\169651|NONE_0 (r_pcomp) by_8\IN\0|blockade_59|surmountable_13|._38 (r_prep) was_6\VBD\0|NONE_0 (l_nsubj) blockade_0\NN\952963|surmountable_46|by_59|._97 (l_prep) of_1\IN\0|NONE_0 (l_pobj) arrhythmias_2\NNS\14103288|NONE_0
D010042_D017180 CID ouabain_13\NN\0|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_agent) caused_11\VBN\1617192|ventricular_24 (r_acl) tachycardia_10\NN\14110674|NONE_0
D006221_D001145 CID halothane_17\NN\3570838|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) anaesthetized_15\VBN\84738|NONE_0 (r_acl) cats_14\NNS\2120997|NONE_0 (r_pobj) in_13\IN\13603305|induced_28|cardiac_20 (r_prep) arrhythmias_12\NNS\14103288|NONE_0
D011433_D001145 NONE propranolol_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_20|optical_16|and_15|effects_25 (r_prep) isomers_6\NNS\14818238|NONE_0 (l_conj) effects_11\NNS\13245626|the_45|optical_41|of_25|and_10 (l_prep) on_12\IN\0|their_14 (l_pobj) arrhythmias_14\NNS\14103288|NONE_0
D011433_D001145 NONE propranolol_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|both_13 (r_prep) isomers_1\NNS\14818238|capable_28|,_125|but_127|was_164 (r_nsubj) were_4\VBD\0|NONE_0 (l_acomp) capable_5\JJ\0|isomers_28|,_97|but_99|was_136 (l_prep) of_6\IN\0|NONE_0 (l_pcomp) preventing_7\VBG\0|NONE_0 (l_dobj) arrhythmias_12\NNS\14103288|NONE_0
D011433_D001145 NONE -)-propranolol_25\,\0|NONE_0 (r_pobj) of_23\IN\0|the_14|mean_10 (r_prep) dose_22\NN\3740161|0.09+/-0.02_28|mg/kg_40|was_78|._97 (r_nsubj) was_26\VBD\0|isomers_164|capable_136|,_39|but_37 (r_conj) were_4\VBD\0|NONE_0 (l_acomp) capable_5\JJ\0|isomers_28|,_97|but_99|was_136 (l_prep) of_6\IN\0|NONE_0 (l_pcomp) preventing_7\VBG\0|NONE_0 (l_dobj) arrhythmias_12\NNS\14103288|NONE_0
D011433_D001145 NONE -propranolol_35\,\0|(_3|+_2 (r_conj) of_31\IN\0|NONE_0 (r_prep) that_30\DT\0|whereas_8|4.2+/-1.2_28|mg/kg_38 (r_nsubj) was_36\VBD\0|dose_78|0.09+/-0.02_50|mg/kg_38|._19 (r_advcl) was_26\VBD\0|isomers_164|capable_136|,_39|but_37 (r_conj) were_4\VBD\0|NONE_0 (l_acomp) capable_5\JJ\0|isomers_28|,_97|but_99|was_136 (l_prep) of_6\IN\0|NONE_0 (l_pcomp) preventing_7\VBG\0|NONE_0 (l_dobj) arrhythmias_12\NNS\14103288|NONE_0
1451544
D017275_D005483 CID isradipine_25\NN\0|or_11|with_14 (r_pobj) with_24\IN\0|other_14 (r_prep) studies_23\NNS\635850|NONE_0 (r_pobj) in_21\IN\13603305|than_14 (r_prep) reported_20\VBN\831651|more_19 (r_advcl) frequent_18\JJ\2556126|headache_70|not_9 (r_acomp) were_15\VBD\0|effects_69|._85 (l_nsubj) headache_6\NN\5829480|not_61|frequent_70 (l_conj) dizziness_8\NN\14299637|,_2 (l_conj) palpitation_10\NN\14299637|,_2 (l_conj) flushing_12\NN\281101|and_4|and_9|these_13
D017275_D006261 CID isradipine_25\NN\0|or_11|with_14 (r_pobj) with_24\IN\0|other_14 (r_prep) studies_23\NNS\635850|NONE_0 (r_pobj) in_21\IN\13603305|than_14 (r_prep) reported_20\VBN\831651|more_19 (r_advcl) frequent_18\JJ\2556126|headache_70|not_9 (r_acomp) were_15\VBD\0|effects_69|._85 (l_nsubj) headache_6\NN\5829480|not_61|frequent_70
D017275_D006973 NONE isradipine_0\NNP\0|for_21|._70 (r_compound) treatment_1\NN\654885|NONE_0 (l_prep) for_2\IN\0|isradipine_21|._49 (l_pobj) hypertension_3\NN\14057371|NONE_0
D017275_-1 NONE isradipine_25\NN\0|or_11|with_14 (r_pobj) with_24\IN\0|other_14 (r_prep) studies_23\NNS\635850|NONE_0 (r_pobj) in_21\IN\13603305|than_14 (r_prep) reported_20\VBN\831651|more_19 (r_advcl) frequent_18\JJ\2556126|headache_70|not_9 (r_acomp) were_15\VBD\0|effects_69|._85 (l_nsubj) headache_6\NN\5829480|not_61|frequent_70 (l_conj) dizziness_8\NN\14299637|,_2 (l_conj) palpitation_10\NN\14299637|,_2
D017275_D004244 CID isradipine_25\NN\0|or_11|with_14 (r_pobj) with_24\IN\0|other_14 (r_prep) studies_23\NNS\635850|NONE_0 (r_pobj) in_21\IN\13603305|than_14 (r_prep) reported_20\VBN\831651|more_19 (r_advcl) frequent_18\JJ\2556126|headache_70|not_9 (r_acomp) were_15\VBD\0|effects_69|._85 (l_nsubj) headache_6\NN\5829480|not_61|frequent_70 (l_conj) dizziness_8\NN\14299637|,_2
1395192
D001971_D009203 CID bromocriptine_8\NN\0|NONE_0 (r_dobj) receiving_7\VBG\2210855|a_21|postpartum_19 (r_acl) patient_6\NN\9898892|NONE_0 (r_pobj) in_3\IN\13603305|recurrent_32|myocardial_22|._47 (r_prep) infarction_2\NN\14204950|NONE_0
D001971_D009203 CID bromocriptine_0\NNP\0|has_14|been_18|in_34|._109 (r_nsubjpass) implicated_3\VBN\2677097|NONE_0 (l_prep) in_4\IN\13603305|bromocriptine_34|has_20|been_16|._75 (l_pobj) reports_8\NNS\6470073|NONE_0 (l_prep) of_9\IN\0|several_30|previous_22|case_13 (l_pobj) infarction_11\NN\14204950|NONE_0
3475563
D001507_D002177 NONE beclomethasone_7\NN\0|oral_28|and_12 (r_conj) prednisone_4\NN\2721538|NONE_0 (r_pobj) of_2\IN\0|concomitant_16 (r_prep) use_1\NN\407535|may_50|risk_67|._111 (r_nsubj) increase_9\VB\13576355|NONE_0 (l_dobj) risk_11\NN\14541044|use_67|may_17|._44 (l_prep) of_12\IN\0|the_9 (l_pcomp) developing_13\VBG\13541167|NONE_0 (l_dobj) hoarseness_14\NN\4988666|NONE_0 (l_conj) candidiasis_16\NN\14176895|or_3
D001507_D006685 CID dipropionate_11\NN\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) hoarseness_8\NN\4988666|oral_20|or_3
D001507_D006685 CID beclomethasone_9\NN\0|NONE_0 (r_pobj) on_7\IN\0|who_16|were_12 (r_prep) placed_6\VBN\1850315|158_32|asthmatic_28 (r_relcl) patients_3\NNS\9898892|NONE_0 (r_pobj) of_0\IN\0|hoarseness_96|._140 (r_prep) developed_16\VBD\1753788|NONE_0 (l_dobj) hoarseness_18\NN\4988666|of_96|._44
D001507_D006685 CID beclomethasone_9\NN\0|NONE_0 (r_pobj) on_7\IN\0|that_31|patients_26|may_17|be_13|indicated_42 (r_prep) restarted_6\VBN\1857717|we_33 (r_ccomp) conclude_1\VBP\628491|;_91|however_93|,_100|because_102|should_171|not_178 (r_ccomp) be_29\VB\14625458|-_5 (l_prep) because_16\IN\0|conclude_102|;_11|however_9|,_2|should_69|not_76 (l_pobj) rate_21\NN\13815152|of_23 (l_appos) patients_23\NNS\9898892|the_26|recurrence_17|,_2 (l_relcl) develop_25\VBP\1753788|NONE_0 (l_dobj) hoarseness_26\NN\4988666|who_12
D001507_D006685 CID beclomethasone_7\NN\0|oral_28|and_12 (r_conj) prednisone_4\NN\2721538|NONE_0 (r_pobj) of_2\IN\0|concomitant_16 (r_prep) use_1\NN\407535|may_50|risk_67|._111 (r_nsubj) increase_9\VB\13576355|NONE_0 (l_dobj) risk_11\NN\14541044|use_67|may_17|._44 (l_prep) of_12\IN\0|the_9 (l_pcomp) developing_13\VBG\13541167|NONE_0 (l_dobj) hoarseness_14\NN\4988666|NONE_0
D001507_D002180 CID dipropionate_11\NN\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) hoarseness_8\NN\4988666|oral_20|or_3 (r_conj) candidiasis_6\NN\14176895|who_19
D001507_D002180 CID beclomethasone_9\NN\0|NONE_0 (r_pobj) on_7\IN\0|who_16|were_12 (r_prep) placed_6\VBN\1850315|158_32|asthmatic_28 (r_relcl) patients_3\NNS\9898892|NONE_0 (r_pobj) of_0\IN\0|hoarseness_96|._140 (r_prep) developed_16\VBD\1753788|NONE_0 (l_dobj) hoarseness_18\NN\4988666|of_96|._44 (l_appos) 8)_20\CD\0|either_19|(_1 (l_appos) thrush_23\NN\14181713|,_7
D001507_D001249 NONE beclomethasone_9\NN\0|NONE_0 (r_pobj) on_7\IN\0|who_16|were_12 (r_prep) placed_6\VBN\1850315|158_32|asthmatic_28 (r_relcl) patients_3\NNS\9898892|NONE_0 (l_amod) asthmatic_2\JJ\7846|158_4|placed_28
D011241_D006685 NONE prednisone_4\NN\2721538|NONE_0 (r_pobj) of_2\IN\0|concomitant_16 (r_prep) use_1\NN\407535|may_50|risk_67|._111 (r_nsubj) increase_9\VB\13576355|NONE_0 (l_dobj) risk_11\NN\14541044|use_67|may_17|._44 (l_prep) of_12\IN\0|the_9 (l_pcomp) developing_13\VBG\13541167|NONE_0 (l_dobj) hoarseness_14\NN\4988666|NONE_0
D011241_D002177 NONE prednisone_4\NN\2721538|NONE_0 (r_pobj) of_2\IN\0|concomitant_16 (r_prep) use_1\NN\407535|may_50|risk_67|._111 (r_nsubj) increase_9\VB\13576355|NONE_0 (l_dobj) risk_11\NN\14541044|use_67|may_17|._44 (l_prep) of_12\IN\0|the_9 (l_pcomp) developing_13\VBG\13541167|NONE_0 (l_dobj) hoarseness_14\NN\4988666|NONE_0 (l_conj) candidiasis_16\NN\14176895|or_3
11799346
D008795_D001714 CID metronidazole_2\NNP\2723292|,_2 (r_conj) cotrimoxazole_0\NNP\0|were_47|in_61|._90 (r_nsubjpass) involved_7\VBN\2676054|NONE_0 (l_prep) in_8\IN\13603305|cotrimoxazole_61|were_14|._29 (l_pobj) episodes_12\NNS\7283608|NONE_0 (l_amod) manic_11\JJ\0|15_12|reported_9
D004917_D001714 CID erythromycin_5\NN\2716866|,_6|and_4 (r_conj) metronidazole_2\NNP\2723292|,_2 (r_conj) cotrimoxazole_0\NNP\0|were_47|in_61|._90 (r_nsubjpass) involved_7\VBN\2676054|NONE_0 (l_prep) in_8\IN\13603305|cotrimoxazole_61|were_14|._29 (l_pobj) episodes_12\NNS\7283608|NONE_0 (l_amod) manic_11\JJ\0|15_12|reported_9
D017291_D001714 CID clarithromycin_6\NN\0|cases_33|be_36|._99 (r_dobj) showed_5\VBD\2137132|NONE_0 (l_xcomp) be_10\VB\14625458|cases_69|clarithromycin_36|._63 (l_attr) the_11\DT\0|to_6 (l_acl) associated_14\VBN\628491|NONE_0 (l_prep) with_15\IN\0|frequently_22 (l_pobj) development_17\NN\248977|NONE_0 (l_prep) of_18\IN\0|the_16 (l_pobj) mania_19\NN\9180259|NONE_0
D015662_D001714 CID cotrimoxazole_0\NNP\0|were_47|in_61|._90 (r_nsubjpass) involved_7\VBN\2676054|NONE_0 (l_prep) in_8\IN\13603305|cotrimoxazole_61|were_14|._29 (l_pobj) episodes_12\NNS\7283608|NONE_0 (l_amod) manic_11\JJ\0|15_12|reported_9
D002939_D001714 CID ciprofloxacin_8\NNS\2716866|and_4 (r_conj) clarithromycin_6\NN\0|cases_33|be_36|._99 (r_dobj) showed_5\VBD\2137132|NONE_0 (l_xcomp) be_10\VB\14625458|cases_69|clarithromycin_36|._63 (l_attr) the_11\DT\0|to_6 (l_acl) associated_14\VBN\628491|NONE_0 (l_prep) with_15\IN\0|frequently_22 (l_pobj) development_17\NN\248977|NONE_0 (l_prep) of_18\IN\0|the_16 (l_pobj) mania_19\NN\9180259|NONE_0
10764869
D016559_D015354 NONE tacrolimus_8\NN\0|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) discontinuation_5\NN\209943|NONE_0 (r_pobj) despite_4\IN\7501545|deterioration_33|._41 (r_prep) occurred_3\VBD\0|NONE_0 (l_nsubj) deterioration_0\NN\14560612|despite_33|._74 (l_prep) of_1\IN\0|NONE_0 (l_pobj) vision_2\NN\5767733|NONE_0
D016559_D009901 CID tacrolimus_10\NN\0|NONE_0 (r_pobj) on_9\IN\0|a_10 (r_prep) patient_8\NN\9898892|NONE_0 (r_pobj) in_6\IN\13603305|a_37|of_30|after_43|._70 (r_prep) case_1\NN\7283608|NONE_0 (l_prep) of_2\IN\0|a_7|in_30|after_73|._100 (l_pobj) neuropathy_5\NN\14204950|NONE_0
D016559_D009901 CID fk506_12\NNP\0|(_1|)_5|therapy_7 (r_appos) tacrolimus_10\NN\0|NONE_0 (r_pobj) on_9\IN\0|a_10 (r_prep) patient_8\NN\9898892|NONE_0 (r_pobj) in_6\IN\13603305|a_37|of_30|after_43|._70 (r_prep) case_1\NN\7283608|NONE_0 (l_prep) of_2\IN\0|a_7|in_30|after_73|._100 (l_pobj) neuropathy_5\NN\14204950|NONE_0
D016559_D009901 CID tacrolimus_12\NN\0|NONE_0 (r_dobj) receiving_11\NN\2210855|a_10 (r_acl) patient_10\NN\9898892|NONE_0 (r_pobj) in_8\IN\13603305|a_37|of_30|)_90|for_92 (r_prep) case_3\NN\7283608|to_12|._188 (l_prep) of_4\IN\0|a_7|in_30|)_120|for_122 (l_pobj) neuropathy_7\NN\14204950|NONE_0
D016559_D009901 CID 506_15\CD\0|,_3|prograf_5 (r_nummod) fk_14\NNP\0|(_1|;_15|usa_26 (r_appos) tacrolimus_12\NN\0|NONE_0 (r_dobj) receiving_11\NN\2210855|a_10 (r_acl) patient_10\NN\9898892|NONE_0 (r_pobj) in_8\IN\13603305|a_37|of_30|)_90|for_92 (r_prep) case_3\NN\7283608|to_12|._188 (l_prep) of_4\IN\0|a_7|in_30|)_120|for_122 (l_pobj) neuropathy_7\NN\14204950|NONE_0
D016559_D009901 CID tacrolimus_0\NNP\0|may_46|be_50|with_64|._89 (r_nsubjpass) associated_7\VBN\628491|NONE_0 (l_prep) with_8\IN\0|tacrolimus_64|may_18|be_14|._25 (l_pobj) toxicity_11\NN\13576101|NONE_0
24595967
D018817_D008569 CID ecstasy_5\NN\13985818|NONE_0 (r_compound) users_6\NNS\7846|NONE_0 (r_pobj) in_4\IN\13603305|dysfunctional_45|overnight_31|memory_21|._16 (r_prep) consolidation_3\NN\7373803|NONE_0 (l_compound) memory_2\NN\5926676|dysfunctional_24|overnight_10|in_21|._37
D018817_D008569 CID ecstasy_0\NNP\13985818|NONE_0 (r_compound) users_1\NNS\7846|consolidation_45|._129 (r_nsubj) demonstrated_2\VBD\2137132|NONE_0 (l_dobj) consolidation_6\NN\7373803|users_45|._84 (l_compound) memory_5\NN\5926676|impaired_19|overnight_10|,_20|finding_24
D018817_D008569 CID ecstasy_3\NN\13985818|-_7 (r_npadvmod) associated_5\VBN\628491|that_13|in_23 (r_amod) dysfunction_6\NN\14204950|may_41|impairments_85 (r_nsubj) underlie_13\VB\2604760|we_80|._76 (l_dobj) impairments_17\NNS\7296428|dysfunction_85|may_44
D018817_D008569 CID ecstasy_20\NN\13985818|regular_8 (r_compound) users_21\NNS\7846|NONE_0 (r_pobj) in_18\IN\13603305|overnight_43|memory_19 (r_prep) impairments_17\NNS\7296428|dysfunction_85|may_44
D018817_D012893 CID ecstasy_4\NN\13985818|NONE_0 (r_compound) users_5\NNS\7846|that_13|have_6|and_18|impairments_66 (r_nsubj) marked_7\VBN\1296462|studies_41|._66 (l_conj) impairments_15\NNS\7296428|that_79|users_66|have_60|and_48
48835
D011433_D007003 NONE propranolol_2\NN\0|NONE_0 (l_prep) of_3\IN\0|NONE_0 (l_pobj) effects_5\NNS\13245626|NONE_0 (l_prep) of_6\IN\0|cardiovascular_23 (l_pobj) hypoglycaemia_8\NN\14299637|NONE_0
17572393
D008550_D054220 NONE melatonin_3\NN\5407119|NONE_0 (r_pobj) of_2\IN\0|neuroprotective_24|upon_13|._101 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) upon_4\IN\0|neuroprotective_37|of_13|._88 (l_pobj) cortex_8\NN\5462674|NONE_0 (l_prep) in_9\IN\13603305|the_32|offspring_28|cerebellar_18 (l_pobj) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|the_14|rat_10 (l_pobj) dysplasia_18\NN\14501726|NONE_0
D008550_D054220 NONE melatonin_10\NN\5407119|NONE_0 (l_prep) upon_11\IN\0|exogenous_20 (l_pobj) dysplasia_17\NN\14501726|NONE_0
D002330_D054220 CID bcnu_14\NNP\0|-_4 (r_npadvmod) induced_16\VBN\1627355|cortical_8 (r_amod) dysplasia_18\NN\14501726|NONE_0
D002330_D054220 CID bcnu_1\NNP\0|NONE_0 (l_conj) investigate_5\VB\644583|(_14|)_9|and_7|._139 (l_dobj) effects_7\NNS\13245626|to_19|,_78|using_80 (l_prep) of_8\IN\0|the_12 (l_pobj) melatonin_10\NN\5407119|NONE_0 (l_prep) upon_11\IN\0|exogenous_20 (l_pobj) dysplasia_17\NN\14501726|NONE_0
D002330_D054220 CID bcnu_13\NNP\0|-_4 (r_npadvmod) induced_15\VBN\1627355|cerebellar_16|cortical_8 (r_amod) dysplasia_17\NN\14501726|NONE_0
D002330_D054220 CID bcnu_25\NNP\0|-_4 (r_npadvmod) exposed_27\VBN\2110927|cortical_8|dysplasia_17 (r_amod) group_30\NN\2137|NONE_0 (l_compound) dysplasia_29\NN\14501726|exposed_17|cortical_9
12677626
D002045_D066126 NONE bupivacaine_11\NN\0|NONE_0 (r_pobj) than_9\IN\0|a_33|safer_31|toxicity_17 (r_prep) profile_8\NN\6999802|although_59|levobupivacaine_50|may_34 (l_compound) toxicity_7\NN\13576101|a_16|safer_14|than_17
C476513_D066126 NONE levobupivacaine_1\PRP\0|although_9|may_16|profile_50 (r_nsubj) have_3\VB\7846|,_62|reach_103|,_124|it_126|will_129|in_141|._155 (l_dobj) profile_8\NN\6999802|although_59|levobupivacaine_50|may_34 (l_compound) toxicity_7\NN\13576101|a_16|safer_14|than_17
C476513_D066126 NONE levobupivacaine_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|adequate_17 (r_prep) amounts_15\NNS\13329641|if_12|circulation_37 (r_nsubj) reach_18\VBP\8593130|have_103|,_41|,_21|it_23|will_26|in_38|._52 (r_advcl) result_24\VB\34213|NONE_0 (l_advcl) have_3\VB\7846|,_62|reach_103|,_124|it_126|will_129|in_141|._155 (l_dobj) profile_8\NN\6999802|although_59|levobupivacaine_50|may_34 (l_compound) toxicity_7\NN\13576101|a_16|safer_14|than_17
C476513_D012640 NONE levobupivacaine_1\PRP\0|although_9|may_16|profile_50 (r_nsubj) have_3\VB\7846|,_62|reach_103|,_124|it_126|will_129|in_141|._155 (r_advcl) result_24\VB\34213|NONE_0 (l_prep) in_25\IN\13603305|have_141|,_79|reach_38|,_17|it_15|will_12|._14 (l_pobj) convulsions_26\NNS\14081375|NONE_0
C476513_D012640 NONE levobupivacaine_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|adequate_17 (r_prep) amounts_15\NNS\13329641|if_12|circulation_37 (r_nsubj) reach_18\VBP\8593130|have_103|,_41|,_21|it_23|will_26|in_38|._52 (r_advcl) result_24\VB\34213|NONE_0 (l_prep) in_25\IN\13603305|have_141|,_79|reach_38|,_17|it_15|will_12|._14 (l_pobj) convulsions_26\NNS\14081375|NONE_0
C476513_D020258 NONE levobupivacaine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_19 (r_prep) administration_6\NN\1133281|NONE_0 (r_dobj) following_4\VBG\8180190|central_32|system_16|:_71|report_75|._94 (r_prep) toxicity_3\NN\13576101|NONE_0
D013390_D012640 NONE succinylcholine_11\NN\3800001|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) addition_9\NN\3081021|NONE_0 (r_pobj) in_8\IN\13603305|seizures_58|were_49|successfully_44|with_23|._43 (r_prep) treated_4\VBN\2376958|NONE_0 (l_nsubjpass) seizures_1\NNS\14081375|were_9|successfully_14|with_35|in_58|._101
D002045_D012640 NONE bupivacaine_11\NN\0|NONE_0 (r_pobj) than_9\IN\0|a_33|safer_31|toxicity_17 (r_prep) profile_8\NN\6999802|although_59|levobupivacaine_50|may_34 (r_dobj) have_3\VB\7846|,_62|reach_103|,_124|it_126|will_129|in_141|._155 (r_advcl) result_24\VB\34213|NONE_0 (l_prep) in_25\IN\13603305|have_141|,_79|reach_38|,_17|it_15|will_12|._14 (l_pobj) convulsions_26\NNS\14081375|NONE_0
C476513_D004830 CID levobupivacaine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|accidental_35|intravascular_24 (r_prep) injection_11\NN\320852|NONE_0 (r_pobj) following_8\VBG\8180190|we_42|cases_28|._63 (r_prep) describe_1\VBP\1001294|NONE_0 (l_dobj) cases_3\NNS\7283608|we_14|following_28|._91 (l_prep) of_4\IN\0|2_8 (l_pobj) seizures_7\NNS\14081375|NONE_0
C476513_D004830 CID levobupivacaine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_19|%_22 (r_prep) administration_3\NN\1133281|NONE_0 (r_pobj) after_1\IN\0|immediately_12|,_82|patients_88|seizures_117|,_125|despite_127|._228 (r_prep) developed_17\VBD\1753788|NONE_0 (l_dobj) seizures_20\NNS\14081375|immediately_129|after_117|,_35|patients_29|,_8|despite_10|._111
D013874_D012640 NONE thiopental_7\VBN\2792049|NONE_0 (r_pobj) with_5\IN\0|seizures_35|were_26|successfully_21|in_23|._66 (r_prep) treated_4\VBN\2376958|NONE_0 (l_nsubjpass) seizures_1\NNS\14081375|were_9|successfully_14|with_35|in_58|._101
D004837_D004830 NONE epinephrine_9\NN\14807929|microgram_16|/_25 (r_nmod) ml_13\NNP\13616054|NONE_0 (r_pobj) with_8\IN\0|0.5_5 (r_prep) %_7\NN\0|the_41|of_22 (r_appos) administration_3\NN\1133281|NONE_0 (r_pobj) after_1\IN\0|immediately_12|,_82|patients_88|seizures_117|,_125|despite_127|._228 (r_prep) developed_17\VBD\1753788|NONE_0 (l_dobj) seizures_20\NNS\14081375|immediately_129|after_117|,_35|patients_29|,_8|despite_10|._111
D004837_D004830 NONE epinephrine_33\NN\14807929|intravenous_12 (r_compound) administration_34\NN\1133281|NONE_0 (r_pobj) of_31\IN\0|no_18|clinical_15 (r_prep) signs_30\NNS\6643763|negative_46|for_26|and_16 (r_conj) aspiration_24\NN\4836268|NONE_0 (r_pobj) despite_22\IN\7501545|immediately_139|after_127|,_45|patients_39|seizures_10|,_2|._101 (r_prep) developed_17\VBD\1753788|NONE_0 (l_dobj) seizures_20\NNS\14081375|immediately_129|after_117|,_35|patients_29|,_8|despite_10|._111
7727612
D008140_D009207 CID lorazepam_3\NN\2830852|NONE_0 (r_amod) therapy_4\NN\657604|NONE_0 (r_pobj) with_2\IN\0|in_23 (r_prep) associated_1\VBN\628491|._66 (r_acl) myoclonus_0\NNP\14360459|NONE_0
D008140_D009207 CID lorazepam_19\NN\2830852|NONE_0 (r_pobj) of_18\IN\0|the_31|intravenous_27 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) following_14\VBG\8180190|NONE_0 (r_prep) myoclonus_13\NN\14360459|infants_52|._63
17543491
19293073
D001241_D002318 NONE aspirin_24\NN\2707683|NONE_0 (r_pobj) of_23\IN\0|systematic_19|for_26 (r_prep) reviews_22\NNS\5733583|meta_30|-_26|;_17|and_15 (l_prep) for_27\IN\0|systematic_45|of_26 (l_pobj) prevention_30\NN\1073995|NONE_0 (l_prep) of_31\IN\0|the_23|primary_19 (l_pobj) disease_33\NN\14061805|NONE_0
D001241_D002318 NONE aspirin_24\NN\2707683|NONE_0 (r_pobj) of_23\IN\0|systematic_19|for_26 (r_prep) reviews_22\NNS\5733583|meta_30|-_26|;_17|and_15 (l_prep) for_27\IN\0|systematic_45|of_26 (l_pobj) prevention_30\NN\1073995|NONE_0 (l_prep) of_31\IN\0|the_23|primary_19 (l_pobj) disease_33\NN\14061805|NONE_0 (l_appos) cvd_35\NN\0|cardiovascular_24
D001241_D002318 NONE aspirin_24\NN\2707683|NONE_0 (r_pobj) of_23\IN\0|systematic_19|for_26 (r_prep) reviews_22\NNS\5733583|meta_30|-_26|;_17|and_15 (r_conj) analyses_18\NNS\633864|control_22|;_7 (r_conj) studies_14\NNS\635850|language_60|randomized_51|,_41|controlled_39|(_21|rcts_20|)_16|;_15 (r_conj) trials_6\NNS\786195|were_160|answer_177 (r_nsubjpass) selected_38\VBN\697589|:_42|does_44|aspirin_49|events_81|?_192 (r_ccomp) decrease_47\NN\7296428|NONE_0 (l_dobj) events_50\NNS\23100|selected_81|:_39|does_37|aspirin_32|?_111 (l_conj) strokes_52\NNS\556313|coronary_23|heart_14|,_2 (l_conj) death_54\NN\7296428|,_2 (l_conj) mortality_66\NN\5054863|from_51|,_15|or_13 (l_prep) in_67\IN\13603305|cause_16 (l_pobj) adults_68\NNS\7846|NONE_0 (l_prep) without_69\IN\0|NONE_0 (l_pobj) cvd_71\NN\0|NONE_0
D001241_D002318 NONE aspirin_46\NN\2707683|selected_49|:_7|does_5|events_32|?_143 (r_nsubj) decrease_47\NN\7296428|NONE_0 (l_ccomp) selected_38\VBN\697589|:_42|does_44|aspirin_49|events_81|?_192 (l_nsubjpass) trials_6\NNS\786195|were_160|answer_177 (l_conj) studies_14\NNS\635850|language_60|randomized_51|,_41|controlled_39|(_21|rcts_20|)_16|;_15 (l_conj) analyses_18\NNS\633864|control_22|;_7 (l_conj) reviews_22\NNS\5733583|meta_30|-_26|;_17|and_15 (l_prep) for_27\IN\0|systematic_45|of_26 (l_pobj) prevention_30\NN\1073995|NONE_0 (l_prep) of_31\IN\0|the_23|primary_19 (l_pobj) disease_33\NN\14061805|NONE_0
D001241_D002318 NONE aspirin_46\NN\2707683|selected_49|:_7|does_5|events_32|?_143 (r_nsubj) decrease_47\NN\7296428|NONE_0 (l_ccomp) selected_38\VBN\697589|:_42|does_44|aspirin_49|events_81|?_192 (l_nsubjpass) trials_6\NNS\786195|were_160|answer_177 (l_conj) studies_14\NNS\635850|language_60|randomized_51|,_41|controlled_39|(_21|rcts_20|)_16|;_15 (l_conj) analyses_18\NNS\633864|control_22|;_7 (l_conj) reviews_22\NNS\5733583|meta_30|-_26|;_17|and_15 (l_prep) for_27\IN\0|systematic_45|of_26 (l_pobj) prevention_30\NN\1073995|NONE_0 (l_prep) of_31\IN\0|the_23|primary_19 (l_pobj) disease_33\NN\14061805|NONE_0 (l_appos) cvd_35\NN\0|cardiovascular_24
D001241_D002318 NONE aspirin_46\NN\2707683|selected_49|:_7|does_5|events_32|?_143 (r_nsubj) decrease_47\NN\7296428|NONE_0 (l_dobj) events_50\NNS\23100|selected_81|:_39|does_37|aspirin_32|?_111 (l_conj) strokes_52\NNS\556313|coronary_23|heart_14|,_2 (l_conj) death_54\NN\7296428|,_2 (l_conj) mortality_66\NN\5054863|from_51|,_15|or_13 (l_prep) in_67\IN\13603305|cause_16 (l_pobj) adults_68\NNS\7846|NONE_0 (l_prep) without_69\IN\0|NONE_0 (l_pobj) cvd_71\NN\0|NONE_0
D001241_D002318 NONE aspirin_27\JJ\2707683|NONE_0 (r_compound) use_28\NN\407535|that_13|number_16 (r_nsubj) reduces_29\VBZ\441445|evidence_133|._62 (l_dobj) number_31\NN\5107765|that_29|use_16 (l_prep) of_32\IN\0|the_11 (l_pobj) events_34\NNS\23100|NONE_0 (l_compound) cvd_33\NN\0|in_11
D001241_D002318 NONE aspirin_27\JJ\2707683|NONE_0 (r_compound) use_28\NN\407535|that_13|number_16 (r_nsubj) reduces_29\VBZ\441445|evidence_133|._62 (l_dobj) number_31\NN\5107765|that_29|use_16 (l_prep) of_32\IN\0|the_11 (l_pobj) events_34\NNS\23100|NONE_0 (l_prep) in_35\IN\13603305|cvd_11 (l_pobj) patients_36\NNS\9898892|NONE_0 (l_prep) without_37\IN\0|NONE_0 (l_pobj) cvd_39\NNP\0|NONE_0
D001241_D002318 NONE aspirin_0\NNP\2707683|does_8|not_13|affect_25|._91 (r_nsubj) seem_3\VB\2604760|NONE_0 (l_xcomp) affect_5\VB\26192|aspirin_25|does_17|not_12|._66 (l_dobj) mortality_7\NN\5054863|to_14 (l_compound) cvd_6\NN\0|or_14|mortality_27
D001241_D002318 NONE aspirin_3\NN\2707683|NONE_0 (l_prep) for_4\IN\0|NONE_0 (l_pobj) prevention_7\NN\1073995|NONE_0 (l_prep) of_8\IN\0|the_23|primary_19 (l_pobj) cvd_9\NNP\0|NONE_0
D001241_D020300 CID aspirin_1\NN\2707683|does_5|strokes_58|?_65 (r_nsubj) increase_2\VB\13576355|NONE_0 (l_dobj) strokes_7\NNS\556313|does_63|aspirin_58|?_7
D001241_D020300 CID aspirin_9\JJ\2707683|NONE_0 (r_compound) use_10\NN\407535|NONE_0 (r_pobj) with_8\IN\0|hemorrhagic_20 (r_prep) strokes_7\NNS\556313|NONE_0
D001241_D020521 CID aspirin_8\NN\2707683|for_8 (r_dobj) taking_7\VBG\37396|NONE_0 (l_prep) for_9\IN\0|aspirin_8 (l_pobj) prevention_12\NN\1073995|NONE_0 (l_prep) of_13\IN\0|the_23|primary_19 (l_pobj) infarctions_15\NNS\14204950|NONE_0 (l_conj) strokes_17\NNS\556313|myocardial_24|,_2
D001241_D020521 CID aspirin_24\NN\2707683|NONE_0 (r_pobj) of_23\IN\0|systematic_19|for_26 (r_prep) reviews_22\NNS\5733583|meta_30|-_26|;_17|and_15 (r_conj) analyses_18\NNS\633864|control_22|;_7 (r_conj) studies_14\NNS\635850|language_60|randomized_51|,_41|controlled_39|(_21|rcts_20|)_16|;_15 (r_conj) trials_6\NNS\786195|were_160|answer_177 (r_nsubjpass) selected_38\VBN\697589|:_42|does_44|aspirin_49|events_81|?_192 (r_ccomp) decrease_47\NN\7296428|NONE_0 (l_dobj) events_50\NNS\23100|selected_81|:_39|does_37|aspirin_32|?_111 (l_conj) strokes_52\NNS\556313|coronary_23|heart_14|,_2
D001241_D020521 CID aspirin_24\NN\2707683|NONE_0 (r_pobj) of_23\IN\0|systematic_19|for_26 (r_prep) reviews_22\NNS\5733583|meta_30|-_26|;_17|and_15 (r_conj) analyses_18\NNS\633864|control_22|;_7 (r_conj) studies_14\NNS\635850|language_60|randomized_51|,_41|controlled_39|(_21|rcts_20|)_16|;_15 (r_conj) trials_6\NNS\786195|were_160|answer_177 (r_nsubjpass) selected_38\VBN\697589|:_42|does_44|aspirin_49|events_81|?_192 (r_ccomp) decrease_47\NN\7296428|NONE_0 (l_dobj) events_50\NNS\23100|selected_81|:_39|does_37|aspirin_32|?_111 (l_conj) strokes_52\NNS\556313|coronary_23|heart_14|,_2 (l_conj) death_54\NN\7296428|,_2 (l_prep) from_55\IN\0|,_36|or_38|mortality_51 (l_pobj) events_58\NNS\23100|NONE_0 (l_conj) stroke_60\NN\556313|coronary_25|heart_16|or_3
D001241_D020521 CID aspirin_46\NN\2707683|selected_49|:_7|does_5|events_32|?_143 (r_nsubj) decrease_47\NN\7296428|NONE_0 (l_dobj) events_50\NNS\23100|selected_81|:_39|does_37|aspirin_32|?_111 (l_conj) strokes_52\NNS\556313|coronary_23|heart_14|,_2
D001241_D020521 CID aspirin_46\NN\2707683|selected_49|:_7|does_5|events_32|?_143 (r_nsubj) decrease_47\NN\7296428|NONE_0 (l_dobj) events_50\NNS\23100|selected_81|:_39|does_37|aspirin_32|?_111 (l_conj) strokes_52\NNS\556313|coronary_23|heart_14|,_2 (l_conj) death_54\NN\7296428|,_2 (l_prep) from_55\IN\0|,_36|or_38|mortality_51 (l_pobj) events_58\NNS\23100|NONE_0 (l_conj) stroke_60\NN\556313|coronary_25|heart_16|or_3
D001241_D020521 CID aspirin_1\NN\2707683|does_5|strokes_58|?_65 (r_nsubj) increase_2\VB\13576355|NONE_0 (l_dobj) strokes_7\NNS\556313|does_63|aspirin_58|?_7
D001241_D020521 CID aspirin_9\JJ\2707683|NONE_0 (r_compound) use_10\NN\407535|NONE_0 (r_pobj) with_8\IN\0|hemorrhagic_20 (r_prep) strokes_7\NNS\556313|NONE_0
D001241_D020521 CID aspirin_0\NNP\2707683|risk_20|._78 (r_nsubj) reduces_1\VBZ\441445|NONE_0 (l_dobj) risk_3\NN\14541044|aspirin_20|._58 (l_prep) for_4\IN\0|the_9 (l_pobj) infarction_6\NN\14204950|NONE_0 (l_prep) in_7\IN\13603305|myocardial_22 (l_pobj) men_8\NNS\8208016|NONE_0 (l_conj) strokes_10\NNS\556313|and_4|in_8
D001241_D003327 NONE aspirin_17\NN\2707683|that_24|clinicians_19|with_8 (r_dobj) discuss_16\VB\7466557|in_95|,_88|uspstf_45|strongly_37|._80 (l_prep) with_18\IN\0|that_32|clinicians_27|aspirin_8 (l_pobj) adults_19\NNS\7846|NONE_0 (l_relcl) are_21\VBP\13600404|NONE_0 (l_prep) at_22\IN\14622893|who_8 (l_pobj) risk_24\NN\14541044|NONE_0 (l_prep) for_25\IN\0|increased_15 (l_pobj) disease_28\NN\14061805|NONE_0
D001241_D006471 CID aspirin_1\NN\2707683|does_5|strokes_58|?_65 (r_nsubj) increase_2\VB\13576355|NONE_0 (l_dobj) strokes_7\NNS\556313|does_63|aspirin_58|?_7 (l_nmod) bleeding_4\NN\14285662|NONE_0
D001241_D006471 CID aspirin_3\NN\2707683|NONE_0 (r_pobj) of_2\IN\0|the_8|for_11 (r_prep) use_1\NN\407535|risk_52|._149 (r_nsubj) increases_7\VBZ\13576355|NONE_0 (l_dobj) risk_9\NN\14541044|use_52|._97 (l_prep) for_10\IN\0|the_9 (l_pobj) events_13\NNS\23100|NONE_0 (l_appos) events_18\NNS\23100|major_59|bleeding_53|,_38|,_6|in_8 (l_compound) bleeding_17\NN\14285662|gastrointestinal_17
D001241_D009203 NONE aspirin_8\NN\2707683|for_8 (r_dobj) taking_7\VBG\37396|NONE_0 (l_prep) for_9\IN\0|aspirin_8 (l_pobj) prevention_12\NN\1073995|NONE_0 (l_prep) of_13\IN\0|the_23|primary_19 (l_pobj) infarctions_15\NNS\14204950|NONE_0
D001241_D009203 NONE aspirin_0\NNP\2707683|risk_20|._78 (r_nsubj) reduces_1\VBZ\441445|NONE_0 (l_dobj) risk_3\NN\14541044|aspirin_20|._58 (l_prep) for_4\IN\0|the_9 (l_pobj) infarction_6\NN\14204950|NONE_0
D001241_D006470 NONE aspirin_3\NN\2707683|NONE_0 (r_pobj) of_2\IN\0|the_8|for_11 (r_prep) use_1\NN\407535|risk_52|._149 (r_nsubj) increases_7\VBZ\13576355|NONE_0 (l_dobj) risk_9\NN\14541044|use_52|._97 (l_prep) for_10\IN\0|the_9 (l_pobj) events_13\NNS\23100|NONE_0 (l_compound) bleeding_12\NN\14285662|major_6|,_15|events_53|,_59|in_61
D001241_D006470 NONE aspirin_0\NNP\2707683|NONE_0 (r_compound) use_1\NN\407535|risk_18|._50 (r_nsubj) increases_2\VBZ\13576355|NONE_0 (l_dobj) risk_4\NN\14541044|use_18|._32 (l_prep) for_5\IN\0|the_9 (l_pobj) events_8\NNS\23100|NONE_0 (l_compound) bleeding_7\NN\14285662|serious_8
3125850
D015760_D005207 NONE alfentanil_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_prep) inhibition_13\NN\1068773|induced_43|muscle_35|in_13|:_2 (r_appos) fasciculations_9\NNS\14361664|NONE_0
D015760_D005207 NONE alfentanil_19\NN\0|the_4 (r_compound) group_20\NN\2137|NONE_0 (r_pobj) in_17\IN\13603305|NONE_0 (r_prep) than_16\IN\0|significantly_37|in_15 (r_prep) greater_12\JJR\0|incidence_92|._51 (r_acomp) were_10\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|greater_92|._143 (l_conj) intensity_3\NN\5090441|the_18|and_4 (l_prep) of_4\IN\0|NONE_0 (l_pobj) fasciculations_6\NNS\14361664|NONE_0
D015760_D005207 NONE alfentanil_26\NN\0|the_4 (r_compound) group_27\NN\2137|NONE_0 (r_pobj) in_24\IN\13603305|NONE_0 (r_prep) than_23\IN\0|pressure_110|higher_54|in_47 (r_prep) was_6\VBD\0|NONE_0 (l_nsubj) pressure_2\NN\11419404|higher_56|in_63|than_110 (l_prep) during_3\IN\0|the_26|intragastric_22 (l_pobj) fasciculations_5\NNS\14361664|NONE_0
D015760_D005207 NONE alfentanil_0\NNP\0|kg-1_25|effectively_30|incidence_55 (r_dep) inhibits_5\VBZ\2510337|;_83|moreover_85|,_93|pressure_108|at_125|._145 (l_dobj) incidence_7\NN\13821570|alfentanil_55|kg-1_30|effectively_25 (l_prep) of_10\IN\0|the_28|and_14|intensity_10 (l_pobj) fasciculations_15\NNS\14361664|NONE_0
D013390_D005207 CID suxamethonium_5\NN\0|NONE_0 (r_npadvmod) induced_7\VBN\1627355|muscle_8|in_30|:_41|inhibition_43 (r_amod) fasciculations_9\NNS\14361664|NONE_0
D013390_D005207 CID suxamethonium_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) caused_7\VBN\1617192|muscle_22 (r_acl) fasciculations_6\NNS\14361664|NONE_0
D013390_D005207 CID suxamethonium_13\NN\0|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_agent) caused_11\VBN\1617192|muscle_22 (r_acl) fasciculations_10\NNS\14361664|NONE_0
D013390_D005207 CID suxamethonium_11\NN\0|-_13 (r_npadvmod) induced_13\VBN\1627355|muscle_8 (r_amod) fasciculations_15\NNS\14361664|NONE_0
D014867_D005207 NONE h2o_21\NNP\14618834|the_39|control_35|(_21|)_3 (r_appos) group_12\NN\2137|NONE_0 (r_pobj) in_9\IN\13603305|pressure_63|higher_7|than_47 (r_prep) was_6\VBD\0|NONE_0 (l_nsubj) pressure_2\NN\11419404|higher_56|in_63|than_110 (l_prep) during_3\IN\0|the_26|intragastric_22 (l_pobj) fasciculations_5\NNS\14361664|NONE_0
19655282
D003042_D007511 NONE cocaine_12\NN\3492717|-_7 (r_npadvmod) associated_14\VBN\628491|chest_11 (r_amod) pain_16\NN\14299637|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) efficacious_10\JJ\0|whether_41|strategy_18|would_9|,_44|account_72 (r_acomp) be_9\VB\14625458|it_52|unclear_46|._107 (l_advcl) account_22\VB\6647206|whether_113|strategy_90|would_81|efficacious_72|,_28 (l_prep) for_23\IN\0|as_34|vasospasm_22|may_12 (l_pobj) some_24\DT\0|NONE_0 (l_prep) of_25\IN\0|NONE_0 (l_pobj) ischemia_27\NN\14195315|NONE_0
D003042_D007511 NONE cocaine_1\NN\3492717|-_7 (r_npadvmod) associated_3\VBN\628491|myocardial_11 (r_amod) ischemia_5\NN\14195315|although_39|can_9|from_20|._249 (r_nsubj) result_7\VB\34213|NONE_0 (l_prep) from_8\IN\0|although_59|ischemia_20|can_11|._229 (l_pobj) vasoconstriction_10\NN\1149911|NONE_0 (l_acl) discharged_35\VBN\1640855|coronary_131|,_106 (l_nsubjpass) patients_12\NNS\9898892|may_90|be_94|safely_97|from_115|after_127|with_157 (l_prep) with_13\IN\0|NONE_0 (l_pobj) cocaine_14\NN\3492717|NONE_0 (l_acl) associated_15\VBN\628491|NONE_0 (l_dobj) pain_17\NN\14299637|NONE_0 (l_conj) ecg_23\NNP\7000195|chest_27|,_17 (l_amod) ischemic_22\JJ\0|a_6|,_12|and_14|2_37
D003042_D007511 NONE cocaine_14\NN\3492717|NONE_0 (l_acl) associated_15\VBN\628491|NONE_0 (l_dobj) pain_17\NN\14299637|NONE_0 (l_conj) ecg_23\NNP\7000195|chest_27|,_17 (l_amod) ischemic_22\JJ\0|a_6|,_12|and_14|2_37
D003042_D002637 CID cocaine_13\NN\3492717|-_7 (r_npadvmod) associated_15\VBN\628491|chest_11 (r_amod) pain_17\NN\14299637|NONE_0
D003042_D002637 CID cocaine_10\NN\3492717|-_7 (r_npadvmod) associated_12\VBN\628491|chest_11 (r_amod) pain_14\NN\14299637|NONE_0
D003042_D002637 CID cocaine_12\NN\3492717|-_7 (r_npadvmod) associated_14\VBN\628491|chest_11 (r_amod) pain_16\NN\14299637|NONE_0
D003042_D002637 CID cocaine_10\NN\3492717|-_7 (r_npadvmod) associated_12\VBN\628491|chest_11 (r_amod) pain_14\NN\14299637|NONE_0
D003042_D002637 CID cocaine_6\NN\3492717|-_7 (r_npadvmod) associated_8\VBN\628491|chest_11 (r_amod) pain_10\NN\14299637|NONE_0
D003042_D002637 CID cocaine_1\NN\3492717|-_7 (r_npadvmod) associated_3\VBN\628491|myocardial_11 (r_amod) ischemia_5\NN\14195315|although_39|can_9|from_20|._249 (r_nsubj) result_7\VB\34213|NONE_0 (l_prep) from_8\IN\0|although_59|ischemia_20|can_11|._229 (l_pobj) vasoconstriction_10\NN\1149911|NONE_0 (l_acl) discharged_35\VBN\1640855|coronary_131|,_106 (l_nsubjpass) patients_12\NNS\9898892|may_90|be_94|safely_97|from_115|after_127|with_157 (l_prep) with_13\IN\0|NONE_0 (l_pobj) cocaine_14\NN\3492717|NONE_0 (l_acl) associated_15\VBN\628491|NONE_0 (l_dobj) pain_17\NN\14299637|NONE_0
D003042_D002637 CID cocaine_14\NN\3492717|NONE_0 (l_acl) associated_15\VBN\628491|NONE_0 (l_dobj) pain_17\NN\14299637|NONE_0
D003042_D054058 NONE cocaine_10\NN\3492717|-_7 (r_npadvmod) associated_12\VBN\628491|chest_11 (r_amod) pain_14\NN\14299637|NONE_0 (r_pobj) with_9\IN\0|to_31 (r_prep) presenting_2\VBG\2137132|most_14 (r_acl) patients_1\NNS\9898892|are_86|for_99|and_121|receive_125|._229 (r_nsubjpass) admitted_16\VBN\822367|NONE_0 (l_conj) receive_23\VB\2210855|patients_125|are_39|for_26|and_4|._104 (l_dobj) protocol_32\NN\6652242|prior_41 (l_nmod) syndrome_30\NN\5870365|a_27|"_25|rule_24|acute_15|"_8|,_18|with_26
D003042_D003329 NONE cocaine_12\NN\3492717|-_7 (r_npadvmod) associated_14\VBN\628491|chest_11 (r_amod) pain_16\NN\14299637|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) efficacious_10\JJ\0|whether_41|strategy_18|would_9|,_44|account_72 (r_acomp) be_9\VB\14625458|it_52|unclear_46|._107 (l_advcl) account_22\VB\6647206|whether_113|strategy_90|would_81|efficacious_72|,_28 (l_nsubj) vasospasm_20\NN\0|as_12|may_10|for_22
D003042_D017202 CID cocaine_1\NN\3492717|-_7 (r_npadvmod) associated_3\VBN\628491|myocardial_11 (r_amod) ischemia_5\NN\14195315|although_39|can_9|from_20|._249
D003042_D017202 CID cocaine_14\NN\3492717|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) patients_12\NNS\9898892|may_90|be_94|safely_97|from_115|after_127|with_157 (r_nsubjpass) discharged_35\VBN\1640855|coronary_131|,_106 (r_acl) vasoconstriction_10\NN\1149911|NONE_0 (r_pobj) from_8\IN\0|although_59|ischemia_20|can_11|._229 (r_prep) result_7\VB\34213|NONE_0 (l_nsubj) ischemia_5\NN\14195315|although_39|can_9|from_20|._249
24284476
D047310_D000647 NONE apigenin_2\NN\0|furthermore_13|,_2|did_9|not_13|amnesia_29|)_104|._105 (r_nsubj) prevent_5\VB\0|NONE_0 (l_dobj) amnesia_7\NN\5669934|furthermore_42|,_31|apigenin_29|did_20|not_16|)_75|._76
D012601_D000647 CID scopolamine_10\NN\14712692|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_agent) induced_8\VBN\1627355|the_12 (r_acl) amnesia_7\NN\5669934|furthermore_42|,_31|apigenin_29|did_20|not_16|)_75|._76
10985896
D004317_D013280 CID doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0 (l_appos) syndrome_49\NN\5870365|severe_38 (l_conj) stomatitis_53\NN\14336539|(_27|"_26|foot_20|"_7|)_6|and_4
D004317_D013280 CID doxil_7\NNS\0|liposomal_23 (r_appos) doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0 (l_appos) syndrome_49\NN\5870365|severe_38 (l_conj) stomatitis_53\NN\14336539|(_27|"_26|foot_20|"_7|)_6|and_4
D004317_D013280 CID doxorubicin_3\NN\2716866|NONE_0 (r_compound) regimen_4\NN\5898568|this_36|modified_31|liposomal_22|in_16|than_66|._110 (r_compound) results_5\VBZ\34213|NONE_0 (l_prep) in_6\IN\13603305|this_52|modified_47|liposomal_38|regimen_16|than_50|._94 (l_pobj) toxicity_8\NN\13576101|NONE_0 (l_appos) stomatitis_10\NN\14336539|less_15|(_1|)_30
D010984_D013280 NONE platinum_16\NN\14627081|-_8 (r_npadvmod) resistant_18\JJ\0|ovarian_10 (r_amod) cancer_20\NN\14239425|NONE_0 (r_pobj) in_15\IN\13603305|an_31|active_28|antineoplastic_21 (r_prep) agent_14\NN\7347|to_31|,_42|with_44|q_115 (r_attr) be_10\VB\14625458|studies_59|have_51|doxorubicin_23|being_154|._223 (r_advcl) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0 (l_appos) syndrome_49\NN\5870365|severe_38 (l_conj) stomatitis_53\NN\14336539|(_27|"_26|foot_20|"_7|)_6|and_4
D010984_D060831 NONE platinum_16\NN\14627081|-_8 (r_npadvmod) resistant_18\JJ\0|ovarian_10 (r_amod) cancer_20\NN\14239425|NONE_0 (r_pobj) in_15\IN\13603305|an_31|active_28|antineoplastic_21 (r_prep) agent_14\NN\7347|to_31|,_42|with_44|q_115 (r_attr) be_10\VB\14625458|studies_59|have_51|doxorubicin_23|being_154|._223 (r_advcl) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0
D010984_D060831 NONE platinum_16\NN\14627081|-_8 (r_npadvmod) resistant_18\JJ\0|ovarian_10 (r_amod) cancer_20\NN\14239425|NONE_0 (r_pobj) in_15\IN\13603305|an_31|active_28|antineoplastic_21 (r_prep) agent_14\NN\7347|to_31|,_42|with_44|q_115 (r_attr) be_10\VB\14625458|studies_59|have_51|doxorubicin_23|being_154|._223 (r_advcl) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0 (l_appos) syndrome_49\NN\5870365|severe_38
D017239_D010051 NONE paclitaxel_16\NN\0|platinum_9|/_1|-_10 (r_compound) refractory_18\JJ\3673767|ovarian_11|and_46|carcinoma_58 (r_amod) cancers_23\NNS\14239425|NONE_0
D017239_D010051 NONE paclitaxel_14\NN\0|-_10 (r_compound) refractory_16\JJ\3673767|platinum_20|/_12|(_19|disease_42|months_122|)_140 (r_amod) disease_17\NN\14061805|NONE_0 (r_pobj) with_11\IN\0|primary_29|peritoneal_21 (r_prep) carcinoma_10\NN\14239918|ovarian_56|tube_35|or_22 (r_conj) cancers_6\NNS\14239425|NONE_0
D017239_D010051 NONE paclitaxel_17\NN\0|and_4|refractory_11 (r_conj) platinum-_15\NN\0|defined_8|ovarian_36 (r_nmod) cancer_21\NN\14239425|NONE_0
D004317_D060831 CID doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0
D004317_D060831 CID doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0 (l_appos) syndrome_49\NN\5870365|severe_38
D004317_D060831 CID doxil_7\NNS\0|liposomal_23 (r_appos) doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0
D004317_D060831 CID doxil_7\NNS\0|liposomal_23 (r_appos) doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) being_41\VBG\24720|studies_213|have_205|doxorubicin_177|be_154|._69 (l_attr) erythrodysesthesia_43\NN\0|NONE_0 (l_appos) syndrome_49\NN\5870365|severe_38
D004317_D060831 CID doxorubicin_3\NN\2716866|NONE_0 (r_compound) regimen_4\NN\5898568|this_36|modified_31|liposomal_22|in_16|than_66|._110 (r_compound) results_5\VBZ\34213|NONE_0 (l_prep) in_6\IN\13603305|this_52|modified_47|liposomal_38|regimen_16|than_50|._94 (l_pobj) toxicity_8\NN\13576101|NONE_0 (l_appos) stomatitis_10\NN\14336539|less_15|(_1|)_30 (l_appos) syndrome_15\NN\5870365|,_12
D010984_D005185 NONE platinum_14\NN\14627081|/_8|paclitaxel_9|-_19 (r_nmod) refractory_18\JJ\3673767|ovarian_11|and_46|carcinoma_58 (r_amod) cancers_23\NNS\14239425|NONE_0
D010984_D005185 NONE platinum_12\NN\14627081|/_8|refractory_20|(_39|disease_62|months_142|)_160 (r_nmod) disease_17\NN\14061805|NONE_0 (r_pobj) with_11\IN\0|primary_29|peritoneal_21 (r_prep) carcinoma_10\NN\14239918|ovarian_56|tube_35|or_22 (r_conj) cancers_6\NNS\14239425|NONE_0
D010984_D010051 NONE platinum_14\NN\14627081|/_8|paclitaxel_9|-_19 (r_nmod) refractory_18\JJ\3673767|ovarian_11|and_46|carcinoma_58 (r_amod) cancers_23\NNS\14239425|NONE_0
D010984_D010051 NONE platinum_16\NN\14627081|-_8 (r_npadvmod) resistant_18\JJ\0|ovarian_10 (r_amod) cancer_20\NN\14239425|NONE_0
D010984_D010051 NONE platinum_12\NN\14627081|/_8|refractory_20|(_39|disease_62|months_142|)_160 (r_nmod) disease_17\NN\14061805|NONE_0 (r_pobj) with_11\IN\0|primary_29|peritoneal_21 (r_prep) carcinoma_10\NN\14239918|ovarian_56|tube_35|or_22 (r_conj) cancers_6\NNS\14239425|NONE_0
D010984_D010051 NONE platinum-_15\NN\0|defined_8|ovarian_36 (r_nmod) cancer_21\NN\14239425|NONE_0
D010984_D064420 NONE platinum_16\NN\14627081|-_8 (r_npadvmod) resistant_18\JJ\0|ovarian_10 (r_amod) cancer_20\NN\14239425|NONE_0 (r_pobj) in_15\IN\13603305|an_31|active_28|antineoplastic_21 (r_prep) agent_14\NN\7347|to_31|,_42|with_44|q_115 (r_attr) be_10\VB\14625458|studies_59|have_51|doxorubicin_23|being_154|._223 (l_prep) with_22\IN\0|to_75|agent_44|,_2|q_71 (l_pobj) toxicity_25\NN\13576101|NONE_0
D004317_D010534 NONE doxorubicin_5\NN\2716866|NONE_0 (r_pobj) of_3\IN\0|phase_14|in_38|._146 (r_prep) trial_2\NN\786195|NONE_0 (l_prep) in_13\IN\13603305|phase_52|of_38|._108 (l_pobj) cancers_23\NNS\14239425|NONE_0 (l_conj) carcinoma_26\NN\14239918|refractory_58|ovarian_47|and_12 (l_prep) of_27\IN\0|primary_18 (l_pobj) peritoneum_29\NN\5605944|NONE_0
D004317_D010534 NONE doxorubicin_41\NN\2716866|NONE_0 (r_pobj) with_39\IN\0|patients_260|were_13|at_27|weeks_55|._60 (r_prep) treated_38\VBN\2376958|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_247|with_260|at_287|weeks_315|._320 (l_prep) with_1\IN\0|NONE_0 (l_pobj) cancers_6\NNS\14239425|NONE_0 (l_conj) carcinoma_10\NN\14239918|ovarian_56|tube_35|or_22
D004317_D005185 NONE doxorubicin_5\NN\2716866|NONE_0 (r_pobj) of_3\IN\0|phase_14|in_38|._146 (r_prep) trial_2\NN\786195|NONE_0 (l_prep) in_13\IN\13603305|phase_52|of_38|._108 (l_pobj) cancers_23\NNS\14239425|NONE_0
D004317_D005185 NONE doxorubicin_41\NN\2716866|NONE_0 (r_pobj) with_39\IN\0|patients_260|were_13|at_27|weeks_55|._60 (r_prep) treated_38\VBN\2376958|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_247|with_260|at_287|weeks_315|._320 (l_prep) with_1\IN\0|NONE_0 (l_pobj) cancers_6\NNS\14239425|NONE_0
D004317_D064420 NONE doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) be_10\VB\14625458|studies_59|have_51|doxorubicin_23|being_154|._223 (l_prep) with_22\IN\0|to_75|agent_44|,_2|q_71 (l_pobj) toxicity_25\NN\13576101|NONE_0
D004317_D064420 NONE doxil_7\NNS\0|liposomal_23 (r_appos) doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) be_10\VB\14625458|studies_59|have_51|doxorubicin_23|being_154|._223 (l_prep) with_22\IN\0|to_75|agent_44|,_2|q_71 (l_pobj) toxicity_25\NN\13576101|NONE_0
D004317_D064420 NONE doxorubicin_3\NN\2716866|NONE_0 (r_compound) regimen_4\NN\5898568|this_36|modified_31|liposomal_22|in_16|than_66|._110 (r_compound) results_5\VBZ\34213|NONE_0 (l_prep) in_6\IN\13603305|this_52|modified_47|liposomal_38|regimen_16|than_50|._94 (l_pobj) toxicity_8\NN\13576101|NONE_0
D017239_D005185 NONE paclitaxel_16\NN\0|platinum_9|/_1|-_10 (r_compound) refractory_18\JJ\3673767|ovarian_11|and_46|carcinoma_58 (r_amod) cancers_23\NNS\14239425|NONE_0
D017239_D005185 NONE paclitaxel_14\NN\0|-_10 (r_compound) refractory_16\JJ\3673767|platinum_20|/_12|(_19|disease_42|months_122|)_140 (r_amod) disease_17\NN\14061805|NONE_0 (r_pobj) with_11\IN\0|primary_29|peritoneal_21 (r_prep) carcinoma_10\NN\14239918|ovarian_56|tube_35|or_22 (r_conj) cancers_6\NNS\14239425|NONE_0
D004317_D010051 NONE doxorubicin_5\NN\2716866|NONE_0 (r_pobj) of_3\IN\0|phase_14|in_38|._146 (r_prep) trial_2\NN\786195|NONE_0 (l_prep) in_13\IN\13603305|phase_52|of_38|._108 (l_pobj) cancers_23\NNS\14239425|NONE_0
D004317_D010051 NONE doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) be_10\VB\14625458|studies_59|have_51|doxorubicin_23|being_154|._223 (l_attr) agent_14\NN\7347|to_31|,_42|with_44|q_115 (l_prep) in_15\IN\13603305|an_31|active_28|antineoplastic_21 (l_pobj) cancer_20\NN\14239425|NONE_0
D004317_D010051 NONE doxil_7\NNS\0|liposomal_23 (r_appos) doxorubicin_5\NN\2716866|studies_36|have_28|be_23|being_177|._246 (r_dobj) demonstrated_3\VBN\2137132|NONE_0 (l_advcl) be_10\VB\14625458|studies_59|have_51|doxorubicin_23|being_154|._223 (l_attr) agent_14\NN\7347|to_31|,_42|with_44|q_115 (l_prep) in_15\IN\13603305|an_31|active_28|antineoplastic_21 (l_pobj) cancer_20\NN\14239425|NONE_0
D004317_D010051 NONE doxorubicin_41\NN\2716866|NONE_0 (r_pobj) with_39\IN\0|patients_260|were_13|at_27|weeks_55|._60 (r_prep) treated_38\VBN\2376958|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_247|with_260|at_287|weeks_315|._320 (l_prep) with_1\IN\0|NONE_0 (l_pobj) cancers_6\NNS\14239425|NONE_0
D010984_D010534 NONE platinum_14\NN\14627081|/_8|paclitaxel_9|-_19 (r_nmod) refractory_18\JJ\3673767|ovarian_11|and_46|carcinoma_58 (r_amod) cancers_23\NNS\14239425|NONE_0 (l_conj) carcinoma_26\NN\14239918|refractory_58|ovarian_47|and_12 (l_prep) of_27\IN\0|primary_18 (l_pobj) peritoneum_29\NN\5605944|NONE_0
D010984_D010534 NONE platinum_12\NN\14627081|/_8|refractory_20|(_39|disease_62|months_142|)_160 (r_nmod) disease_17\NN\14061805|NONE_0 (r_pobj) with_11\IN\0|primary_29|peritoneal_21 (r_prep) carcinoma_10\NN\14239918|ovarian_56|tube_35|or_22
D017239_D010534 NONE paclitaxel_16\NN\0|platinum_9|/_1|-_10 (r_compound) refractory_18\JJ\3673767|ovarian_11|and_46|carcinoma_58 (r_amod) cancers_23\NNS\14239425|NONE_0 (l_conj) carcinoma_26\NN\14239918|refractory_58|ovarian_47|and_12 (l_prep) of_27\IN\0|primary_18 (l_pobj) peritoneum_29\NN\5605944|NONE_0
D017239_D010534 NONE paclitaxel_14\NN\0|-_10 (r_compound) refractory_16\JJ\3673767|platinum_20|/_12|(_19|disease_42|months_122|)_140 (r_amod) disease_17\NN\14061805|NONE_0 (r_pobj) with_11\IN\0|primary_29|peritoneal_21 (r_prep) carcinoma_10\NN\14239918|ovarian_56|tube_35|or_22
10939760
D013411_D014123 NONE sulfadiazine_0\NN\4352070|acute_13 (r_nmod) nephrotoxicity_2\NN\0|is_15|because_37|._97 (r_nsubj) reviving_4\VBG\22099|NONE_0 (l_prep) because_6\IN\0|nephrotoxicity_37|is_22|._60 (l_pobj) use_9\NN\407535|specially_25|of_7 (l_prep) in_10\IN\13603305|its_8|in_17 (l_pobj) toxoplasmosis_11\NN\14174549|NONE_0
D013411_D058186 CID sulfadiazine_2\NN\4352070|acute_13 (r_nmod) nephrotoxicity_4\NN\0|NONE_0
D013411_D058186 CID sulfadiazine_0\NN\4352070|acute_13 (r_nmod) nephrotoxicity_2\NN\0|is_15|because_37|._97
14748761
C056507_D066126 NONE gemcitabine_22\NN\0|other_55|cardiotoxic_49|anthracyclines_16|leader_21 (r_appos) drugs_16\NNS\14778436|risk_80|similar_49|and_22|._66 (l_amod) cardiotoxic_15\JJ\0|other_6|anthracyclines_33|gemcitabine_49|leader_70
C056507_D066126 NONE gem_24\NNP\2743547|NONE_0 (r_appos) gemcitabine_22\NN\0|other_55|cardiotoxic_49|anthracyclines_16|leader_21 (r_appos) drugs_16\NNS\14778436|risk_80|similar_49|and_22|._66 (l_amod) cardiotoxic_15\JJ\0|other_6|anthracyclines_33|gemcitabine_49|leader_70
C030852_D009369 NONE vnr_21\VBN\0|with_4 (r_dobj) comparing_20\VBG\635850|clinical_16 (l_prep) with_22\IN\0|vnr_4 (l_pobj) agents_25\NNS\7347|NONE_0 (l_prep) in_26\IN\13603305|other_30|chemotherapeutic_24 (l_pobj) treatment_28\NN\654885|NONE_0 (l_prep) of_29\IN\0|the_14 (l_pobj) malignancies_31\NNS\14070360|NONE_0
C030852_D009369 NONE vnr_4\VBN\0|with_4|in_21 (r_dobj) comparing_3\VBG\635850|randomized_27|clinical_16 (l_prep) in_8\IN\13603305|vnr_21|with_17 (l_pobj) treatment_10\NN\654885|NONE_0 (l_prep) of_11\IN\0|the_14 (l_pobj) cancer_12\NN\14239425|NONE_0
D014751_D066126 NONE vindesine_9\NN\0|NONE_0 (r_xcomp) similar_7\JJ\0|risk_31|and_27|drugs_49|._115 (r_acomp) was_6\VBD\0|NONE_0 (l_conj) drugs_16\NNS\14778436|risk_80|similar_49|and_22|._66 (l_amod) cardiotoxic_15\JJ\0|other_6|anthracyclines_33|gemcitabine_49|leader_70
D014751_D066126 NONE vds_11\NNP\14122235|to_14|(_1|)_3 (r_appos) vindesine_9\NN\0|NONE_0 (r_xcomp) similar_7\JJ\0|risk_31|and_27|drugs_49|._115 (r_acomp) was_6\VBD\0|NONE_0 (l_conj) drugs_16\NNS\14778436|risk_80|similar_49|and_22|._66 (l_amod) cardiotoxic_15\JJ\0|other_6|anthracyclines_33|gemcitabine_49|leader_70
D005472_D066126 NONE fluorouracil_18\NN\2722166|,_28 (r_nmod) anthracyclines_20\NNS\0|other_39|cardiotoxic_33|gemcitabine_16|leader_37 (r_appos) drugs_16\NNS\14778436|risk_80|similar_49|and_22|._66 (l_amod) cardiotoxic_15\JJ\0|other_6|anthracyclines_33|gemcitabine_49|leader_70
D018943_D066126 NONE anthracyclines_20\NNS\0|other_39|cardiotoxic_33|gemcitabine_16|leader_37 (r_appos) drugs_16\NNS\14778436|risk_80|similar_49|and_22|._66 (l_amod) cardiotoxic_15\JJ\0|other_6|anthracyclines_33|gemcitabine_49|leader_70
C030852_D066126 CID vnr_3\VBN\0|cardiac_4 (r_nmod) events_5\NNS\23100|NONE_0 (r_pobj) of_2\IN\0|the_9 (r_prep) risk_1\NN\14541044|similar_31|and_58|drugs_80|._146 (r_nsubj) was_6\VBD\0|NONE_0 (l_conj) drugs_16\NNS\14778436|risk_80|similar_49|and_22|._66 (l_amod) cardiotoxic_15\JJ\0|other_6|anthracyclines_33|gemcitabine_49|leader_70
3423103
D015116_D001919 NONE 5,7-dihydroxytryptamine_16\CD\0|NONE_0 (r_pobj) of_15\IN\0|bilateral_27|spinal_17 (r_prep) injection_14\NN\320852|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) produced_10\VBN\1617192|spinal_20|5-ht_13|,_2|,_65 (r_acl) nerves_8\NNS\14373582|NONE_0 (r_pobj) of_4\IN\0|selective_22 (r_prep) destruction_3\NN\209943|furthermore_23|,_12|magnitude_118|clonidine_182|._283 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) magnitude_20\NN\4916342|furthermore_141|,_130|destruction_118|clonidine_64|._165 (l_prep) of_21\IN\0|the_14 (l_pobj) vasodepressor_23\NN\0|NONE_0 (l_conj) responses_27\NNS\11410625|the_38|or_20 (l_compound) bradycardiac_26\NN\0|the_4
D003000_D001919 CID clonidine_11\NN\2721160|-_9 (r_npadvmod) induced_13\VBN\1627355|and_20|bradycardia_24 (r_amod) hypotension_14\NN\14057371|NONE_0 (l_conj) bradycardia_16\NN\14110674|induced_24|and_4
D003000_D001919 CID clonidine_6\NN\2721160|-_9 (r_npadvmod) induced_8\VBN\1627355|the_14 (r_amod) bradycardia_9\NN\14110674|on_41|,_24|was_12|by_28|,_55|but_57|transection_72|._83
D003000_D001919 CID clonidine_29\NN\2721160|furthermore_205|,_194|destruction_182|magnitude_64|._101 (r_advcl) reduced_18\VBD\441445|NONE_0 (l_dobj) magnitude_20\NN\4916342|furthermore_141|,_130|destruction_118|clonidine_64|._165 (l_prep) of_21\IN\0|the_14 (l_pobj) vasodepressor_23\NN\0|NONE_0 (l_conj) responses_27\NNS\11410625|the_38|or_20 (l_compound) bradycardiac_26\NN\0|the_4
D003000_D001919 CID clonidine_13\NN\2721160|-_9 (r_npadvmod) induced_15\VBN\1627355|and_20|bradycardia_24 (r_amod) hypotension_16\NN\14057371|NONE_0 (l_conj) bradycardia_18\NN\14110674|induced_24|and_4
D003000_D007022 CID clonidine_11\NN\2721160|-_9 (r_npadvmod) induced_13\VBN\1627355|and_20|bradycardia_24 (r_amod) hypotension_14\NN\14057371|NONE_0
D003000_D007022 CID clonidine_1\NN\2721160|-_9 (r_npadvmod) induced_3\VBN\1627355|the_14 (r_amod) hypotension_4\NN\14057371|was_12|by_28|._83
D003000_D007022 CID clonidine_13\NN\2721160|-_9 (r_npadvmod) induced_15\VBN\1627355|and_20|bradycardia_24 (r_amod) hypotension_16\NN\14057371|NONE_0
D012701_D001919 NONE 5-ht_7\CD\0|spinal_7|,_11|produced_13|,_78 (r_nummod) nerves_8\NNS\14373582|NONE_0 (r_pobj) of_4\IN\0|selective_22 (r_prep) destruction_3\NN\209943|furthermore_23|,_12|magnitude_118|clonidine_182|._283 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) magnitude_20\NN\4916342|furthermore_141|,_130|destruction_118|clonidine_64|._165 (l_prep) of_21\IN\0|the_14 (l_pobj) vasodepressor_23\NN\0|NONE_0 (l_conj) responses_27\NNS\11410625|the_38|or_20 (l_compound) bradycardiac_26\NN\0|the_4
15094729
D020888_D014786 CID vigabatrin_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_20|natural_16 (r_prep) history_2\NN\15120823|defects_46|._103 (r_nsubj) associated_5\VBD\628491|NONE_0 (l_dobj) defects_8\NNS\14462666|history_46|._57
D020888_D014786 CID vigabatrin_17\NN\0|-_10 (r_npadvmod) associated_19\VBN\628491|elected_23 (r_amod) changes_20\NNS\7283608|to_30 (r_dobj) have_16\VB\7846|NONE_0 (r_xcomp) known_14\VBN\0|NONE_0 (r_acl) patients_13\NNS\9898892|NONE_0 (r_pobj) of_12\IN\0|a_8 (r_prep) group_11\NN\2137|NONE_0 (r_pobj) in_9\IN\13603305|visual_21|field_14 (r_prep) defects_8\NNS\14462666|NONE_0
D020888_D014786 CID vigabatrin_9\NNP\0|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) due_7\JJ\5174653|to_6 (r_acomp) be_6\VB\14625458|defects_20 (r_xcomp) presumed_4\VBN\719734|did_41|not_45|usually_49|in_66|._110 (l_nsubj) defects_3\NNS\14462666|be_20
D020888_D014786 CID vigabatrin_11\NNP\0|-_10 (r_npadvmod) associated_13\VBN\628491|visual_11|field_18 (r_amod) defects_16\NNS\14462666|NONE_0
D020888_D064420 NONE vigabatrin_11\NNP\0|-_10 (r_npadvmod) associated_13\VBN\628491|visual_11|field_18 (r_amod) defects_16\NNS\14462666|NONE_0 (r_pobj) of_10\IN\0|the_17 (r_prep) pathogenesis_9\NN\13533470|that_9|may_59|reaction_96 (r_nsubj) be_18\VB\14625458|the_87 (l_attr) reaction_23\NN\13446390|that_105|pathogenesis_96|may_37 (l_cc) than_25\IN\0|an_46|idiosyncratic_43|adverse_29|drug_21 (l_pobj) toxicity_29\NN\13576101|rather_27
D020888_D012640 NONE vigabatrin_17\NN\0|-_10 (r_npadvmod) associated_19\VBN\628491|elected_23 (r_amod) changes_20\NNS\7283608|to_30 (l_relcl) elected_22\VBD\674607|associated_23 (l_xcomp) continue_24\VB\2367363|who_15 (l_prep) because_27\IN\0|to_27|medication_11 (l_pobj) control_31\NN\5190804|of_16 (l_compound) seizure_30\NN\14081375|good_5
1280707
D011374_D001145 CID progesterone_32\NN\14747338|NONE_0 (r_compound) hcl_33\NN\0|1-hour_20|on_13 (r_compound) exposure_34\NN\5042871|NONE_0 (r_pobj) of_30\IN\0|the_11 (r_prep) effect_29\NN\34213|after_172|(_133|,_20|we_18|._72 (r_dobj) determined_27\VBD\0|NONE_0 (l_punct) (_5\-LRB-\0|after_39|,_113|we_115|effect_133|._205 (l_preconj) concentration_7\NN\4916342|NONE_0 (l_relcl) caused_11\VBD\1617192|the_38|of_20|)_73 (l_dobj) %_13\NN\0|that_14 (l_prep) of_14\IN\0|50_4 (l_pcomp) beating_16\VBG\1170962|all_4 (l_advcl) become_22\VB\146138|cultures_12 (l_acomp) arrhythmic_23\JJ\0|to_10
D002045_D001145 CID bupivacaine_3\NN\0|ad50_12 (r_dobj) determining_1\VBG\0|NONE_0 (r_pcomp) after_0\IN\0|(_39|,_152|we_154|effect_172|._244 (r_prep) determined_27\VBD\0|NONE_0 (l_punct) (_5\-LRB-\0|after_39|,_113|we_115|effect_133|._205 (l_preconj) concentration_7\NN\4916342|NONE_0 (l_relcl) caused_11\VBD\1617192|the_38|of_20|)_73 (l_dobj) %_13\NN\0|that_14 (l_prep) of_14\IN\0|50_4 (l_pcomp) beating_16\VBG\1170962|all_4 (l_advcl) become_22\VB\146138|cultures_12 (l_acomp) arrhythmic_23\JJ\0|to_10
D002045_D001145 CID bupivacaine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|the_18|caused_20|)_93 (r_prep) concentration_7\NN\4916342|NONE_0 (l_relcl) caused_11\VBD\1617192|the_38|of_20|)_73 (l_dobj) %_13\NN\0|that_14 (l_prep) of_14\IN\0|50_4 (l_pcomp) beating_16\VBG\1170962|all_4 (l_advcl) become_22\VB\146138|cultures_12 (l_acomp) arrhythmic_23\JJ\0|to_10
D002045_D001145 CID bupivacaine_2\NN\0|NONE_0 (r_compound) arrhythmia_3\NN\14103288|NONE_0
D006851_D001145 NONE hcl_33\NN\0|1-hour_20|on_13 (r_compound) exposure_34\NN\5042871|NONE_0 (r_pobj) of_30\IN\0|the_11 (r_prep) effect_29\NN\34213|after_172|(_133|,_20|we_18|._72 (r_dobj) determined_27\VBD\0|NONE_0 (l_punct) (_5\-LRB-\0|after_39|,_113|we_115|effect_133|._205 (l_preconj) concentration_7\NN\4916342|NONE_0 (l_relcl) caused_11\VBD\1617192|the_38|of_20|)_73 (l_dobj) %_13\NN\0|that_14 (l_prep) of_14\IN\0|50_4 (l_pcomp) beating_16\VBG\1170962|all_4 (l_advcl) become_22\VB\146138|cultures_12 (l_acomp) arrhythmic_23\JJ\0|to_10
7477981
D001058_D010300 NONE apomorphine_29\NN\3786417|the_28|dopamine_18|,_2 (r_appos) agonist_27\NN\0|NONE_0 (r_pobj) with_23\IN\0|an_19|acute_16 (r_prep) challenge_22\NN\13927383|NONE_0 (r_pobj) after_19\IN\0|we_125|severity_108|,_69|before_71|)_141|for_143|._160 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_conj) dyskinesias_8\NNS\14084880|the_37|of_24|and_4 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|seven_35|responsive_20 (l_pobj) disease_18\NN\14061805|NONE_0
D001058_D010300 NONE apomorphine_17\NN\3786417|NONE_0 (r_pobj) of_16\IN\0|a_41|significant_39|%_25|(_11|0.05_6|)_2 (r_prep) improvement_10\NN\7359599|after_56|,_30|there_28|induced_38|._111 (r_attr) was_5\VBD\0|NONE_0 (l_advcl) induced_19\VBN\1627355|after_94|,_68|there_66|improvement_38|._73 (l_prep) without_21\IN\0|-_21|dyskinesias_12 (l_pobj) modification_22\NN\191142|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) disability_26\NN\14547369|NONE_0 (l_amod) parkinsonian_24\JJ\0|motor_13
D005473_D004409 CID fluoxetine_7\NN\4169152|NONE_0 (r_pobj) by_6\IN\0|dyskinesias_25|are_13|._13 (r_agent) improved_5\VBN\126264|NONE_0 (l_nsubjpass) dyskinesias_3\NNS\14084880|are_12|by_25|._38
D005473_D004409 CID fluoxetine_37\NN\4169152|NONE_0 (r_pobj) of_36\IN\0|the_19 (r_prep) administration_35\NN\1133281|twice_36 (r_pobj) after_33\IN\0|and_4 (r_conj) before_31\RB\0|we_196|severity_179|after_71|,_2|)_70|for_72|._89 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_conj) dyskinesias_8\NNS\14084880|the_37|of_24|and_4
D005473_D004409 CID fluoxetine_1\NN\4169152|NONE_0 (r_amod) treatment_2\NN\654885|NONE_0 (r_pobj) after_0\IN\0|,_26|there_28|improvement_56|induced_94|._167 (r_prep) was_5\VBD\0|NONE_0 (l_advcl) induced_19\VBN\1627355|after_94|,_68|there_66|improvement_38|._73 (l_dobj) dyskinesias_20\NNS\14084880|-_9|without_12
D005473_D004409 CID fluoxetine_9\NN\4169152|NONE_0 (r_pobj) with_8\IN\0|increased_44|serotoninergic_28 (r_prep) transmission_7\NN\121166|that_36|may_29|dyskinesias_78|without_90 (r_nsubj) reduce_11\VB\441445|results_85|._106 (l_dobj) dyskinesias_18\NNS\14084880|that_114|transmission_78|may_49|without_12
D005473_D010300 NONE fluoxetine_37\NN\4169152|NONE_0 (r_pobj) of_36\IN\0|the_19 (r_prep) administration_35\NN\1133281|twice_36 (r_pobj) after_33\IN\0|and_4 (r_conj) before_31\RB\0|we_196|severity_179|after_71|,_2|)_70|for_72|._89 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_conj) dyskinesias_8\NNS\14084880|the_37|of_24|and_4 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|seven_35|responsive_20 (l_pobj) disease_18\NN\14061805|NONE_0
D005473_D010300 NONE fluoxetine_1\NN\4169152|NONE_0 (r_amod) treatment_2\NN\654885|NONE_0 (r_pobj) after_0\IN\0|,_26|there_28|improvement_56|induced_94|._167 (r_prep) was_5\VBD\0|NONE_0 (l_advcl) induced_19\VBN\1627355|after_94|,_68|there_66|improvement_38|._73 (l_prep) without_21\IN\0|-_21|dyskinesias_12 (l_pobj) modification_22\NN\191142|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) disability_26\NN\14547369|NONE_0 (l_amod) parkinsonian_24\JJ\0|motor_13
D005473_D010300 NONE fluoxetine_9\NN\4169152|NONE_0 (r_pobj) with_8\IN\0|increased_44|serotoninergic_28 (r_prep) transmission_7\NN\121166|that_36|may_29|dyskinesias_78|without_90 (r_nsubj) reduce_11\VB\441445|results_85|._106 (l_prep) without_19\IN\0|that_126|transmission_90|may_61|dyskinesias_12 (l_pobj) disability_23\NN\14547369|NONE_0 (l_amod) parkinsonian_21\JJ\0|aggravating_12|motor_13
D004298_D004409 NONE dopamine_26\NN\14807737|the_10|,_16|apomorphine_18 (r_compound) agonist_27\NN\0|NONE_0 (r_pobj) with_23\IN\0|an_19|acute_16 (r_prep) challenge_22\NN\13927383|NONE_0 (r_pobj) after_19\IN\0|we_125|severity_108|,_69|before_71|)_141|for_143|._160 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_conj) dyskinesias_8\NNS\14084880|the_37|of_24|and_4
D004298_D004409 NONE dopamine_14\NN\14807737|or_3 (r_conj) levodopa-_12\JJ\0|induced_30 (r_nmod) dyskinesias_18\NNS\14084880|that_114|transmission_78|may_49|without_12
D001058_D004409 CID apomorphine_29\NN\3786417|the_28|dopamine_18|,_2 (r_appos) agonist_27\NN\0|NONE_0 (r_pobj) with_23\IN\0|an_19|acute_16 (r_prep) challenge_22\NN\13927383|NONE_0 (r_pobj) after_19\IN\0|we_125|severity_108|,_69|before_71|)_141|for_143|._160 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_conj) dyskinesias_8\NNS\14084880|the_37|of_24|and_4
D001058_D004409 CID apomorphine_17\NN\3786417|NONE_0 (r_pobj) of_16\IN\0|a_41|significant_39|%_25|(_11|0.05_6|)_2 (r_prep) improvement_10\NN\7359599|after_56|,_30|there_28|induced_38|._111 (r_attr) was_5\VBD\0|NONE_0 (l_advcl) induced_19\VBN\1627355|after_94|,_68|there_66|improvement_38|._73 (l_dobj) dyskinesias_20\NNS\14084880|-_9|without_12
D007980_D010300 NONE levodopa_11\JJ\14604959|-_8 (r_npadvmod) responsive_13\JJ\0|seven_15|with_20 (r_amod) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|seven_35|responsive_20 (l_pobj) disease_18\NN\14061805|NONE_0
D007980_D010300 NONE levodopa-_12\JJ\0|induced_30 (r_nmod) dyskinesias_18\NNS\14084880|that_114|transmission_78|may_49|without_12 (r_dobj) reduce_11\VB\441445|results_85|._106 (l_prep) without_19\IN\0|that_126|transmission_90|may_61|dyskinesias_12 (l_pobj) disability_23\NN\14547369|NONE_0 (l_amod) parkinsonian_21\JJ\0|aggravating_12|motor_13
D004298_D009069 NONE dopamine_26\NN\14807737|the_10|,_16|apomorphine_18 (r_compound) agonist_27\NN\0|NONE_0 (r_pobj) with_23\IN\0|an_19|acute_16 (r_prep) challenge_22\NN\13927383|NONE_0 (r_pobj) after_19\IN\0|we_125|severity_108|,_69|before_71|)_141|for_143|._160 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_prep) of_4\IN\0|the_13|and_20|dyskinesias_24 (l_pobj) disability_6\NN\14547369|NONE_0
D004298_D009069 NONE dopamine_14\NN\14807737|or_3 (r_conj) levodopa-_12\JJ\0|induced_30 (r_nmod) dyskinesias_18\NNS\14084880|that_114|transmission_78|may_49|without_12 (r_dobj) reduce_11\VB\441445|results_85|._106 (l_prep) without_19\IN\0|that_126|transmission_90|may_61|dyskinesias_12 (l_pobj) disability_23\NN\14547369|NONE_0
D007980_D004409 NONE levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) dyskinesias_3\NNS\14084880|are_12|by_25|._38
D007980_D004409 NONE levodopa_11\JJ\14604959|-_8 (r_npadvmod) responsive_13\JJ\0|seven_15|with_20 (r_amod) patients_14\NNS\9898892|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) dyskinesias_8\NNS\14084880|the_37|of_24|and_4
D007980_D004409 NONE levodopa-_12\JJ\0|induced_30 (r_nmod) dyskinesias_18\NNS\14084880|that_114|transmission_78|may_49|without_12
D007980_D009069 NONE levodopa_11\JJ\14604959|-_8 (r_npadvmod) responsive_13\JJ\0|seven_15|with_20 (r_amod) patients_14\NNS\9898892|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) dyskinesias_8\NNS\14084880|the_37|of_24|and_4 (r_conj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_prep) of_4\IN\0|the_13|and_20|dyskinesias_24 (l_pobj) disability_6\NN\14547369|NONE_0
D007980_D009069 NONE levodopa-_12\JJ\0|induced_30 (r_nmod) dyskinesias_18\NNS\14084880|that_114|transmission_78|may_49|without_12 (r_dobj) reduce_11\VB\441445|results_85|._106 (l_prep) without_19\IN\0|that_126|transmission_90|may_61|dyskinesias_12 (l_pobj) disability_23\NN\14547369|NONE_0
D005473_D009069 NONE fluoxetine_37\NN\4169152|NONE_0 (r_pobj) of_36\IN\0|the_19 (r_prep) administration_35\NN\1133281|twice_36 (r_pobj) after_33\IN\0|and_4 (r_conj) before_31\RB\0|we_196|severity_179|after_71|,_2|)_70|for_72|._89 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_prep) of_4\IN\0|the_13|and_20|dyskinesias_24 (l_pobj) disability_6\NN\14547369|NONE_0
D005473_D009069 NONE fluoxetine_1\NN\4169152|NONE_0 (r_amod) treatment_2\NN\654885|NONE_0 (r_pobj) after_0\IN\0|,_26|there_28|improvement_56|induced_94|._167 (r_prep) was_5\VBD\0|NONE_0 (l_advcl) induced_19\VBN\1627355|after_94|,_68|there_66|improvement_38|._73 (l_prep) without_21\IN\0|-_21|dyskinesias_12 (l_pobj) modification_22\NN\191142|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) disability_26\NN\14547369|NONE_0
D005473_D009069 NONE fluoxetine_9\NN\4169152|NONE_0 (r_pobj) with_8\IN\0|increased_44|serotoninergic_28 (r_prep) transmission_7\NN\121166|that_36|may_29|dyskinesias_78|without_90 (r_nsubj) reduce_11\VB\441445|results_85|._106 (l_prep) without_19\IN\0|that_126|transmission_90|may_61|dyskinesias_12 (l_pobj) disability_23\NN\14547369|NONE_0
D001058_D009069 NONE apomorphine_29\NN\3786417|the_28|dopamine_18|,_2 (r_appos) agonist_27\NN\0|NONE_0 (r_pobj) with_23\IN\0|an_19|acute_16 (r_prep) challenge_22\NN\13927383|NONE_0 (r_pobj) after_19\IN\0|we_125|severity_108|,_69|before_71|)_141|for_143|._160 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_prep) of_4\IN\0|the_13|and_20|dyskinesias_24 (l_pobj) disability_6\NN\14547369|NONE_0
D001058_D009069 NONE apomorphine_17\NN\3786417|NONE_0 (r_pobj) of_16\IN\0|a_41|significant_39|%_25|(_11|0.05_6|)_2 (r_prep) improvement_10\NN\7359599|after_56|,_30|there_28|induced_38|._111 (r_attr) was_5\VBD\0|NONE_0 (l_advcl) induced_19\VBN\1627355|after_94|,_68|there_66|improvement_38|._73 (l_prep) without_21\IN\0|-_21|dyskinesias_12 (l_pobj) modification_22\NN\191142|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) disability_26\NN\14547369|NONE_0
D004298_D010300 NONE dopamine_26\NN\14807737|the_10|,_16|apomorphine_18 (r_compound) agonist_27\NN\0|NONE_0 (r_pobj) with_23\IN\0|an_19|acute_16 (r_prep) challenge_22\NN\13927383|NONE_0 (r_pobj) after_19\IN\0|we_125|severity_108|,_69|before_71|)_141|for_143|._160 (r_prep) evaluated_1\VBD\670261|NONE_0 (l_dobj) severity_3\NN\5036394|we_17|after_108|,_177|before_179|)_249|for_251|._268 (l_conj) dyskinesias_8\NNS\14084880|the_37|of_24|and_4 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|seven_35|responsive_20 (l_pobj) disease_18\NN\14061805|NONE_0
D004298_D010300 NONE dopamine_14\NN\14807737|or_3 (r_conj) levodopa-_12\JJ\0|induced_30 (r_nmod) dyskinesias_18\NNS\14084880|that_114|transmission_78|may_49|without_12 (r_dobj) reduce_11\VB\441445|results_85|._106 (l_prep) without_19\IN\0|that_126|transmission_90|may_61|dyskinesias_12 (l_pobj) disability_23\NN\14547369|NONE_0 (l_amod) parkinsonian_21\JJ\0|aggravating_12|motor_13
18165598
D015232_D010146 NONE e2_9\NNP\0|prostaglandin_14|,_10|expression_32|in_52 (r_compound) release_10\NN\3748886|NONE_0 (l_conj) expression_14\NN\4679549|prostaglandin_46|e2_32|,_22|in_20 (l_conj) pain_16\NN\14299637|cyclooxygenase_35|gene_20|and_4
D015232_D010146 NONE e2_9\NNP\0|prostaglandin_14|,_10|expression_32|in_52 (r_compound) release_10\NN\3748886|NONE_0 (l_prep) in_17\IN\13603305|prostaglandin_66|e2_52|,_42|expression_20 (l_pobj) model_21\NN\5888929|NONE_0 (l_compound) pain_20\NN\14299637|a_11|clinical_9
D015232_D010146 NONE pge2_15\NNP\0|and_4 (r_conj) h_13\NN\14622893|24_3 (r_nmod) levels_16\NNS\4916342|NONE_0 (r_pobj) at_11\IN\14622893|however_72|,_65|group_39|pain_5|during_24|were_45|._108 (r_prep) reported_7\VBD\831651|NONE_0 (l_dobj) pain_10\NN\14299637|however_67|,_60|group_34|at_5|during_29|were_50|._113
D015232_D010146 NONE pge2_18\NNP\0|higher_7|and_16|pain_20 (r_compound) production_19\NN\30358|NONE_0 (l_conj) pain_21\NN\14299637|higher_27|pge2_20|and_4
D015232_D017695 NONE pge2_18\NNP\0|higher_7|and_16|pain_20 (r_compound) production_19\NN\30358|NONE_0 (r_pobj) with_16\IN\0|which_20|is_14 (r_prep) associated_15\VBN\628491|tissue_24|,_11 (r_relcl) injury_11\NN\14052046|NONE_0
D002045_D017695 NONE bupivacaine_4\NN\0|expression_34|after_45|dissipates_157 (r_nsubj) stimulates_5\VBZ\137313|results_33|._155 (l_prep) after_9\IN\0|bupivacaine_45|expression_11|dissipates_112 (l_pobj) injury_11\NN\14052046|NONE_0
D015232_D010149 NONE e2_15\NNP\0|local_20|prostaglandin_14|and_21|cyclooxygenase_25 (r_nmod) production_19\NN\30358|(_30|cox_31|)_34|gene_36|increases_57 (r_nmod) expression_26\NN\4679549|NONE_0 (l_relcl) increases_28\VBZ\13576355|production_57|(_27|cox_26|)_23|gene_21 (l_dobj) pain_30\NN\14299637|that_29
D015232_D010149 NONE pge2_17\NNP\0|(_1 (r_appos) e2_15\NNP\0|local_20|prostaglandin_14|and_21|cyclooxygenase_25 (r_nmod) production_19\NN\30358|(_30|cox_31|)_34|gene_36|increases_57 (r_nmod) expression_26\NN\4679549|NONE_0 (l_relcl) increases_28\VBZ\13576355|production_57|(_27|cox_26|)_23|gene_21 (l_dobj) pain_30\NN\14299637|that_29
D008012_D010146 NONE lidocaine_6\NN\3681148|the_44|differential_40|of_19|and_4|._103 (l_prep) on_7\IN\0|NONE_0 (l_pobj) release_10\NN\3748886|NONE_0 (l_conj) expression_14\NN\4679549|prostaglandin_46|e2_32|,_22|in_20 (l_conj) pain_16\NN\14299637|cyclooxygenase_35|gene_20|and_4
D008012_D010146 NONE lidocaine_6\NN\3681148|the_44|differential_40|of_19|and_4|._103 (l_prep) on_7\IN\0|NONE_0 (l_pobj) release_10\NN\3748886|NONE_0 (l_prep) in_17\IN\13603305|prostaglandin_66|e2_52|,_42|expression_20 (l_pobj) model_21\NN\5888929|NONE_0 (l_compound) pain_20\NN\14299637|a_11|clinical_9
D002045_D010149 CID bupivacaine_11\NN\0|NONE_0 (l_prep) on_12\IN\0|NONE_0 (l_pobj) expression_26\NN\4679549|NONE_0 (l_relcl) increases_28\VBZ\13576355|production_57|(_27|cox_26|)_23|gene_21 (l_dobj) pain_30\NN\14299637|that_29
C116926_D010146 NONE rofecoxib_3\NN\3124700|the_16 (r_compound) group_4\NN\2137|pain_34|,_38|assessed_43|,_76|compared_78 (r_nsubj) reported_5\VBD\831651|NONE_0 (l_dobj) pain_8\NN\14299637|group_34|,_4|assessed_9|,_42|compared_44
D002045_D010146 NONE bupivacaine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_25|differential_21|and_15|lidocaine_19|._122 (r_prep) effects_2\NNS\13245626|NONE_0 (l_conj) lidocaine_6\NN\3681148|the_44|differential_40|of_19|and_4|._103 (l_prep) on_7\IN\0|NONE_0 (l_pobj) release_10\NN\3748886|NONE_0 (l_conj) expression_14\NN\4679549|prostaglandin_46|e2_32|,_22|in_20 (l_conj) pain_16\NN\14299637|cyclooxygenase_35|gene_20|and_4
D002045_D010146 NONE bupivacaine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_25|differential_21|and_15|lidocaine_19|._122 (r_prep) effects_2\NNS\13245626|NONE_0 (l_conj) lidocaine_6\NN\3681148|the_44|differential_40|of_19|and_4|._103 (l_prep) on_7\IN\0|NONE_0 (l_pobj) release_10\NN\3748886|NONE_0 (l_prep) in_17\IN\13603305|prostaglandin_66|e2_52|,_42|expression_20 (l_pobj) model_21\NN\5888929|NONE_0 (l_compound) pain_20\NN\14299637|a_11|clinical_9
D002045_D010146 NONE bupivacaine_1\NN\0|/_11 (r_nmod) rofecoxib_3\NN\3124700|the_16 (r_compound) group_4\NN\2137|pain_34|,_38|assessed_43|,_76|compared_78 (r_nsubj) reported_5\VBD\831651|NONE_0 (l_dobj) pain_8\NN\14299637|group_34|,_4|assessed_9|,_42|compared_44
D002045_D010146 NONE bupivacaine_3\NN\0|/_11 (r_nmod) placebo_5\NN\3740161|the_16 (r_compound) group_6\NN\2137|however_33|,_26|pain_34|at_39|during_63|were_84|._147 (r_nsubj) reported_7\VBD\831651|NONE_0 (l_dobj) pain_10\NN\14299637|however_67|,_60|group_34|at_5|during_29|were_50|._113
D002045_D010146 NONE bupivacaine_4\NN\0|expression_34|after_45|dissipates_157 (r_nsubj) stimulates_5\VBZ\137313|results_33|._155 (l_prep) after_9\IN\0|bupivacaine_45|expression_11|dissipates_112 (l_pobj) injury_11\NN\14052046|NONE_0 (l_relcl) associated_15\VBN\628491|tissue_24|,_11 (l_prep) with_16\IN\0|which_20|is_14 (l_pobj) production_19\NN\30358|NONE_0 (l_conj) pain_21\NN\14299637|higher_27|pge2_20|and_4
